[{"path":"index.html","id":"about","chapter":"About","heading":"About","text":"Information intended assist preparation Clinical Hematology content ASCP BOC’s MLS, H, SH certification exams Content Guidelines MLS, H, SH certification examsYou recommend use information supplement “Reading List” cited ASCP BOC certificationMedical Laboratory Scientist, MLS(ASCP)Technologist Hematology, H(ASCP)Specialist Hematology, SH(ASCP)","code":""},{"path":"content-areas.html","id":"content-areas","chapter":"Content Areas","heading":"Content Areas","text":"Major content areas covered:ErythrocytesLeukocytesPlateletsLaboratoryHemostasis","code":""},{"path":"content-areas.html","id":"last-updated","chapter":"Content Areas","heading":"Last Updated","text":"Last edit pushed site 2025-04-04","code":""},{"path":"author.html","id":"author","chapter":"Author","heading":"Author","text":"Author: Brett M. Rice, MLS(ASCP)SH,SCYMHe graduate Augusta University’s Clinical Laboratory Science program. worked Clinical Hematology bench Wellstar MCG Health’s Core Laboratory full time 2013-18. 2016, earned Specialist Hematology (ASCP). time, gained experience Bone Marrow Flow Cytometry bench successful Specialist Cytometry (ASCP) 2018Since September 2018, teaching full time Augusta University’s Clinical Laboratory Science (BS-CLS | MHS-CLS) program primary teaching focus Clinical Hematology. still practices Clinical Hematology, Bone Marrow, Flow Cytometry Laboratory one day week","code":""},{"path":"author.html","id":"disclaimer","chapter":"Author","heading":"Disclaimer","text":"AI used creation site. AI makes mistakes, double-check informationIf see mistakes omissions, please let know edits need made using “Edit page” feature displayed right column (desktop view). hoping time can build project reliable resource . Along line, considering project perpetual state “-progress”","code":""},{"path":"author.html","id":"license","chapter":"Author","heading":"License","text":"work licensed CC -NC-SA 4.0","code":""},{"path":"author.html","id":"contribute","chapter":"Author","heading":"Contribute","text":"author appreciates help maintain reference material. use resource, please consider using “Edit page” feature right side page (desktop view) suggest changes content. Another way can contribute keep author caffeinated!","code":""},{"path":"ascp-boc.html","id":"ascp-boc","chapter":"ASCP BOC","heading":"ASCP BOC","text":"ASCP BOC’s Content Guideline Technologist Hematology, H(ASCP), Specialist Hematology, SH(ASCP), certification exams consists five major content areas. information last revised ASCP’s website October 2023","code":""},{"path":"ascp-boc.html","id":"hematology-physiology","chapter":"ASCP BOC","heading":"Hematology Physiology","text":"Exam Percentage: 10% - 15%\nDescription: Physiology (production, destruction, function) blood, body fluids, bone marrow","code":""},{"path":"ascp-boc.html","id":"hematology-disease-states","chapter":"ASCP BOC","heading":"Hematology Disease States","text":"Exam Percentage: 20% - 25%\nDescription: Disease states associated qualitative/quantitative abnormalities erythrocytes, leukocytes, platelets","code":""},{"path":"ascp-boc.html","id":"hematology-laboratory-testing","chapter":"ASCP BOC","heading":"Hematology Laboratory Testing","text":"Exam Percentage: 20% - 25%\nDescription: Cell counts, differentials/morphology evaluation, hemoglobin/hematocrit, indices, hemolytic indicators, special stains, flow cytometry immunophenotyping, molecular/cytogenetic testing","code":""},{"path":"ascp-boc.html","id":"hemostasis","chapter":"ASCP BOC","heading":"Hemostasis","text":"Exam Percentage: 20% - 25%\nDescription: Physiology (pathways vascular system), hemostasis-related disease states, hemostasis laboratory determinations","code":""},{"path":"ascp-boc.html","id":"laboratory-operations","chapter":"ASCP BOC","heading":"Laboratory Operations","text":"Exam Percentage: 15% - 20%\nDescription: Quality assessment/troubleshooting, point--care testing (POCT), regulations, safety, laboratory mathematics, instrumentation, laboratory administration (SH )","code":""},{"path":"reading-list.html","id":"reading-list","chapter":"Reading List","heading":"Reading List","text":"ASCP makes clear suggested reading/reference list Technologist Hematology, H(ASCP), Specialist Hematology, SH(ASCP), certification exams “intended partial reference source”. suggested reading/reference list last revised ASCP’s website January 2025","code":""},{"path":"reading-list.html","id":"journals","chapter":"Reading List","heading":"Journals","text":"Clinical Laboratory Science. Published American Society Clinical Laboratory ScienceLaboratory Medicine. Published Oxford University PressMedical Laboratory Observer. Published Endeavor Business Media, LLC","code":""},{"path":"reading-list.html","id":"texts","chapter":"Reading List","heading":"Texts","text":"","code":""},{"path":"reading-list.html","id":"hematology-hemostasis","chapter":"Reading List","heading":"Hematology & Hemostasis","text":"Glassy, E.F. (2018). Color Atlas Hematology: Illustrated Field Guide Based Proficiency Testing (2nd ed.). College American Pathologists.Keohane, E.M., et al. (2024). Rodak’s Hematology: Clinical Principles & Applications (7th ed.). St. Louis, MO: Elsevier.McKenzie, S.B., Landis-Piwowar, K., & Williams, L. (2019). Clinical Laboratory Hematology (4th ed.). New Jersey: Prentice\nHall.McPherson, R.. & Pincus, M.R. (2021). Henry’s Clinical Diagnosis Management Laboratory Methods (24th ed.). Philadelphia: Elsevier.Means Jr., R.T., et al. (2023). Wintrobe’s Clinical Hematology (15th ed.). Wolters Kluwer.Classification Tumours Editorial Board. (2024). Classification Tumours: Haematolymphoid Tumours,\nPart (5th ed., Vol. 11). Lyon, France: IARC Press.","code":""},{"path":"reading-list.html","id":"body-fluids","chapter":"Reading List","heading":"Body Fluids","text":"Brunzel, N.. (2022). Fundamentals Urine Body Fluid Analysis (5th ed.). St. Louis, MO: Elsevier.Galagan, K.., et al. (2006). Color Atlas Body Fluids: Illustrated Field Guide Based Proficiency Testing. College American Pathologists.Kjeldsberg, C. & Hussong, J. (2015). Kjeldsberg’s Body Fluid Analysis. Chicago, IL: ASCP Press.Strasinger, S.K. & Di Lorenzo, M.S. (2021). Urinalysis Body Fluids (7th ed.). Philadelphia: F.. Davis Company.","code":""},{"path":"reading-list.html","id":"laboratory-operations-1","chapter":"Reading List","heading":"Laboratory Operations","text":"Davis, D.L. (2016). Laboratory Safety: Self-Assessment Workbook (2nd ed.) Chicago: ASCP Press.Doucette, L.J. (2021). Mathematics Clinical Laboratory (4th ed.). St. Louis: Elsevier.Harmening, D.M. (2020). Laboratory Management, Principles Processes (4th ed.). St. Petersburg, FL: D. H. Publishing & Consulting Inc (appropriate Specialist (SH) level)","code":""},{"path":"reading-list.html","id":"online","chapter":"Reading List","heading":"Online","text":"Bloodline Image Atlas (Hematology Images)CellaVision CellAtlas App – Blood Cell Morphology GuideCenters Medicare Medicaid Services (CMS) - includes CLIA regulationsCollege American Pathologists (CAP) - includes inspector trainingHematology Outlines – Online Textbook & AtlasOccupational Safety & Health Administration (OSHA)Practical-Haemostasis (appropriate Specialist (SH) level)Fritsma FactorThe Joint Commission","code":""},{"path":"rbc-production.html","id":"rbc-production","chapter":"RBC Production","heading":"RBC Production","text":"","code":""},{"path":"rbc-production.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"RBC Production","heading":"\nAudio Overview\n","text":"","code":""},{"path":"rbc-production.html","id":"overview-of-erythropoiesis","chapter":"RBC Production","heading":"Overview of Erythropoiesis","text":"Definition: process red blood cell (RBC) production bone marrowLocation: Primarily occurs bone marrow adults. Can occur liver spleen fetal development certain disease states (extramedullary hematopoiesis)Regulation: Tightly regulated maintain constant red cell mass adequate oxygen delivery tissues","code":""},{"path":"rbc-production.html","id":"stages-of-erythropoiesis","chapter":"RBC Production","heading":"Stages of Erythropoiesis","text":"Hematopoietic Stem Cell (HSC):\nSelf-renewing cells can differentiate blood cell lineages\nSelf-renewing cells can differentiate blood cell lineagesCommon Myeloid Progenitor (CMP):\nGives rise myeloid lineages (erythrocytes, granulocytes, monocytes, megakaryocytes)\nGives rise myeloid lineages (erythrocytes, granulocytes, monocytes, megakaryocytes)Burst-Forming Unit-Erythroid (BFU-E):\nEarly erythroid progenitor\nLess responsive erythropoietin (EPO) CFU-E\nEarly erythroid progenitorLess responsive erythropoietin (EPO) CFU-EColony-Forming Unit-Erythroid (CFU-E):\nmature erythroid progenitor\nHighly responsive EPO\nmature erythroid progenitorHighly responsive EPOErythroid Precursors (Normoblasts/Erythroblasts):\nPronormoblast/Proerythroblast:\nLarge cell high nucleus--cytoplasm (N:C) ratio\nBasophilic cytoplasm\n\nBasophilic Normoblast:\nSmaller pronormoblast\nIntensely basophilic cytoplasm\n\nPolychromatic Normoblast:\nSmaller basophilic normoblast\nGray-blue cytoplasm due presence ribosomes hemoglobin\n\nOrthochromic Normoblast:\nSmaller polychromatic normoblast\nPink cytoplasm due increased hemoglobin\nNucleus condensed extruded\n\nPronormoblast/Proerythroblast:\nLarge cell high nucleus--cytoplasm (N:C) ratio\nBasophilic cytoplasm\nLarge cell high nucleus--cytoplasm (N:C) ratioBasophilic cytoplasmBasophilic Normoblast:\nSmaller pronormoblast\nIntensely basophilic cytoplasm\nSmaller pronormoblastIntensely basophilic cytoplasmPolychromatic Normoblast:\nSmaller basophilic normoblast\nGray-blue cytoplasm due presence ribosomes hemoglobin\nSmaller basophilic normoblastGray-blue cytoplasm due presence ribosomes hemoglobinOrthochromic Normoblast:\nSmaller polychromatic normoblast\nPink cytoplasm due increased hemoglobin\nNucleus condensed extruded\nSmaller polychromatic normoblastPink cytoplasm due increased hemoglobinNucleus condensed extrudedReticulocyte:\nAnucleated red blood cell residual RNA\nSlightly larger mature RBCs\nSpends 1-2 days bone marrow 1 day peripheral blood maturing erythrocyte\nAnucleated red blood cell residual RNASlightly larger mature RBCsSpends 1-2 days bone marrow 1 day peripheral blood maturing erythrocyteErythrocyte (Mature Red Blood Cell):\nAnucleated biconcave disc filled hemoglobin\nLifespan approximately 120 days\nAnucleated biconcave disc filled hemoglobinLifespan approximately 120 days","code":""},{"path":"rbc-production.html","id":"key-regulators-of-erythropoiesis","chapter":"RBC Production","heading":"Key Regulators of Erythropoiesis","text":"Erythropoietin (EPO):\nPrimary growth factor erythropoiesis\nProduced mainly kidneys response hypoxia\nStimulates proliferation differentiation erythroid progenitors (BFU-E CFU-E)\nPrevents apoptosis (programmed cell death) erythroid precursors\nPrimary growth factor erythropoiesisProduced mainly kidneys response hypoxiaStimulates proliferation differentiation erythroid progenitors (BFU-E CFU-E)Prevents apoptosis (programmed cell death) erythroid precursorsIron:\nEssential heme synthesis\nSources: Dietary intake, recycling senescent RBCs, storage liver spleen\nTransported plasma transferrin\nStored cells ferritin hemosiderin\nEssential heme synthesisSources: Dietary intake, recycling senescent RBCs, storage liver spleenTransported plasma transferrinStored cells ferritin hemosiderinVitamins:\nVitamin B12 (Cobalamin) Folate (Folic Acid):\nEssential DNA synthesis\nDeficiency leads impaired cell division maturation, resulting megaloblastic anemia\n\nVitamin B12 (Cobalamin) Folate (Folic Acid):\nEssential DNA synthesis\nDeficiency leads impaired cell division maturation, resulting megaloblastic anemia\nEssential DNA synthesisDeficiency leads impaired cell division maturation, resulting megaloblastic anemiaCytokines Growth Factors:\nInterleukin-3 (IL-3):\nMulti-lineage growth factor affects early hematopoietic progenitors\nStem Cell Factor (SCF):\nSupports survival proliferation HSCs early progenitors\n\nInterleukin-3 (IL-3):Multi-lineage growth factor affects early hematopoietic progenitorsStem Cell Factor (SCF):\nSupports survival proliferation HSCs early progenitors\nSupports survival proliferation HSCs early progenitors","code":""},{"path":"rbc-production.html","id":"hemoglobin-synthesis","chapter":"RBC Production","heading":"Hemoglobin Synthesis","text":"Components:\nHeme: Iron-containing porphyrin ring\nGlobin: Protein chains (alpha, beta, gamma, delta)\nHeme: Iron-containing porphyrin ringGlobin: Protein chains (alpha, beta, gamma, delta)Process:\nPorphyrin Synthesis:\nOccurs mitochondria cytoplasm\nStarts condensation succinyl CoA glycine\nInvolves series enzymatic reactions\nKey enzyme: ALA synthase (rate-limiting step)\n\nIron Incorporation:\nIron (Fe2+) incorporated protoporphyrin form heme\nKey enzyme: Ferrochelatase\n\nGlobin Synthesis:\nOccurs ribosomes cytoplasm\nDifferent globin chains produced depending stage development (embryonic, fetal, adult)\n\nHemoglobin Assembly:\nFour globin chains (two alpha-like two beta-like) combine form globin tetramer\nglobin chain binds one heme molecule\n\nPorphyrin Synthesis:\nOccurs mitochondria cytoplasm\nStarts condensation succinyl CoA glycine\nInvolves series enzymatic reactions\nKey enzyme: ALA synthase (rate-limiting step)\nOccurs mitochondria cytoplasmStarts condensation succinyl CoA glycineInvolves series enzymatic reactionsKey enzyme: ALA synthase (rate-limiting step)Iron Incorporation:\nIron (Fe2+) incorporated protoporphyrin form heme\nKey enzyme: Ferrochelatase\nIron (Fe2+) incorporated protoporphyrin form hemeKey enzyme: FerrochelataseGlobin Synthesis:\nOccurs ribosomes cytoplasm\nDifferent globin chains produced depending stage development (embryonic, fetal, adult)\nOccurs ribosomes cytoplasmDifferent globin chains produced depending stage development (embryonic, fetal, adult)Hemoglobin Assembly:\nFour globin chains (two alpha-like two beta-like) combine form globin tetramer\nglobin chain binds one heme molecule\nFour globin chains (two alpha-like two beta-like) combine form globin tetramerEach globin chain binds one heme moleculeTypes Hemoglobin:\nHemoglobin (HbA):\nα2β2 (two alpha two beta chains)\nPredominant hemoglobin adults\n\nHemoglobin A2 (HbA2):\nα2δ2 (two alpha two delta chains)\nMinor component adults\n\nHemoglobin F (HbF):\nα2γ2 (two alpha two gamma chains)\nPredominant hemoglobin fetuses newborns\nHigher affinity oxygen HbA\n\nHemoglobin (HbA):\nα2β2 (two alpha two beta chains)\nPredominant hemoglobin adults\nα2β2 (two alpha two beta chains)Predominant hemoglobin adultsHemoglobin A2 (HbA2):\nα2δ2 (two alpha two delta chains)\nMinor component adults\nα2δ2 (two alpha two delta chains)Minor component adultsHemoglobin F (HbF):\nα2γ2 (two alpha two gamma chains)\nPredominant hemoglobin fetuses newborns\nHigher affinity oxygen HbA\nα2γ2 (two alpha two gamma chains)Predominant hemoglobin fetuses newbornsHigher affinity oxygen HbA","code":""},{"path":"rbc-production.html","id":"factors-affecting-erythropoiesis","chapter":"RBC Production","heading":"Factors Affecting Erythropoiesis","text":"Hypoxia:\nLow oxygen levels stimulate EPO production\nCauses include high altitude, lung disease, heart failure, anemia\nLow oxygen levels stimulate EPO productionCauses include high altitude, lung disease, heart failure, anemiaAnemia:\nDecreased red cell mass stimulates erythropoiesis\nDecreased red cell mass stimulates erythropoiesisHemorrhage:\nBlood loss leads decreased oxygen delivery increased erythropoiesis\nBlood loss leads decreased oxygen delivery increased erythropoiesisKidney Disease:\nImpaired EPO production, leading decreased erythropoiesis\nImpaired EPO production, leading decreased erythropoiesisInflammation:\nChronic inflammation can suppress erythropoiesis increased hepcidin production reduced EPO responsiveness\nChronic inflammation can suppress erythropoiesis increased hepcidin production reduced EPO responsivenessNutritional Deficiencies:\nIron, vitamin B12, folate deficiency can impair erythropoiesis\nIron, vitamin B12, folate deficiency can impair erythropoiesis","code":""},{"path":"rbc-production.html","id":"assessment-of-erythropoiesis","chapter":"RBC Production","heading":"Assessment of Erythropoiesis","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Measures amount hemoglobin blood\nHematocrit (HCT): Measures percentage blood volume occupied red blood cells\nRed Blood Cell Count (RBC): Measures number red blood cells volume blood\nMCV, MCH, MCHC\nHemoglobin (HGB): Measures amount hemoglobin bloodHematocrit (HCT): Measures percentage blood volume occupied red blood cellsRed Blood Cell Count (RBC): Measures number red blood cells volume bloodMCV, MCH, MCHCReticulocyte Count:\nMeasures percentage absolute number reticulocytes blood\nIndicates rate red blood cell production bone marrow\nMeasures percentage absolute number reticulocytes bloodIndicates rate red blood cell production bone marrowPeripheral Blood Smear:\nEvaluates morphology (size, shape, color) red blood cells\nCan identify abnormalities :\nAnisocytosis (variation size)\nPoikilocytosis (variation shape)\nHypochromia (decreased color)\nPolychromasia (increased blueness due residual RNA reticulocytes)\n\nEvaluates morphology (size, shape, color) red blood cellsCan identify abnormalities :\nAnisocytosis (variation size)\nPoikilocytosis (variation shape)\nHypochromia (decreased color)\nPolychromasia (increased blueness due residual RNA reticulocytes)\nAnisocytosis (variation size)Poikilocytosis (variation shape)Hypochromia (decreased color)Polychromasia (increased blueness due residual RNA reticulocytes)Iron Studies:\nSerum Iron: Measures amount iron blood\nTotal Iron-Binding Capacity (TIBC): Measures blood’s capacity bind iron\nTransferrin Saturation: percentage transferrin saturated iron\nFerritin: Measures body’s iron stores\nSerum Iron: Measures amount iron bloodTotal Iron-Binding Capacity (TIBC): Measures blood’s capacity bind ironTransferrin Saturation: percentage transferrin saturated ironFerritin: Measures body’s iron storesErythropoietin (EPO) Level:\nMeasures amount EPO blood\nUseful differentiating causes anemia polycythemia\nMeasures amount EPO bloodUseful differentiating causes anemia polycythemiaBone Marrow Examination:\nProvides information cellularity maturation erythroid precursors bone marrow\nCan identify abnormalities :\nDysplasia (abnormal cell development)\nInfections\nMalignancies\n\nProvides information cellularity maturation erythroid precursors bone marrowCan identify abnormalities :\nDysplasia (abnormal cell development)\nInfections\nMalignancies\nDysplasia (abnormal cell development)InfectionsMalignancies","code":""},{"path":"rbc-production.html","id":"key-terms","chapter":"RBC Production","heading":"Key Terms","text":"Erythropoiesis: Red blood cell productionHematopoiesis: Blood cell productionHypoxia: Low oxygen levelsErythropoietin (EPO): Hormone stimulates erythropoiesisHemoglobin: Oxygen-carrying protein red blood cellsHeme: Iron-containing porphyrin ringGlobin: Protein chains make hemoglobinReticulocyte: Immature red blood cellFerritin: Storage form ironTransferrin: Transport protein ironAnemia: Deficiency red blood cells hemoglobinPolycythemia: Excess red blood cellsDysplasia: Abnormal cell developmentApoptosis: Programmed cell death","code":""},{"path":"rbc-function.html","id":"rbc-function","chapter":"RBC Function","heading":"RBC Function","text":"","code":""},{"path":"rbc-function.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"RBC Function","heading":"\nAudio Overview\n","text":"","code":""},{"path":"rbc-function.html","id":"overview-of-erythrocyte-function","chapter":"RBC Function","heading":"Overview of Erythrocyte Function","text":"Primary Function: Oxygen transport lungs tissues carbon dioxide transport tissues lungsKey Components Function:\nHemoglobin (HGB): oxygen-carrying molecule within RBC\nRBC Membrane: Provides flexibility structural integrity\nMetabolic Pathways: Maintain RBC shape, flexibility, hemoglobin function\nHemoglobin (HGB): oxygen-carrying molecule within RBCRBC Membrane: Provides flexibility structural integrityMetabolic Pathways: Maintain RBC shape, flexibility, hemoglobin function","code":""},{"path":"rbc-function.html","id":"hemoglobin-structure-and-function","chapter":"RBC Function","heading":"Hemoglobin Structure and Function","text":"Structure:\nTetramer composed four globin chains (two alpha-like two beta-like)\nglobin chain contains heme molecule\nheme molecule contains iron (Fe2+) atom, binds oxygen\nTetramer composed four globin chains (two alpha-like two beta-like)globin chain contains heme moleculeEach heme molecule contains iron (Fe2+) atom, binds oxygenOxygen Binding:\nhemoglobin molecule can bind four oxygen molecules\nBinding cooperative, meaning binding one oxygen molecule increases affinity subsequent oxygen molecules\nhemoglobin molecule can bind four oxygen moleculesBinding cooperative, meaning binding one oxygen molecule increases affinity subsequent oxygen moleculesOxygen Dissociation Curve:\nSigmoidal shape reflects cooperative binding oxygen\nP50: partial pressure oxygen hemoglobin 50% saturated\nIncreased P50: Indicates decreased oxygen affinity (right shift)\nDecreased P50: Indicates increased oxygen affinity (left shift)\n\nSigmoidal shape reflects cooperative binding oxygenP50: partial pressure oxygen hemoglobin 50% saturated\nIncreased P50: Indicates decreased oxygen affinity (right shift)\nDecreased P50: Indicates increased oxygen affinity (left shift)\nIncreased P50: Indicates decreased oxygen affinity (right shift)Decreased P50: Indicates increased oxygen affinity (left shift)Factors Affecting Oxygen Affinity:\npH:\nDecreased pH (acidosis): Decreases oxygen affinity (Bohr effect)\nIncreased pH (alkalosis): Increases oxygen affinity\n\nCarbon Dioxide (CO2):\nIncreased CO2: Decreases oxygen affinity (Bohr effect)\nDecreased CO2: Increases oxygen affinity\n\nTemperature:\nIncreased temperature: Decreases oxygen affinity\nDecreased temperature: Increases oxygen affinity\n\n2,3-Diphosphoglycerate (2,3-DPG):\nIncreased 2,3-DPG: Decreases oxygen affinity\nDecreased 2,3-DPG: Increases oxygen affinity\n\npH:\nDecreased pH (acidosis): Decreases oxygen affinity (Bohr effect)\nIncreased pH (alkalosis): Increases oxygen affinity\nDecreased pH (acidosis): Decreases oxygen affinity (Bohr effect)Increased pH (alkalosis): Increases oxygen affinityCarbon Dioxide (CO2):\nIncreased CO2: Decreases oxygen affinity (Bohr effect)\nDecreased CO2: Increases oxygen affinity\nIncreased CO2: Decreases oxygen affinity (Bohr effect)Decreased CO2: Increases oxygen affinityTemperature:\nIncreased temperature: Decreases oxygen affinity\nDecreased temperature: Increases oxygen affinity\nIncreased temperature: Decreases oxygen affinityDecreased temperature: Increases oxygen affinity2,3-Diphosphoglycerate (2,3-DPG):\nIncreased 2,3-DPG: Decreases oxygen affinity\nDecreased 2,3-DPG: Increases oxygen affinity\nIncreased 2,3-DPG: Decreases oxygen affinityDecreased 2,3-DPG: Increases oxygen affinity","code":""},{"path":"rbc-function.html","id":"hemoglobin-variants-and-their-functions","chapter":"RBC Function","heading":"Hemoglobin Variants and Their Functions","text":"Hemoglobin (HbA):\nα2β2 (two alpha two beta chains)\nPredominant hemoglobin adults\nα2β2 (two alpha two beta chains)Predominant hemoglobin adultsHemoglobin A2 (HbA2):\nα2δ2 (two alpha two delta chains)\nMinor component adults\nα2δ2 (two alpha two delta chains)Minor component adultsHemoglobin F (HbF):\nα2γ2 (two alpha two gamma chains)\nPredominant hemoglobin fetuses newborns\nHigher affinity oxygen HbA\nα2γ2 (two alpha two gamma chains)Predominant hemoglobin fetuses newbornsHigher affinity oxygen HbAAbnormal Hemoglobins:\nHemoglobin S (HbS):\nCauses sickle cell anemia\nPolymerizes low oxygen conditions, leading sickling red blood cells\n\nHemoglobin C (HbC):\nCauses mild hemolytic anemia\nForms crystals within red blood cells\n\nMethemoglobin:\nIron heme molecule oxidized Fe3+ state\nbind oxygen\n\nCarboxyhemoglobin:\nHemoglobin bound carbon monoxide (CO)\nmuch higher affinity CO oxygen\nImpairs oxygen delivery tissues\n\nHemoglobin S (HbS):\nCauses sickle cell anemia\nPolymerizes low oxygen conditions, leading sickling red blood cells\nCauses sickle cell anemiaPolymerizes low oxygen conditions, leading sickling red blood cellsHemoglobin C (HbC):\nCauses mild hemolytic anemia\nForms crystals within red blood cells\nCauses mild hemolytic anemiaForms crystals within red blood cellsMethemoglobin:\nIron heme molecule oxidized Fe3+ state\nbind oxygen\nIron heme molecule oxidized Fe3+ stateCannot bind oxygenCarboxyhemoglobin:\nHemoglobin bound carbon monoxide (CO)\nmuch higher affinity CO oxygen\nImpairs oxygen delivery tissues\nHemoglobin bound carbon monoxide (CO)much higher affinity CO oxygenImpairs oxygen delivery tissues","code":""},{"path":"rbc-function.html","id":"red-blood-cell-membrane","chapter":"RBC Function","heading":"Red Blood Cell Membrane","text":"Structure:\nLipid bilayer embedded proteins\nProvides flexibility structural integrity red blood cell\nLipid bilayer embedded proteinsProvides flexibility structural integrity red blood cellKey Membrane Proteins:\nSpectrin:\nMajor component cytoskeleton\nProvides structural support\n\nAnkyrin:\nAnchors cytoskeleton cell membrane\n\nBand 3:\nAnion exchange protein (exchanges chloride bicarbonate)\nImportant CO2 transport\n\nGlycophorin :\nMajor sialoglycoprotein\nProvides negative charge prevents RBC aggregation\n\nSpectrin:\nMajor component cytoskeleton\nProvides structural support\nMajor component cytoskeletonProvides structural supportAnkyrin:\nAnchors cytoskeleton cell membrane\nAnchors cytoskeleton cell membraneBand 3:\nAnion exchange protein (exchanges chloride bicarbonate)\nImportant CO2 transport\nAnion exchange protein (exchanges chloride bicarbonate)Important CO2 transportGlycophorin :\nMajor sialoglycoprotein\nProvides negative charge prevents RBC aggregation\nMajor sialoglycoproteinProvides negative charge prevents RBC aggregationMembrane Defects:\nHereditary Spherocytosis:\nDefects spectrin, ankyrin, membrane proteins\nResults spherical-shaped red blood cells prone destruction spleen\n\nHereditary Elliptocytosis:\nDefects spectrin membrane proteins\nResults elliptical-shaped red blood cells\n\nHereditary Spherocytosis:\nDefects spectrin, ankyrin, membrane proteins\nResults spherical-shaped red blood cells prone destruction spleen\nDefects spectrin, ankyrin, membrane proteinsResults spherical-shaped red blood cells prone destruction spleenHereditary Elliptocytosis:\nDefects spectrin membrane proteins\nResults elliptical-shaped red blood cells\nDefects spectrin membrane proteinsResults elliptical-shaped red blood cells","code":""},{"path":"rbc-function.html","id":"red-blood-cell-metabolism","chapter":"RBC Function","heading":"Red Blood Cell Metabolism","text":"Key Metabolic Pathways:\nGlycolysis (Embden-Meyerhof Pathway):\nProvides ATP maintaining cell shape, membrane integrity, ion transport\nDeficiency pyruvate kinase (PK) can lead hemolytic anemia\n\nPentose Phosphate Pathway (Hexose Monophosphate Shunt):\nProduces NADPH, protects oxidative damage\nDeficiency glucose-6-phosphate dehydrogenase (G6PD) can lead hemolytic anemia\n\nMethemoglobin Reductase Pathway:\nMaintains iron reduced (Fe2+) state\nDeficiency can lead methemoglobinemia\n\nRapport-Luebering Shunt:\nProduces 2,3-DPG, regulates hemoglobin’s oxygen affinity\n\nGlycolysis (Embden-Meyerhof Pathway):\nProvides ATP maintaining cell shape, membrane integrity, ion transport\nDeficiency pyruvate kinase (PK) can lead hemolytic anemia\nProvides ATP maintaining cell shape, membrane integrity, ion transportDeficiency pyruvate kinase (PK) can lead hemolytic anemiaPentose Phosphate Pathway (Hexose Monophosphate Shunt):\nProduces NADPH, protects oxidative damage\nDeficiency glucose-6-phosphate dehydrogenase (G6PD) can lead hemolytic anemia\nProduces NADPH, protects oxidative damageDeficiency glucose-6-phosphate dehydrogenase (G6PD) can lead hemolytic anemiaMethemoglobin Reductase Pathway:\nMaintains iron reduced (Fe2+) state\nDeficiency can lead methemoglobinemia\nMaintains iron reduced (Fe2+) stateDeficiency can lead methemoglobinemiaRapport-Luebering Shunt:\nProduces 2,3-DPG, regulates hemoglobin’s oxygen affinity\nProduces 2,3-DPG, regulates hemoglobin’s oxygen affinity","code":""},{"path":"rbc-function.html","id":"carbon-dioxide-transport","chapter":"RBC Function","heading":"Carbon Dioxide Transport","text":"Mechanisms:\nDissolved CO2 Plasma:\nSmall amount CO2 transported plasma\n\nCarbaminohemoglobin:\nCO2 binds hemoglobin\n\nBicarbonate (HCO3-):\nCO2 transported bicarbonate\nCO2 enters red blood cells converted carbonic acid (H2CO3) carbonic anhydrase\nCarbonic acid dissociates H+ HCO3-\nHCO3- exchanged chloride (Cl-) via anion exchange protein (Band 3) (chloride shift)\n\nDissolved CO2 Plasma:\nSmall amount CO2 transported plasma\nSmall amount CO2 transported plasmaCarbaminohemoglobin:\nCO2 binds hemoglobin\nCO2 binds hemoglobinBicarbonate (HCO3-):\nCO2 transported bicarbonate\nCO2 enters red blood cells converted carbonic acid (H2CO3) carbonic anhydrase\nCarbonic acid dissociates H+ HCO3-\nHCO3- exchanged chloride (Cl-) via anion exchange protein (Band 3) (chloride shift)\nCO2 transported bicarbonateCO2 enters red blood cells converted carbonic acid (H2CO3) carbonic anhydraseCarbonic acid dissociates H+ HCO3-HCO3- exchanged chloride (Cl-) via anion exchange protein (Band 3) (chloride shift)","code":""},{"path":"rbc-function.html","id":"red-blood-cell-destruction-senescence","chapter":"RBC Function","heading":"Red Blood Cell Destruction (Senescence)","text":"Process:\nred blood cells age, become less flexible susceptible damage\nSenescent red blood cells removed circulation macrophages spleen\nred blood cells age, become less flexible susceptible damageSenescent red blood cells removed circulation macrophages spleenHemoglobin Breakdown:\nHemoglobin broken globin, iron, porphyrin\nGlobin broken amino acids\nIron recycled stored\nPorphyrin converted bilirubin, excreted bile\nHemoglobin broken globin, iron, porphyrinGlobin broken amino acidsIron recycled storedPorphyrin converted bilirubin, excreted bileClinical Significance:\nIncreased red blood cell destruction (hemolysis) can lead anemia elevated bilirubin levels\nIncreased red blood cell destruction (hemolysis) can lead anemia elevated bilirubin levels","code":""},{"path":"rbc-function.html","id":"assessment-of-erythrocyte-function","chapter":"RBC Function","heading":"Assessment of Erythrocyte Function","text":"Hemoglobin (HGB):\nMeasures amount hemoglobin blood\nMeasures amount hemoglobin bloodHematocrit (HCT):\nMeasures percentage blood volume occupied red blood cells\nMeasures percentage blood volume occupied red blood cellsRed Blood Cell Count (RBC):\nMeasures number red blood cells volume blood\nMeasures number red blood cells volume bloodMean Corpuscular Volume (MCV):\nMeasures average size red blood cells\nMeasures average size red blood cellsPeripheral Blood Smear:\nEvaluates morphology (size, shape, color) red blood cells\nCan identify abnormalities :\nSpherocytes\nElliptocytes\nSickle cells\nTarget cells\n\nEvaluates morphology (size, shape, color) red blood cellsCan identify abnormalities :\nSpherocytes\nElliptocytes\nSickle cells\nTarget cells\nSpherocytesElliptocytesSickle cellsTarget cellsReticulocyte Count:\nMeasures percentage absolute number reticulocytes blood\nIndicates rate red blood cell production bone marrow\nMeasures percentage absolute number reticulocytes bloodIndicates rate red blood cell production bone marrowHemoglobin Electrophoresis:\nSeparates identifies different types hemoglobin\nUsed diagnose hemoglobinopathies (e.g., sickle cell anemia, thalassemia)\nSeparates identifies different types hemoglobinUsed diagnose hemoglobinopathies (e.g., sickle cell anemia, thalassemia)Direct Antiglobulin Test (DAT):\nDetects antibodies complement proteins surface red blood cells\nUsed diagnose autoimmune hemolytic anemia\nDetects antibodies complement proteins surface red blood cellsUsed diagnose autoimmune hemolytic anemiaOsmotic Fragility Test:\nMeasures resistance red blood cells hemolysis hypotonic solutions\nUsed diagnose hereditary spherocytosis\nMeasures resistance red blood cells hemolysis hypotonic solutionsUsed diagnose hereditary spherocytosisGlucose-6-Phosphate Dehydrogenase (G6PD) Assay:\nMeasures activity G6PD enzyme\nUsed diagnose G6PD deficiency\nMeasures activity G6PD enzymeUsed diagnose G6PD deficiencyPyruvate Kinase (PK) Assay:\nMeasures activity PK enzyme\nUsed diagnose PK deficiency\nMeasures activity PK enzymeUsed diagnose PK deficiencyHaptoglobin:\nProtein binds free hemoglobin released plasma\nDecreased hemolytic anemia\nProtein binds free hemoglobin released plasmaDecreased hemolytic anemiaLactate Dehydrogenase (LDH):\nEnzyme released damaged cells\nElevated hemolytic anemia\nEnzyme released damaged cellsElevated hemolytic anemiaUnconjugated Bilirubin:\nProduct heme breakdown\nElevated hemolytic anemia\nProduct heme breakdownElevated hemolytic anemia","code":""},{"path":"rbc-function.html","id":"key-terms-1","chapter":"RBC Function","heading":"Key Terms","text":"Hemoglobin: Oxygen-carrying protein red blood cellsHeme: Iron-containing porphyrin ringGlobin: Protein chains make hemoglobinOxygen Affinity: strength binding hemoglobin oxygen2,3-DPG: Regulates hemoglobin’s oxygen affinityReticulocyte: Immature red blood cellAnemia: Deficiency red blood cells hemoglobinHemolysis: Destruction red blood cellsSpherocyte: Spherical-shaped red blood cellElliptocyte: Elliptical-shaped red blood cell","code":""},{"path":"rbc-destruction.html","id":"rbc-destruction","chapter":"RBC Destruction","heading":"RBC Destruction","text":"","code":""},{"path":"rbc-destruction.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"RBC Destruction","heading":"\nAudio Overview\n","text":"","code":""},{"path":"rbc-destruction.html","id":"overview-of-erythrocyte-destruction","chapter":"RBC Destruction","heading":"Overview of Erythrocyte Destruction","text":"Purpose: remove aged damaged red blood cells (RBCs) circulation, preventing release potentially harmful intracellular components recycling valuable components like ironMechanisms:\nExtravascular Hemolysis: primary pathway, occurring mainly spleen liver\nIntravascular Hemolysis: Occurs within blood vessels\nExtravascular Hemolysis: primary pathway, occurring mainly spleen liverIntravascular Hemolysis: Occurs within blood vesselsLifespan Normal RBC: Approximately 120 days","code":""},{"path":"rbc-destruction.html","id":"extravascular-hemolysis","chapter":"RBC Destruction","heading":"Extravascular Hemolysis","text":"Location: Mononuclear Phagocyte System (MPS); primarily spleen, also liver bone marrowProcess:\nSenescence (Aging): RBCs age, undergo changes:\nDecreased flexibility\nDecreased enzyme activity\nChanges membrane proteins\nIncreased binding antibodies complement proteins\n\nRecognition Macrophages:\nMacrophages spleen recognize senescent damaged RBCs based surface markers (e.g., altered glycoproteins, bound antibodies)\n\nPhagocytosis:\nMacrophages engulf RBCs\n\nHemoglobin Breakdown:\nWithin macrophage, hemoglobin broken :\nGlobin: Degraded amino acids, recycled\nIron: Stored ferritin hemosiderin within macrophage, transported bone marrow transferrin new RBC production\nHeme: Broken biliverdin, converted bilirubin\n\n\nBilirubin Metabolism:\nBilirubin released macrophage plasma, binds albumin (unconjugated indirect bilirubin)\nalbumin-bilirubin complex transported liver\nliver, bilirubin conjugated glucuronic acid (conjugated direct bilirubin)\nConjugated bilirubin excreted bile intestines\nintestines, bilirubin converted urobilinogen bacteria\nUrobilinogen either:\nExcreted feces (stercobilin, gives feces brown color)\nReabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)\n\n\nSenescence (Aging): RBCs age, undergo changes:\nDecreased flexibility\nDecreased enzyme activity\nChanges membrane proteins\nIncreased binding antibodies complement proteins\nDecreased flexibilityDecreased enzyme activityChanges membrane proteinsIncreased binding antibodies complement proteinsRecognition Macrophages:\nMacrophages spleen recognize senescent damaged RBCs based surface markers (e.g., altered glycoproteins, bound antibodies)\nMacrophages spleen recognize senescent damaged RBCs based surface markers (e.g., altered glycoproteins, bound antibodies)Phagocytosis:\nMacrophages engulf RBCs\nMacrophages engulf RBCsHemoglobin Breakdown:\nWithin macrophage, hemoglobin broken :\nGlobin: Degraded amino acids, recycled\nIron: Stored ferritin hemosiderin within macrophage, transported bone marrow transferrin new RBC production\nHeme: Broken biliverdin, converted bilirubin\n\nWithin macrophage, hemoglobin broken :\nGlobin: Degraded amino acids, recycled\nIron: Stored ferritin hemosiderin within macrophage, transported bone marrow transferrin new RBC production\nHeme: Broken biliverdin, converted bilirubin\nGlobin: Degraded amino acids, recycledIron: Stored ferritin hemosiderin within macrophage, transported bone marrow transferrin new RBC productionHeme: Broken biliverdin, converted bilirubinBilirubin Metabolism:\nBilirubin released macrophage plasma, binds albumin (unconjugated indirect bilirubin)\nalbumin-bilirubin complex transported liver\nliver, bilirubin conjugated glucuronic acid (conjugated direct bilirubin)\nConjugated bilirubin excreted bile intestines\nintestines, bilirubin converted urobilinogen bacteria\nUrobilinogen either:\nExcreted feces (stercobilin, gives feces brown color)\nReabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)\n\nBilirubin released macrophage plasma, binds albumin (unconjugated indirect bilirubin)albumin-bilirubin complex transported liverIn liver, bilirubin conjugated glucuronic acid (conjugated direct bilirubin)Conjugated bilirubin excreted bile intestinesIn intestines, bilirubin converted urobilinogen bacteriaUrobilinogen either:\nExcreted feces (stercobilin, gives feces brown color)\nReabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)\nExcreted feces (stercobilin, gives feces brown color)Reabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)Mononuclear Phagocyte System (MPS)\nNote: “Reticuloendothelial System” older term, ’ll still encounter . modern accurate term “Mononuclear Phagocyte System.”\nNote: “Reticuloendothelial System” older term, ’ll still encounter . modern accurate term “Mononuclear Phagocyte System.”Definition: MPS diffuse network phagocytic cells (primarily macrophages) located throughout body, strategically positioned filter blood tissues, remove debris, participate immune responses.Key Components:\nMacrophages: main effector cells MPS. derived monocytes capable phagocytosis (engulfing destroying particles).\nLocations: Macrophages found :\nSpleen: Red pulp macrophages critical filtering blood removing damaged senescent RBCs.\nLiver: Kupffer cells (macrophages liver sinusoids) remove bacteria, debris, old blood cells.\nBone Marrow: Macrophages support erythropoiesis remove cellular debris.\nLymph Nodes: Macrophages filter lymph present antigens immune cells.\nLungs: Alveolar macrophages clear debris pathogens air spaces.\nConnective Tissues: Histiocytes (tissue macrophages) engulf debris participate inflammation.\n\nMacrophages: main effector cells MPS. derived monocytes capable phagocytosis (engulfing destroying particles).Locations: Macrophages found :\nSpleen: Red pulp macrophages critical filtering blood removing damaged senescent RBCs.\nLiver: Kupffer cells (macrophages liver sinusoids) remove bacteria, debris, old blood cells.\nBone Marrow: Macrophages support erythropoiesis remove cellular debris.\nLymph Nodes: Macrophages filter lymph present antigens immune cells.\nLungs: Alveolar macrophages clear debris pathogens air spaces.\nConnective Tissues: Histiocytes (tissue macrophages) engulf debris participate inflammation.\nSpleen: Red pulp macrophages critical filtering blood removing damaged senescent RBCs.Liver: Kupffer cells (macrophages liver sinusoids) remove bacteria, debris, old blood cells.Bone Marrow: Macrophages support erythropoiesis remove cellular debris.Lymph Nodes: Macrophages filter lymph present antigens immune cells.Lungs: Alveolar macrophages clear debris pathogens air spaces.Connective Tissues: Histiocytes (tissue macrophages) engulf debris participate inflammation.Functions:\nPhagocytosis: Engulfing destroying pathogens, cellular debris, senescent damaged cells.\nAntigen Presentation: Presenting antigens T lymphocytes initiate adaptive immune responses.\nCytokine Production: Producing cytokines regulate inflammation immune responses.\nIron Recycling: Recycling iron senescent RBCs.\nLipid Metabolism: Processing metabolizing lipids.\nPhagocytosis: Engulfing destroying pathogens, cellular debris, senescent damaged cells.Antigen Presentation: Presenting antigens T lymphocytes initiate adaptive immune responses.Cytokine Production: Producing cytokines regulate inflammation immune responses.Iron Recycling: Recycling iron senescent RBCs.Lipid Metabolism: Processing metabolizing lipids.Splenic Functions: Pitting CullingThe spleen key organ MPS plays vital role filtering blood removing abnormal RBCs. Two important splenic functions pitting culling:Culling:\nDefinition: process spleen removes entire senescent damaged red blood cells circulation. complete phagocytosis destruction RBC.\nMechanism:\nRBCs circulate splenic red pulp, must squeeze narrow interendothelial slits re-enter circulation.\nSenescent damaged RBCs less flexible difficulty passing slits.\nMacrophages spleen recognize engulf less deformable RBCs, leading complete destruction.\n\nOutcome:\nRemoval old damaged RBCs, preventing causing harm.\nBreakdown hemoglobin components (globin, iron, porphyrin).\nRecycling iron.\nProduction bilirubin (porphyrin), transported liver excretion.\n\nDefinition: process spleen removes entire senescent damaged red blood cells circulation. complete phagocytosis destruction RBC.Mechanism:\nRBCs circulate splenic red pulp, must squeeze narrow interendothelial slits re-enter circulation.\nSenescent damaged RBCs less flexible difficulty passing slits.\nMacrophages spleen recognize engulf less deformable RBCs, leading complete destruction.\nRBCs circulate splenic red pulp, must squeeze narrow interendothelial slits re-enter circulation.Senescent damaged RBCs less flexible difficulty passing slits.Macrophages spleen recognize engulf less deformable RBCs, leading complete destruction.Outcome:\nRemoval old damaged RBCs, preventing causing harm.\nBreakdown hemoglobin components (globin, iron, porphyrin).\nRecycling iron.\nProduction bilirubin (porphyrin), transported liver excretion.\nRemoval old damaged RBCs, preventing causing harm.Breakdown hemoglobin components (globin, iron, porphyrin).Recycling iron.Production bilirubin (porphyrin), transported liver excretion.Pitting:\nDefinition: process spleen removes inclusions damaged components RBCs without destroying entire cell.\nMechanism:\nRBCs pass spleen, macrophages can “pluck ” certain inclusions RBCs, :\nHowell-Jolly bodies (nuclear remnants).\nHeinz bodies (denatured hemoglobin).\nParasites (e.g., malaria).\nIron granules (Pappenheimer bodies).\n\nRBC membrane reseals inclusion removed, allowing RBC continue circulating.\n\nOutcome:\nRemoval harmful inclusions RBCs, improving function lifespan.\nRBCs can continue circulate transport oxygen.\n\nClinical Significance:\nsplenectomy (removal spleen), patients may increased numbers RBCs inclusions (e.g., Howell-Jolly bodies) peripheral blood, pitting function lost.\n\nDefinition: process spleen removes inclusions damaged components RBCs without destroying entire cell.Mechanism:\nRBCs pass spleen, macrophages can “pluck ” certain inclusions RBCs, :\nHowell-Jolly bodies (nuclear remnants).\nHeinz bodies (denatured hemoglobin).\nParasites (e.g., malaria).\nIron granules (Pappenheimer bodies).\n\nRBC membrane reseals inclusion removed, allowing RBC continue circulating.\nRBCs pass spleen, macrophages can “pluck ” certain inclusions RBCs, :\nHowell-Jolly bodies (nuclear remnants).\nHeinz bodies (denatured hemoglobin).\nParasites (e.g., malaria).\nIron granules (Pappenheimer bodies).\nHowell-Jolly bodies (nuclear remnants).Heinz bodies (denatured hemoglobin).Parasites (e.g., malaria).Iron granules (Pappenheimer bodies).RBC membrane reseals inclusion removed, allowing RBC continue circulating.Outcome:\nRemoval harmful inclusions RBCs, improving function lifespan.\nRBCs can continue circulate transport oxygen.\nRemoval harmful inclusions RBCs, improving function lifespan.RBCs can continue circulate transport oxygen.Clinical Significance:\nsplenectomy (removal spleen), patients may increased numbers RBCs inclusions (e.g., Howell-Jolly bodies) peripheral blood, pitting function lost.\nsplenectomy (removal spleen), patients may increased numbers RBCs inclusions (e.g., Howell-Jolly bodies) peripheral blood, pitting function lost.SummaryThe Mononuclear Phagocyte System (MPS) network phagocytic cells, primarily macrophages, remove debris participate immune responses.spleen key organ MPS, responsible filtering blood.Culling complete removal destruction senescent damaged RBCs splenic macrophages.Pitting removal inclusions RBCs splenic macrophages without destroying entire cell.","code":""},{"path":"rbc-destruction.html","id":"intravascular-hemolysis","chapter":"RBC Destruction","heading":"Intravascular Hemolysis","text":"Location: Within blood vesselsCauses:\nMechanical trauma (e.g., microangiopathic hemolytic anemia)\nComplement activation via immune-mediated\nInfections\nToxic substances\nMechanical trauma (e.g., microangiopathic hemolytic anemia)Complement activation via immune-mediatedInfectionsToxic substancesProcess:\nRBC Lysis: RBCs rupture within bloodstream, releasing hemoglobin directly plasma\nHemoglobin Binding Haptoglobin:\nFree hemoglobin binds haptoglobin, plasma protein\nhemoglobin-haptoglobin complex rapidly cleared circulation liver\n\nHemoglobin Breakdown (Haptoglobin Saturated):\nhaptoglobin saturated, free hemoglobin can:\noxidized methemoglobin (Fe3+), dissociates globin heme\nHeme binds hemopexin, plasma protein, transported liver\nGlobin broken amino acids\n\nFree hemoglobin can also filtered kidneys:\nhemoglobin reabsorbed renal tubules\nExcess hemoglobin excreted urine (hemoglobinuria)\nIron can accumulate renal tubular cells hemosiderin (hemosiderinuria)\n\n\nRBC Lysis: RBCs rupture within bloodstream, releasing hemoglobin directly plasmaHemoglobin Binding Haptoglobin:\nFree hemoglobin binds haptoglobin, plasma protein\nhemoglobin-haptoglobin complex rapidly cleared circulation liver\nFree hemoglobin binds haptoglobin, plasma proteinThe hemoglobin-haptoglobin complex rapidly cleared circulation liverHemoglobin Breakdown (Haptoglobin Saturated):\nhaptoglobin saturated, free hemoglobin can:\noxidized methemoglobin (Fe3+), dissociates globin heme\nHeme binds hemopexin, plasma protein, transported liver\nGlobin broken amino acids\n\nFree hemoglobin can also filtered kidneys:\nhemoglobin reabsorbed renal tubules\nExcess hemoglobin excreted urine (hemoglobinuria)\nIron can accumulate renal tubular cells hemosiderin (hemosiderinuria)\n\nhaptoglobin saturated, free hemoglobin can:\noxidized methemoglobin (Fe3+), dissociates globin heme\nHeme binds hemopexin, plasma protein, transported liver\nGlobin broken amino acids\noxidized methemoglobin (Fe3+), dissociates globin hemeHeme binds hemopexin, plasma protein, transported liverGlobin broken amino acidsFree hemoglobin can also filtered kidneys:\nhemoglobin reabsorbed renal tubules\nExcess hemoglobin excreted urine (hemoglobinuria)\nIron can accumulate renal tubular cells hemosiderin (hemosiderinuria)\nhemoglobin reabsorbed renal tubulesExcess hemoglobin excreted urine (hemoglobinuria)Iron can accumulate renal tubular cells hemosiderin (hemosiderinuria)","code":""},{"path":"rbc-destruction.html","id":"key-enzymes-and-proteins-involved","chapter":"RBC Destruction","heading":"Key Enzymes and Proteins Involved","text":"Heme Oxygenase:\nEnzyme breaks heme biliverdin\nEnzyme breaks heme biliverdinBiliverdin Reductase:\nEnzyme converts biliverdin bilirubin\nEnzyme converts biliverdin bilirubinUDP-Glucuronosyltransferase (UGT):\nEnzyme liver conjugates bilirubin glucuronic acid\nEnzyme liver conjugates bilirubin glucuronic acidHaptoglobin:\nPlasma protein binds free hemoglobin\nPlasma protein binds free hemoglobinHemopexin:\nPlasma protein binds free heme\nPlasma protein binds free hemeTransferrin:\nProtein transports iron plasma\nProtein transports iron plasmaFerritin:\nStorage form iron within cells\nStorage form iron within cells","code":""},{"path":"rbc-destruction.html","id":"clinical-significance-of-erythrocyte-destruction","chapter":"RBC Destruction","heading":"Clinical Significance of Erythrocyte Destruction","text":"Anemia:\nIncreased RBC destruction can lead hemolytic anemia\nIncreased RBC destruction can lead hemolytic anemiaJaundice:\nElevated bilirubin levels (hyperbilirubinemia) can cause jaundice (yellowing skin eyes)\nElevated bilirubin levels (hyperbilirubinemia) can cause jaundice (yellowing skin eyes)Splenomegaly:\nEnlargement spleen due increased RBC destruction\nEnlargement spleen due increased RBC destructionHemoglobinuria:\nHemoglobin urine\nHemoglobin urineHemosiderinuria:\nHemosiderin (iron) urine\nHemosiderin (iron) urineElevated Lactate Dehydrogenase (LDH):\nEnzyme released damaged cells, including RBCs\nEnzyme released damaged cells, including RBCsDecreased Haptoglobin:\nDue binding free hemoglobin clearance circulation\nDue binding free hemoglobin clearance circulation","code":""},{"path":"rbc-destruction.html","id":"laboratory-assessment-of-erythrocyte-destruction","chapter":"RBC Destruction","heading":"Laboratory Assessment of Erythrocyte Destruction","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Low hemolytic anemia\nHematocrit (HCT): Low hemolytic anemia\nReticulocyte Count: Elevated due increased RBC production response hemolysis\nHemoglobin (HGB): Low hemolytic anemiaHematocrit (HCT): Low hemolytic anemiaReticulocyte Count: Elevated due increased RBC production response hemolysisPeripheral Blood Smear:\nSchistocytes (fragmented RBCs): Indicate mechanical hemolysis\nSpherocytes: Indicate extravascular hemolysis (e.g., hereditary spherocytosis)\nPolychromasia: Increased number reticulocytes\nSchistocytes (fragmented RBCs): Indicate mechanical hemolysisSpherocytes: Indicate extravascular hemolysis (e.g., hereditary spherocytosis)Polychromasia: Increased number reticulocytesBilirubin Levels:\nTotal Bilirubin: Elevated, especially indirect (unconjugated) fraction\nDirect Bilirubin: May elevated liver disease biliary obstruction\nTotal Bilirubin: Elevated, especially indirect (unconjugated) fractionDirect Bilirubin: May elevated liver disease biliary obstructionLactate Dehydrogenase (LDH):\nElevated hemolytic anemia\nElevated hemolytic anemiaHaptoglobin Level:\nDecreased hemolytic anemia\nDecreased hemolytic anemiaDirect Antiglobulin Test (DAT):\nDetects antibodies complement proteins surface RBCs\nUsed diagnose autoimmune hemolytic anemia\nDetects antibodies complement proteins surface RBCsUsed diagnose autoimmune hemolytic anemiaCoombs Test:\nDAT\nDATUrine Hemoglobin Hemosiderin:\nPresent intravascular hemolysis\nPresent intravascular hemolysisOsmotic Fragility Test:\nIncreased fragility hereditary spherocytosis\nIncreased fragility hereditary spherocytosisGlucose-6-Phosphate Dehydrogenase (G6PD) Assay:\nUsed diagnose G6PD deficiency\nUsed diagnose G6PD deficiency","code":""},{"path":"rbc-destruction.html","id":"key-terms-2","chapter":"RBC Destruction","heading":"Key Terms","text":"Hemolysis: Destruction red blood cellsExtravascular Hemolysis: RBC destruction outside blood vessels (primarily spleen)Intravascular Hemolysis: RBC destruction within blood vesselsSenescence: AgingSchistocytes: Fragmented red blood cellsSpherocytes: Spherical red blood cellsHaptoglobin: Protein binds free hemoglobinHemopexin: Protein binds free hemeBilirubin: Product heme breakdownJaundice: Yellowing skin eyes due elevated bilirubin levelsReticulocyte: Immature red blood cell","code":""},{"path":"anemais.html","id":"anemais","chapter":"Anemais","heading":"Anemais","text":"","code":""},{"path":"anemais.html","id":"overview-of-anemias","chapter":"Anemais","heading":"Overview of Anemias","text":"Definition: condition characterized decrease number red blood cells (RBCs) decrease concentration hemoglobin (HGB) blood, resulting reduced oxygen-carrying capacitySymptoms: Fatigue, weakness, pallor (pale skin), shortness breath, dizziness, headache, tachycardiaDiagnosis: Based combination clinical evaluation, complete blood count (CBC), peripheral blood smear, laboratory tests","code":""},{"path":"anemais.html","id":"classification-of-anemias","chapter":"Anemais","heading":"Classification of Anemias","text":"Morphological Classification: Based RBC size (Mean Corpuscular Volume - MCV) hemoglobin content (Mean Corpuscular Hemoglobin Concentration - MCHC)\nMicrocytic Anemias: Small RBCs (MCV < 80 fL)\nImpaired hemoglobin synthesis\n\nNormocytic Anemias: Normal-sized RBCs (MCV 80-100 fL)\nCan due variety causes, including acute blood loss, hemolysis, bone marrow disorders\n\nMacrocytic Anemias: Large RBCs (MCV > 100 fL)\nImpaired DNA synthesis abnormal RBC maturation\n\nMicrocytic Anemias: Small RBCs (MCV < 80 fL)\nImpaired hemoglobin synthesis\nImpaired hemoglobin synthesisNormocytic Anemias: Normal-sized RBCs (MCV 80-100 fL)\nCan due variety causes, including acute blood loss, hemolysis, bone marrow disorders\nCan due variety causes, including acute blood loss, hemolysis, bone marrow disordersMacrocytic Anemias: Large RBCs (MCV > 100 fL)\nImpaired DNA synthesis abnormal RBC maturation\nImpaired DNA synthesis abnormal RBC maturationPathophysiological Classification: Based underlying mechanism causing anemia\nDecreased RBC Production:\nBone marrow disorders\nNutritional deficiencies\nChronic diseases\n\nIncreased RBC Destruction (Hemolytic Anemias):\nInherited RBC disorders\nAcquired hemolytic anemias\n\nBlood Loss:\nAcute chronic blood loss\n\nDecreased RBC Production:\nBone marrow disorders\nNutritional deficiencies\nChronic diseases\nBone marrow disordersNutritional deficienciesChronic diseasesIncreased RBC Destruction (Hemolytic Anemias):\nInherited RBC disorders\nAcquired hemolytic anemias\nInherited RBC disordersAcquired hemolytic anemiasBlood Loss:\nAcute chronic blood loss\nAcute chronic blood loss","code":""},{"path":"anemais.html","id":"laboratory-tests-for-anemia","chapter":"Anemais","heading":"Laboratory Tests for Anemia","text":"Complete Blood Count (CBC):\nHemoglobin (HGB)\nHematocrit (HCT)\nRed Blood Cell Count (RBC)\nMean Corpuscular Volume (MCV)\nMean Corpuscular Hemoglobin (MCH)\nMean Corpuscular Hemoglobin Concentration (MCHC)\nRed Cell Distribution Width (RDW)\nWhite Blood Cell Count (WBC) Differential\nPlatelet Count\nHemoglobin (HGB)Hematocrit (HCT)Red Blood Cell Count (RBC)Mean Corpuscular Volume (MCV)Mean Corpuscular Hemoglobin (MCH)Mean Corpuscular Hemoglobin Concentration (MCHC)Red Cell Distribution Width (RDW)White Blood Cell Count (WBC) DifferentialPlatelet CountPeripheral Blood Smear:\nRBC morphology (size, shape, color)\nWBC differential\nPlatelet estimate\nRBC morphology (size, shape, color)WBC differentialPlatelet estimateReticulocyte Count:\nPercentage absolute number reticulocytes\nCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)\nPercentage absolute number reticulocytesCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)Iron Studies:\nSerum Iron\nTotal Iron-Binding Capacity (TIBC)\nTransferrin Saturation\nFerritin\nSerum IronTotal Iron-Binding Capacity (TIBC)Transferrin SaturationFerritinVitamin B12 Folate Levels:\nSerum B12\nRed Blood Cell Folate\nSerum B12Red Blood Cell FolateMethylmalonic Acid (MMA) Homocysteine Levels:\nElevated B12 Deficiency\nHomocysteine also Elevated Folate Deficiency\nElevated B12 DeficiencyHomocysteine also Elevated Folate DeficiencyHemoglobin Electrophoresis:\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)Direct Antiglobulin Test (DAT):\nDetects antibodies complement proteins surface RBCs\nDetects antibodies complement proteins surface RBCsBone Marrow Examination:\nCellularity\nMaturation cell lines\nPresence abnormal cells\nCellularityMaturation cell linesPresence abnormal cellsOther Tests:\nHaptoglobin LDH (hemolysis)\nCoombs test (autoimmune hemolytic anemia)\nOsmotic Fragility Test (hereditary spherocytosis)\nG6PD Assay (G6PD deficiency)\nHaptoglobin LDH (hemolysis)Coombs test (autoimmune hemolytic anemia)Osmotic Fragility Test (hereditary spherocytosis)G6PD Assay (G6PD deficiency)","code":""},{"path":"anemais.html","id":"key-terms-3","chapter":"Anemais","heading":"Key Terms","text":"Anemia: Deficiency red blood cells hemoglobinMicrocytic: Small red blood cells (MCV < 80 fL)Normocytic: Normal-sized red blood cells (MCV 80-100 fL)Macrocytic: Large red blood cells (MCV > 100 fL)Hypochromic: Decreased hemoglobin content (pale color)Hyperchromic: Increased hemoglobin content (intensely colored)Reticulocyte: Immature red blood cellHemolysis: Destruction red blood cellsExtramedullary Hematopoiesis: Blood cell production outside bone marrowPancytopenia: Deficiency blood cell lines (RBCs, WBCs, platelets)Megaloblastic: Abnormal maturation blood cells due impaired DNA synthesis","code":""},{"path":"microcytic.html","id":"microcytic","chapter":"Microcytic","heading":"Microcytic","text":"","code":""},{"path":"microcytic.html","id":"overview-of-microcytic-anemias","chapter":"Microcytic","heading":"Overview of Microcytic Anemias","text":"Definition: type anemia characterized red blood cells (RBCs) smaller normalKey Indicator: Mean Corpuscular Volume (MCV) less 80 femtoliters (fL)Underlying Cause: Typically results impaired hemoglobin synthesisCommon Causes (Think “TICS”):\nThalassemia\nIron Deficiency Anemia (IDA)\nAnemia Chronic Disease/Inflammation\nSideroblastic Anemia\nThalassemiaIron Deficiency Anemia (IDA)Anemia Chronic Disease/InflammationSideroblastic Anemia","code":""},{"path":"microcytic.html","id":"general-laboratory-findings-in-microcytic-anemias","chapter":"Microcytic","heading":"General Laboratory Findings in Microcytic Anemias","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nMean Corpuscular Volume (MCV): Decreased (< 80 fL)\nMean Corpuscular Hemoglobin (MCH): Decreased (hypochromia)\nMean Corpuscular Hemoglobin Concentration (MCHC): Decreased (hypochromia)\nRed Cell Distribution Width (RDW): Often increased, may normal cases (e.g., thalassemia trait)\nHemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedMean Corpuscular Volume (MCV): Decreased (< 80 fL)Mean Corpuscular Hemoglobin (MCH): Decreased (hypochromia)Mean Corpuscular Hemoglobin Concentration (MCHC): Decreased (hypochromia)Red Cell Distribution Width (RDW): Often increased, may normal cases (e.g., thalassemia trait)Peripheral Blood Smear:\nMicrocytes (small RBCs)\nHypochromia (pale RBCs)\nAnisocytosis (variation RBC size)\nPoikilocytosis (variation RBC shape) - varies depending specific cause\nMicrocytes (small RBCs)Hypochromia (pale RBCs)Anisocytosis (variation RBC size)Poikilocytosis (variation RBC shape) - varies depending specific cause","code":""},{"path":"microcytic.html","id":"iron-deficiency-anemia-ida","chapter":"Microcytic","heading":"Iron Deficiency Anemia (IDA)","text":"Definition: Anemia caused inadequate iron stores, leading decreased hemoglobin productionEtiology:\nInadequate iron intake (dietary deficiency)\nIncreased iron loss (bleeding)\nImpaired iron absorption\nIncreased iron requirements (e.g., pregnancy)\nInadequate iron intake (dietary deficiency)Increased iron loss (bleeding)Impaired iron absorptionIncreased iron requirements (e.g., pregnancy)Pathophysiology:\nIron essential heme synthesis\nInsufficient iron leads decreased hemoglobin production, resulting smaller paler red blood cells\nIron essential heme synthesisInsufficient iron leads decreased hemoglobin production, resulting smaller paler red blood cellsClinical Manifestations:\nGeneral anemia symptoms: Fatigue, weakness, pallor\nSpecific IDA symptoms:\nPica (unusual cravings non-food substances)\nKoilonychia (spoon-shaped nails)\nAngular cheilitis (inflammation corners mouth)\nGlossitis (inflammation tongue)\n\nGeneral anemia symptoms: Fatigue, weakness, pallorSpecific IDA symptoms:\nPica (unusual cravings non-food substances)\nKoilonychia (spoon-shaped nails)\nAngular cheilitis (inflammation corners mouth)\nGlossitis (inflammation tongue)\nPica (unusual cravings non-food substances)Koilonychia (spoon-shaped nails)Angular cheilitis (inflammation corners mouth)Glossitis (inflammation tongue)Laboratory Findings:\nCBC:\nMicrocytic, hypochromic anemia\nIncreased RDW\n\nPeripheral Blood Smear:\nMicrocytes\nHypochromia\nPencil cells (elongated, thin RBCs)\nTarget cells (less common thalassemia)\n\nReticulocyte Count:\nLow normal (inappropriately low degree anemia)\n\nIron Studies:\nSerum Iron: Decreased\nTotal Iron-Binding Capacity (TIBC): Increased\nTransferrin Saturation: Decreased\nFerritin: Decreased (specific indicator iron deficiency)\n\nCBC:\nMicrocytic, hypochromic anemia\nIncreased RDW\nMicrocytic, hypochromic anemiaIncreased RDWPeripheral Blood Smear:\nMicrocytes\nHypochromia\nPencil cells (elongated, thin RBCs)\nTarget cells (less common thalassemia)\nMicrocytesHypochromiaPencil cells (elongated, thin RBCs)Target cells (less common thalassemia)Reticulocyte Count:\nLow normal (inappropriately low degree anemia)\nLow normal (inappropriately low degree anemia)Iron Studies:\nSerum Iron: Decreased\nTotal Iron-Binding Capacity (TIBC): Increased\nTransferrin Saturation: Decreased\nFerritin: Decreased (specific indicator iron deficiency)\nSerum Iron: DecreasedTotal Iron-Binding Capacity (TIBC): IncreasedTransferrin Saturation: DecreasedFerritin: Decreased (specific indicator iron deficiency)Treatment:\nIdentify treat underlying cause iron loss (e.g., bleeding)\nOral iron supplementation (ferrous sulfate, ferrous gluconate)\nParenteral iron (IV iron) patients tolerate absorb oral iron\nDietary advice increase iron intake\nIdentify treat underlying cause iron loss (e.g., bleeding)Oral iron supplementation (ferrous sulfate, ferrous gluconate)Parenteral iron (IV iron) patients tolerate absorb oral ironDietary advice increase iron intake","code":""},{"path":"microcytic.html","id":"anemia-of-chronic-disease-acd","chapter":"Microcytic","heading":"Anemia of Chronic Disease (ACD)","text":"Definition: Anemia associated chronic inflammatory, infectious, malignant conditionsEtiology:\nChronic inflammatory diseases: Rheumatoid arthritis, systemic lupus erythematosus (SLE)\nChronic infections: Tuberculosis (TB), HIV\nMalignancies: Cancer, lymphoma\nChronic inflammatory diseases: Rheumatoid arthritis, systemic lupus erythematosus (SLE)Chronic infections: Tuberculosis (TB), HIVMalignancies: Cancer, lymphomaPathophysiology:\nInflammatory cytokines (e.g., IL-6) stimulate production hepcidin liver\nHepcidin inhibits iron release macrophages enterocytes binding ferroportin, leading iron trapping\nEPO production may suppressed\nInflammatory cytokines (e.g., IL-6) stimulate production hepcidin liverHepcidin inhibits iron release macrophages enterocytes binding ferroportin, leading iron trappingEPO production may suppressedClinical Manifestations:\nOften masked symptoms underlying chronic disease\nMild moderate anemia symptoms: Fatigue, weakness\nOften masked symptoms underlying chronic diseaseMild moderate anemia symptoms: Fatigue, weaknessLaboratory Findings:\nCBC:\nUsually normocytic normochromic, can microcytic cases\n\nPeripheral Blood Smear:\nUsually normocytic normochromic, may show microcytes hypochromia cases\n\nReticulocyte Count:\nLow normal (inappropriately low degree anemia)\n\nIron Studies:\nSerum Iron: Decreased\nTotal Iron-Binding Capacity (TIBC): Normal decreased\nTransferrin Saturation: Normal decreased\nFerritin: Normal increased (key differentiating factor IDA)\n\nMarkers Inflammation:\nElevated ESR CRP\n\nCBC:\nUsually normocytic normochromic, can microcytic cases\nUsually normocytic normochromic, can microcytic casesPeripheral Blood Smear:\nUsually normocytic normochromic, may show microcytes hypochromia cases\nUsually normocytic normochromic, may show microcytes hypochromia casesReticulocyte Count:\nLow normal (inappropriately low degree anemia)\nLow normal (inappropriately low degree anemia)Iron Studies:\nSerum Iron: Decreased\nTotal Iron-Binding Capacity (TIBC): Normal decreased\nTransferrin Saturation: Normal decreased\nFerritin: Normal increased (key differentiating factor IDA)\nSerum Iron: DecreasedTotal Iron-Binding Capacity (TIBC): Normal decreasedTransferrin Saturation: Normal decreasedFerritin: Normal increased (key differentiating factor IDA)Markers Inflammation:\nElevated ESR CRP\nElevated ESR CRPTreatment:\nTreat underlying chronic condition\nErythropoiesis-stimulating agents (ESAs) selected patients (e.g., CKD)\nIron supplementation (IV iron) iron deficiency present patients ESAs\nBlood transfusions severe anemia\nTreat underlying chronic conditionErythropoiesis-stimulating agents (ESAs) selected patients (e.g., CKD)Iron supplementation (IV iron) iron deficiency present patients ESAsBlood transfusions severe anemia","code":""},{"path":"microcytic.html","id":"thalassemia","chapter":"Microcytic","heading":"Thalassemia","text":"Definition: group inherited blood disorders characterized decreased absent synthesis one globin chains (alpha beta) make hemoglobinGenetic Basis: Mutations alpha- beta-globin genesPathophysiology:\nReduced globin chain synthesis leads :\nDecreased hemoglobin production, resulting microcytic, hypochromic anemia\nImbalance globin chain ratios, leading precipitation excess globin chains within RBC precursors, causing cellular damage premature destruction (ineffective erythropoiesis)\n\nReduced globin chain synthesis leads :\nDecreased hemoglobin production, resulting microcytic, hypochromic anemia\nImbalance globin chain ratios, leading precipitation excess globin chains within RBC precursors, causing cellular damage premature destruction (ineffective erythropoiesis)\nDecreased hemoglobin production, resulting microcytic, hypochromic anemiaImbalance globin chain ratios, leading precipitation excess globin chains within RBC precursors, causing cellular damage premature destruction (ineffective erythropoiesis)Classification:\nAlpha (α) Thalassemia: Decreased absent synthesis alpha-globin chains\nBeta (β) Thalassemia: Decreased absent synthesis beta-globin chains\nAlpha (α) Thalassemia: Decreased absent synthesis alpha-globin chainsBeta (β) Thalassemia: Decreased absent synthesis beta-globin chainsClinical Features: Varies widely depending specific genetic defect number affected genesLaboratory Findings:\nCBC:\nMicrocytic, hypochromic anemia\nRBC count may normal elevated relative degree anemia\n\nPeripheral Blood Smear:\nMicrocytes\nHypochromia\nTarget cells\nBasophilic stippling\nNucleated RBCs (severe cases)\n\nReticulocyte Count:\nElevated\n\nIron Studies:\nNormal elevated (iron deficient)\n\nHemoglobin Electrophoresis:\nAbnormal hemoglobin patterns (e.g., elevated HbA2 beta-thalassemia trait, presence HbH alpha-thalassemia)\n\nCBC:\nMicrocytic, hypochromic anemia\nRBC count may normal elevated relative degree anemia\nMicrocytic, hypochromic anemiaRBC count may normal elevated relative degree anemiaPeripheral Blood Smear:\nMicrocytes\nHypochromia\nTarget cells\nBasophilic stippling\nNucleated RBCs (severe cases)\nMicrocytesHypochromiaTarget cellsBasophilic stipplingNucleated RBCs (severe cases)Reticulocyte Count:\nElevated\nElevatedIron Studies:\nNormal elevated (iron deficient)\nNormal elevated (iron deficient)Hemoglobin Electrophoresis:\nAbnormal hemoglobin patterns (e.g., elevated HbA2 beta-thalassemia trait, presence HbH alpha-thalassemia)\nAbnormal hemoglobin patterns (e.g., elevated HbA2 beta-thalassemia trait, presence HbH alpha-thalassemia)Diagnosis:\nBased clinical presentation, peripheral blood smear, hemoglobin electrophoresis, genetic testing\nBased clinical presentation, peripheral blood smear, hemoglobin electrophoresis, genetic testingTreatment:\nVaries depending severity disease:\nMild thalassemia: treatment folic acid supplementation\nModerate thalassemia: Occasional blood transfusions\nSevere thalassemia (thalassemia major): Regular blood transfusions, iron chelation therapy, hematopoietic stem cell transplantation (HSCT)\n\nVaries depending severity disease:\nMild thalassemia: treatment folic acid supplementation\nModerate thalassemia: Occasional blood transfusions\nSevere thalassemia (thalassemia major): Regular blood transfusions, iron chelation therapy, hematopoietic stem cell transplantation (HSCT)\nMild thalassemia: treatment folic acid supplementationModerate thalassemia: Occasional blood transfusionsSevere thalassemia (thalassemia major): Regular blood transfusions, iron chelation therapy, hematopoietic stem cell transplantation (HSCT)","code":""},{"path":"microcytic.html","id":"sideroblastic-anemia","chapter":"Microcytic","heading":"Sideroblastic Anemia","text":"Definition: group disorders characterized ineffective erythropoiesis presence ringed sideroblasts bone marrowPathophysiology:\nImpaired ability bone marrow incorporate iron hemoglobin\nIron accumulates mitochondria erythroblasts, forming ringed sideroblasts\nImpaired ability bone marrow incorporate iron hemoglobinIron accumulates mitochondria erythroblasts, forming ringed sideroblastsClassification:\nHereditary Sideroblastic Anemias\nAcquired Sideroblastic Anemias\nReversible (e.g., alcohol-induced, drug-induced, copper deficiency)\nIrreversible (e.g., myelodysplastic syndromes)\n\nHereditary Sideroblastic AnemiasAcquired Sideroblastic Anemias\nReversible (e.g., alcohol-induced, drug-induced, copper deficiency)\nIrreversible (e.g., myelodysplastic syndromes)\nReversible (e.g., alcohol-induced, drug-induced, copper deficiency)Irreversible (e.g., myelodysplastic syndromes)Clinical Features:\nAnemia symptoms: Fatigue, weakness, pallor\nIron overload: Can lead liver damage, heart failure, endocrine dysfunction\nAnemia symptoms: Fatigue, weakness, pallorIron overload: Can lead liver damage, heart failure, endocrine dysfunctionLaboratory Findings:\nCBC:\nMCV may low, normal, high\nDimorphic red cell population (mixture normal abnormal RBCs)\n\nPeripheral Blood Smear:\nMicrocytes\nHypochromia\nPappenheimer bodies (iron-containing inclusions RBCs)\nBasophilic stippling\n\nReticulocyte Count:\nLow normal\n\nIron Studies:\nSerum Iron: Increased\nTotal Iron-Binding Capacity (TIBC): Decreased normal\nTransferrin Saturation: Increased\nFerritin: Increased\n\nBone Marrow Aspiration Biopsy:\nHypercellular marrow erythroid hyperplasia\nRinged sideroblasts (erythroblasts iron-laden mitochondria encircling nucleus)\n\nCBC:\nMCV may low, normal, high\nDimorphic red cell population (mixture normal abnormal RBCs)\nMCV may low, normal, highDimorphic red cell population (mixture normal abnormal RBCs)Peripheral Blood Smear:\nMicrocytes\nHypochromia\nPappenheimer bodies (iron-containing inclusions RBCs)\nBasophilic stippling\nMicrocytesHypochromiaPappenheimer bodies (iron-containing inclusions RBCs)Basophilic stipplingReticulocyte Count:\nLow normal\nLow normalIron Studies:\nSerum Iron: Increased\nTotal Iron-Binding Capacity (TIBC): Decreased normal\nTransferrin Saturation: Increased\nFerritin: Increased\nSerum Iron: IncreasedTotal Iron-Binding Capacity (TIBC): Decreased normalTransferrin Saturation: IncreasedFerritin: IncreasedBone Marrow Aspiration Biopsy:\nHypercellular marrow erythroid hyperplasia\nRinged sideroblasts (erythroblasts iron-laden mitochondria encircling nucleus)\nHypercellular marrow erythroid hyperplasiaRinged sideroblasts (erythroblasts iron-laden mitochondria encircling nucleus)Diagnosis:\nBased CBC, peripheral blood smear, iron studies, bone marrow examination\nBased CBC, peripheral blood smear, iron studies, bone marrow examinationTreatment:\nIdentify treat underlying cause\nPyridoxine (vitamin B6) supplementation (may effective cases)\nBlood transfusions severe anemia\nIron chelation therapy prevent iron overload\nIdentify treat underlying causePyridoxine (vitamin B6) supplementation (may effective cases)Blood transfusions severe anemiaIron chelation therapy prevent iron overload","code":""},{"path":"microcytic.html","id":"differential-diagnosis-of-microcytic-anemias","chapter":"Microcytic","heading":"Differential Diagnosis of Microcytic Anemias","text":"","code":""},{"path":"microcytic.html","id":"key-terms-4","chapter":"Microcytic","heading":"Key Terms","text":"Microcytic Anemia: Anemia characterized small RBCs (MCV < 80 fL)Iron Deficiency Anemia (IDA): Anemia caused inadequate iron storesFerritin: storage protein ironAnemia Chronic Disease (ACD): Anemia associated chronic inflammationHepcidin: Hormone regulates iron homeostasisThalassemia: Inherited blood disorder decreased globin chain synthesisSideroblastic Anemia: Anemia characterized ringed sideroblasts bone marrowRinged Sideroblasts: Erythroblasts iron-laden mitochondria","code":""},{"path":"iron-deficiency.html","id":"iron-deficiency","chapter":"Iron Deficiency","heading":"Iron Deficiency","text":"","code":""},{"path":"iron-deficiency.html","id":"overview-of-iron-deficiency-anemia-ida","chapter":"Iron Deficiency","heading":"Overview of Iron Deficiency Anemia (IDA)","text":"Definition: microcytic, hypochromic anemia characterized decreased red blood cell production due insufficient iron storesEtiology:\nInadequate iron intake\nIncreased iron loss (bleeding)\nImpaired iron absorption\nIncreased iron requirements (e.g., pregnancy)\nInadequate iron intakeIncreased iron loss (bleeding)Impaired iron absorptionIncreased iron requirements (e.g., pregnancy)Epidemiology: common cause anemia worldwide, particularly affecting women childbearing age, infants, childrenPathophysiology:\nIron essential hemoglobin synthesis\nInsufficient iron leads decreased hemoglobin production, resulting smaller paler red blood cells\nIron essential hemoglobin synthesisInsufficient iron leads decreased hemoglobin production, resulting smaller paler red blood cells","code":""},{"path":"iron-deficiency.html","id":"iron-metabolism","chapter":"Iron Deficiency","heading":"Iron Metabolism","text":"Dietary Iron:\nSources: Heme iron (animal products) non-heme iron (plant-based foods)\nAbsorption: Heme iron absorbed efficiently non-heme iron\nSources: Heme iron (animal products) non-heme iron (plant-based foods)Absorption: Heme iron absorbed efficiently non-heme ironIron Absorption:\nOccurs primarily duodenum proximal jejunum\nNon-heme iron converted ferric (Fe3+) ferrous (Fe2+) form duodenal cytochrome B reductase (DcytB)\nFerrous iron (Fe2+) transported enterocytes divalent metal transporter 1 (DMT1)\nHeme iron transported enterocytes heme carrier protein 1 (HCP1)\nOccurs primarily duodenum proximal jejunumNon-heme iron converted ferric (Fe3+) ferrous (Fe2+) form duodenal cytochrome B reductase (DcytB)Ferrous iron (Fe2+) transported enterocytes divalent metal transporter 1 (DMT1)Heme iron transported enterocytes heme carrier protein 1 (HCP1)Iron Storage:\nWithin enterocytes, iron can stored ferritin transported bloodstream ferroportin\nFerritin: primary storage form iron cells (liver, spleen, bone marrow)\nHemosiderin: insoluble storage form iron accumulates iron stores excessive\nWithin enterocytes, iron can stored ferritin transported bloodstream ferroportinFerritin: primary storage form iron cells (liver, spleen, bone marrow)Hemosiderin: insoluble storage form iron accumulates iron stores excessiveIron Transport:\nFerroportin transports iron enterocytes bloodstream\nbloodstream, iron oxidized back ferric form (Fe3+) hephaestin ceruloplasmin\nFerric iron (Fe3+) binds transferrin, iron transport protein\nFerroportin transports iron enterocytes bloodstreamIn bloodstream, iron oxidized back ferric form (Fe3+) hephaestin ceruloplasminFerric iron (Fe3+) binds transferrin, iron transport proteinIron Delivery:\nTransferrin transports iron various tissues, including bone marrow hemoglobin synthesis\nTransferrin binds transferrin receptors cell surfaces, iron internalized via receptor-mediated endocytosis\nTransferrin transports iron various tissues, including bone marrow hemoglobin synthesisTransferrin binds transferrin receptors cell surfaces, iron internalized via receptor-mediated endocytosisIron Recycling:\nSenescent red blood cells phagocytized macrophages spleen liver\nHemoglobin broken , iron released\nIron either stored ferritin transported back bone marrow transferrin new RBC production\nSenescent red blood cells phagocytized macrophages spleen liverHemoglobin broken , iron releasedIron either stored ferritin transported back bone marrow transferrin new RBC productionRegulation Iron Metabolism:\nHepcidin: hormone produced liver regulates iron homeostasis\nIncreased hepcidin levels: Inhibit iron release enterocytes macrophages binding ferroportin, leading internalization degradation. decreases iron availability circulation\nDecreased hepcidin levels: Promote iron release enterocytes macrophages, increasing iron availability circulation\n\nHepcidin production regulated :\nIron levels\nInflammation\nErythropoietic activity\n\nHepcidin: hormone produced liver regulates iron homeostasis\nIncreased hepcidin levels: Inhibit iron release enterocytes macrophages binding ferroportin, leading internalization degradation. decreases iron availability circulation\nDecreased hepcidin levels: Promote iron release enterocytes macrophages, increasing iron availability circulation\nIncreased hepcidin levels: Inhibit iron release enterocytes macrophages binding ferroportin, leading internalization degradation. decreases iron availability circulationDecreased hepcidin levels: Promote iron release enterocytes macrophages, increasing iron availability circulationHepcidin production regulated :\nIron levels\nInflammation\nErythropoietic activity\nIron levelsInflammationErythropoietic activity","code":""},{"path":"iron-deficiency.html","id":"causes-of-iron-deficiency-anemia","chapter":"Iron Deficiency","heading":"Causes of Iron Deficiency Anemia","text":"Inadequate Iron Intake:\nDietary deficiency (especially infants, children, vegetarians)\nMalnutrition\nDietary deficiency (especially infants, children, vegetarians)MalnutritionIncreased Iron Loss (Bleeding):\nChronic blood loss (e.g., menorrhagia, gastrointestinal bleeding)\nAcute blood loss (e.g., trauma, surgery)\nFrequent blood donations\nChronic blood loss (e.g., menorrhagia, gastrointestinal bleeding)Acute blood loss (e.g., trauma, surgery)Frequent blood donationsImpaired Iron Absorption:\nGastrectomy bariatric surgery\nCeliac disease\nInflammatory bowel disease\nUse certain medications (e.g., proton pump inhibitors, antacids)\nGastrectomy bariatric surgeryCeliac diseaseInflammatory bowel diseaseUse certain medications (e.g., proton pump inhibitors, antacids)Increased Iron Requirements:\nPregnancy\nInfancy childhood (periods rapid growth)\nErythropoietin-stimulating agent (ESA) therapy\nPregnancyInfancy childhood (periods rapid growth)Erythropoietin-stimulating agent (ESA) therapy","code":""},{"path":"iron-deficiency.html","id":"clinical-manifestations-of-iron-deficiency-anemia","chapter":"Iron Deficiency","heading":"Clinical Manifestations of Iron Deficiency Anemia","text":"General Anemia Symptoms:\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nDizziness\nHeadache\nTachycardia\nFatigueWeaknessPallor (pale skin)Shortness breathDizzinessHeadacheTachycardiaSpecific IDA Symptoms:\nPica (unusual cravings non-food substances ice, dirt, clay)\nKoilonychia (spoon-shaped nails)\nAngular cheilitis (inflammation cracking corners mouth)\nGlossitis (inflammation tongue)\nPlummer-Vinson syndrome (rare): Dysphagia (difficulty swallowing), iron deficiency anemia, esophageal webs\nPica (unusual cravings non-food substances ice, dirt, clay)Koilonychia (spoon-shaped nails)Angular cheilitis (inflammation cracking corners mouth)Glossitis (inflammation tongue)Plummer-Vinson syndrome (rare): Dysphagia (difficulty swallowing), iron deficiency anemia, esophageal webs","code":""},{"path":"iron-deficiency.html","id":"laboratory-findings-in-iron-deficiency-anemia","chapter":"Iron Deficiency","heading":"Laboratory Findings in Iron Deficiency Anemia","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased\nHematocrit (HCT): Decreased\nRed Blood Cell Count (RBC): Decreased normal\nMean Corpuscular Volume (MCV): Decreased (microcytic)\nMean Corpuscular Hemoglobin (MCH): Decreased (hypochromic)\nMean Corpuscular Hemoglobin Concentration (MCHC): Decreased (hypochromic)\nRed Cell Distribution Width (RDW): Increased (anisocytosis - variation RBC size)\nPlatelet Count: May normal slightly elevated\nHemoglobin (HGB): DecreasedHematocrit (HCT): DecreasedRed Blood Cell Count (RBC): Decreased normalMean Corpuscular Volume (MCV): Decreased (microcytic)Mean Corpuscular Hemoglobin (MCH): Decreased (hypochromic)Mean Corpuscular Hemoglobin Concentration (MCHC): Decreased (hypochromic)Red Cell Distribution Width (RDW): Increased (anisocytosis - variation RBC size)Platelet Count: May normal slightly elevatedPeripheral Blood Smear:\nMicrocytes (small RBCs)\nHypochromia (pale RBCs)\nAnisocytosis (variation RBC size)\nPoikilocytosis (variation RBC shape)\nPencil cells (elongated, thin RBCs)\nTarget cells\n\nMicrocytes (small RBCs)Hypochromia (pale RBCs)Anisocytosis (variation RBC size)Poikilocytosis (variation RBC shape)\nPencil cells (elongated, thin RBCs)\nTarget cells\nPencil cells (elongated, thin RBCs)Target cellsReticulocyte Count:\nLow normal (inappropriately low degree anemia)\nLow normal (inappropriately low degree anemia)Iron Studies:\nSerum Iron: Decreased\nTotal Iron-Binding Capacity (TIBC): Increased\nTransferrin Saturation: Decreased\nFerritin: Decreased (specific indicator iron deficiency)\nSerum Iron: DecreasedTotal Iron-Binding Capacity (TIBC): IncreasedTransferrin Saturation: DecreasedFerritin: Decreased (specific indicator iron deficiency)Tests:\nStool occult blood test: detect gastrointestinal bleeding\nEndoscopy colonoscopy: investigate gastrointestinal bleeding\nStool occult blood test: detect gastrointestinal bleedingEndoscopy colonoscopy: investigate gastrointestinal bleeding","code":""},{"path":"iron-deficiency.html","id":"differential-diagnosis","chapter":"Iron Deficiency","heading":"Differential Diagnosis","text":"Thalassemia: Microcytic anemia normal elevated iron studiesAnemia Chronic Disease: Often normocytic microcytic, low serum iron, normal low TIBC, normal high ferritinSideroblastic Anemia: Microcytic anemia elevated serum iron ferritin ringed sideroblasts bone marrow","code":""},{"path":"iron-deficiency.html","id":"treatment-of-iron-deficiency-anemia","chapter":"Iron Deficiency","heading":"Treatment of Iron Deficiency Anemia","text":"Identify Treat Underlying Cause:\nAddress sources bleeding (e.g., treat ulcers, manage menorrhagia)\nTreat underlying conditions affecting iron absorption (e.g., celiac disease)\nAddress sources bleeding (e.g., treat ulcers, manage menorrhagia)Treat underlying conditions affecting iron absorption (e.g., celiac disease)Iron Supplementation:\nOral Iron:\nFerrous sulfate, ferrous gluconate, ferrous fumarate\nTake empty stomach (tolerated) maximize absorption\nVitamin C can enhance iron absorption\nAvoid taking calcium, antacids, tea, can inhibit absorption\nCommon side effects: Nausea, constipation, abdominal discomfort, dark stools\n\nParenteral Iron (Intravenous Intramuscular):\nUsed patients tolerate oral iron, severe malabsorption, require rapid iron repletion\nIron dextran, iron sucrose, ferric gluconate, ferumoxytol\nPotential side effects: Allergic reactions, anaphylaxis (rare), injection site reactions\n\nOral Iron:\nFerrous sulfate, ferrous gluconate, ferrous fumarate\nTake empty stomach (tolerated) maximize absorption\nVitamin C can enhance iron absorption\nAvoid taking calcium, antacids, tea, can inhibit absorption\nCommon side effects: Nausea, constipation, abdominal discomfort, dark stools\nFerrous sulfate, ferrous gluconate, ferrous fumarateTake empty stomach (tolerated) maximize absorptionVitamin C can enhance iron absorptionAvoid taking calcium, antacids, tea, can inhibit absorptionCommon side effects: Nausea, constipation, abdominal discomfort, dark stoolsParenteral Iron (Intravenous Intramuscular):\nUsed patients tolerate oral iron, severe malabsorption, require rapid iron repletion\nIron dextran, iron sucrose, ferric gluconate, ferumoxytol\nPotential side effects: Allergic reactions, anaphylaxis (rare), injection site reactions\nUsed patients tolerate oral iron, severe malabsorption, require rapid iron repletionIron dextran, iron sucrose, ferric gluconate, ferumoxytolPotential side effects: Allergic reactions, anaphylaxis (rare), injection site reactionsDietary Modifications:\nIncrease intake iron-rich foods (e.g., red meat, poultry, fish, legumes, dark leafy greens)\nConsume foods rich vitamin C enhance iron absorption\nIncrease intake iron-rich foods (e.g., red meat, poultry, fish, legumes, dark leafy greens)Consume foods rich vitamin C enhance iron absorptionMonitoring Response Treatment:\nReticulocyte count: increase within 1-2 weeks starting iron supplementation\nHemoglobin: increase least 1 g/dL every 2-3 weeks\nContinue iron supplementation several months replenish iron stores (indicated normalization ferritin levels)\nReticulocyte count: increase within 1-2 weeks starting iron supplementationHemoglobin: increase least 1 g/dL every 2-3 weeksContinue iron supplementation several months replenish iron stores (indicated normalization ferritin levels)","code":""},{"path":"iron-deficiency.html","id":"key-terms-5","chapter":"Iron Deficiency","heading":"Key Terms","text":"Iron Deficiency Anemia (IDA): Microcytic, hypochromic anemia due insufficient iron storesFerritin: Primary storage form iron cellsTransferrin: Iron transport protein bloodTIBC (Total Iron-Binding Capacity): Measures blood’s capacity bind ironHepcidin: Hormone regulates iron homeostasisMicrocytic: Small red blood cells (MCV < 80 fL)Hypochromic: Decreased hemoglobin content (pale color)Pica: Unusual cravings non-food substancesKoilonychia: Spoon-shaped nails","code":""},{"path":"chronic-disease.html","id":"chronic-disease","chapter":"Chronic Disease","heading":"Chronic Disease","text":"","code":""},{"path":"chronic-disease.html","id":"overview-of-anemia-of-chronic-disease-acd","chapter":"Chronic Disease","heading":"Overview of Anemia of Chronic Disease (ACD)","text":"Definition: Anemia associated chronic inflammatory, infectious, malignant conditionsAlternative Name: Anemia InflammationCharacteristics:\nTypically normocytic normochromic, can microcytic cases\nCharacterized impaired iron utilization decreased red blood cell production\nTypically normocytic normochromic, can microcytic casesCharacterized impaired iron utilization decreased red blood cell productionPrevalence: Second common cause anemia worldwide, iron deficiency anemiaEtiology Associated ConditionsChronic Inflammatory Conditions:\nRheumatoid arthritis\nSystemic lupus erythematosus (SLE)\nInflammatory bowel disease (IBD): Crohn’s disease ulcerative colitis\nChronic infections: Tuberculosis (TB), HIV, osteomyelitis\nRheumatoid arthritisSystemic lupus erythematosus (SLE)Inflammatory bowel disease (IBD): Crohn’s disease ulcerative colitisChronic infections: Tuberculosis (TB), HIV, osteomyelitisMalignancies:\nCancer\nLymphoma\nMultiple myeloma\nCancerLymphomaMultiple myelomaChronic Kidney Disease (CKD):\nDecreased erythropoietin (EPO) production\nAccumulation uremic toxins\nDecreased erythropoietin (EPO) productionAccumulation uremic toxinsChronic Heart Failure:\nReduced renal perfusion EPO production\nInflammatory cytokines\nReduced renal perfusion EPO productionInflammatory cytokines","code":""},{"path":"chronic-disease.html","id":"pathophysiology","chapter":"Chronic Disease","heading":"Pathophysiology","text":"Iron Dysregulation:\nHepcidin: key hormone iron regulation, produced liver\nACD, chronic inflammation leads increased hepcidin production\nHepcidin binds ferroportin, iron export protein found enterocytes, macrophages, hepatocytes\nBinding hepcidin ferroportin causes ferroportin internalization degradation, :\nInhibits iron absorption gut\nBlocks release iron macrophages (iron recycled senescent RBCs)\nTraps iron hepatocytes\n\nResult: Decreased iron availability erythropoiesis, despite adequate iron stores\n\nIron-Restricted Erythropoiesis:\nLimited iron availability impairs hemoglobin synthesis, leading decreased RBC production\nErythroid progenitors bone marrow unable acquire sufficient iron hemoglobin production\n\nHepcidin: key hormone iron regulation, produced liver\nACD, chronic inflammation leads increased hepcidin production\nHepcidin binds ferroportin, iron export protein found enterocytes, macrophages, hepatocytes\nBinding hepcidin ferroportin causes ferroportin internalization degradation, :\nInhibits iron absorption gut\nBlocks release iron macrophages (iron recycled senescent RBCs)\nTraps iron hepatocytes\n\nResult: Decreased iron availability erythropoiesis, despite adequate iron stores\nACD, chronic inflammation leads increased hepcidin productionHepcidin binds ferroportin, iron export protein found enterocytes, macrophages, hepatocytesBinding hepcidin ferroportin causes ferroportin internalization degradation, :\nInhibits iron absorption gut\nBlocks release iron macrophages (iron recycled senescent RBCs)\nTraps iron hepatocytes\nInhibits iron absorption gutBlocks release iron macrophages (iron recycled senescent RBCs)Traps iron hepatocytesResult: Decreased iron availability erythropoiesis, despite adequate iron storesIron-Restricted Erythropoiesis:\nLimited iron availability impairs hemoglobin synthesis, leading decreased RBC production\nErythroid progenitors bone marrow unable acquire sufficient iron hemoglobin production\nLimited iron availability impairs hemoglobin synthesis, leading decreased RBC productionErythroid progenitors bone marrow unable acquire sufficient iron hemoglobin productionDecreased Erythropoietin (EPO) Production Response:\nSuppressed EPO Production:\nInflammatory cytokines (e.g., IL-1, TNF-α) can suppress EPO production kidneys\n\nImpaired EPO Response:\nInflammatory cytokines can also blunt response erythroid progenitors EPO\nMechanisms may involve interference EPO receptor signaling\n\nSuppressed EPO Production:\nInflammatory cytokines (e.g., IL-1, TNF-α) can suppress EPO production kidneys\nInflammatory cytokines (e.g., IL-1, TNF-α) can suppress EPO production kidneysImpaired EPO Response:\nInflammatory cytokines can also blunt response erythroid progenitors EPO\nMechanisms may involve interference EPO receptor signaling\nInflammatory cytokines can also blunt response erythroid progenitors EPOMechanisms may involve interference EPO receptor signalingShortened Red Blood Cell Survival:\nInflammatory cytokines can increase red blood cell destruction, leading slightly shortened RBC lifespan\nInflammatory cytokines can increase red blood cell destruction, leading slightly shortened RBC lifespan","code":""},{"path":"chronic-disease.html","id":"clinical-manifestations","chapter":"Chronic Disease","heading":"Clinical Manifestations","text":"Symptoms Anemia:\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nDizziness\nFatigueWeaknessPallor (pale skin)Shortness breathDizzinessSymptoms Underlying Condition:\nclinical presentation often dominated symptoms underlying chronic disease (e.g., joint pain rheumatoid arthritis, diarrhea abdominal pain IBD)\nclinical presentation often dominated symptoms underlying chronic disease (e.g., joint pain rheumatoid arthritis, diarrhea abdominal pain IBD)","code":""},{"path":"chronic-disease.html","id":"diagnostic-evaluation","chapter":"Chronic Disease","heading":"Diagnostic Evaluation","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (typically mild moderate anemia)\nHematocrit (HCT): Decreased\nMean Corpuscular Volume (MCV): Usually normal (normocytic) can low (microcytic) cases, especially long-standing ACD coexisting iron deficiency\nMean Corpuscular Hemoglobin Concentration (MCHC): Usually normal (normochromic)\nRed Cell Distribution Width (RDW): Usually normal\nReticulocyte Count: Low normal (inappropriately low degree anemia)\nHemoglobin (HGB): Decreased (typically mild moderate anemia)Hematocrit (HCT): DecreasedMean Corpuscular Volume (MCV): Usually normal (normocytic) can low (microcytic) cases, especially long-standing ACD coexisting iron deficiencyMean Corpuscular Hemoglobin Concentration (MCHC): Usually normal (normochromic)Red Cell Distribution Width (RDW): Usually normalReticulocyte Count: Low normal (inappropriately low degree anemia)Peripheral Blood Smear:\nUsually normocytic normochromic\nMay show mild anisocytosis (variation RBC size) poikilocytosis (variation RBC shape)\nUsually normocytic normochromicMay show mild anisocytosis (variation RBC size) poikilocytosis (variation RBC shape)Iron Studies:\nSerum Iron: Low\nTotal Iron-Binding Capacity (TIBC): Normal low\nTransferrin Saturation: Normal low\nFerritin: Normal elevated (helps distinguish ACD iron deficiency anemia)\nSerum Iron: LowTotal Iron-Binding Capacity (TIBC): Normal lowTransferrin Saturation: Normal lowFerritin: Normal elevated (helps distinguish ACD iron deficiency anemia)Markers Inflammation:\nErythrocyte Sedimentation Rate (ESR): Elevated\nC-Reactive Protein (CRP): Elevated\ninflammatory markers: IL-6, TNF-α\nErythrocyte Sedimentation Rate (ESR): ElevatedC-Reactive Protein (CRP): ElevatedOther inflammatory markers: IL-6, TNF-αOther Tests:\nSerum erythropoietin (EPO) level: May low inappropriately normal degree anemia\nTests evaluate underlying chronic conditions:\nRheumatoid factor, anti-CCP antibodies (rheumatoid arthritis)\nAntinuclear antibody (ANA) (SLE)\nStool studies, colonoscopy (IBD)\nChest X-ray, sputum culture (TB)\n\nBone Marrow Aspiration Biopsy:\nMay performed rule causes anemia evaluate MDS\n\nSerum erythropoietin (EPO) level: May low inappropriately normal degree anemiaTests evaluate underlying chronic conditions:\nRheumatoid factor, anti-CCP antibodies (rheumatoid arthritis)\nAntinuclear antibody (ANA) (SLE)\nStool studies, colonoscopy (IBD)\nChest X-ray, sputum culture (TB)\nRheumatoid factor, anti-CCP antibodies (rheumatoid arthritis)Antinuclear antibody (ANA) (SLE)Stool studies, colonoscopy (IBD)Chest X-ray, sputum culture (TB)Bone Marrow Aspiration Biopsy:\nMay performed rule causes anemia evaluate MDS\nMay performed rule causes anemia evaluate MDS","code":""},{"path":"chronic-disease.html","id":"differential-diagnosis-1","chapter":"Chronic Disease","heading":"Differential Diagnosis","text":"Iron Deficiency Anemia (IDA):\nMicrocytic, hypochromic anemia low serum iron, high TIBC, low transferrin saturation, low ferritin\nMicrocytic, hypochromic anemia low serum iron, high TIBC, low transferrin saturation, low ferritinThalassemia:\nMicrocytic anemia normal elevated iron studies abnormal hemoglobin electrophoresis\nMicrocytic anemia normal elevated iron studies abnormal hemoglobin electrophoresisSideroblastic Anemia:\nMicrocytic normocytic anemia elevated serum iron ferritin, ringed sideroblasts bone marrow\nMicrocytic normocytic anemia elevated serum iron ferritin, ringed sideroblasts bone marrowAnemia Chronic Kidney Disease:\nNormocytic anemia low EPO level evidence kidney dysfunction\nNormocytic anemia low EPO level evidence kidney dysfunctionAplastic Anemia:\nPancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow\nPancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow","code":""},{"path":"chronic-disease.html","id":"treatment-and-management","chapter":"Chronic Disease","heading":"Treatment and Management","text":"Treat Underlying Condition:\nprimary goal treat underlying inflammatory, infectious, malignant disease\nEffective treatment underlying condition may improve anemia\nprimary goal treat underlying inflammatory, infectious, malignant diseaseEffective treatment underlying condition may improve anemiaErythropoiesis-Stimulating Agents (ESAs):\nEpoetin alfa darbepoetin alfa\nMay used stimulate red blood cell production, especially patients CKD cancer-related anemia\nUse ESAs cautiously due potential side effects:\nIncreased risk thromboembolic events (blood clots)\nIncreased mortality cancer patients\nESAs typically used hemoglobin levels 10 g/dL causes anemia ruled \n\nIron supplementation often necessary ensure adequate response ESAs\nEpoetin alfa darbepoetin alfaMay used stimulate red blood cell production, especially patients CKD cancer-related anemiaUse ESAs cautiously due potential side effects:\nIncreased risk thromboembolic events (blood clots)\nIncreased mortality cancer patients\nESAs typically used hemoglobin levels 10 g/dL causes anemia ruled \nIncreased risk thromboembolic events (blood clots)Increased mortality cancer patientsESAs typically used hemoglobin levels 10 g/dL causes anemia ruled outIron supplementation often necessary ensure adequate response ESAsIron Supplementation:\nOral iron supplementation generally effective ACD due hepcidin-mediated iron restriction\nIntravenous (IV) iron may considered selected patients iron-deficient receiving ESAs\nMonitor iron studies avoid iron overload\nOral iron supplementation generally effective ACD due hepcidin-mediated iron restrictionIntravenous (IV) iron may considered selected patients iron-deficient receiving ESAsMonitor iron studies avoid iron overloadBlood Transfusions:\nReserved patients severe anemia significant symptoms\nGoal alleviate symptoms improve oxygen delivery tissues\nReserved patients severe anemia significant symptomsGoal alleviate symptoms improve oxygen delivery tissuesNovel Therapies:\nHepcidin antagonists:\nInhibit hepcidin activity, promoting iron release improving erythropoiesis\n\nInhibition inflammatory cytokines:\nTargeting IL-6 TNF-α reduce inflammation improve iron utilization\n\nHepcidin antagonists:\nInhibit hepcidin activity, promoting iron release improving erythropoiesis\nInhibit hepcidin activity, promoting iron release improving erythropoiesisInhibition inflammatory cytokines:\nTargeting IL-6 TNF-α reduce inflammation improve iron utilization\nTargeting IL-6 TNF-α reduce inflammation improve iron utilization","code":""},{"path":"chronic-disease.html","id":"key-laboratory-findings","chapter":"Chronic Disease","heading":"Key Laboratory Findings","text":"Complete Blood Count (CBC):\nMild moderate anemia (low HGB HCT)\nUsually normocytic normochromic (normal MCV MCHC)\nLow normal reticulocyte count\nMild moderate anemia (low HGB HCT)Usually normocytic normochromic (normal MCV MCHC)Low normal reticulocyte countPeripheral Blood Smear:\nUsually normal, may show mild anisocytosis poikilocytosis\nUsually normal, may show mild anisocytosis poikilocytosisIron Studies:\nLow serum iron\nNormal low TIBC\nNormal low transferrin saturation\nNormal elevated ferritin (key differentiating factor iron deficiency anemia)\nLow serum ironNormal low TIBCNormal low transferrin saturationNormal elevated ferritin (key differentiating factor iron deficiency anemia)Markers Inflammation:\nElevated ESR CRP\nElevated ESR CRPErythropoietin (EPO) Level:\nMay low inappropriately normal degree anemia\nMay low inappropriately normal degree anemia","code":""},{"path":"chronic-disease.html","id":"key-terms-6","chapter":"Chronic Disease","heading":"Key Terms","text":"Anemia Chronic Disease (ACD): Anemia associated chronic inflammatory, infectious, malignant conditionsHepcidin: Hormone regulates iron homeostasisFerritin: Iron storage proteinTIBC (Total Iron-Binding Capacity): Measures blood’s capacity bind ironTransferrin Saturation: Percentage transferrin bound ironErythropoietin (EPO): Hormone stimulates red blood cell productionErythropoiesis-Stimulating Agents (ESAs): Medications used stimulate red blood cell productionIron-Restricted Erythropoiesis: Impaired red blood cell production due limited iron availability","code":""},{"path":"thalassemias.html","id":"thalassemias","chapter":"Thalassemias","heading":"Thalassemias","text":"","code":""},{"path":"thalassemias.html","id":"overview-of-thalassemias","chapter":"Thalassemias","heading":"Overview of Thalassemias","text":"Definition: group inherited (genetic) blood disorders characterized decreased absent synthesis one globin chains (alpha beta) make hemoglobinPathophysiology:\nReduced globin chain synthesis leads :\nDecreased hemoglobin production, resulting microcytic, hypochromic anemia\nImbalance globin chain ratios, leading precipitation excess globin chains within red blood cell precursors, causing cellular damage premature destruction (ineffective erythropoiesis)\n\nReduced globin chain synthesis leads :\nDecreased hemoglobin production, resulting microcytic, hypochromic anemia\nImbalance globin chain ratios, leading precipitation excess globin chains within red blood cell precursors, causing cellular damage premature destruction (ineffective erythropoiesis)\nDecreased hemoglobin production, resulting microcytic, hypochromic anemiaImbalance globin chain ratios, leading precipitation excess globin chains within red blood cell precursors, causing cellular damage premature destruction (ineffective erythropoiesis)Classification: Based affected globin chain:\nAlpha (α) Thalassemia: Decreased absent synthesis alpha-globin chains\nBeta (β) Thalassemia: Decreased absent synthesis beta-globin chains\nAlpha (α) Thalassemia: Decreased absent synthesis alpha-globin chainsBeta (β) Thalassemia: Decreased absent synthesis beta-globin chainsSeverity: Varies widely depending specific genetic defect number affected genes","code":""},{"path":"thalassemias.html","id":"genetics-and-molecular-basis","chapter":"Thalassemias","heading":"Genetics and Molecular Basis","text":"Globin Genes:\nAlpha-globin genes: Located chromosome 16 (two α-globin genes: αα/αα)\nBeta-globin gene: Located chromosome 11 (one β-globin gene: β/β)\nAlpha-globin genes: Located chromosome 16 (two α-globin genes: αα/αα)Beta-globin gene: Located chromosome 11 (one β-globin gene: β/β)Inheritance:\nAutosomal recessive: parents must carry affected gene child inherit disease\nCarriers: Individuals one affected gene usually asymptomatic (thalassemia trait minor)\nAutosomal recessive: parents must carry affected gene child inherit diseaseCarriers: Individuals one affected gene usually asymptomatic (thalassemia trait minor)Mutations:\nAlpha-thalassemia: Usually caused gene deletions\nBeta-thalassemia: Usually caused point mutations small insertions/deletions\nAlpha-thalassemia: Usually caused gene deletionsBeta-thalassemia: Usually caused point mutations small insertions/deletionsNomenclature:\nNormal: αα/αα (alpha), β/β (beta)\nTrait/Minor: α-/αα - -/αα (alpha), β/βo β/β+ (beta)\nMajor/Disease: α-/–, –/– (alpha), βo/βo, β+/βo, β+/β+ (beta)\nHemoglobin H disease: –/αα (alpha). Excess beta chains form HbH tetramers\nHydrops fetalis: –/– (alpha). alpha chains produced, incompatible life\nβo: beta-globin chain production\nβ+: Reduced beta-globin chain production\nNormal: αα/αα (alpha), β/β (beta)Trait/Minor: α-/αα - -/αα (alpha), β/βo β/β+ (beta)Major/Disease: α-/–, –/– (alpha), βo/βo, β+/βo, β+/β+ (beta)Hemoglobin H disease: –/αα (alpha). Excess beta chains form HbH tetramersHydrops fetalis: –/– (alpha). alpha chains produced, incompatible lifeβo: beta-globin chain productionβ+: Reduced beta-globin chain production","code":""},{"path":"thalassemias.html","id":"alpha-α-thalassemia","chapter":"Thalassemias","heading":"Alpha (α) Thalassemia","text":"Genetic Basis: Decreased absent synthesis alpha-globin chainsSeverity: Depends number affected alpha-globin genesClinical Syndromes:\nSilent Carrier (αα/α-):\nOne alpha-globin gene deleted mutated\nUsually asymptomatic\nCan diagnosed genetic testing\n\nAlpha-Thalassemia Trait (α- /α- αα/–):\nTwo alpha-globin genes deleted mutated\nMild microcytic, hypochromic anemia\nMay slightly decreased MCV MCH\nDiagnosis often made exclusion causes microcytic anemia\n\nHemoglobin H Disease (–/αα):\nThree alpha-globin genes deleted mutated\nModerate severe microcytic, hypochromic anemia\nPeripheral blood smear: Microcytes, hypochromia, target cells, HbH inclusions (use brilliant cresyl blue stain)\nHbH inclusions: Precipitated excess beta-globin chains\n\nHydrops Fetalis (–/–):\nfour alpha-globin genes deleted mutated\nalpha-globin chain production\nIncompatible life\nResults severe anemia, edema, heart failure fetus\n\nSilent Carrier (αα/α-):\nOne alpha-globin gene deleted mutated\nUsually asymptomatic\nCan diagnosed genetic testing\nOne alpha-globin gene deleted mutatedUsually asymptomaticCan diagnosed genetic testingAlpha-Thalassemia Trait (α- /α- αα/–):\nTwo alpha-globin genes deleted mutated\nMild microcytic, hypochromic anemia\nMay slightly decreased MCV MCH\nDiagnosis often made exclusion causes microcytic anemia\nTwo alpha-globin genes deleted mutatedMild microcytic, hypochromic anemiaMay slightly decreased MCV MCHDiagnosis often made exclusion causes microcytic anemiaHemoglobin H Disease (–/αα):\nThree alpha-globin genes deleted mutated\nModerate severe microcytic, hypochromic anemia\nPeripheral blood smear: Microcytes, hypochromia, target cells, HbH inclusions (use brilliant cresyl blue stain)\nHbH inclusions: Precipitated excess beta-globin chains\nThree alpha-globin genes deleted mutatedModerate severe microcytic, hypochromic anemiaPeripheral blood smear: Microcytes, hypochromia, target cells, HbH inclusions (use brilliant cresyl blue stain)HbH inclusions: Precipitated excess beta-globin chainsHydrops Fetalis (–/–):\nfour alpha-globin genes deleted mutated\nalpha-globin chain production\nIncompatible life\nResults severe anemia, edema, heart failure fetus\nfour alpha-globin genes deleted mutatedNo alpha-globin chain productionIncompatible lifeResults severe anemia, edema, heart failure fetusLaboratory Findings:\nCBC: Decreased HGB, HCT, MCV\nPeripheral Blood Smear: Microcytes, hypochromia, target cells, poikilocytosis\nHemoglobin Electrophoresis:\nSilent carrier: Usually normal\nAlpha-thalassemia trait: Usually normal\nHbH disease: Presence HbH (fast-migrating band)\nHydrops fetalis: Predominantly Hb Bart’s (gamma tetramers) fetal blood\n\nIron Studies: Normal elevated (iron deficient)\nGenetic Testing: Confirms diagnosis detecting alpha-globin gene deletions mutations\nCBC: Decreased HGB, HCT, MCVPeripheral Blood Smear: Microcytes, hypochromia, target cells, poikilocytosisHemoglobin Electrophoresis:\nSilent carrier: Usually normal\nAlpha-thalassemia trait: Usually normal\nHbH disease: Presence HbH (fast-migrating band)\nHydrops fetalis: Predominantly Hb Bart’s (gamma tetramers) fetal blood\nSilent carrier: Usually normalAlpha-thalassemia trait: Usually normalHbH disease: Presence HbH (fast-migrating band)Hydrops fetalis: Predominantly Hb Bart’s (gamma tetramers) fetal bloodIron Studies: Normal elevated (iron deficient)Genetic Testing: Confirms diagnosis detecting alpha-globin gene deletions mutations","code":""},{"path":"thalassemias.html","id":"beta-β-thalassemia","chapter":"Thalassemias","heading":"Beta (β) Thalassemia","text":"Genetic Basis: Decreased absent synthesis beta-globin chainsSeverity: Depends type beta-globin gene mutationClinical Syndromes:\nBeta-Thalassemia Minor (β/βo β/β+):\nHeterozygous beta-globin gene mutation\nMild microcytic, hypochromic anemia\nOften asymptomatic mildly symptomatic\nPeripheral blood smear: Microcytes, hypochromia, target cells\nHemoglobin electrophoresis: Elevated HbA2 (3.5-7%) slightly elevated HbF\n\nBeta-Thalassemia Intermedia:\nVariable severity depending specific mutations\nModerate microcytic, hypochromic anemia\nMay require occasional blood transfusions\nPeripheral blood smear: Microcytes, hypochromia, target cells, nucleated RBCs\nHemoglobin electrophoresis: Variable increase HbF HbA2\n\nBeta-Thalassemia Major (Cooley’s Anemia) (βo/βo, β+/βo, β+/β+):\nHomozygous compound heterozygous severe beta-globin gene mutations\nSevere microcytic, hypochromic anemia\nRequires regular blood transfusions survive\nIneffective erythropoiesis leads bone marrow expansion, skeletal deformities, hepatosplenomegaly, iron overload\nPeripheral blood smear: Severe microcytes, hypochromia, target cells, nucleated RBCs, poikilocytosis\nHemoglobin electrophoresis: Little HbA, marked increase HbF, elevated HbA2\n\nBeta-Thalassemia Minor (β/βo β/β+):\nHeterozygous beta-globin gene mutation\nMild microcytic, hypochromic anemia\nOften asymptomatic mildly symptomatic\nPeripheral blood smear: Microcytes, hypochromia, target cells\nHemoglobin electrophoresis: Elevated HbA2 (3.5-7%) slightly elevated HbF\nHeterozygous beta-globin gene mutationMild microcytic, hypochromic anemiaOften asymptomatic mildly symptomaticPeripheral blood smear: Microcytes, hypochromia, target cellsHemoglobin electrophoresis: Elevated HbA2 (3.5-7%) slightly elevated HbFBeta-Thalassemia Intermedia:\nVariable severity depending specific mutations\nModerate microcytic, hypochromic anemia\nMay require occasional blood transfusions\nPeripheral blood smear: Microcytes, hypochromia, target cells, nucleated RBCs\nHemoglobin electrophoresis: Variable increase HbF HbA2\nVariable severity depending specific mutationsModerate microcytic, hypochromic anemiaMay require occasional blood transfusionsPeripheral blood smear: Microcytes, hypochromia, target cells, nucleated RBCsHemoglobin electrophoresis: Variable increase HbF HbA2Beta-Thalassemia Major (Cooley’s Anemia) (βo/βo, β+/βo, β+/β+):\nHomozygous compound heterozygous severe beta-globin gene mutations\nSevere microcytic, hypochromic anemia\nRequires regular blood transfusions survive\nIneffective erythropoiesis leads bone marrow expansion, skeletal deformities, hepatosplenomegaly, iron overload\nPeripheral blood smear: Severe microcytes, hypochromia, target cells, nucleated RBCs, poikilocytosis\nHemoglobin electrophoresis: Little HbA, marked increase HbF, elevated HbA2\nHomozygous compound heterozygous severe beta-globin gene mutationsSevere microcytic, hypochromic anemiaRequires regular blood transfusions surviveIneffective erythropoiesis leads bone marrow expansion, skeletal deformities, hepatosplenomegaly, iron overloadPeripheral blood smear: Severe microcytes, hypochromia, target cells, nucleated RBCs, poikilocytosisHemoglobin electrophoresis: Little HbA, marked increase HbF, elevated HbA2Laboratory Findings:\nCBC: Decreased HGB, HCT, MCV\nPeripheral Blood Smear: Microcytes, hypochromia, target cells, basophilic stippling, nucleated RBCs (especially thalassemia major)\nReticulocyte Count: Elevated (due increased erythropoiesis)\nIron Studies: Normal elevated (iron deficient)\nHemoglobin Electrophoresis:\nBeta-thalassemia minor: Elevated HbA2 (3.5-7%) slightly elevated HbF\nBeta-thalassemia intermedia: Variable increase HbF HbA2\nBeta-thalassemia major: Little HbA, marked increase HbF, elevated HbA2\n\nGenetic Testing: Confirms diagnosis detecting beta-globin gene mutations\nCBC: Decreased HGB, HCT, MCVPeripheral Blood Smear: Microcytes, hypochromia, target cells, basophilic stippling, nucleated RBCs (especially thalassemia major)Reticulocyte Count: Elevated (due increased erythropoiesis)Iron Studies: Normal elevated (iron deficient)Hemoglobin Electrophoresis:\nBeta-thalassemia minor: Elevated HbA2 (3.5-7%) slightly elevated HbF\nBeta-thalassemia intermedia: Variable increase HbF HbA2\nBeta-thalassemia major: Little HbA, marked increase HbF, elevated HbA2\nBeta-thalassemia minor: Elevated HbA2 (3.5-7%) slightly elevated HbFBeta-thalassemia intermedia: Variable increase HbF HbA2Beta-thalassemia major: Little HbA, marked increase HbF, elevated HbA2Genetic Testing: Confirms diagnosis detecting beta-globin gene mutations","code":""},{"path":"thalassemias.html","id":"clinical-management-of-thalassemia","chapter":"Thalassemias","heading":"Clinical Management of Thalassemia","text":"Beta-Thalassemia Minor:\nUsually requires specific treatment\nGenetic counseling family planning\nAvoid unnecessary iron supplementation\nUsually requires specific treatmentGenetic counseling family planningAvoid unnecessary iron supplementationBeta-Thalassemia Intermedia:\nMay require occasional blood transfusions manage anemia\nFolic acid supplementation\nMonitoring complications iron overload splenomegaly\nMay require occasional blood transfusions manage anemiaFolic acid supplementationMonitoring complications iron overload splenomegalyBeta-Thalassemia Major:\nRegular Blood Transfusions:\nMaintain hemoglobin levels 9-10 g/dL\n\nIron Chelation Therapy:\nprevent iron overload chronic transfusions\nDeferoxamine (intravenous subcutaneous)\nDeferasirox Deferiprone (oral)\n\nFolic Acid Supplementation\nSplenectomy:\nMay considered reduce transfusion requirements\nIncreases risk infection encapsulated organisms (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination organisms\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially children\nRequires matched donor\n\nRegular Blood Transfusions:\nMaintain hemoglobin levels 9-10 g/dL\nMaintain hemoglobin levels 9-10 g/dLIron Chelation Therapy:\nprevent iron overload chronic transfusions\nDeferoxamine (intravenous subcutaneous)\nDeferasirox Deferiprone (oral)\nprevent iron overload chronic transfusionsDeferoxamine (intravenous subcutaneous)Deferasirox Deferiprone (oral)Folic Acid SupplementationSplenectomy:\nMay considered reduce transfusion requirements\nIncreases risk infection encapsulated organisms (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination organisms\nMay considered reduce transfusion requirementsIncreases risk infection encapsulated organisms (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)Patients require vaccination organismsHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially children\nRequires matched donor\nPotentially curative option, especially childrenRequires matched donorGeneral Management:\nGenetic Counseling:\naffected individuals families\nPrenatal diagnosis carrier screening\n\nMonitoring Complications:\nIron overload (liver, heart, endocrine organs)\nInfections\nThrombosis\nPulmonary hypertension\nEndocrine dysfunction (e.g., diabetes, hypothyroidism)\n\nGenetic Counseling:\naffected individuals families\nPrenatal diagnosis carrier screening\naffected individuals familiesPrenatal diagnosis carrier screeningMonitoring Complications:\nIron overload (liver, heart, endocrine organs)\nInfections\nThrombosis\nPulmonary hypertension\nEndocrine dysfunction (e.g., diabetes, hypothyroidism)\nIron overload (liver, heart, endocrine organs)InfectionsThrombosisPulmonary hypertensionEndocrine dysfunction (e.g., diabetes, hypothyroidism)New Therapies\nGene Therapy\nGene Therapy","code":""},{"path":"thalassemias.html","id":"key-laboratory-tests-for-thalassemia","chapter":"Thalassemias","heading":"Key Laboratory Tests for Thalassemia","text":"Complete Blood Count (CBC):\nHGB HCT: Decreased\nMCV: Decreased (microcytic)\nMCH: Decreased (hypochromic)\nRBC count: May normal elevated relative degree anemia\nHGB HCT: DecreasedMCV: Decreased (microcytic)MCH: Decreased (hypochromic)RBC count: May normal elevated relative degree anemiaPeripheral Blood Smear:\nMicrocytes\nHypochromia\nTarget cells\nBasophilic stippling\nNucleated RBCs (severe cases)\nHbH inclusions (alpha-thalassemia)\nMicrocytesHypochromiaTarget cellsBasophilic stipplingNucleated RBCs (severe cases)HbH inclusions (alpha-thalassemia)Reticulocyte Count:\nUsually elevated (due increased erythropoiesis)\nUsually elevated (due increased erythropoiesis)Iron Studies:\nNormal elevated (rule iron deficiency)\nNormal elevated (rule iron deficiency)Hemoglobin Electrophoresis:\nQuantifies percentages different hemoglobin types (HbA, HbA2, HbF, HbS, HbC)\nKey diagnosing classifying thalassemia\nQuantifies percentages different hemoglobin types (HbA, HbA2, HbF, HbS, HbC)Key diagnosing classifying thalassemiaGenetic Testing:\nConfirms diagnosis identifies specific gene mutations deletions\nConfirms diagnosis identifies specific gene mutations deletionsPrenatal Testing:\nChorionic villus sampling (CVS) amniocentesis\nChorionic villus sampling (CVS) amniocentesis","code":""},{"path":"thalassemias.html","id":"key-terms-7","chapter":"Thalassemias","heading":"Key Terms","text":"Thalassemia: Inherited blood disorder decreased globin chain synthesisAlpha-Thalassemia: Decreased alpha-globin chain synthesisBeta-Thalassemia: Decreased beta-globin chain synthesisMicrocytic: Small red blood cells (MCV < 80 fL)Hypochromic: Decreased hemoglobin content (pale color)Target Cells: Red blood cells bullseye appearanceHemoglobin Electrophoresis: Technique separate quantify hemoglobin typesIron Chelation Therapy: Treatment remove excess ironHydrops Fetalis: Severe fetal condition fluid accumulationIneffective Erythropoiesis: Premature destruction red blood cell precursors bone marrow","code":""},{"path":"sideroblastic.html","id":"sideroblastic","chapter":"Sideroblastic","heading":"Sideroblastic","text":"","code":""},{"path":"sideroblastic.html","id":"overview-of-sideroblastic-anemias","chapter":"Sideroblastic","heading":"Overview of Sideroblastic Anemias","text":"Definition: group heterogeneous hematologic disorders characterized ineffective erythropoiesis presence ringed sideroblasts bone marrowPathophysiology:\nImpaired ability bone marrow incorporate iron hemoglobin\nIron accumulates mitochondria erythroblasts, forming ringed sideroblasts\nIneffective erythropoiesis leads anemia\nImpaired ability bone marrow incorporate iron hemoglobinIron accumulates mitochondria erythroblasts, forming ringed sideroblastsIneffective erythropoiesis leads anemiaClassification:\nHereditary Sideroblastic Anemias\nAcquired Sideroblastic Anemias\nReversible\nIrreversible\n\nHereditary Sideroblastic AnemiasAcquired Sideroblastic Anemias\nReversible\nIrreversible\nReversibleIrreversible","code":""},{"path":"sideroblastic.html","id":"etiology-and-classification","chapter":"Sideroblastic","heading":"Etiology and Classification","text":"Hereditary Sideroblastic Anemias\nX-Linked Sideroblastic Anemia (XLSA):\ncommon form hereditary sideroblastic anemia\nCaused mutations ALAS2 gene, encodes erythroid-specific 5-aminolevulinate synthase (ALAS2), key enzyme heme synthesis\n\nAutosomal Recessive Sideroblastic Anemias:\nRare disorders caused mutations genes involved heme synthesis, mitochondrial function, iron metabolism\nExamples: Mutations ABCB7, GLRX5, HSPA9, SLC25A38 genes\n\nMitochondrial Myopathy Sideroblastic Anemia (MLASA):\nAssociated mutations mitochondrial DNA (mtDNA) nuclear genes affect mitochondrial function\n\nX-Linked Sideroblastic Anemia (XLSA):\ncommon form hereditary sideroblastic anemia\nCaused mutations ALAS2 gene, encodes erythroid-specific 5-aminolevulinate synthase (ALAS2), key enzyme heme synthesis\ncommon form hereditary sideroblastic anemiaCaused mutations ALAS2 gene, encodes erythroid-specific 5-aminolevulinate synthase (ALAS2), key enzyme heme synthesisAutosomal Recessive Sideroblastic Anemias:\nRare disorders caused mutations genes involved heme synthesis, mitochondrial function, iron metabolism\nExamples: Mutations ABCB7, GLRX5, HSPA9, SLC25A38 genes\nRare disorders caused mutations genes involved heme synthesis, mitochondrial function, iron metabolismExamples: Mutations ABCB7, GLRX5, HSPA9, SLC25A38 genesMitochondrial Myopathy Sideroblastic Anemia (MLASA):\nAssociated mutations mitochondrial DNA (mtDNA) nuclear genes affect mitochondrial function\nAssociated mutations mitochondrial DNA (mtDNA) nuclear genes affect mitochondrial functionAcquired Sideroblastic Anemias\nReversible Acquired Sideroblastic Anemias:\nCaused exposure certain drugs, toxins, nutritional deficiencies\nExamples:\nAlcohol-induced sideroblastic anemia: Alcohol interferes heme synthesis\nDrug-induced sideroblastic anemia: Isoniazid, pyrazinamide, chloramphenicol, linezolid\nCopper deficiency: Copper required iron transport incorporation heme\nVitamin B6 (Pyridoxine) deficiency: Vitamin B6 cofactor ALAS2\n\n\nIrreversible Acquired Sideroblastic Anemias:\nAssociated myelodysplastic syndromes (MDS):\ngroup clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis risk progression acute myeloid leukemia (AML)\nRefractory Anemia Ring Sideroblasts (RARS): subtype MDS characterized anemia increased ring sideroblasts bone marrow\n\nAssociated Myeloproliferative Neoplasms (MPN):\ngroup disorders characterized overproduction one blood cell lines bone marrow\n\n\nReversible Acquired Sideroblastic Anemias:\nCaused exposure certain drugs, toxins, nutritional deficiencies\nExamples:\nAlcohol-induced sideroblastic anemia: Alcohol interferes heme synthesis\nDrug-induced sideroblastic anemia: Isoniazid, pyrazinamide, chloramphenicol, linezolid\nCopper deficiency: Copper required iron transport incorporation heme\nVitamin B6 (Pyridoxine) deficiency: Vitamin B6 cofactor ALAS2\n\nCaused exposure certain drugs, toxins, nutritional deficienciesExamples:\nAlcohol-induced sideroblastic anemia: Alcohol interferes heme synthesis\nDrug-induced sideroblastic anemia: Isoniazid, pyrazinamide, chloramphenicol, linezolid\nCopper deficiency: Copper required iron transport incorporation heme\nVitamin B6 (Pyridoxine) deficiency: Vitamin B6 cofactor ALAS2\nAlcohol-induced sideroblastic anemia: Alcohol interferes heme synthesisDrug-induced sideroblastic anemia: Isoniazid, pyrazinamide, chloramphenicol, linezolidCopper deficiency: Copper required iron transport incorporation hemeVitamin B6 (Pyridoxine) deficiency: Vitamin B6 cofactor ALAS2Irreversible Acquired Sideroblastic Anemias:\nAssociated myelodysplastic syndromes (MDS):\ngroup clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis risk progression acute myeloid leukemia (AML)\nRefractory Anemia Ring Sideroblasts (RARS): subtype MDS characterized anemia increased ring sideroblasts bone marrow\n\nAssociated Myeloproliferative Neoplasms (MPN):\ngroup disorders characterized overproduction one blood cell lines bone marrow\n\nAssociated myelodysplastic syndromes (MDS):\ngroup clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis risk progression acute myeloid leukemia (AML)\nRefractory Anemia Ring Sideroblasts (RARS): subtype MDS characterized anemia increased ring sideroblasts bone marrow\ngroup clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis risk progression acute myeloid leukemia (AML)Refractory Anemia Ring Sideroblasts (RARS): subtype MDS characterized anemia increased ring sideroblasts bone marrowAssociated Myeloproliferative Neoplasms (MPN):\ngroup disorders characterized overproduction one blood cell lines bone marrow\ngroup disorders characterized overproduction one blood cell lines bone marrow","code":""},{"path":"sideroblastic.html","id":"pathophysiology-1","chapter":"Sideroblastic","heading":"Pathophysiology","text":"Impaired Heme Synthesis:\nMutations deficiencies affecting enzymes involved heme synthesis lead buildup porphyrin precursors impaired iron incorporation protoporphyrin\nXLSA, mutations ALAS2 result decreased production δ-aminolevulinic acid (ALA), first committed step porphyrin synthesis\nMutations deficiencies affecting enzymes involved heme synthesis lead buildup porphyrin precursors impaired iron incorporation protoporphyrinIn XLSA, mutations ALAS2 result decreased production δ-aminolevulinic acid (ALA), first committed step porphyrin synthesisMitochondrial Dysfunction:\nDefects mitochondrial function impair iron-sulfur cluster synthesis mitochondrial processes essential heme synthesis\nIron accumulates mitochondria, leading formation ringed sideroblasts.\nDefects mitochondrial function impair iron-sulfur cluster synthesis mitochondrial processes essential heme synthesisIron accumulates mitochondria, leading formation ringed sideroblasts.Ringed Sideroblasts:\nErythroblasts iron-laden mitochondria encircling nucleus\npresence ≥15% ring sideroblasts bone marrow key diagnostic criterion sideroblastic anemia\nErythroblasts iron-laden mitochondria encircling nucleusThe presence ≥15% ring sideroblasts bone marrow key diagnostic criterion sideroblastic anemiaIneffective Erythropoiesis:\nAccumulation iron dysfunctional mitochondria erythroblasts leads cellular damage apoptosis (programmed cell death)\nResults decreased red blood cell production anemia\nAccumulation iron dysfunctional mitochondria erythroblasts leads cellular damage apoptosis (programmed cell death)Results decreased red blood cell production anemia","code":""},{"path":"sideroblastic.html","id":"clinical-manifestations-1","chapter":"Sideroblastic","heading":"Clinical Manifestations","text":"Symptoms Anemia:\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nDizziness\nFatigueWeaknessPallor (pale skin)Shortness breathDizzinessIron Overload:\nhereditary sideroblastic anemias MDS-associated sideroblastic anemias, chronic anemia ineffective erythropoiesis lead increased iron absorption\nFrequent blood transfusions can also contribute iron overload\nIron accumulates various organs, leading :\nLiver damage (cirrhosis)\nHeart failure\nEndocrine dysfunction (diabetes, hypothyroidism)\nSkin pigmentation (bronze diabetes)\n\nhereditary sideroblastic anemias MDS-associated sideroblastic anemias, chronic anemia ineffective erythropoiesis lead increased iron absorptionFrequent blood transfusions can also contribute iron overloadIron accumulates various organs, leading :\nLiver damage (cirrhosis)\nHeart failure\nEndocrine dysfunction (diabetes, hypothyroidism)\nSkin pigmentation (bronze diabetes)\nLiver damage (cirrhosis)Heart failureEndocrine dysfunction (diabetes, hypothyroidism)Skin pigmentation (bronze diabetes)Symptoms:\nSplenomegaly (enlarged spleen)\nHepatomegaly (enlarged liver)\nNeurological symptoms (mitochondrial disorders)\nSplenomegaly (enlarged spleen)Hepatomegaly (enlarged liver)Neurological symptoms (mitochondrial disorders)","code":""},{"path":"sideroblastic.html","id":"diagnostic-evaluation-1","chapter":"Sideroblastic","heading":"Diagnostic Evaluation","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nMean Corpuscular Volume (MCV): Usually microcytic (low), can normocytic macrocytic cases\nRed Cell Distribution Width (RDW): Increased (anisocytosis)\nHemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedMean Corpuscular Volume (MCV): Usually microcytic (low), can normocytic macrocytic casesRed Cell Distribution Width (RDW): Increased (anisocytosis)Peripheral Blood Smear:\nMicrocytes, hypochromia (cases)\nDimorphic red cell population (mixture normal abnormal RBCs)\nPappenheimer bodies (iron-containing inclusions RBCs)\nBasophilic stippling\nMicrocytes, hypochromia (cases)Dimorphic red cell population (mixture normal abnormal RBCs)Pappenheimer bodies (iron-containing inclusions RBCs)Basophilic stipplingReticulocyte Count:\nLow normal (inappropriately low degree anemia)\nLow normal (inappropriately low degree anemia)Iron Studies:\nSerum Iron: Increased\nTotal Iron-Binding Capacity (TIBC): Decreased normal\nTransferrin Saturation: Increased\nFerritin: Increased (often markedly elevated)\nSerum Iron: IncreasedTotal Iron-Binding Capacity (TIBC): Decreased normalTransferrin Saturation: IncreasedFerritin: Increased (often markedly elevated)Bone Marrow Aspiration Biopsy:\nHypercellular marrow erythroid hyperplasia\nRinged sideroblasts (erythroblasts iron-laden mitochondria encircling nucleus)\nPrussian blue stain: Highlights iron deposits bone marrow\nCytogenetic analysis: detect chromosomal abnormalities MDS\nHypercellular marrow erythroid hyperplasiaRinged sideroblasts (erythroblasts iron-laden mitochondria encircling nucleus)Prussian blue stain: Highlights iron deposits bone marrowCytogenetic analysis: detect chromosomal abnormalities MDSOther Tests:\nVitamin B6 level: rule pyridoxine deficiency\nCopper level: rule copper deficiency\nAlcohol history liver function tests: assess alcohol-induced sideroblastic anemia\nDrug history: identify potential drug-induced causes\nGenetic testing: identify mutations genes associated hereditary sideroblastic anemias (e.g., ALAS2, ABCB7, GLRX5, SF3B1)\nVitamin B6 level: rule pyridoxine deficiencyCopper level: rule copper deficiencyAlcohol history liver function tests: assess alcohol-induced sideroblastic anemiaDrug history: identify potential drug-induced causesGenetic testing: identify mutations genes associated hereditary sideroblastic anemias (e.g., ALAS2, ABCB7, GLRX5, SF3B1)","code":""},{"path":"sideroblastic.html","id":"differential-diagnosis-2","chapter":"Sideroblastic","heading":"Differential Diagnosis","text":"Iron Deficiency Anemia: Low serum iron ferritin, high TIBCAnemia Chronic Disease: Low serum iron, normal low TIBC, normal high ferritinThalassemia: Microcytic anemia normal elevated iron studies, abnormal hemoglobin electrophoresisLead Poisoning: Basophilic stippling elevated lead levels","code":""},{"path":"sideroblastic.html","id":"treatment-and-management-1","chapter":"Sideroblastic","heading":"Treatment and Management","text":"Reversible Acquired Sideroblastic Anemias:\nIdentify remove causative agent (e.g., alcohol, drugs, toxins)\nCorrect nutritional deficiencies (e.g., copper, vitamin B6)\nIdentify remove causative agent (e.g., alcohol, drugs, toxins)Correct nutritional deficiencies (e.g., copper, vitamin B6)Hereditary Sideroblastic Anemias:\nPyridoxine (Vitamin B6) Supplementation:\npatients XLSA respond high doses pyridoxine\nTrial pyridoxine recommended patients suspected sideroblastic anemia\n\nBlood Transfusions:\nmanage severe anemia\nIron chelation therapy necessary prevent iron overload\n\nIron Chelation Therapy:\nDeferoxamine (intravenous subcutaneous)\nDeferasirox Deferiprone (oral)\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option severe cases\n\nPyridoxine (Vitamin B6) Supplementation:\npatients XLSA respond high doses pyridoxine\nTrial pyridoxine recommended patients suspected sideroblastic anemia\npatients XLSA respond high doses pyridoxineTrial pyridoxine recommended patients suspected sideroblastic anemiaBlood Transfusions:\nmanage severe anemia\nIron chelation therapy necessary prevent iron overload\nmanage severe anemiaIron chelation therapy necessary prevent iron overloadIron Chelation Therapy:\nDeferoxamine (intravenous subcutaneous)\nDeferasirox Deferiprone (oral)\nDeferoxamine (intravenous subcutaneous)Deferasirox Deferiprone (oral)Hematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option severe cases\nPotentially curative option severe casesMDS-Associated Sideroblastic Anemias:\nSupportive Care:\nBlood transfusions manage anemia\nErythropoiesis-stimulating agents (ESAs) stimulate red blood cell production (may effective patients)\n\nHypomethylating Agents (e.g., Azacitidine, Decitabine):\nUsed improve hematopoiesis reduce risk progression AML\n\nLuspatercept:\nrecombinant fusion protein binds TGF-β superfamily ligands, promoting erythroid maturation reducing transfusion burden RARS-T patients (MDS ring sideroblasts thrombocytosis)\n\nLenalidomide:\nUsed patients MDS deletion 5q\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\n\nSupportive Care:\nBlood transfusions manage anemia\nErythropoiesis-stimulating agents (ESAs) stimulate red blood cell production (may effective patients)\nBlood transfusions manage anemiaErythropoiesis-stimulating agents (ESAs) stimulate red blood cell production (may effective patients)Hypomethylating Agents (e.g., Azacitidine, Decitabine):\nUsed improve hematopoiesis reduce risk progression AML\nUsed improve hematopoiesis reduce risk progression AMLLuspatercept:\nrecombinant fusion protein binds TGF-β superfamily ligands, promoting erythroid maturation reducing transfusion burden RARS-T patients (MDS ring sideroblasts thrombocytosis)\nrecombinant fusion protein binds TGF-β superfamily ligands, promoting erythroid maturation reducing transfusion burden RARS-T patients (MDS ring sideroblasts thrombocytosis)Lenalidomide:\nUsed patients MDS deletion 5q\nUsed patients MDS deletion 5qHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\nPotentially curative option younger patients high-risk MDS","code":""},{"path":"sideroblastic.html","id":"key-laboratory-findings-1","chapter":"Sideroblastic","heading":"Key Laboratory Findings","text":"Complete Blood Count (CBC):\nAnemia (low HGB HCT)\nMCV may low, normal, high\nAnemia (low HGB HCT)MCV may low, normal, highPeripheral Blood Smear:\nDimorphic red cell population\nPappenheimer bodies\nBasophilic stippling\nDimorphic red cell populationPappenheimer bodiesBasophilic stipplingIron Studies:\nHigh serum iron\nLow normal TIBC\nHigh transferrin saturation\nHigh ferritin\nHigh serum ironLow normal TIBCHigh transferrin saturationHigh ferritinBone Marrow Examination:\nHypercellular marrow erythroid hyperplasia\nRinged sideroblasts (≥15% erythroblasts)\nHypercellular marrow erythroid hyperplasiaRinged sideroblasts (≥15% erythroblasts)Genetic Testing:\nidentify specific gene mutations associated hereditary sideroblastic anemias\nidentify specific gene mutations associated hereditary sideroblastic anemias","code":""},{"path":"sideroblastic.html","id":"key-terms-8","chapter":"Sideroblastic","heading":"Key Terms","text":"Sideroblastic Anemia: Anemia characterized ringed sideroblasts bone marrowRinged Sideroblasts: Erythroblasts iron-laden mitochondria encircling nucleusALAS2: Erythroid-specific 5-aminolevulinate synthase, key enzyme heme synthesisMDS: Myelodysplastic syndromes, group clonal hematopoietic stem cell disordersIneffective Erythropoiesis: Premature destruction red blood cell precursors bone marrowPappenheimer Bodies: Iron-containing inclusions red blood cellsIron Chelation Therapy: Treatment remove excess iron body","code":""},{"path":"porphyria.html","id":"porphyria","chapter":"Porphyria","heading":"Porphyria","text":"","code":""},{"path":"porphyria.html","id":"porphyrias-and-microcytic-anemia","chapter":"Porphyria","heading":"Porphyrias and Microcytic Anemia","text":"Overview: porphyrias primarily known causing neurological /cutaneous symptoms due accumulation porphyrin precursors, types can also associated microcytic anemiaMechanism:\nunderlying defect heme synthesis can, certain porphyrias, lead secondary disruption iron metabolism globin chain synthesis, contributing microcytosis\nprimary mechanism, build-toxic porphyrin precursors\nunderlying defect heme synthesis can, certain porphyrias, lead secondary disruption iron metabolism globin chain synthesis, contributing microcytosisThis primary mechanism, build-toxic porphyrin precursorsWhich Porphyrias Can Associated Microcytosis?\nALA Dehydratase Deficiency Porphyria (ADP): rare, autosomal recessive porphyria, one likely microcytic anemia. buildup ALA toxic\nCongenital Erythropoietic Porphyria (CEP): rare, autosomal recessive erythropoietic porphyria, can sometimes present microcytic features due overall disruption erythropoiesis, though common presentation\nALA Dehydratase Deficiency Porphyria (ADP): rare, autosomal recessive porphyria, one likely microcytic anemia. buildup ALA toxicCongenital Erythropoietic Porphyria (CEP): rare, autosomal recessive erythropoietic porphyria, can sometimes present microcytic features due overall disruption erythropoiesis, though common presentationKey Lab Findings Consider Porphyria (context Microcytic Anemia):\nUnexplained Microcytic Anemia: microcytosis present iron studies normal thalassemia ruled , consider porphyria, especially suggestive symptoms\nPhotosensitivity: key symptom point away typical IDA, thalassemia, ACD, towards porphyria\nNeurological Symptoms: Acute porphyrias may manifest abdominal pain, neurological issues (seizures, neuropathy), psychiatric symptoms\nRed Dark Urine: present many conditions, also raise suspicion porphyria\nElevated Porphyrin Levels: Testing urine, stool, blood porphyrins precursors (ALA, PBG) essential confirm diagnosis\nUnexplained Microcytic Anemia: microcytosis present iron studies normal thalassemia ruled , consider porphyria, especially suggestive symptomsPhotosensitivity: key symptom point away typical IDA, thalassemia, ACD, towards porphyriaNeurological Symptoms: Acute porphyrias may manifest abdominal pain, neurological issues (seizures, neuropathy), psychiatric symptomsRed Dark Urine: present many conditions, also raise suspicion porphyriaElevated Porphyrin Levels: Testing urine, stool, blood porphyrins precursors (ALA, PBG) essential confirm diagnosis","code":""},{"path":"porphyria.html","id":"how-to-distinguish-from-other-microcytic-anemias","chapter":"Porphyria","heading":"How to Distinguish from Other Microcytic Anemias","text":"History Symptoms: presence photosensitivity, neurological symptoms, abdominal pain raise suspicion porphyriaPorphyrin Studies: key diagnosis\nUnlike IDA, iron studies show iron deficiency\nUnlike thalassemia, hemoglobin electrophoresis show abnormal hemoglobins\nUnlike IDA, iron studies show iron deficiencyUnlike thalassemia, hemoglobin electrophoresis show abnormal hemoglobinsFamily History: family history porphyria can clue","code":""},{"path":"porphyria.html","id":"adding-to-the-differential-diagnosis-table","chapter":"Porphyria","heading":"Adding to the Differential Diagnosis Table:","text":"’s can expand differential diagnosis table incorporate Porphyrias:","code":""},{"path":"porphyria.html","id":"key-points-to-remember","chapter":"Porphyria","heading":"Key Points to Remember:","text":"less common, porphyrias can sometimes present microcytic anemiaAlways consider porphyria differential diagnosis microcytic anemia common causes ruled suggestive clinical symptoms (photosensitivity, neurological issues, abdominal pain)Porphyrin studies essential diagnosis","code":""},{"path":"normocytic.html","id":"normocytic","chapter":"Normocytic","heading":"Normocytic","text":"","code":""},{"path":"normocytic.html","id":"normocytic-anemias","chapter":"Normocytic","heading":"Normocytic Anemias","text":"Characteristics: Normal-sized RBCs (MCV 80-100 fL)Key Considerations:\nEvaluate reticulocyte count determine bone marrow responding appropriately anemia\nHigh Reticulocyte Count: Suggests increased RBC destruction (hemolysis) acute blood loss\nLow Reticulocyte Count: Suggests decreased RBC production due bone marrow disorders, chronic diseases, early nutritional deficiencies\n\nEvaluate reticulocyte count determine bone marrow responding appropriately anemia\nHigh Reticulocyte Count: Suggests increased RBC destruction (hemolysis) acute blood loss\nLow Reticulocyte Count: Suggests decreased RBC production due bone marrow disorders, chronic diseases, early nutritional deficiencies\nHigh Reticulocyte Count: Suggests increased RBC destruction (hemolysis) acute blood lossLow Reticulocyte Count: Suggests decreased RBC production due bone marrow disorders, chronic diseases, early nutritional deficienciesCommon Causes:\nAcute Blood Loss:\nSudden loss blood due trauma, surgery, gastrointestinal bleeding\nInitial CBC may normocytic normochromic, iron deficiency can develop time\n\nHemolytic Anemias:\nIncreased destruction RBCs due inherited acquired causes\nPeripheral blood smear: May show spherocytes, schistocytes, abnormal RBC morphologies\nLab findings:\nElevated reticulocyte count\nElevated indirect bilirubin\nElevated lactate dehydrogenase (LDH)\nDecreased haptoglobin\nPositive direct antiglobulin test (DAT) autoimmune hemolytic anemia\n\nInherited Hemolytic Anemias:\nHereditary spherocytosis: Membrane defect leading spherical RBCs\nSickle cell anemia: Abnormal hemoglobin (HbS) leading sickling RBCs\nThalassemia: (Can also cause microcytic anemia.)\nG6PD deficiency: Enzyme deficiency leading oxidative damage\n\nAcquired Hemolytic Anemias:\nAutoimmune hemolytic anemia: Antibodies RBCs\nDrug-induced hemolytic anemia: Caused certain medications\nMicroangiopathic hemolytic anemia (MAHA): Mechanical destruction RBCs small blood vessels (e.g., thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC))\n\n\nAnemia Chronic Disease/Inflammation:\n(Can also cause microcytic anemia.)\n\nAplastic Anemia:\nBone marrow failure resulting decreased production blood cell lines (pancytopenia)\nCauses: Autoimmune, drug-induced, infections, inherited\nBone marrow examination: Hypocellular marrow\n\nChronic Kidney Disease:\nDecreased production erythropoietin (EPO)\nPeripheral blood smear: Normocytic, normochromic RBCs\n\nAcute Blood Loss:\nSudden loss blood due trauma, surgery, gastrointestinal bleeding\nInitial CBC may normocytic normochromic, iron deficiency can develop time\nSudden loss blood due trauma, surgery, gastrointestinal bleedingInitial CBC may normocytic normochromic, iron deficiency can develop timeHemolytic Anemias:\nIncreased destruction RBCs due inherited acquired causes\nPeripheral blood smear: May show spherocytes, schistocytes, abnormal RBC morphologies\nLab findings:\nElevated reticulocyte count\nElevated indirect bilirubin\nElevated lactate dehydrogenase (LDH)\nDecreased haptoglobin\nPositive direct antiglobulin test (DAT) autoimmune hemolytic anemia\n\nInherited Hemolytic Anemias:\nHereditary spherocytosis: Membrane defect leading spherical RBCs\nSickle cell anemia: Abnormal hemoglobin (HbS) leading sickling RBCs\nThalassemia: (Can also cause microcytic anemia.)\nG6PD deficiency: Enzyme deficiency leading oxidative damage\n\nAcquired Hemolytic Anemias:\nAutoimmune hemolytic anemia: Antibodies RBCs\nDrug-induced hemolytic anemia: Caused certain medications\nMicroangiopathic hemolytic anemia (MAHA): Mechanical destruction RBCs small blood vessels (e.g., thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC))\n\nIncreased destruction RBCs due inherited acquired causesPeripheral blood smear: May show spherocytes, schistocytes, abnormal RBC morphologiesLab findings:\nElevated reticulocyte count\nElevated indirect bilirubin\nElevated lactate dehydrogenase (LDH)\nDecreased haptoglobin\nPositive direct antiglobulin test (DAT) autoimmune hemolytic anemia\nElevated reticulocyte countElevated indirect bilirubinElevated lactate dehydrogenase (LDH)Decreased haptoglobinPositive direct antiglobulin test (DAT) autoimmune hemolytic anemiaInherited Hemolytic Anemias:\nHereditary spherocytosis: Membrane defect leading spherical RBCs\nSickle cell anemia: Abnormal hemoglobin (HbS) leading sickling RBCs\nThalassemia: (Can also cause microcytic anemia.)\nG6PD deficiency: Enzyme deficiency leading oxidative damage\nHereditary spherocytosis: Membrane defect leading spherical RBCsSickle cell anemia: Abnormal hemoglobin (HbS) leading sickling RBCsThalassemia: (Can also cause microcytic anemia.)G6PD deficiency: Enzyme deficiency leading oxidative damageAcquired Hemolytic Anemias:\nAutoimmune hemolytic anemia: Antibodies RBCs\nDrug-induced hemolytic anemia: Caused certain medications\nMicroangiopathic hemolytic anemia (MAHA): Mechanical destruction RBCs small blood vessels (e.g., thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC))\nAutoimmune hemolytic anemia: Antibodies RBCsDrug-induced hemolytic anemia: Caused certain medicationsMicroangiopathic hemolytic anemia (MAHA): Mechanical destruction RBCs small blood vessels (e.g., thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC))Anemia Chronic Disease/Inflammation:\n(Can also cause microcytic anemia.)\n(Can also cause microcytic anemia.)Aplastic Anemia:\nBone marrow failure resulting decreased production blood cell lines (pancytopenia)\nCauses: Autoimmune, drug-induced, infections, inherited\nBone marrow examination: Hypocellular marrow\nBone marrow failure resulting decreased production blood cell lines (pancytopenia)Causes: Autoimmune, drug-induced, infections, inheritedBone marrow examination: Hypocellular marrowChronic Kidney Disease:\nDecreased production erythropoietin (EPO)\nPeripheral blood smear: Normocytic, normochromic RBCs\nDecreased production erythropoietin (EPO)Peripheral blood smear: Normocytic, normochromic RBCs","code":""},{"path":"normocytic.html","id":"laboratory-tests-for-anemia-1","chapter":"Normocytic","heading":"Laboratory Tests for Anemia","text":"Complete Blood Count (CBC):\nHemoglobin (HGB)\nHematocrit (HCT)\nRed Blood Cell Count (RBC)\nMean Corpuscular Volume (MCV)\nMean Corpuscular Hemoglobin (MCH)\nMean Corpuscular Hemoglobin Concentration (MCHC)\nRed Cell Distribution Width (RDW)\nWhite Blood Cell Count (WBC) Differential\nPlatelet Count\nHemoglobin (HGB)Hematocrit (HCT)Red Blood Cell Count (RBC)Mean Corpuscular Volume (MCV)Mean Corpuscular Hemoglobin (MCH)Mean Corpuscular Hemoglobin Concentration (MCHC)Red Cell Distribution Width (RDW)White Blood Cell Count (WBC) DifferentialPlatelet CountPeripheral Blood Smear:\nRBC morphology (size, shape, color)\nWBC differential\nPlatelet estimate\nRBC morphology (size, shape, color)WBC differentialPlatelet estimateReticulocyte Count:\nPercentage absolute number reticulocytes\nCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)\nPercentage absolute number reticulocytesCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)Iron Studies:\nSerum Iron\nTotal Iron-Binding Capacity (TIBC)\nTransferrin Saturation\nFerritin\nSerum IronTotal Iron-Binding Capacity (TIBC)Transferrin SaturationFerritinVitamin B12 Folate Levels:\nSerum B12\nRed Blood Cell Folate\nSerum B12Red Blood Cell FolateMethylmalonic Acid (MMA) Homocysteine Levels:\nElevated B12 Deficiency\nHomocysteine also Elevated Folate Deficiency\nElevated B12 DeficiencyHomocysteine also Elevated Folate DeficiencyHemoglobin Electrophoresis:\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)Direct Antiglobulin Test (DAT):\nDetects antibodies complement proteins surface RBCs\nDetects antibodies complement proteins surface RBCsBone Marrow Examination:\nCellularity\nMaturation cell lines\nPresence abnormal cells\nCellularityMaturation cell linesPresence abnormal cellsOther Tests:\nHaptoglobin LDH (hemolysis)\nCoombs test (autoimmune hemolytic anemia)\nOsmotic Fragility Test (hereditary spherocytosis)\nG6PD Assay (G6PD deficiency)\nHaptoglobin LDH (hemolysis)Coombs test (autoimmune hemolytic anemia)Osmotic Fragility Test (hereditary spherocytosis)G6PD Assay (G6PD deficiency)","code":""},{"path":"normocytic.html","id":"key-terms-9","chapter":"Normocytic","heading":"Key Terms","text":"Anemia: Deficiency red blood cells hemoglobinNormocytic: Normal-sized red blood cells (MCV 80-100 fL)Hyperchromic: Increased hemoglobin content (intensely colored)Reticulocyte: Immature red blood cellHemolysis: Destruction red blood cellsExtramedullary Hematopoiesis: Blood cell production outside bone marrowPancytopenia: Deficiency blood cell lines (RBCs, WBCs, platelets)","code":""},{"path":"hereditary-hemolytic.html","id":"hereditary-hemolytic","chapter":"Hereditary Hemolytic","heading":"Hereditary Hemolytic","text":"","code":""},{"path":"hereditary-hemolytic.html","id":"overview-of-hemolytic-anemias","chapter":"Hereditary Hemolytic","heading":"Overview of Hemolytic Anemias","text":"Definition: Anemia caused increased red blood cell (RBC) destruction (hemolysis), either intravascularly (within blood vessels) extravascularly (primarily spleen liver)Hallmarks:\nShortened RBC lifespan\nIncreased erythropoiesis (increased reticulocyte count)\nAccumulation hemoglobin breakdown products (e.g., bilirubin, LDH)\nShortened RBC lifespanIncreased erythropoiesis (increased reticulocyte count)Accumulation hemoglobin breakdown products (e.g., bilirubin, LDH)Classification:\nIntrinsic (Inherited) Hemolytic Anemias:\nResult defects within RBC \nInclude membrane defects, enzyme deficiencies, hemoglobinopathies\n\nExtrinsic (Acquired) Hemolytic Anemias:\nResult external factors cause RBC destruction\nInclude immune-mediated hemolysis, mechanical trauma, infections, chemical injury\n\nIntrinsic (Inherited) Hemolytic Anemias:\nResult defects within RBC \nInclude membrane defects, enzyme deficiencies, hemoglobinopathies\nResult defects within RBC itselfInclude membrane defects, enzyme deficiencies, hemoglobinopathiesExtrinsic (Acquired) Hemolytic Anemias:\nResult external factors cause RBC destruction\nInclude immune-mediated hemolysis, mechanical trauma, infections, chemical injury\nResult external factors cause RBC destructionInclude immune-mediated hemolysis, mechanical trauma, infections, chemical injury","code":""},{"path":"hereditary-hemolytic.html","id":"intrinsic-hemolytic-anemias-membrane-defects","chapter":"Hereditary Hemolytic","heading":"Intrinsic Hemolytic Anemias: Membrane Defects","text":"General Pathophysiology:\nDefects RBC membrane proteins disrupt structural integrity flexibility membrane\nAbnormally shaped RBCs susceptible splenic sequestration destruction\nGeneral Pathophysiology:Defects RBC membrane proteins disrupt structural integrity flexibility membraneAbnormally shaped RBCs susceptible splenic sequestration destructionCommon Features:\nSplenomegaly (due increased splenic workload)\nJaundice (due elevated bilirubin levels)\nIncreased osmotic fragility\nCommon Features:Splenomegaly (due increased splenic workload)Jaundice (due elevated bilirubin levels)Increased osmotic fragilitySpecific Membrane Defects:\nHereditary Spherocytosis (HS):\nDefect: Primarily caused mutations genes encoding spectrin, ankyrin, band 3, protein 4.2\nproteins essential maintaining biconcave shape flexibility RBCs\n\nPathophysiology: Protein deficiencies lead loss membrane surface area, resulting spherical-shaped RBCs (spherocytes)\nSpherocytes decreased deformability trapped destroyed spleen\n\nClinical Findings:\nAnemia (variable severity)\nJaundice\nSplenomegaly\nBilirubin gallstones (cholelithiasis)\n\nLaboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal decreased MCV (may falsely low due spherocytes)\nIncreased MCHC (often >36 g/dL)\nIncreased RDW\n\nPeripheral Blood Smear:\nSpherocytes (hallmark finding)\nPolychromasia (increased reticulocytes)\nAbsence central pallor spherocytes\n\nReticulocyte Count: Elevated\nDirect Antiglobulin Test (DAT): Negative (unless coexisting autoimmune process)\nOsmotic Fragility Test: Increased osmotic fragility (RBCs lyse readily hypotonic solutions)\n\nTreatment:\nSplenectomy: Mainstay treatment severe HS\nReduces hemolysis improves anemia\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\n\nFolic acid supplementation\nBlood transfusions (severe cases)\n\n\nHereditary Elliptocytosis ():\nDefect: Primarily caused mutations genes encoding spectrin, protein 4.1, glycophorin C\nPathophysiology: Protein defects disrupt horizontal interactions RBC cytoskeleton, leading elliptical-shaped RBCs (elliptocytes)\nClinical Findings:\npatients asymptomatic\nVariable degrees anemia, splenomegaly, jaundice\nSevere forms (e.g., hereditary pyropoikilocytosis) can cause significant hemolysis\n\nLaboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal MCV\nNormal MCHC\n\nPeripheral Blood Smear:\nElliptocytes (hallmark finding, >25% RBCs)\nPoikilocytosis (severe forms)\n\nReticulocyte Count: Normal slightly elevated\nOsmotic Fragility Test: Usually normal\n\nTreatment:\npatients require treatment\nSplenectomy: May considered patients severe hemolysis\nFolic acid supplementation\nBlood transfusions (severe cases)\n\n\nHereditary Pyropoikilocytosis (HPP):\nDefect: severe form hereditary elliptocytosis compound heterozygosity spectrin mutations\nPathophysiology: Marked spectrin deficiency leads extreme poikilocytosis (abnormal RBC shapes) heat sensitivity\nRBCs fragment temperatures normally well-tolerated\n\nClinical Findings:\nSevere microcytic hemolytic anemia\nMarked poikilocytosis\nSplenomegaly\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\nlow MCV\nIncreased RDW\n\nPeripheral Blood Smear:\nExtreme poikilocytosis (hallmark finding)\nMicrospherocytes, elliptocytes, fragmented cells\n\nReticulocyte Count: Elevated\n\nTreatment:\nSplenectomy: Mainstay treatment\nFolic acid supplementation\nBlood transfusions (often required)\n\n\nHereditary Stomatocytosis:\nDefect: Mutations affecting membrane cation permeability, particularly PIEZO1 stomatin (band 7) proteins\nPathophysiology: Altered cation permeability leads changes RBC volume shape\nOverhydrated Hereditary Stomatocytosis (OHS): Increased influx sodium water RBCs, leading swelling stomatocytes (mouth-like appearance)\nDehydrated Hereditary Stomatocytosis (DHS): Increased efflux potassium water RBCs, leading dehydration spiculated cells (e.g., echinocytes)\n\nClinical Findings:\nVariable degrees hemolytic anemia\nSplenomegaly\nJaundice\n\nLaboratory Findings:\nCBC:\nVariable HGB HCT (depending severity hemolysis)\nIncreased MCV (OHS) decreased MCV (DHS)\n\nPeripheral Blood Smear:\nStomatocytes (OHS): RBCs slit-like area central pallor\nSpiculated cells (echinocytes) (DHS)\n\nReticulocyte Count: Elevated\nOsmotic Fragility Test: Variable (increased OHS, decreased DHS)\n\nTreatment:\nSplenectomy: May considered severe cases OHS, carries risk thrombosis\nIron overload: Can occur DHS due increased iron absorption\nFolic acid supplementation\nBlood transfusions (severe cases)\n\n\nSpecific Membrane Defects:Hereditary Spherocytosis (HS):\nDefect: Primarily caused mutations genes encoding spectrin, ankyrin, band 3, protein 4.2\nproteins essential maintaining biconcave shape flexibility RBCs\n\nPathophysiology: Protein deficiencies lead loss membrane surface area, resulting spherical-shaped RBCs (spherocytes)\nSpherocytes decreased deformability trapped destroyed spleen\n\nClinical Findings:\nAnemia (variable severity)\nJaundice\nSplenomegaly\nBilirubin gallstones (cholelithiasis)\n\nLaboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal decreased MCV (may falsely low due spherocytes)\nIncreased MCHC (often >36 g/dL)\nIncreased RDW\n\nPeripheral Blood Smear:\nSpherocytes (hallmark finding)\nPolychromasia (increased reticulocytes)\nAbsence central pallor spherocytes\n\nReticulocyte Count: Elevated\nDirect Antiglobulin Test (DAT): Negative (unless coexisting autoimmune process)\nOsmotic Fragility Test: Increased osmotic fragility (RBCs lyse readily hypotonic solutions)\n\nTreatment:\nSplenectomy: Mainstay treatment severe HS\nReduces hemolysis improves anemia\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\n\nFolic acid supplementation\nBlood transfusions (severe cases)\n\nDefect: Primarily caused mutations genes encoding spectrin, ankyrin, band 3, protein 4.2\nproteins essential maintaining biconcave shape flexibility RBCs\nproteins essential maintaining biconcave shape flexibility RBCsPathophysiology: Protein deficiencies lead loss membrane surface area, resulting spherical-shaped RBCs (spherocytes)\nSpherocytes decreased deformability trapped destroyed spleen\nSpherocytes decreased deformability trapped destroyed spleenClinical Findings:\nAnemia (variable severity)\nJaundice\nSplenomegaly\nBilirubin gallstones (cholelithiasis)\nAnemia (variable severity)JaundiceSplenomegalyBilirubin gallstones (cholelithiasis)Laboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal decreased MCV (may falsely low due spherocytes)\nIncreased MCHC (often >36 g/dL)\nIncreased RDW\n\nPeripheral Blood Smear:\nSpherocytes (hallmark finding)\nPolychromasia (increased reticulocytes)\nAbsence central pallor spherocytes\n\nReticulocyte Count: Elevated\nDirect Antiglobulin Test (DAT): Negative (unless coexisting autoimmune process)\nOsmotic Fragility Test: Increased osmotic fragility (RBCs lyse readily hypotonic solutions)\nCBC:\nNormal decreased HGB HCT\nNormal decreased MCV (may falsely low due spherocytes)\nIncreased MCHC (often >36 g/dL)\nIncreased RDW\nNormal decreased HGB HCTNormal decreased MCV (may falsely low due spherocytes)Increased MCHC (often >36 g/dL)Increased RDWPeripheral Blood Smear:\nSpherocytes (hallmark finding)\nPolychromasia (increased reticulocytes)\nAbsence central pallor spherocytes\nSpherocytes (hallmark finding)Polychromasia (increased reticulocytes)Absence central pallor spherocytesReticulocyte Count: ElevatedDirect Antiglobulin Test (DAT): Negative (unless coexisting autoimmune process)Osmotic Fragility Test: Increased osmotic fragility (RBCs lyse readily hypotonic solutions)Treatment:\nSplenectomy: Mainstay treatment severe HS\nReduces hemolysis improves anemia\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\n\nFolic acid supplementation\nBlood transfusions (severe cases)\nSplenectomy: Mainstay treatment severe HS\nReduces hemolysis improves anemia\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\nReduces hemolysis improves anemiaIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)Patients require vaccination splenectomyFolic acid supplementationBlood transfusions (severe cases)Hereditary Elliptocytosis ():\nDefect: Primarily caused mutations genes encoding spectrin, protein 4.1, glycophorin C\nPathophysiology: Protein defects disrupt horizontal interactions RBC cytoskeleton, leading elliptical-shaped RBCs (elliptocytes)\nClinical Findings:\npatients asymptomatic\nVariable degrees anemia, splenomegaly, jaundice\nSevere forms (e.g., hereditary pyropoikilocytosis) can cause significant hemolysis\n\nLaboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal MCV\nNormal MCHC\n\nPeripheral Blood Smear:\nElliptocytes (hallmark finding, >25% RBCs)\nPoikilocytosis (severe forms)\n\nReticulocyte Count: Normal slightly elevated\nOsmotic Fragility Test: Usually normal\n\nTreatment:\npatients require treatment\nSplenectomy: May considered patients severe hemolysis\nFolic acid supplementation\nBlood transfusions (severe cases)\n\nDefect: Primarily caused mutations genes encoding spectrin, protein 4.1, glycophorin CPathophysiology: Protein defects disrupt horizontal interactions RBC cytoskeleton, leading elliptical-shaped RBCs (elliptocytes)Clinical Findings:\npatients asymptomatic\nVariable degrees anemia, splenomegaly, jaundice\nSevere forms (e.g., hereditary pyropoikilocytosis) can cause significant hemolysis\npatients asymptomaticVariable degrees anemia, splenomegaly, jaundiceSevere forms (e.g., hereditary pyropoikilocytosis) can cause significant hemolysisLaboratory Findings:\nCBC:\nNormal decreased HGB HCT\nNormal MCV\nNormal MCHC\n\nPeripheral Blood Smear:\nElliptocytes (hallmark finding, >25% RBCs)\nPoikilocytosis (severe forms)\n\nReticulocyte Count: Normal slightly elevated\nOsmotic Fragility Test: Usually normal\nCBC:\nNormal decreased HGB HCT\nNormal MCV\nNormal MCHC\nNormal decreased HGB HCTNormal MCVNormal MCHCPeripheral Blood Smear:\nElliptocytes (hallmark finding, >25% RBCs)\nPoikilocytosis (severe forms)\nElliptocytes (hallmark finding, >25% RBCs)Poikilocytosis (severe forms)Reticulocyte Count: Normal slightly elevatedOsmotic Fragility Test: Usually normalTreatment:\npatients require treatment\nSplenectomy: May considered patients severe hemolysis\nFolic acid supplementation\nBlood transfusions (severe cases)\npatients require treatmentSplenectomy: May considered patients severe hemolysisFolic acid supplementationBlood transfusions (severe cases)Hereditary Pyropoikilocytosis (HPP):\nDefect: severe form hereditary elliptocytosis compound heterozygosity spectrin mutations\nPathophysiology: Marked spectrin deficiency leads extreme poikilocytosis (abnormal RBC shapes) heat sensitivity\nRBCs fragment temperatures normally well-tolerated\n\nClinical Findings:\nSevere microcytic hemolytic anemia\nMarked poikilocytosis\nSplenomegaly\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\nlow MCV\nIncreased RDW\n\nPeripheral Blood Smear:\nExtreme poikilocytosis (hallmark finding)\nMicrospherocytes, elliptocytes, fragmented cells\n\nReticulocyte Count: Elevated\n\nTreatment:\nSplenectomy: Mainstay treatment\nFolic acid supplementation\nBlood transfusions (often required)\n\nDefect: severe form hereditary elliptocytosis compound heterozygosity spectrin mutationsPathophysiology: Marked spectrin deficiency leads extreme poikilocytosis (abnormal RBC shapes) heat sensitivity\nRBCs fragment temperatures normally well-tolerated\nRBCs fragment temperatures normally well-toleratedClinical Findings:\nSevere microcytic hemolytic anemia\nMarked poikilocytosis\nSplenomegaly\nSevere microcytic hemolytic anemiaMarked poikilocytosisSplenomegalyLaboratory Findings:\nCBC:\nDecreased HGB HCT\nlow MCV\nIncreased RDW\n\nPeripheral Blood Smear:\nExtreme poikilocytosis (hallmark finding)\nMicrospherocytes, elliptocytes, fragmented cells\n\nReticulocyte Count: Elevated\nCBC:\nDecreased HGB HCT\nlow MCV\nIncreased RDW\nDecreased HGB HCTVery low MCVIncreased RDWPeripheral Blood Smear:\nExtreme poikilocytosis (hallmark finding)\nMicrospherocytes, elliptocytes, fragmented cells\nExtreme poikilocytosis (hallmark finding)Microspherocytes, elliptocytes, fragmented cellsReticulocyte Count: ElevatedTreatment:\nSplenectomy: Mainstay treatment\nFolic acid supplementation\nBlood transfusions (often required)\nSplenectomy: Mainstay treatmentFolic acid supplementationBlood transfusions (often required)Hereditary Stomatocytosis:\nDefect: Mutations affecting membrane cation permeability, particularly PIEZO1 stomatin (band 7) proteins\nPathophysiology: Altered cation permeability leads changes RBC volume shape\nOverhydrated Hereditary Stomatocytosis (OHS): Increased influx sodium water RBCs, leading swelling stomatocytes (mouth-like appearance)\nDehydrated Hereditary Stomatocytosis (DHS): Increased efflux potassium water RBCs, leading dehydration spiculated cells (e.g., echinocytes)\n\nClinical Findings:\nVariable degrees hemolytic anemia\nSplenomegaly\nJaundice\n\nLaboratory Findings:\nCBC:\nVariable HGB HCT (depending severity hemolysis)\nIncreased MCV (OHS) decreased MCV (DHS)\n\nPeripheral Blood Smear:\nStomatocytes (OHS): RBCs slit-like area central pallor\nSpiculated cells (echinocytes) (DHS)\n\nReticulocyte Count: Elevated\nOsmotic Fragility Test: Variable (increased OHS, decreased DHS)\n\nTreatment:\nSplenectomy: May considered severe cases OHS, carries risk thrombosis\nIron overload: Can occur DHS due increased iron absorption\nFolic acid supplementation\nBlood transfusions (severe cases)\n\nDefect: Mutations affecting membrane cation permeability, particularly PIEZO1 stomatin (band 7) proteinsPathophysiology: Altered cation permeability leads changes RBC volume shape\nOverhydrated Hereditary Stomatocytosis (OHS): Increased influx sodium water RBCs, leading swelling stomatocytes (mouth-like appearance)\nDehydrated Hereditary Stomatocytosis (DHS): Increased efflux potassium water RBCs, leading dehydration spiculated cells (e.g., echinocytes)\nOverhydrated Hereditary Stomatocytosis (OHS): Increased influx sodium water RBCs, leading swelling stomatocytes (mouth-like appearance)Dehydrated Hereditary Stomatocytosis (DHS): Increased efflux potassium water RBCs, leading dehydration spiculated cells (e.g., echinocytes)Clinical Findings:\nVariable degrees hemolytic anemia\nSplenomegaly\nJaundice\nVariable degrees hemolytic anemiaSplenomegalyJaundiceLaboratory Findings:\nCBC:\nVariable HGB HCT (depending severity hemolysis)\nIncreased MCV (OHS) decreased MCV (DHS)\n\nPeripheral Blood Smear:\nStomatocytes (OHS): RBCs slit-like area central pallor\nSpiculated cells (echinocytes) (DHS)\n\nReticulocyte Count: Elevated\nOsmotic Fragility Test: Variable (increased OHS, decreased DHS)\nCBC:\nVariable HGB HCT (depending severity hemolysis)\nIncreased MCV (OHS) decreased MCV (DHS)\nVariable HGB HCT (depending severity hemolysis)Increased MCV (OHS) decreased MCV (DHS)Peripheral Blood Smear:\nStomatocytes (OHS): RBCs slit-like area central pallor\nSpiculated cells (echinocytes) (DHS)\nStomatocytes (OHS): RBCs slit-like area central pallorSpiculated cells (echinocytes) (DHS)Reticulocyte Count: ElevatedOsmotic Fragility Test: Variable (increased OHS, decreased DHS)Treatment:\nSplenectomy: May considered severe cases OHS, carries risk thrombosis\nIron overload: Can occur DHS due increased iron absorption\nFolic acid supplementation\nBlood transfusions (severe cases)\nSplenectomy: May considered severe cases OHS, carries risk thrombosisIron overload: Can occur DHS due increased iron absorptionFolic acid supplementationBlood transfusions (severe cases)","code":""},{"path":"hereditary-hemolytic.html","id":"intrinsic-hemolytic-anemias-enzyme-deficiencies","chapter":"Hereditary Hemolytic","heading":"Intrinsic Hemolytic Anemias: Enzyme Deficiencies","text":"General Pathophysiology:\nDeficiencies enzymes essential RBC metabolism disrupt energy production antioxidant defenses\nLeads premature RBC destruction, especially conditions stress\nGeneral Pathophysiology:Deficiencies enzymes essential RBC metabolism disrupt energy production antioxidant defensesLeads premature RBC destruction, especially conditions stressCommon Features:\nHemolytic anemia\nElevated reticulocyte count\nElevated indirect bilirubin\nDecreased haptoglobin\nCommon Features:Hemolytic anemiaElevated reticulocyte countElevated indirect bilirubinDecreased haptoglobinSpecific Enzyme Deficiencies:\nGlucose-6-Phosphate Dehydrogenase (G6PD) Deficiency:\nDefect: Deficiency G6PD, enzyme pentose phosphate pathway (hexose monophosphate shunt)\nPathophysiology:\nG6PD essential producing NADPH, protects RBCs oxidative damage\nWithout NADPH, RBCs vulnerable oxidative stress infections, drugs, certain foods (e.g., fava beans)\nOxidative stress leads hemoglobin denaturation formation Heinz bodies (denatured hemoglobin precipitates)\nHeinz bodies damage RBC membrane, leading intravascular extravascular hemolysis\n\nInheritance: X-linked recessive; common males\nClinical Findings:\nindividuals asymptomatic exposed oxidative stressor\nAcute hemolytic anemia:\nSudden onset jaundice, dark urine, fatigue\nSymptoms usually resolve within weeks oxidative stressor removed\n\nChronic nonspherocytic hemolytic anemia (severe variants)\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\n\nPeripheral Blood Smear:\nBite cells (RBCs portion removed splenic macrophages)\nHeinz bodies (require special stain, e.g., crystal violet brilliant green)\nPolychromasia\n\nReticulocyte Count: Elevated\nG6PD Assay:\nDecreased G6PD enzyme activity (may normal acute hemolytic episodes due increased reticulocytes)\n\n\nTreatment:\nAvoidance oxidative stressors (certain drugs, foods, infections)\nSupportive care hemolytic episodes:\nHydration\nBlood transfusions (severe cases)\n\nFolic acid supplementation\n\n\nPyruvate Kinase (PK) Deficiency:\nDefect: Deficiency pyruvate kinase (PK), enzyme glycolytic pathway (Embden-Meyerhof pathway)\nPathophysiology:\nPK essential generating ATP, required maintain RBC shape, membrane integrity, ion transport\nWithout sufficient ATP, RBCs become rigid, dehydrated, prone splenic sequestration\nResults chronic hemolytic anemia\n\nInheritance: Autosomal recessive\nClinical Findings:\nChronic hemolytic anemia\nJaundice\nSplenomegaly\nGallstones (cholelithiasis)\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\nNormal decreased MCV (can slightly macrocytic cases)\nNormal MCHC\n\nPeripheral Blood Smear:\nNormal shape slight poikilocytosis\nspherocytes\n\nReticulocyte Count: Markedly elevated\nPyruvate Kinase (PK) Assay:\nDecreased PK enzyme activity\n\n\nTreatment:\nBlood transfusions (may needed, especially severe cases)\nSplenectomy: May reduce transfusion requirements increases risk thrombosis\nFolic acid supplementation\n\n\nSpecific Enzyme Deficiencies:Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency:\nDefect: Deficiency G6PD, enzyme pentose phosphate pathway (hexose monophosphate shunt)\nPathophysiology:\nG6PD essential producing NADPH, protects RBCs oxidative damage\nWithout NADPH, RBCs vulnerable oxidative stress infections, drugs, certain foods (e.g., fava beans)\nOxidative stress leads hemoglobin denaturation formation Heinz bodies (denatured hemoglobin precipitates)\nHeinz bodies damage RBC membrane, leading intravascular extravascular hemolysis\n\nInheritance: X-linked recessive; common males\nClinical Findings:\nindividuals asymptomatic exposed oxidative stressor\nAcute hemolytic anemia:\nSudden onset jaundice, dark urine, fatigue\nSymptoms usually resolve within weeks oxidative stressor removed\n\nChronic nonspherocytic hemolytic anemia (severe variants)\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\n\nPeripheral Blood Smear:\nBite cells (RBCs portion removed splenic macrophages)\nHeinz bodies (require special stain, e.g., crystal violet brilliant green)\nPolychromasia\n\nReticulocyte Count: Elevated\nG6PD Assay:\nDecreased G6PD enzyme activity (may normal acute hemolytic episodes due increased reticulocytes)\n\n\nTreatment:\nAvoidance oxidative stressors (certain drugs, foods, infections)\nSupportive care hemolytic episodes:\nHydration\nBlood transfusions (severe cases)\n\nFolic acid supplementation\n\nDefect: Deficiency G6PD, enzyme pentose phosphate pathway (hexose monophosphate shunt)Pathophysiology:\nG6PD essential producing NADPH, protects RBCs oxidative damage\nWithout NADPH, RBCs vulnerable oxidative stress infections, drugs, certain foods (e.g., fava beans)\nOxidative stress leads hemoglobin denaturation formation Heinz bodies (denatured hemoglobin precipitates)\nHeinz bodies damage RBC membrane, leading intravascular extravascular hemolysis\nG6PD essential producing NADPH, protects RBCs oxidative damageWithout NADPH, RBCs vulnerable oxidative stress infections, drugs, certain foods (e.g., fava beans)Oxidative stress leads hemoglobin denaturation formation Heinz bodies (denatured hemoglobin precipitates)Heinz bodies damage RBC membrane, leading intravascular extravascular hemolysisInheritance: X-linked recessive; common malesClinical Findings:\nindividuals asymptomatic exposed oxidative stressor\nAcute hemolytic anemia:\nSudden onset jaundice, dark urine, fatigue\nSymptoms usually resolve within weeks oxidative stressor removed\n\nChronic nonspherocytic hemolytic anemia (severe variants)\nindividuals asymptomatic exposed oxidative stressorAcute hemolytic anemia:\nSudden onset jaundice, dark urine, fatigue\nSymptoms usually resolve within weeks oxidative stressor removed\nSudden onset jaundice, dark urine, fatigueSymptoms usually resolve within weeks oxidative stressor removedChronic nonspherocytic hemolytic anemia (severe variants)Laboratory Findings:\nCBC:\nDecreased HGB HCT\n\nPeripheral Blood Smear:\nBite cells (RBCs portion removed splenic macrophages)\nHeinz bodies (require special stain, e.g., crystal violet brilliant green)\nPolychromasia\n\nReticulocyte Count: Elevated\nG6PD Assay:\nDecreased G6PD enzyme activity (may normal acute hemolytic episodes due increased reticulocytes)\n\nCBC:\nDecreased HGB HCT\nDecreased HGB HCTPeripheral Blood Smear:\nBite cells (RBCs portion removed splenic macrophages)\nHeinz bodies (require special stain, e.g., crystal violet brilliant green)\nPolychromasia\nBite cells (RBCs portion removed splenic macrophages)Heinz bodies (require special stain, e.g., crystal violet brilliant green)PolychromasiaReticulocyte Count: ElevatedG6PD Assay:\nDecreased G6PD enzyme activity (may normal acute hemolytic episodes due increased reticulocytes)\nDecreased G6PD enzyme activity (may normal acute hemolytic episodes due increased reticulocytes)Treatment:\nAvoidance oxidative stressors (certain drugs, foods, infections)\nSupportive care hemolytic episodes:\nHydration\nBlood transfusions (severe cases)\n\nFolic acid supplementation\nAvoidance oxidative stressors (certain drugs, foods, infections)Supportive care hemolytic episodes:\nHydration\nBlood transfusions (severe cases)\nHydrationBlood transfusions (severe cases)Folic acid supplementationPyruvate Kinase (PK) Deficiency:\nDefect: Deficiency pyruvate kinase (PK), enzyme glycolytic pathway (Embden-Meyerhof pathway)\nPathophysiology:\nPK essential generating ATP, required maintain RBC shape, membrane integrity, ion transport\nWithout sufficient ATP, RBCs become rigid, dehydrated, prone splenic sequestration\nResults chronic hemolytic anemia\n\nInheritance: Autosomal recessive\nClinical Findings:\nChronic hemolytic anemia\nJaundice\nSplenomegaly\nGallstones (cholelithiasis)\n\nLaboratory Findings:\nCBC:\nDecreased HGB HCT\nNormal decreased MCV (can slightly macrocytic cases)\nNormal MCHC\n\nPeripheral Blood Smear:\nNormal shape slight poikilocytosis\nspherocytes\n\nReticulocyte Count: Markedly elevated\nPyruvate Kinase (PK) Assay:\nDecreased PK enzyme activity\n\n\nTreatment:\nBlood transfusions (may needed, especially severe cases)\nSplenectomy: May reduce transfusion requirements increases risk thrombosis\nFolic acid supplementation\n\nDefect: Deficiency pyruvate kinase (PK), enzyme glycolytic pathway (Embden-Meyerhof pathway)Pathophysiology:\nPK essential generating ATP, required maintain RBC shape, membrane integrity, ion transport\nWithout sufficient ATP, RBCs become rigid, dehydrated, prone splenic sequestration\nResults chronic hemolytic anemia\nPK essential generating ATP, required maintain RBC shape, membrane integrity, ion transportWithout sufficient ATP, RBCs become rigid, dehydrated, prone splenic sequestrationResults chronic hemolytic anemiaInheritance: Autosomal recessiveClinical Findings:\nChronic hemolytic anemia\nJaundice\nSplenomegaly\nGallstones (cholelithiasis)\nChronic hemolytic anemiaJaundiceSplenomegalyGallstones (cholelithiasis)Laboratory Findings:\nCBC:\nDecreased HGB HCT\nNormal decreased MCV (can slightly macrocytic cases)\nNormal MCHC\n\nPeripheral Blood Smear:\nNormal shape slight poikilocytosis\nspherocytes\n\nReticulocyte Count: Markedly elevated\nPyruvate Kinase (PK) Assay:\nDecreased PK enzyme activity\n\nCBC:\nDecreased HGB HCT\nNormal decreased MCV (can slightly macrocytic cases)\nNormal MCHC\nDecreased HGB HCTNormal decreased MCV (can slightly macrocytic cases)Normal MCHCPeripheral Blood Smear:\nNormal shape slight poikilocytosis\nspherocytes\nNormal shape slight poikilocytosisNo spherocytesReticulocyte Count: Markedly elevatedPyruvate Kinase (PK) Assay:\nDecreased PK enzyme activity\nDecreased PK enzyme activityTreatment:\nBlood transfusions (may needed, especially severe cases)\nSplenectomy: May reduce transfusion requirements increases risk thrombosis\nFolic acid supplementation\nBlood transfusions (may needed, especially severe cases)Splenectomy: May reduce transfusion requirements increases risk thrombosisFolic acid supplementation","code":""},{"path":"hereditary-hemolytic.html","id":"general-laboratory-findings-in-hemolytic-anemias","chapter":"Hereditary Hemolytic","heading":"General Laboratory Findings in Hemolytic Anemias","text":"Increased Red Blood Cell Destruction:\nElevated indirect (unconjugated) bilirubin\nElevated lactate dehydrogenase (LDH)\nDecreased haptoglobin (due binding free hemoglobin)\nHemoglobinuria (hemoglobin urine) intravascular hemolysis\nHemosiderinuria (iron urine) chronic intravascular hemolysis\nElevated indirect (unconjugated) bilirubinElevated lactate dehydrogenase (LDH)Decreased haptoglobin (due binding free hemoglobin)Hemoglobinuria (hemoglobin urine) intravascular hemolysisHemosiderinuria (iron urine) chronic intravascular hemolysisIncreased Red Blood Cell Production:\nElevated reticulocyte count\nPolychromasia peripheral blood smear\nElevated reticulocyte countPolychromasia peripheral blood smear","code":""},{"path":"hereditary-hemolytic.html","id":"key-terms-10","chapter":"Hereditary Hemolytic","heading":"Key Terms","text":"Hemolytic Anemia: Anemia caused increased red blood cell destructionIntrinsic Hemolytic Anemia: Hemolysis due defects within red blood cellExtrinsic Hemolytic Anemia: Hemolysis due external factorsSpherocytes: Spherical-shaped red blood cells (hallmark hereditary spherocytosis)Elliptocytes: Elliptical-shaped red blood cells (hallmark hereditary elliptocytosis)Stomatocytes: Red blood cells mouth-like appearance (seen hereditary stomatocytosis)Heinz Bodies: Denatured hemoglobin precipitates (seen G6PD deficiency)Osmotic Fragility: measure resistance red blood cells lysis hypotonic solutionsReticulocyte: Immature red blood cellHaptoglobin: Protein binds free hemoglobinBilirubin: Product heme breakdownEnzyme Deficiency: Lack specific enzyme needed proper red blood cell metabolismSplenectomy: Surgical removal spleen","code":""},{"path":"acquired-hemolytic.html","id":"acquired-hemolytic","chapter":"Acquired Hemolytic","heading":"Acquired Hemolytic","text":"","code":""},{"path":"acquired-hemolytic.html","id":"overview-of-acquired-immune-mediated-hemolytic-anemias","chapter":"Acquired Hemolytic","heading":"Overview of Acquired [Immune-Mediated] Hemolytic Anemias","text":"Definition: Hemolysis (RBC destruction) occurs due binding antibodies /complement proteins surface RBCsHallmark: positive Direct Antiglobulin Test (DAT), also known Coombs test. DAT detects presence antibodies complement proteins bound RBCsClassification:\nAutoimmune Hemolytic Anemia (AIHA): Antibodies directed individual’s RBC antigens\nWarm AIHA\nCold AIHA (Cold Agglutinin Disease)\nParoxysmal Cold Hemoglobinuria (PCH)\n\nDrug-Induced Hemolytic Anemia: Antibodies produced result drug exposure\nAlloimmune Hemolytic Anemia: Antibodies directed foreign RBC antigens, typically following transfusion pregnancy\nHemolytic Disease Fetus Newborn (HDFN)\nHemolytic Transfusion Reactions\n\nAutoimmune Hemolytic Anemia (AIHA): Antibodies directed individual’s RBC antigens\nWarm AIHA\nCold AIHA (Cold Agglutinin Disease)\nParoxysmal Cold Hemoglobinuria (PCH)\nWarm AIHACold AIHA (Cold Agglutinin Disease)Paroxysmal Cold Hemoglobinuria (PCH)Drug-Induced Hemolytic Anemia: Antibodies produced result drug exposureAlloimmune Hemolytic Anemia: Antibodies directed foreign RBC antigens, typically following transfusion pregnancy\nHemolytic Disease Fetus Newborn (HDFN)\nHemolytic Transfusion Reactions\nHemolytic Disease Fetus Newborn (HDFN)Hemolytic Transfusion Reactions","code":""},{"path":"acquired-hemolytic.html","id":"mechanisms-of-immune-mediated-hemolysis","chapter":"Acquired Hemolytic","heading":"Mechanisms of Immune-Mediated Hemolysis","text":"Players\nRed Blood Cells (RBCs): innocent bystanders scenario, carrying antigens surface can mistakenly targeted immune system\nAntibodies: Immunoglobulins (IgG IgM) produced B lymphocytes can bind specific antigens RBC surface\nComplement System: group plasma proteins , activated, can lead cell lysis, inflammation, enhanced phagocytosis\nMononuclear Phagocyte System (MPS) / Reticuloendothelial System (RES): network phagocytic cells (macrophages) located throughout body (especially spleen liver) engulf destroy antibody- /complement-coated RBCs\nRed Blood Cells (RBCs): innocent bystanders scenario, carrying antigens surface can mistakenly targeted immune systemAntibodies: Immunoglobulins (IgG IgM) produced B lymphocytes can bind specific antigens RBC surfaceComplement System: group plasma proteins , activated, can lead cell lysis, inflammation, enhanced phagocytosisMononuclear Phagocyte System (MPS) / Reticuloendothelial System (RES): network phagocytic cells (macrophages) located throughout body (especially spleen liver) engulf destroy antibody- /complement-coated RBCsThe Process\nSensitization (Antibody Binding):\nprocess begins antibodies bind antigens surface RBCs. antigens can :\nSelf-antigens: autoimmune hemolytic anemia (AIHA), antibodies autoantibodies mistakenly recognize individual’s RBC antigens foreign\nDrug-related antigens: drug-induced hemolytic anemia, antibodies may directed drug adsorbed RBC surface drug-antibody complex\nForeign antigens: alloimmune hemolytic anemia, antibodies alloantibodies recognize foreign RBC antigens previous transfusion fetus pregnancy\n\ntype antibody involved (IgG IgM) density antigen sites RBC influence subsequent steps\n\nActivation Complement System (Complement-Mediated Hemolysis):\ncommon IgM antibodies, IgG can also activate complement\nclassical pathway complement activation triggered C1q binds Fc region IgM IgG antibodies RBC surface\nleads cascade events, resulting sequential activation complement proteins (C1, C4, C2, C3, C5, C6, C7, C8, C9)\nKey Steps:\nC3 Convertase Formation: C4b2a (C3 convertase) cleaves C3 C3a C3b\nC5 Convertase Formation: C4b2a3b (C5 convertase) cleaves C5 C5a C5b\nMembrane Attack Complex (MAC) Assembly: C5b initiates assembly MAC (C5b-C6-C7-C8-C9) RBC membrane\n\nOutcomes Complement Activation:\nIntravascular Hemolysis: MAC inserts RBC membrane, creating pores disrupt cell’s osmotic balance, leading lysis (rupture) within blood vessels\nOpsonization: C3b opsonizes (coats) RBCs, making recognizable phagocytes MPS (see )\nAnaphylatoxins: C3a C5a released act anaphylatoxins, promoting inflammation attracting immune cells\n\n\nExtravascular Hemolysis (MPS-Mediated):\nEven complement cascade isn’t fully activated point forming MAC, antibody- /complement-coated RBCs targeted destruction MPS, primarily spleen liver\nProcess:\nOpsonization: RBCs coated IgG antibodies /complement fragments (primarily C3b)\nRecognition Macrophages: Macrophages spleen liver express:\nFc receptors bind Fc region IgG antibodies\nComplement receptors (e.g., CR1) bind C3b\n\nPhagocytosis: Macrophages engulf destroy antibody- /complement-coated RBCs\n\nConsequences Phagocytosis:\nRBC Destruction: RBC broken within macrophage\nHemoglobin Breakdown: Hemoglobin metabolized :\nGlobin: Broken amino acids\nIron: Recycled stored ferritin/hemosiderin\nPorphyrin: Converted bilirubin, released circulation\n\n\n\nSensitization (Antibody Binding):\nprocess begins antibodies bind antigens surface RBCs. antigens can :\nSelf-antigens: autoimmune hemolytic anemia (AIHA), antibodies autoantibodies mistakenly recognize individual’s RBC antigens foreign\nDrug-related antigens: drug-induced hemolytic anemia, antibodies may directed drug adsorbed RBC surface drug-antibody complex\nForeign antigens: alloimmune hemolytic anemia, antibodies alloantibodies recognize foreign RBC antigens previous transfusion fetus pregnancy\n\ntype antibody involved (IgG IgM) density antigen sites RBC influence subsequent steps\nprocess begins antibodies bind antigens surface RBCs. antigens can :\nSelf-antigens: autoimmune hemolytic anemia (AIHA), antibodies autoantibodies mistakenly recognize individual’s RBC antigens foreign\nDrug-related antigens: drug-induced hemolytic anemia, antibodies may directed drug adsorbed RBC surface drug-antibody complex\nForeign antigens: alloimmune hemolytic anemia, antibodies alloantibodies recognize foreign RBC antigens previous transfusion fetus pregnancy\nSelf-antigens: autoimmune hemolytic anemia (AIHA), antibodies autoantibodies mistakenly recognize individual’s RBC antigens foreignDrug-related antigens: drug-induced hemolytic anemia, antibodies may directed drug adsorbed RBC surface drug-antibody complexForeign antigens: alloimmune hemolytic anemia, antibodies alloantibodies recognize foreign RBC antigens previous transfusion fetus pregnancyThe type antibody involved (IgG IgM) density antigen sites RBC influence subsequent stepsActivation Complement System (Complement-Mediated Hemolysis):\ncommon IgM antibodies, IgG can also activate complement\nclassical pathway complement activation triggered C1q binds Fc region IgM IgG antibodies RBC surface\nleads cascade events, resulting sequential activation complement proteins (C1, C4, C2, C3, C5, C6, C7, C8, C9)\nKey Steps:\nC3 Convertase Formation: C4b2a (C3 convertase) cleaves C3 C3a C3b\nC5 Convertase Formation: C4b2a3b (C5 convertase) cleaves C5 C5a C5b\nMembrane Attack Complex (MAC) Assembly: C5b initiates assembly MAC (C5b-C6-C7-C8-C9) RBC membrane\n\nOutcomes Complement Activation:\nIntravascular Hemolysis: MAC inserts RBC membrane, creating pores disrupt cell’s osmotic balance, leading lysis (rupture) within blood vessels\nOpsonization: C3b opsonizes (coats) RBCs, making recognizable phagocytes MPS (see )\nAnaphylatoxins: C3a C5a released act anaphylatoxins, promoting inflammation attracting immune cells\n\ncommon IgM antibodies, IgG can also activate complementThe classical pathway complement activation triggered C1q binds Fc region IgM IgG antibodies RBC surfaceThis leads cascade events, resulting sequential activation complement proteins (C1, C4, C2, C3, C5, C6, C7, C8, C9)Key Steps:\nC3 Convertase Formation: C4b2a (C3 convertase) cleaves C3 C3a C3b\nC5 Convertase Formation: C4b2a3b (C5 convertase) cleaves C5 C5a C5b\nMembrane Attack Complex (MAC) Assembly: C5b initiates assembly MAC (C5b-C6-C7-C8-C9) RBC membrane\nC3 Convertase Formation: C4b2a (C3 convertase) cleaves C3 C3a C3bC5 Convertase Formation: C4b2a3b (C5 convertase) cleaves C5 C5a C5bMembrane Attack Complex (MAC) Assembly: C5b initiates assembly MAC (C5b-C6-C7-C8-C9) RBC membraneOutcomes Complement Activation:\nIntravascular Hemolysis: MAC inserts RBC membrane, creating pores disrupt cell’s osmotic balance, leading lysis (rupture) within blood vessels\nOpsonization: C3b opsonizes (coats) RBCs, making recognizable phagocytes MPS (see )\nAnaphylatoxins: C3a C5a released act anaphylatoxins, promoting inflammation attracting immune cells\nIntravascular Hemolysis: MAC inserts RBC membrane, creating pores disrupt cell’s osmotic balance, leading lysis (rupture) within blood vesselsOpsonization: C3b opsonizes (coats) RBCs, making recognizable phagocytes MPS (see )Anaphylatoxins: C3a C5a released act anaphylatoxins, promoting inflammation attracting immune cellsExtravascular Hemolysis (MPS-Mediated):\nEven complement cascade isn’t fully activated point forming MAC, antibody- /complement-coated RBCs targeted destruction MPS, primarily spleen liver\nProcess:\nOpsonization: RBCs coated IgG antibodies /complement fragments (primarily C3b)\nRecognition Macrophages: Macrophages spleen liver express:\nFc receptors bind Fc region IgG antibodies\nComplement receptors (e.g., CR1) bind C3b\n\nPhagocytosis: Macrophages engulf destroy antibody- /complement-coated RBCs\n\nConsequences Phagocytosis:\nRBC Destruction: RBC broken within macrophage\nHemoglobin Breakdown: Hemoglobin metabolized :\nGlobin: Broken amino acids\nIron: Recycled stored ferritin/hemosiderin\nPorphyrin: Converted bilirubin, released circulation\n\n\nEven complement cascade isn’t fully activated point forming MAC, antibody- /complement-coated RBCs targeted destruction MPS, primarily spleen liverThe Process:\nOpsonization: RBCs coated IgG antibodies /complement fragments (primarily C3b)\nRecognition Macrophages: Macrophages spleen liver express:\nFc receptors bind Fc region IgG antibodies\nComplement receptors (e.g., CR1) bind C3b\n\nPhagocytosis: Macrophages engulf destroy antibody- /complement-coated RBCs\nOpsonization: RBCs coated IgG antibodies /complement fragments (primarily C3b)Recognition Macrophages: Macrophages spleen liver express:\nFc receptors bind Fc region IgG antibodies\nComplement receptors (e.g., CR1) bind C3b\nFc receptors bind Fc region IgG antibodiesComplement receptors (e.g., CR1) bind C3bPhagocytosis: Macrophages engulf destroy antibody- /complement-coated RBCsConsequences Phagocytosis:\nRBC Destruction: RBC broken within macrophage\nHemoglobin Breakdown: Hemoglobin metabolized :\nGlobin: Broken amino acids\nIron: Recycled stored ferritin/hemosiderin\nPorphyrin: Converted bilirubin, released circulation\n\nRBC Destruction: RBC broken within macrophageHemoglobin Breakdown: Hemoglobin metabolized :\nGlobin: Broken amino acids\nIron: Recycled stored ferritin/hemosiderin\nPorphyrin: Converted bilirubin, released circulation\nGlobin: Broken amino acidsIron: Recycled stored ferritin/hemosiderinPorphyrin: Converted bilirubin, released circulationKey Players Detail\nAntibodies (IgG IgM):\nIgG:\nefficient opsonization promoting extravascular hemolysis\nCan cross placenta cause HDFN\nWarm AIHA typically IgG-mediated\n\nIgM:\nefficient activating complement cascade, leading intravascular hemolysis\ncross placenta (due large size)\nCold AIHA typically IgM-mediated\n\n\nComplement System:\ncascade plasma proteins , activated, can lead :\nCell lysis (formation MAC)\nOpsonization (coating cells enhance phagocytosis)\nInflammation (release anaphylatoxins)\n\n\nMononuclear Phagocyte System (MPS) / Reticuloendothelial System (RES):\nnetwork phagocytic cells (primarily macrophages) remove debris participate immune responses\nimmune-mediated hemolysis, MPS responsible :\nRecognizing engulfing antibody- /complement-coated RBCs\nBreaking RBCs recycling components\n\n\nAntibodies (IgG IgM):\nIgG:\nefficient opsonization promoting extravascular hemolysis\nCan cross placenta cause HDFN\nWarm AIHA typically IgG-mediated\n\nIgM:\nefficient activating complement cascade, leading intravascular hemolysis\ncross placenta (due large size)\nCold AIHA typically IgM-mediated\n\nIgG:\nefficient opsonization promoting extravascular hemolysis\nCan cross placenta cause HDFN\nWarm AIHA typically IgG-mediated\nefficient opsonization promoting extravascular hemolysisCan cross placenta cause HDFNWarm AIHA typically IgG-mediatedIgM:\nefficient activating complement cascade, leading intravascular hemolysis\ncross placenta (due large size)\nCold AIHA typically IgM-mediated\nefficient activating complement cascade, leading intravascular hemolysisCannot cross placenta (due large size)Cold AIHA typically IgM-mediatedComplement System:\ncascade plasma proteins , activated, can lead :\nCell lysis (formation MAC)\nOpsonization (coating cells enhance phagocytosis)\nInflammation (release anaphylatoxins)\n\ncascade plasma proteins , activated, can lead :\nCell lysis (formation MAC)\nOpsonization (coating cells enhance phagocytosis)\nInflammation (release anaphylatoxins)\nCell lysis (formation MAC)Opsonization (coating cells enhance phagocytosis)Inflammation (release anaphylatoxins)Mononuclear Phagocyte System (MPS) / Reticuloendothelial System (RES):\nnetwork phagocytic cells (primarily macrophages) remove debris participate immune responses\nimmune-mediated hemolysis, MPS responsible :\nRecognizing engulfing antibody- /complement-coated RBCs\nBreaking RBCs recycling components\n\nnetwork phagocytic cells (primarily macrophages) remove debris participate immune responsesIn immune-mediated hemolysis, MPS responsible :\nRecognizing engulfing antibody- /complement-coated RBCs\nBreaking RBCs recycling components\nRecognizing engulfing antibody- /complement-coated RBCsBreaking RBCs recycling components","code":""},{"path":"acquired-hemolytic.html","id":"types-of-immune-mediated-hemolytic-anemias","chapter":"Acquired Hemolytic","heading":"Types of Immune-Mediated Hemolytic Anemias","text":"Autoimmune Hemolytic Anemia (AIHA)\nDefinition: Anemia caused autoantibodies directed individual’s RBC antigens\nWarm Autoimmune Hemolytic Anemia (Warm AIHA):\nAntibody Type: IgG\nTemperature Reactivity: Reacts optimally body temperature (37°C)\nMechanism:\nIgG antibodies bind RBCs\nRBCs opsonized phagocytized macrophages spleen (extravascular hemolysis)\ncomplement activation may occur\n\nEtiology:\nPrimary (idiopathic): underlying cause\nSecondary: Associated autoimmune disorders (e.g., SLE), lymphoproliferative disorders (e.g., CLL), infections, drugs\n\nLaboratory Findings:\nDAT: Positive IgG (sometimes complement)\nPeripheral Blood Smear: Spherocytes, polychromasia\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\n\n\nCold Autoimmune Hemolytic Anemia (Cold AIHA):\nAntibody Type: IgM.\nTemperature Reactivity: Reacts optimally low temperatures (4°C)\nMechanism:\nIgM antibodies bind RBCs colder parts body (e.g., extremities)\nactivates complement cascade, leading :\nIntravascular hemolysis (formation MAC)\nOpsonization RBCs C3b, leading splenic sequestration (extravascular hemolysis)\n\nIgM antibodies may detach RBCs warmer temperatures, complement fragments remain bound, leading RBC destruction\n\nEtiology:\nAcute Cold AIHA (Cold Agglutinin Disease): Often associated infections (e.g., Mycoplasma pneumoniae, infectious mononucleosis). IgM antibodies often transient disappear infection resolves\nChronic Cold AIHA: Associated lymphoproliferative disorders (e.g., Waldenström macroglobulinemia)\n\nLaboratory Findings:\nDAT: Positive complement (C3d) . IgG usually negative IgM detaches RBCs\nPeripheral Blood Smear: RBC agglutination (clumping RBCs)\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\nCold Agglutinin Titer: Elevated (measures concentration cold-reacting IgM antibodies)\n\n\nParoxysmal Cold Hemoglobinuria (PCH):\nAntibody Type: IgG antibody called Donath-Landsteiner antibody\nTemperature Reactivity: Binds RBCs low temperatures causes complement-mediated hemolysis upon warming\nMechanism:\nDonath-Landsteiner antibody binds P antigen RBCs low temperatures\nUpon warming body temperature, antibody activates complement cascade, leading intravascular hemolysis\n\nEtiology:\nHistorically associated syphilis\nNow commonly associated viral infections children\n\nClinical Features:\nSudden onset hemolytic anemia, often exposure cold\nHemoglobinuria (dark urine)\nFever, chills, abdominal pain\n\nLaboratory Findings:\nCBC: Anemia\nPeripheral Blood Smear: May show spherocytes, polychromasia\nReticulocyte Count: Elevated\nElevated bilirubin LDH\nDecreased haptoglobin\nDAT: Positive complement (C3d) \nDonath-Landsteiner Test: Positive (confirms presence Donath-Landsteiner antibody)\n\n\nDefinition: Anemia caused autoantibodies directed individual’s RBC antigensWarm Autoimmune Hemolytic Anemia (Warm AIHA):\nAntibody Type: IgG\nTemperature Reactivity: Reacts optimally body temperature (37°C)\nMechanism:\nIgG antibodies bind RBCs\nRBCs opsonized phagocytized macrophages spleen (extravascular hemolysis)\ncomplement activation may occur\n\nEtiology:\nPrimary (idiopathic): underlying cause\nSecondary: Associated autoimmune disorders (e.g., SLE), lymphoproliferative disorders (e.g., CLL), infections, drugs\n\nLaboratory Findings:\nDAT: Positive IgG (sometimes complement)\nPeripheral Blood Smear: Spherocytes, polychromasia\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\n\nAntibody Type: IgGTemperature Reactivity: Reacts optimally body temperature (37°C)Mechanism:\nIgG antibodies bind RBCs\nRBCs opsonized phagocytized macrophages spleen (extravascular hemolysis)\ncomplement activation may occur\nIgG antibodies bind RBCsRBCs opsonized phagocytized macrophages spleen (extravascular hemolysis)complement activation may occurEtiology:\nPrimary (idiopathic): underlying cause\nSecondary: Associated autoimmune disorders (e.g., SLE), lymphoproliferative disorders (e.g., CLL), infections, drugs\nPrimary (idiopathic): underlying causeSecondary: Associated autoimmune disorders (e.g., SLE), lymphoproliferative disorders (e.g., CLL), infections, drugsLaboratory Findings:\nDAT: Positive IgG (sometimes complement)\nPeripheral Blood Smear: Spherocytes, polychromasia\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\nDAT: Positive IgG (sometimes complement)Peripheral Blood Smear: Spherocytes, polychromasiaIncreased reticulocyte countElevated bilirubin LDHDecreased haptoglobinCold Autoimmune Hemolytic Anemia (Cold AIHA):\nAntibody Type: IgM.\nTemperature Reactivity: Reacts optimally low temperatures (4°C)\nMechanism:\nIgM antibodies bind RBCs colder parts body (e.g., extremities)\nactivates complement cascade, leading :\nIntravascular hemolysis (formation MAC)\nOpsonization RBCs C3b, leading splenic sequestration (extravascular hemolysis)\n\nIgM antibodies may detach RBCs warmer temperatures, complement fragments remain bound, leading RBC destruction\n\nEtiology:\nAcute Cold AIHA (Cold Agglutinin Disease): Often associated infections (e.g., Mycoplasma pneumoniae, infectious mononucleosis). IgM antibodies often transient disappear infection resolves\nChronic Cold AIHA: Associated lymphoproliferative disorders (e.g., Waldenström macroglobulinemia)\n\nLaboratory Findings:\nDAT: Positive complement (C3d) . IgG usually negative IgM detaches RBCs\nPeripheral Blood Smear: RBC agglutination (clumping RBCs)\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\nCold Agglutinin Titer: Elevated (measures concentration cold-reacting IgM antibodies)\n\nAntibody Type: IgM.Temperature Reactivity: Reacts optimally low temperatures (4°C)Mechanism:\nIgM antibodies bind RBCs colder parts body (e.g., extremities)\nactivates complement cascade, leading :\nIntravascular hemolysis (formation MAC)\nOpsonization RBCs C3b, leading splenic sequestration (extravascular hemolysis)\n\nIgM antibodies may detach RBCs warmer temperatures, complement fragments remain bound, leading RBC destruction\nIgM antibodies bind RBCs colder parts body (e.g., extremities)activates complement cascade, leading :\nIntravascular hemolysis (formation MAC)\nOpsonization RBCs C3b, leading splenic sequestration (extravascular hemolysis)\nIntravascular hemolysis (formation MAC)Opsonization RBCs C3b, leading splenic sequestration (extravascular hemolysis)IgM antibodies may detach RBCs warmer temperatures, complement fragments remain bound, leading RBC destructionEtiology:\nAcute Cold AIHA (Cold Agglutinin Disease): Often associated infections (e.g., Mycoplasma pneumoniae, infectious mononucleosis). IgM antibodies often transient disappear infection resolves\nChronic Cold AIHA: Associated lymphoproliferative disorders (e.g., Waldenström macroglobulinemia)\nAcute Cold AIHA (Cold Agglutinin Disease): Often associated infections (e.g., Mycoplasma pneumoniae, infectious mononucleosis). IgM antibodies often transient disappear infection resolvesChronic Cold AIHA: Associated lymphoproliferative disorders (e.g., Waldenström macroglobulinemia)Laboratory Findings:\nDAT: Positive complement (C3d) . IgG usually negative IgM detaches RBCs\nPeripheral Blood Smear: RBC agglutination (clumping RBCs)\nIncreased reticulocyte count\nElevated bilirubin LDH\nDecreased haptoglobin\nCold Agglutinin Titer: Elevated (measures concentration cold-reacting IgM antibodies)\nDAT: Positive complement (C3d) . IgG usually negative IgM detaches RBCsPeripheral Blood Smear: RBC agglutination (clumping RBCs)Increased reticulocyte countElevated bilirubin LDHDecreased haptoglobinCold Agglutinin Titer: Elevated (measures concentration cold-reacting IgM antibodies)Paroxysmal Cold Hemoglobinuria (PCH):\nAntibody Type: IgG antibody called Donath-Landsteiner antibody\nTemperature Reactivity: Binds RBCs low temperatures causes complement-mediated hemolysis upon warming\nMechanism:\nDonath-Landsteiner antibody binds P antigen RBCs low temperatures\nUpon warming body temperature, antibody activates complement cascade, leading intravascular hemolysis\n\nEtiology:\nHistorically associated syphilis\nNow commonly associated viral infections children\n\nClinical Features:\nSudden onset hemolytic anemia, often exposure cold\nHemoglobinuria (dark urine)\nFever, chills, abdominal pain\n\nLaboratory Findings:\nCBC: Anemia\nPeripheral Blood Smear: May show spherocytes, polychromasia\nReticulocyte Count: Elevated\nElevated bilirubin LDH\nDecreased haptoglobin\nDAT: Positive complement (C3d) \nDonath-Landsteiner Test: Positive (confirms presence Donath-Landsteiner antibody)\n\nAntibody Type: IgG antibody called Donath-Landsteiner antibodyTemperature Reactivity: Binds RBCs low temperatures causes complement-mediated hemolysis upon warmingMechanism:\nDonath-Landsteiner antibody binds P antigen RBCs low temperatures\nUpon warming body temperature, antibody activates complement cascade, leading intravascular hemolysis\nDonath-Landsteiner antibody binds P antigen RBCs low temperaturesUpon warming body temperature, antibody activates complement cascade, leading intravascular hemolysisEtiology:\nHistorically associated syphilis\nNow commonly associated viral infections children\nHistorically associated syphilisNow commonly associated viral infections childrenClinical Features:\nSudden onset hemolytic anemia, often exposure cold\nHemoglobinuria (dark urine)\nFever, chills, abdominal pain\nSudden onset hemolytic anemia, often exposure coldHemoglobinuria (dark urine)Fever, chills, abdominal painLaboratory Findings:\nCBC: Anemia\nPeripheral Blood Smear: May show spherocytes, polychromasia\nReticulocyte Count: Elevated\nElevated bilirubin LDH\nDecreased haptoglobin\nDAT: Positive complement (C3d) \nDonath-Landsteiner Test: Positive (confirms presence Donath-Landsteiner antibody)\nCBC: AnemiaPeripheral Blood Smear: May show spherocytes, polychromasiaReticulocyte Count: ElevatedElevated bilirubin LDHDecreased haptoglobinDAT: Positive complement (C3d) onlyDonath-Landsteiner Test: Positive (confirms presence Donath-Landsteiner antibody)Drug-Induced Hemolytic Anemia\nMechanism:\nDrug Adsorption: Drug binds RBC membrane, antibodies directed drug-RBC complex\nImmune Complex Formation: Drug binds antibody plasma, immune complex binds RBCs, leading complement activation\nAutoantibody Formation: Drug induces production autoantibodies RBCs (similar warm AIHA)\n\nCommon Drugs:\nPenicillin cephalosporins (drug adsorption)\nQuinidine quinine (immune complex formation)\nMethyldopa (autoantibody formation)\n\nLaboratory Findings:\nCBC: Anemia\nPeripheral Blood Smear: Spherocytes, polychromasia\nReticulocyte Count: Elevated\nDAT: Positive (may positive IgG, complement, )\nDrug-specific antibody testing (may available)\n\nTreatment: Discontinue offending drug\nMechanism:\nDrug Adsorption: Drug binds RBC membrane, antibodies directed drug-RBC complex\nImmune Complex Formation: Drug binds antibody plasma, immune complex binds RBCs, leading complement activation\nAutoantibody Formation: Drug induces production autoantibodies RBCs (similar warm AIHA)\nDrug Adsorption: Drug binds RBC membrane, antibodies directed drug-RBC complexImmune Complex Formation: Drug binds antibody plasma, immune complex binds RBCs, leading complement activationAutoantibody Formation: Drug induces production autoantibodies RBCs (similar warm AIHA)Common Drugs:\nPenicillin cephalosporins (drug adsorption)\nQuinidine quinine (immune complex formation)\nMethyldopa (autoantibody formation)\nPenicillin cephalosporins (drug adsorption)Quinidine quinine (immune complex formation)Methyldopa (autoantibody formation)Laboratory Findings:\nCBC: Anemia\nPeripheral Blood Smear: Spherocytes, polychromasia\nReticulocyte Count: Elevated\nDAT: Positive (may positive IgG, complement, )\nDrug-specific antibody testing (may available)\nCBC: AnemiaPeripheral Blood Smear: Spherocytes, polychromasiaReticulocyte Count: ElevatedDAT: Positive (may positive IgG, complement, )Drug-specific antibody testing (may available)Treatment: Discontinue offending drugAlloimmune Hemolytic Anemia\nHemolytic Disease Fetus Newborn (HDFN):\nMechanism:\nMaternal alloantibodies (usually IgG) cross placenta attack fetal RBCs\ncommonly caused Rh incompatibility (anti-D) ABO incompatibility\nRh Incompatibility: Rh-negative mother exposed Rh-positive fetal blood pregnancy delivery, leading production anti-D antibodies. subsequent pregnancies, antibodies cross placenta attack Rh-positive fetal RBCs\nABO Incompatibility: Mother blood type O anti-anti-B IgG antibodies can cross placenta attack fetal RBCs (usually milder Rh incompatibility)\n\nClinical Features:\nFetal anemia, hydrops fetalis (severe edema), jaundice birth\n\nLaboratory Findings:\nMaternal Antibody Screening: Detects presence alloantibodies mother’s serum\nDAT Newborn RBCs: Positive IgG (sometimes complement)\nBilirubin: Elevated newborn\n\nPrevention:\nRhoGAM (Rh immune globulin) administered Rh-negative mothers pregnancy delivery prevent Rh sensitization\n\nTreatment:\nIntrauterine transfusions severe fetal anemia\nExchange transfusions birth reduce bilirubin levels\n\n\nHemolytic Transfusion Reactions:\nMechanism:\nRecipient produces alloantibodies donor RBC antigens (e.g., anti-, anti-B, anti-Rh antibodies)\nTransfused RBCs attacked recipient antibodies, leading hemolysis\n\nTypes:\nAcute Hemolytic Transfusion Reaction: Occurs within minutes hours transfusion. Symptoms include fever, chills, chest pain, back pain, hemoglobinuria\nDelayed Hemolytic Transfusion Reaction: Occurs days weeks transfusion. Symptoms may milder\n\nLaboratory Findings:\nDAT: Positive post-transfusion RBCs\nAntibody Identification: Detects alloantibodies patient’s serum\nElevated bilirubin LDH\nDecreased haptoglobin\n\nTreatment:\nStop transfusion immediately\nSupportive care (IV fluids, vasopressors)\nManage complications (e.g., acute renal failure, DIC)\n\n\nHemolytic Disease Fetus Newborn (HDFN):\nMechanism:\nMaternal alloantibodies (usually IgG) cross placenta attack fetal RBCs\ncommonly caused Rh incompatibility (anti-D) ABO incompatibility\nRh Incompatibility: Rh-negative mother exposed Rh-positive fetal blood pregnancy delivery, leading production anti-D antibodies. subsequent pregnancies, antibodies cross placenta attack Rh-positive fetal RBCs\nABO Incompatibility: Mother blood type O anti-anti-B IgG antibodies can cross placenta attack fetal RBCs (usually milder Rh incompatibility)\n\nClinical Features:\nFetal anemia, hydrops fetalis (severe edema), jaundice birth\n\nLaboratory Findings:\nMaternal Antibody Screening: Detects presence alloantibodies mother’s serum\nDAT Newborn RBCs: Positive IgG (sometimes complement)\nBilirubin: Elevated newborn\n\nPrevention:\nRhoGAM (Rh immune globulin) administered Rh-negative mothers pregnancy delivery prevent Rh sensitization\n\nTreatment:\nIntrauterine transfusions severe fetal anemia\nExchange transfusions birth reduce bilirubin levels\n\nMechanism:\nMaternal alloantibodies (usually IgG) cross placenta attack fetal RBCs\ncommonly caused Rh incompatibility (anti-D) ABO incompatibility\nRh Incompatibility: Rh-negative mother exposed Rh-positive fetal blood pregnancy delivery, leading production anti-D antibodies. subsequent pregnancies, antibodies cross placenta attack Rh-positive fetal RBCs\nABO Incompatibility: Mother blood type O anti-anti-B IgG antibodies can cross placenta attack fetal RBCs (usually milder Rh incompatibility)\nMaternal alloantibodies (usually IgG) cross placenta attack fetal RBCsMost commonly caused Rh incompatibility (anti-D) ABO incompatibilityRh Incompatibility: Rh-negative mother exposed Rh-positive fetal blood pregnancy delivery, leading production anti-D antibodies. subsequent pregnancies, antibodies cross placenta attack Rh-positive fetal RBCsABO Incompatibility: Mother blood type O anti-anti-B IgG antibodies can cross placenta attack fetal RBCs (usually milder Rh incompatibility)Clinical Features:\nFetal anemia, hydrops fetalis (severe edema), jaundice birth\nFetal anemia, hydrops fetalis (severe edema), jaundice birthLaboratory Findings:\nMaternal Antibody Screening: Detects presence alloantibodies mother’s serum\nDAT Newborn RBCs: Positive IgG (sometimes complement)\nBilirubin: Elevated newborn\nMaternal Antibody Screening: Detects presence alloantibodies mother’s serumDAT Newborn RBCs: Positive IgG (sometimes complement)Bilirubin: Elevated newbornPrevention:\nRhoGAM (Rh immune globulin) administered Rh-negative mothers pregnancy delivery prevent Rh sensitization\nRhoGAM (Rh immune globulin) administered Rh-negative mothers pregnancy delivery prevent Rh sensitizationTreatment:\nIntrauterine transfusions severe fetal anemia\nExchange transfusions birth reduce bilirubin levels\nIntrauterine transfusions severe fetal anemiaExchange transfusions birth reduce bilirubin levelsHemolytic Transfusion Reactions:\nMechanism:\nRecipient produces alloantibodies donor RBC antigens (e.g., anti-, anti-B, anti-Rh antibodies)\nTransfused RBCs attacked recipient antibodies, leading hemolysis\n\nTypes:\nAcute Hemolytic Transfusion Reaction: Occurs within minutes hours transfusion. Symptoms include fever, chills, chest pain, back pain, hemoglobinuria\nDelayed Hemolytic Transfusion Reaction: Occurs days weeks transfusion. Symptoms may milder\n\nLaboratory Findings:\nDAT: Positive post-transfusion RBCs\nAntibody Identification: Detects alloantibodies patient’s serum\nElevated bilirubin LDH\nDecreased haptoglobin\n\nTreatment:\nStop transfusion immediately\nSupportive care (IV fluids, vasopressors)\nManage complications (e.g., acute renal failure, DIC)\n\nMechanism:\nRecipient produces alloantibodies donor RBC antigens (e.g., anti-, anti-B, anti-Rh antibodies)\nTransfused RBCs attacked recipient antibodies, leading hemolysis\nRecipient produces alloantibodies donor RBC antigens (e.g., anti-, anti-B, anti-Rh antibodies)Transfused RBCs attacked recipient antibodies, leading hemolysisTypes:\nAcute Hemolytic Transfusion Reaction: Occurs within minutes hours transfusion. Symptoms include fever, chills, chest pain, back pain, hemoglobinuria\nDelayed Hemolytic Transfusion Reaction: Occurs days weeks transfusion. Symptoms may milder\nAcute Hemolytic Transfusion Reaction: Occurs within minutes hours transfusion. Symptoms include fever, chills, chest pain, back pain, hemoglobinuriaDelayed Hemolytic Transfusion Reaction: Occurs days weeks transfusion. Symptoms may milderLaboratory Findings:\nDAT: Positive post-transfusion RBCs\nAntibody Identification: Detects alloantibodies patient’s serum\nElevated bilirubin LDH\nDecreased haptoglobin\nDAT: Positive post-transfusion RBCsAntibody Identification: Detects alloantibodies patient’s serumElevated bilirubin LDHDecreased haptoglobinTreatment:\nStop transfusion immediately\nSupportive care (IV fluids, vasopressors)\nManage complications (e.g., acute renal failure, DIC)\nStop transfusion immediatelySupportive care (IV fluids, vasopressors)Manage complications (e.g., acute renal failure, DIC)","code":""},{"path":"acquired-hemolytic.html","id":"general-laboratory-findings-in-immune-mediated-hemolytic-anemias","chapter":"Acquired Hemolytic","heading":"General Laboratory Findings in Immune-Mediated Hemolytic Anemias","text":"Complete Blood Count (CBC):\nAnemia (low HGB HCT)\nMCV: May normocytic macrocytic (due reticulocytosis)\nAnemia (low HGB HCT)MCV: May normocytic macrocytic (due reticulocytosis)Peripheral Blood Smear:\nSpherocytes\nPolychromasia\nRBC agglutination (cold AIHA)\nSpherocytesPolychromasiaRBC agglutination (cold AIHA)Reticulocyte Count:\nElevated\nElevatedBilirubin:\nElevated unconjugated (indirect) bilirubin\nElevated unconjugated (indirect) bilirubinLactate Dehydrogenase (LDH):\nElevated\nElevatedHaptoglobin:\nDecreased absent\nDecreased absentDirect Antiglobulin Test (DAT):\nPositive:\nWarm AIHA: Positive IgG (sometimes complement)\nCold AIHA: Positive complement (C3d) \nDrug-Induced Hemolytic Anemia: May positive IgG, complement, \nHDFN: Positive IgG\nHemolytic Transfusion Reactions: Positive IgG, complement, \n\nPositive:\nWarm AIHA: Positive IgG (sometimes complement)\nCold AIHA: Positive complement (C3d) \nDrug-Induced Hemolytic Anemia: May positive IgG, complement, \nHDFN: Positive IgG\nHemolytic Transfusion Reactions: Positive IgG, complement, \nWarm AIHA: Positive IgG (sometimes complement)Cold AIHA: Positive complement (C3d) onlyDrug-Induced Hemolytic Anemia: May positive IgG, complement, bothHDFN: Positive IgGHemolytic Transfusion Reactions: Positive IgG, complement, ","code":""},{"path":"acquired-hemolytic.html","id":"key-terms-11","chapter":"Acquired Hemolytic","heading":"Key Terms","text":"Autoimmune Hemolytic Anemia (AIHA): Anemia caused autoantibodies RBCsWarm AIHA: IgG-mediated hemolysis body temperatureCold AIHA: IgM-mediated hemolysis low temperaturesParoxysmal Cold Hemoglobinuria (PCH): IgG-mediated hemolysis triggered cold exposureDrug-Induced Hemolytic Anemia: Hemolysis caused drug-induced antibodiesAlloimmune Hemolytic Anemia: Hemolysis due alloantibodies foreign RBC antigensHemolytic Disease Fetus Newborn (HDFN): Maternal antibodies attack fetal RBCsDirect Antiglobulin Test (DAT): Test detect antibodies complement RBCsSpherocytes: Spherical red blood cellsPolychromasia: Increased number reticulocytesCold Agglutinins: IgM antibodies cause RBC agglutination low temperatures","code":""},{"path":"hypoproliferative.html","id":"hypoproliferative","chapter":"Hypoproliferative","heading":"Hypoproliferative","text":"","code":""},{"path":"hypoproliferative.html","id":"overview-of-hypoproliferative-anemias","chapter":"Hypoproliferative","heading":"Overview of Hypoproliferative Anemias","text":"Definition: group anemias characterized decreased production red blood cells (RBCs) bone marrow. due problem bone marrow’s ability produce RBCs, despite adequate nutrients (like iron, vitamin B12, folate)Hallmark: low reticulocyte count (corrected reticulocyte count reticulocyte production index) setting anemia. indicates bone marrow responding appropriately anemia increasing RBC productionKey Feature: Reduced erythropoiesis (RBC production) bone marrowClassification:\nPrimary Bone Marrow Disorders: Intrinsic problems within bone marrow (e.g., aplastic anemia, myelodysplastic syndromes)\nSecondary Causes: Extrinsic factors suppress erythropoiesis (e.g., chronic kidney disease, endocrine disorders, anemia chronic disease)\nPrimary Bone Marrow Disorders: Intrinsic problems within bone marrow (e.g., aplastic anemia, myelodysplastic syndromes)Secondary Causes: Extrinsic factors suppress erythropoiesis (e.g., chronic kidney disease, endocrine disorders, anemia chronic disease)","code":""},{"path":"hypoproliferative.html","id":"key-concepts","chapter":"Hypoproliferative","heading":"Key Concepts","text":"Reticulocyte Response: normal, healthy individual anemia, bone marrow respond increasing RBC production, leading elevated reticulocyte count. hypoproliferative anemias, response absent inadequateBone Marrow Examination: bone marrow aspiration biopsy often essential diagnosing hypoproliferative anemias, provides direct information cellularity maturation bone marrowExclusion Causes: ’s important rule causes anemia (e.g., blood loss, hemolysis, nutritional deficiencies) diagnosing hypoproliferative anemia","code":""},{"path":"hypoproliferative.html","id":"causes-of-hypoproliferative-anemias","chapter":"Hypoproliferative","heading":"Causes of Hypoproliferative Anemias","text":"Primary Bone Marrow Disorders:\nAplastic Anemia (AA):\nDefinition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow\nEtiology: Can acquired (idiopathic, autoimmune, drug-induced, radiation-induced, infection-related) inherited (e.g., Fanconi anemia)\nPathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell lines\nClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (increased susceptibility infections)\n\nLaboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (hallmark finding)\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\n\nTreatment:\nSupportive care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nsuppress autoimmune attack bone marrow stem cells\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\n\n\n\nMyelodysplastic Syndromes (MDS):\nDefinition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis variable risk progression acute myeloid leukemia (AML)\nEtiology: Acquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\n\nPathophysiology: Dysplastic (abnormal) development one myeloid cell lines (RBCs, WBCs, platelets), leading cytopenias increased risk AML\nClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (infections)\n\nLaboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nRBCs: Oval macrocytes, hypochromia, basophilic stippling\nNeutrophils: Pseudo-Pelger-Huët anomaly (bi-lobed neutrophils), hypogranulation\nPlatelets: Large platelets, abnormal granulation\n\nReticulocyte Count: Low normal (inappropriately low degree anemia)\nBone Marrow Examination: Hypercellular hypocellular marrow dysplasia one cell lines\nCytogenetic Analysis: Chromosomal abnormalities (e.g., deletion 5q, trisomy 8) common\n\nTreatment:\nSupportive care:\nTransfusions manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\n\nHypomethylating Agents:\nAzacitidine decitabine: Improve hematopoiesis reduce risk AML transformation\n\nLenalidomide:\nUsed patients MDS deletion 5q\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\n\n\n\nPure Red Cell Aplasia (PRCA):\nDefinition: Selective destruction erythroid precursors bone marrow, leading severe anemia marked decrease reticulocytes\nEtiology:\nAcquired:\nAutoimmune: Antibodies erythroid precursors erythropoietin\nInfections: Parvovirus B19 infection (especially patients chronic hemolytic anemias)\nDrug-induced: Certain medications (e.g., erythropoietin, immunosuppressants)\nThymoma: Tumor thymus gland\n\nInherited: Diamond-Blackfan anemia\n\nPathophysiology:\nAutoantibodies cytotoxic T cells target destroy erythroid precursors (CFU-Es proerythroblasts) bone marrow\nParvovirus B19 directly infects destroys erythroid precursors\n\nClinical Features:\nSevere anemia\nAbsence cytopenias (normal WBC platelet counts)\n\nLaboratory Findings:\nCBC: Severe anemia normal WBC platelet counts\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (near zero)\nBone Marrow Examination: Normal cellularity marked decrease absence erythroid precursors\nAntibody Testing: May detect antibodies erythroid precursors erythropoietin\nParvovirus B19 PCR: detect parvovirus B19 infection\n\nTreatment:\nTreat Underlying Cause:\nDiscontinue offending medications\nTreat infections (e.g., parvovirus B19)\nRemove thymoma (present)\n\nImmunosuppressive Therapy:\nCorticosteroids\nCyclosporine\n\nIntravenous Immunoglobulin (IVIG):\nMay used parvovirus B19-related PRCA\n\nBlood Transfusions:\nmanage severe anemia\n\nErythropoiesis-Stimulating Agents (ESAs):\nMay effective cases, especially EPO levels low\n\n\n\nAplastic Anemia (AA):\nDefinition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow\nEtiology: Can acquired (idiopathic, autoimmune, drug-induced, radiation-induced, infection-related) inherited (e.g., Fanconi anemia)\nPathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell lines\nClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (increased susceptibility infections)\n\nLaboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (hallmark finding)\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\n\nTreatment:\nSupportive care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nsuppress autoimmune attack bone marrow stem cells\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\n\n\nDefinition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrowEtiology: Can acquired (idiopathic, autoimmune, drug-induced, radiation-induced, infection-related) inherited (e.g., Fanconi anemia)Pathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell linesClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (increased susceptibility infections)\nAnemia (fatigue, weakness, pallor)Thrombocytopenia (bleeding, bruising)Neutropenia (increased susceptibility infections)Laboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (hallmark finding)\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)Peripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cellsReticulocyte Count: low (hallmark finding)Bone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cellsFlow cytometry: May show decreased abnormal hematopoietic stem cellsTreatment:\nSupportive care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nsuppress autoimmune attack bone marrow stem cells\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\n\nSupportive care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\nTransfusions (RBCs platelets) alleviate symptomsAntibiotics treat infectionsImmunosuppressive Therapy:\nsuppress autoimmune attack bone marrow stem cells\nAntithymocyte globulin (ATG)\nCyclosporine\nsuppress autoimmune attack bone marrow stem cellsAntithymocyte globulin (ATG)CyclosporineHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\nPotentially curative option, especially younger patients matched donorsInvolves replacing patient’s damaged bone marrow healthy stem cells donorMyelodysplastic Syndromes (MDS):\nDefinition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis variable risk progression acute myeloid leukemia (AML)\nEtiology: Acquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\n\nPathophysiology: Dysplastic (abnormal) development one myeloid cell lines (RBCs, WBCs, platelets), leading cytopenias increased risk AML\nClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (infections)\n\nLaboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nRBCs: Oval macrocytes, hypochromia, basophilic stippling\nNeutrophils: Pseudo-Pelger-Huët anomaly (bi-lobed neutrophils), hypogranulation\nPlatelets: Large platelets, abnormal granulation\n\nReticulocyte Count: Low normal (inappropriately low degree anemia)\nBone Marrow Examination: Hypercellular hypocellular marrow dysplasia one cell lines\nCytogenetic Analysis: Chromosomal abnormalities (e.g., deletion 5q, trisomy 8) common\n\nTreatment:\nSupportive care:\nTransfusions manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\n\nHypomethylating Agents:\nAzacitidine decitabine: Improve hematopoiesis reduce risk AML transformation\n\nLenalidomide:\nUsed patients MDS deletion 5q\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\n\n\nDefinition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis variable risk progression acute myeloid leukemia (AML)Etiology: Acquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapyPathophysiology: Dysplastic (abnormal) development one myeloid cell lines (RBCs, WBCs, platelets), leading cytopenias increased risk AMLClinical Features:\nAnemia (fatigue, weakness, pallor)\nThrombocytopenia (bleeding, bruising)\nNeutropenia (infections)\nAnemia (fatigue, weakness, pallor)Thrombocytopenia (bleeding, bruising)Neutropenia (infections)Laboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nRBCs: Oval macrocytes, hypochromia, basophilic stippling\nNeutrophils: Pseudo-Pelger-Huët anomaly (bi-lobed neutrophils), hypogranulation\nPlatelets: Large platelets, abnormal granulation\n\nReticulocyte Count: Low normal (inappropriately low degree anemia)\nBone Marrow Examination: Hypercellular hypocellular marrow dysplasia one cell lines\nCytogenetic Analysis: Chromosomal abnormalities (e.g., deletion 5q, trisomy 8) common\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)Peripheral Blood Smear: Dysplastic features one cell lines\nRBCs: Oval macrocytes, hypochromia, basophilic stippling\nNeutrophils: Pseudo-Pelger-Huët anomaly (bi-lobed neutrophils), hypogranulation\nPlatelets: Large platelets, abnormal granulation\nRBCs: Oval macrocytes, hypochromia, basophilic stipplingNeutrophils: Pseudo-Pelger-Huët anomaly (bi-lobed neutrophils), hypogranulationPlatelets: Large platelets, abnormal granulationReticulocyte Count: Low normal (inappropriately low degree anemia)Bone Marrow Examination: Hypercellular hypocellular marrow dysplasia one cell linesCytogenetic Analysis: Chromosomal abnormalities (e.g., deletion 5q, trisomy 8) commonTreatment:\nSupportive care:\nTransfusions manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\n\nHypomethylating Agents:\nAzacitidine decitabine: Improve hematopoiesis reduce risk AML transformation\n\nLenalidomide:\nUsed patients MDS deletion 5q\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\n\nSupportive care:\nTransfusions manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\nTransfusions manage anemia thrombocytopeniaGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell productionAntibiotics treat infectionsHypomethylating Agents:\nAzacitidine decitabine: Improve hematopoiesis reduce risk AML transformation\nAzacitidine decitabine: Improve hematopoiesis reduce risk AML transformationLenalidomide:\nUsed patients MDS deletion 5q\nUsed patients MDS deletion 5qHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option younger patients high-risk MDS\nPotentially curative option younger patients high-risk MDSPure Red Cell Aplasia (PRCA):\nDefinition: Selective destruction erythroid precursors bone marrow, leading severe anemia marked decrease reticulocytes\nEtiology:\nAcquired:\nAutoimmune: Antibodies erythroid precursors erythropoietin\nInfections: Parvovirus B19 infection (especially patients chronic hemolytic anemias)\nDrug-induced: Certain medications (e.g., erythropoietin, immunosuppressants)\nThymoma: Tumor thymus gland\n\nInherited: Diamond-Blackfan anemia\n\nPathophysiology:\nAutoantibodies cytotoxic T cells target destroy erythroid precursors (CFU-Es proerythroblasts) bone marrow\nParvovirus B19 directly infects destroys erythroid precursors\n\nClinical Features:\nSevere anemia\nAbsence cytopenias (normal WBC platelet counts)\n\nLaboratory Findings:\nCBC: Severe anemia normal WBC platelet counts\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (near zero)\nBone Marrow Examination: Normal cellularity marked decrease absence erythroid precursors\nAntibody Testing: May detect antibodies erythroid precursors erythropoietin\nParvovirus B19 PCR: detect parvovirus B19 infection\n\nTreatment:\nTreat Underlying Cause:\nDiscontinue offending medications\nTreat infections (e.g., parvovirus B19)\nRemove thymoma (present)\n\nImmunosuppressive Therapy:\nCorticosteroids\nCyclosporine\n\nIntravenous Immunoglobulin (IVIG):\nMay used parvovirus B19-related PRCA\n\nBlood Transfusions:\nmanage severe anemia\n\nErythropoiesis-Stimulating Agents (ESAs):\nMay effective cases, especially EPO levels low\n\n\nDefinition: Selective destruction erythroid precursors bone marrow, leading severe anemia marked decrease reticulocytesEtiology:\nAcquired:\nAutoimmune: Antibodies erythroid precursors erythropoietin\nInfections: Parvovirus B19 infection (especially patients chronic hemolytic anemias)\nDrug-induced: Certain medications (e.g., erythropoietin, immunosuppressants)\nThymoma: Tumor thymus gland\n\nInherited: Diamond-Blackfan anemia\nAcquired:\nAutoimmune: Antibodies erythroid precursors erythropoietin\nInfections: Parvovirus B19 infection (especially patients chronic hemolytic anemias)\nDrug-induced: Certain medications (e.g., erythropoietin, immunosuppressants)\nThymoma: Tumor thymus gland\nAutoimmune: Antibodies erythroid precursors erythropoietinInfections: Parvovirus B19 infection (especially patients chronic hemolytic anemias)Drug-induced: Certain medications (e.g., erythropoietin, immunosuppressants)Thymoma: Tumor thymus glandInherited: Diamond-Blackfan anemiaPathophysiology:\nAutoantibodies cytotoxic T cells target destroy erythroid precursors (CFU-Es proerythroblasts) bone marrow\nParvovirus B19 directly infects destroys erythroid precursors\nAutoantibodies cytotoxic T cells target destroy erythroid precursors (CFU-Es proerythroblasts) bone marrowParvovirus B19 directly infects destroys erythroid precursorsClinical Features:\nSevere anemia\nAbsence cytopenias (normal WBC platelet counts)\nSevere anemiaAbsence cytopenias (normal WBC platelet counts)Laboratory Findings:\nCBC: Severe anemia normal WBC platelet counts\nPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cells\nReticulocyte Count: low (near zero)\nBone Marrow Examination: Normal cellularity marked decrease absence erythroid precursors\nAntibody Testing: May detect antibodies erythroid precursors erythropoietin\nParvovirus B19 PCR: detect parvovirus B19 infection\nCBC: Severe anemia normal WBC platelet countsPeripheral Blood Smear: Normocytic, normochromic RBCs; absence abnormal cellsReticulocyte Count: low (near zero)Bone Marrow Examination: Normal cellularity marked decrease absence erythroid precursorsAntibody Testing: May detect antibodies erythroid precursors erythropoietinParvovirus B19 PCR: detect parvovirus B19 infectionTreatment:\nTreat Underlying Cause:\nDiscontinue offending medications\nTreat infections (e.g., parvovirus B19)\nRemove thymoma (present)\n\nImmunosuppressive Therapy:\nCorticosteroids\nCyclosporine\n\nIntravenous Immunoglobulin (IVIG):\nMay used parvovirus B19-related PRCA\n\nBlood Transfusions:\nmanage severe anemia\n\nErythropoiesis-Stimulating Agents (ESAs):\nMay effective cases, especially EPO levels low\n\nTreat Underlying Cause:\nDiscontinue offending medications\nTreat infections (e.g., parvovirus B19)\nRemove thymoma (present)\nDiscontinue offending medicationsTreat infections (e.g., parvovirus B19)Remove thymoma (present)Immunosuppressive Therapy:\nCorticosteroids\nCyclosporine\nCorticosteroidsCyclosporineIntravenous Immunoglobulin (IVIG):\nMay used parvovirus B19-related PRCA\nMay used parvovirus B19-related PRCABlood Transfusions:\nmanage severe anemia\nmanage severe anemiaErythropoiesis-Stimulating Agents (ESAs):\nMay effective cases, especially EPO levels low\nMay effective cases, especially EPO levels lowSecondary Causes Hypoproliferative Anemia:\nChronic Kidney Disease (CKD):\nDecreased erythropoietin (EPO) production kidneys\nUremic toxins can also suppress erythropoiesis\nTreatment:\nErythropoiesis-stimulating agents (ESAs)\nIron supplementation\n\n\nEndocrine Disorders:\nHypothyroidism: Decreased thyroid hormone can reduce erythropoiesis\nHypopituitarism: Decreased production hormones stimulate erythropoiesis (e.g., growth hormone, androgens)\nTreatment: Hormone replacement therapy\n\nAnemia Chronic Disease/Inflammation:\nChronic inflammation leads increased hepcidin production, impairs iron release reduces erythropoiesis\nTreatment:\nTreat underlying inflammatory condition\nErythropoiesis-stimulating agents (ESAs) (use cautiously)\n\n\nNutritional Deficiencies (Less Common Cause Hypoproliferative Anemia):\nSevere protein-calorie malnutrition\nScurvy (vitamin C deficiency)\ndeficiencies primarily affect RBC maturation can also impair erythropoiesis\nTreatment: Correct underlying nutritional deficiency\n\nChronic Kidney Disease (CKD):\nDecreased erythropoietin (EPO) production kidneys\nUremic toxins can also suppress erythropoiesis\nTreatment:\nErythropoiesis-stimulating agents (ESAs)\nIron supplementation\n\nDecreased erythropoietin (EPO) production kidneysUremic toxins can also suppress erythropoiesisTreatment:\nErythropoiesis-stimulating agents (ESAs)\nIron supplementation\nErythropoiesis-stimulating agents (ESAs)Iron supplementationEndocrine Disorders:\nHypothyroidism: Decreased thyroid hormone can reduce erythropoiesis\nHypopituitarism: Decreased production hormones stimulate erythropoiesis (e.g., growth hormone, androgens)\nTreatment: Hormone replacement therapy\nHypothyroidism: Decreased thyroid hormone can reduce erythropoiesisHypopituitarism: Decreased production hormones stimulate erythropoiesis (e.g., growth hormone, androgens)Treatment: Hormone replacement therapyAnemia Chronic Disease/Inflammation:\nChronic inflammation leads increased hepcidin production, impairs iron release reduces erythropoiesis\nTreatment:\nTreat underlying inflammatory condition\nErythropoiesis-stimulating agents (ESAs) (use cautiously)\n\nChronic inflammation leads increased hepcidin production, impairs iron release reduces erythropoiesisTreatment:\nTreat underlying inflammatory condition\nErythropoiesis-stimulating agents (ESAs) (use cautiously)\nTreat underlying inflammatory conditionErythropoiesis-stimulating agents (ESAs) (use cautiously)Nutritional Deficiencies (Less Common Cause Hypoproliferative Anemia):\nSevere protein-calorie malnutrition\nScurvy (vitamin C deficiency)\ndeficiencies primarily affect RBC maturation can also impair erythropoiesis\nTreatment: Correct underlying nutritional deficiency\nSevere protein-calorie malnutritionScurvy (vitamin C deficiency)deficiencies primarily affect RBC maturation can also impair erythropoiesisTreatment: Correct underlying nutritional deficiency","code":""},{"path":"hypoproliferative.html","id":"key-laboratory-findings-in-hypoproliferative-anemias","chapter":"Hypoproliferative","heading":"Key Laboratory Findings in Hypoproliferative Anemias","text":"Complete Blood Count (CBC):\nAnemia (low HGB HCT)\nMCV: Can normocytic, microcytic, macrocytic, depending underlying cause\nAnemia (low HGB HCT)MCV: Can normocytic, microcytic, macrocytic, depending underlying causePeripheral Blood Smear:\nRBC morphology: Usually normocytic normochromic, may show abnormalities depending cause (e.g., oval macrocytes MDS)\nRBC morphology: Usually normocytic normochromic, may show abnormalities depending cause (e.g., oval macrocytes MDS)Reticulocyte Count:\nLow (hallmark finding)\nLow (hallmark finding)Iron Studies:\nVariable, depending underlying cause\nVariable, depending underlying causeSerum Erythropoietin (EPO) Level:\nMay low, normal, elevated, depending underlying cause\nMay low, normal, elevated, depending underlying causeBone Marrow Examination:\nEssential diagnosis\nCellularity: Can hypocellular (aplastic anemia) normocellular/hypercellular (MDS)\nMaturation: May show dysplastic features (MDS) selective decrease erythroid precursors (PRCA)\nCytogenetics: detect chromosomal abnormalities MDS\nSpecial stains flow cytometry: evaluate specific abnormalities\nEssential diagnosisCellularity: Can hypocellular (aplastic anemia) normocellular/hypercellular (MDS)Maturation: May show dysplastic features (MDS) selective decrease erythroid precursors (PRCA)Cytogenetics: detect chromosomal abnormalities MDSSpecial stains flow cytometry: evaluate specific abnormalities","code":""},{"path":"hypoproliferative.html","id":"key-terms-12","chapter":"Hypoproliferative","heading":"Key Terms","text":"Hypoproliferative Anemia: Anemia due decreased red blood cell productionAplastic Anemia: Bone marrow failure pancytopenia hypocellular marrowMyelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders ineffective hematopoiesisPure Red Cell Aplasia (PRCA): Selective destruction erythroid precursors bone marrowReticulocyte Count: Measure new red blood cell productionBone Marrow Examination: Aspiration biopsy assess cellularity maturation blood cell precursorsErythropoietin (EPO): Hormone stimulates red blood cell productionCytopenia: Deficiency blood cells (e.g., anemia, neutropenia, thrombocytopenia)Dysplasia: Abnormal cell development","code":""},{"path":"acute-hemorrhage.html","id":"acute-hemorrhage","chapter":"Acute Hemorrhage","heading":"Acute Hemorrhage","text":"","code":""},{"path":"acute-hemorrhage.html","id":"overview-of-acute-hemorrhage","chapter":"Acute Hemorrhage","heading":"Overview of Acute Hemorrhage","text":"Definition: Sudden significant blood loss occurring short period timePathophysiology:\nRapid loss blood volume leads decreased oxygen delivery tissues\nbody compensates various mechanisms, including increased heart rate, vasoconstriction, fluid shifts\nblood loss severe /compensation inadequate, hypovolemic shock organ damage can occur\nRapid loss blood volume leads decreased oxygen delivery tissuesThe body compensates various mechanisms, including increased heart rate, vasoconstriction, fluid shiftsIf blood loss severe /compensation inadequate, hypovolemic shock organ damage can occurKey Considerations:\ninitial laboratory findings may reflect severity blood loss due proportional loss blood components (RBCs, WBCs, platelets, plasma).\nChanges laboratory values (e.g., decreased HGB HCT) become apparent body attempts restore blood volume fluid shifts\ninitial laboratory findings may reflect severity blood loss due proportional loss blood components (RBCs, WBCs, platelets, plasma).Changes laboratory values (e.g., decreased HGB HCT) become apparent body attempts restore blood volume fluid shiftsClassification:\nExternal Hemorrhage: Blood loss visible outside body (e.g., trauma, surgery)\nInternal Hemorrhage: Blood loss within body (e.g., gastrointestinal bleeding, ruptured ectopic pregnancy, ruptured aneurysm)\nExternal Hemorrhage: Blood loss visible outside body (e.g., trauma, surgery)Internal Hemorrhage: Blood loss within body (e.g., gastrointestinal bleeding, ruptured ectopic pregnancy, ruptured aneurysm)","code":""},{"path":"acute-hemorrhage.html","id":"causes-of-acute-hemorrhage","chapter":"Acute Hemorrhage","heading":"Causes of Acute Hemorrhage","text":"Trauma:\nAccidents\nSurgery\nGunshot wounds\nStabbing injuries\nAccidentsSurgeryGunshot woundsStabbing injuriesGastrointestinal Bleeding:\nPeptic ulcers\nEsophageal varices\nDiverticulosis\nColorectal cancer\nPeptic ulcersEsophageal varicesDiverticulosisColorectal cancerObstetrical Gynecological Causes:\nEctopic pregnancy rupture\nPostpartum hemorrhage\nPlacenta previa abruption\nEctopic pregnancy rupturePostpartum hemorrhagePlacenta previa abruptionVascular Rupture:\nAortic aneurysm rupture\nArteriovenous malformation (AVM) rupture\nAortic aneurysm ruptureArteriovenous malformation (AVM) ruptureCoagulation Disorders:\nHemophilia\nVon Willebrand disease\nDisseminated intravascular coagulation (DIC)\nAnticoagulant medication overdose\nHemophiliaVon Willebrand diseaseDisseminated intravascular coagulation (DIC)Anticoagulant medication overdose","code":""},{"path":"acute-hemorrhage.html","id":"clinical-manifestations-2","chapter":"Acute Hemorrhage","heading":"Clinical Manifestations","text":"Symptoms Depend Severity Rate Blood Loss:\nMild Blood Loss (15% Blood Volume):\nMay asymptomatic\nMild lightheadedness dizziness\n\nModerate Blood Loss (15-30% Blood Volume):\nTachycardia (increased heart rate)\nTachypnea (increased respiratory rate)\nPallor (pale skin)\nDiaphoresis (sweating)\nOrthostatic hypotension (drop blood pressure upon standing)\n\nSevere Blood Loss (30-40% Blood Volume):\nMarked tachycardia tachypnea\nHypotension (low blood pressure)\nRestlessness anxiety\nOliguria (decreased urine output)\nCool, clammy skin\n\nLife-Threatening Blood Loss ( >40% Blood Volume):\nSevere hypotension\nAltered mental status (confusion, lethargy)\nAnuria (urine output)\nLoss consciousness\nShock (hypovolemic shock)\n\nSymptoms Depend Severity Rate Blood Loss:Mild Blood Loss (15% Blood Volume):\nMay asymptomatic\nMild lightheadedness dizziness\nMay asymptomaticMild lightheadedness dizzinessModerate Blood Loss (15-30% Blood Volume):\nTachycardia (increased heart rate)\nTachypnea (increased respiratory rate)\nPallor (pale skin)\nDiaphoresis (sweating)\nOrthostatic hypotension (drop blood pressure upon standing)\nTachycardia (increased heart rate)Tachypnea (increased respiratory rate)Pallor (pale skin)Diaphoresis (sweating)Orthostatic hypotension (drop blood pressure upon standing)Severe Blood Loss (30-40% Blood Volume):\nMarked tachycardia tachypnea\nHypotension (low blood pressure)\nRestlessness anxiety\nOliguria (decreased urine output)\nCool, clammy skin\nMarked tachycardia tachypneaHypotension (low blood pressure)Restlessness anxietyOliguria (decreased urine output)Cool, clammy skinLife-Threatening Blood Loss ( >40% Blood Volume):\nSevere hypotension\nAltered mental status (confusion, lethargy)\nAnuria (urine output)\nLoss consciousness\nShock (hypovolemic shock)\nSevere hypotensionAltered mental status (confusion, lethargy)Anuria (urine output)Loss consciousnessShock (hypovolemic shock)Signs Internal Hemorrhage:\nAbdominal pain distension\nChest pain\nBack pain\nBlood stool (melena hematochezia)\nVaginal bleeding\nSigns Internal Hemorrhage:Abdominal pain distensionChest painBack painBlood stool (melena hematochezia)Vaginal bleeding","code":""},{"path":"acute-hemorrhage.html","id":"laboratory-findings","chapter":"Acute Hemorrhage","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nInitial CBC may appear normal! blood components (RBCs, WBCs, platelets, plasma) lost proportionally\nChanges become apparent body attempts restore blood volume:\nHemoglobin (HGB): Decreases time (usually within hours) fluid shifts occur\nHematocrit (HCT): Decreases time (HCT lags behind HGB changes)\nRed Blood Cell Count (RBC): Decreases time\nMean Corpuscular Volume (MCV): Initially normal (normocytic) may become microcytic time chronic blood loss leads iron deficiency\nPlatelet Count: May initially increase due splenic contraction, can decrease prolonged bleeding consumptive coagulopathy (DIC)\nWhite Blood Cell Count (WBC): May initially increase due stress response\n\nComplete Blood Count (CBC):Initial CBC may appear normal! blood components (RBCs, WBCs, platelets, plasma) lost proportionallyChanges become apparent body attempts restore blood volume:\nHemoglobin (HGB): Decreases time (usually within hours) fluid shifts occur\nHematocrit (HCT): Decreases time (HCT lags behind HGB changes)\nRed Blood Cell Count (RBC): Decreases time\nMean Corpuscular Volume (MCV): Initially normal (normocytic) may become microcytic time chronic blood loss leads iron deficiency\nPlatelet Count: May initially increase due splenic contraction, can decrease prolonged bleeding consumptive coagulopathy (DIC)\nWhite Blood Cell Count (WBC): May initially increase due stress response\nHemoglobin (HGB): Decreases time (usually within hours) fluid shifts occurHematocrit (HCT): Decreases time (HCT lags behind HGB changes)Red Blood Cell Count (RBC): Decreases timeMean Corpuscular Volume (MCV): Initially normal (normocytic) may become microcytic time chronic blood loss leads iron deficiencyPlatelet Count: May initially increase due splenic contraction, can decrease prolonged bleeding consumptive coagulopathy (DIC)White Blood Cell Count (WBC): May initially increase due stress responseReticulocyte Count:\nIncreases within 2-3 days bone marrow responds anemia\nPeaks 7-10 days\nReticulocyte Count:Increases within 2-3 days bone marrow responds anemiaPeaks 7-10 daysCoagulation Studies:\nProthrombin Time (PT) Activated Partial Thromboplastin Time (aPTT): Usually normal initially unless underlying coagulation disorder consumptive coagulopathy (DIC)\nFibrinogen: May normal decreased (DIC)\nD-dimer: May elevated (especially associated activation coagulation system fibrinolysis)\nCoagulation Studies:Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT): Usually normal initially unless underlying coagulation disorder consumptive coagulopathy (DIC)Fibrinogen: May normal decreased (DIC)D-dimer: May elevated (especially associated activation coagulation system fibrinolysis)Iron Studies:\nInitially normal\nchronic blood loss, iron deficiency can develop, leading :\nLow serum iron\nHigh Total Iron-Binding Capacity (TIBC)\nLow Transferrin Saturation\nLow Ferritin\n\nIron Studies:Initially normalWith chronic blood loss, iron deficiency can develop, leading :\nLow serum iron\nHigh Total Iron-Binding Capacity (TIBC)\nLow Transferrin Saturation\nLow Ferritin\nLow serum ironHigh Total Iron-Binding Capacity (TIBC)Low Transferrin SaturationLow FerritinOther Tests:\nStool occult blood test: detect gastrointestinal bleeding\nBlood type crossmatch: prepare potential blood transfusions\nImaging studies (e.g., CT scan, ultrasound, angiography): identify source bleeding\nTests:Stool occult blood test: detect gastrointestinal bleedingBlood type crossmatch: prepare potential blood transfusionsImaging studies (e.g., CT scan, ultrasound, angiography): identify source bleeding","code":""},{"path":"acute-hemorrhage.html","id":"compensatory-mechanisms-in-response-to-acute-hemorrhage","chapter":"Acute Hemorrhage","heading":"Compensatory Mechanisms in Response to Acute Hemorrhage","text":"Vasoconstriction:\nActivation sympathetic nervous system causes constriction blood vessels, helping maintain blood pressure\nShunts blood flow vital organs (e.g., heart, brain)\nActivation sympathetic nervous system causes constriction blood vessels, helping maintain blood pressureShunts blood flow vital organs (e.g., heart, brain)Increased Heart Rate (Tachycardia):\nIncreases cardiac output compensate reduced blood volume\nIncreases cardiac output compensate reduced blood volumeFluid Shifts:\nMovement interstitial fluid vascular space increase blood volume\nhemodilution leads decrease HGB HCT\nMovement interstitial fluid vascular space increase blood volumeThis hemodilution leads decrease HGB HCTHormonal Responses:\nRelease antidiuretic hormone (ADH) pituitary gland, promoting water retention kidneys\nActivation renin-angiotensin-aldosterone system (RAAS), leading sodium water retention vasoconstriction\nRelease antidiuretic hormone (ADH) pituitary gland, promoting water retention kidneysActivation renin-angiotensin-aldosterone system (RAAS), leading sodium water retention vasoconstrictionIncreased Erythropoiesis:\nKidneys sense decreased oxygen delivery increase production erythropoietin (EPO)\nEPO stimulates bone marrow increase RBC production, leading reticulocytosis\nKidneys sense decreased oxygen delivery increase production erythropoietin (EPO)EPO stimulates bone marrow increase RBC production, leading reticulocytosis","code":""},{"path":"acute-hemorrhage.html","id":"treatment-of-acute-hemorrhage","chapter":"Acute Hemorrhage","heading":"Treatment of Acute Hemorrhage","text":"Assess Severity Blood Loss:\nEvaluate vital signs (heart rate, blood pressure, respiratory rate)\nAssess mental status urine output\nAssess Severity Blood Loss:Evaluate vital signs (heart rate, blood pressure, respiratory rate)Assess mental status urine outputStop Bleeding:\nApply direct pressure external wounds\nSurgical intervention may needed control internal bleeding\nStop Bleeding:Apply direct pressure external woundsSurgical intervention may needed control internal bleedingRestore Blood Volume Oxygen-Carrying Capacity:\nIntravenous Fluids:\nCrystalloids (e.g., normal saline, lactated Ringer’s solution) restore blood volume\n\nBlood Transfusions:\nPacked red blood cells (PRBCs) increase hemoglobin improve oxygen delivery\nTransfusion triggers depend patient’s clinical condition underlying comorbidities\nTypically, transfuse HGB < 7 g/dL patient symptomatic (e.g., chest pain, shortness breath)\nHigher transfusion thresholds may used patients cardiac pulmonary disease\n\nConsider blood products needed:\nPlatelets thrombocytopenia platelet dysfunction\nFresh frozen plasma (FFP) coagulation factor deficiencies\nCryoprecipitate fibrinogen deficiency\n\n\nRestore Blood Volume Oxygen-Carrying Capacity:Intravenous Fluids:\nCrystalloids (e.g., normal saline, lactated Ringer’s solution) restore blood volume\nCrystalloids (e.g., normal saline, lactated Ringer’s solution) restore blood volumeBlood Transfusions:\nPacked red blood cells (PRBCs) increase hemoglobin improve oxygen delivery\nTransfusion triggers depend patient’s clinical condition underlying comorbidities\nTypically, transfuse HGB < 7 g/dL patient symptomatic (e.g., chest pain, shortness breath)\nHigher transfusion thresholds may used patients cardiac pulmonary disease\n\nConsider blood products needed:\nPlatelets thrombocytopenia platelet dysfunction\nFresh frozen plasma (FFP) coagulation factor deficiencies\nCryoprecipitate fibrinogen deficiency\n\nPacked red blood cells (PRBCs) increase hemoglobin improve oxygen deliveryTransfusion triggers depend patient’s clinical condition underlying comorbidities\nTypically, transfuse HGB < 7 g/dL patient symptomatic (e.g., chest pain, shortness breath)\nHigher transfusion thresholds may used patients cardiac pulmonary disease\nTypically, transfuse HGB < 7 g/dL patient symptomatic (e.g., chest pain, shortness breath)Higher transfusion thresholds may used patients cardiac pulmonary diseaseConsider blood products needed:\nPlatelets thrombocytopenia platelet dysfunction\nFresh frozen plasma (FFP) coagulation factor deficiencies\nCryoprecipitate fibrinogen deficiency\nPlatelets thrombocytopenia platelet dysfunctionFresh frozen plasma (FFP) coagulation factor deficienciesCryoprecipitate fibrinogen deficiencyAddress Underlying Cause:\nTreat peptic ulcers, esophageal varices, sources bleeding\nCorrect coagulation disorders\nAddress Underlying Cause:Treat peptic ulcers, esophageal varices, sources bleedingCorrect coagulation disordersMonitor Complications:\nHypovolemic shock\nAcute respiratory distress syndrome (ARDS)\nAcute kidney injury (AKI)\nDisseminated intravascular coagulation (DIC)\nMonitor Complications:Hypovolemic shockAcute respiratory distress syndrome (ARDS)Acute kidney injury (AKI)Disseminated intravascular coagulation (DIC)","code":""},{"path":"acute-hemorrhage.html","id":"key-laboratory-findings-2","chapter":"Acute Hemorrhage","heading":"Key Laboratory Findings","text":"Initial CBC may appear normal!Decreasing HGB HCT timeElevated reticulocyte count (2-3 days)Normal coagulation studies (unless underlying coagulopathy)Normal iron studies initially, may show iron deficiency chronic blood loss","code":""},{"path":"acute-hemorrhage.html","id":"key-terms-13","chapter":"Acute Hemorrhage","heading":"Key Terms","text":"Acute Hemorrhage: Sudden significant blood lossHypovolemic Shock: Shock due decreased blood volumeTachycardia: Increased heart rateTachypnea: Increased respiratory rateOrthostatic Hypotension: Drop blood pressure upon standingReticulocyte Count: Measure new red blood cell productionBlood Transfusion: Infusion blood products restore blood volume oxygen-carrying capacity","code":""},{"path":"macrocytic.html","id":"macrocytic","chapter":"Macrocytic","heading":"Macrocytic","text":"","code":""},{"path":"macrocytic.html","id":"macrocytic-anemias","chapter":"Macrocytic","heading":"Macrocytic Anemias","text":"Characteristics: Large RBCs (MCV > 100 fL)Causes:\nMegaloblastic Anemias:\nImpaired DNA synthesis due vitamin B12 folate deficiency\nPeripheral blood smear: Oval macrocytes, hypersegmented neutrophils (5 lobes)\nLab findings:\nLow vitamin B12 folate levels\nElevated methylmalonic acid (MMA) homocysteine levels (B12 deficiency)\nElevated homocysteine levels (folate deficiency)\n\nCauses B12 deficiency:\nPernicious anemia (autoimmune destruction parietal cells stomach, leading decreased intrinsic factor)\nMalabsorption (e.g., Crohn’s disease, celiac disease)\nDietary deficiency (rare)\n\nCauses Folate Deficiency:\nInadequate intake (e.g., poor diet, alcoholism)\nMalabsorption\nIncreased demand (e.g., pregnancy, hemolytic anemia)\nMedications (e.g., methotrexate)\n\n\nNon-Megaloblastic Anemias:\nMacrocytosis without hypersegmented neutrophils\nCauses:\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\nReticulocytosis (increased number reticulocytes due hemolysis blood loss)\nMedications (e.g., hydroxyurea)\n\n\nMegaloblastic Anemias:\nImpaired DNA synthesis due vitamin B12 folate deficiency\nPeripheral blood smear: Oval macrocytes, hypersegmented neutrophils (5 lobes)\nLab findings:\nLow vitamin B12 folate levels\nElevated methylmalonic acid (MMA) homocysteine levels (B12 deficiency)\nElevated homocysteine levels (folate deficiency)\n\nCauses B12 deficiency:\nPernicious anemia (autoimmune destruction parietal cells stomach, leading decreased intrinsic factor)\nMalabsorption (e.g., Crohn’s disease, celiac disease)\nDietary deficiency (rare)\n\nCauses Folate Deficiency:\nInadequate intake (e.g., poor diet, alcoholism)\nMalabsorption\nIncreased demand (e.g., pregnancy, hemolytic anemia)\nMedications (e.g., methotrexate)\n\nImpaired DNA synthesis due vitamin B12 folate deficiencyPeripheral blood smear: Oval macrocytes, hypersegmented neutrophils (5 lobes)Lab findings:\nLow vitamin B12 folate levels\nElevated methylmalonic acid (MMA) homocysteine levels (B12 deficiency)\nElevated homocysteine levels (folate deficiency)\nLow vitamin B12 folate levelsElevated methylmalonic acid (MMA) homocysteine levels (B12 deficiency)Elevated homocysteine levels (folate deficiency)Causes B12 deficiency:\nPernicious anemia (autoimmune destruction parietal cells stomach, leading decreased intrinsic factor)\nMalabsorption (e.g., Crohn’s disease, celiac disease)\nDietary deficiency (rare)\nPernicious anemia (autoimmune destruction parietal cells stomach, leading decreased intrinsic factor)Malabsorption (e.g., Crohn’s disease, celiac disease)Dietary deficiency (rare)Causes Folate Deficiency:\nInadequate intake (e.g., poor diet, alcoholism)\nMalabsorption\nIncreased demand (e.g., pregnancy, hemolytic anemia)\nMedications (e.g., methotrexate)\nInadequate intake (e.g., poor diet, alcoholism)MalabsorptionIncreased demand (e.g., pregnancy, hemolytic anemia)Medications (e.g., methotrexate)Non-Megaloblastic Anemias:\nMacrocytosis without hypersegmented neutrophils\nCauses:\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\nReticulocytosis (increased number reticulocytes due hemolysis blood loss)\nMedications (e.g., hydroxyurea)\n\nMacrocytosis without hypersegmented neutrophilsCauses:\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\nReticulocytosis (increased number reticulocytes due hemolysis blood loss)\nMedications (e.g., hydroxyurea)\nAlcoholismLiver diseaseHypothyroidismMyelodysplastic syndromes (MDS)Reticulocytosis (increased number reticulocytes due hemolysis blood loss)Medications (e.g., hydroxyurea)","code":""},{"path":"macrocytic.html","id":"laboratory-tests-for-anemia-2","chapter":"Macrocytic","heading":"Laboratory Tests for Anemia","text":"Complete Blood Count (CBC):\nHemoglobin (HGB)\nHematocrit (HCT)\nRed Blood Cell Count (RBC)\nMean Corpuscular Volume (MCV)\nMean Corpuscular Hemoglobin (MCH)\nMean Corpuscular Hemoglobin Concentration (MCHC)\nRed Cell Distribution Width (RDW)\nWhite Blood Cell Count (WBC) Differential\nPlatelet Count\nHemoglobin (HGB)Hematocrit (HCT)Red Blood Cell Count (RBC)Mean Corpuscular Volume (MCV)Mean Corpuscular Hemoglobin (MCH)Mean Corpuscular Hemoglobin Concentration (MCHC)Red Cell Distribution Width (RDW)White Blood Cell Count (WBC) DifferentialPlatelet CountPeripheral Blood Smear:\nRBC morphology (size, shape, color)\nWBC differential\nPlatelet estimate\nRBC morphology (size, shape, color)WBC differentialPlatelet estimateReticulocyte Count:\nPercentage absolute number reticulocytes\nCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)\nPercentage absolute number reticulocytesCorrected Reticulocyte Count/Reticulocyte Production Index (RPI)Iron Studies:\nSerum Iron\nTotal Iron-Binding Capacity (TIBC)\nTransferrin Saturation\nFerritin\nSerum IronTotal Iron-Binding Capacity (TIBC)Transferrin SaturationFerritinVitamin B12 Folate Levels:\nSerum B12\nRed Blood Cell Folate\nSerum B12Red Blood Cell FolateMethylmalonic Acid (MMA) Homocysteine Levels:\nElevated B12 Deficiency\nHomocysteine also Elevated Folate Deficiency\nElevated B12 DeficiencyHomocysteine also Elevated Folate DeficiencyHemoglobin Electrophoresis:\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)\nIdentifies abnormal hemoglobin variants (e.g., HbS, HbC)Direct Antiglobulin Test (DAT):\nDetects antibodies complement proteins surface RBCs\nDetects antibodies complement proteins surface RBCsBone Marrow Examination:\nCellularity\nMaturation cell lines\nPresence abnormal cells\nCellularityMaturation cell linesPresence abnormal cellsOther Tests:\nHaptoglobin LDH (hemolysis)\nCoombs test (autoimmune hemolytic anemia)\nOsmotic Fragility Test (hereditary spherocytosis)\nG6PD Assay (G6PD deficiency)\nHaptoglobin LDH (hemolysis)Coombs test (autoimmune hemolytic anemia)Osmotic Fragility Test (hereditary spherocytosis)G6PD Assay (G6PD deficiency)","code":""},{"path":"macrocytic.html","id":"key-terms-14","chapter":"Macrocytic","heading":"Key Terms","text":"Anemia: Deficiency red blood cells hemoglobinMacrocytic: Large red blood cells (MCV > 100 fL)Reticulocyte: Immature red blood cellHemolysis: Destruction red blood cellsExtramedullary Hematopoiesis: Blood cell production outside bone marrowMegaloblastic: Abnormal maturation blood cells due impaired DNA synthesis","code":""},{"path":"megaloblastic.html","id":"megaloblastic","chapter":"Megaloblastic","heading":"Megaloblastic","text":"","code":""},{"path":"megaloblastic.html","id":"overview-of-megaloblastic-anemias","chapter":"Megaloblastic","heading":"Overview of Megaloblastic Anemias","text":"Definition: group macrocytic anemias characterized impaired DNA synthesis, resulting abnormal maturation hematopoietic cells bone marrow distinctive morphological changes red blood cellsHallmark: presence megaloblasts (large, abnormal erythroid precursors) bone marrow macrocytes (large red blood cells) peripheral blood. Hypersegmented neutrophils (neutrophils 5 lobes) also characteristic findingCause: Primarily caused deficiencies vitamin B12 (cobalamin) folate (folic acid), essential DNA synthesisKey Feature: Ineffective erythropoiesis (premature destruction abnormal RBC precursors bone marrow)","code":""},{"path":"megaloblastic.html","id":"etiology","chapter":"Megaloblastic","heading":"Etiology","text":"Vitamin B12 Deficiency:\nPernicious Anemia: Autoimmune destruction parietal cells stomach, leading decreased production intrinsic factor (). required vitamin B12 absorption ileum.\nMalabsorption Syndromes:\nGastrectomy: Removal stomach, leading decreased production\nIleal Resection Disease (e.g., Crohn’s disease): Impairs vitamin B12 absorption\nBacterial Overgrowth Small Intestine: Bacteria compete host vitamin B12\nPancreatic Insufficiency: Decreased release pancreatic proteases needed release vitamin B12 binding proteins\n\nDietary Deficiency:\nRare, can occur strict vegetarians (vegans) supplement vitamin B12\n\nCauses:\nFish tapeworm (Diphyllobothrium latum) infection: tapeworm absorbs vitamin B12 intestine\nCertain Medications (e.g., metformin, proton pump inhibitors)\n\nPernicious Anemia: Autoimmune destruction parietal cells stomach, leading decreased production intrinsic factor (). required vitamin B12 absorption ileum.Malabsorption Syndromes:\nGastrectomy: Removal stomach, leading decreased production\nIleal Resection Disease (e.g., Crohn’s disease): Impairs vitamin B12 absorption\nBacterial Overgrowth Small Intestine: Bacteria compete host vitamin B12\nPancreatic Insufficiency: Decreased release pancreatic proteases needed release vitamin B12 binding proteins\nGastrectomy: Removal stomach, leading decreased productionIleal Resection Disease (e.g., Crohn’s disease): Impairs vitamin B12 absorptionBacterial Overgrowth Small Intestine: Bacteria compete host vitamin B12Pancreatic Insufficiency: Decreased release pancreatic proteases needed release vitamin B12 binding proteinsDietary Deficiency:\nRare, can occur strict vegetarians (vegans) supplement vitamin B12\nRare, can occur strict vegetarians (vegans) supplement vitamin B12Other Causes:\nFish tapeworm (Diphyllobothrium latum) infection: tapeworm absorbs vitamin B12 intestine\nCertain Medications (e.g., metformin, proton pump inhibitors)\nFish tapeworm (Diphyllobothrium latum) infection: tapeworm absorbs vitamin B12 intestineCertain Medications (e.g., metformin, proton pump inhibitors)Folate Deficiency:\nInadequate Dietary Intake:\ncommon cause folate deficiency\nOccurs individuals poor diets, alcoholism, fad diets\n\nIncreased Folate Requirements:\nPregnancy: Folate requirements increase support fetal development\nHemolytic Anemia: Increased erythropoiesis increases folate demand\nMalignancies: Rapidly dividing cells require folate\n\nMalabsorption:\nCeliac disease\nInflammatory bowel disease\n\nMedications:\nMethotrexate: Inhibits dihydrofolate reductase (DHFR), enzyme required folate metabolism\nTrimethoprim: Also inhibits DHFR\nPhenytoin: Can interfere folate absorption\n\nAlcohol Abuse:\nImpairs folate absorption utilization\n\nInadequate Dietary Intake:\ncommon cause folate deficiency\nOccurs individuals poor diets, alcoholism, fad diets\ncommon cause folate deficiencyOccurs individuals poor diets, alcoholism, fad dietsIncreased Folate Requirements:\nPregnancy: Folate requirements increase support fetal development\nHemolytic Anemia: Increased erythropoiesis increases folate demand\nMalignancies: Rapidly dividing cells require folate\nPregnancy: Folate requirements increase support fetal developmentHemolytic Anemia: Increased erythropoiesis increases folate demandMalignancies: Rapidly dividing cells require folateMalabsorption:\nCeliac disease\nInflammatory bowel disease\nCeliac diseaseInflammatory bowel diseaseMedications:\nMethotrexate: Inhibits dihydrofolate reductase (DHFR), enzyme required folate metabolism\nTrimethoprim: Also inhibits DHFR\nPhenytoin: Can interfere folate absorption\nMethotrexate: Inhibits dihydrofolate reductase (DHFR), enzyme required folate metabolismTrimethoprim: Also inhibits DHFRPhenytoin: Can interfere folate absorptionAlcohol Abuse:\nImpairs folate absorption utilization\nImpairs folate absorption utilization","code":""},{"path":"megaloblastic.html","id":"pathophysiology-2","chapter":"Megaloblastic","heading":"Pathophysiology","text":"Impaired DNA Synthesis:\nVitamin B12 folate essential synthesis thymidine, nucleotide required DNA synthesis\nVitamin B12 acts cofactor methionine synthase, converts homocysteine methionine. Methionine needed synthesis tetrahydrofolate (THF), active form folate\nFolate, form tetrahydrofolate (THF), required several steps DNA synthesis, including conversion deoxyuridine monophosphate (dUMP) deoxythymidine monophosphate (dTMP)\nDeficiency either vitamin B12 folate leads impaired DNA synthesis\nVitamin B12 folate essential synthesis thymidine, nucleotide required DNA synthesisVitamin B12 acts cofactor methionine synthase, converts homocysteine methionine. Methionine needed synthesis tetrahydrofolate (THF), active form folateFolate, form tetrahydrofolate (THF), required several steps DNA synthesis, including conversion deoxyuridine monophosphate (dUMP) deoxythymidine monophosphate (dTMP)Deficiency either vitamin B12 folate leads impaired DNA synthesisMegaloblastic Changes:\nImpaired DNA synthesis affects rapidly dividing cells, particularly hematopoietic cells bone marrow\nMegaloblasts: Abnormal, large erythroid precursors delayed nuclear maturation asynchronous development nucleus cytoplasm\nNuclear maturation delayed due impaired DNA synthesis\nCytoplasmic maturation proceeds normally (RNA protein synthesis affected), resulting large cell relatively immature nucleus\n\nDysplasia: Megaloblastic changes also occur myeloid megakaryocytic cell lines, leading abnormal granulocytes (e.g., hypersegmented neutrophils) platelets\nImpaired DNA synthesis affects rapidly dividing cells, particularly hematopoietic cells bone marrowMegaloblasts: Abnormal, large erythroid precursors delayed nuclear maturation asynchronous development nucleus cytoplasm\nNuclear maturation delayed due impaired DNA synthesis\nCytoplasmic maturation proceeds normally (RNA protein synthesis affected), resulting large cell relatively immature nucleus\nNuclear maturation delayed due impaired DNA synthesisCytoplasmic maturation proceeds normally (RNA protein synthesis affected), resulting large cell relatively immature nucleusDysplasia: Megaloblastic changes also occur myeloid megakaryocytic cell lines, leading abnormal granulocytes (e.g., hypersegmented neutrophils) plateletsIneffective Hematopoiesis:\nMegaloblastic changes DNA damage lead increased apoptosis (programmed cell death) hematopoietic precursors bone marrow\nResults decreased production mature RBCs, WBCs, platelets, leading cytopenias\nMegaloblastic changes DNA damage lead increased apoptosis (programmed cell death) hematopoietic precursors bone marrowResults decreased production mature RBCs, WBCs, platelets, leading cytopeniasNeurological Manifestations (Vitamin B12 Deficiency):\nVitamin B12 required maintenance myelin, protective sheath around nerve fibers\nB12 deficiency can cause demyelination spinal cord peripheral nerves, leading neurological symptoms\nVitamin B12 required maintenance myelin, protective sheath around nerve fibersB12 deficiency can cause demyelination spinal cord peripheral nerves, leading neurological symptoms","code":""},{"path":"megaloblastic.html","id":"clinical-manifestations-3","chapter":"Megaloblastic","heading":"Clinical Manifestations","text":"Symptoms Anemia:\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nDizziness\nFatigueWeaknessPallor (pale skin)Shortness breathDizzinessGastrointestinal Symptoms:\nGlossitis (sore, red tongue)\nLoss appetite\nDiarrhea\nGlossitis (sore, red tongue)Loss appetiteDiarrheaNeurological Symptoms (Vitamin B12 Deficiency):\nPeripheral neuropathy (numbness, tingling, burning sensations hands feet)\nLoss balance\nDifficulty walking\nMemory loss, confusion, dementia\nDepression\nOptic neuropathy (vision problems)\nPeripheral neuropathy (numbness, tingling, burning sensations hands feet)Loss balanceDifficulty walkingMemory loss, confusion, dementiaDepressionOptic neuropathy (vision problems)Physical Examination Findings:\nPallor\nGlossitis (smooth, beefy-red tongue)\nNeurological abnormalities:\nDecreased vibratory sense proprioception\nImpaired reflexes\nPositive Romberg sign (loss balance standing eyes closed)\n\nPallorGlossitis (smooth, beefy-red tongue)Neurological abnormalities:\nDecreased vibratory sense proprioception\nImpaired reflexes\nPositive Romberg sign (loss balance standing eyes closed)\nDecreased vibratory sense proprioceptionImpaired reflexesPositive Romberg sign (loss balance standing eyes closed)","code":""},{"path":"megaloblastic.html","id":"laboratory-findings-1","chapter":"Megaloblastic","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nRed Blood Cell Count (RBC): Decreased\nMean Corpuscular Volume (MCV): Increased (macrocytic) >100 fL.\nMean Corpuscular Hemoglobin (MCH): Increased\nMean Corpuscular Hemoglobin Concentration (MCHC): Normal\nRed Cell Distribution Width (RDW): Increased (anisocytosis)\nWhite Blood Cell Count (WBC): May decreased (leukopenia)\nPlatelet Count: May decreased (thrombocytopenia)\nHemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedRed Blood Cell Count (RBC): DecreasedMean Corpuscular Volume (MCV): Increased (macrocytic) >100 fL.Mean Corpuscular Hemoglobin (MCH): IncreasedMean Corpuscular Hemoglobin Concentration (MCHC): NormalRed Cell Distribution Width (RDW): Increased (anisocytosis)White Blood Cell Count (WBC): May decreased (leukopenia)Platelet Count: May decreased (thrombocytopenia)Peripheral Blood Smear:\nMacrocytes (large RBCs): Often oval shape\nAnisocytosis (variation RBC size) poikilocytosis (variation RBC shape)\nHypersegmented neutrophils: Neutrophils 5 lobes\nHowell-Jolly bodies: Nuclear remnants RBCs\nBasophilic stippling: Ribosomal RNA precipitates RBCs\nMacrocytes (large RBCs): Often oval shapeAnisocytosis (variation RBC size) poikilocytosis (variation RBC shape)Hypersegmented neutrophils: Neutrophils 5 lobesHowell-Jolly bodies: Nuclear remnants RBCsBasophilic stippling: Ribosomal RNA precipitates RBCsReticulocyte Count:\nLow (inappropriately low degree anemia)\nLow (inappropriately low degree anemia)Bone Marrow Aspiration Biopsy:\nHypercellular marrow erythroid hyperplasia\nMegaloblasts: Large, abnormal erythroid precursors delayed nuclear maturation\nDysplastic changes myeloid megakaryocytic cell lines\nHypercellular marrow erythroid hyperplasiaMegaloblasts: Large, abnormal erythroid precursors delayed nuclear maturationDysplastic changes myeloid megakaryocytic cell linesVitamin B12 Folate Levels:\nSerum Vitamin B12: Decreased vitamin B12 deficiency\nRed Blood Cell Folate: Decreased folate deficiency\nSerum Vitamin B12: Decreased vitamin B12 deficiencyRed Blood Cell Folate: Decreased folate deficiencyOther Tests:\nSerum Methylmalonic Acid (MMA): Elevated vitamin B12 deficiency\nSerum Homocysteine: Elevated vitamin B12 folate deficiency\nAntibodies Intrinsic Factor (): Present pernicious anemia\nParietal Cell Antibodies: May present pernicious anemia\nSchilling Test: (Historically used assess vitamin B12 absorption, now rarely performed)\nSerum Methylmalonic Acid (MMA): Elevated vitamin B12 deficiencySerum Homocysteine: Elevated vitamin B12 folate deficiencyAntibodies Intrinsic Factor (): Present pernicious anemiaParietal Cell Antibodies: May present pernicious anemiaSchilling Test: (Historically used assess vitamin B12 absorption, now rarely performed)Potential Lab Results:\nElevated Iron\nElevated Lactate Dehydrogenase\nElevated Bilirubin\nElevated IronElevated Lactate DehydrogenaseElevated Bilirubin","code":""},{"path":"megaloblastic.html","id":"differential-diagnosis-3","chapter":"Megaloblastic","heading":"Differential Diagnosis","text":"Non-Megaloblastic Macrocytic Anemias:\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\nReticulocytosis (increased reticulocytes can falsely elevate MCV)\nMedications (e.g., hydroxyurea)\nAlcoholismLiver diseaseHypothyroidismMyelodysplastic syndromes (MDS)Reticulocytosis (increased reticulocytes can falsely elevate MCV)Medications (e.g., hydroxyurea)Causes Anemia:\nIron deficiency anemia\nAnemia chronic disease\nThalassemia\nAplastic anemia\nIron deficiency anemiaAnemia chronic diseaseThalassemiaAplastic anemiaNeurological Disorders:\nMultiple sclerosis\nPeripheral neuropathy causes\nMultiple sclerosisPeripheral neuropathy causes","code":""},{"path":"megaloblastic.html","id":"treatment-and-management-2","chapter":"Megaloblastic","heading":"Treatment and Management","text":"Vitamin B12 Deficiency:\nVitamin B12 Injections:\nCyanocobalamin hydroxocobalamin\nAdministered intramuscularly subcutaneously\nInitial treatment: Daily injections 1-2 weeks, followed monthly maintenance injections life\nOral Vitamin B12:\nHigh-dose oral vitamin B12 may effective patients without severe malabsorption\n\n\nTreatment Underlying Cause:\nAddress cause malabsorption (e.g., treat bacterial overgrowth, discontinue offending medications)\n\nMonitoring:\nMonitor hemoglobin reticulocyte count assess response treatment\nNeurological symptoms may take several months improve\n\nVitamin B12 Injections:\nCyanocobalamin hydroxocobalamin\nAdministered intramuscularly subcutaneously\nInitial treatment: Daily injections 1-2 weeks, followed monthly maintenance injections life\nOral Vitamin B12:\nHigh-dose oral vitamin B12 may effective patients without severe malabsorption\n\nCyanocobalamin hydroxocobalaminAdministered intramuscularly subcutaneouslyInitial treatment: Daily injections 1-2 weeks, followed monthly maintenance injections lifeOral Vitamin B12:\nHigh-dose oral vitamin B12 may effective patients without severe malabsorption\nHigh-dose oral vitamin B12 may effective patients without severe malabsorptionTreatment Underlying Cause:\nAddress cause malabsorption (e.g., treat bacterial overgrowth, discontinue offending medications)\nAddress cause malabsorption (e.g., treat bacterial overgrowth, discontinue offending medications)Monitoring:\nMonitor hemoglobin reticulocyte count assess response treatment\nNeurological symptoms may take several months improve\nMonitor hemoglobin reticulocyte count assess response treatmentNeurological symptoms may take several months improveFolate Deficiency:\nOral Folic Acid Supplementation:\nTypically 1-5 mg daily\nTreatment usually effective restoring normal folate levels resolving anemia\n\nDietary Modifications:\nIncrease intake folate-rich foods (e.g., leafy green vegetables, citrus fruits, beans)\n\nAvoid Alcohol Abuse\nTreatment Underlying Cause:\nAddress malabsorption discontinue offending medications\n\nOral Folic Acid Supplementation:\nTypically 1-5 mg daily\nTreatment usually effective restoring normal folate levels resolving anemia\nTypically 1-5 mg dailyTreatment usually effective restoring normal folate levels resolving anemiaDietary Modifications:\nIncrease intake folate-rich foods (e.g., leafy green vegetables, citrus fruits, beans)\nIncrease intake folate-rich foods (e.g., leafy green vegetables, citrus fruits, beans)Avoid Alcohol AbuseTreatment Underlying Cause:\nAddress malabsorption discontinue offending medications\nAddress malabsorption discontinue offending medicationsGeneral Management:\nMonitor complete blood counts assess response therapy\nAddress neurological complications vitamin B12 deficiency\nGenetic counseling (inherited causes malabsorption)\nMonitor complete blood counts assess response therapyAddress neurological complications vitamin B12 deficiencyGenetic counseling (inherited causes malabsorption)","code":""},{"path":"megaloblastic.html","id":"key-laboratory-findings-3","chapter":"Megaloblastic","heading":"Key Laboratory Findings","text":"Complete Blood Count (CBC):\nMacrocytic anemia (high MCV)\nPossible leukopenia thrombocytopenia\nMacrocytic anemia (high MCV)Possible leukopenia thrombocytopeniaPeripheral Blood Smear:\nOval macrocytes\nHypersegmented neutrophils\nOval macrocytesHypersegmented neutrophilsReticulocyte Count:\nLow\nLowVitamin B12 Folate Levels:\nLow serum vitamin B12 /red blood cell folate\nLow serum vitamin B12 /red blood cell folateSerum Methylmalonic Acid (MMA):\nElevated vitamin B12 deficiency\nElevated vitamin B12 deficiencySerum Homocysteine:\nElevated vitamin B12 folate deficiency\nElevated vitamin B12 folate deficiency","code":""},{"path":"megaloblastic.html","id":"key-terms-15","chapter":"Megaloblastic","heading":"Key Terms","text":"Megaloblastic Anemia: Macrocytic anemia due impaired DNA synthesisMegaloblast: Abnormal, large erythroid precursor bone marrowMacrocytosis: Presence large red blood cells (MCV > 100 fL)Hypersegmented Neutrophil: Neutrophil 5 lobesVitamin B12 (Cobalamin): Essential vitamin DNA synthesis neurological functionFolate (Folic Acid): Essential vitamin DNA synthesisIntrinsic Factor (): Protein produced parietal cells stomach, required vitamin B12 absorptionSchilling Test: (Historical) Test assess vitamin B12 absorptionMethylmalonic Acid (MMA): Metabolite elevated vitamin B12 deficiencyHomocysteine: Amino acid elevated vitamin B12 folate deficiencyPernicious Anemia: Autoimmune destruction parietal cells, leading vitamin B12 deficiency","code":""},{"path":"nonmegaloblastic.html","id":"nonmegaloblastic","chapter":"Nonmegaloblastic","heading":"Nonmegaloblastic","text":"","code":""},{"path":"nonmegaloblastic.html","id":"overview-of-non-megaloblastic-macrocytic-anemias","chapter":"Nonmegaloblastic","heading":"Overview of Non-Megaloblastic Macrocytic Anemias","text":"Definition: Macrocytic anemias (MCV > 100 fL) caused vitamin B12 folate deficiency. words, megaloblastic anemias. macrocytosis due mechanisms affecting RBC size.Key Feature: Macrocytosis (large RBCs), without typical morphological changes seen megaloblastic anemia (.e., hypersegmented neutrophils oval macrocytes). Bone marrow examination (performed) show megaloblasts.Common Causes:\nAlcoholism\nLiver Disease\nHypothyroidism\nMyelodysplastic Syndromes (MDS)\nReticulocytosis\nMedications\nAlcoholismLiver DiseaseHypothyroidismMyelodysplastic Syndromes (MDS)ReticulocytosisMedications","code":""},{"path":"nonmegaloblastic.html","id":"pathophysiology-3","chapter":"Nonmegaloblastic","heading":"Pathophysiology","text":"exact mechanisms leading macrocytosis anemias complex may vary depending underlying cause. common mechanisms include:Altered Lipid Metabolism:\nAlcohol liver disease can disrupt lipid metabolism, leading increased cholesterol deposition RBC membrane\nincreases surface area RBC membrane, resulting larger cell size (macrocytosis)\nAlcohol liver disease can disrupt lipid metabolism, leading increased cholesterol deposition RBC membraneThis increases surface area RBC membrane, resulting larger cell size (macrocytosis)Accelerated Erythropoiesis:\nconditions increased red blood cell turnover (e.g., hemolysis, acute blood loss), increased number reticulocytes peripheral blood\nReticulocytes larger mature RBCs, high reticulocyte count can increase MCV, leading macrocytosis\nconditions increased red blood cell turnover (e.g., hemolysis, acute blood loss), increased number reticulocytes peripheral bloodReticulocytes larger mature RBCs, high reticulocyte count can increase MCV, leading macrocytosisMembrane Abnormalities:\nHypothyroidism can alter RBC membrane composition, leading increased cell size\nHypothyroidism can alter RBC membrane composition, leading increased cell sizeClonal Hematopoiesis:\nmyelodysplastic syndromes (MDS), abnormal stem cells bone marrow produce dysplastic blood cells, including macrocytes\nmyelodysplastic syndromes (MDS), abnormal stem cells bone marrow produce dysplastic blood cells, including macrocytes","code":""},{"path":"nonmegaloblastic.html","id":"etiology-and-associated-conditions","chapter":"Nonmegaloblastic","heading":"Etiology and Associated Conditions","text":"Alcoholism:\ncommon cause non-megaloblastic macrocytosis\nAlcohol can directly affect RBC membrane lipids also lead folate deficiency (contributing mixed picture)\ncommon cause non-megaloblastic macrocytosisAlcohol can directly affect RBC membrane lipids also lead folate deficiency (contributing mixed picture)Liver Disease:\nAltered lipid metabolism increased cholesterol deposition RBC membranes\nAlso, can associated spur cell anemia (acanthocytes)\nAltered lipid metabolism increased cholesterol deposition RBC membranesAlso, can associated spur cell anemia (acanthocytes)Hypothyroidism:\nDecreased thyroid hormone affects RBC membrane composition slows erythropoiesis\nDecreased thyroid hormone affects RBC membrane composition slows erythropoiesisMyelodysplastic Syndromes (MDS):\nClonal hematopoietic stem cell disorders dysplastic changes one cell lines\nMacrocytosis may present due abnormal maturation erythroid precursors\nClonal hematopoietic stem cell disorders dysplastic changes one cell linesMacrocytosis may present due abnormal maturation erythroid precursorsReticulocytosis:\nIncreased number reticulocytes response hemolysis blood loss\nReticulocytes larger mature RBCs, increasing MCV\nIncreased number reticulocytes response hemolysis blood lossReticulocytes larger mature RBCs, increasing MCVMedications:\nHydroxyurea: Interferes DNA synthesis\nAzathioprine immunosuppressants: Can disrupt cell division\nAntiretroviral drugs (e.g., zidovudine): Can cause macrocytosis, especially patients HIV\nHydroxyurea: Interferes DNA synthesisAzathioprine immunosuppressants: Can disrupt cell divisionAntiretroviral drugs (e.g., zidovudine): Can cause macrocytosis, especially patients HIV","code":""},{"path":"nonmegaloblastic.html","id":"clinical-manifestations-4","chapter":"Nonmegaloblastic","heading":"Clinical Manifestations","text":"Symptoms Anemia (present):\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nDizziness\nFatigueWeaknessPallor (pale skin)Shortness breathDizzinessOther Symptoms Depend Underlying Cause:\nAlcoholism: Liver disease, neuropathy, cognitive impairment\nLiver disease: Jaundice, edema, ascites, coagulopathy\nHypothyroidism: Fatigue, weight gain, constipation, dry skin, cold intolerance\nMyelodysplastic Syndromes (MDS): Infections, bleeding, fatigue\nAlcoholism: Liver disease, neuropathy, cognitive impairmentLiver disease: Jaundice, edema, ascites, coagulopathyHypothyroidism: Fatigue, weight gain, constipation, dry skin, cold intoleranceMyelodysplastic Syndromes (MDS): Infections, bleeding, fatigue","code":""},{"path":"nonmegaloblastic.html","id":"laboratory-findings-2","chapter":"Nonmegaloblastic","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nRed Blood Cell Count (RBC): Decreased\nMean Corpuscular Volume (MCV): Increased (macrocytic) > 100 fL\nMean Corpuscular Hemoglobin (MCH): Increased\nMean Corpuscular Hemoglobin Concentration (MCHC): Normal\nRed Cell Distribution Width (RDW): Normal Increased\nWhite Blood Cell Count (WBC): May normal, decreased (leukopenia), increased (leukocytosis), depending cause\nPlatelet Count: May normal, decreased (thrombocytopenia), increased (thrombocytosis), depending cause\nHemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedRed Blood Cell Count (RBC): DecreasedMean Corpuscular Volume (MCV): Increased (macrocytic) > 100 fLMean Corpuscular Hemoglobin (MCH): IncreasedMean Corpuscular Hemoglobin Concentration (MCHC): NormalRed Cell Distribution Width (RDW): Normal IncreasedWhite Blood Cell Count (WBC): May normal, decreased (leukopenia), increased (leukocytosis), depending causePlatelet Count: May normal, decreased (thrombocytopenia), increased (thrombocytosis), depending causePeripheral Blood Smear:\nMacrocytes: Large RBCs, typically round (oval)\nAnisocytosis (variation RBC size) poikilocytosis (variation RBC shape) may present, prominent megaloblastic anemias\nAbsence hypersegmented neutrophils absence oval macrocytes (helps rule megaloblastic anemia)\nfindings may present, depending underlying cause:\nAcanthocytes (spur cells) liver disease\nTarget cells\nSchistocytes (cases MDS)\n\nMacrocytes: Large RBCs, typically round (oval)Anisocytosis (variation RBC size) poikilocytosis (variation RBC shape) may present, prominent megaloblastic anemiasAbsence hypersegmented neutrophils absence oval macrocytes (helps rule megaloblastic anemia)findings may present, depending underlying cause:\nAcanthocytes (spur cells) liver disease\nTarget cells\nSchistocytes (cases MDS)\nAcanthocytes (spur cells) liver diseaseTarget cellsSchistocytes (cases MDS)Reticulocyte Count:\nMay low, normal, elevated, depending underlying cause\nMay low, normal, elevated, depending underlying causeVitamin B12 Folate Levels:\nNormal (rules megaloblastic anemia)\nNormal (rules megaloblastic anemia)Liver Function Tests (LFTs):\nElevated liver disease\nElevated liver diseaseThyroid Function Tests (TFTs):\nAbnormal hypothyroidism (low T4, high TSH)\nAbnormal hypothyroidism (low T4, high TSH)Bone Marrow Aspiration Biopsy:\nCellularity: Variable (can normocellular, hypercellular, hypocellular)\nMaturation: May show dysplastic changes one cell lines (MDS)\nAbsence megaloblasts\nCytogenetic Analysis: detect chromosomal abnormalities MDS\nCellularity: Variable (can normocellular, hypercellular, hypocellular)Maturation: May show dysplastic changes one cell lines (MDS)Absence megaloblastsCytogenetic Analysis: detect chromosomal abnormalities MDSOther Tests:\nReticulocyte count\nLiver thyroid test panels\nReticulocyte countLiver thyroid test panels","code":""},{"path":"nonmegaloblastic.html","id":"differential-diagnosis-4","chapter":"Nonmegaloblastic","heading":"Differential Diagnosis","text":"Megaloblastic Anemias:\nVitamin B12 deficiency\nFolate deficiency\nDistinguished hypersegmented neutrophils, oval macrocytes peripheral smear, abnormal B12/folate studies\nVitamin B12 deficiencyFolate deficiencyDistinguished hypersegmented neutrophils, oval macrocytes peripheral smear, abnormal B12/folate studiesHemolytic Anemias:\nMay cause macrocytosis due increased reticulocytes\nElevated reticulocyte count, elevated bilirubin LDH, decreased haptoglobin\nMay cause macrocytosis due increased reticulocytesElevated reticulocyte count, elevated bilirubin LDH, decreased haptoglobinCold Agglutinin Disease:\nAgglutinated red blood cells can falsely elevate MCV\nAgglutinated red blood cells can falsely elevate MCVMedication Side Effects","code":""},{"path":"nonmegaloblastic.html","id":"treatment-and-management-3","chapter":"Nonmegaloblastic","heading":"Treatment and Management","text":"Treat Underlying Cause: important aspect management\nAlcoholism:\nAlcohol cessation\nNutritional support (thiamine, folate, multivitamin)\n\nLiver Disease:\nManagement underlying liver disease (e.g., antiviral therapy hepatitis, abstinence alcohol)\nSupportive care (e.g., diuretics ascites)\n\nHypothyroidism:\nThyroid hormone replacement therapy (levothyroxine)\n\nMyelodysplastic Syndromes (MDS):\nSupportive care (transfusions, growth factors)\nHypomethylating agents (azacitidine, decitabine)\nLenalidomide (MDS deletion 5q)\nHematopoietic Stem Cell Transplantation (HSCT)\n\nMedications:\nDiscontinue offending medications (possible)\n\nTreat Underlying Cause: important aspect managementAlcoholism:\nAlcohol cessation\nNutritional support (thiamine, folate, multivitamin)\nAlcohol cessationNutritional support (thiamine, folate, multivitamin)Liver Disease:\nManagement underlying liver disease (e.g., antiviral therapy hepatitis, abstinence alcohol)\nSupportive care (e.g., diuretics ascites)\nManagement underlying liver disease (e.g., antiviral therapy hepatitis, abstinence alcohol)Supportive care (e.g., diuretics ascites)Hypothyroidism:\nThyroid hormone replacement therapy (levothyroxine)\nThyroid hormone replacement therapy (levothyroxine)Myelodysplastic Syndromes (MDS):\nSupportive care (transfusions, growth factors)\nHypomethylating agents (azacitidine, decitabine)\nLenalidomide (MDS deletion 5q)\nHematopoietic Stem Cell Transplantation (HSCT)\nSupportive care (transfusions, growth factors)Hypomethylating agents (azacitidine, decitabine)Lenalidomide (MDS deletion 5q)Hematopoietic Stem Cell Transplantation (HSCT)Medications:\nDiscontinue offending medications (possible)\nDiscontinue offending medications (possible)Supportive Care:\nFolic acid supplementation\nAlthough folate deficiency primary cause non-megaloblastic macrocytosis, folate supplementation may improve RBC production overall hematopoiesis. controversial, undertaken concern folate deficiency addition another condition\n\nBlood transfusions:\nmanage severe anemia\n\nSupportive Care:Folic acid supplementation\nAlthough folate deficiency primary cause non-megaloblastic macrocytosis, folate supplementation may improve RBC production overall hematopoiesis. controversial, undertaken concern folate deficiency addition another condition\nAlthough folate deficiency primary cause non-megaloblastic macrocytosis, folate supplementation may improve RBC production overall hematopoiesis. controversial, undertaken concern folate deficiency addition another conditionBlood transfusions:\nmanage severe anemia\nmanage severe anemia","code":""},{"path":"nonmegaloblastic.html","id":"key-laboratory-findings-4","chapter":"Nonmegaloblastic","heading":"Key Laboratory Findings","text":"Complete Blood Count (CBC):\nMacrocytosis (high MCV)\nNormal MCHC\nNormal increased RDW\nMacrocytosis (high MCV)Normal MCHCNormal increased RDWPeripheral Blood Smear:\nMacrocytes (round, oval)\nhypersegmented neutrophils\nMacrocytes (round, oval)hypersegmented neutrophilsVitamin B12 Folate Levels:\nNormal\nNormalOther Tests:\nElevated liver function tests (LFTs) liver disease\nAbnormal thyroid function tests (TFTs) hypothyroidism\nElevated liver function tests (LFTs) liver diseaseAbnormal thyroid function tests (TFTs) hypothyroidism","code":""},{"path":"nonmegaloblastic.html","id":"key-terms-16","chapter":"Nonmegaloblastic","heading":"Key Terms","text":"Non-Megaloblastic Macrocytic Anemia: Macrocytic anemia caused vitamin B12 folate deficiencyMacrocytosis: Large red blood cells (MCV > 100 fL)Myelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders ineffective hematopoiesisReticulocytosis: Increased number reticulocytes bloodAcanthocytes (Spur Cells): RBCs irregular, spiky projections seen liver diseaseHypersegmented Neutrophils: Neutrophils 5 lobes (seen megaloblastic anemia, non-megaloblastic)Megaloblasts: Abnormal erythroid precursors delayed nuclear maturation (seen megaloblastic anemia, non-megaloblastic)","code":""},{"path":"hemoglobinopathies.html","id":"hemoglobinopathies","chapter":"Hemoglobinopathies","heading":"Hemoglobinopathies","text":"","code":""},{"path":"hemoglobinopathies.html","id":"overview-of-hemoglobinopathies","chapter":"Hemoglobinopathies","heading":"Overview of Hemoglobinopathies","text":"Definition: group inherited (genetic) disorders characterized abnormalities structure synthesis hemoglobin (HGB)Genetic Basis: Caused mutations genes encoding globin chains (alpha, beta, gamma, delta) hemoglobin moleculeClassification:\nStructural Hemoglobin Variants: Abnormal hemoglobin molecules due amino acid substitutions structural changes globin chains (e.g., Hemoglobin S, Hemoglobin C)\nThalassemias: Reduced absent synthesis one globin chains (see separate study guide Thalassemias)\nStructural Hemoglobin Variants: Abnormal hemoglobin molecules due amino acid substitutions structural changes globin chains (e.g., Hemoglobin S, Hemoglobin C)Thalassemias: Reduced absent synthesis one globin chains (see separate study guide Thalassemias)Prevalence: Common worldwide, particularly populations Africa, Mediterranean, Middle East, AsiaClinical Significance: Can range asymptomatic severe, life-threatening conditions depending specific mutation effect hemoglobin function RBC survival","code":""},{"path":"hemoglobinopathies.html","id":"normal-hemoglobin-structure-and-types","chapter":"Hemoglobinopathies","heading":"Normal Hemoglobin Structure and Types","text":"Hemoglobin (Hb): tetrameric protein found red blood cells (RBCs) responsible oxygen transportStructure:\nComposed four globin chains (two alpha-like two beta-like)\nglobin chain contains heme molecule, contains iron (Fe2+) atom binds oxygen\nComposed four globin chains (two alpha-like two beta-like)globin chain contains heme molecule, contains iron (Fe2+) atom binds oxygenNormal Hemoglobin Types:\nHemoglobin (HbA): α2β2 (two alpha two beta chains). Predominant hemoglobin adults (95-98%)\nHemoglobin A2 (HbA2): α2δ2 (two alpha two delta chains). Minor component adults (2-3%)\nHemoglobin F (HbF): α2γ2 (two alpha two gamma chains). Predominant hemoglobin fetuses newborns. Normally <1% adults\nHemoglobin (HbA): α2β2 (two alpha two beta chains). Predominant hemoglobin adults (95-98%)Hemoglobin A2 (HbA2): α2δ2 (two alpha two delta chains). Minor component adults (2-3%)Hemoglobin F (HbF): α2γ2 (two alpha two gamma chains). Predominant hemoglobin fetuses newborns. Normally <1% adults","code":""},{"path":"hemoglobinopathies.html","id":"structural-hemoglobin-variants","chapter":"Hemoglobinopathies","heading":"Structural Hemoglobin Variants","text":"Hemoglobin S (HbS) - Sickle Cell Anemia\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution valine glutamic acid 6th position beta-globin chain (β6 Glu→Val)\n\nPathophysiology:\nconditions low oxygen tension, HbS molecules polymerize, forming long fibers distort RBC sickle shape\nSickled RBCs rigid, less deformable, prone :\nVaso-occlusion: Blockage small blood vessels, leading tissue ischemia pain\nHemolysis: Premature destruction sickled RBCs spleen\n\n\nClinical Features:\nSickle Cell Trait (HbAS):\nHeterozygous HbS (one normal beta-globin gene one HbS gene)\nUsually asymptomatic\nMay experience hematuria splenic infarction high altitudes extreme exercise\n\nSickle Cell Anemia (HbSS):\nHomozygous HbS (two HbS genes)\nSevere chronic hemolytic anemia\nVaso-occlusive crises: Painful episodes caused blockage blood vessels\nAcute chest syndrome: Vaso-occlusion lungs, leading chest pain, fever, respiratory distress\nStroke: Vaso-occlusion brain\nSplenic sequestration: Sudden pooling blood spleen, leading severe anemia hypovolemic shock\nAplastic crisis: Temporary cessation erythropoiesis due parvovirus B19 infection\nChronic organ damage: Affects lungs, kidneys, heart, bones\n\n\nLaboratory Findings:\nCBC:\nHGB: Decreased (6-8 g/dL HbSS)\nHCT: Decreased\nMCV: Normal slightly increased\nMCH: Normal decreased\nMCHC: Increased (often > 36 g/dL)\nWBC: Elevated (especially crises)\nPlatelets: Elevated\n\nPeripheral Blood Smear:\nSickle cells (drepanocytes)\nTarget cells\nHowell-Jolly bodies\nPolychromasia\nNucleated RBCs (splenectomy severe anemia)\n\nReticulocyte Count: Elevated (often > 10%)\nHemoglobin Electrophoresis:\nHbAS (Sickle Cell Trait): HbA (50-60%) HbS (35-45%)\nHbSS (Sickle Cell Anemia): Predominantly HbS (80-95%) elevated HbF (5-15%); HbA absent\n\nSickle Solubility Test:\nPositive: Detects presence HbS (specific sickle cell anemia)\nUsed screening test\n\n\nDiagnosis:\nBased clinical presentation, peripheral blood smear, hemoglobin electrophoresis, genetic testing\n\nTreatment:\nHydroxyurea: Increases HbF production, reducing sickling vaso-occlusive crises\nL-glutamine: Reduces oxidative stress\nCrizanlizumab: Monoclonal antibody prevents vaso-occlusion\nVoxelotor: Binds hemoglobin increases affinity oxygen, reducing sickling\nPain Management: Analgesics vaso-occlusive crises\nVaccinations: prevent infections (especially encapsulated organisms)\nProphylactic Penicillin: children prevent pneumococcal infections\nBlood Transfusions: severe anemia, acute chest syndrome, stroke, complications\nHematopoietic Stem Cell Transplantation (HSCT): Potentially curative option\n\nGene Therapy: Emerging therapeutic approach\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution valine glutamic acid 6th position beta-globin chain (β6 Glu→Val)\npoint mutation β-globin gene chromosome 11Substitution valine glutamic acid 6th position beta-globin chain (β6 Glu→Val)Pathophysiology:\nconditions low oxygen tension, HbS molecules polymerize, forming long fibers distort RBC sickle shape\nSickled RBCs rigid, less deformable, prone :\nVaso-occlusion: Blockage small blood vessels, leading tissue ischemia pain\nHemolysis: Premature destruction sickled RBCs spleen\n\nconditions low oxygen tension, HbS molecules polymerize, forming long fibers distort RBC sickle shapeSickled RBCs rigid, less deformable, prone :\nVaso-occlusion: Blockage small blood vessels, leading tissue ischemia pain\nHemolysis: Premature destruction sickled RBCs spleen\nVaso-occlusion: Blockage small blood vessels, leading tissue ischemia painHemolysis: Premature destruction sickled RBCs spleenClinical Features:\nSickle Cell Trait (HbAS):\nHeterozygous HbS (one normal beta-globin gene one HbS gene)\nUsually asymptomatic\nMay experience hematuria splenic infarction high altitudes extreme exercise\n\nSickle Cell Anemia (HbSS):\nHomozygous HbS (two HbS genes)\nSevere chronic hemolytic anemia\nVaso-occlusive crises: Painful episodes caused blockage blood vessels\nAcute chest syndrome: Vaso-occlusion lungs, leading chest pain, fever, respiratory distress\nStroke: Vaso-occlusion brain\nSplenic sequestration: Sudden pooling blood spleen, leading severe anemia hypovolemic shock\nAplastic crisis: Temporary cessation erythropoiesis due parvovirus B19 infection\nChronic organ damage: Affects lungs, kidneys, heart, bones\n\nSickle Cell Trait (HbAS):\nHeterozygous HbS (one normal beta-globin gene one HbS gene)\nUsually asymptomatic\nMay experience hematuria splenic infarction high altitudes extreme exercise\nHeterozygous HbS (one normal beta-globin gene one HbS gene)Usually asymptomaticMay experience hematuria splenic infarction high altitudes extreme exerciseSickle Cell Anemia (HbSS):\nHomozygous HbS (two HbS genes)\nSevere chronic hemolytic anemia\nVaso-occlusive crises: Painful episodes caused blockage blood vessels\nAcute chest syndrome: Vaso-occlusion lungs, leading chest pain, fever, respiratory distress\nStroke: Vaso-occlusion brain\nSplenic sequestration: Sudden pooling blood spleen, leading severe anemia hypovolemic shock\nAplastic crisis: Temporary cessation erythropoiesis due parvovirus B19 infection\nChronic organ damage: Affects lungs, kidneys, heart, bones\nHomozygous HbS (two HbS genes)Severe chronic hemolytic anemiaVaso-occlusive crises: Painful episodes caused blockage blood vesselsAcute chest syndrome: Vaso-occlusion lungs, leading chest pain, fever, respiratory distressStroke: Vaso-occlusion brainSplenic sequestration: Sudden pooling blood spleen, leading severe anemia hypovolemic shockAplastic crisis: Temporary cessation erythropoiesis due parvovirus B19 infectionChronic organ damage: Affects lungs, kidneys, heart, bonesLaboratory Findings:\nCBC:\nHGB: Decreased (6-8 g/dL HbSS)\nHCT: Decreased\nMCV: Normal slightly increased\nMCH: Normal decreased\nMCHC: Increased (often > 36 g/dL)\nWBC: Elevated (especially crises)\nPlatelets: Elevated\n\nPeripheral Blood Smear:\nSickle cells (drepanocytes)\nTarget cells\nHowell-Jolly bodies\nPolychromasia\nNucleated RBCs (splenectomy severe anemia)\n\nReticulocyte Count: Elevated (often > 10%)\nHemoglobin Electrophoresis:\nHbAS (Sickle Cell Trait): HbA (50-60%) HbS (35-45%)\nHbSS (Sickle Cell Anemia): Predominantly HbS (80-95%) elevated HbF (5-15%); HbA absent\n\nSickle Solubility Test:\nPositive: Detects presence HbS (specific sickle cell anemia)\nUsed screening test\n\nCBC:\nHGB: Decreased (6-8 g/dL HbSS)\nHCT: Decreased\nMCV: Normal slightly increased\nMCH: Normal decreased\nMCHC: Increased (often > 36 g/dL)\nWBC: Elevated (especially crises)\nPlatelets: Elevated\nHGB: Decreased (6-8 g/dL HbSS)HCT: DecreasedMCV: Normal slightly increasedMCH: Normal decreasedMCHC: Increased (often > 36 g/dL)WBC: Elevated (especially crises)Platelets: ElevatedPeripheral Blood Smear:\nSickle cells (drepanocytes)\nTarget cells\nHowell-Jolly bodies\nPolychromasia\nNucleated RBCs (splenectomy severe anemia)\nSickle cells (drepanocytes)Target cellsHowell-Jolly bodiesPolychromasiaNucleated RBCs (splenectomy severe anemia)Reticulocyte Count: Elevated (often > 10%)Hemoglobin Electrophoresis:\nHbAS (Sickle Cell Trait): HbA (50-60%) HbS (35-45%)\nHbSS (Sickle Cell Anemia): Predominantly HbS (80-95%) elevated HbF (5-15%); HbA absent\nHbAS (Sickle Cell Trait): HbA (50-60%) HbS (35-45%)HbSS (Sickle Cell Anemia): Predominantly HbS (80-95%) elevated HbF (5-15%); HbA absentSickle Solubility Test:\nPositive: Detects presence HbS (specific sickle cell anemia)\nUsed screening test\nPositive: Detects presence HbS (specific sickle cell anemia)Used screening testDiagnosis:\nBased clinical presentation, peripheral blood smear, hemoglobin electrophoresis, genetic testing\nBased clinical presentation, peripheral blood smear, hemoglobin electrophoresis, genetic testingTreatment:\nHydroxyurea: Increases HbF production, reducing sickling vaso-occlusive crises\nL-glutamine: Reduces oxidative stress\nCrizanlizumab: Monoclonal antibody prevents vaso-occlusion\nVoxelotor: Binds hemoglobin increases affinity oxygen, reducing sickling\nPain Management: Analgesics vaso-occlusive crises\nVaccinations: prevent infections (especially encapsulated organisms)\nProphylactic Penicillin: children prevent pneumococcal infections\nBlood Transfusions: severe anemia, acute chest syndrome, stroke, complications\nHematopoietic Stem Cell Transplantation (HSCT): Potentially curative option\nHydroxyurea: Increases HbF production, reducing sickling vaso-occlusive crisesL-glutamine: Reduces oxidative stressCrizanlizumab: Monoclonal antibody prevents vaso-occlusionVoxelotor: Binds hemoglobin increases affinity oxygen, reducing sicklingPain Management: Analgesics vaso-occlusive crisesVaccinations: prevent infections (especially encapsulated organisms)Prophylactic Penicillin: children prevent pneumococcal infectionsBlood Transfusions: severe anemia, acute chest syndrome, stroke, complicationsHematopoietic Stem Cell Transplantation (HSCT): Potentially curative optionGene Therapy: Emerging therapeutic approachHemoglobin C (HbC)\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution lysine glutamic acid 6th position beta-globin chain (β6 Glu→Lys)\n\nPathophysiology:\nHbC molecules tend crystallize within RBCs, leading increased rigidity premature destruction spleen\n\nClinical Features:\nHbAC (Hemoglobin C Trait):\nHeterozygous HbC\nUsually asymptomatic\n\nHbCC (Hemoglobin C Disease):\nHomozygous HbC\nMild moderate hemolytic anemia\nSplenomegaly\n\n\nLaboratory Findings:\nCBC:\nHGB: Decreased (10-12 g/dL HbCC)\nHCT: Decreased\nMCV: Normal slightly decreased\nMCHC: Increased (often > 36 g/dL)\n\nPeripheral Blood Smear:\nTarget cells (prominent)\nHbC crystals (may seen splenectomy)\nMicrospherocytes\n\nReticulocyte Count: Slightly elevated\nHemoglobin Electrophoresis:\nHbAC (Hemoglobin C Trait): HbA (60%) HbC (40%)\nHbCC (Hemoglobin C Disease): Predominantly HbC (90-95%); HbF may slightly elevated\n\nDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\n\n\nTreatment:\nUsually supportive\nFolic acid supplementation\nSplenectomy may considered severe cases\n\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution lysine glutamic acid 6th position beta-globin chain (β6 Glu→Lys)\npoint mutation β-globin gene chromosome 11Substitution lysine glutamic acid 6th position beta-globin chain (β6 Glu→Lys)Pathophysiology:\nHbC molecules tend crystallize within RBCs, leading increased rigidity premature destruction spleen\nHbC molecules tend crystallize within RBCs, leading increased rigidity premature destruction spleenClinical Features:\nHbAC (Hemoglobin C Trait):\nHeterozygous HbC\nUsually asymptomatic\n\nHbCC (Hemoglobin C Disease):\nHomozygous HbC\nMild moderate hemolytic anemia\nSplenomegaly\n\nHbAC (Hemoglobin C Trait):\nHeterozygous HbC\nUsually asymptomatic\nHeterozygous HbCUsually asymptomaticHbCC (Hemoglobin C Disease):\nHomozygous HbC\nMild moderate hemolytic anemia\nSplenomegaly\nHomozygous HbCMild moderate hemolytic anemiaSplenomegalyLaboratory Findings:\nCBC:\nHGB: Decreased (10-12 g/dL HbCC)\nHCT: Decreased\nMCV: Normal slightly decreased\nMCHC: Increased (often > 36 g/dL)\n\nPeripheral Blood Smear:\nTarget cells (prominent)\nHbC crystals (may seen splenectomy)\nMicrospherocytes\n\nReticulocyte Count: Slightly elevated\nHemoglobin Electrophoresis:\nHbAC (Hemoglobin C Trait): HbA (60%) HbC (40%)\nHbCC (Hemoglobin C Disease): Predominantly HbC (90-95%); HbF may slightly elevated\n\nDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\n\nCBC:\nHGB: Decreased (10-12 g/dL HbCC)\nHCT: Decreased\nMCV: Normal slightly decreased\nMCHC: Increased (often > 36 g/dL)\nHGB: Decreased (10-12 g/dL HbCC)HCT: DecreasedMCV: Normal slightly decreasedMCHC: Increased (often > 36 g/dL)Peripheral Blood Smear:\nTarget cells (prominent)\nHbC crystals (may seen splenectomy)\nMicrospherocytes\nTarget cells (prominent)HbC crystals (may seen splenectomy)MicrospherocytesReticulocyte Count: Slightly elevatedHemoglobin Electrophoresis:\nHbAC (Hemoglobin C Trait): HbA (60%) HbC (40%)\nHbCC (Hemoglobin C Disease): Predominantly HbC (90-95%); HbF may slightly elevated\nHbAC (Hemoglobin C Trait): HbA (60%) HbC (40%)HbCC (Hemoglobin C Disease): Predominantly HbC (90-95%); HbF may slightly elevatedDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\nBased peripheral blood smear hemoglobin electrophoresisTreatment:\nUsually supportive\nFolic acid supplementation\nSplenectomy may considered severe cases\nUsually supportiveFolic acid supplementationSplenectomy may considered severe casesHemoglobin E (HbE)\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution lysine glutamic acid 26th position beta-globin chain (β26 Glu→Lys)\n\nPathophysiology:\nHbE unstable can lead mild reduction beta-globin chain synthesis\n\nClinical Features:\nHbAE (Hemoglobin E Trait):\nHeterozygous HbE\nUsually asymptomatic mild microcytic anemia\n\nHbEE (Hemoglobin E Disease):\nHomozygous HbE\nMild microcytic anemia\nSplenomegaly may occur\n\nHbE-Beta Thalassemia:\nInheritance HbE gene beta-thalassemia gene\nSeverity varies depending specific beta-thalassemia mutation\nCan range mild anemia severe thalassemia major\n\n\nLaboratory Findings:\nCBC:\nHGB: Decreased (variable)\nHCT: Decreased (variable)\nMCV: Decreased (microcytic)\nMCH: Decreased\n\nPeripheral Blood Smear:\nTarget cells\nMicrocytes\n\nHemoglobin Electrophoresis:\nHbAE (Hemoglobin E Trait): HbA HbE\nHbEE (Hemoglobin E Disease): Predominantly HbE\nHbE-Beta Thalassemia: HbE elevated HbF\n\nDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\n\n\nTreatment:\nHbAE (Hemoglobin E Trait): treatment required\nHbEE (Hemoglobin E Disease): Usually treatment required; folic acid supplementation may beneficial\nHbE-Beta Thalassemia: Treatment depends severity; may require blood transfusions iron chelation\n\nGenetic Defect:\npoint mutation β-globin gene chromosome 11\nSubstitution lysine glutamic acid 26th position beta-globin chain (β26 Glu→Lys)\npoint mutation β-globin gene chromosome 11Substitution lysine glutamic acid 26th position beta-globin chain (β26 Glu→Lys)Pathophysiology:\nHbE unstable can lead mild reduction beta-globin chain synthesis\nHbE unstable can lead mild reduction beta-globin chain synthesisClinical Features:\nHbAE (Hemoglobin E Trait):\nHeterozygous HbE\nUsually asymptomatic mild microcytic anemia\n\nHbEE (Hemoglobin E Disease):\nHomozygous HbE\nMild microcytic anemia\nSplenomegaly may occur\n\nHbE-Beta Thalassemia:\nInheritance HbE gene beta-thalassemia gene\nSeverity varies depending specific beta-thalassemia mutation\nCan range mild anemia severe thalassemia major\n\nHbAE (Hemoglobin E Trait):\nHeterozygous HbE\nUsually asymptomatic mild microcytic anemia\nHeterozygous HbEUsually asymptomatic mild microcytic anemiaHbEE (Hemoglobin E Disease):\nHomozygous HbE\nMild microcytic anemia\nSplenomegaly may occur\nHomozygous HbEMild microcytic anemiaSplenomegaly may occurHbE-Beta Thalassemia:\nInheritance HbE gene beta-thalassemia gene\nSeverity varies depending specific beta-thalassemia mutation\nCan range mild anemia severe thalassemia major\nInheritance HbE gene beta-thalassemia geneSeverity varies depending specific beta-thalassemia mutationCan range mild anemia severe thalassemia majorLaboratory Findings:\nCBC:\nHGB: Decreased (variable)\nHCT: Decreased (variable)\nMCV: Decreased (microcytic)\nMCH: Decreased\n\nPeripheral Blood Smear:\nTarget cells\nMicrocytes\n\nHemoglobin Electrophoresis:\nHbAE (Hemoglobin E Trait): HbA HbE\nHbEE (Hemoglobin E Disease): Predominantly HbE\nHbE-Beta Thalassemia: HbE elevated HbF\n\nDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\n\nCBC:\nHGB: Decreased (variable)\nHCT: Decreased (variable)\nMCV: Decreased (microcytic)\nMCH: Decreased\nHGB: Decreased (variable)HCT: Decreased (variable)MCV: Decreased (microcytic)MCH: DecreasedPeripheral Blood Smear:\nTarget cells\nMicrocytes\nTarget cellsMicrocytesHemoglobin Electrophoresis:\nHbAE (Hemoglobin E Trait): HbA HbE\nHbEE (Hemoglobin E Disease): Predominantly HbE\nHbE-Beta Thalassemia: HbE elevated HbF\nHbAE (Hemoglobin E Trait): HbA HbEHbEE (Hemoglobin E Disease): Predominantly HbEHbE-Beta Thalassemia: HbE elevated HbFDiagnosis:\nBased peripheral blood smear hemoglobin electrophoresis\nBased peripheral blood smear hemoglobin electrophoresisTreatment:\nHbAE (Hemoglobin E Trait): treatment required\nHbEE (Hemoglobin E Disease): Usually treatment required; folic acid supplementation may beneficial\nHbE-Beta Thalassemia: Treatment depends severity; may require blood transfusions iron chelation\nHbAE (Hemoglobin E Trait): treatment requiredHbEE (Hemoglobin E Disease): Usually treatment required; folic acid supplementation may beneficialHbE-Beta Thalassemia: Treatment depends severity; may require blood transfusions iron chelation","code":""},{"path":"hemoglobinopathies.html","id":"diagnostic-approach-to-hemoglobinopathies","chapter":"Hemoglobinopathies","heading":"Diagnostic Approach to Hemoglobinopathies","text":"Suspect Hemoglobinopathy:\nAnemia suggestive features (e.g., microcytosis, hemolysis)\nFamily history hemoglobinopathy\nEthnic background\nAnemia suggestive features (e.g., microcytosis, hemolysis)Family history hemoglobinopathyEthnic backgroundComplete Blood Count (CBC) Peripheral Blood Smear:\nAssess RBC morphology (e.g., sickle cells, target cells, spherocytes)\nDetermine MCV, MCH, MCHC\nAssess RBC morphology (e.g., sickle cells, target cells, spherocytes)Determine MCV, MCH, MCHCHemoglobin Electrophoresis:\nSeparates quantifies different hemoglobin types (HbA, HbA2, HbF, HbS, HbC)\nEssential diagnosing structural hemoglobin variants thalassemias\nSeparates quantifies different hemoglobin types (HbA, HbA2, HbF, HbS, HbC)Essential diagnosing structural hemoglobin variants thalassemiasSickle Solubility Test:\nPositive presence HbS\nUsed screening test sickle cell disease\nPositive presence HbSUsed screening test sickle cell diseaseSpecialized Tests (Indicated):\nGlobin chain synthesis assays\nDNA analysis specific mutations\nGlobin chain synthesis assaysDNA analysis specific mutations","code":""},{"path":"hemoglobinopathies.html","id":"key-terms-17","chapter":"Hemoglobinopathies","heading":"Key Terms","text":"Hemoglobinopathy: genetic disorder affecting structure synthesis hemoglobinHemoglobin S (HbS): Abnormal hemoglobin causes sickle cell anemiaHemoglobin C (HbC): Abnormal hemoglobin can cause mild hemolytic anemiaHemoglobin E (HbE): Abnormal hemoglobin can cause mild microcytic anemiaSickle Cell Trait (HbAS): Heterozygous carrier HbS; usually asymptomaticSickle Cell Anemia (HbSS): Homozygous HbS; causes severe hemolytic anemia vaso-occlusive crisesHemoglobin Electrophoresis: Technique separate quantify hemoglobin typesTarget Cells: Red blood cells bullseye appearanceVaso-occlusion: Blockage blood vessels sickled RBCs","code":""},{"path":"erythrocytosis.html","id":"erythrocytosis","chapter":"Erythrocytosis","heading":"Erythrocytosis","text":"","code":""},{"path":"erythrocytosis.html","id":"overview-of-erythrocytosis","chapter":"Erythrocytosis","heading":"Overview of Erythrocytosis","text":"Definition: abnormal increase number red blood cells (RBCs) blood, leading elevated hemoglobin (HGB) concentration hematocrit (HCT) valueAlternative Terms: Polycythemia, erythremiaClassification:\nRelative Erythrocytosis: apparent increase RBC count due decrease plasma volume\nAbsolute Erythrocytosis: true increase total red blood cell mass body\nRelative Erythrocytosis: apparent increase RBC count due decrease plasma volumeAbsolute Erythrocytosis: true increase total red blood cell mass bodyCauses: Can range benign life-threatening conditionsSymptoms: May asymptomatic present variety symptoms, including headache, dizziness, fatigue, blurred vision, pruritus (itching), thrombosis (blood clots)","code":""},{"path":"erythrocytosis.html","id":"relative-erythrocytosis","chapter":"Erythrocytosis","heading":"Relative Erythrocytosis","text":"Definition: elevated hematocrit (HCT) hemoglobin (HGB) concentration due decrease plasma volume, rather actual increase red blood cell massCauses:\nDehydration:\nReduced fluid intake\nExcessive fluid loss (e.g., vomiting, diarrhea, diuretic use, burns)\n\nStress Erythrocytosis (Gaisböck Syndrome):\ncommon middle-aged men obese, hypertensive, smokers\nUnderlying mechanism fully understood may involve increased catecholamines, lead decreased plasma volume\nOften associated anxiety stress\n\nDehydration:\nReduced fluid intake\nExcessive fluid loss (e.g., vomiting, diarrhea, diuretic use, burns)\nReduced fluid intakeExcessive fluid loss (e.g., vomiting, diarrhea, diuretic use, burns)Stress Erythrocytosis (Gaisböck Syndrome):\ncommon middle-aged men obese, hypertensive, smokers\nUnderlying mechanism fully understood may involve increased catecholamines, lead decreased plasma volume\nOften associated anxiety stress\ncommon middle-aged men obese, hypertensive, smokersUnderlying mechanism fully understood may involve increased catecholamines, lead decreased plasma volumeOften associated anxiety stressLaboratory Findings:\nElevated HGB HCT\nNormal red blood cell mass\nElevated RBC count\nNormal elevated serum protein albumin levels (due hemoconcentration)\nNormal low-normal Erythropoietin level (EPO)\nNormal Oxygen Saturation (SaO2)\nElevated HGB HCTNormal red blood cell massElevated RBC countNormal elevated serum protein albumin levels (due hemoconcentration)Normal low-normal Erythropoietin level (EPO)Normal Oxygen Saturation (SaO2)","code":""},{"path":"erythrocytosis.html","id":"absolute-erythrocytosis","chapter":"Erythrocytosis","heading":"Absolute Erythrocytosis","text":"Definition: true increase total red blood cell mass bodyClassification:\nPrimary Erythrocytosis:\nCaused intrinsic abnormalities bone marrow, leading uncontrolled RBC production\nIndependent erythropoietin (EPO) levels\n\nSecondary Erythrocytosis:\nCaused factors external bone marrow stimulate increased RBC production\nAssociated elevated erythropoietin (EPO) levels\n\nPrimary Erythrocytosis:\nCaused intrinsic abnormalities bone marrow, leading uncontrolled RBC production\nIndependent erythropoietin (EPO) levels\nCaused intrinsic abnormalities bone marrow, leading uncontrolled RBC productionIndependent erythropoietin (EPO) levelsSecondary Erythrocytosis:\nCaused factors external bone marrow stimulate increased RBC production\nAssociated elevated erythropoietin (EPO) levels\nCaused factors external bone marrow stimulate increased RBC productionAssociated elevated erythropoietin (EPO) levels","code":""},{"path":"erythrocytosis.html","id":"primary-erythrocytosis","chapter":"Erythrocytosis","heading":"Primary Erythrocytosis","text":"Polycythemia Vera (PV):\nmyeloproliferative neoplasm characterized uncontrolled proliferation myeloid cell lines (RBCs, WBCs, platelets), predominant increase RBCs\nCause: cases (>95%), caused mutation JAK2 gene (Janus kinase 2), leads constitutive activation EPO receptor signaling pathway\nSymptoms: Headache, dizziness, fatigue, pruritus (especially warm bath), erythromelalgia (burning pain redness extremities), splenomegaly, thrombosis (arterial venous)\nLaboratory Findings:\nElevated HGB HCT\nElevated RBC count\nNormal decreased EPO level\nIncreased WBC count platelet count cases\nPositive JAK2 mutation\nBone marrow examination: Hypercellular marrow increased erythroid, myeloid, megakaryocytic lineages\n\nmyeloproliferative neoplasm characterized uncontrolled proliferation myeloid cell lines (RBCs, WBCs, platelets), predominant increase RBCsCause: cases (>95%), caused mutation JAK2 gene (Janus kinase 2), leads constitutive activation EPO receptor signaling pathwaySymptoms: Headache, dizziness, fatigue, pruritus (especially warm bath), erythromelalgia (burning pain redness extremities), splenomegaly, thrombosis (arterial venous)Laboratory Findings:\nElevated HGB HCT\nElevated RBC count\nNormal decreased EPO level\nIncreased WBC count platelet count cases\nPositive JAK2 mutation\nBone marrow examination: Hypercellular marrow increased erythroid, myeloid, megakaryocytic lineages\nElevated HGB HCTElevated RBC countNormal decreased EPO levelIncreased WBC count platelet count casesPositive JAK2 mutationBone marrow examination: Hypercellular marrow increased erythroid, myeloid, megakaryocytic lineages","code":""},{"path":"erythrocytosis.html","id":"secondary-erythrocytosis","chapter":"Erythrocytosis","heading":"Secondary Erythrocytosis","text":"Definition: Increased RBC production due underlying condition stimulates erythropoietin (EPO) productionCauses:\nHypoxia-Induced Erythrocytosis:\nChronic lung disease (e.g., COPD, emphysema)\nHigh altitude\nObstructive sleep apnea\nCyanotic heart disease\nReduced oxygen levels stimulate EPO production kidneys\n\nEPO-Producing Tumors:\nRenal cell carcinoma\nHepatocellular carcinoma\nHemangioblastoma\ntumors secrete EPO, leading increased RBC production\n\nCauses:\nExogenous EPO administration (e.g., athletes performance enhancement)\nAndrogen use\nCertain medications\nPost-kidney transplant erythrocytosis\n\nHypoxia-Induced Erythrocytosis:\nChronic lung disease (e.g., COPD, emphysema)\nHigh altitude\nObstructive sleep apnea\nCyanotic heart disease\nReduced oxygen levels stimulate EPO production kidneys\nChronic lung disease (e.g., COPD, emphysema)High altitudeObstructive sleep apneaCyanotic heart diseaseReduced oxygen levels stimulate EPO production kidneysEPO-Producing Tumors:\nRenal cell carcinoma\nHepatocellular carcinoma\nHemangioblastoma\ntumors secrete EPO, leading increased RBC production\nRenal cell carcinomaHepatocellular carcinomaHemangioblastomaThese tumors secrete EPO, leading increased RBC productionOther Causes:\nExogenous EPO administration (e.g., athletes performance enhancement)\nAndrogen use\nCertain medications\nPost-kidney transplant erythrocytosis\nExogenous EPO administration (e.g., athletes performance enhancement)Androgen useCertain medicationsPost-kidney transplant erythrocytosisLaboratory Findings:\nElevated HGB HCT\nElevated RBC count\nElevated EPO level (except cases exogenous EPO administration)\nNormal elevated WBC count platelet count\nArterial blood gas analysis: May show hypoxemia (low oxygen levels) hypoxia-induced erythrocytosis\nImaging studies: detect EPO-producing tumors\nElevated HGB HCTElevated RBC countElevated EPO level (except cases exogenous EPO administration)Normal elevated WBC count platelet countArterial blood gas analysis: May show hypoxemia (low oxygen levels) hypoxia-induced erythrocytosisImaging studies: detect EPO-producing tumors","code":""},{"path":"erythrocytosis.html","id":"diagnostic-approach-to-erythrocytosis","chapter":"Erythrocytosis","heading":"Diagnostic Approach to Erythrocytosis","text":"Confirm Erythrocytosis:\nCheck HGB HCT levels\nCheck HGB HCT levelsRule Relative Erythrocytosis:\nAssess hydration status\nCheck serum protein albumin levels\nAssess hydration statusCheck serum protein albumin levelsMeasure Red Blood Cell Mass:\navailable, direct measurement RBC mass can differentiate relative absolute erythrocytosis\navailable, direct measurement RBC mass can differentiate relative absolute erythrocytosisMeasure Serum Erythropoietin (EPO) Level:\nLow normal EPO: Suggests primary erythrocytosis (e.g., PV)\nElevated EPO: Suggests secondary erythrocytosis\nLow normal EPO: Suggests primary erythrocytosis (e.g., PV)Elevated EPO: Suggests secondary erythrocytosisIf EPO Low Normal:\nTest JAK2 mutation (highly suggestive PV)\nJAK2 negative, consider myeloproliferative neoplasms rare causes primary erythrocytosis\nBone marrow examination may necessary\nTest JAK2 mutation (highly suggestive PV)JAK2 negative, consider myeloproliferative neoplasms rare causes primary erythrocytosisBone marrow examination may necessaryIf EPO Elevated:\nAssess hypoxia:\nArterial blood gas analysis\nPulse oximetry\n\nEvaluate EPO-producing tumors:\nImaging studies (e.g., CT scan, MRI)\n\nConsider causes:\nExogenous EPO administration\nAndrogen use\nmedications\n\nAssess hypoxia:\nArterial blood gas analysis\nPulse oximetry\nArterial blood gas analysisPulse oximetryEvaluate EPO-producing tumors:\nImaging studies (e.g., CT scan, MRI)\nImaging studies (e.g., CT scan, MRI)Consider causes:\nExogenous EPO administration\nAndrogen use\nmedications\nExogenous EPO administrationAndrogen useOther medications","code":""},{"path":"erythrocytosis.html","id":"complications-of-erythrocytosis","chapter":"Erythrocytosis","heading":"Complications of Erythrocytosis","text":"Thrombosis:\nIncreased risk blood clots due increased blood viscosity platelet activation\nCan lead stroke, heart attack, pulmonary embolism, deep vein thrombosis (DVT)\nIncreased risk blood clots due increased blood viscosity platelet activationCan lead stroke, heart attack, pulmonary embolism, deep vein thrombosis (DVT)Bleeding:\nParadoxically, patients PV may experience bleeding due abnormal platelet function\nParadoxically, patients PV may experience bleeding due abnormal platelet functionSplenomegaly:\nEnlargement spleen due increased workload\nEnlargement spleen due increased workloadMyelofibrosis:\nPV, bone marrow can become fibrotic time, leading cytopenias\nPV, bone marrow can become fibrotic time, leading cytopeniasTransformation Acute Leukemia:\nSmall risk transformation acute myeloid leukemia (AML) PV, especially treatment certain agents\nSmall risk transformation acute myeloid leukemia (AML) PV, especially treatment certain agents","code":""},{"path":"erythrocytosis.html","id":"treatment-of-erythrocytosis","chapter":"Erythrocytosis","heading":"Treatment of Erythrocytosis","text":"Relative Erythrocytosis:\nAddress underlying cause (e.g., rehydration)\nAddress underlying cause (e.g., rehydration)Polycythemia Vera:\nPhlebotomy: reduce HCT <45%\nLow-dose aspirin: reduce risk thrombosis\nCytoreductive therapy:\nHydroxyurea: suppress bone marrow proliferation\nRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyurea\n\nPhlebotomy: reduce HCT <45%Low-dose aspirin: reduce risk thrombosisCytoreductive therapy:\nHydroxyurea: suppress bone marrow proliferation\nRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyurea\nHydroxyurea: suppress bone marrow proliferationRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyureaSecondary Erythrocytosis:\nAddress underlying cause:\nOxygen therapy hypoxia\nSurgical removal EPO-producing tumors\n\nPhlebotomy: May used reduce Hct symptomatic patients\nAddress underlying cause:\nOxygen therapy hypoxia\nSurgical removal EPO-producing tumors\nOxygen therapy hypoxiaSurgical removal EPO-producing tumorsPhlebotomy: May used reduce Hct symptomatic patients","code":""},{"path":"erythrocytosis.html","id":"key-laboratory-tests-for-erythrocytosis","chapter":"Erythrocytosis","heading":"Key Laboratory Tests for Erythrocytosis","text":"Complete Blood Count (CBC):\nHGB HCT: Elevated\nRBC count: Elevated\nWBC count: May normal elevated\nPlatelet count: May normal elevated\nHGB HCT: ElevatedRBC count: ElevatedWBC count: May normal elevatedPlatelet count: May normal elevatedSerum Erythropoietin (EPO) Level:\nLow normal: Suggests primary erythrocytosis\nElevated: Suggests secondary erythrocytosis\nLow normal: Suggests primary erythrocytosisElevated: Suggests secondary erythrocytosisArterial Blood Gas Analysis:\nassess oxygen saturation partial pressure oxygen (PaO2) hypoxia-induced erythrocytosis\nassess oxygen saturation partial pressure oxygen (PaO2) hypoxia-induced erythrocytosisJAK2 Mutation Analysis:\ndiagnose polycythemia vera\ndiagnose polycythemia veraBone Marrow Examination:\nassess cellularity morphology hematopoietic cells\nassess cellularity morphology hematopoietic cellsImaging Studies (CT Scan, MRI):\ndetect EPO-producing tumors\ndetect EPO-producing tumors","code":""},{"path":"erythrocytosis.html","id":"key-terms-18","chapter":"Erythrocytosis","heading":"Key Terms","text":"Erythrocytosis: Increased red blood cell countPolycythemia: Increased red blood cell countRelative Erythrocytosis: Decreased plasma volumeAbsolute Erythrocytosis: Increased red blood cell massPolycythemia Vera (PV): Myeloproliferative neoplasm increased RBCs, WBCs, PLTsJAK2 Mutation: Mutation associated PVErythropoietin (EPO): Hormone stimulates RBC productionPhlebotomy: Removal bloodHydroxyurea: Cytoreductive agentRuxolitinib: JAK2 inhibitor","code":""},{"path":"wbc-production.html","id":"wbc-production","chapter":"WBC Production","heading":"WBC Production","text":"","code":""},{"path":"wbc-production.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"WBC Production","heading":"\nAudio Overview\n","text":"","code":""},{"path":"wbc-production.html","id":"overview-of-leukocyte-production","chapter":"WBC Production","heading":"Overview of Leukocyte Production","text":"Definition: process white blood cell (leukocyte) production, development, maturation bone marrow , lymphocytes, also secondary lymphoid organsPurpose: maintain adequate supply functional leukocytes defend body infection, inflammation, threats.Regulation: Complex interplay growth factors, cytokines, transcription factorsLocation: Primarily occurs bone marrow, except lymphocytes, also undergo maturation differentiation thymus secondary lymphoid organs (e.g., lymph nodes, spleen)Types Leukocytes:\nGranulocytes: Neutrophils, eosinophils, basophils\nMonocytes\nLymphocytes: T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cells\nGranulocytes: Neutrophils, eosinophils, basophilsMonocytesLymphocytes: T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cells","code":""},{"path":"wbc-production.html","id":"hematopoietic-stem-cells-hscs-and-leukocyte-development","chapter":"WBC Production","heading":"Hematopoietic Stem Cells (HSCs) and Leukocyte Development","text":"Hematopoietic Stem Cells (HSCs):\nSelf-renewing cells can differentiate blood cell lineages\nReside bone marrow\nSelf-renewing cells can differentiate blood cell lineagesReside bone marrowCommon Myeloid Progenitor (CMP):\nGives rise granulocytes, monocytes, macrophages, megakaryocytes\nGives rise granulocytes, monocytes, macrophages, megakaryocytesCommon Lymphoid Progenitor (CLP):\nGives rise lymphocytes (T cells, B cells, NK cells)\nGives rise lymphocytes (T cells, B cells, NK cells)","code":""},{"path":"wbc-production.html","id":"granulopoiesis-production-of-granulocytes","chapter":"WBC Production","heading":"Granulopoiesis (Production of Granulocytes)","text":"Myeloblast:\nEarliest recognizable granulocyte precursor\nLarge cell high nucleus--cytoplasm (N:C) ratio\nFine chromatin prominent nucleoli\nCytoplasm basophilic lacks granules\nEarliest recognizable granulocyte precursorLarge cell high nucleus--cytoplasm (N:C) ratioFine chromatin prominent nucleoliCytoplasm basophilic lacks granulesPromyelocyte:\nLarge cell slightly lower N:C ratio myeloblast\nPrimary (azurophilic) granules appear cytoplasm\nPrimary granules contain enzymes substances involved killing digesting microorganisms (e.g., myeloperoxidase, lysozyme, elastase)\nLarge cell slightly lower N:C ratio myeloblastPrimary (azurophilic) granules appear cytoplasmPrimary granules contain enzymes substances involved killing digesting microorganisms (e.g., myeloperoxidase, lysozyme, elastase)Myelocyte:\nSmaller promyelocyte\nNucleus round eccentric\nSecondary (specific) granules appear cytoplasm\nNeutrophilic myelocyte: Produces neutrophilic granules (stain pink lavender)\nEosinophilic myelocyte: Produces eosinophilic granules (stain orange-red)\nBasophilic myelocyte: Produces basophilic granules (stain dark blue purple)\n\n“Dawn neutrophilia”: Refers appearance pinkish cytoplasm neutrophilic myelocytes\nSmaller promyelocyteNucleus round eccentricSecondary (specific) granules appear cytoplasm\nNeutrophilic myelocyte: Produces neutrophilic granules (stain pink lavender)\nEosinophilic myelocyte: Produces eosinophilic granules (stain orange-red)\nBasophilic myelocyte: Produces basophilic granules (stain dark blue purple)\nNeutrophilic myelocyte: Produces neutrophilic granules (stain pink lavender)Eosinophilic myelocyte: Produces eosinophilic granules (stain orange-red)Basophilic myelocyte: Produces basophilic granules (stain dark blue purple)“Dawn neutrophilia”: Refers appearance pinkish cytoplasm neutrophilic myelocytesMetamyelocyte:\nSmaller myelocyte\nNucleus indented (kidney bean-shaped)\nCytoplasm contains secondary granules\nSmaller myelocyteNucleus indented (kidney bean-shaped)Cytoplasm contains secondary granulesBand Form:\nNucleus horseshoe-shaped (band-shaped)\nRepresents late stage neutrophil maturation\nSmall percentage band neutrophils normally found peripheral blood\nNucleus horseshoe-shaped (band-shaped)Represents late stage neutrophil maturationSmall percentage band neutrophils normally found peripheral bloodMature Granulocytes:\nNeutrophil:\nabundant WBC peripheral blood\nMulti-lobed nucleus (3-5 lobes)\nCytoplasm contains fine, pinkish-lilac granules\nFunction: Phagocytosis killing bacteria fungi\n\nEosinophil:\nBilobed nucleus\nCytoplasm contains large, orange-red granules\nFunction: Defense parasites involvement allergic reactions\n\nBasophil:\nLobulated nucleus (often obscured granules)\nCytoplasm contains large, dark blue purple granules\nFunction: Release histamine mediators involved allergic inflammatory responses\n\nNeutrophil:\nabundant WBC peripheral blood\nMulti-lobed nucleus (3-5 lobes)\nCytoplasm contains fine, pinkish-lilac granules\nFunction: Phagocytosis killing bacteria fungi\nabundant WBC peripheral bloodMulti-lobed nucleus (3-5 lobes)Cytoplasm contains fine, pinkish-lilac granulesFunction: Phagocytosis killing bacteria fungiEosinophil:\nBilobed nucleus\nCytoplasm contains large, orange-red granules\nFunction: Defense parasites involvement allergic reactions\nBilobed nucleusCytoplasm contains large, orange-red granulesFunction: Defense parasites involvement allergic reactionsBasophil:\nLobulated nucleus (often obscured granules)\nCytoplasm contains large, dark blue purple granules\nFunction: Release histamine mediators involved allergic inflammatory responses\nLobulated nucleus (often obscured granules)Cytoplasm contains large, dark blue purple granulesFunction: Release histamine mediators involved allergic inflammatory responses","code":""},{"path":"wbc-production.html","id":"monocytopoiesis-production-of-monocytes","chapter":"WBC Production","heading":"Monocytopoiesis (Production of Monocytes)","text":"Monoblast:\nEarliest recognizable monocyte precursor\nLarge cell high N:C ratio\nFine chromatin prominent nucleoli\nCytoplasm basophilic lacks granules\nEarliest recognizable monocyte precursorLarge cell high N:C ratioFine chromatin prominent nucleoliCytoplasm basophilic lacks granulesPromonocyte:\nLarge cell indented folded nucleus\nCytoplasm gray-blue contains fine granules\nLarge cell indented folded nucleusCytoplasm gray-blue contains fine granulesMonocyte:\nLarge cell horseshoe-shaped kidney bean-shaped nucleus\nCytoplasm gray-blue contains fine granules vacuoles\nCirculates blood days migrates tissues, differentiates macrophages\nLarge cell horseshoe-shaped kidney bean-shaped nucleusCytoplasm gray-blue contains fine granules vacuolesCirculates blood days migrates tissues, differentiates macrophages","code":""},{"path":"wbc-production.html","id":"lymphopoiesis-production-of-lymphocytes","chapter":"WBC Production","heading":"Lymphopoiesis (Production of Lymphocytes)","text":"Lymphoblast:\nEarliest recognizable lymphocyte precursor\nSmall medium-sized cell high N:C ratio\nFine chromatin prominent nucleoli\nCytoplasm scant basophilic\nEarliest recognizable lymphocyte precursorSmall medium-sized cell high N:C ratioFine chromatin prominent nucleoliCytoplasm scant basophilicProlymphocyte:\nSlightly larger lymphoblast\nSlightly condensed chromatin\nMay azurophilic granules\nSlightly larger lymphoblastSlightly condensed chromatinMay azurophilic granulesMature Lymphocytes:\nB Lymphocytes (B Cells):\nMature bone marrow migrate secondary lymphoid organs\nResponsible humoral immunity (antibody production)\nactivated, differentiate plasma cells, produce antibodies\n\nT Lymphocytes (T Cells):\nMature thymus\nResponsible cell-mediated immunity\nTypes T cells:\nHelper T cells (CD4+): Help activate immune cells\nCytotoxic T cells (CD8+): Kill infected cancerous cells\nRegulatory T cells: Suppress immune responses\n\n\nNatural Killer (NK) Cells:\nLarge granular lymphocytes\nPart innate immune system\nKill infected cancerous cells without prior sensitization\n\nB Lymphocytes (B Cells):\nMature bone marrow migrate secondary lymphoid organs\nResponsible humoral immunity (antibody production)\nactivated, differentiate plasma cells, produce antibodies\nMature bone marrow migrate secondary lymphoid organsResponsible humoral immunity (antibody production)activated, differentiate plasma cells, produce antibodiesT Lymphocytes (T Cells):\nMature thymus\nResponsible cell-mediated immunity\nTypes T cells:\nHelper T cells (CD4+): Help activate immune cells\nCytotoxic T cells (CD8+): Kill infected cancerous cells\nRegulatory T cells: Suppress immune responses\n\nMature thymusResponsible cell-mediated immunityTypes T cells:\nHelper T cells (CD4+): Help activate immune cells\nCytotoxic T cells (CD8+): Kill infected cancerous cells\nRegulatory T cells: Suppress immune responses\nHelper T cells (CD4+): Help activate immune cellsCytotoxic T cells (CD8+): Kill infected cancerous cellsRegulatory T cells: Suppress immune responsesNatural Killer (NK) Cells:\nLarge granular lymphocytes\nPart innate immune system\nKill infected cancerous cells without prior sensitization\nLarge granular lymphocytesPart innate immune systemKill infected cancerous cells without prior sensitization","code":""},{"path":"wbc-production.html","id":"regulation-of-leukopoiesis","chapter":"WBC Production","heading":"Regulation of Leukopoiesis","text":"Growth Factors Cytokines:\nColony-Stimulating Factors (CSFs):\nStimulate proliferation differentiation hematopoietic progenitor cells\nExamples:\nGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Stimulates production granulocytes macrophages\nGranulocyte Colony-Stimulating Factor (G-CSF): Stimulates production neutrophils\nMacrophage Colony-Stimulating Factor (M-CSF): Stimulates production monocytes macrophages\n\nInterleukins (ILs):\ndiverse group cytokines various effects leukocyte development function\nExamples:\nIL-3: Stimulates growth differentiation early hematopoietic progenitors\nIL-5: Promotes growth differentiation eosinophils\nIL-7: Important B T cell development\n\n\n\nTumor Necrosis Factor (TNF):\nInvolved inflammation immune responses\nCan stimulate inhibit leukocyte production depending context\n\nTransforming Growth Factor-beta (TGF-β):\nInhibits proliferation hematopoietic cells\nPromotes differentiation regulatory T cells\n\nColony-Stimulating Factors (CSFs):\nStimulate proliferation differentiation hematopoietic progenitor cells\nExamples:\nGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Stimulates production granulocytes macrophages\nGranulocyte Colony-Stimulating Factor (G-CSF): Stimulates production neutrophils\nMacrophage Colony-Stimulating Factor (M-CSF): Stimulates production monocytes macrophages\n\nInterleukins (ILs):\ndiverse group cytokines various effects leukocyte development function\nExamples:\nIL-3: Stimulates growth differentiation early hematopoietic progenitors\nIL-5: Promotes growth differentiation eosinophils\nIL-7: Important B T cell development\n\n\nStimulate proliferation differentiation hematopoietic progenitor cellsExamples:\nGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Stimulates production granulocytes macrophages\nGranulocyte Colony-Stimulating Factor (G-CSF): Stimulates production neutrophils\nMacrophage Colony-Stimulating Factor (M-CSF): Stimulates production monocytes macrophages\nGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Stimulates production granulocytes macrophagesGranulocyte Colony-Stimulating Factor (G-CSF): Stimulates production neutrophilsMacrophage Colony-Stimulating Factor (M-CSF): Stimulates production monocytes macrophagesInterleukins (ILs):\ndiverse group cytokines various effects leukocyte development function\nExamples:\nIL-3: Stimulates growth differentiation early hematopoietic progenitors\nIL-5: Promotes growth differentiation eosinophils\nIL-7: Important B T cell development\n\ndiverse group cytokines various effects leukocyte development functionExamples:\nIL-3: Stimulates growth differentiation early hematopoietic progenitors\nIL-5: Promotes growth differentiation eosinophils\nIL-7: Important B T cell development\nIL-3: Stimulates growth differentiation early hematopoietic progenitorsIL-5: Promotes growth differentiation eosinophilsIL-7: Important B T cell developmentTumor Necrosis Factor (TNF):\nInvolved inflammation immune responses\nCan stimulate inhibit leukocyte production depending context\nInvolved inflammation immune responsesCan stimulate inhibit leukocyte production depending contextTransforming Growth Factor-beta (TGF-β):\nInhibits proliferation hematopoietic cells\nPromotes differentiation regulatory T cells\nInhibits proliferation hematopoietic cellsPromotes differentiation regulatory T cellsTranscription Factors:\nPU.1:\nEssential development myeloid lymphoid cells\n\nGATA-1:\nImportant erythroid megakaryocytic development\n\nIkaros:\nRequired lymphoid development\n\nPU.1:\nEssential development myeloid lymphoid cells\nEssential development myeloid lymphoid cellsGATA-1:\nImportant erythroid megakaryocytic development\nImportant erythroid megakaryocytic developmentIkaros:\nRequired lymphoid development\nRequired lymphoid development","code":""},{"path":"wbc-production.html","id":"disorders-of-leukopoiesis","chapter":"WBC Production","heading":"Disorders of Leukopoiesis","text":"Leukopenia:\nDecreased number WBCs\nNeutropenia: Decreased neutrophils\nCauses: Infections, medications, autoimmune disorders, bone marrow disorders\n\nLymphopenia: Decreased lymphocytes\nCauses: HIV infection, immunosuppressive drugs, congenital immunodeficiency syndromes\n\nDecreased number WBCsNeutropenia: Decreased neutrophils\nCauses: Infections, medications, autoimmune disorders, bone marrow disorders\nCauses: Infections, medications, autoimmune disorders, bone marrow disordersLymphopenia: Decreased lymphocytes\nCauses: HIV infection, immunosuppressive drugs, congenital immunodeficiency syndromes\nCauses: HIV infection, immunosuppressive drugs, congenital immunodeficiency syndromesLeukocytosis:\nIncreased number WBCs\nNeutrophilia: Increased neutrophils\nCauses: Bacterial infections, inflammation, stress\n\nLymphocytosis: Increased lymphocytes\nCauses: Viral infections, chronic lymphocytic leukemia\n\nEosinophilia: Increased eosinophils\nCauses: Parasitic infections, allergic reactions\n\nIncreased number WBCsNeutrophilia: Increased neutrophils\nCauses: Bacterial infections, inflammation, stress\nCauses: Bacterial infections, inflammation, stressLymphocytosis: Increased lymphocytes\nCauses: Viral infections, chronic lymphocytic leukemia\nCauses: Viral infections, chronic lymphocytic leukemiaEosinophilia: Increased eosinophils\nCauses: Parasitic infections, allergic reactions\nCauses: Parasitic infections, allergic reactionsLeukemia:\nMalignant disorders characterized uncontrolled proliferation abnormal leukocytes bone marrow peripheral blood\nClassified acute chronic, myeloid lymphoid, based cell lineage stage maturation\nMalignant disorders characterized uncontrolled proliferation abnormal leukocytes bone marrow peripheral bloodClassified acute chronic, myeloid lymphoid, based cell lineage stage maturation","code":""},{"path":"wbc-production.html","id":"laboratory-evaluation-of-leukopoiesis","chapter":"WBC Production","heading":"Laboratory Evaluation of Leukopoiesis","text":"Complete Blood Count (CBC) Differential:\nWBC count: Measures total number leukocytes blood\nDifferential count: Determines percentages absolute numbers type leukocyte (neutrophils, lymphocytes, monocytes, eosinophils, basophils)\nAbnormal cells: Identifies presence immature abnormal cells (e.g., blasts, atypical lymphocytes)\nWBC count: Measures total number leukocytes bloodDifferential count: Determines percentages absolute numbers type leukocyte (neutrophils, lymphocytes, monocytes, eosinophils, basophils)Abnormal cells: Identifies presence immature abnormal cells (e.g., blasts, atypical lymphocytes)Peripheral Blood Smear Examination:\nMorphology: Evaluates morphology leukocytes\nToxic granulation neutrophils (indicates severe infection inflammation)\nAtypical lymphocytes (seen viral infections lymphoproliferative disorders)\nBlast cells (suggestive acute leukemia)\n\nCell counts: Verifies accuracy automated differential count\nMorphology: Evaluates morphology leukocytes\nToxic granulation neutrophils (indicates severe infection inflammation)\nAtypical lymphocytes (seen viral infections lymphoproliferative disorders)\nBlast cells (suggestive acute leukemia)\nToxic granulation neutrophils (indicates severe infection inflammation)Atypical lymphocytes (seen viral infections lymphoproliferative disorders)Blast cells (suggestive acute leukemia)Cell counts: Verifies accuracy automated differential countBone Marrow Aspiration Biopsy:\nCellularity: Assesses cellularity bone marrow\nMaturation: Evaluates maturation hematopoietic cells\nDysplasia: Detects abnormal cell development (e.g., myelodysplastic syndromes)\nSpecial stains: Used identify specific cell types abnormalities (e.g., myeloperoxidase stain, esterase stain)\nFlow cytometry: identify cell surface markers classify leukemias lymphomas\nCytogenetic analysis: detect chromosomal abnormalities\nMolecular testing: identify gene mutations\nCellularity: Assesses cellularity bone marrowMaturation: Evaluates maturation hematopoietic cellsDysplasia: Detects abnormal cell development (e.g., myelodysplastic syndromes)Special stains: Used identify specific cell types abnormalities (e.g., myeloperoxidase stain, esterase stain)Flow cytometry: identify cell surface markers classify leukemias lymphomasCytogenetic analysis: detect chromosomal abnormalitiesMolecular testing: identify gene mutations","code":""},{"path":"wbc-production.html","id":"key-terms-19","chapter":"WBC Production","heading":"Key Terms","text":"Leukopoiesis: White blood cell productionGranulopoiesis: Production granulocytes (neutrophils, eosinophils, basophils)Monocytopoiesis: Production monocytesLymphopoiesis: Production lymphocytes (T cells, B cells, NK cells)Myeloblast: Earliest recognizable granulocyte precursorLymphoblast: Earliest recognizable lymphocyte precursorColony-Stimulating Factors (CSFs): Growth factors stimulate leukocyte productionInterleukins (ILs): Cytokines regulate leukocyte development functionLeukocytosis: Increased number WBCsLeukopenia: Decreased number WBCsNeutrophilia: Increased neutrophilsNeutropenia: Decreased neutrophilsLymphocytosis: Increased lymphocytesLymphopenia: Decreased lymphocytesAgranulocytosis: Severe neutropenia (virtual absence granulocytes)Blast Cells: Immature, abnormal cells seen acute leukemiaMyelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders ineffective hematopoiesisLeukemia: Malignant disorder leukocytes","code":""},{"path":"wbc-function.html","id":"wbc-function","chapter":"WBC Function","heading":"WBC Function","text":"","code":""},{"path":"wbc-function.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"WBC Function","heading":"\nAudio Overview\n","text":"","code":""},{"path":"wbc-function.html","id":"overview-of-leukocyte-function","chapter":"WBC Function","heading":"Overview of Leukocyte Function","text":"Definition: Leukocytes (white blood cells) essential components immune system, responsible defending body infection, inflammation, threatsClassification:\nGranulocytes: Neutrophils, eosinophils, basophils\nMonocytes\nLymphocytes: T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cells\nGranulocytes: Neutrophils, eosinophils, basophilsMonocytesLymphocytes: T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cellsGeneral Functions:\nInnate Immunity: Immediate, non-specific defense mechanisms (e.g., phagocytosis, inflammation)\nAdaptive Immunity: Slower, antigen-specific immune responses mediated lymphocytes\nInnate Immunity: Immediate, non-specific defense mechanisms (e.g., phagocytosis, inflammation)Adaptive Immunity: Slower, antigen-specific immune responses mediated lymphocytes","code":""},{"path":"wbc-function.html","id":"granulocytes","chapter":"WBC Function","heading":"Granulocytes","text":"Neutrophils:\nFunction: Primary role defense bacterial fungal infections\nMechanisms Action:\nPhagocytosis: Engulfing destroying pathogens debris\nDegranulation: Releasing antimicrobial substances granules:\nLysozyme: Breaks bacterial cell walls\nMyeloperoxidase (MPO): Generates reactive oxygen species (ROS) kill pathogens\nDefensins: Antimicrobial peptides\nElastase: Degrades bacterial proteins\n\nOxidative Burst: Production reactive oxygen species (ROS) kill phagocytosed pathogens:\nNADPH oxidase: Enzyme responsible generating superoxide (O2-)\nSuperoxide dismutase (SOD): Converts superoxide hydrogen peroxide (H2O2)\nMyeloperoxidase (MPO): Uses H2O2 chloride ions produce hypochlorous acid (HOCl, bleach)\n\nNeutrophil Extracellular Traps (NETs): Extruding meshwork DNA, histones, antimicrobial proteins trap kill bacteria extracellularly\n\nChemotaxis: Migration neutrophils sites infection inflammation response chemical signals (chemokines)\nClinical Significance:\nNeutrophilia: Increased neutrophils, often seen bacterial infections, inflammation, stress\nNeutropenia: Decreased neutrophils, increasing susceptibility infections\nAgranulocytosis: Severe neutropenia (ANC < 200 cells/μL)\n\n\nFunction: Primary role defense bacterial fungal infectionsMechanisms Action:\nPhagocytosis: Engulfing destroying pathogens debris\nDegranulation: Releasing antimicrobial substances granules:\nLysozyme: Breaks bacterial cell walls\nMyeloperoxidase (MPO): Generates reactive oxygen species (ROS) kill pathogens\nDefensins: Antimicrobial peptides\nElastase: Degrades bacterial proteins\n\nOxidative Burst: Production reactive oxygen species (ROS) kill phagocytosed pathogens:\nNADPH oxidase: Enzyme responsible generating superoxide (O2-)\nSuperoxide dismutase (SOD): Converts superoxide hydrogen peroxide (H2O2)\nMyeloperoxidase (MPO): Uses H2O2 chloride ions produce hypochlorous acid (HOCl, bleach)\n\nNeutrophil Extracellular Traps (NETs): Extruding meshwork DNA, histones, antimicrobial proteins trap kill bacteria extracellularly\nPhagocytosis: Engulfing destroying pathogens debrisDegranulation: Releasing antimicrobial substances granules:\nLysozyme: Breaks bacterial cell walls\nMyeloperoxidase (MPO): Generates reactive oxygen species (ROS) kill pathogens\nDefensins: Antimicrobial peptides\nElastase: Degrades bacterial proteins\nLysozyme: Breaks bacterial cell wallsMyeloperoxidase (MPO): Generates reactive oxygen species (ROS) kill pathogensDefensins: Antimicrobial peptidesElastase: Degrades bacterial proteinsOxidative Burst: Production reactive oxygen species (ROS) kill phagocytosed pathogens:\nNADPH oxidase: Enzyme responsible generating superoxide (O2-)\nSuperoxide dismutase (SOD): Converts superoxide hydrogen peroxide (H2O2)\nMyeloperoxidase (MPO): Uses H2O2 chloride ions produce hypochlorous acid (HOCl, bleach)\nNADPH oxidase: Enzyme responsible generating superoxide (O2-)Superoxide dismutase (SOD): Converts superoxide hydrogen peroxide (H2O2)Myeloperoxidase (MPO): Uses H2O2 chloride ions produce hypochlorous acid (HOCl, bleach)Neutrophil Extracellular Traps (NETs): Extruding meshwork DNA, histones, antimicrobial proteins trap kill bacteria extracellularlyChemotaxis: Migration neutrophils sites infection inflammation response chemical signals (chemokines)Clinical Significance:\nNeutrophilia: Increased neutrophils, often seen bacterial infections, inflammation, stress\nNeutropenia: Decreased neutrophils, increasing susceptibility infections\nAgranulocytosis: Severe neutropenia (ANC < 200 cells/μL)\n\nNeutrophilia: Increased neutrophils, often seen bacterial infections, inflammation, stressNeutropenia: Decreased neutrophils, increasing susceptibility infections\nAgranulocytosis: Severe neutropenia (ANC < 200 cells/μL)\nAgranulocytosis: Severe neutropenia (ANC < 200 cells/μL)Eosinophils:\nFunction: Primarily involved defense parasitic infections allergic reactions\nMechanisms Action:\nDegranulation: Releasing substances granules kill parasites modulate allergic responses:\nMajor basic protein (MBP): Toxic parasites\nEosinophil peroxidase (EPO): Generates reactive oxygen species\nEosinophil cationic protein (ECP): Toxic parasites causes mast cell degranulation\nEosinophil-derived neurotoxin (EDN): Involved nerve damage parasitic infections\n\nPhagocytosis: Engulfing antigen-antibody complexes debris\nModulation Allergic Reactions:\nReleasing enzymes degrade mediators released mast cells basophils (e.g., histaminase, arylsulfatase)\n\n\nClinical Significance:\nEosinophilia: Increased eosinophils, often seen parasitic infections, allergic reactions, asthma, certain malignancies\nEosinopenia: Decreased eosinophils, can occur acute infections corticosteroid use\n\nFunction: Primarily involved defense parasitic infections allergic reactionsMechanisms Action:\nDegranulation: Releasing substances granules kill parasites modulate allergic responses:\nMajor basic protein (MBP): Toxic parasites\nEosinophil peroxidase (EPO): Generates reactive oxygen species\nEosinophil cationic protein (ECP): Toxic parasites causes mast cell degranulation\nEosinophil-derived neurotoxin (EDN): Involved nerve damage parasitic infections\n\nPhagocytosis: Engulfing antigen-antibody complexes debris\nModulation Allergic Reactions:\nReleasing enzymes degrade mediators released mast cells basophils (e.g., histaminase, arylsulfatase)\n\nDegranulation: Releasing substances granules kill parasites modulate allergic responses:\nMajor basic protein (MBP): Toxic parasites\nEosinophil peroxidase (EPO): Generates reactive oxygen species\nEosinophil cationic protein (ECP): Toxic parasites causes mast cell degranulation\nEosinophil-derived neurotoxin (EDN): Involved nerve damage parasitic infections\nMajor basic protein (MBP): Toxic parasitesEosinophil peroxidase (EPO): Generates reactive oxygen speciesEosinophil cationic protein (ECP): Toxic parasites causes mast cell degranulationEosinophil-derived neurotoxin (EDN): Involved nerve damage parasitic infectionsPhagocytosis: Engulfing antigen-antibody complexes debrisModulation Allergic Reactions:\nReleasing enzymes degrade mediators released mast cells basophils (e.g., histaminase, arylsulfatase)\nReleasing enzymes degrade mediators released mast cells basophils (e.g., histaminase, arylsulfatase)Clinical Significance:\nEosinophilia: Increased eosinophils, often seen parasitic infections, allergic reactions, asthma, certain malignancies\nEosinopenia: Decreased eosinophils, can occur acute infections corticosteroid use\nEosinophilia: Increased eosinophils, often seen parasitic infections, allergic reactions, asthma, certain malignanciesEosinopenia: Decreased eosinophils, can occur acute infections corticosteroid useBasophils:\nFunction: Primarily involved allergic reactions inflammation\nMechanisms Action:\nDegranulation: Releasing substances granules mediate allergic inflammatory responses:\nHistamine: Increases vascular permeability causes smooth muscle contraction\nHeparin: Anticoagulant\nLeukotrienes: Promote inflammation bronchoconstriction\n\nIgE Receptors: Basophils express high-affinity IgE receptors, bind IgE antibodies\nCrosslinking IgE receptors antigens triggers basophil degranulation\n\n\nClinical Significance:\nBasophilia: Increased basophils, seen myeloproliferative neoplasms, allergic reactions, certain infections\nBasopenia: Decreased basophils, difficult detect due normally low number basophils blood\n\nFunction: Primarily involved allergic reactions inflammationMechanisms Action:\nDegranulation: Releasing substances granules mediate allergic inflammatory responses:\nHistamine: Increases vascular permeability causes smooth muscle contraction\nHeparin: Anticoagulant\nLeukotrienes: Promote inflammation bronchoconstriction\n\nIgE Receptors: Basophils express high-affinity IgE receptors, bind IgE antibodies\nCrosslinking IgE receptors antigens triggers basophil degranulation\n\nDegranulation: Releasing substances granules mediate allergic inflammatory responses:\nHistamine: Increases vascular permeability causes smooth muscle contraction\nHeparin: Anticoagulant\nLeukotrienes: Promote inflammation bronchoconstriction\nHistamine: Increases vascular permeability causes smooth muscle contractionHeparin: AnticoagulantLeukotrienes: Promote inflammation bronchoconstrictionIgE Receptors: Basophils express high-affinity IgE receptors, bind IgE antibodies\nCrosslinking IgE receptors antigens triggers basophil degranulation\nCrosslinking IgE receptors antigens triggers basophil degranulationClinical Significance:\nBasophilia: Increased basophils, seen myeloproliferative neoplasms, allergic reactions, certain infections\nBasopenia: Decreased basophils, difficult detect due normally low number basophils blood\nBasophilia: Increased basophils, seen myeloproliferative neoplasms, allergic reactions, certain infectionsBasopenia: Decreased basophils, difficult detect due normally low number basophils blood","code":""},{"path":"wbc-function.html","id":"monocytes-and-macrophages","chapter":"WBC Function","heading":"Monocytes and Macrophages","text":"Monocytes:\nFunction: Circulate blood migrate tissues, differentiate macrophages dendritic cells\nMechanisms Action:\nPhagocytosis: Engulfing pathogens, debris, dead cells\nCytokine Production: Secreting cytokines regulate inflammation immune responses (e.g., TNF-α, IL-1, IL-6)\nAntigen Presentation: Presenting antigens T lymphocytes initiate adaptive immune responses\n\nFunction: Circulate blood migrate tissues, differentiate macrophages dendritic cellsMechanisms Action:\nPhagocytosis: Engulfing pathogens, debris, dead cells\nCytokine Production: Secreting cytokines regulate inflammation immune responses (e.g., TNF-α, IL-1, IL-6)\nAntigen Presentation: Presenting antigens T lymphocytes initiate adaptive immune responses\nPhagocytosis: Engulfing pathogens, debris, dead cellsCytokine Production: Secreting cytokines regulate inflammation immune responses (e.g., TNF-α, IL-1, IL-6)Antigen Presentation: Presenting antigens T lymphocytes initiate adaptive immune responsesMacrophages:\nFunction: Tissue-resident phagocytes play critical role innate adaptive immunity, tissue remodeling, wound healing\nTypes Macrophages:\nKupffer cells (liver)\nAlveolar macrophages (lungs)\nHistiocytes (connective tissue)\nMicroglia (brain)\nOsteoclasts (bone)\nSplenic macrophages (spleen)\n\nMechanisms Action:\nPhagocytosis: Engulfing pathogens, debris, dead cells\nAntigen Presentation: Processing presenting antigens T lymphocytes\nCytokine Production: Secreting cytokines regulate inflammation immune responses\n\nClinical Significance:\nMonocytosis: Increased monocytes, seen chronic infections, inflammation, certain malignancies\nMonocytopenia: Decreased monocytes, can occur severe infections bone marrow disorders\n\nFunction: Tissue-resident phagocytes play critical role innate adaptive immunity, tissue remodeling, wound healingTypes Macrophages:\nKupffer cells (liver)\nAlveolar macrophages (lungs)\nHistiocytes (connective tissue)\nMicroglia (brain)\nOsteoclasts (bone)\nSplenic macrophages (spleen)\nKupffer cells (liver)Alveolar macrophages (lungs)Histiocytes (connective tissue)Microglia (brain)Osteoclasts (bone)Splenic macrophages (spleen)Mechanisms Action:\nPhagocytosis: Engulfing pathogens, debris, dead cells\nAntigen Presentation: Processing presenting antigens T lymphocytes\nCytokine Production: Secreting cytokines regulate inflammation immune responses\nPhagocytosis: Engulfing pathogens, debris, dead cellsAntigen Presentation: Processing presenting antigens T lymphocytesCytokine Production: Secreting cytokines regulate inflammation immune responsesClinical Significance:\nMonocytosis: Increased monocytes, seen chronic infections, inflammation, certain malignancies\nMonocytopenia: Decreased monocytes, can occur severe infections bone marrow disorders\nMonocytosis: Increased monocytes, seen chronic infections, inflammation, certain malignanciesMonocytopenia: Decreased monocytes, can occur severe infections bone marrow disordersDifferentiation Macrophages: Macrophages can differentiate functionally distinct populations:\nM1 Macrophages (classically activated): Promote inflammation kill pathogens\nM2 Macrophages (alternatively activated): Promote tissue repair suppress inflammation\nM1 Macrophages (classically activated): Promote inflammation kill pathogensM2 Macrophages (alternatively activated): Promote tissue repair suppress inflammation","code":""},{"path":"wbc-function.html","id":"lymphocytes","chapter":"WBC Function","heading":"Lymphocytes","text":"T Lymphocytes (T Cells):\nFunction: Mediate cell-mediated immunity, recognize antigens presented antigen-presenting cells (APCs)\nTypes T Cells:\nHelper T Cells (CD4+ T Cells):\nRecognize antigens presented MHC class II molecules\nSecrete cytokines activate immune cells (e.g., B cells, cytotoxic T cells, macrophages)\nEssential coordinating adaptive immune responses\nSubsets:\nTh1 cells: Promote cell-mediated immunity defense intracellular pathogens\nTh2 cells: Promote humoral immunity defense extracellular parasites\nTh17 cells: Involved inflammation defense extracellular bacteria fungi\nTreg cells: Suppress immune responses maintain tolerance\n\n\nCytotoxic T Cells (CD8+ T Cells):\nRecognize antigens presented MHC class molecules\nKill infected cancerous cells releasing cytotoxic granules containing perforin granzymes\n\n\nMechanisms Action:\nT Cell Receptor (TCR): Recognizes specific antigens presented MHC molecules\nCytokine Production: Secreting cytokines regulate immune responses\nCytotoxicity: Killing target cells direct cell--cell contact\n\nFunction: Mediate cell-mediated immunity, recognize antigens presented antigen-presenting cells (APCs)Types T Cells:\nHelper T Cells (CD4+ T Cells):\nRecognize antigens presented MHC class II molecules\nSecrete cytokines activate immune cells (e.g., B cells, cytotoxic T cells, macrophages)\nEssential coordinating adaptive immune responses\nSubsets:\nTh1 cells: Promote cell-mediated immunity defense intracellular pathogens\nTh2 cells: Promote humoral immunity defense extracellular parasites\nTh17 cells: Involved inflammation defense extracellular bacteria fungi\nTreg cells: Suppress immune responses maintain tolerance\n\n\nCytotoxic T Cells (CD8+ T Cells):\nRecognize antigens presented MHC class molecules\nKill infected cancerous cells releasing cytotoxic granules containing perforin granzymes\n\nHelper T Cells (CD4+ T Cells):\nRecognize antigens presented MHC class II molecules\nSecrete cytokines activate immune cells (e.g., B cells, cytotoxic T cells, macrophages)\nEssential coordinating adaptive immune responses\nSubsets:\nTh1 cells: Promote cell-mediated immunity defense intracellular pathogens\nTh2 cells: Promote humoral immunity defense extracellular parasites\nTh17 cells: Involved inflammation defense extracellular bacteria fungi\nTreg cells: Suppress immune responses maintain tolerance\n\nRecognize antigens presented MHC class II moleculesSecrete cytokines activate immune cells (e.g., B cells, cytotoxic T cells, macrophages)Essential coordinating adaptive immune responsesSubsets:\nTh1 cells: Promote cell-mediated immunity defense intracellular pathogens\nTh2 cells: Promote humoral immunity defense extracellular parasites\nTh17 cells: Involved inflammation defense extracellular bacteria fungi\nTreg cells: Suppress immune responses maintain tolerance\nTh1 cells: Promote cell-mediated immunity defense intracellular pathogensTh2 cells: Promote humoral immunity defense extracellular parasitesTh17 cells: Involved inflammation defense extracellular bacteria fungiTreg cells: Suppress immune responses maintain toleranceCytotoxic T Cells (CD8+ T Cells):\nRecognize antigens presented MHC class molecules\nKill infected cancerous cells releasing cytotoxic granules containing perforin granzymes\nRecognize antigens presented MHC class moleculesKill infected cancerous cells releasing cytotoxic granules containing perforin granzymesMechanisms Action:\nT Cell Receptor (TCR): Recognizes specific antigens presented MHC molecules\nCytokine Production: Secreting cytokines regulate immune responses\nCytotoxicity: Killing target cells direct cell--cell contact\nT Cell Receptor (TCR): Recognizes specific antigens presented MHC moleculesCytokine Production: Secreting cytokines regulate immune responsesCytotoxicity: Killing target cells direct cell--cell contactB Lymphocytes (B Cells):\nFunction: Mediate humoral immunity, produce antibodies\nMechanisms Action:\nAntibody Production:\nB cells recognize antigens via B cell receptor (BCR), membrane-bound antibody\nUpon activation, B cells differentiate plasma cells, secrete large amounts antibodies\n\nAntibody Functions:\nNeutralization: Binding pathogens prevent infecting cells\nOpsonization: Coating pathogens enhance phagocytosis\nComplement Activation: Triggering classical pathway complement activation\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Targeting infected cells destruction NK cells immune cells\n\n\nMemory B Cells:\nLong-lived B cells provide long-term immunity\nUpon re-exposure antigen, memory B cells rapidly differentiate plasma cells produce antibodies\n\nFunction: Mediate humoral immunity, produce antibodiesMechanisms Action:\nAntibody Production:\nB cells recognize antigens via B cell receptor (BCR), membrane-bound antibody\nUpon activation, B cells differentiate plasma cells, secrete large amounts antibodies\n\nAntibody Functions:\nNeutralization: Binding pathogens prevent infecting cells\nOpsonization: Coating pathogens enhance phagocytosis\nComplement Activation: Triggering classical pathway complement activation\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Targeting infected cells destruction NK cells immune cells\n\nAntibody Production:\nB cells recognize antigens via B cell receptor (BCR), membrane-bound antibody\nUpon activation, B cells differentiate plasma cells, secrete large amounts antibodies\nB cells recognize antigens via B cell receptor (BCR), membrane-bound antibodyUpon activation, B cells differentiate plasma cells, secrete large amounts antibodiesAntibody Functions:\nNeutralization: Binding pathogens prevent infecting cells\nOpsonization: Coating pathogens enhance phagocytosis\nComplement Activation: Triggering classical pathway complement activation\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Targeting infected cells destruction NK cells immune cells\nNeutralization: Binding pathogens prevent infecting cellsOpsonization: Coating pathogens enhance phagocytosisComplement Activation: Triggering classical pathway complement activationAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Targeting infected cells destruction NK cells immune cellsMemory B Cells:\nLong-lived B cells provide long-term immunity\nUpon re-exposure antigen, memory B cells rapidly differentiate plasma cells produce antibodies\nLong-lived B cells provide long-term immunityUpon re-exposure antigen, memory B cells rapidly differentiate plasma cells produce antibodiesNatural Killer (NK) Cells:\nFunction: Part innate immune system, kill infected cancerous cells without prior sensitization\nMechanisms Action:\nRelease Cytotoxic Granules: Perforin granzymes\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Recognize kill antibody-coated cells\nRelease Cytokines: IFN-γ TNF-α\n\nActivation Inhibition: NK cell activity regulated balance activating inhibitory receptors\nActivating receptors: Recognize stress-induced ligands target cells\nInhibitory receptors: Recognize MHC class molecules normal cells, preventing NK cell activation\n\nFunction: Part innate immune system, kill infected cancerous cells without prior sensitizationMechanisms Action:\nRelease Cytotoxic Granules: Perforin granzymes\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Recognize kill antibody-coated cells\nRelease Cytokines: IFN-γ TNF-α\nRelease Cytotoxic Granules: Perforin granzymesAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Recognize kill antibody-coated cellsRelease Cytokines: IFN-γ TNF-αActivation Inhibition: NK cell activity regulated balance activating inhibitory receptors\nActivating receptors: Recognize stress-induced ligands target cells\nInhibitory receptors: Recognize MHC class molecules normal cells, preventing NK cell activation\nActivating receptors: Recognize stress-induced ligands target cellsInhibitory receptors: Recognize MHC class molecules normal cells, preventing NK cell activation","code":""},{"path":"wbc-function.html","id":"leukocyte-extravasation","chapter":"WBC Function","heading":"Leukocyte Extravasation","text":"Definition: process leukocytes leave bloodstream migrate tissues reach sites infection inflammationSteps:\nRolling: Leukocytes loosely attach endothelium via selectins (endothelial cells) ligands (leukocytes)\nActivation: Chemokines activate leukocytes, increasing affinity integrins\nAdhesion: Integrins (leukocytes) bind tightly adhesion molecules (ICAMs VCAMs) endothelial cells\nTransmigration (Diapedesis): Leukocytes squeeze endothelial cells migrate tissues\nRolling: Leukocytes loosely attach endothelium via selectins (endothelial cells) ligands (leukocytes)Activation: Chemokines activate leukocytes, increasing affinity integrinsAdhesion: Integrins (leukocytes) bind tightly adhesion molecules (ICAMs VCAMs) endothelial cellsTransmigration (Diapedesis): Leukocytes squeeze endothelial cells migrate tissues","code":""},{"path":"wbc-function.html","id":"regulation-of-leukocyte-function","chapter":"WBC Function","heading":"Regulation of Leukocyte Function","text":"Cytokines:\nInterleukins (ILs): diverse group cytokines regulate leukocyte development, activation, function\nInterferons (IFNs): Inhibit viral replication modulate immune responses\nTumor Necrosis Factor (TNF): Pro-inflammatory cytokine activates leukocytes\nChemokines: Attract leukocytes sites infection inflammation\nInterleukins (ILs): diverse group cytokines regulate leukocyte development, activation, functionInterferons (IFNs): Inhibit viral replication modulate immune responsesTumor Necrosis Factor (TNF): Pro-inflammatory cytokine activates leukocytesChemokines: Attract leukocytes sites infection inflammationComplement System:\nComplement fragments (e.g., C3a, C5a) attract activate leukocytes\nComplement fragments (e.g., C3a, C5a) attract activate leukocytesLipid Mediators:\nLeukotrienes prostaglandins: Promote inflammation leukocyte recruitment\nLeukotrienes prostaglandins: Promote inflammation leukocyte recruitmentCell-Cell Interactions:\nInteractions leukocytes cells (e.g., endothelial cells, fibroblasts) regulate leukocyte function\nInteractions leukocytes cells (e.g., endothelial cells, fibroblasts) regulate leukocyte function","code":""},{"path":"wbc-function.html","id":"disorders-of-leukocyte-function","chapter":"WBC Function","heading":"Disorders of Leukocyte Function","text":"Quantitative Disorders:\nLeukopenia: Decreased number WBCs\nLeukocytosis: Increased number WBCs\nLeukopenia: Decreased number WBCsLeukocytosis: Increased number WBCsQualitative Disorders:\nPhagocytic Disorders: Impaired ability phagocytes (neutrophils macrophages) engulf kill pathogens\nChronic granulomatous disease (CGD): Defect NADPH oxidase, leading impaired production reactive oxygen species\nChediak-Higashi syndrome: Defect lysosomal trafficking, leading impaired phagocytosis degranulation\n\nAdhesion Disorders: Impaired ability leukocytes adhere endothelial cells migrate tissues\nLeukocyte adhesion deficiency (LAD): Defects integrins selectin ligands\n\nFunctional Defects: Impaired chemotaxis, degranulation, cytokine production\nPhagocytic Disorders: Impaired ability phagocytes (neutrophils macrophages) engulf kill pathogens\nChronic granulomatous disease (CGD): Defect NADPH oxidase, leading impaired production reactive oxygen species\nChediak-Higashi syndrome: Defect lysosomal trafficking, leading impaired phagocytosis degranulation\nChronic granulomatous disease (CGD): Defect NADPH oxidase, leading impaired production reactive oxygen speciesChediak-Higashi syndrome: Defect lysosomal trafficking, leading impaired phagocytosis degranulationAdhesion Disorders: Impaired ability leukocytes adhere endothelial cells migrate tissues\nLeukocyte adhesion deficiency (LAD): Defects integrins selectin ligands\nLeukocyte adhesion deficiency (LAD): Defects integrins selectin ligandsOther Functional Defects: Impaired chemotaxis, degranulation, cytokine production","code":""},{"path":"wbc-function.html","id":"laboratory-evaluation-of-leukocyte-function","chapter":"WBC Function","heading":"Laboratory Evaluation of Leukocyte Function","text":"Complete Blood Count (CBC) Differential:\nWBC count: Measures total number leukocytes\nDifferential count: Determines percentages absolute numbers type leukocyte\nWBC count: Measures total number leukocytesDifferential count: Determines percentages absolute numbers type leukocytePeripheral Blood Smear Examination:\nMorphology: Evaluates morphology leukocytes (e.g., toxic granulation, Dohle bodies)\nMorphology: Evaluates morphology leukocytes (e.g., toxic granulation, Dohle bodies)Flow Cytometry:\nImmunophenotyping: Identifies cell surface markers classifies leukocytes\nFunctional assays: Measures leukocyte activation, proliferation, cytokine production\nImmunophenotyping: Identifies cell surface markers classifies leukocytesFunctional assays: Measures leukocyte activation, proliferation, cytokine productionFunctional Assays:\nNeutrophil oxidative burst assay: Measures production reactive oxygen species\nChemotaxis assay: Measures ability leukocytes migrate response chemical gradients\nPhagocytosis assay: Measures ability leukocytes engulf particles\nAdhesion assay: Measures ability leukocytes adhere endothelial cells\nNeutrophil oxidative burst assay: Measures production reactive oxygen speciesChemotaxis assay: Measures ability leukocytes migrate response chemical gradientsPhagocytosis assay: Measures ability leukocytes engulf particlesAdhesion assay: Measures ability leukocytes adhere endothelial cellsGenetic Testing:\nIdentifies mutations genes associated inherited leukocyte disorders\nIdentifies mutations genes associated inherited leukocyte disorders","code":""},{"path":"wbc-function.html","id":"key-terms-20","chapter":"WBC Function","heading":"Key Terms","text":"Leukocytes: White blood cellsNeutrophil: abundant WBC, involved bacterial fungal infectionsEosinophil: WBC involved parasitic infections allergic reactionsBasophil: WBC involved allergic reactions inflammationMonocyte: WBC differentiates macrophagesMacrophage: Tissue-resident phagocyteLymphocyte: T cell, B cell, NK cellPhagocytosis: Engulfment destruction particlesChemotaxis: Migration cells response chemical signalsCytokines: Signaling molecules regulate immune responsesExtravasation: Migration leukocytes bloodstream tissuesInnate Immunity: Immediate, non-specific defense mechanismsAdaptive Immunity: Slower, antigen-specific immune responses","code":""},{"path":"wbc-destruction.html","id":"wbc-destruction","chapter":"WBC Destruction","heading":"WBC Destruction","text":"","code":""},{"path":"wbc-destruction.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"WBC Destruction","heading":"\nAudio Overview\n","text":"","code":""},{"path":"wbc-destruction.html","id":"overview-of-leukocyte-destruction","chapter":"WBC Destruction","heading":"Overview of Leukocyte Destruction","text":"Definition: normal, regulated process leukocytes (white blood cells) removed circulation tissues. essential maintaining homeostasis preventing excessive inflammation autoimmune reactionsMechanisms: Leukocyte destruction primarily occurs apoptosis (programmed cell death), can also involve necrosis (uncontrolled cell death) phagocytosisImportance: Proper leukocyte turnover crucial :\nRegulating immune response\nRemoving senescent dysfunctional leukocytes\nPreventing accumulation auto-reactive lymphocytes\nMaintaining balance leukocyte production destruction\nRegulating immune responseRemoving senescent dysfunctional leukocytesPreventing accumulation auto-reactive lymphocytesMaintaining balance leukocyte production destruction","code":""},{"path":"wbc-destruction.html","id":"mechanisms-of-leukocyte-destruction","chapter":"WBC Destruction","heading":"Mechanisms of Leukocyte Destruction","text":"Apoptosis (Programmed Cell Death):\nDefinition: highly regulated process cell self-destruction characterized specific morphological biochemical changes\nInitiation Apoptosis:\nIntrinsic Pathway (Mitochondrial Pathway):\nTriggered cellular stress, DNA damage, growth factor deprivation\nInvolves release cytochrome c mitochondria cytoplasm\nCytochrome c activates caspases (family proteases)\n\nExtrinsic Pathway (Death Receptor Pathway):\nTriggered binding death ligands (e.g., Fas ligand, TNF-α) death receptors (e.g., Fas, TNF receptor) cell surface\nActivates caspases directly\n\n\nExecution Phase Apoptosis:\nCaspases activate cascade caspases, leading :\nDNA fragmentation\nCell shrinkage\nMembrane blebbing (formation bubble-like protrusions cell surface)\nFormation apoptotic bodies (small membrane-bound vesicles containing cellular contents)\n\n\nClearance Apoptotic Cells:\nApoptotic cells express “eat ” signals surface (e.g., phosphatidylserine)\nPhagocytes (macrophages) recognize engulf apoptotic cells, preventing release intracellular contents minimizing inflammation\n\nSignificance Leukocyte Destruction:\nApoptosis primary mechanism removing senescent dysfunctional leukocytes, especially lymphocytes\nplays critical role maintaining immune homeostasis preventing autoimmunity\n\nDefinition: highly regulated process cell self-destruction characterized specific morphological biochemical changesInitiation Apoptosis:\nIntrinsic Pathway (Mitochondrial Pathway):\nTriggered cellular stress, DNA damage, growth factor deprivation\nInvolves release cytochrome c mitochondria cytoplasm\nCytochrome c activates caspases (family proteases)\n\nExtrinsic Pathway (Death Receptor Pathway):\nTriggered binding death ligands (e.g., Fas ligand, TNF-α) death receptors (e.g., Fas, TNF receptor) cell surface\nActivates caspases directly\n\nIntrinsic Pathway (Mitochondrial Pathway):\nTriggered cellular stress, DNA damage, growth factor deprivation\nInvolves release cytochrome c mitochondria cytoplasm\nCytochrome c activates caspases (family proteases)\nTriggered cellular stress, DNA damage, growth factor deprivationInvolves release cytochrome c mitochondria cytoplasmCytochrome c activates caspases (family proteases)Extrinsic Pathway (Death Receptor Pathway):\nTriggered binding death ligands (e.g., Fas ligand, TNF-α) death receptors (e.g., Fas, TNF receptor) cell surface\nActivates caspases directly\nTriggered binding death ligands (e.g., Fas ligand, TNF-α) death receptors (e.g., Fas, TNF receptor) cell surfaceActivates caspases directlyExecution Phase Apoptosis:\nCaspases activate cascade caspases, leading :\nDNA fragmentation\nCell shrinkage\nMembrane blebbing (formation bubble-like protrusions cell surface)\nFormation apoptotic bodies (small membrane-bound vesicles containing cellular contents)\n\nCaspases activate cascade caspases, leading :\nDNA fragmentation\nCell shrinkage\nMembrane blebbing (formation bubble-like protrusions cell surface)\nFormation apoptotic bodies (small membrane-bound vesicles containing cellular contents)\nDNA fragmentationCell shrinkageMembrane blebbing (formation bubble-like protrusions cell surface)Formation apoptotic bodies (small membrane-bound vesicles containing cellular contents)Clearance Apoptotic Cells:\nApoptotic cells express “eat ” signals surface (e.g., phosphatidylserine)\nPhagocytes (macrophages) recognize engulf apoptotic cells, preventing release intracellular contents minimizing inflammation\nApoptotic cells express “eat ” signals surface (e.g., phosphatidylserine)Phagocytes (macrophages) recognize engulf apoptotic cells, preventing release intracellular contents minimizing inflammationSignificance Leukocyte Destruction:\nApoptosis primary mechanism removing senescent dysfunctional leukocytes, especially lymphocytes\nplays critical role maintaining immune homeostasis preventing autoimmunity\nApoptosis primary mechanism removing senescent dysfunctional leukocytes, especially lymphocytesIt plays critical role maintaining immune homeostasis preventing autoimmunityNecrosis (Uncontrolled Cell Death):\nDefinition: Cell death caused injury, infection, external factors\nMechanism:\nCell swelling rupture, leading release intracellular contents surrounding tissue\nTriggers inflammatory response\n\nSignificance Leukocyte Destruction:\nNecrosis can occur situations leukocytes overwhelmed infection exposed toxins\nHowever, less common mechanism normal leukocyte turnover compared apoptosis\n\nDefinition: Cell death caused injury, infection, external factorsMechanism:\nCell swelling rupture, leading release intracellular contents surrounding tissue\nTriggers inflammatory response\nCell swelling rupture, leading release intracellular contents surrounding tissueTriggers inflammatory responseSignificance Leukocyte Destruction:\nNecrosis can occur situations leukocytes overwhelmed infection exposed toxins\nHowever, less common mechanism normal leukocyte turnover compared apoptosis\nNecrosis can occur situations leukocytes overwhelmed infection exposed toxinsHowever, less common mechanism normal leukocyte turnover compared apoptosisPhagocytosis:\nDefinition: Engulfment destruction cells particles phagocytes (macrophages neutrophils)\nMechanisms:\nRecognition: Phagocytes recognize target cells via:\nOpsonization: Coating target cells antibodies complement fragments (C3b)\nPattern Recognition Receptors (PRRs): Recognize pathogen-associated molecular patterns (PAMPs) pathogens damage-associated molecular patterns (DAMPs) damaged cells\n\nEngulfment: Phagocyte extends pseudopods around target cell, forming phagosome\nDigestion: phagosome fuses lysosome, forming phagolysosome\nLysosomes contain enzymes break engulfed material\n\nRespiratory Burst: Production reactive oxygen species (ROS) kill ingested microorganisms\n\nSignificance Leukocyte Destruction:\nMacrophages play key role clearing apoptotic cells cellular debris\nNeutrophils can also undergo phagocytosis performed functions sites infection\n\nDefinition: Engulfment destruction cells particles phagocytes (macrophages neutrophils)Mechanisms:\nRecognition: Phagocytes recognize target cells via:\nOpsonization: Coating target cells antibodies complement fragments (C3b)\nPattern Recognition Receptors (PRRs): Recognize pathogen-associated molecular patterns (PAMPs) pathogens damage-associated molecular patterns (DAMPs) damaged cells\n\nEngulfment: Phagocyte extends pseudopods around target cell, forming phagosome\nDigestion: phagosome fuses lysosome, forming phagolysosome\nLysosomes contain enzymes break engulfed material\n\nRespiratory Burst: Production reactive oxygen species (ROS) kill ingested microorganisms\nRecognition: Phagocytes recognize target cells via:\nOpsonization: Coating target cells antibodies complement fragments (C3b)\nPattern Recognition Receptors (PRRs): Recognize pathogen-associated molecular patterns (PAMPs) pathogens damage-associated molecular patterns (DAMPs) damaged cells\nOpsonization: Coating target cells antibodies complement fragments (C3b)Pattern Recognition Receptors (PRRs): Recognize pathogen-associated molecular patterns (PAMPs) pathogens damage-associated molecular patterns (DAMPs) damaged cellsEngulfment: Phagocyte extends pseudopods around target cell, forming phagosomeDigestion: phagosome fuses lysosome, forming phagolysosome\nLysosomes contain enzymes break engulfed material\nLysosomes contain enzymes break engulfed materialRespiratory Burst: Production reactive oxygen species (ROS) kill ingested microorganismsSignificance Leukocyte Destruction:\nMacrophages play key role clearing apoptotic cells cellular debris\nNeutrophils can also undergo phagocytosis performed functions sites infection\nMacrophages play key role clearing apoptotic cells cellular debrisNeutrophils can also undergo phagocytosis performed functions sites infection","code":""},{"path":"wbc-destruction.html","id":"regulation-of-leukocyte-destruction","chapter":"WBC Destruction","heading":"Regulation of Leukocyte Destruction","text":"Growth Factors Cytokines:\nGrowth factors (e.g., G-CSF, GM-CSF) promote leukocyte survival inhibit apoptosis\nCytokines (e.g., IL-2, TNF-α) can either promote inhibit apoptosis depending context\nGrowth factors (e.g., G-CSF, GM-CSF) promote leukocyte survival inhibit apoptosisCytokines (e.g., IL-2, TNF-α) can either promote inhibit apoptosis depending contextCellular Interactions:\nInteractions leukocytes cells (e.g., stromal cells, endothelial cells) can influence leukocyte survival death\nInteractions leukocytes cells (e.g., stromal cells, endothelial cells) can influence leukocyte survival deathHormones:\nGlucocorticoids (e.g., cortisol) can induce apoptosis lymphocytes\nGlucocorticoids (e.g., cortisol) can induce apoptosis lymphocytesCellular Senescence:\nleukocytes age, may become less responsive survival signals susceptible apoptosis\nleukocytes age, may become less responsive survival signals susceptible apoptosisFeedback Mechanisms:\nNegative feedback loops involving cytokines factors help maintain balance leukocyte production destruction\nNegative feedback loops involving cytokines factors help maintain balance leukocyte production destruction","code":""},{"path":"wbc-destruction.html","id":"clinical-significance-of-leukocyte-destruction","chapter":"WBC Destruction","heading":"Clinical Significance of Leukocyte Destruction","text":"Leukopenia:\nDecreased number WBCs\nCan result :\nIncreased leukocyte destruction\nDecreased leukocyte production\nSequestration leukocytes spleen organs\n\nIncreases susceptibility infections\nDecreased number WBCsCan result :\nIncreased leukocyte destruction\nDecreased leukocyte production\nSequestration leukocytes spleen organs\nIncreased leukocyte destructionDecreased leukocyte productionSequestration leukocytes spleen organsIncreases susceptibility infectionsAutoimmune Disorders:\nDysregulation leukocyte apoptosis can contribute development autoimmune diseases\nFailure eliminate autoreactive lymphocytes can lead immune responses self-antigens\nDysregulation leukocyte apoptosis can contribute development autoimmune diseasesFailure eliminate autoreactive lymphocytes can lead immune responses self-antigensLymphoproliferative Disorders:\nInhibition apoptosis can contribute accumulation malignant lymphocytes lymphomas leukemias\nInhibition apoptosis can contribute accumulation malignant lymphocytes lymphomas leukemiasInflammation:\nExcessive uncontrolled leukocyte destruction can release inflammatory mediators, contributing chronic inflammation\nExcessive uncontrolled leukocyte destruction can release inflammatory mediators, contributing chronic inflammation","code":""},{"path":"wbc-destruction.html","id":"laboratory-assessment-of-leukocyte-destruction","chapter":"WBC Destruction","heading":"Laboratory Assessment of Leukocyte Destruction","text":"Complete Blood Count (CBC) Differential:\nWBC count: Measures total number leukocytes blood\nDifferential count: Determines percentages absolute numbers type leukocyte\nMay reveal leukopenia abnormal leukocyte populations\nWBC count: Measures total number leukocytes bloodDifferential count: Determines percentages absolute numbers type leukocyteMay reveal leukopenia abnormal leukocyte populationsPeripheral Blood Smear Examination:\nMorphology: Evaluates morphology leukocytes signs apoptosis necrosis\nApoptotic cells: Condensed chromatin, cell shrinkage, membrane blebbing\nNecrotic cells: Swollen cells disrupted membranes\n\nMorphology: Evaluates morphology leukocytes signs apoptosis necrosis\nApoptotic cells: Condensed chromatin, cell shrinkage, membrane blebbing\nNecrotic cells: Swollen cells disrupted membranes\nApoptotic cells: Condensed chromatin, cell shrinkage, membrane blebbingNecrotic cells: Swollen cells disrupted membranesFlow Cytometry:\nImmunophenotyping: Identifies cell surface markers classifies leukocytes\nApoptosis assays: Measures markers apoptosis (e.g., Annexin V binding, caspase activation)\nImmunophenotyping: Identifies cell surface markers classifies leukocytesApoptosis assays: Measures markers apoptosis (e.g., Annexin V binding, caspase activation)Bone Marrow Aspiration Biopsy:\nCellularity: Assesses cellularity bone marrow\nMaturation: Evaluates maturation hematopoietic cells\nDysplasia: Detects abnormal cell development (e.g., myelodysplastic syndromes)\nSpecial stains: Used identify specific cell types abnormalities\nCellularity: Assesses cellularity bone marrowMaturation: Evaluates maturation hematopoietic cellsDysplasia: Detects abnormal cell development (e.g., myelodysplastic syndromes)Special stains: Used identify specific cell types abnormalitiesSpecific Tests Autoimmune Disorders:\nAntinuclear antibody (ANA) test: detect autoantibodies\nRheumatoid factor (RF): detect antibodies associated rheumatoid arthritis\nAntinuclear antibody (ANA) test: detect autoantibodiesRheumatoid factor (RF): detect antibodies associated rheumatoid arthritisTests Viral Infections:\nHIV antibody test\nEpstein-Barr virus (EBV) serology\nCytomegalovirus (CMV) serology\nHIV antibody testEpstein-Barr virus (EBV) serologyCytomegalovirus (CMV) serology","code":""},{"path":"wbc-destruction.html","id":"key-terms-21","chapter":"WBC Destruction","heading":"Key Terms","text":"Leukocyte Destruction: Removal white blood cells circulation tissuesApoptosis: Programmed cell deathNecrosis: Uncontrolled cell deathPhagocytosis: Engulfment destruction cells particles phagocytesCaspases: Proteases mediate apoptosisCytokines: Signaling molecules regulate immune responsesLeukopenia: Decreased number WBCsLymphoproliferative Disorders: Disorders characterized abnormal proliferation lymphocytesAutoimmunity: Immune response self-antigens","code":""},{"path":"benign-disorders.html","id":"benign-disorders","chapter":"Benign Disorders","heading":"Benign Disorders","text":"","code":""},{"path":"benign-disorders.html","id":"benign-leukocyte-disorders","chapter":"Benign Disorders","heading":"Benign Leukocyte Disorders","text":"Definition: broad category encompassing variety non-cancerous conditions result abnormal leukocyte counts, morphology, function. often reactive processes, meaning occur response underlying stimulus (e.g., infection, inflammation, medication)Key Characteristics:\nNon-clonal: disorders typically involve uncontrolled proliferation single, abnormal clone cells (seen leukemias lymphomas)\nReactive: Usually triggered underlying condition (e.g., infection, inflammation)\nSelf-Limiting: Often resolve underlying cause addressed\nLack Significant Dysplasia: Leukocytes generally mature normally, although morphological changes (e.g., toxic granulation) may present\nNon-clonal: disorders typically involve uncontrolled proliferation single, abnormal clone cells (seen leukemias lymphomas)Reactive: Usually triggered underlying condition (e.g., infection, inflammation)Self-Limiting: Often resolve underlying cause addressedLack Significant Dysplasia: Leukocytes generally mature normally, although morphological changes (e.g., toxic granulation) may presentImportance Differentiation: ’s crucial differentiate benign leukocyte disorders malignant hematologic conditions (leukemias lymphomas), require aggressive treatmentClassification: Benign leukocyte disorders can broadly classified based :\nCell Lineage Affected:\nNeutrophilic Disorders\nLymphocytic Disorders\nMonocytic Disorders\nEosinophilic Disorders\nBasophilic Disorders\n\nQuantitative Changes (Changes Cell Numbers):\nLeukocytosis: Increased WBC count\nLeukopenia: Decreased WBC count\nNeutrophilia, Neutropenia, Lymphocytosis, Lymphopenia, Monocytosis, Monocytopenia, Eosinophilia, Basophilia\n\nQualitative Changes (Changes Cell Appearance/Function):\nMorphological abnormalities (e.g., toxic granulation, Döhle bodies, Pelger-Huët anomaly)\nFunctional defects (e.g., impaired phagocytosis, chemotaxis, killing)\n\nCell Lineage Affected:\nNeutrophilic Disorders\nLymphocytic Disorders\nMonocytic Disorders\nEosinophilic Disorders\nBasophilic Disorders\nNeutrophilic DisordersLymphocytic DisordersMonocytic DisordersEosinophilic DisordersBasophilic DisordersQuantitative Changes (Changes Cell Numbers):\nLeukocytosis: Increased WBC count\nLeukopenia: Decreased WBC count\nNeutrophilia, Neutropenia, Lymphocytosis, Lymphopenia, Monocytosis, Monocytopenia, Eosinophilia, Basophilia\nLeukocytosis: Increased WBC countLeukopenia: Decreased WBC countNeutrophilia, Neutropenia, Lymphocytosis, Lymphopenia, Monocytosis, Monocytopenia, Eosinophilia, BasophiliaQualitative Changes (Changes Cell Appearance/Function):\nMorphological abnormalities (e.g., toxic granulation, Döhle bodies, Pelger-Huët anomaly)\nFunctional defects (e.g., impaired phagocytosis, chemotaxis, killing)\nMorphological abnormalities (e.g., toxic granulation, Döhle bodies, Pelger-Huët anomaly)Functional defects (e.g., impaired phagocytosis, chemotaxis, killing)","code":""},{"path":"benign-disorders.html","id":"key-steps-in-evaluating-benign-leukocyte-disorders","chapter":"Benign Disorders","heading":"Key Steps in Evaluating Benign Leukocyte Disorders","text":"Review Patient History: Medications, recent infections, underlying medical conditionsComplete Blood Count (CBC) Differential: Essential quantifying WBC counts identifying cell populationsPeripheral Blood Smear Examination: assess leukocyte morphology identify abnormalitiesRule Malignancy: suspicion malignant process (e.g., unexplained cytopenias, blasts peripheral blood), consider:\nBone marrow aspiration biopsy\nFlow cytometry\nCytogenetic analysis\nMolecular testing\nBone marrow aspiration biopsyFlow cytometryCytogenetic analysisMolecular testingInvestigate Underlying Cause: Perform appropriate tests identify underlying cause leukocyte abnormality (e.g., viral serology, autoimmune markers, allergy testing)Monitor Patient: Many benign leukocyte disorders resolve spontaneously underlying cause addressed. Follow-CBCs may needed monitor WBC counts","code":""},{"path":"benign-disorders.html","id":"key-terms-22","chapter":"Benign Disorders","heading":"Key Terms","text":"Leukocyte: White blood cellNeutrophil: type granulocyte; abundant WBCLymphocyte: T cell, B cell, NK cellMonocyte: phagocytic WBC differentiates macrophagesEosinophil: type granulocyte involved parasitic infections allergiesBasophil: type granulocyte involved allergic reactions inflammationLeukocytosis: Increased number WBCsLeukopenia: Decreased number WBCsCytopenia: Deficiency blood cells (e.g., anemia, neutropenia, thrombocytopenia)Myeloproliferative Neoplasms (MPNs): Clonal disorders bone marrow can cause increased production myeloid cellsLymphoproliferative Disorders: Disorders characterized abnormal lymphocyte proliferationReactive Lymphocytosis: Increased lymphocytes due benign cause, infectionAtypical Lymphocyte: lymphocyte abnormal morphology, often seen viral infections","code":""},{"path":"myeloid.html","id":"myeloid","chapter":"Myeloid","heading":"Myeloid","text":"","code":""},{"path":"myeloid.html","id":"overview-of-benign-myeloid-disorders","chapter":"Myeloid","heading":"Overview of Benign Myeloid Disorders","text":"Definition: Non-cancerous conditions affecting myeloid lineage leukocytes (neutrophils, eosinophils, basophils, monocytes).Key Features:\nUsually reactive (secondary) underlying condition, rather primary disorders bone marrow.\nOften transient, resolving underlying cause addressed.\nGenerally, involve clonal proliferation significant dysplasia (abnormal cell development).\nUsually reactive (secondary) underlying condition, rather primary disorders bone marrow.Often transient, resolving underlying cause addressed.Generally, involve clonal proliferation significant dysplasia (abnormal cell development).","code":""},{"path":"myeloid.html","id":"quantitative-changes-in-benign-myeloid-disorders","chapter":"Myeloid","heading":"Quantitative Changes in Benign Myeloid Disorders","text":"Quantitative changes refer alterations number specific types myeloid cells peripheral blood.Neutrophilia: Increased number neutrophils blood (Absolute Neutrophil Count > 7.7 x 10^9/L adults)\nCauses:\nInfections: Bacterial infections common cause neutrophilia\nInflammation: Tissue injury, surgery, burns, autoimmune diseases\nStress: Emotional stress, exercise\nMedications: Corticosteroids, lithium\nMyeloproliferative Neoplasms (MPNs): Must ruled , considered “benign”\nPhysiologic: Newborns pregnant patients slightly higher ranges\n\nMechanisms:\nIncreased release neutrophils bone marrow storage pool\nIncreased production neutrophils bone marrow (stimulated G-CSF cytokines)\nDecreased migration neutrophils tissues\n\nLeukemoid Reaction: extreme neutrophilic response (WBC count > 50 x 10^9/L) mimics leukemia.\nKey Features:\nAbsence blasts peripheral blood\nElevated leukocyte alkaline phosphatase (LAP) score (see )\nLack clonal cytogenetic abnormalities\n\n\nLaboratory Findings:\nElevated WBC count\nIncreased absolute neutrophil count\nMay see “left shift” increased band neutrophils , occasionally, metamyelocytes myelocytes peripheral smear\nToxic granulation, Dohle bodies, vacuolization may present neutrophils (see “Qualitative Changes” )\n\nNeutrophilia: Increased number neutrophils blood (Absolute Neutrophil Count > 7.7 x 10^9/L adults)Causes:\nInfections: Bacterial infections common cause neutrophilia\nInflammation: Tissue injury, surgery, burns, autoimmune diseases\nStress: Emotional stress, exercise\nMedications: Corticosteroids, lithium\nMyeloproliferative Neoplasms (MPNs): Must ruled , considered “benign”\nPhysiologic: Newborns pregnant patients slightly higher ranges\nInfections: Bacterial infections common cause neutrophiliaInflammation: Tissue injury, surgery, burns, autoimmune diseasesStress: Emotional stress, exerciseMedications: Corticosteroids, lithiumMyeloproliferative Neoplasms (MPNs): Must ruled , considered “benign”Physiologic: Newborns pregnant patients slightly higher rangesMechanisms:\nIncreased release neutrophils bone marrow storage pool\nIncreased production neutrophils bone marrow (stimulated G-CSF cytokines)\nDecreased migration neutrophils tissues\nIncreased release neutrophils bone marrow storage poolIncreased production neutrophils bone marrow (stimulated G-CSF cytokines)Decreased migration neutrophils tissuesLeukemoid Reaction: extreme neutrophilic response (WBC count > 50 x 10^9/L) mimics leukemia.\nKey Features:\nAbsence blasts peripheral blood\nElevated leukocyte alkaline phosphatase (LAP) score (see )\nLack clonal cytogenetic abnormalities\n\nKey Features:\nAbsence blasts peripheral blood\nElevated leukocyte alkaline phosphatase (LAP) score (see )\nLack clonal cytogenetic abnormalities\nAbsence blasts peripheral bloodElevated leukocyte alkaline phosphatase (LAP) score (see )Lack clonal cytogenetic abnormalitiesLaboratory Findings:\nElevated WBC count\nIncreased absolute neutrophil count\nMay see “left shift” increased band neutrophils , occasionally, metamyelocytes myelocytes peripheral smear\nToxic granulation, Dohle bodies, vacuolization may present neutrophils (see “Qualitative Changes” )\nElevated WBC countIncreased absolute neutrophil countMay see “left shift” increased band neutrophils , occasionally, metamyelocytes myelocytes peripheral smearToxic granulation, Dohle bodies, vacuolization may present neutrophils (see “Qualitative Changes” )Neutropenia: Decreased number neutrophils blood (Absolute Neutrophil Count < 2.0 x 10^9/L adults)\nCauses:\nDrug-Induced: Chemotherapy, antibiotics (e.g., trimethoprim-sulfamethoxazole), anticonvulsants\nInfections: Viral infections (e.g., influenza, HIV), severe bacterial infections (sepsis)\nAutoimmune Disorders: Systemic lupus erythematosus (SLE), rheumatoid arthritis\nNutritional Deficiencies: Vitamin B12 folate deficiency\nBone Marrow Disorders: Aplastic anemia, myelodysplastic syndromes (MDS)\nEthnic Neutropenia: Benign condition seen individuals African descent\n\nMechanisms:\nDecreased production neutrophils bone marrow\nIncreased destruction neutrophils peripheral blood\nSequestration neutrophils spleen\n\nClinical Significance: Increased risk bacterial fungal infections.\nLaboratory Findings:\nDecreased WBC count\nDecreased absolute neutrophil count\nPeripheral blood smear: May show normal neutrophils abnormal morphology (e.g., dysplastic neutrophils MDS)\nBone marrow examination: May necessary evaluate bone marrow disorders\n\nNeutropenia: Decreased number neutrophils blood (Absolute Neutrophil Count < 2.0 x 10^9/L adults)Causes:\nDrug-Induced: Chemotherapy, antibiotics (e.g., trimethoprim-sulfamethoxazole), anticonvulsants\nInfections: Viral infections (e.g., influenza, HIV), severe bacterial infections (sepsis)\nAutoimmune Disorders: Systemic lupus erythematosus (SLE), rheumatoid arthritis\nNutritional Deficiencies: Vitamin B12 folate deficiency\nBone Marrow Disorders: Aplastic anemia, myelodysplastic syndromes (MDS)\nEthnic Neutropenia: Benign condition seen individuals African descent\nDrug-Induced: Chemotherapy, antibiotics (e.g., trimethoprim-sulfamethoxazole), anticonvulsantsInfections: Viral infections (e.g., influenza, HIV), severe bacterial infections (sepsis)Autoimmune Disorders: Systemic lupus erythematosus (SLE), rheumatoid arthritisNutritional Deficiencies: Vitamin B12 folate deficiencyBone Marrow Disorders: Aplastic anemia, myelodysplastic syndromes (MDS)Ethnic Neutropenia: Benign condition seen individuals African descentMechanisms:\nDecreased production neutrophils bone marrow\nIncreased destruction neutrophils peripheral blood\nSequestration neutrophils spleen\nDecreased production neutrophils bone marrowIncreased destruction neutrophils peripheral bloodSequestration neutrophils spleenClinical Significance: Increased risk bacterial fungal infections.Laboratory Findings:\nDecreased WBC count\nDecreased absolute neutrophil count\nPeripheral blood smear: May show normal neutrophils abnormal morphology (e.g., dysplastic neutrophils MDS)\nBone marrow examination: May necessary evaluate bone marrow disorders\nDecreased WBC countDecreased absolute neutrophil countPeripheral blood smear: May show normal neutrophils abnormal morphology (e.g., dysplastic neutrophils MDS)Bone marrow examination: May necessary evaluate bone marrow disordersMonocytosis: Increased number monocytes blood (Absolute Monocyte Count > 1.0 x 10^9/L adults)\nCauses:\nChronic Infections: Tuberculosis, fungal infections, bacterial endocarditis\nInflammatory Conditions: Inflammatory bowel disease (IBD), sarcoidosis\nMalignancies: Hodgkin lymphoma, non-Hodgkin lymphoma, myelodysplastic syndromes (MDS)\nRecovery Neutropenia\n\nClinical Significance: Often associated chronic inflammatory infectious processes.\nLaboratory Findings:\nElevated WBC count\nIncreased absolute monocyte count\nPeripheral blood smear: May show normal activated monocytes\n\nMonocytosis: Increased number monocytes blood (Absolute Monocyte Count > 1.0 x 10^9/L adults)Causes:\nChronic Infections: Tuberculosis, fungal infections, bacterial endocarditis\nInflammatory Conditions: Inflammatory bowel disease (IBD), sarcoidosis\nMalignancies: Hodgkin lymphoma, non-Hodgkin lymphoma, myelodysplastic syndromes (MDS)\nRecovery Neutropenia\nChronic Infections: Tuberculosis, fungal infections, bacterial endocarditisInflammatory Conditions: Inflammatory bowel disease (IBD), sarcoidosisMalignancies: Hodgkin lymphoma, non-Hodgkin lymphoma, myelodysplastic syndromes (MDS)Recovery NeutropeniaClinical Significance: Often associated chronic inflammatory infectious processes.Laboratory Findings:\nElevated WBC count\nIncreased absolute monocyte count\nPeripheral blood smear: May show normal activated monocytes\nElevated WBC countIncreased absolute monocyte countPeripheral blood smear: May show normal activated monocytesMonocytopenia: Decreased number monocytes blood (Absolute Monocyte Count < 0.2 x 10^9/L adults)\nCauses:\nAplastic Anemia: Bone marrow failure leads decreased production blood cell lines\nHairy Cell Leukemia: Malignant B cells infiltrate bone marrow, suppressing normal hematopoiesis\nGlucocorticoid Therapy: Corticosteroids can cause monocytopenia\n\nClinical Significance: May increase susceptibility certain infections.\nLaboratory Findings:\nDecreased WBC count\nDecreased absolute monocyte count\nPeripheral blood smear: May show normal abnormal cells, depending underlying cause\nBone marrow examination: Often necessary evaluate bone marrow disorders\n\nMonocytopenia: Decreased number monocytes blood (Absolute Monocyte Count < 0.2 x 10^9/L adults)Causes:\nAplastic Anemia: Bone marrow failure leads decreased production blood cell lines\nHairy Cell Leukemia: Malignant B cells infiltrate bone marrow, suppressing normal hematopoiesis\nGlucocorticoid Therapy: Corticosteroids can cause monocytopenia\nAplastic Anemia: Bone marrow failure leads decreased production blood cell linesHairy Cell Leukemia: Malignant B cells infiltrate bone marrow, suppressing normal hematopoiesisGlucocorticoid Therapy: Corticosteroids can cause monocytopeniaClinical Significance: May increase susceptibility certain infections.Laboratory Findings:\nDecreased WBC count\nDecreased absolute monocyte count\nPeripheral blood smear: May show normal abnormal cells, depending underlying cause\nBone marrow examination: Often necessary evaluate bone marrow disorders\nDecreased WBC countDecreased absolute monocyte countPeripheral blood smear: May show normal abnormal cells, depending underlying causeBone marrow examination: Often necessary evaluate bone marrow disordersEosinophilia: Increased number eosinophils blood (Absolute Eosinophil Count > 0.4 x 10^9/L adults)\nCauses:\nParasitic Infections: Especially helminth infections (e.g., hookworm, roundworm)\nAllergic Reactions: Asthma, allergic rhinitis, eczema\nDrug Reactions\nCertain Malignancies: Hodgkin lymphoma, T-cell lymphoma\nAddison’s Disease: Adrenal insufficiency\nHypereosinophilic Syndrome (HES): rare disorder characterized persistent eosinophilia organ damage\n\nClinical Significance: Can indicate parasitic infection, allergic disease, underlying conditions\nLaboratory Findings:\nElevated WBC count\nIncreased absolute eosinophil count\nPeripheral blood smear: May show normal activated eosinophils\n\nEosinophilia: Increased number eosinophils blood (Absolute Eosinophil Count > 0.4 x 10^9/L adults)Causes:\nParasitic Infections: Especially helminth infections (e.g., hookworm, roundworm)\nAllergic Reactions: Asthma, allergic rhinitis, eczema\nDrug Reactions\nCertain Malignancies: Hodgkin lymphoma, T-cell lymphoma\nAddison’s Disease: Adrenal insufficiency\nHypereosinophilic Syndrome (HES): rare disorder characterized persistent eosinophilia organ damage\nParasitic Infections: Especially helminth infections (e.g., hookworm, roundworm)Allergic Reactions: Asthma, allergic rhinitis, eczemaDrug ReactionsCertain Malignancies: Hodgkin lymphoma, T-cell lymphomaAddison’s Disease: Adrenal insufficiencyHypereosinophilic Syndrome (HES): rare disorder characterized persistent eosinophilia organ damageClinical Significance: Can indicate parasitic infection, allergic disease, underlying conditionsLaboratory Findings:\nElevated WBC count\nIncreased absolute eosinophil count\nPeripheral blood smear: May show normal activated eosinophils\nElevated WBC countIncreased absolute eosinophil countPeripheral blood smear: May show normal activated eosinophilsBasophilia: Increased number basophils blood (Absolute Basophil Count > 0.1 x 10^9/L adults)\nCauses:\nMyeloproliferative Neoplasms (MPNs): Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET)\nAllergic Reactions: Urticaria, angioedema\nHypothyroidism\nInfections: Certain viral infections\n\nClinical Significance: Often associated MPNs allergic reactions.\nLaboratory Findings:\nElevated WBC count\nIncreased absolute basophil count\nPeripheral blood smear: May show normal increased basophils\n\nBasophilia: Increased number basophils blood (Absolute Basophil Count > 0.1 x 10^9/L adults)Causes:\nMyeloproliferative Neoplasms (MPNs): Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET)\nAllergic Reactions: Urticaria, angioedema\nHypothyroidism\nInfections: Certain viral infections\nMyeloproliferative Neoplasms (MPNs): Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET)Allergic Reactions: Urticaria, angioedemaHypothyroidismInfections: Certain viral infectionsClinical Significance: Often associated MPNs allergic reactions.Laboratory Findings:\nElevated WBC count\nIncreased absolute basophil count\nPeripheral blood smear: May show normal increased basophils\nElevated WBC countIncreased absolute basophil countPeripheral blood smear: May show normal increased basophils","code":""},{"path":"myeloid.html","id":"qualitative-changes-in-benign-myeloid-disorders","chapter":"Myeloid","heading":"Qualitative Changes in Benign Myeloid Disorders","text":"Qualitative changes refer alterations appearance function myeloid cells. changes often observed peripheral blood smear.Toxic Granulation:\nDescription: Prominent, dark-blue purple granules cytoplasm neutrophils\nSignificance: Indicates accelerated granulopoiesis response severe infection inflammation\nMechanism: Abnormal maturation neutrophils bone marrow, leading increased granule formation\nAssociated Findings: Dohle bodies, cytoplasmic vacuolization\nDescription: Prominent, dark-blue purple granules cytoplasm neutrophilsSignificance: Indicates accelerated granulopoiesis response severe infection inflammationMechanism: Abnormal maturation neutrophils bone marrow, leading increased granule formationOther Associated Findings: Dohle bodies, cytoplasmic vacuolizationDöhle Bodies:\nDescription: Light-blue gray-blue, irregular inclusions cytoplasm neutrophils\nSignificance: Represent aggregates rough endoplasmic reticulum (RNA)\nAssociated Conditions: Bacterial infections, burns, trauma, pregnancy\nDescription: Light-blue gray-blue, irregular inclusions cytoplasm neutrophilsSignificance: Represent aggregates rough endoplasmic reticulum (RNA)Associated Conditions: Bacterial infections, burns, trauma, pregnancyCytoplasmic Vacuolization:\nDescription: Presence vacuoles (clear, round spaces) cytoplasm neutrophils, monocytes, lymphocytes\nSignificance: Can indicate phagocytosis bacteria fungi, toxic effects drugs, artifacts due improper staining\nAssociated Conditions: Infections, alcohol toxicity, exposure certain chemicals\nDescription: Presence vacuoles (clear, round spaces) cytoplasm neutrophils, monocytes, lymphocytesSignificance: Can indicate phagocytosis bacteria fungi, toxic effects drugs, artifacts due improper stainingAssociated Conditions: Infections, alcohol toxicity, exposure certain chemicalsPelger-Huët Anomaly:\nDescription: Neutrophils bilobed unlobed nuclei (” pince-nez” appearance)\nInherited (True) Pelger-Huët Anomaly: Benign condition normal neutrophil function.\nCaused mutation Lamin B Receptor gene (LBR)\nneutrophils affected\n\nAcquired (Pseudo) Pelger-Huët Anomaly: Occurs myelodysplastic syndromes (MDS) conditions affecting neutrophil maturation.\nneutrophils affected\nMay associated dysplastic features (e.g., abnormal granulation)\n\nClinical Significance: Important distinguish true Pelger-Huët anomaly pseudo-Pelger-Huët anomaly, latter may indicate serious underlying disorder.\nDescription: Neutrophils bilobed unlobed nuclei (” pince-nez” appearance)Inherited (True) Pelger-Huët Anomaly: Benign condition normal neutrophil function.\nCaused mutation Lamin B Receptor gene (LBR)\nneutrophils affected\nCaused mutation Lamin B Receptor gene (LBR)neutrophils affectedAcquired (Pseudo) Pelger-Huët Anomaly: Occurs myelodysplastic syndromes (MDS) conditions affecting neutrophil maturation.\nneutrophils affected\nMay associated dysplastic features (e.g., abnormal granulation)\nneutrophils affectedMay associated dysplastic features (e.g., abnormal granulation)Clinical Significance: Important distinguish true Pelger-Huët anomaly pseudo-Pelger-Huët anomaly, latter may indicate serious underlying disorder.Alder-Reilly Anomaly:\nDescription: Large, azurophilic (purple-red) granules types leukocytes (neutrophils, lymphocytes, monocytes)\nSignificance: Results abnormal lysosomal storage due deficiency certain mucopolysaccharidases\nAssociated Conditions: Mucopolysaccharidoses (MPS), group inherited metabolic disorders\nDistinction Toxic Granulation: Alder-Reilly granules larger prominent, present types leukocytes, toxic granulation usually limited neutrophils\nDescription: Large, azurophilic (purple-red) granules types leukocytes (neutrophils, lymphocytes, monocytes)Significance: Results abnormal lysosomal storage due deficiency certain mucopolysaccharidasesAssociated Conditions: Mucopolysaccharidoses (MPS), group inherited metabolic disordersDistinction Toxic Granulation: Alder-Reilly granules larger prominent, present types leukocytes, toxic granulation usually limited neutrophilsMay-Hegglin Anomaly:\nDescription: Large, pale-blue inclusions (Döhle bodies) neutrophils, eosinophils, basophils, monocytes, accompanied thrombocytopenia giant platelets\nSignificance: Caused mutation MYH9 gene, encodes nonmuscle myosin heavy chain IIA\nClinical Features: Mild moderate thrombocytopenia bleeding tendencies (e.g., easy bruising, epistaxis)\nLaboratory Findings:\nThrombocytopenia\nGiant platelets peripheral blood smear\nDöhle-like inclusions leukocytes\n\nDescription: Large, pale-blue inclusions (Döhle bodies) neutrophils, eosinophils, basophils, monocytes, accompanied thrombocytopenia giant plateletsSignificance: Caused mutation MYH9 gene, encodes nonmuscle myosin heavy chain IIAClinical Features: Mild moderate thrombocytopenia bleeding tendencies (e.g., easy bruising, epistaxis)Laboratory Findings:\nThrombocytopenia\nGiant platelets peripheral blood smear\nDöhle-like inclusions leukocytes\nThrombocytopeniaGiant platelets peripheral blood smearDöhle-like inclusions leukocytesChédiak-Higashi Syndrome:\nDescription: Rare autosomal recessive disorder characterized giant granules neutrophils, eosinophils, basophils, monocytes, lymphocytes\nSignificance: Caused mutation LYST gene, regulates lysosomal trafficking\nClinical Features:\nPartial albinism (skin hair)\nRecurrent bacterial infections\nNeurological abnormalities\nIncreased susceptibility lymphoma\n\nLaboratory Findings:\nGiant granules leukocytes peripheral blood smear\nNeutropenia\nThrombocytopenia\nImpaired neutrophil chemotaxis killing\n\nDescription: Rare autosomal recessive disorder characterized giant granules neutrophils, eosinophils, basophils, monocytes, lymphocytesSignificance: Caused mutation LYST gene, regulates lysosomal traffickingClinical Features:\nPartial albinism (skin hair)\nRecurrent bacterial infections\nNeurological abnormalities\nIncreased susceptibility lymphoma\nPartial albinism (skin hair)Recurrent bacterial infectionsNeurological abnormalitiesIncreased susceptibility lymphomaLaboratory Findings:\nGiant granules leukocytes peripheral blood smear\nNeutropenia\nThrombocytopenia\nImpaired neutrophil chemotaxis killing\nGiant granules leukocytes peripheral blood smearNeutropeniaThrombocytopeniaImpaired neutrophil chemotaxis killing","code":""},{"path":"myeloid.html","id":"key-laboratory-tests-for-benign-myeloid-disorders","chapter":"Myeloid","heading":"Key Laboratory Tests for Benign Myeloid Disorders","text":"Complete Blood Count (CBC) Differential:\nassess number types leukocytes blood\nassess number types leukocytes bloodPeripheral Blood Smear Examination:\nevaluate morphology leukocytes identify qualitative abnormalities\nevaluate morphology leukocytes identify qualitative abnormalitiesSpecial Stains:\nMay used identify specific types granules inclusions leukocytes\nMay used identify specific types granules inclusions leukocytesFlow Cytometry:\nidentify cell surface markers classify leukocytes\nidentify cell surface markers classify leukocytesBone Marrow Aspiration Biopsy:\nMay necessary evaluate bone marrow disorders malignancies\nMay necessary evaluate bone marrow disorders malignanciesGenetic Testing:\nidentify mutations associated certain inherited leukocyte disorders (e.g., Pelger-Huët anomaly, Chédiak-Higashi syndrome)\nidentify mutations associated certain inherited leukocyte disorders (e.g., Pelger-Huët anomaly, Chédiak-Higashi syndrome)","code":""},{"path":"myeloid.html","id":"key-terms-23","chapter":"Myeloid","heading":"Key Terms","text":"Leukocyte: white blood cell; general term cells involved immune systemMyeloid Cells: Leukocytes develop myeloid progenitor cell bone marrow; includes neutrophils, eosinophils, basophils, monocytesGranulocytes: type leukocyte characterized granules cytoplasm; includes neutrophils, eosinophils, basophilsNeutrophil: abundant type WBC; primarily responsible fighting bacterial fungal infectionsEosinophil: type WBC primarily involved defense parasites allergic reactionsBasophil: type WBC involved allergic reactions inflammation; contains histamine heparin granulesMonocyte: type WBC circulates blood differentiates macrophage dendritic cell tissuesMacrophage: tissue-resident phagocyte engulfs destroys pathogens, debris, dead cells; also involved antigen presentation cytokine productionLeukopoiesis: production white blood cellsNeutrophilia: increased number neutrophils bloodNeutropenia: decreased number neutrophils bloodMonocytosis: increased number monocytes bloodMonocytopenia: decreased number monocytes bloodEosinophilia: increased number eosinophils bloodBasophilia: increased number basophils bloodLeukemoid Reaction: benign increase white blood cells (usually neutrophils) mimics leukemiaAbsolute Neutrophil Count (ANC): actual number neutrophils sample blood; used assess risk infection patients neutropeniaLeft Shift: presence increased numbers immature neutrophils (e.g., bands, metamyelocytes, myelocytes) peripheral blood, indicating increased bone marrow activityQualitative Changes: Alterations appearance function cellsToxic Granulation: Prominent, dark granules neutrophils, indicating severe infection inflammationDöhle Bodies: Light-blue cytoplasmic inclusions neutrophils, consisting rough endoplasmic reticulum; seen infection, burns, conditionsCytoplasmic Vacuolization: presence vacuoles (clear spaces) cytoplasm cells, often indicating phagocytosis toxic effectsPelger-Huët Anomaly: Neutrophils bilobed unlobed nucleiAlder-Reilly Anomaly: Large, azurophilic granules types leukocytes, seen mucopolysaccharidosesMay-Hegglin Anomaly: Large, pale-blue inclusions (Döhle bodies) leukocytes, accompanied thrombocytopenia giant plateletsChédiak-Higashi Syndrome: rare autosomal recessive disorder characterized giant granules leukocytes cellsDysplasia: Abnormal cell development maturationBone Marrow Aspiration Biopsy: Procedures collect examine bone marrow cells","code":""},{"path":"lymphoid.html","id":"lymphoid","chapter":"Lymphoid","heading":"Lymphoid","text":"","code":""},{"path":"lymphoid.html","id":"overview-of-benign-lymphoid-disorders","chapter":"Lymphoid","heading":"Overview of Benign Lymphoid Disorders","text":"Definition: Non-cancerous conditions affecting lymphoid lineage leukocytes (lymphocytes: T cells, B cells, NK cells). disorders involve changes lymphocyte numbers, appearance, function due malignancyKey Features:\nUsually reactive (secondary) underlying condition (e.g., infection, inflammation)\nOften transient, resolving underlying cause addressed\nGenerally involve clonal proliferation significant dysplasia\nUsually reactive (secondary) underlying condition (e.g., infection, inflammation)Often transient, resolving underlying cause addressedGenerally involve clonal proliferation significant dysplasiaBenign vs. Malignant: ’s important differentiate benign lymphoid disorders malignant lymphomas leukemias, characterized uncontrolled proliferation clonal lymphoid cells","code":""},{"path":"lymphoid.html","id":"quantitative-changes-in-benign-lymphoid-disorders","chapter":"Lymphoid","heading":"Quantitative Changes in Benign Lymphoid Disorders","text":"Quantitative changes refer alterations number lymphocytes peripheral bloodLymphocytosis: Increased number lymphocytes blood (Absolute Lymphocyte Count > 4.0 x 10^9/L adults)\nCauses:\nViral Infections:\nInfectious mononucleosis (Epstein-Barr virus - EBV)\nCytomegalovirus (CMV) infection\nPertussis (Whooping Cough)\nviral infections (e.g., influenza, measles, mumps, rubella)\n\nBacterial Infections:\nLess common viral infections\nPertussis (Whooping Cough): Characterized marked lymphocytosis (often > 20 x 10^9/L) small, mature lymphocytes\n\nChronic Infections:\nTuberculosis (TB)\nBrucellosis\n\nAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\n\nDrug Reactions:\nCertain medications (e.g., phenytoin) can cause lymphocytosis\n\nPost-Splenectomy:\nSlight increase lymphocyte count spleen removal\n\nLymphoproliferative Disorders:\n*Must ruled , considered “benign.” CLL often high lymphocyte counts, smudge cells, can involve cell lines time\n\n\nLaboratory Findings:\nElevated WBC count\nIncreased absolute lymphocyte count\nPeripheral Blood Smear:\nSmall, mature lymphocytes (cases)\nAtypical lymphocytes (reactive lymphocytes) viral infections (see “Qualitative Changes” )\n\n\nLymphocytosis: Increased number lymphocytes blood (Absolute Lymphocyte Count > 4.0 x 10^9/L adults)Causes:\nViral Infections:\nInfectious mononucleosis (Epstein-Barr virus - EBV)\nCytomegalovirus (CMV) infection\nPertussis (Whooping Cough)\nviral infections (e.g., influenza, measles, mumps, rubella)\n\nBacterial Infections:\nLess common viral infections\nPertussis (Whooping Cough): Characterized marked lymphocytosis (often > 20 x 10^9/L) small, mature lymphocytes\n\nChronic Infections:\nTuberculosis (TB)\nBrucellosis\n\nAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\n\nDrug Reactions:\nCertain medications (e.g., phenytoin) can cause lymphocytosis\n\nPost-Splenectomy:\nSlight increase lymphocyte count spleen removal\n\nLymphoproliferative Disorders:\n*Must ruled , considered “benign.” CLL often high lymphocyte counts, smudge cells, can involve cell lines time\n\nViral Infections:\nInfectious mononucleosis (Epstein-Barr virus - EBV)\nCytomegalovirus (CMV) infection\nPertussis (Whooping Cough)\nviral infections (e.g., influenza, measles, mumps, rubella)\nInfectious mononucleosis (Epstein-Barr virus - EBV)Cytomegalovirus (CMV) infectionPertussis (Whooping Cough)viral infections (e.g., influenza, measles, mumps, rubella)Bacterial Infections:\nLess common viral infections\nPertussis (Whooping Cough): Characterized marked lymphocytosis (often > 20 x 10^9/L) small, mature lymphocytes\nLess common viral infectionsPertussis (Whooping Cough): Characterized marked lymphocytosis (often > 20 x 10^9/L) small, mature lymphocytesChronic Infections:\nTuberculosis (TB)\nBrucellosis\nTuberculosis (TB)BrucellosisAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\nSystemic lupus erythematosus (SLE)Rheumatoid arthritis (RA)Drug Reactions:\nCertain medications (e.g., phenytoin) can cause lymphocytosis\nCertain medications (e.g., phenytoin) can cause lymphocytosisPost-Splenectomy:\nSlight increase lymphocyte count spleen removal\nSlight increase lymphocyte count spleen removalLymphoproliferative Disorders:\n*Must ruled , considered “benign.” CLL often high lymphocyte counts, smudge cells, can involve cell lines time\n*Must ruled , considered “benign.” CLL often high lymphocyte counts, smudge cells, can involve cell lines timeLaboratory Findings:\nElevated WBC count\nIncreased absolute lymphocyte count\nPeripheral Blood Smear:\nSmall, mature lymphocytes (cases)\nAtypical lymphocytes (reactive lymphocytes) viral infections (see “Qualitative Changes” )\n\nElevated WBC countIncreased absolute lymphocyte countPeripheral Blood Smear:\nSmall, mature lymphocytes (cases)\nAtypical lymphocytes (reactive lymphocytes) viral infections (see “Qualitative Changes” )\nSmall, mature lymphocytes (cases)Atypical lymphocytes (reactive lymphocytes) viral infections (see “Qualitative Changes” )Lymphopenia: Decreased number lymphocytes blood (Absolute Lymphocyte Count < 1.0 x 10^9/L adults)\nCauses:\nInfections:\nHIV/AIDS: Destruction CD4+ T helper cells\nSevere acute infections (e.g., sepsis)\n\nImmunodeficiency Disorders:\nSevere Combined Immunodeficiency (SCID): Inherited disorders affecting T B cell development\nDiGeorge Syndrome: Thymic hypoplasia, leading T cell deficiency\n\nMedications:\nCorticosteroids: Induce lymphocyte apoptosis\nChemotherapy: Damage lymphocytes blood cells\nImmunosuppressants: Cyclosporine, tacrolimus\n\nAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\n\nRadiation Exposure:\nDamages lymphocytes bone marrow\n\nMalnutrition:\nProtein-energy malnutrition\nZinc deficiency\n\nHodgkin Lymphoma:\nAdvanced stages disease can cause lymphopenia\n\n\nLaboratory Findings:\nDecreased WBC count\nDecreased absolute lymphocyte count\nPeripheral Blood Smear: May show normal lymphocytes abnormal morphology (depending underlying cause)\nHIV Testing: rule HIV infection\nImmunoglobulin Levels: evaluate humoral immunodeficiency\nFlow Cytometry: enumerate CD4+ T cells (HIV infection) assess lymphocyte subsets\nLymph Node Biopsy: May necessary evaluate lymphoma lymphoproliferative disorders\n\nLymphopenia: Decreased number lymphocytes blood (Absolute Lymphocyte Count < 1.0 x 10^9/L adults)Causes:\nInfections:\nHIV/AIDS: Destruction CD4+ T helper cells\nSevere acute infections (e.g., sepsis)\n\nImmunodeficiency Disorders:\nSevere Combined Immunodeficiency (SCID): Inherited disorders affecting T B cell development\nDiGeorge Syndrome: Thymic hypoplasia, leading T cell deficiency\n\nMedications:\nCorticosteroids: Induce lymphocyte apoptosis\nChemotherapy: Damage lymphocytes blood cells\nImmunosuppressants: Cyclosporine, tacrolimus\n\nAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\n\nRadiation Exposure:\nDamages lymphocytes bone marrow\n\nMalnutrition:\nProtein-energy malnutrition\nZinc deficiency\n\nHodgkin Lymphoma:\nAdvanced stages disease can cause lymphopenia\n\nInfections:\nHIV/AIDS: Destruction CD4+ T helper cells\nSevere acute infections (e.g., sepsis)\nHIV/AIDS: Destruction CD4+ T helper cellsSevere acute infections (e.g., sepsis)Immunodeficiency Disorders:\nSevere Combined Immunodeficiency (SCID): Inherited disorders affecting T B cell development\nDiGeorge Syndrome: Thymic hypoplasia, leading T cell deficiency\nSevere Combined Immunodeficiency (SCID): Inherited disorders affecting T B cell developmentDiGeorge Syndrome: Thymic hypoplasia, leading T cell deficiencyMedications:\nCorticosteroids: Induce lymphocyte apoptosis\nChemotherapy: Damage lymphocytes blood cells\nImmunosuppressants: Cyclosporine, tacrolimus\nCorticosteroids: Induce lymphocyte apoptosisChemotherapy: Damage lymphocytes blood cellsImmunosuppressants: Cyclosporine, tacrolimusAutoimmune Disorders:\nSystemic lupus erythematosus (SLE)\nRheumatoid arthritis (RA)\nSystemic lupus erythematosus (SLE)Rheumatoid arthritis (RA)Radiation Exposure:\nDamages lymphocytes bone marrow\nDamages lymphocytes bone marrowMalnutrition:\nProtein-energy malnutrition\nZinc deficiency\nProtein-energy malnutritionZinc deficiencyHodgkin Lymphoma:\nAdvanced stages disease can cause lymphopenia\nAdvanced stages disease can cause lymphopeniaLaboratory Findings:\nDecreased WBC count\nDecreased absolute lymphocyte count\nPeripheral Blood Smear: May show normal lymphocytes abnormal morphology (depending underlying cause)\nHIV Testing: rule HIV infection\nImmunoglobulin Levels: evaluate humoral immunodeficiency\nFlow Cytometry: enumerate CD4+ T cells (HIV infection) assess lymphocyte subsets\nLymph Node Biopsy: May necessary evaluate lymphoma lymphoproliferative disorders\nDecreased WBC countDecreased absolute lymphocyte countPeripheral Blood Smear: May show normal lymphocytes abnormal morphology (depending underlying cause)HIV Testing: rule HIV infectionImmunoglobulin Levels: evaluate humoral immunodeficiencyFlow Cytometry: enumerate CD4+ T cells (HIV infection) assess lymphocyte subsetsLymph Node Biopsy: May necessary evaluate lymphoma lymphoproliferative disorders","code":""},{"path":"lymphoid.html","id":"qualitative-changes-in-benign-lymphoid-disorders","chapter":"Lymphoid","heading":"Qualitative Changes in Benign Lymphoid Disorders","text":"Qualitative changes refer alterations appearance function lymphocytes. changes often observed peripheral blood smearReactive Lymphocytes (Atypical Lymphocytes):\nDescription: Lymphocytes abnormal morphology, typically seen response viral infections (especially infectious mononucleosis)\nCharacteristics:\nIncreased cell size\nAbundant cytoplasm (may basophilic vacuolated)\nIrregular nuclear shape\nLoosely packed chromatin\nProminent nucleoli\n\nSignificance: Indicate lymphocyte activation response antigen\nAssociated Conditions:\nInfectious Mononucleosis (EBV)\nCytomegalovirus (CMV) infection\nToxoplasmosis\nViral hepatitis\nDrug reactions\n\nDifferentiation Malignant Lymphocytes:\nReactive lymphocytes typically mixed population T B cells\nclonal (identical immunoglobulin T cell receptor gene rearrangements)\nlack specific markers immunophenotype associated lymphoma leukemia\n\nReactive Lymphocytes (Atypical Lymphocytes):Description: Lymphocytes abnormal morphology, typically seen response viral infections (especially infectious mononucleosis)Characteristics:\nIncreased cell size\nAbundant cytoplasm (may basophilic vacuolated)\nIrregular nuclear shape\nLoosely packed chromatin\nProminent nucleoli\nIncreased cell sizeAbundant cytoplasm (may basophilic vacuolated)Irregular nuclear shapeLoosely packed chromatinProminent nucleoliSignificance: Indicate lymphocyte activation response antigenAssociated Conditions:\nInfectious Mononucleosis (EBV)\nCytomegalovirus (CMV) infection\nToxoplasmosis\nViral hepatitis\nDrug reactions\nInfectious Mononucleosis (EBV)Cytomegalovirus (CMV) infectionToxoplasmosisViral hepatitisDrug reactionsDifferentiation Malignant Lymphocytes:\nReactive lymphocytes typically mixed population T B cells\nclonal (identical immunoglobulin T cell receptor gene rearrangements)\nlack specific markers immunophenotype associated lymphoma leukemia\nReactive lymphocytes typically mixed population T B cellsThey clonal (identical immunoglobulin T cell receptor gene rearrangements)lack specific markers immunophenotype associated lymphoma leukemiaSmudge Cells:\nDescription: Damaged lymphocytes appear smudged smeared nuclear chromatin peripheral blood smear\nSignificance: Often artifact caused mechanical damage smear preparation\nAssociated Conditions: Can seen condition increased numbers fragile lymphocytes, classically associated Chronic Lymphocytic Leukemia (CLL). key point rule CLL\nSmudge cells diagnostic specific benign lymphoid disorder, presence prompt investigation\nSmudge Cells:Description: Damaged lymphocytes appear smudged smeared nuclear chromatin peripheral blood smearSignificance: Often artifact caused mechanical damage smear preparationAssociated Conditions: Can seen condition increased numbers fragile lymphocytes, classically associated Chronic Lymphocytic Leukemia (CLL). key point rule CLLSmudge cells diagnostic specific benign lymphoid disorder, presence prompt investigationLymphocytosis Atypical Lymphocytes Infectious Mononucleosis (EBV):\nInfectious Mononucleosis (Mono): viral infection caused Epstein-Barr virus (EBV)\nClinical Features:\nFever\nSore throat (pharyngitis)\nFatigue\nLymphadenopathy (swollen lymph nodes, especially neck)\nSplenomegaly (enlarged spleen)\n\nLaboratory Findings:\nElevated WBC count lymphocytosis\nAtypical lymphocytes peripheral blood smear (often >20% WBCs)\nPositive Monospot test (heterophile antibody test)\nPositive EBV-specific antibodies (e.g., anti-VCA IgM, anti-VCA IgG, anti-EBNA)\n\nLymphocytosis Atypical Lymphocytes Infectious Mononucleosis (EBV):Infectious Mononucleosis (Mono): viral infection caused Epstein-Barr virus (EBV)Clinical Features:\nFever\nSore throat (pharyngitis)\nFatigue\nLymphadenopathy (swollen lymph nodes, especially neck)\nSplenomegaly (enlarged spleen)\nFeverSore throat (pharyngitis)FatigueLymphadenopathy (swollen lymph nodes, especially neck)Splenomegaly (enlarged spleen)Laboratory Findings:\nElevated WBC count lymphocytosis\nAtypical lymphocytes peripheral blood smear (often >20% WBCs)\nPositive Monospot test (heterophile antibody test)\nPositive EBV-specific antibodies (e.g., anti-VCA IgM, anti-VCA IgG, anti-EBNA)\nElevated WBC count lymphocytosisAtypical lymphocytes peripheral blood smear (often >20% WBCs)Positive Monospot test (heterophile antibody test)Positive EBV-specific antibodies (e.g., anti-VCA IgM, anti-VCA IgG, anti-EBNA)Lymphocytosis Atypical Lymphocytes Cytomegalovirus (CMV) Infection:\nCytomegalovirus (CMV) Infection: common viral infection can cause mononucleosis-like illness\nClinical Features:\nOften asymptomatic healthy individuals\nCan cause fever, fatigue, malaise, lymphadenopathy\nsevere immunocompromised individuals (e.g., transplant recipients, HIV patients)\n\nLaboratory Findings:\nElevated WBC count lymphocytosis\nAtypical lymphocytes peripheral blood smear\nNegative Monospot test\nPositive CMV-specific antibodies (e.g., CMV IgM, CMV IgG)\nCMV DNA detection PCR\n\nLymphocytosis Atypical Lymphocytes Cytomegalovirus (CMV) Infection:Cytomegalovirus (CMV) Infection: common viral infection can cause mononucleosis-like illnessClinical Features:\nOften asymptomatic healthy individuals\nCan cause fever, fatigue, malaise, lymphadenopathy\nsevere immunocompromised individuals (e.g., transplant recipients, HIV patients)\nOften asymptomatic healthy individualsCan cause fever, fatigue, malaise, lymphadenopathyMore severe immunocompromised individuals (e.g., transplant recipients, HIV patients)Laboratory Findings:\nElevated WBC count lymphocytosis\nAtypical lymphocytes peripheral blood smear\nNegative Monospot test\nPositive CMV-specific antibodies (e.g., CMV IgM, CMV IgG)\nCMV DNA detection PCR\nElevated WBC count lymphocytosisAtypical lymphocytes peripheral blood smearNegative Monospot testPositive CMV-specific antibodies (e.g., CMV IgM, CMV IgG)CMV DNA detection PCROther Qualitative Changes:\nIncreased Cytoplasmic Basophilia: May seen activated lymphocytes\nIncreased Granularity: May seen NK cells\nNuclear Abnormalities: Rare benign conditions can seen drug reactions\nQualitative Changes:Increased Cytoplasmic Basophilia: May seen activated lymphocytesIncreased Granularity: May seen NK cellsNuclear Abnormalities: Rare benign conditions can seen drug reactions","code":""},{"path":"lymphoid.html","id":"laboratory-evaluation-of-benign-lymphoid-disorders","chapter":"Lymphoid","heading":"Laboratory Evaluation of Benign Lymphoid Disorders","text":"Complete Blood Count (CBC) Differential:\nassess number types lymphocytes blood\nassess number types lymphocytes bloodPeripheral Blood Smear Examination:\nevaluate morphology lymphocytes identify qualitative abnormalities\nevaluate morphology lymphocytes identify qualitative abnormalitiesHeterophile Antibody Test (Monospot Test):\ndiagnose infectious mononucleosis (EBV)\ndiagnose infectious mononucleosis (EBV)Epstein-Barr Virus (EBV) Serology:\ndetect EBV-specific antibodies (e.g., anti-VCA IgM, anti-VCA IgG, anti-EBNA)\ndetect EBV-specific antibodies (e.g., anti-VCA IgM, anti-VCA IgG, anti-EBNA)Cytomegalovirus (CMV) Serology:\ndetect CMV-specific antibodies (e.g., CMV IgM, CMV IgG)\ndetect CMV-specific antibodies (e.g., CMV IgM, CMV IgG)Flow Cytometry Immunophenotyping:\nidentify lymphocyte subsets (CD4+ T cells, CD8+ T cells, B cells, NK cells)\ndetect clonal lymphocyte populations (lymphoma leukemia suspected)\nidentify lymphocyte subsets (CD4+ T cells, CD8+ T cells, B cells, NK cells)detect clonal lymphocyte populations (lymphoma leukemia suspected)Lymph Node Biopsy:\nMay necessary evaluate lymphoma lymphoproliferative disorders, especially lymphadenopathy persistent unexplained\nMay necessary evaluate lymphoma lymphoproliferative disorders, especially lymphadenopathy persistent unexplained","code":""},{"path":"lymphoid.html","id":"key-terms-24","chapter":"Lymphoid","heading":"Key Terms","text":"Lymphocyte: type white blood cell includes T cells, B cells, NK cellsLymphocytosis: increased number lymphocytes bloodLymphopenia: decreased number lymphocytes bloodReactive Lymphocyte (Atypical Lymphocyte): activated lymphocyte abnormal morphology, typically seen viral infectionsSmudge Cell: damaged lymphocyte appears smeared nuclear chromatinInfectious Mononucleosis (Mono): viral infection caused Epstein-Barr virus (EBV)Cytomegalovirus (CMV): common viral infection can cause mononucleosis-like illnessHeterophile Antibody Test (Monospot Test): rapid test infectious mononucleosisFlow Cytometry Immunophenotyping: technique identify cell surface markers classify leukocytesEBV Serology: Tests detect EBV-specific antibodies","code":""},{"path":"myeloid-neoplasia.html","id":"myeloid-neoplasia","chapter":"Myeloid Neoplasia","heading":"Myeloid Neoplasia","text":"","code":""},{"path":"myeloid-neoplasia.html","id":"overview-of-myeloid-neoplasms","chapter":"Myeloid Neoplasia","heading":"Overview of Myeloid Neoplasms","text":"Definition: group hematologic malignancies originating clonal hematopoietic stem cells early progenitor cells myeloid lineage bone marrowKey Characteristics:\nAbnormal Proliferation: Uncontrolled growth myeloid cells\nDysplasia: Abnormal cell maturation morphology\nVariable Differentiation: myeloid neoplasms primarily involve immature cells (blasts), others involve mature cells\nRisk Transformation: Many myeloid neoplasms can progress acute myeloid leukemia (AML)\nAbnormal Proliferation: Uncontrolled growth myeloid cellsDysplasia: Abnormal cell maturation morphologyVariable Differentiation: myeloid neoplasms primarily involve immature cells (blasts), others involve mature cellsRisk Transformation: Many myeloid neoplasms can progress acute myeloid leukemia (AML)Classification: World Health Organization () classification system used categorize myeloid neoplasms based clinical, morphological, immunophenotypic, cytogenetic, molecular featuresGeneral Categories:\nAcute Myeloid Leukemia (AML)\nMyelodysplastic Syndromes (MDS)\nMyeloproliferative Neoplasms (MPNs)\nMyeloid/Lymphoid Neoplasms Eosinophilia Defining Genetic Abnormalities\nMyeloid Sarcoma\nAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)Myeloproliferative Neoplasms (MPNs)Myeloid/Lymphoid Neoplasms Eosinophilia Defining Genetic AbnormalitiesMyeloid Sarcoma","code":""},{"path":"myeloid-neoplasia.html","id":"acute-myeloid-leukemia-aml","chapter":"Myeloid Neoplasia","heading":"Acute Myeloid Leukemia (AML)","text":"Definition: Aggressive hematologic malignancy characterized accumulation ≥20% myeloid blasts bone marrow peripheral bloodPathophysiology:\nGenetic mutations block myeloid differentiation, leading buildup immature blasts\nBlasts crowd normal hematopoietic cells, causing cytopenias (anemia, thrombocytopenia, neutropenia)\nGenetic mutations block myeloid differentiation, leading buildup immature blastsBlasts crowd normal hematopoietic cells, causing cytopenias (anemia, thrombocytopenia, neutropenia)Classification:\nAML Recurrent Genetic Abnormalities: AML specific chromosomal translocations gene mutations (e.g., AML t(8;21), AML t(15;17), AML NPM1 mutation, AML FLT3-ITD)\nAML Myelodysplasia-Related Changes: AML arising associated prior myelodysplastic syndrome\nTherapy-Related AML: AML arising late complication cytotoxic chemotherapy radiation therapy\nAML Otherwise Specified (AML-NOS): AML meet criteria categories classified based morphology cytochemistry\nAML Recurrent Genetic Abnormalities: AML specific chromosomal translocations gene mutations (e.g., AML t(8;21), AML t(15;17), AML NPM1 mutation, AML FLT3-ITD)AML Myelodysplasia-Related Changes: AML arising associated prior myelodysplastic syndromeTherapy-Related AML: AML arising late complication cytotoxic chemotherapy radiation therapyAML Otherwise Specified (AML-NOS): AML meet criteria categories classified based morphology cytochemistry","code":""},{"path":"myeloid-neoplasia.html","id":"myelodysplastic-syndromes-mds","chapter":"Myeloid Neoplasia","heading":"Myelodysplastic Syndromes (MDS)","text":"Definition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis, dysplasia one cell lines, variable risk progression AMLPathophysiology:\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasia\nDysplastic cells prone apoptosis (programmed cell death), contributing ineffective hematopoiesis\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasiaDysplastic cells prone apoptosis (programmed cell death), contributing ineffective hematopoiesisClassification:\nBased morphological features, cytogenetic abnormalities, blast percentage bone marrow peripheral blood\nKey subtypes include:\nRefractory Anemia (RA)\nRefractory Anemia Ring Sideroblasts (RARS)\nRefractory Cytopenia Multilineage Dysplasia (RCMD)\nRefractory Anemia Excess Blasts (RAEB-1 RAEB-2)\nMDS Isolated del(5q)\n\nBased morphological features, cytogenetic abnormalities, blast percentage bone marrow peripheral bloodKey subtypes include:\nRefractory Anemia (RA)\nRefractory Anemia Ring Sideroblasts (RARS)\nRefractory Cytopenia Multilineage Dysplasia (RCMD)\nRefractory Anemia Excess Blasts (RAEB-1 RAEB-2)\nMDS Isolated del(5q)\nRefractory Anemia (RA)Refractory Anemia Ring Sideroblasts (RARS)Refractory Cytopenia Multilineage Dysplasia (RCMD)Refractory Anemia Excess Blasts (RAEB-1 RAEB-2)MDS Isolated del(5q)","code":""},{"path":"myeloid-neoplasia.html","id":"myeloproliferative-neoplasms-mpns","chapter":"Myeloid Neoplasia","heading":"Myeloproliferative Neoplasms (MPNs)","text":"Definition: group clonal hematopoietic stem cell disorders characterized overproduction one myeloid cell lines bone marrowKey Features:\nIncreased Blood Cell Counts: Elevated WBC count, RBC count, /platelet count\nSplenomegaly: Enlargement spleen due extramedullary hematopoiesis increased workload\nRisk Thrombosis Bleeding: Due abnormal platelet function elevated blood cell counts\nRisk Transformation: Can progress myelofibrosis acute leukemia\nIncreased Blood Cell Counts: Elevated WBC count, RBC count, /platelet countSplenomegaly: Enlargement spleen due extramedullary hematopoiesis increased workloadRisk Thrombosis Bleeding: Due abnormal platelet function elevated blood cell countsRisk Transformation: Can progress myelofibrosis acute leukemiaClassification:\nChronic Myeloid Leukemia (CML): Characterized presence BCR-ABL1 fusion gene\nPolycythemia Vera (PV): Primarily involves increased RBC production; associated JAK2 V617F mutation\nEssential Thrombocythemia (ET): Primarily involves increased platelet production; associated mutations JAK2, CALR, MPL\nPrimary Myelofibrosis (PMF): Characterized bone marrow fibrosis, splenomegaly, extramedullary hematopoiesis; associated mutations JAK2, CALR, MPL\nChronic Myeloid Leukemia (CML): Characterized presence BCR-ABL1 fusion genePolycythemia Vera (PV): Primarily involves increased RBC production; associated JAK2 V617F mutationEssential Thrombocythemia (ET): Primarily involves increased platelet production; associated mutations JAK2, CALR, MPLPrimary Myelofibrosis (PMF): Characterized bone marrow fibrosis, splenomegaly, extramedullary hematopoiesis; associated mutations JAK2, CALR, MPL","code":""},{"path":"myeloid-neoplasia.html","id":"general-laboratory-features","chapter":"Myeloid Neoplasia","heading":"General Laboratory Features","text":"Complete Blood Count (CBC) Differential: assess number types blood cells, well assess abnormalities cytopenias increased numbers blastsPeripheral Blood Smear: evaluate morphology blood cells identify qualitative abnormalities (e.g., dysplasia)Bone Marrow Aspiration Biopsy: assess cellularity morphology bone marrow, well detect dysplasia abnormal cell populationsCytogenetic Analysis: identify chromosomal abnormalities, translocations, deletions, inversionsFlow Cytometry: identify cell surface markers classify blood cellsMolecular Testing: detect gene mutations (e.g., JAK2, CALR, MPL, FLT3, NPM1, CEBPA) fusion genes (e.g., BCR-ABL1)","code":""},{"path":"myeloid-neoplasia.html","id":"key-terms-25","chapter":"Myeloid Neoplasia","heading":"Key Terms","text":"Myeloid Neoplasm: hematologic malignancy arising myeloid progenitor cellsAcute Myeloid Leukemia (AML): aggressive leukemia ≥20% blasts bone marrow bloodMyelodysplastic Syndromes (MDS): group clonal bone marrow disorders characterized ineffective hematopoiesis dysplasiaMyeloproliferative Neoplasms (MPNs): group clonal bone marrow disorders characterized overproduction one blood cell linesBlast Cells: Immature, abnormal cells seen acute leukemiaDysplasia: Abnormal cell development maturationCytopenia: Deficiency blood cells (e.g., anemia, neutropenia, thrombocytopenia)BCR-ABL1 Fusion Gene: fusion gene created translocation chromosomes 9 22, resulting Philadelphia chromosome (seen CML)JAK2 Mutation: mutation JAK2 gene commonly found MPNsPhlebotomy: Removal blood reduce red cell mass","code":""},{"path":"aml.html","id":"aml","chapter":"AML","heading":"AML","text":"","code":""},{"path":"aml.html","id":"overview-of-acute-myeloid-leukemia-aml","chapter":"AML","heading":"Overview of Acute Myeloid Leukemia (AML)","text":"Definition: group aggressive hematologic malignancies characterized rapid proliferation accumulation myeloblasts (immature myeloid cells) bone marrow peripheral bloodHallmark: >20% blasts bone marrowClassification:\nWorld Health Organization () classification widely used system based :\nMorphology\nImmunophenotype\nGenetic abnormalities (cytogenetics molecular genetics)\nClinical features\n\nKey Categories (According ):\nAML Recurrent Genetic Abnormalities\nAML Myelodysplasia-Related Changes\nTherapy-Related AML (t-AML)\nAML Otherwise Specified (AML-NOS)\n\nWorld Health Organization () classification widely used system based :\nMorphology\nImmunophenotype\nGenetic abnormalities (cytogenetics molecular genetics)\nClinical features\nMorphologyImmunophenotypeGenetic abnormalities (cytogenetics molecular genetics)Clinical featuresKey Categories (According ):\nAML Recurrent Genetic Abnormalities\nAML Myelodysplasia-Related Changes\nTherapy-Related AML (t-AML)\nAML Otherwise Specified (AML-NOS)\nAML Recurrent Genetic AbnormalitiesAML Myelodysplasia-Related ChangesTherapy-Related AML (t-AML)AML Otherwise Specified (AML-NOS)Pathophysiology:\nGenetic mutations disrupt normal myeloid differentiation, leading buildup myeloblasts\nMyeloblasts crowd normal hematopoietic cells bone marrow, causing cytopenias (anemia, thrombocytopenia, neutropenia)\nGenetic mutations disrupt normal myeloid differentiation, leading buildup myeloblastsMyeloblasts crowd normal hematopoietic cells bone marrow, causing cytopenias (anemia, thrombocytopenia, neutropenia)Clinical Significance: Rapidly progressive life-threatening untreated","code":""},{"path":"aml.html","id":"etiology-and-risk-factors","chapter":"AML","heading":"Etiology and Risk Factors","text":"Genetic Mutations:\nAML typically caused acquired genetic mutations hematopoietic stem cells early myeloid progenitors\nmutations can affect:\nTranscription factors (e.g., RUNX1, CEBPA)\nSignal transduction pathways (e.g., FLT3, RAS)\nEpigenetic modifiers (e.g., DNMT3A, TET2)\nSpliceosome components (e.g., SF3B1)\n\nAML typically caused acquired genetic mutations hematopoietic stem cells early myeloid progenitorsThese mutations can affect:\nTranscription factors (e.g., RUNX1, CEBPA)\nSignal transduction pathways (e.g., FLT3, RAS)\nEpigenetic modifiers (e.g., DNMT3A, TET2)\nSpliceosome components (e.g., SF3B1)\nTranscription factors (e.g., RUNX1, CEBPA)Signal transduction pathways (e.g., FLT3, RAS)Epigenetic modifiers (e.g., DNMT3A, TET2)Spliceosome components (e.g., SF3B1)Prior Chemotherapy Radiation Therapy:\nTherapy-related AML (t-AML) secondary leukemia develops exposure cytotoxic agents radiation\nt-AML often poor prognosis\nTherapy-related AML (t-AML) secondary leukemia develops exposure cytotoxic agents radiationt-AML often poor prognosisUnderlying Hematologic Disorders:\nMyelodysplastic syndromes (MDS) can transform AML\nMyeloproliferative neoplasms (MPNs) can transform AML\nMyelodysplastic syndromes (MDS) can transform AMLMyeloproliferative neoplasms (MPNs) can transform AMLGenetic Predisposition:\nCertain inherited genetic syndromes increase risk developing AML (e.g., Fanconi anemia, syndrome)\nCertain inherited genetic syndromes increase risk developing AML (e.g., Fanconi anemia, syndrome)Environmental Factors:\nExposure benzene chemicals\nSmoking\nExposure benzene chemicalsSmoking","code":""},{"path":"aml.html","id":"classification-of-aml-who-2016","chapter":"AML","heading":"Classification of AML (WHO 2016)","text":"AML Recurrent Genetic Abnormalities:\nAML t(8;21)(q22;q22.1); RUNX1-RUNX1T1\nFavorable prognosis\nOften associated Auer rods maturation\n\nAML inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11\nFavorable prognosis\nOften associated increased eosinophils bone marrow\n\nAcute Promyelocytic Leukemia (APL) t(15;17)(q24.1;q21.1); PML-RARA\nGood prognosis appropriate treatment\nAssociated disseminated intravascular coagulation (DIC)\nAbnormal promyelocytes Auer rods\n\nAML t(9;11)(p21.3;q23.3); MLLT3-KMT2A\nIntermediate prognosis\nOften associated monocytic differentiation\n\nAML t(v;11q23.3); KMT2A rearranged:\nAML t(6;9)(p23;q34.1); DEK-NUP214\nAML inv(3)(q21.3q26.2) t(3;3)(q21.3;q26.2); GATA2, MECOM\nAML t(1;22)(p13.3;q13.1); RBM15-MKL1\nAML Recurrent Genetic Abnormalities:AML t(8;21)(q22;q22.1); RUNX1-RUNX1T1\nFavorable prognosis\nOften associated Auer rods maturation\nFavorable prognosisOften associated Auer rods maturationAML inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11\nFavorable prognosis\nOften associated increased eosinophils bone marrow\nFavorable prognosisOften associated increased eosinophils bone marrowAcute Promyelocytic Leukemia (APL) t(15;17)(q24.1;q21.1); PML-RARA\nGood prognosis appropriate treatment\nAssociated disseminated intravascular coagulation (DIC)\nAbnormal promyelocytes Auer rods\nGood prognosis appropriate treatmentAssociated disseminated intravascular coagulation (DIC)Abnormal promyelocytes Auer rodsAML t(9;11)(p21.3;q23.3); MLLT3-KMT2A\nIntermediate prognosis\nOften associated monocytic differentiation\nIntermediate prognosisOften associated monocytic differentiationAML t(v;11q23.3); KMT2A rearranged:AML t(6;9)(p23;q34.1); DEK-NUP214AML inv(3)(q21.3q26.2) t(3;3)(q21.3;q26.2); GATA2, MECOMAML t(1;22)(p13.3;q13.1); RBM15-MKL1AML Myelodysplasia-Related Changes:\nHistory myelodysplastic syndrome (MDS) myeloproliferative neoplasm (MPN)\nMultilineage dysplasia bone marrow (dysplasia ≥50% cells least 2 cell lineages)\nSpecific cytogenetic abnormalities\nAML Myelodysplasia-Related Changes:History myelodysplastic syndrome (MDS) myeloproliferative neoplasm (MPN)Multilineage dysplasia bone marrow (dysplasia ≥50% cells least 2 cell lineages)Specific cytogenetic abnormalitiesTherapy-Related AML (t-AML):\nOccurs exposure cytotoxic chemotherapy radiation therapy\nOften associated specific cytogenetic abnormalities poor prognosis\nTherapy-Related AML (t-AML):Occurs exposure cytotoxic chemotherapy radiation therapyOften associated specific cytogenetic abnormalities poor prognosisAML Otherwise Specified (AML-NOS):\nAML cases meet criteria subtypes\nSubclassified based morphology:\nAML minimal differentiation\nAML without maturation\nAML maturation\nAcute myelomonocytic leukemia\nAcute monoblastic/monocytic leukemia\nAcute erythroid leukemia\nAcute megakaryoblastic leukemia\nAcute basophilic leukemia\nAcute panmyelosis myelofibrosis\n\nAML Otherwise Specified (AML-NOS):AML cases meet criteria subtypesSubclassified based morphology:\nAML minimal differentiation\nAML without maturation\nAML maturation\nAcute myelomonocytic leukemia\nAcute monoblastic/monocytic leukemia\nAcute erythroid leukemia\nAcute megakaryoblastic leukemia\nAcute basophilic leukemia\nAcute panmyelosis myelofibrosis\nAML minimal differentiationAML without maturationAML maturationAcute myelomonocytic leukemiaAcute monoblastic/monocytic leukemiaAcute erythroid leukemiaAcute megakaryoblastic leukemiaAcute basophilic leukemiaAcute panmyelosis myelofibrosis","code":""},{"path":"aml.html","id":"clinical-features","chapter":"AML","heading":"Clinical Features","text":"Symptoms Anemia:\nFatigue\nWeakness\nPallor (pale skin)\nShortness breath\nFatigueWeaknessPallor (pale skin)Shortness breathSymptoms Thrombocytopenia:\nBleeding (e.g., nosebleeds, gum bleeding, easy bruising)\nPetechiae (small, pinpoint hemorrhages)\nEcchymoses (bruises)\nBleeding (e.g., nosebleeds, gum bleeding, easy bruising)Petechiae (small, pinpoint hemorrhages)Ecchymoses (bruises)Symptoms Neutropenia:\nFrequent infections\nFever\nSore throat\nFrequent infectionsFeverSore throatOther Symptoms:\nBone pain\nSplenomegaly (enlarged spleen)\nHepatomegaly (enlarged liver)\nLymphadenopathy (swollen lymph nodes) - less common AML \nGingival hyperplasia (swelling gums), especially acute monocytic leukemia\nSkin infiltration (leukemia cutis)\nDisseminated Intravascular Coagulation (DIC):\nCan occur, especially acute promyelocytic leukemia (APL)\n\nBone painSplenomegaly (enlarged spleen)Hepatomegaly (enlarged liver)Lymphadenopathy (swollen lymph nodes) - less common AML ALLGingival hyperplasia (swelling gums), especially acute monocytic leukemiaSkin infiltration (leukemia cutis)Disseminated Intravascular Coagulation (DIC):\nCan occur, especially acute promyelocytic leukemia (APL)\nCan occur, especially acute promyelocytic leukemia (APL)","code":""},{"path":"aml.html","id":"laboratory-findings-3","chapter":"AML","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nRed Blood Cell Count (RBC): Decreased\nPlatelet Count: Decreased (thrombocytopenia)\nWhite Blood Cell Count (WBC): Variable; can low, normal, elevated\nNeutropenia: Often present, patients may elevated neutrophil counts\n\nPresence blasts peripheral blood (usually >20% WBCs)\nHemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedRed Blood Cell Count (RBC): DecreasedPlatelet Count: Decreased (thrombocytopenia)White Blood Cell Count (WBC): Variable; can low, normal, elevated\nNeutropenia: Often present, patients may elevated neutrophil counts\nNeutropenia: Often present, patients may elevated neutrophil countsPresence blasts peripheral blood (usually >20% WBCs)Peripheral Blood Smear:\nMyeloblasts: Large, immature cells :\nHigh nucleus--cytoplasm (N:C) ratio\nFine chromatin\nProminent nucleoli\nAuer rods: Rod-shaped inclusions cytoplasm (especially AML t(15;17))\n\nDecreased mature granulocytes platelets\nMyeloblasts: Large, immature cells :\nHigh nucleus--cytoplasm (N:C) ratio\nFine chromatin\nProminent nucleoli\nAuer rods: Rod-shaped inclusions cytoplasm (especially AML t(15;17))\nHigh nucleus--cytoplasm (N:C) ratioFine chromatinProminent nucleoliAuer rods: Rod-shaped inclusions cytoplasm (especially AML t(15;17))Decreased mature granulocytes plateletsCoagulation Studies (PT, aPTT, Fibrinogen, D-dimer):\nMay abnormal, especially acute promyelocytic leukemia (APL) due disseminated intravascular coagulation (DIC)\nMay abnormal, especially acute promyelocytic leukemia (APL) due disseminated intravascular coagulation (DIC)Bone Marrow Aspiration Biopsy:\nHypercellular marrow >20% blasts\nDysplastic changes one cell lines\nSpecial stains:\nMyeloperoxidase (MPO): Positive myeloblasts\nSudan Black B (SBB): Positive myeloblasts\nEsterase stains: Differentiate myeloblasts monoblasts\n\nHypercellular marrow >20% blastsDysplastic changes one cell linesSpecial stains:\nMyeloperoxidase (MPO): Positive myeloblasts\nSudan Black B (SBB): Positive myeloblasts\nEsterase stains: Differentiate myeloblasts monoblasts\nMyeloperoxidase (MPO): Positive myeloblastsSudan Black B (SBB): Positive myeloblastsEsterase stains: Differentiate myeloblasts monoblastsFlow Cytometry Immunophenotyping:\nIdentifies cell surface markers blasts determine lineage (myeloid) subtype AML\nCommon markers:\nMyeloid markers: CD13, CD33, CD117, myeloperoxidase (MPO), CD15\nStem cell markers: CD34, HLA-DR\n\nIdentifies cell surface markers blasts determine lineage (myeloid) subtype AMLCommon markers:\nMyeloid markers: CD13, CD33, CD117, myeloperoxidase (MPO), CD15\nStem cell markers: CD34, HLA-DR\nMyeloid markers: CD13, CD33, CD117, myeloperoxidase (MPO), CD15Stem cell markers: CD34, HLA-DRCytogenetic Analysis:\nIdentifies chromosomal abnormalities (e.g., translocations, inversions, deletions) used diagnosis prognosis\nIdentifies chromosomal abnormalities (e.g., translocations, inversions, deletions) used diagnosis prognosisMolecular Testing:\nDetects gene mutations (e.g., FLT3, NPM1, CEBPA) used diagnosis, prognosis, treatment planning\nDetects gene mutations (e.g., FLT3, NPM1, CEBPA) used diagnosis, prognosis, treatment planning","code":""},{"path":"aml.html","id":"diagnosis","chapter":"AML","heading":"Diagnosis","text":"Based Following Criteria:\nBone Marrow Aspiration Biopsy: >20% blasts bone marrow\nPeripheral Blood Smear: Presence blasts\nImmunophenotyping: Identifies lineage subtype AML\nCytogenetic Analysis: Detects chromosomal abnormalities\nMolecular Testing: Detects gene mutations\nBone Marrow Aspiration Biopsy: >20% blasts bone marrowPeripheral Blood Smear: Presence blastsImmunophenotyping: Identifies lineage subtype AMLCytogenetic Analysis: Detects chromosomal abnormalitiesMolecular Testing: Detects gene mutations","code":""},{"path":"aml.html","id":"treatment","chapter":"AML","heading":"Treatment","text":"Goals Treatment:\nAchieve complete remission (CR): Eradication blasts bone marrow restoration normal hematopoiesis\nPrevent relapse\nProlong survival\nGoals Treatment:Achieve complete remission (CR): Eradication blasts bone marrow restoration normal hematopoiesisPrevent relapseProlong survivalPhases Treatment:\nInduction Chemotherapy:\nIntensive chemotherapy rapidly reduce number leukemic cells bone marrow peripheral blood\nCommon regimens:\n“7+3” (cytarabine 7 days daunorubicin idarubicin 3 days)\n\nPatients high risk complications (e.g., infection, bleeding) induction\n\nConsolidation Therapy:\nAdministered achieving remission eliminate remaining leukemic cells prevent relapse\nOptions:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy many patients high-risk AML\n\n\n\nPhases Treatment:Induction Chemotherapy:\nIntensive chemotherapy rapidly reduce number leukemic cells bone marrow peripheral blood\nCommon regimens:\n“7+3” (cytarabine 7 days daunorubicin idarubicin 3 days)\n\nPatients high risk complications (e.g., infection, bleeding) induction\nIntensive chemotherapy rapidly reduce number leukemic cells bone marrow peripheral bloodCommon regimens:\n“7+3” (cytarabine 7 days daunorubicin idarubicin 3 days)\n“7+3” (cytarabine 7 days daunorubicin idarubicin 3 days)Patients high risk complications (e.g., infection, bleeding) inductionConsolidation Therapy:\nAdministered achieving remission eliminate remaining leukemic cells prevent relapse\nOptions:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy many patients high-risk AML\n\n\nAdministered achieving remission eliminate remaining leukemic cells prevent relapseOptions:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy many patients high-risk AML\n\nChemotherapyHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy many patients high-risk AML\nAllogeneic HSCT (matched donor) preferred consolidation therapy many patients high-risk AMLTreatment Acute Promyelocytic Leukemia (APL):\n-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) preferred treatment patients APL\ncombination therapy targets PML-RARA fusion protein promotes differentiation promyelocytes\nChemotherapy may added high-risk cases\nTreatment Acute Promyelocytic Leukemia (APL):-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) preferred treatment patients APLThis combination therapy targets PML-RARA fusion protein promotes differentiation promyelocytesChemotherapy may added high-risk casesSupportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nAntibiotics antifungals treat infections\nGrowth factors (e.g., G-CSF) stimulate neutrophil production\nManagement tumor lysis syndrome (TLS): metabolic complication caused rapid breakdown leukemic cells\nSupportive Care:Transfusions (RBCs platelets) manage anemia thrombocytopeniaAntibiotics antifungals treat infectionsGrowth factors (e.g., G-CSF) stimulate neutrophil productionManagement tumor lysis syndrome (TLS): metabolic complication caused rapid breakdown leukemic cells","code":""},{"path":"aml.html","id":"prognosis","chapter":"AML","heading":"Prognosis","text":"Factors Influencing Prognosis:\nCytogenetic Abnormalities: Certain chromosomal abnormalities associated favorable unfavorable outcomes\nGene Mutations: presence certain gene mutations (e.g., FLT3-ITD) associated poorer prognosis, others (e.g., NPM1) associated favorable outcomes\nAge: Younger patients generally better outcomes older patients\nPerformance Status: Overall health fitness patient\nResponse Induction Chemotherapy: Achievement complete remission key prognostic factor\nFactors Influencing Prognosis:Cytogenetic Abnormalities: Certain chromosomal abnormalities associated favorable unfavorable outcomesGene Mutations: presence certain gene mutations (e.g., FLT3-ITD) associated poorer prognosis, others (e.g., NPM1) associated favorable outcomesAge: Younger patients generally better outcomes older patientsPerformance Status: Overall health fitness patientResponse Induction Chemotherapy: Achievement complete remission key prognostic factorRisk Stratification:\nPatients classified risk groups (favorable, intermediate, adverse) based cytogenetic molecular abnormalities\nRisk stratification guides treatment decisions helps predict likelihood achieving long-term remission\nRisk Stratification:Patients classified risk groups (favorable, intermediate, adverse) based cytogenetic molecular abnormalitiesRisk stratification guides treatment decisions helps predict likelihood achieving long-term remission","code":""},{"path":"aml.html","id":"key-laboratory-findings-5","chapter":"AML","heading":"Key Laboratory Findings","text":"CBC:\nAnemia\nThrombocytopenia\nNeutropenia\nPresence blasts peripheral blood\nAnemiaThrombocytopeniaNeutropeniaPresence blasts peripheral bloodPeripheral Blood Smear:\nMyeloblasts\nAuer rods (cases)\nMyeloblastsAuer rods (cases)Bone Marrow Examination:\nHypercellular marrow >20% blasts\nHypercellular marrow >20% blastsFlow Cytometry:\nIdentifies cell surface markers blasts\nIdentifies cell surface markers blastsCytogenetic Analysis:\nDetects chromosomal abnormalities\nDetects chromosomal abnormalitiesMolecular Testing:\nDetects gene mutations\nDetects gene mutations","code":""},{"path":"aml.html","id":"key-terms-26","chapter":"AML","heading":"Key Terms","text":"Acute Myeloid Leukemia (AML): aggressive leukemia characterized >20% blasts bone marrowMyeloblast: Immature myeloid cellAuer Rods: Rod-shaped inclusions cytoplasm myeloblastsCytopenia: Deficiency blood cells (e.g., anemia, thrombocytopenia, neutropenia)Complete Remission (CR): Eradication blasts bone marrow restoration normal hematopoiesisInduction Chemotherapy: Initial intensive chemotherapy achieve remissionConsolidation Therapy: Treatment prevent relapse achieving remissionHematopoietic Stem Cell Transplantation (HSCT): Procedure replace damaged bone marrow healthy stem cellsCytogenetic Analysis: study chromosomes abnormalitiesMolecular Testing: Techniques detect gene mutations molecular abnormalities","code":""},{"path":"myelodysplastic.html","id":"myelodysplastic","chapter":"Myelodysplastic","heading":"Myelodysplastic","text":"","code":""},{"path":"myelodysplastic.html","id":"overview-of-myelodysplastic-syndromes-mds","chapter":"Myelodysplastic","heading":"Overview of Myelodysplastic Syndromes (MDS)","text":"Definition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis, resulting cytopenias (anemia, thrombocytopenia, /neutropenia) variable risk transformation acute myeloid leukemia (AML)Key Features:\nDysplasia: Abnormal morphology maturation hematopoietic cells bone marrow\nIneffective Hematopoiesis: Increased apoptosis (programmed cell death) hematopoietic precursors bone marrow, leading decreased production mature blood cells\nCytopenias: One peripheral blood cytopenias (anemia, thrombocytopenia, /neutropenia)\nRisk Transformation: Variable risk progression acute myeloid leukemia (AML)\nDysplasia: Abnormal morphology maturation hematopoietic cells bone marrowIneffective Hematopoiesis: Increased apoptosis (programmed cell death) hematopoietic precursors bone marrow, leading decreased production mature blood cellsCytopenias: One peripheral blood cytopenias (anemia, thrombocytopenia, /neutropenia)Risk Transformation: Variable risk progression acute myeloid leukemia (AML)Epidemiology: Primarily affects older adults (median age diagnosis >65 years)Etiology:\ncases de novo (arising without known cause)\ncases therapy-related (t-MDS), occurring exposure cytotoxic chemotherapy radiation therapy\nGenetic predisposition plays role small number cases\ncases de novo (arising without known cause)cases therapy-related (t-MDS), occurring exposure cytotoxic chemotherapy radiation therapyGenetic predisposition plays role small number cases","code":""},{"path":"myelodysplastic.html","id":"pathophysiology-4","chapter":"Myelodysplastic","heading":"Pathophysiology","text":"Clonal Hematopoiesis: MDS arises mutated hematopoietic stem cell proliferative advantage normal stem cellsGenetic Mutations: Acquired mutations genes involved :\nSplicing factors (e.g., SF3B1, SRSF2, U2AF1)\nDNA methylation (e.g., TET2, DNMT3A)\nTranscription factors (e.g., RUNX1, TP53)\nSignaling pathways (e.g., RAS pathway)\nSplicing factors (e.g., SF3B1, SRSF2, U2AF1)DNA methylation (e.g., TET2, DNMT3A)Transcription factors (e.g., RUNX1, TP53)Signaling pathways (e.g., RAS pathway)Impaired Differentiation: Mutations disrupt normal differentiation maturation hematopoietic cellsDysplasia: Abnormal morphological features one cell lines (erythroid, myeloid, megakaryocytic)Increased Apoptosis: Dysplastic cells prone apoptosis (programmed cell death) bone marrow, contributing ineffective hematopoiesisCytokine Dysregulation: Abnormal production cytokines bone marrow cells can contribute ineffective hematopoiesis cytopeniasImmune Dysregulation: Abnormal immune responses may contribute bone marrow failure cases","code":""},{"path":"myelodysplastic.html","id":"who-classification-of-mds-2016-revision","chapter":"Myelodysplastic","heading":"WHO Classification of MDS (2016 Revision)","text":"World Health Organization () classification used categorize MDS based :Morphological Features: Dysplasia one cell lines, blast percentageCytogenetic Abnormalities: Specific chromosomal abnormalitiesBlast Percentage: Percentage blasts bone marrow peripheral bloodKey Subtypes MDS:MDS Single Lineage Dysplasia (MDS-SLD):\nCytopenia one cell line (anemia, thrombocytopenia, neutropenia)\nDysplasia one cell line \n<5% blasts bone marrow <1% blasts peripheral blood\nCytopenia one cell line (anemia, thrombocytopenia, neutropenia)Dysplasia one cell line <5% blasts bone marrow <1% blasts peripheral bloodMDS Ring Sideroblasts (MDS-RS):\nSubclassified :\nMDS-RS-SLD: Single lineage dysplasia ≥15% ring sideroblasts bone marrow\nMDS-RS-MLD: Multilineage dysplasia ≥15% ring sideroblasts bone marrow\n\nCytopenia one cell lines\n<5% blasts bone marrow <1% blasts peripheral blood\nOften associated SF3B1 mutation\nSubclassified :\nMDS-RS-SLD: Single lineage dysplasia ≥15% ring sideroblasts bone marrow\nMDS-RS-MLD: Multilineage dysplasia ≥15% ring sideroblasts bone marrow\nMDS-RS-SLD: Single lineage dysplasia ≥15% ring sideroblasts bone marrowMDS-RS-MLD: Multilineage dysplasia ≥15% ring sideroblasts bone marrowCytopenia one cell lines<5% blasts bone marrow <1% blasts peripheral bloodOften associated SF3B1 mutationMDS Multilineage Dysplasia (MDS-MLD):\nCytopenia one cell lines\nDysplasia ≥50% cells least two cell lines\n<5% blasts bone marrow <1% blasts peripheral blood\nCytopenia one cell linesDysplasia ≥50% cells least two cell lines<5% blasts bone marrow <1% blasts peripheral bloodMDS Excess Blasts (MDS-EB):\nSubclassified :\nMDS-EB-1: 5-9% blasts bone marrow 2-4% blasts peripheral blood\nMDS-EB-2: 10-19% blasts bone marrow 5-9% blasts peripheral blood\n\nCytopenias one cell lines\nMay Auer rods\nSubclassified :\nMDS-EB-1: 5-9% blasts bone marrow 2-4% blasts peripheral blood\nMDS-EB-2: 10-19% blasts bone marrow 5-9% blasts peripheral blood\nMDS-EB-1: 5-9% blasts bone marrow 2-4% blasts peripheral bloodMDS-EB-2: 10-19% blasts bone marrow 5-9% blasts peripheral bloodCytopenias one cell linesMay Auer rodsMDS Isolated del(5q):\nAnemia\nNormal increased platelet count\n<5% blasts bone marrow <1% blasts peripheral blood\nIsolated del(5q) cytogenetic abnormality\nOften responsive lenalidomide\nAnemiaNormal increased platelet count<5% blasts bone marrow <1% blasts peripheral bloodIsolated del(5q) cytogenetic abnormalityOften responsive lenalidomide","code":""},{"path":"myelodysplastic.html","id":"clinical-manifestations-5","chapter":"Myelodysplastic","heading":"Clinical Manifestations","text":"Symptoms Cytopenias:\nAnemia: Fatigue, weakness, pallor, shortness breath\nThrombocytopenia: Bleeding, bruising, petechiae (small, pinpoint hemorrhages)\nNeutropenia: Increased susceptibility infections\nSymptoms Cytopenias:Anemia: Fatigue, weakness, pallor, shortness breathThrombocytopenia: Bleeding, bruising, petechiae (small, pinpoint hemorrhages)Neutropenia: Increased susceptibility infectionsOther Symptoms:\npatients asymptomatic MDS found incidentally blood test\nSplenomegaly (enlarged spleen): Less common myeloproliferative neoplasms\nHepatosplenomegaly (enlarged liver spleen)\nSystemic Symptoms (Less Common): Fever, weight loss, night sweats\nSymptoms:patients asymptomatic MDS found incidentally blood testSplenomegaly (enlarged spleen): Less common myeloproliferative neoplasmsHepatosplenomegaly (enlarged liver spleen)Systemic Symptoms (Less Common): Fever, weight loss, night sweats","code":""},{"path":"myelodysplastic.html","id":"laboratory-findings-4","chapter":"Myelodysplastic","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nCytopenias one cell lines (anemia, thrombocytopenia, neutropenia)\nMay see macrocytosis (increased MCV) dimorphic RBC population\n\nVariable WBC count (may low, normal, high)\nPresence blasts peripheral blood (variable, depends subtype MDS)\nComplete Blood Count (CBC):Cytopenias one cell lines (anemia, thrombocytopenia, neutropenia)\nMay see macrocytosis (increased MCV) dimorphic RBC population\nMay see macrocytosis (increased MCV) dimorphic RBC populationVariable WBC count (may low, normal, high)Presence blasts peripheral blood (variable, depends subtype MDS)Peripheral Blood Smear:\nDysplastic Features One Cell Lines:\nRBCs: Oval macrocytes, hypochromia, basophilic stippling, Howell-Jolly bodies, teardrop cells\nNeutrophils: Pseudo-Pelger-Huët anomaly (bilobed unsegmented neutrophils), hypogranulation, abnormal nuclear segmentation\nPlatelets: Large platelets, abnormal granulation\n\nPeripheral Blood Smear:Dysplastic Features One Cell Lines:\nRBCs: Oval macrocytes, hypochromia, basophilic stippling, Howell-Jolly bodies, teardrop cells\nNeutrophils: Pseudo-Pelger-Huët anomaly (bilobed unsegmented neutrophils), hypogranulation, abnormal nuclear segmentation\nPlatelets: Large platelets, abnormal granulation\nRBCs: Oval macrocytes, hypochromia, basophilic stippling, Howell-Jolly bodies, teardrop cellsNeutrophils: Pseudo-Pelger-Huët anomaly (bilobed unsegmented neutrophils), hypogranulation, abnormal nuclear segmentationPlatelets: Large platelets, abnormal granulationReticulocyte Count:\nLow Normal (inappropriately low degree anemia)\nReticulocyte Count:Low Normal (inappropriately low degree anemia)Bone Marrow Aspiration Biopsy:\nIncreased Cellularity (Hypercellular) Decreased Cellularity (Hypocellular)\nDysplasia One Cell Lines:\nErythroid dysplasia: Multinucleated erythroid precursors, nuclear budding, megaloblastoid changes\nMyeloid dysplasia: Abnormal nuclear segmentation, hypogranulation, Auer rods (rare)\nMegakaryocytic dysplasia: Micromegakaryocytes, hypolobated megakaryocytes\n\nIncreased Blast Percentage: Used classify MDS subtypes\nRing Sideroblasts: Erythroid precursors iron-laden mitochondria encircling nucleus (≥15% ring sideroblasts MDS-RS subtypes)\nBone Marrow Aspiration Biopsy:Increased Cellularity (Hypercellular) Decreased Cellularity (Hypocellular)Dysplasia One Cell Lines:\nErythroid dysplasia: Multinucleated erythroid precursors, nuclear budding, megaloblastoid changes\nMyeloid dysplasia: Abnormal nuclear segmentation, hypogranulation, Auer rods (rare)\nMegakaryocytic dysplasia: Micromegakaryocytes, hypolobated megakaryocytes\nErythroid dysplasia: Multinucleated erythroid precursors, nuclear budding, megaloblastoid changesMyeloid dysplasia: Abnormal nuclear segmentation, hypogranulation, Auer rods (rare)Megakaryocytic dysplasia: Micromegakaryocytes, hypolobated megakaryocytesIncreased Blast Percentage: Used classify MDS subtypesRing Sideroblasts: Erythroid precursors iron-laden mitochondria encircling nucleus (≥15% ring sideroblasts MDS-RS subtypes)Cytogenetic Analysis:\nChromosomal Abnormalities Common MDS\ndel(5q): Seen MDS isolated del(5q)\nTrisomy 8 (+8)\ndel(20q)\ndel(7q) monosomy 7 (-7)\nComplex Karyotype: Presence multiple cytogenetic abnormalities; associated poor prognosis\n\nCytogenetic Analysis:Chromosomal Abnormalities Common MDS\ndel(5q): Seen MDS isolated del(5q)\nTrisomy 8 (+8)\ndel(20q)\ndel(7q) monosomy 7 (-7)\nComplex Karyotype: Presence multiple cytogenetic abnormalities; associated poor prognosis\ndel(5q): Seen MDS isolated del(5q)Trisomy 8 (+8)del(20q)del(7q) monosomy 7 (-7)Complex Karyotype: Presence multiple cytogenetic abnormalities; associated poor prognosisFlow Cytometry Immunophenotyping:\nIdentify Abnormal Cell Populations Assess Dysplasia\nAberrant expression cell surface markers\nAbnormal cell ratios\nHelps differentiate MDS conditions\n\nFlow Cytometry Immunophenotyping:Identify Abnormal Cell Populations Assess Dysplasia\nAberrant expression cell surface markers\nAbnormal cell ratios\nHelps differentiate MDS conditions\nAberrant expression cell surface markersAbnormal cell ratiosHelps differentiate MDS conditionsMolecular Testing:\nDetect Gene Mutations Important Diagnosis, Prognosis, Treatment Planning\nCommonly Mutated Genes:\nSF3B1 (splicing factor)\nTET2 (DNA methylation)\nDNMT3A (DNA methylation)\nASXL1 (chromatin modifier)\nRUNX1 (transcription factor)\nTP53 (tumor suppressor)\nEZH2 (chromatin modifier)\n\n\nMolecular Testing:Detect Gene Mutations Important Diagnosis, Prognosis, Treatment Planning\nCommonly Mutated Genes:\nSF3B1 (splicing factor)\nTET2 (DNA methylation)\nDNMT3A (DNA methylation)\nASXL1 (chromatin modifier)\nRUNX1 (transcription factor)\nTP53 (tumor suppressor)\nEZH2 (chromatin modifier)\n\nCommonly Mutated Genes:\nSF3B1 (splicing factor)\nTET2 (DNA methylation)\nDNMT3A (DNA methylation)\nASXL1 (chromatin modifier)\nRUNX1 (transcription factor)\nTP53 (tumor suppressor)\nEZH2 (chromatin modifier)\nSF3B1 (splicing factor)TET2 (DNA methylation)DNMT3A (DNA methylation)ASXL1 (chromatin modifier)RUNX1 (transcription factor)TP53 (tumor suppressor)EZH2 (chromatin modifier)","code":""},{"path":"myelodysplastic.html","id":"diagnostic-criteria","chapter":"Myelodysplastic","heading":"Diagnostic Criteria","text":"Presence One Cytopenias (Anemia, Thrombocytopenia, /Neutropenia)Dysplasia least One Cell Line (Erythroid, Myeloid, Megakaryocytic) Bone MarrowBlast Percentage Bone Marrow <20%Absence Myeloid Neoplasms (e.g., CML, AML recurrent genetic abnormalities)Cytogenetic Abnormalities - Helpful Classification Prognosis","code":""},{"path":"myelodysplastic.html","id":"prognostic-scoring-systems","chapter":"Myelodysplastic","heading":"Prognostic Scoring Systems","text":"Revised International Prognostic Scoring System (IPSS-R):\nUsed estimate prognosis risk AML transformation patients MDS\nBased :\nPercentage blasts bone marrow\nCytogenetic abnormalities\nNumber cytopenias\nAssigns patients risk categories: low, low, intermediate, high, high\n\nUsed estimate prognosis risk AML transformation patients MDSBased :\nPercentage blasts bone marrow\nCytogenetic abnormalities\nNumber cytopenias\nAssigns patients risk categories: low, low, intermediate, high, high\nPercentage blasts bone marrowCytogenetic abnormalitiesNumber cytopeniasAssigns patients risk categories: low, low, intermediate, high, high","code":""},{"path":"myelodysplastic.html","id":"treatment-and-management-4","chapter":"Myelodysplastic","heading":"Treatment and Management","text":"Goals Treatment:\nImprove blood counts\nReduce risk infections bleeding\nDelay prevent transformation AML\nImprove quality life survival\nGoals Treatment:Improve blood countsReduce risk infections bleedingDelay prevent transformation AMLImprove quality life survivalTreatment Options:\nSupportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\nIron chelation therapy manage iron overload chronic transfusions (needed)\n\nHypomethylating Agents (HMAs):\nAzacitidine decitabine\nInhibit DNA methylation, leading improved hematopoiesis reduced risk AML transformation\nUsed higher-risk MDS\n\nLenalidomide:\nimmunomodulatory drug used patients MDS deletion 5q\nEffective reducing transfusion dependence improving cytopenias\n\nLuspatercept:\nrecombinant fusion protein binds TGF-β superfamily ligands\nPromotes erythroid maturation reduces transfusion burden patients MDS-RS\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients high-risk MDS\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\n\nTreatment Options:Supportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell production\nAntibiotics treat infections\nIron chelation therapy manage iron overload chronic transfusions (needed)\nTransfusions (RBCs platelets) manage anemia thrombocytopeniaGrowth factors (e.g., erythropoietin, G-CSF) stimulate blood cell productionAntibiotics treat infectionsIron chelation therapy manage iron overload chronic transfusions (needed)Hypomethylating Agents (HMAs):\nAzacitidine decitabine\nInhibit DNA methylation, leading improved hematopoiesis reduced risk AML transformation\nUsed higher-risk MDS\nAzacitidine decitabineInhibit DNA methylation, leading improved hematopoiesis reduced risk AML transformationUsed higher-risk MDSLenalidomide:\nimmunomodulatory drug used patients MDS deletion 5q\nEffective reducing transfusion dependence improving cytopenias\nimmunomodulatory drug used patients MDS deletion 5qEffective reducing transfusion dependence improving cytopeniasLuspatercept:\nrecombinant fusion protein binds TGF-β superfamily ligands\nPromotes erythroid maturation reduces transfusion burden patients MDS-RS\nrecombinant fusion protein binds TGF-β superfamily ligandsPromotes erythroid maturation reduces transfusion burden patients MDS-RSHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients high-risk MDS\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\nPotentially curative option, especially younger patients high-risk MDSInvolves replacing patient’s damaged bone marrow healthy stem cells donor","code":""},{"path":"myelodysplastic.html","id":"key-terms-27","chapter":"Myelodysplastic","heading":"Key Terms","text":"Myelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders ineffective hematopoiesis dysplasiaDysplasia: Abnormal cell development maturationCytopenia: Deficiency blood cells (e.g., anemia, neutropenia, thrombocytopenia)Ring Sideroblasts: Erythroid precursors iron-laden mitochondria encircling nucleusRefractory Anemia: Anemia respond standard treatmentsHypomethylating Agents: Drugs inhibit DNA methylationHematopoietic Stem Cell Transplantation (HSCT): Procedure replace damaged bone marrow healthy stem cells","code":""},{"path":"myeloproliferative.html","id":"myeloproliferative","chapter":"Myeloproliferative","heading":"Myeloproliferative","text":"","code":""},{"path":"myeloproliferative.html","id":"overview-of-myeloproliferative-neoplasms-mpns","chapter":"Myeloproliferative","heading":"Overview of Myeloproliferative Neoplasms (MPNs)","text":"Definition: group clonal hematopoietic stem cell disorders characterized increased proliferation one myeloid cell lines bone marrowKey Features:\nIncreased Blood Cell Counts: Elevated WBC count, RBC count, /platelet count\nExtramedullary Hematopoiesis: Hematopoiesis (blood cell production) occurs outside bone marrow, often spleen (leading splenomegaly) liver\nRisk Thrombosis Bleeding: Due abnormal platelet function /elevated blood cell counts\nRisk Transformation: Can progress myelofibrosis (scarring bone marrow) acute leukemia\nIncreased Blood Cell Counts: Elevated WBC count, RBC count, /platelet countExtramedullary Hematopoiesis: Hematopoiesis (blood cell production) occurs outside bone marrow, often spleen (leading splenomegaly) liverRisk Thrombosis Bleeding: Due abnormal platelet function /elevated blood cell countsRisk Transformation: Can progress myelofibrosis (scarring bone marrow) acute leukemiaDiagnostic Hallmark: MPNs often characterized specific genetic mutations drive increased proliferationClassification:\nChronic Myeloid Leukemia (CML)\nPolycythemia Vera (PV)\nEssential Thrombocythemia (ET)\nPrimary Myelofibrosis (PMF)\n, rarer MPNs\nChronic Myeloid Leukemia (CML)Polycythemia Vera (PV)Essential Thrombocythemia (ET)Primary Myelofibrosis (PMF), rarer MPNs","code":""},{"path":"myeloproliferative.html","id":"chronic-myeloid-leukemia-cml","chapter":"Myeloproliferative","heading":"Chronic Myeloid Leukemia (CML)","text":"Definition: myeloproliferative neoplasm characterized presence BCR-ABL1 fusion gene, resulting reciprocal translocation chromosomes 9 22 (t(9;22)(q34.1;q11.2))Pathophysiology:\nBCR-ABL1 Fusion Gene: translocation creates Philadelphia chromosome (Ph chromosome) results fusion BCR gene chromosome 22 ABL1 gene chromosome 9\nConstitutive Tyrosine Kinase Activity: BCR-ABL1 fusion protein constitutive (always “”) tyrosine kinase activity, drives uncontrolled proliferation myeloid cells\nBCR-ABL1 Fusion Gene: translocation creates Philadelphia chromosome (Ph chromosome) results fusion BCR gene chromosome 22 ABL1 gene chromosome 9Constitutive Tyrosine Kinase Activity: BCR-ABL1 fusion protein constitutive (always “”) tyrosine kinase activity, drives uncontrolled proliferation myeloid cellsPhases CML:\nChronic Phase (CP):\nRelatively indolent phase increased WBC count, <10% blasts bone marrow peripheral blood\n\nAccelerated Phase (AP):\nIncreasing WBC count, blasts 10-19% bone marrow peripheral blood, resistance treatment, new cytogenetic abnormalities\n\nBlast Phase (BP):\nTransformation acute leukemia (either myeloid lymphoid) ≥20% blasts bone marrow peripheral blood\n\nChronic Phase (CP):\nRelatively indolent phase increased WBC count, <10% blasts bone marrow peripheral blood\nRelatively indolent phase increased WBC count, <10% blasts bone marrow peripheral bloodAccelerated Phase (AP):\nIncreasing WBC count, blasts 10-19% bone marrow peripheral blood, resistance treatment, new cytogenetic abnormalities\nIncreasing WBC count, blasts 10-19% bone marrow peripheral blood, resistance treatment, new cytogenetic abnormalitiesBlast Phase (BP):\nTransformation acute leukemia (either myeloid lymphoid) ≥20% blasts bone marrow peripheral blood\nTransformation acute leukemia (either myeloid lymphoid) ≥20% blasts bone marrow peripheral bloodClinical Features:\nChronic Phase:\nOften asymptomatic\nFatigue\nSplenomegaly\nNight sweats\nWeight loss\n\nAccelerated Phase Blast Phase:\nWorsening symptoms\nFever\nBone pain\nBleeding\nInfections\n\nChronic Phase:\nOften asymptomatic\nFatigue\nSplenomegaly\nNight sweats\nWeight loss\nOften asymptomaticFatigueSplenomegalyNight sweatsWeight lossAccelerated Phase Blast Phase:\nWorsening symptoms\nFever\nBone pain\nBleeding\nInfections\nWorsening symptomsFeverBone painBleedingInfectionsLaboratory Findings:\nCBC:\nElevated WBC count (often > 25 x 10^9/L)\nNeutrophilia “left shift” (increased band neutrophils, metamyelocytes, myelocytes)\nBasophilia\nEosinophilia\nAnemia (variable)\nPlatelet count: Normal elevated\n\nPeripheral Blood Smear:\nIncreased granulocytes various stages maturation\nBasophilia\nSmall number blasts (chronic phase)\nPresence blasts promyelocytes (accelerated blast phases)\n\nBone Marrow Aspiration Biopsy:\nHypercellular marrow increased granulopoiesis\nMyeloid:erythroid (M:E) ratio increased\nBlast percentage: <10% chronic phase, 10-19% accelerated phase, ≥20% blast phase\n\nCytogenetic Analysis:\nPhiladelphia chromosome (Ph chromosome): t(9;22)(q34.1;q11.2)\n\nMolecular Testing:\nBCR-ABL1 Fusion Gene: Detected PCR FISH (fluorescence situ hybridization)\n\nCBC:\nElevated WBC count (often > 25 x 10^9/L)\nNeutrophilia “left shift” (increased band neutrophils, metamyelocytes, myelocytes)\nBasophilia\nEosinophilia\nAnemia (variable)\nPlatelet count: Normal elevated\nElevated WBC count (often > 25 x 10^9/L)Neutrophilia “left shift” (increased band neutrophils, metamyelocytes, myelocytes)BasophiliaEosinophiliaAnemia (variable)Platelet count: Normal elevatedPeripheral Blood Smear:\nIncreased granulocytes various stages maturation\nBasophilia\nSmall number blasts (chronic phase)\nPresence blasts promyelocytes (accelerated blast phases)\nIncreased granulocytes various stages maturationBasophiliaSmall number blasts (chronic phase)Presence blasts promyelocytes (accelerated blast phases)Bone Marrow Aspiration Biopsy:\nHypercellular marrow increased granulopoiesis\nMyeloid:erythroid (M:E) ratio increased\nBlast percentage: <10% chronic phase, 10-19% accelerated phase, ≥20% blast phase\nHypercellular marrow increased granulopoiesisMyeloid:erythroid (M:E) ratio increasedBlast percentage: <10% chronic phase, 10-19% accelerated phase, ≥20% blast phaseCytogenetic Analysis:\nPhiladelphia chromosome (Ph chromosome): t(9;22)(q34.1;q11.2)\nPhiladelphia chromosome (Ph chromosome): t(9;22)(q34.1;q11.2)Molecular Testing:\nBCR-ABL1 Fusion Gene: Detected PCR FISH (fluorescence situ hybridization)\nBCR-ABL1 Fusion Gene: Detected PCR FISH (fluorescence situ hybridization)Treatment:\nTyrosine Kinase Inhibitors (TKIs):\nImatinib, dasatinib, nilotinib, bosutinib, ponatinib\nTarget BCR-ABL1 tyrosine kinase activity, leading apoptosis leukemic cells\nHighly effective achieving maintaining remission patients chronic phase CML\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option\nTypically reserved patients fail TKI therapy accelerated blast phase\n\nInterferon-alpha:\nolder treatment option now less commonly used\n\nTyrosine Kinase Inhibitors (TKIs):\nImatinib, dasatinib, nilotinib, bosutinib, ponatinib\nTarget BCR-ABL1 tyrosine kinase activity, leading apoptosis leukemic cells\nHighly effective achieving maintaining remission patients chronic phase CML\nImatinib, dasatinib, nilotinib, bosutinib, ponatinibTarget BCR-ABL1 tyrosine kinase activity, leading apoptosis leukemic cellsHighly effective achieving maintaining remission patients chronic phase CMLHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option\nTypically reserved patients fail TKI therapy accelerated blast phase\nPotentially curative optionTypically reserved patients fail TKI therapy accelerated blast phaseInterferon-alpha:\nolder treatment option now less commonly used\nolder treatment option now less commonly used","code":""},{"path":"myeloproliferative.html","id":"polycythemia-vera-pv","chapter":"Myeloproliferative","heading":"Polycythemia Vera (PV)","text":"Definition: myeloproliferative neoplasm characterized increased production red blood cells (erythrocytosis), often accompanied increased production white blood cells plateletsDiagnostic Criteria:\nElevated hemoglobin hematocrit\nPresence JAK2 V617F mutation (JAK2 exon 12 mutation)\nBone marrow showing erythroid, granulocytic, megakaryocytic proliferation\nElevated hemoglobin hematocritPresence JAK2 V617F mutation (JAK2 exon 12 mutation)Bone marrow showing erythroid, granulocytic, megakaryocytic proliferationPathophysiology:\nJAK2 Mutation: mutation JAK2 gene (Janus kinase 2), commonly V617F mutation\nJAK2 tyrosine kinase involved signal transduction several growth factors, including erythropoietin (EPO)\nJAK2 mutation leads constitutive activation EPO receptor signaling pathway, resulting uncontrolled RBC production, independent EPO levels\n\nErythroid Progenitor Hypersensitivity: Erythroid progenitors become hypersensitive growth factors\nJAK2 Mutation: mutation JAK2 gene (Janus kinase 2), commonly V617F mutation\nJAK2 tyrosine kinase involved signal transduction several growth factors, including erythropoietin (EPO)\nJAK2 mutation leads constitutive activation EPO receptor signaling pathway, resulting uncontrolled RBC production, independent EPO levels\nJAK2 tyrosine kinase involved signal transduction several growth factors, including erythropoietin (EPO)JAK2 mutation leads constitutive activation EPO receptor signaling pathway, resulting uncontrolled RBC production, independent EPO levelsErythroid Progenitor Hypersensitivity: Erythroid progenitors become hypersensitive growth factorsClinical Features:\nElevated red cell mass causes:\nHeadache\nDizziness\nFatigue\nBlurred Vision\nPruritus (itching, especially warm bath)\nErythromelalgia (burning pain redness extremities)\nThrombosis: Increased risk blood clots (stroke, heart attack, pulmonary embolism, DVT)\nBleeding: Paradoxically, patients may experience bleeding due abnormal platelet function\nSplenomegaly: Enlarged spleen\n\nElevated red cell mass causes:\nHeadache\nDizziness\nFatigue\nBlurred Vision\nPruritus (itching, especially warm bath)\nErythromelalgia (burning pain redness extremities)\nThrombosis: Increased risk blood clots (stroke, heart attack, pulmonary embolism, DVT)\nBleeding: Paradoxically, patients may experience bleeding due abnormal platelet function\nSplenomegaly: Enlarged spleen\nHeadacheDizzinessFatigueBlurred VisionPruritus (itching, especially warm bath)Erythromelalgia (burning pain redness extremities)Thrombosis: Increased risk blood clots (stroke, heart attack, pulmonary embolism, DVT)Bleeding: Paradoxically, patients may experience bleeding due abnormal platelet functionSplenomegaly: Enlarged spleenLaboratory Findings:\nCBC:\nElevated HGB HCT\nElevated RBC count\nWBC count: May normal elevated\nPlatelet count: May normal elevated\n\nPeripheral Blood Smear:\nMay show erythrocytosis (increased RBCs)\nMay see granulocytosis thrombocytosis\n\nSerum Erythropoietin (EPO) Level:\nLow Normal\n\nJAK2 Mutation Analysis:\nPositive JAK2 V617F mutation (JAK2 mutation)\n\nBone Marrow Examination (always required):\nHypercellular marrow increased erythroid, granulocytic, megakaryocytic lineages\n\nCBC:\nElevated HGB HCT\nElevated RBC count\nWBC count: May normal elevated\nPlatelet count: May normal elevated\nElevated HGB HCTElevated RBC countWBC count: May normal elevatedPlatelet count: May normal elevatedPeripheral Blood Smear:\nMay show erythrocytosis (increased RBCs)\nMay see granulocytosis thrombocytosis\nMay show erythrocytosis (increased RBCs)May see granulocytosis thrombocytosisSerum Erythropoietin (EPO) Level:\nLow Normal\nLow NormalJAK2 Mutation Analysis:\nPositive JAK2 V617F mutation (JAK2 mutation)\nPositive JAK2 V617F mutation (JAK2 mutation)Bone Marrow Examination (always required):\nHypercellular marrow increased erythroid, granulocytic, megakaryocytic lineages\nHypercellular marrow increased erythroid, granulocytic, megakaryocytic lineagesTreatment:\nPhlebotomy:\nreduce HCT <45%\nMainstay therapy\n\nLow-Dose Aspirin:\nreduce risk thrombosis\n\nCytoreductive Therapy:\nHydroxyurea: suppress bone marrow proliferation\nRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyurea\n\nInterferon-alpha:\nMay used younger patients pregnant women\n\nPhlebotomy:\nreduce HCT <45%\nMainstay therapy\nreduce HCT <45%Mainstay therapyLow-Dose Aspirin:\nreduce risk thrombosis\nreduce risk thrombosisCytoreductive Therapy:\nHydroxyurea: suppress bone marrow proliferation\nRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyurea\nHydroxyurea: suppress bone marrow proliferationRuxolitinib: JAK2 inhibitor used patients resistant intolerant hydroxyureaInterferon-alpha:\nMay used younger patients pregnant women\nMay used younger patients pregnant women","code":""},{"path":"myeloproliferative.html","id":"essential-thrombocythemia-et","chapter":"Myeloproliferative","heading":"Essential Thrombocythemia (ET)","text":"Definition: myeloproliferative neoplasm characterized sustained thrombocytosis (elevated platelet count)Diagnostic Criteria:\nSustained Platelet Count ≥450 x 10^9/L\nBone Marrow Showing Increased Numbers Megakaryocytes\nExclusion MPNs: Absence criteria PV, PMF, CML\nPresence Clonal Marker (e.g., JAK2, CALR, MPL mutation) Evidence Clonal Hematopoiesis Absence Causes Thrombocytosis\nSustained Platelet Count ≥450 x 10^9/LBone Marrow Showing Increased Numbers MegakaryocytesExclusion MPNs: Absence criteria PV, PMF, CMLPresence Clonal Marker (e.g., JAK2, CALR, MPL mutation) Evidence Clonal Hematopoiesis Absence Causes ThrombocytosisPathophysiology:\nMutations JAK2, CALR, MPL genes lead increased megakaryocyte proliferation platelet production\nJAK2 mutation (Janus kinase 2): Affects signal transduction\nCALR mutation (calreticulin): Affects protein folding calcium signaling\nMPL mutation (thrombopoietin receptor): Affects thrombopoietin signaling\n\nMutations JAK2, CALR, MPL genes lead increased megakaryocyte proliferation platelet production\nJAK2 mutation (Janus kinase 2): Affects signal transduction\nCALR mutation (calreticulin): Affects protein folding calcium signaling\nMPL mutation (thrombopoietin receptor): Affects thrombopoietin signaling\nJAK2 mutation (Janus kinase 2): Affects signal transductionCALR mutation (calreticulin): Affects protein folding calcium signalingMPL mutation (thrombopoietin receptor): Affects thrombopoietin signalingClinical Features:\nOften asymptomatic\nThrombosis: Increased risk blood clots (stroke, heart attack, DVT, pulmonary embolism)\nBleeding: Paradoxically, patients may experience bleeding due abnormal platelet function\nErythromelalgia: Burning pain redness extremities\nSplenomegaly: Enlarged spleen (less common PV PMF)\nOften asymptomaticThrombosis: Increased risk blood clots (stroke, heart attack, DVT, pulmonary embolism)Bleeding: Paradoxically, patients may experience bleeding due abnormal platelet functionErythromelalgia: Burning pain redness extremitiesSplenomegaly: Enlarged spleen (less common PV PMF)Laboratory Findings:\nCBC:\nElevated platelet count (≥450 x 10^9/L)\nWBC count: May normal slightly elevated\nRBC count: Usually normal\n\nPeripheral Blood Smear:\nThrombocytosis: Increased number platelets\nLarge platelets (megathrombocytes)\nAbnormal platelet morphology (e.g., hypogranular platelets)\n\nBone Marrow Examination (always required):\nIncreased numbers megakaryocytes abnormal morphology\n\nMolecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\n\nCBC:\nElevated platelet count (≥450 x 10^9/L)\nWBC count: May normal slightly elevated\nRBC count: Usually normal\nElevated platelet count (≥450 x 10^9/L)WBC count: May normal slightly elevatedRBC count: Usually normalPeripheral Blood Smear:\nThrombocytosis: Increased number platelets\nLarge platelets (megathrombocytes)\nAbnormal platelet morphology (e.g., hypogranular platelets)\nThrombocytosis: Increased number plateletsLarge platelets (megathrombocytes)Abnormal platelet morphology (e.g., hypogranular platelets)Bone Marrow Examination (always required):\nIncreased numbers megakaryocytes abnormal morphology\nIncreased numbers megakaryocytes abnormal morphologyMolecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\nPositive JAK2, CALR, MPL mutation (cases)Treatment:\nLow-Dose Aspirin:\nreduce risk thrombosis\n\nCytoreductive Therapy:\nHydroxyurea: lower platelet count\nAnagrelide: Inhibits platelet production\nInterferon-alpha: May used younger patients pregnant women\n\nLow-Dose Aspirin:\nreduce risk thrombosis\nreduce risk thrombosisCytoreductive Therapy:\nHydroxyurea: lower platelet count\nAnagrelide: Inhibits platelet production\nInterferon-alpha: May used younger patients pregnant women\nHydroxyurea: lower platelet countAnagrelide: Inhibits platelet productionInterferon-alpha: May used younger patients pregnant women","code":""},{"path":"myeloproliferative.html","id":"primary-myelofibrosis-pmf","chapter":"Myeloproliferative","heading":"Primary Myelofibrosis (PMF)","text":"Definition: myeloproliferative neoplasm characterized progressive bone marrow fibrosis (scarring), splenomegaly, extramedullary hematopoiesisDiagnostic Criteria:\nMegakaryocyte proliferation dysplasia bone marrow\nReticulin /collagen fibrosis\nExclusion MPNs: Absence criteria PV, ET, CML\nPresence Clonal Marker (e.g., JAK2, CALR, MPL mutation) Evidence Clonal Hematopoiesis Absence Causes Myelofibrosis\nMegakaryocyte proliferation dysplasia bone marrowReticulin /collagen fibrosisExclusion MPNs: Absence criteria PV, ET, CMLPresence Clonal Marker (e.g., JAK2, CALR, MPL mutation) Evidence Clonal Hematopoiesis Absence Causes MyelofibrosisPathophysiology:\nMutations JAK2, CALR, MPL genes lead :\nAbnormal megakaryocyte proliferation activation\nRelease cytokines (e.g., TGF-β, PDGF, VEGF) stimulate fibroblast proliferation collagen deposition bone marrow\n\nProgressive bone marrow fibrosis impairs normal hematopoiesis, leading :\nCytopenias (anemia, thrombocytopenia)\nExtramedullary hematopoiesis (blood cell production spleen, liver, organs)\n\nMutations JAK2, CALR, MPL genes lead :\nAbnormal megakaryocyte proliferation activation\nRelease cytokines (e.g., TGF-β, PDGF, VEGF) stimulate fibroblast proliferation collagen deposition bone marrow\nAbnormal megakaryocyte proliferation activationRelease cytokines (e.g., TGF-β, PDGF, VEGF) stimulate fibroblast proliferation collagen deposition bone marrowProgressive bone marrow fibrosis impairs normal hematopoiesis, leading :\nCytopenias (anemia, thrombocytopenia)\nExtramedullary hematopoiesis (blood cell production spleen, liver, organs)\nCytopenias (anemia, thrombocytopenia)Extramedullary hematopoiesis (blood cell production spleen, liver, organs)Clinical Features:\nAnemia: Fatigue, weakness\nSplenomegaly: Abdominal discomfort, early satiety\nConstitutional Symptoms: Fatigue, weight loss, night sweats, fever\nBone Pain\nThrombosis Bleeding: Due abnormal platelet function\nAnemia: Fatigue, weaknessSplenomegaly: Abdominal discomfort, early satietyConstitutional Symptoms: Fatigue, weight loss, night sweats, feverBone PainThrombosis Bleeding: Due abnormal platelet functionLaboratory Findings:\nCBC:\nAnemia (usually present)\nThrombocytopenia thrombocytosis (variable)\nLeukoerythroblastosis: Presence immature granulocytes nucleated RBCs peripheral blood\n\nPeripheral Blood Smear:\nTeardrop cells (dacrocytes): Abnormally shaped RBCs characteristic PMF\nLeukoerythroblastosis: Immature granulocytes nucleated RBCs\nLarge, abnormal platelets\n\nBone Marrow Aspiration Biopsy:\nHypercellular marrow (early stages)\nIncreased megakaryocytes abnormal morphology\nReticulin /collagen fibrosis (graded scale 0-3)\n\nMolecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\n\nCBC:\nAnemia (usually present)\nThrombocytopenia thrombocytosis (variable)\nLeukoerythroblastosis: Presence immature granulocytes nucleated RBCs peripheral blood\nAnemia (usually present)Thrombocytopenia thrombocytosis (variable)Leukoerythroblastosis: Presence immature granulocytes nucleated RBCs peripheral bloodPeripheral Blood Smear:\nTeardrop cells (dacrocytes): Abnormally shaped RBCs characteristic PMF\nLeukoerythroblastosis: Immature granulocytes nucleated RBCs\nLarge, abnormal platelets\nTeardrop cells (dacrocytes): Abnormally shaped RBCs characteristic PMFLeukoerythroblastosis: Immature granulocytes nucleated RBCsLarge, abnormal plateletsBone Marrow Aspiration Biopsy:\nHypercellular marrow (early stages)\nIncreased megakaryocytes abnormal morphology\nReticulin /collagen fibrosis (graded scale 0-3)\nHypercellular marrow (early stages)Increased megakaryocytes abnormal morphologyReticulin /collagen fibrosis (graded scale 0-3)Molecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\nPositive JAK2, CALR, MPL mutation (cases)Treatment:\nSupportive Care:\nTransfusions manage anemia thrombocytopenia\nRuxolitinib: JAK2 inhibitor reduces spleen size, improves constitutional symptoms, may prolong survival\nDanazol thalidomide: May improve anemia thrombocytopenia\nHydroxyurea: manage thrombocytosis leukocytosis\n\nSplenectomy: May considered symptomatic splenomegaly refractory cytopenias, carries significant risks\nHematopoietic Stem Cell Transplantation (HSCT):\npotentially curative option\nReserved younger patients high-risk disease\n\nSupportive Care:\nTransfusions manage anemia thrombocytopenia\nRuxolitinib: JAK2 inhibitor reduces spleen size, improves constitutional symptoms, may prolong survival\nDanazol thalidomide: May improve anemia thrombocytopenia\nHydroxyurea: manage thrombocytosis leukocytosis\nTransfusions manage anemia thrombocytopeniaRuxolitinib: JAK2 inhibitor reduces spleen size, improves constitutional symptoms, may prolong survivalDanazol thalidomide: May improve anemia thrombocytopeniaHydroxyurea: manage thrombocytosis leukocytosisSplenectomy: May considered symptomatic splenomegaly refractory cytopenias, carries significant risksHematopoietic Stem Cell Transplantation (HSCT):\npotentially curative option\nReserved younger patients high-risk disease\npotentially curative optionReserved younger patients high-risk disease","code":""},{"path":"myeloproliferative.html","id":"key-terms-28","chapter":"Myeloproliferative","heading":"Key Terms","text":"Myeloproliferative Neoplasm (MPN): clonal hematopoietic stem cell disorder increased production myeloid cellsChronic Myeloid Leukemia (CML): MPN BCR-ABL1 fusion genePolycythemia Vera (PV): MPN increased red blood cell production; often associated JAK2 V617F mutationEssential Thrombocythemia (ET): MPN increased platelet production; associated JAK2, CALR, MPL mutationsPrimary Myelofibrosis (PMF): MPN characterized bone marrow fibrosis extramedullary hematopoiesis; associated JAK2, CALR, MPL mutationsExtramedullary Hematopoiesis: Blood cell production outside bone marrow (e.g., spleen liver)Splenomegaly: Enlargement spleenThrombosis: Formation blood clotsHepatomegaly: Enlargement liverLeukoerythroblastosis: Presence immature granulocytes nucleated RBCs peripheral bloodTeardrop Cells (Dacrocytes): Abnormally shaped RBCs seen primary myelofibrosisHydroxyurea: chemotherapeutic drug used suppress bone marrow proliferationRuxolitinib: JAK2 inhibitor used treat MPNs","code":""},{"path":"lymphoid-neoplasia.html","id":"lymphoid-neoplasia","chapter":"Lymphoid Neoplasia","heading":"Lymphoid Neoplasia","text":"","code":""},{"path":"lymphoid-neoplasia.html","id":"overview-of-lymphoid-neoplasms","chapter":"Lymphoid Neoplasia","heading":"Overview of Lymphoid Neoplasms","text":"Definition: diverse group hematologic malignancies originating lymphocytes (B cells, T cells, NK cells) precursors. cancers involve uncontrolled proliferation abnormal lymphocytes, leading various clinical pathological manifestationsHallmarks:\nClonal Proliferation: disorders arise single, genetically abnormal lymphocyte proliferates excessively\nVariable Differentiation: cells may immature (blasts) mature lymphocytes, depending specific type neoplasm\nDisruption Normal Hematopoiesis: malignant cells often crowd normal blood cells bone marrow lymphoid organs, leading cytopenias (anemia, thrombocytopenia, /neutropenia)\nClonal Proliferation: disorders arise single, genetically abnormal lymphocyte proliferates excessivelyVariable Differentiation: cells may immature (blasts) mature lymphocytes, depending specific type neoplasmDisruption Normal Hematopoiesis: malignant cells often crowd normal blood cells bone marrow lymphoid organs, leading cytopenias (anemia, thrombocytopenia, /neutropenia)Classification:\nWorld Health Organization () classification widely used system\nLymphoid neoplasms broadly classified :\nPrecursor Lymphoid Neoplasms: Involve immature lymphoid cells (lymphoblasts)\nMature Lymphoid Neoplasms: Involve mature B cells, T cells, NK cells\n\nWithin categories, disorders classified based :\nCell Morphology\nImmunophenotype (expression cell surface markers)\nGenetic Abnormalities (cytogenetics molecular genetics)\nClinical Features\n\nWorld Health Organization () classification widely used systemLymphoid neoplasms broadly classified :\nPrecursor Lymphoid Neoplasms: Involve immature lymphoid cells (lymphoblasts)\nMature Lymphoid Neoplasms: Involve mature B cells, T cells, NK cells\nPrecursor Lymphoid Neoplasms: Involve immature lymphoid cells (lymphoblasts)Mature Lymphoid Neoplasms: Involve mature B cells, T cells, NK cellsWithin categories, disorders classified based :\nCell Morphology\nImmunophenotype (expression cell surface markers)\nGenetic Abnormalities (cytogenetics molecular genetics)\nClinical Features\nCell MorphologyImmunophenotype (expression cell surface markers)Genetic Abnormalities (cytogenetics molecular genetics)Clinical FeaturesKey Differentiations:\nLeukemia vs. Lymphoma: distinction often blurred, generally:\nLeukemias primarily involve bone marrow peripheral blood.\nLymphomas primarily involve lymph nodes lymphoid tissues (spleen, thymus, etc.). However, many lymphoid neoplasms can involve bone marrow lymphoid tissues.\n\nAcute vs. Chronic:\nAcute: Aggressive neoplasms rapid proliferation immature cells (blasts).\nChronic: indolent (slow-growing) neoplasms proliferation mature cells.\n\nLeukemia vs. Lymphoma: distinction often blurred, generally:\nLeukemias primarily involve bone marrow peripheral blood.\nLymphomas primarily involve lymph nodes lymphoid tissues (spleen, thymus, etc.). However, many lymphoid neoplasms can involve bone marrow lymphoid tissues.\nLeukemias primarily involve bone marrow peripheral blood.Lymphomas primarily involve lymph nodes lymphoid tissues (spleen, thymus, etc.). However, many lymphoid neoplasms can involve bone marrow lymphoid tissues.Acute vs. Chronic:\nAcute: Aggressive neoplasms rapid proliferation immature cells (blasts).\nChronic: indolent (slow-growing) neoplasms proliferation mature cells.\nAcute: Aggressive neoplasms rapid proliferation immature cells (blasts).Chronic: indolent (slow-growing) neoplasms proliferation mature cells.","code":""},{"path":"lymphoid-neoplasia.html","id":"precursor-lymphoid-neoplasms","chapter":"Lymphoid Neoplasia","heading":"Precursor Lymphoid Neoplasms","text":"involve immature lymphoid cells (lymphoblasts) aggressive malignancies.B-Lymphoblastic Leukemia/Lymphoma (B-/LBL):\nDefinition: neoplasm precursor B cells (B lymphoblasts). primarily involves bone marrow, called acute lymphoblastic leukemia (). primarily involves lymph nodes extramedullary sites, called lymphoblastic lymphoma (LBL)\nDefinition: neoplasm precursor B cells (B lymphoblasts). primarily involves bone marrow, called acute lymphoblastic leukemia (). primarily involves lymph nodes extramedullary sites, called lymphoblastic lymphoma (LBL)T-Lymphoblastic Leukemia/Lymphoma (T-/LBL):\nDefinition: neoplasm precursor T cells (T lymphoblasts). Similar B-/LBL, classified leukemia lymphoma based primary site involvement\nDefinition: neoplasm precursor T cells (T lymphoblasts). Similar B-/LBL, classified leukemia lymphoma based primary site involvementMature Lymphoid Neoplasms {-}neoplasms involve mature B cells, T cells, NK cells generally less aggressive precursor neoplasms.B-Cell Neoplasms\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):\nDefinition: common indolent (slow-growing) neoplasm mature, usually naive B cells. disease primarily involves blood bone marrow, called chronic lymphocytic leukemia (CLL). primarily involves lymph nodes, called small lymphocytic lymphoma (SLL)\n\nDiffuse Large B-Cell Lymphoma (DLBCL):\nDefinition: aggressive lymphoma composed large, transformed B cells\n\nFollicular Lymphoma:\nDefinition: indolent lymphoma characterized follicular (nodular) growth pattern lymph nodes\n\nBurkitt Lymphoma:\nDefinition: highly aggressive B-cell lymphoma characterized rapid proliferation high rate cell turnover\n\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):\nDefinition: common indolent (slow-growing) neoplasm mature, usually naive B cells. disease primarily involves blood bone marrow, called chronic lymphocytic leukemia (CLL). primarily involves lymph nodes, called small lymphocytic lymphoma (SLL)\nDefinition: common indolent (slow-growing) neoplasm mature, usually naive B cells. disease primarily involves blood bone marrow, called chronic lymphocytic leukemia (CLL). primarily involves lymph nodes, called small lymphocytic lymphoma (SLL)Diffuse Large B-Cell Lymphoma (DLBCL):\nDefinition: aggressive lymphoma composed large, transformed B cells\nDefinition: aggressive lymphoma composed large, transformed B cellsFollicular Lymphoma:\nDefinition: indolent lymphoma characterized follicular (nodular) growth pattern lymph nodes\nDefinition: indolent lymphoma characterized follicular (nodular) growth pattern lymph nodesBurkitt Lymphoma:\nDefinition: highly aggressive B-cell lymphoma characterized rapid proliferation high rate cell turnover\nDefinition: highly aggressive B-cell lymphoma characterized rapid proliferation high rate cell turnoverT-Cell NK-Cell Neoplasms\nPeripheral T-Cell Lymphomas (PTCL):\ndiverse group lymphomas derived mature T cells NK cells\n\nAdult T-Cell Leukemia/Lymphoma (ATLL):\nT-cell leukemia/lymphoma caused human T-cell lymphotropic virus type 1 (HTLV-1)\n\nPeripheral T-Cell Lymphomas (PTCL):\ndiverse group lymphomas derived mature T cells NK cells\ndiverse group lymphomas derived mature T cells NK cellsAdult T-Cell Leukemia/Lymphoma (ATLL):\nT-cell leukemia/lymphoma caused human T-cell lymphotropic virus type 1 (HTLV-1)\nT-cell leukemia/lymphoma caused human T-cell lymphotropic virus type 1 (HTLV-1)","code":""},{"path":"lymphoid-neoplasia.html","id":"general-diagnostic-approach-to-lymphoid-neoplasms","chapter":"Lymphoid Neoplasia","heading":"General Diagnostic Approach to Lymphoid Neoplasms","text":"Clinical Evaluation: History, physical exam, symptoms (e.g., lymphadenopathy, B symptoms)Complete Blood Count (CBC) Peripheral Blood Smear: Assess cell counts morphologyLymph Node Biopsy: lymphadenopathy presentBone Marrow Aspiration Biopsy: Assess bone marrow involvementFlow Cytometry: Immunophenotyping identify cell surface markersCytogenetic Analysis: detect chromosomal abnormalitiesMolecular Testing: detect gene mutations fusion genesImaging Studies (CT Scan, PET/CT): stage disease assess organ involvement","code":""},{"path":"lymphoid-neoplasia.html","id":"key-terms-29","chapter":"Lymphoid Neoplasia","heading":"Key Terms","text":"Lymphoid Neoplasm: Malignancy originating lymphocytesAcute Lymphoblastic Leukemia (): Aggressive leukemia lymphoblastsLymphoblastic Lymphoma (LBL): Lymphoma lymphoblastsChronic Lymphocytic Leukemia (CLL): Indolent leukemia mature B cellsSmall Lymphocytic Lymphoma (SLL): Lymphoma mature B cells, similar CLLDiffuse Large B-Cell Lymphoma (DLBCL): Aggressive lymphoma large B cellsFollicular Lymphoma: Indolent lymphoma follicular growth patternBurkitt Lymphoma: Highly aggressive lymphoma MYC translocationPeripheral T-Cell Lymphomas (PTCL): Diverse group lymphomas mature T cells NK cellsAdult T-Cell Leukemia/Lymphoma (ATLL): T-cell leukemia/lymphoma caused HTLV-1Lymphadenopathy: Swollen lymph nodesSplenomegaly: Enlarged spleenImmunophenotyping: Identification cell surface markers using flow cytometryCytogenetic Analysis: study chromosomes abnormalitiesMolecular Testing: Techniques detect gene mutations fusion genes","code":""},{"path":"acute-lymphoid.html","id":"acute-lymphoid","chapter":"Acute Lymphoid","heading":"Acute Lymphoid","text":"","code":""},{"path":"acute-lymphoid.html","id":"overview-of-acute-lymphoblastic-leukemia-all","chapter":"Acute Lymphoid","heading":"Overview of Acute Lymphoblastic Leukemia (ALL)","text":"Definition: aggressive hematologic malignancy characterized rapid proliferation accumulation immature lymphoid cells (lymphoblasts) bone marrow, blood, extramedullary sites. uncontrolled proliferation crowds normal hematopoietic cellsAlso Known : Acute Lymphocytic LeukemiaCell Types Involved: can classified subtypes based cell lineage:\nB-Cell (B-): common type, involving precursor B cells\nT-Cell (T-): Less common type, involving precursor T cells\nB-Cell (B-): common type, involving precursor B cellsT-Cell (T-): Less common type, involving precursor T cellsKey Feature: >20% lymphoblasts bone marrowEpidemiology:\ncommon type childhood leukemia, peak incidence 2 5 years age\nalso occurs adults, less common\ncommon type childhood leukemia, peak incidence 2 5 years ageIt also occurs adults, less commonPrognosis: Varies depending subtype , genetic abnormalities, age, factorsOverall, treated, survival rates generally higher children adults.","code":""},{"path":"acute-lymphoid.html","id":"pathophysiology-5","chapter":"Acute Lymphoid","heading":"Pathophysiology","text":"Genetic Mutations: Acquired genetic mutations lymphoid progenitor cells disrupt normal differentiation proliferation, leading :\nUncontrolled proliferation lymphoblasts\nArrest cell maturation, buildup immature cells\nChromosomal translocations, deletions, genetic abnormalities common\nUncontrolled proliferation lymphoblastsArrest cell maturation, buildup immature cellsChromosomal translocations, deletions, genetic abnormalities commonImpaired Hematopoiesis: Lymphoblasts accumulate bone marrow, crowding normal hematopoietic cells leading :\nAnemia (decreased red blood cells)\nThrombocytopenia (decreased platelets)\nNeutropenia (decreased neutrophils)\nAnemia (decreased red blood cells)Thrombocytopenia (decreased platelets)Neutropenia (decreased neutrophils)Extramedullary Infiltration: Lymphoblasts can infiltrate extramedullary sites, :\nLymph nodes\nSpleen\nLiver\nCentral nervous system (CNS)\nTestes\nLymph nodesSpleenLiverCentral nervous system (CNS)Testes","code":""},{"path":"acute-lymphoid.html","id":"etiology-and-risk-factors-1","chapter":"Acute Lymphoid","heading":"Etiology and Risk Factors","text":"Genetic Factors:\nChromosomal abnormalities:\nt(12;21)(p13.2;q22.1): ETV6-RUNX1 (favorable prognosis, common childhood B-)\nt(9;22)(q34.1;q11.2): BCR-ABL1 (poor prognosis, common adult B-)\nt(4;11)(q21;q23.3): KMT2A (MLL) rearrangement (poor prognosis, common infants)\n\nGene mutations:\nNOTCH1 mutations (common T-)\nTP53 mutations (associated poor prognosis)\n\nChromosomal abnormalities:\nt(12;21)(p13.2;q22.1): ETV6-RUNX1 (favorable prognosis, common childhood B-)\nt(9;22)(q34.1;q11.2): BCR-ABL1 (poor prognosis, common adult B-)\nt(4;11)(q21;q23.3): KMT2A (MLL) rearrangement (poor prognosis, common infants)\nt(12;21)(p13.2;q22.1): ETV6-RUNX1 (favorable prognosis, common childhood B-)t(9;22)(q34.1;q11.2): BCR-ABL1 (poor prognosis, common adult B-)t(4;11)(q21;q23.3): KMT2A (MLL) rearrangement (poor prognosis, common infants)Gene mutations:\nNOTCH1 mutations (common T-)\nTP53 mutations (associated poor prognosis)\nNOTCH1 mutations (common T-)TP53 mutations (associated poor prognosis)Environmental Factors:\nExposure ionizing radiation\nExposure certain chemicals (e.g., benzene)\nPrior chemotherapy radiation therapy (therapy-related )\nExposure ionizing radiationExposure certain chemicals (e.g., benzene)Prior chemotherapy radiation therapy (therapy-related )Genetic Syndromes:\nsyndrome (increased risk B-)\nNeurofibromatosis type 1\nFanconi anemia\nsyndrome (increased risk B-)Neurofibromatosis type 1Fanconi anemiaAge:\nPeak incidence childhood (2-5 years)\nIncidence increases age 50\nPeak incidence childhood (2-5 years)Incidence increases age 50","code":""},{"path":"acute-lymphoid.html","id":"classification","chapter":"Acute Lymphoid","heading":"Classification","text":"Classification:\nB-Lymphoblastic Leukemia/Lymphoma, Otherwise Specified (B-/LBL, NOS):\nB-cases meet criteria subtypes\nClassified based morphology, immunophenotype, cytogenetic abnormalities\n\nB-Lymphoblastic Leukemia/Lymphoma Recurrent Genetic Abnormalities:\nB-t(9;22)(q34.1;q11.2); BCR-ABL1 (Philadelphia chromosome-positive )\nB-t(v;11q23.3); KMT2A rearranged\nB-t(12;21)(p13.2;q22.1); ETV6-RUNX1\nB-t(1;19)(q23;p13.3); TCF3-PBX1\nB-hyperdiploidy (50 chromosomes)\nB-hypodiploidy (less 46 chromosomes)\n\nT-Lymphoblastic Leukemia/Lymphoma:\nT-/LBL cases involving precursor T cells\nOften presents mediastinal mass adolescents young adults\n\nB-Lymphoblastic Leukemia/Lymphoma, Otherwise Specified (B-/LBL, NOS):\nB-cases meet criteria subtypes\nClassified based morphology, immunophenotype, cytogenetic abnormalities\nB-cases meet criteria subtypesClassified based morphology, immunophenotype, cytogenetic abnormalitiesB-Lymphoblastic Leukemia/Lymphoma Recurrent Genetic Abnormalities:\nB-t(9;22)(q34.1;q11.2); BCR-ABL1 (Philadelphia chromosome-positive )\nB-t(v;11q23.3); KMT2A rearranged\nB-t(12;21)(p13.2;q22.1); ETV6-RUNX1\nB-t(1;19)(q23;p13.3); TCF3-PBX1\nB-hyperdiploidy (50 chromosomes)\nB-hypodiploidy (less 46 chromosomes)\nB-t(9;22)(q34.1;q11.2); BCR-ABL1 (Philadelphia chromosome-positive )B-t(v;11q23.3); KMT2A rearrangedB-t(12;21)(p13.2;q22.1); ETV6-RUNX1B-t(1;19)(q23;p13.3); TCF3-PBX1B-hyperdiploidy (50 chromosomes)B-hypodiploidy (less 46 chromosomes)T-Lymphoblastic Leukemia/Lymphoma:\nT-/LBL cases involving precursor T cells\nOften presents mediastinal mass adolescents young adults\nT-/LBL cases involving precursor T cellsOften presents mediastinal mass adolescents young adults","code":""},{"path":"acute-lymphoid.html","id":"clinical-manifestations-6","chapter":"Acute Lymphoid","heading":"Clinical Manifestations","text":"Symptoms Bone Marrow Failure:\nFatigue, weakness, pallor (anemia)\nBleeding (e.g., nosebleeds, gum bleeding, petechiae, ecchymoses) - thrombocytopenia\nInfections (e.g., fever, pneumonia) - neutropenia\nFatigue, weakness, pallor (anemia)Bleeding (e.g., nosebleeds, gum bleeding, petechiae, ecchymoses) - thrombocytopeniaInfections (e.g., fever, pneumonia) - neutropeniaSymptoms Extramedullary Involvement:\nLymphadenopathy (swollen lymph nodes)\nSplenomegaly (enlarged spleen)\nHepatomegaly (enlarged liver)\nMediastinal mass (especially T-, causing cough, shortness breath, superior vena cava syndrome)\nCentral Nervous System (CNS) Involvement:\nHeadache\nVomiting\nSeizures\nCranial nerve palsies\n\nTesticular Involvement:\nPainless testicular swelling (common males)\n\nLymphadenopathy (swollen lymph nodes)Splenomegaly (enlarged spleen)Hepatomegaly (enlarged liver)Mediastinal mass (especially T-, causing cough, shortness breath, superior vena cava syndrome)Central Nervous System (CNS) Involvement:\nHeadache\nVomiting\nSeizures\nCranial nerve palsies\nHeadacheVomitingSeizuresCranial nerve palsiesTesticular Involvement:\nPainless testicular swelling (common males)\nPainless testicular swelling (common males)Symptoms:\nBone pain (due bone marrow infiltration)\nWeight loss\nNight sweats\nBone pain (due bone marrow infiltration)Weight lossNight sweats","code":""},{"path":"acute-lymphoid.html","id":"laboratory-findings-5","chapter":"Acute Lymphoid","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nWhite Blood Cell (WBC) Count: Variable (can low, normal, high)\nHemoglobin (HGB): Decreased (anemia)\nHematocrit (HCT): Decreased\nPlatelet Count: Decreased (thrombocytopenia)\nNeutrophil Count: Decreased (neutropenia)\nPresence Lymphoblasts Peripheral Blood:\nLymphoblasts immature lymphoid cells :\nHigh nucleus--cytoplasm (N:C) ratio\nFine chromatin\nOne distinct nucleoli\nScant cytoplasm\n\n\nWhite Blood Cell (WBC) Count: Variable (can low, normal, high)Hemoglobin (HGB): Decreased (anemia)Hematocrit (HCT): DecreasedPlatelet Count: Decreased (thrombocytopenia)Neutrophil Count: Decreased (neutropenia)Presence Lymphoblasts Peripheral Blood:\nLymphoblasts immature lymphoid cells :\nHigh nucleus--cytoplasm (N:C) ratio\nFine chromatin\nOne distinct nucleoli\nScant cytoplasm\n\nLymphoblasts immature lymphoid cells :\nHigh nucleus--cytoplasm (N:C) ratio\nFine chromatin\nOne distinct nucleoli\nScant cytoplasm\nHigh nucleus--cytoplasm (N:C) ratioFine chromatinOne distinct nucleoliScant cytoplasmPeripheral Blood Smear:\nLymphoblasts: Predominant cell type\nCytopenias: Decreased mature RBCs, WBCs, platelets\nLymphoblasts: Predominant cell typeCytopenias: Decreased mature RBCs, WBCs, plateletsBone Marrow Aspiration Biopsy:\nHypercellular Bone Marrow: Replaced >20% lymphoblasts\nSpecial Stains:\nTerminal deoxynucleotidyl transferase (TdT): Positive lymphoblasts\nMyeloperoxidase (MPO): Negative lymphoblasts\n\nFlow Cytometry Immunophenotyping:\nEssential classifying subtypes\nIdentifies cell surface markers lymphoblasts\nB-Markers: CD19, CD22, CD10, CD34, TdT\nT-Markers: CD2, CD3, CD5, CD7, CD1a, TdT\n\n\nHypercellular Bone Marrow: Replaced >20% lymphoblastsSpecial Stains:\nTerminal deoxynucleotidyl transferase (TdT): Positive lymphoblasts\nMyeloperoxidase (MPO): Negative lymphoblasts\nTerminal deoxynucleotidyl transferase (TdT): Positive lymphoblastsMyeloperoxidase (MPO): Negative lymphoblastsFlow Cytometry Immunophenotyping:\nEssential classifying subtypes\nIdentifies cell surface markers lymphoblasts\nB-Markers: CD19, CD22, CD10, CD34, TdT\nT-Markers: CD2, CD3, CD5, CD7, CD1a, TdT\n\nEssential classifying subtypesIdentifies cell surface markers lymphoblasts\nB-Markers: CD19, CD22, CD10, CD34, TdT\nT-Markers: CD2, CD3, CD5, CD7, CD1a, TdT\nB-Markers: CD19, CD22, CD10, CD34, TdTT-Markers: CD2, CD3, CD5, CD7, CD1a, TdTCytogenetic Analysis:\nIdentifies Chromosomal Abnormalities (e.g., translocations, deletions, inversions)\nt(9;22)(q34.1;q11.2): BCR-ABL1 (Philadelphia chromosome)\nt(12;21)(p13.2;q22.1): ETV6-RUNX1\nt(4;11)(q21;q23.3): KMT2A (MLL) rearrangement\n\nIdentifies Chromosomal Abnormalities (e.g., translocations, deletions, inversions)\nt(9;22)(q34.1;q11.2): BCR-ABL1 (Philadelphia chromosome)\nt(12;21)(p13.2;q22.1): ETV6-RUNX1\nt(4;11)(q21;q23.3): KMT2A (MLL) rearrangement\nt(9;22)(q34.1;q11.2): BCR-ABL1 (Philadelphia chromosome)t(12;21)(p13.2;q22.1): ETV6-RUNX1t(4;11)(q21;q23.3): KMT2A (MLL) rearrangementMolecular Testing:\nDetects Gene Mutations Fusion Genes\nBCR-ABL1 fusion gene (Ph+ )\nFLT3 mutations\nNPM1 mutations\nTP53 mutations\nNOTCH1 mutations (T-)\n\nDetects Gene Mutations Fusion Genes\nBCR-ABL1 fusion gene (Ph+ )\nFLT3 mutations\nNPM1 mutations\nTP53 mutations\nNOTCH1 mutations (T-)\nBCR-ABL1 fusion gene (Ph+ )FLT3 mutationsNPM1 mutationsTP53 mutationsNOTCH1 mutations (T-)Lumbar Puncture:\nAssess Central Nervous System (CNS) Involvement\nCerebrospinal Fluid (CSF) Examination:\nCytology: detect lymphoblasts CSF\nProtein Glucose Levels: May abnormal\n\nAssess Central Nervous System (CNS) InvolvementCerebrospinal Fluid (CSF) Examination:\nCytology: detect lymphoblasts CSF\nProtein Glucose Levels: May abnormal\nCytology: detect lymphoblasts CSFProtein Glucose Levels: May abnormal","code":""},{"path":"acute-lymphoid.html","id":"treatment-1","chapter":"Acute Lymphoid","heading":"Treatment","text":"Treatment Complex Multi-Phased:\nInduction Therapy:\nIntensive chemotherapy achieve complete remission (eradication blasts bone marrow)\nCommon agents: Vincristine, prednisone, daunorubicin, asparaginase, cyclophosphamide\n\nConsolidation Therapy (Post-Remission Therapy):\neliminate remaining leukemic cells prevent relapse\nOptions include:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy patients high-risk \n\n\n\nMaintenance Therapy:\nProlonged, lower-intensity chemotherapy maintain remission\nTypically lasts 2-3 years\n\nCentral Nervous System (CNS) Prophylaxis:\nprevent CNS relapse\nIntrathecal chemotherapy (methotrexate cytarabine)\nCranial irradiation (cases)\n\nTreatment Complex Multi-Phased:Induction Therapy:\nIntensive chemotherapy achieve complete remission (eradication blasts bone marrow)\nCommon agents: Vincristine, prednisone, daunorubicin, asparaginase, cyclophosphamide\nIntensive chemotherapy achieve complete remission (eradication blasts bone marrow)Common agents: Vincristine, prednisone, daunorubicin, asparaginase, cyclophosphamideConsolidation Therapy (Post-Remission Therapy):\neliminate remaining leukemic cells prevent relapse\nOptions include:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy patients high-risk \n\n\neliminate remaining leukemic cells prevent relapseOptions include:\nChemotherapy\nHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy patients high-risk \n\nChemotherapyHematopoietic Stem Cell Transplantation (HSCT):\nAllogeneic HSCT (matched donor) preferred consolidation therapy patients high-risk \nAllogeneic HSCT (matched donor) preferred consolidation therapy patients high-risk ALLMaintenance Therapy:\nProlonged, lower-intensity chemotherapy maintain remission\nTypically lasts 2-3 years\nProlonged, lower-intensity chemotherapy maintain remissionTypically lasts 2-3 yearsCentral Nervous System (CNS) Prophylaxis:\nprevent CNS relapse\nIntrathecal chemotherapy (methotrexate cytarabine)\nCranial irradiation (cases)\nprevent CNS relapseIntrathecal chemotherapy (methotrexate cytarabine)Cranial irradiation (cases)Targeted Therapies:\nTyrosine Kinase Inhibitors (TKIs):\nUsed Philadelphia chromosome-positive (Ph+) target BCR-ABL1 tyrosine kinase activity\nImatinib, dasatinib, nilotinib\n\nMonoclonal Antibodies:\nBlinatumomab: bispecific T-cell engager (BiTE) antibody binds CD19 B cells CD3 T cells, bringing together kill B cells\nInotuzumab Ozogamicin: anti-CD22 antibody conjugated calicheamicin, cytotoxic agent\n\nTargeted Therapies:Tyrosine Kinase Inhibitors (TKIs):\nUsed Philadelphia chromosome-positive (Ph+) target BCR-ABL1 tyrosine kinase activity\nImatinib, dasatinib, nilotinib\nUsed Philadelphia chromosome-positive (Ph+) target BCR-ABL1 tyrosine kinase activityImatinib, dasatinib, nilotinibMonoclonal Antibodies:\nBlinatumomab: bispecific T-cell engager (BiTE) antibody binds CD19 B cells CD3 T cells, bringing together kill B cells\nInotuzumab Ozogamicin: anti-CD22 antibody conjugated calicheamicin, cytotoxic agent\nBlinatumomab: bispecific T-cell engager (BiTE) antibody binds CD19 B cells CD3 T cells, bringing together kill B cellsInotuzumab Ozogamicin: anti-CD22 antibody conjugated calicheamicin, cytotoxic agentSupportive Care:\nTransfusions (RBCs platelets) manage cytopenias\nAntibiotics antifungals treat infections\nGrowth factors (e.g., G-CSF) stimulate neutrophil production\nManagement tumor lysis syndrome (TLS): metabolic complication caused rapid breakdown leukemic cells\nSupportive Care:Transfusions (RBCs platelets) manage cytopeniasAntibiotics antifungals treat infectionsGrowth factors (e.g., G-CSF) stimulate neutrophil productionManagement tumor lysis syndrome (TLS): metabolic complication caused rapid breakdown leukemic cells","code":""},{"path":"acute-lymphoid.html","id":"prognosis-1","chapter":"Acute Lymphoid","heading":"Prognosis","text":"Factors Influencing Prognosis:\nCytogenetic Abnormalities: Certain chromosomal abnormalities associated favorable unfavorable outcomes\nAge: Younger patients generally better outcomes older patients\nWBC Count Diagnosis: High WBC count associated poorer prognosis\nResponse Induction Chemotherapy: Achievement minimal residual disease (MRD) negativity key prognostic factor\nMinimal Residual Disease (MRD):\npresence small number leukemic cells remain treatment\nMeasured flow cytometry PCR\nMRD negativity associated improved outcomes\n\nCytogenetic Abnormalities: Certain chromosomal abnormalities associated favorable unfavorable outcomesAge: Younger patients generally better outcomes older patientsWBC Count Diagnosis: High WBC count associated poorer prognosisResponse Induction Chemotherapy: Achievement minimal residual disease (MRD) negativity key prognostic factorMinimal Residual Disease (MRD):\npresence small number leukemic cells remain treatment\nMeasured flow cytometry PCR\nMRD negativity associated improved outcomes\npresence small number leukemic cells remain treatmentMeasured flow cytometry PCRMRD negativity associated improved outcomesRisk Stratification:\nPatients classified risk groups (standard, high, high risk) based prognostic factors\nRisk stratification guides treatment decisions helps predict likelihood achieving long-term remission\nPatients classified risk groups (standard, high, high risk) based prognostic factorsRisk stratification guides treatment decisions helps predict likelihood achieving long-term remission","code":""},{"path":"acute-lymphoid.html","id":"key-laboratory-findings-6","chapter":"Acute Lymphoid","heading":"Key Laboratory Findings","text":"CBC:\nAnemia\nThrombocytopenia\nNeutropenia\nPresence lymphoblasts peripheral blood\nAnemiaThrombocytopeniaNeutropeniaPresence lymphoblasts peripheral bloodPeripheral Blood Smear:\nLymphoblasts\nLymphoblastsBone Marrow Examination:\nHypercellular marrow >20% lymphoblasts\nHypercellular marrow >20% lymphoblastsFlow Cytometry Immunophenotyping:\nIdentifies cell surface markers lymphoblasts\nIdentifies cell surface markers lymphoblastsCytogenetic Analysis:\nDetects chromosomal abnormalities\nDetects chromosomal abnormalitiesMolecular Testing:\nDetects gene mutations fusion genes\nDetects gene mutations fusion genes","code":""},{"path":"acute-lymphoid.html","id":"key-terms-30","chapter":"Acute Lymphoid","heading":"Key Terms","text":"Acute Lymphoblastic Leukemia (): aggressive leukemia characterized >20% lymphoblasts bone marrowLymphoblast: Immature lymphoid cellCytopenia: Deficiency blood cells (e.g., anemia, neutropenia, thrombocytopenia)Complete Remission (CR): Eradication blasts bone marrow restoration normal hematopoiesisInduction Chemotherapy: Initial intensive chemotherapy achieve remissionConsolidation Therapy: Treatment prevent relapse achieving remissionMaintenance Therapy: Prolonged, lower-intensity chemotherapy maintain remissionHematopoietic Stem Cell Transplantation (HSCT): Procedure replace damaged bone marrow healthy stem cellsTyrosine Kinase Inhibitor (TKI): drug inhibits tyrosine kinase activityMinimal Residual Disease (MRD): small number leukemic cells remaining treatment","code":""},{"path":"chronic-b-cell.html","id":"chronic-b-cell","chapter":"Chronic B-Cell","heading":"Chronic B-Cell","text":"","code":""},{"path":"chronic-b-cell.html","id":"overview-of-chronicmature-b-cell-leukemialymphoma","chapter":"Chronic B-Cell","heading":"Overview of Chronic/Mature B-Cell Leukemia/Lymphoma","text":"Definition: diverse group lymphoid neoplasms arising mature B lymphocytes. generally indolent (slow-growing) malignancies, though can aggressiveKey Features:\nClonal Proliferation: Proliferation single, abnormal clone B cells\nMature B-Cell Phenotype: Cells express markers mature B cells (e.g., CD19, CD20)\nVariable Morphology: Cells may variable size, shape, nuclear features\nLymph Node Bone Marrow Involvement: Often involve lymph nodes, spleen, liver, bone marrow\nClonal Proliferation: Proliferation single, abnormal clone B cellsMature B-Cell Phenotype: Cells express markers mature B cells (e.g., CD19, CD20)Variable Morphology: Cells may variable size, shape, nuclear featuresLymph Node Bone Marrow Involvement: Often involve lymph nodes, spleen, liver, bone marrowClassification: World Health Organization () classification used categorize disorders based clinical, morphological, immunophenotypic, genetic featuresCommon Disorders Included:\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)\nProlymphocytic Leukemia (PLL)\nHairy Cell Leukemia (HCL)\nBurkitt Lymphoma\nWaldenström Macroglobulinemia (WM)\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Prolymphocytic Leukemia (PLL)Hairy Cell Leukemia (HCL)Burkitt LymphomaWaldenström Macroglobulinemia (WM)","code":""},{"path":"chronic-b-cell.html","id":"chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll","chapter":"Chronic B-Cell","heading":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","text":"Definition: CLL SLL considered disease, differing primarily site involvement. CLL primarily involves blood bone marrow, SLL primarily involves lymph nodesDiagnostic Criteria:\nPeripheral Blood:\nSustained absolute lymphocytosis (≥5.0 x 10^9/L) characteristic immunophenotype\nSmudge cells often present peripheral blood smear\n\nBone Marrow (Usually Required Diagnosis):\nLymphocytic infiltration\n\nImmunophenotype (Flow Cytometry):\nCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-\n\nPeripheral Blood:\nSustained absolute lymphocytosis (≥5.0 x 10^9/L) characteristic immunophenotype\nSmudge cells often present peripheral blood smear\nSustained absolute lymphocytosis (≥5.0 x 10^9/L) characteristic immunophenotypeSmudge cells often present peripheral blood smearBone Marrow (Usually Required Diagnosis):\nLymphocytic infiltration\nLymphocytic infiltrationImmunophenotype (Flow Cytometry):\nCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-\nCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-Pathophysiology:\nClonal proliferation mature, usually naive B cells express CD5 (T-cell marker)\nCells accumulate bone marrow, lymph nodes, spleen, blood\nAbnormal B cells relatively immunocompetent, leading increased susceptibility infections\nClonal proliferation mature, usually naive B cells express CD5 (T-cell marker)Cells accumulate bone marrow, lymph nodes, spleen, bloodAbnormal B cells relatively immunocompetent, leading increased susceptibility infectionsClinical Features:\nOften asymptomatic diagnosis\nLymphadenopathy (swollen lymph nodes)\nSplenomegaly (enlarged spleen)\nFatigue\nWeight loss\nNight sweats\nIncreased susceptibility infections\nOften asymptomatic diagnosisLymphadenopathy (swollen lymph nodes)Splenomegaly (enlarged spleen)FatigueWeight lossNight sweatsIncreased susceptibility infectionsLaboratory Findings:\nCBC:\nLymphocytosis (often marked, >20 x 10^9/L)\nAnemia (advanced stages)\nThrombocytopenia (advanced stages)\n\nPeripheral Blood Smear:\nSmall, mature lymphocytes condensed chromatin\nSmudge cells: Fragile lymphocytes rupture smear preparation\n\nFlow Cytometry Immunophenotyping:\nConfirms diagnosis differentiates CLL lymphoproliferative disorders\nCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-\n\nCytogenetic Analysis:\nUsed assess prognosis\nCommon abnormalities: del(13q14), trisomy 12, del(11q22.3), del(17p13.1)\n\nCBC:\nLymphocytosis (often marked, >20 x 10^9/L)\nAnemia (advanced stages)\nThrombocytopenia (advanced stages)\nLymphocytosis (often marked, >20 x 10^9/L)Anemia (advanced stages)Thrombocytopenia (advanced stages)Peripheral Blood Smear:\nSmall, mature lymphocytes condensed chromatin\nSmudge cells: Fragile lymphocytes rupture smear preparation\nSmall, mature lymphocytes condensed chromatinSmudge cells: Fragile lymphocytes rupture smear preparationFlow Cytometry Immunophenotyping:\nConfirms diagnosis differentiates CLL lymphoproliferative disorders\nCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-\nConfirms diagnosis differentiates CLL lymphoproliferative disordersCD5+, CD19+, CD20 (dim), CD23+, sIg (weak), CD10-Cytogenetic Analysis:\nUsed assess prognosis\nCommon abnormalities: del(13q14), trisomy 12, del(11q22.3), del(17p13.1)\nUsed assess prognosisCommon abnormalities: del(13q14), trisomy 12, del(11q22.3), del(17p13.1)Staging:\nRai Staging System (CLL): Based presence extent lymphadenopathy, splenomegaly, hepatomegaly, anemia, thrombocytopenia\nBinet Staging System (CLL): Similar Rai staging, based number involved lymphoid areas\nRai Staging System (CLL): Based presence extent lymphadenopathy, splenomegaly, hepatomegaly, anemia, thrombocytopeniaBinet Staging System (CLL): Similar Rai staging, based number involved lymphoid areasPrognosis:\nVariable; patients indolent course, others aggressive disease\nPrognostic factors: Stage, cytogenetic abnormalities, immunoglobulin heavy chain variable region (IGHV) mutation status\nVariable; patients indolent course, others aggressive diseasePrognostic factors: Stage, cytogenetic abnormalities, immunoglobulin heavy chain variable region (IGHV) mutation statusTreatment:\nWatch Wait: Many patients early-stage CLL require immediate treatment\nChemoimmunotherapy:\nCombination chemotherapy drugs (e.g., fludarabine, cyclophosphamide) monoclonal antibodies (e.g., rituximab, obinutuzumab)\n\nTargeted Therapies:\nBTK Inhibitors: Ibrutinib, acalabrutinib\nInhibit Bruton’s tyrosine kinase (BTK), key signaling molecule B-cell receptor pathway\n\nBCL-2 Inhibitors: Venetoclax\nInhibits BCL-2, anti-apoptotic protein\n\nPI3K Inhibitors:\nCopanlisib, duvelisib\n\n\nCAR T-Cell Therapy:\nChimeric antigen receptor (CAR) T-cell therapy: Genetically engineered T cells target CD19 B cells\n\nWatch Wait: Many patients early-stage CLL require immediate treatmentChemoimmunotherapy:\nCombination chemotherapy drugs (e.g., fludarabine, cyclophosphamide) monoclonal antibodies (e.g., rituximab, obinutuzumab)\nCombination chemotherapy drugs (e.g., fludarabine, cyclophosphamide) monoclonal antibodies (e.g., rituximab, obinutuzumab)Targeted Therapies:\nBTK Inhibitors: Ibrutinib, acalabrutinib\nInhibit Bruton’s tyrosine kinase (BTK), key signaling molecule B-cell receptor pathway\n\nBCL-2 Inhibitors: Venetoclax\nInhibits BCL-2, anti-apoptotic protein\n\nPI3K Inhibitors:\nCopanlisib, duvelisib\n\nBTK Inhibitors: Ibrutinib, acalabrutinib\nInhibit Bruton’s tyrosine kinase (BTK), key signaling molecule B-cell receptor pathway\nInhibit Bruton’s tyrosine kinase (BTK), key signaling molecule B-cell receptor pathwayBCL-2 Inhibitors: Venetoclax\nInhibits BCL-2, anti-apoptotic protein\nInhibits BCL-2, anti-apoptotic proteinPI3K Inhibitors:\nCopanlisib, duvelisib\nCopanlisib, duvelisibCAR T-Cell Therapy:\nChimeric antigen receptor (CAR) T-cell therapy: Genetically engineered T cells target CD19 B cells\nChimeric antigen receptor (CAR) T-cell therapy: Genetically engineered T cells target CD19 B cells","code":""},{"path":"chronic-b-cell.html","id":"prolymphocytic-leukemia-pll","chapter":"Chronic B-Cell","heading":"Prolymphocytic Leukemia (PLL)","text":"Definition: rare, aggressive B-cell T-cell neoplasm characterized high white blood cell count predominance prolymphocytes peripheral bloodTypes:\nB-PLL: common; derived mature B cells\nT-PLL: Less common; derived mature T cells\nB-PLL: common; derived mature B cellsT-PLL: Less common; derived mature T cellsPathophysiology:\nClonal proliferation prolymphocytes bone marrow, spleen, peripheral blood\nClonal proliferation prolymphocytes bone marrow, spleen, peripheral bloodClinical Features:\nMarked splenomegaly\nLymphadenopathy (less common CLL)\nHigh WBC count\nFatigue\nB symptoms (fever, weight loss, night sweats)\nMarked splenomegalyLymphadenopathy (less common CLL)High WBC countFatigueB symptoms (fever, weight loss, night sweats)Laboratory Findings:\nCBC:\nElevated WBC count (often > 100 x 10^9/L)\nAnemia\nThrombocytopenia\n\nPeripheral Blood Smear:\nPredominance prolymphocytes (typically >55% WBCs)\nProlymphocytes: Medium large lymphocytes prominent nucleolus moderately condensed chromatin\n\nSmudge cells uncommon\n\nImmunophenotyping:\nB-PLL: CD5-, CD19+, CD20+, CD22+, CD23 (variable), FMC7+, sIg (bright)\nT-PLL: CD3+, CD4+ CD8+, CD7+, CD5 (variable), CD26-\n\nCytogenetic Analysis:\nCommon abnormalities: t(11;14)(q13;q32) B-PLL; inv(14)(q11q32) t(14;14)(q11;q32) T-PLL\n\nCBC:\nElevated WBC count (often > 100 x 10^9/L)\nAnemia\nThrombocytopenia\nElevated WBC count (often > 100 x 10^9/L)AnemiaThrombocytopeniaPeripheral Blood Smear:\nPredominance prolymphocytes (typically >55% WBCs)\nProlymphocytes: Medium large lymphocytes prominent nucleolus moderately condensed chromatin\n\nSmudge cells uncommon\nPredominance prolymphocytes (typically >55% WBCs)\nProlymphocytes: Medium large lymphocytes prominent nucleolus moderately condensed chromatin\nProlymphocytes: Medium large lymphocytes prominent nucleolus moderately condensed chromatinSmudge cells uncommonImmunophenotyping:\nB-PLL: CD5-, CD19+, CD20+, CD22+, CD23 (variable), FMC7+, sIg (bright)\nT-PLL: CD3+, CD4+ CD8+, CD7+, CD5 (variable), CD26-\nB-PLL: CD5-, CD19+, CD20+, CD22+, CD23 (variable), FMC7+, sIg (bright)T-PLL: CD3+, CD4+ CD8+, CD7+, CD5 (variable), CD26-Cytogenetic Analysis:\nCommon abnormalities: t(11;14)(q13;q32) B-PLL; inv(14)(q11q32) t(14;14)(q11;q32) T-PLL\nCommon abnormalities: t(11;14)(q13;q32) B-PLL; inv(14)(q11q32) t(14;14)(q11;q32) T-PLLTreatment:\nChemoimmunotherapy:\nAlemtuzumab (anti-CD52 monoclonal antibody) combination chemotherapy\n\nTargeted Therapies:\nBTK inhibitors (e.g., ibrutinib)\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option\n\nChemoimmunotherapy:\nAlemtuzumab (anti-CD52 monoclonal antibody) combination chemotherapy\nAlemtuzumab (anti-CD52 monoclonal antibody) combination chemotherapyTargeted Therapies:\nBTK inhibitors (e.g., ibrutinib)\nBTK inhibitors (e.g., ibrutinib)Hematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option\nPotentially curative option","code":""},{"path":"chronic-b-cell.html","id":"hairy-cell-leukemia-hcl","chapter":"Chronic B-Cell","heading":"Hairy Cell Leukemia (HCL)","text":"Definition: rare, indolent B-cell neoplasm characterized infiltration bone marrow, spleen, liver small lymphocytes “hairy” cytoplasmic projectionsPathophysiology:\nClonal proliferation mature B cells distinct immunophenotype\nAlmost cases BRAF V600E mutation\nCells infiltrate bone marrow spleen, leading cytopenias splenomegaly\nClonal proliferation mature B cells distinct immunophenotypeAlmost cases BRAF V600E mutationCells infiltrate bone marrow spleen, leading cytopenias splenomegalyClinical Features:\nSplenomegaly (often massive)\nPancytopenia (anemia, thrombocytopenia, neutropenia)\nFatigue\nInfections\nSplenomegaly (often massive)Pancytopenia (anemia, thrombocytopenia, neutropenia)FatigueInfectionsLaboratory Findings:\nCBC:\nPancytopenia (variable severity)\nMonocytopenia (almost always present)\n\nPeripheral Blood Smear:\nHairy cells: Small lymphocytes irregular cytoplasmic projections (“hairy” appearance)\n\nBone Marrow Aspiration Biopsy:\nInfiltration bone marrow hairy cells\n“Fried egg” appearance hairy cells biopsy\n\nImmunophenotyping:\nCD19+, CD20+, CD22+, CD11c+, CD25+, CD103+\nAnnexin A1+\n\nMolecular Testing:\nBRAF V600E mutation\n\nCBC:\nPancytopenia (variable severity)\nMonocytopenia (almost always present)\nPancytopenia (variable severity)Monocytopenia (almost always present)Peripheral Blood Smear:\nHairy cells: Small lymphocytes irregular cytoplasmic projections (“hairy” appearance)\nHairy cells: Small lymphocytes irregular cytoplasmic projections (“hairy” appearance)Bone Marrow Aspiration Biopsy:\nInfiltration bone marrow hairy cells\n“Fried egg” appearance hairy cells biopsy\nInfiltration bone marrow hairy cells“Fried egg” appearance hairy cells biopsyImmunophenotyping:\nCD19+, CD20+, CD22+, CD11c+, CD25+, CD103+\nAnnexin A1+\nCD19+, CD20+, CD22+, CD11c+, CD25+, CD103+Annexin A1+Molecular Testing:\nBRAF V600E mutation\nBRAF V600E mutationTreatment:\nPurine Analogs:\nCladribine (2-CdA) pentostatin\nHighly effective inducing durable remissions\n\nRituximab (anti-CD20 monoclonal antibody):\nMay used single agent combination purine analogs\n\nSplenectomy:\nMay considered patients symptomatic splenomegaly cytopenias respond treatments\n\nPurine Analogs:\nCladribine (2-CdA) pentostatin\nHighly effective inducing durable remissions\nCladribine (2-CdA) pentostatinHighly effective inducing durable remissionsRituximab (anti-CD20 monoclonal antibody):\nMay used single agent combination purine analogs\nMay used single agent combination purine analogsSplenectomy:\nMay considered patients symptomatic splenomegaly cytopenias respond treatments\nMay considered patients symptomatic splenomegaly cytopenias respond treatments","code":""},{"path":"chronic-b-cell.html","id":"burkitt-lymphoma","chapter":"Chronic B-Cell","heading":"Burkitt Lymphoma","text":"Definition: highly aggressive B-cell lymphoma characterized rapid proliferation high rate cell turnoverGenetic Abnormality: Translocation involving MYC gene chromosome 8 (typically t(8;14)(q24;q32)), leading overexpression MYC, transcription factor promotes cell growth proliferationTypes:\nEndemic Burkitt Lymphoma: Associated Epstein-Barr virus (EBV) infection; common Africa\nSporadic Burkitt Lymphoma: associated EBV; occurs worldwide\nImmunodeficiency-Associated Burkitt Lymphoma: Occurs individuals HIV/AIDS immunodeficiency states\nEndemic Burkitt Lymphoma: Associated Epstein-Barr virus (EBV) infection; common AfricaSporadic Burkitt Lymphoma: associated EBV; occurs worldwideImmunodeficiency-Associated Burkitt Lymphoma: Occurs individuals HIV/AIDS immunodeficiency statesClinical Features:\nRapidly growing tumor mass, often involving jaw, abdomen, extranodal sites\nB symptoms (fever, weight loss, night sweats)\nMay present bowel obstruction, abdominal pain, symptoms depending location tumor\nRapidly growing tumor mass, often involving jaw, abdomen, extranodal sitesB symptoms (fever, weight loss, night sweats)May present bowel obstruction, abdominal pain, symptoms depending location tumorLaboratory Findings:\nCBC:\nMay show leukocytosis, anemia, thrombocytopenia\n\nPeripheral Blood Smear:\nMay show “starry sky” pattern due numerous macrophages engulfing apoptotic cells\n\nBone Marrow Aspiration Biopsy:\nInfiltration bone marrow Burkitt lymphoma cells\n\nFlow Cytometry Immunophenotyping:\nCD19+, CD20+, CD10+, BCL6+, Ki-67 (proliferation marker) high (approaching 100%)\nCD5-, CD23-\n\nCytogenetic Analysis:\nt(8;14)(q24;q32) MYC translocation\n\nCBC:\nMay show leukocytosis, anemia, thrombocytopenia\nMay show leukocytosis, anemia, thrombocytopeniaPeripheral Blood Smear:\nMay show “starry sky” pattern due numerous macrophages engulfing apoptotic cells\nMay show “starry sky” pattern due numerous macrophages engulfing apoptotic cellsBone Marrow Aspiration Biopsy:\nInfiltration bone marrow Burkitt lymphoma cells\nInfiltration bone marrow Burkitt lymphoma cellsFlow Cytometry Immunophenotyping:\nCD19+, CD20+, CD10+, BCL6+, Ki-67 (proliferation marker) high (approaching 100%)\nCD5-, CD23-\nCD19+, CD20+, CD10+, BCL6+, Ki-67 (proliferation marker) high (approaching 100%)CD5-, CD23-Cytogenetic Analysis:\nt(8;14)(q24;q32) MYC translocation\nt(8;14)(q24;q32) MYC translocationTreatment:\nIntensive Chemotherapy:\nShort-duration, high-intensity chemotherapy regimens used rapidly eradicate tumor cells\nExamples: R-hyperCVAD, CODOX-M/IVAC\n\nCNS Prophylaxis:\nIntrathecal chemotherapy prevent CNS involvement\n\nManagement Tumor Lysis Syndrome (TLS):\nAggressive hydration, allopurinol, rasburicase prevent TLS\n\nIntensive Chemotherapy:\nShort-duration, high-intensity chemotherapy regimens used rapidly eradicate tumor cells\nExamples: R-hyperCVAD, CODOX-M/IVAC\nShort-duration, high-intensity chemotherapy regimens used rapidly eradicate tumor cellsExamples: R-hyperCVAD, CODOX-M/IVACCNS Prophylaxis:\nIntrathecal chemotherapy prevent CNS involvement\nIntrathecal chemotherapy prevent CNS involvementManagement Tumor Lysis Syndrome (TLS):\nAggressive hydration, allopurinol, rasburicase prevent TLS\nAggressive hydration, allopurinol, rasburicase prevent TLS","code":""},{"path":"chronic-b-cell.html","id":"waldenström-macroglobulinemia-wm","chapter":"Chronic B-Cell","heading":"Waldenström Macroglobulinemia (WM)","text":"Definition: rare, indolent B-cell lymphoma characterized presence IgM monoclonal gammopathy infiltration bone marrow tissues lymphoplasmacytic cellsGenetic Abnormality: cases mutation MYD88 genePathophysiology:\nClonal proliferation lymphoplasmacytic cells (mixture lymphocytes plasma cells) secrete IgM antibodies\nAccumulation IgM serum can lead hyperviscosity syndrome\nClonal proliferation lymphoplasmacytic cells (mixture lymphocytes plasma cells) secrete IgM antibodiesAccumulation IgM serum can lead hyperviscosity syndromeClinical Features:\nOften asymptomatic\nFatigue\nWeakness\nWeight loss\nNight sweats\nLymphadenopathy\nSplenomegaly\nHyperviscosity Syndrome:\nBlurred vision\nHeadache\nDizziness\nNeuropathy\nBleeding\n\nCryoglobulinemia:\nPrecipitation IgM antibodies low temperatures, leading vascular symptoms (e.g., Raynaud phenomenon, purpura)\n\nOften asymptomaticFatigueWeaknessWeight lossNight sweatsLymphadenopathySplenomegalyHyperviscosity Syndrome:\nBlurred vision\nHeadache\nDizziness\nNeuropathy\nBleeding\nBlurred visionHeadacheDizzinessNeuropathyBleedingCryoglobulinemia:\nPrecipitation IgM antibodies low temperatures, leading vascular symptoms (e.g., Raynaud phenomenon, purpura)\nPrecipitation IgM antibodies low temperatures, leading vascular symptoms (e.g., Raynaud phenomenon, purpura)Laboratory Findings:\nCBC:\nAnemia\nThrombocytopenia (cases)\nLeukocytosis lymphocytosis (variable)\n\nPeripheral Blood Smear:\nMay show lymphoplasmacytic cells\nRouleaux formation (stacking RBCs) due increased serum protein\n\nSerum Protein Electrophoresis (SPEP):\nIgM monoclonal spike\n\nSerum Immunofixation Electrophoresis (IFE):\nConfirms presence IgM monoclonal gammopathy\n\nBone Marrow Aspiration Biopsy:\nInfiltration bone marrow lymphoplasmacytic cells\n\nMolecular Testing:\nMYD88 L265P mutation (common)\nCXCR4 mutations (cases)\n\nCBC:\nAnemia\nThrombocytopenia (cases)\nLeukocytosis lymphocytosis (variable)\nAnemiaThrombocytopenia (cases)Leukocytosis lymphocytosis (variable)Peripheral Blood Smear:\nMay show lymphoplasmacytic cells\nRouleaux formation (stacking RBCs) due increased serum protein\nMay show lymphoplasmacytic cellsRouleaux formation (stacking RBCs) due increased serum proteinSerum Protein Electrophoresis (SPEP):\nIgM monoclonal spike\nIgM monoclonal spikeSerum Immunofixation Electrophoresis (IFE):\nConfirms presence IgM monoclonal gammopathy\nConfirms presence IgM monoclonal gammopathyBone Marrow Aspiration Biopsy:\nInfiltration bone marrow lymphoplasmacytic cells\nInfiltration bone marrow lymphoplasmacytic cellsMolecular Testing:\nMYD88 L265P mutation (common)\nCXCR4 mutations (cases)\nMYD88 L265P mutation (common)CXCR4 mutations (cases)Treatment:\nAsymptomatic Patients:\nWatchful waiting\n\nSymptomatic Patients:\nRituximab: Anti-CD20 monoclonal antibody\nChemotherapy: Cyclophosphamide, bendamustine\nBTK Inhibitors: Ibrutinib, zanubrutinib\nProteasome Inhibitors: Bortezomib\nPlasmapheresis: remove IgM serum hyperviscosity syndrome\n\nAsymptomatic Patients:\nWatchful waiting\nWatchful waitingSymptomatic Patients:\nRituximab: Anti-CD20 monoclonal antibody\nChemotherapy: Cyclophosphamide, bendamustine\nBTK Inhibitors: Ibrutinib, zanubrutinib\nProteasome Inhibitors: Bortezomib\nPlasmapheresis: remove IgM serum hyperviscosity syndrome\nRituximab: Anti-CD20 monoclonal antibodyChemotherapy: Cyclophosphamide, bendamustineBTK Inhibitors: Ibrutinib, zanubrutinibProteasome Inhibitors: BortezomibPlasmapheresis: remove IgM serum hyperviscosity syndrome","code":""},{"path":"chronic-b-cell.html","id":"key-terms-31","chapter":"Chronic B-Cell","heading":"Key Terms","text":"Lymphoid Neoplasm: Malignancy originating lymphocytesChronic Lymphocytic Leukemia (CLL): Indolent leukemia mature B cellsSmall Lymphocytic Lymphoma (SLL): Lymphoma mature B cells, similar CLLProlymphocytic Leukemia (PLL): Aggressive leukemia prolymphocytesHairy Cell Leukemia (HCL): Indolent leukemia B cells “hairy” cytoplasmic projectionsBurkitt Lymphoma: Highly aggressive lymphoma MYC translocationWaldenström Macroglobulinemia (WM): Lymphoma IgM monoclonal gammopathyImmunophenotyping: Identification cell surface markers using flow cytometryCytogenetic Analysis: study chromosomes abnormalitiesB Symptoms: Fever, weight loss, night sweats","code":""},{"path":"chronic-t-cell.html","id":"chronic-t-cell","chapter":"Chronic T-Cell","heading":"Chronic T-Cell","text":"","code":""},{"path":"chronic-t-cell.html","id":"overview-of-chronicmature-t-cell-leukemialymphoma","chapter":"Chronic T-Cell","heading":"Overview of Chronic/Mature T-Cell Leukemia/Lymphoma","text":"Definition: heterogeneous group lymphoid neoplasms derived mature (post-thymic) T lymphocytes natural killer (NK) cells. disorders can present leukemias (primarily involving blood bone marrow) lymphomas (primarily involving lymph nodes tissues)Key Features:\nClonal Proliferation: malignant disorders arising single, genetically abnormal T cell NK cell proliferates uncontrollably\nMature T-Cell Phenotype: cells express markers characteristic mature T cells NK cells (e.g., CD3, CD4, CD8)\nVariable Morphology: cells may variable size, shape, nuclear features\nExtranodal Involvement: Many lymphomas can involve extranodal sites, skin, gastrointestinal tract, liver\nClonal Proliferation: malignant disorders arising single, genetically abnormal T cell NK cell proliferates uncontrollablyMature T-Cell Phenotype: cells express markers characteristic mature T cells NK cells (e.g., CD3, CD4, CD8)Variable Morphology: cells may variable size, shape, nuclear featuresExtranodal Involvement: Many lymphomas can involve extranodal sites, skin, gastrointestinal tract, liverClassification: World Health Organization () classification system used categorize disorders based clinical, morphological, immunophenotypic, genetic features. T-cell NK-cell neoplasms can broadly classified :\nT-cell lymphomas\nT-cell leukemias\nNK-cell lymphomas/leukemias\nT-cell lymphomasT-cell leukemiasNK-cell lymphomas/leukemias","code":""},{"path":"chronic-t-cell.html","id":"key-disorders","chapter":"Chronic T-Cell","heading":"Key Disorders","text":"Large Granular Lymphocytic Leukemia (LGL Leukemia):\nDefinition: chronic lymphoproliferative disorder characterized sustained increase large granular lymphocytes (LGLs) peripheral blood. two main subtypes:\nT-LGL Leukemia: common; derived cytotoxic T cells (CD3+, CD8+)\nNK-LGL Leukemia: Less common; derived natural killer cells (CD3-, CD56+)\n\nPathophysiology:\nClonal proliferation LGLs cytotoxic activity\nAssociated STAT3 mutations many cases\n\nClinical Features:\nOften asymptomatic mild symptoms\nFatigue\nNeutropenia: Increased susceptibility infections\nAnemia: Due pure red cell aplasia (PRCA) mechanisms\nSplenomegaly (less common)\nAssociation autoimmune disorders (e.g., rheumatoid arthritis)\n\nLaboratory Findings:\nCBC:\nLymphocytosis increased LGLs (typically >2.0 x 10^9/L)\nNeutropenia\nAnemia\n\nPeripheral Blood Smear:\nLarge granular lymphocytes abundant cytoplasm azurophilic granules\n\nImmunophenotyping:\nT-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+\nNK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silent\n\nBone Marrow Examination:\nInfiltration bone marrow LGLs\n\nMolecular Testing:\nSTAT3 mutations (cases)\n\n\nTreatment:\nMany patients asymptomatic LGL leukemia require treatment\nImmunosuppressive Therapy:\nMethotrexate, cyclosporine, corticosteroids\nUsed treat cytopenias autoimmune manifestations\n\nCyclophosphamide fludarabine:\nMay used patients aggressive disease\n\nSplenectomy:\nMay considered patients symptomatic splenomegaly cytopenias\n\n\nDefinition: chronic lymphoproliferative disorder characterized sustained increase large granular lymphocytes (LGLs) peripheral blood. two main subtypes:\nT-LGL Leukemia: common; derived cytotoxic T cells (CD3+, CD8+)\nNK-LGL Leukemia: Less common; derived natural killer cells (CD3-, CD56+)\nT-LGL Leukemia: common; derived cytotoxic T cells (CD3+, CD8+)NK-LGL Leukemia: Less common; derived natural killer cells (CD3-, CD56+)Pathophysiology:\nClonal proliferation LGLs cytotoxic activity\nAssociated STAT3 mutations many cases\nClonal proliferation LGLs cytotoxic activityAssociated STAT3 mutations many casesClinical Features:\nOften asymptomatic mild symptoms\nFatigue\nNeutropenia: Increased susceptibility infections\nAnemia: Due pure red cell aplasia (PRCA) mechanisms\nSplenomegaly (less common)\nAssociation autoimmune disorders (e.g., rheumatoid arthritis)\nOften asymptomatic mild symptomsFatigueNeutropenia: Increased susceptibility infectionsAnemia: Due pure red cell aplasia (PRCA) mechanismsSplenomegaly (less common)Association autoimmune disorders (e.g., rheumatoid arthritis)Laboratory Findings:\nCBC:\nLymphocytosis increased LGLs (typically >2.0 x 10^9/L)\nNeutropenia\nAnemia\n\nPeripheral Blood Smear:\nLarge granular lymphocytes abundant cytoplasm azurophilic granules\n\nImmunophenotyping:\nT-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+\nNK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silent\n\nBone Marrow Examination:\nInfiltration bone marrow LGLs\n\nMolecular Testing:\nSTAT3 mutations (cases)\n\nCBC:\nLymphocytosis increased LGLs (typically >2.0 x 10^9/L)\nNeutropenia\nAnemia\nLymphocytosis increased LGLs (typically >2.0 x 10^9/L)NeutropeniaAnemiaPeripheral Blood Smear:\nLarge granular lymphocytes abundant cytoplasm azurophilic granules\nLarge granular lymphocytes abundant cytoplasm azurophilic granulesImmunophenotyping:\nT-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+\nNK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silent\nT-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+NK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silentBone Marrow Examination:\nInfiltration bone marrow LGLs\nInfiltration bone marrow LGLsMolecular Testing:\nSTAT3 mutations (cases)\nSTAT3 mutations (cases)Treatment:\nMany patients asymptomatic LGL leukemia require treatment\nImmunosuppressive Therapy:\nMethotrexate, cyclosporine, corticosteroids\nUsed treat cytopenias autoimmune manifestations\n\nCyclophosphamide fludarabine:\nMay used patients aggressive disease\n\nSplenectomy:\nMay considered patients symptomatic splenomegaly cytopenias\n\nMany patients asymptomatic LGL leukemia require treatmentImmunosuppressive Therapy:\nMethotrexate, cyclosporine, corticosteroids\nUsed treat cytopenias autoimmune manifestations\nMethotrexate, cyclosporine, corticosteroidsUsed treat cytopenias autoimmune manifestationsCyclophosphamide fludarabine:\nMay used patients aggressive disease\nMay used patients aggressive diseaseSplenectomy:\nMay considered patients symptomatic splenomegaly cytopenias\nMay considered patients symptomatic splenomegaly cytopeniasSézary Syndrome (SS):\nDefinition: rare aggressive form cutaneous T-cell lymphoma (CTCL) characterized widespread skin involvement, lymphadenopathy, presence malignant T cells (Sézary cells) skin, lymph nodes, peripheral blood\nPathophysiology:\nClonal proliferation malignant CD4+ T helper cells skin-homing properties\nCells infiltrate skin, causing erythroderma (generalized redness scaling skin) plaques\n\nClinical Features:\nErythroderma: Generalized redness scaling skin\nIntense Pruritus (itching)\nLymphadenopathy: Swollen lymph nodes\nSézary cells skin peripheral blood\nHepatosplenomegaly (enlarged liver spleen)\n\nLaboratory Findings:\nCBC:\nLeukocytosis lymphocytosis\nEosinophilia\n\nPeripheral Blood Smear:\nSézary cells: Lymphocytes cerebriform (brain-like) nuclei\n\nImmunophenotyping:\nCD3+, CD4+, CD45RO+, CD7- (loss CD7 common finding)\nAbnormal T cell receptor expression\n\nSkin Biopsy:\nConfirms diagnosis CTCL demonstrates presence Sézary cells skin\n\nT Cell Receptor (TCR) Gene Rearrangement Studies:\nDemonstrates clonality T cell population\n\n\nTreatment:\nSkin-Directed Therapies:\nTopical corticosteroids\nPhototherapy (PUVA, UVB)\nTopical chemotherapy (e.g., mechlorethamine)\n\nSystemic Therapies:\nExtracorporeal photopheresis (ECP): Treats blood outside body ultraviolet light kill malignant cells\nInterferon-alpha\nHistone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)\nChemotherapy (e.g., CHOP)\nMogamulizumab: anti-CCR4 monoclonal antibody\n\nStem Cell Transplantation\n\nDefinition: rare aggressive form cutaneous T-cell lymphoma (CTCL) characterized widespread skin involvement, lymphadenopathy, presence malignant T cells (Sézary cells) skin, lymph nodes, peripheral bloodPathophysiology:\nClonal proliferation malignant CD4+ T helper cells skin-homing properties\nCells infiltrate skin, causing erythroderma (generalized redness scaling skin) plaques\nClonal proliferation malignant CD4+ T helper cells skin-homing propertiesCells infiltrate skin, causing erythroderma (generalized redness scaling skin) plaquesClinical Features:\nErythroderma: Generalized redness scaling skin\nIntense Pruritus (itching)\nLymphadenopathy: Swollen lymph nodes\nSézary cells skin peripheral blood\nHepatosplenomegaly (enlarged liver spleen)\nErythroderma: Generalized redness scaling skinIntense Pruritus (itching)Lymphadenopathy: Swollen lymph nodesSézary cells skin peripheral bloodHepatosplenomegaly (enlarged liver spleen)Laboratory Findings:\nCBC:\nLeukocytosis lymphocytosis\nEosinophilia\n\nPeripheral Blood Smear:\nSézary cells: Lymphocytes cerebriform (brain-like) nuclei\n\nImmunophenotyping:\nCD3+, CD4+, CD45RO+, CD7- (loss CD7 common finding)\nAbnormal T cell receptor expression\n\nSkin Biopsy:\nConfirms diagnosis CTCL demonstrates presence Sézary cells skin\n\nT Cell Receptor (TCR) Gene Rearrangement Studies:\nDemonstrates clonality T cell population\n\nCBC:\nLeukocytosis lymphocytosis\nEosinophilia\nLeukocytosis lymphocytosisEosinophiliaPeripheral Blood Smear:\nSézary cells: Lymphocytes cerebriform (brain-like) nuclei\nSézary cells: Lymphocytes cerebriform (brain-like) nucleiImmunophenotyping:\nCD3+, CD4+, CD45RO+, CD7- (loss CD7 common finding)\nAbnormal T cell receptor expression\nCD3+, CD4+, CD45RO+, CD7- (loss CD7 common finding)Abnormal T cell receptor expressionSkin Biopsy:\nConfirms diagnosis CTCL demonstrates presence Sézary cells skin\nConfirms diagnosis CTCL demonstrates presence Sézary cells skinT Cell Receptor (TCR) Gene Rearrangement Studies:\nDemonstrates clonality T cell population\nDemonstrates clonality T cell populationTreatment:\nSkin-Directed Therapies:\nTopical corticosteroids\nPhototherapy (PUVA, UVB)\nTopical chemotherapy (e.g., mechlorethamine)\n\nSystemic Therapies:\nExtracorporeal photopheresis (ECP): Treats blood outside body ultraviolet light kill malignant cells\nInterferon-alpha\nHistone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)\nChemotherapy (e.g., CHOP)\nMogamulizumab: anti-CCR4 monoclonal antibody\n\nStem Cell Transplantation\nSkin-Directed Therapies:\nTopical corticosteroids\nPhototherapy (PUVA, UVB)\nTopical chemotherapy (e.g., mechlorethamine)\nTopical corticosteroidsPhototherapy (PUVA, UVB)Topical chemotherapy (e.g., mechlorethamine)Systemic Therapies:\nExtracorporeal photopheresis (ECP): Treats blood outside body ultraviolet light kill malignant cells\nInterferon-alpha\nHistone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)\nChemotherapy (e.g., CHOP)\nMogamulizumab: anti-CCR4 monoclonal antibody\nExtracorporeal photopheresis (ECP): Treats blood outside body ultraviolet light kill malignant cellsInterferon-alphaHistone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)Chemotherapy (e.g., CHOP)Mogamulizumab: anti-CCR4 monoclonal antibodyStem Cell TransplantationHodgkin Lymphoma (HL):\nDefinition: type lymphoma characterized presence Reed-Sternberg cells (large, abnormal lymphocytes)\nDistinction lymphomas: Hodgkin Lymphoma spreads predictably treatable\nClassical Hodgkin Lymphoma (cHL): common subtype, characterized presence Reed-Sternberg cells variants background reactive inflammatory cells. Subtypes cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted\nNodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): less common subtype characterized lymphocyte-predominant Reed-Sternberg cells (L&H cells) different immunophenotype\nPathophysiology:\nArises germinal center post-germinal center B cells\nReed-Sternberg cells secrete cytokines attract activate immune cells, leading formation tumor microenvironment\n\nClinical Features:\nPainless Lymphadenopathy: Often cervical (neck) mediastinal (chest) region\nB Symptoms: Fever, night sweats, weight loss\nPruritus (itching)\nFatigue\n\nLaboratory Findings:\nCBC: Variable; may normal show anemia, leukocytosis, lymphopenia\nPeripheral Blood Smear: Usually normal; may show eosinophilia\nErythrocyte Sedimentation Rate (ESR) C-Reactive Protein (CRP): Often elevated\nLymph Node Biopsy: Essential diagnosis\nPresence Reed-Sternberg cells (hallmark HL)\nImmunohistochemistry:\nReed-Sternberg cells cHL: CD30+, CD15+, PAX5+, CD45-\nL&H cells NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-\n\n\nImaging Studies (CT Scan, PET/CT): stage disease assess extent involvement\n\nTreatment:\nChemotherapy:\nABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)\nBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)\n\nRadiation Therapy:\nMay used combination chemotherapy\n\nBrentuximab Vedotin:\nanti-CD30 antibody-drug conjugate used relapsed refractory HL\n\nNivolumab Pembrolizumab:\nPD-1 inhibitors used relapsed refractory HL\n\nHematopoietic Stem Cell Transplantation (HSCT):\nMay considered relapsed refractory disease\n\n\nDefinition: type lymphoma characterized presence Reed-Sternberg cells (large, abnormal lymphocytes)Distinction lymphomas: Hodgkin Lymphoma spreads predictably treatableClassical Hodgkin Lymphoma (cHL): common subtype, characterized presence Reed-Sternberg cells variants background reactive inflammatory cells. Subtypes cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depletedNodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): less common subtype characterized lymphocyte-predominant Reed-Sternberg cells (L&H cells) different immunophenotypePathophysiology:\nArises germinal center post-germinal center B cells\nReed-Sternberg cells secrete cytokines attract activate immune cells, leading formation tumor microenvironment\nArises germinal center post-germinal center B cellsReed-Sternberg cells secrete cytokines attract activate immune cells, leading formation tumor microenvironmentClinical Features:\nPainless Lymphadenopathy: Often cervical (neck) mediastinal (chest) region\nB Symptoms: Fever, night sweats, weight loss\nPruritus (itching)\nFatigue\nPainless Lymphadenopathy: Often cervical (neck) mediastinal (chest) regionB Symptoms: Fever, night sweats, weight lossPruritus (itching)FatigueLaboratory Findings:\nCBC: Variable; may normal show anemia, leukocytosis, lymphopenia\nPeripheral Blood Smear: Usually normal; may show eosinophilia\nErythrocyte Sedimentation Rate (ESR) C-Reactive Protein (CRP): Often elevated\nLymph Node Biopsy: Essential diagnosis\nPresence Reed-Sternberg cells (hallmark HL)\nImmunohistochemistry:\nReed-Sternberg cells cHL: CD30+, CD15+, PAX5+, CD45-\nL&H cells NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-\n\n\nImaging Studies (CT Scan, PET/CT): stage disease assess extent involvement\nCBC: Variable; may normal show anemia, leukocytosis, lymphopeniaPeripheral Blood Smear: Usually normal; may show eosinophiliaErythrocyte Sedimentation Rate (ESR) C-Reactive Protein (CRP): Often elevatedLymph Node Biopsy: Essential diagnosis\nPresence Reed-Sternberg cells (hallmark HL)\nImmunohistochemistry:\nReed-Sternberg cells cHL: CD30+, CD15+, PAX5+, CD45-\nL&H cells NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-\n\nPresence Reed-Sternberg cells (hallmark HL)Immunohistochemistry:\nReed-Sternberg cells cHL: CD30+, CD15+, PAX5+, CD45-\nL&H cells NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-\nReed-Sternberg cells cHL: CD30+, CD15+, PAX5+, CD45-L&H cells NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-Imaging Studies (CT Scan, PET/CT): stage disease assess extent involvementTreatment:\nChemotherapy:\nABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)\nBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)\n\nRadiation Therapy:\nMay used combination chemotherapy\n\nBrentuximab Vedotin:\nanti-CD30 antibody-drug conjugate used relapsed refractory HL\n\nNivolumab Pembrolizumab:\nPD-1 inhibitors used relapsed refractory HL\n\nHematopoietic Stem Cell Transplantation (HSCT):\nMay considered relapsed refractory disease\n\nChemotherapy:\nABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)\nBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)\nABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)Radiation Therapy:\nMay used combination chemotherapy\nMay used combination chemotherapyBrentuximab Vedotin:\nanti-CD30 antibody-drug conjugate used relapsed refractory HL\nanti-CD30 antibody-drug conjugate used relapsed refractory HLNivolumab Pembrolizumab:\nPD-1 inhibitors used relapsed refractory HL\nPD-1 inhibitors used relapsed refractory HLHematopoietic Stem Cell Transplantation (HSCT):\nMay considered relapsed refractory disease\nMay considered relapsed refractory disease","code":""},{"path":"chronic-t-cell.html","id":"important-considerations","chapter":"Chronic T-Cell","heading":"Important Considerations","text":"simplified overviews, many disorders subtypes variationsDifferential diagnosis area can challenging, often requires integration clinical, morphological, immunophenotypic, cytogenetic, molecular data.Treatment evolving rapidly, new targeted therapies immunotherapies becoming available.","code":""},{"path":"chronic-t-cell.html","id":"key-terms-32","chapter":"Chronic T-Cell","heading":"Key Terms","text":"Lymphoid Neoplasm: Malignancy originating lymphocytesT Cells: Lymphocytes responsible cell-mediated immunityB Cells: Lymphocytes responsible humoral immunity (antibody production)NK Cells: Large granular lymphocytes involved innate immunityLymphoma: Malignancy primarily involving lymph nodes lymphoid tissuesLeukemia: Malignancy primarily involving bone marrow peripheral bloodLarge Granular Lymphocytic Leukemia (LGL Leukemia): Leukemia LGLsSézary Syndrome (SS): Aggressive cutaneous T-cell lymphomaHodgkin Lymphoma (HL): Lymphoma characterized Reed-Sternberg cellsReed-Sternberg Cells: Large, abnormal lymphocytes characteristic Hodgkin lymphomaImmunophenotyping: Identification cell surface markers using flow cytometryCytogenetic Analysis: study chromosomes abnormalitiesMolecular Testing: Techniques detect gene mutations fusion genes","code":""},{"path":"plasma-cell.html","id":"plasma-cell","chapter":"Plasma Cell","heading":"Plasma Cell","text":"","code":""},{"path":"plasma-cell.html","id":"overview-of-plasma-cell-dyscrasias","chapter":"Plasma Cell","heading":"Overview of Plasma Cell Dyscrasias","text":"Definition: group disorders characterized abnormal proliferation single clone plasma cells, leading overproduction monoclonal immunoglobulin (M protein)Synonyms: Monoclonal Gammopathies, Plasma Cell DisordersKey Features:\nMonoclonal Gammopathy: presence monoclonal immunoglobulin (M protein) serum urine. M protein produced abnormal clone plasma cells\nBone Marrow Involvement: bone marrow often infiltrated clonal plasma cells\nOrgan Damage: May lead organ damage due M protein deposition, bone lesions, hypercalcemia, renal dysfunction, increased susceptibility infections\nMonoclonal Gammopathy: presence monoclonal immunoglobulin (M protein) serum urine. M protein produced abnormal clone plasma cellsBone Marrow Involvement: bone marrow often infiltrated clonal plasma cellsOrgan Damage: May lead organ damage due M protein deposition, bone lesions, hypercalcemia, renal dysfunction, increased susceptibility infectionsSpectrum Disorders: Range benign malignant:\nMonoclonal Gammopathy Undetermined Significance (MGUS): Benign condition low levels M protein evidence end-organ damage\nSmoldering Multiple Myeloma (SMM): Intermediate condition higher levels M protein still end-organ damage\nMultiple Myeloma (MM): Malignant plasma cell disorder M protein, bone marrow involvement, end-organ damage\nWaldenström Macroglobulinemia (WM): lymphoplasmacytic lymphoma produces IgM M protein (covered previous study guide)\nPlasma Cell Dyscrasias: Rare disorders heavy chain diseases plasma cell leukemia\nMonoclonal Gammopathy Undetermined Significance (MGUS): Benign condition low levels M protein evidence end-organ damageSmoldering Multiple Myeloma (SMM): Intermediate condition higher levels M protein still end-organ damageMultiple Myeloma (MM): Malignant plasma cell disorder M protein, bone marrow involvement, end-organ damageWaldenström Macroglobulinemia (WM): lymphoplasmacytic lymphoma produces IgM M protein (covered previous study guide)Plasma Cell Dyscrasias: Rare disorders heavy chain diseases plasma cell leukemia","code":""},{"path":"plasma-cell.html","id":"multiple-myeloma-mm","chapter":"Plasma Cell","heading":"Multiple Myeloma (MM)","text":"Definition: malignant plasma cell disorder characterized clonal proliferation plasma cells bone marrow, leading overproduction monoclonal immunoglobulin (M protein) associated end-organ damageDiagnostic Criteria:\nClonal Bone Marrow Plasma Cells ≥10% Biopsy-Proven Extramedullary Plasmacytoma\nPresence M Protein Serum /Urine (except rare cases nonsecretory myeloma)\nEvidence End-Organ Damage (CRAB Criteria):\nHypercalcemia: Elevated serum calcium level\nRenal Insufficiency: Elevated creatinine decreased glomerular filtration rate (GFR)\nAnemia: Low hemoglobin level\nBone Lesions: Lytic lesions, fractures, osteopenia skeletal survey imaging studies\n\nClonal Bone Marrow Plasma Cells ≥10% Biopsy-Proven Extramedullary PlasmacytomaPresence M Protein Serum /Urine (except rare cases nonsecretory myeloma)Evidence End-Organ Damage (CRAB Criteria):\nHypercalcemia: Elevated serum calcium level\nRenal Insufficiency: Elevated creatinine decreased glomerular filtration rate (GFR)\nAnemia: Low hemoglobin level\nBone Lesions: Lytic lesions, fractures, osteopenia skeletal survey imaging studies\nHypercalcemia: Elevated serum calcium levelRenal Insufficiency: Elevated creatinine decreased glomerular filtration rate (GFR)Anemia: Low hemoglobin levelBone Lesions: Lytic lesions, fractures, osteopenia skeletal survey imaging studiesPathophysiology:\nClonal Plasma Cell Proliferation: Abnormal plasma cells accumulate bone marrow, disrupting normal hematopoiesis\nM Protein Production: Excessive production monoclonal immunoglobulin (IgG, IgA, IgD, IgE) light chains (kappa lambda)\nBone Destruction: Myeloma cells secrete factors stimulate osteoclast activity, leading bone resorption lytic lesions\nImmunosuppression: Myeloma cells suppress normal immune system, increasing susceptibility infections\nClonal Plasma Cell Proliferation: Abnormal plasma cells accumulate bone marrow, disrupting normal hematopoiesisM Protein Production: Excessive production monoclonal immunoglobulin (IgG, IgA, IgD, IgE) light chains (kappa lambda)Bone Destruction: Myeloma cells secrete factors stimulate osteoclast activity, leading bone resorption lytic lesionsImmunosuppression: Myeloma cells suppress normal immune system, increasing susceptibility infectionsClinical Features:\nBone Pain: common symptom\nFatigue Weakness: Due anemia\nPathologic Fractures: Fractures occur minimal trauma due weakened bones\nRecurrent Infections: Due immunosuppression\nRenal Insufficiency: Due M protein deposition kidneys (myeloma cast nephropathy)\nHypercalcemia: Can cause confusion, constipation, kidney damage\nNeurological Symptoms: Due spinal cord compression hyperviscosity syndrome\nAmyloidosis: Deposition light chains tissues, causing organ damage\nBone Pain: common symptomFatigue Weakness: Due anemiaPathologic Fractures: Fractures occur minimal trauma due weakened bonesRecurrent Infections: Due immunosuppressionRenal Insufficiency: Due M protein deposition kidneys (myeloma cast nephropathy)Hypercalcemia: Can cause confusion, constipation, kidney damageNeurological Symptoms: Due spinal cord compression hyperviscosity syndromeAmyloidosis: Deposition light chains tissues, causing organ damageLaboratory Findings:\nCBC:\nAnemia (normocytic normochromic)\nThrombocytopenia\nLeukopenia (less common)\nRouleaux formation: Stacking RBCs due increased serum protein\n\nPeripheral Blood Smear:\nNormal abnormal RBC morphology\nMay see plasma cells circulating myeloma cells (rare)\n\nSerum Protein Electrophoresis (SPEP):\nMonoclonal spike (M protein) gamma region (usually IgG IgA)\n\nSerum Immunofixation Electrophoresis (IFE):\nConfirms presence type M protein (IgG kappa, IgA lambda, etc.)\n\nSerum Free Light Chain (FLC) Assay:\nMeasures free kappa lambda light chains serum\nIncreased FLC ratio (kappa/lambda lambda/kappa) common\n\nUrine Protein Electrophoresis (UPEP) Immunofixation:\nMay detect Bence Jones protein (free light chains) urine\n\nSerum Beta-2 Microglobulin:\nElevated levels indicate increased tumor burden\nUsed staging prognosis\n\nSerum Albumin:\nDecreased levels associated poorer prognosis\n\nSerum Calcium:\nElevated hypercalcemia\n\nRenal Function Tests:\nElevated creatinine decreased GFR renal insufficiency\n\nSkeletal Survey (X-rays):\nLytic lesions (“punched-” lesions) bones\nOsteopenia\nFractures\n\nBone Marrow Aspiration Biopsy:\nIncreased plasma cells (≥10%)\nAbnormal plasma cell morphology\nImmunohistochemistry: identify plasma cell markers (CD138, CD56)\n\nCytogenetic Analysis:\nKaryotyping FISH (fluorescence situ hybridization)\nDetect chromosomal abnormalities used prognosis risk stratification (e.g., del(17p), t(4;14), t(14;16))\n\nMolecular Testing:\ndetect gene mutations used prognosis (e.g., TP53, BRAF)\n\nCBC:\nAnemia (normocytic normochromic)\nThrombocytopenia\nLeukopenia (less common)\nRouleaux formation: Stacking RBCs due increased serum protein\nAnemia (normocytic normochromic)ThrombocytopeniaLeukopenia (less common)Rouleaux formation: Stacking RBCs due increased serum proteinPeripheral Blood Smear:\nNormal abnormal RBC morphology\nMay see plasma cells circulating myeloma cells (rare)\nNormal abnormal RBC morphologyMay see plasma cells circulating myeloma cells (rare)Serum Protein Electrophoresis (SPEP):\nMonoclonal spike (M protein) gamma region (usually IgG IgA)\nMonoclonal spike (M protein) gamma region (usually IgG IgA)Serum Immunofixation Electrophoresis (IFE):\nConfirms presence type M protein (IgG kappa, IgA lambda, etc.)\nConfirms presence type M protein (IgG kappa, IgA lambda, etc.)Serum Free Light Chain (FLC) Assay:\nMeasures free kappa lambda light chains serum\nIncreased FLC ratio (kappa/lambda lambda/kappa) common\nMeasures free kappa lambda light chains serumIncreased FLC ratio (kappa/lambda lambda/kappa) commonUrine Protein Electrophoresis (UPEP) Immunofixation:\nMay detect Bence Jones protein (free light chains) urine\nMay detect Bence Jones protein (free light chains) urineSerum Beta-2 Microglobulin:\nElevated levels indicate increased tumor burden\nUsed staging prognosis\nElevated levels indicate increased tumor burdenUsed staging prognosisSerum Albumin:\nDecreased levels associated poorer prognosis\nDecreased levels associated poorer prognosisSerum Calcium:\nElevated hypercalcemia\nElevated hypercalcemiaRenal Function Tests:\nElevated creatinine decreased GFR renal insufficiency\nElevated creatinine decreased GFR renal insufficiencySkeletal Survey (X-rays):\nLytic lesions (“punched-” lesions) bones\nOsteopenia\nFractures\nLytic lesions (“punched-” lesions) bonesOsteopeniaFracturesBone Marrow Aspiration Biopsy:\nIncreased plasma cells (≥10%)\nAbnormal plasma cell morphology\nImmunohistochemistry: identify plasma cell markers (CD138, CD56)\nIncreased plasma cells (≥10%)Abnormal plasma cell morphologyImmunohistochemistry: identify plasma cell markers (CD138, CD56)Cytogenetic Analysis:\nKaryotyping FISH (fluorescence situ hybridization)\nDetect chromosomal abnormalities used prognosis risk stratification (e.g., del(17p), t(4;14), t(14;16))\nKaryotyping FISH (fluorescence situ hybridization)Detect chromosomal abnormalities used prognosis risk stratification (e.g., del(17p), t(4;14), t(14;16))Molecular Testing:\ndetect gene mutations used prognosis (e.g., TP53, BRAF)\ndetect gene mutations used prognosis (e.g., TP53, BRAF)Staging:\nRevised International Staging System (R-ISS):\nUsed determine treatment outcomes.\nSerum beta2-microglobulin level\nSerum albumin level\nCytogenetic abnormalities (detected FISH)\n\nRevised International Staging System (R-ISS):\nUsed determine treatment outcomes.\nSerum beta2-microglobulin level\nSerum albumin level\nCytogenetic abnormalities (detected FISH)\nUsed determine treatment outcomes.Serum beta2-microglobulin levelSerum albumin levelCytogenetic abnormalities (detected FISH)Treatment:\nTreatment depends risk assessment patient fitness\nProteasome Inhibitors:\nBortezomib, carfilzomib, ixazomib\n\nImmunomodulatory Drugs (IMiDs):\nLenalidomide, thalidomide, pomalidomide\n\nMonoclonal Antibodies:\nDaratumumab (anti-CD38)\nElotuzumab (anti-SLAMF7)\n\nChemotherapy:\nAlkylating agents (e.g., melphalan, cyclophosphamide)\n\nCorticosteroids:\nDexamethasone, prednisone\n\nAutologous Hematopoietic Stem Cell Transplantation (ASCT):\nstandard treatment eligible patients\n\nCAR T-Cell Therapy:\nUsed relapsed/refractory myeloma\n\nBispecific Antibodies:\nEmerging therapies bind CD3 T cells BCMA myeloma cells, bringing together kill myeloma cells\n\nTreatment depends risk assessment patient fitnessProteasome Inhibitors:\nBortezomib, carfilzomib, ixazomib\nBortezomib, carfilzomib, ixazomibImmunomodulatory Drugs (IMiDs):\nLenalidomide, thalidomide, pomalidomide\nLenalidomide, thalidomide, pomalidomideMonoclonal Antibodies:\nDaratumumab (anti-CD38)\nElotuzumab (anti-SLAMF7)\nDaratumumab (anti-CD38)Elotuzumab (anti-SLAMF7)Chemotherapy:\nAlkylating agents (e.g., melphalan, cyclophosphamide)\nAlkylating agents (e.g., melphalan, cyclophosphamide)Corticosteroids:\nDexamethasone, prednisone\nDexamethasone, prednisoneAutologous Hematopoietic Stem Cell Transplantation (ASCT):\nstandard treatment eligible patients\nstandard treatment eligible patientsCAR T-Cell Therapy:\nUsed relapsed/refractory myeloma\nUsed relapsed/refractory myelomaBispecific Antibodies:\nEmerging therapies bind CD3 T cells BCMA myeloma cells, bringing together kill myeloma cells\nEmerging therapies bind CD3 T cells BCMA myeloma cells, bringing together kill myeloma cells","code":""},{"path":"plasma-cell.html","id":"monoclonal-gammopathy-of-undetermined-significance-mgus","chapter":"Plasma Cell","heading":"Monoclonal Gammopathy of Undetermined Significance (MGUS)","text":"Definition: benign condition characterized presence monoclonal immunoglobulin (M protein) serum urine, without evidence end-organ damage features multiple myeloma, Waldenström macroglobulinemia, lymphoid disordersDiagnostic Criteria:\nSerum M protein < 3 g/dL\nBone marrow plasma cells <10%\nAbsence end-organ damage (CRAB criteria):\nHypercalcemia\nRenal insufficiency\nAnemia\nBone lesions\n\nSerum M protein < 3 g/dLBone marrow plasma cells <10%Absence end-organ damage (CRAB criteria):\nHypercalcemia\nRenal insufficiency\nAnemia\nBone lesions\nHypercalcemiaRenal insufficiencyAnemiaBone lesionsEpidemiology: Common, especially older adultsPathophysiology:\nUnknown cause\nThought premalignant condition low risk progression multiple myeloma lymphoid malignancies\nUnknown causeThought premalignant condition low risk progression multiple myeloma lymphoid malignanciesClinical Features:\nTypically asymptomatic\nUsually discovered incidentally routine blood tests\nTypically asymptomaticUsually discovered incidentally routine blood testsLaboratory Findings:\nSerum Protein Electrophoresis (SPEP): Small monoclonal spike (M protein)\nSerum Immunofixation Electrophoresis (IFE): Confirms presence type M protein (IgG, IgA, IgM, etc.)\nSerum Free Light Chain (FLC) Assay: May normal show slightly elevated kappa/lambda ratio\nCBC, Renal Function Tests, Calcium Level: Normal\nBone Marrow Aspiration Biopsy: typically required diagnosis, may performed rule disorders\nSerum Protein Electrophoresis (SPEP): Small monoclonal spike (M protein)Serum Immunofixation Electrophoresis (IFE): Confirms presence type M protein (IgG, IgA, IgM, etc.)Serum Free Light Chain (FLC) Assay: May normal show slightly elevated kappa/lambda ratioCBC, Renal Function Tests, Calcium Level: NormalBone Marrow Aspiration Biopsy: typically required diagnosis, may performed rule disordersManagement:\ntreatment required\nPeriodic monitoring SPEP, IFE, serum FLC assay assess progression multiple myeloma malignancies\nRisk Progression: Approximately 1% per year progress multiple myeloma related disorders\ntreatment requiredPeriodic monitoring SPEP, IFE, serum FLC assay assess progression multiple myeloma malignanciesRisk Progression: Approximately 1% per year progress multiple myeloma related disorders","code":""},{"path":"plasma-cell.html","id":"key-terms-33","chapter":"Plasma Cell","heading":"Key Terms","text":"Plasma Cell Dyscrasia: disorder characterized abnormal proliferation single clone plasma cellsMonoclonal Gammopathy: presence monoclonal immunoglobulin (M protein) serum urineM Protein: monoclonal immunoglobulin produced abnormal clone plasma cellsMGUS (Monoclonal Gammopathy Undetermined Significance): Benign condition low levels M protein end-organ damageMultiple Myeloma (MM): Malignant plasma cell disorder M protein, bone marrow involvement, end-organ damageBence Jones Protein: Free light chains urineLytic Lesions: “Punched-” lesions bones seen X-rayCRAB Criteria: Hypercalcemia, Renal insufficiency, Anemia, Bone lesions (used define end-organ damage myeloma)Serum Protein Electrophoresis (SPEP): test separates proteins serum based electrical chargeImmunofixation Electrophoresis (IFE): test identifies type M protein (IgG, IgA, IgM, etc.)Autologous Stem Cell Transplant: Stem cells collected transplanted person","code":""},{"path":"hereditary.html","id":"hereditary","chapter":"Hereditary","heading":"Hereditary","text":"category encompasses several rare, inherited disorders affect morphology /function leukocytes, listed classification","code":""},{"path":"hereditary.html","id":"hereditary-anomalies-of-leukocytes","chapter":"Hereditary","heading":"Hereditary Anomalies of Leukocytes","text":"Definition: group inherited disorders characterized distinct morphological functional abnormalities leukocytesKey Features\nPresent Birth: abnormalities present birth persist throughout life\nTypically Benign: asymptomatic cause significant clinical problems\nRecognizable Morphology: recognized distinctive morphological features peripheral blood smear\nGenetic Basis: Caused mutations specific genes\nPresent Birth: abnormalities present birth persist throughout lifeTypically Benign: asymptomatic cause significant clinical problemsRecognizable Morphology: recognized distinctive morphological features peripheral blood smearGenetic Basis: Caused mutations specific genesImportance Recognition: Crucial laboratory personnel recognize anomalies avoid misdiagnosis serious conditions, myelodysplastic syndromes (MDS) acute leukemia","code":""},{"path":"hereditary.html","id":"specific-hereditary-anomalies","chapter":"Hereditary","heading":"Specific Hereditary Anomalies","text":"’s breakdown key hereditary anomalies, including genetic basis, morphological features, clinical significance, laboratory findings:","code":""},{"path":"hereditary.html","id":"pelger-huët-anomaly-pha","chapter":"Hereditary","heading":"Pelger-Huët Anomaly (PHA)","text":"Definition: benign inherited disorder characterized high percentage neutrophils bilobed unsegmented nuclei (hyposegmentation)Genetic Basis:\nAutosomal dominant inheritance\ncommonly caused mutation Lamin B Receptor (LBR) gene chromosome 1q42.13\nAutosomal dominant inheritanceMost commonly caused mutation Lamin B Receptor (LBR) gene chromosome 1q42.13Pathophysiology: Mutation LBR gene disrupts normal neutrophil nuclear segmentation. Remember one later steps maturation!Morphological Features\nIncreased number neutrophils bilobed unsegmented nuclei\nNuclei “pince-nez” “dumbbell” shape\nNormal chromatin condensation\nCells otherwise appear normal, typically don’t qualitative features\nMay see occasional unsegmented neutrophils (band forms)\nneutrophils affected (uniformity findings)\nIncreased number neutrophils bilobed unsegmented nucleiNuclei “pince-nez” “dumbbell” shapeNormal chromatin condensationCells otherwise appear normal, typically don’t qualitative featuresMay see occasional unsegmented neutrophils (band forms)neutrophils affected (uniformity findings)Clinical Significance\nBenign Asymptomatic: cause health problems\nImportance Recognition: Must distinguished pseudo-Pelger-Huët anomaly, associated serious conditions like MDS\nBenign Asymptomatic: cause health problemsImportance Recognition: Must distinguished pseudo-Pelger-Huët anomaly, associated serious conditions like MDSLaboratory Findings\nCBC: Normal WBC count\nPeripheral Blood Smear:\nIncreased percentage neutrophils bilobed unsegmented nuclei\nNormal neutrophils 3-4 lobes may present, less common bilobed cells\nLack toxic granulation dysplastic features\n\nReticulocyte Count\nFamily Testing: required diagnosis may done confirm hereditary nature abnormality\nCBC: Normal WBC countPeripheral Blood Smear:\nIncreased percentage neutrophils bilobed unsegmented nuclei\nNormal neutrophils 3-4 lobes may present, less common bilobed cells\nLack toxic granulation dysplastic features\nIncreased percentage neutrophils bilobed unsegmented nucleiNormal neutrophils 3-4 lobes may present, less common bilobed cellsLack toxic granulation dysplastic featuresReticulocyte CountFamily Testing: required diagnosis may done confirm hereditary nature abnormalityHow Distinguish Pseudo-Pelger-Huët Anomaly: “true” PHA usually occurs cell lines, always present, exhibits cells still properly shaped","code":""},{"path":"hereditary.html","id":"may-hegglin-anomaly-mha","chapter":"Hereditary","heading":"May-Hegglin Anomaly (MHA)","text":"Definition: rare autosomal dominant disorder characterized :\nLarge, pale-blue inclusions (Döhle bodies) neutrophils, eosinophils, basophils, monocytes\nThrombocytopenia (low platelet count)\nGiant Platelets (megathrombocytes)\nLarge, pale-blue inclusions (Döhle bodies) neutrophils, eosinophils, basophils, monocytesThrombocytopenia (low platelet count)Giant Platelets (megathrombocytes)Genetic Basis: Caused mutations MYH9 gene, encodes nonmuscle myosin heavy chain IIAPathophysiology\nAbnormal Myosin Heavy Chain: Affects normal platelet leukocyte function\nDöhle Bodies: Consist aggregates abnormal myosin heavy chain\nThrombocytopenia: Results impaired platelet production increased platelet destruction\nAbnormal Myosin Heavy Chain: Affects normal platelet leukocyte functionDöhle Bodies: Consist aggregates abnormal myosin heavy chainThrombocytopenia: Results impaired platelet production increased platelet destructionMorphological Features\nNeutrophils, Eosinophils, Basophils, Monocytes: Contain large, pale-blue, spindle-shaped round inclusions (Döhle bodies)\nPlatelets: Thrombocytopenia giant platelets\nEasy see PBS 40X lens strength\nNeutrophils, Eosinophils, Basophils, Monocytes: Contain large, pale-blue, spindle-shaped round inclusions (Döhle bodies)Platelets: Thrombocytopenia giant plateletsEasy see PBS 40X lens strengthClinical Features\nMild moderate bleeding tendencies:\nEasy bruising\nNosebleeds\nProlonged bleeding cuts surgery\n\npatients asymptomatic\nMild moderate bleeding tendencies:\nEasy bruising\nNosebleeds\nProlonged bleeding cuts surgery\nEasy bruisingNosebleedsProlonged bleeding cuts surgeryMost patients asymptomaticLaboratory Findings\nCBC:\nThrombocytopenia (platelet count often 50-100 x 10^9/L)\nNormal WBC count\n\nPeripheral Blood Smear:\nDöhle-like inclusions neutrophils, eosinophils, basophils, monocytes\nGiant platelets (macrothrombocytes)\n\nCBC:\nThrombocytopenia (platelet count often 50-100 x 10^9/L)\nNormal WBC count\nThrombocytopenia (platelet count often 50-100 x 10^9/L)Normal WBC countPeripheral Blood Smear:\nDöhle-like inclusions neutrophils, eosinophils, basophils, monocytes\nGiant platelets (macrothrombocytes)\nDöhle-like inclusions neutrophils, eosinophils, basophils, monocytesGiant platelets (macrothrombocytes)Treatment\nUsually supportive\nAvoid aspirin antiplatelet agents\nPlatelet transfusions may necessary severe bleeding\nDesmopressin may helpful cases\nGenetic counseling\nUsually supportiveAvoid aspirin antiplatelet agentsPlatelet transfusions may necessary severe bleedingDesmopressin may helpful casesGenetic counseling","code":""},{"path":"hereditary.html","id":"alder-reilly-anomaly","chapter":"Hereditary","heading":"Alder-Reilly Anomaly","text":"Definition: rare, inherited anomaly characterized large, intensely staining granules types leukocytes (neutrophils, lymphocytes, monocytes, eosinophils, basophils)Genetic Basis\nAutosomal recessive inheritance\nCaused deficiency certain lysosomal enzymes involved degradation mucopolysaccharides\nAutosomal recessive inheritanceCaused deficiency certain lysosomal enzymes involved degradation mucopolysaccharidesPathophysiology\nLysosomal Storage Disorder: Deficiency lysosomal enzymes leads accumulation undigested mucopolysaccharides lysosomes\nGranule Formation: accumulated mucopolysaccharides form large granules visible cytoplasm leukocytes\nLysosomal Storage Disorder: Deficiency lysosomal enzymes leads accumulation undigested mucopolysaccharides lysosomesGranule Formation: accumulated mucopolysaccharides form large granules visible cytoplasm leukocytesMorphological Features\nLarge, intensely staining azurophilic (purple-red) granules types leukocytes\nGranules typically larger prominent normal granules\nDistinction Toxic Granulation: Alder-Reilly granules present types leukocytes, toxic granulation usually limited neutrophils\nLarge, intensely staining azurophilic (purple-red) granules types leukocytesGranules typically larger prominent normal granulesDistinction Toxic Granulation: Alder-Reilly granules present types leukocytes, toxic granulation usually limited neutrophilsAssociated Conditions: Mucopolysaccharidoses (MPS), group inherited metabolic disorders:\nHurler syndrome (MPS IH)\nHunter syndrome (MPS II)\nSanfilippo syndrome (MPS III)\nMorquio syndrome (MPS IV)\nHurler syndrome (MPS IH)Hunter syndrome (MPS II)Sanfilippo syndrome (MPS III)Morquio syndrome (MPS IV)Clinical Features\nRelated Mucopolysaccharidoses\nSkeletal abnormalities\nMental retardation\nHepatosplenomegaly\nCorneal clouding\nRelated MucopolysaccharidosesSkeletal abnormalitiesMental retardationHepatosplenomegalyCorneal cloudingLaboratory Findings\nCBC: May normal\nPeripheral Blood Smear:\nLarge, intensely staining granules types leukocytes\n\nBone Marrow Examination:\nMay show storage cells containing mucopolysaccharides\n\nEnzyme Assays:\nDemonstrate deficiency specific lysosomal enzyme affected particular mucopolysaccharidosis\n\nGenetic Testing:\nCan confirm diagnosis identify specific mutation\n\nCBC: May normalPeripheral Blood Smear:\nLarge, intensely staining granules types leukocytes\nLarge, intensely staining granules types leukocytesBone Marrow Examination:\nMay show storage cells containing mucopolysaccharides\nMay show storage cells containing mucopolysaccharidesEnzyme Assays:\nDemonstrate deficiency specific lysosomal enzyme affected particular mucopolysaccharidosis\nDemonstrate deficiency specific lysosomal enzyme affected particular mucopolysaccharidosisGenetic Testing:\nCan confirm diagnosis identify specific mutation\nCan confirm diagnosis identify specific mutationTreatment\nSupportive care underlying mucopolysaccharidosis\nEnzyme replacement therapy available MPS disorders\nHematopoietic stem cell transplantation (HSCT) may considered cases\nSupportive care underlying mucopolysaccharidosisEnzyme replacement therapy available MPS disordersHematopoietic stem cell transplantation (HSCT) may considered cases","code":""},{"path":"hereditary.html","id":"chédiak-higashi-syndrome-chs","chapter":"Hereditary","heading":"Chédiak-Higashi Syndrome (CHS)","text":"Definition: rare autosomal recessive disorder characterized :\nGiant granules leukocytes, melanocytes, cells\nPartial albinism (skin hair)\nRecurrent bacterial infections\nNeurological abnormalities\nGiant granules leukocytes, melanocytes, cellsPartial albinism (skin hair)Recurrent bacterial infectionsNeurological abnormalitiesGenetic Basis: Caused mutations LYST (also known CHS1) gene, regulates lysosomal traffickingPathophysiology\nAbnormal Lysosomal Trafficking: Defective LYST protein disrupts normal fusion trafficking lysosomes organelles\nGiant Granule Formation: Leads formation abnormally large granules various cell types, including leukocytes, melanocytes, nerve cells\nImpaired Function: giant granules impair normal function cells, leading clinical manifestations syndrome\nAbnormal Lysosomal Trafficking: Defective LYST protein disrupts normal fusion trafficking lysosomes organellesGiant Granule Formation: Leads formation abnormally large granules various cell types, including leukocytes, melanocytes, nerve cellsImpaired Function: giant granules impair normal function cells, leading clinical manifestations syndromeMorphological Features\nNeutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes: Contain giant granules stain Wright-Giemsa stain\ngranules often irregular shape size\nNeutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes: Contain giant granules stain Wright-Giemsa stainThe granules often irregular shape sizeClinical Features\nPartial Albinism: Light skin hair color due abnormal melanosomes\nRecurrent Bacterial Infections: Due impaired neutrophil chemotaxis killing\nNeurological Abnormalities: Peripheral neuropathy, seizures, developmental delay\nAccelerated Phase: patients develop accelerated phase characterized uncontrolled lymphocyte proliferation, hepatosplenomegaly, lymphadenopathy, pancytopenia\nPartial Albinism: Light skin hair color due abnormal melanosomesRecurrent Bacterial Infections: Due impaired neutrophil chemotaxis killingNeurological Abnormalities: Peripheral neuropathy, seizures, developmental delayAccelerated Phase: patients develop accelerated phase characterized uncontrolled lymphocyte proliferation, hepatosplenomegaly, lymphadenopathy, pancytopeniaLaboratory Findings\nCBC:\nMay normal show neutropenia, thrombocytopenia, anemia\n\nPeripheral Blood Smear:\nGiant granules leukocytes (neutrophils, eosinophils, basophils, monocytes, lymphocytes)\nLarge platelets may present\n\nBone Marrow Examination:\nMay show giant granules hematopoietic cells\n\nMicroscopy Skin Hair:\nMelanocytes contain large, abnormal melanosomes\n\nGenetic Testing:\nCan confirm diagnosis identifying mutations LYST gene\n\nCBC:\nMay normal show neutropenia, thrombocytopenia, anemia\nMay normal show neutropenia, thrombocytopenia, anemiaPeripheral Blood Smear:\nGiant granules leukocytes (neutrophils, eosinophils, basophils, monocytes, lymphocytes)\nLarge platelets may present\nGiant granules leukocytes (neutrophils, eosinophils, basophils, monocytes, lymphocytes)Large platelets may presentBone Marrow Examination:\nMay show giant granules hematopoietic cells\nMay show giant granules hematopoietic cellsMicroscopy Skin Hair:\nMelanocytes contain large, abnormal melanosomes\nMelanocytes contain large, abnormal melanosomesGenetic Testing:\nCan confirm diagnosis identifying mutations LYST gene\nCan confirm diagnosis identifying mutations LYST geneTreatment\nSupportive Care:\nAntibiotics treat infections\nAntiviral medications (e.g., acyclovir) viral infections\n\nHematopoietic Stem Cell Transplantation (HSCT):\ncurative treatment\neffective performed early life, development severe neurological complications\n\nTherapies:\nAscorbic acid (vitamin C) may improve aspects immune function\nInterferon-gamma may reduce frequency infections\n\nSupportive Care:\nAntibiotics treat infections\nAntiviral medications (e.g., acyclovir) viral infections\nAntibiotics treat infectionsAntiviral medications (e.g., acyclovir) viral infectionsHematopoietic Stem Cell Transplantation (HSCT):\ncurative treatment\neffective performed early life, development severe neurological complications\ncurative treatmentMost effective performed early life, development severe neurological complicationsOther Therapies:\nAscorbic acid (vitamin C) may improve aspects immune function\nInterferon-gamma may reduce frequency infections\nAscorbic acid (vitamin C) may improve aspects immune functionInterferon-gamma may reduce frequency infections","code":""},{"path":"hereditary.html","id":"laboratory-evaluation","chapter":"Hereditary","heading":"Laboratory Evaluation","text":"Complete Blood Count (CBC) Differential\nUsed assess number types leukocytes blood\nComplete Blood Count (CBC) DifferentialUsed assess number types leukocytes bloodPeripheral Blood Smear Examination\nimportant test identifying hereditary anomalies leukocytes\nCareful examination smear morphology essential accurate diagnosis\nPeripheral Blood Smear ExaminationThe important test identifying hereditary anomalies leukocytesCareful examination smear morphology essential accurate diagnosisSpecial Stains\nMay used highlight specific features cells\nSpecial StainsMay used highlight specific features cellsFlow Cytometry Immunophenotyping\nCan used identify cell surface markers\nFlow Cytometry ImmunophenotypingCan used identify cell surface markersGenetic Testing\nUsed confirm diagnosis identify specific gene mutation\nGenetic TestingUsed confirm diagnosis identify specific gene mutationKey TermsHereditary Anomaly: inherited disorder characterized distinct morphological functional abnormalitiesPelger-Huët Anomaly: Neutrophils bilobed unsegmented nucleiMay-Hegglin Anomaly: Döhle-like inclusions leukocytes, thrombocytopenia, giant plateletsAlder-Reilly Anomaly: Large granules leukocytesChédiak-Higashi Syndrome: Giant granules leukocytes, partial albinism, recurrent infectionsPeripheral Blood Smear: blood sample spread thinly slide microscopic examinationLysosomal Storage Disorder: group inherited metabolic disorders characterized accumulation undigested materials lysosomes","code":""},{"path":"plt-production.html","id":"plt-production","chapter":"PLT Production","heading":"PLT Production","text":"","code":""},{"path":"plt-production.html","id":"overview-of-thrombopoiesis","chapter":"PLT Production","heading":"Overview of Thrombopoiesis","text":"Definition: process platelet production, development, maturation, primarily occurring bone marrowPurpose: maintain adequate number platelets circulation ensure proper hemostasis (blood clotting) prevent excessive bleedingKey Cell: Megakaryocyte (MK) - large, multinucleated cell responsible producing plateletsRegulation: Primarily regulated thrombopoietin (TPO), factors also play role","code":""},{"path":"plt-production.html","id":"hematopoietic-stem-cells-hscs-and-megakaryocyte-development","chapter":"PLT Production","heading":"Hematopoietic Stem Cells (HSCs) and Megakaryocyte Development","text":"Hematopoietic Stem Cells (HSCs):\nSelf-renewing cells can differentiate blood cell lineages\nReside bone marrow\nSelf-renewing cells can differentiate blood cell lineagesReside bone marrowCommon Myeloid Progenitor (CMP):\nGives rise granulocytes, monocytes, macrophages, megakaryocytes, erythrocytes\nGives rise granulocytes, monocytes, macrophages, megakaryocytes, erythrocytesMegakaryocyte-Erythroid Progenitor (MEP):\nprogenitor cell can differentiate either megakaryocytes erythrocytes\nprogenitor cell can differentiate either megakaryocytes erythrocytesMegakaryoblast:\nEarliest identifiable megakaryocyte precursor\nLarge cell single, round nucleus\nCytoplasm basophilic lacks granules\nEarliest identifiable megakaryocyte precursorLarge cell single, round nucleusCytoplasm basophilic lacks granulesPromegakaryocyte:\nLarger megakaryoblast\nNucleus undergoes endomitosis (DNA replication without cell division), resulting multilobed polyploid nucleus\nCytoplasm becomes abundant contains granules\nLarger megakaryoblastNucleus undergoes endomitosis (DNA replication without cell division), resulting multilobed polyploid nucleusCytoplasm becomes abundant contains granulesMegakaryocyte (MK):\nlargest cell bone marrow\nLarge, multilobed nucleus condensed chromatin\nAbundant cytoplasm filled granules (alpha granules dense granules)\nResponsible platelet production\nlargest cell bone marrowLarge, multilobed nucleus condensed chromatinAbundant cytoplasm filled granules (alpha granules dense granules)Responsible platelet productionPlatelet Production:\nMegakaryocytes extend long, branching cytoplasmic processes called proplatelets bone marrow sinusoids (blood vessels)\nProplatelets fragment individual platelets, released circulation\nMegakaryocytes extend long, branching cytoplasmic processes called proplatelets bone marrow sinusoids (blood vessels)Proplatelets fragment individual platelets, released circulation","code":""},{"path":"plt-production.html","id":"thrombopoietin-tpo-and-regulation-of-thrombopoiesis","chapter":"PLT Production","heading":"Thrombopoietin (TPO) and Regulation of Thrombopoiesis","text":"Thrombopoietin (TPO):\nPrimary regulator megakaryopoiesis thrombopoiesis\nProduced mainly liver, smaller amounts produced kidney bone marrow stromal cells\nBinds MPL receptor (also known c-MPL) hematopoietic stem cells, megakaryocyte progenitors, platelets\nPrimary regulator megakaryopoiesis thrombopoiesisProduced mainly liver, smaller amounts produced kidney bone marrow stromal cellsBinds MPL receptor (also known c-MPL) hematopoietic stem cells, megakaryocyte progenitors, plateletsMechanisms Action TPO:\nStimulates proliferation differentiation megakaryocyte progenitors\nPromotes megakaryocyte maturation polyploidization (endomitosis)\nIncreases platelet production megakaryocytes\nPrevents apoptosis (programmed cell death) megakaryocytes\nStimulates proliferation differentiation megakaryocyte progenitorsPromotes megakaryocyte maturation polyploidization (endomitosis)Increases platelet production megakaryocytesPrevents apoptosis (programmed cell death) megakaryocytesRegulation TPO Levels:\nTPO production relatively constant\nPlatelets megakaryocytes bind internalize TPO, reducing amount TPO available stimulate platelet production\nthrombocytopenia (low platelet count), fewer platelets bind TPO, TPO levels increase, stimulating megakaryopoiesis\nthrombocytosis (high platelet count), platelets bind TPO, TPO levels decrease, suppressing megakaryopoiesis\nTPO production relatively constantPlatelets megakaryocytes bind internalize TPO, reducing amount TPO available stimulate platelet productionIn thrombocytopenia (low platelet count), fewer platelets bind TPO, TPO levels increase, stimulating megakaryopoiesisIn thrombocytosis (high platelet count), platelets bind TPO, TPO levels decrease, suppressing megakaryopoiesis","code":""},{"path":"plt-production.html","id":"other-factors-influencing-thrombopoiesis","chapter":"PLT Production","heading":"Other Factors Influencing Thrombopoiesis","text":"Cytokines:\nInterleukin-6 (IL-6): Stimulates megakaryocyte proliferation maturation\nInterleukin-11 (IL-11): Promotes megakaryocyte maturation platelet production\nStem Cell Factor (SCF): Supports survival proliferation HSCs early progenitors\nInterleukin-6 (IL-6): Stimulates megakaryocyte proliferation maturationInterleukin-11 (IL-11): Promotes megakaryocyte maturation platelet productionStem Cell Factor (SCF): Supports survival proliferation HSCs early progenitorsGrowth Factors:\nThrombopoietin (TPO) main driver!\nThrombopoietin (TPO) main driver!Transcription Factors:\nGATA-1: Essential megakaryocyte development\nFLI1: Involved megakaryocyte differentiation function\nGATA-1: Essential megakaryocyte developmentFLI1: Involved megakaryocyte differentiation functionBone Marrow Microenvironment:\nStromal cells bone marrow provide supportive niche megakaryocytes\nExtracellular matrix components, adhesion molecules, growth factors influence megakaryopoiesis\nStromal cells bone marrow provide supportive niche megakaryocytesExtracellular matrix components, adhesion molecules, growth factors influence megakaryopoiesis","code":""},{"path":"plt-production.html","id":"platelet-structure-and-function","chapter":"PLT Production","heading":"Platelet Structure and Function","text":"Platelets (Thrombocytes):\nSmall, anucleate cell fragments produced megakaryocytes\nEssential hemostasis (blood clotting)\nNormal Platelet Count: 150-450 x 10^9/L\nSmall, anucleate cell fragments produced megakaryocytesEssential hemostasis (blood clotting)Normal Platelet Count: 150-450 x 10^9/LStructure:\nPlasma membrane: Contains receptors adhesion, activation, aggregation\nGlycocalyx: Outer coating containing glycoproteins mediate adhesion subendothelial matrix platelets\nCytoplasm:\nGranules:\nAlpha granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor), growth factors, adhesion molecules\nDense granules (δ-granules): Contain ADP, ATP, serotonin, calcium\n\nOpen Canalicular System (OCS): System channels connect platelet interior external environment\nDense Tubular System (DTS): Storage site calcium ions\nMicrotubules Actin Filaments: Provide structural support facilitate shape change movement\n\nPlasma membrane: Contains receptors adhesion, activation, aggregationGlycocalyx: Outer coating containing glycoproteins mediate adhesion subendothelial matrix plateletsCytoplasm:\nGranules:\nAlpha granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor), growth factors, adhesion molecules\nDense granules (δ-granules): Contain ADP, ATP, serotonin, calcium\n\nOpen Canalicular System (OCS): System channels connect platelet interior external environment\nDense Tubular System (DTS): Storage site calcium ions\nMicrotubules Actin Filaments: Provide structural support facilitate shape change movement\nGranules:\nAlpha granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor), growth factors, adhesion molecules\nDense granules (δ-granules): Contain ADP, ATP, serotonin, calcium\nAlpha granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor), growth factors, adhesion moleculesDense granules (δ-granules): Contain ADP, ATP, serotonin, calciumOpen Canalicular System (OCS): System channels connect platelet interior external environmentDense Tubular System (DTS): Storage site calcium ionsMicrotubules Actin Filaments: Provide structural support facilitate shape change movementFunctions:\nPrimary Hemostasis: Formation platelet plug\nSecondary Hemostasis: Contributing coagulation cascade fibrin clot formation\nVessel Repair: Releasing growth factors promote wound healing angiogenesis\nInflammation: Releasing inflammatory mediators\nPrimary Hemostasis: Formation platelet plugSecondary Hemostasis: Contributing coagulation cascade fibrin clot formationVessel Repair: Releasing growth factors promote wound healing angiogenesisInflammation: Releasing inflammatory mediators","code":""},{"path":"plt-production.html","id":"disorders-of-thrombopoiesis","chapter":"PLT Production","heading":"Disorders of Thrombopoiesis","text":"Thrombocytopenia: Decreased platelet count (<150 x 10^9/L)\nDecreased Production:\nAplastic anemia\nMyelodysplastic syndromes (MDS)\nInfections\nMedications\nAlcohol abuse\n\nIncreased Destruction:\nImmune thrombocytopenic purpura (ITP)\nThrombotic thrombocytopenic purpura (TTP)\nHeparin-induced thrombocytopenia (HIT)\nDisseminated intravascular coagulation (DIC)\n\nSequestration:\nSplenomegaly\n\nDecreased Production:\nAplastic anemia\nMyelodysplastic syndromes (MDS)\nInfections\nMedications\nAlcohol abuse\nAplastic anemiaMyelodysplastic syndromes (MDS)InfectionsMedicationsAlcohol abuseIncreased Destruction:\nImmune thrombocytopenic purpura (ITP)\nThrombotic thrombocytopenic purpura (TTP)\nHeparin-induced thrombocytopenia (HIT)\nDisseminated intravascular coagulation (DIC)\nImmune thrombocytopenic purpura (ITP)Thrombotic thrombocytopenic purpura (TTP)Heparin-induced thrombocytopenia (HIT)Disseminated intravascular coagulation (DIC)Sequestration:\nSplenomegaly\nSplenomegalyThrombocytosis: Increased platelet count (>450 x 10^9/L)\nReactive Thrombocytosis:\nOccurs response another condition (e.g., infection, inflammation, iron deficiency, splenectomy)\nPlatelet count usually mildly elevated transient\n\nEssential Thrombocythemia (ET):\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\nAssociated mutations JAK2, CALR, MPL\n\nReactive Thrombocytosis:\nOccurs response another condition (e.g., infection, inflammation, iron deficiency, splenectomy)\nPlatelet count usually mildly elevated transient\nOccurs response another condition (e.g., infection, inflammation, iron deficiency, splenectomy)Platelet count usually mildly elevated transientEssential Thrombocythemia (ET):\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\nAssociated mutations JAK2, CALR, MPL\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleedingAssociated mutations JAK2, CALR, MPL","code":""},{"path":"plt-production.html","id":"laboratory-evaluation-of-thrombopoiesis","chapter":"PLT Production","heading":"Laboratory Evaluation of Thrombopoiesis","text":"Complete Blood Count (CBC):\nPlatelet Count: Measures number platelets blood\nPlatelet Count: Measures number platelets bloodPeripheral Blood Smear Examination:\nPlatelet Estimate: Evaluates number platelets smear confirms automated platelet count\nPlatelet Morphology: Identifies abnormal platelet morphology (e.g., giant platelets, hypogranular platelets)\nPlatelet Estimate: Evaluates number platelets smear confirms automated platelet countPlatelet Morphology: Identifies abnormal platelet morphology (e.g., giant platelets, hypogranular platelets)Bone Marrow Aspiration Biopsy:\nMegakaryocyte Number Morphology: Assesses number morphology megakaryocytes bone marrow\nMegakaryocyte Number Morphology: Assesses number morphology megakaryocytes bone marrowFlow Cytometry:\nidentify cell surface markers megakaryocytes\nidentify cell surface markers megakaryocytesMolecular Testing:\ndetect mutations genes involved megakaryopoiesis (e.g., JAK2, CALR, MPL)\ndetect mutations genes involved megakaryopoiesis (e.g., JAK2, CALR, MPL)Platelet Function Tests:\nevaluate platelet adhesion, aggregation, secretion\nPlatelet aggregation studies\nPlatelet function analyzer (PFA-100)\nevaluate platelet adhesion, aggregation, secretionPlatelet aggregation studiesPlatelet function analyzer (PFA-100)","code":""},{"path":"plt-production.html","id":"key-terms-34","chapter":"PLT Production","heading":"Key Terms","text":"Thrombopoiesis: Platelet productionMegakaryocyte: Large, multinucleated cell responsible producing plateletsThrombopoietin (TPO): Hormone regulates megakaryopoiesis thrombopoiesisPlatelet (Thrombocyte): Small, anucleate cell fragment involved hemostasisThrombocytopenia: Decreased platelet countThrombocytosis: Increased platelet countEssential Thrombocythemia (ET): Myeloproliferative neoplasm sustained thrombocytosisEndomitosis: DNA replication without cell divisionProplatelets: Cytoplasmic extensions megakaryocytes fragment plateletsPlatelet Aggregation: clumping together platelets form platelet plugMean Platelet Volume (MPV): average size platelets","code":""},{"path":"plt-function.html","id":"plt-function","chapter":"PLT Function","heading":"PLT Function","text":"","code":""},{"path":"plt-function.html","id":"overview-of-platelet-function","chapter":"PLT Function","heading":"Overview of Platelet Function","text":"Definition: Platelets (thrombocytes) small, anucleate cell fragments play critical role hemostasis (blood clotting), thrombosis (blood clot formation), inflammationPrimary Function: initiate participate formation platelet plug sites vascular injury, thereby preventing excessive bleedingSecondary Functions: Contributing coagulation cascade fibrin clot formationNormal Platelet Count: 150,000 - 450,000 /μL (150-450 x 10^9/L)Thrombocytopenia: Platelet count < 150,000 /μLThrombocytosis: Platelet count > 450,000 /μL","code":""},{"path":"plt-function.html","id":"platelet-structure","chapter":"PLT Function","heading":"Platelet Structure","text":"Plasma Membrane:\nPhospholipid bilayer embedded glycoproteins receptors\nGlycocalyx: Outer coating containing glycoproteins mediate adhesion subendothelial matrix platelets\nPhospholipid bilayer embedded glycoproteins receptorsGlycocalyx: Outer coating containing glycoproteins mediate adhesion subendothelial matrix plateletsCytoplasm:\nGranules:\nAlpha Granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor [vWF]), growth factors (e.g., platelet-derived growth factor [PDGF]), adhesion molecules (e.g., P-selectin)\nDense Granules (δ-granules): Contain ADP, ATP, serotonin, calcium\nLysosomes: Contain hydrolytic enzymes\n\nOpen Canalicular System (OCS): System channels connect platelet interior external environment, facilitating release granular contents increasing surface area\nDense Tubular System (DTS): Storage site calcium ions enzymes involved prostaglandin thromboxane synthesis\nMicrotubules Actin Filaments: Provide structural support facilitate shape change, movement, clot retraction\nGranules:\nAlpha Granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor [vWF]), growth factors (e.g., platelet-derived growth factor [PDGF]), adhesion molecules (e.g., P-selectin)\nDense Granules (δ-granules): Contain ADP, ATP, serotonin, calcium\nLysosomes: Contain hydrolytic enzymes\nAlpha Granules: Contain clotting factors (e.g., fibrinogen, von Willebrand factor [vWF]), growth factors (e.g., platelet-derived growth factor [PDGF]), adhesion molecules (e.g., P-selectin)Dense Granules (δ-granules): Contain ADP, ATP, serotonin, calciumLysosomes: Contain hydrolytic enzymesOpen Canalicular System (OCS): System channels connect platelet interior external environment, facilitating release granular contents increasing surface areaDense Tubular System (DTS): Storage site calcium ions enzymes involved prostaglandin thromboxane synthesisMicrotubules Actin Filaments: Provide structural support facilitate shape change, movement, clot retraction","code":""},{"path":"plt-function.html","id":"key-steps-in-platelet-function","chapter":"PLT Function","heading":"Key Steps in Platelet Function","text":"Adhesion:\nMechanism:\nPlatelets adhere exposed subendothelial matrix sites vascular injury\nVon Willebrand factor (vWF) acts bridge platelet glycoprotein Ib/IX/V receptor (GPIb/IX/V) collagen subendothelium\nadhesion molecules: Collagen receptors (e.g., GPVI), integrins (e.g., α2β1)\n\nDisorders Adhesion:\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, leading impaired vWF binding\nvon Willebrand Disease: Deficiency dysfunction vWF, leading impaired platelet adhesion\n\nMechanism:\nPlatelets adhere exposed subendothelial matrix sites vascular injury\nVon Willebrand factor (vWF) acts bridge platelet glycoprotein Ib/IX/V receptor (GPIb/IX/V) collagen subendothelium\nadhesion molecules: Collagen receptors (e.g., GPVI), integrins (e.g., α2β1)\nPlatelets adhere exposed subendothelial matrix sites vascular injuryVon Willebrand factor (vWF) acts bridge platelet glycoprotein Ib/IX/V receptor (GPIb/IX/V) collagen subendotheliumOther adhesion molecules: Collagen receptors (e.g., GPVI), integrins (e.g., α2β1)Disorders Adhesion:\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, leading impaired vWF binding\nvon Willebrand Disease: Deficiency dysfunction vWF, leading impaired platelet adhesion\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, leading impaired vWF bindingvon Willebrand Disease: Deficiency dysfunction vWF, leading impaired platelet adhesionActivation:\nMechanism:\nAdhesion triggers platelet activation, leading cascade intracellular signaling events\nRelease ADP thromboxane A2 (TXA2) amplifies activation process\nActivation leads :\nShape change: Platelets transform discoid shape spherical shape pseudopodia (filopodia)\nGranule release (degranulation): Secretion granular contents surrounding environment\nIncreased expression GPIIb/IIIa receptors platelet surface\n\n\nKey Receptors Signaling Molecules:\nADP receptors (P2Y1 P2Y12): Bind ADP, promoting platelet activation aggregation\nThromboxane A2 (TXA2): potent platelet activator vasoconstrictor, synthesized arachidonic acid cyclooxygenase (COX) thromboxane synthase\nThrombin: potent activator platelets via protease-activated receptors (PARs)\nCollagen: Activates platelets via GPVI receptor\n\nDisorders Activation:\nStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)\nGray Platelet Syndrome: Deficiency alpha granules, leading impaired platelet function\n\nMechanism:\nAdhesion triggers platelet activation, leading cascade intracellular signaling events\nRelease ADP thromboxane A2 (TXA2) amplifies activation process\nActivation leads :\nShape change: Platelets transform discoid shape spherical shape pseudopodia (filopodia)\nGranule release (degranulation): Secretion granular contents surrounding environment\nIncreased expression GPIIb/IIIa receptors platelet surface\n\nAdhesion triggers platelet activation, leading cascade intracellular signaling eventsRelease ADP thromboxane A2 (TXA2) amplifies activation processActivation leads :\nShape change: Platelets transform discoid shape spherical shape pseudopodia (filopodia)\nGranule release (degranulation): Secretion granular contents surrounding environment\nIncreased expression GPIIb/IIIa receptors platelet surface\nShape change: Platelets transform discoid shape spherical shape pseudopodia (filopodia)Granule release (degranulation): Secretion granular contents surrounding environmentIncreased expression GPIIb/IIIa receptors platelet surfaceKey Receptors Signaling Molecules:\nADP receptors (P2Y1 P2Y12): Bind ADP, promoting platelet activation aggregation\nThromboxane A2 (TXA2): potent platelet activator vasoconstrictor, synthesized arachidonic acid cyclooxygenase (COX) thromboxane synthase\nThrombin: potent activator platelets via protease-activated receptors (PARs)\nCollagen: Activates platelets via GPVI receptor\nADP receptors (P2Y1 P2Y12): Bind ADP, promoting platelet activation aggregationThromboxane A2 (TXA2): potent platelet activator vasoconstrictor, synthesized arachidonic acid cyclooxygenase (COX) thromboxane synthaseThrombin: potent activator platelets via protease-activated receptors (PARs)Collagen: Activates platelets via GPVI receptorDisorders Activation:\nStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)\nGray Platelet Syndrome: Deficiency alpha granules, leading impaired platelet function\nStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)Gray Platelet Syndrome: Deficiency alpha granules, leading impaired platelet functionAggregation:\nMechanism:\nActivated platelets bind , forming platelet plug (primary hemostatic plug)\nGPIIb/IIIa receptor (integrin αIIbβ3) activated platelets binds fibrinogen, acts bridge adjacent platelets\ncross-linking fibrinogen molecules promotes platelet aggregation\n\nDisorders Aggregation:\nGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, leading impaired platelet aggregation\n\nMechanism:\nActivated platelets bind , forming platelet plug (primary hemostatic plug)\nGPIIb/IIIa receptor (integrin αIIbβ3) activated platelets binds fibrinogen, acts bridge adjacent platelets\ncross-linking fibrinogen molecules promotes platelet aggregation\nActivated platelets bind , forming platelet plug (primary hemostatic plug)GPIIb/IIIa receptor (integrin αIIbβ3) activated platelets binds fibrinogen, acts bridge adjacent plateletsThis cross-linking fibrinogen molecules promotes platelet aggregationDisorders Aggregation:\nGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, leading impaired platelet aggregation\nGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, leading impaired platelet aggregationSecretion (Release Reaction):\nMechanism:\nActivated platelets release contents granules (alpha granules dense granules)\nADP TXA2 amplify platelet activation promote aggregation\nSerotonin contributes vasoconstriction\nClotting factors (e.g., fibrinogen, vWF) contribute secondary hemostasis\n\nDisorders Secretion:\nStorage pool deficiencies (e.g., Wiskott-Aldrich syndrome)\n\nMechanism:\nActivated platelets release contents granules (alpha granules dense granules)\nADP TXA2 amplify platelet activation promote aggregation\nSerotonin contributes vasoconstriction\nClotting factors (e.g., fibrinogen, vWF) contribute secondary hemostasis\nActivated platelets release contents granules (alpha granules dense granules)ADP TXA2 amplify platelet activation promote aggregationSerotonin contributes vasoconstrictionClotting factors (e.g., fibrinogen, vWF) contribute secondary hemostasisDisorders Secretion:\nStorage pool deficiencies (e.g., Wiskott-Aldrich syndrome)\nStorage pool deficiencies (e.g., Wiskott-Aldrich syndrome)Stabilization Platelet Plug:\nMechanism:\ncoagulation cascade activated, leading formation fibrin\nFibrinogen binds activated GPIIb/IIIa receptors, forming fibrin meshwork stabilizes platelet plug\nClot retraction: Platelets contract, pulling edges damaged vessel together strengthening clot\n\nRole Thrombin: Thrombin key enzyme coagulation cascade also potent platelet activator, creating positive feedback loop\nMechanism:\ncoagulation cascade activated, leading formation fibrin\nFibrinogen binds activated GPIIb/IIIa receptors, forming fibrin meshwork stabilizes platelet plug\nClot retraction: Platelets contract, pulling edges damaged vessel together strengthening clot\ncoagulation cascade activated, leading formation fibrinFibrinogen binds activated GPIIb/IIIa receptors, forming fibrin meshwork stabilizes platelet plugClot retraction: Platelets contract, pulling edges damaged vessel together strengthening clotRole Thrombin: Thrombin key enzyme coagulation cascade also potent platelet activator, creating positive feedback loop","code":""},{"path":"plt-function.html","id":"regulation-of-platelet-function","chapter":"PLT Function","heading":"Regulation of Platelet Function","text":"Prostacyclin (PGI2):\nProduced endothelial cells\nInhibits platelet activation aggregation\nCauses vasodilation\nProduced endothelial cellsInhibits platelet activation aggregationCauses vasodilationNitric Oxide ():\nProduced endothelial cells\nInhibits platelet adhesion, activation, aggregation\nCauses vasodilation\nProduced endothelial cellsInhibits platelet adhesion, activation, aggregationCauses vasodilationADPase (CD39):\nenzyme endothelial cells degrades ADP, reducing platelet activation\nenzyme endothelial cells degrades ADP, reducing platelet activationThrombomodulin-Thrombin Complex:\nThrombomodulin binds thrombin, changing substrate specificity\nthrombomodulin-thrombin complex activates protein C, inactivates factors Va VIIIa, inhibiting coagulation\nThrombomodulin binds thrombin, changing substrate specificityThe thrombomodulin-thrombin complex activates protein C, inactivates factors Va VIIIa, inhibiting coagulationInhibitory Receptors Platelets:\nPlatelets express receptors can inhibit platelet activation (e.g., FcγRIIB, GPVI)\nPlatelets express receptors can inhibit platelet activation (e.g., FcγRIIB, GPVI)","code":""},{"path":"plt-function.html","id":"platelet-function-tests","chapter":"PLT Function","heading":"Platelet Function Tests","text":"Platelet Count:\nMeasures number platelets blood\nUsed detect thrombocytopenia thrombocytosis\nMeasures number platelets bloodUsed detect thrombocytopenia thrombocytosisBleeding Time:\nHistorical test (now rarely used)\nMeasures time takes bleeding stop standardized skin incision\nProlonged bleeding time suggests platelet disorder von Willebrand disease\nHistorical test (now rarely used)Measures time takes bleeding stop standardized skin incisionProlonged bleeding time suggests platelet disorder von Willebrand diseasePlatelet Function Analyzer (PFA-100):\nMeasures platelet function high shear stress\nBlood passed small aperture coated collagen either epinephrine ADP\nMeasures time takes platelet plug form occlude aperture (closure time)\nProlonged closure time suggests platelet disorder von Willebrand disease\nMeasures platelet function high shear stressBlood passed small aperture coated collagen either epinephrine ADPMeasures time takes platelet plug form occlude aperture (closure time)Prolonged closure time suggests platelet disorder von Willebrand diseasePlatelet Aggregation Studies:\nMeasures ability platelets aggregate response various agonists (e.g., ADP, collagen, epinephrine, thrombin, arachidonic acid, ristocetin)\nAgonists added platelet-rich plasma, change light transmission measured platelets aggregate\nAbnormal aggregation patterns can help identify specific platelet disorders\nMeasures ability platelets aggregate response various agonists (e.g., ADP, collagen, epinephrine, thrombin, arachidonic acid, ristocetin)Agonists added platelet-rich plasma, change light transmission measured platelets aggregateAbnormal aggregation patterns can help identify specific platelet disordersFlow Cytometry:\nMeasures platelet surface markers (e.g., GPIIb/IIIa, GPIb/IX/V)\nCan assess platelet activation binding agonists\nMeasures platelet surface markers (e.g., GPIIb/IIIa, GPIb/IX/V)Can assess platelet activation binding agonistsThromboelastography (TEG) Thromboelastometry (ROTEM):\nViscoelastic tests assess overall hemostatic function blood\nMeasure strength elasticity developing clot\nProvide information platelet function, coagulation factors, fibrinolysis\nViscoelastic tests assess overall hemostatic function bloodMeasure strength elasticity developing clotProvide information platelet function, coagulation factors, fibrinolysis","code":""},{"path":"plt-function.html","id":"disorders-of-platelet-function","chapter":"PLT Function","heading":"Disorders of Platelet Function","text":"Quantitative Disorders:\nThrombocytopenia: Decreased platelet count\nThrombocytosis: Increased platelet count\nThrombocytopenia: Decreased platelet countThrombocytosis: Increased platelet countQualitative Disorders:\nInherited Platelet Function Disorders:\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, impairing vWF binding\nGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, impairing platelet aggregation\nStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)\n\nAcquired Platelet Function Disorders:\nUremia: Accumulation uremic toxins kidney failure impairs platelet function\nMedications: Aspirin, clopidogrel, antiplatelet drugs inhibit platelet function\nMyeloproliferative Neoplasms (MPNs): Abnormal platelet function common ET PMF\nVon Willebrand Disease (vWD): Deficiency dysfunction vWF, impairing platelet adhesion\n\nInherited Platelet Function Disorders:\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, impairing vWF binding\nGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, impairing platelet aggregation\nStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)\nBernard-Soulier Syndrome: Deficiency GPIb/IX/V complex, impairing vWF bindingGlanzmann Thrombasthenia: Deficiency GPIIb/IIIa receptor, impairing platelet aggregationStorage Pool Deficiencies: Deficiencies platelet granules (e.g., dense granule deficiency, alpha granule deficiency)Acquired Platelet Function Disorders:\nUremia: Accumulation uremic toxins kidney failure impairs platelet function\nMedications: Aspirin, clopidogrel, antiplatelet drugs inhibit platelet function\nMyeloproliferative Neoplasms (MPNs): Abnormal platelet function common ET PMF\nVon Willebrand Disease (vWD): Deficiency dysfunction vWF, impairing platelet adhesion\nUremia: Accumulation uremic toxins kidney failure impairs platelet functionMedications: Aspirin, clopidogrel, antiplatelet drugs inhibit platelet functionMyeloproliferative Neoplasms (MPNs): Abnormal platelet function common ET PMFVon Willebrand Disease (vWD): Deficiency dysfunction vWF, impairing platelet adhesion","code":""},{"path":"plt-function.html","id":"key-terms-35","chapter":"PLT Function","heading":"Key Terms","text":"Platelet (Thrombocyte): Small, anucleate cell fragment involved hemostasisAdhesion: Platelet attachment subendothelial matrixActivation: Platelet stimulation leading shape change, degranulation, increased GPIIb/IIIa expressionAggregation: Platelet--platelet bindingSecretion: Release granular contents plateletsvWF (von Willebrand Factor): protein mediates platelet adhesionGPIIb/IIIa: platelet surface receptor binds fibrinogen mediates platelet aggregationThromboxane A2 (TXA2): potent platelet activator vasoconstrictorProstacyclin (PGI2): inhibitor platelet activation aggregationPFA-100: Platelet function analyzerThromboelastography (TEG): viscoelastic test hemostasis","code":""},{"path":"plt-destruction.html","id":"plt-destruction","chapter":"PLT Destruction","heading":"PLT Destruction","text":"","code":""},{"path":"plt-destruction.html","id":"overview-of-thrombocytopenia-due-to-increased-platelet-destruction","chapter":"PLT Destruction","heading":"Overview of Thrombocytopenia Due to Increased Platelet Destruction","text":"Definition: group disorders characterized decreased platelet count (<150 x 10^9/L) resulting accelerated destruction consumption platelets.Definition: group disorders characterized decreased platelet count (<150 x 10^9/L) resulting accelerated destruction consumption platelets.Key Distinctions:\nDifferentiating increased destruction decreased production key. bone marrow response (megakaryocyte number activity) essential distinction.\nnormal, even increased, megakaryocyte number bone marrow suggests problem lies destruction platelets.\nKey Distinctions:Differentiating increased destruction decreased production key. bone marrow response (megakaryocyte number activity) essential distinction.normal, even increased, megakaryocyte number bone marrow suggests problem lies destruction platelets.General Mechanisms:\nImmune-Mediated Destruction: Antibodies complement proteins bind platelets, leading destruction mononuclear phagocyte system (MPS) complement-mediated lysis\nNon-Immune-Mediated Destruction: Platelets mechanically damaged consumed thrombotic microangiopathies (TMAs)\nSequestration: Platelets trapped spleen due splenomegaly\nGeneral Mechanisms:Immune-Mediated Destruction: Antibodies complement proteins bind platelets, leading destruction mononuclear phagocyte system (MPS) complement-mediated lysisNon-Immune-Mediated Destruction: Platelets mechanically damaged consumed thrombotic microangiopathies (TMAs)Sequestration: Platelets trapped spleen due splenomegaly","code":""},{"path":"plt-destruction.html","id":"key-laboratory-tests","chapter":"PLT Destruction","heading":"Key Laboratory Tests","text":"Complete Blood Count (CBC):\nevaluate platelet count blood cell parameters\nevaluate platelet count blood cell parametersPeripheral Blood Smear Examination:\nassess platelet morphology rule causes thrombocytopenia\nassess platelet morphology rule causes thrombocytopeniaDirect Antiglobulin Test (DAT):\nrule immune hemolysis\nrule immune hemolysisCoagulation Studies (PT, aPTT, Fibrinogen, D-dimer):\nrule DIC\nrule DICADAMTS13 Activity Level:\ndiagnose TTP\ndiagnose TTPStool Shiga Toxin Assay:\ndiagnose typical HUS\ndiagnose typical HUSHIT Antibody Testing:\ndiagnose heparin-induced thrombocytopenia\ndiagnose heparin-induced thrombocytopeniaBone Marrow Aspiration Biopsy:\nevaluate megakaryocytes rule bone marrow disorders\nevaluate megakaryocytes rule bone marrow disorders","code":""},{"path":"plt-destruction.html","id":"key-terms-36","chapter":"PLT Destruction","heading":"Key Terms","text":"Thrombocytopenia: Decreased platelet count (<150 x 10^9/L)ITP (Immune Thrombocytopenic Purpura): Autoimmune destruction plateletsTTP (Thrombotic Thrombocytopenic Purpura): Microangiopathic hemolytic anemia thrombocytopenia due ADAMTS13 deficiencyHUS (Hemolytic Uremic Syndrome): Microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injuryDIC (Disseminated Intravascular Coagulation): Systemic activation coagulation fibrinolysisSchistocytes: Fragmented red blood cellsADAMTS13: metalloprotease cleaves von Willebrand factor (vWF)Haptoglobin: Protein binds free hemoglobin released plasma","code":""},{"path":"quantitative.html","id":"quantitative","chapter":"Quantitative","heading":"Quantitative","text":"","code":""},{"path":"quantitative.html","id":"overview-of-platelet-quantitative-abnormalities","chapter":"Quantitative","heading":"Overview of Platelet Quantitative Abnormalities","text":"Platelets (Thrombocytes): Small, anucleate cell fragments essential hemostasis (blood clotting)Normal Platelet Count: 150,000 - 450,000 /μL (150-450 x 10^9/L)Quantitative Abnormalities:\nThrombocytopenia: Decreased platelet count\nThrombocytosis: Increased platelet count\nThrombocytopenia: Decreased platelet countThrombocytosis: Increased platelet countClinical Significance: Abnormal platelet counts can lead bleeding (thrombocytopenia) thrombosis (thrombocytosis)Laboratory Evaluation: Accurate platelet counting peripheral blood smear examination essential diagnosis management","code":""},{"path":"quantitative.html","id":"thrombocytopenia","chapter":"Quantitative","heading":"Thrombocytopenia","text":"Definition: decreased platelet count, defined platelet count <150 x 10^9/LClassification:\nBased Mechanism:\nDecreased Platelet Production: bone marrow producing enough platelets\nIncreased Platelet Destruction: Platelets destroyed consumed accelerated rate\nSequestration: Platelets trapped spleen\nDilutional: result blood transfusions fluid administration.\n\nBased Severity:\nMild Thrombocytopenia: 100-150 x 10^9/L\nModerate Thrombocytopenia: 50-100 x 10^9/L\nSevere Thrombocytopenia: <50 x 10^9/L\n\nBased Mechanism:\nDecreased Platelet Production: bone marrow producing enough platelets\nIncreased Platelet Destruction: Platelets destroyed consumed accelerated rate\nSequestration: Platelets trapped spleen\nDilutional: result blood transfusions fluid administration.\nDecreased Platelet Production: bone marrow producing enough plateletsIncreased Platelet Destruction: Platelets destroyed consumed accelerated rateSequestration: Platelets trapped spleenDilutional: result blood transfusions fluid administration.Based Severity:\nMild Thrombocytopenia: 100-150 x 10^9/L\nModerate Thrombocytopenia: 50-100 x 10^9/L\nSevere Thrombocytopenia: <50 x 10^9/L\nMild Thrombocytopenia: 100-150 x 10^9/LModerate Thrombocytopenia: 50-100 x 10^9/LSevere Thrombocytopenia: <50 x 10^9/LPseudothrombocytopenia: falsely low platelet count due platelet clumping presence EDTA anticoagulant","code":""},{"path":"quantitative.html","id":"causes-of-thrombocytopenia","chapter":"Quantitative","heading":"Causes of Thrombocytopenia","text":"Decreased Platelet Production:\nBone Marrow Disorders:\nAplastic Anemia: Bone marrow failure decreased production blood cell lines\nMyelodysplastic Syndromes (MDS): Dysplastic changes megakaryocytes leading impaired platelet production\nLeukemia: Infiltration bone marrow leukemic cells, crowding normal megakaryocytes\nMyelofibrosis: Scarring bone marrow, impairing megakaryopoiesis\n\nInfections:\nViral Infections: Parvovirus B19, HIV, hepatitis C\nBacterial Infections: Sepsis\n\nNutritional Deficiencies:\nVitamin B12 folate deficiency (megaloblastic anemia)\nIron deficiency\n\nAlcohol Abuse:\nDirect toxic effect megakaryocytes\n\nMedications:\nChemotherapy\nThiazide diuretics\nAlcohol abuse\nOthers\n\nDecreased Platelet Production:Bone Marrow Disorders:\nAplastic Anemia: Bone marrow failure decreased production blood cell lines\nMyelodysplastic Syndromes (MDS): Dysplastic changes megakaryocytes leading impaired platelet production\nLeukemia: Infiltration bone marrow leukemic cells, crowding normal megakaryocytes\nMyelofibrosis: Scarring bone marrow, impairing megakaryopoiesis\nAplastic Anemia: Bone marrow failure decreased production blood cell linesMyelodysplastic Syndromes (MDS): Dysplastic changes megakaryocytes leading impaired platelet productionLeukemia: Infiltration bone marrow leukemic cells, crowding normal megakaryocytesMyelofibrosis: Scarring bone marrow, impairing megakaryopoiesisInfections:\nViral Infections: Parvovirus B19, HIV, hepatitis C\nBacterial Infections: Sepsis\nViral Infections: Parvovirus B19, HIV, hepatitis CBacterial Infections: SepsisNutritional Deficiencies:\nVitamin B12 folate deficiency (megaloblastic anemia)\nIron deficiency\nVitamin B12 folate deficiency (megaloblastic anemia)Iron deficiencyAlcohol Abuse:\nDirect toxic effect megakaryocytes\nDirect toxic effect megakaryocytesMedications:\nChemotherapy\nThiazide diuretics\nAlcohol abuse\nOthers\nChemotherapyThiazide diureticsAlcohol abuseOthersIncreased Platelet Destruction:\nImmune Thrombocytopenic Purpura (ITP):\nAutoantibodies (usually IgG) bind platelet surface antigens, leading destruction spleen\nCan acute (often children viral infection) chronic (common adults)\nWarm Autoimmune Hemolytic Anemia (AIHA):\nRBC also destroyed\nEvans Syndrome AIHA Immune Thrombocytopenia Purpura (ITP) time\n\nDrug-Induced Thrombocytopenia:\nCertain drugs (e.g., heparin, quinine, sulfonamides) can induce antibody formation leads platelet destruction\n\nHeparin-Induced Thrombocytopenia (HIT):\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosis\n\n\nThrombotic Microangiopathies (TMAs):\nThrombotic Thrombocytopenic Purpura (TTP):\nDeficiency ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)\nLarge vWF multimers accumulate microvasculature, leading platelet activation, microthrombi formation, organ damage\nPENTAD: Thrombocytopenia, Microangiopathic Hemolytic Anemia (MAHA), Neurologic Abnormalities, Fever, Renal abnormalities.\n\nHemolytic Uremic Syndrome (HUS):\nPrimarily caused Shiga toxin-producing Escherichia coli (STEC-HUS)\nShiga toxin damages endothelial cells kidneys, leading platelet activation, microthrombi formation, renal failure\nTriad: Thrombocytopenia, MAHA, acute kidney injury\n\nDisseminated Intravascular Coagulation (DIC):\nSystemic activation coagulation fibrinolysis, leading consumption platelets clotting factors\nCaused infection, trauma, malignancy, obstetric complications\n\n\nHELLP Syndrome (Hemolysis, Elevated Liver Enzymes, Low Platelet Count):\ncomplication pregnancy characterized hemolysis, elevated liver enzymes, thrombocytopenia\n\nPost-Transfusion Purpura (PTP):\nRare, delayed hemolytic transfusion reaction patient develops antibodies platelet antigens, leading thrombocytopenia\n\nIncreased Platelet Destruction:Immune Thrombocytopenic Purpura (ITP):\nAutoantibodies (usually IgG) bind platelet surface antigens, leading destruction spleen\nCan acute (often children viral infection) chronic (common adults)\nWarm Autoimmune Hemolytic Anemia (AIHA):\nRBC also destroyed\nEvans Syndrome AIHA Immune Thrombocytopenia Purpura (ITP) time\n\nDrug-Induced Thrombocytopenia:\nCertain drugs (e.g., heparin, quinine, sulfonamides) can induce antibody formation leads platelet destruction\n\nHeparin-Induced Thrombocytopenia (HIT):\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosis\n\nAutoantibodies (usually IgG) bind platelet surface antigens, leading destruction spleenCan acute (often children viral infection) chronic (common adults)Warm Autoimmune Hemolytic Anemia (AIHA):\nRBC also destroyed\nEvans Syndrome AIHA Immune Thrombocytopenia Purpura (ITP) time\nRBC also destroyedEvans Syndrome AIHA Immune Thrombocytopenia Purpura (ITP) timeDrug-Induced Thrombocytopenia:\nCertain drugs (e.g., heparin, quinine, sulfonamides) can induce antibody formation leads platelet destruction\nCertain drugs (e.g., heparin, quinine, sulfonamides) can induce antibody formation leads platelet destructionHeparin-Induced Thrombocytopenia (HIT):\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosis\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosisThrombotic Microangiopathies (TMAs):\nThrombotic Thrombocytopenic Purpura (TTP):\nDeficiency ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)\nLarge vWF multimers accumulate microvasculature, leading platelet activation, microthrombi formation, organ damage\nPENTAD: Thrombocytopenia, Microangiopathic Hemolytic Anemia (MAHA), Neurologic Abnormalities, Fever, Renal abnormalities.\n\nHemolytic Uremic Syndrome (HUS):\nPrimarily caused Shiga toxin-producing Escherichia coli (STEC-HUS)\nShiga toxin damages endothelial cells kidneys, leading platelet activation, microthrombi formation, renal failure\nTriad: Thrombocytopenia, MAHA, acute kidney injury\n\nDisseminated Intravascular Coagulation (DIC):\nSystemic activation coagulation fibrinolysis, leading consumption platelets clotting factors\nCaused infection, trauma, malignancy, obstetric complications\n\nThrombotic Thrombocytopenic Purpura (TTP):\nDeficiency ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)\nLarge vWF multimers accumulate microvasculature, leading platelet activation, microthrombi formation, organ damage\nPENTAD: Thrombocytopenia, Microangiopathic Hemolytic Anemia (MAHA), Neurologic Abnormalities, Fever, Renal abnormalities.\nDeficiency ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)Large vWF multimers accumulate microvasculature, leading platelet activation, microthrombi formation, organ damagePENTAD: Thrombocytopenia, Microangiopathic Hemolytic Anemia (MAHA), Neurologic Abnormalities, Fever, Renal abnormalities.Hemolytic Uremic Syndrome (HUS):\nPrimarily caused Shiga toxin-producing Escherichia coli (STEC-HUS)\nShiga toxin damages endothelial cells kidneys, leading platelet activation, microthrombi formation, renal failure\nTriad: Thrombocytopenia, MAHA, acute kidney injury\nPrimarily caused Shiga toxin-producing Escherichia coli (STEC-HUS)Shiga toxin damages endothelial cells kidneys, leading platelet activation, microthrombi formation, renal failureTriad: Thrombocytopenia, MAHA, acute kidney injuryDisseminated Intravascular Coagulation (DIC):\nSystemic activation coagulation fibrinolysis, leading consumption platelets clotting factors\nCaused infection, trauma, malignancy, obstetric complications\nSystemic activation coagulation fibrinolysis, leading consumption platelets clotting factorsCaused infection, trauma, malignancy, obstetric complicationsHELLP Syndrome (Hemolysis, Elevated Liver Enzymes, Low Platelet Count):\ncomplication pregnancy characterized hemolysis, elevated liver enzymes, thrombocytopenia\ncomplication pregnancy characterized hemolysis, elevated liver enzymes, thrombocytopeniaPost-Transfusion Purpura (PTP):\nRare, delayed hemolytic transfusion reaction patient develops antibodies platelet antigens, leading thrombocytopenia\nRare, delayed hemolytic transfusion reaction patient develops antibodies platelet antigens, leading thrombocytopeniaSequestration:\nHypersplenism: Enlargement spleen, leading increased trapping destruction platelets\nSequestration:Hypersplenism: Enlargement spleen, leading increased trapping destruction plateletsDilutional:\nMassive transfusion fluid resuscitation may cause dilutional thrombocytopenia\nDilutional:Massive transfusion fluid resuscitation may cause dilutional thrombocytopenia","code":""},{"path":"quantitative.html","id":"laboratory-findings-6","chapter":"Quantitative","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nPlatelet Count: Decreased (<150 x 10^9/L)\nCell Lines: May normal abnormal depending underlying cause\nAnemia: May present cases\nLeukopenia Leukocytosis: May present depending cause\n\nPlatelet Count: Decreased (<150 x 10^9/L)Cell Lines: May normal abnormal depending underlying cause\nAnemia: May present cases\nLeukopenia Leukocytosis: May present depending cause\nAnemia: May present casesLeukopenia Leukocytosis: May present depending causePeripheral Blood Smear Examination:\nPlatelet Estimate: confirm accuracy automated platelet count\nPlatelet Morphology:\nLarge platelets (megathrombocytes): May seen ITP conditions increased platelet turnover\nSchistocytes (fragmented RBCs): Seen thrombotic microangiopathies (TTP, HUS, DIC)\n\nRed Blood Cell Morphology:\nSpherocytes: May seen AIHA\nSchistocytes: Seen thrombotic microangiopathies\n\nPresence Abnormal Cells:\nBlasts: May seen bone marrow disorders\n\nPlatelet Estimate: confirm accuracy automated platelet countPlatelet Morphology:\nLarge platelets (megathrombocytes): May seen ITP conditions increased platelet turnover\nSchistocytes (fragmented RBCs): Seen thrombotic microangiopathies (TTP, HUS, DIC)\nLarge platelets (megathrombocytes): May seen ITP conditions increased platelet turnoverSchistocytes (fragmented RBCs): Seen thrombotic microangiopathies (TTP, HUS, DIC)Red Blood Cell Morphology:\nSpherocytes: May seen AIHA\nSchistocytes: Seen thrombotic microangiopathies\nSpherocytes: May seen AIHASchistocytes: Seen thrombotic microangiopathiesPresence Abnormal Cells:\nBlasts: May seen bone marrow disorders\nBlasts: May seen bone marrow disordersBone Marrow Aspiration Biopsy (Indicated):\nMegakaryocyte Number: assess platelet production\nIncreased thrombocytopenia due increased destruction\nDecreased thrombocytopenia due decreased production\n\nMegakaryocyte Morphology: evaluate dysplasia\nMegakaryocyte Number: assess platelet production\nIncreased thrombocytopenia due increased destruction\nDecreased thrombocytopenia due decreased production\nIncreased thrombocytopenia due increased destructionDecreased thrombocytopenia due decreased productionMegakaryocyte Morphology: evaluate dysplasiaCoagulation Studies (PT, aPTT, Fibrinogen, D-dimer):\nevaluate DIC\nevaluate DICDirect Antiglobulin Test (DAT Coombs Test):\ndetect antibodies complement proteins surface RBCs (used rule AIHA)\ndetect antibodies complement proteins surface RBCs (used rule AIHA)Specific Tests Immune-Mediated Thrombocytopenia:\nPlatelet Antibody Testing: Detects antibodies platelet surface antigens (e.g., GPIIb/IIIa, GPIb/IX)\nHIT Antibody Testing: Detects antibodies heparin-platelet factor 4 (PF4) complex\nPlatelet Antibody Testing: Detects antibodies platelet surface antigens (e.g., GPIIb/IIIa, GPIb/IX)HIT Antibody Testing: Detects antibodies heparin-platelet factor 4 (PF4) complexADAMTS13 Activity Assay:\nMeasures activity ADAMTS13, decreased absent TTP\nMeasures activity ADAMTS13, decreased absent TTPStool Shiga Toxin Assay:\nDetects Shiga toxin stool, associated STEC-HUS\nDetects Shiga toxin stool, associated STEC-HUSThrombocytosisDefinition: increased platelet count, defined platelet count >450 x 10^9/LClassification:\nReactive (Secondary) Thrombocytosis:\nTransient elevation platelet count due underlying condition\n\nPrimary (Essential) Thrombocythemia (ET):\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\n\nReactive (Secondary) Thrombocytosis:\nTransient elevation platelet count due underlying condition\nTransient elevation platelet count due underlying conditionPrimary (Essential) Thrombocythemia (ET):\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding","code":""},{"path":"quantitative.html","id":"causes-of-thrombocytosis","chapter":"Quantitative","heading":"Causes of Thrombocytosis","text":"Reactive (Secondary) Thrombocytosis:\nInfections:\nAcute chronic infections (bacterial, viral, fungal)\n\nInflammation:\nRheumatoid arthritis\nInflammatory bowel disease (IBD)\nVasculitis\n\nIron Deficiency Anemia:\nMechanism fully understood may involve increased thrombopoietin (TPO) levels\n\nSplenectomy:\nLoss splenic sequestration leads increased circulating platelets\n\nSurgery Trauma\nMalignancy:\nCertain cancers can stimulate thrombocytosis\n\nRebound Thrombocytosis:\nrecovery thrombocytopenia\n\nPhysiologic:\nExercise\nStress\nPregnancy\nPostpartum\n\nReactive (Secondary) Thrombocytosis:Infections:\nAcute chronic infections (bacterial, viral, fungal)\nAcute chronic infections (bacterial, viral, fungal)Inflammation:\nRheumatoid arthritis\nInflammatory bowel disease (IBD)\nVasculitis\nRheumatoid arthritisInflammatory bowel disease (IBD)VasculitisIron Deficiency Anemia:\nMechanism fully understood may involve increased thrombopoietin (TPO) levels\nMechanism fully understood may involve increased thrombopoietin (TPO) levelsSplenectomy:\nLoss splenic sequestration leads increased circulating platelets\nLoss splenic sequestration leads increased circulating plateletsSurgery TraumaMalignancy:\nCertain cancers can stimulate thrombocytosis\nCertain cancers can stimulate thrombocytosisRebound Thrombocytosis:\nrecovery thrombocytopenia\nrecovery thrombocytopeniaPhysiologic:\nExercise\nStress\nPregnancy\nPostpartum\nExerciseStressPregnancyPostpartumEssential Thrombocythemia (ET):\nmyeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\nCaused mutations JAK2, CALR, MPL genes\nEssential Thrombocythemia (ET):myeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleedingCaused mutations JAK2, CALR, MPL genes","code":""},{"path":"quantitative.html","id":"laboratory-findings-7","chapter":"Quantitative","heading":"Laboratory Findings","text":"Thrombocytopenia:\nPlatelet Count: Decreased (<150 x 10^9/L)\nPeripheral Blood Smear: Decreased number platelets, may show large platelets (megathrombocytes)\nBone Marrow Examination:\nIncreased, normal, decreased megakaryocytes depending cause\n\nPlatelet Count: Decreased (<150 x 10^9/L)Peripheral Blood Smear: Decreased number platelets, may show large platelets (megathrombocytes)Bone Marrow Examination:\nIncreased, normal, decreased megakaryocytes depending cause\nIncreased, normal, decreased megakaryocytes depending causeThrombocytosis:\nPlatelet Count: Increased (>450 x 10^9/L)\nPeripheral Blood Smear:\nIncreased number platelets\nMay show large platelets abnormal platelet morphology\n\nTests Evaluate Underlying Causes (Reactive Thrombocytosis):\nInflammatory markers (ESR, CRP)\nIron studies (serum iron, TIBC, ferritin)\nComplete blood count (CBC) assess infection hematologic abnormalities\n\nMolecular Testing (Suspected ET):\nJAK2, CALR, MPL mutation analysis\n\nPlatelet Count: Increased (>450 x 10^9/L)Peripheral Blood Smear:\nIncreased number platelets\nMay show large platelets abnormal platelet morphology\nIncreased number plateletsMay show large platelets abnormal platelet morphologyTests Evaluate Underlying Causes (Reactive Thrombocytosis):\nInflammatory markers (ESR, CRP)\nIron studies (serum iron, TIBC, ferritin)\nComplete blood count (CBC) assess infection hematologic abnormalities\nInflammatory markers (ESR, CRP)Iron studies (serum iron, TIBC, ferritin)Complete blood count (CBC) assess infection hematologic abnormalitiesMolecular Testing (Suspected ET):\nJAK2, CALR, MPL mutation analysis\nJAK2, CALR, MPL mutation analysis","code":""},{"path":"quantitative.html","id":"key-terms-37","chapter":"Quantitative","heading":"Key Terms","text":"Thrombocytopenia: Decreased platelet count (<150 x 10^9/L)Thrombocytosis: Increased platelet count (>450 x 10^9/L)Reactive Thrombocytosis: Transient increase platelet count due underlying conditionEssential Thrombocythemia (ET): Myeloproliferative neoplasm sustained thrombocytosisMegathrombocytes: Large plateletsJAK2, CALR, MPL: Genes mutated myeloproliferative neoplasmsADAMTS13: metalloprotease cleaves von Willebrand factor (vWF)Schistocytes: Fragmented red blood cellsBone Marrow Aspiration Biopsy: Procedures collect examine bone marrow cells","code":""},{"path":"thrombocytopenia-1.html","id":"thrombocytopenia-1","chapter":"Thrombocytopenia","heading":"Thrombocytopenia","text":"","code":""},{"path":"thrombocytopenia-1.html","id":"overview-of-thrombocytopenia","chapter":"Thrombocytopenia","heading":"Overview of Thrombocytopenia","text":"Definition: condition characterized decreased platelet count peripheral blood. Generally defined platelet count less 150 x 10^9/L (150,000/µL).Significance: Thrombocytopenia increases risk bleeding, severity bleeding correlating degree platelet reduction.Classification:\nBased Mechanism:\nIncreased Platelet Destruction (Immune Non-Immune)\nDecreased Platelet Production\nSequestration (less common)\nDilutional\nPseudothrombocytopenia (Spurious Thrombocytopenia)\n\nBased Severity:\nMild Thrombocytopenia: 100-150 x 10^9/L\nModerate Thrombocytopenia: 50-99 x 10^9/L\nSevere Thrombocytopenia: <50 x 10^9/L\n\nBased Mechanism:\nIncreased Platelet Destruction (Immune Non-Immune)\nDecreased Platelet Production\nSequestration (less common)\nDilutional\nPseudothrombocytopenia (Spurious Thrombocytopenia)\nIncreased Platelet Destruction (Immune Non-Immune)Decreased Platelet ProductionSequestration (less common)DilutionalPseudothrombocytopenia (Spurious Thrombocytopenia)Based Severity:\nMild Thrombocytopenia: 100-150 x 10^9/L\nModerate Thrombocytopenia: 50-99 x 10^9/L\nSevere Thrombocytopenia: <50 x 10^9/L\nMild Thrombocytopenia: 100-150 x 10^9/LModerate Thrombocytopenia: 50-99 x 10^9/LSevere Thrombocytopenia: <50 x 10^9/L","code":""},{"path":"thrombocytopenia-1.html","id":"increased-platelet-destruction","chapter":"Thrombocytopenia","heading":"Increased Platelet Destruction","text":"Immune Thrombocytopenic Purpura (ITP):\nDefinition: acquired autoimmune disorder characterized destruction platelets autoantibodies\nDefinition: acquired autoimmune disorder characterized destruction platelets autoantibodiesThrombotic Thrombocytopenic Purpura (TTP):\nDefinition: life-threatening disorder characterized thrombotic microangiopathy (TMA), leading microvascular thrombosis, thrombocytopenia, hemolytic anemia\nDefinition: life-threatening disorder characterized thrombotic microangiopathy (TMA), leading microvascular thrombosis, thrombocytopenia, hemolytic anemiaHeparin-Induced Thrombocytopenia (HIT):\nDefinition: prothrombotic disorder caused antibodies heparin-platelet factor 4 (PF4) complexes\nDefinition: prothrombotic disorder caused antibodies heparin-platelet factor 4 (PF4) complexes","code":""},{"path":"thrombocytopenia-1.html","id":"decreased-platelet-production","chapter":"Thrombocytopenia","heading":"Decreased Platelet Production","text":"Bone Marrow Failure:Medications:","code":""},{"path":"thrombocytopenia-1.html","id":"pseudothrombocytopenia-spurious-thrombocytopenia","chapter":"Thrombocytopenia","heading":"Pseudothrombocytopenia (Spurious Thrombocytopenia)","text":"Definition: falsely low platelet count due vitro platelet clumping satellitism","code":""},{"path":"thrombocytopenia-1.html","id":"general-laboratory-tests","chapter":"Thrombocytopenia","heading":"General Laboratory Tests","text":"Complete Blood Count (CBC) Peripheral Blood Smear: Essential diagnosing classifying thrombocytopeniaReticulocyte Count: Assesses bone marrow responseCoagulation Studies (PT, aPTT, Fibrinogen, D-dimer): evaluate DICDirect Antiglobulin Test (DAT): evaluate autoimmune hemolytic anemia (Evans syndrome)HIV Testing: rule HIV-associated thrombocytopeniaHepatitis C Testing: rule hepatitis C-associated thrombocytopeniaBone Marrow Aspiration Biopsy: May necessary evaluate bone marrow disorders (e.g., aplastic anemia, MDS)ADAMTS13 Activity Assay: diagnose TTPHIT Antibody Testing: diagnose heparin-induced thrombocytopenia","code":""},{"path":"thrombocytopenia-1.html","id":"key-terms-38","chapter":"Thrombocytopenia","heading":"Key Terms","text":"Thrombocytopenia: Decreased platelet countPurpura: Bruising due bleeding skinPetechiae: Small, pinpoint hemorrhagesIdiopathic Thrombocytopenic Purpura (ITP): Autoimmune destruction plateletsThrombotic Thrombocytopenic Purpura (TTP): Thrombotic microangiopathy due ADAMTS13 deficiencyHeparin-Induced Thrombocytopenia (HIT): Thrombocytopenia caused antibodies heparin-PF4 complexesSchistocytes: Fragmented red blood cells (seen TTP microangiopathic hemolytic anemias)Pseudothrombocytopenia: Falsely low platelet count due vitro platelet clumping satellitismMegakaryocytes: Bone marrow cells produce platelets","code":""},{"path":"destruction.html","id":"destruction","chapter":"Destruction","heading":"Destruction","text":"","code":""},{"path":"destruction.html","id":"overview-of-thrombocytopenias-due-to-increased-destruction","chapter":"Destruction","heading":"Overview of Thrombocytopenias due to Increased Destruction","text":"Definition Thrombocytopenia: Abnormally low platelet count, defined platelet count less 150 x 10^9/L (150,000/µL)Definition Thrombocytopenia: Abnormally low platelet count, defined platelet count less 150 x 10^9/L (150,000/µL)Clinical Significance: Increases risk bleeding, ranging minor skin bruising severe life-threatening hemorrhagesClinical Significance: Increases risk bleeding, ranging minor skin bruising severe life-threatening hemorrhagesMajor Causes Thrombocytopenia Due Increased Destruction (Immune Non-Immune):\nImmune Thrombocytopenic Purpura (ITP)\nThrombotic Thrombocytopenic Purpura (TTP)\nHeparin-Induced Thrombocytopenia (HIT)\nDisseminated Intravascular Coagulation (DIC): Consumptive Coagulopathy, may also due non-immune consumptive process\nHemolytic Uremic Syndrome (HUS)\nMajor Causes Thrombocytopenia Due Increased Destruction (Immune Non-Immune):Immune Thrombocytopenic Purpura (ITP)Thrombotic Thrombocytopenic Purpura (TTP)Heparin-Induced Thrombocytopenia (HIT)Disseminated Intravascular Coagulation (DIC): Consumptive Coagulopathy, may also due non-immune consumptive processHemolytic Uremic Syndrome (HUS)General Laboratory Findings:\nReduced platelet count.\nNormal increased megakaryocytes bone marrow (thrombocytopenias due increased destruction)\nProlonged bleeding time /abnormal platelet function tests\nfindings specific disorder (see )\nGeneral Laboratory Findings:Reduced platelet count.Normal increased megakaryocytes bone marrow (thrombocytopenias due increased destruction)Prolonged bleeding time /abnormal platelet function testsOther findings specific disorder (see )","code":""},{"path":"destruction.html","id":"immune-thrombocytopenic-purpura-itp","chapter":"Destruction","heading":"Immune Thrombocytopenic Purpura (ITP)","text":"Definition: acquired autoimmune disorder characterized isolated thrombocytopenia (low platelet count) normal bone marrow causes thrombocytopeniaAlso Known : Idiopathic Thrombocytopenic PurpuraTypes:\nPrimary ITP: identifiable underlying cause\nSecondary ITP: Associated underlying conditions, :\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)\nInfections (e.g., HIV, hepatitis C, Helicobacter pylori)\nLymphoproliferative disorders (e.g., CLL)\nMedications\n\nPrimary ITP: identifiable underlying causeSecondary ITP: Associated underlying conditions, :\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)\nInfections (e.g., HIV, hepatitis C, Helicobacter pylori)\nLymphoproliferative disorders (e.g., CLL)\nMedications\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)Infections (e.g., HIV, hepatitis C, Helicobacter pylori)Lymphoproliferative disorders (e.g., CLL)MedicationsPathophysiology:\nAutoantibody Production: Autoantibodies (typically IgG) produced platelet membrane glycoproteins (e.g., GPIIb/IIIa, GPIb/IX)\nPlatelet Destruction: Antibody-coated platelets recognized destroyed macrophages spleen (extravascular hemolysis)\nImpaired Platelet Production: autoantibodies may also target megakaryocytes, impairing platelet production\nAutoantibody Production: Autoantibodies (typically IgG) produced platelet membrane glycoproteins (e.g., GPIIb/IIIa, GPIb/IX)Platelet Destruction: Antibody-coated platelets recognized destroyed macrophages spleen (extravascular hemolysis)Impaired Platelet Production: autoantibodies may also target megakaryocytes, impairing platelet productionClinical Features:\nMany patients asymptomatic\nBleeding Manifestations:\nPetechiae (small, pinpoint hemorrhages)\nPurpura (bruising)\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual periods)\nGastrointestinal bleeding (less common)\nIntracranial hemorrhage (rare life-threatening)\n\nMany patients asymptomaticBleeding Manifestations:\nPetechiae (small, pinpoint hemorrhages)\nPurpura (bruising)\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual periods)\nGastrointestinal bleeding (less common)\nIntracranial hemorrhage (rare life-threatening)\nPetechiae (small, pinpoint hemorrhages)Purpura (bruising)Nosebleeds (epistaxis)Gum bleedingMenorrhagia (heavy menstrual periods)Gastrointestinal bleeding (less common)Intracranial hemorrhage (rare life-threatening)Laboratory Findings:\nComplete Blood Count (CBC):\nIsolated thrombocytopenia (platelet count <150 x 10^9/L)\nNormal hemoglobin, white blood cell count, differential\n\nPeripheral Blood Smear:\nDecreased number platelets\nMay see large platelets (megathrombocytes), reflecting increased platelet production bone marrow\nsignificant abnormalities (e.g., schistocytes, blasts)\n\nBone Marrow Aspiration Biopsy (always necessary; usually performed rule causes thrombocytopenia):\nNormal increased megakaryocytes (platelet precursors)\nNormal cellularity maturation cell lines\n\nDirect Antibody Test (DAT) Platelets:\nDetects presence anti-platelet antibodies\nalways performed, sensitivity specificity tests limited\n\nExclusion Causes Thrombocytopenia:\nRule drug-induced thrombocytopenia, TTP, HUS, DIC, conditions can cause thrombocytopenia\n\nComplete Blood Count (CBC):\nIsolated thrombocytopenia (platelet count <150 x 10^9/L)\nNormal hemoglobin, white blood cell count, differential\nIsolated thrombocytopenia (platelet count <150 x 10^9/L)Normal hemoglobin, white blood cell count, differentialPeripheral Blood Smear:\nDecreased number platelets\nMay see large platelets (megathrombocytes), reflecting increased platelet production bone marrow\nsignificant abnormalities (e.g., schistocytes, blasts)\nDecreased number plateletsMay see large platelets (megathrombocytes), reflecting increased platelet production bone marrowNo significant abnormalities (e.g., schistocytes, blasts)Bone Marrow Aspiration Biopsy (always necessary; usually performed rule causes thrombocytopenia):\nNormal increased megakaryocytes (platelet precursors)\nNormal cellularity maturation cell lines\nNormal increased megakaryocytes (platelet precursors)Normal cellularity maturation cell linesDirect Antibody Test (DAT) Platelets:\nDetects presence anti-platelet antibodies\nalways performed, sensitivity specificity tests limited\nDetects presence anti-platelet antibodiesNot always performed, sensitivity specificity tests limitedExclusion Causes Thrombocytopenia:\nRule drug-induced thrombocytopenia, TTP, HUS, DIC, conditions can cause thrombocytopenia\nRule drug-induced thrombocytopenia, TTP, HUS, DIC, conditions can cause thrombocytopeniaDiagnosis: Diagnosis exclusion. ITP diagnosed causes thrombocytopenia ruled supported normal increased megakaryocytes bone marrowTreatment:\nObservation: Mild thrombocytopenia asymptomatic patients may require immediate treatment\nCorticosteroids: Prednisone dexamethasone\nSuppress autoantibody production decrease platelet destruction\nFirst-line treatment symptomatic ITP\n\nIntravenous Immunoglobulin (IVIG):\nUsed rapidly increase platelet count patients significant bleeding requiring urgent surgery\nMechanism: Blocks Fc receptors macrophages, reducing platelet destruction\n\nAnti-D Immunoglobulin (WinRho):\nUsed Rh-positive patients ITP\nMechanism: Antibody-coated RBCs cleared spleen, “sparing” platelets destruction\n\nRituximab:\nAnti-CD20 monoclonal antibody depletes B cells, reducing autoantibody production\nUsed patients refractory corticosteroids IVIG\n\nThrombopoietin Receptor Agonists (TPO-RAs):\nEltrombopag romiplostim\nStimulate platelet production binding activating thrombopoietin receptor megakaryocytes\nUsed patients failed treatments\n\nSplenectomy:\nSurgical removal spleen\nUsed patients severe, refractory ITP\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\n\nObservation: Mild thrombocytopenia asymptomatic patients may require immediate treatmentCorticosteroids: Prednisone dexamethasone\nSuppress autoantibody production decrease platelet destruction\nFirst-line treatment symptomatic ITP\nSuppress autoantibody production decrease platelet destructionFirst-line treatment symptomatic ITPIntravenous Immunoglobulin (IVIG):\nUsed rapidly increase platelet count patients significant bleeding requiring urgent surgery\nMechanism: Blocks Fc receptors macrophages, reducing platelet destruction\nUsed rapidly increase platelet count patients significant bleeding requiring urgent surgeryMechanism: Blocks Fc receptors macrophages, reducing platelet destructionAnti-D Immunoglobulin (WinRho):\nUsed Rh-positive patients ITP\nMechanism: Antibody-coated RBCs cleared spleen, “sparing” platelets destruction\nUsed Rh-positive patients ITPMechanism: Antibody-coated RBCs cleared spleen, “sparing” platelets destructionRituximab:\nAnti-CD20 monoclonal antibody depletes B cells, reducing autoantibody production\nUsed patients refractory corticosteroids IVIG\nAnti-CD20 monoclonal antibody depletes B cells, reducing autoantibody productionUsed patients refractory corticosteroids IVIGThrombopoietin Receptor Agonists (TPO-RAs):\nEltrombopag romiplostim\nStimulate platelet production binding activating thrombopoietin receptor megakaryocytes\nUsed patients failed treatments\nEltrombopag romiplostimStimulate platelet production binding activating thrombopoietin receptor megakaryocytesUsed patients failed treatmentsSplenectomy:\nSurgical removal spleen\nUsed patients severe, refractory ITP\nIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)\nPatients require vaccination splenectomy\nSurgical removal spleenUsed patients severe, refractory ITPIncreases risk infection encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)Patients require vaccination splenectomy","code":""},{"path":"destruction.html","id":"thrombotic-thrombocytopenic-purpura-ttp","chapter":"Destruction","heading":"Thrombotic Thrombocytopenic Purpura (TTP)","text":"Definition: life-threatening thrombotic microangiopathy (TMA) characterized microangiopathic hemolytic anemia (MAHA) thrombocytopeniaHallmark: Pentad Thrombocytopenia, Microangiopathic Hemolytic Anemia, Neurologic Abnormalities, Fever, Renal AbnormalitiesTypes:\nAcquired TTP:\nAutoimmune: Antibodies ADAMTS13\nIdiopathic: known underlying cause\nSecondary: Associated pregnancy, autoimmune disorders, medications, stem cell transplantation\n\nHereditary TTP (Upshaw-Schulman Syndrome):\nInherited deficiency ADAMTS13\n\nAcquired TTP:\nAutoimmune: Antibodies ADAMTS13\nIdiopathic: known underlying cause\nSecondary: Associated pregnancy, autoimmune disorders, medications, stem cell transplantation\nAutoimmune: Antibodies ADAMTS13Idiopathic: known underlying causeSecondary: Associated pregnancy, autoimmune disorders, medications, stem cell transplantationHereditary TTP (Upshaw-Schulman Syndrome):\nInherited deficiency ADAMTS13\nInherited deficiency ADAMTS13Pathophysiology:\nADAMTS13 Deficiency: Reduced absent activity ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)\nvWF Multimer Accumulation: Ultra-large vWF multimers accumulate microvasculature\nPlatelet Activation Microthrombi Formation: vWF multimers bind platelets, leading platelet activation, aggregation, formation microthrombi small blood vessels\nMicroangiopathic Hemolytic Anemia (MAHA): RBCs damaged pass microthrombi, resulting fragmentation (schistocytes) hemolysis\nThrombocytopenia: Platelets consumed formation microthrombi\nOrgan Ischemia: Microthrombi obstruct blood flow vital organs (brain, kidneys, heart), leading organ damage\nADAMTS13 Deficiency: Reduced absent activity ADAMTS13, metalloprotease cleaves von Willebrand factor (vWF)vWF Multimer Accumulation: Ultra-large vWF multimers accumulate microvasculaturePlatelet Activation Microthrombi Formation: vWF multimers bind platelets, leading platelet activation, aggregation, formation microthrombi small blood vesselsMicroangiopathic Hemolytic Anemia (MAHA): RBCs damaged pass microthrombi, resulting fragmentation (schistocytes) hemolysisThrombocytopenia: Platelets consumed formation microthrombiOrgan Ischemia: Microthrombi obstruct blood flow vital organs (brain, kidneys, heart), leading organ damageClinical Features:\nThrombocytopenia: Bleeding manifestations (petechiae, purpura, etc.)\nMicroangiopathic Hemolytic Anemia (MAHA): Fatigue, pallor, jaundice\nNeurologic Abnormalities: Headache, confusion, seizures, stroke\nFever\nRenal Abnormalities: Elevated creatinine, hematuria, proteinuria\nThrombocytopenia: Bleeding manifestations (petechiae, purpura, etc.)Microangiopathic Hemolytic Anemia (MAHA): Fatigue, pallor, jaundiceNeurologic Abnormalities: Headache, confusion, seizures, strokeFeverRenal Abnormalities: Elevated creatinine, hematuria, proteinuriaLaboratory Findings:\nCBC:\nThrombocytopenia (platelet count <150 x 10^9/L)\nAnemia (decreased HGB HCT)\nIncreased reticulocyte count\n\nPeripheral Blood Smear:\nSchistocytes (fragmented RBCs)\nPolychromasia (increased reticulocytes)\nDecreased platelets\n\nCoagulation Studies:\nPT aPTT: Usually normal\nFibrinogen: Normal slightly increased\nD-dimer: May elevated\n\nLactate Dehydrogenase (LDH): Elevated (due hemolysis)\nIndirect Bilirubin: Elevated (due hemolysis)\nHaptoglobin: Decreased (due hemolysis)\nCreatinine: Elevated (due renal involvement)\nADAMTS13 Activity Assay:\nMarkedly reduced (<10% normal) cases acquired TTP\nAbsent hereditary TTP\n\nADAMTS13 Inhibitor Assay:\nDetects presence autoantibodies ADAMTS13\n\nCBC:\nThrombocytopenia (platelet count <150 x 10^9/L)\nAnemia (decreased HGB HCT)\nIncreased reticulocyte count\nThrombocytopenia (platelet count <150 x 10^9/L)Anemia (decreased HGB HCT)Increased reticulocyte countPeripheral Blood Smear:\nSchistocytes (fragmented RBCs)\nPolychromasia (increased reticulocytes)\nDecreased platelets\nSchistocytes (fragmented RBCs)Polychromasia (increased reticulocytes)Decreased plateletsCoagulation Studies:\nPT aPTT: Usually normal\nFibrinogen: Normal slightly increased\nD-dimer: May elevated\nPT aPTT: Usually normalFibrinogen: Normal slightly increasedD-dimer: May elevatedLactate Dehydrogenase (LDH): Elevated (due hemolysis)Indirect Bilirubin: Elevated (due hemolysis)Haptoglobin: Decreased (due hemolysis)Creatinine: Elevated (due renal involvement)ADAMTS13 Activity Assay:\nMarkedly reduced (<10% normal) cases acquired TTP\nAbsent hereditary TTP\nMarkedly reduced (<10% normal) cases acquired TTPAbsent hereditary TTPADAMTS13 Inhibitor Assay:\nDetects presence autoantibodies ADAMTS13\nDetects presence autoantibodies ADAMTS13Diagnosis: Diagnosis TTP requires prompt recognition treatmentTreatment:\nPlasma Exchange:\nMainstay treatment\nRemoves vWF multimers replaces ADAMTS13\n\nCorticosteroids:\nsuppress autoantibody production\n\nRituximab:\nAnti-CD20 monoclonal antibody depletes B cells reduces autoantibody production\n\nCaplacizumab:\nhumanized nanobody binds vWF inhibits interaction platelets\nReduces risk thrombotic events shortens duration plasma exchange\n\nAvoid Platelet Transfusions: Platelet transfusions may exacerbate thrombotic process generally avoided unless life-threatening bleeding occurs\nPlasma Exchange:\nMainstay treatment\nRemoves vWF multimers replaces ADAMTS13\nMainstay treatmentRemoves vWF multimers replaces ADAMTS13Corticosteroids:\nsuppress autoantibody production\nsuppress autoantibody productionRituximab:\nAnti-CD20 monoclonal antibody depletes B cells reduces autoantibody production\nAnti-CD20 monoclonal antibody depletes B cells reduces autoantibody productionCaplacizumab:\nhumanized nanobody binds vWF inhibits interaction platelets\nReduces risk thrombotic events shortens duration plasma exchange\nhumanized nanobody binds vWF inhibits interaction plateletsReduces risk thrombotic events shortens duration plasma exchangeAvoid Platelet Transfusions: Platelet transfusions may exacerbate thrombotic process generally avoided unless life-threatening bleeding occurs","code":""},{"path":"destruction.html","id":"heparin-induced-thrombocytopenia-hit","chapter":"Destruction","heading":"Heparin-Induced Thrombocytopenia (HIT)","text":"Definition: potentially life-threatening immune-mediated disorder characterized thrombocytopenia increased risk thrombosis following exposure heparinTypes:\nType HIT (Non-Immune): Mild, transient thrombocytopenia occurring within first 2 days heparin exposure. clinically significant\nType II HIT (Immune-Mediated):\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosis\nClinically significant associated high risk venous arterial thrombosis\n\nType HIT (Non-Immune): Mild, transient thrombocytopenia occurring within first 2 days heparin exposure. clinically significantType II HIT (Immune-Mediated):\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosis\nClinically significant associated high risk venous arterial thrombosis\nAntibodies heparin-platelet factor 4 (PF4) complex, leading platelet activation thrombosisClinically significant associated high risk venous arterial thrombosisPathophysiology:\nHeparin-PF4 Complex Formation: Heparin binds platelet factor 4 (PF4), positively charged protein released platelets\nAntibody Production: Patients develop IgG antibodies heparin-PF4 complex\nPlatelet Activation: IgG antibodies bind heparin-PF4 complex platelet surfaces, leading platelet activation aggregation via FcγIIa receptors\nThrombosis: Activated platelets release procoagulant factors, leading thrombin generation thrombosis\nThrombocytopenia: Platelets consumed formation thrombi cleared circulation\nHeparin-PF4 Complex Formation: Heparin binds platelet factor 4 (PF4), positively charged protein released plateletsAntibody Production: Patients develop IgG antibodies heparin-PF4 complexPlatelet Activation: IgG antibodies bind heparin-PF4 complex platelet surfaces, leading platelet activation aggregation via FcγIIa receptorsThrombosis: Activated platelets release procoagulant factors, leading thrombin generation thrombosisThrombocytopenia: Platelets consumed formation thrombi cleared circulationClinical Features:\nThrombocytopenia: Typically occurs 5-10 days starting heparin (can occur earlier prior heparin exposure)\nThrombosis: Venous arterial thromboembolic events (e.g., DVT, pulmonary embolism, stroke, limb ischemia, skin necrosis)\nSkin Necrosis Heparin Injection Sites\nSystemic Reactions: Chills, fever, dyspnea (less common)\nThrombocytopenia: Typically occurs 5-10 days starting heparin (can occur earlier prior heparin exposure)Thrombosis: Venous arterial thromboembolic events (e.g., DVT, pulmonary embolism, stroke, limb ischemia, skin necrosis)Skin Necrosis Heparin Injection SitesSystemic Reactions: Chills, fever, dyspnea (less common)Laboratory Findings:\nCBC:\nThrombocytopenia (platelet count typically <150 x 10^9/L, can variable)\n\nPeripheral Blood Smear:\nUsually normal; may see large platelets\n\nHIT Antibody Testing:\nScreening Assay: ELISA immunoturbidimetric assay detect antibodies heparin-PF4 complex (high sensitivity, lower specificity)\nConfirmatory Assay: Serotonin Release Assay (SRA) Heparin-Induced Platelet Activation (HIPA) assay (high specificity)\n\nCoagulation Studies:\naPTT: May prolonged, normal, shortened\n\nD-dimer: Elevated\nCBC:\nThrombocytopenia (platelet count typically <150 x 10^9/L, can variable)\nThrombocytopenia (platelet count typically <150 x 10^9/L, can variable)Peripheral Blood Smear:\nUsually normal; may see large platelets\nUsually normal; may see large plateletsHIT Antibody Testing:\nScreening Assay: ELISA immunoturbidimetric assay detect antibodies heparin-PF4 complex (high sensitivity, lower specificity)\nConfirmatory Assay: Serotonin Release Assay (SRA) Heparin-Induced Platelet Activation (HIPA) assay (high specificity)\nScreening Assay: ELISA immunoturbidimetric assay detect antibodies heparin-PF4 complex (high sensitivity, lower specificity)Confirmatory Assay: Serotonin Release Assay (SRA) Heparin-Induced Platelet Activation (HIPA) assay (high specificity)Coagulation Studies:\naPTT: May prolonged, normal, shortened\naPTT: May prolonged, normal, shortenedD-dimer: ElevatedDiagnosis: 4Ts Scoring System\nThrombocytopenia: Degree timing platelet count fall\nTiming: thrombocytopenia occur relation Heparin use\nThrombosis: Presence new thrombosis skin necrosis\nCauses Thrombocytopenia: Absence obvious causes thrombocytopenia\nThrombocytopenia: Degree timing platelet count fallTiming: thrombocytopenia occur relation Heparin useThrombosis: Presence new thrombosis skin necrosisOther Causes Thrombocytopenia: Absence obvious causes thrombocytopeniaTreatment:\nStop Heparin Immediately: important step\nAdminister Alternative Anticoagulant:\nDirect Thrombin Inhibitors (DTIs): Argatroban, bivalirudin\nFondaparinux: synthetic pentasaccharide inhibits factor Xa\n\nAvoid Platelet Transfusions: Platelet transfusions may exacerbate thrombosis HIT\nWarfarin: avoided acutely due risk venous limb gangrene; can initiated platelet count recovered patient stable dose non-heparin anticoagulant\nStop Heparin Immediately: important stepAdminister Alternative Anticoagulant:\nDirect Thrombin Inhibitors (DTIs): Argatroban, bivalirudin\nFondaparinux: synthetic pentasaccharide inhibits factor Xa\nDirect Thrombin Inhibitors (DTIs): Argatroban, bivalirudinFondaparinux: synthetic pentasaccharide inhibits factor XaAvoid Platelet Transfusions: Platelet transfusions may exacerbate thrombosis HITWarfarin: avoided acutely due risk venous limb gangrene; can initiated platelet count recovered patient stable dose non-heparin anticoagulant","code":""},{"path":"destruction.html","id":"key-terms-39","chapter":"Destruction","heading":"Key Terms","text":"Thrombocytopenia: Decreased platelet count (<150 x 10^9/L)ITP (Immune Thrombocytopenic Purpura): Autoimmune destruction plateletsTTP (Thrombotic Thrombocytopenic Purpura): Microangiopathic hemolytic anemia thrombocytopenia due ADAMTS13 deficiencyHUS (Hemolytic Uremic Syndrome): Microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injuryDIC (Disseminated Intravascular Coagulation): Systemic activation coagulation fibrinolysisSchistocytes: Fragmented red blood cellsADAMTS13: metalloprotease cleaves von Willebrand factor (vWF)Heparin-Induced Thrombocytopenia (HIT): Immune-mediated thrombocytopenia caused antibodies heparin-PF4 complexHeparin-Platelet Factor 4 (PF4) Complex: Target antibodies HITHaptoglobin: Protein binds free hemoglobin released plasmaMicroangiopathic Hemolytic Anemia (MAHA): Hemolytic anemia caused mechanical destruction RBCs small blood vessels","code":""},{"path":"production.html","id":"production","chapter":"Production","heading":"Production","text":"","code":""},{"path":"production.html","id":"overview-of-thrombocytopenia-due-to-decreased-production","chapter":"Production","heading":"Overview of Thrombocytopenia due to Decreased Production","text":"Definition: type thrombocytopenia (low platelet count) resulting decreased rate platelet production megakaryocytes bone marrow. bone marrow simply isn’t making enough plateletsKey Feature: bone marrow hypoactive (producing megakaryocytes) ineffective (megakaryocytes present producing enough platelets). can often identified bone marrow aspirate biopsyReticulated Platelets: Reticulated platelets, also known immature platelets, newly released platelets contain RNA. low count can correlate decreased rate platelet productionEtiology: Can caused variety factors, including bone marrow disorders, infections, medications, nutritional deficienciesGeneral Mechanisms:\nDamage destruction megakaryocytes (platelet precursor cells bone marrow)\nImpaired megakaryocyte proliferation differentiation\nDisruption thrombopoietin (TPO) signaling\nDamage destruction megakaryocytes (platelet precursor cells bone marrow)Impaired megakaryocyte proliferation differentiationDisruption thrombopoietin (TPO) signaling","code":""},{"path":"production.html","id":"specific-causes-of-thrombocytopenia-due-to-decreased-production","chapter":"Production","heading":"Specific Causes of Thrombocytopenia due to Decreased Production","text":"Bone Marrow Failure Infiltration\nAplastic Anemia:\nDefinition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow\nPathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell lines, including megakaryocytes\nCauses:\nAcquired:\nIdiopathic (common) - thought autoimmune many cases\nDrug-induced (e.g., chloramphenicol, sulfonamides, NSAIDs)\nChemical exposure (e.g., benzene)\nRadiation exposure\nInfections (e.g., parvovirus B19, EBV, HIV)\nAutoimmune disorders\n\nInherited:\nFanconi anemia\nDyskeratosis congenita\n\n\nLaboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear:\nNormocytic, normochromic RBCs\nAbsence abnormal cells\n\nReticulocyte Count: Low\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells (including megakaryocytes)\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\n\nClinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nSymptoms thrombocytopenia (bleeding, bruising)\nSymptoms neutropenia (increased susceptibility infections)\n\nTreatment:\nSupportive Care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\n\n\n\nMyelodysplastic Syndromes (MDS):\nDefinition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis, dysplasia one cell lines, variable risk progression acute myeloid leukemia (AML)\nPathophysiology:\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasia\nDysplastic megakaryocytes may abnormal morphology decreased platelet production\n\nCauses:\nAcquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\n\nLaboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nAbnormal megakaryocytes (e.g., micromegakaryocytes, hypolobated megakaryocytes)\nLarge platelets, abnormal granulation\n\nBone Marrow Examination:\nHypercellular hypocellular marrow dysplasia one cell lines\nIncreased megakaryocytes abnormal morphology\n\nCytogenetic Analysis: Chromosomal abnormalities common (e.g., deletion 5q)\n\nClinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nBleeding bruising due thrombocytopenia\nIncreased susceptibility infections due neutropenia\n\nTreatment:\nSupportive care: Transfusions, growth factors\nHypomethylating Agents: Azacitidine decitabine\nLenalidomide: Used MDS deletion 5q\nHematopoietic Stem Cell Transplantation (HSCT): Potentially curative\n\n\nBone Marrow Infiltration:\nMetastatic Cancer: Cancer cells solid tumors can infiltrate bone marrow, crowding normal hematopoietic cells, including megakaryocytes\nLymphoma: Infiltration bone marrow lymphoma cells can suppress megakaryopoiesis\nMyeloma: Infiltration bone marrow plasma cells multiple myeloma can suppress megakaryopoiesis\nLaboratory Findings:\nCBC: Cytopenias (including thrombocytopenia)\nPeripheral Blood Smear: May show abnormal cells (e.g., tumor cells, lymphoma cells)\nBone Marrow Examination: Evidence infiltration malignant cells\n\n\nBone Marrow Failure InfiltrationAplastic Anemia:\nDefinition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrow\nPathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell lines, including megakaryocytes\nCauses:\nAcquired:\nIdiopathic (common) - thought autoimmune many cases\nDrug-induced (e.g., chloramphenicol, sulfonamides, NSAIDs)\nChemical exposure (e.g., benzene)\nRadiation exposure\nInfections (e.g., parvovirus B19, EBV, HIV)\nAutoimmune disorders\n\nInherited:\nFanconi anemia\nDyskeratosis congenita\n\n\nLaboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear:\nNormocytic, normochromic RBCs\nAbsence abnormal cells\n\nReticulocyte Count: Low\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells (including megakaryocytes)\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\n\nClinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nSymptoms thrombocytopenia (bleeding, bruising)\nSymptoms neutropenia (increased susceptibility infections)\n\nTreatment:\nSupportive Care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\n\n\nAplastic Anemia:Definition: Bone marrow failure characterized pancytopenia (decreased RBCs, WBCs, platelets) hypocellular bone marrowPathophysiology: Damage destruction hematopoietic stem cells (HSCs) bone marrow, leading reduced production blood cell lines, including megakaryocytesCauses:\nAcquired:\nIdiopathic (common) - thought autoimmune many cases\nDrug-induced (e.g., chloramphenicol, sulfonamides, NSAIDs)\nChemical exposure (e.g., benzene)\nRadiation exposure\nInfections (e.g., parvovirus B19, EBV, HIV)\nAutoimmune disorders\n\nInherited:\nFanconi anemia\nDyskeratosis congenita\n\nAcquired:\nIdiopathic (common) - thought autoimmune many cases\nDrug-induced (e.g., chloramphenicol, sulfonamides, NSAIDs)\nChemical exposure (e.g., benzene)\nRadiation exposure\nInfections (e.g., parvovirus B19, EBV, HIV)\nAutoimmune disorders\nIdiopathic (common) - thought autoimmune many casesDrug-induced (e.g., chloramphenicol, sulfonamides, NSAIDs)Chemical exposure (e.g., benzene)Radiation exposureInfections (e.g., parvovirus B19, EBV, HIV)Autoimmune disordersInherited:\nFanconi anemia\nDyskeratosis congenita\nFanconi anemiaDyskeratosis congenitaLaboratory Findings:\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)\nPeripheral Blood Smear:\nNormocytic, normochromic RBCs\nAbsence abnormal cells\n\nReticulocyte Count: Low\nBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells (including megakaryocytes)\nFlow cytometry: May show decreased abnormal hematopoietic stem cells\nCBC: Pancytopenia (low HGB, HCT, RBC count, WBC count, platelet count)Peripheral Blood Smear:\nNormocytic, normochromic RBCs\nAbsence abnormal cells\nNormocytic, normochromic RBCsAbsence abnormal cellsReticulocyte Count: LowBone Marrow Examination: Hypocellular marrow decreased absent hematopoietic cells (including megakaryocytes)Flow cytometry: May show decreased abnormal hematopoietic stem cellsClinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nSymptoms thrombocytopenia (bleeding, bruising)\nSymptoms neutropenia (increased susceptibility infections)\nSymptoms anemia (fatigue, weakness, pallor)Symptoms thrombocytopenia (bleeding, bruising)Symptoms neutropenia (increased susceptibility infections)Treatment:\nSupportive Care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\n\nImmunosuppressive Therapy:\nAntithymocyte globulin (ATG)\nCyclosporine\n\nHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\n\nSupportive Care:\nTransfusions (RBCs platelets) alleviate symptoms\nAntibiotics treat infections\nTransfusions (RBCs platelets) alleviate symptomsAntibiotics treat infectionsImmunosuppressive Therapy:\nAntithymocyte globulin (ATG)\nCyclosporine\nAntithymocyte globulin (ATG)CyclosporineHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option, especially younger patients matched donors\nPotentially curative option, especially younger patients matched donorsMyelodysplastic Syndromes (MDS):\nDefinition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis, dysplasia one cell lines, variable risk progression acute myeloid leukemia (AML)\nPathophysiology:\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasia\nDysplastic megakaryocytes may abnormal morphology decreased platelet production\n\nCauses:\nAcquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\n\nLaboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nAbnormal megakaryocytes (e.g., micromegakaryocytes, hypolobated megakaryocytes)\nLarge platelets, abnormal granulation\n\nBone Marrow Examination:\nHypercellular hypocellular marrow dysplasia one cell lines\nIncreased megakaryocytes abnormal morphology\n\nCytogenetic Analysis: Chromosomal abnormalities common (e.g., deletion 5q)\n\nClinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nBleeding bruising due thrombocytopenia\nIncreased susceptibility infections due neutropenia\n\nTreatment:\nSupportive care: Transfusions, growth factors\nHypomethylating Agents: Azacitidine decitabine\nLenalidomide: Used MDS deletion 5q\nHematopoietic Stem Cell Transplantation (HSCT): Potentially curative\n\nMyelodysplastic Syndromes (MDS):Definition: group clonal hematopoietic stem cell disorders characterized ineffective hematopoiesis, dysplasia one cell lines, variable risk progression acute myeloid leukemia (AML)Pathophysiology:\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasia\nDysplastic megakaryocytes may abnormal morphology decreased platelet production\nGenetic mutations impair differentiation maturation hematopoietic cells, leading cytopenias dysplasiaDysplastic megakaryocytes may abnormal morphology decreased platelet productionCauses:\nAcquired mutations hematopoietic stem cells\nRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapy\nAcquired mutations hematopoietic stem cellsRisk factors: Advanced age, exposure certain chemicals radiation, prior chemotherapy radiation therapyLaboratory Findings:\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)\nPeripheral Blood Smear: Dysplastic features one cell lines\nAbnormal megakaryocytes (e.g., micromegakaryocytes, hypolobated megakaryocytes)\nLarge platelets, abnormal granulation\n\nBone Marrow Examination:\nHypercellular hypocellular marrow dysplasia one cell lines\nIncreased megakaryocytes abnormal morphology\n\nCytogenetic Analysis: Chromosomal abnormalities common (e.g., deletion 5q)\nCBC: Cytopenias (anemia, thrombocytopenia, leukopenia)Peripheral Blood Smear: Dysplastic features one cell lines\nAbnormal megakaryocytes (e.g., micromegakaryocytes, hypolobated megakaryocytes)\nLarge platelets, abnormal granulation\nAbnormal megakaryocytes (e.g., micromegakaryocytes, hypolobated megakaryocytes)Large platelets, abnormal granulationBone Marrow Examination:\nHypercellular hypocellular marrow dysplasia one cell lines\nIncreased megakaryocytes abnormal morphology\nHypercellular hypocellular marrow dysplasia one cell linesIncreased megakaryocytes abnormal morphologyCytogenetic Analysis: Chromosomal abnormalities common (e.g., deletion 5q)Clinical Features:\nSymptoms anemia (fatigue, weakness, pallor)\nBleeding bruising due thrombocytopenia\nIncreased susceptibility infections due neutropenia\nSymptoms anemia (fatigue, weakness, pallor)Bleeding bruising due thrombocytopeniaIncreased susceptibility infections due neutropeniaTreatment:\nSupportive care: Transfusions, growth factors\nHypomethylating Agents: Azacitidine decitabine\nLenalidomide: Used MDS deletion 5q\nHematopoietic Stem Cell Transplantation (HSCT): Potentially curative\nSupportive care: Transfusions, growth factorsHypomethylating Agents: Azacitidine decitabineLenalidomide: Used MDS deletion 5qHematopoietic Stem Cell Transplantation (HSCT): Potentially curativeBone Marrow Infiltration:\nMetastatic Cancer: Cancer cells solid tumors can infiltrate bone marrow, crowding normal hematopoietic cells, including megakaryocytes\nLymphoma: Infiltration bone marrow lymphoma cells can suppress megakaryopoiesis\nMyeloma: Infiltration bone marrow plasma cells multiple myeloma can suppress megakaryopoiesis\nLaboratory Findings:\nCBC: Cytopenias (including thrombocytopenia)\nPeripheral Blood Smear: May show abnormal cells (e.g., tumor cells, lymphoma cells)\nBone Marrow Examination: Evidence infiltration malignant cells\n\nBone Marrow Infiltration:Metastatic Cancer: Cancer cells solid tumors can infiltrate bone marrow, crowding normal hematopoietic cells, including megakaryocytesLymphoma: Infiltration bone marrow lymphoma cells can suppress megakaryopoiesisMyeloma: Infiltration bone marrow plasma cells multiple myeloma can suppress megakaryopoiesisLaboratory Findings:\nCBC: Cytopenias (including thrombocytopenia)\nPeripheral Blood Smear: May show abnormal cells (e.g., tumor cells, lymphoma cells)\nBone Marrow Examination: Evidence infiltration malignant cells\nCBC: Cytopenias (including thrombocytopenia)Peripheral Blood Smear: May show abnormal cells (e.g., tumor cells, lymphoma cells)Bone Marrow Examination: Evidence infiltration malignant cellsInfection\nViral Infections:\nHIV: Can directly infect damage megakaryocytes, leading decreased platelet production\nParvovirus B19: Can transiently suppress erythropoiesis , less commonly, thrombocytopoiesis\nviral infections (e.g., EBV, CMV) can also cause thrombocytopenia various mechanisms\n\nBacterial Infections:\nSepsis: Severe systemic infection can lead bone marrow suppression decreased platelet production\n\nInfectionViral Infections:\nHIV: Can directly infect damage megakaryocytes, leading decreased platelet production\nParvovirus B19: Can transiently suppress erythropoiesis , less commonly, thrombocytopoiesis\nviral infections (e.g., EBV, CMV) can also cause thrombocytopenia various mechanisms\nViral Infections:HIV: Can directly infect damage megakaryocytes, leading decreased platelet productionParvovirus B19: Can transiently suppress erythropoiesis , less commonly, thrombocytopoiesisOther viral infections (e.g., EBV, CMV) can also cause thrombocytopenia various mechanismsBacterial Infections:\nSepsis: Severe systemic infection can lead bone marrow suppression decreased platelet production\nBacterial Infections:Sepsis: Severe systemic infection can lead bone marrow suppression decreased platelet productionNutritional Deficiencies\nVitamin B12 Deficiency:\nImpaired DNA synthesis affects megakaryocyte maturation platelet production\n\nFolate Deficiency:\nImpaired DNA synthesis affects megakaryocyte maturation platelet production\n\nIron Deficiency Anemia:\nSevere iron deficiency can impair megakaryopoiesis platelet production\n\nNutritional DeficienciesVitamin B12 Deficiency:\nImpaired DNA synthesis affects megakaryocyte maturation platelet production\nImpaired DNA synthesis affects megakaryocyte maturation platelet productionFolate Deficiency:\nImpaired DNA synthesis affects megakaryocyte maturation platelet production\nImpaired DNA synthesis affects megakaryocyte maturation platelet productionIron Deficiency Anemia:\nSevere iron deficiency can impair megakaryopoiesis platelet production\nSevere iron deficiency can impair megakaryopoiesis platelet productionMedications\nChemotherapy: Cytotoxic agents can damage megakaryocytes suppress platelet production\nAlcohol: Chronic alcohol abuse can impair megakaryopoiesis\nThiazide Diuretics: Can cause thrombocytopenia individuals\nMedicationsChemotherapy: Cytotoxic agents can damage megakaryocytes suppress platelet productionAlcohol: Chronic alcohol abuse can impair megakaryopoiesisThiazide Diuretics: Can cause thrombocytopenia individuals","code":""},{"path":"production.html","id":"key-laboratory-findings-7","chapter":"Production","heading":"Key Laboratory Findings","text":"Complete Blood Count (CBC):\nThrombocytopenia (platelet count < 150 x 10^9/L)\nMay see cytopenias (anemia /leukopenia), depending underlying cause\nThrombocytopenia (platelet count < 150 x 10^9/L)May see cytopenias (anemia /leukopenia), depending underlying causePeripheral Blood Smear:\nDecreased number platelets\nMay see normal abnormal platelets (depending cause)\nMay see abnormal cells (e.g., blasts, tumor cells, dysplastic cells)\nDecreased number plateletsMay see normal abnormal platelets (depending cause)May see abnormal cells (e.g., blasts, tumor cells, dysplastic cells)Reticulocyte Count:\ncases isolated thrombocytopenia, reticulocyte count normal\nconcurrent anemia, reticulocyte count help classify anemia:\nHigh reticulocyte count: Suggests increased RBC destruction blood loss\nLow reticulocyte count: Suggests decreased RBC production\n\ncases isolated thrombocytopenia, reticulocyte count normalIf concurrent anemia, reticulocyte count help classify anemia:\nHigh reticulocyte count: Suggests increased RBC destruction blood loss\nLow reticulocyte count: Suggests decreased RBC production\nHigh reticulocyte count: Suggests increased RBC destruction blood lossLow reticulocyte count: Suggests decreased RBC productionBone Marrow Aspiration Biopsy:\nEssential evaluating cause thrombocytopenia\nAssess cellularity bone marrow\nEvaluate megakaryocyte number morphology\nRule bone marrow disorders (e.g., aplastic anemia, MDS, bone marrow infiltration)\nEssential evaluating cause thrombocytopeniaAssess cellularity bone marrowEvaluate megakaryocyte number morphologyRule bone marrow disorders (e.g., aplastic anemia, MDS, bone marrow infiltration)Tests:\nVitamin B12 Folate Levels: rule nutritional deficiencies\nHIV Testing: rule HIV-associated thrombocytopenia\nHepC Testing: rule HepC-associated thrombocytopenia\nParvovirus B19 PCR: rule parvovirus B19 infection\nAntinuclear Antibody (ANA) Testing: evaluate autoimmune disorders\nVitamin B12 Folate Levels: rule nutritional deficienciesHIV Testing: rule HIV-associated thrombocytopeniaHepC Testing: rule HepC-associated thrombocytopeniaParvovirus B19 PCR: rule parvovirus B19 infectionAntinuclear Antibody (ANA) Testing: evaluate autoimmune disorders","code":""},{"path":"production.html","id":"key-terms-40","chapter":"Production","heading":"Key Terms","text":"Thrombocytopenia: Decreased platelet countMegakaryocytes: Bone marrow cells produce plateletsAplastic Anemia: Bone marrow failure pancytopenia hypocellular marrowMyelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders ineffective hematopoiesis dysplasiaPancytopenia: Deficiency blood cell lines (RBCs, WBCs, platelets)Hypocellular: Decreased cellularity bone marrowDysplasia: Abnormal cell development maturationThrombopoietin (TPO): Hormone stimulates platelet production","code":""},{"path":"pseudo.html","id":"pseudo","chapter":"Pseudo","heading":"Pseudo","text":"","code":""},{"path":"pseudo.html","id":"overview-of-pseudothrombocytopenia","chapter":"Pseudo","heading":"Overview of Pseudothrombocytopenia","text":"Definition: falsely low platelet count reported automated hematology analyzers due vitro platelet clumping platelet satellitism. actual platelet count patient normal mildly reducedSignificance: Recognizing pseudothrombocytopenia crucial avoid misdiagnosis true thrombocytopenia prevent unnecessary potentially harmful investigations treatments (e.g., bone marrow biopsy, platelet transfusions)Key Feature: Platelet clumping platelet satellitism present peripheral blood smear, patient clinical signs bleeding (e.g., petechiae, purpura, easy bruising)","code":""},{"path":"pseudo.html","id":"mechanisms-of-pseudothrombocytopenia","chapter":"Pseudo","heading":"Mechanisms of Pseudothrombocytopenia","text":"EDTA-Induced Platelet Clumping:\ncommon cause pseudothrombocytopenia\nEDTA (ethylenediaminetetraacetic acid) anticoagulant used CBC collection tubes\nindividuals, EDTA triggers exposure cryptic platelet antigens (e.g., GPIIb/IIIa)\nAutoantibodies (usually IgG IgM) exposed platelet antigens cause platelets clump together vitro\nautomated analyzer counts clumps single events, resulting falsely low platelet count\nEDTA-Induced Platelet Clumping:common cause pseudothrombocytopeniaEDTA (ethylenediaminetetraacetic acid) anticoagulant used CBC collection tubesIn individuals, EDTA triggers exposure cryptic platelet antigens (e.g., GPIIb/IIIa)Autoantibodies (usually IgG IgM) exposed platelet antigens cause platelets clump together vitroThe automated analyzer counts clumps single events, resulting falsely low platelet countPlatelet Satellitism:\nLess common platelet clumping\nPlatelets adhere surface neutrophils , less commonly, blood cells (lymphocytes, RBCs)\nautomated analyzer may misidentify platelets part white blood cell population, leading inaccurate platelet count\nPlatelet Satellitism:Less common platelet clumpingPlatelets adhere surface neutrophils , less commonly, blood cells (lymphocytes, RBCs)automated analyzer may misidentify platelets part white blood cell population, leading inaccurate platelet count","code":""},{"path":"pseudo.html","id":"laboratory-findings-8","chapter":"Pseudo","heading":"Laboratory Findings","text":"Automated Platelet Count:\nFalsely low platelet count (often significantly reduced)\ndegree thrombocytopenia can vary depending severity platelet clumping satellitism\nAutomated Platelet Count:Falsely low platelet count (often significantly reduced)degree thrombocytopenia can vary depending severity platelet clumping satellitismPeripheral Blood Smear:\nEssential diagnosing pseudothrombocytopenia\nPlatelet Clumps:\nAggregates platelets visible smear, ranging small clumps large aggregates\nclumps often unevenly distributed smear\npresence platelet clumping essential diagnosing EDTA-induced pseudothrombocytopenia\n\nPlatelet Satellitism:\nPlatelets adhere surface neutrophils blood cells, forming “ring” “halo” around cells\nMay difficult distinguish true platelet adherence cases\n\nPeripheral Blood Smear:Essential diagnosing pseudothrombocytopeniaPlatelet Clumps:\nAggregates platelets visible smear, ranging small clumps large aggregates\nclumps often unevenly distributed smear\npresence platelet clumping essential diagnosing EDTA-induced pseudothrombocytopenia\nAggregates platelets visible smear, ranging small clumps large aggregatesThe clumps often unevenly distributed smearThe presence platelet clumping essential diagnosing EDTA-induced pseudothrombocytopeniaPlatelet Satellitism:\nPlatelets adhere surface neutrophils blood cells, forming “ring” “halo” around cells\nMay difficult distinguish true platelet adherence cases\nPlatelets adhere surface neutrophils blood cells, forming “ring” “halo” around cellsMay difficult distinguish true platelet adherence cases","code":""},{"path":"pseudo.html","id":"corrective-action-procedure","chapter":"Pseudo","heading":"Corrective Action Procedure","text":"following steps taken pseudothrombocytopenia suspected:Review CBC Results Peripheral Blood Smear:\nAssess platelet count CBC parameters\nExamine peripheral blood smear confirm presence platelet clumping platelet satellitism\nAssess platelet count CBC parametersExamine peripheral blood smear confirm presence platelet clumping platelet satellitismRepeat CBC Sample Collected Different Anticoagulant:\nimportant step\nCollect new blood sample tube containing sodium citrate (light blue top) heparin (green top) anticoagulant\nCitrate heparin typically cause platelet clumping individuals EDTA-induced pseudothrombocytopenia\nImportant Note: Sodium citrate dilutes blood sample, platelet count obtained citrate tube must multiplied correction factor (usually 1.1) account dilution:\nCorrected Platelet Count = Platelet Count (Citrate Tube) x 1.1\nimportant stepThis important stepCollect new blood sample tube containing sodium citrate (light blue top) heparin (green top) anticoagulantCollect new blood sample tube containing sodium citrate (light blue top) heparin (green top) anticoagulantCitrate heparin typically cause platelet clumping individuals EDTA-induced pseudothrombocytopeniaCitrate heparin typically cause platelet clumping individuals EDTA-induced pseudothrombocytopeniaImportant Note: Sodium citrate dilutes blood sample, platelet count obtained citrate tube must multiplied correction factor (usually 1.1) account dilution:\nCorrected Platelet Count = Platelet Count (Citrate Tube) x 1.1Important Note: Sodium citrate dilutes blood sample, platelet count obtained citrate tube must multiplied correction factor (usually 1.1) account dilution:Corrected Platelet Count = Platelet Count (Citrate Tube) x 1.1Perform Manual Platelet Count:\nplatelet clumping persists despite using alternative anticoagulant, manual platelet count may necessary\nPrepare well-made peripheral blood smear count platelets manually, avoiding areas platelet clumping\nUse microscope calibrated eyepiece graticule count platelets defined area number fields\nplatelet clumping persists despite using alternative anticoagulant, manual platelet count may necessaryPrepare well-made peripheral blood smear count platelets manually, avoiding areas platelet clumpingUse microscope calibrated eyepiece graticule count platelets defined area number fieldsWarm Sample:\nWarming sample 37°C may help disperse platelet clumps cases\nIncubate sample 37°C 15-30 minutes re-analyzing\nWarming sample 37°C may help disperse platelet clumps casesIncubate sample 37°C 15-30 minutes re-analyzingDilution:\nDiluting sample saline another appropriate diluent may help disperse platelet clumps\nEnsure dilution factor accounted calculating final platelet count\nDiluting sample saline another appropriate diluent may help disperse platelet clumpsEnsure dilution factor accounted calculating final platelet countRule Causes Thrombocytopenia:\nplatelet count remains low despite corrective actions, consider causes true thrombocytopenia, :\nIncreased platelet destruction (e.g., ITP, TTP, HIT)\nDecreased platelet production (e.g., bone marrow failure)\n\nplatelet count remains low despite corrective actions, consider causes true thrombocytopenia, :\nIncreased platelet destruction (e.g., ITP, TTP, HIT)\nDecreased platelet production (e.g., bone marrow failure)\nIncreased platelet destruction (e.g., ITP, TTP, HIT)Decreased platelet production (e.g., bone marrow failure)Documentation Reporting:\nClearly document corrective actions taken patient’s laboratory record, including:\ninitial platelet count presence platelet clumping smear\ntype anticoagulant used repeat sample\ncorrected platelet count (applicable)\ncomment indicating pseudothrombocytopenia present results corrected accordingly\n\nReport corrected platelet count physician, noting pseudothrombocytopenia identified\nClearly document corrective actions taken patient’s laboratory record, including:\ninitial platelet count presence platelet clumping smear\ntype anticoagulant used repeat sample\ncorrected platelet count (applicable)\ncomment indicating pseudothrombocytopenia present results corrected accordingly\ninitial platelet count presence platelet clumping smearThe type anticoagulant used repeat sampleThe corrected platelet count (applicable)comment indicating pseudothrombocytopenia present results corrected accordinglyReport corrected platelet count physician, noting pseudothrombocytopenia identifiedCommunication Physician:\nNotify physician presence pseudothrombocytopenia corrective actions taken\nExplain potential falsely low platelet counts importance relying corrected results\nDiscuss need investigation patient clinical signs bleeding corrected platelet count significantly low\nNotify physician presence pseudothrombocytopenia corrective actions takenExplain potential falsely low platelet counts importance relying corrected resultsDiscuss need investigation patient clinical signs bleeding corrected platelet count significantly low","code":""},{"path":"pseudo.html","id":"key-considerations","chapter":"Pseudo","heading":"Key Considerations","text":"Prompt Action: ’s essential take prompt action pseudothrombocytopenia suspected avoid unnecessary investigations treatmentsVisual Confirmation: Always confirm presence platelet clumping satellitism peripheral blood smear initiating corrective actionsAccuracy: Ensure accurate measurement replacement plasma volume performing saline replacement proceduresDocumentation: Thorough documentation procedure results essential accurate reporting patient managementCommunication: Clear communication physician critical ensuring appropriate clinical decision-making","code":""},{"path":"pseudo.html","id":"key-terms-41","chapter":"Pseudo","heading":"Key Terms","text":"Pseudothrombocytopenia: Falsely low platelet count due vitro platelet clumping satellitismEDTA: Ethylenediaminetetraacetic acid, anticoagulant used CBC tubesPlatelet Clumping: Aggregation platelets vitroPlatelet Satellitism: Adherence platelets blood cellsCorrected Platelet Count: platelet count obtained correcting effects dilution factors","code":""},{"path":"thrombocytosis.html","id":"thrombocytosis","chapter":"Thrombocytosis","heading":"Thrombocytosis","text":"","code":""},{"path":"thrombocytosis.html","id":"overview-of-thrombocytosis","chapter":"Thrombocytosis","heading":"Overview of Thrombocytosis","text":"Definition: abnormally elevated platelet count peripheral blood, generally defined platelet count greater 450 x 10^9/L (450,000/µL)Clinical Significance: Thrombocytosis can increase risk thrombosis (blood clots) , paradoxically, cases, bleedingClassification:\nReactive (Secondary) Thrombocytosis: common type, caused underlying condition\nEssential (Primary) Thrombocythemia: myeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding\nReactive (Secondary) Thrombocytosis: common type, caused underlying conditionEssential (Primary) Thrombocythemia: myeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding","code":""},{"path":"thrombocytosis.html","id":"reactive-thrombocytosis-secondary-thrombocytosis","chapter":"Thrombocytosis","heading":"Reactive Thrombocytosis (Secondary Thrombocytosis)","text":"Definition: elevated platelet count occurs reaction underlying condition. ’s primary disorder bone marrowCharacteristics:\nTransient: Platelet count usually returns normal underlying condition resolves\nMild Moderate Elevation: Platelet counts typically less 1000 x 10^9/L, strict cutoff\nLack Clonal Marker: Absence genetic mutations (e.g., JAK2, CALR, MPL) associated essential thrombocythemia\nTransient: Platelet count usually returns normal underlying condition resolvesMild Moderate Elevation: Platelet counts typically less 1000 x 10^9/L, strict cutoffLack Clonal Marker: Absence genetic mutations (e.g., JAK2, CALR, MPL) associated essential thrombocythemiaCommon Causes Reactive Thrombocytosis:\nInfections:\nAcute chronic bacterial infections\nFungal infections\nViral infections (less common)\n\nInflammation:\nAutoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease)\nVasculitis\nAcute pancreatitis\nTissue injury (e.g., trauma, surgery, burns)\n\nIron Deficiency Anemia (IDA):\nPlatelet count may normalize iron repletion\n\nHemorrhage:\nFollowing acute blood loss, platelet count may temporarily increase\n\nSplenectomy:\nRemoval spleen leads increased platelet counts, spleen normally removes senescent platelets\nPlatelet counts can high (>1000 x 10^9/L) splenectomy\n\nRebound Thrombocytosis:\nFollowing recovery thrombocytopenia caused chemotherapy bone marrow suppression\n\nMalignancy:\nCertain cancers (e.g., lung, breast, ovarian) can cause reactive thrombocytosis\n\nMedications:\nCorticosteroids\nEpinephrine\n\nInfections:\nAcute chronic bacterial infections\nFungal infections\nViral infections (less common)\nAcute chronic bacterial infectionsFungal infectionsViral infections (less common)Inflammation:\nAutoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease)\nVasculitis\nAcute pancreatitis\nTissue injury (e.g., trauma, surgery, burns)\nAutoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease)VasculitisAcute pancreatitisTissue injury (e.g., trauma, surgery, burns)Iron Deficiency Anemia (IDA):\nPlatelet count may normalize iron repletion\nPlatelet count may normalize iron repletionHemorrhage:\nFollowing acute blood loss, platelet count may temporarily increase\nFollowing acute blood loss, platelet count may temporarily increaseSplenectomy:\nRemoval spleen leads increased platelet counts, spleen normally removes senescent platelets\nPlatelet counts can high (>1000 x 10^9/L) splenectomy\nRemoval spleen leads increased platelet counts, spleen normally removes senescent plateletsPlatelet counts can high (>1000 x 10^9/L) splenectomyRebound Thrombocytosis:\nFollowing recovery thrombocytopenia caused chemotherapy bone marrow suppression\nFollowing recovery thrombocytopenia caused chemotherapy bone marrow suppressionMalignancy:\nCertain cancers (e.g., lung, breast, ovarian) can cause reactive thrombocytosis\nCertain cancers (e.g., lung, breast, ovarian) can cause reactive thrombocytosisMedications:\nCorticosteroids\nEpinephrine\nCorticosteroidsEpinephrinePathophysiology:\nIncreased Thrombopoietin (TPO) Production:\nMany underlying conditions associated reactive thrombocytosis stimulate production thrombopoietin (TPO), primary regulator platelet production\nTPO produced mainly liver kidneys\nTPO stimulates megakaryocyte proliferation differentiation bone marrow, leading increased platelet production\n\nIncreased Release Platelets Bone Marrow:\nInflammatory cytokines can promote release platelets bone marrow storage pool\n\nDecreased Platelet Sequestration:\nSplenectomy removes spleen, main site platelet destruction sequestration, leading increased platelet counts\n\nIncreased Thrombopoietin (TPO) Production:\nMany underlying conditions associated reactive thrombocytosis stimulate production thrombopoietin (TPO), primary regulator platelet production\nTPO produced mainly liver kidneys\nTPO stimulates megakaryocyte proliferation differentiation bone marrow, leading increased platelet production\nMany underlying conditions associated reactive thrombocytosis stimulate production thrombopoietin (TPO), primary regulator platelet productionTPO produced mainly liver kidneysTPO stimulates megakaryocyte proliferation differentiation bone marrow, leading increased platelet productionIncreased Release Platelets Bone Marrow:\nInflammatory cytokines can promote release platelets bone marrow storage pool\nInflammatory cytokines can promote release platelets bone marrow storage poolDecreased Platelet Sequestration:\nSplenectomy removes spleen, main site platelet destruction sequestration, leading increased platelet counts\nSplenectomy removes spleen, main site platelet destruction sequestration, leading increased platelet countsClinical Features Reactive Thrombocytosis:\nOften asymptomatic\nSymptoms underlying condition may present (e.g., fever, pain, inflammation)\nThrombotic bleeding complications rare reactive thrombocytosis, especially platelet counts <1000 x 10^9/L\nOften asymptomaticSymptoms underlying condition may present (e.g., fever, pain, inflammation)Thrombotic bleeding complications rare reactive thrombocytosis, especially platelet counts <1000 x 10^9/LLaboratory Findings Reactive Thrombocytosis:\nComplete Blood Count (CBC):\nElevated platelet count (usually < 1000 x 10^9/L)\nMay see abnormalities depending underlying cause (e.g., elevated WBC count infection, anemia iron deficiency)\n\nPeripheral Blood Smear:\nIncreased number platelets\nPlatelets usually appear normal size morphology\nMay see abnormalities related underlying condition (e.g., microcytes iron deficiency)\n\nIron Studies:\nMay abnormal iron deficiency anemia (low serum iron ferritin, high TIBC)\n\nInflammatory Markers:\nElevated ESR, CRP, /inflammatory markers\n\nJAK2, CALR, MPL Mutation Testing:\nNegative: Helps rule essential thrombocythemia (ET)\n\nComplete Blood Count (CBC):\nElevated platelet count (usually < 1000 x 10^9/L)\nMay see abnormalities depending underlying cause (e.g., elevated WBC count infection, anemia iron deficiency)\nElevated platelet count (usually < 1000 x 10^9/L)May see abnormalities depending underlying cause (e.g., elevated WBC count infection, anemia iron deficiency)Peripheral Blood Smear:\nIncreased number platelets\nPlatelets usually appear normal size morphology\nMay see abnormalities related underlying condition (e.g., microcytes iron deficiency)\nIncreased number plateletsPlatelets usually appear normal size morphologyMay see abnormalities related underlying condition (e.g., microcytes iron deficiency)Iron Studies:\nMay abnormal iron deficiency anemia (low serum iron ferritin, high TIBC)\nMay abnormal iron deficiency anemia (low serum iron ferritin, high TIBC)Inflammatory Markers:\nElevated ESR, CRP, /inflammatory markers\nElevated ESR, CRP, /inflammatory markersJAK2, CALR, MPL Mutation Testing:\nNegative: Helps rule essential thrombocythemia (ET)\nNegative: Helps rule essential thrombocythemia (ET)","code":""},{"path":"thrombocytosis.html","id":"essential-thrombocythemia-primary-thrombocythemia","chapter":"Thrombocytosis","heading":"Essential Thrombocythemia (Primary Thrombocythemia)","text":"Definition: myeloproliferative neoplasm characterized sustained thrombocytosis increased risk thrombosis bleeding. ’s primary disorder bone marrowDiagnostic Criteria (Criteria):\nSustained Platelet Count ≥450 x 10^9/L\nBone Marrow Showing Increased Numbers Megakaryocytes Abnormal Morphology\nIncreased numbers large, mature megakaryocytes hyperlobated nuclei\n\nExclusion MPNs: Absence criteria PV, PMF, CML\nPresence Clonal Marker Evidence Clonal Hematopoiesis:\nJAK2 V617F mutation (present approximately 50-60% patients)\nCALR mutation (present approximately 25% patients)\nMPL mutation (present approximately 5% patients)\nthree mutations negative, evidence clonality required\n\nSustained Platelet Count ≥450 x 10^9/LBone Marrow Showing Increased Numbers Megakaryocytes Abnormal Morphology\nIncreased numbers large, mature megakaryocytes hyperlobated nuclei\nIncreased numbers large, mature megakaryocytes hyperlobated nucleiExclusion MPNs: Absence criteria PV, PMF, CMLPresence Clonal Marker Evidence Clonal Hematopoiesis:\nJAK2 V617F mutation (present approximately 50-60% patients)\nCALR mutation (present approximately 25% patients)\nMPL mutation (present approximately 5% patients)\nthree mutations negative, evidence clonality required\nJAK2 V617F mutation (present approximately 50-60% patients)CALR mutation (present approximately 25% patients)MPL mutation (present approximately 5% patients)three mutations negative, evidence clonality requiredPathophysiology:\nMutations JAK2, CALR, MPL Genes:\nmutations lead constitutive activation signaling pathways control megakaryocyte proliferation platelet production\nJAK2 V617F: point mutation JAK2 gene\nCALR mutations: Insertions deletions CALR gene\nMPL mutations: Mutations MPL gene (thrombopoietin receptor)\n\nMegakaryocyte Hyperplasia: Increased numbers megakaryocytes bone marrow\nIncreased Platelet Production: Megakaryocytes produce excessive numbers platelets\nMutations JAK2, CALR, MPL Genes:\nmutations lead constitutive activation signaling pathways control megakaryocyte proliferation platelet production\nJAK2 V617F: point mutation JAK2 gene\nCALR mutations: Insertions deletions CALR gene\nMPL mutations: Mutations MPL gene (thrombopoietin receptor)\nmutations lead constitutive activation signaling pathways control megakaryocyte proliferation platelet productionJAK2 V617F: point mutation JAK2 geneCALR mutations: Insertions deletions CALR geneMPL mutations: Mutations MPL gene (thrombopoietin receptor)Megakaryocyte Hyperplasia: Increased numbers megakaryocytes bone marrowIncreased Platelet Production: Megakaryocytes produce excessive numbers plateletsClinical Features:\nMany patients asymptomatic diagnosis\nThrombotic Events:\nStroke\nTransient ischemic attack (TIA)\nMyocardial infarction (heart attack)\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nErythromelalgia (burning pain redness extremities)\n\nBleeding Events:\nParadoxically, patients may experience bleeding due abnormal platelet function\nEasy bruising\nNosebleeds\nGastrointestinal bleeding\n\nSplenomegaly: Enlarged spleen (less common PV PMF)\nConstitutional Symptoms: Fatigue, night sweats, weight loss (less common)\nMany patients asymptomatic diagnosisThrombotic Events:\nStroke\nTransient ischemic attack (TIA)\nMyocardial infarction (heart attack)\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nErythromelalgia (burning pain redness extremities)\nStrokeTransient ischemic attack (TIA)Myocardial infarction (heart attack)Deep vein thrombosis (DVT)Pulmonary embolism (PE)Erythromelalgia (burning pain redness extremities)Bleeding Events:\nParadoxically, patients may experience bleeding due abnormal platelet function\nEasy bruising\nNosebleeds\nGastrointestinal bleeding\nParadoxically, patients may experience bleeding due abnormal platelet functionEasy bruisingNosebleedsGastrointestinal bleedingSplenomegaly: Enlarged spleen (less common PV PMF)Constitutional Symptoms: Fatigue, night sweats, weight loss (less common)Laboratory Findings:\nCBC:\nElevated platelet count (sustained >450 x 10^9/L)\nWBC count: May normal slightly elevated\nRBC count: Usually normal, may slightly elevated\n\nPeripheral Blood Smear:\nThrombocytosis (increased platelets)\nLarge platelets (megathrombocytes)\nAbnormal platelet morphology (e.g., hypogranular platelets)\n\nBone Marrow Examination:\nIncreased numbers megakaryocytes abnormal morphology (e.g., large, hyperlobated nuclei)\nMay see increased granulopoiesis\nLittle reticulin fibrosis (unlike primary myelofibrosis)\n\nMolecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\n\nCBC:\nElevated platelet count (sustained >450 x 10^9/L)\nWBC count: May normal slightly elevated\nRBC count: Usually normal, may slightly elevated\nElevated platelet count (sustained >450 x 10^9/L)WBC count: May normal slightly elevatedRBC count: Usually normal, may slightly elevatedPeripheral Blood Smear:\nThrombocytosis (increased platelets)\nLarge platelets (megathrombocytes)\nAbnormal platelet morphology (e.g., hypogranular platelets)\nThrombocytosis (increased platelets)Large platelets (megathrombocytes)Abnormal platelet morphology (e.g., hypogranular platelets)Bone Marrow Examination:\nIncreased numbers megakaryocytes abnormal morphology (e.g., large, hyperlobated nuclei)\nMay see increased granulopoiesis\nLittle reticulin fibrosis (unlike primary myelofibrosis)\nIncreased numbers megakaryocytes abnormal morphology (e.g., large, hyperlobated nuclei)May see increased granulopoiesisLittle reticulin fibrosis (unlike primary myelofibrosis)Molecular Testing:\nPositive JAK2, CALR, MPL mutation (cases)\nPositive JAK2, CALR, MPL mutation (cases)Treatment:\nLow-Risk Patients (Low Risk Thrombosis):\nLow-Dose Aspirin: reduce risk thrombosis\n\nHigh-Risk Patients (High Risk Thrombosis):\nLow-Dose Aspirin\nCytoreductive Therapy:\nHydroxyurea: lower platelet count\nAnagrelide: Inhibits platelet production\nInterferon-alpha: May used younger patients pregnant women\n\n\nRisk Stratification:\nVarious risk scoring systems used estimate risk thrombosis guide treatment decisions\n\nLow-Risk Patients (Low Risk Thrombosis):\nLow-Dose Aspirin: reduce risk thrombosis\nLow-Dose Aspirin: reduce risk thrombosisHigh-Risk Patients (High Risk Thrombosis):\nLow-Dose Aspirin\nCytoreductive Therapy:\nHydroxyurea: lower platelet count\nAnagrelide: Inhibits platelet production\nInterferon-alpha: May used younger patients pregnant women\n\nLow-Dose AspirinCytoreductive Therapy:\nHydroxyurea: lower platelet count\nAnagrelide: Inhibits platelet production\nInterferon-alpha: May used younger patients pregnant women\nHydroxyurea: lower platelet countAnagrelide: Inhibits platelet productionInterferon-alpha: May used younger patients pregnant womenRisk Stratification:\nVarious risk scoring systems used estimate risk thrombosis guide treatment decisions\nVarious risk scoring systems used estimate risk thrombosis guide treatment decisions","code":""},{"path":"thrombocytosis.html","id":"distinguishing-reactive-thrombocytosis-from-essential-thrombocythemia","chapter":"Thrombocytosis","heading":"Distinguishing Reactive Thrombocytosis from Essential Thrombocythemia","text":"","code":""},{"path":"thrombocytosis.html","id":"general-laboratory-tests-for-thrombocytosis","chapter":"Thrombocytosis","heading":"General Laboratory Tests for Thrombocytosis","text":"Complete Blood Count (CBC) Peripheral Blood Smear: Essential diagnosis classificationIron Studies: rule iron deficiency anemiaInflammatory Markers: (ESR, CRP) assess underlying inflammationMutation Testing: (JAK2, CALR, MPL) rule essential thrombocythemia primary myelofibrosisBone Marrow Aspiration Biopsy: May necessary evaluate MPNs bone marrow disorders","code":""},{"path":"thrombocytosis.html","id":"key-terms-42","chapter":"Thrombocytosis","heading":"Key Terms","text":"Thrombocytosis: Elevated platelet countReactive Thrombocytosis: Thrombocytosis due underlying conditionEssential Thrombocythemia (ET): Clonal MPN sustained thrombocytosisMyeloproliferative Neoplasm (MPN): Clonal disorder hematopoietic stem cellsJAK2, CALR, MPL: Genes commonly mutated MPNsPhlebotomy: Removal blood reduce red cell massHydroxyurea: chemotherapeutic drug used suppress bone marrow proliferationAnagrelide: drug inhibits platelet production","code":""},{"path":"qualitative.html","id":"qualitative","chapter":"Qualitative","heading":"Qualitative","text":"","code":""},{"path":"qualitative.html","id":"overview-of-qualitative-platelet-disorders","chapter":"Qualitative","heading":"Overview of Qualitative Platelet Disorders","text":"Definition: group disorders characterized abnormal platelet function, despite normal (near normal) platelet count. disorders, platelets present adequate numbers, function correctly, leading bleeding tendencyTypes:\nInherited (Congenital): Genetic defects platelet membrane glycoproteins, receptors, signaling pathways\nAcquired: Due medications, systemic diseases, factors impair platelet function\nInherited (Congenital): Genetic defects platelet membrane glycoproteins, receptors, signaling pathwaysAcquired: Due medications, systemic diseases, factors impair platelet functionCommon Manifestations:\nMucocutaneous bleeding: Bleeding skin mucous membranes (e.g., nosebleeds, gum bleeding, easy bruising, menorrhagia)\nProlonged bleeding trauma surgery\nMucocutaneous bleeding: Bleeding skin mucous membranes (e.g., nosebleeds, gum bleeding, easy bruising, menorrhagia)Prolonged bleeding trauma surgery","code":""},{"path":"qualitative.html","id":"inherited-qualitative-platelet-disorders","chapter":"Qualitative","heading":"Inherited Qualitative Platelet Disorders","text":"von Willebrand Disease (vWD):\nDefinition: common inherited bleeding disorder, caused deficiency dysfunction von Willebrand factor (vWF)\nDefinition: common inherited bleeding disorder, caused deficiency dysfunction von Willebrand factor (vWF)Bernard-Soulier Syndrome (BSS):\nDefinition: rare inherited bleeding disorder caused deficiency dysfunction platelet glycoprotein Ib/IX/V (GPIb/IX/V) complex\nDefinition: rare inherited bleeding disorder caused deficiency dysfunction platelet glycoprotein Ib/IX/V (GPIb/IX/V) complexGlanzmann Thrombasthenia (GT):\nDefinition: rare inherited bleeding disorder caused deficiency dysfunction platelet glycoprotein IIb/IIIa (GPIIb/IIIa) complex (also known αIIbβ3 integrin)\nDefinition: rare inherited bleeding disorder caused deficiency dysfunction platelet glycoprotein IIb/IIIa (GPIIb/IIIa) complex (also known αIIbβ3 integrin)","code":""},{"path":"qualitative.html","id":"acquired-qualitative-platelet-disorders","chapter":"Qualitative","heading":"Acquired Qualitative Platelet Disorders","text":"Drug-Induced Platelet Dysfunction:\nAspirin: Irreversibly inhibits cyclooxygenase (COX-1), preventing production thromboxane A2 (TxA2), potent platelet activator\nNSAIDs: Reversibly inhibit COX-1 COX-2\nClopidogrel Prasugrel: Block ADP receptor (P2Y12) platelets, inhibiting platelet activation aggregation\nAbciximab, Eptifibatide, Tirofiban: Block GPIIb/IIIa receptor, preventing platelet aggregation\nAspirin: Irreversibly inhibits cyclooxygenase (COX-1), preventing production thromboxane A2 (TxA2), potent platelet activatorNSAIDs: Reversibly inhibit COX-1 COX-2Clopidogrel Prasugrel: Block ADP receptor (P2Y12) platelets, inhibiting platelet activation aggregationAbciximab, Eptifibatide, Tirofiban: Block GPIIb/IIIa receptor, preventing platelet aggregationUremia (Chronic Kidney Disease):\nUremic toxins accumulate plasma impair platelet function\nCorrecting uremia dialysis can improve platelet function\nUremic toxins accumulate plasma impair platelet functionCorrecting uremia dialysis can improve platelet functionMyeloproliferative Neoplasms (MPNs):\nPlatelets may abnormal function despite elevated number\nPlatelets may abnormal function despite elevated number","code":""},{"path":"qualitative.html","id":"general-laboratory-tests-for-qualitative-platelet-disorders","chapter":"Qualitative","heading":"General Laboratory Tests for Qualitative Platelet Disorders","text":"Platelet Count: rule thrombocytopeniaPeripheral Blood Smear: assess platelet morphology (e.g., size, granulation)Bleeding Time: Historically used assess platelet function, now largely replaced specific testsPlatelet Function Analyzer (PFA-100): Measures platelet function high shear stressPlatelet Aggregation Studies: Measure platelet aggregation response various agonists (ADP, collagen, epinephrine, thrombin, ristocetin)Flow Cytometry: assess expression platelet membrane glycoproteins receptorsSpecialized Assays:\nvWF Antigen (vWF:Ag)\nvWF Activity (vWF:RCo)\nFactor VIII Level (FVIII:C)\nADAMTS13 Activity Assay\nvWF Antigen (vWF:Ag)vWF Activity (vWF:RCo)Factor VIII Level (FVIII:C)ADAMTS13 Activity Assay","code":""},{"path":"qualitative.html","id":"key-terms-43","chapter":"Qualitative","heading":"Key Terms","text":"Qualitative Platelet Disorder: disorder platelets present adequate numbers function correctlyVon Willebrand Factor (vWF): protein mediates platelet adhesion carries factor VIIIGPIb/IX/V: Platelet glycoprotein receptor vWFGPIIb/IIIa: Platelet glycoprotein receptor fibrinogenPlatelet Aggregation: clumping together plateletsRistocetin: antibiotic induces vWF-dependent platelet agglutinationPFA-100: test measures platelet function high shear stressThrombopoietin (TPO): hormone stimulates megakaryocyte platelet production","code":""},{"path":"von-willebrand.html","id":"von-willebrand","chapter":"von Willebrand","heading":"von Willebrand","text":"","code":""},{"path":"von-willebrand.html","id":"overview-of-von-willebrand-disease-vwd","chapter":"von Willebrand","heading":"Overview of von Willebrand Disease (vWD)","text":"Definition: common inherited bleeding disorder, characterized quantitative (amount) qualitative (functional) defect von Willebrand factor (vWF)Prevalence: Estimated affect 1-3% population, though many cases mild undiagnosedKey Features:\nMucocutaneous bleeding: Easy bruising, nosebleeds (epistaxis), gum bleeding, menorrhagia (heavy menstrual bleeding)\nProlonged bleeding cuts, dental procedures, surgery\nMucocutaneous bleeding: Easy bruising, nosebleeds (epistaxis), gum bleeding, menorrhagia (heavy menstrual bleeding)Prolonged bleeding cuts, dental procedures, surgeryGenetic Basis: vWD usually inherited autosomal dominant trait, although autosomal recessive inheritance possible subtypes.Treatment: Varies depending type severity vWD, may include desmopressin, vWF/FVIII concentrates, antifibrinolytic agents","code":""},{"path":"von-willebrand.html","id":"von-willebrand-factor-vwf-structure-and-function","chapter":"von Willebrand","heading":"von Willebrand Factor (vWF): Structure and Function","text":"vWF Structure:\nlarge, multimeric glycoprotein found plasma, platelets, subendothelial connective tissue\nSynthesized endothelial cells megakaryocytes\nMonomers vWF assembled dimers, polymerize form large multimers\nsize structure vWF multimers critical function\nlarge, multimeric glycoprotein found plasma, platelets, subendothelial connective tissueSynthesized endothelial cells megakaryocytesMonomers vWF assembled dimers, polymerize form large multimersThe size structure vWF multimers critical functionvWF Functions:\n**Platelet Adhesion:\nvWF binds exposed collagen subendothelium damaged blood vessels\nvWF binds platelet glycoprotein Ib/IX/V (GPIb/IX/V) receptor platelet surface, mediating initial platelet adhesion\ninteraction crucial platelet plug formation sites vascular injury, especially high shear stress conditions\n\n**Factor VIII Carrier:\nvWF binds factor VIII (FVIII), coagulation protein\nvWF protects FVIII degradation prolongs half-life circulation\nDecreased vWF can lead decreased FVIII levels\n\n**Platelet Adhesion:\nvWF binds exposed collagen subendothelium damaged blood vessels\nvWF binds platelet glycoprotein Ib/IX/V (GPIb/IX/V) receptor platelet surface, mediating initial platelet adhesion\ninteraction crucial platelet plug formation sites vascular injury, especially high shear stress conditions\nvWF binds exposed collagen subendothelium damaged blood vesselsvWF binds platelet glycoprotein Ib/IX/V (GPIb/IX/V) receptor platelet surface, mediating initial platelet adhesionThis interaction crucial platelet plug formation sites vascular injury, especially high shear stress conditions**Factor VIII Carrier:\nvWF binds factor VIII (FVIII), coagulation protein\nvWF protects FVIII degradation prolongs half-life circulation\nDecreased vWF can lead decreased FVIII levels\nvWF binds factor VIII (FVIII), coagulation proteinvWF protects FVIII degradation prolongs half-life circulationDecreased vWF can lead decreased FVIII levels","code":""},{"path":"von-willebrand.html","id":"classification-of-vwd","chapter":"von Willebrand","heading":"Classification of vWD","text":"Type 1 vWD: (60-80% cases)\nPartial quantitative deficiency vWF\nvWF present, reduced amounts\nvWF multimers present, decreased concentration\nInheritance: Usually autosomal dominant\nType 1 vWD: (60-80% cases)Partial quantitative deficiency vWFvWF present, reduced amountsAll vWF multimers present, decreased concentrationInheritance: Usually autosomal dominantType 2 vWD: (20-30% cases)\nQualitative defects vWF function\nvWF present normal near-normal amounts, ability perform functions impaired\nSubtypes:\nType 2A:\nDecreased high-molecular-weight vWF multimers\nImpaired platelet adhesion\nOften caused increased proteolysis abnormal multimer assembly\n\nType 2B:\nIncreased affinity vWF platelets\nSpontaneous binding vWF platelets, leading clearance vWF platelets circulation, resulting thrombocytopenia\nRistocetin-induced platelet aggregation (RIPA) enhanced low concentrations ristocetin\n\nType 2M:\nDecreased binding vWF platelets collagen\nNormal vWF multimer distribution\nDifferentiation subtypes depends binding activity affected (platelets collagen)\n\nType 2N:\nDecreased binding vWF factor VIII\nMarkedly reduced factor VIII levels\nMay misdiagnosed mild hemophilia (factor VIII deficiency)\n\n\nInheritance: Usually autosomal dominant\nType 2 vWD: (20-30% cases)Qualitative defects vWF functionvWF present normal near-normal amounts, ability perform functions impairedSubtypes:\nType 2A:\nDecreased high-molecular-weight vWF multimers\nImpaired platelet adhesion\nOften caused increased proteolysis abnormal multimer assembly\n\nType 2B:\nIncreased affinity vWF platelets\nSpontaneous binding vWF platelets, leading clearance vWF platelets circulation, resulting thrombocytopenia\nRistocetin-induced platelet aggregation (RIPA) enhanced low concentrations ristocetin\n\nType 2M:\nDecreased binding vWF platelets collagen\nNormal vWF multimer distribution\nDifferentiation subtypes depends binding activity affected (platelets collagen)\n\nType 2N:\nDecreased binding vWF factor VIII\nMarkedly reduced factor VIII levels\nMay misdiagnosed mild hemophilia (factor VIII deficiency)\n\nType 2A:\nDecreased high-molecular-weight vWF multimers\nImpaired platelet adhesion\nOften caused increased proteolysis abnormal multimer assembly\nDecreased high-molecular-weight vWF multimersImpaired platelet adhesionOften caused increased proteolysis abnormal multimer assemblyType 2B:\nIncreased affinity vWF platelets\nSpontaneous binding vWF platelets, leading clearance vWF platelets circulation, resulting thrombocytopenia\nRistocetin-induced platelet aggregation (RIPA) enhanced low concentrations ristocetin\nIncreased affinity vWF plateletsSpontaneous binding vWF platelets, leading clearance vWF platelets circulation, resulting thrombocytopeniaRistocetin-induced platelet aggregation (RIPA) enhanced low concentrations ristocetinType 2M:\nDecreased binding vWF platelets collagen\nNormal vWF multimer distribution\nDifferentiation subtypes depends binding activity affected (platelets collagen)\nDecreased binding vWF platelets collagenNormal vWF multimer distributionDifferentiation subtypes depends binding activity affected (platelets collagen)Type 2N:\nDecreased binding vWF factor VIII\nMarkedly reduced factor VIII levels\nMay misdiagnosed mild hemophilia (factor VIII deficiency)\nDecreased binding vWF factor VIIIMarkedly reduced factor VIII levelsMay misdiagnosed mild hemophilia (factor VIII deficiency)Inheritance: Usually autosomal dominantType 3 vWD: (Rare)\nSevere quantitative deficiency vWF (vWF virtually absent)\nlow undetectable levels vWF factor VIII\nSevere bleeding symptoms\nInheritance: Autosomal recessive\nType 3 vWD: (Rare)Severe quantitative deficiency vWF (vWF virtually absent)low undetectable levels vWF factor VIIISevere bleeding symptomsInheritance: Autosomal recessive","code":""},{"path":"von-willebrand.html","id":"clinical-features-1","chapter":"von Willebrand","heading":"Clinical Features","text":"Variable bleeding symptoms:\nSeverity bleeding depends type severity vWD\nBleeding symptoms may mild become apparent surgery trauma\nVariable bleeding symptoms:Severity bleeding depends type severity vWDBleeding symptoms may mild become apparent surgery traumaCommon Manifestations:\nNosebleeds (epistaxis)\nEasy bruising\nProlonged bleeding cuts dental procedures\nMenorrhagia (heavy menstrual bleeding) women\nPostpartum hemorrhage\nGastrointestinal bleeding (less common)\nJoint bleeds (hemarthrosis) rare, unlike hemophilia\nCommon Manifestations:Nosebleeds (epistaxis)Easy bruisingProlonged bleeding cuts dental proceduresMenorrhagia (heavy menstrual bleeding) womenPostpartum hemorrhageGastrointestinal bleeding (less common)Joint bleeds (hemarthrosis) rare, unlike hemophiliaSymptoms vWD Type:\nType 1 vWD: Mild moderate bleeding symptoms\nType 2 vWD: Variable bleeding symptoms, depending subtype\nType 2A: Moderate bleeding symptoms\nType 2B: Moderate bleeding symptoms; may also thrombocytopenia\nType 2M: Mild moderate bleeding symptoms\nType 2N: Moderate severe bleeding symptoms; may misdiagnosed hemophilia \n\nType 3 vWD: Severe bleeding symptoms\nSymptoms vWD Type:Type 1 vWD: Mild moderate bleeding symptomsType 2 vWD: Variable bleeding symptoms, depending subtype\nType 2A: Moderate bleeding symptoms\nType 2B: Moderate bleeding symptoms; may also thrombocytopenia\nType 2M: Mild moderate bleeding symptoms\nType 2N: Moderate severe bleeding symptoms; may misdiagnosed hemophilia \nType 2A: Moderate bleeding symptomsType 2B: Moderate bleeding symptoms; may also thrombocytopeniaType 2M: Mild moderate bleeding symptomsType 2N: Moderate severe bleeding symptoms; may misdiagnosed hemophilia AType 3 vWD: Severe bleeding symptoms","code":""},{"path":"von-willebrand.html","id":"laboratory-diagnosis","chapter":"von Willebrand","heading":"Laboratory Diagnosis","text":"Screening Tests:\nComplete Blood Count (CBC):\nPlatelet count usually normal, may decreased cases (e.g., type 2B vWD)\n\nProthrombin Time (PT): Usually normal\nActivated Partial Thromboplastin Time (aPTT): May prolonged factor VIII significantly reduced (especially type 2N type 3 vWD)\nScreening Tests:Complete Blood Count (CBC):\nPlatelet count usually normal, may decreased cases (e.g., type 2B vWD)\nPlatelet count usually normal, may decreased cases (e.g., type 2B vWD)Prothrombin Time (PT): Usually normalActivated Partial Thromboplastin Time (aPTT): May prolonged factor VIII significantly reduced (especially type 2N type 3 vWD)Specific vWD Assays:\nvon Willebrand Factor Antigen (vWF:Ag):\nMeasures amount vWF protein plasma\nDecreased type 1 type 3 vWD\nMay normal type 2 vWD\n\nvon Willebrand Factor Activity (vWF:RCo):\nMeasures ability vWF bind platelets using ristocetin cofactor\nRistocetin-induced platelet aggregation (RIPA)\nDecreased types vWD (except type 2B, increased)\n\nFactor VIII Activity (FVIII:C):\nMeasures activity factor VIII\nMay decreased vWD, especially type 2N type 3\n\nvWF Multimer Analysis:\nEvaluates distribution vWF multimers\nDecreased high molecular weight multimers type 2A vWD\n\nPlatelet Function Analyzer (PFA-100):\nMeasures platelet function high shear stress\nProlonged closure time types vWD\n\nSpecific vWD Assays:von Willebrand Factor Antigen (vWF:Ag):\nMeasures amount vWF protein plasma\nDecreased type 1 type 3 vWD\nMay normal type 2 vWD\nMeasures amount vWF protein plasmaDecreased type 1 type 3 vWDMay normal type 2 vWDvon Willebrand Factor Activity (vWF:RCo):\nMeasures ability vWF bind platelets using ristocetin cofactor\nRistocetin-induced platelet aggregation (RIPA)\nDecreased types vWD (except type 2B, increased)\nMeasures ability vWF bind platelets using ristocetin cofactorRistocetin-induced platelet aggregation (RIPA)Decreased types vWD (except type 2B, increased)Factor VIII Activity (FVIII:C):\nMeasures activity factor VIII\nMay decreased vWD, especially type 2N type 3\nMeasures activity factor VIIIMay decreased vWD, especially type 2N type 3vWF Multimer Analysis:\nEvaluates distribution vWF multimers\nDecreased high molecular weight multimers type 2A vWD\nEvaluates distribution vWF multimersDecreased high molecular weight multimers type 2A vWDPlatelet Function Analyzer (PFA-100):\nMeasures platelet function high shear stress\nProlonged closure time types vWD\nMeasures platelet function high shear stressProlonged closure time types vWDDiagnostic Approach:\nPerform Initial Screening Tests (CBC, PT, aPTT)\nMeasure vWF:Ag vWF:RCo:\ndecreased -> Consider type 1 type 3 vWD\nvWF:Ag normal vWF:RCo decreased -> Consider type 2 vWD\n\nPerform FVIII:C Assay:\nFVIII:C decreased -> Consider type 2N vWD\n\nPerform vWF Multimer Analysis:\ndifferentiate type 2A subtypes\n\nPerform RIPA low concentrations ristocetin:\nidentify type 2B vWD (RIPA enhanced)\n\nGenetic Testing: May considered cases confirm diagnosis classify subtype vWD\nDiagnostic Approach:Perform Initial Screening Tests (CBC, PT, aPTT)Measure vWF:Ag vWF:RCo:\ndecreased -> Consider type 1 type 3 vWD\nvWF:Ag normal vWF:RCo decreased -> Consider type 2 vWD\ndecreased -> Consider type 1 type 3 vWDIf vWF:Ag normal vWF:RCo decreased -> Consider type 2 vWDPerform FVIII:C Assay:\nFVIII:C decreased -> Consider type 2N vWD\nFVIII:C decreased -> Consider type 2N vWDPerform vWF Multimer Analysis:\ndifferentiate type 2A subtypes\ndifferentiate type 2A subtypesPerform RIPA low concentrations ristocetin:\nidentify type 2B vWD (RIPA enhanced)\nidentify type 2B vWD (RIPA enhanced)Genetic Testing: May considered cases confirm diagnosis classify subtype vWD","code":""},{"path":"von-willebrand.html","id":"treatment-2","chapter":"von Willebrand","heading":"Treatment","text":"Desmopressin (DDAVP):\nsynthetic analog vasopressin stimulates release vWF factor VIII endothelial cells\nEffective treating type 1 vWD subtypes type 2 vWD\nAdministered intravenously, subcutaneously, intranasally\nSide effects: Flushing, headache, hyponatremia (low sodium)\nDesmopressin (DDAVP):synthetic analog vasopressin stimulates release vWF factor VIII endothelial cellsEffective treating type 1 vWD subtypes type 2 vWDAdministered intravenously, subcutaneously, intranasallySide effects: Flushing, headache, hyponatremia (low sodium)vWF/Factor VIII Concentrates:\nPlasma-derived concentrates contain vWF factor VIII\nUsed treat bleeding episodes prophylaxis patients severe vWD respond DDAVP\nExamples: Humate-P, Alphanate SDH, Wilate\nvWF/Factor VIII Concentrates:Plasma-derived concentrates contain vWF factor VIIIUsed treat bleeding episodes prophylaxis patients severe vWD respond DDAVPExamples: Humate-P, Alphanate SDH, WilateAntifibrinolytic Agents:\nTranexamic acid aminocaproic acid\nInhibit fibrinolysis (breakdown blood clots)\nUsed prevent treat bleeding, especially mucosal bleeding (e.g., menorrhagia, dental procedures)\nAntifibrinolytic Agents:Tranexamic acid aminocaproic acidInhibit fibrinolysis (breakdown blood clots)Used prevent treat bleeding, especially mucosal bleeding (e.g., menorrhagia, dental procedures)Topical Hemostatic Agents:\nThrombin-soaked gauze fibrin sealants\nUsed control local bleeding\nTopical Hemostatic Agents:Thrombin-soaked gauze fibrin sealantsUsed control local bleedingOther Considerations:\nAvoid Aspirin NSAIDs: medications can impair platelet function increase risk bleeding\nHormonal Therapy: Oral contraceptives hormonal treatments may used manage menorrhagia\nConsiderations:Avoid Aspirin NSAIDs: medications can impair platelet function increase risk bleedingHormonal Therapy: Oral contraceptives hormonal treatments may used manage menorrhagia","code":""},{"path":"von-willebrand.html","id":"key-terms-44","chapter":"von Willebrand","heading":"Key Terms","text":"von Willebrand Factor (vWF): protein mediates platelet adhesion carries factor VIIIvWF Antigen (vWF:Ag): Measures amount vWF proteinvWF Activity (vWF:RCo): Measures ability vWF bind plateletsFactor VIII (FVIII:C): coagulation protein carried vWFRistocetin-Induced Platelet Aggregation (RIPA): test used assess vWF functionDesmopressin (DDAVP): synthetic analog vasopressin stimulates release vWF factor VIIIMultimers: Polymers vWF subunitsPlatelet Function Analyzer (PFA): test measures platelet function high shear stress","code":""},{"path":"bernard-soulier.html","id":"bernard-soulier","chapter":"Bernard-Soulier","heading":"Bernard-Soulier","text":"","code":""},{"path":"bernard-soulier.html","id":"overview-of-bernard-soulier-syndrome-bss","chapter":"Bernard-Soulier","heading":"Overview of Bernard-Soulier Syndrome (BSS)","text":"Definition: rare, inherited bleeding disorder characterized :\nThrombocytopenia (low platelet count)\nGiant platelets (macrothrombocytes)\nDysfunctional platelet adhesion\nThrombocytopenia (low platelet count)Giant platelets (macrothrombocytes)Dysfunctional platelet adhesionGenetic Basis: Autosomal recessive inheritance mutations genes encoding components platelet glycoprotein Ib/IX/V (GPIb/IX/V) complexKey Feature: Impaired platelet adhesion damaged blood vessel walls due defect GPIb/IX/V receptorClinical Significance: Leads mucocutaneous bleeding tendencies, easy bruising, nosebleeds, prolonged bleeding trauma surgery","code":""},{"path":"bernard-soulier.html","id":"platelet-glycoprotein-ibixv-gpibixv-complex","chapter":"Bernard-Soulier","heading":"Platelet Glycoprotein Ib/IX/V (GPIb/IX/V) Complex","text":"Structure: complex four transmembrane glycoproteins:\nGPIbα: primary vWF-binding subunit\nGPIbβ\nGPIX\nGPV\nGPIbα: primary vWF-binding subunitGPIbβGPIXGPVFunction:\nMediates initial adhesion platelets damaged blood vessel walls binding von Willebrand factor (vWF)\ninteraction essential platelet plug formation, especially high shear stress conditions\nAlso involved platelet signaling activation\nMediates initial adhesion platelets damaged blood vessel walls binding von Willebrand factor (vWF)interaction essential platelet plug formation, especially high shear stress conditionsAlso involved platelet signaling activationPathophysiology Bernard-Soulier Syndrome {-}Genetic Mutations: Mutations genes encoding GPIbα (CD42b), GPIbβ (CD42c), GPIX (CD42a) lead :\nDecreased expression GPIb/IX/V complex platelet surface\nAbnormal structure function GPIb/IX/V complex\nDecreased expression GPIb/IX/V complex platelet surfaceAbnormal structure function GPIb/IX/V complexImpaired Platelet Adhesion:\nDefective GPIb/IX/V complex impairs platelet adhesion vWF, particularly high shear stress conditions\nimpairs ability platelets form stable plug sites vascular injury, leading prolonged bleeding time\nDefective GPIb/IX/V complex impairs platelet adhesion vWF, particularly high shear stress conditionsThis impairs ability platelets form stable plug sites vascular injury, leading prolonged bleeding timeMacrothrombocytopenia:\nMegakaryocytes bone marrow may enlarged abnormal morphology due impaired platelet shedding\nreleased platelets often abnormally large (macrothrombocytes)\nMegakaryocytes bone marrow may enlarged abnormal morphology due impaired platelet sheddingThe released platelets often abnormally large (macrothrombocytes)","code":""},{"path":"bernard-soulier.html","id":"clinical-features-2","chapter":"Bernard-Soulier","heading":"Clinical Features","text":"Bleeding Manifestations: Severity varies, patients moderate severe mucocutaneous bleeding:\nEasy bruising\nNosebleeds (epistaxis)\nGum bleeding\nProlonged bleeding minor cuts dental procedures\nMenorrhagia (heavy menstrual bleeding) women\nGastrointestinal bleeding (less common)\nEasy bruisingNosebleeds (epistaxis)Gum bleedingProlonged bleeding minor cuts dental proceduresMenorrhagia (heavy menstrual bleeding) womenGastrointestinal bleeding (less common)Splenomegaly: Enlargement spleen may present casesThrombocytopenia: Platelet counts often mildly moderately decreased, can normal cases","code":""},{"path":"bernard-soulier.html","id":"laboratory-findings-9","chapter":"Bernard-Soulier","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nPlatelet count: Often mildly decreased (thrombocytopenia), typically range 50-150 x 10^9/L, can normal cases\nRBC WBC counts: Usually normal\nComplete Blood Count (CBC):Platelet count: Often mildly decreased (thrombocytopenia), typically range 50-150 x 10^9/L, can normal casesRBC WBC counts: Usually normalPeripheral Blood Smear:\nMacrothrombocytes (Giant Platelets):\nCharacteristically large platelets (often large larger red blood cells)\nEssential diagnosis\n\nDecreased platelet number\nPeripheral Blood Smear:Macrothrombocytes (Giant Platelets):\nCharacteristically large platelets (often large larger red blood cells)\nEssential diagnosis\nCharacteristically large platelets (often large larger red blood cells)Essential diagnosisDecreased platelet numberBleeding Time:\nProlonged (often significantly prolonged)\nNote: bleeding time specific sensitive test rarely used now. PFA testing taken place.\nBleeding Time:Prolonged (often significantly prolonged)Note: bleeding time specific sensitive test rarely used now. PFA testing taken place.Platelet Function Analyzer (PFA-100):\nProlonged closure time epinephrine ADP cartridges\nSuggests platelet adhesion defect\nPlatelet Function Analyzer (PFA-100):Prolonged closure time epinephrine ADP cartridgesSuggests platelet adhesion defectPlatelet Aggregation Studies:\nNormal Aggregation ADP, Collagen, Epinephrine\nagonists stimulate platelet aggregation via pathways independent GPIb/IX/V\nAbsent Aggregation Ristocetin\nRistocetin requires vWF GPIb/IX/V cause platelet aggregation\nEven addition normal plasma (provide vWF), aggregation remains absent\n\nPlatelet Aggregation Studies:Normal Aggregation ADP, Collagen, EpinephrineThese agonists stimulate platelet aggregation via pathways independent GPIb/IX/VAbsent Aggregation Ristocetin\nRistocetin requires vWF GPIb/IX/V cause platelet aggregation\nEven addition normal plasma (provide vWF), aggregation remains absent\nRistocetin requires vWF GPIb/IX/V cause platelet aggregationEven addition normal plasma (provide vWF), aggregation remains absentFlow Cytometry Immunophenotyping:\nDecreased Absent Expression GPIbα (CD42b), GPIbβ (CD42c), GPIX (CD42a) Platelets\nconfirms defect GPIb/IX/V complex\nEssential definitive diagnosis\n\nFlow Cytometry Immunophenotyping:Decreased Absent Expression GPIbα (CD42b), GPIbβ (CD42c), GPIX (CD42a) Platelets\nconfirms defect GPIb/IX/V complex\nEssential definitive diagnosis\nconfirms defect GPIb/IX/V complexEssential definitive diagnosis","code":""},{"path":"bernard-soulier.html","id":"diagnostic-approach","chapter":"Bernard-Soulier","heading":"Diagnostic Approach","text":"Suspect BSS: patient :\nHistory mucocutaneous bleeding\nThrombocytopenia\nLarge platelets peripheral blood smear\nHistory mucocutaneous bleedingThrombocytopeniaLarge platelets peripheral blood smearPerform Platelet Aggregation Studies: Absent ristocetin-induced platelet aggregation corrected addition normal plasma key findingConfirm Diagnosis Flow Cytometry: Demonstrate decreased absent expression GPIbα, GPIbβ, GPIX plateletsRule Causes Thrombocytopenia Giant Platelets:\nMay-Hegglin Anomaly: Döhle bodies neutrophils, normal GPIb/IX/V expression\nGray Platelet Syndrome: Alpha-granule deficiency, normal GPIb/IX/V expression\nInherited thrombocytopenias (e.g., Wiskott-Aldrich syndrome, MYH9-related disorders): Variable clinical features lab findings\nMay-Hegglin Anomaly: Döhle bodies neutrophils, normal GPIb/IX/V expressionGray Platelet Syndrome: Alpha-granule deficiency, normal GPIb/IX/V expressionInherited thrombocytopenias (e.g., Wiskott-Aldrich syndrome, MYH9-related disorders): Variable clinical features lab findings","code":""},{"path":"bernard-soulier.html","id":"treatment-and-management-5","chapter":"Bernard-Soulier","heading":"Treatment and Management","text":"Specific Cure: Treatment primarily supportiveNo Specific Cure: Treatment primarily supportiveAvoid Aspirin NSAIDs: medications can impair platelet function increase risk bleedingAvoid Aspirin NSAIDs: medications can impair platelet function increase risk bleedingMinimize Trauma: Avoid activities lead injuryMinimize Trauma: Avoid activities lead injuryPlatelet Transfusions:\nUsed treat significant bleeding episodes surgery\nPatients may develop alloantibodies (antibodies foreign platelets) repeated transfusions, making subsequent transfusions less effective\nHLA-matched platelets may required patients become alloimmunized\nPlatelet Transfusions:Used treat significant bleeding episodes surgeryPatients may develop alloantibodies (antibodies foreign platelets) repeated transfusions, making subsequent transfusions less effectiveHLA-matched platelets may required patients become alloimmunizedRecombinant Factor VIIa (rFVIIa):\nMay used control bleeding patients BSS\nMechanism action fully understood\nRecombinant Factor VIIa (rFVIIa):May used control bleeding patients BSSMechanism action fully understoodAntifibrinolytic Agents:\nTranexamic acid aminocaproic acid may used control mucosal bleeding (e.g., nosebleeds, menorrhagia)\nmedications inhibit fibrinolysis (breakdown blood clots)\nAntifibrinolytic Agents:Tranexamic acid aminocaproic acid may used control mucosal bleeding (e.g., nosebleeds, menorrhagia)medications inhibit fibrinolysis (breakdown blood clots)Hematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option severe cases BSS\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\nHematopoietic Stem Cell Transplantation (HSCT):Potentially curative option severe cases BSSInvolves replacing patient’s damaged bone marrow healthy stem cells donor","code":""},{"path":"bernard-soulier.html","id":"key-terms-45","chapter":"Bernard-Soulier","heading":"Key Terms","text":"Bernard-Soulier Syndrome (BSS): Rare inherited bleeding disorder characterized thrombocytopenia, giant platelets, dysfunctional platelet adhesionGPIb/IX/V: Platelet glycoprotein receptor von Willebrand factor (vWF)Macrothrombocytes: Abnormally large plateletsRistocetin: antibiotic induces vWF-dependent platelet agglutinationPlatelet Aggregation Studies: Tests measure ability platelets clump togetherFlow Cytometry: Technique identify cell surface markersAlloantibodies: Antibodies foreign antigens (e.g., transfused platelets)","code":""},{"path":"glanzmann.html","id":"glanzmann","chapter":"Glanzmann","heading":"Glanzmann","text":"","code":""},{"path":"glanzmann.html","id":"overview-of-glanzmann-thrombasthenia-gt","chapter":"Glanzmann","heading":"Overview of Glanzmann Thrombasthenia (GT)","text":"Definition: rare, inherited bleeding disorder characterized :\nNormal platelet count\nDefective platelet aggregation\nAbsent severely reduced expression platelet glycoprotein IIb/IIIa (GPIIb/IIIa) complex (also known αIIbβ3 integrin)\nNormal platelet countDefective platelet aggregationAbsent severely reduced expression platelet glycoprotein IIb/IIIa (GPIIb/IIIa) complex (also known αIIbβ3 integrin)Genetic Basis: Autosomal recessive inheritance mutations genes encoding GPIIb (ITGA2B) GPIIIa (ITGB3)Key Feature: Impaired platelet aggregation due defect fibrinogen receptor (GPIIb/IIIa), essential platelet cross-linking thrombus formationClinical Significance: Leads mucocutaneous bleeding tendencies, easy bruising, nosebleeds, gum bleeding, prolonged bleeding trauma surgery","code":""},{"path":"glanzmann.html","id":"platelet-glycoprotein-iibiiia-gpiibiiia-complex","chapter":"Glanzmann","heading":"Platelet Glycoprotein IIb/IIIa (GPIIb/IIIa) Complex","text":"Structure: heterodimeric complex consisting two transmembrane glycoproteins:\nGPIIb (αIIb CD41)\nGPIIIa (β3 CD61)\nGPIIb (αIIb CD41)GPIIIa (β3 CD61)Function:\nMajor Integrin Platelets: GPIIb/IIIa abundant integrin platelet surface\nFibrinogen Receptor: acts receptor fibrinogen, von Willebrand factor (vWF), fibronectin, adhesive ligands\nPlatelet Aggregation: GPIIb/IIIa mediates platelet aggregation binding fibrinogen, forms bridges adjacent platelets, leading thrombus formation\nInside-Signaling: Platelet activation triggers conformational change GPIIb/IIIa increases affinity fibrinogen\nOutside-Signaling: Binding fibrinogen GPIIb/IIIa triggers intracellular signaling pathways stabilize platelet aggregates promote clot retraction\nMajor Integrin Platelets: GPIIb/IIIa abundant integrin platelet surfaceFibrinogen Receptor: acts receptor fibrinogen, von Willebrand factor (vWF), fibronectin, adhesive ligandsPlatelet Aggregation: GPIIb/IIIa mediates platelet aggregation binding fibrinogen, forms bridges adjacent platelets, leading thrombus formationInside-Signaling: Platelet activation triggers conformational change GPIIb/IIIa increases affinity fibrinogenOutside-Signaling: Binding fibrinogen GPIIb/IIIa triggers intracellular signaling pathways stabilize platelet aggregates promote clot retraction","code":""},{"path":"glanzmann.html","id":"pathophysiology-of-glanzmann-thrombasthenia","chapter":"Glanzmann","heading":"Pathophysiology of Glanzmann Thrombasthenia","text":"Genetic Mutations: Mutations genes encoding GPIIb (ITGA2B) GPIIIa (ITGB3) lead :\nDecreased Expression GPIIb/IIIa Platelet Surface:\nType GT: Severely reduced absent GPIIb/IIIa expression (<5% normal)\nType II GT: Reduced GPIIb/IIIa expression (5-20% normal)\n\nDysfunctional GPIIb/IIIa Complex:\nAbnormal structure GPIIb/IIIa complex, impairing ability bind fibrinogen ligands\n\nDecreased Expression GPIIb/IIIa Platelet Surface:\nType GT: Severely reduced absent GPIIb/IIIa expression (<5% normal)\nType II GT: Reduced GPIIb/IIIa expression (5-20% normal)\nType GT: Severely reduced absent GPIIb/IIIa expression (<5% normal)Type II GT: Reduced GPIIb/IIIa expression (5-20% normal)Dysfunctional GPIIb/IIIa Complex:\nAbnormal structure GPIIb/IIIa complex, impairing ability bind fibrinogen ligands\nAbnormal structure GPIIb/IIIa complex, impairing ability bind fibrinogen ligandsImpaired Platelet Aggregation:\nDeficiency dysfunction GPIIb/IIIa impairs platelet aggregation, preventing platelets forming stable clots\nLeads prolonged bleeding time increased susceptibility bleeding\nDeficiency dysfunction GPIIb/IIIa impairs platelet aggregation, preventing platelets forming stable clotsLeads prolonged bleeding time increased susceptibility bleeding","code":""},{"path":"glanzmann.html","id":"clinical-features-3","chapter":"Glanzmann","heading":"Clinical Features","text":"Mucocutaneous Bleeding: hallmark GT\nEasy bruising (purpura)\nNosebleeds (epistaxis)\nGum bleeding (gingival bleeding)\nMenorrhagia (heavy menstrual bleeding) women\nProlonged bleeding minor cuts dental procedures\nEasy bruising (purpura)Nosebleeds (epistaxis)Gum bleeding (gingival bleeding)Menorrhagia (heavy menstrual bleeding) womenProlonged bleeding minor cuts dental proceduresSeverity:\nSeverity bleeding varies among patients, even within type GT\nBleeding episodes can spontaneous triggered trauma surgery\nSeverity bleeding varies among patients, even within type GTBleeding episodes can spontaneous triggered trauma surgeryJoint Bleeds (Hemarthrosis): Rare GT, unlike hemophilia","code":""},{"path":"glanzmann.html","id":"laboratory-findings-10","chapter":"Glanzmann","heading":"Laboratory Findings","text":"Complete Blood Count (CBC):\nPlatelet count: Usually normal\nRBC WBC counts: Normal\nPlatelet count: Usually normalRBC WBC counts: NormalPeripheral Blood Smear:\nNormal platelet morphology number (except possible macroplatelets)\nplatelet clumps\nNormal platelet morphology number (except possible macroplatelets)platelet clumpsBleeding Time:\nProlonged (often significantly prolonged)\nNote: bleeding time specific sensitive test rarely used now. PFA testing taken place.\nProlonged (often significantly prolonged)Note: bleeding time specific sensitive test rarely used now. PFA testing taken place.Platelet Function Analyzer (PFA-100):\nProlonged Closure Time Epinephrine ADP Cartridges\nSuggests global platelet dysfunction\n\nProlonged Closure Time Epinephrine ADP Cartridges\nSuggests global platelet dysfunction\nSuggests global platelet dysfunctionPlatelet Aggregation Studies: key diagnostic test GT\nAbsent Severely Reduced Aggregation ADP, Collagen, Epinephrine, Thrombin\nagonists require functional GPIIb/IIIa induce platelet aggregation\n\nNormal Aggregation Ristocetin\nRistocetin induces platelet aggregation binding vWF GPIb/IX/V (normal GT)\nSince GPIIb/IIIa complex required interaction, ristocetin-induced aggregation normal GT\n\nAbsent Severely Reduced Aggregation ADP, Collagen, Epinephrine, Thrombin\nagonists require functional GPIIb/IIIa induce platelet aggregation\nagonists require functional GPIIb/IIIa induce platelet aggregationNormal Aggregation Ristocetin\nRistocetin induces platelet aggregation binding vWF GPIb/IX/V (normal GT)\nSince GPIIb/IIIa complex required interaction, ristocetin-induced aggregation normal GT\nRistocetin induces platelet aggregation binding vWF GPIb/IX/V (normal GT)Since GPIIb/IIIa complex required interaction, ristocetin-induced aggregation normal GTClot Retraction:\nAbsent Impaired\nGPIIb/IIIa required clot retraction, process abnormal GT\nAbsent ImpairedGPIIb/IIIa required clot retraction, process abnormal GTFlow Cytometry Immunophenotyping:\nDecreased Absent Expression GPIIb (CD41) /GPIIIa (CD61) Platelets\nConfirms defect GPIIb/IIIa complex\nCan differentiate Type (severely reduced expression) Type II (reduced expression) GT\n\nDecreased Absent Expression GPIIb (CD41) /GPIIIa (CD61) Platelets\nConfirms defect GPIIb/IIIa complex\nCan differentiate Type (severely reduced expression) Type II (reduced expression) GT\nConfirms defect GPIIb/IIIa complexCan differentiate Type (severely reduced expression) Type II (reduced expression) GT","code":""},{"path":"glanzmann.html","id":"diagnostic-approach-1","chapter":"Glanzmann","heading":"Diagnostic Approach","text":"Suspect GT: patient :\nLifelong history mucocutaneous bleeding\nNormal platelet count\nProlonged bleeding time (abnormal PFA result)\nLifelong history mucocutaneous bleedingNormal platelet countProlonged bleeding time (abnormal PFA result)Perform Platelet Aggregation Studies: Absent aggregation ADP, collagen, epinephrine, thrombin, normal aggregation ristocetin, highly suggestive GTConfirm Diagnosis Flow Cytometry: Demonstrate decreased absent expression GPIIb (CD41) /GPIIIa (CD61) plateletsRule Platelet Function Disorders:\nAcquired platelet dysfunction (e.g., drug-induced): Recent exposure aspirin antiplatelet medications\nBernard-Soulier Syndrome: Giant platelets, absent ristocetin-induced aggregation corrected normal plasma, abnormal GPIb/IX/V expression\nAcquired platelet dysfunction (e.g., drug-induced): Recent exposure aspirin antiplatelet medicationsBernard-Soulier Syndrome: Giant platelets, absent ristocetin-induced aggregation corrected normal plasma, abnormal GPIb/IX/V expression","code":""},{"path":"glanzmann.html","id":"treatment-and-management-6","chapter":"Glanzmann","heading":"Treatment and Management","text":"Specific Cure: Treatment primarily supportive aimed controlling bleeding episodesNo Specific Cure: Treatment primarily supportive aimed controlling bleeding episodesAvoid Platelet Inhibitors: Aspirin antiplatelet medications contraindicatedAvoid Platelet Inhibitors: Aspirin antiplatelet medications contraindicatedLocal Hemostatic Measures:\nTopical thrombin fibrin sealants control minor bleeding\nPressure dressings control bleeding cuts wounds\nLocal Hemostatic Measures:Topical thrombin fibrin sealants control minor bleedingPressure dressings control bleeding cuts woundsAntifibrinolytic Agents:\nTranexamic acid aminocaproic acid may used control mucosal bleeding (e.g., nosebleeds, menorrhagia)\nmedications inhibit fibrinolysis (breakdown blood clots)\nAntifibrinolytic Agents:Tranexamic acid aminocaproic acid may used control mucosal bleeding (e.g., nosebleeds, menorrhagia)medications inhibit fibrinolysis (breakdown blood clots)Recombinant Factor VIIa (rFVIIa):\nMay used control bleeding patients GT\nMechanism action fully understood, may promote thrombin generation platelet activation\nRecombinant Factor VIIa (rFVIIa):May used control bleeding patients GTMechanism action fully understood, may promote thrombin generation platelet activationPlatelet Transfusions:\nUsed treat severe bleeding episodes surgery\nPatients may develop alloantibodies (antibodies foreign platelets) repeated transfusions, making subsequent transfusions less effective\nHLA-matched platelets may required patients become alloimmunized\nPlatelet Transfusions:Used treat severe bleeding episodes surgeryPatients may develop alloantibodies (antibodies foreign platelets) repeated transfusions, making subsequent transfusions less effectiveHLA-matched platelets may required patients become alloimmunizedHematopoietic Stem Cell Transplantation (HSCT):\nPotentially curative option severe cases GT\nInvolves replacing patient’s damaged bone marrow healthy stem cells donor\nHematopoietic Stem Cell Transplantation (HSCT):Potentially curative option severe cases GTInvolves replacing patient’s damaged bone marrow healthy stem cells donor","code":""},{"path":"glanzmann.html","id":"key-terms-46","chapter":"Glanzmann","heading":"Key Terms","text":"Glanzmann Thrombasthenia (GT): Rare inherited bleeding disorder characterized defective platelet aggregationGPIIb/IIIa (αIIbβ3 Integrin): Platelet glycoprotein complex binds fibrinogen mediates platelet aggregationPlatelet Aggregation Studies: Tests measure ability platelets clump togetherRistocetin: antibiotic induces vWF-dependent platelet agglutinationAlloantibodies: Antibodies foreign antigens (e.g., transfused platelets)","code":""},{"path":"cell-counts.html","id":"cell-counts","chapter":"Cell Counts","heading":"Cell Counts","text":"","code":""},{"path":"cell-counts.html","id":"overview-of-cell-counts","chapter":"Cell Counts","heading":"Overview of Cell Counts","text":"Definition: fundamental laboratory test used enumerate cellular components blood body fluidsClinical Significance:\nDiagnosis monitoring wide range medical conditions, including:\nInfections\nInflammatory disorders\nHematologic malignancies\nBone marrow disorders\nBleeding disorders\n\nDiagnosis monitoring wide range medical conditions, including:\nInfections\nInflammatory disorders\nHematologic malignancies\nBone marrow disorders\nBleeding disorders\nInfectionsInflammatory disordersHematologic malignanciesBone marrow disordersBleeding disordersTypes Cell Counts:\nComplete Blood Count (CBC): Measures number RBCs, WBCs, PLTs whole blood\nBody Fluid Cell Counts: Measures number RBCs TNCs (total nucleated cells) various body fluids (e.g., cerebrospinal fluid, synovial fluid, serous fluids)\nReticulocyte Count: Measures number immature red blood cells (reticulocytes) whole blood\nComplete Blood Count (CBC): Measures number RBCs, WBCs, PLTs whole bloodBody Fluid Cell Counts: Measures number RBCs TNCs (total nucleated cells) various body fluids (e.g., cerebrospinal fluid, synovial fluid, serous fluids)Reticulocyte Count: Measures number immature red blood cells (reticulocytes) whole bloodMethods:\nManual Cell Counts: Performed using microscope specialized counting chamber\nAutomated Cell Counts: Performed using automated hematology analyzers\nManual Cell Counts: Performed using microscope specialized counting chamberAutomated Cell Counts: Performed using automated hematology analyzers","code":""},{"path":"cell-counts.html","id":"manual-cell-counts","chapter":"Cell Counts","heading":"Manual Cell Counts","text":"Principle:\nknown volume diluted fluid placed specialized counting chamber (hemocytometer)\ncells counted within defined area counting chamber microscope\ncell count per unit volume calculated using formula takes account dilution factor area counting chamber\nknown volume diluted fluid placed specialized counting chamber (hemocytometer)cells counted within defined area counting chamber microscopeThe cell count per unit volume calculated using formula takes account dilution factor area counting chamber","code":""},{"path":"cell-counts.html","id":"automated-cell-counts","chapter":"Cell Counts","heading":"Automated Cell Counts","text":"Principle:\nAutomated hematology analyzers use various technologies count characterize blood cells\nCommon technologies include:\nElectrical Impedance (Coulter Principle): Cells pass small aperture, disrupting electrical current; number size disruptions measured\nOptical Scatter: Cells pass light beam, amount angle light scattered measured; provides information cell size, shape, granularity\nFlow Cytometry: Cells stained fluorescent dyes passed laser beam; fluorescence intensity scatter patterns measured\n\nAutomated hematology analyzers use various technologies count characterize blood cellsCommon technologies include:\nElectrical Impedance (Coulter Principle): Cells pass small aperture, disrupting electrical current; number size disruptions measured\nOptical Scatter: Cells pass light beam, amount angle light scattered measured; provides information cell size, shape, granularity\nFlow Cytometry: Cells stained fluorescent dyes passed laser beam; fluorescence intensity scatter patterns measured\nElectrical Impedance (Coulter Principle): Cells pass small aperture, disrupting electrical current; number size disruptions measuredOptical Scatter: Cells pass light beam, amount angle light scattered measured; provides information cell size, shape, granularityFlow Cytometry: Cells stained fluorescent dyes passed laser beam; fluorescence intensity scatter patterns measured","code":""},{"path":"cell-counts.html","id":"reticulocyte-counts","chapter":"Cell Counts","heading":"Reticulocyte Counts","text":"Principle: Measurement number immature red blood cells (reticulocytes) peripheral blood","code":""},{"path":"cell-counts.html","id":"quality-control-qc-and-troubleshooting","chapter":"Cell Counts","heading":"Quality Control (QC) and Troubleshooting","text":"Manual Cell Counts:\nUse calibrated pipettes equipment\nMaintain clean equipment\nUse proper staining techniques\nCount adequate number cells\nFollow established procedures\nPerform duplicate counts assess precision\nUse calibrated pipettes equipmentMaintain clean equipmentUse proper staining techniquesCount adequate number cellsFollow established proceduresPerform duplicate counts assess precisionAutomated Cell Counts:\nPerform daily instrument calibration maintenance\nRun control materials regular intervals\nReview control results take corrective action necessary\nInvestigate flags alarms generated instrument\nCorrelate automated results peripheral blood smear findings\nPerform daily instrument calibration maintenanceRun control materials regular intervalsReview control results take corrective action necessaryInvestigate flags alarms generated instrumentCorrelate automated results peripheral blood smear findingsGeneral Troubleshooting:\nIdentify correct pre-analytical errors (e.g., clotted sample, improper collection)\nRepeat test fresh sample\nPerform manual cell counts confirm automated results\nConsult supervisor pathologist cause discrepancy determined\nIdentify correct pre-analytical errors (e.g., clotted sample, improper collection)Repeat test fresh samplePerform manual cell counts confirm automated resultsConsult supervisor pathologist cause discrepancy determined","code":""},{"path":"cell-counts.html","id":"reporting-results","chapter":"Cell Counts","heading":"Reporting Results","text":"Report cell counts appropriate units (e.g., cells/μL, x 10^9/L)Include reference range parameterNote abnormal results flagsDocument quality control procedures corrective actions taken","code":""},{"path":"cell-counts.html","id":"key-terms-47","chapter":"Cell Counts","heading":"Key Terms","text":"Cell Count: Enumeration cells fluid sampleHemocytometer: specialized counting chamber used manual cell countsDilution Factor: ratio final volume initial sample volumeReticulocyte: Immature red blood cellSupravital Stain: dye used stain living cellsElectrical Impedance (Coulter Principle): method counting sizing cellsOptical Scatter: method characterizing cells based light scattering propertiesFlow Cytometry: technique identifying quantifying cells based surface markers characteristics","code":""},{"path":"manual.html","id":"manual","chapter":"Manual","heading":"Manual","text":"","code":""},{"path":"manual.html","id":"overview-of-manual-cell-counts","chapter":"Manual","heading":"Overview of Manual Cell Counts","text":"Definition: Manual cell counts performed trained laboratory personnel using microscope specialized counting chamber (hemocytometer) enumerate cells fluid sampleClinical Significance: Although automated cell counters now commonly used, manual cell counts remain important certain situations:\nautomated cell counts inaccurate unavailable\ncounting cells body fluids automated methods may validated\nconfirm abnormal results obtained automated methods\nautomated cell counts inaccurate unavailableFor counting cells body fluids automated methods may validatedTo confirm abnormal results obtained automated methodsFluids Analyzed:\nWhole Blood: Red blood cells (RBCs), white blood cells (WBCs), platelets\nBody Fluids: Cerebrospinal fluid (CSF), synovial fluid, serous fluids (pleural, peritoneal, pericardial), others\nWhole Blood: Red blood cells (RBCs), white blood cells (WBCs), plateletsBody Fluids: Cerebrospinal fluid (CSF), synovial fluid, serous fluids (pleural, peritoneal, pericardial), others","code":""},{"path":"manual.html","id":"principles-of-manual-cell-counting","chapter":"Manual","heading":"Principles of Manual Cell Counting","text":"Dilution: sample diluted specific diluent reduce cell concentration manageable levelCounting Chamber (Hemocytometer): specialized glass slide precisely ruled grid known dimensions Neubauer counting chamber common typeMicroscopy: microscope used visualize cells within counting chamberCell Identification: Cells identified based morphology staining characteristicsCalculation: cell count per unit volume calculated using formula takes account dilution factor, area counting chamber, depth chamber","code":""},{"path":"manual.html","id":"equipment-and-materials","chapter":"Manual","heading":"Equipment and Materials","text":"Microscope: calibrated eyepiece 10x 40x objectivesCounting Chamber (Hemocytometer): Neubauer chamber commonCoverslip: special coverslip designed use counting chamber create known volume counting gridPipettes: Accurate pipettes measuring sample diluentDiluent: appropriate diluent specific cell type counted:\nWBC Count: Acetic acid (3%) Turk’s solution (lyses red blood cells)\nRBC Count: Isotonic saline (0.85% NaCl)\nPlatelet Count: Ammonium oxalate (1%) sodium citrate (3.8%)\nBody Fluid Cell Counts: Isotonic saline (0.85% NaCl) crystal violet stain\nWBC Count: Acetic acid (3%) Turk’s solution (lyses red blood cells)RBC Count: Isotonic saline (0.85% NaCl)Platelet Count: Ammonium oxalate (1%) sodium citrate (3.8%)Body Fluid Cell Counts: Isotonic saline (0.85% NaCl) crystal violet stainTally Counter: manual electronic tally counter keep track cells counted","code":""},{"path":"manual.html","id":"procedure-for-manual-cell-counts","chapter":"Manual","heading":"Procedure for Manual Cell Counts","text":"Sample Preparation:\nMix Sample: Ensure blood body fluid sample well-mixed\nPrepare Dilution:\nUse calibrated pipette accurately measure sample diluent\nPrepare appropriate dilution according established laboratory procedures\nWBC Count: Typically 1:20 1:100 dilution\nRBC Count: Typically 1:200 dilution\nPlatelet Count: Typically 1:100 dilution\nBody Fluid Cell Counts: May require dilution 1:20 dilution, depending cell concentration\n\nMix sample diluent thoroughly\n\nAllow Stand: WBC counts using lytic diluent, allow mixture stand least 10 minutes allow red blood cells lyse\nSample Preparation:Mix Sample: Ensure blood body fluid sample well-mixedPrepare Dilution:\nUse calibrated pipette accurately measure sample diluent\nPrepare appropriate dilution according established laboratory procedures\nWBC Count: Typically 1:20 1:100 dilution\nRBC Count: Typically 1:200 dilution\nPlatelet Count: Typically 1:100 dilution\nBody Fluid Cell Counts: May require dilution 1:20 dilution, depending cell concentration\n\nMix sample diluent thoroughly\nUse calibrated pipette accurately measure sample diluentPrepare appropriate dilution according established laboratory procedures\nWBC Count: Typically 1:20 1:100 dilution\nRBC Count: Typically 1:200 dilution\nPlatelet Count: Typically 1:100 dilution\nBody Fluid Cell Counts: May require dilution 1:20 dilution, depending cell concentration\nWBC Count: Typically 1:20 1:100 dilutionRBC Count: Typically 1:200 dilutionPlatelet Count: Typically 1:100 dilutionBody Fluid Cell Counts: May require dilution 1:20 dilution, depending cell concentrationMix sample diluent thoroughlyAllow Stand: WBC counts using lytic diluent, allow mixture stand least 10 minutes allow red blood cells lyseCharging Counting Chamber:\nClean Hemocytometer Coverslip: Use lens paper thoroughly clean hemocytometer coverslip\nPosition Coverslip: Carefully place coverslip hemocytometer, ensuring properly seated covers counting area\nCharge Counting Chamber: Gently introduce small amount diluted sample counting chamber capillary action. Avoid overfilling introducing air bubbles\nAllow Cells Settle: Allow cells settle minutes counting\nCharging Counting Chamber:Clean Hemocytometer Coverslip: Use lens paper thoroughly clean hemocytometer coverslipPosition Coverslip: Carefully place coverslip hemocytometer, ensuring properly seated covers counting areaCharge Counting Chamber: Gently introduce small amount diluted sample counting chamber capillary action. Avoid overfilling introducing air bubblesAllow Cells Settle: Allow cells settle minutes countingMicroscopic Examination Counting:\nPosition Counting Chamber: Place hemocytometer microscope stage secure clips\nFocus: Use 10x objective focus counting grid\nCounting Rules: Follow consistent counting rules avoid - undercounting cells:\nCount cells touch upper left-hand boundaries counting area\ncount cells touch lower right-hand boundaries\nCount cells within defined area counting chamber\n\nCounting Patterns:\nSystematically count cells within designated squares counting chamber\nUse consistent counting pattern (e.g., serpentine pattern) ensure cells counted\n\nWBC Count: Count cells four large corner squares Neubauer chamber\nRBC Count: Count cells five small squares within central large square Neubauer chamber\nPlatelet Count: Count platelets twenty-five small squares within central large square Neubauer chamber\nBody Fluid Cell Counts: Count cells nine large squares Neubauer chamber\nRecord Counts: Use tally counter keep track number cells counted\nPerform Duplicate Counts: Perform duplicate counts second chamber assess precision\nMicroscopic Examination Counting:Position Counting Chamber: Place hemocytometer microscope stage secure clipsFocus: Use 10x objective focus counting gridCounting Rules: Follow consistent counting rules avoid - undercounting cells:\nCount cells touch upper left-hand boundaries counting area\ncount cells touch lower right-hand boundaries\nCount cells within defined area counting chamber\nCount cells touch upper left-hand boundaries counting areaDo count cells touch lower right-hand boundariesCount cells within defined area counting chamberCounting Patterns:\nSystematically count cells within designated squares counting chamber\nUse consistent counting pattern (e.g., serpentine pattern) ensure cells counted\nSystematically count cells within designated squares counting chamberUse consistent counting pattern (e.g., serpentine pattern) ensure cells countedWBC Count: Count cells four large corner squares Neubauer chamberRBC Count: Count cells five small squares within central large square Neubauer chamberPlatelet Count: Count platelets twenty-five small squares within central large square Neubauer chamberBody Fluid Cell Counts: Count cells nine large squares Neubauer chamberRecord Counts: Use tally counter keep track number cells countedPerform Duplicate Counts: Perform duplicate counts second chamber assess precisionCalculation Results:\nApply Appropriate Formula: formula calculating cell count depends dilution factor area depth counting chamber\nGeneral Formula:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (Area Counted (mm2) x Depth Chamber (mm))\nSpecific Formulas (Neubauer Chamber):\nWBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (4 mm2 x 0.1 mm)\nRBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (0.2 mm2 x 0.1 mm)\nPlatelet Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (1.0 mm2 x 0.1 mm)\nBody Fluid Cell Counts:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (9 mm2 x 0.1 mm)\n\n\nAverage Duplicate Counts: duplicate counts performed, calculate average two counts\nReport Result: Report cell count appropriate units (e.g., cells/μL)\nCalculation Results:Apply Appropriate Formula: formula calculating cell count depends dilution factor area depth counting chamber\nGeneral Formula:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (Area Counted (mm2) x Depth Chamber (mm))\nSpecific Formulas (Neubauer Chamber):\nWBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (4 mm2 x 0.1 mm)\nRBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (0.2 mm2 x 0.1 mm)\nPlatelet Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (1.0 mm2 x 0.1 mm)\nBody Fluid Cell Counts:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (9 mm2 x 0.1 mm)\n\nGeneral Formula:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (Area Counted (mm2) x Depth Chamber (mm))Specific Formulas (Neubauer Chamber):\nWBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (4 mm2 x 0.1 mm)\nRBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (0.2 mm2 x 0.1 mm)\nPlatelet Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (1.0 mm2 x 0.1 mm)\nBody Fluid Cell Counts:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (9 mm2 x 0.1 mm)\nWBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (4 mm2 x 0.1 mm)RBC Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (0.2 mm2 x 0.1 mm)Platelet Count:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (1.0 mm2 x 0.1 mm)Body Fluid Cell Counts:\nCell Count (cells/μL) = (Number Cells Counted x Dilution Factor) / (9 mm2 x 0.1 mm)Average Duplicate Counts: duplicate counts performed, calculate average two countsReport Result: Report cell count appropriate units (e.g., cells/μL)","code":""},{"path":"manual.html","id":"specific-procedures-for-blood-cell-counts","chapter":"Manual","heading":"Specific Procedures for Blood Cell Counts","text":"White Blood Cell (WBC) Count:\nDiluent: Acetic acid (3%) Turk’s solution (lyses red blood cells)\nDilution: Typically 1:20 1:100\nCounting Area: Four large corner squares Neubauer chamber\nCounting Cells touching upper left-hand boundaries, touching lower right-hand boundaries\nDiluent: Acetic acid (3%) Turk’s solution (lyses red blood cells)Dilution: Typically 1:20 1:100Counting Area: Four large corner squares Neubauer chamberCounting Cells touching upper left-hand boundaries, touching lower right-hand boundariesRed Blood Cell (RBC) Count:\nDiluent: Isotonic saline (0.85% NaCl)\nDilution: Typically 1:200\nCounting Area: Five small squares within central large square Neubauer chamber\nAvoid air bubbles\nDiluent: Isotonic saline (0.85% NaCl)Dilution: Typically 1:200Counting Area: Five small squares within central large square Neubauer chamberAvoid air bubblesPlatelet Count:\nDiluent: Ammonium oxalate (1%) sodium citrate (3.8%)\nDilution: Typically 1:100\nCounting Area: Twenty-five small squares within central large square Neubauer chamber\nAllow platelets settle 10-15 minutes counting\nUse phase-contrast microscopy available enhance platelet visualization\nDiluent: Ammonium oxalate (1%) sodium citrate (3.8%)Dilution: Typically 1:100Counting Area: Twenty-five small squares within central large square Neubauer chamberAllow platelets settle 10-15 minutes countingUse phase-contrast microscopy available enhance platelet visualization","code":""},{"path":"manual.html","id":"specific-procedures-for-body-fluid-cell-counts","chapter":"Manual","heading":"Specific Procedures for Body Fluid Cell Counts","text":"Cerebrospinal Fluid (CSF):\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stain\nDilution: May require dilution 1:20 dilution, depending cell concentration\nCounting Area: nine large squares Neubauer chamber\nReport RBC count total nucleated cell (TNC) count\nPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, monocytes)\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stainDilution: May require dilution 1:20 dilution, depending cell concentrationCounting Area: nine large squares Neubauer chamberReport RBC count total nucleated cell (TNC) countPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, monocytes)Serous Fluids (Pleural, Peritoneal, Pericardial):\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stain\nDilution: May require dilution 1:20 dilution, depending cell concentration\nCounting Area: nine large squares Neubauer chamber\nReport RBC count total nucleated cell (TNC) count\nPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, mesothelial cells)\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stainDilution: May require dilution 1:20 dilution, depending cell concentrationCounting Area: nine large squares Neubauer chamberReport RBC count total nucleated cell (TNC) countPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, mesothelial cells)Synovial Fluid:\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stain\nDilution: May require dilution 1:20 dilution, depending cell concentration\nHyaluronidase Pre-Treatment: synovial fluid viscous, pretreat hyaluronidase reduce viscosity improve cell dispersal\nCounting Area: nine large squares Neubauer chamber\nReport RBC count total nucleated cell (TNC) count\nPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, monocytes, synovial lining cells)\nDiluent: Isotonic saline (0.85% NaCl) crystal violet stainDilution: May require dilution 1:20 dilution, depending cell concentrationHyaluronidase Pre-Treatment: synovial fluid viscous, pretreat hyaluronidase reduce viscosity improve cell dispersalCounting Area: nine large squares Neubauer chamberReport RBC count total nucleated cell (TNC) countPerform cytospin preparation differentiate types nucleated cells (e.g., neutrophils, lymphocytes, monocytes, synovial lining cells)","code":""},{"path":"manual.html","id":"quality-control-and-troubleshooting","chapter":"Manual","heading":"Quality Control and Troubleshooting","text":"Use Calibrated Equipment:\nEnsure pipettes counting chambers properly calibrated\nEnsure pipettes counting chambers properly calibratedMaintain Clean Equipment:\nThoroughly clean hemocytometer coverslip use\nUse fresh, clean diluent\nThoroughly clean hemocytometer coverslip useUse fresh, clean diluentFollow Established Procedures:\nAdhere standardized procedures dilution, charging counting chamber, counting cells, calculating results\nAdhere standardized procedures dilution, charging counting chamber, counting cells, calculating resultsCount Adequate Number Cells:\nCount least 100 cells () improve accuracy, especially body fluid cell counts low cell concentrations\nCount least 100 cells () improve accuracy, especially body fluid cell counts low cell concentrationsPerform Duplicate Counts:\nPerform duplicate counts second chamber assess precision\ntwo counts agree within acceptable range (e.g., +/- 10%)\nPerform duplicate counts second chamber assess precisionThe two counts agree within acceptable range (e.g., +/- 10%)Identify Correct Errors:\nUneven Cell Distribution: Ensure cells evenly distributed counting chamber\nAir Bubbles: Avoid introducing air bubbles charging chamber\nContamination: Prevent contamination sample diluent\nInaccurate Pipetting: Use calibrated pipettes ensure accurate measurement sample diluent\nImproper Cell Identification: Develop expertise identifying different cell types minimize counting errors\nUneven Cell Distribution: Ensure cells evenly distributed counting chamberAir Bubbles: Avoid introducing air bubbles charging chamberContamination: Prevent contamination sample diluentInaccurate Pipetting: Use calibrated pipettes ensure accurate measurement sample diluentImproper Cell Identification: Develop expertise identifying different cell types minimize counting errors","code":""},{"path":"manual.html","id":"reporting-results-1","chapter":"Manual","heading":"Reporting Results","text":"Report cell counts appropriate units (e.g., cells/μL, x 10^9/L)Include reference range parameterNote abnormal results flagsDocument quality control procedures corrective actions taken","code":""},{"path":"manual.html","id":"key-terms-48","chapter":"Manual","heading":"Key Terms","text":"Hemocytometer: specialized counting chamber used manual cell countsNeubauer Chamber: common type hemocytometerDiluent: fluid used dilute sampleTotal Nucleated Cell (TNC) Count: number nucleated cells body fluid sampleCytospin Preparation: method concentrating cells fluid sample onto slide microscopic examinationHyaluronidase: enzyme used reduce viscosity synovial fluidControls: Testing known samples ensure proper testing technique","code":""},{"path":"automated.html","id":"automated","chapter":"Automated","heading":"Automated","text":"","code":""},{"path":"automated.html","id":"overview-of-automated-cell-counts","chapter":"Automated","heading":"Overview of Automated Cell Counts","text":"Definition: Automated cell counts performed using sophisticated instruments called hematology analyzers, rapidly accurately count characterize blood cells whole blood body fluidsAdvantages Manual Methods:\nIncreased Speed Efficiency: Automated analyzers can process large number samples quickly efficiently\nImproved Accuracy Precision: Automated methods generally provide accurate precise results manual methods\nReduced Labor Costs: Automated analyzers reduce need manual cell counts, freeing laboratory personnel tasks\nStandardization: Automated methods provide standardized reproducible results\nAbility Measure Additional Parameters: Automated analyzers can measure wide range parameters beyond just cell counts (e.g., cell size, hemoglobin concentration, cell differentials)\nIncreased Speed Efficiency: Automated analyzers can process large number samples quickly efficientlyImproved Accuracy Precision: Automated methods generally provide accurate precise results manual methodsReduced Labor Costs: Automated analyzers reduce need manual cell counts, freeing laboratory personnel tasksStandardization: Automated methods provide standardized reproducible resultsAbility Measure Additional Parameters: Automated analyzers can measure wide range parameters beyond just cell counts (e.g., cell size, hemoglobin concentration, cell differentials)Limitations:\nCost: Automated analyzers expensive purchase maintain\nComplexity: Requires trained personnel operate maintain instruments\nInterference: Certain substances conditions can interfere automated cell counts, leading inaccurate results\nNeed Validation: Automated methods body fluid cell counts must validated clinical use\nCost: Automated analyzers expensive purchase maintainComplexity: Requires trained personnel operate maintain instrumentsInterference: Certain substances conditions can interfere automated cell counts, leading inaccurate resultsNeed Validation: Automated methods body fluid cell counts must validated clinical use","code":""},{"path":"automated.html","id":"principles-of-automated-cell-counting-technologies","chapter":"Automated","heading":"Principles of Automated Cell Counting Technologies","text":"Electrical Impedance (Coulter Principle):\nPrinciple: Cells suspended electrolyte solution pass small aperture. cell passes aperture, displaces volume electrolyte, causing change electrical impedance\nCell Counting: number impedance changes proportional number cells\nCell Sizing: magnitude impedance change proportional cell volume\nAdvantages: Simple reliable method cell counting sizing\nLimitations: differentiate different cell types based size alone; susceptible interference non-cellular particles\nPrinciple: Cells suspended electrolyte solution pass small aperture. cell passes aperture, displaces volume electrolyte, causing change electrical impedanceCell Counting: number impedance changes proportional number cellsCell Sizing: magnitude impedance change proportional cell volumeAdvantages: Simple reliable method cell counting sizingLimitations: differentiate different cell types based size alone; susceptible interference non-cellular particlesOptical Scatter:\nPrinciple: Cells pass focused light beam (laser tungsten-halogen lamp), amount angle light scattered cell measured\nForward Scatter (FS): Measures amount light scattered forward direction; related cell size\nSide Scatter (SS): Measures amount light scattered 90-degree angle; related cell granularity internal complexity\nCell Differentiation: Different cell types scatter light different ways, allowing analyzer differentiate RBCs, WBCs, platelets\nAdvantages: Can differentiate different cell types provide information cell structure\nLimitations: Can affected interfering substances (e.g., lipemia, protein)\nPrinciple: Cells pass focused light beam (laser tungsten-halogen lamp), amount angle light scattered cell measuredForward Scatter (FS): Measures amount light scattered forward direction; related cell sizeSide Scatter (SS): Measures amount light scattered 90-degree angle; related cell granularity internal complexityCell Differentiation: Different cell types scatter light different ways, allowing analyzer differentiate RBCs, WBCs, plateletsAdvantages: Can differentiate different cell types provide information cell structureLimitations: Can affected interfering substances (e.g., lipemia, protein)Flow Cytometry:\nPrinciple: Cells stained fluorescent dyes bind specific cell surface markers intracellular components passed laser beam. fluorescence intensity scatter patterns measured\nCell Identification: Cells identified quantified based fluorescence scatter properties\nImmunophenotyping: Can identify specific cell populations based expression cell surface markers (e.g., CD4+ T cells, CD8+ T cells, B cells)\nAdvantages: High sensitivity specificity cell identification; can measure multiple parameters simultaneously\nLimitations: complex expensive methods\nPrinciple: Cells stained fluorescent dyes bind specific cell surface markers intracellular components passed laser beam. fluorescence intensity scatter patterns measuredCell Identification: Cells identified quantified based fluorescence scatter propertiesImmunophenotyping: Can identify specific cell populations based expression cell surface markers (e.g., CD4+ T cells, CD8+ T cells, B cells)Advantages: High sensitivity specificity cell identification; can measure multiple parameters simultaneouslyLimitations: complex expensive methodsCytochemical Staining:\nPrinciple: analyzer uses cytochemical stains differentiate cell types based enzymatic activity chemical properties\nExample:\nMyeloperoxidase (MPO) stain: Used differentiate myeloblasts (positive MPO) lymphoblasts (negative MPO) acute leukemia\n\nAdvantages: Can provide additional information cell classification\nLimitations: Requires specific reagents controls\nPrinciple: analyzer uses cytochemical stains differentiate cell types based enzymatic activity chemical propertiesExample:\nMyeloperoxidase (MPO) stain: Used differentiate myeloblasts (positive MPO) lymphoblasts (negative MPO) acute leukemia\nMyeloperoxidase (MPO) stain: Used differentiate myeloblasts (positive MPO) lymphoblasts (negative MPO) acute leukemiaAdvantages: Can provide additional information cell classificationLimitations: Requires specific reagents controls","code":""},{"path":"automated.html","id":"automated-hematology-analyzer-parameters","chapter":"Automated","heading":"Automated Hematology Analyzer Parameters","text":"Red Blood Cell (RBC) Parameters:\nRBC Count: Number red blood cells per unit volume blood (e.g., x 10^12/L)\nHemoglobin (HGB): Concentration hemoglobin whole blood (g/dL)\nHematocrit (HCT): Percentage blood volume occupied red blood cells (%)\nMean Corpuscular Volume (MCV): Average volume individual red blood cells (fL)\nMCV = (HCT / RBC) x 10\n\nMean Corpuscular Hemoglobin (MCH): Average amount hemoglobin per red blood cell (pg)\nMCH = HGB / RBC x 10\n\nMean Corpuscular Hemoglobin Concentration (MCHC): Average concentration hemoglobin given volume red blood cells (g/dL)\nMCHC = HGB / HCT x 100\n\nRed Cell Distribution Width (RDW): measure variation red blood cell size (anisocytosis) (%)\nRBC Count: Number red blood cells per unit volume blood (e.g., x 10^12/L)Hemoglobin (HGB): Concentration hemoglobin whole blood (g/dL)Hematocrit (HCT): Percentage blood volume occupied red blood cells (%)Mean Corpuscular Volume (MCV): Average volume individual red blood cells (fL)\nMCV = (HCT / RBC) x 10\nMCV = (HCT / RBC) x 10Mean Corpuscular Hemoglobin (MCH): Average amount hemoglobin per red blood cell (pg)\nMCH = HGB / RBC x 10\nMCH = HGB / RBC x 10Mean Corpuscular Hemoglobin Concentration (MCHC): Average concentration hemoglobin given volume red blood cells (g/dL)\nMCHC = HGB / HCT x 100\nMCHC = HGB / HCT x 100Red Cell Distribution Width (RDW): measure variation red blood cell size (anisocytosis) (%)White Blood Cell (WBC) Parameters:\nWBC Count: Total number white blood cells per unit volume blood (e.g., x 10^9/L)\nDifferential Count: Percentages absolute numbers type leukocyte:\nNeutrophils\nLymphocytes\nMonocytes\nEosinophils\nBasophils\n\nImmature Granulocytes (IG): Percentage absolute number immature granulocytes (e.g., metamyelocytes, myelocytes, promyelocytes) - used assess “left shift”\nWBC Count: Total number white blood cells per unit volume blood (e.g., x 10^9/L)Differential Count: Percentages absolute numbers type leukocyte:\nNeutrophils\nLymphocytes\nMonocytes\nEosinophils\nBasophils\nNeutrophilsLymphocytesMonocytesEosinophilsBasophilsImmature Granulocytes (IG): Percentage absolute number immature granulocytes (e.g., metamyelocytes, myelocytes, promyelocytes) - used assess “left shift”Platelet Parameters:\nPlatelet Count: Number platelets per unit volume blood (e.g., x 10^9/L)\nMean Platelet Volume (MPV): Average volume individual platelets (fL)\nPlatelet Distribution Width (PDW): Measure variation platelet size\nPlatelet Count: Number platelets per unit volume blood (e.g., x 10^9/L)Mean Platelet Volume (MPV): Average volume individual platelets (fL)Platelet Distribution Width (PDW): Measure variation platelet sizeReticulocyte Parameters:\nReticulocyte Percentage (%): Percentage RBCs reticulocytes\nAbsolute Reticulocyte Count: Number reticulocytes per unit volume blood (e.g., x 10^9/L)\nImmature Reticulocyte Fraction (IRF): Percentage reticulocytes least mature\nReticulocyte Hemoglobin Content (CHr Ret-): Hemoglobin content reticulocytes\nReticulocyte Percentage (%): Percentage RBCs reticulocytesAbsolute Reticulocyte Count: Number reticulocytes per unit volume blood (e.g., x 10^9/L)Immature Reticulocyte Fraction (IRF): Percentage reticulocytes least matureReticulocyte Hemoglobin Content (CHr Ret-): Hemoglobin content reticulocytes","code":""},{"path":"automated.html","id":"body-fluid-cell-counts","chapter":"Automated","heading":"Body Fluid Cell Counts","text":"Fluids Analyzed:\nCerebrospinal fluid (CSF)\nSynovial fluid\nSerous fluids (pleural, peritoneal, pericardial)\nbody fluids (e.g., ascites, bronchoalveolar lavage)\nCerebrospinal fluid (CSF)Synovial fluidSerous fluids (pleural, peritoneal, pericardial)body fluids (e.g., ascites, bronchoalveolar lavage)Parameters Measured:\nRed Blood Cell (RBC) Count\nTotal Nucleated Cell (TNC) Count: Includes nucleated cells (e.g., WBCs, malignant cells)\nCell Differential: May performed manually automated methods identify types nucleated cells present\nRed Blood Cell (RBC) CountTotal Nucleated Cell (TNC) Count: Includes nucleated cells (e.g., WBCs, malignant cells)Cell Differential: May performed manually automated methods identify types nucleated cells presentAutomated Methods Body Fluid Cell Counts:\nhematology analyzers validated use certain body fluids\nanalyzers typically use:\nElectrical impedance\nOptical scatter\nFlow cytometry\n\nCell Differentials: analyzers can perform automated cell differentials body fluids using flow cytometry techniques\nhematology analyzers validated use certain body fluidsThese analyzers typically use:\nElectrical impedance\nOptical scatter\nFlow cytometry\nElectrical impedanceOptical scatterFlow cytometryCell Differentials: analyzers can perform automated cell differentials body fluids using flow cytometry techniquesManual Methods:\nManual Cell Counts: May necessary automated method validated particular fluid automated results questionable\nCytospin Preparation: Cells concentrated onto slide using cytocentrifuge, allowing better visualization differentiation\nManual Cell Counts: May necessary automated method validated particular fluid automated results questionableCytospin Preparation: Cells concentrated onto slide using cytocentrifuge, allowing better visualization differentiation","code":""},{"path":"automated.html","id":"quality-control-qc-and-troubleshooting-1","chapter":"Automated","heading":"Quality Control (QC) and Troubleshooting","text":"Instrument Calibration:\nPerform regular calibration according manufacturer’s instructions\nPerform regular calibration according manufacturer’s instructionsControl Materials:\nRun control materials regular intervals (e.g., daily, batch samples)\nUse controls appropriate types samples analyzed (e.g., whole blood controls, body fluid controls)\nRecord control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)\nRun control materials regular intervals (e.g., daily, batch samples)Use controls appropriate types samples analyzed (e.g., whole blood controls, body fluid controls)Record control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)Maintenance:\nPerform routine maintenance analyzer according manufacturer’s recommendations\nincludes cleaning, replacing reagents, performing preventative maintenance procedures\nPerform routine maintenance analyzer according manufacturer’s recommendationsThis includes cleaning, replacing reagents, performing preventative maintenance proceduresTroubleshooting:\nInvestigate flags alarms generated instrument\nCheck sample clots, hemolysis, lipemia\nRepeat test fresh sample\nPerform manual cell counts confirm automated results\nConsult supervisor pathologist cause discrepancy determined\nInvestigate flags alarms generated instrumentCheck sample clots, hemolysis, lipemiaRepeat test fresh samplePerform manual cell counts confirm automated resultsConsult supervisor pathologist cause discrepancy determined","code":""},{"path":"automated.html","id":"reporting-results-2","chapter":"Automated","heading":"Reporting Results","text":"Report cell counts appropriate units (e.g., cells/μL, x 10^9/L)Include reference range parameterNote abnormal results flagsDocument quality control procedures corrective actions takenFor body fluid cell counts, include description fluid (e.g., CSF, synovial fluid) source fluid","code":""},{"path":"automated.html","id":"key-terms-49","chapter":"Automated","heading":"Key Terms","text":"Automated Cell Count: Enumeration cells using automated hematology analyzersElectrical Impedance (Coulter Principle): method counting sizing cellsOptical Scatter: method characterizing cells based light scattering propertiesFlow Cytometry: technique identifying quantifying cells based surface markers characteristicsCalibration: process adjusting instrument ensure accurate reliable resultsControl Materials: Samples known values used assess accuracy precision instrumentQuality Control: Procedures used monitor accuracy reliability laboratory testingBody Fluid: fluid blood (e.g., cerebrospinal fluid, synovial fluid, serous fluid)Reticulocyte: Immature red blood cellFlags Alarms: Indications instrument reporting abnormal results","code":""},{"path":"retics.html","id":"retics","chapter":"Retics","heading":"Retics","text":"","code":""},{"path":"retics.html","id":"overview-of-reticulocyte-counts","chapter":"Retics","heading":"Overview of Reticulocyte Counts","text":"Definition: reticulocyte count hematology test measures percentage absolute number reticulocytes (immature red blood cells) bloodClinical Significance:\nIndicator Bone Marrow Activity: Reflects rate red blood cell production bone marrow\nClassification Anemias: Helps differentiate anemias based whether bone marrow responding appropriately (increased reticulocytes) (decreased reticulocytes)\nMonitoring Response Therapy: Used assess effectiveness treatment anemia (e.g., iron supplementation, vitamin B12 injections, erythropoietin-stimulating agents)\nEvaluation Bone Marrow Function: Helps detect bone marrow disorders (e.g., aplastic anemia, myelodysplastic syndromes)\nIndicator Bone Marrow Activity: Reflects rate red blood cell production bone marrowClassification Anemias: Helps differentiate anemias based whether bone marrow responding appropriately (increased reticulocytes) (decreased reticulocytes)Monitoring Response Therapy: Used assess effectiveness treatment anemia (e.g., iron supplementation, vitamin B12 injections, erythropoietin-stimulating agents)Evaluation Bone Marrow Function: Helps detect bone marrow disorders (e.g., aplastic anemia, myelodysplastic syndromes)Methods:\nManual Reticulocyte Count: Microscopic examination stained peripheral blood smear\nAutomated Reticulocyte Count: Automated hematology analyzers use various technologies identify count reticulocytes\nManual Reticulocyte Count: Microscopic examination stained peripheral blood smearAutomated Reticulocyte Count: Automated hematology analyzers use various technologies identify count reticulocytes","code":""},{"path":"retics.html","id":"principles-of-reticulocyte-counting","chapter":"Retics","heading":"Principles of Reticulocyte Counting","text":"Reticulocytes:\nImmature red blood cells recently released bone marrow peripheral blood\nSlightly larger mature RBCs contain residual ribosomal RNA (rRNA)\nCirculate blood 1-2 days maturing erythrocytes\nImmature red blood cells recently released bone marrow peripheral bloodSlightly larger mature RBCs contain residual ribosomal RNA (rRNA)Circulate blood 1-2 days maturing erythrocytesStaining:\nReticulocytes identified counted based presence rRNA, can stained specific dyes:\nSupravital Stains: Dyes stain living cells (e.g., new methylene blue, brilliant cresyl blue)\ndyes enter cells bind rRNA, forming visible network precipitate\n\nFluorescent Dyes: Used automated reticulocyte counts (e.g., thiazole orange, auramine O, acridine orange)\ndyes bind RNA emit fluorescence excited laser beam\n\n\nReticulocytes identified counted based presence rRNA, can stained specific dyes:\nSupravital Stains: Dyes stain living cells (e.g., new methylene blue, brilliant cresyl blue)\ndyes enter cells bind rRNA, forming visible network precipitate\n\nFluorescent Dyes: Used automated reticulocyte counts (e.g., thiazole orange, auramine O, acridine orange)\ndyes bind RNA emit fluorescence excited laser beam\n\nSupravital Stains: Dyes stain living cells (e.g., new methylene blue, brilliant cresyl blue)\ndyes enter cells bind rRNA, forming visible network precipitate\ndyes enter cells bind rRNA, forming visible network precipitateFluorescent Dyes: Used automated reticulocyte counts (e.g., thiazole orange, auramine O, acridine orange)\ndyes bind RNA emit fluorescence excited laser beam\ndyes bind RNA emit fluorescence excited laser beam","code":""},{"path":"retics.html","id":"manual-reticulocyte-count","chapter":"Retics","heading":"Manual Reticulocyte Count","text":"Principle:\nsupravital stain used stain residual rRNA reticulocytes\nstained blood smear examined microscope, number reticulocytes counted among known number RBCs\nsupravital stain used stain residual rRNA reticulocytesThe stained blood smear examined microscope, number reticulocytes counted among known number RBCsProcedure:\nMix Equal Volumes: Mix equal volumes supravital stain (e.g., new methylene blue) whole blood test tube\nIncubation: Incubate mixture room temperature 15-30 minutes allow stain penetrate cells\nPrepare Smear: Prepare wedge (push) smear glass slide\nAir Dry: Allow smear air dry completely\nMicroscopic Examination:\nExamine stained smear oil immersion (100x objective)\nCount reticulocytes total RBCs consistent manner:\nCount reticulocytes RBCs defined area number fields (e.g., 1000 RBCs 10 fields)\nCount least 1000 RBCs improve accuracy\nUse hand tally counter keep track counts\nFollow consistent counting rules:\nCount reticulocytes reticular material clearly visible\ncount cells fragmented distorted\n\n\n\nCalculate Reticulocyte Percentage (%):\nFormula:\nReticulocyte % = (Number Reticulocytes / Total Number RBCs Counted) x 100\n\nMix Equal Volumes: Mix equal volumes supravital stain (e.g., new methylene blue) whole blood test tubeIncubation: Incubate mixture room temperature 15-30 minutes allow stain penetrate cellsPrepare Smear: Prepare wedge (push) smear glass slideAir Dry: Allow smear air dry completelyMicroscopic Examination:\nExamine stained smear oil immersion (100x objective)\nCount reticulocytes total RBCs consistent manner:\nCount reticulocytes RBCs defined area number fields (e.g., 1000 RBCs 10 fields)\nCount least 1000 RBCs improve accuracy\nUse hand tally counter keep track counts\nFollow consistent counting rules:\nCount reticulocytes reticular material clearly visible\ncount cells fragmented distorted\n\n\nExamine stained smear oil immersion (100x objective)Count reticulocytes total RBCs consistent manner:\nCount reticulocytes RBCs defined area number fields (e.g., 1000 RBCs 10 fields)\nCount least 1000 RBCs improve accuracy\nUse hand tally counter keep track counts\nFollow consistent counting rules:\nCount reticulocytes reticular material clearly visible\ncount cells fragmented distorted\n\nCount reticulocytes RBCs defined area number fields (e.g., 1000 RBCs 10 fields)Count least 1000 RBCs improve accuracyUse hand tally counter keep track countsFollow consistent counting rules:\nCount reticulocytes reticular material clearly visible\ncount cells fragmented distorted\nCount reticulocytes reticular material clearly visibleDo count cells fragmented distortedCalculate Reticulocyte Percentage (%):\nFormula:\nReticulocyte % = (Number Reticulocytes / Total Number RBCs Counted) x 100\nFormula:\nReticulocyte % = (Number Reticulocytes / Total Number RBCs Counted) x 100Advantages:\nSimple inexpensive\nRequires minimal equipment\nSimple inexpensiveRequires minimal equipmentLimitations:\nSubjective: Results depend skills experience technologist\nTime-Consuming: Requires manual counting, can tedious\nLower Precision: Compared automated methods\nUneven Distribution RBCs Smear: Can lead inaccurate results\nSubjective: Results depend skills experience technologistTime-Consuming: Requires manual counting, can tediousLower Precision: Compared automated methodsUneven Distribution RBCs Smear: Can lead inaccurate results","code":""},{"path":"retics.html","id":"automated-reticulocyte-count","chapter":"Retics","heading":"Automated Reticulocyte Count","text":"Principle: Automated hematology analyzers use various technologies identify count reticulocytes based RNA content:\nFluorescent Dye Method:\nfluorescent dye (e.g., thiazole orange, auramine O, acridine orange) binds RNA reticulocytes\nCells pass laser beam, amount fluorescence measured\nReticulocytes differentiated mature RBCs based higher fluorescence intensity\n\nLight Scattering Method:\nanalyzers use light scattering properties RBCs differentiate reticulocytes mature RBCs\n\nFluorescent Dye Method:\nfluorescent dye (e.g., thiazole orange, auramine O, acridine orange) binds RNA reticulocytes\nCells pass laser beam, amount fluorescence measured\nReticulocytes differentiated mature RBCs based higher fluorescence intensity\nfluorescent dye (e.g., thiazole orange, auramine O, acridine orange) binds RNA reticulocytesCells pass laser beam, amount fluorescence measuredReticulocytes differentiated mature RBCs based higher fluorescence intensityLight Scattering Method:\nanalyzers use light scattering properties RBCs differentiate reticulocytes mature RBCs\nanalyzers use light scattering properties RBCs differentiate reticulocytes mature RBCsAdvantages:\nIncreased Accuracy Precision: Automated methods accurate precise manual methods\nImproved Speed Efficiency: Automated analyzers can process samples quickly\nReduced Labor Costs: Reduces need manual counting\nObjective Results: Provides objective reproducible results\nAbility Measure Additional Reticulocyte Parameters (see )\nIncreased Accuracy Precision: Automated methods accurate precise manual methodsImproved Speed Efficiency: Automated analyzers can process samples quicklyReduced Labor Costs: Reduces need manual countingObjective Results: Provides objective reproducible resultsAbility Measure Additional Reticulocyte Parameters (see )","code":""},{"path":"retics.html","id":"reticulocyte-parameters","chapter":"Retics","heading":"Reticulocyte Parameters","text":"Reticulocyte Percentage (%):\npercentage RBCs reticulocytes\nExpressed percentage (%)\nReticulocyte Percentage (%):percentage RBCs reticulocytesExpressed percentage (%)Absolute Reticulocyte Count:\nactual number reticulocytes per microliter (μL) blood\nFormula:\nAbsolute Reticulocyte Count (cells/μL) = (Reticulocyte % / 100) x RBC Count (cells/μL)\nAdult reference range: 20 - 115 x 10^9/L\nclinically useful reticulocyte percentage alone, corrects variations total RBC count\nAbsolute Reticulocyte Count:actual number reticulocytes per microliter (μL) bloodFormula:\nAbsolute Reticulocyte Count (cells/μL) = (Reticulocyte % / 100) x RBC Count (cells/μL)Adult reference range: 20 - 115 x 10^9/LMore clinically useful reticulocyte percentage alone, corrects variations total RBC countCorrected Reticulocyte Count (CRC):\nUsed correct effects anemia reticulocyte count\nreticulocyte percentage can falsely elevated anemic patients due decreased number mature RBCs\nFormula:\nCRC = Reticulocyte % x (Patient’s HCT / Normal Mean HCT)\n*Normal Mean HCT = 45% (adults)\nInterpretation:\nCRC > 2-3%: Appropriate bone marrow response anemia\nCRC < 2%: Inadequate bone marrow response (hypoproliferative anemia)\n\nCorrected Reticulocyte Count (CRC):Used correct effects anemia reticulocyte countThe reticulocyte percentage can falsely elevated anemic patients due decreased number mature RBCsFormula:\nCRC = Reticulocyte % x (Patient’s HCT / Normal Mean HCT)\n*Normal Mean HCT = 45% (adults)Interpretation:\nCRC > 2-3%: Appropriate bone marrow response anemia\nCRC < 2%: Inadequate bone marrow response (hypoproliferative anemia)\nCRC > 2-3%: Appropriate bone marrow response anemiaCRC < 2%: Inadequate bone marrow response (hypoproliferative anemia)Reticulocyte Production Index (RPI):\nProvides accurate assessment erythropoiesis correcting anemia premature release reticulocytes bone marrow\nPrematurely released reticulocytes circulate longer period normal reticulocytes, artificially inflating reticulocyte count\nFormula:\nRPI = Corrected Reticulocyte Count (CRC) / Shift Correction Factor\nShift Correction Factor: Based patient’s HCT\nHCT 45% = 1.0\nHCT 35% = 1.5\nHCT 25% = 2.0\n*HCT 15% = 2.5\nInterpretation:\nRPI > 2-3: Adequate bone marrow response anemia (increased erythropoiesis)\nRPI < 2: Inadequate bone marrow response (hypoproliferative anemia)\n\nReticulocyte Production Index (RPI):Provides accurate assessment erythropoiesis correcting anemia premature release reticulocytes bone marrowPrematurely released reticulocytes circulate longer period normal reticulocytes, artificially inflating reticulocyte countFormula:\nRPI = Corrected Reticulocyte Count (CRC) / Shift Correction Factor\nShift Correction Factor: Based patient’s HCT\nHCT 45% = 1.0\nHCT 35% = 1.5\nHCT 25% = 2.0\n*HCT 15% = 2.5Interpretation:\nRPI > 2-3: Adequate bone marrow response anemia (increased erythropoiesis)\nRPI < 2: Inadequate bone marrow response (hypoproliferative anemia)\nRPI > 2-3: Adequate bone marrow response anemia (increased erythropoiesis)RPI < 2: Inadequate bone marrow response (hypoproliferative anemia)Immature Reticulocyte Fraction (IRF):\npercentage reticulocytes least mature (.e., highest RNA content)\nIRF reflects rate erythropoiesis can provide earlier indication changes bone marrow activity reticulocyte percentage\nIncreased IRF: Suggests increased erythropoiesis\nDecreased IRF: Suggests decreased erythropoiesis ineffective erythropoiesis\nImmature Reticulocyte Fraction (IRF):percentage reticulocytes least mature (.e., highest RNA content)IRF reflects rate erythropoiesis can provide earlier indication changes bone marrow activity reticulocyte percentageIncreased IRF: Suggests increased erythropoiesisDecreased IRF: Suggests decreased erythropoiesis ineffective erythropoiesisReticulocyte Hemoglobin Content (CHr Ret-):\nMeasures hemoglobin content reticulocytes\nProvides indication iron availability erythropoiesis\nDecreased Ret-: Suggests iron-restricted erythropoiesis (e.g., iron deficiency anemia, anemia chronic disease)\nAdvantages:\nsensitive rapid indicator iron-restricted erythropoiesis traditional iron studies (e.g., serum iron, ferritin)\naffected acute phase reactants (inflammatory markers)\n\nReticulocyte Hemoglobin Content (CHr Ret-):Measures hemoglobin content reticulocytesProvides indication iron availability erythropoiesisDecreased Ret-: Suggests iron-restricted erythropoiesis (e.g., iron deficiency anemia, anemia chronic disease)Advantages:\nsensitive rapid indicator iron-restricted erythropoiesis traditional iron studies (e.g., serum iron, ferritin)\naffected acute phase reactants (inflammatory markers)\nsensitive rapid indicator iron-restricted erythropoiesis traditional iron studies (e.g., serum iron, ferritin)affected acute phase reactants (inflammatory markers)","code":""},{"path":"retics.html","id":"interpretation-of-reticulocyte-results","chapter":"Retics","heading":"Interpretation of Reticulocyte Results","text":"Elevated Reticulocyte Count (Anemia):\nIndicates bone marrow responding anemia increasing RBC production\nSeen :\nHemolytic anemias\nAcute blood loss\nResponse iron, vitamin B12, folate therapy\n\nIndicates bone marrow responding anemia increasing RBC productionSeen :\nHemolytic anemias\nAcute blood loss\nResponse iron, vitamin B12, folate therapy\nHemolytic anemiasAcute blood lossResponse iron, vitamin B12, folate therapyLow Reticulocyte Count (Anemia):\nIndicates inadequate bone marrow response anemia\nSeen :\nHypoproliferative anemias\nAplastic anemia\nMyelodysplastic syndromes\nAnemia chronic disease\nChronic kidney disease\nNutritional deficiencies (e.g., iron, vitamin B12, folate)\n\nIndicates inadequate bone marrow response anemiaSeen :\nHypoproliferative anemias\nAplastic anemia\nMyelodysplastic syndromes\nAnemia chronic disease\nChronic kidney disease\nNutritional deficiencies (e.g., iron, vitamin B12, folate)\nHypoproliferative anemiasAplastic anemiaMyelodysplastic syndromesAnemia chronic diseaseChronic kidney diseaseNutritional deficiencies (e.g., iron, vitamin B12, folate)Normal Reticulocyte Count (Anemia):\nMay indicate early mild anemia, compensated hemolytic anemia\nMay indicate early mild anemia, compensated hemolytic anemia","code":""},{"path":"retics.html","id":"quality-control-and-troubleshooting-1","chapter":"Retics","heading":"Quality Control and Troubleshooting","text":"Manual Reticulocyte Counts:\nUse properly prepared stained smears\nFollow consistent counting rules\nCount adequate number RBCs (least 1000)\nPerform duplicate counts check acceptable agreement\nManual Reticulocyte Counts:Use properly prepared stained smearsFollow consistent counting rulesCount adequate number RBCs (least 1000)Perform duplicate counts check acceptable agreementAutomated Reticulocyte Counts:\nPerform daily instrument calibration maintenance\nRun control materials regular intervals\nReview control results take corrective action necessary\nInvestigate flags alarms generated instrument\nCorrelate automated results peripheral blood smear findings\nAutomated Reticulocyte Counts:Perform daily instrument calibration maintenanceRun control materials regular intervalsReview control results take corrective action necessaryInvestigate flags alarms generated instrumentCorrelate automated results peripheral blood smear findings","code":""},{"path":"retics.html","id":"key-terms-50","chapter":"Retics","heading":"Key Terms","text":"Reticulocyte: Immature red blood cell containing residual RNASupravital Stain: dye used stain living cells (e.g., new methylene blue, brilliant cresyl blue)Reticulocyte Percentage: Percentage RBCs reticulocytesAbsolute Reticulocyte Count: Number reticulocytes per microliter (μL) bloodCorrected Reticulocyte Count (CRC): Reticulocyte percentage corrected degree anemiaReticulocyte Production Index (RPI): Reticulocyte count corrected anemia premature reticulocyte releaseImmature Reticulocyte Fraction (IRF): Percentage reticulocytes highest RNA contentReticulocyte Hemoglobin Content (CHr Ret-): Hemoglobin content reticulocytesErythropoiesis: Red blood cell productionHypoproliferative Anemia: Anemia due decreased red blood cell production","code":""},{"path":"differentials.html","id":"differentials","chapter":"Differentials","heading":"Differentials","text":"","code":""},{"path":"differentials.html","id":"overview-of-differentials-and-morphology-evaluation","chapter":"Differentials","heading":"Overview of Differentials and Morphology Evaluation","text":"Definition: process identifying, classifying, quantifying cells blood body fluid sample, well evaluating morphological characteristics (size, shape, color, nuclear cytoplasmic features)Purpose:\nDiagnose monitor wide range hematologic non-hematologic disorders\nAssess relative proportions different cell types\nIdentify abnormal cells (e.g., blasts, atypical lymphocytes)\nDetect morphological abnormalities cells\nEvaluate response therapy\nDiagnose monitor wide range hematologic non-hematologic disordersAssess relative proportions different cell typesIdentify abnormal cells (e.g., blasts, atypical lymphocytes)Detect morphological abnormalities cellsEvaluate response therapyMethods:\nManual Differential: Microscopic examination stained peripheral blood smear body fluid cytospin preparation\nAutomated Differential: Automated hematology analyzers use various technologies identify classify cells\nManual Differential: Microscopic examination stained peripheral blood smear body fluid cytospin preparationAutomated Differential: Automated hematology analyzers use various technologies identify classify cells","code":""},{"path":"differentials.html","id":"peripheral-blood-smear-preparation-and-staining","chapter":"Differentials","heading":"Peripheral Blood Smear Preparation and Staining","text":"Blood Collection:\nCollect blood EDTA (purple-top) tubes CBC peripheral blood smear preparation\nEnsure proper collection technique avoid clots\nCollect blood EDTA (purple-top) tubes CBC peripheral blood smear preparationEnsure proper collection technique avoid clotsSmear Preparation:\nWedge Smear Technique: common method preparing blood smears\nPlace small drop blood near one end clean glass slide\nHold second slide (spreader slide) 30-45 degree angle first slide\nBring spreader slide back contact blood drop, allowing blood spread along edge spreader slide\nPush spreader slide forward smooth, continuous motion, creating thin film blood\nAllow smear air dry completely\n\nFactors Affecting Smear Quality:\nAngle spreader slide\nSpeed spreading\nSize blood drop\nBlood viscosity\n\nWedge Smear Technique: common method preparing blood smears\nPlace small drop blood near one end clean glass slide\nHold second slide (spreader slide) 30-45 degree angle first slide\nBring spreader slide back contact blood drop, allowing blood spread along edge spreader slide\nPush spreader slide forward smooth, continuous motion, creating thin film blood\nAllow smear air dry completely\nPlace small drop blood near one end clean glass slideHold second slide (spreader slide) 30-45 degree angle first slideBring spreader slide back contact blood drop, allowing blood spread along edge spreader slidePush spreader slide forward smooth, continuous motion, creating thin film bloodAllow smear air dry completelyFactors Affecting Smear Quality:\nAngle spreader slide\nSpeed spreading\nSize blood drop\nBlood viscosity\nAngle spreader slideSpeed spreadingSize blood dropBlood viscosityStaining:\nWright Stain Wright-Giemsa Stain: commonly used stains blood smears\nStaining Procedure:\nFlood air-dried smear Wright Wright-Giemsa stain 3-5 minutes\nAdd equal volume buffer (distilled water phosphate buffer) slide mix gently 5-10 minutes\nWash slide gently buffer\nAllow slide air dry completely\n\nProper Staining Technique:\nUse fresh stain buffer\nUse appropriate staining washing times\nAvoid overstaining understaining\nCheck buffer pH\n\nWright Stain Wright-Giemsa Stain: commonly used stains blood smearsStaining Procedure:\nFlood air-dried smear Wright Wright-Giemsa stain 3-5 minutes\nAdd equal volume buffer (distilled water phosphate buffer) slide mix gently 5-10 minutes\nWash slide gently buffer\nAllow slide air dry completely\nFlood air-dried smear Wright Wright-Giemsa stain 3-5 minutesAdd equal volume buffer (distilled water phosphate buffer) slide mix gently 5-10 minutesWash slide gently bufferAllow slide air dry completelyProper Staining Technique:\nUse fresh stain buffer\nUse appropriate staining washing times\nAvoid overstaining understaining\nCheck buffer pH\nUse fresh stain bufferUse appropriate staining washing timesAvoid overstaining understainingCheck buffer pH","code":""},{"path":"differentials.html","id":"manual-differential-count","chapter":"Differentials","heading":"Manual Differential Count","text":"Principle:\ntrained medical laboratory scientist examines stained peripheral blood smear microscope identifies, classifies, counts 100 leukocytes\nresults expressed percentages cell type can converted absolute counts\ntrained medical laboratory scientist examines stained peripheral blood smear microscope identifies, classifies, counts 100 leukocytesThe results expressed percentages cell type can converted absolute countsProcedure:\nPreparation Key\nUse Well-Prepared Stained Peripheral Blood Smear: mentioned earlier, wedge smear technique common. want thin area blood, well stained, minimal artifacts. important poor technique can lead poor test results\nGood Lighting Microscope Settings: bright properly aligned microscope essential. Make sure good oil immersion lens (100x objective) microscope routinely serviced\n\nFinding “Counting Area”\nScan Low Power (10x Objective): get started, ’ll want get big picture view. 10x, use coarse fine focus adjustments find “counting area.” region smear:\nRBCs evenly distributed\nRBCs mostly monolayered (piled top )\nCells distorted\n’s usually found thickest part (near applied blood) thinnest part (feathered edge)\n\n\nSystematic Counting Technique\nUse Consistent Pattern: goal count every cell way avoids bias double-counting. common approaches:\nMeandering (Serpentine) Pattern: Start one edge counting area move across smear zigzag winding pattern. reach edge, shift slightly continue counting opposite direction\nBattlement (Greek Key) Pattern: Count cells along edges defined area (like square rectangle) move inward, creating “battlement” effect.\n\nCount 40x 50x Objective: ’ve found good spot count, switch higher power (100x)\n\nCell Identification\nRely Cellular Morphology 100x: Accurately identifying cells !\nCount least 100 WBCs: number needed create good count smear.\n\nRepeat Needed\nPeripheral Blood Smear shows WBC, can count fewer locations. little, can try make better slide ask another blood sample.\n\nPreparation Key\nUse Well-Prepared Stained Peripheral Blood Smear: mentioned earlier, wedge smear technique common. want thin area blood, well stained, minimal artifacts. important poor technique can lead poor test results\nGood Lighting Microscope Settings: bright properly aligned microscope essential. Make sure good oil immersion lens (100x objective) microscope routinely serviced\nUse Well-Prepared Stained Peripheral Blood Smear: mentioned earlier, wedge smear technique common. want thin area blood, well stained, minimal artifacts. important poor technique can lead poor test resultsGood Lighting Microscope Settings: bright properly aligned microscope essential. Make sure good oil immersion lens (100x objective) microscope routinely servicedFinding “Counting Area”\nScan Low Power (10x Objective): get started, ’ll want get big picture view. 10x, use coarse fine focus adjustments find “counting area.” region smear:\nRBCs evenly distributed\nRBCs mostly monolayered (piled top )\nCells distorted\n’s usually found thickest part (near applied blood) thinnest part (feathered edge)\n\nScan Low Power (10x Objective): get started, ’ll want get big picture view. 10x, use coarse fine focus adjustments find “counting area.” region smear:\nRBCs evenly distributed\nRBCs mostly monolayered (piled top )\nCells distorted\n’s usually found thickest part (near applied blood) thinnest part (feathered edge)\nRBCs evenly distributedRBCs mostly monolayered (piled top )Cells distortedIt’s usually found thickest part (near applied blood) thinnest part (feathered edge)Systematic Counting Technique\nUse Consistent Pattern: goal count every cell way avoids bias double-counting. common approaches:\nMeandering (Serpentine) Pattern: Start one edge counting area move across smear zigzag winding pattern. reach edge, shift slightly continue counting opposite direction\nBattlement (Greek Key) Pattern: Count cells along edges defined area (like square rectangle) move inward, creating “battlement” effect.\n\nCount 40x 50x Objective: ’ve found good spot count, switch higher power (100x)\nUse Consistent Pattern: goal count every cell way avoids bias double-counting. common approaches:\nMeandering (Serpentine) Pattern: Start one edge counting area move across smear zigzag winding pattern. reach edge, shift slightly continue counting opposite direction\nBattlement (Greek Key) Pattern: Count cells along edges defined area (like square rectangle) move inward, creating “battlement” effect.\nMeandering (Serpentine) Pattern: Start one edge counting area move across smear zigzag winding pattern. reach edge, shift slightly continue counting opposite directionBattlement (Greek Key) Pattern: Count cells along edges defined area (like square rectangle) move inward, creating “battlement” effect.Count 40x 50x Objective: ’ve found good spot count, switch higher power (100x)Cell Identification\nRely Cellular Morphology 100x: Accurately identifying cells !\nCount least 100 WBCs: number needed create good count smear.\nRely Cellular Morphology 100x: Accurately identifying cells !Count least 100 WBCs: number needed create good count smear.Repeat Needed\nPeripheral Blood Smear shows WBC, can count fewer locations. little, can try make better slide ask another blood sample.\nPeripheral Blood Smear shows WBC, can count fewer locations. little, can try make better slide ask another blood sample.Sources Error:\nUneven Cell Distribution: Scan smear ensure even cell distribution\nCell Clumping Overlap: Choose area well-separated cells\nStaining Artifacts: Use proper staining techniques fresh reagents\nInaccurate Cell Identification: Proper training experience essential\nHigh nRBC Count: nucleated red blood cells (nRBCs) present, corrected WBC count must calculated: Corrected WBC = (Uncorrected WBC x 100) / (100 + Number nRBCs per 100 WBCs)\nUneven Cell Distribution: Scan smear ensure even cell distributionCell Clumping Overlap: Choose area well-separated cellsStaining Artifacts: Use proper staining techniques fresh reagentsInaccurate Cell Identification: Proper training experience essentialHigh nRBC Count: nucleated red blood cells (nRBCs) present, corrected WBC count must calculated: Corrected WBC = (Uncorrected WBC x 100) / (100 + Number nRBCs per 100 WBCs)","code":""},{"path":"differentials.html","id":"body-fluid-cytospin-preparation-and-staining","chapter":"Differentials","heading":"Body Fluid Cytospin Preparation and Staining","text":"Cytospin Preparation:\nUsed concentrate cells fluid sample onto slide microscopic examination\nProcedure:\nMix Fluid Sample: Gently mix body fluid sample ensure even cell distribution\nPrepare Cytospin:\nLoad known volume fluid sample cytospin funnel\nAttach funnel microscope slide\nPlace assembly cytocentrifuge\n\nCentrifugation:\nCentrifuge sample specific speed time concentrate cells onto slide\n\nAir Dry:\nCarefully remove slide cytocentrifuge allow air dry completely\n\n\nCytospin Preparation:Used concentrate cells fluid sample onto slide microscopic examinationProcedure:\nMix Fluid Sample: Gently mix body fluid sample ensure even cell distribution\nPrepare Cytospin:\nLoad known volume fluid sample cytospin funnel\nAttach funnel microscope slide\nPlace assembly cytocentrifuge\n\nCentrifugation:\nCentrifuge sample specific speed time concentrate cells onto slide\n\nAir Dry:\nCarefully remove slide cytocentrifuge allow air dry completely\n\nMix Fluid Sample: Gently mix body fluid sample ensure even cell distributionPrepare Cytospin:\nLoad known volume fluid sample cytospin funnel\nAttach funnel microscope slide\nPlace assembly cytocentrifuge\nLoad known volume fluid sample cytospin funnelAttach funnel microscope slidePlace assembly cytocentrifugeCentrifugation:\nCentrifuge sample specific speed time concentrate cells onto slide\nCentrifuge sample specific speed time concentrate cells onto slideAir Dry:\nCarefully remove slide cytocentrifuge allow air dry completely\nCarefully remove slide cytocentrifuge allow air dry completelyStaining:\nWright Wright-Giemsa Stain: commonly used stains\nFollow staining procedure peripheral blood smears\nEnsure staining appropriate type cells examined\nStaining:Wright Wright-Giemsa Stain: commonly used stainsFollow staining procedure peripheral blood smearsEnsure staining appropriate type cells examined","code":""},{"path":"differentials.html","id":"body-fluid-cell-differential","chapter":"Differentials","heading":"Body Fluid Cell Differential","text":"Cerebrospinal Fluid (CSF):\nCell Types:\nLymphocytes (predominant cell type normal CSF)\nMonocytes\nNeutrophils (rare normal CSF)\nEpendymal Cells (cells lining ventricles brain)\n\nAbnormal Cells:\nBlast cells (suggestive leukemia lymphoma)\nMalignant cells (metastatic cancer)\n\nInterpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial meningitis\nIncreased lymphocytes: Suggests viral meningitis inflammatory conditions\nPresence blasts malignant cells: Suggests leukemia, lymphoma, metastatic cancer\n\nCerebrospinal Fluid (CSF):Cell Types:\nLymphocytes (predominant cell type normal CSF)\nMonocytes\nNeutrophils (rare normal CSF)\nEpendymal Cells (cells lining ventricles brain)\nLymphocytes (predominant cell type normal CSF)MonocytesNeutrophils (rare normal CSF)Ependymal Cells (cells lining ventricles brain)Abnormal Cells:\nBlast cells (suggestive leukemia lymphoma)\nMalignant cells (metastatic cancer)\nBlast cells (suggestive leukemia lymphoma)Malignant cells (metastatic cancer)Interpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial meningitis\nIncreased lymphocytes: Suggests viral meningitis inflammatory conditions\nPresence blasts malignant cells: Suggests leukemia, lymphoma, metastatic cancer\nIncreased neutrophils: Suggests bacterial meningitisIncreased lymphocytes: Suggests viral meningitis inflammatory conditionsPresence blasts malignant cells: Suggests leukemia, lymphoma, metastatic cancerSerous Fluids (Pleural, Peritoneal, Pericardial):\nCell Types:\nMesothelial cells (cells lining serous membranes)\nLymphocytes\nMacrophages\nNeutrophils (may present inflammation infection)\n\nAbnormal Cells:\nMalignant cells (metastatic cancer)\nBlast cells (rare)\n\nInterpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial infection inflammation\nIncreased lymphocytes: Suggests viral infection, tuberculosis, autoimmune disease\nPresence malignant cells: Suggests metastatic cancer\n\nSerous Fluids (Pleural, Peritoneal, Pericardial):Cell Types:\nMesothelial cells (cells lining serous membranes)\nLymphocytes\nMacrophages\nNeutrophils (may present inflammation infection)\nMesothelial cells (cells lining serous membranes)LymphocytesMacrophagesNeutrophils (may present inflammation infection)Abnormal Cells:\nMalignant cells (metastatic cancer)\nBlast cells (rare)\nMalignant cells (metastatic cancer)Blast cells (rare)Interpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial infection inflammation\nIncreased lymphocytes: Suggests viral infection, tuberculosis, autoimmune disease\nPresence malignant cells: Suggests metastatic cancer\nIncreased neutrophils: Suggests bacterial infection inflammationIncreased lymphocytes: Suggests viral infection, tuberculosis, autoimmune diseasePresence malignant cells: Suggests metastatic cancerSynovial Fluid:\nCell Types:\nSynovial lining cells (cells lining joint space)\nMonocytes/macrophages\nLymphocytes ()\nNeutrophils (minimal normal sample)\n\nAbnormal Cells:\nCrystals (urate crystals gout, calcium pyrophosphate dihydrate (CPPD) crystals pseudogout)\nCartilage debris\nBacteria\n\nInterpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial arthritis\nPresence crystals: Suggests crystal-induced arthritis (e.g., gout, pseudogout)\n\nSynovial Fluid:Cell Types:\nSynovial lining cells (cells lining joint space)\nMonocytes/macrophages\nLymphocytes ()\nNeutrophils (minimal normal sample)\nSynovial lining cells (cells lining joint space)Monocytes/macrophagesLymphocytes ()Neutrophils (minimal normal sample)Abnormal Cells:\nCrystals (urate crystals gout, calcium pyrophosphate dihydrate (CPPD) crystals pseudogout)\nCartilage debris\nBacteria\nCrystals (urate crystals gout, calcium pyrophosphate dihydrate (CPPD) crystals pseudogout)Cartilage debrisBacteriaInterpreting Cell Differential:\nIncreased neutrophils: Suggests bacterial arthritis\nPresence crystals: Suggests crystal-induced arthritis (e.g., gout, pseudogout)\nIncreased neutrophils: Suggests bacterial arthritisPresence crystals: Suggests crystal-induced arthritis (e.g., gout, pseudogout)","code":""},{"path":"differentials.html","id":"cell-identification","chapter":"Differentials","heading":"Cell Identification","text":"Develop expertise identifying different cell types based :\nSize\nNuclear Morphology (shape, chromatin pattern, nucleoli)\nCytoplasmic Characteristics (color, granules, vacuoles)\nUse reliable cell atlas reference guide\nSizeNuclear Morphology (shape, chromatin pattern, nucleoli)Cytoplasmic Characteristics (color, granules, vacuoles)Use reliable cell atlas reference guideAccurate cell identification essential performing accurate differential counts","code":""},{"path":"differentials.html","id":"automated-cell-differentials","chapter":"Differentials","heading":"Automated Cell Differentials","text":"Automated hematology analyzers can perform cell differentials using various technologies:\nElectrical Impedance: Cells classified based size\nOptical Scatter: Cells classified based light scattering properties\nFlow Cytometry: Cells stained fluorescent dyes classified based fluorescence scatter properties\nElectrical Impedance: Cells classified based sizeOptical Scatter: Cells classified based light scattering propertiesFlow Cytometry: Cells stained fluorescent dyes classified based fluorescence scatter propertiesAdvantages Automated Differentials:\nIncreased Speed Efficiency\nImproved Precision\nReduced Labor Costs\nIncreased Speed EfficiencyImproved PrecisionReduced Labor CostsLimitations Automated Differentials:\nInability Identify Cell Types: abnormal immature cells may accurately identified analyzer\nInterference: Certain substances can interfere automated cell counts differentials\nInability Identify Cell Types: abnormal immature cells may accurately identified analyzerInterference: Certain substances can interfere automated cell counts differentialsManual Review Criteria: Peripheral blood smears reviewed manually automated differential flags abnormal cells results correlate patient’s clinical condition","code":""},{"path":"differentials.html","id":"reporting-results-3","chapter":"Differentials","heading":"Reporting Results","text":"Report cell counts percentages cell typeInclude description morphological abnormalities observedNote flags comments generated instrumentFor body fluid cell differentials, include description fluid source fluidCorrelate laboratory findings patient’s clinical information","code":""},{"path":"differentials.html","id":"key-terms-51","chapter":"Differentials","heading":"Key Terms","text":"Peripheral Blood Smear: blood sample spread thinly slide microscopic examinationDifferential Count: Enumeration classification different types leukocytesMorphology: study cell structure formAnisocytosis: Variation red blood cell sizePoikilocytosis: Variation red blood cell shapeHypochromia: Decreased hemoglobin content red blood cells (pale color)Polychromasia: Increased blueness red blood cells due residual RNASpherocytes: Spherical-shaped red blood cellsSchistocytes: Fragmented red blood cellsTarget Cells: Red blood cells bullseye appearanceAuer Rods: Rod-shaped inclusions myeloblastsBlasts: Immature blood cells seen acute leukemiaAtypical Lymphocytes: Activated lymphocytes abnormal morphologyMegaloblasts: Abnormal, large erythroid precursorsHypersegmented Neutrophils: Neutrophils 5 lobesCytospin Preparation: method concentrating cells fluid sample onto slideSupernatant: fluid component sample centrifugationQuality Control: Procedures used monitor accuracy precision laboratory testing","code":""},{"path":"morphologies.html","id":"morphologies","chapter":"Morphologies","heading":"Morphologies","text":"","code":""},{"path":"morphologies.html","id":"blood-and-bone-marrow","chapter":"Morphologies","heading":"Blood and Bone Marrow","text":"Neutrophils (Granulocyte Family)\nNeutrophil (PMN, Polymorphonuclear Neutrophil):\nSize: 10-15 μm\nNucleus: Segmented (3-5 lobes), condensed chromatin, generally nucleoli\nCytoplasm: Pale pink lilac color, fine, faint granules\nFunction: Phagocytosis killing bacteria fungi (primary defense infection)\nKey Features: Segmented nucleus, small pinkish granules\n\nBand Neutrophil:\nAlso known “stab cell”\nSize: 10-15 μm\nNucleus: Horseshoe-shaped (banded, segmented)\nCytoplasm: neutrophil\nSignificance: Immature neutrophil; increased numbers indicate “left shift,” often seen infection\nKey Features: Banded nucleus, similar neutrophil\n\nMetamyelocyte:\nSize: 10-18 μm\nNucleus: Kidney bean-shaped (indented), coarser chromatin band\nCytoplasm: Pale blue pink, many granules\nSignificance: Less mature neutrophil precursor band\nKey Features: Indented nucleus, segmented like neutrophil\n\nMyelocyte:\nSize: 12-20 μm\nNucleus: Round oval, eccentric (-center), coarser chromatin, may visible nucleoli\nCytoplasm: abundant promyelocyte, distinct granules\nSignificance: Immature neutrophil precursor\nKey Features: cytoplasm distinct granules compared immature precursors\n\nPromyelocyte:\nSize: 14-24 μm\nNucleus: Round oval, prominent nucleoli\nCytoplasm: Basophilic, many large, azurophilic (purple) primary granules\nSignificance: Immature neutrophil precursor\nKey Features: Large size, prominent nucleoli, many large granules\n\nMyeloblast:\nSize: 14-20 μm\nNucleus: Round oval, fine chromatin, prominent nucleoli\nCytoplasm: Scant, basophilic, granules\nSignificance: immature granulocyte precursor; increased numbers suggest acute myeloid leukemia (AML)\nKey Features: Immature chromatin, prominent nucleoli, lack abundant granules\n\nNeutrophils (Granulocyte Family)Neutrophil (PMN, Polymorphonuclear Neutrophil):\nSize: 10-15 μm\nNucleus: Segmented (3-5 lobes), condensed chromatin, generally nucleoli\nCytoplasm: Pale pink lilac color, fine, faint granules\nFunction: Phagocytosis killing bacteria fungi (primary defense infection)\nKey Features: Segmented nucleus, small pinkish granules\nSize: 10-15 μmNucleus: Segmented (3-5 lobes), condensed chromatin, generally nucleoliCytoplasm: Pale pink lilac color, fine, faint granulesFunction: Phagocytosis killing bacteria fungi (primary defense infection)Key Features: Segmented nucleus, small pinkish granulesBand Neutrophil:\nAlso known “stab cell”\nSize: 10-15 μm\nNucleus: Horseshoe-shaped (banded, segmented)\nCytoplasm: neutrophil\nSignificance: Immature neutrophil; increased numbers indicate “left shift,” often seen infection\nKey Features: Banded nucleus, similar neutrophil\nAlso known “stab cell”Size: 10-15 μmNucleus: Horseshoe-shaped (banded, segmented)Cytoplasm: neutrophilSignificance: Immature neutrophil; increased numbers indicate “left shift,” often seen infectionKey Features: Banded nucleus, similar neutrophilMetamyelocyte:\nSize: 10-18 μm\nNucleus: Kidney bean-shaped (indented), coarser chromatin band\nCytoplasm: Pale blue pink, many granules\nSignificance: Less mature neutrophil precursor band\nKey Features: Indented nucleus, segmented like neutrophil\nSize: 10-18 μmNucleus: Kidney bean-shaped (indented), coarser chromatin bandCytoplasm: Pale blue pink, many granulesSignificance: Less mature neutrophil precursor bandKey Features: Indented nucleus, segmented like neutrophilMyelocyte:\nSize: 12-20 μm\nNucleus: Round oval, eccentric (-center), coarser chromatin, may visible nucleoli\nCytoplasm: abundant promyelocyte, distinct granules\nSignificance: Immature neutrophil precursor\nKey Features: cytoplasm distinct granules compared immature precursors\nSize: 12-20 μmNucleus: Round oval, eccentric (-center), coarser chromatin, may visible nucleoliCytoplasm: abundant promyelocyte, distinct granulesSignificance: Immature neutrophil precursorKey Features: cytoplasm distinct granules compared immature precursorsPromyelocyte:\nSize: 14-24 μm\nNucleus: Round oval, prominent nucleoli\nCytoplasm: Basophilic, many large, azurophilic (purple) primary granules\nSignificance: Immature neutrophil precursor\nKey Features: Large size, prominent nucleoli, many large granules\nSize: 14-24 μmNucleus: Round oval, prominent nucleoliCytoplasm: Basophilic, many large, azurophilic (purple) primary granulesSignificance: Immature neutrophil precursorKey Features: Large size, prominent nucleoli, many large granulesMyeloblast:\nSize: 14-20 μm\nNucleus: Round oval, fine chromatin, prominent nucleoli\nCytoplasm: Scant, basophilic, granules\nSignificance: immature granulocyte precursor; increased numbers suggest acute myeloid leukemia (AML)\nKey Features: Immature chromatin, prominent nucleoli, lack abundant granules\nSize: 14-20 μmNucleus: Round oval, fine chromatin, prominent nucleoliCytoplasm: Scant, basophilic, granulesSignificance: immature granulocyte precursor; increased numbers suggest acute myeloid leukemia (AML)Key Features: Immature chromatin, prominent nucleoli, lack abundant granulesEosinophils (Granulocyte Family)\nEosinophil:\nSize: 12-17 μm\nNucleus: Usually bilobed (2 lobes)\nCytoplasm: Packed large, uniform, refractile granules stain bright orange-red eosin dye\nFunction: Defense parasites, allergic reactions\nKey Features: Bilobed nucleus, large orange-red granules\n\nEosinophils (Granulocyte Family)Eosinophil:\nSize: 12-17 μm\nNucleus: Usually bilobed (2 lobes)\nCytoplasm: Packed large, uniform, refractile granules stain bright orange-red eosin dye\nFunction: Defense parasites, allergic reactions\nKey Features: Bilobed nucleus, large orange-red granules\nSize: 12-17 μmNucleus: Usually bilobed (2 lobes)Cytoplasm: Packed large, uniform, refractile granules stain bright orange-red eosin dyeFunction: Defense parasites, allergic reactionsKey Features: Bilobed nucleus, large orange-red granulesBasophils (Granulocyte Family)\nBasophil:\nSize: 10-14 μm\nNucleus: Lobulated, often obscured granules\nCytoplasm: Packed large, irregular granules stain dark blue purple basic dyes\nFunction: Release histamine mediators involved allergic inflammatory responses\nKey Features: Dark blue/purple granules obscuring nucleus\n\nBasophils (Granulocyte Family)Basophil:\nSize: 10-14 μm\nNucleus: Lobulated, often obscured granules\nCytoplasm: Packed large, irregular granules stain dark blue purple basic dyes\nFunction: Release histamine mediators involved allergic inflammatory responses\nKey Features: Dark blue/purple granules obscuring nucleus\nSize: 10-14 μmNucleus: Lobulated, often obscured granulesCytoplasm: Packed large, irregular granules stain dark blue purple basic dyesFunction: Release histamine mediators involved allergic inflammatory responsesKey Features: Dark blue/purple granules obscuring nucleusMonocytes\nMonocyte:\nSize: 12-20 μm (largest normal WBCs)\nNucleus: Kidney-shaped, horseshoe-shaped, convoluted; lacy, less condensed chromatin; may nucleoli\nCytoplasm: Gray-blue, abundant, fine granules vacuoles (“ground glass” appearance)\nFunction: Phagocytosis, antigen presentation, cytokine production\nKey Features: Large size, kidney-shaped nucleus, “ground glass” cytoplasm\n\nMonocytesMonocyte:\nSize: 12-20 μm (largest normal WBCs)\nNucleus: Kidney-shaped, horseshoe-shaped, convoluted; lacy, less condensed chromatin; may nucleoli\nCytoplasm: Gray-blue, abundant, fine granules vacuoles (“ground glass” appearance)\nFunction: Phagocytosis, antigen presentation, cytokine production\nKey Features: Large size, kidney-shaped nucleus, “ground glass” cytoplasm\nSize: 12-20 μm (largest normal WBCs)Nucleus: Kidney-shaped, horseshoe-shaped, convoluted; lacy, less condensed chromatin; may nucleoliCytoplasm: Gray-blue, abundant, fine granules vacuoles (“ground glass” appearance)Function: Phagocytosis, antigen presentation, cytokine productionKey Features: Large size, kidney-shaped nucleus, “ground glass” cytoplasmLymphocytes\nSmall Lymphocyte:\nSize: 7-10 μm (similar RBC size)\nNucleus: Round slightly indented, dense darkly stained chromatin, usually nucleoli\nCytoplasm: Scant, light blue\nFunction: Involved adaptive immunity (T cells B cells)\nKey Features: High N:C ratio, round nucleus, scant cytoplasm\n\nLarge Lymphocyte:\nSize: 12-16 μm (larger RBCs)\nNucleus: Round slightly indented, may open chromatin\nCytoplasm: abundant small lymphocytes, may contain granules\nFunction: Can include activated T cells, B cells, NK cells\nKey Features: cytoplasm small lymphocytes, still high N:C ratio\n\nReactive (Atypical) Lymphocyte:\nSize: Variable, often larger normal lymphocytes\nNucleus: Variable shape (may indented, folded, irregular), less condensed chromatin, may prominent nucleoli\nCytoplasm: Abundant, may basophilic (dark blue) vacuolated, may indent around RBCs\nFunction: Lymphocytes responding antigen (e.g., viral infection)\nKey Features: Abundant, often dark-staining cytoplasm, irregular nucleus\n\nPlasma Cell:\nSize: 10-20 μm\nNucleus: Eccentric (-center), round, “clock-face” “cartwheel” chromatin pattern\nCytoplasm: Deeply basophilic, often perinuclear halo (area near nucleus less stained)\nFunction: Antibody production\nKey Features: Eccentric nucleus, “clock-face” chromatin, deeply basophilic cytoplasm\n\nLymphocytesSmall Lymphocyte:\nSize: 7-10 μm (similar RBC size)\nNucleus: Round slightly indented, dense darkly stained chromatin, usually nucleoli\nCytoplasm: Scant, light blue\nFunction: Involved adaptive immunity (T cells B cells)\nKey Features: High N:C ratio, round nucleus, scant cytoplasm\nSize: 7-10 μm (similar RBC size)Nucleus: Round slightly indented, dense darkly stained chromatin, usually nucleoliCytoplasm: Scant, light blueFunction: Involved adaptive immunity (T cells B cells)Key Features: High N:C ratio, round nucleus, scant cytoplasmLarge Lymphocyte:\nSize: 12-16 μm (larger RBCs)\nNucleus: Round slightly indented, may open chromatin\nCytoplasm: abundant small lymphocytes, may contain granules\nFunction: Can include activated T cells, B cells, NK cells\nKey Features: cytoplasm small lymphocytes, still high N:C ratio\nSize: 12-16 μm (larger RBCs)Nucleus: Round slightly indented, may open chromatinCytoplasm: abundant small lymphocytes, may contain granulesFunction: Can include activated T cells, B cells, NK cellsKey Features: cytoplasm small lymphocytes, still high N:C ratioReactive (Atypical) Lymphocyte:\nSize: Variable, often larger normal lymphocytes\nNucleus: Variable shape (may indented, folded, irregular), less condensed chromatin, may prominent nucleoli\nCytoplasm: Abundant, may basophilic (dark blue) vacuolated, may indent around RBCs\nFunction: Lymphocytes responding antigen (e.g., viral infection)\nKey Features: Abundant, often dark-staining cytoplasm, irregular nucleus\nSize: Variable, often larger normal lymphocytesNucleus: Variable shape (may indented, folded, irregular), less condensed chromatin, may prominent nucleoliCytoplasm: Abundant, may basophilic (dark blue) vacuolated, may indent around RBCsFunction: Lymphocytes responding antigen (e.g., viral infection)Key Features: Abundant, often dark-staining cytoplasm, irregular nucleusPlasma Cell:\nSize: 10-20 μm\nNucleus: Eccentric (-center), round, “clock-face” “cartwheel” chromatin pattern\nCytoplasm: Deeply basophilic, often perinuclear halo (area near nucleus less stained)\nFunction: Antibody production\nKey Features: Eccentric nucleus, “clock-face” chromatin, deeply basophilic cytoplasm\nSize: 10-20 μmNucleus: Eccentric (-center), round, “clock-face” “cartwheel” chromatin patternCytoplasm: Deeply basophilic, often perinuclear halo (area near nucleus less stained)Function: Antibody productionKey Features: Eccentric nucleus, “clock-face” chromatin, deeply basophilic cytoplasmAdditional Cells (Less Common)\nBlasts:\nGeneral Features:\nLarge size\nHigh N:C ratio\nFine, dispersed chromatin\nProminent nucleoli\nMay scant cytoplasm\n\nMyeloblast:\nGranules may present\nMay Auer rods (rod-shaped inclusions) - Pathognomonic AML (always present)\nPositive myeloperoxidase (MPO) stain\n\nLymphoblast:\nUsually lack granules Auer rods\nNegative MPO stain\n\n\nNucleated Red Blood Cells (nRBCs):\nAlso known erythroblasts\nImmature RBCs nucleus\nNormally found bone marrow, can appear peripheral blood certain conditions\nStages nRBCs:\nPronormoblast (Proerythroblast)\nBasophilic Normoblast\nPolychromatic Normoblast\nOrthochromic Normoblast\n\n\nAdditional Cells (Less Common)Blasts:\nGeneral Features:\nLarge size\nHigh N:C ratio\nFine, dispersed chromatin\nProminent nucleoli\nMay scant cytoplasm\n\nMyeloblast:\nGranules may present\nMay Auer rods (rod-shaped inclusions) - Pathognomonic AML (always present)\nPositive myeloperoxidase (MPO) stain\n\nLymphoblast:\nUsually lack granules Auer rods\nNegative MPO stain\n\nGeneral Features:\nLarge size\nHigh N:C ratio\nFine, dispersed chromatin\nProminent nucleoli\nMay scant cytoplasm\nLarge sizeHigh N:C ratioFine, dispersed chromatinProminent nucleoliMay scant cytoplasmMyeloblast:\nGranules may present\nMay Auer rods (rod-shaped inclusions) - Pathognomonic AML (always present)\nPositive myeloperoxidase (MPO) stain\nGranules may presentMay Auer rods (rod-shaped inclusions) - Pathognomonic AML (always present)Positive myeloperoxidase (MPO) stainLymphoblast:\nUsually lack granules Auer rods\nNegative MPO stain\nUsually lack granules Auer rodsNegative MPO stainNucleated Red Blood Cells (nRBCs):\nAlso known erythroblasts\nImmature RBCs nucleus\nNormally found bone marrow, can appear peripheral blood certain conditions\nStages nRBCs:\nPronormoblast (Proerythroblast)\nBasophilic Normoblast\nPolychromatic Normoblast\nOrthochromic Normoblast\n\nAlso known erythroblastsImmature RBCs nucleusNormally found bone marrow, can appear peripheral blood certain conditionsStages nRBCs:\nPronormoblast (Proerythroblast)\nBasophilic Normoblast\nPolychromatic Normoblast\nOrthochromic Normoblast\nPronormoblast (Proerythroblast)Basophilic NormoblastPolychromatic NormoblastOrthochromic Normoblast","code":""},{"path":"morphologies.html","id":"blood","chapter":"Morphologies","heading":"Blood","text":"Normal Red Blood Cells\nNormocytes:\nDescription: Normal-sized RBCs\nSize: Approximately 6-8 μm diameter (roughly size lymphocyte nucleus)\nShape: Biconcave disc (round central pallor)\nColor: Pink orange-red central pallor occupies 1/3 cell diameter\nClinical Significance: predominant cell type healthy individuals\n\nNormal Red Blood CellsNormocytes:\nDescription: Normal-sized RBCs\nSize: Approximately 6-8 μm diameter (roughly size lymphocyte nucleus)\nShape: Biconcave disc (round central pallor)\nColor: Pink orange-red central pallor occupies 1/3 cell diameter\nClinical Significance: predominant cell type healthy individuals\nDescription: Normal-sized RBCsSize: Approximately 6-8 μm diameter (roughly size lymphocyte nucleus)Shape: Biconcave disc (round central pallor)Color: Pink orange-red central pallor occupies 1/3 cell diameterClinical Significance: predominant cell type healthy individualsAbnormal Red Blood Cells (Poikilocytes)\nAnisocytosis = General term variation RBC size\nMicrocytes:\nDescription: Small RBCs\nSize: <6 μm diameter (MCV <80 fL)\nAssociated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia, anemia chronic disease\n\nMacrocytes:\nDescription: Large RBCs\nSize: >9 μm diameter (MCV >100 fL)\nShape: Round (oval, unless megaloblastic)\nAssociated Conditions: Vitamin B12 deficiency, folate deficiency, alcoholism, liver disease, hypothyroidism, myelodysplastic syndromes (MDS), reticulocytosis\n\n\nHypochromia:\nDescription: RBCs decreased hemoglobin content\nAppearance: Pale increased central pallor (>1/3 cell diameter)\nAssociated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia\n\nPolychromasia:\nDescription: RBCs bluish tint due residual RNA\nAppearance: Larger mature RBCs, lack central pallor, stain blue-gray Wright stain\nSignificance: Indicates increased erythropoiesis (reticulocytes)\nAssociated Conditions: Hemolytic anemia, acute blood loss, response therapy\n\nSpherocytes:\nDescription: Small, spherical RBCs central pallor\nAppearance: Small, round, intensely stained (lack central pallor)\nAssociated Conditions: Hereditary spherocytosis, autoimmune hemolytic anemia\n\nElliptocytes (Ovalocytes):\nDescription: Elongated oval-shaped RBCs\nAppearance: Elliptical oval shape\nAssociated Conditions: Hereditary elliptocytosis, iron deficiency anemia, thalassemia\n\nTarget Cells (Codocytes):\nDescription: RBCs bullseye appearance\nAppearance: Central area hemoglobin surrounded clear ring outer ring hemoglobin\nAssociated Conditions: Liver disease, thalassemia, hemoglobinopathies (e.g., HbC disease), iron deficiency anemia, post-splenectomy\n\nSickle Cells (Drepanocytes):\nDescription: Crescent-shaped sickle-shaped RBCs\nAppearance: Elongated, crescent sickle shape\nAssociated Conditions: Sickle cell anemia (HbSS), sickle cell trait (HbAS)\n\nSchistocytes (Fragmented Cells):\nDescription: Fragments RBCs irregular shapes pointed ends\nAppearance: Small, irregularly shaped fragments\nAssociated Conditions: Microangiopathic hemolytic anemia (MAHA) - thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), mechanical heart valves\n\nAcanthocytes (Spur Cells):\nDescription: RBCs irregularly spaced, thorny projections\nAppearance: Irregular, spiky projections varying length\nAssociated Conditions: Liver disease, abetalipoproteinemia\n\nEchinocytes (Burr Cells):\nDescription: RBCs evenly spaced, blunt projections\nAppearance: Small, uniform, spiky projections\nAssociated Conditions: Uremia (kidney failure), pyruvate kinase deficiency, artifact (crenation)\n\nTeardrop Cells (Dacrocytes):\nDescription: RBCs shaped like teardrops pears\nAppearance: One end rounded, end elongated pointed\nAssociated Conditions: Primary myelofibrosis, thalassemia, myelodysplastic syndromes, extramedullary hematopoiesis\n\nStomatocytes:\nDescription: RBCs slit-like area central pallor (mouth-like appearance)\nAppearance: Slit-like central pallor\nAssociated Conditions: Hereditary stomatocytosis, alcoholism, liver disease\n\nAgglutination\nDefinition: clumping aggregation red blood cells due antibody- complement-mediated interactions\nAppearance:\nIrregular Clumps: RBCs form irregular, three-dimensional clumps clusters\nGrape-like Clusters: Agglutinates often appear grape-like clusters RBCs\nRandom Distribution: clumps randomly distributed throughout smear\nMacroscopic Agglutination: cases, agglutination may visible naked eye clumping EDTA tube\n\nAssociated Conditions:\nCold Agglutinin Disease (Cold AIHA): IgM autoantibodies bind RBCs low temperatures\nAutoimmune Hemolytic Anemia (AIHA): IgG IgM autoantibodies RBCs\nTransfusion Reactions: Antibodies donor RBC antigens\nParoxysmal Cold Hemoglobinuria (PCH): Donath-Landsteiner antibody (IgG) binds RBCs low temperatures\n\n\nRouleaux Formation\nDefinition: stacking red blood cells linear arrangement, resembling stacks coins poker chips\nAppearance:*\nStacks Coins: RBCs arranged linear stacks, resembling stacks coins poker chips\nEven Distribution: stacks relatively uniform evenly distributed\nReversible: Rouleaux formation reversible; RBCs can easily dispersed adding saline\n\nAssociated Conditions:\nMultiple Myeloma: Increased levels monoclonal immunoglobulins (paraproteins)\nWaldenström Macroglobulinemia: Increased levels IgM\nChronic Inflammatory Conditions: Increased fibrinogen acute phase reactants\nHypergammaglobulinemia: Increased levels immunoglobulins\nArtifact: Can artifact counting area smear thick\n\n\nBasophilic Stippling:\nDescription: Presence small, dark-blue granules scattered throughout RBC cytoplasm\nComposition: Ribosomal RNA precipitates\nAssociated Conditions: Thalassemia, lead poisoning, myelodysplastic syndromes (MDS)\n\nHowell-Jolly Bodies:\nDescription: Round, dark-purple nuclear remnants RBCs\nComposition: DNA fragments\nAssociated Conditions: Splenectomy splenic dysfunction, hemolytic anemia, megaloblastic anemia\n\nPappenheimer Bodies:\nDescription: Small, irregular, iron-containing granules RBCs\nComposition: Iron (non-heme iron)\nRequire Prussian blue stain visualize\nAssociated Conditions: Sideroblastic anemia, post-splenectomy, myelodysplastic syndromes\n\nHeinz Bodies:\nDescription: Inclusions composed denatured hemoglobin\nRequire supravital stain (e.g., crystal violet brilliant cresyl blue) visualize\nAssociated Conditions: G6PD deficiency, unstable hemoglobin variants\n\nAbnormal Red Blood Cells (Poikilocytes)Anisocytosis = General term variation RBC size\nMicrocytes:\nDescription: Small RBCs\nSize: <6 μm diameter (MCV <80 fL)\nAssociated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia, anemia chronic disease\n\nMacrocytes:\nDescription: Large RBCs\nSize: >9 μm diameter (MCV >100 fL)\nShape: Round (oval, unless megaloblastic)\nAssociated Conditions: Vitamin B12 deficiency, folate deficiency, alcoholism, liver disease, hypothyroidism, myelodysplastic syndromes (MDS), reticulocytosis\n\nAnisocytosis = General term variation RBC sizeMicrocytes:\nDescription: Small RBCs\nSize: <6 μm diameter (MCV <80 fL)\nAssociated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia, anemia chronic disease\nDescription: Small RBCsSize: <6 μm diameter (MCV <80 fL)Associated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia, anemia chronic diseaseMacrocytes:\nDescription: Large RBCs\nSize: >9 μm diameter (MCV >100 fL)\nShape: Round (oval, unless megaloblastic)\nAssociated Conditions: Vitamin B12 deficiency, folate deficiency, alcoholism, liver disease, hypothyroidism, myelodysplastic syndromes (MDS), reticulocytosis\nDescription: Large RBCsSize: >9 μm diameter (MCV >100 fL)Shape: Round (oval, unless megaloblastic)Associated Conditions: Vitamin B12 deficiency, folate deficiency, alcoholism, liver disease, hypothyroidism, myelodysplastic syndromes (MDS), reticulocytosisHypochromia:\nDescription: RBCs decreased hemoglobin content\nAppearance: Pale increased central pallor (>1/3 cell diameter)\nAssociated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemia\nHypochromia:Description: RBCs decreased hemoglobin contentAppearance: Pale increased central pallor (>1/3 cell diameter)Associated Conditions: Iron deficiency anemia, thalassemia, sideroblastic anemiaPolychromasia:\nDescription: RBCs bluish tint due residual RNA\nAppearance: Larger mature RBCs, lack central pallor, stain blue-gray Wright stain\nSignificance: Indicates increased erythropoiesis (reticulocytes)\nAssociated Conditions: Hemolytic anemia, acute blood loss, response therapy\nPolychromasia:Description: RBCs bluish tint due residual RNAAppearance: Larger mature RBCs, lack central pallor, stain blue-gray Wright stainSignificance: Indicates increased erythropoiesis (reticulocytes)Associated Conditions: Hemolytic anemia, acute blood loss, response therapySpherocytes:\nDescription: Small, spherical RBCs central pallor\nAppearance: Small, round, intensely stained (lack central pallor)\nAssociated Conditions: Hereditary spherocytosis, autoimmune hemolytic anemia\nSpherocytes:Description: Small, spherical RBCs central pallorAppearance: Small, round, intensely stained (lack central pallor)Associated Conditions: Hereditary spherocytosis, autoimmune hemolytic anemiaElliptocytes (Ovalocytes):\nDescription: Elongated oval-shaped RBCs\nAppearance: Elliptical oval shape\nAssociated Conditions: Hereditary elliptocytosis, iron deficiency anemia, thalassemia\nElliptocytes (Ovalocytes):Description: Elongated oval-shaped RBCsAppearance: Elliptical oval shapeAssociated Conditions: Hereditary elliptocytosis, iron deficiency anemia, thalassemiaTarget Cells (Codocytes):\nDescription: RBCs bullseye appearance\nAppearance: Central area hemoglobin surrounded clear ring outer ring hemoglobin\nAssociated Conditions: Liver disease, thalassemia, hemoglobinopathies (e.g., HbC disease), iron deficiency anemia, post-splenectomy\nTarget Cells (Codocytes):Description: RBCs bullseye appearanceAppearance: Central area hemoglobin surrounded clear ring outer ring hemoglobinAssociated Conditions: Liver disease, thalassemia, hemoglobinopathies (e.g., HbC disease), iron deficiency anemia, post-splenectomySickle Cells (Drepanocytes):\nDescription: Crescent-shaped sickle-shaped RBCs\nAppearance: Elongated, crescent sickle shape\nAssociated Conditions: Sickle cell anemia (HbSS), sickle cell trait (HbAS)\nSickle Cells (Drepanocytes):Description: Crescent-shaped sickle-shaped RBCsAppearance: Elongated, crescent sickle shapeAssociated Conditions: Sickle cell anemia (HbSS), sickle cell trait (HbAS)Schistocytes (Fragmented Cells):\nDescription: Fragments RBCs irregular shapes pointed ends\nAppearance: Small, irregularly shaped fragments\nAssociated Conditions: Microangiopathic hemolytic anemia (MAHA) - thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), mechanical heart valves\nSchistocytes (Fragmented Cells):Description: Fragments RBCs irregular shapes pointed endsAppearance: Small, irregularly shaped fragmentsAssociated Conditions: Microangiopathic hemolytic anemia (MAHA) - thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), mechanical heart valvesAcanthocytes (Spur Cells):\nDescription: RBCs irregularly spaced, thorny projections\nAppearance: Irregular, spiky projections varying length\nAssociated Conditions: Liver disease, abetalipoproteinemia\nAcanthocytes (Spur Cells):Description: RBCs irregularly spaced, thorny projectionsAppearance: Irregular, spiky projections varying lengthAssociated Conditions: Liver disease, abetalipoproteinemiaEchinocytes (Burr Cells):\nDescription: RBCs evenly spaced, blunt projections\nAppearance: Small, uniform, spiky projections\nAssociated Conditions: Uremia (kidney failure), pyruvate kinase deficiency, artifact (crenation)\nEchinocytes (Burr Cells):Description: RBCs evenly spaced, blunt projectionsAppearance: Small, uniform, spiky projectionsAssociated Conditions: Uremia (kidney failure), pyruvate kinase deficiency, artifact (crenation)Teardrop Cells (Dacrocytes):\nDescription: RBCs shaped like teardrops pears\nAppearance: One end rounded, end elongated pointed\nAssociated Conditions: Primary myelofibrosis, thalassemia, myelodysplastic syndromes, extramedullary hematopoiesis\nTeardrop Cells (Dacrocytes):Description: RBCs shaped like teardrops pearsAppearance: One end rounded, end elongated pointedAssociated Conditions: Primary myelofibrosis, thalassemia, myelodysplastic syndromes, extramedullary hematopoiesisStomatocytes:\nDescription: RBCs slit-like area central pallor (mouth-like appearance)\nAppearance: Slit-like central pallor\nAssociated Conditions: Hereditary stomatocytosis, alcoholism, liver disease\nStomatocytes:Description: RBCs slit-like area central pallor (mouth-like appearance)Appearance: Slit-like central pallorAssociated Conditions: Hereditary stomatocytosis, alcoholism, liver diseaseAgglutination\nDefinition: clumping aggregation red blood cells due antibody- complement-mediated interactions\nAppearance:\nIrregular Clumps: RBCs form irregular, three-dimensional clumps clusters\nGrape-like Clusters: Agglutinates often appear grape-like clusters RBCs\nRandom Distribution: clumps randomly distributed throughout smear\nMacroscopic Agglutination: cases, agglutination may visible naked eye clumping EDTA tube\n\nAssociated Conditions:\nCold Agglutinin Disease (Cold AIHA): IgM autoantibodies bind RBCs low temperatures\nAutoimmune Hemolytic Anemia (AIHA): IgG IgM autoantibodies RBCs\nTransfusion Reactions: Antibodies donor RBC antigens\nParoxysmal Cold Hemoglobinuria (PCH): Donath-Landsteiner antibody (IgG) binds RBCs low temperatures\n\nAgglutinationDefinition: clumping aggregation red blood cells due antibody- complement-mediated interactionsAppearance:\nIrregular Clumps: RBCs form irregular, three-dimensional clumps clusters\nGrape-like Clusters: Agglutinates often appear grape-like clusters RBCs\nRandom Distribution: clumps randomly distributed throughout smear\nMacroscopic Agglutination: cases, agglutination may visible naked eye clumping EDTA tube\nIrregular Clumps: RBCs form irregular, three-dimensional clumps clustersGrape-like Clusters: Agglutinates often appear grape-like clusters RBCsRandom Distribution: clumps randomly distributed throughout smearMacroscopic Agglutination: cases, agglutination may visible naked eye clumping EDTA tubeAssociated Conditions:\nCold Agglutinin Disease (Cold AIHA): IgM autoantibodies bind RBCs low temperatures\nAutoimmune Hemolytic Anemia (AIHA): IgG IgM autoantibodies RBCs\nTransfusion Reactions: Antibodies donor RBC antigens\nParoxysmal Cold Hemoglobinuria (PCH): Donath-Landsteiner antibody (IgG) binds RBCs low temperatures\nCold Agglutinin Disease (Cold AIHA): IgM autoantibodies bind RBCs low temperaturesAutoimmune Hemolytic Anemia (AIHA): IgG IgM autoantibodies RBCsTransfusion Reactions: Antibodies donor RBC antigensParoxysmal Cold Hemoglobinuria (PCH): Donath-Landsteiner antibody (IgG) binds RBCs low temperaturesRouleaux Formation\nDefinition: stacking red blood cells linear arrangement, resembling stacks coins poker chips\nAppearance:*\nStacks Coins: RBCs arranged linear stacks, resembling stacks coins poker chips\nEven Distribution: stacks relatively uniform evenly distributed\nReversible: Rouleaux formation reversible; RBCs can easily dispersed adding saline\n\nAssociated Conditions:\nMultiple Myeloma: Increased levels monoclonal immunoglobulins (paraproteins)\nWaldenström Macroglobulinemia: Increased levels IgM\nChronic Inflammatory Conditions: Increased fibrinogen acute phase reactants\nHypergammaglobulinemia: Increased levels immunoglobulins\nArtifact: Can artifact counting area smear thick\n\nRouleaux FormationDefinition: stacking red blood cells linear arrangement, resembling stacks coins poker chipsAppearance:*\nStacks Coins: RBCs arranged linear stacks, resembling stacks coins poker chips\nEven Distribution: stacks relatively uniform evenly distributed\nReversible: Rouleaux formation reversible; RBCs can easily dispersed adding saline\nStacks Coins: RBCs arranged linear stacks, resembling stacks coins poker chipsEven Distribution: stacks relatively uniform evenly distributedReversible: Rouleaux formation reversible; RBCs can easily dispersed adding salineAssociated Conditions:\nMultiple Myeloma: Increased levels monoclonal immunoglobulins (paraproteins)\nWaldenström Macroglobulinemia: Increased levels IgM\nChronic Inflammatory Conditions: Increased fibrinogen acute phase reactants\nHypergammaglobulinemia: Increased levels immunoglobulins\nArtifact: Can artifact counting area smear thick\nMultiple Myeloma: Increased levels monoclonal immunoglobulins (paraproteins)Waldenström Macroglobulinemia: Increased levels IgMChronic Inflammatory Conditions: Increased fibrinogen acute phase reactantsHypergammaglobulinemia: Increased levels immunoglobulinsArtifact: Can artifact counting area smear thickBasophilic Stippling:\nDescription: Presence small, dark-blue granules scattered throughout RBC cytoplasm\nComposition: Ribosomal RNA precipitates\nAssociated Conditions: Thalassemia, lead poisoning, myelodysplastic syndromes (MDS)\nBasophilic Stippling:Description: Presence small, dark-blue granules scattered throughout RBC cytoplasmComposition: Ribosomal RNA precipitatesAssociated Conditions: Thalassemia, lead poisoning, myelodysplastic syndromes (MDS)Howell-Jolly Bodies:\nDescription: Round, dark-purple nuclear remnants RBCs\nComposition: DNA fragments\nAssociated Conditions: Splenectomy splenic dysfunction, hemolytic anemia, megaloblastic anemia\nHowell-Jolly Bodies:Description: Round, dark-purple nuclear remnants RBCsComposition: DNA fragmentsAssociated Conditions: Splenectomy splenic dysfunction, hemolytic anemia, megaloblastic anemiaPappenheimer Bodies:\nDescription: Small, irregular, iron-containing granules RBCs\nComposition: Iron (non-heme iron)\nRequire Prussian blue stain visualize\nAssociated Conditions: Sideroblastic anemia, post-splenectomy, myelodysplastic syndromes\nPappenheimer Bodies:Description: Small, irregular, iron-containing granules RBCsComposition: Iron (non-heme iron)Require Prussian blue stain visualizeAssociated Conditions: Sideroblastic anemia, post-splenectomy, myelodysplastic syndromesHeinz Bodies:\nDescription: Inclusions composed denatured hemoglobin\nRequire supravital stain (e.g., crystal violet brilliant cresyl blue) visualize\nAssociated Conditions: G6PD deficiency, unstable hemoglobin variants\nHeinz Bodies:Description: Inclusions composed denatured hemoglobinRequire supravital stain (e.g., crystal violet brilliant cresyl blue) visualizeAssociated Conditions: G6PD deficiency, unstable hemoglobin variants","code":""},{"path":"morphologies.html","id":"bone-marrow","chapter":"Morphologies","heading":"Bone Marrow","text":"Hematopoietic Stem Cells Progenitor Cells (Blasts)\nHematopoietic Stem Cells (HSCs):\nDescription: Rare, self-renewing cells give rise blood cell lineages\nMorphology: Difficult identify morphologically\nIdentification: Best identified immunophenotyping using flow cytometry (e.g., CD34+, CD38-)\nSignificance: source blood cells; mutations HSCs can lead hematologic malignancies\n\nMultipotent Progenitors (MPPs):\nDescription: Cells derived HSCs lost self-renewal capacity can still differentiate multiple lineages\nMorphology: Difficult distinguish morphologically HSCs\nIdentification: Identified immunophenotyping\n\nCommon Myeloid Progenitor (CMP):\nDescription: progenitor cell gives rise granulocytes, monocytes, macrophages, megakaryocytes\nMorphology: Difficult distinguish morphologically progenitor cells\nIdentification: Identified immunophenotyping\n\nCommon Lymphoid Progenitor (CLP):\nDescription: progenitor cell gives rise lymphocytes (T cells, B cells, NK cells)\nMorphology: Difficult distinguish morphologically progenitor cells\nIdentification: Identified immunophenotyping\n\nHematopoietic Stem Cells Progenitor Cells (Blasts)Hematopoietic Stem Cells (HSCs):\nDescription: Rare, self-renewing cells give rise blood cell lineages\nMorphology: Difficult identify morphologically\nIdentification: Best identified immunophenotyping using flow cytometry (e.g., CD34+, CD38-)\nSignificance: source blood cells; mutations HSCs can lead hematologic malignancies\nDescription: Rare, self-renewing cells give rise blood cell lineagesMorphology: Difficult identify morphologicallyIdentification: Best identified immunophenotyping using flow cytometry (e.g., CD34+, CD38-)Significance: source blood cells; mutations HSCs can lead hematologic malignanciesMultipotent Progenitors (MPPs):\nDescription: Cells derived HSCs lost self-renewal capacity can still differentiate multiple lineages\nMorphology: Difficult distinguish morphologically HSCs\nIdentification: Identified immunophenotyping\nDescription: Cells derived HSCs lost self-renewal capacity can still differentiate multiple lineagesMorphology: Difficult distinguish morphologically HSCsIdentification: Identified immunophenotypingCommon Myeloid Progenitor (CMP):\nDescription: progenitor cell gives rise granulocytes, monocytes, macrophages, megakaryocytes\nMorphology: Difficult distinguish morphologically progenitor cells\nIdentification: Identified immunophenotyping\nDescription: progenitor cell gives rise granulocytes, monocytes, macrophages, megakaryocytesMorphology: Difficult distinguish morphologically progenitor cellsIdentification: Identified immunophenotypingCommon Lymphoid Progenitor (CLP):\nDescription: progenitor cell gives rise lymphocytes (T cells, B cells, NK cells)\nMorphology: Difficult distinguish morphologically progenitor cells\nIdentification: Identified immunophenotyping\nDescription: progenitor cell gives rise lymphocytes (T cells, B cells, NK cells)Morphology: Difficult distinguish morphologically progenitor cellsIdentification: Identified immunophenotypingMyeloid LineageMyeloid LineageThese cells part granulocytic monocytic series\n* Myeloblast:\n* Description: Immature granulocyte precursor\n* Size: 14-20 μm\n* Nucleus: Large, round oval, fine chromatin, 1-5 distinct nucleoli\n* Cytoplasm: Scant moderate amount, deeply basophilic, lacks granules\n* Distinguishing Features:\n* High nucleus--cytoplasm (N:C) ratio\n* Prominent nucleoli\n* Lack granules\n* Clinical Significance: Increased acute myeloid leukemia (AML)Erythroid Lineage\nPronormoblast (Proerythroblast):\nDescription: earliest recognizable erythroid precursor\nSize: 14-20 μm\nNucleus: Large, round, fine chromatin, 1-2 distinct nucleoli\nCytoplasm: Deeply basophilic (due high RNA content)\nDistinguishing Features:\nHigh N:C ratio\nIntense basophilia cytoplasm\n\n\nBasophilic Normoblast:\nDescription: mature pronormoblast\nSize: 12-17 μm\nNucleus: Round, slightly condensed chromatin, nucleoli\nCytoplasm: Intensely basophilic\nDistinguishing Features:\nSmaller size pronormoblast\ncondensed chromatin\n\n\nPolychromatic Normoblast:\nDescription: hemoglobin synthesis increases, cytoplasm becomes less basophilic\nSize: 10-15 μm\nNucleus: Round, condensed chromatin\nCytoplasm: Gray-blue (polychromatic) due presence hemoglobin ribosomes\nDistinguishing Features:\nGray-blue cytoplasm\ncondensed chromatin\n\n\nOrthochromic Normoblast:\nDescription: final nucleated stage erythroid maturation\nSize: 8-10 μm\nNucleus: Small, dense, pyknotic (extruded)\nCytoplasm: Pink (due predominant hemoglobin)\nDistinguishing Features:\nSmall, dense nucleus\nMostly pink cytoplasm\n\n\nReticulocyte:\nAnucleated red blood cell residual RNA, found bone marrow\n\nErythroid LineagePronormoblast (Proerythroblast):\nDescription: earliest recognizable erythroid precursor\nSize: 14-20 μm\nNucleus: Large, round, fine chromatin, 1-2 distinct nucleoli\nCytoplasm: Deeply basophilic (due high RNA content)\nDistinguishing Features:\nHigh N:C ratio\nIntense basophilia cytoplasm\n\nDescription: earliest recognizable erythroid precursorSize: 14-20 μmNucleus: Large, round, fine chromatin, 1-2 distinct nucleoliCytoplasm: Deeply basophilic (due high RNA content)Distinguishing Features:\nHigh N:C ratio\nIntense basophilia cytoplasm\nHigh N:C ratioIntense basophilia cytoplasmBasophilic Normoblast:\nDescription: mature pronormoblast\nSize: 12-17 μm\nNucleus: Round, slightly condensed chromatin, nucleoli\nCytoplasm: Intensely basophilic\nDistinguishing Features:\nSmaller size pronormoblast\ncondensed chromatin\n\nDescription: mature pronormoblastSize: 12-17 μmNucleus: Round, slightly condensed chromatin, nucleoliCytoplasm: Intensely basophilicDistinguishing Features:\nSmaller size pronormoblast\ncondensed chromatin\nSmaller size pronormoblastMore condensed chromatinPolychromatic Normoblast:\nDescription: hemoglobin synthesis increases, cytoplasm becomes less basophilic\nSize: 10-15 μm\nNucleus: Round, condensed chromatin\nCytoplasm: Gray-blue (polychromatic) due presence hemoglobin ribosomes\nDistinguishing Features:\nGray-blue cytoplasm\ncondensed chromatin\n\nDescription: hemoglobin synthesis increases, cytoplasm becomes less basophilicSize: 10-15 μmNucleus: Round, condensed chromatinCytoplasm: Gray-blue (polychromatic) due presence hemoglobin ribosomesDistinguishing Features:\nGray-blue cytoplasm\ncondensed chromatin\nGray-blue cytoplasmMore condensed chromatinOrthochromic Normoblast:\nDescription: final nucleated stage erythroid maturation\nSize: 8-10 μm\nNucleus: Small, dense, pyknotic (extruded)\nCytoplasm: Pink (due predominant hemoglobin)\nDistinguishing Features:\nSmall, dense nucleus\nMostly pink cytoplasm\n\nDescription: final nucleated stage erythroid maturationSize: 8-10 μmNucleus: Small, dense, pyknotic (extruded)Cytoplasm: Pink (due predominant hemoglobin)Distinguishing Features:\nSmall, dense nucleus\nMostly pink cytoplasm\nSmall, dense nucleusMostly pink cytoplasmReticulocyte:\nAnucleated red blood cell residual RNA, found bone marrow\nAnucleated red blood cell residual RNA, found bone marrowKey Considerations\nMast Cells: Although present bone marrow, mast cells technically tissue cells part hematopoietic lineages. granulated cells important allergic responses.\nPlasma Cells: Although derived lymphocytes, plasma cells can also reside bone marrow. distinct eccentric nuclei deeply basophilic cytoplasm.\nKey ConsiderationsMast Cells: Although present bone marrow, mast cells technically tissue cells part hematopoietic lineages. granulated cells important allergic responses.Plasma Cells: Although derived lymphocytes, plasma cells can also reside bone marrow. distinct eccentric nuclei deeply basophilic cytoplasm.","code":"*   **Promyelocyte:**\n    *   Description: More mature than myeloblast\n    *   Size: 15-25 μm\n    *   Nucleus: Round to oval, slightly coarser chromatin than myeloblast, 1-3 nucleoli\n    *   Cytoplasm: More abundant than myeloblast, basophilic, contains primary (azurophilic) granules\n    *   Distinguishing Features:\n        *   Presence of primary (azurophilic) granules\n        *   Nucleoli may still be visible\n    *   Clinical Significance: Increased in AML, especially acute promyelocytic leukemia (APL)\n\n*   **Myelocyte:**\n    *   Description: Intermediate stage in granulocyte maturation\n    *   Size: 12-18 μm\n    *   Nucleus: Round and eccentric (off-center), condensed chromatin, nucleoli usually absent\n    *   Cytoplasm: Less basophilic than promyelocyte, contains both primary and secondary (specific) granules\n    *   Distinguishing Features:\n        *   Smaller size than promyelocyte\n        *   Eccentric nucleus\n        *   \"Dawn of neutrophilia\": The cytoplasm appears pinkish due to the development of secondary granules (in neutrophilic myelocytes)\n    *   Types:\n        *   Neutrophilic myelocyte: Produces neutrophilic granules (stain pink or lavender)\n        *   Eosinophilic myelocyte: Produces eosinophilic granules (stain orange-red)\n        *   Basophilic myelocyte: Produces basophilic granules (stain dark blue or purple)\n\n*   **Metamyelocyte:**\n    *   Description: A stage in granulocyte maturation intermediate between myelocyte and band neutrophil\n    *   Size: 10-15 μm\n    *   Nucleus: Indented (kidney bean-shaped), condensed chromatin, no nucleoli\n    *   Cytoplasm: Abundant, contains secondary granules\n    *   Distinguishing Features:\n        *   Indented nucleus\n        *   No nucleoli\n    *   Types:\n        *   Neutrophilic metamyelocyte\n        *   Eosinophilic metamyelocyte\n        *   Basophilic metamyelocyte\n\n*   **Band Neutrophil:**\n    *   Description: An immature neutrophil with a horseshoe-shaped (band-shaped) nucleus\n    *   Size: 10-12 μm\n    *   Nucleus: Band-shaped, condensed chromatin, no nucleoli\n    *   Cytoplasm: Pinkish-lilac, fine granules\n    *   Distinguishing Features:\n        *   Band-shaped nucleus with parallel sides and no segmentation\n        *   Absence of a thin filament connecting the nuclear lobes\n\n*   **Monoblast:**\n    *   Description: Earliest recognizable monocyte precursor\n    *   Size: 12-20 μm\n    *   Nucleus: Large, round to oval, fine chromatin, prominent nucleoli\n    *   Cytoplasm: Abundant, basophilic, lacks granules\n    *   Distinguishing Features:\n        *   High N:C ratio\n        *   Prominent nucleoli\n        *   Lack of granules\n\n*   **Promonocyte:**\n    *   Description: More mature than monoblast\n    *   Size: 14-18 μm\n    *   Nucleus: Large, indented or folded, lacy chromatin, may have nucleoli\n    *   Cytoplasm: Gray-blue, abundant, fine granules\n    *   Distinguishing Features:\n        *   Indented or folded nucleus\n        *   Cytoplasmic granules\n\n*   **Megakaryoblast:**\n    *   Description: Immature megakaryocyte precursor\n    *   Size: 20-50 μm\n    *   Nucleus: Large, single nucleus with multiple lobes, prominent nucleoli\n    *   Cytoplasm: Deeply basophilic, lacks granules\n    *   Distinguishing Features:\n        *   Large size\n        *   Multi-lobated nucleus\n        *   Lacks granules\n\n*   **Promegakaryocyte:**\n    *   Description: More mature than megakaryoblast\n    *   Size: 25-80 μm\n    *   Nucleus: Large, multi-lobated, less distinct nucleoli\n    *   Cytoplasm: More abundant than megakaryoblast, less basophilic, contains some granules\n    *   Distinguishing Features:\n        *   Large size\n        *   Granular cytoplasm\n\n*   **Megakaryocyte:**\n    *   Description: Mature platelet-producing cell\n    *   Size: 30-100 μm (largest cell in the bone marrow)\n    *   Nucleus: Large, multi-lobated, condensed chromatin\n    *   Cytoplasm: Abundant, pinkish-blue, contains numerous granules\n    *   Distinguishing Features:\n        *   Extremely large size\n        *   Multi-lobated nucleus\n        *   Abundant granular cytoplasm\n    *   Function: Produces platelets by shedding portions of its cytoplasm"},{"path":"morphologies.html","id":"body-fluids-1","chapter":"Morphologies","heading":"Body Fluids","text":"Neutrophils:\nMorphology: Similar neutrophils peripheral blood (segmented nucleus, pink-lilac granules)\nSignificance: Increased numbers often indicate bacterial infection inflammation\nDegenerated Neutrophils: older fluids, neutrophils may appear pyknotic (shrunken, dark nucleus) may lysed\n\nNeutrophils:Morphology: Similar neutrophils peripheral blood (segmented nucleus, pink-lilac granules)Significance: Increased numbers often indicate bacterial infection inflammation\nDegenerated Neutrophils: older fluids, neutrophils may appear pyknotic (shrunken, dark nucleus) may lysed\nDegenerated Neutrophils: older fluids, neutrophils may appear pyknotic (shrunken, dark nucleus) may lysedLymphocytes:\nMorphology: Similar lymphocytes peripheral blood (round nucleus, scant cytoplasm)\nSignificance: Increased numbers may suggest viral infection, tuberculosis, fungal infection, chronic inflammation\nReactive Lymphocytes: (Atypical lymphocytes)\nabundant cytoplasm\nBasophilic cytoplasm\nMay nucleoli\n\nLymphocytes:Morphology: Similar lymphocytes peripheral blood (round nucleus, scant cytoplasm)Significance: Increased numbers may suggest viral infection, tuberculosis, fungal infection, chronic inflammationReactive Lymphocytes: (Atypical lymphocytes)\nabundant cytoplasm\nBasophilic cytoplasm\nMay nucleoli\nabundant cytoplasmBasophilic cytoplasmMay nucleoliMonocytes/Macrophages:\nMorphology: Large cells kidney bean-shaped horseshoe-shaped nucleus, abundant gray-blue cytoplasm, vacuoles\nSignificance: Found various inflammatory conditions infections; can also indicate hemorrhage (erythrophagocytosis)\nDistinguishing Features: Cytoplasmic vacuoles /phagocytized material can diagnostic specific processes\nMonocytes/Macrophages:Morphology: Large cells kidney bean-shaped horseshoe-shaped nucleus, abundant gray-blue cytoplasm, vacuolesSignificance: Found various inflammatory conditions infections; can also indicate hemorrhage (erythrophagocytosis)Distinguishing Features: Cytoplasmic vacuoles /phagocytized material can diagnostic specific processesEosinophils:\nMorphology: Similar eosinophils peripheral blood (bilobed nucleus, large, orange-red granules)\nSignificance: Often associated parasitic infections, allergic reactions, hypersensitivity reactions\nEosinophils:Morphology: Similar eosinophils peripheral blood (bilobed nucleus, large, orange-red granules)Significance: Often associated parasitic infections, allergic reactions, hypersensitivity reactionsBasophils:\nMorphology: Similar basophils peripheral blood (irregular, lobulated nucleus obscured dark blue/purple granules)\nSignificance: Less common cell types; may seen allergic reactions certain malignancies\nBasophils:Morphology: Similar basophils peripheral blood (irregular, lobulated nucleus obscured dark blue/purple granules)Significance: Less common cell types; may seen allergic reactions certain malignanciesMesothelial Cells (Serous Fluids - Pleural, Peritoneal, Pericardial):\nMorphology:\nRound oval cells\nEccentric nucleus (-center)\nAbundant cytoplasm (often blue-gray pink)\nMay “skirt” “ruffled border”\nMay multinucleated\n\nSignificance: Normal lining cells serous membranes\nIncreased numbers can indicate inflammation irritation serous membranes\n\nReactive Mesothelial Cells: May prominent nucleoli, increased cytoplasm, mitotic figures\nMesothelial Cells (Serous Fluids - Pleural, Peritoneal, Pericardial):Morphology:\nRound oval cells\nEccentric nucleus (-center)\nAbundant cytoplasm (often blue-gray pink)\nMay “skirt” “ruffled border”\nMay multinucleated\nRound oval cellsEccentric nucleus (-center)Abundant cytoplasm (often blue-gray pink)May “skirt” “ruffled border”May multinucleatedSignificance: Normal lining cells serous membranes\nIncreased numbers can indicate inflammation irritation serous membranes\nIncreased numbers can indicate inflammation irritation serous membranesReactive Mesothelial Cells: May prominent nucleoli, increased cytoplasm, mitotic figuresSynovial Lining Cells (Synovial Fluid):\nMorphology:\nRound oval cells\nEccentric nucleus\nModerate amount cytoplasm\n\nSignificance: Normal cells found synovial fluid\nIncreased numbers may indicate inflammation joint damage\n\nSynovial Lining Cells (Synovial Fluid):Morphology:\nRound oval cells\nEccentric nucleus\nModerate amount cytoplasm\nRound oval cellsEccentric nucleusModerate amount cytoplasmSignificance: Normal cells found synovial fluid\nIncreased numbers may indicate inflammation joint damage\nIncreased numbers may indicate inflammation joint damageAdditional Cells (Less Common)Additional Cells (Less Common)Blast Cells:\nMorphology:\nLarge cells high nuclear--cytoplasmic (N:C) ratio\nFine chromatin\nProminent nucleoli\nMay scant cytoplasm\n\nSignificance: Suggestive leukemia lymphoma involvement body fluid\nClassification: Requires flow cytometry specialized tests determine lineage (myeloid vs. lymphoid)\nBlast Cells:Morphology:\nLarge cells high nuclear--cytoplasmic (N:C) ratio\nFine chromatin\nProminent nucleoli\nMay scant cytoplasm\nLarge cells high nuclear--cytoplasmic (N:C) ratioFine chromatinProminent nucleoliMay scant cytoplasmSignificance: Suggestive leukemia lymphoma involvement body fluidClassification: Requires flow cytometry specialized tests determine lineage (myeloid vs. lymphoid)Malignant Cells (Non-Hematologic):\nMorphology:\nHighly variable, depending type cancer\nMay abnormal nuclear features (e.g., irregular shape, coarse chromatin, prominent nucleoli)\nMay abundant cytoplasm vacuoles inclusions\n\nSignificance: Indicates metastatic cancer body fluid\nOrigin: Usually represent metastatic carcinoma solid tumor\nIdentification: Requires careful cytological evaluation correlation clinical history imaging studies\nMalignant Cells (Non-Hematologic):Morphology:\nHighly variable, depending type cancer\nMay abnormal nuclear features (e.g., irregular shape, coarse chromatin, prominent nucleoli)\nMay abundant cytoplasm vacuoles inclusions\nHighly variable, depending type cancerMay abnormal nuclear features (e.g., irregular shape, coarse chromatin, prominent nucleoli)May abundant cytoplasm vacuoles inclusionsSignificance: Indicates metastatic cancer body fluidOrigin: Usually represent metastatic carcinoma solid tumorIdentification: Requires careful cytological evaluation correlation clinical history imaging studiesEpendymal Cells (Cerebrospinal Fluid - CSF):\nMorphology:\nColumnar cuboidal cells\nRound oval nucleus\nFinely granular cytoplasm\n\nSignificance: Normal cells lining ventricles brain central canal spinal cord\nIncreased numbers may indicate disruption ventricular system\n\nEpendymal Cells (Cerebrospinal Fluid - CSF):Morphology:\nColumnar cuboidal cells\nRound oval nucleus\nFinely granular cytoplasm\nColumnar cuboidal cellsRound oval nucleusFinely granular cytoplasmSignificance: Normal cells lining ventricles brain central canal spinal cord\nIncreased numbers may indicate disruption ventricular system\nIncreased numbers may indicate disruption ventricular systemHemosiderin-Laden Macrophages (Fluid Types):\nMorphology:\nPhagocytes contain pigment granules broken-red blood cells hemosiderin (iron storage complex).\n\nSignificance: Indicate prior hemorrhage (bleeding) body fluid\nHemosiderin-Laden Macrophages (Fluid Types):Morphology:\nPhagocytes contain pigment granules broken-red blood cells hemosiderin (iron storage complex).\nPhagocytes contain pigment granules broken-red blood cells hemosiderin (iron storage complex).Significance: Indicate prior hemorrhage (bleeding) body fluidLipophages (Fat-Laden Macrophages, Gitter Cells):\nMorphology:\nMacrophages numerous vacuoles containing lipids\n\nSignificance: Indicate tissue destruction fat necrosis\nCommonly seen CSF stroke traumatic brain injury\n\nLipophages (Fat-Laden Macrophages, Gitter Cells):Morphology:\nMacrophages numerous vacuoles containing lipids\nMacrophages numerous vacuoles containing lipidsSignificance: Indicate tissue destruction fat necrosis\nCommonly seen CSF stroke traumatic brain injury\nCommonly seen CSF stroke traumatic brain injuryCrystals (Synovial Fluid):\nUrate Crystals: Needle-shaped, negatively birefringent crystals seen gout\nCalcium Pyrophosphate Dihydrate (CPPD) Crystals: Rhomboid rod-shaped, weakly positively birefringent crystals seen pseudogout\nCholesterol Crystals: Flat, notched, rhomboid-shaped crystals seen chronic effusions\nCrystals (Synovial Fluid):Urate Crystals: Needle-shaped, negatively birefringent crystals seen goutCalcium Pyrophosphate Dihydrate (CPPD) Crystals: Rhomboid rod-shaped, weakly positively birefringent crystals seen pseudogoutCholesterol Crystals: Flat, notched, rhomboid-shaped crystals seen chronic effusionsOrganisms:\nBacteria: Small, round, rod-shaped organisms may seen within outside cells\nFungi: May appear yeast hyphae\nParasites: Rare, may seen certain infections\nOrganisms:Bacteria: Small, round, rod-shaped organisms may seen within outside cellsFungi: May appear yeast hyphaeParasites: Rare, may seen certain infectionsOther Artifacts Contaminants:\nAir Bubbles\nStarch Granules (gloves)\nContaminating Cells Adjacent Tissues\nArtifacts Contaminants:Air BubblesStarch Granules (gloves)Contaminating Cells Adjacent Tissues","code":""},{"path":"hemoglobin.html","id":"hemoglobin","chapter":"Hemoglobin","heading":"Hemoglobin","text":"","code":""},{"path":"hemoglobin.html","id":"overview-of-hemoglobin-hb-analysis","chapter":"Hemoglobin","heading":"Overview of Hemoglobin (Hb) Analysis","text":"Definition: Hemoglobin analysis involves range laboratory tests used measure characterize hemoglobin, oxygen-carrying protein found red blood cells (RBCs)Clinical Significance: Used :\nDiagnose anemias\nDetect hemoglobinopathies (inherited disorders hemoglobin structure synthesis)\nMonitor treatment hemoglobin disorders\nDiagnose anemiasDetect hemoglobinopathies (inherited disorders hemoglobin structure synthesis)Monitor treatment hemoglobin disordersTypes Hemoglobin Analysis:\nQuantitative: Measures total amount hemoglobin blood\nQualitative: Identifies characterizes different types hemoglobin\nQuantitative: Measures total amount hemoglobin bloodQualitative: Identifies characterizes different types hemoglobinMethods:\nQuantitative: Automated hematology analyzers\nQualitative: Hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), specialized tests (e.g., sickle solubility test)\nQuantitative: Automated hematology analyzersQualitative: Hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), specialized tests (e.g., sickle solubility test)","code":""},{"path":"hemoglobin.html","id":"quantitative-hemoglobin-measurement","chapter":"Hemoglobin","heading":"Quantitative Hemoglobin Measurement","text":"Principle:\nAutomated hematology analyzers measure hemoglobin concentration using spectrophotometry\nRBCs lysed (broken open) release hemoglobin\nHemoglobin converted stable colored compound (e.g., cyanmethemoglobin)\nanalyzer measures absorbance (optical density) solution specific wavelength\nabsorbance directly proportional hemoglobin concentration (Beer-Lambert Law)\nAutomated hematology analyzers measure hemoglobin concentration using spectrophotometryRBCs lysed (broken open) release hemoglobinHemoglobin converted stable colored compound (e.g., cyanmethemoglobin)analyzer measures absorbance (optical density) solution specific wavelengthThe absorbance directly proportional hemoglobin concentration (Beer-Lambert Law)","code":""},{"path":"hemoglobin.html","id":"qualitative-hemoglobin-analysis","chapter":"Hemoglobin","heading":"Qualitative Hemoglobin Analysis","text":"Qualitative methods used identify characterize different types hemoglobinHemoglobin Electrophoresis:\nPrinciple: Separates hemoglobin variants based electrical charge migration patterns electric field\nPrinciple: Separates hemoglobin variants based electrical charge migration patterns electric fieldHigh-Performance Liquid Chromatography (HPLC):\nPrinciple: Separates hemoglobin variants based interaction stationary phase column, followed detection using spectrophotometry\nPrinciple: Separates hemoglobin variants based interaction stationary phase column, followed detection using spectrophotometrySickle Solubility Test:\nPrinciple: Hemoglobin S (HbS) insoluble concentrated phosphate buffer deoxygenated, causing solution become turbid.\nPrinciple: Hemoglobin S (HbS) insoluble concentrated phosphate buffer deoxygenated, causing solution become turbid.","code":""},{"path":"hemoglobin.html","id":"interpreting-results-and-correlating-with-clinical-findings","chapter":"Hemoglobin","heading":"Interpreting Results and Correlating with Clinical Findings","text":"Consider Patient’s Age, Ethnicity, Clinical History: factors can provide valuable clues interpreting hemoglobin analysis resultsCorrelate RBC Indices Peripheral Blood Smear Findings: RBC indices (MCV, MCH, MCHC) peripheral blood smear morphology can help narrow differential diagnosisConsider Test Results: Look test results together determine potential cause disease","code":""},{"path":"hemoglobin.html","id":"key-terms-52","chapter":"Hemoglobin","heading":"Key Terms","text":"Hemoglobin (Hb): oxygen-carrying protein red blood cellsHemoglobinopathy: genetic disorder affecting structure synthesis hemoglobinHemoglobin Variant: abnormal hemoglobin moleculeHemoglobin Electrophoresis: technique separate identify hemoglobin typesHigh Performance Liquid Chromatography (HPLC): chromatographic method hemoglobin separationSickle Solubility Test: screening test sickle cell diseaseHemolysate: Lysed red blood cells used hemoglobin analysisDensitometry: technique quantifying amount hemoglobin type electrophoretic gelPoint Mutation: Change occurs replication single base either inserted, deleted, replacedTurbidity: Cloudiness haziness solution","code":""},{"path":"quantitative-1.html","id":"quantitative-1","chapter":"Quantitative","heading":"Quantitative","text":"","code":""},{"path":"quantitative-1.html","id":"overview-of-quantitative-hemoglobin-measurement","chapter":"Quantitative","heading":"Overview of Quantitative Hemoglobin Measurement","text":"Definition: Quantitative hemoglobin (HGB) measurement refers laboratory techniques used determine concentration hemoglobin blood sampleClinical Significance:\nDiagnosis Anemia: Decreased HGB levels indicate anemia\nDiagnosis Polycythemia: Increased HGB levels indicate polycythemia\nMonitoring Treatment: Used monitor response treatment anemia polycythemia\nAssessing Blood Loss: Helps estimate severity blood loss\nEvaluating Overall Health: Provides information oxygen-carrying capacity blood\nDiagnosis Anemia: Decreased HGB levels indicate anemiaDiagnosis Polycythemia: Increased HGB levels indicate polycythemiaMonitoring Treatment: Used monitor response treatment anemia polycythemiaAssessing Blood Loss: Helps estimate severity blood lossEvaluating Overall Health: Provides information oxygen-carrying capacity bloodMethod: Spectrophotometry primary method used quantitative hemoglobin measurement automated hematology analyzersReporting Units: Hemoglobin concentration typically reported grams per deciliter (g/dL) grams per liter (g/L)","code":""},{"path":"quantitative-1.html","id":"principle-of-spectrophotometric-hemoglobin-measurement","chapter":"Quantitative","heading":"Principle of Spectrophotometric Hemoglobin Measurement","text":"Spectrophotometry relies Beer-Lambert Law, states absorbance solution directly proportional concentration analyte path length light beam solution:= εbc\n= Absorbance\nε = Molar absorptivity (constant specific substance)\nb = Path length (distance light beam travels solution)\nc = Concentration\n= Absorbanceε = Molar absorptivity (constant specific substance)b = Path length (distance light beam travels solution)c = ConcentrationIn context hemoglobin measurement:intensity color produced converted hemoglobin directly proportional hemoglobin concentrationThe spectrophotometer measures absorbance solution, hemoglobin concentration calculated based Beer-Lambert Law","code":""},{"path":"quantitative-1.html","id":"detailed-steps-of-spectrophotometric-hemoglobin-measurement","chapter":"Quantitative","heading":"Detailed Steps of Spectrophotometric Hemoglobin Measurement","text":"Sample Preparation:\nWhole Blood Collection: Blood collected EDTA (purple-top) tube prevent clotting\nLysis Red Blood Cells (RBCs):\nlysing reagent added whole blood sample rupture RBC membranes release hemoglobin solution\nlysing reagent also clears solution, reducing turbidity\nDifferent lysing reagents may used, depending specific method used analyzer\n\nConversion Hemoglobin Stable Form:\nreleased hemoglobin converted stable, colored compound can accurately measured spectrophotometry\ncommon method cyanmethemoglobin (hemiglobincyanide) method\n\nWhole Blood Collection: Blood collected EDTA (purple-top) tube prevent clottingLysis Red Blood Cells (RBCs):\nlysing reagent added whole blood sample rupture RBC membranes release hemoglobin solution\nlysing reagent also clears solution, reducing turbidity\nDifferent lysing reagents may used, depending specific method used analyzer\nlysing reagent added whole blood sample rupture RBC membranes release hemoglobin solutionThe lysing reagent also clears solution, reducing turbidityDifferent lysing reagents may used, depending specific method used analyzerConversion Hemoglobin Stable Form:\nreleased hemoglobin converted stable, colored compound can accurately measured spectrophotometry\ncommon method cyanmethemoglobin (hemiglobincyanide) method\nreleased hemoglobin converted stable, colored compound can accurately measured spectrophotometryThe common method cyanmethemoglobin (hemiglobincyanide) methodCyanmethemoglobin (HiCN) Method:\nPotassium Ferricyanide:\nConverts hemoglobin methemoglobin (Hi), iron ferric (Fe3+) state\n\nPotassium Cyanide:\nReacts methemoglobin form cyanmethemoglobin (HiCN), stable, colored compound\nreaction follows:\nHb + K3Fe(CN)6 → Hi + KCN → HiCN\n\nAbsorbance Measurement:\nsolution passed spectrophotometer, absorbance measured specific wavelength (typically 540 nm)\nblank (containing lysing reagent blood) used zero spectrophotometer\nabsorbance directly proportional cyanmethemoglobin concentration, turn directly proportional hemoglobin concentration original sample\n\nCalculation:\nhemoglobin concentration calculated using calibration curve factor derived Beer-Lambert Law\n\nPotassium Ferricyanide:\nConverts hemoglobin methemoglobin (Hi), iron ferric (Fe3+) state\nConverts hemoglobin methemoglobin (Hi), iron ferric (Fe3+) statePotassium Cyanide:\nReacts methemoglobin form cyanmethemoglobin (HiCN), stable, colored compound\nreaction follows:\nHb + K3Fe(CN)6 → Hi + KCN → HiCN\nReacts methemoglobin form cyanmethemoglobin (HiCN), stable, colored compoundThe reaction follows:\nHb + K3Fe(CN)6 → Hi + KCN → HiCNAbsorbance Measurement:\nsolution passed spectrophotometer, absorbance measured specific wavelength (typically 540 nm)\nblank (containing lysing reagent blood) used zero spectrophotometer\nabsorbance directly proportional cyanmethemoglobin concentration, turn directly proportional hemoglobin concentration original sample\nsolution passed spectrophotometer, absorbance measured specific wavelength (typically 540 nm)blank (containing lysing reagent blood) used zero spectrophotometerThe absorbance directly proportional cyanmethemoglobin concentration, turn directly proportional hemoglobin concentration original sampleCalculation:\nhemoglobin concentration calculated using calibration curve factor derived Beer-Lambert Law\nhemoglobin concentration calculated using calibration curve factor derived Beer-Lambert LawAutomated Hematology Analyzer Process:\nSample Aspiration: automated analyzer aspirates small amount prepared blood sample\nMixing Incubation: analyzer mixes sample lysing reagent allows sufficient time reaction occur\nFlow Cell: solution passed flow cell, light beam spectrophotometer passes solution\nDetection: photodetector measures amount light passes solution\nCalculation: analyzer calculates hemoglobin concentration based absorbance calibration data\nReporting: hemoglobin concentration displayed reported analyzer’s printout screen\nSample Aspiration: automated analyzer aspirates small amount prepared blood sampleMixing Incubation: analyzer mixes sample lysing reagent allows sufficient time reaction occurFlow Cell: solution passed flow cell, light beam spectrophotometer passes solutionDetection: photodetector measures amount light passes solutionCalculation: analyzer calculates hemoglobin concentration based absorbance calibration dataReporting: hemoglobin concentration displayed reported analyzer’s printout screen","code":""},{"path":"quantitative-1.html","id":"interfering-substances-and-troubleshooting","chapter":"Quantitative","heading":"Interfering Substances and Troubleshooting","text":"Several substances can interfere spectrophotometric hemoglobin measurement, leading inaccurate results. ’s crucial aware interferences take appropriate corrective actions.Turbidity: Lipemia (excessive lipids blood), high white blood cell counts (leukocytosis), presence non-lysed red blood cells can cause turbidity, increasing absorbance falsely elevating hemoglobin result\nCorrective Actions:\nLipemia: Perform saline replacement procedure use lipemia clearing agent\nHigh WBC Count: Dilute sample multiply results dilution factor\nNon-Lysed RBCs: Ensure adequate mixing incubation time lysing reagent\n\nCorrective Actions:\nLipemia: Perform saline replacement procedure use lipemia clearing agent\nHigh WBC Count: Dilute sample multiply results dilution factor\nNon-Lysed RBCs: Ensure adequate mixing incubation time lysing reagent\nLipemia: Perform saline replacement procedure use lipemia clearing agentHigh WBC Count: Dilute sample multiply results dilution factorNon-Lysed RBCs: Ensure adequate mixing incubation time lysing reagentHigh White Blood Cell Count (Leukocytosis):\nExtreme leukocytosis can cause falsely elevated hemoglobin readings.\ndue light scattering caused high concentration cells.\nCorrective Action:\nDilute sample isotonic diluent (e.g., saline) repeat measurement.\nMultiply result dilution factor.\nmanual hemoglobin method can also used confirm accuracy.\n\nExtreme leukocytosis can cause falsely elevated hemoglobin readings.due light scattering caused high concentration cells.Corrective Action:\nDilute sample isotonic diluent (e.g., saline) repeat measurement.\nMultiply result dilution factor.\nmanual hemoglobin method can also used confirm accuracy.\nDilute sample isotonic diluent (e.g., saline) repeat measurement.Multiply result dilution factor.manual hemoglobin method can also used confirm accuracy.Lipemia (High Lipid Levels):\nTurbidity high lipid content can falsely elevate hemoglobin reading.\nCorrective Actions:\nSaline Replacement: Replace lipemic plasma equal volume isotonic saline centrifugation.\nLipemia Clearing Agents: Use commercial reagents clear lipemia analysis.\nUltracentrifugation: Remove lipids ultracentrifugation.\n\nTurbidity high lipid content can falsely elevate hemoglobin reading.Corrective Actions:\nSaline Replacement: Replace lipemic plasma equal volume isotonic saline centrifugation.\nLipemia Clearing Agents: Use commercial reagents clear lipemia analysis.\nUltracentrifugation: Remove lipids ultracentrifugation.\nSaline Replacement: Replace lipemic plasma equal volume isotonic saline centrifugation.Lipemia Clearing Agents: Use commercial reagents clear lipemia analysis.Ultracentrifugation: Remove lipids ultracentrifugation.Cold Agglutinins:\nantibodies can cause RBCs clump together, leading inaccurate cell counts hemoglobin measurement\nCorrective Actions:\nWarm sample 37°C dissociate agglutinins\nRepeat analysis promptly warming\n\n\nantibodies can cause RBCs clump together, leading inaccurate cell counts hemoglobin measurement\nCorrective Actions:\nWarm sample 37°C dissociate agglutinins\nRepeat analysis promptly warming\n\nCorrective Actions:\nWarm sample 37°C dissociate agglutinins\nRepeat analysis promptly warming\nWarm sample 37°C dissociate agglutininsRepeat analysis promptly warming","code":""},{"path":"quantitative-1.html","id":"quality-control","chapter":"Quantitative","heading":"Quality Control","text":"Calibration:\nPerform regular calibration spectrophotometer according manufacturer’s instructions\nUse certified reference materials (calibrators) known hemoglobin concentrations\nCalibration:Perform regular calibration spectrophotometer according manufacturer’s instructionsUse certified reference materials (calibrators) known hemoglobin concentrationsControl Materials:\nRun control materials (low, normal, high levels) regular intervals (e.g., daily, batch samples)\nUse controls appropriate types samples analyzed\nControl Materials:Run control materials (low, normal, high levels) regular intervals (e.g., daily, batch samples)Use controls appropriate types samples analyzedReview Control Results:\nReview control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)\nTake corrective action control results outside acceptable range\nReview Control Results:Review control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)Take corrective action control results outside acceptable range","code":""},{"path":"quantitative-1.html","id":"reporting-results-4","chapter":"Quantitative","heading":"Reporting Results","text":"Report hemoglobin concentration appropriate units (g/dL g/L)Include reference range patient’s age sexNote abnormal results flagsDocument quality control procedures corrective actions taken","code":""},{"path":"quantitative-1.html","id":"key-terms-53","chapter":"Quantitative","heading":"Key Terms","text":"Hemoglobin (Hb): oxygen-carrying protein red blood cellsSpectrophotometry: technique measuring absorbance transmittance light solutionBeer-Lambert Law: law states absorbance solution directly proportional concentration analyte path length light beam solutionLysing Reagent: chemical used rupture red blood cell membranes release hemoglobinCyanmethemoglobin (HiCN): stable, colored compound formed reaction hemoglobin potassium ferricyanide potassium cyanideAbsorbance: measure amount light absorbed solutionPath Length: distance light beam travels solutionCalibration: process adjusting instrument ensure accurate reliable resultsControl Materials: Samples known values used assess accuracy precision instrument","code":""},{"path":"qualitative-1.html","id":"qualitative-1","chapter":"Qualitative","heading":"Qualitative","text":"","code":""},{"path":"qualitative-1.html","id":"overview-of-qualitative-hemoglobin-analysis","chapter":"Qualitative","heading":"Overview of Qualitative Hemoglobin Analysis","text":"Definition: Laboratory tests used identify characterize different types hemoglobin blood sample. tests crucial diagnosing hemoglobinopathies, sickle cell anemia thalassemiaPurpose:\nDetect quantify normal abnormal hemoglobin variants (e.g., HbA, HbA2, HbF, HbS, HbC, HbD, HbE)\nIdentify hemoglobinopathies patients anemia, jaundice, family history hemoglobin disorders\nScreen newborns sickle cell disease hemoglobinopathies\nMonitor treatment response patients hemoglobinopathies\nDetect quantify normal abnormal hemoglobin variants (e.g., HbA, HbA2, HbF, HbS, HbC, HbD, HbE)Identify hemoglobinopathies patients anemia, jaundice, family history hemoglobin disordersScreen newborns sickle cell disease hemoglobinopathiesMonitor treatment response patients hemoglobinopathiesMethods:\nHemoglobin Electrophoresis\nHigh-Performance Liquid Chromatography (HPLC)\nSickle Solubility Testing\nHemoglobin ElectrophoresisHigh-Performance Liquid Chromatography (HPLC)Sickle Solubility Testing","code":""},{"path":"qualitative-1.html","id":"hemoglobin-electrophoresis","chapter":"Qualitative","heading":"Hemoglobin Electrophoresis","text":"Principle:\nSeparates hemoglobin variants based electrical charge migration patterns electric field\nHemoglobin molecules placed supporting medium (e.g., cellulose acetate agarose gel) electric current applied\nDifferent hemoglobin types migrate different rates depending charge\nelectrophoresis, separated hemoglobin bands visualized using stain\nSeparates hemoglobin variants based electrical charge migration patterns electric fieldHemoglobin molecules placed supporting medium (e.g., cellulose acetate agarose gel) electric current appliedDifferent hemoglobin types migrate different rates depending chargeAfter electrophoresis, separated hemoglobin bands visualized using stain","code":""},{"path":"qualitative-1.html","id":"high-performance-liquid-chromatography-hplc","chapter":"Qualitative","heading":"High-Performance Liquid Chromatography (HPLC)","text":"Principle:\n* Separates hemoglobin variants based interaction stationary phase column, followed detection using spectrophotometry\nSteps:\nhemolysate injected column packed solid material (stationary phase)\nliquid solvent (mobile phase) pumped column\nHemoglobin variants interact differently stationary phase based size, charge, hydrophobicity\nhemoglobin variant elutes column, passes detector (spectrophotometer) measures absorbance specific wavelength\ndetector generates chromatogram, shows series peaks corresponding different hemoglobin types\n\nSteps:\nhemolysate injected column packed solid material (stationary phase)\nliquid solvent (mobile phase) pumped column\nHemoglobin variants interact differently stationary phase based size, charge, hydrophobicity\nhemoglobin variant elutes column, passes detector (spectrophotometer) measures absorbance specific wavelength\ndetector generates chromatogram, shows series peaks corresponding different hemoglobin types\nhemolysate injected column packed solid material (stationary phase)liquid solvent (mobile phase) pumped columnHemoglobin variants interact differently stationary phase based size, charge, hydrophobicityAs hemoglobin variant elutes column, passes detector (spectrophotometer) measures absorbance specific wavelengthThe detector generates chromatogram, shows series peaks corresponding different hemoglobin types","code":""},{"path":"qualitative-1.html","id":"sickle-solubility-testing","chapter":"Qualitative","heading":"Sickle Solubility Testing","text":"Principle:\nHemoglobin S (HbS) insoluble concentrated phosphate buffer deoxygenated, causing solution become turbid (cloudy)\nhemoglobins remain soluble buffer\nHemoglobin S (HbS) insoluble concentrated phosphate buffer deoxygenated, causing solution become turbid (cloudy)hemoglobins remain soluble buffer","code":""},{"path":"qualitative-1.html","id":"quality-control-1","chapter":"Qualitative","heading":"Quality Control","text":"Run Controls Known Hemoglobin Patterns:\nInclude normal abnormal controls electrophoresis HPLC run\ncontrol results fall within established reference ranges\nInclude normal abnormal controls electrophoresis HPLC runThe control results fall within established reference rangesDocument Quality Control Procedures:\nRecord dates, lot numbers, results quality control procedures\nRecord dates, lot numbers, results quality control proceduresFollow Established Laboratory Procedures:\nAdhere standardized operating procedures performing interpreting hemoglobin analysis\nAdhere standardized operating procedures performing interpreting hemoglobin analysisParticipate Proficiency Testing Programs:\nassess accuracy reliability laboratory’s testing\nassess accuracy reliability laboratory’s testing","code":""},{"path":"qualitative-1.html","id":"key-terms-54","chapter":"Qualitative","heading":"Key Terms","text":"Hemoglobin Electrophoresis: technique separate identify hemoglobin typesHigh Performance Liquid Chromatography (HPLC): chromatographic method hemoglobin separationSickle Solubility Test: screening test sickle cell diseaseHemoglobinopathy: genetic disorder affecting structure synthesis hemoglobinHemoglobin Variant: abnormal hemoglobin moleculeCellulose Acetate: supporting medium used hemoglobin electrophoresisAgarose Gel: Another supporting medium used hemoglobin electrophoresisHemolysate: Lysed red blood cells used hemoglobin analysisDensitometry: technique quantifying amount hemoglobin type electrophoretic gelPoint Mutation: Single nucleotide polymorphism (SNP)","code":""},{"path":"electrophoresis.html","id":"electrophoresis","chapter":"Electrophoresis","heading":"Electrophoresis","text":"","code":""},{"path":"electrophoresis.html","id":"overview-of-hemoglobin-electrophoresis","chapter":"Electrophoresis","heading":"Overview of Hemoglobin Electrophoresis","text":"Definition: Hemoglobin electrophoresis analytical technique used separate identify different types hemoglobin (Hb) based electrical charge migration patterns supporting medium subjected electric fieldClinical Significance:\nDetection Identification Hemoglobin Variants: Helps identify normal (HbA, HbA2, HbF) abnormal (HbS, HbC, HbD, HbE) hemoglobins\nDiagnosis Hemoglobinopathies: Essential diagnosing sickle cell anemia, thalassemias, inherited hemoglobin disorders\nPrenatal Screening: Can used screen hemoglobinopathies pregnant women diagnose affected fetuses\nMonitoring Transfusion Therapy: Useful tracking changes hemoglobin composition blood transfusions\nDetection Identification Hemoglobin Variants: Helps identify normal (HbA, HbA2, HbF) abnormal (HbS, HbC, HbD, HbE) hemoglobinsDiagnosis Hemoglobinopathies: Essential diagnosing sickle cell anemia, thalassemias, inherited hemoglobin disordersPrenatal Screening: Can used screen hemoglobinopathies pregnant women diagnose affected fetusesMonitoring Transfusion Therapy: Useful tracking changes hemoglobin composition blood transfusionsKey Principle: Exploits differences electrical charge among hemoglobin variants separate distinct bands supporting medium","code":""},{"path":"electrophoresis.html","id":"components-of-a-hemoglobin-electrophoresis-system","chapter":"Electrophoresis","heading":"Components of a Hemoglobin Electrophoresis System","text":"Sample: hemolysate (lysed red blood cells) containing hemoglobinSupporting Medium: solid semi-solid matrix provides surface hemoglobin migration\nCommon media: Cellulose acetate, agarose gel, capillary\nCommon media: Cellulose acetate, agarose gel, capillaryBuffer: electrolyte solution provides constant pH ionic strength, influencing charge migration hemoglobinElectrophoresis Chamber: device holds supporting medium provides electrodes applying electric fieldPower Supply: device generates controls electric currentStain: dye binds hemoglobin makes separated bands visibleDensitometer: device measures optical density stained bands, allowing quantification hemoglobin type","code":""},{"path":"electrophoresis.html","id":"methodologies-for-hemoglobin-electrophoresis","chapter":"Electrophoresis","heading":"Methodologies for Hemoglobin Electrophoresis","text":"Cellulose Acetate Electrophoresis\nPrinciple: Separates hemoglobin variants cellulose acetate membrane alkaline pH\nSupporting Medium: thin, flexible cellulose acetate membrane\nBuffer: Tris-EDTA-borate (TEB) buffer (pH 8.4 - 8.6)\nProcedure:\nPrepare Hemolysate: Lyse red blood cells release hemoglobin\nSaturate Membrane: Soak cellulose acetate membrane buffer\nApply Sample: Apply small amount hemolysate membrane\nElectrophoresis: Place membrane electrophoresis chamber, apply electric current, allow hemoglobin migrate specific time (typically 20-30 minutes)\nStaining: Remove membrane stain Ponceau S suitable stain visualize hemoglobin bands\nDestaining: Remove excess stain destaining solution\nInterpretation: Examine membrane visually using densitometry identify quantify hemoglobin bands\n\nMigration Pattern (fastest slowest migration):\nHbA1\nHbF\nHbS\nHbC\nHbA2\n\nAdvantages:\nSimple relatively inexpensive\nGood resolution common hemoglobin variants (HbA, HbS, HbC, HbF)\n\nLimitations:\nhemoglobins comigrate (e.g., HbS HbD, HbC HbE) alkaline pH\nused detect unstable hemoglobins\nLower sensitivity compared methods\n\nPrinciple: Separates hemoglobin variants cellulose acetate membrane alkaline pHSupporting Medium: thin, flexible cellulose acetate membraneBuffer: Tris-EDTA-borate (TEB) buffer (pH 8.4 - 8.6)Procedure:\nPrepare Hemolysate: Lyse red blood cells release hemoglobin\nSaturate Membrane: Soak cellulose acetate membrane buffer\nApply Sample: Apply small amount hemolysate membrane\nElectrophoresis: Place membrane electrophoresis chamber, apply electric current, allow hemoglobin migrate specific time (typically 20-30 minutes)\nStaining: Remove membrane stain Ponceau S suitable stain visualize hemoglobin bands\nDestaining: Remove excess stain destaining solution\nInterpretation: Examine membrane visually using densitometry identify quantify hemoglobin bands\nPrepare Hemolysate: Lyse red blood cells release hemoglobinSaturate Membrane: Soak cellulose acetate membrane bufferApply Sample: Apply small amount hemolysate membraneElectrophoresis: Place membrane electrophoresis chamber, apply electric current, allow hemoglobin migrate specific time (typically 20-30 minutes)Staining: Remove membrane stain Ponceau S suitable stain visualize hemoglobin bandsDestaining: Remove excess stain destaining solutionInterpretation: Examine membrane visually using densitometry identify quantify hemoglobin bandsMigration Pattern (fastest slowest migration):\nHbA1\nHbF\nHbS\nHbC\nHbA2\nHbA1HbFHbSHbCHbA2Advantages:\nSimple relatively inexpensive\nGood resolution common hemoglobin variants (HbA, HbS, HbC, HbF)\nSimple relatively inexpensiveGood resolution common hemoglobin variants (HbA, HbS, HbC, HbF)Limitations:\nhemoglobins comigrate (e.g., HbS HbD, HbC HbE) alkaline pH\nused detect unstable hemoglobins\nLower sensitivity compared methods\nhemoglobins comigrate (e.g., HbS HbD, HbC HbE) alkaline pHCannot used detect unstable hemoglobinsLower sensitivity compared methodsAgarose Gel Electrophoresis\nPrinciple: Separates hemoglobin variants agarose gel acidic pH\nSupporting Medium: Agarose gel\nBuffer: Citrate buffer (pH 6.0 - 6.2)\nProcedure: Similar cellulose acetate electrophoresis, using agarose gel supporting medium acidic buffer\nMigration Pattern (fastest slowest migration):\nHbF\nHbA\nHbS\nHbC\n\nAdvantages:\nCan used confirm identity certain hemoglobin variants comigrate cellulose acetate (e.g., HbS HbD)\n\nLimitations:\ncommonly used cellulose acetate electrophoresis routine screening\nLower resolution hemoglobin variants\n\nPrinciple: Separates hemoglobin variants agarose gel acidic pHSupporting Medium: Agarose gelBuffer: Citrate buffer (pH 6.0 - 6.2)Procedure: Similar cellulose acetate electrophoresis, using agarose gel supporting medium acidic bufferMigration Pattern (fastest slowest migration):\nHbF\nHbA\nHbS\nHbC\nHbFHbAHbSHbCAdvantages:\nCan used confirm identity certain hemoglobin variants comigrate cellulose acetate (e.g., HbS HbD)\nCan used confirm identity certain hemoglobin variants comigrate cellulose acetate (e.g., HbS HbD)Limitations:\ncommonly used cellulose acetate electrophoresis routine screening\nLower resolution hemoglobin variants\ncommonly used cellulose acetate electrophoresis routine screeningLower resolution hemoglobin variantsCapillary Electrophoresis (CE)\nPrinciple: Separates hemoglobin variants based charge--size ratio migrate capillary tube filled electrolyte solution influence electric field\nProcedure:\nCapillary Filling: capillary tube filled appropriate electrolyte solution\nSample Injection: small amount hemolysate injected capillary\nElectrophoresis: electric field applied, causing hemoglobin variants migrate capillary\nDetection: detector end capillary measures absorbance fluorescence separated hemoglobin variants\nData Analysis: data analyzed specialized software identify quantify hemoglobin types\n\nAdvantages:\nHigh resolution sensitivity\nAutomated rapid\nCan quantify small amounts abnormal hemoglobins\nReduced manual handling\n\nLimitations:\nexpensive cellulose acetate electrophoresis\nRequires specialized equipment training\n\nPrinciple: Separates hemoglobin variants based charge--size ratio migrate capillary tube filled electrolyte solution influence electric fieldProcedure:\nCapillary Filling: capillary tube filled appropriate electrolyte solution\nSample Injection: small amount hemolysate injected capillary\nElectrophoresis: electric field applied, causing hemoglobin variants migrate capillary\nDetection: detector end capillary measures absorbance fluorescence separated hemoglobin variants\nData Analysis: data analyzed specialized software identify quantify hemoglobin types\nCapillary Filling: capillary tube filled appropriate electrolyte solutionSample Injection: small amount hemolysate injected capillaryElectrophoresis: electric field applied, causing hemoglobin variants migrate capillaryDetection: detector end capillary measures absorbance fluorescence separated hemoglobin variantsData Analysis: data analyzed specialized software identify quantify hemoglobin typesAdvantages:\nHigh resolution sensitivity\nAutomated rapid\nCan quantify small amounts abnormal hemoglobins\nReduced manual handling\nHigh resolution sensitivityAutomated rapidCan quantify small amounts abnormal hemoglobinsReduced manual handlingLimitations:\nexpensive cellulose acetate electrophoresis\nRequires specialized equipment training\nexpensive cellulose acetate electrophoresisRequires specialized equipment training","code":""},{"path":"electrophoresis.html","id":"common-hemoglobin-variants-and-their-electrophoretic-patterns","chapter":"Electrophoresis","heading":"Common Hemoglobin Variants and their Electrophoretic Patterns","text":"’s table summarizing electrophoretic mobility common hemoglobin variants alkaline pH (cellulose acetate electrophoresis):Important Note: Remember migration patterns alkaline pH. order may differ acidic pH (agarose gel electrophoresis).","code":""},{"path":"electrophoresis.html","id":"quality-control-qc-procedures","chapter":"Electrophoresis","heading":"Quality Control (QC) Procedures","text":"Run Controls Known Hemoglobin Patterns:\nInclude normal abnormal controls electrophoresis run\ncontrol results fall within established reference ranges\nRun Controls Known Hemoglobin Patterns:Include normal abnormal controls electrophoresis runThe control results fall within established reference rangesCheck Reagents Buffers:\nUse high-quality reagents buffers\nPrepare reagents according manufacturer’s instructions\nMonitor pH expiration dates buffers\nCheck Reagents Buffers:Use high-quality reagents buffersPrepare reagents according manufacturer’s instructionsMonitor pH expiration dates buffersMonitor Temperature Humidity:\nMaintain recommended temperature humidity electrophoresis laboratory\nMonitor Temperature Humidity:Maintain recommended temperature humidity electrophoresis laboratoryInspect Electrophoresis Equipment:\nRegularly inspect electrophoresis chamber, power supply, equipment damage malfunction\nInspect Electrophoresis Equipment:Regularly inspect electrophoresis chamber, power supply, equipment damage malfunctionDocument Quality Control Procedures:\nRecord dates, lot numbers, results quality control procedures\nDocument Quality Control Procedures:Record dates, lot numbers, results quality control procedures","code":""},{"path":"electrophoresis.html","id":"troubleshooting","chapter":"Electrophoresis","heading":"Troubleshooting","text":"Poor Band Resolution:\nCheck buffer pH ionic strength\nEnsure proper staining destaining techniques\nCheck contamination sample reagents\nPoor Band Resolution:Check buffer pH ionic strengthEnsure proper staining destaining techniquesCheck contamination sample reagentsDistorted Uneven Bands:\nEnsure supporting medium properly hydrated free defects\nCheck electrode polarity\nCheck proper sample application\nDistorted Uneven Bands:Ensure supporting medium properly hydrated free defectsCheck electrode polarityCheck proper sample applicationWeak Faint Bands:\nEnsure sample concentration adequate\nCheck staining procedure\nWeak Faint Bands:Ensure sample concentration adequateCheck staining procedureUnexpected Unidentified Bands:\nConsider possibility rare hemoglobin variants hemoglobin derivatives\nPerform additional testing (e.g., HPLC, globin chain analysis) confirm identity unknown band\nUnexpected Unidentified Bands:Consider possibility rare hemoglobin variants hemoglobin derivativesPerform additional testing (e.g., HPLC, globin chain analysis) confirm identity unknown bandInstrument Errors:\nConsult instrument’s troubleshooting guide contact manufacturer assistance\nInstrument Errors:Consult instrument’s troubleshooting guide contact manufacturer assistance","code":""},{"path":"electrophoresis.html","id":"reporting-results-5","chapter":"Electrophoresis","heading":"Reporting Results","text":"Report percentage hemoglobin type (e.g., HbA, HbA2, HbF, HbS, HbC)Include visual representation electrophoresis pattern (possible)Provide interpretation results, noting abnormal findingsCorrelate laboratory findings patient’s clinical information","code":""},{"path":"electrophoresis.html","id":"key-terms-55","chapter":"Electrophoresis","heading":"Key Terms","text":"Hemoglobin Electrophoresis: Technique separate identify hemoglobin typesHemoglobinopathy: genetic disorder affecting structure synthesis hemoglobinHemoglobin Variant: abnormal hemoglobin moleculeCellulose Acetate Electrophoresis: common method hemoglobin electrophoresisAgarose Gel Electrophoresis: Another method hemoglobin electrophoresisCapillary Electrophoresis (CE): automated method hemoglobin separationHPLC: High Performance Liquid ChromatographyIsoelectric Focusing (IEF): high-resolution electrophoretic techniqueHbA, HbA2, HbF, HbS, HbC: Common hemoglobin typesSickle Cell Trait (HbAS): Heterozygous carrier HbSSickle Cell Anemia (HbSS): Homozygous HbSMigration Pattern: order different hemoglobin types move across electrophoresis medium","code":""},{"path":"hplc.html","id":"hplc","chapter":"HPLC","heading":"HPLC","text":"","code":""},{"path":"hplc.html","id":"overview-of-hemoglobin-hplc","chapter":"HPLC","heading":"Overview of Hemoglobin HPLC","text":"Definition: High-Performance Liquid Chromatography (HPLC) powerful analytical technique used separate, identify, quantify different hemoglobin variants blood sample.Clinical Significance:\nDiagnosis Hemoglobinopathies: Essential detecting characterizing hemoglobin variants associated sickle cell disease, thalassemias, hemoglobin disorders\nNewborn Screening: Used newborn screening programs identify infants hemoglobinopathies\nMonitoring Glycated Hemoglobin (HbA1c): HPLC also used measure HbA1c levels, key indicator long-term glycemic control individuals diabetes\nResearch Applications: Used research studies investigate hemoglobin structure function\nDiagnosis Hemoglobinopathies: Essential detecting characterizing hemoglobin variants associated sickle cell disease, thalassemias, hemoglobin disordersNewborn Screening: Used newborn screening programs identify infants hemoglobinopathiesMonitoring Glycated Hemoglobin (HbA1c): HPLC also used measure HbA1c levels, key indicator long-term glycemic control individuals diabetesResearch Applications: Used research studies investigate hemoglobin structure functionAdvantages Hemoglobin Electrophoresis:\nHigher Resolution: Can separate quantify wider range hemoglobin variants, including comigrate electrophoresis\nImproved Sensitivity: Can detect small amounts abnormal hemoglobins\nAutomation: Automated systems available, reducing manual handling improving throughput\nQuantitative Results: Provides accurate quantitative measurements hemoglobin type\nVersatility: Can used measure hemoglobin variants glycated hemoglobin (HbA1c)\nHigher Resolution: Can separate quantify wider range hemoglobin variants, including comigrate electrophoresisImproved Sensitivity: Can detect small amounts abnormal hemoglobinsAutomation: Automated systems available, reducing manual handling improving throughputQuantitative Results: Provides accurate quantitative measurements hemoglobin typeVersatility: Can used measure hemoglobin variants glycated hemoglobin (HbA1c)Limitations:\nHigher Cost: expensive traditional electrophoresis methods\nComplexity: Requires trained personnel operate maintain equipment\nInterferences: Certain substances can interfere separation detection hemoglobin variants\nHigher Cost: expensive traditional electrophoresis methodsComplexity: Requires trained personnel operate maintain equipmentInterferences: Certain substances can interfere separation detection hemoglobin variants","code":""},{"path":"hplc.html","id":"principle-of-hemoglobin-hplc","chapter":"HPLC","heading":"Principle of Hemoglobin HPLC","text":"Separation: Hemoglobin variants separated based interactions stationary phase within columnDetection: separated hemoglobin variants detected elute column using spectrophotometryKey Components:\nSample: Hemolysate (lysed red blood cells) containing hemoglobin\nColumn: column packed solid stationary phase material (e.g., reversed-phase, ion exchange)\nMobile Phase: liquid solvent pumped column\ncomposition mobile phase (e.g., pH, organic solvent concentration) carefully controlled optimize separation hemoglobin variants\n\nPump: high-pressure pump deliver mobile phase column constant flow rate\nDetector: spectrophotometer measures absorbance eluting hemoglobin variants specific wavelength (typically 415 nm)\nData Acquisition System: computer system records analyzes detector signal, generating chromatogram\nSample: Hemolysate (lysed red blood cells) containing hemoglobinColumn: column packed solid stationary phase material (e.g., reversed-phase, ion exchange)Mobile Phase: liquid solvent pumped column\ncomposition mobile phase (e.g., pH, organic solvent concentration) carefully controlled optimize separation hemoglobin variants\ncomposition mobile phase (e.g., pH, organic solvent concentration) carefully controlled optimize separation hemoglobin variantsPump: high-pressure pump deliver mobile phase column constant flow rateDetector: spectrophotometer measures absorbance eluting hemoglobin variants specific wavelength (typically 415 nm)Data Acquisition System: computer system records analyzes detector signal, generating chromatogram","code":""},{"path":"hplc.html","id":"hplc-methodologies","chapter":"HPLC","heading":"HPLC Methodologies","text":"Ion-Exchange Chromatography:\nStationary Phase: solid material charged groups (e.g., negatively charged sulfonate groups cation exchange, positively charged amino groups anion exchange)\nSeparation Principle: Hemoglobin variants separated based charge interactions stationary phase\nMobile Phase: buffer solution controlled pH ionic strength\nionic strength gradually increased elute bound hemoglobin variants\n\nDetection: Spectrophotometry 415 nm\nAdvantages: Good separating HbA2 HbF hemoglobin variants\nIon-Exchange Chromatography:Stationary Phase: solid material charged groups (e.g., negatively charged sulfonate groups cation exchange, positively charged amino groups anion exchange)Separation Principle: Hemoglobin variants separated based charge interactions stationary phaseMobile Phase: buffer solution controlled pH ionic strength\nionic strength gradually increased elute bound hemoglobin variants\nionic strength gradually increased elute bound hemoglobin variantsDetection: Spectrophotometry 415 nmAdvantages: Good separating HbA2 HbF hemoglobin variantsReversed-Phase Chromatography:\nStationary Phase: solid material hydrophobic groups (e.g., C8 C18 alkyl chains)\nSeparation Principle: Hemoglobin variants separated based hydrophobic interactions stationary phase\nMobile Phase: mixture water organic solvent (e.g., acetonitrile methanol)\norganic solvent concentration gradually increased elute bound hemoglobin variants\n\nDetection: Spectrophotometry 415 nm\nAdvantages: High resolution sensitivity; can used separate wide range hemoglobin variants\nReversed-Phase Chromatography:Stationary Phase: solid material hydrophobic groups (e.g., C8 C18 alkyl chains)Separation Principle: Hemoglobin variants separated based hydrophobic interactions stationary phaseMobile Phase: mixture water organic solvent (e.g., acetonitrile methanol)\norganic solvent concentration gradually increased elute bound hemoglobin variants\norganic solvent concentration gradually increased elute bound hemoglobin variantsDetection: Spectrophotometry 415 nmAdvantages: High resolution sensitivity; can used separate wide range hemoglobin variantsHemoglobin Variant Analysis\nSample Preparation: hemolysate prepared EDTA whole blood\nInjection: small amount hemolysate injected HPLC system\nSeparation: Hemoglobin variants separated column based charge hydrophobicity\nDetection: hemoglobin variant elutes column, passes detector, measures absorbance 415 nm\nData Analysis: detector generates chromatogram, shows series peaks corresponding different hemoglobin types\nretention time (time takes hemoglobin variant elute column) used identify hemoglobin type\narea peak proportional amount hemoglobin variant sample\n\nHemoglobin Variant AnalysisSample Preparation: hemolysate prepared EDTA whole bloodInjection: small amount hemolysate injected HPLC systemSeparation: Hemoglobin variants separated column based charge hydrophobicityDetection: hemoglobin variant elutes column, passes detector, measures absorbance 415 nmData Analysis: detector generates chromatogram, shows series peaks corresponding different hemoglobin types\nretention time (time takes hemoglobin variant elute column) used identify hemoglobin type\narea peak proportional amount hemoglobin variant sample\nretention time (time takes hemoglobin variant elute column) used identify hemoglobin typeThe area peak proportional amount hemoglobin variant sampleGlycated Hemoglobin (HbA1c) Analysis\nPrinciple: Hemoglobin A1c (HbA1c) form hemoglobin glycated (glucose attached)\namount HbA1c proportional average blood glucose level preceding 2-3 months\n\nSample Preparation: Blood collected EDTA tube lysed release hemoglobin\nSeparation: Glycated non-glycated hemoglobins separated column\nDetection: glycated non-glycated hemoglobins detected, percentage HbA1c calculated\nGlycated Hemoglobin (HbA1c) AnalysisPrinciple: Hemoglobin A1c (HbA1c) form hemoglobin glycated (glucose attached)\namount HbA1c proportional average blood glucose level preceding 2-3 months\namount HbA1c proportional average blood glucose level preceding 2-3 monthsSample Preparation: Blood collected EDTA tube lysed release hemoglobinSeparation: Glycated non-glycated hemoglobins separated columnDetection: glycated non-glycated hemoglobins detected, percentage HbA1c calculated","code":""},{"path":"hplc.html","id":"interferences","chapter":"HPLC","heading":"Interferences","text":"Elevated Fetal Hemoglobin (HbF):\nCan interfere separation quantification hemoglobin variants, especially HbA2\nMay require special methods accurately measure HbA2 presence elevated HbF\nElevated Fetal Hemoglobin (HbF):Can interfere separation quantification hemoglobin variants, especially HbA2May require special methods accurately measure HbA2 presence elevated HbFUnstable Hemoglobins:\nCan degrade HPLC process, leading inaccurate results\nUse fresh samples appropriate sample handling techniques\nUnstable Hemoglobins:Can degrade HPLC process, leading inaccurate resultsUse fresh samples appropriate sample handling techniquesChemical Modifications:\nCarbamylated hemoglobin (patients renal failure) can interfere HPLC results\nChemical Modifications:Carbamylated hemoglobin (patients renal failure) can interfere HPLC resultsLipemia Turbidity:\nCan interfere spectrophotometric detection, leading inaccurate results\nUse appropriate sample preparation techniques remove lipids\nLipemia Turbidity:Can interfere spectrophotometric detection, leading inaccurate resultsUse appropriate sample preparation techniques remove lipidsCertain Hemoglobin Variants:\nrare hemoglobin variants may co-elute hemoglobin types, leading misidentification\nCertain Hemoglobin Variants:rare hemoglobin variants may co-elute hemoglobin types, leading misidentification","code":""},{"path":"hplc.html","id":"quality-control-qc","chapter":"HPLC","heading":"Quality Control (QC)","text":"Run Controls Known Hemoglobin Patterns:\nInclude normal abnormal controls HPLC run\ncontrol results fall within established reference ranges\nInclude normal abnormal controls HPLC runThe control results fall within established reference rangesCheck Reagents Buffers:\nUse high-quality reagents buffers\nPrepare reagents according manufacturer’s instructions\nMonitor pH expiration dates buffers\nUse high-quality reagents buffersPrepare reagents according manufacturer’s instructionsMonitor pH expiration dates buffersMaintain HPLC System:\nPerform routine maintenance HPLC system according manufacturer’s recommendations\nincludes cleaning column, replacing mobile phase, performing preventative maintenance procedures\nPerform routine maintenance HPLC system according manufacturer’s recommendationsThis includes cleaning column, replacing mobile phase, performing preventative maintenance proceduresDocument Quality Control Procedures:\nRecord dates, lot numbers, results quality control procedures\nRecord dates, lot numbers, results quality control procedures","code":""},{"path":"hplc.html","id":"reporting-results-6","chapter":"HPLC","heading":"Reporting Results","text":"Report percentage hemoglobin type (e.g., HbA, HbA2, HbF, HbS, HbC)Include visual representation chromatogramProvide interpretation results, noting abnormal findingsCorrelate laboratory findings patient’s clinical information","code":""},{"path":"hplc.html","id":"key-terms-56","chapter":"HPLC","heading":"Key Terms","text":"High-Performance Liquid Chromatography (HPLC): chromatographic technique used separate, identify, quantify different substances mixtureMobile Phase: liquid solvent pumped columnStationary Phase: solid material packed column interacts analytesRetention Time: time takes analyte elute columnChromatogram: graphical representation detector signal versus timeGlycated Hemoglobin (HbA1c): Hemoglobin glycated (glucose attached)Hemoglobinopathy: genetic disorder affecting structure synthesis hemoglobinHemoglobin Variant: abnormal hemoglobin molecule","code":""},{"path":"sickle-solubility.html","id":"sickle-solubility","chapter":"Sickle Solubility","heading":"Sickle Solubility","text":"","code":""},{"path":"sickle-solubility.html","id":"overview-of-sickle-solubility-testing","chapter":"Sickle Solubility","heading":"Overview of Sickle Solubility Testing","text":"Definition: rapid, qualitative screening test used detect presence Hemoglobin S (HbS) blood sampleClinical Significance:\nScreening Sickle Cell Disease: Used preliminary test identify individuals may sickle cell trait (HbAS) sickle cell anemia (HbSS)\nSimple Inexpensive: Can performed resource-limited settings sophisticated tests (e.g., hemoglobin electrophoresis, HPLC) readily available\nScreening Sickle Cell Disease: Used preliminary test identify individuals may sickle cell trait (HbAS) sickle cell anemia (HbSS)Simple Inexpensive: Can performed resource-limited settings sophisticated tests (e.g., hemoglobin electrophoresis, HPLC) readily availableLimitations:\nQualitative Test: detects presence HbS, quantify amount\nDifferentiate HbAS (sickle cell trait) HbSS (sickle cell anemia)\nFalse-Negative Results: Can occur infants < 6 months old (due high levels HbF), patients low hemoglobin levels, patients received recent blood transfusions\nFalse-Positive Results: Can occur patients hemoglobinopathies (e.g., HbC-Harlem) hyperglobulinemia\nConfirmatory Testing Required: Positive results must confirmed hemoglobin electrophoresis HPLC\nQualitative Test: detects presence HbS, quantify amountCannot Differentiate HbAS (sickle cell trait) HbSS (sickle cell anemia)False-Negative Results: Can occur infants < 6 months old (due high levels HbF), patients low hemoglobin levels, patients received recent blood transfusionsFalse-Positive Results: Can occur patients hemoglobinopathies (e.g., HbC-Harlem) hyperglobulinemiaConfirmatory Testing Required: Positive results must confirmed hemoglobin electrophoresis HPLC","code":""},{"path":"sickle-solubility.html","id":"principle-of-the-sickle-solubility-test","chapter":"Sickle Solubility","heading":"Principle of the Sickle Solubility Test","text":"Solubility Hemoglobin S:\nHbS insoluble concentrated phosphate buffer deoxygenated (oxygen removed)\ndeoxygenated, HbS molecules polymerize, forming long fibers cause red blood cells sickle\npolymerization sickling process leads turbidity (cloudiness) solution\nHbS insoluble concentrated phosphate buffer deoxygenated (oxygen removed)deoxygenated, HbS molecules polymerize, forming long fibers cause red blood cells sickleThe polymerization sickling process leads turbidity (cloudiness) solutionOther Hemoglobins:\nNormal hemoglobin (HbA) hemoglobin variants remain soluble buffer, solution remains clear\nNormal hemoglobin (HbA) hemoglobin variants remain soluble buffer, solution remains clearProcedure:\nBlood mixed lysing agent release hemoglobin\nreducing agent added deoxygenate hemoglobin\nhemolysate added concentrated phosphate buffer\nmixture observed turbidity\nHbS present, solution become turbid\nHbS absent, solution remain clear\nBlood mixed lysing agent release hemoglobinA reducing agent added deoxygenate hemoglobinThe hemolysate added concentrated phosphate bufferThe mixture observed turbidityIf HbS present, solution become turbidIf HbS absent, solution remain clear","code":""},{"path":"sickle-solubility.html","id":"reagents-and-materials","chapter":"Sickle Solubility","heading":"Reagents and Materials","text":"Lysing Reagent: Saponin reagent lyse red blood cells release hemoglobinReducing Agent: Sodium hydrosulfite (sodium dithionite) deoxygenate hemoglobinPhosphate Buffer: Concentrated phosphate buffer (e.g., sodium phosphate) reduce solubility HbSDistilled Water: prepare reagents dilute samplesTest Tubes Microcentrifuge Tubes: mix reagents samplePipettes: accurately measure reagents samplesLight Source: light source (e.g., flashlight viewbox) observe turbidity solutionControl Samples: Positive negative controls known HbS status","code":""},{"path":"sickle-solubility.html","id":"procedure","chapter":"Sickle Solubility","heading":"Procedure","text":"Prepare Reagents: Follow manufacturer’s instructions prepare lysing reagent, reducing agent, phosphate bufferPrepare Sample:\nCollect blood EDTA (purple-top) tube\nMix blood thoroughly\nAdd specified amount blood test tube microcentrifuge tube\nCollect blood EDTA (purple-top) tubeMix blood thoroughlyAdd specified amount blood test tube microcentrifuge tubeLyse Red Blood Cells:\nAdd lysing reagent blood sample\nMix gently allow mixture stand minutes ensure complete lysis\nAdd lysing reagent blood sampleMix gently allow mixture stand minutes ensure complete lysisDeoxygenate Hemoglobin:\nAdd reducing agent (sodium hydrosulfite) hemolysate\nMix gently\nAdd reducing agent (sodium hydrosulfite) hemolysateMix gentlyAdd Phosphate Buffer:\nAdd concentrated phosphate buffer mixture\nMix gently\nAdd concentrated phosphate buffer mixtureMix gentlyIncubate (Optional):\nprotocols recommend incubating mixture room temperature specific time (e.g., 5-10 minutes)\nprotocols recommend incubating mixture room temperature specific time (e.g., 5-10 minutes)Observe Turbidity:\nHold tube front light source observe turbidity solution\nCompare test sample positive negative controls\nHold tube front light source observe turbidity solutionCompare test sample positive negative controlsInterpret Results:\nPositive Result: solution turbid, indicating presence HbS\nNegative Result: solution remains clear, indicating absence HbS\nPositive Result: solution turbid, indicating presence HbSNegative Result: solution remains clear, indicating absence HbS","code":""},{"path":"sickle-solubility.html","id":"interpreting-results","chapter":"Sickle Solubility","heading":"Interpreting Results","text":"Positive Result (Turbid Solution): Indicates presence HbS\ndifferentiate sickle cell trait (HbAS) sickle cell anemia (HbSS)\nRequires confirmation hemoglobin electrophoresis HPLC\ndifferentiate sickle cell trait (HbAS) sickle cell anemia (HbSS)Requires confirmation hemoglobin electrophoresis HPLCNegative Result (Clear Solution): Indicates absence HbS\nrule hemoglobinopathies\nFalse-negative results can occur, especially infants < 6 months old due high levels HbF\nrule hemoglobinopathiesFalse-negative results can occur, especially infants < 6 months old due high levels HbF","code":""},{"path":"sickle-solubility.html","id":"factors-affecting-accuracy","chapter":"Sickle Solubility","heading":"Factors Affecting Accuracy","text":"High Hematocrit:\nHigh concentrations hemoglobin can lead false-positive results\nDilute sample performing test\nHigh Hematocrit:High concentrations hemoglobin can lead false-positive resultsDilute sample performing testLipemia:\nTurbidity lipemia can interfere visual interpretation test\nCentrifuge sample use clear bottom layer testing\nLipemia:Turbidity lipemia can interfere visual interpretation testCentrifuge sample use clear bottom layer testingHigh White Blood Cell Count:\nCan interfere visual interpretation\nLyse white blood cells performing test\nHigh White Blood Cell Count:Can interfere visual interpretationLyse white blood cells performing testRecent Transfusion:\nCan lead false-negative results patient recently transfused blood contain HbS\nWait least 3 months transfusion performing test\nRecent Transfusion:Can lead false-negative results patient recently transfused blood contain HbSWait least 3 months transfusion performing testHemoglobin Variants HbS:\nrare hemoglobin variants (e.g., HbC-Harlem) can also cause positive result\nConfirm positive results hemoglobin electrophoresis HPLC\nHemoglobin Variants HbS:rare hemoglobin variants (e.g., HbC-Harlem) can also cause positive resultConfirm positive results hemoglobin electrophoresis HPLC","code":""},{"path":"sickle-solubility.html","id":"quality-control-2","chapter":"Sickle Solubility","heading":"Quality Control","text":"Run Positive Negative Controls Test Batch:\nPositive Control: sample known HbS\nNegative Control: sample normal hemoglobin (HbA)\nPositive Control: sample known HbSNegative Control: sample normal hemoglobin (HbA)Use Fresh Reagents:\nEnsure reagents expired stored properly\nEnsure reagents expired stored properlyFollow Manufacturer’s Instructions Carefully:\nAdhere recommended sample volumes, reagent concentrations, incubation times\nAdhere recommended sample volumes, reagent concentrations, incubation timesInspect Reagents Equipment:\nCheck signs contamination deterioration\nEnsure light source adequate visualizing turbidity solution\nCheck signs contamination deteriorationEnsure light source adequate visualizing turbidity solution","code":""},{"path":"sickle-solubility.html","id":"reporting-results-7","chapter":"Sickle Solubility","heading":"Reporting Results","text":"Report result “Positive” “Negative” HbSIndicate test screening test requires confirmation hemoglobin electrophoresis HPLC definitive diagnosisInclude comments qualifications, “False negative possible infants < 6 months old” “Heterozygous result”","code":""},{"path":"sickle-solubility.html","id":"key-terms-57","chapter":"Sickle Solubility","heading":"Key Terms","text":"Sickle Solubility Test: screening test sickle cell disease detects presence HbSHemoglobin S (HbS): abnormal hemoglobin found sickle cell diseaseDeoxygenation: Removal oxygenTurbidity: Cloudiness haziness solutionSickle Cell Anemia: severe inherited blood disorder caused HbSS genotypeSickle Cell Trait: heterozygous carrier state HbS (HbAS)Lysing Agent: chemical used rupture red blood cell membranes release hemoglobinReducing Agent: chemical donates electrons reduces substances","code":""},{"path":"hematocrit.html","id":"hematocrit","chapter":"Hematocrit","heading":"Hematocrit","text":"","code":""},{"path":"hematocrit.html","id":"overview-of-hematocrit-hct","chapter":"Hematocrit","heading":"Overview of Hematocrit (HCT)","text":"Definition: hematocrit percentage blood volume occupied red blood cells (RBCs). ’s simple valuable measurement assessing patient’s red blood cell statusAlternate Names: Packed Cell Volume (PCV)Clinical Significance:\nDetection Monitoring Anemia: Low HCT indicates anemia (decreased red blood cell mass)\nDetection Polycythemia/Erythrocytosis: High HCT indicates increased red blood cell mass\nAssessment Dehydration: Can elevated dehydration due decreased plasma volume\nMonitoring Fluid Balance: Helps assess changes blood volume\nDetection Monitoring Anemia: Low HCT indicates anemia (decreased red blood cell mass)Detection Polycythemia/Erythrocytosis: High HCT indicates increased red blood cell massAssessment Dehydration: Can elevated dehydration due decreased plasma volumeMonitoring Fluid Balance: Helps assess changes blood volumeMethods:\nManual Methods: Centrifugation blood capillary tube (microhematocrit method)\nAutomated Methods: Calculated automated hematology analyzers based RBC count MCV\nManual Methods: Centrifugation blood capillary tube (microhematocrit method)Automated Methods: Calculated automated hematology analyzers based RBC count MCV","code":""},{"path":"hematocrit.html","id":"manual-microhematocrit-method","chapter":"Hematocrit","heading":"Manual Microhematocrit Method","text":"Principle:\nWhole blood collected capillary tube coated anticoagulant (usually heparin)\ntube centrifuged pack red blood cells bottom tube\nheight packed red blood cell column measured compared total height blood column determine hematocrit percentage\nPrinciple:Whole blood collected capillary tube coated anticoagulant (usually heparin)tube centrifuged pack red blood cells bottom tubeThe height packed red blood cell column measured compared total height blood column determine hematocrit percentageMaterials:\nCapillary Tubes:\nGlass plastic capillary tubes (typically 75 mm long internal diameter 1-2 mm)\nCoated anticoagulant (heparin)\n\nCentrifuge:\nspecialized centrifuge designed hold spin capillary tubes high speeds\ncapable generating relative centrifugal force (RCF) least 10,000 g\n\nReader:\ndevice accurately measuring height packed red blood cell column total blood column capillary tube\nCan microhematocrit reader card digital reader\n\nSealing Clay:\nUsed seal one end capillary tube filling\n\nMaterials:Capillary Tubes:\nGlass plastic capillary tubes (typically 75 mm long internal diameter 1-2 mm)\nCoated anticoagulant (heparin)\nGlass plastic capillary tubes (typically 75 mm long internal diameter 1-2 mm)Coated anticoagulant (heparin)Centrifuge:\nspecialized centrifuge designed hold spin capillary tubes high speeds\ncapable generating relative centrifugal force (RCF) least 10,000 g\nspecialized centrifuge designed hold spin capillary tubes high speedsShould capable generating relative centrifugal force (RCF) least 10,000 gReader:\ndevice accurately measuring height packed red blood cell column total blood column capillary tube\nCan microhematocrit reader card digital reader\ndevice accurately measuring height packed red blood cell column total blood column capillary tubeCan microhematocrit reader card digital readerSealing Clay:\nUsed seal one end capillary tube filling\nUsed seal one end capillary tube fillingProcedure:\nSample Collection:\nCollect whole blood EDTA (purple-top) tube\nCapillary blood (fingerstick heelstick) can also used, less accurate\n\nFilling Capillary Tube:\nMix blood sample thoroughly\nHold capillary tube horizontally touch one end blood sample\nAllow tube fill capillary action least 2/3 length\nAvoid introducing air bubbles tube\n\nSealing Tube:\nWipe outside capillary tube clean\nSeal one end tube sealing clay prevent leakage centrifugation\n\nCentrifugation:\nPlace filled sealed capillary tubes microhematocrit centrifuge\nCentrifuge recommended time (typically 5 minutes) specified RCF (10,000-12,000 g)\n\nReading Hematocrit:\nRemove capillary tubes centrifuge\nCarefully place tube microhematocrit reader\nAlign bottom packed red blood cell column 0% line reader\nAlign top plasma layer 100% line reader\nRead hematocrit value interface packed red blood cells plasma\n\nRecord Report Results:\nRecord hematocrit value percentage (%)\nReport result along reference range\nPerform duplicate measurements average results (duplicate results within acceptable limits)\n\nProcedure:Sample Collection:\nCollect whole blood EDTA (purple-top) tube\nCapillary blood (fingerstick heelstick) can also used, less accurate\nCollect whole blood EDTA (purple-top) tubeCapillary blood (fingerstick heelstick) can also used, less accurateFilling Capillary Tube:\nMix blood sample thoroughly\nHold capillary tube horizontally touch one end blood sample\nAllow tube fill capillary action least 2/3 length\nAvoid introducing air bubbles tube\nMix blood sample thoroughlyHold capillary tube horizontally touch one end blood sampleAllow tube fill capillary action least 2/3 lengthAvoid introducing air bubbles tubeSealing Tube:\nWipe outside capillary tube clean\nSeal one end tube sealing clay prevent leakage centrifugation\nWipe outside capillary tube cleanSeal one end tube sealing clay prevent leakage centrifugationCentrifugation:\nPlace filled sealed capillary tubes microhematocrit centrifuge\nCentrifuge recommended time (typically 5 minutes) specified RCF (10,000-12,000 g)\nPlace filled sealed capillary tubes microhematocrit centrifugeCentrifuge recommended time (typically 5 minutes) specified RCF (10,000-12,000 g)Reading Hematocrit:\nRemove capillary tubes centrifuge\nCarefully place tube microhematocrit reader\nAlign bottom packed red blood cell column 0% line reader\nAlign top plasma layer 100% line reader\nRead hematocrit value interface packed red blood cells plasma\nRemove capillary tubes centrifugeCarefully place tube microhematocrit readerAlign bottom packed red blood cell column 0% line readerAlign top plasma layer 100% line readerRead hematocrit value interface packed red blood cells plasmaRecord Report Results:\nRecord hematocrit value percentage (%)\nReport result along reference range\nPerform duplicate measurements average results (duplicate results within acceptable limits)\nRecord hematocrit value percentage (%)Report result along reference rangePerform duplicate measurements average results (duplicate results within acceptable limits)Sources Error Manual Hematocrit Measurement:\nImproper Sealing Capillary Tube: Can lead leakage falsely low results\nInadequate Centrifugation: Insufficient packing red blood cells can lead falsely low results\nDelay Reading: Prolonged delay centrifugation can lead cell settling inaccurate readings\nAir Bubbles: Air bubbles capillary tube can interfere reading\nIncorrect Use Reader: aligning tube properly reader can lead inaccurate results\nExcess Anticoagulant: Overfilling capillary tube blood sample anticoagulant collection tube recommended\nSources Error Manual Hematocrit Measurement:Improper Sealing Capillary Tube: Can lead leakage falsely low resultsInadequate Centrifugation: Insufficient packing red blood cells can lead falsely low resultsDelay Reading: Prolonged delay centrifugation can lead cell settling inaccurate readingsAir Bubbles: Air bubbles capillary tube can interfere readingIncorrect Use Reader: aligning tube properly reader can lead inaccurate resultsExcess Anticoagulant: Overfilling capillary tube blood sample anticoagulant collection tube recommended","code":""},{"path":"hematocrit.html","id":"automated-hematocrit-measurement","chapter":"Hematocrit","heading":"Automated Hematocrit Measurement","text":"Principle:\nAutomated hematology analyzers typically calculate hematocrit based red blood cell count mean corpuscular volume (MCV)\nFormula: HCT = (RBC Count x MCV) / 10\nPrinciple:Automated hematology analyzers typically calculate hematocrit based red blood cell count mean corpuscular volume (MCV)Formula: HCT = (RBC Count x MCV) / 10Procedure:\nautomated analyzer aspirates small amount whole blood sample\nRBC count MCV measured using electrical impedance, optical scatter, methods\nhematocrit calculated using formula \nProcedure:automated analyzer aspirates small amount whole blood sampleThe RBC count MCV measured using electrical impedance, optical scatter, methodsThe hematocrit calculated using formula aboveAdvantages:\nIncreased Speed Efficiency\nImproved Accuracy Precision\nReduced Labor Costs\nAdvantages:Increased Speed EfficiencyImproved Accuracy PrecisionReduced Labor CostsLimitations:\nCan affected certain interfering substances conditions (see )\ndirectly measure packed cell volume; calculated value\nLimitations:Can affected certain interfering substances conditions (see )directly measure packed cell volume; calculated value","code":""},{"path":"hematocrit.html","id":"interfering-substances-and-conditions","chapter":"Hematocrit","heading":"Interfering Substances and Conditions","text":"Several factors can interfere manual automated hematocrit measurements, leading inaccurate results. ’s crucial aware interferences take appropriate corrective actions:Lipemia:\nTurbidity high lipid content can falsely elevate hemoglobin reading, can affect calculated hematocrit\nCorrective Action: Perform saline replacement procedure use lipemia clearing agent\nTurbidity high lipid content can falsely elevate hemoglobin reading, can affect calculated hematocritCorrective Action: Perform saline replacement procedure use lipemia clearing agentHigh White Blood Cell Count (Leukocytosis):\nExtreme leukocytosis can cause falsely elevated hemoglobin hematocrit readings\nCorrective Action: Dilute sample multiply results dilution factor\nExtreme leukocytosis can cause falsely elevated hemoglobin hematocrit readingsCorrective Action: Dilute sample multiply results dilution factorCold Agglutinins:\nantibodies can cause RBCs clump together, leading inaccurate cell counts hematocrit measurement\nCorrective Action: Warm sample 37°C dissociate agglutinins\nantibodies can cause RBCs clump together, leading inaccurate cell counts hematocrit measurementCorrective Action: Warm sample 37°C dissociate agglutininsAbnormal Red Blood Cell Size Shape:\nSpherocytes, schistocytes, abnormally shaped RBCs can affect accuracy manual automated hematocrit measurements\nSpherocytes, schistocytes, abnormally shaped RBCs can affect accuracy manual automated hematocrit measurementsHigh Hemoglobin (Results beyond linearity instrument)\nDilute blood Hgb result within linear range instrument\nDilute blood Hgb result within linear range instrument","code":""},{"path":"hematocrit.html","id":"quality-control-qc-1","chapter":"Hematocrit","heading":"Quality Control (QC)","text":"Calibrate Instruments:\nPerform regular calibration microhematocrit centrifuge automated hematology analyzer according manufacturer’s instructions\nCalibrate Instruments:Perform regular calibration microhematocrit centrifuge automated hematology analyzer according manufacturer’s instructionsRun Control Materials:\nRun control materials regular intervals (e.g., daily, batch samples)\nUse controls appropriate types samples analyzed (e.g., whole blood controls)\nRun Control Materials:Run control materials regular intervals (e.g., daily, batch samples)Use controls appropriate types samples analyzed (e.g., whole blood controls)Review Control Results:\nReview control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)\nTake corrective action control results outside acceptable range\nReview Control Results:Review control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)Take corrective action control results outside acceptable rangeCheck Rule Three:\nVerify hemoglobin, hematocrit, RBC count consistent , using “Rule Three”:\nHGB x 3 = HCT (± 3)\n\nRule Three met, investigate potential errors\nCheck Rule Three:Verify hemoglobin, hematocrit, RBC count consistent , using “Rule Three”:\nHGB x 3 = HCT (± 3)\nHGB x 3 = HCT (± 3)Rule Three met, investigate potential errors","code":""},{"path":"hematocrit.html","id":"reporting-results-8","chapter":"Hematocrit","heading":"Reporting Results","text":"Report hematocrit value percentage (%)Include reference range patient’s age sexNote abnormal results flagsDocument quality control procedures corrective actions taken","code":""},{"path":"hematocrit.html","id":"key-terms-58","chapter":"Hematocrit","heading":"Key Terms","text":"Hematocrit (HCT): percentage blood volume occupied red blood cellsPacked Cell Volume (PCV): Another name hematocritMicrohematocrit: manual method measuring hematocrit using capillary tubeEDTA: Ethylenediaminetetraacetic acid, anticoagulant used blood collection tubesRCF: Relative centrifugal force, measure force applied centrifugationLipemia: presence excessive lipids bloodSaline Replacement: procedure remove lipemic plasma replace salineQuality Control: Procedures used monitor accuracy precision laboratory testingCalibration: process adjusting instrument ensure accurate reliable results","code":""},{"path":"indices.html","id":"indices","chapter":"Indices","heading":"Indices","text":"","code":""},{"path":"indices.html","id":"overview-of-cbc-indices","chapter":"Indices","heading":"Overview of CBC Indices","text":"Definition: red blood cell (RBC) indices set calculations derived complete blood count (CBC) provide information size, hemoglobin content, concentration hemoglobin red blood cellsClinical Significance:\nClassification Anemias: RBC indices essential classifying anemias microcytic, normocytic, macrocytic, determining degree hemoglobinization (hypochromic vs. normochromic)\nDifferential Diagnosis: Help narrow differential diagnosis guide testing\nMonitoring Treatment: Useful monitoring response treatment anemia\nClassification Anemias: RBC indices essential classifying anemias microcytic, normocytic, macrocytic, determining degree hemoglobinization (hypochromic vs. normochromic)Differential Diagnosis: Help narrow differential diagnosis guide testingMonitoring Treatment: Useful monitoring response treatment anemiaMeasured Parameters:\nRBC indices calculated following parameters, directly measured automated hematology analyzers:\nRed Blood Cell Count (RBC): Number red blood cells per unit volume blood (e.g., x 10^12/L)\nHemoglobin (HGB): Concentration hemoglobin whole blood (g/dL)\nHematocrit (HCT): Percentage blood volume occupied red blood cells (%)\n\nRBC indices calculated following parameters, directly measured automated hematology analyzers:\nRed Blood Cell Count (RBC): Number red blood cells per unit volume blood (e.g., x 10^12/L)\nHemoglobin (HGB): Concentration hemoglobin whole blood (g/dL)\nHematocrit (HCT): Percentage blood volume occupied red blood cells (%)\nRed Blood Cell Count (RBC): Number red blood cells per unit volume blood (e.g., x 10^12/L)Hemoglobin (HGB): Concentration hemoglobin whole blood (g/dL)Hematocrit (HCT): Percentage blood volume occupied red blood cells (%)Calculated Indices:\nRBC indices calculated using measured parameters following formulas:\nMean Corpuscular Volume (MCV)\nMean Corpuscular Hemoglobin (MCH)\nMean Corpuscular Hemoglobin Concentration (MCHC)\n\nRBC indices calculated using measured parameters following formulas:\nMean Corpuscular Volume (MCV)\nMean Corpuscular Hemoglobin (MCH)\nMean Corpuscular Hemoglobin Concentration (MCHC)\nMean Corpuscular Volume (MCV)Mean Corpuscular Hemoglobin (MCH)Mean Corpuscular Hemoglobin Concentration (MCHC)","code":""},{"path":"indices.html","id":"key-rbc-indices-and-their-significance","chapter":"Indices","heading":"Key RBC Indices and Their Significance","text":"Mean Corpuscular Volume (MCV):\nDefinition: average volume individual red blood cells\nFormula: MCV (fL) = (HCT / RBC) x 10\nUnits: femtoliters (fL)\nReference Range: Typically 80-100 fL (varies slightly laboratory)\nClinical Significance:\nMCV < 80 fL: Microcytic Anemia (small RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nAnemia chronic disease (cases)\n\nMCV 80-100 fL: Normocytic Anemia (normal-sized RBCs)\nAcute blood loss\nHemolytic anemia\nAplastic anemia\nAnemia chronic disease (many cases)\nEarly iron deficiency\n\nMCV > 100 fL: Macrocytic Anemia (large RBCs)\nVitamin B12 deficiency\nFolate deficiency\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\n\n\nDefinition: average volume individual red blood cellsFormula: MCV (fL) = (HCT / RBC) x 10Units: femtoliters (fL)Reference Range: Typically 80-100 fL (varies slightly laboratory)Clinical Significance:\nMCV < 80 fL: Microcytic Anemia (small RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nAnemia chronic disease (cases)\n\nMCV 80-100 fL: Normocytic Anemia (normal-sized RBCs)\nAcute blood loss\nHemolytic anemia\nAplastic anemia\nAnemia chronic disease (many cases)\nEarly iron deficiency\n\nMCV > 100 fL: Macrocytic Anemia (large RBCs)\nVitamin B12 deficiency\nFolate deficiency\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\n\nMCV < 80 fL: Microcytic Anemia (small RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nAnemia chronic disease (cases)\nIron deficiency anemiaThalassemiaSideroblastic anemiaAnemia chronic disease (cases)MCV 80-100 fL: Normocytic Anemia (normal-sized RBCs)\nAcute blood loss\nHemolytic anemia\nAplastic anemia\nAnemia chronic disease (many cases)\nEarly iron deficiency\nAcute blood lossHemolytic anemiaAplastic anemiaAnemia chronic disease (many cases)Early iron deficiencyMCV > 100 fL: Macrocytic Anemia (large RBCs)\nVitamin B12 deficiency\nFolate deficiency\nAlcoholism\nLiver disease\nHypothyroidism\nMyelodysplastic syndromes (MDS)\nVitamin B12 deficiencyFolate deficiencyAlcoholismLiver diseaseHypothyroidismMyelodysplastic syndromes (MDS)Mean Corpuscular Hemoglobin (MCH):\nDefinition: average amount hemoglobin per red blood cell\nFormula: MCH (pg) = HGB / RBC x 10\nUnits: picograms (pg)\nReference Range: Typically 27-33 pg (varies slightly laboratory)\nClinical Significance:\nMCH generally proportional MCV, useful assessing hemoglobin content relation cell size\nIncreased MCH: Macrocytic anemias\nDecreased MCH: Microcytic anemias\nNote: MCH less useful MCV MCHC classifying anemias\n\nDefinition: average amount hemoglobin per red blood cellFormula: MCH (pg) = HGB / RBC x 10Units: picograms (pg)Reference Range: Typically 27-33 pg (varies slightly laboratory)Clinical Significance:\nMCH generally proportional MCV, useful assessing hemoglobin content relation cell size\nIncreased MCH: Macrocytic anemias\nDecreased MCH: Microcytic anemias\nNote: MCH less useful MCV MCHC classifying anemias\nMCH generally proportional MCV, useful assessing hemoglobin content relation cell sizeIncreased MCH: Macrocytic anemiasDecreased MCH: Microcytic anemiasNote: MCH less useful MCV MCHC classifying anemiasMean Corpuscular Hemoglobin Concentration (MCHC):\nDefinition: average concentration hemoglobin given volume red blood cells\nFormula: MCHC (g/dL) = HGB / HCT x 100\nUnits: grams per deciliter (g/dL) grams per liter (g/L)\nReference Range: Typically 32-36 g/dL (varies slightly laboratory)\nClinical Significance:\nMCHC Provides information degree hemoglobinization red blood cells (.e., “full” RBCs hemoglobin)\nIncreased MCHC: Hyperchromia (rare); seen :\nHereditary spherocytosis: Due dehydration red blood cells\nCold agglutinin disease: Due interference hemoglobin measurement\n\nDecreased MCHC: Hypochromia (pale RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nNote: MCHC critical index quality control. MCHC values > 36 g/dL rare often indicate laboratory error (e.g., lipemia, cold agglutinins)\n\n\nDefinition: average concentration hemoglobin given volume red blood cellsFormula: MCHC (g/dL) = HGB / HCT x 100Units: grams per deciliter (g/dL) grams per liter (g/L)Reference Range: Typically 32-36 g/dL (varies slightly laboratory)Clinical Significance:\nMCHC Provides information degree hemoglobinization red blood cells (.e., “full” RBCs hemoglobin)\nIncreased MCHC: Hyperchromia (rare); seen :\nHereditary spherocytosis: Due dehydration red blood cells\nCold agglutinin disease: Due interference hemoglobin measurement\n\nDecreased MCHC: Hypochromia (pale RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nNote: MCHC critical index quality control. MCHC values > 36 g/dL rare often indicate laboratory error (e.g., lipemia, cold agglutinins)\n\nMCHC Provides information degree hemoglobinization red blood cells (.e., “full” RBCs hemoglobin)Increased MCHC: Hyperchromia (rare); seen :\nHereditary spherocytosis: Due dehydration red blood cells\nCold agglutinin disease: Due interference hemoglobin measurement\nHereditary spherocytosis: Due dehydration red blood cellsCold agglutinin disease: Due interference hemoglobin measurementDecreased MCHC: Hypochromia (pale RBCs)\nIron deficiency anemia\nThalassemia\nSideroblastic anemia\nNote: MCHC critical index quality control. MCHC values > 36 g/dL rare often indicate laboratory error (e.g., lipemia, cold agglutinins)\nIron deficiency anemiaThalassemiaSideroblastic anemiaNote: MCHC critical index quality control. MCHC values > 36 g/dL rare often indicate laboratory error (e.g., lipemia, cold agglutinins)Red Cell Distribution Width (RDW):\nDefinition: measure variation red blood cell size (anisocytosis)\nUnits: Expressed coefficient variation (CV) standard deviation (SD)\nReference Range:\nRDW-CV: Typically 11.5-14.5%\nRDW-SD: Typically 35-56 fL\n\nClinical Significance:\nIncreased RDW: Indicates greater variation RBC size\nUsed combination MCV narrow differential diagnosis anemia\nHelpful Distinguishing Different Anemias:\nIron Deficiency Anemia: High RDW (due increased variation RBC size)\nThalassemia: Normal slightly elevated RDW (RBCs uniformly small)\nAnemia Chronic Disease: Normal RDW (unless coexisting iron deficiency)\n\n\nDefinition: measure variation red blood cell size (anisocytosis)Units: Expressed coefficient variation (CV) standard deviation (SD)Reference Range:\nRDW-CV: Typically 11.5-14.5%\nRDW-SD: Typically 35-56 fL\nRDW-CV: Typically 11.5-14.5%RDW-SD: Typically 35-56 fLClinical Significance:\nIncreased RDW: Indicates greater variation RBC size\nUsed combination MCV narrow differential diagnosis anemia\nHelpful Distinguishing Different Anemias:\nIron Deficiency Anemia: High RDW (due increased variation RBC size)\nThalassemia: Normal slightly elevated RDW (RBCs uniformly small)\nAnemia Chronic Disease: Normal RDW (unless coexisting iron deficiency)\n\nIncreased RDW: Indicates greater variation RBC sizeUsed combination MCV narrow differential diagnosis anemiaHelpful Distinguishing Different Anemias:\nIron Deficiency Anemia: High RDW (due increased variation RBC size)\nThalassemia: Normal slightly elevated RDW (RBCs uniformly small)\nAnemia Chronic Disease: Normal RDW (unless coexisting iron deficiency)\nIron Deficiency Anemia: High RDW (due increased variation RBC size)Thalassemia: Normal slightly elevated RDW (RBCs uniformly small)Anemia Chronic Disease: Normal RDW (unless coexisting iron deficiency)","code":""},{"path":"indices.html","id":"interpretation-of-rbc-indices","chapter":"Indices","heading":"Interpretation of RBC Indices","text":"Microcytic Anemias (MCV < 80 fL):\nIron Deficiency Anemia: Low MCV, low MCH, low MCHC, high RDW, low serum iron ferritin, high TIBC\nThalassemia: Low MCV, low MCH, normal high RBC count, normal elevated serum iron ferritin, normal low RDW\nSideroblastic Anemia: Low normal MCV, normal high serum iron ferritin, ringed sideroblasts bone marrow\nAnemia Chronic Disease: Low normal MCV, low serum iron, normal high ferritin\nIron Deficiency Anemia: Low MCV, low MCH, low MCHC, high RDW, low serum iron ferritin, high TIBCThalassemia: Low MCV, low MCH, normal high RBC count, normal elevated serum iron ferritin, normal low RDWSideroblastic Anemia: Low normal MCV, normal high serum iron ferritin, ringed sideroblasts bone marrowAnemia Chronic Disease: Low normal MCV, low serum iron, normal high ferritinNormocytic Anemias (MCV 80-100 fL):\nAcute Blood Loss: Normal RBC indices initially, can develop microcytic anemia time iron stores depleted\nHemolytic Anemias: Normal slightly elevated MCV, elevated reticulocyte count, elevated bilirubin LDH, decreased haptoglobin\nAplastic Anemia: Normal RBC indices, pancytopenia, hypocellular bone marrow\nAnemia Chronic Disease: Normal RBC indices, low serum iron, normal high ferritin\nAcute Blood Loss: Normal RBC indices initially, can develop microcytic anemia time iron stores depletedHemolytic Anemias: Normal slightly elevated MCV, elevated reticulocyte count, elevated bilirubin LDH, decreased haptoglobinAplastic Anemia: Normal RBC indices, pancytopenia, hypocellular bone marrowAnemia Chronic Disease: Normal RBC indices, low serum iron, normal high ferritinMacrocytic Anemias (MCV > 100 fL):\nVitamin B12 Deficiency: High MCV, oval macrocytes, hypersegmented neutrophils, low serum vitamin B12, elevated MMA homocysteine\nFolate Deficiency: High MCV, oval macrocytes, hypersegmented neutrophils, low serum folate, elevated homocysteine\nAlcoholism: High MCV, round macrocytes, normal vitamin B12 folate levels\nLiver Disease: High MCV, round macrocytes, abnormal liver function tests\nHypothyroidism: High MCV, round macrocytes, abnormal thyroid function tests\nMyelodysplastic Syndromes (MDS): High MCV, dysplastic features bone marrow\nVitamin B12 Deficiency: High MCV, oval macrocytes, hypersegmented neutrophils, low serum vitamin B12, elevated MMA homocysteineFolate Deficiency: High MCV, oval macrocytes, hypersegmented neutrophils, low serum folate, elevated homocysteineAlcoholism: High MCV, round macrocytes, normal vitamin B12 folate levelsLiver Disease: High MCV, round macrocytes, abnormal liver function testsHypothyroidism: High MCV, round macrocytes, abnormal thyroid function testsMyelodysplastic Syndromes (MDS): High MCV, dysplastic features bone marrow","code":""},{"path":"indices.html","id":"sources-of-error-and-troubleshooting","chapter":"Indices","heading":"Sources of Error and Troubleshooting","text":"Cold Agglutinins: Cause falsely elevated MCV MCHC falsely decreased RBC count\nCorrective Action: Warm sample 37°C reanalyze\nCorrective Action: Warm sample 37°C reanalyzeLipemia: Falsely elevates hemoglobin, can affect MCV MCHC calculations\nCorrective Action: Perform saline replacement use lipemia clearing agent\nCorrective Action: Perform saline replacement use lipemia clearing agentHigh White Blood Cell Count (Leukocytosis): Can interfere hemoglobin measurement affect RBC indices\nCorrective Action: Dilute sample correct results dilution factor\nCorrective Action: Dilute sample correct results dilution factorClotted Sample: Invalidates results requires recollection new sample","code":""},{"path":"indices.html","id":"key-terms-59","chapter":"Indices","heading":"Key Terms","text":"MCV (Mean Corpuscular Volume): Average volume red blood cellsMCH (Mean Corpuscular Hemoglobin): Average amount hemoglobin per red blood cellMCHC (Mean Corpuscular Hemoglobin Concentration): Average concentration hemoglobin red blood cellsRDW (Red Cell Distribution Width): Measure variation red blood cell size (anisocytosis)Microcytic: Small red blood cellsNormocytic: Normal-sized red blood cellsMacrocytic: Large red blood cellsHypochromic: Decreased hemoglobin content (pale color)Hyperchromic: Increased hemoglobin content (intensely colored)Anisocytosis: Variation red blood cell sizeAnemia: Deficiency red blood cells hemoglobin","code":""},{"path":"hemolysis.html","id":"hemolysis","chapter":"Hemolysis","heading":"Hemolysis","text":"","code":""},{"path":"hemolysis.html","id":"overview-of-hemolytic-indicators","chapter":"Hemolysis","heading":"Overview of Hemolytic Indicators","text":"Definition: Laboratory tests used identify quantify presence hemolysis (RBC destruction) vivo (within body)Clinical Significance:\nDiagnosis Hemolytic Anemia: Helps confirm presence hemolytic anemia distinguish causes anemia\nAssessment Hemolysis Severity: Helps evaluate degree RBC destruction\nDifferentiation Hemolytic Anemia Types: Helps differentiate intravascular extravascular hemolysis\nMonitoring Response Therapy: Used assess effectiveness treatment hemolytic anemia\nDiagnosis Hemolytic Anemia: Helps confirm presence hemolytic anemia distinguish causes anemiaAssessment Hemolysis Severity: Helps evaluate degree RBC destructionDifferentiation Hemolytic Anemia Types: Helps differentiate intravascular extravascular hemolysisMonitoring Response Therapy: Used assess effectiveness treatment hemolytic anemiaKey Indicators:\nHaptoglobin\nLactate Dehydrogenase (LDH)\nUnconjugated (Indirect) Bilirubin\nUrine Hemoglobin Hemosiderin\nHaptoglobinLactate Dehydrogenase (LDH)Unconjugated (Indirect) BilirubinUrine Hemoglobin HemosiderinMethods: tests typically performed using spectrophotometric immunochemical methods serum, plasma, urine samples","code":""},{"path":"hemolysis.html","id":"haptoglobin","chapter":"Hemolysis","heading":"Haptoglobin","text":"Definition: alpha-2 globulin protein synthesized liver binds free hemoglobin (Hb) released plasmaFunction:\nBinding Free Hemoglobin: Haptoglobin binds free hemoglobin, forming stable hemoglobin-haptoglobin complex\nClearance Hemoglobin: hemoglobin-haptoglobin complex rapidly cleared circulation liver via CD163 receptor macrophages\nPrevents Kidney Damage: Binding haptoglobin prevents free hemoglobin filtered kidneys, can cause kidney damage\nAntioxidant Activity: Haptoglobin antioxidant properties, protecting tissues oxidative damage caused free hemoglobin\nBinding Free Hemoglobin: Haptoglobin binds free hemoglobin, forming stable hemoglobin-haptoglobin complexClearance Hemoglobin: hemoglobin-haptoglobin complex rapidly cleared circulation liver via CD163 receptor macrophagesPrevents Kidney Damage: Binding haptoglobin prevents free hemoglobin filtered kidneys, can cause kidney damageAntioxidant Activity: Haptoglobin antioxidant properties, protecting tissues oxidative damage caused free hemoglobinMeasurement:\nImmunoturbidimetric Assay: common method\nAntibodies specific haptoglobin added sample\nantibodies bind haptoglobin, forming immune complexes\nturbidity (cloudiness) solution measured, proportional haptoglobin concentration\n\nNephelometry: Similar immunoturbidimetry, measures light scattered immune complexes\nImmunoturbidimetric Assay: common method\nAntibodies specific haptoglobin added sample\nantibodies bind haptoglobin, forming immune complexes\nturbidity (cloudiness) solution measured, proportional haptoglobin concentration\nAntibodies specific haptoglobin added sampleThe antibodies bind haptoglobin, forming immune complexesThe turbidity (cloudiness) solution measured, proportional haptoglobin concentrationNephelometry: Similar immunoturbidimetry, measures light scattered immune complexesReference Range:\nVaries depending laboratory assay used\nTypical reference range: 30-200 mg/dL (adults)\nVaries depending laboratory assay usedTypical reference range: 30-200 mg/dL (adults)Interpretation:\nDecreased Haptoglobin:\nIncreased hemolysis: Haptoglobin consumed binds free hemoglobin\nLiver disease: Impaired haptoglobin synthesis\nCongenital haptoglobin deficiency\n\nElevated Haptoglobin:\nAcute phase reaction: Haptoglobin acute phase reactant, levels can increase inflammation infection\nCorticosteroid use\n\nDecreased Haptoglobin:\nIncreased hemolysis: Haptoglobin consumed binds free hemoglobin\nLiver disease: Impaired haptoglobin synthesis\nCongenital haptoglobin deficiency\nIncreased hemolysis: Haptoglobin consumed binds free hemoglobinLiver disease: Impaired haptoglobin synthesisCongenital haptoglobin deficiencyElevated Haptoglobin:\nAcute phase reaction: Haptoglobin acute phase reactant, levels can increase inflammation infection\nCorticosteroid use\nAcute phase reaction: Haptoglobin acute phase reactant, levels can increase inflammation infectionCorticosteroid use","code":""},{"path":"hemolysis.html","id":"lactate-dehydrogenase-ldh","chapter":"Hemolysis","heading":"Lactate Dehydrogenase (LDH)","text":"Definition: intracellular enzyme present many tissues, including red blood cells, liver, muscle, heartFunction: Catalyzes interconversion lactate pyruvateIsoenzymes: LDH exists five isoenzymes (LDH1-LDH5), different tissue distribution:\nLDH1: Heart, red blood cells\nLDH2: Heart, red blood cells\nLDH3: Lungs, lymphocytes\nLDH4: Liver, muscle\nLDH5: Liver, skeletal muscle\nLDH1: Heart, red blood cellsLDH2: Heart, red blood cellsLDH3: Lungs, lymphocytesLDH4: Liver, muscleLDH5: Liver, skeletal muscleMeasurement:\nEnzymatic Assay: Measures rate conversion lactate pyruvate pyruvate lactate\nSpectrophotometry: change absorbance NADH (nicotinamide adenine dinucleotide) measured specific wavelength\nEnzymatic Assay: Measures rate conversion lactate pyruvate pyruvate lactateSpectrophotometry: change absorbance NADH (nicotinamide adenine dinucleotide) measured specific wavelengthReference Range:\nVaries depending laboratory assay used\nTypical reference range: 100-225 U/L (adults)\nVaries depending laboratory assay usedTypical reference range: 100-225 U/L (adults)Interpretation:\nElevated LDH:\nHemolysis: LDH released damaged red blood cells\nTissue Injury: LDH released damaged tissues (e.g., heart, liver, muscle)\nMalignancy: cancers can cause elevated LDH levels\nPulmonary Embolism\n\nIsoenzyme Analysis (Less Common): May performed identify source LDH elevation\nElevated LDH1 LDH2: Suggests cardiac RBC damage\nElevated LDH5: Suggests liver muscle damage\n\nElevated LDH:\nHemolysis: LDH released damaged red blood cells\nTissue Injury: LDH released damaged tissues (e.g., heart, liver, muscle)\nMalignancy: cancers can cause elevated LDH levels\nPulmonary Embolism\nHemolysis: LDH released damaged red blood cellsTissue Injury: LDH released damaged tissues (e.g., heart, liver, muscle)Malignancy: cancers can cause elevated LDH levelsPulmonary EmbolismIsoenzyme Analysis (Less Common): May performed identify source LDH elevation\nElevated LDH1 LDH2: Suggests cardiac RBC damage\nElevated LDH5: Suggests liver muscle damage\nElevated LDH1 LDH2: Suggests cardiac RBC damageElevated LDH5: Suggests liver muscle damage","code":""},{"path":"hemolysis.html","id":"unconjugated-indirect-bilirubin","chapter":"Hemolysis","heading":"Unconjugated (Indirect) Bilirubin","text":"Definition: yellow pigment formed breakdown heme (iron-containing portion hemoglobin)Formation Metabolism:\nHeme converted biliverdin heme oxygenase\nBiliverdin converted unconjugated bilirubin biliverdin reductase\nUnconjugated bilirubin transported blood bound albumin\nliver, unconjugated bilirubin conjugated glucuronic acid UDP-glucuronosyltransferase (UGT)\nConjugated bilirubin excreted bile intestines\nintestines, bilirubin converted urobilinogen bacteria\nUrobilinogen either:\nExcreted feces (stercobilin, gives feces brown color)\nReabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)\n\nHeme converted biliverdin heme oxygenaseBiliverdin converted unconjugated bilirubin biliverdin reductaseUnconjugated bilirubin transported blood bound albuminIn liver, unconjugated bilirubin conjugated glucuronic acid UDP-glucuronosyltransferase (UGT)Conjugated bilirubin excreted bile intestinesIn intestines, bilirubin converted urobilinogen bacteriaUrobilinogen either:\nExcreted feces (stercobilin, gives feces brown color)\nReabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)\nExcreted feces (stercobilin, gives feces brown color)Reabsorbed bloodstream excreted urine (urobilin, gives urine yellow color)Measurement:\nDiazo Reaction: Bilirubin reacts diazo reagent form colored product\nSpectrophotometry: intensity color measured specific wavelength\nDirect Bilirubin: Reacts directly diazo reagent\nTotal Bilirubin: Requires addition accelerator (e.g., methanol) react conjugated unconjugated bilirubin\nIndirect Bilirubin: Calculated subtracting direct bilirubin total bilirubin (Indirect = Total - Direct)\nDiazo Reaction: Bilirubin reacts diazo reagent form colored productSpectrophotometry: intensity color measured specific wavelengthDirect Bilirubin: Reacts directly diazo reagentTotal Bilirubin: Requires addition accelerator (e.g., methanol) react conjugated unconjugated bilirubinIndirect Bilirubin: Calculated subtracting direct bilirubin total bilirubin (Indirect = Total - Direct)Reference Range:\nVaries depending laboratory assay used\nTypical reference range:\nTotal Bilirubin: 0.3-1.0 mg/dL\nDirect Bilirubin: 0.0-0.3 mg/dL\nIndirect Bilirubin: 0.2-0.8 mg/dL\n\nVaries depending laboratory assay usedTypical reference range:\nTotal Bilirubin: 0.3-1.0 mg/dL\nDirect Bilirubin: 0.0-0.3 mg/dL\nIndirect Bilirubin: 0.2-0.8 mg/dL\nTotal Bilirubin: 0.3-1.0 mg/dLDirect Bilirubin: 0.0-0.3 mg/dLIndirect Bilirubin: 0.2-0.8 mg/dLInterpretation:\nElevated Unconjugated (Indirect) Bilirubin:\nIncreased bilirubin production due hemolysis\nImpaired bilirubin uptake conjugation liver\nExamples: Hemolytic anemia, Gilbert syndrome, Crigler-Najjar syndrome\n\nElevated Conjugated (Direct) Bilirubin:\nImpaired excretion conjugated bilirubin liver\nBiliary obstruction (e.g., gallstones, tumor)\nLiver disease (e.g., hepatitis, cirrhosis)\n\nElevated Unconjugated (Indirect) Bilirubin:\nIncreased bilirubin production due hemolysis\nImpaired bilirubin uptake conjugation liver\nExamples: Hemolytic anemia, Gilbert syndrome, Crigler-Najjar syndrome\nIncreased bilirubin production due hemolysisImpaired bilirubin uptake conjugation liverExamples: Hemolytic anemia, Gilbert syndrome, Crigler-Najjar syndromeElevated Conjugated (Direct) Bilirubin:\nImpaired excretion conjugated bilirubin liver\nBiliary obstruction (e.g., gallstones, tumor)\nLiver disease (e.g., hepatitis, cirrhosis)\nImpaired excretion conjugated bilirubin liverBiliary obstruction (e.g., gallstones, tumor)Liver disease (e.g., hepatitis, cirrhosis)","code":""},{"path":"hemolysis.html","id":"urine-hemoglobin-and-hemosiderin","chapter":"Hemolysis","heading":"Urine Hemoglobin and Hemosiderin","text":"Urine Hemoglobin:\nNormally, little hemoglobin urine\nintravascular hemolysis, free hemoglobin released plasma\nHaptoglobin becomes saturated, free hemoglobin filtered kidneys\nhemoglobin reabsorbed renal tubules\nExcess hemoglobin excreted urine (hemoglobinuria), causing urine appear red brown\nMeasured using urine dipstick test\nFalse-positive results can occur myoglobinuria certain medications\nNormally, little hemoglobin urineIn intravascular hemolysis, free hemoglobin released plasmaHaptoglobin becomes saturated, free hemoglobin filtered kidneysSome hemoglobin reabsorbed renal tubulesExcess hemoglobin excreted urine (hemoglobinuria), causing urine appear red brownMeasured using urine dipstick testFalse-positive results can occur myoglobinuria certain medicationsUrine Hemosiderin:\nHemosiderin iron-storage complex derived hemoglobin\nchronic intravascular hemolysis, renal tubular cells reabsorb hemoglobin store hemosiderin\nHemosiderin eventually sloughed urine (hemosiderinuria)\nUrine hemosiderin can detected using Prussian blue stain urine sediment sample\nHemosiderin iron-storage complex derived hemoglobinIn chronic intravascular hemolysis, renal tubular cells reabsorb hemoglobin store hemosiderinHemosiderin eventually sloughed urine (hemosiderinuria)Urine hemosiderin can detected using Prussian blue stain urine sediment sample","code":""},{"path":"hemolysis.html","id":"summary-table-of-hemolytic-indicators","chapter":"Hemolysis","heading":"Summary Table of Hemolytic Indicators","text":"","code":""},{"path":"hemolysis.html","id":"differential-diagnosis-of-hemolytic-anemias","chapter":"Hemolysis","heading":"Differential Diagnosis of Hemolytic Anemias","text":"Hemolytic Anemia:\nElevated Reticulocyte Count: Increased bone marrow response\nElevated Indirect Bilirubin LDH: Release intracellular contents\nDecreased Haptoglobin: Consumption free hemoglobin\nHemolytic Anemia:Elevated Reticulocyte Count: Increased bone marrow responseElevated Indirect Bilirubin LDH: Release intracellular contentsDecreased Haptoglobin: Consumption free hemoglobinExtravascular Hemolysis: (e.g., Hereditary Spherocytosis, Warm Autoimmune Hemolytic Anemia)\nSpherocytes Peripheral Smear:\nPositive DAT (AIHA):\nSplenomegaly:\nExtravascular Hemolysis: (e.g., Hereditary Spherocytosis, Warm Autoimmune Hemolytic Anemia)Spherocytes Peripheral Smear:Positive DAT (AIHA):Splenomegaly:Intravascular Hemolysis: (e.g., TTP, PNH)\nSchistocytes Peripheral Smear:\nHemoglobinuria:\nHemosiderinuria:\nIntravascular Hemolysis: (e.g., TTP, PNH)Schistocytes Peripheral Smear:Hemoglobinuria:Hemosiderinuria:","code":""},{"path":"hemolysis.html","id":"key-terms-60","chapter":"Hemolysis","heading":"Key Terms","text":"Hemolysis: Destruction red blood cellsIntravascular Hemolysis: RBC destruction within blood vesselsExtravascular Hemolysis: RBC destruction outside blood vessels (primarily spleen)Haptoglobin: Protein binds free hemoglobinLactate Dehydrogenase (LDH): Enzyme released damaged cellsBilirubin: Product heme breakdownUnconjugated (Indirect) Bilirubin: Bilirubin processed liverHemoglobinuria: Hemoglobin urineHemosiderinuria: Hemosiderin (iron) urine","code":""},{"path":"special-stains.html","id":"special-stains","chapter":"Special Stains","heading":"Special Stains","text":"","code":""},{"path":"special-stains.html","id":"overview-of-special-stains","chapter":"Special Stains","heading":"Overview of Special Stains","text":"Definition: Histochemical staining techniques used hematology identify specific cellular components enzymatic activities aid classification diagnosis hematologic disordersPurpose:\nDifferentiate Cell Lineages: Distinguish myeloid, lymphoid, erythroid cells\nIdentify Abnormalities: Detect specific inclusions enzymatic activities characteristic certain diseases\nClassify Leukemias: Aid classification acute leukemias\nAssess Iron Stores: Evaluate iron levels bone marrow identify abnormal iron deposition\nDetect Fetal-Maternal Hemorrhage: Quantify fetal cells maternal circulation\nDifferentiate Cell Lineages: Distinguish myeloid, lymphoid, erythroid cellsIdentify Abnormalities: Detect specific inclusions enzymatic activities characteristic certain diseasesClassify Leukemias: Aid classification acute leukemiasAssess Iron Stores: Evaluate iron levels bone marrow identify abnormal iron depositionDetect Fetal-Maternal Hemorrhage: Quantify fetal cells maternal circulationMethods: Involve specific staining procedures performed peripheral blood smears bone marrow aspirate smears, followed microscopic examination","code":""},{"path":"special-stains.html","id":"myeloperoxidase-mpo-stain","chapter":"Special Stains","heading":"Myeloperoxidase (MPO) Stain:","text":"Principle: Detects presence myeloperoxidase, enzyme found primary granules myeloid cells (neutrophils, eosinophils, monocytes)Procedure:\nPrepare smear bone marrow aspirate peripheral blood\nFix smear\nIncubate smear substrate (e.g., benzidine dihydrochloride 3,3’-diaminobenzidine) hydrogen peroxide (H2O2)\nMPO cells catalyzes oxidation substrate, producing colored precipitate\nCounterstain smear (e.g., hematoxylin)\nExamine smear microscope\nPrepare smear bone marrow aspirate peripheral bloodFix smearIncubate smear substrate (e.g., benzidine dihydrochloride 3,3’-diaminobenzidine) hydrogen peroxide (H2O2)MPO cells catalyzes oxidation substrate, producing colored precipitateCounterstain smear (e.g., hematoxylin)Examine smear microscopeInterpretation:\nPositive: Myeloblasts, promyelocytes, neutrophils, eosinophils show granular staining pattern\nNegative: Lymphoblasts, megakaryocytes, erythrocytes negative\nMonocytes: Show weak, diffuse positivity\nPositive: Myeloblasts, promyelocytes, neutrophils, eosinophils show granular staining patternNegative: Lymphoblasts, megakaryocytes, erythrocytes negativeMonocytes: Show weak, diffuse positivityClinical Significance:\nDifferentiate AML : MPO positive myeloblasts negative lymphoblasts, helping distinguish acute myeloid leukemia (AML) acute lymphoblastic leukemia ()\nSubclassification AML: Helps identify specific AML subtypes (e.g., AML minimal differentiation may MPO-negative)\nDifferentiate AML : MPO positive myeloblasts negative lymphoblasts, helping distinguish acute myeloid leukemia (AML) acute lymphoblastic leukemia ()Subclassification AML: Helps identify specific AML subtypes (e.g., AML minimal differentiation may MPO-negative)","code":""},{"path":"special-stains.html","id":"esterase-stains","chapter":"Special Stains","heading":"Esterase Stains:","text":"Principle: Detect presence esterase enzymes myeloid monocytic cells; two main types:\nSpecific Esterase (Chloroacetate Esterase, CAE): Detects chloroacetate esterase, primarily found granulocytes (neutrophils)\nNon-Specific Esterase (α-Naphthyl Butyrate Esterase, ANBE): Detects α-naphthyl butyrate esterase, found monocytes macrophages\nSpecific Esterase (Chloroacetate Esterase, CAE): Detects chloroacetate esterase, primarily found granulocytes (neutrophils)Non-Specific Esterase (α-Naphthyl Butyrate Esterase, ANBE): Detects α-naphthyl butyrate esterase, found monocytes macrophagesProcedure:\nPrepare smear bone marrow aspirate peripheral blood\nFix smear\nIncubate smear appropriate substrate (chloroacetate ester α-naphthyl butyrate) diazonium salt\nEsterase enzymes cells hydrolyze substrate, released product reacts diazonium salt form colored precipitate\nCounterstain smear\nExamine smear microscope\nPrepare smear bone marrow aspirate peripheral bloodFix smearIncubate smear appropriate substrate (chloroacetate ester α-naphthyl butyrate) diazonium saltEsterase enzymes cells hydrolyze substrate, released product reacts diazonium salt form colored precipitateCounterstain smearExamine smear microscopeInterpretation:\nSpecific Esterase (CAE):\nPositive: Neutrophils precursors show granular staining\nNegative: Monocytes, lymphocytes, erythrocytes negative\n\nNon-Specific Esterase (ANBE):\nPositive: Monocytes macrophages show diffuse staining\nNegative: Neutrophils lymphocytes negative\n\nCombined Esterase Stains:\nprocedures use specific non-specific esterase stains better differentiate cell types\nInhibition Non-Specific Esterase Sodium Fluoride (NaF): Monocytic staining inhibited NaF, granulocytic staining \n\nSpecific Esterase (CAE):\nPositive: Neutrophils precursors show granular staining\nNegative: Monocytes, lymphocytes, erythrocytes negative\nPositive: Neutrophils precursors show granular stainingNegative: Monocytes, lymphocytes, erythrocytes negativeNon-Specific Esterase (ANBE):\nPositive: Monocytes macrophages show diffuse staining\nNegative: Neutrophils lymphocytes negative\nPositive: Monocytes macrophages show diffuse stainingNegative: Neutrophils lymphocytes negativeCombined Esterase Stains:\nprocedures use specific non-specific esterase stains better differentiate cell types\nInhibition Non-Specific Esterase Sodium Fluoride (NaF): Monocytic staining inhibited NaF, granulocytic staining \nprocedures use specific non-specific esterase stains better differentiate cell typesInhibition Non-Specific Esterase Sodium Fluoride (NaF): Monocytic staining inhibited NaF, granulocytic staining notClinical Significance:\nDifferentiate Myeloid Monocytic Lineages: ANBE CAE used identify leukemias monocytic lineage (e.g., acute monoblastic leukemia) myeloblastic lineage (e.g., AML minimal differentiation)\nClassification AML: Helps subclassify AML based degree monocytic differentiation\nDifferentiate Myeloid Monocytic Lineages: ANBE CAE used identify leukemias monocytic lineage (e.g., acute monoblastic leukemia) myeloblastic lineage (e.g., AML minimal differentiation)Classification AML: Helps subclassify AML based degree monocytic differentiation","code":""},{"path":"special-stains.html","id":"periodic-acid-schiff-pas-stain","chapter":"Special Stains","heading":"Periodic Acid-Schiff (PAS) Stain:","text":"Principle: Detects glycogen carbohydrate-containing molecules cellsProcedure:\nPrepare smear bone marrow aspirate peripheral blood\nOxidize smear periodic acid\nReact oxidized carbohydrates Schiff reagent, forming magenta-colored product\nCounterstain smear (e.g., hematoxylin)\nExamine smear microscope\nPrepare smear bone marrow aspirate peripheral bloodOxidize smear periodic acidReact oxidized carbohydrates Schiff reagent, forming magenta-colored productCounterstain smear (e.g., hematoxylin)Examine smear microscopeInterpretation:\nDiffuse Positivity: Seen erythroblasts\nBlock-Like Positivity: Seen lymphoblasts\nNegative: cell types, staining light present\nDiffuse Positivity: Seen erythroblastsBlock-Like Positivity: Seen lymphoblastsNegative: cell types, staining light presentClinical Significance:\nDiagnosis Acute Lymphoblastic Leukemia (): Lymphoblasts often show coarse, block-like PAS positivity\nDiagnosis Erythroleukemia: Erythroid precursors show strong PAS positivity\nIdentification Certain Storage Diseases: Used detect glycogen storage certain lysosomal storage disorders\nDiagnosis Acute Lymphoblastic Leukemia (): Lymphoblasts often show coarse, block-like PAS positivityDiagnosis Erythroleukemia: Erythroid precursors show strong PAS positivityIdentification Certain Storage Diseases: Used detect glycogen storage certain lysosomal storage disorders","code":""},{"path":"special-stains.html","id":"prussian-blue-stain-iron-stain","chapter":"Special Stains","heading":"Prussian Blue Stain (Iron Stain):","text":"Principle: Detects ferric iron (Fe3+) tissues cells\nUses potassium ferrocyanide react ferric iron produce insoluble blue complexProcedure:\nPrepare smear bone marrow aspirate\nFix smear\nFlood smear solution potassium ferrocyanide hydrochloric acid (Perl’s Prussian blue reagent)\nCounterstain smear (e.g., nuclear fast red)\nExamine smear microscope\nPrepare smear bone marrow aspirateFix smearFlood smear solution potassium ferrocyanide hydrochloric acid (Perl’s Prussian blue reagent)Counterstain smear (e.g., nuclear fast red)Examine smear microscopeInterpretation:\nIron Granules:\nSideroblasts: Normal erythroblasts contain iron granules\nRinged Sideroblasts: Abnormal erythroblasts iron-laden mitochondria encircling nucleus (seen sideroblastic anemias)\n\nMacrophages: Iron stores macrophages can assessed (increased iron overload, decreased iron deficiency)\nIron Granules:\nSideroblasts: Normal erythroblasts contain iron granules\nRinged Sideroblasts: Abnormal erythroblasts iron-laden mitochondria encircling nucleus (seen sideroblastic anemias)\nSideroblasts: Normal erythroblasts contain iron granulesRinged Sideroblasts: Abnormal erythroblasts iron-laden mitochondria encircling nucleus (seen sideroblastic anemias)Macrophages: Iron stores macrophages can assessed (increased iron overload, decreased iron deficiency)Clinical Significance:\nDiagnosis Sideroblastic Anemia: Identification ringed sideroblasts bone marrow\nAssessment Iron Stores: Evaluates iron levels bone marrow helps differentiate iron deficiency anemia chronic disease\nDiagnosis Hemochromatosis: Detects iron overload tissues\nDiagnosis Sideroblastic Anemia: Identification ringed sideroblasts bone marrowAssessment Iron Stores: Evaluates iron levels bone marrow helps differentiate iron deficiency anemia chronic diseaseDiagnosis Hemochromatosis: Detects iron overload tissues","code":""},{"path":"special-stains.html","id":"sudan-black-b-sbb-stain","chapter":"Special Stains","heading":"Sudan Black B (SBB) Stain:","text":"Principle: Detects lipids (phospholipids, neutral fats, sterols) cellsProcedure:\nPrepare smear bone marrow aspirate peripheral blood\nFix smear\nIncubate smear Sudan Black B stain\nWash smear\nCounterstain smear\nExamine smear microscope\nPrepare smear bone marrow aspirate peripheral bloodFix smearIncubate smear Sudan Black B stainWash smearCounterstain smearExamine smear microscopeInterpretation:\nPositive: Granulocytes, monocytes, blasts show black granular staining\nNegative: Lymphocytes erythrocytes negative\nPositive: Granulocytes, monocytes, blasts show black granular stainingNegative: Lymphocytes erythrocytes negativeClinical Significance:\nDifferentiate AML : SBB positive myeloblasts negative lymphoblasts\nDifferentiate AML : SBB positive myeloblasts negative lymphoblasts","code":""},{"path":"special-stains.html","id":"terminal-deoxynucleotidyl-transferase-tdt-stain","chapter":"Special Stains","heading":"Terminal Deoxynucleotidyl Transferase (TdT) Stain:","text":"Principle: Detects presence terminal deoxynucleotidyl transferase (TdT), DNA polymerase expressed immature lymphocytes (T B lymphoblasts)Procedure:\nPrepare smear bone marrow aspirate peripheral blood\nFix smear\nIncubate smear anti-TdT antibody\nAdd secondary antibody conjugated enzyme (e.g., horseradish peroxidase)\nAdd substrate reacts enzyme produce colored product\nExamine smear microscope\nPrepare smear bone marrow aspirate peripheral bloodFix smearIncubate smear anti-TdT antibodyAdd secondary antibody conjugated enzyme (e.g., horseradish peroxidase)Add substrate reacts enzyme produce colored productExamine smear microscopeInterpretation:\nPositive: Lymphoblasts show nuclear staining\nNegative: Mature lymphocytes, myeloid cells, erythroid cells negative\nPositive: Lymphoblasts show nuclear stainingNegative: Mature lymphocytes, myeloid cells, erythroid cells negativeClinical Significance:\nDifferentiate AML : TdT positive cases T-cell cases B-cell , usually negative AML\nDiagnosis Lymphoblastic Lymphoma: TdT positive lymphoblasts lymphoblastic lymphoma\nDifferentiate AML : TdT positive cases T-cell cases B-cell , usually negative AMLDiagnosis Lymphoblastic Lymphoma: TdT positive lymphoblasts lymphoblastic lymphoma","code":""},{"path":"special-stains.html","id":"tartrate-resistant-acid-phosphatase-trap","chapter":"Special Stains","heading":"Tartrate-Resistant Acid Phosphatase (TRAP)","text":"Principle: Detects activity isoenzyme 5 acid phosphatase, resistant tartaric acid.Procedure:\nPrepare blood smear bone marrow aspirate\nIncubate naphthol -BI phosphate fast red violet LB, without tartrate.\nPrepare blood smear bone marrow aspirateIncubate naphthol -BI phosphate fast red violet LB, without tartrate.Interpretation:\nPositive: Hairy cell stains positive. cells negative, including T lymphocytes, B lymphocytes, monocytes.\nPositive: Hairy cell stains positive. cells negative, including T lymphocytes, B lymphocytes, monocytes.Clinical Significance: Distinguish hairy cell leukemia B-cell neoplasms","code":""},{"path":"special-stains.html","id":"kleihauer-betke-acid-elution","chapter":"Special Stains","heading":"Kleihauer-Betke (Acid Elution)","text":"Principle: Detects fetal hemoglobin (HbF) maternal bloodProcedure:\nPrepare blood smear maternal blood\nTreat smear acid solution, elutes (removes) adult hemoglobin (HbA) red blood cells\nStain smear counterstain (e.g., erythrosine)\nExamine smear microscope\nPrepare blood smear maternal bloodTreat smear acid solution, elutes (removes) adult hemoglobin (HbA) red blood cellsStain smear counterstain (e.g., erythrosine)Examine smear microscopeInterpretation:\nAdult Red Blood Cells: Appear “ghost cells” (pale colorless) adult hemoglobin eluted\nFetal Red Blood Cells: Contain HbF, resistant acid elution, stain pink\nAdult Red Blood Cells: Appear “ghost cells” (pale colorless) adult hemoglobin elutedFetal Red Blood Cells: Contain HbF, resistant acid elution, stain pinkQuantitative Determination Fetal Cells:\nCount number fetal cells per 100 adult cells microscope\nCalculate percentage fetal cells maternal circulation\nCount number fetal cells per 100 adult cells microscopeCalculate percentage fetal cells maternal circulationClinical Significance:\nDetection Quantification Fetal-Maternal Hemorrhage (FMH): FMH occurs fetal red blood cells enter maternal circulation\nCalculation RhoGAM Dose: Used determine appropriate dose RhoGAM (Rh immune globulin) administer Rh-negative mothers prevent Rh sensitization\nDetection Quantification Fetal-Maternal Hemorrhage (FMH): FMH occurs fetal red blood cells enter maternal circulationCalculation RhoGAM Dose: Used determine appropriate dose RhoGAM (Rh immune globulin) administer Rh-negative mothers prevent Rh sensitizationCalculation RhoGAM Dose:\nEstimate volume fetal blood maternal circulation using following formula:\n% Fetal Cells x Maternal Blood Volume = Volume Fetal Blood (mL)\nmaternal blood volume estimated based mother’s weight hematocrit\n\nOne vial RhoGAM (300 μg) covers 30 mL fetal whole blood 15 mL fetal red blood cells\nCalculate number RhoGAM vials needed:\nNumber Vials = Volume Fetal Blood (mL) / 30 mL\nRound nearest whole number add one additional vial safety\nEstimate volume fetal blood maternal circulation using following formula:\n% Fetal Cells x Maternal Blood Volume = Volume Fetal Blood (mL)\nmaternal blood volume estimated based mother’s weight hematocrit\nmaternal blood volume estimated based mother’s weight hematocritOne vial RhoGAM (300 μg) covers 30 mL fetal whole blood 15 mL fetal red blood cellsCalculate number RhoGAM vials needed:\nNumber Vials = Volume Fetal Blood (mL) / 30 mLRound nearest whole number add one additional vial safety","code":""},{"path":"special-stains.html","id":"summary-table-of-key-special-stains","chapter":"Special Stains","heading":"Summary Table of Key Special Stains","text":"","code":""},{"path":"special-stains.html","id":"key-terms-61","chapter":"Special Stains","heading":"Key Terms:","text":"Special Stains: Histochemical staining techniques used identify specific cellular components enzymatic activitiesMyeloperoxidase (MPO): Enzyme found primary granules myeloid cellsEsterase: Enzyme hydrolyzes ester bondsSpecific Esterase (Chloroacetate Esterase, CAE): Esterase primarily found granulocytes (neutrophils)Non-Specific Esterase (α-Naphthyl Butyrate Esterase, ANBE): Esterase found monocytes macrophagesPeriodic Acid-Schiff (PAS): Stain detects glycogen carbohydrate-containing moleculesPrussian Blue Stain: Stain detects ferric iron (Fe3+)Ringed Sideroblasts: Erythroblasts iron-laden mitochondria encircling nucleusTerminal Deoxynucleotidyl Transferase (TdT): DNA polymerase expressed immature lymphocytesAcute Myeloid Leukemia (AML): Aggressive leukemia myeloid cellsAcute Lymphoblastic Leukemia (): Aggressive leukemia lymphoid cellsLymphoblasts: Immature lymphocytesMyeloblasts: Immature myeloid cellsCytochemistry: Use chemical reactions identify cellular componentsFixation: Treatment cells tissues preserve structure prevent degradationCounterstain: stain used provide contrast primary stain enhance visualization cellular structuresKleihauer-Betke: Detects fetal hemoglobin (HbF) maternal bloodAuer Rods: Rod-shaped inclusions myeloblasts, seen AMLBasophilic Stippling: Presence small, dark-blue granules scattered throughout RBC cytoplasmHeinz Bodies: Inclusions composed denatured hemoglobin","code":""},{"path":"other-studies.html","id":"other-studies","chapter":"Other Studies","heading":"Other Studies","text":"","code":""},{"path":"other-studies.html","id":"overview-or-other-studies-esr-g6pd-heinz-body","chapter":"Other Studies","heading":"Overview or Other Studies (ESR, G6PD, Heinz Body)","text":"study guide cover three key laboratory tests , part standard CBC, can provide valuable information diagnosing monitoring various conditions, particularly involving inflammation, hemolysis, enzyme deficiencies.","code":""},{"path":"other-studies.html","id":"erythrocyte-sedimentation-rate-esr","chapter":"Other Studies","heading":"Erythrocyte Sedimentation Rate (ESR)","text":"Definition: erythrocyte sedimentation rate (ESR) nonspecific test measures rate red blood cells (RBCs) sediment (settle) vertical tube period one hour","code":""},{"path":"other-studies.html","id":"glucose-6-phosphate-dehydrogenase-g6pd-assay","chapter":"Other Studies","heading":"Glucose-6-Phosphate Dehydrogenase (G6PD) Assay","text":"Definition: quantitative qualitative test used measure activity G6PD enzyme red blood cells (RBCs)","code":""},{"path":"other-studies.html","id":"heinz-body-stain","chapter":"Other Studies","heading":"Heinz Body Stain","text":"Definition: staining technique used visualize Heinz bodies red blood cells (RBCs)","code":""},{"path":"other-studies.html","id":"key-terms-62","chapter":"Other Studies","heading":"Key Terms","text":"Erythrocyte Sedimentation Rate (ESR): nonspecific test measures rate red blood cells settle tubeAcute-Phase Proteins: Proteins whose serum concentrations increase decrease response inflammationRouleaux Formation: Stacking red blood cellsG6PD (Glucose-6-Phosphate Dehydrogenase): enzyme protects red blood cells oxidative damageHeinz Bodies: Inclusions composed denatured hemoglobinSupravital Stain: dye used stain living cellsHemolysis: Destruction red blood cellsNormocytic Anemia: Anemia normal MCVMicrocytic Anemia: Anemia low MCVMacrocytic Anemia: Anemia high MCVHemoglobinopathy: disorder occurs mutation results abnormal structure","code":""},{"path":"esr.html","id":"esr","chapter":"ESR","heading":"ESR","text":"","code":""},{"path":"esr.html","id":"overview-of-erythrocyte-sedimentation-rate-esr","chapter":"ESR","heading":"Overview of Erythrocyte Sedimentation Rate (ESR)","text":"Definition: erythrocyte sedimentation rate (ESR) non-specific blood test measures rate red blood cells (RBCs) settle vertical tube period one hourAlternative Name: Sedimentation Rate, Sed RatePrinciple:\nErythrocytes settle rapidly presence increased levels acute-phase proteins plasma (e.g., fibrinogen, globulins)\nproteins neutralize negative charge RBC surface, reducing repulsion promoting rouleaux formation (stacking RBCs), increases sedimentation rate.\nErythrocytes settle rapidly presence increased levels acute-phase proteins plasma (e.g., fibrinogen, globulins)proteins neutralize negative charge RBC surface, reducing repulsion promoting rouleaux formation (stacking RBCs), increases sedimentation rate.Clinical Significance:\nScreening Test: general indicator inflammation infection body, diagnostic specific condition\nMonitoring Disease Activity: Used monitor course inflammatory diseases (e.g., rheumatoid arthritis, polymyalgia rheumatica) response treatment\nDetecting Occult Disease: Can helpful detecting hidden occult inflammatory conditions\nScreening Test: general indicator inflammation infection body, diagnostic specific conditionMonitoring Disease Activity: Used monitor course inflammatory diseases (e.g., rheumatoid arthritis, polymyalgia rheumatica) response treatmentDetecting Occult Disease: Can helpful detecting hidden occult inflammatory conditionsLimitations:\nNon-Specific: ESR affected many factors can elevated wide range conditions\nLacks Sensitivity: ESR may normal patients active inflammation\nAffected Physiological Factors: Age, sex, pregnancy, certain medications can affect ESR\nlocalize affected region\nNon-Specific: ESR affected many factors can elevated wide range conditionsLacks Sensitivity: ESR may normal patients active inflammationAffected Physiological Factors: Age, sex, pregnancy, certain medications can affect ESRCannot localize affected region","code":""},{"path":"esr.html","id":"methods-for-measuring-esr","chapter":"ESR","heading":"Methods for Measuring ESR","text":"Westergren Method:\ncommonly used method\nUses Westergren tube (long, glass plastic tube calibrated scale)\nProcedure:\nCollect blood EDTA (purple-top) tube\nMix blood thoroughly\nDilute blood sodium citrate saline (4:1 ratio blood diluent)\nFill Westergren tube 0 mm mark\nPlace tube vertical rack allow stand undisturbed room temperature 1 hour\nRead distance (millimeters) RBCs fallen top column top packed red cells 1 hour\nReport result mm/hr\n\nWestergren Method:commonly used methodUses Westergren tube (long, glass plastic tube calibrated scale)Procedure:\nCollect blood EDTA (purple-top) tube\nMix blood thoroughly\nDilute blood sodium citrate saline (4:1 ratio blood diluent)\nFill Westergren tube 0 mm mark\nPlace tube vertical rack allow stand undisturbed room temperature 1 hour\nRead distance (millimeters) RBCs fallen top column top packed red cells 1 hour\nReport result mm/hr\nCollect blood EDTA (purple-top) tubeMix blood thoroughlyDilute blood sodium citrate saline (4:1 ratio blood diluent)Fill Westergren tube 0 mm markPlace tube vertical rack allow stand undisturbed room temperature 1 hourRead distance (millimeters) RBCs fallen top column top packed red cells 1 hourReport result mm/hrWintrobe Method:\nLess commonly used\nUses Wintrobe tube (shorter, thicker glass tube calibrated scale)\nProcedure:\nCollect blood EDTA (purple-top) tube\nMix blood thoroughly\nFill Wintrobe tube 0 mm mark\nPlace tube vertical rack allow stand undisturbed room temperature 1 hour\nRead distance (millimeters) RBCs fallen top column top packed red cells 1 hour\nReport result mm/hr\n\nWintrobe Method:Less commonly usedUses Wintrobe tube (shorter, thicker glass tube calibrated scale)Procedure:\nCollect blood EDTA (purple-top) tube\nMix blood thoroughly\nFill Wintrobe tube 0 mm mark\nPlace tube vertical rack allow stand undisturbed room temperature 1 hour\nRead distance (millimeters) RBCs fallen top column top packed red cells 1 hour\nReport result mm/hr\nCollect blood EDTA (purple-top) tubeMix blood thoroughlyFill Wintrobe tube 0 mm markPlace tube vertical rack allow stand undisturbed room temperature 1 hourRead distance (millimeters) RBCs fallen top column top packed red cells 1 hourReport result mm/hrAutomated ESR Analyzers:\nautomated hematology analyzers can perform ESR measurements\nmethods based different principles manual methods, :\nCapillary photometry: Measures rate RBC aggregation capillary tube using optical sensors\nMicrofluidic technology: Measures sedimentation rate microfluidic channel\n\nAutomated ESR Analyzers:automated hematology analyzers can perform ESR measurementsThese methods based different principles manual methods, :\nCapillary photometry: Measures rate RBC aggregation capillary tube using optical sensors\nMicrofluidic technology: Measures sedimentation rate microfluidic channel\nCapillary photometry: Measures rate RBC aggregation capillary tube using optical sensorsMicrofluidic technology: Measures sedimentation rate microfluidic channel","code":""},{"path":"esr.html","id":"factors-affecting-the-esr","chapter":"ESR","heading":"Factors Affecting the ESR","text":"ESR can affected several factors, physiological pathological. ’s important consider factors interpreting ESR results.Factors Increase ESR:\nIncreased Acute Phase Reactants: Fibrinogen, α-globulins, acute-phase proteins increase RBC aggregation\nRouleaux Formation: Increased rouleaux formation accelerates RBC sedimentation\nAnemia: Decreased RBC concentration reduces competition sedimentation\nMacrocytosis: Larger RBCs settle faster\nFemale Sex: Females tend higher ESR values males due hormonal influences\nAge: ESR tends increase age\nPregnancy: ESR elevated pregnancy\nTechnical Factors: Tilting ESR tube, improper temperature\nFactors Increase ESR:Increased Acute Phase Reactants: Fibrinogen, α-globulins, acute-phase proteins increase RBC aggregationRouleaux Formation: Increased rouleaux formation accelerates RBC sedimentationAnemia: Decreased RBC concentration reduces competition sedimentationMacrocytosis: Larger RBCs settle fasterFemale Sex: Females tend higher ESR values males due hormonal influencesAge: ESR tends increase agePregnancy: ESR elevated pregnancyTechnical Factors: Tilting ESR tube, improper temperatureFactors Decrease ESR:\nAbnormal Red Blood Cell Shape: Sickle cells spherocytes hinder rouleaux formation sedimentation\nPolycythemia: Increased RBC concentration slows sedimentation\nHypofibrinogenemia: Decreased fibrinogen levels reduce rouleaux formation\nHigh Leukocytosis: Increased cell numbers can affect test\nTechnical Factors: Clotted sample, air bubbles tube\nFactors Decrease ESR:Abnormal Red Blood Cell Shape: Sickle cells spherocytes hinder rouleaux formation sedimentationPolycythemia: Increased RBC concentration slows sedimentationHypofibrinogenemia: Decreased fibrinogen levels reduce rouleaux formationVery High Leukocytosis: Increased cell numbers can affect testTechnical Factors: Clotted sample, air bubbles tube","code":""},{"path":"esr.html","id":"clinical-significance-of-esr","chapter":"ESR","heading":"Clinical Significance of ESR","text":"Elevated ESR:\nInflammatory Conditions:\nRheumatoid arthritis\nSystemic lupus erythematosus (SLE)\nPolymyalgia rheumatica\nGiant cell arteritis\n\nInfections:\nBacterial infections (e.g., pneumonia, osteomyelitis)\nTuberculosis\nFungal infections\n\nMalignancies:\nMultiple myeloma\nLymphoma\nMetastatic cancer\n\nTissue Damage:\nTrauma\nSurgery\n\nConditions:\nPregnancy\nChronic kidney disease\nThyroid disorders\n\nInflammatory Conditions:\nRheumatoid arthritis\nSystemic lupus erythematosus (SLE)\nPolymyalgia rheumatica\nGiant cell arteritis\nRheumatoid arthritisSystemic lupus erythematosus (SLE)Polymyalgia rheumaticaGiant cell arteritisInfections:\nBacterial infections (e.g., pneumonia, osteomyelitis)\nTuberculosis\nFungal infections\nBacterial infections (e.g., pneumonia, osteomyelitis)TuberculosisFungal infectionsMalignancies:\nMultiple myeloma\nLymphoma\nMetastatic cancer\nMultiple myelomaLymphomaMetastatic cancerTissue Damage:\nTrauma\nSurgery\nTraumaSurgeryOther Conditions:\nPregnancy\nChronic kidney disease\nThyroid disorders\nPregnancyChronic kidney diseaseThyroid disordersNormal Decreased ESR:\nrule significant disease\nMay seen :\nEarly stages inflammatory conditions\nNon-inflammatory conditions\nTechnical errors\n\nrule significant diseaseMay seen :\nEarly stages inflammatory conditions\nNon-inflammatory conditions\nTechnical errors\nEarly stages inflammatory conditionsNon-inflammatory conditionsTechnical errors","code":""},{"path":"esr.html","id":"quality-control-3","chapter":"ESR","heading":"Quality Control","text":"Use Proper Technique:\nFollow standardized procedures sample collection, dilution, reading\nAvoid introducing air bubbles tube\nEnsure tube placed vertical rack\nFollow standardized procedures sample collection, dilution, readingAvoid introducing air bubbles tubeEnsure tube placed vertical rackCheck Reagents Equipment:\nUse fresh reagents ensure stored properly\nVerify accuracy pipettes measuring devices\nMaintain centrifuge equipment according manufacturer’s instructions\nUse fresh reagents ensure stored properlyVerify accuracy pipettes measuring devicesMaintain centrifuge equipment according manufacturer’s instructionsRun Controls:\nUse control materials known ESR values\nMonitor control results ensure accuracy precision\nUse control materials known ESR valuesMonitor control results ensure accuracy precisionExternal Quality Assurance:\nParticipate proficiency testing programs assess performance laboratory’s ESR testing\nParticipate proficiency testing programs assess performance laboratory’s ESR testing","code":""},{"path":"esr.html","id":"reporting-results-9","chapter":"ESR","heading":"Reporting Results","text":"Report ESR value appropriate units (mm/hr)Include reference range patient’s age sexNote method used (e.g., Westergren, Wintrobe)Qualify results relevant comments (e.g., “Elevated ESR, clinical correlation advised”)Always interpret results conjunction clinical information!","code":""},{"path":"esr.html","id":"key-terms-63","chapter":"ESR","heading":"Key Terms","text":"Erythrocyte Sedimentation Rate (ESR): test measures rate red blood cells settle tubeWestergren Method: common method measuring ESRWintrobe Method: Another method measuring ESRRouleaux Formation: Stacking red blood cellsAcute-Phase Proteins: Proteins whose serum concentrations increase decrease response inflammationInflammation: complex biological response harmful stimuliESR specific: lot things can cause elevateESR monitor therapy: disease already known, ESR can used see treatments working alleviate elevated ESR","code":""},{"path":"g6pd.html","id":"g6pd","chapter":"G6PD","heading":"G6PD","text":"","code":""},{"path":"g6pd.html","id":"overview-of-g6pd-assay","chapter":"G6PD","heading":"Overview of G6PD Assay","text":"Definition: laboratory test used measure activity enzyme glucose-6-phosphate dehydrogenase (G6PD) red blood cells (RBCs)Clinical Significance:\nDiagnosis G6PD Deficiency: G6PD deficiency common inherited enzyme deficiency can cause hemolytic anemia\nIdentifying -Risk Individuals: Helps identify individuals risk developing hemolytic anemia exposure certain triggers (e.g., drugs, infections, foods)\nGenetic Counseling: Provides information genetic counseling family planning\nDiagnosis G6PD Deficiency: G6PD deficiency common inherited enzyme deficiency can cause hemolytic anemiaIdentifying -Risk Individuals: Helps identify individuals risk developing hemolytic anemia exposure certain triggers (e.g., drugs, infections, foods)Genetic Counseling: Provides information genetic counseling family planningBackground:\nG6PD enzyme pentose phosphate pathway (also known hexose monophosphate shunt)\nG6PD catalyzes first step pathway, produces NADPH\nNADPH essential reducing glutathione, turn protects RBCs oxidative damage\nG6PD deficiency impairs NADPH production, making RBCs vulnerable oxidative stress, leads hemoglobin denaturation hemolysis\nG6PD enzyme pentose phosphate pathway (also known hexose monophosphate shunt)G6PD catalyzes first step pathway, produces NADPHNADPH essential reducing glutathione, turn protects RBCs oxidative damageG6PD deficiency impairs NADPH production, making RBCs vulnerable oxidative stress, leads hemoglobin denaturation hemolysis","code":""},{"path":"g6pd.html","id":"principle-of-g6pd-assay","chapter":"G6PD","heading":"Principle of G6PD Assay","text":"G6PD assays based measuring rate NADPH production. general principle :G6PD catalyzes reaction glucose-6-phosphate (G6P) 6-phosphogluconate, producing NADPHThe rate NADPH production measured spectrophotometrically monitoring increase absorbance 340 nm (NADPH absorbs light wavelength)rate NADPH production directly proportional G6PD activity","code":""},{"path":"g6pd.html","id":"methods-for-measuring-g6pd-activity","chapter":"G6PD","heading":"Methods for Measuring G6PD Activity","text":"Quantitative Spectrophotometric Assay (Gold Standard):\nPrinciple: Measures rate NADPH production monitoring change absorbance 340 nm time\nProcedure:\nPrepare Hemolysate: Lyse red blood cells release G6PD\nAdd Substrate Coenzyme: Mix hemolysate buffer containing glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide phosphate (NADP)\nMeasure Absorbance: Monitor absorbance 340 nm fixed period (e.g., 5 minutes)\nCalculate G6PD Activity: Calculate change absorbance per minute (ΔA/min), proportional G6PD activity\nNormalize Hemoglobin: Normalize G6PD activity hemoglobin concentration sample correct variations RBC number\nG6PD Activity = (ΔA/min / Hemoglobin Concentration)\n\n\nUnits:\nUnits per gram hemoglobin (U/g Hb)\nInternational units (IU) per liter\n\nAdvantages:\nQuantitative: Provides precise measurement G6PD activity\naccurate method diagnosing G6PD deficiency\n\nLimitations:\ncomplex time-consuming screening tests\nRequires spectrophotometer trained personnel\n\nQuantitative Spectrophotometric Assay (Gold Standard):Principle: Measures rate NADPH production monitoring change absorbance 340 nm timeProcedure:\nPrepare Hemolysate: Lyse red blood cells release G6PD\nAdd Substrate Coenzyme: Mix hemolysate buffer containing glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide phosphate (NADP)\nMeasure Absorbance: Monitor absorbance 340 nm fixed period (e.g., 5 minutes)\nCalculate G6PD Activity: Calculate change absorbance per minute (ΔA/min), proportional G6PD activity\nNormalize Hemoglobin: Normalize G6PD activity hemoglobin concentration sample correct variations RBC number\nG6PD Activity = (ΔA/min / Hemoglobin Concentration)\n\nPrepare Hemolysate: Lyse red blood cells release G6PDAdd Substrate Coenzyme: Mix hemolysate buffer containing glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide phosphate (NADP)Measure Absorbance: Monitor absorbance 340 nm fixed period (e.g., 5 minutes)Calculate G6PD Activity: Calculate change absorbance per minute (ΔA/min), proportional G6PD activityNormalize Hemoglobin: Normalize G6PD activity hemoglobin concentration sample correct variations RBC number\nG6PD Activity = (ΔA/min / Hemoglobin Concentration)\nG6PD Activity = (ΔA/min / Hemoglobin Concentration)Units:\nUnits per gram hemoglobin (U/g Hb)\nInternational units (IU) per liter\nUnits per gram hemoglobin (U/g Hb)International units (IU) per literAdvantages:\nQuantitative: Provides precise measurement G6PD activity\naccurate method diagnosing G6PD deficiency\nQuantitative: Provides precise measurement G6PD activityMost accurate method diagnosing G6PD deficiencyLimitations:\ncomplex time-consuming screening tests\nRequires spectrophotometer trained personnel\ncomplex time-consuming screening testsRequires spectrophotometer trained personnelQualitative Fluorescent Spot Test (Screening Test):\nPrinciple: Detects NADPH production observing fluorescence NADPH UV light\nProcedure:\nPrepare Blood Sample: Collect blood anticoagulant (e.g., EDTA heparin)\nIncubate: Incubate drop blood filter paper G6PD substrate (glucose-6-phosphate) NADP\nObserve Fluorescence: Examine filter paper UV light specific incubation period\n\nInterpretation:\nPositive (Normal): spot fluoresces brightly UV light, indicating sufficient NADPH production normal G6PD activity\nNegative (Deficient): spot fluoresce fluoresces weakly, indicating impaired NADPH production G6PD deficiency\n\nAdvantages:\nSimple rapid\nInexpensive\nRequires minimal equipment\n\nLimitations:\nQualitative: provides yes/result, quantify G6PD activity\nLess sensitive quantitative assays\nFalse-negative results can occur :\nFemales G6PD deficiency due X-chromosome inactivation (mosaicism)\nPatients recent hemolytic episodes (young red cells higher G6PD activity)\n\nFalse-positive results can occur due :\nBlood Transfusions: recent transfusion skew value\nHigh Blood Sugar: hyperglycemia\n\n\nQualitative Fluorescent Spot Test (Screening Test):Principle: Detects NADPH production observing fluorescence NADPH UV lightProcedure:\nPrepare Blood Sample: Collect blood anticoagulant (e.g., EDTA heparin)\nIncubate: Incubate drop blood filter paper G6PD substrate (glucose-6-phosphate) NADP\nObserve Fluorescence: Examine filter paper UV light specific incubation period\nPrepare Blood Sample: Collect blood anticoagulant (e.g., EDTA heparin)Incubate: Incubate drop blood filter paper G6PD substrate (glucose-6-phosphate) NADPObserve Fluorescence: Examine filter paper UV light specific incubation periodInterpretation:\nPositive (Normal): spot fluoresces brightly UV light, indicating sufficient NADPH production normal G6PD activity\nNegative (Deficient): spot fluoresce fluoresces weakly, indicating impaired NADPH production G6PD deficiency\nPositive (Normal): spot fluoresces brightly UV light, indicating sufficient NADPH production normal G6PD activityNegative (Deficient): spot fluoresce fluoresces weakly, indicating impaired NADPH production G6PD deficiencyAdvantages:\nSimple rapid\nInexpensive\nRequires minimal equipment\nSimple rapidInexpensiveRequires minimal equipmentLimitations:\nQualitative: provides yes/result, quantify G6PD activity\nLess sensitive quantitative assays\nFalse-negative results can occur :\nFemales G6PD deficiency due X-chromosome inactivation (mosaicism)\nPatients recent hemolytic episodes (young red cells higher G6PD activity)\n\nFalse-positive results can occur due :\nBlood Transfusions: recent transfusion skew value\nHigh Blood Sugar: hyperglycemia\n\nQualitative: provides yes/result, quantify G6PD activityLess sensitive quantitative assaysFalse-negative results can occur :\nFemales G6PD deficiency due X-chromosome inactivation (mosaicism)\nPatients recent hemolytic episodes (young red cells higher G6PD activity)\nFemales G6PD deficiency due X-chromosome inactivation (mosaicism)Patients recent hemolytic episodes (young red cells higher G6PD activity)False-positive results can occur due :\nBlood Transfusions: recent transfusion skew value\nHigh Blood Sugar: hyperglycemia\nBlood Transfusions: recent transfusion skew valueHigh Blood Sugar: hyperglycemiaFlow Cytometry:\nPrinciple: Uses fluorescent dyes measure G6PD activity individual RBCs\nProcedure:\nLabel Blood Cells: Red blood cells labeled fluorescent substrate converted fluorescent product G6PD\nFlow Cytometry Analysis: cells analyzed flow cytometry, fluorescence intensity cell measured\nQuantification: G6PD activity determined based fluorescence intensity\n\nAdvantages:\nsensitive quantitative fluorescent spot test\nCan detect G6PD deficiency heterozygous females due ability measure G6PD activity individual cells\n\nLimitations:\nRequires flow cytometer trained personnel\n\nFlow Cytometry:Principle: Uses fluorescent dyes measure G6PD activity individual RBCsProcedure:\nLabel Blood Cells: Red blood cells labeled fluorescent substrate converted fluorescent product G6PD\nFlow Cytometry Analysis: cells analyzed flow cytometry, fluorescence intensity cell measured\nQuantification: G6PD activity determined based fluorescence intensity\nLabel Blood Cells: Red blood cells labeled fluorescent substrate converted fluorescent product G6PDFlow Cytometry Analysis: cells analyzed flow cytometry, fluorescence intensity cell measuredQuantification: G6PD activity determined based fluorescence intensityAdvantages:\nsensitive quantitative fluorescent spot test\nCan detect G6PD deficiency heterozygous females due ability measure G6PD activity individual cells\nsensitive quantitative fluorescent spot testCan detect G6PD deficiency heterozygous females due ability measure G6PD activity individual cellsLimitations:\nRequires flow cytometer trained personnel\nRequires flow cytometer trained personnel","code":""},{"path":"g6pd.html","id":"interpretation-of-results","chapter":"G6PD","heading":"Interpretation of Results","text":"Normal G6PD Activity: Indicates individual sufficient G6PD enzyme activity risk hemolytic anemiaDecreased G6PD Activity: Indicates G6PD deficiencyImportant Considerations:\nTesting Performed Remotely Hemolytic Episode: G6PD activity may falsely normal shortly hemolytic episode due increased numbers reticulocytes (young RBCs higher G6PD activity)\nRepeat Testing: often recommended repeat G6PD assay several weeks months hemolytic episode resolved obtain accurate result\nClinical Correlation: G6PD activity always interpreted conjunction patient’s clinical history, ethnicity, family history\nTesting Performed Remotely Hemolytic Episode: G6PD activity may falsely normal shortly hemolytic episode due increased numbers reticulocytes (young RBCs higher G6PD activity)Repeat Testing: often recommended repeat G6PD assay several weeks months hemolytic episode resolved obtain accurate resultClinical Correlation: G6PD activity always interpreted conjunction patient’s clinical history, ethnicity, family history","code":""},{"path":"g6pd.html","id":"factors-affecting-accuracy-1","chapter":"G6PD","heading":"Factors Affecting Accuracy","text":"Sample Storage: G6PD activity decreases time, testing performed soon possible sample collectionTransfusions: Recent blood transfusions can affect results, transfused RBCs may normal G6PD activityHemolysis: Hemolyzed samples used, can interfere assayMedications: Certain medications can interfere G6PD assayReticulocytosis: hemolytic episodes, increased reticulocyte count can falsely elevate G6PD activityAssay Validation: Ensure G6PD assay properly validated patient population tested","code":""},{"path":"g6pd.html","id":"quality-control-4","chapter":"G6PD","heading":"Quality Control","text":"Run Controls Known G6PD Activity Levels:\nInclude normal deficient controls assay run\ncontrol results fall within established reference ranges\nInclude normal deficient controls assay runThe control results fall within established reference rangesCheck Reagents Buffers:\nUse high-quality reagents buffers\nPrepare reagents according manufacturer’s instructions\nMonitor expiration dates reagents\nUse high-quality reagents buffersPrepare reagents according manufacturer’s instructionsMonitor expiration dates reagentsFollow Standardized Procedures:\nAdhere standardized operating procedures performing interpreting G6PD assay\nAdhere standardized operating procedures performing interpreting G6PD assayParticipate Proficiency Testing Programs:\nassess accuracy reliability laboratory’s G6PD testing\nassess accuracy reliability laboratory’s G6PD testing","code":""},{"path":"g6pd.html","id":"reporting-results-10","chapter":"G6PD","heading":"Reporting Results","text":"Report G6PD activity level appropriate units (e.g., U/g Hb)Include reference range assayNote method used (e.g., quantitative spectrophotometric assay, fluorescent spot test)Provide interpretation results, noting abnormal findingsInclude comments qualifications, “G6PD activity may falsely normal shortly hemolytic episode; repeat testing recommended”","code":""},{"path":"g6pd.html","id":"key-terms-64","chapter":"G6PD","heading":"Key Terms","text":"Glucose-6-Phosphate Dehydrogenase (G6PD): enzyme protects red blood cells oxidative damageNADPH: reducing agent essential protecting cells oxidative stressHemolytic Anemia: Anemia caused increased destruction red blood cellsFluorescent Spot Test: qualitative screening test G6PD deficiencySpectrophotometric Assay: quantitative method measuring G6PD activityHeinz Bodies: Inclusions composed denatured hemoglobin","code":""},{"path":"heinz-body.html","id":"heinz-body","chapter":"Heinz Body","heading":"Heinz Body","text":"","code":""},{"path":"heinz-body.html","id":"overview-of-heinz-body-staining","chapter":"Heinz Body","heading":"Overview of Heinz Body Staining","text":"Definition: histochemical staining technique used visualize Heinz bodies within red blood cells (RBCs)Heinz Bodies?\nInclusions within RBCs composed denatured precipitated hemoglobin\nFormed due oxidative damage hemoglobin, causing globin chains unfold aggregate\nnormally visible Wright-Giemsa stain (routine stain used peripheral blood smears)\nInclusions within RBCs composed denatured precipitated hemoglobinFormed due oxidative damage hemoglobin, causing globin chains unfold aggregateNot normally visible Wright-Giemsa stain (routine stain used peripheral blood smears)Clinical Significance: presence Heinz bodies indicates oxidative damage red blood cells associated several conditions, particularly G6PD deficiency exposure certain toxinsKey Principle: Heinz bodies can visualized supravital stains, stain living cells, allowing denatured hemoglobin precipitate form visible inclusions","code":""},{"path":"heinz-body.html","id":"principle-of-heinz-body-staining","chapter":"Heinz Body","heading":"Principle of Heinz Body Staining","text":"Supravital Staining:\nblood sample stained cells still living (vitro) using supravital dye\nsupravital stain penetrates RBCs binds denatured hemoglobin, causing precipitate form Heinz bodies\nblood sample stained cells still living (vitro) using supravital dyeThe supravital stain penetrates RBCs binds denatured hemoglobin, causing precipitate form Heinz bodiesStaining Mechanism:\nsupravital dye (typically crystal violet brilliant cresyl blue) interacts denatured hemoglobin, causing aggregate precipitate within RBC\nprecipitated hemoglobin forms small, round irregular inclusions visible microscope\nsupravital dye (typically crystal violet brilliant cresyl blue) interacts denatured hemoglobin, causing aggregate precipitate within RBCThe precipitated hemoglobin forms small, round irregular inclusions visible microscope","code":""},{"path":"heinz-body.html","id":"materials-and-reagents","chapter":"Heinz Body","heading":"Materials and Reagents","text":"Whole Blood: Fresh EDTA (purple-top) heparin (green-top) whole blood sampleSupravital Stain:\nCrystal Violet Stain:\nCrystal violet\nEthanol\n\nBrilliant Cresyl Blue Stain:\nBrilliant cresyl blue\nSodium chloride\nDistilled water\n\nCrystal Violet Stain:\nCrystal violet\nEthanol\nCrystal violetEthanolBrilliant Cresyl Blue Stain:\nBrilliant cresyl blue\nSodium chloride\nDistilled water\nBrilliant cresyl blueSodium chlorideDistilled waterGlass Slides: Clean, grease-free microscope slidesCoverslips:Test Tubes Microcentrifuge Tubes:Pipettes: accurately measure reagents samplesIncubator Water Bath: maintain constant temperature incubationMicroscope: oil immersion objective (100x)","code":""},{"path":"heinz-body.html","id":"procedure-1","chapter":"Heinz Body","heading":"Procedure","text":"Prepare Stain Solution:\nFollow manufacturer’s instructions established laboratory protocols prepare crystal violet brilliant cresyl blue stain solution\nFilter stain solution remove particulate matter\nFollow manufacturer’s instructions established laboratory protocols prepare crystal violet brilliant cresyl blue stain solutionFilter stain solution remove particulate matterMix Blood Stain:\nsmall test tube microcentrifuge tube, mix equal volumes whole blood supravital stain solution (e.g., 0.5 mL blood + 0.5 mL stain)\nsmall test tube microcentrifuge tube, mix equal volumes whole blood supravital stain solution (e.g., 0.5 mL blood + 0.5 mL stain)Incubate:\nIncubate mixture 37°C (98.6°F) 15-30 minutes. allows stain penetrate cells react denatured hemoglobin\nIncubate mixture 37°C (98.6°F) 15-30 minutes. allows stain penetrate cells react denatured hemoglobinPrepare Smears:\nincubation, gently mix blood-stain mixture\nPrepare thin wedge (push) smears clean glass slides, similar preparing routine peripheral blood smear\nincubation, gently mix blood-stain mixturePrepare thin wedge (push) smears clean glass slides, similar preparing routine peripheral blood smearAir Dry:\nAllow smears air dry completely room temperature\nheat-fix smears, heat fixation can distort destroy Heinz bodies\nAllow smears air dry completely room temperatureDo heat-fix smears, heat fixation can distort destroy Heinz bodiesMicroscopic Examination:\nExamine air-dried smears oil immersion (100x objective)\nSelect well-stained area smear RBCs evenly distributed overlapping\nExamine air-dried smears oil immersion (100x objective)Select well-stained area smear RBCs evenly distributed overlappingIdentify Count Heinz Bodies:\nLook small, round irregular inclusions within RBCs\nHeinz bodies stain dark blue purple crystal violet dark blue brilliant cresyl blue\nCount number Heinz bodies per 100 RBCs (, necessary obtain accurate count)\nReport number Heinz bodies per 100 RBCs (e.g., “5 Heinz bodies per 100 RBCs”)\nLook small, round irregular inclusions within RBCsHeinz bodies stain dark blue purple crystal violet dark blue brilliant cresyl blueCount number Heinz bodies per 100 RBCs (, necessary obtain accurate count)Report number Heinz bodies per 100 RBCs (e.g., “5 Heinz bodies per 100 RBCs”)","code":""},{"path":"heinz-body.html","id":"interpretation-of-results-1","chapter":"Heinz Body","heading":"Interpretation of Results","text":"Normal: Heinz bodies seen normal red blood cellsNormal: Heinz bodies seen normal red blood cellsHeinz Bodies Present: Indicates oxidative damage hemoglobin suggests:\nG6PD Deficiency: Exposure oxidative stressors (e.g., drugs, infections, fava beans) individuals G6PD deficiency\nUnstable Hemoglobin Variants: Hemoglobin variants prone denaturation\nExposure Oxidant Drugs Chemicals: Certain drugs (e.g., dapsone, sulfonamides, phenazopyridine) chemicals can cause oxidative damage\nSplenectomy: spleen normally removes Heinz bodies RBCs, may readily seen patients splenectomy\nHeinz Bodies Present: Indicates oxidative damage hemoglobin suggests:G6PD Deficiency: Exposure oxidative stressors (e.g., drugs, infections, fava beans) individuals G6PD deficiencyUnstable Hemoglobin Variants: Hemoglobin variants prone denaturationExposure Oxidant Drugs Chemicals: Certain drugs (e.g., dapsone, sulfonamides, phenazopyridine) chemicals can cause oxidative damageSplenectomy: spleen normally removes Heinz bodies RBCs, may readily seen patients splenectomyImportant Considerations:\nnumber Heinz bodies may vary depending severity oxidative stress time elapsed since exposure\nHeinz bodies typically removed spleen, may seen patients intact spleen, even evidence oxidative damage\nImportant Considerations:number Heinz bodies may vary depending severity oxidative stress time elapsed since exposureHeinz bodies typically removed spleen, may seen patients intact spleen, even evidence oxidative damage","code":""},{"path":"heinz-body.html","id":"sources-of-error-and-troubleshooting-1","chapter":"Heinz Body","heading":"Sources of Error and Troubleshooting","text":"Poor Smear Preparation:\nEnsure smears thin, evenly distributed, free artifacts\nEnsure smears thin, evenly distributed, free artifactsStaining Artifacts:\nUse fresh stain solutions follow proper staining procedures\nAvoid prolonged staining washing times\nUse fresh stain solutions follow proper staining proceduresAvoid prolonged staining washing timesImproper Microscope Settings:\nEnsure microscope properly aligned light source adequate\nUse correct objective lens (100x oil immersion)\nEnsure microscope properly aligned light source adequateUse correct objective lens (100x oil immersion)Misidentification Heinz Bodies:\nDistinguish Heinz bodies inclusions (e.g., Howell-Jolly bodies, Pappenheimer bodies) staining artifacts\nConsult reference atlas experienced hematologist needed\nDistinguish Heinz bodies inclusions (e.g., Howell-Jolly bodies, Pappenheimer bodies) staining artifactsConsult reference atlas experienced hematologist neededDelay Smear Preparation:\nPrepare smears promptly mixing blood stain prevent Heinz bodies disappearing\nPrepare smears promptly mixing blood stain prevent Heinz bodies disappearing","code":""},{"path":"heinz-body.html","id":"reporting-results-11","chapter":"Heinz Body","heading":"Reporting Results","text":"Report presence absence Heinz bodiesQuantify number Heinz bodies per 100 RBCs (present)Indicate type stain used (e.g., crystal violet, brilliant cresyl blue)Include comment noting factors may affected results (e.g., recent transfusion, splenectomy)Correlate results patient’s clinical information","code":""},{"path":"heinz-body.html","id":"key-terms-65","chapter":"Heinz Body","heading":"Key Terms","text":"Heinz Bodies: Inclusions composed denatured hemoglobin RBCsSupravital Stain: dye used stain living cellsCrystal Violet: supravital stain used visualize Heinz bodiesBrilliant Cresyl Blue: Another supravital stain used visualize Heinz bodiesG6PD Deficiency: genetic enzyme deficiency predisposes oxidative damage Heinz body formationOxidative Stress: imbalance production reactive oxygen species body’s ability detoxify themSplenectomy: Surgical removal spleen","code":""},{"path":"flow-cytometry.html","id":"flow-cytometry","chapter":"Flow Cytometry","heading":"Flow Cytometry","text":"","code":""},{"path":"flow-cytometry.html","id":"overview-of-flow-cytometry-immunophenotyping","chapter":"Flow Cytometry","heading":"Overview of Flow Cytometry Immunophenotyping","text":"Definition: powerful versatile technique allows identification, characterization, quantification cells based expression specific cell surface markers (antigens)Principle:\nCells labeled fluorescently labeled antibodies bind specific cell surface intracellular antigens\nlabeled cells passed laser beam flow cytometer\ninstrument measures amount light scattered fluorescence emitted cell\ndata analyzed identify quantify different cell populations\nCells labeled fluorescently labeled antibodies bind specific cell surface intracellular antigensThe labeled cells passed laser beam flow cytometerThe instrument measures amount light scattered fluorescence emitted cellThe data analyzed identify quantify different cell populationsClinical Significance:\nDiagnosis Classification Hematologic Malignancies: Essential diagnosing classifying leukemias lymphomas\nMonitoring Minimal Residual Disease (MRD): Used detect small numbers residual cancer cells treatment\nAssessment Immune Function: Used enumerate lymphocyte subsets (e.g., CD4+ T cells, CD8+ T cells) assess immune cell activation\nDiagnosis Paroxysmal Nocturnal Hemoglobinuria (PNH): Detects deficiency GPI-linked proteins blood cells\nTransplant Monitoring: Used assess chimerism detect graft-versus-host disease (GVHD)\nDiagnosis Classification Hematologic Malignancies: Essential diagnosing classifying leukemias lymphomasMonitoring Minimal Residual Disease (MRD): Used detect small numbers residual cancer cells treatmentAssessment Immune Function: Used enumerate lymphocyte subsets (e.g., CD4+ T cells, CD8+ T cells) assess immune cell activationDiagnosis Paroxysmal Nocturnal Hemoglobinuria (PNH): Detects deficiency GPI-linked proteins blood cellsTransplant Monitoring: Used assess chimerism detect graft-versus-host disease (GVHD)","code":""},{"path":"flow-cytometry.html","id":"basic-principles-of-flow-cytometry","chapter":"Flow Cytometry","heading":"Basic Principles of Flow Cytometry","text":"Sample Preparation:\nWhole Blood Bone Marrow Aspirate: Samples collected EDTA (purple-top) tubes heparin tubes\nCell Separation: RBCs lysed remove , remaining cells washed resuspended buffer\nWhole Blood Bone Marrow Aspirate: Samples collected EDTA (purple-top) tubes heparin tubesCell Separation: RBCs lysed remove , remaining cells washed resuspended bufferAntibody Labeling:\nAntibodies: Monoclonal antibodies specific different cell surface intracellular antigens used\nFluorochromes: antibody conjugated fluorescent dye (fluorochrome) emits light specific wavelength excited laser\nAntibody Combinations: Multiple antibodies different fluorochromes often used simultaneously identify multiple markers cell (multicolor flow cytometry)\nIncubation: cells incubated antibody cocktail, allowing antibodies bind target antigens\nAntibodies: Monoclonal antibodies specific different cell surface intracellular antigens usedFluorochromes: antibody conjugated fluorescent dye (fluorochrome) emits light specific wavelength excited laserAntibody Combinations: Multiple antibodies different fluorochromes often used simultaneously identify multiple markers cell (multicolor flow cytometry)Incubation: cells incubated antibody cocktail, allowing antibodies bind target antigensFlow Cytometry Analysis:\nFlow Cell: labeled cells passed flow cell single stream\nLaser Excitation: laser beam illuminates cells pass flow cell\nLight Scatter: instrument measures:\nForward Scatter (FSC): Proportional cell size\nSide Scatter (SSC): Proportional cell granularity internal complexity\n\nFluorescence Detection: Detectors measure intensity fluorescence emitted fluorochrome\nFlow Cell: labeled cells passed flow cell single streamLaser Excitation: laser beam illuminates cells pass flow cellLight Scatter: instrument measures:\nForward Scatter (FSC): Proportional cell size\nSide Scatter (SSC): Proportional cell granularity internal complexity\nForward Scatter (FSC): Proportional cell sizeSide Scatter (SSC): Proportional cell granularity internal complexityFluorescence Detection: Detectors measure intensity fluorescence emitted fluorochromeData Analysis:\nGating: Cell populations identified gated based FSC SSC properties\nSequential Gating: cells first gated based FSC SSC isolate population interest (e.g., lymphocytes, blasts), gated based expression specific markers\n“Backgating”: Starting specific population looking source based side forward scatter.\n\nData Display: Data typically displayed dot plots histograms, showing expression different markers cell population\nQuadrant Statistics: Quadrant markers placed dot plots divide cell population four quadrants, percentage cells quadrant calculated\nAllows quantification cells positive negative two different markers\n\nGating: Cell populations identified gated based FSC SSC properties\nSequential Gating: cells first gated based FSC SSC isolate population interest (e.g., lymphocytes, blasts), gated based expression specific markers\n“Backgating”: Starting specific population looking source based side forward scatter.\nSequential Gating: cells first gated based FSC SSC isolate population interest (e.g., lymphocytes, blasts), gated based expression specific markers“Backgating”: Starting specific population looking source based side forward scatter.Data Display: Data typically displayed dot plots histograms, showing expression different markers cell populationQuadrant Statistics: Quadrant markers placed dot plots divide cell population four quadrants, percentage cells quadrant calculated\nAllows quantification cells positive negative two different markers\nAllows quantification cells positive negative two different markers","code":""},{"path":"flow-cytometry.html","id":"applications-of-flow-cytometry-immunophenotyping","chapter":"Flow Cytometry","heading":"Applications of Flow Cytometry Immunophenotyping","text":"Leukemia Lymphoma Diagnosis Classification\nAcute Leukemias:\nLineage Assignment\nSubtyping AML\n\nChronic Lymphoproliferative Disorders\nMinimal Residual Disease (MRD) Monitoring\nLeukemia Lymphoma Diagnosis ClassificationAcute Leukemias:\nLineage Assignment\nSubtyping AML\nLineage AssignmentSubtyping AMLChronic Lymphoproliferative DisordersMinimal Residual Disease (MRD) MonitoringLymphocyte Subset Analysis\nCD4+ T Cell Count\nCD8+ T Cell Count\nB Cell Quantification\nNK Cell Quantification\nLymphocyte Subset AnalysisCD4+ T Cell CountCD8+ T Cell CountB Cell QuantificationNK Cell QuantificationParoxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)","code":""},{"path":"flow-cytometry.html","id":"quality-control-5","chapter":"Flow Cytometry","heading":"Quality Control","text":"Instrument Calibration Standardization:\nRegular calibration flow cytometer ensure accurate reproducible results\nUse standardized reagents protocols\nRegular calibration flow cytometer ensure accurate reproducible resultsUse standardized reagents protocolsCompensation:\nCorrection spectral overlap different fluorochromes\nUsing compensation controls set appropriate compensation values\nCorrection spectral overlap different fluorochromesUsing compensation controls set appropriate compensation valuesGating Strategies:\nUse consistent reproducible gating strategies\nInclude appropriate controls identify exclude non-specific staining\nUse consistent reproducible gating strategiesInclude appropriate controls identify exclude non-specific staining","code":""},{"path":"flow-cytometry.html","id":"factors-affecting-accuracy-2","chapter":"Flow Cytometry","heading":"Factors Affecting Accuracy","text":"Sample Handling:\nCollect blood EDTA (purple-top) tubes\nProcess samples within 24 hours collection minimize cell degradation\nCollect blood EDTA (purple-top) tubesProcess samples within 24 hours collection minimize cell degradationAntibody Selection:\nUse high-quality, well-characterized antibodies\nSelect antibodies known sensitive specific GPI-linked proteins\nUse high-quality, well-characterized antibodiesSelect antibodies known sensitive specific GPI-linked proteinsInstrument Calibration:\nPerform daily instrument calibration quality control procedures\nPerform daily instrument calibration quality control proceduresCompensation:\nProperly compensate spectral overlap different fluorochromes\nProperly compensate spectral overlap different fluorochromesGating Strategy:\nUse consistent well-defined gating strategy accurately identify cell populations\nUse consistent well-defined gating strategy accurately identify cell populationsData Analysis:\nEnsure data analysis performed trained personnel\nEnsure data analysis performed trained personnel","code":""},{"path":"flow-cytometry.html","id":"key-terms-66","chapter":"Flow Cytometry","heading":"Key Terms","text":"Flow Cytometry: technique identifying quantifying cells based surface markers characteristicsImmunophenotyping: Using flow cytometry identify cell surface markersGating: Selecting population cells analysis based forward side scatter characteristicsFluorochrome: fluorescent dye used label antibodies moleculesAntibody: protein binds specific antigenAntigen: molecule recognized antibodyLeukemia: malignant disorder blood-forming cellsLymphoma: malignant disorder lymphocytes typically arises lymph nodesMinimal Residual Disease (MRD): Small numbers residual cancer cells remain treatmentParoxysmal Nocturnal Hemoglobinuria (PNH): acquired stem cell disorder characterized deficiency GPI-anchored proteins","code":""},{"path":"leukemia.html","id":"leukemia","chapter":"Leukemia","heading":"Leukemia","text":"","code":""},{"path":"leukemia.html","id":"overview-of-flow-cytometry-immunophenotyping-in-leukemia","chapter":"Leukemia","heading":"Overview of Flow Cytometry Immunophenotyping in Leukemia","text":"Definition: Flow cytometry immunophenotyping critical tool identifying classifying leukemias. allows rapid accurate characterization leukemic cells based expression cell surface intracellular antigens (markers).Importance: Distinguishing different types leukemia (acute vs. chronic, myeloid vs. lymphoid) identifying specific subtypes within category.\nLineage Assignment (Myeloid, B-lymphoid, T-lymphoid)\nDefining Stage Maturation Arrest\nIdentifying Aberrant Antigen Expression\nPrognostic Stratification\nMonitoring Minimal Residual Disease (MRD)\nLineage Assignment (Myeloid, B-lymphoid, T-lymphoid)Defining Stage Maturation ArrestIdentifying Aberrant Antigen ExpressionPrognostic StratificationMonitoring Minimal Residual Disease (MRD)","code":""},{"path":"leukemia.html","id":"key-markers-used-in-leukemia-immunophenotyping","chapter":"Leukemia","heading":"Key Markers Used in Leukemia Immunophenotyping","text":"’s breakdown commonly used markers, caveat specific panels vary labs:","code":""},{"path":"leukemia.html","id":"key-leukemia-subtypes-and-immunophenotypic-features","chapter":"Leukemia","heading":"Key Leukemia Subtypes and Immunophenotypic Features","text":"Acute Myeloid Leukemia (AML)\nKey Immunophenotypic Features:\nMyeloid Blast Population: Cells positive one myeloid markers (CD13, CD33, CD117, MPO)\nAbsence Lymphoid Markers: Blasts typically negative T-cell markers (CD3, CD5, CD7) B-cell markers (CD19, CD20)\nVariable Expression CD34 HLA-DR: May positive negative, depending AML subtype\n\nLineage Assignment: MPO best reliable marker separate (Acute Lymphoblastic Leukemia) AML. CD34 can used measure cell population MPO present.\nSpecific AML Subtypes:\nAML t(8;21)(q22;q22); RUNX1-RUNX1T1:\nOften expresses CD34, CD117, CD13, MPO\nMay also express CD19\n\nAML inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11:\nOften expresses CD117, CD13, CD33, MPO, CD11b\nMay also express CD2\n\nAcute Promyelocytic Leukemia (APL) t(15;17)(q24.1;q21.1); PML-RARA:\nTypically expresses CD33 MPO\nLacks HLA-DR CD34 expression\n\nAML mutated NPM1:\nUsually expresses CD34 HLA-DR\nLacks CD14 CD11b expression\n\nAML mutated CEBPA:\nDisplays variable often aberrant marker expression\n\n\nKey Immunophenotypic Features:\nMyeloid Blast Population: Cells positive one myeloid markers (CD13, CD33, CD117, MPO)\nAbsence Lymphoid Markers: Blasts typically negative T-cell markers (CD3, CD5, CD7) B-cell markers (CD19, CD20)\nVariable Expression CD34 HLA-DR: May positive negative, depending AML subtype\nMyeloid Blast Population: Cells positive one myeloid markers (CD13, CD33, CD117, MPO)Absence Lymphoid Markers: Blasts typically negative T-cell markers (CD3, CD5, CD7) B-cell markers (CD19, CD20)Variable Expression CD34 HLA-DR: May positive negative, depending AML subtypeLineage Assignment: MPO best reliable marker separate (Acute Lymphoblastic Leukemia) AML. CD34 can used measure cell population MPO present.Specific AML Subtypes:\nAML t(8;21)(q22;q22); RUNX1-RUNX1T1:\nOften expresses CD34, CD117, CD13, MPO\nMay also express CD19\n\nAML inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11:\nOften expresses CD117, CD13, CD33, MPO, CD11b\nMay also express CD2\n\nAcute Promyelocytic Leukemia (APL) t(15;17)(q24.1;q21.1); PML-RARA:\nTypically expresses CD33 MPO\nLacks HLA-DR CD34 expression\n\nAML mutated NPM1:\nUsually expresses CD34 HLA-DR\nLacks CD14 CD11b expression\n\nAML mutated CEBPA:\nDisplays variable often aberrant marker expression\n\nAML t(8;21)(q22;q22); RUNX1-RUNX1T1:\nOften expresses CD34, CD117, CD13, MPO\nMay also express CD19\nOften expresses CD34, CD117, CD13, MPOMay also express CD19AML inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11:\nOften expresses CD117, CD13, CD33, MPO, CD11b\nMay also express CD2\nOften expresses CD117, CD13, CD33, MPO, CD11bMay also express CD2Acute Promyelocytic Leukemia (APL) t(15;17)(q24.1;q21.1); PML-RARA:\nTypically expresses CD33 MPO\nLacks HLA-DR CD34 expression\nTypically expresses CD33 MPOLacks HLA-DR CD34 expressionAML mutated NPM1:\nUsually expresses CD34 HLA-DR\nLacks CD14 CD11b expression\nUsually expresses CD34 HLA-DRLacks CD14 CD11b expressionAML mutated CEBPA:\nDisplays variable often aberrant marker expression\nDisplays variable often aberrant marker expressionAcute Lymphoblastic Leukemia/Lymphoma (/LBL)\nGeneral Features:\nLymphoblasts express markers associated B- T-cell lineage, myeloid markers\nTdT (terminal deoxynucleotidyl transferase): marker immature lymphocytes, usually positive\n\nB-Lymphoblastic Leukemia/Lymphoma (B-/LBL):\n* Common Markers: CD19+, CD10+, CD34+, TdT+, HLA-DR+\n* Cytoplasmic CD79a /CD22\n* Surface Ig usually negative (except pre-B )\n* Classification Divides B-based Genetics\n* Common Genetic Abnormalities Include: t(9;22), t(12;21), t(4;11)\nT-Lymphoblastic Leukemia/Lymphoma (T-/LBL):\n* Common Markers: CD3+, CD7+, TdT+, CD1a+ (often), CD34+\n* May Express CD4, CD8, \n* Often involves thymus\n* Classification divides based genetics, NOTCH1 mutations common\nGeneral Features:\nLymphoblasts express markers associated B- T-cell lineage, myeloid markers\nTdT (terminal deoxynucleotidyl transferase): marker immature lymphocytes, usually positive\nLymphoblasts express markers associated B- T-cell lineage, myeloid markersTdT (terminal deoxynucleotidyl transferase): marker immature lymphocytes, usually positiveB-Lymphoblastic Leukemia/Lymphoma (B-/LBL):\n* Common Markers: CD19+, CD10+, CD34+, TdT+, HLA-DR+\n* Cytoplasmic CD79a /CD22\n* Surface Ig usually negative (except pre-B )\n* Classification Divides B-based Genetics\n* Common Genetic Abnormalities Include: t(9;22), t(12;21), t(4;11)T-Lymphoblastic Leukemia/Lymphoma (T-/LBL):\n* Common Markers: CD3+, CD7+, TdT+, CD1a+ (often), CD34+\n* May Express CD4, CD8, \n* Often involves thymus\n* Classification divides based genetics, NOTCH1 mutations common","code":""},{"path":"leukemia.html","id":"important-considerations-1","chapter":"Leukemia","heading":"Important Considerations","text":"Aberrant Antigen Expression: Leukemic cells may express antigens normally found cells lineage. helpful diagnosis.\nExample: Myeloid markers (e.g., CD13, CD33) lymphoblasts B-\nExample: Myeloid markers (e.g., CD13, CD33) lymphoblasts B-ALLAntigen Co-expression: Cells can express antigens multiple lineages, particularly acute leukemias.Antigenic Modulation: Expression certain antigens can altered treatment, assessing pre-treatment samples idealIsotype Controls: used differentiate specific non-specific antibody staining. especially useful confirming presence low-level antigen expression“Antigenic Fidelity”: Term used describe correlation expected staining protein production specific cell.","code":""},{"path":"leukemia.html","id":"key-terms-67","chapter":"Leukemia","heading":"Key Terms","text":"Flow Cytometry: technique identifying quantifying cells based surface markersImmunophenotyping: Using flow cytometry identify cell surface markersGating: Selecting population cells analysis based light scatter properties /expression specific markersFluorochrome: fluorescent dye used label antibodies moleculesAntibody: protein binds specific antigenAntigen: molecule recognized antibodyLeukemia: malignant disorder blood-forming cells bone marrowLymphoma: malignant disorder lymphocytes typically arises lymph nodesBlast Cells: Immature, abnormal cells seen acute leukemiaLineage Assignment: Determining cell type leukemia lymphoma derived (e.g., myeloid, B-lymphoid, T-lymphoid)Aberrant Antigen Expression: Expression antigens normally found cells lineage","code":""},{"path":"lymphoma.html","id":"lymphoma","chapter":"Lymphoma","heading":"Lymphoma","text":"","code":""},{"path":"lymphoma.html","id":"overview-of-flow-cytometry-immunophenotyping-in-lymphoma","chapter":"Lymphoma","heading":"Overview of Flow Cytometry Immunophenotyping in Lymphoma","text":"Definition: use flow cytometry identify characterize lymphoma cells based expression cell surface intracellular proteins (antigens). ’s powerful tool, needs used context morphology cytology histology samples.Purpose:\nDiagnosis Lymphoma: Helps distinguish lymphoma reactive lymphoid proliferations types cancer\nClassification Lymphoma: Identifies specific subtypes lymphoma based immunophenotype malignant cells\nPrognosis: Can provide information prognosis (likely outcome) disease\nMonitoring Treatment Response: Used assess effectiveness treatment detect minimal residual disease (MRD)\nDiagnosis Lymphoma: Helps distinguish lymphoma reactive lymphoid proliferations types cancerClassification Lymphoma: Identifies specific subtypes lymphoma based immunophenotype malignant cellsPrognosis: Can provide information prognosis (likely outcome) diseaseMonitoring Treatment Response: Used assess effectiveness treatment detect minimal residual disease (MRD)Sample Types:\nLymph Node Biopsy: common sample type; single cell suspension prepared lymph node tissue\nBone Marrow Aspirate: Used assess bone marrow involvement lymphoma\nPeripheral Blood: Can used evaluate circulating lymphoma cells (e.g., Sézary syndrome)\nTissue Biopsies: Can used evaluate lymphoma extranodal sites (e.g., spleen, liver, skin)\nLymph Node Biopsy: common sample type; single cell suspension prepared lymph node tissueBone Marrow Aspirate: Used assess bone marrow involvement lymphomaPeripheral Blood: Can used evaluate circulating lymphoma cells (e.g., Sézary syndrome)Tissue Biopsies: Can used evaluate lymphoma extranodal sites (e.g., spleen, liver, skin)","code":""},{"path":"lymphoma.html","id":"common-markers-used-in-lymphoma-immunophenotyping","chapter":"Lymphoma","heading":"Common Markers Used in Lymphoma Immunophenotyping","text":"MHC (Major Histocompatibility Complex) Class II markers:\n*HLA-DR, DP, DQ - helps identify antigen presenting cells B-cells","code":""},{"path":"lymphoma.html","id":"key-lymphoma-subtypes-and-immunophenotypic-features","chapter":"Lymphoma","heading":"Key Lymphoma Subtypes and Immunophenotypic Features","text":"B-Cell Lymphomas:\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):\nCD5+, CD19+, CD20dim, CD23+, FMC7-, Cyclin D1-, kappa lambda restricted\n\nFollicular Lymphoma (FL):\nCD19+, CD20+, CD10+, BCL2+, CD5-, kappa lambda restricted\n\nMantle Cell Lymphoma (MCL):\nCD19+, CD20+, CD5+, Cyclin D1+, CD10-, kappa lambda restricted\n\nMarginal Zone Lymphoma (MZL):\nCD19+, CD20+, CD5-, CD10-, BCL6-, kappa lambda restricted\n\nDiffuse Large B-Cell Lymphoma (DLBCL):\nCD19+, CD20+, variable expression markers (CD10, BCL6, MUM1)\nRequires correlation morphology genetic studies\n\nBurkitt Lymphoma:\nCD19+, CD20+, CD10+, BCL6+, Ki-67 > 95%, kappa lambda restricted\n\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):\nCD5+, CD19+, CD20dim, CD23+, FMC7-, Cyclin D1-, kappa lambda restricted\nCD5+, CD19+, CD20dim, CD23+, FMC7-, Cyclin D1-, kappa lambda restrictedFollicular Lymphoma (FL):\nCD19+, CD20+, CD10+, BCL2+, CD5-, kappa lambda restricted\nCD19+, CD20+, CD10+, BCL2+, CD5-, kappa lambda restrictedMantle Cell Lymphoma (MCL):\nCD19+, CD20+, CD5+, Cyclin D1+, CD10-, kappa lambda restricted\nCD19+, CD20+, CD5+, Cyclin D1+, CD10-, kappa lambda restrictedMarginal Zone Lymphoma (MZL):\nCD19+, CD20+, CD5-, CD10-, BCL6-, kappa lambda restricted\nCD19+, CD20+, CD5-, CD10-, BCL6-, kappa lambda restrictedDiffuse Large B-Cell Lymphoma (DLBCL):\nCD19+, CD20+, variable expression markers (CD10, BCL6, MUM1)\nRequires correlation morphology genetic studies\nCD19+, CD20+, variable expression markers (CD10, BCL6, MUM1)Requires correlation morphology genetic studiesBurkitt Lymphoma:\nCD19+, CD20+, CD10+, BCL6+, Ki-67 > 95%, kappa lambda restricted\nCD19+, CD20+, CD10+, BCL6+, Ki-67 > 95%, kappa lambda restrictedT-Cell Lymphomas:\nPeripheral T-Cell Lymphoma, Otherwise Specified (PTCL, NOS):\ndiagnosis exclusion - must rule T-cell lymphomas\nCD4+, loss normal T-cell antigens\nClonality can confirmed T-cell receptor (TCR) gene rearrangement studies\n\nAnaplastic Large Cell Lymphoma (ALCL):\nCD30+, ALK-1+ (cases), CD4+, CD8-\n\nAdult T-Cell Leukemia/Lymphoma (ATLL):\nCD3+, CD4+, CD25+, FoxP3+\n\nPeripheral T-Cell Lymphoma, Otherwise Specified (PTCL, NOS):\ndiagnosis exclusion - must rule T-cell lymphomas\nCD4+, loss normal T-cell antigens\nClonality can confirmed T-cell receptor (TCR) gene rearrangement studies\ndiagnosis exclusion - must rule T-cell lymphomasMost CD4+, loss normal T-cell antigensClonality can confirmed T-cell receptor (TCR) gene rearrangement studiesAnaplastic Large Cell Lymphoma (ALCL):\nCD30+, ALK-1+ (cases), CD4+, CD8-\nCD30+, ALK-1+ (cases), CD4+, CD8-Adult T-Cell Leukemia/Lymphoma (ATLL):\nCD3+, CD4+, CD25+, FoxP3+\nCD3+, CD4+, CD25+, FoxP3+","code":""},{"path":"lymphoma.html","id":"interpreting-flow-cytometry-results","chapter":"Lymphoma","heading":"Interpreting Flow Cytometry Results","text":"Establish Gating Strategy:\nUse forward scatter (FSC) side scatter (SSC) gate lymphocyte population\nExclude debris, doublets, non-lymphoid cells\nUse forward scatter (FSC) side scatter (SSC) gate lymphocyte populationExclude debris, doublets, non-lymphoid cellsIdentify Cell Populations:\nUse lineage-specific markers (e.g., CD19 B cells, CD3 T cells) identify different lymphocyte populations\nUse lineage-specific markers (e.g., CD19 B cells, CD3 T cells) identify different lymphocyte populationsAssess Antigen Expression Patterns:\nDetermine whether cells express expected antigens\nIdentify aberrant antigen expression patterns (e.g., co-expression myeloid markers lymphoid cells)\nDetermine whether cells express expected antigensIdentify aberrant antigen expression patterns (e.g., co-expression myeloid markers lymphoid cells)Evaluate Clonality:\nAssess light chain restriction B-cell populations (kappa lambda)\nPerform T-cell receptor (TCR) gene rearrangement studies assess T-cell clonality\nAssess light chain restriction B-cell populations (kappa lambda)Perform T-cell receptor (TCR) gene rearrangement studies assess T-cell clonality","code":""},{"path":"lymphoma.html","id":"reporting-results-12","chapter":"Lymphoma","heading":"Reporting Results","text":"Report percentage cells expressing markerProvide interpretation results, noting abnormal findingsCorrelate flow cytometry results patient’s clinical information, morphology, laboratory data","code":""},{"path":"lymphoma.html","id":"key-terms-68","chapter":"Lymphoma","heading":"Key Terms","text":"Flow Cytometry: technique identifying quantifying cells based surface markersImmunophenotyping: Using flow cytometry identify cell surface markersGating: Selecting population cells analysis based forward side scatter characteristicsFluorochrome: fluorescent dye used label antibodies moleculesAntibody: protein binds specific antigenAntigen: molecule recognized antibodyLymphoma: malignant disorder lymphocytes typically arises lymph nodesLeukemia: malignant disorder blood-forming cells bone marrowCell surface marker: Proteins surface cell assist identification.TdT: Terminal deoxynucleotidyl transferase; expressed immature lymphocytesClonality: presence single, genetically identical population cells","code":""},{"path":"lymphocyte-subsets.html","id":"lymphocyte-subsets","chapter":"Lymphocyte Subsets","heading":"Lymphocyte Subsets","text":"","code":""},{"path":"lymphocyte-subsets.html","id":"overview-of-lymphocyte-subset-analysis-by-flow-cytometry","chapter":"Lymphocyte Subsets","heading":"Overview of Lymphocyte Subset Analysis by Flow Cytometry","text":"Definition: Flow cytometry immunophenotyping used identify, quantify, characterize lymphocyte populations (T cells, B cells, NK cells) based expression specific cell surface markersClinical Significance:\nAssessment Immune Function: Provides information number proportions different lymphocyte subsets, essential evaluating immune competence detecting immune deficiencies\nDiagnosis Monitoring Immunodeficiency Disorders: Used diagnose monitor patients HIV/AIDS, severe combined immunodeficiency (SCID), immunodeficiency disorders\nMonitoring Immunosuppressive Therapy: Used monitor effects immunosuppressive drugs transplant recipients patients autoimmune diseases\nDiagnosis Monitoring Lymphoproliferative Disorders: Can help identify characterize abnormal lymphocyte populations leukemia lymphoma\nAssessment Immune Function: Provides information number proportions different lymphocyte subsets, essential evaluating immune competence detecting immune deficienciesDiagnosis Monitoring Immunodeficiency Disorders: Used diagnose monitor patients HIV/AIDS, severe combined immunodeficiency (SCID), immunodeficiency disordersMonitoring Immunosuppressive Therapy: Used monitor effects immunosuppressive drugs transplant recipients patients autoimmune diseasesDiagnosis Monitoring Lymphoproliferative Disorders: Can help identify characterize abnormal lymphocyte populations leukemia lymphomaKey Cell Types:\nT Lymphocytes (T cells):\nHelper T Cells (CD4+ T Cells)\nCytotoxic T Cells (CD8+ T Cells)\nRegulatory T Cells (Tregs)\n\nB Lymphocytes (B Cells)\nNatural Killer (NK) Cells\nT Lymphocytes (T cells):\nHelper T Cells (CD4+ T Cells)\nCytotoxic T Cells (CD8+ T Cells)\nRegulatory T Cells (Tregs)\nHelper T Cells (CD4+ T Cells)Cytotoxic T Cells (CD8+ T Cells)Regulatory T Cells (Tregs)B Lymphocytes (B Cells)Natural Killer (NK) Cells","code":""},{"path":"lymphocyte-subsets.html","id":"cell-surface-markers-and-their-significance","chapter":"Lymphocyte Subsets","heading":"Cell Surface Markers and Their Significance","text":"following table outlines key cell surface markers used identify characterize lymphocyte subsets:","code":""},{"path":"lymphocyte-subsets.html","id":"common-lymphocyte-subset-combinations","chapter":"Lymphocyte Subsets","heading":"Common Lymphocyte Subset Combinations","text":"T Cell Analysis:\nCD45, CD3: identify T cells\nCD4: identify helper T cells\nCD8: identify cytotoxic T cells\nCD4:CD8 Ratio: useful marker classifying types T-Cells\nCD25 FoxP3 can identify regulatory T cells\nCD45, CD3: identify T cellsCD4: identify helper T cellsCD8: identify cytotoxic T cellsCD4:CD8 Ratio: useful marker classifying types T-CellsCD25 FoxP3 can identify regulatory T cellsB Cell Analysis:\nCD45, CD19: identify B cells\nKappa Lambda Light Chains: assess clonality B-cell populations\nCD45, CD19: identify B cellsKappa Lambda Light Chains: assess clonality B-cell populationsNK Cell Analysis:\nCD45, CD3-: Used exclude T cells\nCD56 CD16: identify NK cells\nCD45, CD3-: Used exclude T cellsCD56 CD16: identify NK cells","code":""},{"path":"lymphocyte-subsets.html","id":"applications-of-lymphocyte-subset-analysis","chapter":"Lymphocyte Subsets","heading":"Applications of Lymphocyte Subset Analysis","text":"HIV/AIDS:\nMonitoring CD4+ T Cell Count: CD4+ T cell count key indicator immune function HIV-infected individuals\nLow CD4+ T cell counts indicate immune deficiency increased susceptibility opportunistic infections\nMonitoring Treatment Response: Used assess effectiveness antiretroviral therapy (ART) monitoring increases CD4+ T cell counts\nMonitoring CD4+ T Cell Count: CD4+ T cell count key indicator immune function HIV-infected individualsLow CD4+ T cell counts indicate immune deficiency increased susceptibility opportunistic infectionsMonitoring Treatment Response: Used assess effectiveness antiretroviral therapy (ART) monitoring increases CD4+ T cell countsSevere Combined Immunodeficiency (SCID):\nDiagnosis: Flow cytometry used identify absence severe reduction T cells, B cells, /NK cells infants suspected SCID\nT-B+NK+ SCID: Absence T cells, presence B NK cells\nT-B-NK+ SCID: Absence T cells B cells, presence NK cells\nT-B+NK- SCID: Absence T cells NK cells, presence B cells\nT-B-NK- SCID: Absence T cells, B cells, NK cells\nDiagnosis: Flow cytometry used identify absence severe reduction T cells, B cells, /NK cells infants suspected SCIDT-B+NK+ SCID: Absence T cells, presence B NK cellsT-B-NK+ SCID: Absence T cells B cells, presence NK cellsT-B+NK- SCID: Absence T cells NK cells, presence B cellsT-B-NK- SCID: Absence T cells, B cells, NK cellsAutoimmune Disorders:\nMonitoring Immunosuppressive Therapy: Flow cytometry can used monitor effects immunosuppressive drugs lymphocyte subsets patients autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)\nAssessment Disease Activity: Changes lymphocyte subset numbers activation markers may correlate disease activity\nMonitoring Immunosuppressive Therapy: Flow cytometry can used monitor effects immunosuppressive drugs lymphocyte subsets patients autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)Assessment Disease Activity: Changes lymphocyte subset numbers activation markers may correlate disease activityTransplant Monitoring:\nChimerism Analysis: Used assess proportion donor recipient cells blood bone marrow hematopoietic stem cell transplantation (HSCT)\nDetection Graft-versus-Host Disease (GVHD): Flow cytometry can used identify activated T cells involved GVHD\nChimerism Analysis: Used assess proportion donor recipient cells blood bone marrow hematopoietic stem cell transplantation (HSCT)Detection Graft-versus-Host Disease (GVHD): Flow cytometry can used identify activated T cells involved GVHD","code":""},{"path":"lymphocyte-subsets.html","id":"reporting-results-13","chapter":"Lymphocyte Subsets","heading":"Reporting Results","text":"Report absolute counts percentages lymphocyte subset (e.g., CD4+ T cells, CD8+ T cells, B cells, NK cells)Include reference range parameterNote abnormal results deviations normal lymphocyte subset distributionsCorrelate laboratory findings patient’s clinical information","code":""},{"path":"lymphocyte-subsets.html","id":"key-terms-69","chapter":"Lymphocyte Subsets","heading":"Key Terms","text":"Flow Cytometry: technique identifying quantifying cells based surface markersImmunophenotyping: Using flow cytometry identify cell surface markersGating: Selecting population cells analysis based light scatter properties /expression specific markersFluorochrome: fluorescent dye used label antibodies moleculesAntibody: protein binds specific antigenAntigen: molecule recognized antibodyT Lymphocyte (T Cell): type lymphocyte mediates cell-mediated immunityHelper T Cell (CD4+ T Cell): type T cell helps activate immune cellsCytotoxic T Cell (CD8+ T Cell): type T cell kills infected cancerous cellsB Lymphocyte (B Cell): type lymphocyte produces antibodiesNatural Killer (NK) Cell: type lymphocyte kills infected cancerous cells without prior sensitization","code":""},{"path":"pnh.html","id":"pnh","chapter":"PNH","heading":"PNH","text":"","code":""},{"path":"pnh.html","id":"overview-of-paroxysmal-nocturnal-hemoglobinuria-pnh","chapter":"PNH","heading":"Overview of Paroxysmal Nocturnal Hemoglobinuria (PNH)","text":"Definition: rare, acquired, life-threatening hematopoietic stem cell disorder characterized deficiency glycosylphosphatidylinositol (GPI)-anchored proteins surface blood cellsPathophysiology:\nAcquired Mutation: PNH arises acquired mutation PIGA gene (phosphatidylinositol glycan anchor biosynthesis class ), located X chromosome\nDefective GPI Anchor Synthesis: PIGA gene essential synthesis glycosylphosphatidylinositol (GPI) anchor, attaches certain proteins cell surface\nDeficiency GPI-Anchored Proteins: PIGA mutation leads deficiency GPI-anchored proteins surface affected blood cells, including:\nCD55 (Decay-Accelerating Factor): Regulates complement activation cell surfaces\nCD59 (Membrane Inhibitor Reactive Lysis): Inhibits formation membrane attack complex (MAC), terminal component complement cascade\nGPI-linked Proteins: CD16 (FcγRIII), CD48, CD14, many others\n\nUnregulated Complement Activation: deficiency CD55 CD59 results uncontrolled complement activation surface RBCs, WBCs, platelets\nIntravascular Hemolysis: Complement activation RBCs leads formation MAC, causing RBC lysis within blood vessels (intravascular hemolysis)\nAcquired Mutation: PNH arises acquired mutation PIGA gene (phosphatidylinositol glycan anchor biosynthesis class ), located X chromosomeDefective GPI Anchor Synthesis: PIGA gene essential synthesis glycosylphosphatidylinositol (GPI) anchor, attaches certain proteins cell surfaceDeficiency GPI-Anchored Proteins: PIGA mutation leads deficiency GPI-anchored proteins surface affected blood cells, including:\nCD55 (Decay-Accelerating Factor): Regulates complement activation cell surfaces\nCD59 (Membrane Inhibitor Reactive Lysis): Inhibits formation membrane attack complex (MAC), terminal component complement cascade\nGPI-linked Proteins: CD16 (FcγRIII), CD48, CD14, many others\nCD55 (Decay-Accelerating Factor): Regulates complement activation cell surfacesCD59 (Membrane Inhibitor Reactive Lysis): Inhibits formation membrane attack complex (MAC), terminal component complement cascadeOther GPI-linked Proteins: CD16 (FcγRIII), CD48, CD14, many othersUnregulated Complement Activation: deficiency CD55 CD59 results uncontrolled complement activation surface RBCs, WBCs, plateletsIntravascular Hemolysis: Complement activation RBCs leads formation MAC, causing RBC lysis within blood vessels (intravascular hemolysis)Clinical Features:\nHemolytic Anemia:\nFatigue\nWeakness\nJaundice (yellowing skin eyes)\nDark urine (hemoglobinuria), especially morning (paroxysmal)\n\nThrombosis:\nIncreased risk blood clots due platelet activation complement-mediated endothelial damage\nVenous thrombosis (DVT, PE) common arterial thrombosis\nUnusual sites thrombosis (e.g., hepatic vein thrombosis)\n\nBone Marrow Failure:\nCytopenias (anemia, thrombocytopenia, leukopenia) may occur due bone marrow dysfunction\npatients PNH may also underlying aplastic anemia myelodysplastic syndromes (MDS)\n\nManifestations:\nSmooth muscle dystonia (abdominal pain, dysphagia, erectile dysfunction)\nPulmonary hypertension\nChronic kidney disease\n\nHemolytic Anemia:\nFatigue\nWeakness\nJaundice (yellowing skin eyes)\nDark urine (hemoglobinuria), especially morning (paroxysmal)\nFatigueWeaknessJaundice (yellowing skin eyes)Dark urine (hemoglobinuria), especially morning (paroxysmal)Thrombosis:\nIncreased risk blood clots due platelet activation complement-mediated endothelial damage\nVenous thrombosis (DVT, PE) common arterial thrombosis\nUnusual sites thrombosis (e.g., hepatic vein thrombosis)\nIncreased risk blood clots due platelet activation complement-mediated endothelial damageVenous thrombosis (DVT, PE) common arterial thrombosisUnusual sites thrombosis (e.g., hepatic vein thrombosis)Bone Marrow Failure:\nCytopenias (anemia, thrombocytopenia, leukopenia) may occur due bone marrow dysfunction\npatients PNH may also underlying aplastic anemia myelodysplastic syndromes (MDS)\nCytopenias (anemia, thrombocytopenia, leukopenia) may occur due bone marrow dysfunctionSome patients PNH may also underlying aplastic anemia myelodysplastic syndromes (MDS)Manifestations:\nSmooth muscle dystonia (abdominal pain, dysphagia, erectile dysfunction)\nPulmonary hypertension\nChronic kidney disease\nSmooth muscle dystonia (abdominal pain, dysphagia, erectile dysfunction)Pulmonary hypertensionChronic kidney disease","code":""},{"path":"pnh.html","id":"flow-cytometry-immunophenotyping-for-pnh","chapter":"PNH","heading":"Flow Cytometry Immunophenotyping for PNH","text":"Principle:\nFlow cytometry gold standard diagnosing PNH\ndetects absence reduced expression GPI-linked proteins blood cells (RBCs, granulocytes, monocytes)\nFluorescently labeled antibodies used bind specific GPI-linked proteins, fluorescence intensity measured flow cytometry\nPrinciple:Flow cytometry gold standard diagnosing PNHIt detects absence reduced expression GPI-linked proteins blood cells (RBCs, granulocytes, monocytes)Fluorescently labeled antibodies used bind specific GPI-linked proteins, fluorescence intensity measured flow cytometryCell Populations Analyzed:\nGranulocytes:\nCD15, CD45: Used identify gate granulocyte population\nGPI-linked proteins: CD16, CD24\n\nMonocytes:\nCD14, CD45: Used identify gate monocyte population\nGPI-linked proteins: CD14, CD48\n\nRed Blood Cells (RBCs):\nAnti-glycophorin anti-CD71: Used identify gate RBC population\nFLAER (Fluorescently Labeled Aerolysin): bacterial toxin binds GPI anchor . stains GPI-anchored cells, including RBCs.\n\nCell Populations Analyzed:Granulocytes:\nCD15, CD45: Used identify gate granulocyte population\nGPI-linked proteins: CD16, CD24\nCD15, CD45: Used identify gate granulocyte populationGPI-linked proteins: CD16, CD24Monocytes:\nCD14, CD45: Used identify gate monocyte population\nGPI-linked proteins: CD14, CD48\nCD14, CD45: Used identify gate monocyte populationGPI-linked proteins: CD14, CD48Red Blood Cells (RBCs):\nAnti-glycophorin anti-CD71: Used identify gate RBC population\nFLAER (Fluorescently Labeled Aerolysin): bacterial toxin binds GPI anchor . stains GPI-anchored cells, including RBCs.\nAnti-glycophorin anti-CD71: Used identify gate RBC populationFLAER (Fluorescently Labeled Aerolysin): bacterial toxin binds GPI anchor . stains GPI-anchored cells, including RBCs.Antibodies Used:\nCD55 (Decay-Accelerating Factor, DAF): GPI-linked protein regulates complement activation\nCD59 (Membrane Inhibitor Reactive Lysis, MIRL): GPI-linked protein inhibits formation membrane attack complex (MAC)\nGPI-Linked Proteins: CD16 (FcγRIII), CD24, CD14, CD48, CD66b\nFluorescently Labeled Aerolysin (FLAER): bacterial toxin binds GPI anchor \nAntibodies Used:CD55 (Decay-Accelerating Factor, DAF): GPI-linked protein regulates complement activationCD59 (Membrane Inhibitor Reactive Lysis, MIRL): GPI-linked protein inhibits formation membrane attack complex (MAC)GPI-Linked Proteins: CD16 (FcγRIII), CD24, CD14, CD48, CD66bFluorescently Labeled Aerolysin (FLAER): bacterial toxin binds GPI anchor itselfGating Strategy:\nForward Scatter (FSC) Side Scatter (SSC): Used identify gate granulocyte monocyte populations\nCD45 Expression: Used refine gating exclude debris non-leukocyte events\nCD15 CD14 Expression: Used specifically identify granulocytes (CD15+) monocytes (CD14+)\nGating Strategy:Forward Scatter (FSC) Side Scatter (SSC): Used identify gate granulocyte monocyte populationsCD45 Expression: Used refine gating exclude debris non-leukocyte eventsCD15 CD14 Expression: Used specifically identify granulocytes (CD15+) monocytes (CD14+)Analysis Interpretation:\nNormal Cells: Express normal levels GPI-linked proteins (CD55, CD59, CD16, CD24, CD14, CD48)\nPNH Cells: Show decreased absent expression one GPI-linked proteins\nTypes PNH Cell Populations:\nType Cells: Normal cells normal expression GPI-linked proteins\nType II Cells: Cells partial deficiency GPI-linked proteins (intermediate expression)\nType III Cells: Cells complete deficiency GPI-linked proteins (absent expression)\n\nQuantification: percentage PNH cells (Type II Type III cells) calculated cell population (granulocytes, monocytes, RBCs)\nClinical Correlation: percentage PNH cells correlates severity disease risk complications\nAnalysis Interpretation:Normal Cells: Express normal levels GPI-linked proteins (CD55, CD59, CD16, CD24, CD14, CD48)PNH Cells: Show decreased absent expression one GPI-linked proteinsTypes PNH Cell Populations:\nType Cells: Normal cells normal expression GPI-linked proteins\nType II Cells: Cells partial deficiency GPI-linked proteins (intermediate expression)\nType III Cells: Cells complete deficiency GPI-linked proteins (absent expression)\nType Cells: Normal cells normal expression GPI-linked proteinsType II Cells: Cells partial deficiency GPI-linked proteins (intermediate expression)Type III Cells: Cells complete deficiency GPI-linked proteins (absent expression)Quantification: percentage PNH cells (Type II Type III cells) calculated cell population (granulocytes, monocytes, RBCs)Clinical Correlation: percentage PNH cells correlates severity disease risk complications","code":""},{"path":"pnh.html","id":"reporting-results-14","chapter":"PNH","heading":"Reporting Results","text":"Report percentage PNH cells (Type II Type III cells) cell population (granulocytes, monocytes, RBCs)Include histograms dot plots showing expression CD55 CD59 (GPI-linked proteins)Provide interpretation results, noting presence absence PNH size PNH cloneCorrelate laboratory findings patient’s clinical information","code":""},{"path":"pnh.html","id":"key-terms-70","chapter":"PNH","heading":"Key Terms","text":"Paroxysmal Nocturnal Hemoglobinuria (PNH): acquired stem cell disorder characterized deficiency GPI-anchored proteinsGPI Anchor: Glycosylphosphatidylinositol, glycolipid anchors certain proteins cell surfaceCD55 (DAF): Decay-accelerating factor, GPI-linked protein regulates complement activationCD59 (MIRL): Membrane inhibitor reactive lysis, GPI-linked protein inhibits formation membrane attack complex (MAC)FLAER: Fluorescently Labeled Aerolysin, bacterial toxin binds GPI anchorFlow Cytometry: technique identifying quantifying cells based surface markersImmunophenotyping: Using flow cytometry identify cell surface markersClone: population cells derived single progenitor cell","code":""},{"path":"molecularcytogenetic.html","id":"molecularcytogenetic","chapter":"Molecular/Cytogenetic","heading":"Molecular/Cytogenetic","text":"","code":""},{"path":"molecularcytogenetic.html","id":"overview-of-molecular-and-cytogenetic-testing-in-hematology","chapter":"Molecular/Cytogenetic","heading":"Overview of Molecular and Cytogenetic Testing in Hematology","text":"Definition: Laboratory techniques used identify genetic abnormalities (chromosomal molecular) blood bone marrow cellsClinical Significance:\nDiagnosis Classification: Essential diagnosing classifying hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms\nPrognosis: Many genetic abnormalities prognostic significance can help predict course disease\nTherapeutic Decision-Making: genetic abnormalities targets specific therapies\nMonitoring Treatment Response: Used detect minimal residual disease (MRD) monitor treatment response\nDiagnosis Classification: Essential diagnosing classifying hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasmsPrognosis: Many genetic abnormalities prognostic significance can help predict course diseaseTherapeutic Decision-Making: genetic abnormalities targets specific therapiesMonitoring Treatment Response: Used detect minimal residual disease (MRD) monitor treatment responseTypes Tests:\nCytogenetic Analysis (Karyotyping)\nFluorescence Situ Hybridization (FISH)\nPolymerase Chain Reaction (PCR)\nNext-Generation Sequencing (NGS)\nCytogenetic Analysis (Karyotyping)Fluorescence Situ Hybridization (FISH)Polymerase Chain Reaction (PCR)Next-Generation Sequencing (NGS)","code":""},{"path":"molecularcytogenetic.html","id":"cytogenetic-analysis-karyotyping","chapter":"Molecular/Cytogenetic","heading":"Cytogenetic Analysis (Karyotyping)","text":"Principle:\nAnalyzes structure number chromosomes cell\nCells cultured, arrested metaphase, stained visualize chromosomes\nChromosomes arranged standardized format (karyotype)\nAnalyzes structure number chromosomes cellCells cultured, arrested metaphase, stained visualize chromosomesChromosomes arranged standardized format (karyotype)Procedure:\nSample Collection: Bone marrow aspirate peripheral blood\nCell Culture: Cells cultured increase number cells metaphase\nChromosome Preparation: Cells treated chemical (e.g., colchicine) arrest metaphase, lysed fixed\nStaining: Chromosomes stained Giemsa banding techniques reveal structure\nMicroscopic Examination: trained cytogeneticist examines stained chromosomes microscope\nKaryotype Analysis: Chromosomes arranged standardized format, abnormalities (e.g., translocations, deletions, inversions) identified\nSample Collection: Bone marrow aspirate peripheral bloodCell Culture: Cells cultured increase number cells metaphaseChromosome Preparation: Cells treated chemical (e.g., colchicine) arrest metaphase, lysed fixedStaining: Chromosomes stained Giemsa banding techniques reveal structureMicroscopic Examination: trained cytogeneticist examines stained chromosomes microscopeKaryotype Analysis: Chromosomes arranged standardized format, abnormalities (e.g., translocations, deletions, inversions) identifiedReporting:\nKaryotype described using International System Human Cytogenetic Nomenclature (ISCN)\nExample: 46,XY,t(9;22)(q34;q11.2) indicates male karyotype translocation chromosomes 9 22\nKaryotype described using International System Human Cytogenetic Nomenclature (ISCN)Example: 46,XY,t(9;22)(q34;q11.2) indicates male karyotype translocation chromosomes 9 22Advantages:\nProvides global view entire genome\nCan detect complex chromosomal rearrangements\nProvides global view entire genomeCan detect complex chromosomal rearrangementsLimitations:\nRequires viable cells cell culture\nTime-consuming\nLimited resolution (detect small deletions point mutations)\ndetect abnormalities non-dividing cells\nRequires viable cells cell cultureTime-consumingLimited resolution (detect small deletions point mutations)detect abnormalities non-dividing cells","code":""},{"path":"molecularcytogenetic.html","id":"fluorescence-in-situ-hybridization-fish","chapter":"Molecular/Cytogenetic","heading":"Fluorescence In Situ Hybridization (FISH)","text":"Principle:\nUses fluorescently labeled DNA probes bind specific DNA sequences chromosomes\nAllows detection specific chromosomal abnormalities (e.g., translocations, deletions, amplifications) individual cells\nUses fluorescently labeled DNA probes bind specific DNA sequences chromosomesAllows detection specific chromosomal abnormalities (e.g., translocations, deletions, amplifications) individual cellsProcedure:\nPrepare Cell Suspension: Bone marrow aspirate, peripheral blood, tissue sample\nHybridization: Fluorescently labeled DNA probes hybridized chromosomes slide\nWashing: Unbound probes washed away\nMicroscopic Examination: slide examined fluorescence microscope, number location fluorescent signals counted\nPrepare Cell Suspension: Bone marrow aspirate, peripheral blood, tissue sampleHybridization: Fluorescently labeled DNA probes hybridized chromosomes slideWashing: Unbound probes washed awayMicroscopic Examination: slide examined fluorescence microscope, number location fluorescent signals countedTypes FISH Probes:\nBreak-Apart Probes: Detect chromosomal translocations flanking breakpoint region; normal cell show two fusion signals, cell translocation show separated signals\nFusion Probes: Detect chromosomal translocations hybridizing fusion partners; normal cell show separate signals, cell translocation show fusion signal\nEnumeration Probes: Detect number copies specific gene chromosome; used identify deletions amplifications\nBreak-Apart Probes: Detect chromosomal translocations flanking breakpoint region; normal cell show two fusion signals, cell translocation show separated signalsFusion Probes: Detect chromosomal translocations hybridizing fusion partners; normal cell show separate signals, cell translocation show fusion signalEnumeration Probes: Detect number copies specific gene chromosome; used identify deletions amplificationsAdvantages:\nRelatively rapid turnaround time compared karyotyping\nCan performed non-dividing cells\nCan detect submicroscopic deletions translocations\nRelatively rapid turnaround time compared karyotypingCan performed non-dividing cellsCan detect submicroscopic deletions translocationsLimitations:\ndetects known chromosomal abnormalities probes available\ndetect novel complex chromosomal rearrangements\ndetects known chromosomal abnormalities probes availableCannot detect novel complex chromosomal rearrangements","code":""},{"path":"molecularcytogenetic.html","id":"molecular-testing-pcr-and-next-generation-sequencing","chapter":"Molecular/Cytogenetic","heading":"Molecular Testing (PCR and Next-Generation Sequencing)","text":"Polymerase Chain Reaction (PCR):\nPrinciple: Amplifies specific DNA sequences, allowing detection gene mutations fusion genes\nProcedure:\nDNA Extraction: Extract DNA bone marrow aspirate peripheral blood\nAmplification: Use PCR amplify target DNA sequence using specific primers\nDetection: Detect amplified DNA product using gel electrophoresis, real-time PCR, methods\n\nReal-Time Quantitative PCR (RQ-PCR):\nAllows quantification amplified DNA product\nUsed monitoring minimal residual disease (MRD) leukemia\n\nAdvantages:\nHigh sensitivity specificity\nRelatively rapid turnaround time\n\nLimitations:\nCan detect known mutations fusion genes primers available\ndetect novel unknown genetic abnormalities\n\nPrinciple: Amplifies specific DNA sequences, allowing detection gene mutations fusion genesProcedure:\nDNA Extraction: Extract DNA bone marrow aspirate peripheral blood\nAmplification: Use PCR amplify target DNA sequence using specific primers\nDetection: Detect amplified DNA product using gel electrophoresis, real-time PCR, methods\nDNA Extraction: Extract DNA bone marrow aspirate peripheral bloodAmplification: Use PCR amplify target DNA sequence using specific primersDetection: Detect amplified DNA product using gel electrophoresis, real-time PCR, methodsReal-Time Quantitative PCR (RQ-PCR):\nAllows quantification amplified DNA product\nUsed monitoring minimal residual disease (MRD) leukemia\nAllows quantification amplified DNA productUsed monitoring minimal residual disease (MRD) leukemiaAdvantages:\nHigh sensitivity specificity\nRelatively rapid turnaround time\nHigh sensitivity specificityRelatively rapid turnaround timeLimitations:\nCan detect known mutations fusion genes primers available\ndetect novel unknown genetic abnormalities\nCan detect known mutations fusion genes primers availableCannot detect novel unknown genetic abnormalitiesNext-Generation Sequencing (NGS):\nPrinciple: Massively parallel sequencing technology allows simultaneous sequencing millions DNA fragments\nProcedure:\nDNA Extraction: Extract DNA bone marrow aspirate peripheral blood\nLibrary Preparation: Prepare DNA library fragmenting DNA adding adaptors\nSequencing: Sequence DNA fragments using NGS platform\nData Analysis: Align sequencing reads reference genome identify gene mutations, insertions, deletions, genomic alterations\n\nAdvantages:\nCan detect known novel mutations\nCan detect multiple mutations simultaneously\nCan used identify gene expression changes\n\nLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\n\nPrinciple: Massively parallel sequencing technology allows simultaneous sequencing millions DNA fragmentsProcedure:\nDNA Extraction: Extract DNA bone marrow aspirate peripheral blood\nLibrary Preparation: Prepare DNA library fragmenting DNA adding adaptors\nSequencing: Sequence DNA fragments using NGS platform\nData Analysis: Align sequencing reads reference genome identify gene mutations, insertions, deletions, genomic alterations\nDNA Extraction: Extract DNA bone marrow aspirate peripheral bloodLibrary Preparation: Prepare DNA library fragmenting DNA adding adaptorsSequencing: Sequence DNA fragments using NGS platformData Analysis: Align sequencing reads reference genome identify gene mutations, insertions, deletions, genomic alterationsAdvantages:\nCan detect known novel mutations\nCan detect multiple mutations simultaneously\nCan used identify gene expression changes\nCan detect known novel mutationsCan detect multiple mutations simultaneouslyCan used identify gene expression changesLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\ncomplex expensive PCR-based methodsRequires bioinformatics expertise data analysis","code":""},{"path":"molecularcytogenetic.html","id":"key-genetic-abnormalities-in-myeloid-neoplasms","chapter":"Molecular/Cytogenetic","heading":"Key Genetic Abnormalities in Myeloid Neoplasms","text":"’s table summarizing key genetic abnormalities associated myeloid neoplasms (defined classification):","code":""},{"path":"molecularcytogenetic.html","id":"specific-genetic-abnormalities","chapter":"Molecular/Cytogenetic","heading":"Specific Genetic Abnormalities","text":"BCR-ABL1 Fusion Gene (Chronic Myeloid Leukemia)\nCreated reciprocal translocation t(9;22)(q34.1;q11.2), resulting Philadelphia chromosome (Ph chromosome)\nResults fusion protein constitutive tyrosine kinase activity, driving uncontrolled cell proliferation\nDetected :\nCytogenetic analysis (karyotyping)\nFISH (fluorescence situ hybridization)\nRT-PCR (reverse transcription polymerase chain reaction): Used quantify BCR-ABL1 transcript levels monitor minimal residual disease (MRD)\n\nCreated reciprocal translocation t(9;22)(q34.1;q11.2), resulting Philadelphia chromosome (Ph chromosome)Results fusion protein constitutive tyrosine kinase activity, driving uncontrolled cell proliferationDetected :\nCytogenetic analysis (karyotyping)\nFISH (fluorescence situ hybridization)\nRT-PCR (reverse transcription polymerase chain reaction): Used quantify BCR-ABL1 transcript levels monitor minimal residual disease (MRD)\nCytogenetic analysis (karyotyping)FISH (fluorescence situ hybridization)RT-PCR (reverse transcription polymerase chain reaction): Used quantify BCR-ABL1 transcript levels monitor minimal residual disease (MRD)JAK2 V617F Mutation (MPNs)\npoint mutation JAK2 gene (Janus kinase 2)\nLeads constitutive activation JAK-STAT signaling pathway, resulting increased cell proliferation\nFound :\nPolycythemia Vera (PV): >95% cases\nEssential Thrombocythemia (ET): ~50-60% cases\nPrimary Myelofibrosis (PMF): ~50-60% cases\n\nDetected :\nPCR-based assays\n\npoint mutation JAK2 gene (Janus kinase 2)Leads constitutive activation JAK-STAT signaling pathway, resulting increased cell proliferationFound :\nPolycythemia Vera (PV): >95% cases\nEssential Thrombocythemia (ET): ~50-60% cases\nPrimary Myelofibrosis (PMF): ~50-60% cases\nPolycythemia Vera (PV): >95% casesEssential Thrombocythemia (ET): ~50-60% casesPrimary Myelofibrosis (PMF): ~50-60% casesDetected :\nPCR-based assays\nPCR-based assays","code":""},{"path":"molecularcytogenetic.html","id":"key-terms-71","chapter":"Molecular/Cytogenetic","heading":"Key Terms","text":"Cytogenetic Analysis (Karyotyping): study chromosomes abnormalitiesFISH (Fluorescence Situ Hybridization): technique uses fluorescent probes detect specific DNA sequences chromosomesPCR (Polymerase Chain Reaction): technique amplify specific DNA sequencesNext-Generation Sequencing (NGS): high-throughput sequencing technologyMutation: change DNA sequence geneTranslocation: transfer genetic material one chromosome anotherDeletion: loss portion chromosomeInversion: reversal segment chromosomeFusion Gene: gene formed fusion two separate genes due chromosomal translocation deletionImmunophenotyping:\nTechnique uses antibodies identify cell surface intracellular markers,Minimal Residual Disease (MRD): Small numbers residual cancer cells remain treatment","code":""},{"path":"recurring-abnormalities.html","id":"recurring-abnormalities","chapter":"Recurring Abnormalities","heading":"Recurring Abnormalities","text":"","code":""},{"path":"recurring-abnormalities.html","id":"overview-of-recurring-cytogenetic-abnormalities-in-hematologic-malignancies","chapter":"Recurring Abnormalities","heading":"Overview of Recurring Cytogenetic Abnormalities in Hematologic Malignancies","text":"Definition: Recurring cytogenetic abnormalities specific chromosomal changes (translocations, deletions, inversions, etc.) frequently observed certain types hematologic malignanciesImportance Classification:\nDiagnostic: presence certain recurring cytogenetic abnormalities used defining criterion specific subtypes leukemia, lymphoma, myeloproliferative neoplasms classification\nPrognostic: Many recurring cytogenetic abnormalities prognostic significance, meaning can help predict likely outcome disease\nTherapeutic: genetic abnormalities targets specific therapies\nDiagnostic: presence certain recurring cytogenetic abnormalities used defining criterion specific subtypes leukemia, lymphoma, myeloproliferative neoplasms classificationPrognostic: Many recurring cytogenetic abnormalities prognostic significance, meaning can help predict likely outcome diseaseTherapeutic: genetic abnormalities targets specific therapiesTesting Methods:\nCytogenetic Analysis (Karyotyping): Traditional method identifying chromosomal abnormalities\nFluorescence Situ Hybridization (FISH): Used detect specific chromosomal abnormalities rapidly sensitively\nMolecular Testing (PCR, NGS): Can detect gene mutations fusion genes result chromosomal rearrangements\nCytogenetic Analysis (Karyotyping): Traditional method identifying chromosomal abnormalitiesFluorescence Situ Hybridization (FISH): Used detect specific chromosomal abnormalities rapidly sensitivelyMolecular Testing (PCR, NGS): Can detect gene mutations fusion genes result chromosomal rearrangements","code":""},{"path":"recurring-abnormalities.html","id":"recurring-cytogenetic-abnormalities-by-who-classification","chapter":"Recurring Abnormalities","heading":"Recurring Cytogenetic Abnormalities by WHO Classification","text":", ’ll break key cytogenetic abnormalities associated different types myeloid lymphoid neoplasms according classification. Please note classification updated periodically, ’s important consult recent version current information.","code":""},{"path":"recurring-abnormalities.html","id":"myeloid-neoplasms","chapter":"Recurring Abnormalities","heading":"Myeloid Neoplasms","text":"Acute Myeloid Leukemia (AML) Recurrent Genetic Abnormalities\nt(8;21)(q22;q22.1); RUNX1-RUNX1T1 (AML1-ETO):\nFavorable prognosis\nMorphology: AML maturation, often showing Auer rods\nImmunophenotype: Expresses myeloid markers (CD13, CD33, CD117), often co-expresses CD19\n\ninv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11:\nFavorable prognosis\nMorphology: AML abnormal eosinophils bone marrow\nImmunophenotype: Expresses myeloid markers, CD11b, CD2; eosinophil markers\n\nt(15;17)(q24.1;q21.1); PML-RARA (Acute Promyelocytic Leukemia - APL):\nFavorable prognosis appropriate treatment\nMorphology: Abnormal promyelocytes Auer rods\nClinical Significance: Associated disseminated intravascular coagulation (DIC)\nTreatment: -trans retinoic acid (ATRA) arsenic trioxide (ATO)\n\nt(9;11)(p21.3;q23.3); MLLT3-KMT2A:\nPoor prognosis\nMorphology: Acute monocytic leukemia acute myelomonocytic leukemia\nImmunophenotype: Expresses monocytic markers (CD14, CD11b, CD4, CD36, CD64)\n\ninv(3)(q21.3q26.2) t(3;3)(q21.3;q26.2); GATA2, MECOM (EVI1):\nUnfavorable prognosis\nAssociated increased blasts multi-lineage dysplasia\n\nAcute Myeloid Leukemia (AML) Recurrent Genetic Abnormalitiest(8;21)(q22;q22.1); RUNX1-RUNX1T1 (AML1-ETO):\nFavorable prognosis\nMorphology: AML maturation, often showing Auer rods\nImmunophenotype: Expresses myeloid markers (CD13, CD33, CD117), often co-expresses CD19\nFavorable prognosisMorphology: AML maturation, often showing Auer rodsImmunophenotype: Expresses myeloid markers (CD13, CD33, CD117), often co-expresses CD19inv(16)(p13.1q22) t(16;16)(p13.1;q22); CBFB-MYH11:\nFavorable prognosis\nMorphology: AML abnormal eosinophils bone marrow\nImmunophenotype: Expresses myeloid markers, CD11b, CD2; eosinophil markers\nFavorable prognosisMorphology: AML abnormal eosinophils bone marrowImmunophenotype: Expresses myeloid markers, CD11b, CD2; eosinophil markerst(15;17)(q24.1;q21.1); PML-RARA (Acute Promyelocytic Leukemia - APL):\nFavorable prognosis appropriate treatment\nMorphology: Abnormal promyelocytes Auer rods\nClinical Significance: Associated disseminated intravascular coagulation (DIC)\nTreatment: -trans retinoic acid (ATRA) arsenic trioxide (ATO)\nFavorable prognosis appropriate treatmentMorphology: Abnormal promyelocytes Auer rodsClinical Significance: Associated disseminated intravascular coagulation (DIC)Treatment: -trans retinoic acid (ATRA) arsenic trioxide (ATO)t(9;11)(p21.3;q23.3); MLLT3-KMT2A:\nPoor prognosis\nMorphology: Acute monocytic leukemia acute myelomonocytic leukemia\nImmunophenotype: Expresses monocytic markers (CD14, CD11b, CD4, CD36, CD64)\nPoor prognosisMorphology: Acute monocytic leukemia acute myelomonocytic leukemiaImmunophenotype: Expresses monocytic markers (CD14, CD11b, CD4, CD36, CD64)inv(3)(q21.3q26.2) t(3;3)(q21.3;q26.2); GATA2, MECOM (EVI1):\nUnfavorable prognosis\nAssociated increased blasts multi-lineage dysplasia\nUnfavorable prognosisAssociated increased blasts multi-lineage dysplasiaMyelodysplastic Syndromes (MDS)\ndel(5q):\nMDS Isolated del(5q):\nAnemia\nNormal elevated platelet count\nHypolobated megakaryocytes bone marrow\nGood response lenalidomide\n\n\nTrisomy 8 (+8):\nCommon MDS AML\nMay associated dysplasia multiple cell lines\nVariable prognosis\n\ndel(20q):\nOften associated isolated anemia relatively indolent course\n\ndel(7q) Monosomy 7 (-7):\nAssociated poor prognosis high risk transformation AML\n\nMyelodysplastic Syndromes (MDS)del(5q):\nMDS Isolated del(5q):\nAnemia\nNormal elevated platelet count\nHypolobated megakaryocytes bone marrow\nGood response lenalidomide\n\nMDS Isolated del(5q):\nAnemia\nNormal elevated platelet count\nHypolobated megakaryocytes bone marrow\nGood response lenalidomide\nAnemiaNormal elevated platelet countHypolobated megakaryocytes bone marrowGood response lenalidomideTrisomy 8 (+8):\nCommon MDS AML\nMay associated dysplasia multiple cell lines\nVariable prognosis\nCommon MDS AMLMay associated dysplasia multiple cell linesVariable prognosisdel(20q):\nOften associated isolated anemia relatively indolent course\nOften associated isolated anemia relatively indolent coursedel(7q) Monosomy 7 (-7):\nAssociated poor prognosis high risk transformation AML\nAssociated poor prognosis high risk transformation AMLMyeloproliferative Neoplasms (MPNs)\nt(9;22)(q34.1;q11.2); BCR-ABL1 (Chronic Myeloid Leukemia - CML):\nDiagnostic hallmark CML\nResults fusion protein constitutive tyrosine kinase activity\n\nJAK2 V617F Mutation:\nPresent >95% Polycythemia Vera (PV) cases approximately 50-60% Essential Thrombocythemia (ET) Primary Myelofibrosis (PMF) cases\ngain--function mutation activates JAK-STAT signaling pathway\n\nCALR Mutations:\nMutations calreticulin (CALR) gene found approximately 25% ET PMF cases JAK2-negative\nInvolve insertions deletions exon 9 CALR, leading frameshift altered protein function\n\nMPL Mutations:\nMutations thrombopoietin receptor gene (MPL) found approximately 5-10% ET PMF cases JAK2-negative CALR-negative\n\nMyeloproliferative Neoplasms (MPNs)t(9;22)(q34.1;q11.2); BCR-ABL1 (Chronic Myeloid Leukemia - CML):\nDiagnostic hallmark CML\nResults fusion protein constitutive tyrosine kinase activity\nDiagnostic hallmark CMLResults fusion protein constitutive tyrosine kinase activityJAK2 V617F Mutation:\nPresent >95% Polycythemia Vera (PV) cases approximately 50-60% Essential Thrombocythemia (ET) Primary Myelofibrosis (PMF) cases\ngain--function mutation activates JAK-STAT signaling pathway\nPresent >95% Polycythemia Vera (PV) cases approximately 50-60% Essential Thrombocythemia (ET) Primary Myelofibrosis (PMF) casesA gain--function mutation activates JAK-STAT signaling pathwayCALR Mutations:\nMutations calreticulin (CALR) gene found approximately 25% ET PMF cases JAK2-negative\nInvolve insertions deletions exon 9 CALR, leading frameshift altered protein function\nMutations calreticulin (CALR) gene found approximately 25% ET PMF cases JAK2-negativeInvolve insertions deletions exon 9 CALR, leading frameshift altered protein functionMPL Mutations:\nMutations thrombopoietin receptor gene (MPL) found approximately 5-10% ET PMF cases JAK2-negative CALR-negative\nMutations thrombopoietin receptor gene (MPL) found approximately 5-10% ET PMF cases JAK2-negative CALR-negative","code":""},{"path":"recurring-abnormalities.html","id":"lymphoid-neoplasms","chapter":"Recurring Abnormalities","heading":"Lymphoid Neoplasms","text":"Precursor B-Cell Neoplasms (B-Lymphoblastic Leukemia/Lymphoma):\nt(9;22)(q34.1;q11.2); BCR-ABL1:\nSeen ~25% adult B-cases\nAssociated poor prognosis\n\nt(12;21)(p13.2;q22.1); ETV6-RUNX1:\ncommon translocation childhood B-\nAssociated favorable prognosis\n\nt(v;11q23.3); KMT2A (MLL) rearranged:\nSeen infants adults B-\nAssociated poor prognosis\n\nt(1;19)(q23;p13.3); TCF3-PBX1:\nSeen ~25% childhood B-cases\nAssociated increased risk relapse\nHyperdiploidy:\nGain multiple chromosomes (50 chromosomes)\nAssociated favorable prognosis childhood B-\n\n\nHypodiploidy:\nLoss multiple chromosomes (less 46 chromosomes)\nAssociated poor prognosis childhood B-\n\nPrecursor B-Cell Neoplasms (B-Lymphoblastic Leukemia/Lymphoma):t(9;22)(q34.1;q11.2); BCR-ABL1:\nSeen ~25% adult B-cases\nAssociated poor prognosis\nSeen ~25% adult B-casesAssociated poor prognosist(12;21)(p13.2;q22.1); ETV6-RUNX1:\ncommon translocation childhood B-\nAssociated favorable prognosis\ncommon translocation childhood B-ALLAssociated favorable prognosist(v;11q23.3); KMT2A (MLL) rearranged:\nSeen infants adults B-\nAssociated poor prognosis\nSeen infants adults B-ALLAssociated poor prognosist(1;19)(q23;p13.3); TCF3-PBX1:\nSeen ~25% childhood B-cases\nAssociated increased risk relapse\nHyperdiploidy:\nGain multiple chromosomes (50 chromosomes)\nAssociated favorable prognosis childhood B-\n\nSeen ~25% childhood B-casesAssociated increased risk relapseHyperdiploidy:\nGain multiple chromosomes (50 chromosomes)\nAssociated favorable prognosis childhood B-\nGain multiple chromosomes (50 chromosomes)Associated favorable prognosis childhood B-ALLHypodiploidy:\nLoss multiple chromosomes (less 46 chromosomes)\nAssociated poor prognosis childhood B-\nLoss multiple chromosomes (less 46 chromosomes)Associated poor prognosis childhood B-ALLMature B-Cell Neoplasms:\nt(14;18)(q32;q21); IGH-BCL2 (Follicular Lymphoma):\nDiagnostic hallmark follicular lymphoma\nResults overexpression BCL2, anti-apoptotic protein\n\nt(11;14)(q13;q32); CCND1-IGH (Mantle Cell Lymphoma):\nDiagnostic hallmark mantle cell lymphoma\nResults overexpression cyclin D1, cell cycle regulator\n\nt(8;14)(q24;q32); MYC-IGH (Burkitt Lymphoma):\nDiagnostic hallmark Burkitt lymphoma\nResults overexpression MYC, transcription factor promotes cell growth\n\ndel(13q14.3) (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma):\n*Good Prognosis\nMature B-Cell Neoplasms:t(14;18)(q32;q21); IGH-BCL2 (Follicular Lymphoma):\nDiagnostic hallmark follicular lymphoma\nResults overexpression BCL2, anti-apoptotic protein\nDiagnostic hallmark follicular lymphomaResults overexpression BCL2, anti-apoptotic proteint(11;14)(q13;q32); CCND1-IGH (Mantle Cell Lymphoma):\nDiagnostic hallmark mantle cell lymphoma\nResults overexpression cyclin D1, cell cycle regulator\nDiagnostic hallmark mantle cell lymphomaResults overexpression cyclin D1, cell cycle regulatort(8;14)(q24;q32); MYC-IGH (Burkitt Lymphoma):\nDiagnostic hallmark Burkitt lymphoma\nResults overexpression MYC, transcription factor promotes cell growth\nDiagnostic hallmark Burkitt lymphomaResults overexpression MYC, transcription factor promotes cell growthdel(13q14.3) (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma):\n*Good Prognosis","code":""},{"path":"recurring-abnormalities.html","id":"molecular-testing-pcr-and-ngs","chapter":"Recurring Abnormalities","heading":"Molecular Testing (PCR and NGS)","text":"Molecular testing plays increasingly important role diagnosis, classification, monitoring hematologic malignanciesPCR-Based Assays:\nUsed detect gene mutations fusion genes visible cytogenetic analysis\nExample: JAK2 V617F mutation MPNs\nPCR-Based Assays:Used detect gene mutations fusion genes visible cytogenetic analysisExample: JAK2 V617F mutation MPNsNext-Generation Sequencing (NGS):\nAllows simultaneous sequencing multiple genes, providing comprehensive analysis genetic landscape tumor cells\nUsed identify gene mutations, insertions, deletions, copy number variations\nProvides valuable information diagnosis, prognosis, treatment planning\nNext-Generation Sequencing (NGS):Allows simultaneous sequencing multiple genes, providing comprehensive analysis genetic landscape tumor cellsUsed identify gene mutations, insertions, deletions, copy number variationsProvides valuable information diagnosis, prognosis, treatment planning","code":""},{"path":"recurring-abnormalities.html","id":"reporting-and-interpretation","chapter":"Recurring Abnormalities","heading":"Reporting and Interpretation","text":"Karyotype: Describe karyotype using ISCN nomenclature indicate presence absence chromosomal abnormalitiesFISH Results: Report percentage cells specific chromosomal abnormalityMolecular Testing Results: Report presence absence specific gene mutations fusion genesIntegrate Cytogenetic Molecular Findings Patient’s Clinical, Morphologic, Immunophenotypic DataPrognostic Interpretation: reporting results, ’s important convey prognostic significance findings clinician","code":""},{"path":"recurring-abnormalities.html","id":"key-terms-72","chapter":"Recurring Abnormalities","heading":"Key Terms","text":"Cytogenetic Analysis (Karyotyping): study chromosomes abnormalitiesFISH (Fluorescence Situ Hybridization): technique uses fluorescent probes detect specific DNA sequences chromosomesMolecular Testing: Techniques detect gene mutations fusion genesMutation: change DNA sequence geneTranslocation: transfer genetic material one chromosome anotherDeletion: loss portion chromosomeInversion: reversal segment chromosomeFusion Gene: gene formed fusion two separate genes due chromosomal translocation deletionMyeloid Neoplasm: hematologic malignancy arising myeloid progenitor cellsLymphoid Neoplasm: hematologic malignancy arising lymphocytesLeukemia: malignant disorder blood-forming cellsLymphoma: malignant disorder lymphocytes typically arises lymph nodes","code":""},{"path":"bcrabl1.html","id":"bcrabl1","chapter":"BCR/ABL1","heading":"BCR/ABL1","text":"","code":""},{"path":"bcrabl1.html","id":"overview-of-the-bcrabl1-fusion-gene","chapter":"BCR/ABL1","heading":"Overview of the BCR/ABL1 Fusion Gene","text":"Definition: BCR-ABL1 fusion gene abnormal gene formed reciprocal translocation chromosomes 9 22, denoted t(9;22)(q34.1;q11.2)Historical Context: translocation results formation Philadelphia chromosome (Ph chromosome), named city discoveredSignificance:\nDiagnostic Marker CML: presence BCR-ABL1 defining characteristic Chronic Myeloid Leukemia (CML)\nPrognostic Marker: CML, level BCR-ABL1 transcript used monitor treatment response predict risk disease progression\nDiagnostic Prognostic Marker : Present cases Acute Lymphoblastic Leukemia (), particularly adult B-, associated poorer prognosis\nTarget Therapy: BCR-ABL1 fusion protein tyrosine kinase, making target specific tyrosine kinase inhibitors (TKIs)\nDiagnostic Marker CML: presence BCR-ABL1 defining characteristic Chronic Myeloid Leukemia (CML)Prognostic Marker: CML, level BCR-ABL1 transcript used monitor treatment response predict risk disease progressionDiagnostic Prognostic Marker : Present cases Acute Lymphoblastic Leukemia (), particularly adult B-, associated poorer prognosisTarget Therapy: BCR-ABL1 fusion protein tyrosine kinase, making target specific tyrosine kinase inhibitors (TKIs)","code":""},{"path":"bcrabl1.html","id":"molecular-basis-of-the-bcr-abl1-fusion-gene","chapter":"BCR/ABL1","heading":"Molecular Basis of the BCR-ABL1 Fusion Gene","text":"Normal Genes:\nABL1 (Abelson murine leukemia viral oncogene homolog 1): Located chromosome 9 (9q34.1)\nEncodes non-receptor tyrosine kinase involved cell growth, differentiation, survival\n\nBCR (Breakpoint Cluster Region): Located chromosome 22 (22q11.2)\nEncodes serine/threonine kinase involved signal transduction\n\nABL1 (Abelson murine leukemia viral oncogene homolog 1): Located chromosome 9 (9q34.1)\nEncodes non-receptor tyrosine kinase involved cell growth, differentiation, survival\nEncodes non-receptor tyrosine kinase involved cell growth, differentiation, survivalBCR (Breakpoint Cluster Region): Located chromosome 22 (22q11.2)\nEncodes serine/threonine kinase involved signal transduction\nEncodes serine/threonine kinase involved signal transductionTranslocation Process:\nreciprocal translocation occurs chromosomes 9 22:\nPart ABL1 gene chromosome 9 translocates BCR gene chromosome 22\nPart BCR gene chromosome 22 translocates chromosome 9\n\nreciprocal translocation occurs chromosomes 9 22:\nPart ABL1 gene chromosome 9 translocates BCR gene chromosome 22\nPart BCR gene chromosome 22 translocates chromosome 9\nPart ABL1 gene chromosome 9 translocates BCR gene chromosome 22Part BCR gene chromosome 22 translocates chromosome 9Resulting Fusion Gene:\ntranslocation creates new fusion gene, BCR-ABL1, Philadelphia chromosome (derivative chromosome 22)\nBCR-ABL1 fusion gene encodes 210 kDa protein constitutive tyrosine kinase activity\ntranslocation creates new fusion gene, BCR-ABL1, Philadelphia chromosome (derivative chromosome 22)BCR-ABL1 fusion gene encodes 210 kDa protein constitutive tyrosine kinase activity","code":""},{"path":"bcrabl1.html","id":"pathophysiology-6","chapter":"BCR/ABL1","heading":"Pathophysiology","text":"Constitutive Tyrosine Kinase Activity:\nBCR-ABL1 fusion protein uncontrolled tyrosine kinase activity, meaning always “switched ”\nunregulated kinase activity leads :\nUncontrolled cell proliferation\nInhibition apoptosis (programmed cell death)\nGenomic instability\n\neffects result clonal expansion malignant myeloid cells (CML) lymphoid cells (Ph+ )\nBCR-ABL1 fusion protein uncontrolled tyrosine kinase activity, meaning always “switched ”unregulated kinase activity leads :\nUncontrolled cell proliferation\nInhibition apoptosis (programmed cell death)\nGenomic instability\nUncontrolled cell proliferationInhibition apoptosis (programmed cell death)Genomic instabilityThese effects result clonal expansion malignant myeloid cells (CML) lymphoid cells (Ph+ )Downstream Signaling Pathways:\nBCR-ABL1 activates multiple downstream signaling pathways, including:\nRAS/MAPK pathway\nPI3K/AKT pathway\nJAK/STAT pathway\n\npathways regulate cell growth, survival, differentiation\nBCR-ABL1 activates multiple downstream signaling pathways, including:\nRAS/MAPK pathway\nPI3K/AKT pathway\nJAK/STAT pathway\nRAS/MAPK pathwayPI3K/AKT pathwayJAK/STAT pathwayThese pathways regulate cell growth, survival, differentiation","code":""},{"path":"bcrabl1.html","id":"laboratory-detection-of-bcr-abl1","chapter":"BCR/ABL1","heading":"Laboratory Detection of BCR-ABL1","text":"Cytogenetic Analysis (Karyotyping):\nPrinciple: Visualizes Philadelphia chromosome (Ph chromosome) resulting t(9;22) translocation\nProcedure:\nCells cultured, arrested metaphase, stained visualize chromosomes\nKaryotype analyzed identify Ph chromosome\n\nReporting:\nt(9;22)(q34.1;q11.2)\n\nAdvantages:\nCan detect chromosomal abnormalities addition Ph chromosome\n\nLimitations:\nRequires viable cells cell culture\nTime-consuming\ndetect cryptic translocations variant translocations\n\nPrinciple: Visualizes Philadelphia chromosome (Ph chromosome) resulting t(9;22) translocationProcedure:\nCells cultured, arrested metaphase, stained visualize chromosomes\nKaryotype analyzed identify Ph chromosome\nCells cultured, arrested metaphase, stained visualize chromosomesKaryotype analyzed identify Ph chromosomeReporting:\nt(9;22)(q34.1;q11.2)\nt(9;22)(q34.1;q11.2)Advantages:\nCan detect chromosomal abnormalities addition Ph chromosome\nCan detect chromosomal abnormalities addition Ph chromosomeLimitations:\nRequires viable cells cell culture\nTime-consuming\ndetect cryptic translocations variant translocations\nRequires viable cells cell cultureTime-consumingCannot detect cryptic translocations variant translocationsFluorescence Situ Hybridization (FISH):\nPrinciple: Uses fluorescently labeled DNA probes detect BCR ABL1 genes BCR-ABL1 fusion gene\nProcedure:\nInterphase FISH: Performed uncultured bone marrow cells\nMetaphase FISH: Performed cultured cells\nHybridization: Fluorescent probes hybridized chromosomes slide\nMicroscopic Examination: slide examined fluorescence microscope, number location fluorescent signals counted\n\nAdvantages:\nrapid karyotyping\nCan performed non-dividing cells\nCan detect cryptic translocations\n\nLimitations:\ndetects known chromosomal abnormalities probes available\ndetect novel translocations complex rearrangements\n\nPrinciple: Uses fluorescently labeled DNA probes detect BCR ABL1 genes BCR-ABL1 fusion geneProcedure:\nInterphase FISH: Performed uncultured bone marrow cells\nMetaphase FISH: Performed cultured cells\nHybridization: Fluorescent probes hybridized chromosomes slide\nMicroscopic Examination: slide examined fluorescence microscope, number location fluorescent signals counted\nInterphase FISH: Performed uncultured bone marrow cellsMetaphase FISH: Performed cultured cellsHybridization: Fluorescent probes hybridized chromosomes slideMicroscopic Examination: slide examined fluorescence microscope, number location fluorescent signals countedAdvantages:\nrapid karyotyping\nCan performed non-dividing cells\nCan detect cryptic translocations\nrapid karyotypingCan performed non-dividing cellsCan detect cryptic translocationsLimitations:\ndetects known chromosomal abnormalities probes available\ndetect novel translocations complex rearrangements\ndetects known chromosomal abnormalities probes availableCannot detect novel translocations complex rearrangementsReverse Transcription Polymerase Chain Reaction (RT-PCR):\nPrinciple: Amplifies detects BCR-ABL1 fusion transcript (mRNA)\nProcedure:\nRNA Extraction: Extract RNA bone marrow aspirate peripheral blood\nReverse Transcription: Convert RNA complementary DNA (cDNA) using reverse transcriptase\nAmplification: Use PCR amplify BCR-ABL1 fusion transcript using specific primers\nDetection: Detect amplified DNA product using gel electrophoresis real-time PCR\n\nQualitative RT-PCR:\nDetects presence absence BCR-ABL1 transcript\nUsed initial diagnosis\n\nQuantitative Real-Time PCR (RQ-PCR):\nMeasures level BCR-ABL1 transcript\nUsed monitoring minimal residual disease (MRD) assessing treatment response\nResults typically reported percentage BCR-ABL1 transcript relative control gene (e.g., ABL1 GUS)\nInternational Scale () used standardize BCR-ABL1 transcript levels across different laboratories\n\nAdvantages:\nHigh sensitivity specificity\nCan quantify amount BCR-ABL1 transcript\nRapid turnaround time\n\nLimitations:\ndetects known fusion transcripts primers available\nRequires specialized equipment expertise\nSusceptible contamination\n\nPrinciple: Amplifies detects BCR-ABL1 fusion transcript (mRNA)Procedure:\nRNA Extraction: Extract RNA bone marrow aspirate peripheral blood\nReverse Transcription: Convert RNA complementary DNA (cDNA) using reverse transcriptase\nAmplification: Use PCR amplify BCR-ABL1 fusion transcript using specific primers\nDetection: Detect amplified DNA product using gel electrophoresis real-time PCR\nRNA Extraction: Extract RNA bone marrow aspirate peripheral bloodReverse Transcription: Convert RNA complementary DNA (cDNA) using reverse transcriptaseAmplification: Use PCR amplify BCR-ABL1 fusion transcript using specific primersDetection: Detect amplified DNA product using gel electrophoresis real-time PCRQualitative RT-PCR:\nDetects presence absence BCR-ABL1 transcript\nUsed initial diagnosis\nDetects presence absence BCR-ABL1 transcriptUsed initial diagnosisQuantitative Real-Time PCR (RQ-PCR):\nMeasures level BCR-ABL1 transcript\nUsed monitoring minimal residual disease (MRD) assessing treatment response\nResults typically reported percentage BCR-ABL1 transcript relative control gene (e.g., ABL1 GUS)\nInternational Scale () used standardize BCR-ABL1 transcript levels across different laboratories\nMeasures level BCR-ABL1 transcriptUsed monitoring minimal residual disease (MRD) assessing treatment responseResults typically reported percentage BCR-ABL1 transcript relative control gene (e.g., ABL1 GUS)International Scale () used standardize BCR-ABL1 transcript levels across different laboratoriesAdvantages:\nHigh sensitivity specificity\nCan quantify amount BCR-ABL1 transcript\nRapid turnaround time\nHigh sensitivity specificityCan quantify amount BCR-ABL1 transcriptRapid turnaround timeLimitations:\ndetects known fusion transcripts primers available\nRequires specialized equipment expertise\nSusceptible contamination\ndetects known fusion transcripts primers availableRequires specialized equipment expertiseSusceptible contaminationNext-Generation Sequencing (NGS):\nPrinciple: Massively parallel sequencing technology can detect BCR-ABL1 fusion gene mutations\nAdvantages:\nCan detect known novel fusion genes mutations\nCan identify co-occurring mutations may affect prognosis treatment response\n\nLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\n\nPrinciple: Massively parallel sequencing technology can detect BCR-ABL1 fusion gene mutationsAdvantages:\nCan detect known novel fusion genes mutations\nCan identify co-occurring mutations may affect prognosis treatment response\nCan detect known novel fusion genes mutationsCan identify co-occurring mutations may affect prognosis treatment responseLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\ncomplex expensive PCR-based methodsRequires bioinformatics expertise data analysis","code":""},{"path":"bcrabl1.html","id":"clinical-interpretation","chapter":"BCR/ABL1","heading":"Clinical Interpretation","text":"CML Diagnosis:\ndiagnosis CML requires presence BCR-ABL1 fusion gene Philadelphia chromosome\nBCR-ABL1 transcript level used monitor treatment response\ndiagnosis CML requires presence BCR-ABL1 fusion gene Philadelphia chromosomeThe BCR-ABL1 transcript level used monitor treatment responseCML Response TKI Therapy:\nHematologic Response: Normalization blood counts\nCytogenetic Response: Reduction elimination Ph chromosome\nMolecular Response: Reduction BCR-ABL1 transcript levels, measured RQ-PCR\nMajor Molecular Response (MMR): BCR-ABL1 transcript level ≤ 0.1% International Scale ()\nDeep Molecular Response (MR4, MR4.5): low undetectable BCR-ABL1 transcript levels\n\nHematologic Response: Normalization blood countsCytogenetic Response: Reduction elimination Ph chromosomeMolecular Response: Reduction BCR-ABL1 transcript levels, measured RQ-PCR\nMajor Molecular Response (MMR): BCR-ABL1 transcript level ≤ 0.1% International Scale ()\nDeep Molecular Response (MR4, MR4.5): low undetectable BCR-ABL1 transcript levels\nMajor Molecular Response (MMR): BCR-ABL1 transcript level ≤ 0.1% International Scale ()Deep Molecular Response (MR4, MR4.5): low undetectable BCR-ABL1 transcript levelsPrognosis:\nlevel BCR-ABL1 transcript key prognostic factor CML\nPatients achieve deep molecular response lower risk disease progression\nlevel BCR-ABL1 transcript key prognostic factor CMLPatients achieve deep molecular response lower risk disease progressionResistance TKI Therapy:\nMutations ABL1 kinase domain can lead resistance tyrosine kinase inhibitors (TKIs)\nABL1 kinase domain mutation testing performed identify resistance mutations guide treatment decisions\nMutations ABL1 kinase domain can lead resistance tyrosine kinase inhibitors (TKIs)ABL1 kinase domain mutation testing performed identify resistance mutations guide treatment decisions","code":""},{"path":"bcrabl1.html","id":"key-terms-73","chapter":"BCR/ABL1","heading":"Key Terms","text":"BCR-ABL1* Fusion Gene: fusion gene created translocation chromosomes 9 22, resulting Philadelphia chromosomePhiladelphia Chromosome (Ph Chromosome): derivative chromosome 22 contains BCR-ABL1 fusion geneTranslocation: transfer genetic material one chromosome anotherTyrosine Kinase Inhibitor (TKI): drug inhibits activity tyrosine kinases, BCR-ABL1 proteinMinimal Residual Disease (MRD): Small numbers residual cancer cells remain treatmentMajor Molecular Response (MMR): significant reduction BCR-ABL1 transcript levelDeep Molecular Response: low undetectable BCR-ABL1 transcript levelsABL1 Kinase Domain Mutation: Mutations ABL1 kinase domain can cause resistance TKIsFISH (Fluorescence Situ Hybridization): Uses fluorescent probes identify certain mutations body","code":""},{"path":"jak2.html","id":"jak2","chapter":"JAK2","heading":"JAK2","text":"","code":""},{"path":"jak2.html","id":"overview-of-jak2-mutation-testing","chapter":"JAK2","heading":"Overview of JAK2 Mutation Testing","text":"Definition: Molecular testing mutations JAK2 gene (Janus kinase 2) used diagnose classify certain myeloproliferative neoplasms (MPNs)Clinical Significance:\nDiagnosis MPNs: JAK2 mutation, particularly JAK2 V617F, major diagnostic criterion Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)\nDifferential Diagnosis: Helps distinguish MPNs conditions similar clinical features (e.g., secondary erythrocytosis, reactive thrombocytosis)\nPrognosis: Certain JAK2 mutations may prognostic significance MPNs\nTherapeutic Decision-Making: JAK2 inhibitors used treat MPNs JAK2 mutations\nDiagnosis MPNs: JAK2 mutation, particularly JAK2 V617F, major diagnostic criterion Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)Differential Diagnosis: Helps distinguish MPNs conditions similar clinical features (e.g., secondary erythrocytosis, reactive thrombocytosis)Prognosis: Certain JAK2 mutations may prognostic significance MPNsTherapeutic Decision-Making: JAK2 inhibitors used treat MPNs JAK2 mutationsKey Mutations:\nJAK2 V617F: common mutation, found majority PV cases approximately 50-60% ET PMF cases\nJAK2 Exon 12 Mutations: Less common, primarily found PV patients JAK2 V617F-negative\nJAK2 V617F: common mutation, found majority PV cases approximately 50-60% ET PMF casesJAK2 Exon 12 Mutations: Less common, primarily found PV patients JAK2 V617F-negative","code":""},{"path":"jak2.html","id":"the-jak2-gene-and-its-function","chapter":"JAK2","heading":"The JAK2 Gene and Its Function","text":"Gene Location: JAK2 gene located chromosome 9p24Protein Product: JAK2 encodes Janus kinase 2, non-receptor tyrosine kinase essential signal transduction various cytokine receptorsFunction:\nJAK-STAT Signaling Pathway: JAK2 key component JAK-STAT signaling pathway, involved hematopoiesis, immune function, cell growth\nCytokine Receptor Signaling: cytokines (e.g., erythropoietin, thrombopoietin, granulocyte colony-stimulating factor) bind receptors cell surface, activate JAK2\nPhosphorylation: Activated JAK2 phosphorylates (adds phosphate groups ) STAT proteins (signal transducers activators transcription)\nTranscription Activation: Phosphorylated STATs dimerize translocate nucleus, bind DNA activate transcription genes involved cell proliferation, differentiation, survival\nJAK-STAT Signaling Pathway: JAK2 key component JAK-STAT signaling pathway, involved hematopoiesis, immune function, cell growthCytokine Receptor Signaling: cytokines (e.g., erythropoietin, thrombopoietin, granulocyte colony-stimulating factor) bind receptors cell surface, activate JAK2Phosphorylation: Activated JAK2 phosphorylates (adds phosphate groups ) STAT proteins (signal transducers activators transcription)Transcription Activation: Phosphorylated STATs dimerize translocate nucleus, bind DNA activate transcription genes involved cell proliferation, differentiation, survival","code":""},{"path":"jak2.html","id":"pathophysiology-of-jak2-mutations-in-mpns","chapter":"JAK2","heading":"Pathophysiology of JAK2 Mutations in MPNs","text":"Constitutive Activation: JAK2 mutations, particularly JAK2 V617F, result constitutive activation JAK-STAT signaling pathway\nV617F mutation causes JAK2 protein constantly active, even absence cytokine stimulation\nV617F mutation causes JAK2 protein constantly active, even absence cytokine stimulationUncontrolled Cell Proliferation: constitutive activation JAK-STAT leads :\nIncreased proliferation myeloid cells (erythrocytes, granulocytes, megakaryocytes)\nCytokine Independence: Hematopoietic cells become less dependent cytokines survival proliferation\nIncreased proliferation myeloid cells (erythrocytes, granulocytes, megakaryocytes)Cytokine Independence: Hematopoietic cells become less dependent cytokines survival proliferationSpecific Effects MPNs:\nPolycythemia Vera (PV): Increased sensitivity EPO leads erythrocytosis\nEssential Thrombocythemia (ET): Increased sensitivity thrombopoietin leads thrombocytosis\nPrimary Myelofibrosis (PMF): Activation signaling pathways leads increased megakaryocyte proliferation, release fibrogenic cytokines, bone marrow fibrosis\nPolycythemia Vera (PV): Increased sensitivity EPO leads erythrocytosisEssential Thrombocythemia (ET): Increased sensitivity thrombopoietin leads thrombocytosisPrimary Myelofibrosis (PMF): Activation signaling pathways leads increased megakaryocyte proliferation, release fibrogenic cytokines, bone marrow fibrosis","code":""},{"path":"jak2.html","id":"laboratory-methods-for-detecting-jak2-mutations","chapter":"JAK2","heading":"Laboratory Methods for Detecting JAK2 Mutations","text":"Polymerase Chain Reaction (PCR)-Based Assays:\nPrinciple: PCR used amplify specific region JAK2 gene contains V617F mutation exon 12 mutations.\nMethods:\nAllele-Specific PCR (-PCR): Uses primers specific mutated sequence\nQuantitative Real-Time PCR (RQ-PCR): Measures amount mutated sequence relative normal sequence\n\nAdvantages:\nHigh sensitivity specificity\nRelatively rapid turnaround time\n\nLimitations:\ndetects known mutations primers available\ndetect novel mutations genetic abnormalities\n\nPrinciple: PCR used amplify specific region JAK2 gene contains V617F mutation exon 12 mutations.Methods:\nAllele-Specific PCR (-PCR): Uses primers specific mutated sequence\nQuantitative Real-Time PCR (RQ-PCR): Measures amount mutated sequence relative normal sequence\nAllele-Specific PCR (-PCR): Uses primers specific mutated sequenceQuantitative Real-Time PCR (RQ-PCR): Measures amount mutated sequence relative normal sequenceAdvantages:\nHigh sensitivity specificity\nRelatively rapid turnaround time\nHigh sensitivity specificityRelatively rapid turnaround timeLimitations:\ndetects known mutations primers available\ndetect novel mutations genetic abnormalities\ndetects known mutations primers availableCannot detect novel mutations genetic abnormalitiesNext-Generation Sequencing (NGS):\nPrinciple: Massively parallel sequencing technology allows simultaneous sequencing multiple genes, including JAK2\nProcedure:\nDNA extracted bone marrow aspirate peripheral blood\nTargeted sequencing: coding regions specific genes (e.g., JAK2, CALR, MPL) sequenced\nWhole-exome sequencing: entire coding region genome sequenced\nsequencing data analyzed identify gene mutations, insertions, deletions, copy number variations\n\nAdvantages:\nCan detect known novel mutations\nCan detect multiple mutations simultaneously\nCan used identify gene expression changes\n\nLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\n\nPrinciple: Massively parallel sequencing technology allows simultaneous sequencing multiple genes, including JAK2Procedure:\nDNA extracted bone marrow aspirate peripheral blood\nTargeted sequencing: coding regions specific genes (e.g., JAK2, CALR, MPL) sequenced\nWhole-exome sequencing: entire coding region genome sequenced\nsequencing data analyzed identify gene mutations, insertions, deletions, copy number variations\nDNA extracted bone marrow aspirate peripheral bloodTargeted sequencing: coding regions specific genes (e.g., JAK2, CALR, MPL) sequencedWhole-exome sequencing: entire coding region genome sequencedThe sequencing data analyzed identify gene mutations, insertions, deletions, copy number variationsAdvantages:\nCan detect known novel mutations\nCan detect multiple mutations simultaneously\nCan used identify gene expression changes\nCan detect known novel mutationsCan detect multiple mutations simultaneouslyCan used identify gene expression changesLimitations:\ncomplex expensive PCR-based methods\nRequires bioinformatics expertise data analysis\ncomplex expensive PCR-based methodsRequires bioinformatics expertise data analysis","code":""},{"path":"jak2.html","id":"interpreting-results-1","chapter":"JAK2","heading":"Interpreting Results","text":"JAK2 V617F Positive: Indicates presence JAK2 V617F mutation\nSupports diagnosis PV, ET, PMF\nQuantitative results RQ-PCR can used monitor treatment response\nJAK2 V617F Positive: Indicates presence JAK2 V617F mutationSupports diagnosis PV, ET, PMFQuantitative results RQ-PCR can used monitor treatment responseJAK2 Exon 12 Mutation Positive: Indicates presence mutation exon 12 JAK2 gene\nSupports diagnosis PV patients JAK2 V617F-negative\nJAK2 Exon 12 Mutation Positive: Indicates presence mutation exon 12 JAK2 geneSupports diagnosis PV patients JAK2 V617F-negativeJAK2 Mutation Negative: rule MPN\nConsider testing CALR MPL mutations JAK2-negative patients suspected ET PMF\nEvaluate diagnostic criteria (e.g., bone marrow morphology, clinical features)\nJAK2 Mutation Negative: rule MPNConsider testing CALR MPL mutations JAK2-negative patients suspected ET PMFEvaluate diagnostic criteria (e.g., bone marrow morphology, clinical features)Variant Allele Frequency (VAF):\npercentage alleles contain mutation\ngeneral, higher VAF associated greater disease burden\nVariant Allele Frequency (VAF):percentage alleles contain mutationIn general, higher VAF associated greater disease burdenSomatic vs. Germline Mutations:\nJAK2 mutations typically somatic (acquired) mutations present hematopoietic cells\nRarely, JAK2 mutations can germline (inherited), may predispose MPNs\nSomatic vs. Germline Mutations:JAK2 mutations typically somatic (acquired) mutations present hematopoietic cellsRarely, JAK2 mutations can germline (inherited), may predispose MPNs","code":""},{"path":"jak2.html","id":"reporting-results-15","chapter":"JAK2","heading":"Reporting Results","text":"Clearly indicate presence absence JAK2 V617F mutation exon 12 mutationsReport quantitative results (applicable) methodology usedProvide interpretation results, noting limitations qualificationsCorrelate molecular findings patient’s clinical, morphologic, cytogenetic data","code":""},{"path":"jak2.html","id":"key-terms-74","chapter":"JAK2","heading":"Key Terms","text":"JAK2* (Janus Kinase 2): tyrosine kinase involved signal transductionJAK2* V617F: point mutation JAK2 gene commonly found MPNsJAK2* Exon 12 Mutations: Mutations exon 12 JAK2 gene primarily found PV patients JAK2 V617F-negativeMyeloproliferative Neoplasm (MPN): clonal hematopoietic stem cell disorder characterized overproduction one blood cell linesPolycythemia Vera (PV): MPN increased red blood cell productionEssential Thrombocythemia (ET): MPN increased platelet productionPrimary Myelofibrosis (PMF): MPN characterized bone marrow fibrosisPCR (Polymerase Chain Reaction): technique amplify specific DNA sequencesNext-Generation Sequencing (NGS): high-throughput sequencing technology","code":""},{"path":"coagulation-pathways.html","id":"coagulation-pathways","chapter":"Coagulation Pathways","heading":"Coagulation Pathways","text":"","code":""},{"path":"coagulation-pathways.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"Coagulation Pathways","heading":"\nAudio Overview\n","text":"","code":""},{"path":"coagulation-pathways.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"Coagulation Pathways","heading":"\nAudio Overview\n","text":"","code":""},{"path":"coagulation-pathways.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"Coagulation Pathways","heading":"\nAudio Overview\n","text":"","code":""},{"path":"coagulation-pathways.html","id":"overview-of-coagulation-pathways","chapter":"Coagulation Pathways","heading":"Overview of Coagulation Pathways","text":"Definition: process body stops bleeding, involving complex interplay blood vessels, platelets, coagulation factorsPhases Hemostasis:\nPrimary Hemostasis: Formation temporary platelet plug site vascular injury\nSecondary Hemostasis: Activation coagulation cascade, leading formation stable fibrin clot\nFibrinolysis: Breakdown fibrin clot vessel healed\nPrimary Hemostasis: Formation temporary platelet plug site vascular injurySecondary Hemostasis: Activation coagulation cascade, leading formation stable fibrin clotFibrinolysis: Breakdown fibrin clot vessel healedCoagulation Pathways: series enzymatic reactions involving coagulation factors ultimately result formation fibrin","code":""},{"path":"coagulation-pathways.html","id":"components-of-the-coagulation-system","chapter":"Coagulation Pathways","heading":"Components of the Coagulation System","text":"Coagulation Factors:\nserine proteases (enzymes cleave peptide bonds proteins)\nSynthesized primarily liver\nCirculate blood inactive form (zymogens)\nActivated specific activators coagulation factors\nNumbered Roman numerals (e.g., Factor , Factor II, Factor III)\nserine proteases (enzymes cleave peptide bonds proteins)Synthesized primarily liverCirculate blood inactive form (zymogens)Activated specific activators coagulation factorsNumbered Roman numerals (e.g., Factor , Factor II, Factor III)Cofactors:\nNon-enzymatic proteins enhance activity coagulation factors\nExamples: Factor V, Factor VIII, Tissue Factor (Factor III)\nNon-enzymatic proteins enhance activity coagulation factorsExamples: Factor V, Factor VIII, Tissue Factor (Factor III)Calcium (Ca2+):\nEssential activity several coagulation factors (e.g., Factors II, VII, IX, X)\nEssential activity several coagulation factors (e.g., Factors II, VII, IX, X)Phospholipids:\nProvide surface assembly coagulation complexes\nPlatelet membranes activated endothelial cells provide phospholipid surfaces\nProvide surface assembly coagulation complexesPlatelet membranes activated endothelial cells provide phospholipid surfaces","code":""},{"path":"coagulation-pathways.html","id":"the-coagulation-cascade","chapter":"Coagulation Pathways","heading":"The Coagulation Cascade","text":"coagulation cascade traditionally divided three pathways: intrinsic pathway, extrinsic pathway, common pathwayIntrinsic Pathway: (Also known Contact Activation Pathway)\nInitiated factors within blood\nInvolves Factors XII, XI, IX, VIII\nSteps:\nFactor XII activated Factor XIIa upon contact negatively charged surfaces (e.g., collagen, phospholipids)\nFactor XIIa activates Factor XI Factor XIa\nFactor XIa activates Factor IX Factor IXa\nFactor IXa, along cofactor Factor VIIIa, forms complex platelet surface activates Factor X\n\nIntrinsic Pathway: (Also known Contact Activation Pathway)Initiated factors within bloodInvolves Factors XII, XI, IX, VIIISteps:\nFactor XII activated Factor XIIa upon contact negatively charged surfaces (e.g., collagen, phospholipids)\nFactor XIIa activates Factor XI Factor XIa\nFactor XIa activates Factor IX Factor IXa\nFactor IXa, along cofactor Factor VIIIa, forms complex platelet surface activates Factor X\nFactor XII activated Factor XIIa upon contact negatively charged surfaces (e.g., collagen, phospholipids)Factor XIIa activates Factor XI Factor XIaFactor XIa activates Factor IX Factor IXaFactor IXa, along cofactor Factor VIIIa, forms complex platelet surface activates Factor XExtrinsic Pathway: (Also known Tissue Factor Pathway)\nInitiated factors outside blood, specifically tissue factor (TF)\nInvolves Tissue Factor (Factor III) Factor VII\nSteps:\nTissue factor (TF) exposed site vascular injury\nFactor VII binds TF, forming TF-VIIa complex\nTF-VIIa complex activates Factor X Factor Xa\n\nExtrinsic Pathway: (Also known Tissue Factor Pathway)Initiated factors outside blood, specifically tissue factor (TF)Involves Tissue Factor (Factor III) Factor VIISteps:\nTissue factor (TF) exposed site vascular injury\nFactor VII binds TF, forming TF-VIIa complex\nTF-VIIa complex activates Factor X Factor Xa\nTissue factor (TF) exposed site vascular injuryFactor VII binds TF, forming TF-VIIa complexThe TF-VIIa complex activates Factor X Factor XaCommon Pathway:\nfinal pathway coagulation cascade, leading formation fibrin\nInvolves Factors X, V, II (prothrombin), (fibrinogen)\nSteps:\nFactor Xa, along cofactor Factor Va, forms prothrombinase complex platelet surface\nprothrombinase complex converts prothrombin (Factor II) thrombin (Factor IIa)\nThrombin converts fibrinogen (Factor ) fibrin monomers\nFibrin monomers spontaneously polymerize form fibrin polymer (loose, unstable clot)\n\nCommon Pathway:final pathway coagulation cascade, leading formation fibrinInvolves Factors X, V, II (prothrombin), (fibrinogen)Steps:\nFactor Xa, along cofactor Factor Va, forms prothrombinase complex platelet surface\nprothrombinase complex converts prothrombin (Factor II) thrombin (Factor IIa)\nThrombin converts fibrinogen (Factor ) fibrin monomers\nFibrin monomers spontaneously polymerize form fibrin polymer (loose, unstable clot)\nFactor Xa, along cofactor Factor Va, forms prothrombinase complex platelet surfaceThe prothrombinase complex converts prothrombin (Factor II) thrombin (Factor IIa)Thrombin converts fibrinogen (Factor ) fibrin monomersFibrin monomers spontaneously polymerize form fibrin polymer (loose, unstable clot)Note:\ntraditional division pathways useful understanding steps involved, ’s important recognize coagulation cascade highly interconnected system significant cross-talk pathways.\nvivo, extrinsic pathway considered primary initiator coagulation\nNote:traditional division pathways useful understanding steps involved, ’s important recognize coagulation cascade highly interconnected system significant cross-talk pathways.vivo, extrinsic pathway considered primary initiator coagulation","code":""},{"path":"coagulation-pathways.html","id":"stabilization-of-the-fibrin-clot","chapter":"Coagulation Pathways","heading":"Stabilization of the Fibrin Clot","text":"Factor XIIIa (Fibrin-Stabilizing Factor):\ntransglutaminase cross-links fibrin monomers, forming stable, insoluble fibrin clot\nActivated thrombin\nCross-linking fibrin provides strength stability clot, making resistant degradation plasmin\ntransglutaminase cross-links fibrin monomers, forming stable, insoluble fibrin clotActivated thrombinCross-linking fibrin provides strength stability clot, making resistant degradation plasmin","code":""},{"path":"coagulation-pathways.html","id":"cell-based-model-of-coagulation","chapter":"Coagulation Pathways","heading":"Cell-Based Model of Coagulation","text":"modern model coagulation emphasizes role cells (tissue factor-bearing cells platelets) regulating coagulation process. divides coagulation three phases:Initiation:\nOccurs tissue factor-bearing cells (e.g., subendothelial cells) site vascular injury\nTF binds Factor VIIa, forming TF-VIIa complex\nTF-VIIa activates Factor X Factor IX\nSmall amounts thrombin generated\nOccurs tissue factor-bearing cells (e.g., subendothelial cells) site vascular injuryTF binds Factor VIIa, forming TF-VIIa complexTF-VIIa activates Factor X Factor IXSmall amounts thrombin generatedAmplification:\nOccurs platelet surface\nThrombin activates platelets coagulation factors (Factors XI, VIII, V)\nActivated platelets provide phospholipid surface assembly coagulation complexes\nOccurs platelet surfaceThrombin activates platelets coagulation factors (Factors XI, VIII, V)Activated platelets provide phospholipid surface assembly coagulation complexesPropagation:\nFormation large amounts thrombin platelet surface\nFactor IXa Factor VIIIa form complex efficiently activates Factor X\nFactor Xa Factor Va form prothrombinase complex, converts prothrombin thrombin\nThrombin activates fibrinogen fibrin, leading clot formation\nFormation large amounts thrombin platelet surfaceFactor IXa Factor VIIIa form complex efficiently activates Factor XFactor Xa Factor Va form prothrombinase complex, converts prothrombin thrombinThrombin activates fibrinogen fibrin, leading clot formation","code":""},{"path":"coagulation-pathways.html","id":"natural-anticoagulant-mechanisms","chapter":"Coagulation Pathways","heading":"Natural Anticoagulant Mechanisms","text":"prevent excessive clot formation thrombosis, body several natural anticoagulant mechanisms:Antithrombin:\nserine protease inhibitor (serpin) inhibits thrombin coagulation factors (e.g., Factors IXa, Xa, XIa, XIIa)\nHeparin enhances activity antithrombin\nserine protease inhibitor (serpin) inhibits thrombin coagulation factors (e.g., Factors IXa, Xa, XIa, XIIa)Heparin enhances activity antithrombinProtein C Pathway:\nThrombin binds thrombomodulin, endothelial cell receptor\nthrombin-thrombomodulin complex activates protein C\nActivated protein C (APC), along cofactor protein S, inactivates Factors Va VIIIa, inhibiting thrombin generation\nThrombin binds thrombomodulin, endothelial cell receptorThe thrombin-thrombomodulin complex activates protein CActivated protein C (APC), along cofactor protein S, inactivates Factors Va VIIIa, inhibiting thrombin generationTissue Factor Pathway Inhibitor (TFPI):\nInhibits TF-VIIa complex, preventing initiation coagulation\nInhibits TF-VIIa complex, preventing initiation coagulation","code":""},{"path":"coagulation-pathways.html","id":"vitamin-k-dependent-coagulation-factors","chapter":"Coagulation Pathways","heading":"Vitamin K-Dependent Coagulation Factors","text":"Vitamin K required cofactor carboxylation certain glutamate residues Factors II (prothrombin), VII, IX, X, well proteins C SCarboxylation necessary proteins bind calcium become fully functionalVitamin K deficiency warfarin (Coumadin) inhibits carboxylation process, leading decreased levels functional coagulation factors","code":""},{"path":"coagulation-pathways.html","id":"laboratory-testing","chapter":"Coagulation Pathways","heading":"Laboratory Testing","text":"Prothrombin Time (PT):\nMeasures function extrinsic common pathways\nProlonged PT indicates deficiency dysfunction one factors pathways (e.g., Factor VII, Factor X, Factor V, prothrombin, fibrinogen)\nUsed monitor warfarin therapy\nMeasures function extrinsic common pathwaysProlonged PT indicates deficiency dysfunction one factors pathways (e.g., Factor VII, Factor X, Factor V, prothrombin, fibrinogen)Used monitor warfarin therapyActivated Partial Thromboplastin Time (aPTT):\nMeasures function intrinsic common pathways\nProlonged aPTT indicates deficiency dysfunction one factors pathways (e.g., Factors XII, XI, IX, VIII, X, V, prothrombin, fibrinogen)\nUsed monitor heparin therapy\nMeasures function intrinsic common pathwaysProlonged aPTT indicates deficiency dysfunction one factors pathways (e.g., Factors XII, XI, IX, VIII, X, V, prothrombin, fibrinogen)Used monitor heparin therapyMixing Studies:\nUsed differentiate factor deficiencies factor inhibitors\nPlasma normal individual mixed patient’s plasma\naPTT PT corrects mixing, suggests factor deficiency\naPTT PT correct mixing, suggests presence factor inhibitor (e.g., lupus anticoagulant, factor VIII inhibitor)\nUsed differentiate factor deficiencies factor inhibitorsPlasma normal individual mixed patient’s plasmaIf aPTT PT corrects mixing, suggests factor deficiencyIf aPTT PT correct mixing, suggests presence factor inhibitor (e.g., lupus anticoagulant, factor VIII inhibitor)Individual Factor Assays:\nMeasure activity specific coagulation factors\nUsed identify specific factor deficiencies (e.g., Factor VIII deficiency hemophilia , Factor IX deficiency hemophilia B)\nMeasure activity specific coagulation factorsUsed identify specific factor deficiencies (e.g., Factor VIII deficiency hemophilia , Factor IX deficiency hemophilia B)Fibrinogen Assay:\nMeasures concentration fibrinogen plasma\nDecreased DIC severe liver disease\nMeasures concentration fibrinogen plasmaDecreased DIC severe liver diseaseD-dimer Assay:\nMeasures level D-dimer, fibrin degradation product\nElevated DIC, pulmonary embolism (PE), deep vein thrombosis (DVT), thrombotic conditions\nMeasures level D-dimer, fibrin degradation productElevated DIC, pulmonary embolism (PE), deep vein thrombosis (DVT), thrombotic conditions","code":""},{"path":"coagulation-pathways.html","id":"key-terms-75","chapter":"Coagulation Pathways","heading":"Key Terms","text":"Hemostasis: process stopping bleedingCoagulation Cascade: series enzymatic reactions leading fibrin formationCoagulation Factors: Proteins involved coagulation cascadeThrombin: key enzyme converts fibrinogen fibrinFibrinogen: protein converted fibrin, main component blood clotFibrin: insoluble protein forms meshwork blood clotProthrombin Time (PT): Test extrinsic common pathwaysActivated Partial Thromboplastin Time (aPTT): Test intrinsic common pathwaysDisseminated Intravascular Coagulation (DIC): life-threatening condition widespread clotting bleeding","code":""},{"path":"fibrinolytic-pathways.html","id":"fibrinolytic-pathways","chapter":"Fibrinolytic Pathways","heading":"Fibrinolytic Pathways","text":"","code":""},{"path":"fibrinolytic-pathways.html","id":"overview-of-fibrinolysis","chapter":"Fibrinolytic Pathways","heading":"Overview of Fibrinolysis","text":"Definition: process fibrin clots broken removed blood vessels tissue repair occurredPurpose: restore normal blood flow, prevent excessive clot formation, maintain vascular patencyKey Components:\nPlasminogen\nPlasmin\nPlasminogen Activators\nPlasmin Inhibitors\nFibrin Degradation Products (FDPs)\nPlasminogenPlasminPlasminogen ActivatorsPlasmin InhibitorsFibrin Degradation Products (FDPs)","code":""},{"path":"fibrinolytic-pathways.html","id":"components-of-the-fibrinolytic-system","chapter":"Fibrinolytic Pathways","heading":"Components of the Fibrinolytic System","text":"Plasminogen:\nDefinition: inactive zymogen (precursor) synthesized liver found plasma body fluids\nStructure: single-chain glycoprotein\nFunction: activated, plasminogen converted plasmin, primary enzyme responsible breaking fibrin\nBinding Fibrin: Plasminogen binds fibrin, making available activation site clot\nPlasminogen:Definition: inactive zymogen (precursor) synthesized liver found plasma body fluidsStructure: single-chain glycoproteinFunction: activated, plasminogen converted plasmin, primary enzyme responsible breaking fibrinBinding Fibrin: Plasminogen binds fibrin, making available activation site clotPlasmin:\nDefinition: active serine protease enzyme degrades fibrin, leading clot breakdown\nFormation: Formed activation plasminogen plasminogen activators\nFunction:\nDegradation Fibrin: Breaks fibrin fibrin degradation products (FDPs)\nDegradation Proteins: Plasmin can also degrade proteins, including fibrinogen, factors V VIII, components coagulation system\n\nPlasmin:Definition: active serine protease enzyme degrades fibrin, leading clot breakdownFormation: Formed activation plasminogen plasminogen activatorsFunction:\nDegradation Fibrin: Breaks fibrin fibrin degradation products (FDPs)\nDegradation Proteins: Plasmin can also degrade proteins, including fibrinogen, factors V VIII, components coagulation system\nDegradation Fibrin: Breaks fibrin fibrin degradation products (FDPs)Degradation Proteins: Plasmin can also degrade proteins, including fibrinogen, factors V VIII, components coagulation systemPlasminogen Activators:\nDefinition: Enzymes convert plasminogen plasmin\nKey Plasminogen Activators:\nTissue Plasminogen Activator (tPA):\nSynthesized released endothelial cells\nactive bound fibrin\nPlays key role dissolving clots within blood vessels\n\nUrokinase Plasminogen Activator (uPA):\nFound various tissues body fluids\nActivates plasminogen extravascular space\n\nStreptokinase:\nExogenous plasminogen activator produced streptococcal bacteria\nUsed therapeutically thrombolytic agent\n\n\nPlasminogen Activators:Definition: Enzymes convert plasminogen plasminKey Plasminogen Activators:\nTissue Plasminogen Activator (tPA):\nSynthesized released endothelial cells\nactive bound fibrin\nPlays key role dissolving clots within blood vessels\n\nUrokinase Plasminogen Activator (uPA):\nFound various tissues body fluids\nActivates plasminogen extravascular space\n\nStreptokinase:\nExogenous plasminogen activator produced streptococcal bacteria\nUsed therapeutically thrombolytic agent\n\nTissue Plasminogen Activator (tPA):\nSynthesized released endothelial cells\nactive bound fibrin\nPlays key role dissolving clots within blood vessels\nSynthesized released endothelial cellsMost active bound fibrinPlays key role dissolving clots within blood vesselsUrokinase Plasminogen Activator (uPA):\nFound various tissues body fluids\nActivates plasminogen extravascular space\nFound various tissues body fluidsActivates plasminogen extravascular spaceStreptokinase:\nExogenous plasminogen activator produced streptococcal bacteria\nUsed therapeutically thrombolytic agent\nExogenous plasminogen activator produced streptococcal bacteriaUsed therapeutically thrombolytic agentPlasmin Inhibitors:\nDefinition: Proteins regulate activity plasmin plasminogen activators\nKey Inhibitors:\nAlpha-2-Antiplasmin (α2-AP):\nprimary inhibitor plasmin\nRapidly inactivates plasmin free circulation, preventing degrading proteins\nForms stable complex plasmin, cleared circulation\n\nPlasminogen Activator Inhibitor-1 (PAI-1):\nprimary inhibitor tPA uPA\nProduced endothelial cells, platelets, tissues\n\nThrombin Activatable Fibrinolysis Inhibitor (TAFI):\nTAFI, activated thrombin, modifies fibrin make less susceptible plasminogen binding subsequent degradation plasmin.\n\n\nPlasmin Inhibitors:Definition: Proteins regulate activity plasmin plasminogen activatorsKey Inhibitors:\nAlpha-2-Antiplasmin (α2-AP):\nprimary inhibitor plasmin\nRapidly inactivates plasmin free circulation, preventing degrading proteins\nForms stable complex plasmin, cleared circulation\n\nPlasminogen Activator Inhibitor-1 (PAI-1):\nprimary inhibitor tPA uPA\nProduced endothelial cells, platelets, tissues\n\nThrombin Activatable Fibrinolysis Inhibitor (TAFI):\nTAFI, activated thrombin, modifies fibrin make less susceptible plasminogen binding subsequent degradation plasmin.\n\nAlpha-2-Antiplasmin (α2-AP):\nprimary inhibitor plasmin\nRapidly inactivates plasmin free circulation, preventing degrading proteins\nForms stable complex plasmin, cleared circulation\nprimary inhibitor plasminRapidly inactivates plasmin free circulation, preventing degrading proteinsForms stable complex plasmin, cleared circulationPlasminogen Activator Inhibitor-1 (PAI-1):\nprimary inhibitor tPA uPA\nProduced endothelial cells, platelets, tissues\nprimary inhibitor tPA uPAProduced endothelial cells, platelets, tissuesThrombin Activatable Fibrinolysis Inhibitor (TAFI):\nTAFI, activated thrombin, modifies fibrin make less susceptible plasminogen binding subsequent degradation plasmin.\nTAFI, activated thrombin, modifies fibrin make less susceptible plasminogen binding subsequent degradation plasmin.Fibrin Degradation Products (FDPs):\nDefinition: Fragments produced plasmin degrades fibrin\nExamples:\nD-dimer: specific marker cross-linked fibrin degradation\nFibrin monomers\nFragment X, Fragment Y, Fragment D, Fragment E\n\nCleared circulation liver kidneys\nFibrin Degradation Products (FDPs):Definition: Fragments produced plasmin degrades fibrinExamples:\nD-dimer: specific marker cross-linked fibrin degradation\nFibrin monomers\nFragment X, Fragment Y, Fragment D, Fragment E\nD-dimer: specific marker cross-linked fibrin degradationFibrin monomersFragment X, Fragment Y, Fragment D, Fragment ECleared circulation liver kidneys","code":""},{"path":"fibrinolytic-pathways.html","id":"process-of-fibrinolysis","chapter":"Fibrinolytic Pathways","heading":"Process of Fibrinolysis","text":"Clot Formation:\ncoagulation cascade activated, leading formation fibrin clot site vascular injury\ncoagulation cascade activated, leading formation fibrin clot site vascular injuryPlasminogen Binding:\nPlasminogen binds fibrin clot\nPlasminogen binds fibrin clottPA Release:\nEndothelial cells release tPA, also binds fibrin\nEndothelial cells release tPA, also binds fibrinPlasmin Activation:\ntPA activates plasminogen plasmin surface fibrin clot\ntPA activates plasminogen plasmin surface fibrin clotFibrin Degradation:\nPlasmin degrades fibrin fibrin degradation products (FDPs), including D-dimer\nPlasmin degrades fibrin fibrin degradation products (FDPs), including D-dimerInhibition:\nα2-AP rapidly inactivates plasmin escapes clot circulation, preventing degrading proteins\nPAI-1 inhibits tPA uPA\nTAFI inhibits plasminogen binding\nα2-AP rapidly inactivates plasmin escapes clot circulation, preventing degrading proteinsPAI-1 inhibits tPA uPATAFI inhibits plasminogen bindingClearance:\nFDPs cleared circulation liver kidneys\nFDPs cleared circulation liver kidneys","code":""},{"path":"fibrinolytic-pathways.html","id":"regulation-of-fibrinolysis","chapter":"Fibrinolytic Pathways","heading":"Regulation of Fibrinolysis","text":"Localized Activation: tPA active bound fibrin, ensures plasmin primarily generated site clotInhibition: PAI-1 α2-AP inhibit activity plasminogen activators plasmin, respectivelyTAFI Thrombin-activatable fibrinolysis inhibitor inhibits activity plasminogen activator.Clinical SignificanceThrombosis: Impaired fibrinolysis can lead excessive clot formation thrombosis (e.g., deep vein thrombosis, pulmonary embolism)Bleeding: Excessive fibrinolysis can lead bleeding disorders (e.g., disseminated intravascular coagulation, DIC)Therapeutic Use: Fibrinolytic agents (like tPA streptokinase) used treat thromboembolic disorders (e.g., myocardial infarction, stroke)","code":""},{"path":"fibrinolytic-pathways.html","id":"laboratory-testing-1","chapter":"Fibrinolytic Pathways","heading":"Laboratory Testing","text":"D-dimer Assay:\nMeasures level D-dimer blood\nElevated conditions increased fibrinolysis (e.g., DVT, PE, DIC)\nUsed screening test venous thromboembolism (VTE)\nD-dimer Assay:Measures level D-dimer bloodElevated conditions increased fibrinolysis (e.g., DVT, PE, DIC)Used screening test venous thromboembolism (VTE)Fibrinogen Level:\nMeasures amount fibrinogen blood\nDecreased conditions excessive fibrinolysis (e.g., DIC)\nFibrinogen Level:Measures amount fibrinogen bloodDecreased conditions excessive fibrinolysis (e.g., DIC)tPA PAI-1 Assays:\nMeasure levels tPA PAI-1 blood\ntPA PAI-1 Assays:Measure levels tPA PAI-1 bloodEuglobulin Lysis Time:\nAssesses global fibrinolytic activity.\nEuglobulin Lysis Time:Assesses global fibrinolytic activity.","code":""},{"path":"fibrinolytic-pathways.html","id":"key-terms-76","chapter":"Fibrinolytic Pathways","heading":"Key Terms","text":"Fibrinolysis: breakdown fibrin clotsPlasminogen: Inactive precursor plasminPlasmin: Active enzyme degrades fibrintPA (Tissue Plasminogen Activator): Plasminogen activator released endothelial cellsuPA (Urokinase Plasminogen Activator): Plasminogen activator found various tissues body fluidsα2-Antiplasmin (α2-AP): Primary inhibitor plasminPAI-1 (Plasminogen Activator Inhibitor-1): Inhibitor tPA uPATAFI Thrombin-activatable fibrinolysis inhibitor: inhibits activity plasminogen activator.Fibrin Degradation Products (FDPs): Fragments produced plasmin degrades fibrinD-dimer: specific marker cross-linked fibrin degradation","code":""},{"path":"vascular-system.html","id":"vascular-system","chapter":"Vascular System","heading":"Vascular System","text":"","code":""},{"path":"vascular-system.html","id":"overview-of-the-vascular-system-in-hemostasis","chapter":"Vascular System","heading":"Overview of the Vascular System in Hemostasis","text":"Definition: vascular system, comprised arteries, veins, capillaries, much just network pipes. plays dynamic integral role maintaining hemostasis, rest response injuryKey Roles:\nProvides physical barrier prevent blood loss injury\nRegulates blood flow site injury\nReleases substances activate platelets coagulation factors\nInhibits coagulation prevent excessive clot formation\nParticipates fibrinolysis remove clots tissue repair\nProvides physical barrier prevent blood loss injuryRegulates blood flow site injuryReleases substances activate platelets coagulation factorsInhibits coagulation prevent excessive clot formationParticipates fibrinolysis remove clots tissue repairComponents:\nEndothelial Cells: inner lining blood vessels\nSubendothelial Matrix: Located beneath endothelial cells, containing collagen, von Willebrand factor (vWF), substances\nEndothelial Cells: inner lining blood vesselsSubendothelial Matrix: Located beneath endothelial cells, containing collagen, von Willebrand factor (vWF), substances","code":""},{"path":"vascular-system.html","id":"endothelial-cells-the-gatekeepers-of-hemostasis","chapter":"Vascular System","heading":"Endothelial Cells: The Gatekeepers of Hemostasis","text":"Endothelial cells key regulators hemostasis. procoagulant anticoagulant properties, maintaining delicate balance prevent bleeding thrombosisIntact Endothelium (Antithrombotic Properties):\nPhysical Barrier:\nProvides smooth, non-thrombogenic surface prevents platelets coagulation factors adhering vessel wall\n\nInhibition Platelet Activation:\nProduction Prostacyclin (PGI2): PGI2 vasodilator inhibits platelet activation aggregation\nProduction Nitric Oxide (): vasodilator inhibits platelet adhesion aggregation\nCD39 (Ecto-ADPase): Degrades ADP, potent platelet activator\n\nInhibition Coagulation:\nThrombomodulin: Binds thrombin, converting procoagulant anticoagulant enzyme activates Protein C. Protein C inhibits Factors Va VIIIa\nHeparan Sulfate: Binds antithrombin, enhancing ability inhibit thrombin coagulation factors (IXa, Xa, XIa, XIIa)\nTissue Factor Pathway Inhibitor (TFPI): Inhibits Tissue Factor-VIIa complex, preventing initiation extrinsic pathway coagulation\n\nPromotion Fibrinolysis:\nTissue Plasminogen Activator (tPA): Released endothelial cells activate plasminogen promote fibrinolysis\n\nIntact Endothelium (Antithrombotic Properties):Physical Barrier:\nProvides smooth, non-thrombogenic surface prevents platelets coagulation factors adhering vessel wall\nProvides smooth, non-thrombogenic surface prevents platelets coagulation factors adhering vessel wallInhibition Platelet Activation:\nProduction Prostacyclin (PGI2): PGI2 vasodilator inhibits platelet activation aggregation\nProduction Nitric Oxide (): vasodilator inhibits platelet adhesion aggregation\nCD39 (Ecto-ADPase): Degrades ADP, potent platelet activator\nProduction Prostacyclin (PGI2): PGI2 vasodilator inhibits platelet activation aggregationProduction Nitric Oxide (): vasodilator inhibits platelet adhesion aggregationCD39 (Ecto-ADPase): Degrades ADP, potent platelet activatorInhibition Coagulation:\nThrombomodulin: Binds thrombin, converting procoagulant anticoagulant enzyme activates Protein C. Protein C inhibits Factors Va VIIIa\nHeparan Sulfate: Binds antithrombin, enhancing ability inhibit thrombin coagulation factors (IXa, Xa, XIa, XIIa)\nTissue Factor Pathway Inhibitor (TFPI): Inhibits Tissue Factor-VIIa complex, preventing initiation extrinsic pathway coagulation\nThrombomodulin: Binds thrombin, converting procoagulant anticoagulant enzyme activates Protein C. Protein C inhibits Factors Va VIIIaHeparan Sulfate: Binds antithrombin, enhancing ability inhibit thrombin coagulation factors (IXa, Xa, XIa, XIIa)Tissue Factor Pathway Inhibitor (TFPI): Inhibits Tissue Factor-VIIa complex, preventing initiation extrinsic pathway coagulationPromotion Fibrinolysis:\nTissue Plasminogen Activator (tPA): Released endothelial cells activate plasminogen promote fibrinolysis\nTissue Plasminogen Activator (tPA): Released endothelial cells activate plasminogen promote fibrinolysisInjured Endothelium (Procoagulant Properties):\nExposure Subendothelial Matrix:\nDamage endothelium exposes underlying subendothelial matrix, contains collagen von Willebrand factor (vWF)\nCollagen: Activates platelets initiates intrinsic pathway coagulation\nvWF: Binds platelet GPIb/IX/V, mediating platelet adhesion damaged vessel wall\n\nTissue Factor (TF) Expression:\nEndothelial cells express tissue factor (TF) surface upon activation inflammatory cytokines stimuli\nTF initiates extrinsic pathway coagulation\n\nInhibition Natural Anticoagulants:\nDamaged endothelial cells reduce production thrombomodulin, heparan sulfate, TFPI, diminishing anticoagulant properties\n\nRelease Platelet Activating Factors:\nvon Willebrand Factor (vWF): vWF released Weibel-Palade bodies endothelial cells\nPlatelet Activating Factor (PAF): endothelial cells can synthesize release PAF\n\nInjured Endothelium (Procoagulant Properties):Exposure Subendothelial Matrix:\nDamage endothelium exposes underlying subendothelial matrix, contains collagen von Willebrand factor (vWF)\nCollagen: Activates platelets initiates intrinsic pathway coagulation\nvWF: Binds platelet GPIb/IX/V, mediating platelet adhesion damaged vessel wall\nDamage endothelium exposes underlying subendothelial matrix, contains collagen von Willebrand factor (vWF)Collagen: Activates platelets initiates intrinsic pathway coagulationvWF: Binds platelet GPIb/IX/V, mediating platelet adhesion damaged vessel wallTissue Factor (TF) Expression:\nEndothelial cells express tissue factor (TF) surface upon activation inflammatory cytokines stimuli\nTF initiates extrinsic pathway coagulation\nEndothelial cells express tissue factor (TF) surface upon activation inflammatory cytokines stimuliTF initiates extrinsic pathway coagulationInhibition Natural Anticoagulants:\nDamaged endothelial cells reduce production thrombomodulin, heparan sulfate, TFPI, diminishing anticoagulant properties\nDamaged endothelial cells reduce production thrombomodulin, heparan sulfate, TFPI, diminishing anticoagulant propertiesRelease Platelet Activating Factors:\nvon Willebrand Factor (vWF): vWF released Weibel-Palade bodies endothelial cells\nPlatelet Activating Factor (PAF): endothelial cells can synthesize release PAF\nvon Willebrand Factor (vWF): vWF released Weibel-Palade bodies endothelial cellsPlatelet Activating Factor (PAF): endothelial cells can synthesize release PAF","code":""},{"path":"vascular-system.html","id":"the-subendothelial-matrix-a-scaffold-for-hemostasis","chapter":"Vascular System","heading":"The Subendothelial Matrix: A Scaffold for Hemostasis","text":"subendothelial matrix complex layer located beneath endothelial cells contains various proteins substances play crucial role hemostasisCollagen:\nProvides surface platelet adhesion activation\nBinds platelet glycoprotein VI (GPVI), initiating intracellular signaling pathways lead platelet activation aggregation\nAlso activates intrinsic pathway coagulation activating Factor XII\nCollagen:Provides surface platelet adhesion activationBinds platelet glycoprotein VI (GPVI), initiating intracellular signaling pathways lead platelet activation aggregationAlso activates intrinsic pathway coagulation activating Factor XIIvon Willebrand Factor (vWF):\nBinds platelet GPIb/IX/V, mediating platelet adhesion damaged vessel wall\nEspecially important high shear stress conditions, small arteries arterioles\nAlso binds Factor VIII, protecting degradation\nvon Willebrand Factor (vWF):Binds platelet GPIb/IX/V, mediating platelet adhesion damaged vessel wallEspecially important high shear stress conditions, small arteries arteriolesAlso binds Factor VIII, protecting degradationOther Components:\nFibronectin, laminin, adhesive proteins contribute platelet adhesion cell migration\nComponents:Fibronectin, laminin, adhesive proteins contribute platelet adhesion cell migration","code":""},{"path":"vascular-system.html","id":"regulation-of-blood-flow-vasoconstriction-and-vasodilation","chapter":"Vascular System","heading":"Regulation of Blood Flow: Vasoconstriction and Vasodilation","text":"vascular system regulates blood flow site injury vasoconstriction vasodilation:Vasoconstriction:\nImmediate response vascular injury\nReduces blood flow injured area, limiting blood loss promoting platelet adhesion\nMediated :\nEndothelin-1: potent vasoconstrictor released endothelial cells\nThromboxane A2 (TxA2): Released activated platelets\nNervous system reflexes\n\nVasoconstriction:Immediate response vascular injuryReduces blood flow injured area, limiting blood loss promoting platelet adhesionMediated :\nEndothelin-1: potent vasoconstrictor released endothelial cells\nThromboxane A2 (TxA2): Released activated platelets\nNervous system reflexes\nEndothelin-1: potent vasoconstrictor released endothelial cellsThromboxane A2 (TxA2): Released activated plateletsNervous system reflexesVasodilation:\nOccurs later hemostatic process promote tissue repair angiogenesis (formation new blood vessels)\nMediated :\nNitric Oxide (): Released endothelial cells\nProstacyclin (PGI2): Released endothelial cells\nVascular endothelial growth factor (VEGF): Promotes angiogenesis\n\nVasodilation:Occurs later hemostatic process promote tissue repair angiogenesis (formation new blood vessels)Mediated :\nNitric Oxide (): Released endothelial cells\nProstacyclin (PGI2): Released endothelial cells\nVascular endothelial growth factor (VEGF): Promotes angiogenesis\nNitric Oxide (): Released endothelial cellsProstacyclin (PGI2): Released endothelial cellsVascular endothelial growth factor (VEGF): Promotes angiogenesis","code":""},{"path":"vascular-system.html","id":"angiogenesis","chapter":"Vascular System","heading":"Angiogenesis","text":"Definition: formation new blood vessels pre-existing vesselsRole Hemostasis Wound Healing:\nProvides nutrients oxygen healing tissue\nRemoves waste products\nProvides nutrients oxygen healing tissueRemoves waste productsRegulation:\nVascular Endothelial Growth Factor (VEGF): primary driver angiogenesis\ngrowth factors cytokines: Also involved regulating angiogenesis\nVascular Endothelial Growth Factor (VEGF): primary driver angiogenesisOther growth factors cytokines: Also involved regulating angiogenesis","code":""},{"path":"vascular-system.html","id":"key-terms-77","chapter":"Vascular System","heading":"Key Terms","text":"Endothelial Cells: Cells line inner surface blood vesselsSubendothelial Matrix: layer beneath endothelial cells, containing collagen vWFTissue Factor (TF): protein initiates extrinsic pathway coagulationVon Willebrand Factor (vWF): protein mediates platelet adhesion carries factor VIIIProstacyclin (PGI2): vasodilator inhibitor platelet activationNitric Oxide (): vasodilator inhibitor platelet adhesionThrombomodulin: endothelial cell receptor binds thrombin activates protein CTissue Factor Pathway Inhibitor (TFPI): inhibitor TF-VIIa complexVasoconstriction: Narrowing blood vesselsVasodilation: Widening blood vesselsSelectins: Adhesion molecules endothelial cells promote leukocyte rollingIntegrins: Adhesion molecules leukocytes mediate firm adhesionExtravasation: process leukocytes migrate bloodstream tissuesAngiogenesis: formation new blood vessels","code":""},{"path":"disorders.html","id":"disorders","chapter":"Disorders","heading":"Disorders","text":"","code":""},{"path":"disorders.html","id":"overview-of-hemostasis-disease-states","chapter":"Disorders","heading":"Overview of Hemostasis Disease States","text":"Hemostasis: process stopping bleeding, involving balance procoagulant anticoagulant forcesDisruption Balance: Disease states arise balance disrupted, leading either:\nBleeding Disorders: Impaired clot formation excessive clot breakdown\nThrombotic Disorders (Hypercoagulable States): Excessive clot formation impaired clot breakdown\nBleeding Disorders: Impaired clot formation excessive clot breakdownThrombotic Disorders (Hypercoagulable States): Excessive clot formation impaired clot breakdown","code":""},{"path":"disorders.html","id":"key-components-and-processes","chapter":"Disorders","heading":"Key Components and Processes","text":"Vascular System: Endothelial cells regulate blood flow, platelet activation, coagulationPlatelets: Form primary plug site injury (primary hemostasis)Coagulation Cascade: series enzymatic reactions involving coagulation factors, leading fibrin formation (secondary hemostasis)Fibrinolytic System: Breaks fibrin clots restore blood flow","code":""},{"path":"disorders.html","id":"disease-states","chapter":"Disorders","heading":"Disease States","text":"Coagulation Factor Deficiencies: Bleeding Disorders\nGeneral Cause: Insufficient amount impaired function coagulation factors\nClassification:\nHereditary: Genetic mutations affecting factor synthesis (e.g., Hemophilia , Hemophilia B)\nAcquired: External factors reducing factor levels (e.g., vitamin K deficiency, liver disease, DIC)\n\nGeneral Effect Lab Tests: Prolonged PT /aPTT, depending factor affected\nCommon Examples:\nHemophilia (Factor VIII Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor VIII activity\nHemophilia B (Factor IX Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor IX activity\nVitamin K Deficiency: Affects Factors II, VII, IX, X. Prolonged PT aPTT\nLiver Disease: Impaired synthesis multiple factors. Prolonged PT aPTT\n\nCoagulation Factor Deficiencies: Bleeding DisordersGeneral Cause: Insufficient amount impaired function coagulation factorsClassification:\nHereditary: Genetic mutations affecting factor synthesis (e.g., Hemophilia , Hemophilia B)\nAcquired: External factors reducing factor levels (e.g., vitamin K deficiency, liver disease, DIC)\nHereditary: Genetic mutations affecting factor synthesis (e.g., Hemophilia , Hemophilia B)Acquired: External factors reducing factor levels (e.g., vitamin K deficiency, liver disease, DIC)General Effect Lab Tests: Prolonged PT /aPTT, depending factor affectedCommon Examples:\nHemophilia (Factor VIII Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor VIII activity\nHemophilia B (Factor IX Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor IX activity\nVitamin K Deficiency: Affects Factors II, VII, IX, X. Prolonged PT aPTT\nLiver Disease: Impaired synthesis multiple factors. Prolonged PT aPTT\nHemophilia (Factor VIII Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor VIII activityHemophilia B (Factor IX Deficiency): X-linked recessive, affects intrinsic pathway. Prolonged aPTT, low Factor IX activityVitamin K Deficiency: Affects Factors II, VII, IX, X. Prolonged PT aPTTLiver Disease: Impaired synthesis multiple factors. Prolonged PT aPTTInhibitors: Bleeding Thrombotic Disorders\nGeneral Cause: Antibodies interfere function coagulation factors phospholipid-binding proteins\nClassification:\nAcquired: Autoantibodies (e.g., Factor VIII inhibitors, Lupus Anticoagulant)\n\nGeneral Effect Lab Tests: Prolonged PT /aPTT correct mixing normal plasma\nCommon Examples:\nFactor VIII Inhibitors (Acquired Hemophilia ): Autoantibodies Factor VIII. Prolonged aPTT doesn’t correct, low Factor VIII activity\nLupus Anticoagulant (LA): Antibodies phospholipids. Prolonged aPTT, increased risk thrombosis\n\nInhibitors: Bleeding Thrombotic DisordersGeneral Cause: Antibodies interfere function coagulation factors phospholipid-binding proteinsClassification:\nAcquired: Autoantibodies (e.g., Factor VIII inhibitors, Lupus Anticoagulant)\nAcquired: Autoantibodies (e.g., Factor VIII inhibitors, Lupus Anticoagulant)General Effect Lab Tests: Prolonged PT /aPTT correct mixing normal plasmaCommon Examples:\nFactor VIII Inhibitors (Acquired Hemophilia ): Autoantibodies Factor VIII. Prolonged aPTT doesn’t correct, low Factor VIII activity\nLupus Anticoagulant (LA): Antibodies phospholipids. Prolonged aPTT, increased risk thrombosis\nFactor VIII Inhibitors (Acquired Hemophilia ): Autoantibodies Factor VIII. Prolonged aPTT doesn’t correct, low Factor VIII activityLupus Anticoagulant (LA): Antibodies phospholipids. Prolonged aPTT, increased risk thrombosisFibrinolytic Disorders: Bleeding Thrombotic Disorders\nGeneral Cause: Imbalance fibrinolytic system, leading either excessive clot breakdown impaired clot removal\nClassification:\nExcessive Fibrinolysis (Hyperfibrinolysis): Increased breakdown fibrin clots\nImpaired Fibrinolysis (Hypofibrinolysis): Decreased breakdown fibrin clots\n\nCommon Examples:\nExcessive Fibrinolysis (e.g., DIC): Widespread activation fibrinolysis leads bleeding. Elevated D-dimer, decreased fibrinogen\nImpaired Fibrinolysis: Often associated increased risk thrombosis (e.g., elevated PAI-1)\n\nFibrinolytic Disorders: Bleeding Thrombotic DisordersGeneral Cause: Imbalance fibrinolytic system, leading either excessive clot breakdown impaired clot removalClassification:\nExcessive Fibrinolysis (Hyperfibrinolysis): Increased breakdown fibrin clots\nImpaired Fibrinolysis (Hypofibrinolysis): Decreased breakdown fibrin clots\nExcessive Fibrinolysis (Hyperfibrinolysis): Increased breakdown fibrin clotsImpaired Fibrinolysis (Hypofibrinolysis): Decreased breakdown fibrin clotsCommon Examples:\nExcessive Fibrinolysis (e.g., DIC): Widespread activation fibrinolysis leads bleeding. Elevated D-dimer, decreased fibrinogen\nImpaired Fibrinolysis: Often associated increased risk thrombosis (e.g., elevated PAI-1)\nExcessive Fibrinolysis (e.g., DIC): Widespread activation fibrinolysis leads bleeding. Elevated D-dimer, decreased fibrinogenImpaired Fibrinolysis: Often associated increased risk thrombosis (e.g., elevated PAI-1)Hypercoagulable States (Thrombophilia): Thrombotic Disorders\nGeneral Cause: Inherited acquired conditions increase risk thrombosis\nKey Feature: Increased thrombin generation /impaired anticoagulant mechanisms\nClassification:\nInherited (Genetic): Mutations genes encoding coagulation factors natural anticoagulants\nAcquired: External factors affecting coagulation system\n\nCommon Examples:\nFactor V Leiden Mutation: Resistance activated protein C (APC)\nProthrombin G20210A Mutation: Increased prothrombin production\nProtein C Deficiency, Protein S Deficiency, Antithrombin Deficiency: Reduced levels natural anticoagulants\nAntiphospholipid Syndrome (APS): Autoantibodies phospholipids, causing thrombosis pregnancy morbidity\n\nHypercoagulable States (Thrombophilia): Thrombotic DisordersGeneral Cause: Inherited acquired conditions increase risk thrombosisKey Feature: Increased thrombin generation /impaired anticoagulant mechanismsClassification:\nInherited (Genetic): Mutations genes encoding coagulation factors natural anticoagulants\nAcquired: External factors affecting coagulation system\nInherited (Genetic): Mutations genes encoding coagulation factors natural anticoagulantsAcquired: External factors affecting coagulation systemCommon Examples:\nFactor V Leiden Mutation: Resistance activated protein C (APC)\nProthrombin G20210A Mutation: Increased prothrombin production\nProtein C Deficiency, Protein S Deficiency, Antithrombin Deficiency: Reduced levels natural anticoagulants\nAntiphospholipid Syndrome (APS): Autoantibodies phospholipids, causing thrombosis pregnancy morbidity\nFactor V Leiden Mutation: Resistance activated protein C (APC)Prothrombin G20210A Mutation: Increased prothrombin productionProtein C Deficiency, Protein S Deficiency, Antithrombin Deficiency: Reduced levels natural anticoagulantsAntiphospholipid Syndrome (APS): Autoantibodies phospholipids, causing thrombosis pregnancy morbidityDisseminated Intravascular Coagulation (DIC): Bleeding Thrombotic Disorder\nDefinition: complex, acquired disorder involving widespread activation coagulation fibrinolysis\nKey Features:\nPrimary Disease: Always secondary underlying condition (e.g., sepsis, trauma, malignancy, obstetric complications)\nSimultaneous Clotting Bleeding: Microthrombi formation leads organ damage, consumption clotting factors platelets causes bleeding\n\nPathophysiology: Triggering event leads :\nUncontrolled activation coagulation\nConsumption clotting factors platelets\nSecondary activation fibrinolysis\n\nLaboratory Findings:\nProlonged PT aPTT\nLow fibrinogen\nThrombocytopenia\nElevated D-dimer\nSchistocytes peripheral blood smear\n\nDisseminated Intravascular Coagulation (DIC): Bleeding Thrombotic DisorderDefinition: complex, acquired disorder involving widespread activation coagulation fibrinolysisKey Features:\nPrimary Disease: Always secondary underlying condition (e.g., sepsis, trauma, malignancy, obstetric complications)\nSimultaneous Clotting Bleeding: Microthrombi formation leads organ damage, consumption clotting factors platelets causes bleeding\nPrimary Disease: Always secondary underlying condition (e.g., sepsis, trauma, malignancy, obstetric complications)Simultaneous Clotting Bleeding: Microthrombi formation leads organ damage, consumption clotting factors platelets causes bleedingPathophysiology: Triggering event leads :\nUncontrolled activation coagulation\nConsumption clotting factors platelets\nSecondary activation fibrinolysis\nUncontrolled activation coagulationConsumption clotting factors plateletsSecondary activation fibrinolysisLaboratory Findings:\nProlonged PT aPTT\nLow fibrinogen\nThrombocytopenia\nElevated D-dimer\nSchistocytes peripheral blood smear\nProlonged PT aPTTLow fibrinogenThrombocytopeniaElevated D-dimerSchistocytes peripheral blood smear","code":""},{"path":"disorders.html","id":"summary-table","chapter":"Disorders","heading":"Summary Table","text":"","code":""},{"path":"factor-deficiencies.html","id":"factor-deficiencies","chapter":"Factor Deficiencies","heading":"Factor Deficiencies","text":"","code":""},{"path":"factor-deficiencies.html","id":"overview-of-coagulation-factor-deficiencies","chapter":"Factor Deficiencies","heading":"Overview of Coagulation Factor Deficiencies","text":"Definition: group bleeding disorders caused deficiency dysfunction one coagulation factors, essential normal blood clotting processClassification:\nHereditary (Inherited) Coagulation Factor Deficiencies: Genetic disorders caused mutations genes encoding coagulation factors\nAcquired Coagulation Factor Deficiencies: Caused external factors impair coagulation factor synthesis function\nHereditary (Inherited) Coagulation Factor Deficiencies: Genetic disorders caused mutations genes encoding coagulation factorsAcquired Coagulation Factor Deficiencies: Caused external factors impair coagulation factor synthesis functionClinical Features:\nBleeding Tendency: severity bleeding depends specific factor involved degree deficiency\nCommon Manifestations:\nEasy bruising\nProlonged bleeding cuts, dental procedures, surgery\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual bleeding) women\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare life-threatening)\n\nBleeding Tendency: severity bleeding depends specific factor involved degree deficiencyCommon Manifestations:\nEasy bruising\nProlonged bleeding cuts, dental procedures, surgery\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual bleeding) women\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare life-threatening)\nEasy bruisingProlonged bleeding cuts, dental procedures, surgeryNosebleeds (epistaxis)Gum bleedingMenorrhagia (heavy menstrual bleeding) womenHemarthrosis (bleeding joints)Intracranial hemorrhage (rare life-threatening)","code":""},{"path":"factor-deficiencies.html","id":"hereditary-coagulation-factor-deficiencies","chapter":"Factor Deficiencies","heading":"Hereditary Coagulation Factor Deficiencies","text":"General Characteristics:\nInherited autosomal recessive X-linked recessive pattern\nOften present bleeding symptoms early life\nSpecific diagnosis requires factor assays\nGeneral Characteristics:Inherited autosomal recessive X-linked recessive patternOften present bleeding symptoms early lifeSpecific diagnosis requires factor assaysHemophilia (Factor VIII Deficiency):\nDefinition: X-linked recessive bleeding disorder caused deficiency Factor VIII (FVIII)\nHemophilia (Factor VIII Deficiency):Definition: X-linked recessive bleeding disorder caused deficiency Factor VIII (FVIII)Hemophilia B (Factor IX Deficiency, Christmas Disease):\nDefinition: X-linked recessive bleeding disorder caused deficiency Factor IX (FIX)\nHemophilia B (Factor IX Deficiency, Christmas Disease):Definition: X-linked recessive bleeding disorder caused deficiency Factor IX (FIX)Rare Hereditary Factor Deficiencies:\nFactor XI Deficiency (Hemophilia C):\nFactor V Deficiency:\nCombined Factor V VIII Deficiency\nFactor VII Deficiency:\nFactor X Deficiency:\nFactor XIII Deficiency:\nRare Hereditary Factor Deficiencies:Factor XI Deficiency (Hemophilia C):Factor V Deficiency:Combined Factor V VIII DeficiencyFactor VII Deficiency:Factor X Deficiency:Factor XIII Deficiency:","code":""},{"path":"factor-deficiencies.html","id":"acquired-coagulation-factor-deficiencies","chapter":"Factor Deficiencies","heading":"Acquired Coagulation Factor Deficiencies","text":"Vitamin K Deficiency:\nPathophysiology: Vitamin K cofactor carboxylation glutamate residues Factors II (prothrombin), VII, IX, X, well proteins C S\nPathophysiology: Vitamin K cofactor carboxylation glutamate residues Factors II (prothrombin), VII, IX, X, well proteins C SLiver Disease:\nPathophysiology: liver primary site synthesis coagulation factors\nPathophysiology: liver primary site synthesis coagulation factorsDisseminated Intravascular Coagulation (DIC):\nDefinition: complex disorder characterized widespread activation coagulation fibrinolysis, leading thrombosis bleeding\nDefinition: complex disorder characterized widespread activation coagulation fibrinolysis, leading thrombosis bleeding","code":""},{"path":"factor-deficiencies.html","id":"key-terms-78","chapter":"Factor Deficiencies","heading":"Key Terms","text":"Coagulation Factors: Proteins involved coagulation cascadeHemophilia : Factor VIII deficiencyHemophilia B: Factor IX deficiencyVitamin K: cofactor carboxylation certain coagulation factorsLiver Disease: Impairs synthesis coagulation factorsDisseminated Intravascular Coagulation (DIC): consumptive coagulopathy widespread clotting bleedingProthrombin Time (PT): Test extrinsic common pathwaysActivated Partial Thromboplastin Time (aPTT): Test intrinsic common pathways","code":""},{"path":"hereditary-1.html","id":"hereditary-1","chapter":"Hereditary","heading":"Hereditary","text":"","code":""},{"path":"hereditary-1.html","id":"overview-of-hereditary-coagulation-factor-deficiencies","chapter":"Hereditary","heading":"Overview of Hereditary Coagulation Factor Deficiencies","text":"Definition: group rare, inherited bleeding disorders caused genetic mutations result deficiency dysfunction one coagulation factorsInheritance: Typically inherited X-linked recessive autosomal recessive patternClinical Features:\nBleeding Tendency: primary symptom, severity varying depending specific factor involved degree deficiency\nCommon Manifestations:\nEasy bruising\nProlonged bleeding cuts, dental procedures, surgery\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual bleeding) women\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare life-threatening)\n\nBleeding Tendency: primary symptom, severity varying depending specific factor involved degree deficiencyCommon Manifestations:\nEasy bruising\nProlonged bleeding cuts, dental procedures, surgery\nNosebleeds (epistaxis)\nGum bleeding\nMenorrhagia (heavy menstrual bleeding) women\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare life-threatening)\nEasy bruisingProlonged bleeding cuts, dental procedures, surgeryNosebleeds (epistaxis)Gum bleedingMenorrhagia (heavy menstrual bleeding) womenHemarthrosis (bleeding joints)Intracranial hemorrhage (rare life-threatening)Diagnosis:\nBased clinical history, bleeding symptoms, family history, laboratory testing (coagulation assays)\nSpecific diagnosis requires factor assays measure activity individual coagulation factors\nBased clinical history, bleeding symptoms, family history, laboratory testing (coagulation assays)Specific diagnosis requires factor assays measure activity individual coagulation factors","code":""},{"path":"hereditary-1.html","id":"specific-hereditary-coagulation-factor-deficiencies","chapter":"Hereditary","heading":"Specific Hereditary Coagulation Factor Deficiencies","text":"X-Linked Recessive Disorders\nHemophilia (Factor VIII Deficiency):\nDefinition: common inherited bleeding disorder; caused mutations F8 gene, encodes Factor VIII (FVIII)\nPathophysiology: Deficiency FVIII impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formation\nSeverity: Classified based level FVIII activity:\nSevere Hemophilia : FVIII < 1% normal\nModerate Hemophilia : FVIII 1-5% normal\nMild Hemophilia : FVIII 5-40% normal\n\nClinical Features:\nSeverity bleeding correlated level FVIII activity\nSevere Hemophilia:\nSpontaneous bleeding joints (hemarthrosis) muscles\nProlonged bleeding minor trauma surgery\nIntracranial hemorrhage\n\nModerate Mild Hemophilia:\nBleeding typically occurs trauma surgery\nSpontaneous bleeding less common\n\n\nLaboratory Findings:\nCBC: Normal platelet count\nProthrombin Time (PT): Normal\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor VIII Assay: Decreased FVIII activity level\nFactor Inhibitor Assay: rule acquired FVIII inhibitors\n\nTreatment:\nReplacement Therapy: Infusion FVIII concentrates\nRecombinant FVIII products preferred minimize risk viral transmission\nProphylactic therapy: Regular infusions FVIII prevent bleeding\n-demand therapy: FVIII infusions treat acute bleeding episodes\n\nDesmopressin (DDAVP):\nMay effective mild hemophilia stimulate release FVIII endothelial cells\n\nEmicizumab:\nbispecific antibody mimics cofactor function FVIII, bridging Factors IXa X restore coagulation\nUsed prophylaxis patients hemophilia without FVIII inhibitors\n\nGene Therapy:\nEmerging therapeutic approach correct F8 gene mutation restore FVIII production\n\n\n\nHemophilia B (Factor IX Deficiency, Christmas Disease):\nDefinition: less common X-linked recessive bleeding disorder caused mutations F9 gene, encodes Factor IX (FIX)\nPathophysiology: Deficiency FIX impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formation\nClinical Features Laboratory Findings: Similar hemophilia , FVIII levels normal FIX levels decreased.\nTreatment:\nReplacement Therapy: Infusion FIX concentrates\nGene Therapy: Emerging therapeutic approach correct F9 gene mutation restore FIX production\n\n\nX-Linked Recessive DisordersHemophilia (Factor VIII Deficiency):\nDefinition: common inherited bleeding disorder; caused mutations F8 gene, encodes Factor VIII (FVIII)\nPathophysiology: Deficiency FVIII impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formation\nSeverity: Classified based level FVIII activity:\nSevere Hemophilia : FVIII < 1% normal\nModerate Hemophilia : FVIII 1-5% normal\nMild Hemophilia : FVIII 5-40% normal\n\nClinical Features:\nSeverity bleeding correlated level FVIII activity\nSevere Hemophilia:\nSpontaneous bleeding joints (hemarthrosis) muscles\nProlonged bleeding minor trauma surgery\nIntracranial hemorrhage\n\nModerate Mild Hemophilia:\nBleeding typically occurs trauma surgery\nSpontaneous bleeding less common\n\n\nLaboratory Findings:\nCBC: Normal platelet count\nProthrombin Time (PT): Normal\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor VIII Assay: Decreased FVIII activity level\nFactor Inhibitor Assay: rule acquired FVIII inhibitors\n\nTreatment:\nReplacement Therapy: Infusion FVIII concentrates\nRecombinant FVIII products preferred minimize risk viral transmission\nProphylactic therapy: Regular infusions FVIII prevent bleeding\n-demand therapy: FVIII infusions treat acute bleeding episodes\n\nDesmopressin (DDAVP):\nMay effective mild hemophilia stimulate release FVIII endothelial cells\n\nEmicizumab:\nbispecific antibody mimics cofactor function FVIII, bridging Factors IXa X restore coagulation\nUsed prophylaxis patients hemophilia without FVIII inhibitors\n\nGene Therapy:\nEmerging therapeutic approach correct F8 gene mutation restore FVIII production\n\n\nDefinition: common inherited bleeding disorder; caused mutations F8 gene, encodes Factor VIII (FVIII)Pathophysiology: Deficiency FVIII impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formationSeverity: Classified based level FVIII activity:\nSevere Hemophilia : FVIII < 1% normal\nModerate Hemophilia : FVIII 1-5% normal\nMild Hemophilia : FVIII 5-40% normal\nSevere Hemophilia : FVIII < 1% normalModerate Hemophilia : FVIII 1-5% normalMild Hemophilia : FVIII 5-40% normalClinical Features:\nSeverity bleeding correlated level FVIII activity\nSevere Hemophilia:\nSpontaneous bleeding joints (hemarthrosis) muscles\nProlonged bleeding minor trauma surgery\nIntracranial hemorrhage\n\nModerate Mild Hemophilia:\nBleeding typically occurs trauma surgery\nSpontaneous bleeding less common\n\nSeverity bleeding correlated level FVIII activitySevere Hemophilia:\nSpontaneous bleeding joints (hemarthrosis) muscles\nProlonged bleeding minor trauma surgery\nIntracranial hemorrhage\nSpontaneous bleeding joints (hemarthrosis) musclesProlonged bleeding minor trauma surgeryIntracranial hemorrhageModerate Mild Hemophilia:\nBleeding typically occurs trauma surgery\nSpontaneous bleeding less common\nBleeding typically occurs trauma surgerySpontaneous bleeding less commonLaboratory Findings:\nCBC: Normal platelet count\nProthrombin Time (PT): Normal\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor VIII Assay: Decreased FVIII activity level\nFactor Inhibitor Assay: rule acquired FVIII inhibitors\nCBC: Normal platelet countProthrombin Time (PT): NormalActivated Partial Thromboplastin Time (aPTT): ProlongedMixing Study: aPTT corrects mixing normal plasmaFactor VIII Assay: Decreased FVIII activity levelFactor Inhibitor Assay: rule acquired FVIII inhibitorsTreatment:\nReplacement Therapy: Infusion FVIII concentrates\nRecombinant FVIII products preferred minimize risk viral transmission\nProphylactic therapy: Regular infusions FVIII prevent bleeding\n-demand therapy: FVIII infusions treat acute bleeding episodes\n\nDesmopressin (DDAVP):\nMay effective mild hemophilia stimulate release FVIII endothelial cells\n\nEmicizumab:\nbispecific antibody mimics cofactor function FVIII, bridging Factors IXa X restore coagulation\nUsed prophylaxis patients hemophilia without FVIII inhibitors\n\nGene Therapy:\nEmerging therapeutic approach correct F8 gene mutation restore FVIII production\n\nReplacement Therapy: Infusion FVIII concentrates\nRecombinant FVIII products preferred minimize risk viral transmission\nProphylactic therapy: Regular infusions FVIII prevent bleeding\n-demand therapy: FVIII infusions treat acute bleeding episodes\nRecombinant FVIII products preferred minimize risk viral transmissionProphylactic therapy: Regular infusions FVIII prevent bleedingOn-demand therapy: FVIII infusions treat acute bleeding episodesDesmopressin (DDAVP):\nMay effective mild hemophilia stimulate release FVIII endothelial cells\nMay effective mild hemophilia stimulate release FVIII endothelial cellsEmicizumab:\nbispecific antibody mimics cofactor function FVIII, bridging Factors IXa X restore coagulation\nUsed prophylaxis patients hemophilia without FVIII inhibitors\nbispecific antibody mimics cofactor function FVIII, bridging Factors IXa X restore coagulationUsed prophylaxis patients hemophilia without FVIII inhibitorsGene Therapy:\nEmerging therapeutic approach correct F8 gene mutation restore FVIII production\nEmerging therapeutic approach correct F8 gene mutation restore FVIII productionHemophilia B (Factor IX Deficiency, Christmas Disease):\nDefinition: less common X-linked recessive bleeding disorder caused mutations F9 gene, encodes Factor IX (FIX)\nPathophysiology: Deficiency FIX impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formation\nClinical Features Laboratory Findings: Similar hemophilia , FVIII levels normal FIX levels decreased.\nTreatment:\nReplacement Therapy: Infusion FIX concentrates\nGene Therapy: Emerging therapeutic approach correct F9 gene mutation restore FIX production\n\nDefinition: less common X-linked recessive bleeding disorder caused mutations F9 gene, encodes Factor IX (FIX)Pathophysiology: Deficiency FIX impairs intrinsic pathway coagulation, leading decreased thrombin generation impaired clot formationClinical Features Laboratory Findings: Similar hemophilia , FVIII levels normal FIX levels decreased.Treatment:\nReplacement Therapy: Infusion FIX concentrates\nGene Therapy: Emerging therapeutic approach correct F9 gene mutation restore FIX production\nReplacement Therapy: Infusion FIX concentratesGene Therapy: Emerging therapeutic approach correct F9 gene mutation restore FIX productionAutosomal Recessive Disorders\nFactor XI Deficiency (Hemophilia C):\nDefinition: Autosomal recessive bleeding disorder caused mutations F11 gene, encodes Factor XI (FXI)\nPrevalence: common individuals Ashkenazi Jewish descent\nPathophysiology: Deficiency FXI impairs intrinsic pathway coagulation\nClinical Features:\nVariable bleeding symptoms\nBleeding often occurs surgery trauma\nSpontaneous bleeding less common\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Normal\naPTT: Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor XI Assay: Decreased FXI activity level\n\nTreatment:\nPlasma-Derived FXI Concentrates:\nFresh Frozen Plasma (FFP):\nAntifibrinolytic Agents: Tranexamic acid aminocaproic acid\n\n\nFactor XIII Deficiency:\nDefinition: rare autosomal recessive bleeding disorder caused mutations F13A1 F13B genes, encode B subunits Factor XIII (FXIII)\nPathophysiology: Deficiency FXIII impairs cross-linking fibrin, leading unstable clot formation\nClinical Features:\nSevere bleeding tendency\nUmbilical cord bleeding birth\nDelayed bleeding trauma surgery\nRecurrent miscarriages women\nIntracranial hemorrhage\n\nLaboratory Findings:\nCBC: Normal\nPT aPTT: Normal (tests detect FXIII deficiency)\nFibrinogen Level: Normal\nClot Solubility Test: Abnormal\nFactor XIII Assay: Decreased FXIII activity level\n\nTreatment:\nProphylactic FXIII Concentrate Infusions:\nCryoprecipitate: Historically used, less safe due risk viral transmission\n\n\nFactor V Deficiency (Parahemophilia):\nDefinition: rare autosomal recessive bleeding disorder caused mutations F5 gene, encodes Factor V (FV)\nPathophysiology: Deficiency FV impairs intrinsic extrinsic pathways coagulation\nClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nMenorrhagia women\nProlonged bleeding surgery trauma\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor V Assay: Decreased FV activity level\n\nTreatment:\nFresh Frozen Plasma (FFP):\nProthrombin Complex Concentrates (PCCs):\n\nNote: Factor V Leiden common genetic variant causes resistance activated protein C, leading hypercoagulable state (increased risk thrombosis), bleeding disorder. name similarity can cause confusion.\n\nFactor VII Deficiency:\nDefinition: rare autosomal recessive bleeding disorder caused mutations F7 gene, encodes Factor VII (FVII)\nPathophysiology: Deficiency FVII impairs extrinsic pathway coagulation\nClinical Features:\nVariable bleeding symptoms\nMay range asymptomatic severe bleeding\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Normal slightly prolonged\nMixing Study: PT corrects mixing normal plasma\nFactor VII Assay: Decreased FVII activity level\n\nTreatment:\nProthrombin Complex Concentrates (PCCs):\nRecombinant Factor VIIa (rFVIIa):\nFresh Frozen Plasma (FFP):\n\n\nFactor X Deficiency (Stuart-Prower Factor Deficiency):\nDefinition: rare autosomal recessive bleeding disorder caused mutations F10 gene, encodes Factor X (FX)\nPathophysiology: Deficiency FX impairs intrinsic extrinsic pathways coagulation\nClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare)\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor X Assay: Decreased FX activity level\n\nTreatment:\nProthrombin Complex Concentrates (PCCs):\nFresh Frozen Plasma (FFP):\n\n\nAutosomal Recessive DisordersFactor XI Deficiency (Hemophilia C):\nDefinition: Autosomal recessive bleeding disorder caused mutations F11 gene, encodes Factor XI (FXI)\nPrevalence: common individuals Ashkenazi Jewish descent\nPathophysiology: Deficiency FXI impairs intrinsic pathway coagulation\nClinical Features:\nVariable bleeding symptoms\nBleeding often occurs surgery trauma\nSpontaneous bleeding less common\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Normal\naPTT: Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor XI Assay: Decreased FXI activity level\n\nTreatment:\nPlasma-Derived FXI Concentrates:\nFresh Frozen Plasma (FFP):\nAntifibrinolytic Agents: Tranexamic acid aminocaproic acid\n\nDefinition: Autosomal recessive bleeding disorder caused mutations F11 gene, encodes Factor XI (FXI)Prevalence: common individuals Ashkenazi Jewish descentPathophysiology: Deficiency FXI impairs intrinsic pathway coagulationClinical Features:\nVariable bleeding symptoms\nBleeding often occurs surgery trauma\nSpontaneous bleeding less common\nVariable bleeding symptomsBleeding often occurs surgery traumaSpontaneous bleeding less commonLaboratory Findings:\nCBC: Normal platelet count\nPT: Normal\naPTT: Prolonged\nMixing Study: aPTT corrects mixing normal plasma\nFactor XI Assay: Decreased FXI activity level\nCBC: Normal platelet countPT: NormalaPTT: ProlongedMixing Study: aPTT corrects mixing normal plasmaFactor XI Assay: Decreased FXI activity levelTreatment:\nPlasma-Derived FXI Concentrates:\nFresh Frozen Plasma (FFP):\nAntifibrinolytic Agents: Tranexamic acid aminocaproic acid\nPlasma-Derived FXI Concentrates:Fresh Frozen Plasma (FFP):Antifibrinolytic Agents: Tranexamic acid aminocaproic acidFactor XIII Deficiency:\nDefinition: rare autosomal recessive bleeding disorder caused mutations F13A1 F13B genes, encode B subunits Factor XIII (FXIII)\nPathophysiology: Deficiency FXIII impairs cross-linking fibrin, leading unstable clot formation\nClinical Features:\nSevere bleeding tendency\nUmbilical cord bleeding birth\nDelayed bleeding trauma surgery\nRecurrent miscarriages women\nIntracranial hemorrhage\n\nLaboratory Findings:\nCBC: Normal\nPT aPTT: Normal (tests detect FXIII deficiency)\nFibrinogen Level: Normal\nClot Solubility Test: Abnormal\nFactor XIII Assay: Decreased FXIII activity level\n\nTreatment:\nProphylactic FXIII Concentrate Infusions:\nCryoprecipitate: Historically used, less safe due risk viral transmission\n\nDefinition: rare autosomal recessive bleeding disorder caused mutations F13A1 F13B genes, encode B subunits Factor XIII (FXIII)Pathophysiology: Deficiency FXIII impairs cross-linking fibrin, leading unstable clot formationClinical Features:\nSevere bleeding tendency\nUmbilical cord bleeding birth\nDelayed bleeding trauma surgery\nRecurrent miscarriages women\nIntracranial hemorrhage\nSevere bleeding tendencyUmbilical cord bleeding birthDelayed bleeding trauma surgeryRecurrent miscarriages womenIntracranial hemorrhageLaboratory Findings:\nCBC: Normal\nPT aPTT: Normal (tests detect FXIII deficiency)\nFibrinogen Level: Normal\nClot Solubility Test: Abnormal\nFactor XIII Assay: Decreased FXIII activity level\nCBC: NormalPT aPTT: Normal (tests detect FXIII deficiency)Fibrinogen Level: NormalClot Solubility Test: AbnormalFactor XIII Assay: Decreased FXIII activity levelTreatment:\nProphylactic FXIII Concentrate Infusions:\nCryoprecipitate: Historically used, less safe due risk viral transmission\nProphylactic FXIII Concentrate Infusions:Cryoprecipitate: Historically used, less safe due risk viral transmissionFactor V Deficiency (Parahemophilia):\nDefinition: rare autosomal recessive bleeding disorder caused mutations F5 gene, encodes Factor V (FV)\nPathophysiology: Deficiency FV impairs intrinsic extrinsic pathways coagulation\nClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nMenorrhagia women\nProlonged bleeding surgery trauma\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor V Assay: Decreased FV activity level\n\nTreatment:\nFresh Frozen Plasma (FFP):\nProthrombin Complex Concentrates (PCCs):\n\nNote: Factor V Leiden common genetic variant causes resistance activated protein C, leading hypercoagulable state (increased risk thrombosis), bleeding disorder. name similarity can cause confusion.\nDefinition: rare autosomal recessive bleeding disorder caused mutations F5 gene, encodes Factor V (FV)Pathophysiology: Deficiency FV impairs intrinsic extrinsic pathways coagulationClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nMenorrhagia women\nProlonged bleeding surgery trauma\nVariable bleeding symptomsEasy bruisingNosebleedsMenorrhagia womenProlonged bleeding surgery traumaLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor V Assay: Decreased FV activity level\nCBC: Normal platelet countPT: ProlongedaPTT: ProlongedMixing Study: PT aPTT correct mixing normal plasmaFactor V Assay: Decreased FV activity levelTreatment:\nFresh Frozen Plasma (FFP):\nProthrombin Complex Concentrates (PCCs):\nFresh Frozen Plasma (FFP):Prothrombin Complex Concentrates (PCCs):Note: Factor V Leiden common genetic variant causes resistance activated protein C, leading hypercoagulable state (increased risk thrombosis), bleeding disorder. name similarity can cause confusion.Factor VII Deficiency:\nDefinition: rare autosomal recessive bleeding disorder caused mutations F7 gene, encodes Factor VII (FVII)\nPathophysiology: Deficiency FVII impairs extrinsic pathway coagulation\nClinical Features:\nVariable bleeding symptoms\nMay range asymptomatic severe bleeding\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Normal slightly prolonged\nMixing Study: PT corrects mixing normal plasma\nFactor VII Assay: Decreased FVII activity level\n\nTreatment:\nProthrombin Complex Concentrates (PCCs):\nRecombinant Factor VIIa (rFVIIa):\nFresh Frozen Plasma (FFP):\n\nDefinition: rare autosomal recessive bleeding disorder caused mutations F7 gene, encodes Factor VII (FVII)Pathophysiology: Deficiency FVII impairs extrinsic pathway coagulationClinical Features:\nVariable bleeding symptoms\nMay range asymptomatic severe bleeding\nVariable bleeding symptomsMay range asymptomatic severe bleedingLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Normal slightly prolonged\nMixing Study: PT corrects mixing normal plasma\nFactor VII Assay: Decreased FVII activity level\nCBC: Normal platelet countPT: ProlongedaPTT: Normal slightly prolongedMixing Study: PT corrects mixing normal plasmaFactor VII Assay: Decreased FVII activity levelTreatment:\nProthrombin Complex Concentrates (PCCs):\nRecombinant Factor VIIa (rFVIIa):\nFresh Frozen Plasma (FFP):\nProthrombin Complex Concentrates (PCCs):Recombinant Factor VIIa (rFVIIa):Fresh Frozen Plasma (FFP):Factor X Deficiency (Stuart-Prower Factor Deficiency):\nDefinition: rare autosomal recessive bleeding disorder caused mutations F10 gene, encodes Factor X (FX)\nPathophysiology: Deficiency FX impairs intrinsic extrinsic pathways coagulation\nClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare)\n\nLaboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor X Assay: Decreased FX activity level\n\nTreatment:\nProthrombin Complex Concentrates (PCCs):\nFresh Frozen Plasma (FFP):\n\nDefinition: rare autosomal recessive bleeding disorder caused mutations F10 gene, encodes Factor X (FX)Pathophysiology: Deficiency FX impairs intrinsic extrinsic pathways coagulationClinical Features:\nVariable bleeding symptoms\nEasy bruising\nNosebleeds\nHemarthrosis (bleeding joints)\nIntracranial hemorrhage (rare)\nVariable bleeding symptomsEasy bruisingNosebleedsHemarthrosis (bleeding joints)Intracranial hemorrhage (rare)Laboratory Findings:\nCBC: Normal platelet count\nPT: Prolonged\naPTT: Prolonged\nMixing Study: PT aPTT correct mixing normal plasma\nFactor X Assay: Decreased FX activity level\nCBC: Normal platelet countPT: ProlongedaPTT: ProlongedMixing Study: PT aPTT correct mixing normal plasmaFactor X Assay: Decreased FX activity levelTreatment:\nProthrombin Complex Concentrates (PCCs):\nFresh Frozen Plasma (FFP):\nProthrombin Complex Concentrates (PCCs):Fresh Frozen Plasma (FFP):","code":""},{"path":"hereditary-1.html","id":"treatment-strategies-for-hereditary-coagulation-factor-deficiencies","chapter":"Hereditary","heading":"Treatment Strategies for Hereditary Coagulation Factor Deficiencies","text":"Replacement Therapy: Infusion deficient coagulation factor\nPlasma-derived recombinant products\nProphylactic (regular) -demand (treatment bleeding episodes)\nPlasma-derived recombinant productsProphylactic (regular) -demand (treatment bleeding episodes)Bypassing Agents: Used promote thrombin generation independently deficient factorAdjunctive Therapies:\nAntifibrinolytic Agents: Used prevent treat mucosal bleeding\nLocal Hemostatic Measures: Topical thrombin, fibrin sealants, pressure dressings\nAntifibrinolytic Agents: Used prevent treat mucosal bleedingLocal Hemostatic Measures: Topical thrombin, fibrin sealants, pressure dressingsGene Therapy\nHemophilia Hemophilia B, now options gene therapy curative disease.\ntreatment option high factor levels\ntest used monitor production factor.\nHemophilia Hemophilia B, now options gene therapy curative disease.treatment option high factor levelsThis test used monitor production factor.","code":""},{"path":"hereditary-1.html","id":"key-laboratory-tests-for-hereditary-coagulation-factor-deficiencies","chapter":"Hereditary","heading":"Key Laboratory Tests for Hereditary Coagulation Factor Deficiencies","text":"Complete Blood Count (CBC): Usually normalProthrombin Time (PT): May prolonged, depending specific factor deficiencyActivated Partial Thromboplastin Time (aPTT): May prolonged, depending specific factor deficiencyMixing Studies: differentiate factor deficiencies factor inhibitorsIndividual Factor Assays: measure activity specific coagulation factors (definitive test)","code":""},{"path":"hereditary-1.html","id":"key-terms-79","chapter":"Hereditary","heading":"Key Terms","text":"Coagulation Factor: protein involved coagulation cascadeHemophilia : Factor VIII deficiencyHemophilia B: Factor IX deficiencyAutosomal Recessive: Inheritance pattern two copies abnormal gene must present disease developX-Linked Recessive: Inheritance pattern gene located X chromosome (males commonly affected)Factor Assay: laboratory test measure activity specific coagulation factorInhibitor: antibody interferes function coagulation factorReplacement Therapy: Infusion deficient coagulation factor","code":""},{"path":"acquired.html","id":"acquired","chapter":"Acquired","heading":"Acquired","text":"","code":""},{"path":"acquired.html","id":"overview-of-acquired-coagulation-factor-deficiencies","chapter":"Acquired","heading":"Overview of Acquired Coagulation Factor Deficiencies","text":"Definition: Bleeding disorders result decrease level function one coagulation factors due external factors rather genetic mutations. disorders inheritedKey Characteristics:\nDevelop later life, often association underlying medical conditions exposures\nMay involve single multiple coagulation factors\nOften associated abnormal results screening coagulation tests (PT /aPTT)\nTreatment focuses addressing underlying cause providing supportive care\nDevelop later life, often association underlying medical conditions exposuresMay involve single multiple coagulation factorsOften associated abnormal results screening coagulation tests (PT /aPTT)Treatment focuses addressing underlying cause providing supportive careImportant Note: ’s crucial distinguish acquired coagulation factor deficiencies inherited deficiencies, causes management strategies different","code":""},{"path":"acquired.html","id":"specific-acquired-coagulation-factor-deficiencies","chapter":"Acquired","heading":"Specific Acquired Coagulation Factor Deficiencies","text":"Vitamin K Deficiency\nPathophysiology: Vitamin K essential cofactor gamma-carboxylation certain glutamate residues coagulation factors II (prothrombin), VII, IX, X, well proteins C S\nGamma-carboxylation necessary proteins bind calcium become fully functional coagulation cascade\nVitamin K deficiency impairs carboxylation process, leading decreased levels functional coagulation factors\n\nCauses:\nInadequate Dietary Intake: Rare healthy adults balanced diet\nMalabsorption:\nBiliary Obstruction: Prevents absorption fat-soluble vitamins (including vitamin K)\nCystic Fibrosis: Impairs absorption fat-soluble vitamins\nShort Bowel Syndrome: Decreased absorptive surface\n\nAntibiotic Use: Broad-spectrum antibiotics can disrupt gut flora produce vitamin K\nWarfarin (Coumadin) Therapy: Warfarin inhibits vitamin K epoxide reductase, enzyme required recycling vitamin K\n\nClinical Features:\nEasy bruising\nMucosal bleeding (e.g., nosebleeds, gum bleeding)\nProlonged bleeding cuts, dental procedures, surgery\nRarely, severe bleeding intracranial hemorrhage\n\nLaboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged (may normal early stages)\nThrombin Time (TT): Normal\nFibrinogen Level: Normal\nFactor Assays: Decreased levels Factors II, VII, IX, X\nVitamin K Level: May low, routinely measured\n\nTreatment:\nVitamin K Supplementation:\nOral Vitamin K: mild moderate deficiency\nIntravenous Vitamin K: severe deficiency patients malabsorption\n\nFresh Frozen Plasma (FFP): rapidly restore coagulation factors cases severe bleeding\nProthrombin Complex Concentrates (PCCs): rapidly restore coagulation factors cases severe bleeding\nTreatment Underlying Cause: Address underlying condition causing vitamin K deficiency (e.g., treat biliary obstruction, discontinue offending medications)\n\nMonitoring:\nPT/INR: assess response vitamin K therapy\n\nVitamin K DeficiencyPathophysiology: Vitamin K essential cofactor gamma-carboxylation certain glutamate residues coagulation factors II (prothrombin), VII, IX, X, well proteins C S\nGamma-carboxylation necessary proteins bind calcium become fully functional coagulation cascade\nVitamin K deficiency impairs carboxylation process, leading decreased levels functional coagulation factors\nGamma-carboxylation necessary proteins bind calcium become fully functional coagulation cascadeVitamin K deficiency impairs carboxylation process, leading decreased levels functional coagulation factorsCauses:\nInadequate Dietary Intake: Rare healthy adults balanced diet\nMalabsorption:\nBiliary Obstruction: Prevents absorption fat-soluble vitamins (including vitamin K)\nCystic Fibrosis: Impairs absorption fat-soluble vitamins\nShort Bowel Syndrome: Decreased absorptive surface\n\nAntibiotic Use: Broad-spectrum antibiotics can disrupt gut flora produce vitamin K\nWarfarin (Coumadin) Therapy: Warfarin inhibits vitamin K epoxide reductase, enzyme required recycling vitamin K\nInadequate Dietary Intake: Rare healthy adults balanced dietMalabsorption:\nBiliary Obstruction: Prevents absorption fat-soluble vitamins (including vitamin K)\nCystic Fibrosis: Impairs absorption fat-soluble vitamins\nShort Bowel Syndrome: Decreased absorptive surface\nBiliary Obstruction: Prevents absorption fat-soluble vitamins (including vitamin K)Cystic Fibrosis: Impairs absorption fat-soluble vitaminsShort Bowel Syndrome: Decreased absorptive surfaceAntibiotic Use: Broad-spectrum antibiotics can disrupt gut flora produce vitamin KWarfarin (Coumadin) Therapy: Warfarin inhibits vitamin K epoxide reductase, enzyme required recycling vitamin KClinical Features:\nEasy bruising\nMucosal bleeding (e.g., nosebleeds, gum bleeding)\nProlonged bleeding cuts, dental procedures, surgery\nRarely, severe bleeding intracranial hemorrhage\nEasy bruisingMucosal bleeding (e.g., nosebleeds, gum bleeding)Prolonged bleeding cuts, dental procedures, surgeryRarely, severe bleeding intracranial hemorrhageLaboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged (may normal early stages)\nThrombin Time (TT): Normal\nFibrinogen Level: Normal\nFactor Assays: Decreased levels Factors II, VII, IX, X\nVitamin K Level: May low, routinely measured\nProthrombin Time (PT): ProlongedActivated Partial Thromboplastin Time (aPTT): Prolonged (may normal early stages)Thrombin Time (TT): NormalFibrinogen Level: NormalFactor Assays: Decreased levels Factors II, VII, IX, XVitamin K Level: May low, routinely measuredTreatment:\nVitamin K Supplementation:\nOral Vitamin K: mild moderate deficiency\nIntravenous Vitamin K: severe deficiency patients malabsorption\n\nFresh Frozen Plasma (FFP): rapidly restore coagulation factors cases severe bleeding\nProthrombin Complex Concentrates (PCCs): rapidly restore coagulation factors cases severe bleeding\nTreatment Underlying Cause: Address underlying condition causing vitamin K deficiency (e.g., treat biliary obstruction, discontinue offending medications)\nVitamin K Supplementation:\nOral Vitamin K: mild moderate deficiency\nIntravenous Vitamin K: severe deficiency patients malabsorption\nOral Vitamin K: mild moderate deficiencyIntravenous Vitamin K: severe deficiency patients malabsorptionFresh Frozen Plasma (FFP): rapidly restore coagulation factors cases severe bleedingProthrombin Complex Concentrates (PCCs): rapidly restore coagulation factors cases severe bleedingTreatment Underlying Cause: Address underlying condition causing vitamin K deficiency (e.g., treat biliary obstruction, discontinue offending medications)Monitoring:\nPT/INR: assess response vitamin K therapy\nPT/INR: assess response vitamin K therapyLiver Disease\nPathophysiology: liver primary site synthesis coagulation factors, well natural anticoagulants (protein C, protein S, antithrombin). Liver disease impairs synthesis proteins, leading bleeding thrombotic risks\nCauses:\nCirrhosis: Chronic liver damage due alcohol abuse, viral hepatitis, causes\nAcute Liver Failure\nHepatitis\nLiver Tumors\n\nClinical Features:\nVariable bleeding tendency\nEasy bruising\nNosebleeds\nGum bleeding\nVariceal bleeding (bleeding enlarged veins esophagus stomach)\nAscites (fluid accumulation abdomen)\nJaundice (yellowing skin eyes)\n\nLaboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nThrombin Time (TT): Prolonged (due dysfibrinogenemia - abnormal fibrinogen)\nFibrinogen Level: May decreased normal, often dysfunctional\nFactor Assays: Decreased levels multiple coagulation factors (Factors II, V, VII, IX, X)\nPlatelet Count: May decreased (thrombocytopenia) due hypersplenism decreased thrombopoietin production\nLiver Function Tests (LFTs): Elevated (AST, ALT, bilirubin)\n\nTreatment:\nTreatment Underlying Liver Disease: Addressing underlying liver condition (e.g., antiviral therapy hepatitis, alcohol abstinence)\nVitamin K Supplementation: May improve coagulation factor synthesis vitamin K deficiency present\nFresh Frozen Plasma (FFP): provide coagulation factors cases severe bleeding\nProthrombin Complex Concentrates (PCCs): provide coagulation factors cases severe bleeding\nCryoprecipitate: increase fibrinogen levels\nPlatelet Transfusions: manage thrombocytopenia severe bleeding\n\nLiver DiseasePathophysiology: liver primary site synthesis coagulation factors, well natural anticoagulants (protein C, protein S, antithrombin). Liver disease impairs synthesis proteins, leading bleeding thrombotic risksCauses:\nCirrhosis: Chronic liver damage due alcohol abuse, viral hepatitis, causes\nAcute Liver Failure\nHepatitis\nLiver Tumors\nCirrhosis: Chronic liver damage due alcohol abuse, viral hepatitis, causesAcute Liver FailureHepatitisLiver TumorsClinical Features:\nVariable bleeding tendency\nEasy bruising\nNosebleeds\nGum bleeding\nVariceal bleeding (bleeding enlarged veins esophagus stomach)\nAscites (fluid accumulation abdomen)\nJaundice (yellowing skin eyes)\nVariable bleeding tendencyEasy bruisingNosebleedsGum bleedingVariceal bleeding (bleeding enlarged veins esophagus stomach)Ascites (fluid accumulation abdomen)Jaundice (yellowing skin eyes)Laboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nThrombin Time (TT): Prolonged (due dysfibrinogenemia - abnormal fibrinogen)\nFibrinogen Level: May decreased normal, often dysfunctional\nFactor Assays: Decreased levels multiple coagulation factors (Factors II, V, VII, IX, X)\nPlatelet Count: May decreased (thrombocytopenia) due hypersplenism decreased thrombopoietin production\nLiver Function Tests (LFTs): Elevated (AST, ALT, bilirubin)\nProthrombin Time (PT): ProlongedActivated Partial Thromboplastin Time (aPTT): ProlongedThrombin Time (TT): Prolonged (due dysfibrinogenemia - abnormal fibrinogen)Fibrinogen Level: May decreased normal, often dysfunctionalFactor Assays: Decreased levels multiple coagulation factors (Factors II, V, VII, IX, X)Platelet Count: May decreased (thrombocytopenia) due hypersplenism decreased thrombopoietin productionLiver Function Tests (LFTs): Elevated (AST, ALT, bilirubin)Treatment:\nTreatment Underlying Liver Disease: Addressing underlying liver condition (e.g., antiviral therapy hepatitis, alcohol abstinence)\nVitamin K Supplementation: May improve coagulation factor synthesis vitamin K deficiency present\nFresh Frozen Plasma (FFP): provide coagulation factors cases severe bleeding\nProthrombin Complex Concentrates (PCCs): provide coagulation factors cases severe bleeding\nCryoprecipitate: increase fibrinogen levels\nPlatelet Transfusions: manage thrombocytopenia severe bleeding\nTreatment Underlying Liver Disease: Addressing underlying liver condition (e.g., antiviral therapy hepatitis, alcohol abstinence)Vitamin K Supplementation: May improve coagulation factor synthesis vitamin K deficiency presentFresh Frozen Plasma (FFP): provide coagulation factors cases severe bleedingProthrombin Complex Concentrates (PCCs): provide coagulation factors cases severe bleedingCryoprecipitate: increase fibrinogen levelsPlatelet Transfusions: manage thrombocytopenia severe bleedingDisseminated Intravascular Coagulation (DIC)\nDefinition: complex, life-threatening disorder characterized widespread activation coagulation fibrinolysis, leading thrombosis bleeding\nPathophysiology:\nTriggering Event: DIC triggered various conditions, including:\nSepsis: Systemic bacterial fungal infection\nTrauma: Severe tissue injury\nObstetric Complications: Abruptio placentae, amniotic fluid embolism\nMalignancy: Acute promyelocytic leukemia (APL), solid tumors\nTransfusion Reactions\n\nActivation Coagulation: Uncontrolled activation coagulation cascade, leading formation microthrombi throughout vasculature\nConsumption Coagulation Factors Platelets: Widespread clotting consumes coagulation factors platelets, leading deficiencies\nActivation Fibrinolysis: Activation fibrinolytic system break microthrombi, resulting generation fibrin degradation products (FDPs)\nBleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads bleeding thrombotic complications\n\nClinical Features:\nBleeding:\nOozing IV sites wounds\nPetechiae purpura\nGastrointestinal bleeding\nPulmonary hemorrhage\n\nThrombosis:\nMicrothrombi can cause organ damage dysfunction (e.g., kidney failure, respiratory distress)\n\n\nLaboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nThrombin Time (TT): Prolonged\nFibrinogen Level: Decreased\nPlatelet Count: Decreased (thrombocytopenia)\nD-dimer: Markedly Elevated\nPeripheral Blood Smear: Schistocytes (fragmented RBCs) due microangiopathic hemolytic anemia (MAHA)\n\nTreatment:\nTreat Underlying Cause: Essential resolving DIC\nSupportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nFresh Frozen Plasma (FFP): replace coagulation factors\nCryoprecipitate: increase fibrinogen levels\n\nAnticoagulation:\nHeparin: May considered specific situations (e.g., APL-associated DIC) inhibit thrombin generation, use controversial\n\nAntifibrinolytic Agents:\nUse caution, can worsen thrombosis; may considered specific situations life-threatening bleeding\n\n\nDisseminated Intravascular Coagulation (DIC)Definition: complex, life-threatening disorder characterized widespread activation coagulation fibrinolysis, leading thrombosis bleedingPathophysiology:\nTriggering Event: DIC triggered various conditions, including:\nSepsis: Systemic bacterial fungal infection\nTrauma: Severe tissue injury\nObstetric Complications: Abruptio placentae, amniotic fluid embolism\nMalignancy: Acute promyelocytic leukemia (APL), solid tumors\nTransfusion Reactions\n\nActivation Coagulation: Uncontrolled activation coagulation cascade, leading formation microthrombi throughout vasculature\nConsumption Coagulation Factors Platelets: Widespread clotting consumes coagulation factors platelets, leading deficiencies\nActivation Fibrinolysis: Activation fibrinolytic system break microthrombi, resulting generation fibrin degradation products (FDPs)\nBleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads bleeding thrombotic complications\nTriggering Event: DIC triggered various conditions, including:\nSepsis: Systemic bacterial fungal infection\nTrauma: Severe tissue injury\nObstetric Complications: Abruptio placentae, amniotic fluid embolism\nMalignancy: Acute promyelocytic leukemia (APL), solid tumors\nTransfusion Reactions\nSepsis: Systemic bacterial fungal infectionTrauma: Severe tissue injuryObstetric Complications: Abruptio placentae, amniotic fluid embolismMalignancy: Acute promyelocytic leukemia (APL), solid tumorsTransfusion ReactionsActivation Coagulation: Uncontrolled activation coagulation cascade, leading formation microthrombi throughout vasculatureConsumption Coagulation Factors Platelets: Widespread clotting consumes coagulation factors platelets, leading deficienciesActivation Fibrinolysis: Activation fibrinolytic system break microthrombi, resulting generation fibrin degradation products (FDPs)Bleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads bleeding thrombotic complicationsClinical Features:\nBleeding:\nOozing IV sites wounds\nPetechiae purpura\nGastrointestinal bleeding\nPulmonary hemorrhage\n\nThrombosis:\nMicrothrombi can cause organ damage dysfunction (e.g., kidney failure, respiratory distress)\n\nBleeding:\nOozing IV sites wounds\nPetechiae purpura\nGastrointestinal bleeding\nPulmonary hemorrhage\nOozing IV sites woundsPetechiae purpuraGastrointestinal bleedingPulmonary hemorrhageThrombosis:\nMicrothrombi can cause organ damage dysfunction (e.g., kidney failure, respiratory distress)\nMicrothrombi can cause organ damage dysfunction (e.g., kidney failure, respiratory distress)Laboratory Findings:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nThrombin Time (TT): Prolonged\nFibrinogen Level: Decreased\nPlatelet Count: Decreased (thrombocytopenia)\nD-dimer: Markedly Elevated\nPeripheral Blood Smear: Schistocytes (fragmented RBCs) due microangiopathic hemolytic anemia (MAHA)\nProthrombin Time (PT): ProlongedActivated Partial Thromboplastin Time (aPTT): ProlongedThrombin Time (TT): ProlongedFibrinogen Level: DecreasedPlatelet Count: Decreased (thrombocytopenia)D-dimer: Markedly ElevatedPeripheral Blood Smear: Schistocytes (fragmented RBCs) due microangiopathic hemolytic anemia (MAHA)Treatment:\nTreat Underlying Cause: Essential resolving DIC\nSupportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nFresh Frozen Plasma (FFP): replace coagulation factors\nCryoprecipitate: increase fibrinogen levels\n\nAnticoagulation:\nHeparin: May considered specific situations (e.g., APL-associated DIC) inhibit thrombin generation, use controversial\n\nAntifibrinolytic Agents:\nUse caution, can worsen thrombosis; may considered specific situations life-threatening bleeding\n\nTreat Underlying Cause: Essential resolving DICSupportive Care:\nTransfusions (RBCs platelets) manage anemia thrombocytopenia\nFresh Frozen Plasma (FFP): replace coagulation factors\nCryoprecipitate: increase fibrinogen levels\nTransfusions (RBCs platelets) manage anemia thrombocytopeniaFresh Frozen Plasma (FFP): replace coagulation factorsCryoprecipitate: increase fibrinogen levelsAnticoagulation:\nHeparin: May considered specific situations (e.g., APL-associated DIC) inhibit thrombin generation, use controversial\nHeparin: May considered specific situations (e.g., APL-associated DIC) inhibit thrombin generation, use controversialAntifibrinolytic Agents:\nUse caution, can worsen thrombosis; may considered specific situations life-threatening bleeding\nUse caution, can worsen thrombosis; may considered specific situations life-threatening bleeding","code":""},{"path":"acquired.html","id":"other-acquired-coagulation-factor-deficiencies","chapter":"Acquired","heading":"Other Acquired Coagulation Factor Deficiencies","text":"Acquired Hemophilia:\nCaused development autoantibodies (inhibitors) coagulation factor, commonly Factor VIII\nOften occurs older adults association autoimmune disorders, pregnancy, malignancies\nLaboratory Findings:\nProlonged aPTT correct mixing normal plasma\nDecreased Factor VIII activity\nPositive Factor VIII inhibitor assay\n\nCaused development autoantibodies (inhibitors) coagulation factor, commonly Factor VIIIOften occurs older adults association autoimmune disorders, pregnancy, malignanciesLaboratory Findings:\nProlonged aPTT correct mixing normal plasma\nDecreased Factor VIII activity\nPositive Factor VIII inhibitor assay\nProlonged aPTT correct mixing normal plasmaDecreased Factor VIII activityPositive Factor VIII inhibitor assayLupus Anticoagulant (LA):\nantibody binds phospholipids proteins associated cell membrane\nProlonged aPTT correct mixing normal plasma\nIncreased risk blood clots vivo (body)\nantibody binds phospholipids proteins associated cell membraneProlonged aPTT correct mixing normal plasmaIncreased risk blood clots vivo (body)","code":""},{"path":"acquired.html","id":"key-terms-80","chapter":"Acquired","heading":"Key Terms","text":"Acquired Coagulation Factor Deficiency: bleeding disorder due decrease coagulation factors outside conditions genetically linkedVitamin K: factor essential creation proteinsLiver Disease: body’s liver function can lead diseaseProthrombin Time (PT): Test extrinsic common pathwaysActivated Partial Thromboplastin Time (aPTT): Test intrinsic common pathwaysDisseminated Intravascular Coagulation (DIC): consumptive coagulopathy widespread clotting bleeding","code":""},{"path":"inhibitors.html","id":"inhibitors","chapter":"Inhibitors","heading":"Inhibitors","text":"","code":""},{"path":"inhibitors.html","id":"overview-of-coagulation-inhibitors","chapter":"Inhibitors","heading":"Overview of Coagulation Inhibitors","text":"Definition: Substances interfere normal function coagulation factors, leading impaired thrombin generation increased risk bleeding , cases, thrombosisClassification:\nAcquired Inhibitors: Antibodies (usually IgG) develop specific coagulation factors phospholipid-binding proteins\nCongenital Inhibitors: Rare, inherited deficiencies natural anticoagulant proteins (Protein C, Protein S, Antithrombin). typically categorized hypercoagulable states rather factor deficiencies\nAcquired Inhibitors: Antibodies (usually IgG) develop specific coagulation factors phospholipid-binding proteinsCongenital Inhibitors: Rare, inherited deficiencies natural anticoagulant proteins (Protein C, Protein S, Antithrombin). typically categorized hypercoagulable states rather factor deficienciesKey Features:\nProlonged clotting time (PT /aPTT) correct upon mixing normal plasma (demonstrates presence inhibitor)\nMay target specific coagulation factors phospholipid-binding proteins\nClinical manifestations range bleeding thrombosis, depending specific inhibitor underlying mechanism\nProlonged clotting time (PT /aPTT) correct upon mixing normal plasma (demonstrates presence inhibitor)May target specific coagulation factors phospholipid-binding proteinsClinical manifestations range bleeding thrombosis, depending specific inhibitor underlying mechanism","code":""},{"path":"inhibitors.html","id":"acquired-coagulation-inhibitors","chapter":"Inhibitors","heading":"Acquired Coagulation Inhibitors","text":"antibodies develop coagulation factors phospholipid-binding proteins, interfering functionFactor VIII Inhibitors (Acquired Hemophilia ):\nDefinition: Autoantibodies (usually IgG) develop Factor VIII (FVIII), leading FVIII deficiency bleeding disorder\nEtiology:\nIdiopathic (common)\nAssociated :\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)\nPregnancy\nMalignancies\nMedications (e.g., penicillin, sulfonamides)\n\n\nPathophysiology:\nAutoantibodies bind FVIII neutralize activity accelerate clearance circulation\nLeads impaired thrombin generation increased risk bleeding\n\nClinical Features:\nBleeding manifestations similar hemophilia \nEasy bruising\nProlonged bleeding cuts surgery\nNosebleeds\nHemarthrosis (bleeding joints) - less common inherited hemophilia \nIntracranial hemorrhage (rare life-threatening)\n\n\nLaboratory Findings:\nCBC: Normal platelet count\nProthrombin Time (PT): Normal\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nMixing Study: aPTT correct upon mixing normal plasma (demonstrates presence inhibitor)\nFactor VIII Assay: Decreased FVIII activity level\nFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): Measures titer (concentration) FVIII inhibitor\nBethesda titer expressed Bethesda Units (BU)\nOne BU defined amount inhibitor neutralizes 50% FVIII normal plasma\n\n\nTreatment:\nControl Bleeding Episodes:\nBypassing agents:\nActivated prothrombin complex concentrates (aPCCs)\nRecombinant Factor VIIa (rFVIIa)\n\nagents promote thrombin generation independently FVIII\n\nEradication Inhibitor:\nImmunosuppressive Therapy:\nCorticosteroids (e.g., prednisone)\nCyclophosphamide\nRituximab (anti-CD20 antibody)\n\nImmune Tolerance Induction (ITI): High-dose FVIII infusions combined immunosuppressive therapy\n\nAvoid FVIII Concentrates (unless necessary control bleeding)\nRepeated exposure FVIII can boost inhibitor titer\n\n\nFactor VIII Inhibitors (Acquired Hemophilia ):Definition: Autoantibodies (usually IgG) develop Factor VIII (FVIII), leading FVIII deficiency bleeding disorderEtiology:\nIdiopathic (common)\nAssociated :\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)\nPregnancy\nMalignancies\nMedications (e.g., penicillin, sulfonamides)\n\nIdiopathic (common)Associated :\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)\nPregnancy\nMalignancies\nMedications (e.g., penicillin, sulfonamides)\nAutoimmune disorders (e.g., SLE, rheumatoid arthritis)PregnancyMalignanciesMedications (e.g., penicillin, sulfonamides)Pathophysiology:\nAutoantibodies bind FVIII neutralize activity accelerate clearance circulation\nLeads impaired thrombin generation increased risk bleeding\nAutoantibodies bind FVIII neutralize activity accelerate clearance circulationLeads impaired thrombin generation increased risk bleedingClinical Features:\nBleeding manifestations similar hemophilia \nEasy bruising\nProlonged bleeding cuts surgery\nNosebleeds\nHemarthrosis (bleeding joints) - less common inherited hemophilia \nIntracranial hemorrhage (rare life-threatening)\n\nBleeding manifestations similar hemophilia \nEasy bruising\nProlonged bleeding cuts surgery\nNosebleeds\nHemarthrosis (bleeding joints) - less common inherited hemophilia \nIntracranial hemorrhage (rare life-threatening)\nEasy bruisingProlonged bleeding cuts surgeryNosebleedsHemarthrosis (bleeding joints) - less common inherited hemophilia AIntracranial hemorrhage (rare life-threatening)Laboratory Findings:\nCBC: Normal platelet count\nProthrombin Time (PT): Normal\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nMixing Study: aPTT correct upon mixing normal plasma (demonstrates presence inhibitor)\nFactor VIII Assay: Decreased FVIII activity level\nFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): Measures titer (concentration) FVIII inhibitor\nBethesda titer expressed Bethesda Units (BU)\nOne BU defined amount inhibitor neutralizes 50% FVIII normal plasma\n\nCBC: Normal platelet countProthrombin Time (PT): NormalActivated Partial Thromboplastin Time (aPTT): ProlongedMixing Study: aPTT correct upon mixing normal plasma (demonstrates presence inhibitor)Factor VIII Assay: Decreased FVIII activity levelFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): Measures titer (concentration) FVIII inhibitor\nBethesda titer expressed Bethesda Units (BU)\nOne BU defined amount inhibitor neutralizes 50% FVIII normal plasma\nBethesda titer expressed Bethesda Units (BU)One BU defined amount inhibitor neutralizes 50% FVIII normal plasmaTreatment:\nControl Bleeding Episodes:\nBypassing agents:\nActivated prothrombin complex concentrates (aPCCs)\nRecombinant Factor VIIa (rFVIIa)\n\nagents promote thrombin generation independently FVIII\n\nEradication Inhibitor:\nImmunosuppressive Therapy:\nCorticosteroids (e.g., prednisone)\nCyclophosphamide\nRituximab (anti-CD20 antibody)\n\nImmune Tolerance Induction (ITI): High-dose FVIII infusions combined immunosuppressive therapy\n\nAvoid FVIII Concentrates (unless necessary control bleeding)\nRepeated exposure FVIII can boost inhibitor titer\n\nControl Bleeding Episodes:\nBypassing agents:\nActivated prothrombin complex concentrates (aPCCs)\nRecombinant Factor VIIa (rFVIIa)\n\nagents promote thrombin generation independently FVIII\nBypassing agents:\nActivated prothrombin complex concentrates (aPCCs)\nRecombinant Factor VIIa (rFVIIa)\nActivated prothrombin complex concentrates (aPCCs)Recombinant Factor VIIa (rFVIIa)agents promote thrombin generation independently FVIIIEradication Inhibitor:\nImmunosuppressive Therapy:\nCorticosteroids (e.g., prednisone)\nCyclophosphamide\nRituximab (anti-CD20 antibody)\n\nImmune Tolerance Induction (ITI): High-dose FVIII infusions combined immunosuppressive therapy\nImmunosuppressive Therapy:\nCorticosteroids (e.g., prednisone)\nCyclophosphamide\nRituximab (anti-CD20 antibody)\nCorticosteroids (e.g., prednisone)CyclophosphamideRituximab (anti-CD20 antibody)Immune Tolerance Induction (ITI): High-dose FVIII infusions combined immunosuppressive therapyAvoid FVIII Concentrates (unless necessary control bleeding)\nRepeated exposure FVIII can boost inhibitor titer\nRepeated exposure FVIII can boost inhibitor titerLupus Anticoagulant (LA):\nDefinition: Autoantibodies bind phospholipids phospholipid-binding proteins, interfering phospholipid-dependent coagulation assays vitro\nEtiology:\nPrimary (idiopathic)\nSecondary: Associated :\nAutoimmune disorders (e.g., SLE)\nInfections\nMedications\nMalignancies\n\n\nPathophysiology:\nAntibodies bind phospholipids phospholipid-binding proteins (e.g., prothrombin, β2-glycoprotein )\nInterferes assembly coagulation complexes phospholipid surfaces vitro, leading prolonged clotting times\nvivo, LA can promote thrombosis complex mechanisms involving:\nActivation endothelial cells platelets\nDecreased production prostacyclin\nInhibition natural anticoagulant pathways\n\n\nClinical Features:\nParadoxical: Despite prolonging clotting times vitro, LA associated increased risk thrombosis (arterial venous)\nThrombotic events:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nRecurrent pregnancy loss\n\nMay asymptomatic\n\nLaboratory Findings:\nScreening Test:\nProlonged aPTT: common finding, PT may also prolonged cases\n\nMixing Study:\naPTT correct upon mixing normal plasma (demonstrates presence inhibitor)\n\nConfirmatory Tests:\nPhospholipid-Dependent Coagulation Assays:\nDilute Russell’s viper venom time (dRVVT): Prolonged correct addition phospholipid\nSilica Clotting Time (SCT): Prolonged correct addition phospholipid\n\nHexagonal Phase Phospholipid Neutralization Assay:\nDemonstrates prolonged clotting time due phospholipid-dependent inhibitor\nClotting time corrects hexagonal phase phospholipids added test system\n\n\nAnticardiolipin Antibodies Anti-β2 Glycoprotein Antibodies:\nOften present, required diagnosis LA\n\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs) may used cases, less data effectiveness patients LA\nintensity duration anticoagulation depend severity thrombosis presence risk factors\n\nAntiplatelet Therapy:\nAspirin may used patients reduce risk arterial thrombosis\n\nManagement Obstetric Complications:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\n\n\nLupus Anticoagulant (LA):Definition: Autoantibodies bind phospholipids phospholipid-binding proteins, interfering phospholipid-dependent coagulation assays vitroEtiology:\nPrimary (idiopathic)\nSecondary: Associated :\nAutoimmune disorders (e.g., SLE)\nInfections\nMedications\nMalignancies\n\nPrimary (idiopathic)Secondary: Associated :\nAutoimmune disorders (e.g., SLE)\nInfections\nMedications\nMalignancies\nAutoimmune disorders (e.g., SLE)InfectionsMedicationsMalignanciesPathophysiology:\nAntibodies bind phospholipids phospholipid-binding proteins (e.g., prothrombin, β2-glycoprotein )\nInterferes assembly coagulation complexes phospholipid surfaces vitro, leading prolonged clotting times\nvivo, LA can promote thrombosis complex mechanisms involving:\nActivation endothelial cells platelets\nDecreased production prostacyclin\nInhibition natural anticoagulant pathways\n\nAntibodies bind phospholipids phospholipid-binding proteins (e.g., prothrombin, β2-glycoprotein )Interferes assembly coagulation complexes phospholipid surfaces vitro, leading prolonged clotting timesIn vivo, LA can promote thrombosis complex mechanisms involving:\nActivation endothelial cells platelets\nDecreased production prostacyclin\nInhibition natural anticoagulant pathways\nActivation endothelial cells plateletsDecreased production prostacyclinInhibition natural anticoagulant pathwaysClinical Features:\nParadoxical: Despite prolonging clotting times vitro, LA associated increased risk thrombosis (arterial venous)\nThrombotic events:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nRecurrent pregnancy loss\n\nMay asymptomatic\nParadoxical: Despite prolonging clotting times vitro, LA associated increased risk thrombosis (arterial venous)Thrombotic events:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nRecurrent pregnancy loss\nDeep vein thrombosis (DVT)Pulmonary embolism (PE)StrokeRecurrent pregnancy lossMay asymptomaticLaboratory Findings:\nScreening Test:\nProlonged aPTT: common finding, PT may also prolonged cases\n\nMixing Study:\naPTT correct upon mixing normal plasma (demonstrates presence inhibitor)\n\nConfirmatory Tests:\nPhospholipid-Dependent Coagulation Assays:\nDilute Russell’s viper venom time (dRVVT): Prolonged correct addition phospholipid\nSilica Clotting Time (SCT): Prolonged correct addition phospholipid\n\nHexagonal Phase Phospholipid Neutralization Assay:\nDemonstrates prolonged clotting time due phospholipid-dependent inhibitor\nClotting time corrects hexagonal phase phospholipids added test system\n\n\nAnticardiolipin Antibodies Anti-β2 Glycoprotein Antibodies:\nOften present, required diagnosis LA\n\nScreening Test:\nProlonged aPTT: common finding, PT may also prolonged cases\nProlonged aPTT: common finding, PT may also prolonged casesMixing Study:\naPTT correct upon mixing normal plasma (demonstrates presence inhibitor)\naPTT correct upon mixing normal plasma (demonstrates presence inhibitor)Confirmatory Tests:\nPhospholipid-Dependent Coagulation Assays:\nDilute Russell’s viper venom time (dRVVT): Prolonged correct addition phospholipid\nSilica Clotting Time (SCT): Prolonged correct addition phospholipid\n\nHexagonal Phase Phospholipid Neutralization Assay:\nDemonstrates prolonged clotting time due phospholipid-dependent inhibitor\nClotting time corrects hexagonal phase phospholipids added test system\n\nPhospholipid-Dependent Coagulation Assays:\nDilute Russell’s viper venom time (dRVVT): Prolonged correct addition phospholipid\nSilica Clotting Time (SCT): Prolonged correct addition phospholipid\nDilute Russell’s viper venom time (dRVVT): Prolonged correct addition phospholipidSilica Clotting Time (SCT): Prolonged correct addition phospholipidHexagonal Phase Phospholipid Neutralization Assay:\nDemonstrates prolonged clotting time due phospholipid-dependent inhibitor\nClotting time corrects hexagonal phase phospholipids added test system\nDemonstrates prolonged clotting time due phospholipid-dependent inhibitorClotting time corrects hexagonal phase phospholipids added test systemAnticardiolipin Antibodies Anti-β2 Glycoprotein Antibodies:\nOften present, required diagnosis LA\nOften present, required diagnosis LATreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs) may used cases, less data effectiveness patients LA\nintensity duration anticoagulation depend severity thrombosis presence risk factors\n\nAntiplatelet Therapy:\nAspirin may used patients reduce risk arterial thrombosis\n\nManagement Obstetric Complications:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\n\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs) may used cases, less data effectiveness patients LA\nintensity duration anticoagulation depend severity thrombosis presence risk factors\nWarfarin (Coumadin)Direct oral anticoagulants (DOACs) may used cases, less data effectiveness patients LAThe intensity duration anticoagulation depend severity thrombosis presence risk factorsAntiplatelet Therapy:\nAspirin may used patients reduce risk arterial thrombosis\nAspirin may used patients reduce risk arterial thrombosisManagement Obstetric Complications:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy lossFactor V Inhibitors\nrare, happens results prolonged PT PTT\nFactor V InhibitorsVery rare, happens results prolonged PT PTT","code":""},{"path":"inhibitors.html","id":"congenital-inherited-coagulation-inhibitor-deficiencies","chapter":"Inhibitors","heading":"Congenital (Inherited) Coagulation Inhibitor Deficiencies","text":"better classified hypercoagulable statesProtein C DeficiencyProtein S DeficiencyAntithrombin Deficiency","code":""},{"path":"inhibitors.html","id":"key-laboratory-tests-for-coagulation-inhibitors","chapter":"Inhibitors","heading":"Key Laboratory Tests for Coagulation Inhibitors","text":"Prothrombin Time (PT): Measures function extrinsic common pathwaysActivated Partial Thromboplastin Time (aPTT): Measures function intrinsic common pathwaysMixing Studies: differentiate factor deficiencies factor inhibitorsFactor Assays: measure activity specific coagulation factorsFactor Inhibitor Assays: detect quantify factor inhibitorsLupus Anticoagulant Testing:\nDilute Russell’s viper venom time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\nDilute Russell’s viper venom time (dRVVT)Silica Clotting Time (SCT)Hexagonal Phase Phospholipid Neutralization AssayAnticardiolipin Anti-β2 Glycoprotein Antibody AssaysGenetic Testing: inherited thrombophilia mutations","code":""},{"path":"inhibitors.html","id":"key-terms-81","chapter":"Inhibitors","heading":"Key Terms","text":"Coagulation Inhibitor: antibody interferes function coagulation factorLupus Anticoagulant (LA): antibody binds phospholipids proteins associated cell membraneMixing Study: test differentiate factor deficiencies factor inhibitorsBethesda Assay: method quantifying factor VIII inhibitorsThrombosis: Formation blood clot inside blood vesselAntiphospholipid Syndrome (APS): autoimmune disorder characterized thrombosis, pregnancy morbidity, presence antiphospholipid antibodies (including lupus anticoagulant, anticardiolipin antibodies, anti-β2 glycoprotein antibodies)","code":""},{"path":"fibrinolytic.html","id":"fibrinolytic","chapter":"Fibrinolytic","heading":"Fibrinolytic","text":"","code":""},{"path":"fibrinolytic.html","id":"overview-of-the-fibrinolytic-system","chapter":"Fibrinolytic","heading":"Overview of the Fibrinolytic System","text":"Definition: fibrinolytic system responsible breakdown removal fibrin clots blood vessels tissue repair occurredPurpose: restore normal blood flow, prevent excessive clot formation, maintain vascular patencyKey Components:\nPlasminogen\nPlasmin\nPlasminogen Activators\nPlasmin Inhibitors\nFibrin Degradation Products (FDPs)\nPlasminogenPlasminPlasminogen ActivatorsPlasmin InhibitorsFibrin Degradation Products (FDPs)Disorders: Can caused :\nDeficiency dysfunction components fibrinolytic system\nExcessive activation inhibition fibrinolysis\nDeficiency dysfunction components fibrinolytic systemExcessive activation inhibition fibrinolysis","code":""},{"path":"fibrinolytic.html","id":"disorders-of-the-fibrinolytic-system","chapter":"Fibrinolytic","heading":"Disorders of the Fibrinolytic System","text":"Excessive Fibrinolysis (Hyperfibrinolysis)\nGeneral Features: Leads increased breakdown fibrin clots bleeding tendency\nCommon Causes:\nDisseminated Intravascular Coagulation (DIC):\ncomplex disorder characterized widespread activation coagulation fibrinolysis\nDIC can lead excessive fibrinolysis due consumption coagulation factors release plasminogen activators\n\nLiver Disease:\nImpaired synthesis α2-antiplasmin (main inhibitor plasmin) can lead unopposed plasmin activity\n\nMalignancy:\nCertain cancers (e.g., acute promyelocytic leukemia) can release tissue plasminogen activator (tPA), leading excessive fibrinolysis\n\nStreptokinase tPA Therapy:\nOveruse inappropriate use thrombolytic agents can lead excessive fibrinolysis\n\n\nClinical Features:\nBleeding: Oozing IV sites, surgical wounds, mucosal surfaces\nThrombosis: Can also occur due underlying cause (e.g., malignancy)\n\nLaboratory Findings:\nProlonged PT aPTT: Due consumption coagulation factors\nDecreased Fibrinogen Level: Due plasmin degradation\nElevated D-dimer: specific marker cross-linked fibrin degradation\nElevated FDPs: fibrin degradation products also increased\nDecreased α2-Antiplasmin Level: cases severe fibrinolysis\n\nTreatment:\nTreat Underlying Cause: Essential resolving hyperfibrinolytic state\nSupportive Care: Transfusions (platelets, fresh frozen plasma, cryoprecipitate) replace consumed coagulation factors platelets\nAntifibrinolytic Agents:\nAminocaproic acid tranexamic acid: Inhibit plasminogen activation reduce fibrinolysis\nUsed caution, can promote thrombosis underlying cause addressed\n\n\nExcessive Fibrinolysis (Hyperfibrinolysis)General Features: Leads increased breakdown fibrin clots bleeding tendencyCommon Causes:\nDisseminated Intravascular Coagulation (DIC):\ncomplex disorder characterized widespread activation coagulation fibrinolysis\nDIC can lead excessive fibrinolysis due consumption coagulation factors release plasminogen activators\n\nLiver Disease:\nImpaired synthesis α2-antiplasmin (main inhibitor plasmin) can lead unopposed plasmin activity\n\nMalignancy:\nCertain cancers (e.g., acute promyelocytic leukemia) can release tissue plasminogen activator (tPA), leading excessive fibrinolysis\n\nStreptokinase tPA Therapy:\nOveruse inappropriate use thrombolytic agents can lead excessive fibrinolysis\n\nDisseminated Intravascular Coagulation (DIC):\ncomplex disorder characterized widespread activation coagulation fibrinolysis\nDIC can lead excessive fibrinolysis due consumption coagulation factors release plasminogen activators\ncomplex disorder characterized widespread activation coagulation fibrinolysisDIC can lead excessive fibrinolysis due consumption coagulation factors release plasminogen activatorsLiver Disease:\nImpaired synthesis α2-antiplasmin (main inhibitor plasmin) can lead unopposed plasmin activity\nImpaired synthesis α2-antiplasmin (main inhibitor plasmin) can lead unopposed plasmin activityMalignancy:\nCertain cancers (e.g., acute promyelocytic leukemia) can release tissue plasminogen activator (tPA), leading excessive fibrinolysis\nCertain cancers (e.g., acute promyelocytic leukemia) can release tissue plasminogen activator (tPA), leading excessive fibrinolysisStreptokinase tPA Therapy:\nOveruse inappropriate use thrombolytic agents can lead excessive fibrinolysis\nOveruse inappropriate use thrombolytic agents can lead excessive fibrinolysisClinical Features:\nBleeding: Oozing IV sites, surgical wounds, mucosal surfaces\nThrombosis: Can also occur due underlying cause (e.g., malignancy)\nBleeding: Oozing IV sites, surgical wounds, mucosal surfacesThrombosis: Can also occur due underlying cause (e.g., malignancy)Laboratory Findings:\nProlonged PT aPTT: Due consumption coagulation factors\nDecreased Fibrinogen Level: Due plasmin degradation\nElevated D-dimer: specific marker cross-linked fibrin degradation\nElevated FDPs: fibrin degradation products also increased\nDecreased α2-Antiplasmin Level: cases severe fibrinolysis\nProlonged PT aPTT: Due consumption coagulation factorsDecreased Fibrinogen Level: Due plasmin degradationElevated D-dimer: specific marker cross-linked fibrin degradationElevated FDPs: fibrin degradation products also increasedDecreased α2-Antiplasmin Level: cases severe fibrinolysisTreatment:\nTreat Underlying Cause: Essential resolving hyperfibrinolytic state\nSupportive Care: Transfusions (platelets, fresh frozen plasma, cryoprecipitate) replace consumed coagulation factors platelets\nAntifibrinolytic Agents:\nAminocaproic acid tranexamic acid: Inhibit plasminogen activation reduce fibrinolysis\nUsed caution, can promote thrombosis underlying cause addressed\n\nTreat Underlying Cause: Essential resolving hyperfibrinolytic stateSupportive Care: Transfusions (platelets, fresh frozen plasma, cryoprecipitate) replace consumed coagulation factors plateletsAntifibrinolytic Agents:\nAminocaproic acid tranexamic acid: Inhibit plasminogen activation reduce fibrinolysis\nUsed caution, can promote thrombosis underlying cause addressed\nAminocaproic acid tranexamic acid: Inhibit plasminogen activation reduce fibrinolysisUsed caution, can promote thrombosis underlying cause addressedImpaired Fibrinolysis (Hypofibrinolysis)\nGeneral Features: Leads decreased breakdown fibrin clots increased risk thrombosis\nCauses:\nDeficiency Plasminogen: Rare inherited disorder\nDeficiency tPA uPA: Rare inherited disorder\nElevated Levels PAI-1: common; can acquired inherited\nAcquired: Associated obesity, metabolic syndrome, certain inflammatory conditions\nInherited: Rare mutations PAI-1 gene\n\nThrombophilia: Inherited acquired conditions increase risk thrombosis (e.g., factor V Leiden, prothrombin mutation)\n\nClinical Features:\nIncreased Risk Thrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nArterial thrombosis (stroke, myocardial infarction)\n\nMay asymptomatic thrombotic event occurs\n\nLaboratory Findings:\nRoutine coagulation tests (PT aPTT): Usually normal\nD-dimer: May normal slightly elevated\nPlasminogen Activity Assay: Decreased plasminogen deficiency\ntPA PAI-1 Assays: May show decreased tPA increased PAI-1 levels\nThrombophilia Testing: evaluate inherited acquired thrombotic risk factors\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Dabigatran, rivaroxaban, apixaban, edoxaban\n\nThrombolytic Therapy:\nTissue plasminogen activator (tPA) dissolve acute thrombi\n\nManagement Underlying Risk Factors:\nLifestyle modifications (e.g., weight loss, exercise)\nControl underlying medical conditions (e.g., diabetes, hyperlipidemia)\n\n\nImpaired Fibrinolysis (Hypofibrinolysis)General Features: Leads decreased breakdown fibrin clots increased risk thrombosisCauses:\nDeficiency Plasminogen: Rare inherited disorder\nDeficiency tPA uPA: Rare inherited disorder\nElevated Levels PAI-1: common; can acquired inherited\nAcquired: Associated obesity, metabolic syndrome, certain inflammatory conditions\nInherited: Rare mutations PAI-1 gene\n\nThrombophilia: Inherited acquired conditions increase risk thrombosis (e.g., factor V Leiden, prothrombin mutation)\nDeficiency Plasminogen: Rare inherited disorderDeficiency tPA uPA: Rare inherited disorderElevated Levels PAI-1: common; can acquired inherited\nAcquired: Associated obesity, metabolic syndrome, certain inflammatory conditions\nInherited: Rare mutations PAI-1 gene\nAcquired: Associated obesity, metabolic syndrome, certain inflammatory conditionsInherited: Rare mutations PAI-1 geneThrombophilia: Inherited acquired conditions increase risk thrombosis (e.g., factor V Leiden, prothrombin mutation)Clinical Features:\nIncreased Risk Thrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nArterial thrombosis (stroke, myocardial infarction)\n\nMay asymptomatic thrombotic event occurs\nIncreased Risk Thrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nArterial thrombosis (stroke, myocardial infarction)\nDeep vein thrombosis (DVT)Pulmonary embolism (PE)Arterial thrombosis (stroke, myocardial infarction)May asymptomatic thrombotic event occursLaboratory Findings:\nRoutine coagulation tests (PT aPTT): Usually normal\nD-dimer: May normal slightly elevated\nPlasminogen Activity Assay: Decreased plasminogen deficiency\ntPA PAI-1 Assays: May show decreased tPA increased PAI-1 levels\nThrombophilia Testing: evaluate inherited acquired thrombotic risk factors\nRoutine coagulation tests (PT aPTT): Usually normalD-dimer: May normal slightly elevatedPlasminogen Activity Assay: Decreased plasminogen deficiencytPA PAI-1 Assays: May show decreased tPA increased PAI-1 levelsThrombophilia Testing: evaluate inherited acquired thrombotic risk factorsTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Dabigatran, rivaroxaban, apixaban, edoxaban\n\nThrombolytic Therapy:\nTissue plasminogen activator (tPA) dissolve acute thrombi\n\nManagement Underlying Risk Factors:\nLifestyle modifications (e.g., weight loss, exercise)\nControl underlying medical conditions (e.g., diabetes, hyperlipidemia)\n\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Dabigatran, rivaroxaban, apixaban, edoxaban\nWarfarin (Coumadin)Direct oral anticoagulants (DOACs): Dabigatran, rivaroxaban, apixaban, edoxabanThrombolytic Therapy:\nTissue plasminogen activator (tPA) dissolve acute thrombi\nTissue plasminogen activator (tPA) dissolve acute thrombiManagement Underlying Risk Factors:\nLifestyle modifications (e.g., weight loss, exercise)\nControl underlying medical conditions (e.g., diabetes, hyperlipidemia)\nLifestyle modifications (e.g., weight loss, exercise)Control underlying medical conditions (e.g., diabetes, hyperlipidemia)","code":""},{"path":"fibrinolytic.html","id":"laboratory-testing-for-disorders-of-fibrinolysis","chapter":"Fibrinolytic","heading":"Laboratory Testing for Disorders of Fibrinolysis","text":"D-dimer Assay:\nMeasures level D-dimer blood\nnegative D-dimer result can used rule VTE low-risk patients\nD-dimer Assay:Measures level D-dimer bloodA negative D-dimer result can used rule VTE low-risk patientsFibrinogen Level:\nMeasures amount fibrinogen blood\nDecreased DIC severe liver disease\nFibrinogen Level:Measures amount fibrinogen bloodDecreased DIC severe liver diseasetPA PAI-1 Assays:\nMeasure levels tPA PAI-1 blood\nUsed evaluate fibrinolytic capacity\ntPA PAI-1 Assays:Measure levels tPA PAI-1 bloodUsed evaluate fibrinolytic capacityPlasminogen Activity Assay:\nMeasures activity plasminogen blood\nDecreased plasminogen deficiency\nPlasminogen Activity Assay:Measures activity plasminogen bloodDecreased plasminogen deficiencyEuglobulin Lysis Time:\nGlobal assessment fibrinolytic activity\nProlonged lysis time indicates impaired fibrinolysis\nEuglobulin Lysis Time:Global assessment fibrinolytic activityProlonged lysis time indicates impaired fibrinolysis","code":""},{"path":"fibrinolytic.html","id":"key-terms-82","chapter":"Fibrinolytic","heading":"Key Terms","text":"Fibrinolysis: breakdown fibrin clotsPlasminogen: Inactive precursor plasminPlasmin: Active enzyme degrades fibrintPA (Tissue Plasminogen Activator): Plasminogen activator released endothelial cellsuPA (Urokinase Plasminogen Activator): Plasminogen activator found various tissues body fluidsα2-Antiplasmin (α2-AP): Primary inhibitor plasminPAI-1 (Plasminogen Activator Inhibitor-1): Inhibitor tPA uPAFibrin Degradation Products (FDPs): Fragments produced plasmin degrades fibrinD-dimer: specific marker cross-linked fibrin degradationThrombosis: Formation blood clot inside blood vesselEmbolism: blood clot travels one location anotherDisseminated Intravascular Coagulation (DIC): consumptive coagulopathy widespread clotting bleedingThrombophilia: tendency develop blood clots due inherited acquired factors","code":""},{"path":"thrombophilia.html","id":"thrombophilia","chapter":"Thrombophilia","heading":"Thrombophilia","text":"","code":""},{"path":"thrombophilia.html","id":"3c683220636c6173733d226e6f2d737469636b223e","chapter":"Thrombophilia","heading":"\nAudio Overview\n","text":"","code":""},{"path":"thrombophilia.html","id":"overview-of-hypercoagulable-states-thrombophilia","chapter":"Thrombophilia","heading":"Overview of Hypercoagulable States (Thrombophilia)","text":"Definition: group inherited acquired conditions increase risk developing thrombosis (blood clots)Pathophysiology:\nAlterations balance procoagulant anticoagulant factors blood\nIncreased thrombin generation decreased fibrinolysis\nAlterations balance procoagulant anticoagulant factors bloodIncreased thrombin generation decreased fibrinolysisClassification:\nInherited (Genetic) Thrombophilias: Caused genetic mutations affecting coagulation factors natural anticoagulants\nAcquired Thrombophilias: Caused external factors alter coagulation system\nInherited (Genetic) Thrombophilias: Caused genetic mutations affecting coagulation factors natural anticoagulantsAcquired Thrombophilias: Caused external factors alter coagulation systemClinical Significance: Increased risk venous /arterial thrombosis\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nMyocardial infarction\nRecurrent pregnancy loss\nDeep vein thrombosis (DVT)Pulmonary embolism (PE)StrokeMyocardial infarctionRecurrent pregnancy loss","code":""},{"path":"thrombophilia.html","id":"virchows-triad","chapter":"Thrombophilia","heading":"Virchow’s Triad","text":"Virchow’s triad describes three broad categories factors contribute thrombosis:Hypercoagulability: Increased tendency clot due inherited acquired abnormalities coagulation systemHemodynamic Changes (Stasis Turbulence): Altered blood flow, occurs prolonged immobility atrial fibrillationEndothelial Injury: Damage blood vessel wall, exposing subendothelial collagen tissue factor","code":""},{"path":"thrombophilia.html","id":"inherited-thrombophilias-genetic","chapter":"Thrombophilia","heading":"Inherited Thrombophilias (Genetic)","text":"Factor V Leiden Mutation:\nDefinition: common inherited thrombophilia; caused point mutation F5 gene, encodes Factor V\nPathophysiology:\nMutation: single nucleotide change (G ) position 1691 F5 gene, resulting glutamine (Q) arginine (R) substitution position 506 (FV R506Q)\nResistance Activated Protein C (APC): Factor V Leiden mutation makes Factor V resistant inactivation activated protein C (APC), natural anticoagulant\nIncreased Thrombin Generation: Prolonged activity Factor V leads increased thrombin generation prothrombotic state\n\nInheritance: Autosomal dominant\nHeterozygous: One copy mutated gene (increased risk thrombosis)\nHomozygous: Two copies mutated gene (higher risk thrombosis)\n\nClinical Features:\nIncreased risk venous thrombosis (DVT, PE)\nIncreased risk recurrent pregnancy loss\nrisk thrombosis higher individuals Factor V Leiden also risk factors (e.g., oral contraceptives, pregnancy, surgery)\n\nLaboratory Findings:\nActivated Protein C (APC) Resistance Assay:\nProlonged aPTT normal plasma\naPTT prolong APC\n\nFactor V Leiden Mutation Analysis:\nConfirms presence Factor V Leiden mutation (DNA testing)\n\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\n\nDefinition: common inherited thrombophilia; caused point mutation F5 gene, encodes Factor VPathophysiology:\nMutation: single nucleotide change (G ) position 1691 F5 gene, resulting glutamine (Q) arginine (R) substitution position 506 (FV R506Q)\nResistance Activated Protein C (APC): Factor V Leiden mutation makes Factor V resistant inactivation activated protein C (APC), natural anticoagulant\nIncreased Thrombin Generation: Prolonged activity Factor V leads increased thrombin generation prothrombotic state\nMutation: single nucleotide change (G ) position 1691 F5 gene, resulting glutamine (Q) arginine (R) substitution position 506 (FV R506Q)Resistance Activated Protein C (APC): Factor V Leiden mutation makes Factor V resistant inactivation activated protein C (APC), natural anticoagulantIncreased Thrombin Generation: Prolonged activity Factor V leads increased thrombin generation prothrombotic stateInheritance: Autosomal dominant\nHeterozygous: One copy mutated gene (increased risk thrombosis)\nHomozygous: Two copies mutated gene (higher risk thrombosis)\nHeterozygous: One copy mutated gene (increased risk thrombosis)Homozygous: Two copies mutated gene (higher risk thrombosis)Clinical Features:\nIncreased risk venous thrombosis (DVT, PE)\nIncreased risk recurrent pregnancy loss\nrisk thrombosis higher individuals Factor V Leiden also risk factors (e.g., oral contraceptives, pregnancy, surgery)\nIncreased risk venous thrombosis (DVT, PE)Increased risk recurrent pregnancy lossThe risk thrombosis higher individuals Factor V Leiden also risk factors (e.g., oral contraceptives, pregnancy, surgery)Laboratory Findings:\nActivated Protein C (APC) Resistance Assay:\nProlonged aPTT normal plasma\naPTT prolong APC\n\nFactor V Leiden Mutation Analysis:\nConfirms presence Factor V Leiden mutation (DNA testing)\n\nActivated Protein C (APC) Resistance Assay:\nProlonged aPTT normal plasma\naPTT prolong APC\nProlonged aPTT normal plasmaaPTT prolong APCFactor V Leiden Mutation Analysis:\nConfirms presence Factor V Leiden mutation (DNA testing)\nConfirms presence Factor V Leiden mutation (DNA testing)Treatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\nWarfarin (Coumadin)Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatranProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\nMay considered high-risk situations (e.g., surgery, pregnancy)Prothrombin G20210A Mutation:\nDefinition: second common inherited thrombophilia; caused point mutation F2 gene, encodes prothrombin (Factor II)\nPathophysiology:\nMutation: single nucleotide change (G ) position 20210 3’-untranslated region F2 gene\nIncreased Prothrombin Levels: Leads increased prothrombin mRNA stability increased prothrombin production\nIncreased Thrombin Generation: Elevated prothrombin levels result increased thrombin generation prothrombotic state\n\nInheritance: Autosomal dominant\nHeterozygous: One copy mutated gene\nHomozygous: Two copies mutated gene\n\nClinical Features:\nIncreased risk venous thrombosis (DVT, PE)\nIncreased risk arterial thrombosis (stroke, myocardial infarction)\nIncreased risk recurrent pregnancy loss\n\nLaboratory Findings:\nProthrombin G20210A Mutation Analysis:\nConfirms presence prothrombin G20210A mutation (DNA testing)\n\nProthrombin Level: May elevated\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\n\nDefinition: second common inherited thrombophilia; caused point mutation F2 gene, encodes prothrombin (Factor II)Pathophysiology:\nMutation: single nucleotide change (G ) position 20210 3’-untranslated region F2 gene\nIncreased Prothrombin Levels: Leads increased prothrombin mRNA stability increased prothrombin production\nIncreased Thrombin Generation: Elevated prothrombin levels result increased thrombin generation prothrombotic state\nMutation: single nucleotide change (G ) position 20210 3’-untranslated region F2 geneIncreased Prothrombin Levels: Leads increased prothrombin mRNA stability increased prothrombin productionIncreased Thrombin Generation: Elevated prothrombin levels result increased thrombin generation prothrombotic stateInheritance: Autosomal dominant\nHeterozygous: One copy mutated gene\nHomozygous: Two copies mutated gene\nHeterozygous: One copy mutated geneHomozygous: Two copies mutated geneClinical Features:\nIncreased risk venous thrombosis (DVT, PE)\nIncreased risk arterial thrombosis (stroke, myocardial infarction)\nIncreased risk recurrent pregnancy loss\nIncreased risk venous thrombosis (DVT, PE)Increased risk arterial thrombosis (stroke, myocardial infarction)Increased risk recurrent pregnancy lossLaboratory Findings:\nProthrombin G20210A Mutation Analysis:\nConfirms presence prothrombin G20210A mutation (DNA testing)\n\nProthrombin Level: May elevated\nProthrombin G20210A Mutation Analysis:\nConfirms presence prothrombin G20210A mutation (DNA testing)\nConfirms presence prothrombin G20210A mutation (DNA testing)Prothrombin Level: May elevatedTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAnticoagulation:\nWarfarin (Coumadin)\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\nWarfarin (Coumadin)Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatranProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\nMay considered high-risk situations (e.g., surgery, pregnancy)Protein C Deficiency:\nDefinition: Inherited deficiency protein C, natural anticoagulant\nPathophysiology:\nProtein C: vitamin K-dependent serine protease activated thrombin-thrombomodulin complex\nActivated Protein C (APC): Degrades Factors Va VIIIa, inhibiting thrombin generation\nProtein C Deficiency: Reduces ability inactivate Factors Va VIIIa, leading prothrombotic state\n\nInheritance: Autosomal dominant autosomal recessive (severe)\nClinical Features:\nVenous thrombosis (DVT, PE)\nWarfarin-induced skin necrosis: rare serious complication can occur starting warfarin therapy patients severe protein C deficiency\n\nLaboratory Findings:\nProtein C Activity Assay: Decreased protein C activity level\nProtein C Antigen Assay: May decreased normal, depending type deficiency\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\n\nDefinition: Inherited deficiency protein C, natural anticoagulantPathophysiology:\nProtein C: vitamin K-dependent serine protease activated thrombin-thrombomodulin complex\nActivated Protein C (APC): Degrades Factors Va VIIIa, inhibiting thrombin generation\nProtein C Deficiency: Reduces ability inactivate Factors Va VIIIa, leading prothrombotic state\nProtein C: vitamin K-dependent serine protease activated thrombin-thrombomodulin complexActivated Protein C (APC): Degrades Factors Va VIIIa, inhibiting thrombin generationProtein C Deficiency: Reduces ability inactivate Factors Va VIIIa, leading prothrombotic stateInheritance: Autosomal dominant autosomal recessive (severe)Clinical Features:\nVenous thrombosis (DVT, PE)\nWarfarin-induced skin necrosis: rare serious complication can occur starting warfarin therapy patients severe protein C deficiency\nVenous thrombosis (DVT, PE)Warfarin-induced skin necrosis: rare serious complication can occur starting warfarin therapy patients severe protein C deficiencyLaboratory Findings:\nProtein C Activity Assay: Decreased protein C activity level\nProtein C Antigen Assay: May decreased normal, depending type deficiency\nProtein C Activity Assay: Decreased protein C activity levelProtein C Antigen Assay: May decreased normal, depending type deficiencyTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\nStart caution due risk warfarin-induced skin necrosisOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarinDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatranProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\nMay considered high-risk situations (e.g., surgery, pregnancy)Protein S Deficiency:\nDefinition: Inherited deficiency protein S, cofactor activated protein C (APC)\nPathophysiology:\nProtein S: vitamin K-dependent protein acts cofactor APC inactivation Factors Va VIIIa\nProtein S Deficiency: Reduces ability APC inhibit thrombin generation, leading prothrombotic state\n\nInheritance: Autosomal dominant\nClinical Features:\nVenous thrombosis (DVT, PE)\nArterial thrombosis (less common)\nRecurrent pregnancy loss\n\nLaboratory Findings:\nProtein S Activity Assay: Decreased protein S activity level\nProtein S Antigen Assays:\nTotal Protein S: Measures total amount protein S\nFree Protein S: Measures amount protein S bound C4b-binding protein\n\nInterpreting Protein S Assays:\nProtein S activity free protein S antigen levels reliable diagnosis\n\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\n\nDefinition: Inherited deficiency protein S, cofactor activated protein C (APC)Pathophysiology:\nProtein S: vitamin K-dependent protein acts cofactor APC inactivation Factors Va VIIIa\nProtein S Deficiency: Reduces ability APC inhibit thrombin generation, leading prothrombotic state\nProtein S: vitamin K-dependent protein acts cofactor APC inactivation Factors Va VIIIaProtein S Deficiency: Reduces ability APC inhibit thrombin generation, leading prothrombotic stateInheritance: Autosomal dominantClinical Features:\nVenous thrombosis (DVT, PE)\nArterial thrombosis (less common)\nRecurrent pregnancy loss\nVenous thrombosis (DVT, PE)Arterial thrombosis (less common)Recurrent pregnancy lossLaboratory Findings:\nProtein S Activity Assay: Decreased protein S activity level\nProtein S Antigen Assays:\nTotal Protein S: Measures total amount protein S\nFree Protein S: Measures amount protein S bound C4b-binding protein\n\nInterpreting Protein S Assays:\nProtein S activity free protein S antigen levels reliable diagnosis\n\nProtein S Activity Assay: Decreased protein S activity levelProtein S Antigen Assays:\nTotal Protein S: Measures total amount protein S\nFree Protein S: Measures amount protein S bound C4b-binding protein\nTotal Protein S: Measures total amount protein SFree Protein S: Measures amount protein S bound C4b-binding proteinInterpreting Protein S Assays:\nProtein S activity free protein S antigen levels reliable diagnosis\nProtein S activity free protein S antigen levels reliable diagnosisTreatment:\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAnticoagulation:\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\n\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran\nWarfarin (Coumadin)\nStart caution due risk warfarin-induced skin necrosis\nOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarin\nStart caution due risk warfarin-induced skin necrosisOverlap parenteral anticoagulant (e.g., heparin low-molecular-weight heparin) recommended starting warfarinDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatranProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\nMay considered high-risk situations (e.g., surgery, pregnancy)Antithrombin Deficiency:\nDefinition: Inherited deficiency antithrombin (), natural anticoagulant\nPathophysiology:\nAntithrombin: serine protease inhibitor (serpin) inhibits thrombin coagulation factors (Factors IXa, Xa, XIa, XIIa)\nAntithrombin Deficiency: Reduces ability inhibit thrombin coagulation factors, leading prothrombotic state\n\nInheritance: Autosomal dominant\nTypes:\nType : Quantitative deficiency (reduced production antithrombin)\nType II: Qualitative deficiency (dysfunctional antithrombin molecule)\n\nClinical Features:\nVenous thrombosis (DVT, PE)\nArterial thrombosis (less common)\nResistance heparin therapy\n\nLaboratory Findings:\nAntithrombin Activity Assay: Decreased antithrombin activity level\nAntithrombin Antigen Assay: May decreased normal, depending type deficiency\nHeparin-Induced Thrombocytopenia (HIT) Testing: May necessary rule HIT, heparin resistance common feature\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin): Higher doses warfarin may required achieve therapeutic anticoagulation\nDirect thrombin inhibitors (e.g., argatroban, bivalirudin): May used patients heparin resistance HIT\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAntithrombin Concentrates:\nUsed prophylaxis treatment acute thrombotic events, especially surgery pregnancy\n\n\nDefinition: Inherited deficiency antithrombin (), natural anticoagulantPathophysiology:\nAntithrombin: serine protease inhibitor (serpin) inhibits thrombin coagulation factors (Factors IXa, Xa, XIa, XIIa)\nAntithrombin Deficiency: Reduces ability inhibit thrombin coagulation factors, leading prothrombotic state\nAntithrombin: serine protease inhibitor (serpin) inhibits thrombin coagulation factors (Factors IXa, Xa, XIa, XIIa)Antithrombin Deficiency: Reduces ability inhibit thrombin coagulation factors, leading prothrombotic stateInheritance: Autosomal dominantTypes:\nType : Quantitative deficiency (reduced production antithrombin)\nType II: Qualitative deficiency (dysfunctional antithrombin molecule)\nType : Quantitative deficiency (reduced production antithrombin)Type II: Qualitative deficiency (dysfunctional antithrombin molecule)Clinical Features:\nVenous thrombosis (DVT, PE)\nArterial thrombosis (less common)\nResistance heparin therapy\nVenous thrombosis (DVT, PE)Arterial thrombosis (less common)Resistance heparin therapyLaboratory Findings:\nAntithrombin Activity Assay: Decreased antithrombin activity level\nAntithrombin Antigen Assay: May decreased normal, depending type deficiency\nHeparin-Induced Thrombocytopenia (HIT) Testing: May necessary rule HIT, heparin resistance common feature\nAntithrombin Activity Assay: Decreased antithrombin activity levelAntithrombin Antigen Assay: May decreased normal, depending type deficiencyHeparin-Induced Thrombocytopenia (HIT) Testing: May necessary rule HIT, heparin resistance common featureTreatment:\nAnticoagulation:\nWarfarin (Coumadin): Higher doses warfarin may required achieve therapeutic anticoagulation\nDirect thrombin inhibitors (e.g., argatroban, bivalirudin): May used patients heparin resistance HIT\n\nProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\n\nAntithrombin Concentrates:\nUsed prophylaxis treatment acute thrombotic events, especially surgery pregnancy\n\nAnticoagulation:\nWarfarin (Coumadin): Higher doses warfarin may required achieve therapeutic anticoagulation\nDirect thrombin inhibitors (e.g., argatroban, bivalirudin): May used patients heparin resistance HIT\nWarfarin (Coumadin): Higher doses warfarin may required achieve therapeutic anticoagulationDirect thrombin inhibitors (e.g., argatroban, bivalirudin): May used patients heparin resistance HITProphylactic Anticoagulation:\nMay considered high-risk situations (e.g., surgery, pregnancy)\nMay considered high-risk situations (e.g., surgery, pregnancy)Antithrombin Concentrates:\nUsed prophylaxis treatment acute thrombotic events, especially surgery pregnancy\nUsed prophylaxis treatment acute thrombotic events, especially surgery pregnancy","code":""},{"path":"thrombophilia.html","id":"acquired-thrombophilias","chapter":"Thrombophilia","heading":"Acquired Thrombophilias","text":"Antiphospholipid Syndrome (APS):\nDefinition: acquired autoimmune disorder characterized thrombosis (arterial venous) /pregnancy morbidity presence antiphospholipid antibodies (aPL)\nAntibodies:\nLupus Anticoagulant (LA)\nAnticardiolipin Antibodies (aCL)\nAnti-β2 Glycoprotein Antibodies (anti-β2GPI)\n\nPathophysiology:\nAntiphospholipid Antibodies: Bind phospholipids phospholipid-binding proteins, interfering coagulation platelet function\nThrombosis: vivo, aPL can promote thrombosis mechanisms involving:\nActivation endothelial cells platelets\nInhibition natural anticoagulant pathways (e.g., protein C pathway)\nComplement activation\n\nPregnancy Morbidity: aPL can interfere placental development function, leading pregnancy loss\n\nClinical Features:\nThrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nMyocardial infarction\n\nPregnancy Morbidity:\nRecurrent pregnancy loss (especially second third trimester)\nPreeclampsia\nPlacental insufficiency\n\nManifestations:\nThrombocytopenia\nLivedo reticularis (mottled skin rash)\nCardiac valve abnormalities\n\n\nLaboratory Findings:\nLupus Anticoagulant (LA):\nProlonged aPTT correct mixing normal plasma\nPhospholipid-dependent coagulation assays (e.g., dRVVT, SCT) prolonged correct addition phospholipid\n\nAnticardiolipin Antibodies (aCL):\nIncreased levels IgG /IgM aCL antibodies\n\nAnti-β2 Glycoprotein Antibodies (anti-β2GPI):\nIncreased levels IgG /IgM anti-β2GPI antibodies\n\nPersistent Positivity: aPL must present two occasions, least 12 weeks apart, meet laboratory criteria APS\n\nTreatment:\nAnticoagulation:\nWarfarin (Coumadin) traditional anticoagulant\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran - may used patients, caution used\n\nAntiplatelet Therapy:\nLow-dose aspirin may used patients, especially arterial thrombosis\n\nManagement Obstetric APS:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\n\n\nDefinition: acquired autoimmune disorder characterized thrombosis (arterial venous) /pregnancy morbidity presence antiphospholipid antibodies (aPL)Antibodies:\nLupus Anticoagulant (LA)\nAnticardiolipin Antibodies (aCL)\nAnti-β2 Glycoprotein Antibodies (anti-β2GPI)\nLupus Anticoagulant (LA)Anticardiolipin Antibodies (aCL)Anti-β2 Glycoprotein Antibodies (anti-β2GPI)Pathophysiology:\nAntiphospholipid Antibodies: Bind phospholipids phospholipid-binding proteins, interfering coagulation platelet function\nThrombosis: vivo, aPL can promote thrombosis mechanisms involving:\nActivation endothelial cells platelets\nInhibition natural anticoagulant pathways (e.g., protein C pathway)\nComplement activation\n\nPregnancy Morbidity: aPL can interfere placental development function, leading pregnancy loss\nAntiphospholipid Antibodies: Bind phospholipids phospholipid-binding proteins, interfering coagulation platelet functionThrombosis: vivo, aPL can promote thrombosis mechanisms involving:\nActivation endothelial cells platelets\nInhibition natural anticoagulant pathways (e.g., protein C pathway)\nComplement activation\nActivation endothelial cells plateletsInhibition natural anticoagulant pathways (e.g., protein C pathway)Complement activationPregnancy Morbidity: aPL can interfere placental development function, leading pregnancy lossClinical Features:\nThrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nMyocardial infarction\n\nPregnancy Morbidity:\nRecurrent pregnancy loss (especially second third trimester)\nPreeclampsia\nPlacental insufficiency\n\nManifestations:\nThrombocytopenia\nLivedo reticularis (mottled skin rash)\nCardiac valve abnormalities\n\nThrombosis:\nDeep vein thrombosis (DVT)\nPulmonary embolism (PE)\nStroke\nMyocardial infarction\nDeep vein thrombosis (DVT)Pulmonary embolism (PE)StrokeMyocardial infarctionPregnancy Morbidity:\nRecurrent pregnancy loss (especially second third trimester)\nPreeclampsia\nPlacental insufficiency\nRecurrent pregnancy loss (especially second third trimester)PreeclampsiaPlacental insufficiencyOther Manifestations:\nThrombocytopenia\nLivedo reticularis (mottled skin rash)\nCardiac valve abnormalities\nThrombocytopeniaLivedo reticularis (mottled skin rash)Cardiac valve abnormalitiesLaboratory Findings:\nLupus Anticoagulant (LA):\nProlonged aPTT correct mixing normal plasma\nPhospholipid-dependent coagulation assays (e.g., dRVVT, SCT) prolonged correct addition phospholipid\n\nAnticardiolipin Antibodies (aCL):\nIncreased levels IgG /IgM aCL antibodies\n\nAnti-β2 Glycoprotein Antibodies (anti-β2GPI):\nIncreased levels IgG /IgM anti-β2GPI antibodies\n\nPersistent Positivity: aPL must present two occasions, least 12 weeks apart, meet laboratory criteria APS\nLupus Anticoagulant (LA):\nProlonged aPTT correct mixing normal plasma\nPhospholipid-dependent coagulation assays (e.g., dRVVT, SCT) prolonged correct addition phospholipid\nProlonged aPTT correct mixing normal plasmaPhospholipid-dependent coagulation assays (e.g., dRVVT, SCT) prolonged correct addition phospholipidAnticardiolipin Antibodies (aCL):\nIncreased levels IgG /IgM aCL antibodies\nIncreased levels IgG /IgM aCL antibodiesAnti-β2 Glycoprotein Antibodies (anti-β2GPI):\nIncreased levels IgG /IgM anti-β2GPI antibodies\nIncreased levels IgG /IgM anti-β2GPI antibodiesPersistent Positivity: aPL must present two occasions, least 12 weeks apart, meet laboratory criteria APSTreatment:\nAnticoagulation:\nWarfarin (Coumadin) traditional anticoagulant\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran - may used patients, caution used\n\nAntiplatelet Therapy:\nLow-dose aspirin may used patients, especially arterial thrombosis\n\nManagement Obstetric APS:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\n\nAnticoagulation:\nWarfarin (Coumadin) traditional anticoagulant\nDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran - may used patients, caution used\nWarfarin (Coumadin) traditional anticoagulantDirect oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran - may used patients, caution usedAntiplatelet Therapy:\nLow-dose aspirin may used patients, especially arterial thrombosis\nLow-dose aspirin may used patients, especially arterial thrombosisManagement Obstetric APS:\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy loss\nLow-dose aspirin prophylactic heparin pregnancy prevent recurrent pregnancy lossAcquired Antithrombin Deficiency\nReduced levels can seen patients :\nNephrotic syndrome (loss antithrombin urine)\nDisseminated intravascular coagulation (DIC)\n\nReduced levels can seen patients :\nNephrotic syndrome (loss antithrombin urine)\nDisseminated intravascular coagulation (DIC)\nNephrotic syndrome (loss antithrombin urine)Disseminated intravascular coagulation (DIC)","code":""},{"path":"thrombophilia.html","id":"general-laboratory-tests-for-thrombophilia","chapter":"Thrombophilia","heading":"General Laboratory Tests for Thrombophilia","text":"Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT): Used screening tests detect abnormalities coagulation pathwaysMixing Studies: differentiate factor deficiencies factor inhibitorsD-Dimer Assay: assess thrombotic activitySpecific Assays Inherited Thrombophilias:\nFactor V Leiden Mutation Analysis\nProthrombin G20210A Mutation Analysis\nProtein C Activity Assay\nProtein S Activity Antigen Assays\nAntithrombin Activity Antigen Assays\nFactor V Leiden Mutation AnalysisProthrombin G20210A Mutation AnalysisProtein C Activity AssayProtein S Activity Antigen AssaysAntithrombin Activity Antigen AssaysAntiphospholipid Antibody Testing:\nLupus Anticoagulant (LA) testing\nAnticardiolipin (aCL) antibody assay\nAnti-β2 Glycoprotein antibody assay\nLupus Anticoagulant (LA) testingAnticardiolipin (aCL) antibody assayAnti-β2 Glycoprotein antibody assay","code":""},{"path":"thrombophilia.html","id":"key-terms-83","chapter":"Thrombophilia","heading":"Key Terms","text":"Hypercoagulable State (Thrombophilia): condition increased risk thrombosisFactor V Leiden: common genetic mutation causes resistance activated protein CProthrombin G20210A Mutation: genetic mutation leads increased prothrombin levelsProtein C: vitamin K-dependent anticoagulant proteinProtein S: cofactor activated protein CAntithrombin: serine protease inhibitor inhibits thrombin coagulation factorsAntiphospholipid Syndrome (APS): autoimmune disorder characterized thrombosis, pregnancy morbidity, antiphospholipid antibodiesLupus Anticoagulant (LA): antibody interferes phospholipid-dependent coagulation assaysThrombosis: Formation blood clot inside blood vesselEmbolism: blood clot travels one location another","code":""},{"path":"dic.html","id":"dic","chapter":"DIC","heading":"DIC","text":"","code":""},{"path":"dic.html","id":"overview-of-disseminated-intravascular-coagulation-dic","chapter":"DIC","heading":"Overview of Disseminated Intravascular Coagulation (DIC)","text":"Definition: complex life-threatening acquired syndrome characterized widespread activation coagulation fibrinolysis, leading consumption coagulation factors platelets, ultimately resulting thrombosis bleedingKey Features:\nSystemic Activation Coagulation: Uncontrolled activation coagulation cascade, leading formation microthrombi throughout vasculature\nConsumption Coagulation Factors Platelets: Widespread clotting consumes coagulation factors platelets, leading deficiencies\nActivation Fibrinolysis: Activation fibrinolytic system break microthrombi, resulting generation fibrin degradation products (FDPs)\nBleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads bleeding thrombotic complications\nSystemic Activation Coagulation: Uncontrolled activation coagulation cascade, leading formation microthrombi throughout vasculatureConsumption Coagulation Factors Platelets: Widespread clotting consumes coagulation factors platelets, leading deficienciesActivation Fibrinolysis: Activation fibrinolytic system break microthrombi, resulting generation fibrin degradation products (FDPs)Bleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads bleeding thrombotic complicationsAlways Secondary: DIC never primary disease; always secondary underlying disorderHigh Mortality Rate: DIC associated significant morbidity mortality","code":""},{"path":"dic.html","id":"etiology-and-triggering-events","chapter":"DIC","heading":"Etiology and Triggering Events","text":"Sepsis:\nSevere bacterial, fungal, viral infections\nGram-negative bacteria common cause DIC\nSepsis:Severe bacterial, fungal, viral infectionsGram-negative bacteria common cause DICTrauma:\nSevere tissue injury, burns, crush injuries\nRelease tissue factor circulation\nTrauma:Severe tissue injury, burns, crush injuriesRelease tissue factor circulationObstetric Complications:\nAbruptio placentae (premature separation placenta)\nAmniotic fluid embolism\nPreeclampsia eclampsia\nSeptic abortion\nObstetric Complications:Abruptio placentae (premature separation placenta)Amniotic fluid embolismPreeclampsia eclampsiaSeptic abortionMalignancy:\nAcute promyelocytic leukemia (APL): specific subtype AML associated high risk DIC due release procoagulant substances leukemic cells\nSolid tumors (e.g., lung, breast, ovarian, prostate): Can release tissue factor procoagulant substances\nMalignancy:Acute promyelocytic leukemia (APL): specific subtype AML associated high risk DIC due release procoagulant substances leukemic cellsSolid tumors (e.g., lung, breast, ovarian, prostate): Can release tissue factor procoagulant substancesOther Causes:\nSevere allergic toxic reactions\nTransfusion reactions\nSnake bites\nPancreatitis\nLiver disease\nAortic aneurysm\nCauses:Severe allergic toxic reactionsTransfusion reactionsSnake bitesPancreatitisLiver diseaseAortic aneurysm","code":""},{"path":"dic.html","id":"pathophysiology-7","chapter":"DIC","heading":"Pathophysiology","text":"pathophysiology DIC involves complex interplay coagulation fibrinolytic systems:Triggering Event: underlying disorder releases procoagulant substances circulation (e.g., tissue factor, inflammatory cytokines)Triggering Event: underlying disorder releases procoagulant substances circulation (e.g., tissue factor, inflammatory cytokines)Activation Coagulation: extrinsic pathway coagulation activated release tissue factor, leading :\nFormation Thrombin: Activation coagulation cascade leads increased thrombin generation\nFibrin Formation: Thrombin converts fibrinogen fibrin, resulting formation microthrombi throughout vasculature\nActivation Coagulation: extrinsic pathway coagulation activated release tissue factor, leading :Formation Thrombin: Activation coagulation cascade leads increased thrombin generationFibrin Formation: Thrombin converts fibrinogen fibrin, resulting formation microthrombi throughout vasculatureConsumption Coagulation Factors Platelets:\nWidespread clotting consumes coagulation factors (Factors V, VIII, fibrinogen) platelets, leading deficiencies\nConsumption Coagulation Factors Platelets:Widespread clotting consumes coagulation factors (Factors V, VIII, fibrinogen) platelets, leading deficienciesActivation Fibrinolysis:\nThrombin also activates fibrinolytic system releasing tissue plasminogen activator (tPA) endothelial cells\nPlasminogen converted plasmin, degrades fibrin clots fibrin degradation products (FDPs), including D-dimer\nActivation Fibrinolysis:Thrombin also activates fibrinolytic system releasing tissue plasminogen activator (tPA) endothelial cellsPlasminogen converted plasmin, degrades fibrin clots fibrin degradation products (FDPs), including D-dimerBleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads :\nMicrothrombi: Can cause organ ischemia damage, leading kidney failure, respiratory distress, neurological dysfunction\nBleeding: Due deficiency coagulation factors platelets\nBleeding Thrombosis: consumption coagulation factors platelets, combined excessive fibrinolysis, leads :Microthrombi: Can cause organ ischemia damage, leading kidney failure, respiratory distress, neurological dysfunctionBleeding: Due deficiency coagulation factors platelets","code":""},{"path":"dic.html","id":"clinical-features-4","chapter":"DIC","heading":"Clinical Features","text":"Bleeding:\nOozing IV sites, surgical wounds, mucous membranes\nPetechiae (small, pinpoint hemorrhages)\nPurpura (larger areas bleeding skin)\nGastrointestinal bleeding\nPulmonary hemorrhage\nIntracranial hemorrhage\nOozing IV sites, surgical wounds, mucous membranesPetechiae (small, pinpoint hemorrhages)Purpura (larger areas bleeding skin)Gastrointestinal bleedingPulmonary hemorrhageIntracranial hemorrhageThrombosis:\nMicrothrombi can cause organ damage dysfunction\nKidney failure (oliguria, anuria)\nAcute respiratory distress syndrome (ARDS)\nNeurological dysfunction (altered mental status, seizures, coma)\nSkin necrosis\nLimb ischemia\nMicrothrombi can cause organ damage dysfunctionKidney failure (oliguria, anuria)Acute respiratory distress syndrome (ARDS)Neurological dysfunction (altered mental status, seizures, coma)Skin necrosisLimb ischemiaOther Symptoms:\nHypotension (low blood pressure)\nTachycardia (increased heart rate)\nFever\nHypotension (low blood pressure)Tachycardia (increased heart rate)Fever","code":""},{"path":"dic.html","id":"laboratory-findings-11","chapter":"DIC","heading":"Laboratory Findings","text":"Coagulation Studies:\nProthrombin Time (PT): Prolonged\nActivated Partial Thromboplastin Time (aPTT): Prolonged\nThrombin Time (TT): Prolonged\nReptilase Time: Prolonged (may normal cases)\nMixing Studies: PT aPTT typically correct mixing normal plasma\nCoagulation Studies:Prothrombin Time (PT): ProlongedActivated Partial Thromboplastin Time (aPTT): ProlongedThrombin Time (TT): ProlongedReptilase Time: Prolonged (may normal cases)Mixing Studies: PT aPTT typically correct mixing normal plasmaFibrinogen Level:\nDecreased (often <100 mg/dL)\nReflects consumption fibrinogen\nFibrinogen Level:Decreased (often <100 mg/dL)Reflects consumption fibrinogenPlatelet Count:\nDecreased (thrombocytopenia) - often <100 x 10^9/L\nPlatelet count decreases patient’s condition worsen\nPlatelet Count:Decreased (thrombocytopenia) - often <100 x 10^9/LPlatelet count decreases patient’s condition worsenFibrin Degradation Products (FDPs):\nElevated\nLatex agglutination assay positive\nFibrin Degradation Products (FDPs):ElevatedLatex agglutination assay positiveD-dimer:\nMarkedly Elevated\nD-dimer cross-linked fibrin degradation product specific marker DIC FDPs\nD-dimer:Markedly ElevatedD-dimer cross-linked fibrin degradation product specific marker DIC FDPsPeripheral Blood Smear:\nSchistocytes (fragmented RBCs): Indicate microangiopathic hemolytic anemia (MAHA)\nThrombocytopenia\nPeripheral Blood Smear:Schistocytes (fragmented RBCs): Indicate microangiopathic hemolytic anemia (MAHA)ThrombocytopeniaOther Tests:\nAntithrombin Level: Decreased\nProtein C S Levels: Decreased\nFactor Assays: Decreased levels Factors V VIII\nReptilase Time: Reptilase time measures fibrin formation independent thrombin used evaluate fibrinogen function\nProlonged setting dysfibrinogenemia hypofibrinogenemia\n\nTests:Antithrombin Level: DecreasedProtein C S Levels: DecreasedFactor Assays: Decreased levels Factors V VIIIReptilase Time: Reptilase time measures fibrin formation independent thrombin used evaluate fibrinogen function\nProlonged setting dysfibrinogenemia hypofibrinogenemia\nProlonged setting dysfibrinogenemia hypofibrinogenemia","code":""},{"path":"dic.html","id":"diagnostic-scoring-systems","chapter":"DIC","heading":"Diagnostic Scoring Systems","text":"Several scoring systems developed aid diagnosis DICThe International Society Thrombosis Haemostasis (ISTH) scoring system one widely usedScoring systems consider:\nPlatelet count\nProthrombin time (PT)\nFibrinogen level\nD-dimer level\nPlatelet countProthrombin time (PT)Fibrinogen levelD-dimer level","code":""},{"path":"dic.html","id":"treatment-3","chapter":"DIC","heading":"Treatment","text":"Treat Underlying Cause: important step managing DIC.\nAntibiotics sepsis\nSurgical evacuation retained products conception obstetric DIC\nChemotherapy acute promyelocytic leukemia (APL)\nTreat Underlying Cause: important step managing DIC.Antibiotics sepsisSurgical evacuation retained products conception obstetric DICChemotherapy acute promyelocytic leukemia (APL)Supportive Care:\nTransfusions:\nPlatelet transfusions maintain platelet count > 20-30 x 10^9/L (higher active bleeding)\nPacked red blood cells (PRBCs) maintain adequate oxygen delivery\nFresh Frozen Plasma (FFP): provide coagulation factors\nCryoprecipitate: increase fibrinogen levels (target fibrinogen > 100 mg/dL)\n\nSupportive Care:Transfusions:\nPlatelet transfusions maintain platelet count > 20-30 x 10^9/L (higher active bleeding)\nPacked red blood cells (PRBCs) maintain adequate oxygen delivery\nFresh Frozen Plasma (FFP): provide coagulation factors\nCryoprecipitate: increase fibrinogen levels (target fibrinogen > 100 mg/dL)\nPlatelet transfusions maintain platelet count > 20-30 x 10^9/L (higher active bleeding)Packed red blood cells (PRBCs) maintain adequate oxygen deliveryFresh Frozen Plasma (FFP): provide coagulation factorsCryoprecipitate: increase fibrinogen levels (target fibrinogen > 100 mg/dL)Anticoagulation:\nHeparin: May considered specific situations (e.g., APL-associated DIC thrombosis-dominant DIC) inhibit thrombin generation\nUse controversial requires careful monitoring due risk worsening bleeding\nLow-molecular-weight heparin (LMWH) may preferred unfractionated heparin\n\nAnticoagulation:Heparin: May considered specific situations (e.g., APL-associated DIC thrombosis-dominant DIC) inhibit thrombin generation\nUse controversial requires careful monitoring due risk worsening bleeding\nLow-molecular-weight heparin (LMWH) may preferred unfractionated heparin\nUse controversial requires careful monitoring due risk worsening bleedingLow-molecular-weight heparin (LMWH) may preferred unfractionated heparinAntifibrinolytic Therapy:\nControversial generally recommended\nMay considered rare situations life-threatening bleeding evidence primary fibrinolysis (low fibrinogen elevated D-dimer)\nAntifibrinolytic Therapy:Controversial generally recommendedMay considered rare situations life-threatening bleeding evidence primary fibrinolysis (low fibrinogen elevated D-dimer)","code":""},{"path":"dic.html","id":"prognosis-2","chapter":"DIC","heading":"Prognosis","text":"Poor Prognosis: DIC associated high mortality rateFactors Influencing Prognosis:\nSeverity underlying condition\nRapid effective treatment underlying cause\nPrompt recognition management DIC complications\nSeverity underlying conditionRapid effective treatment underlying causePrompt recognition management DIC complications","code":""},{"path":"dic.html","id":"key-laboratory-tests-for-dic","chapter":"DIC","heading":"Key Laboratory Tests for DIC","text":"PT, aPTT, TT: ProlongedPlatelet Count: DecreasedFibrinogen Level: DecreasedD-dimer: Markedly ElevatedPeripheral Blood Smear: Schistocytes","code":""},{"path":"laboratory.html","id":"laboratory","chapter":"Laboratory","heading":"Laboratory","text":"","code":""},{"path":"laboratory.html","id":"overview-of-the-testing-process","chapter":"Laboratory","heading":"Overview of the Testing Process","text":"clinical laboratories, testing process generally divided three phases:Pre-Analytical Phase: Includes steps occur actual testing sample. errors happen, super important know steps!Analytical Phase: Includes actual performance tests quality control proceduresPost-Analytical Phase: Includes steps occur tests performed, result review, interpretation, reporting","code":""},{"path":"laboratory.html","id":"pre-analytical-phase","chapter":"Laboratory","heading":"Pre-Analytical Phase","text":"phase encompasses steps occur sample analyzed, test ordering sample collection transport. Errors pre-analytical phase common source errors laboratory can significantly impact accuracy reliability coagulation resultsTest Ordering:\nAppropriate Test Selection: Ensure correct coagulation tests ordered based patient’s clinical presentation physician’s request\nCommon Coagulation Tests:\nProthrombin Time (PT) International Normalized Ratio (INR)\nActivated Partial Thromboplastin Time (aPTT)\nFibrinogen Level\nD-dimer\nMixing Studies\nFactor Assays (e.g., Factor VIII, Factor IX)\nLupus Anticoagulant Testing\n\n\nReview Patient History: Check patient’s medication list (especially anticoagulants) history bleeding thrombotic disorders\nFollow Laboratory Guidelines: Adhere laboratory’s test ordering policies procedures\nAppropriate Test Selection: Ensure correct coagulation tests ordered based patient’s clinical presentation physician’s request\nCommon Coagulation Tests:\nProthrombin Time (PT) International Normalized Ratio (INR)\nActivated Partial Thromboplastin Time (aPTT)\nFibrinogen Level\nD-dimer\nMixing Studies\nFactor Assays (e.g., Factor VIII, Factor IX)\nLupus Anticoagulant Testing\n\nCommon Coagulation Tests:\nProthrombin Time (PT) International Normalized Ratio (INR)\nActivated Partial Thromboplastin Time (aPTT)\nFibrinogen Level\nD-dimer\nMixing Studies\nFactor Assays (e.g., Factor VIII, Factor IX)\nLupus Anticoagulant Testing\nProthrombin Time (PT) International Normalized Ratio (INR)Activated Partial Thromboplastin Time (aPTT)Fibrinogen LevelD-dimerMixing StudiesFactor Assays (e.g., Factor VIII, Factor IX)Lupus Anticoagulant TestingReview Patient History: Check patient’s medication list (especially anticoagulants) history bleeding thrombotic disordersFollow Laboratory Guidelines: Adhere laboratory’s test ordering policies proceduresPatient Preparation:\nFasting: coagulation tests may require patient fast certain period time\nMedications: Certain medications (e.g., warfarin, heparin, direct oral anticoagulants) can affect coagulation test results noted test requisition\nPatient Identification: Properly identify patient using two unique identifiers prevent errors\nFasting: coagulation tests may require patient fast certain period timeMedications: Certain medications (e.g., warfarin, heparin, direct oral anticoagulants) can affect coagulation test results noted test requisitionPatient Identification: Properly identify patient using two unique identifiers prevent errorsSample Collection:\nCollection Tubes:\nUse correct type blood collection tube:\nSodium Citrate (light blue top): anticoagulant choice coagulation tests\nEDTA (purple top): appropriate coagulation testing\n\nCheck Expiration Date: Ensure collection tube expired\n\nBlood--Anticoagulant Ratio:\ncorrect blood--anticoagulant ratio critical accurate coagulation testing:\nTypically 9:1 (9 parts blood 1 part anticoagulant)\n\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\nAdjust Blood--Anticoagulant Ratio Patients High Hematocrit: patients hematocrits >55%, amount anticoagulant reduced maintain correct ratio\nUse Vacutainer fill line collection tube\n\nOrder Draw:\nFollow recommended order draw prevent contamination coagulation samples:\nBlood culture tubes (applicable)\nCoagulation tube (light blue top)\nSerum tubes (red top)\nHeparin tubes (green top)\nEDTA tubes (purple top)\nFluoride tubes (gray top)\n\n\nVenipuncture Technique:\nPerform clean venipuncture avoid tissue thromboplastin contamination\nAvoid prolonged tourniquet time, can activate coagulation factors\nUse 21-gauge needle larger minimize hemolysis\n\nMixing:\nGently invert collection tube 5-10 times immediately collection mix blood anticoagulant\nAvoid vigorous shaking, can cause hemolysis\n\nLabeling:\nProperly label collection tube patient’s name, date time collection, required information\nEnsure information tube matches information test requisition\n\nCollection Tubes:\nUse correct type blood collection tube:\nSodium Citrate (light blue top): anticoagulant choice coagulation tests\nEDTA (purple top): appropriate coagulation testing\n\nCheck Expiration Date: Ensure collection tube expired\nUse correct type blood collection tube:\nSodium Citrate (light blue top): anticoagulant choice coagulation tests\nEDTA (purple top): appropriate coagulation testing\nSodium Citrate (light blue top): anticoagulant choice coagulation testsEDTA (purple top): appropriate coagulation testingCheck Expiration Date: Ensure collection tube expiredBlood--Anticoagulant Ratio:\ncorrect blood--anticoagulant ratio critical accurate coagulation testing:\nTypically 9:1 (9 parts blood 1 part anticoagulant)\n\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\nAdjust Blood--Anticoagulant Ratio Patients High Hematocrit: patients hematocrits >55%, amount anticoagulant reduced maintain correct ratio\nUse Vacutainer fill line collection tube\ncorrect blood--anticoagulant ratio critical accurate coagulation testing:\nTypically 9:1 (9 parts blood 1 part anticoagulant)\nTypically 9:1 (9 parts blood 1 part anticoagulant)Underfilling tube can lead falsely prolonged clotting times due excess anticoagulantOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulantAdjust Blood--Anticoagulant Ratio Patients High Hematocrit: patients hematocrits >55%, amount anticoagulant reduced maintain correct ratioUse Vacutainer fill line collection tubeOrder Draw:\nFollow recommended order draw prevent contamination coagulation samples:\nBlood culture tubes (applicable)\nCoagulation tube (light blue top)\nSerum tubes (red top)\nHeparin tubes (green top)\nEDTA tubes (purple top)\nFluoride tubes (gray top)\n\nFollow recommended order draw prevent contamination coagulation samples:\nBlood culture tubes (applicable)\nCoagulation tube (light blue top)\nSerum tubes (red top)\nHeparin tubes (green top)\nEDTA tubes (purple top)\nFluoride tubes (gray top)\nBlood culture tubes (applicable)Coagulation tube (light blue top)Serum tubes (red top)Heparin tubes (green top)EDTA tubes (purple top)Fluoride tubes (gray top)Venipuncture Technique:\nPerform clean venipuncture avoid tissue thromboplastin contamination\nAvoid prolonged tourniquet time, can activate coagulation factors\nUse 21-gauge needle larger minimize hemolysis\nPerform clean venipuncture avoid tissue thromboplastin contaminationAvoid prolonged tourniquet time, can activate coagulation factorsUse 21-gauge needle larger minimize hemolysisMixing:\nGently invert collection tube 5-10 times immediately collection mix blood anticoagulant\nAvoid vigorous shaking, can cause hemolysis\nGently invert collection tube 5-10 times immediately collection mix blood anticoagulantAvoid vigorous shaking, can cause hemolysisLabeling:\nProperly label collection tube patient’s name, date time collection, required information\nEnsure information tube matches information test requisition\nProperly label collection tube patient’s name, date time collection, required informationEnsure information tube matches information test requisitionSample Transport Storage:\nTransport:\nTransport sample laboratory promptly (within 1 hour) minimize pre-analytical changes\nTransport room temperature (18-24°C)\nAvoid extreme temperatures (e.g., direct sunlight, freezing)\n\nStorage:\ntesting performed immediately, store sample according laboratory’s guidelines\nPlatelet Poor Plasma (PPP) may need prepared frozen assays:\ncoagulation tests, plasma tested within 4 hours collection frozen testing later. Specifics vary lab lab.\nCentrifuge sample 1500-2000 g 15 minutes obtain platelet-poor plasma (platelet count < 10 x 10^9/L)\nAliquot plasma labeled plastic tubes\nFreeze plasma -20°C -70°C needed test later date\nThaw samples room temperature testing\n\n\n\nTransport:\nTransport sample laboratory promptly (within 1 hour) minimize pre-analytical changes\nTransport room temperature (18-24°C)\nAvoid extreme temperatures (e.g., direct sunlight, freezing)\nTransport sample laboratory promptly (within 1 hour) minimize pre-analytical changesTransport room temperature (18-24°C)Avoid extreme temperatures (e.g., direct sunlight, freezing)Storage:\ntesting performed immediately, store sample according laboratory’s guidelines\nPlatelet Poor Plasma (PPP) may need prepared frozen assays:\ncoagulation tests, plasma tested within 4 hours collection frozen testing later. Specifics vary lab lab.\nCentrifuge sample 1500-2000 g 15 minutes obtain platelet-poor plasma (platelet count < 10 x 10^9/L)\nAliquot plasma labeled plastic tubes\nFreeze plasma -20°C -70°C needed test later date\nThaw samples room temperature testing\n\n\ntesting performed immediately, store sample according laboratory’s guidelinesPlatelet Poor Plasma (PPP) may need prepared frozen assays:\ncoagulation tests, plasma tested within 4 hours collection frozen testing later. Specifics vary lab lab.\nCentrifuge sample 1500-2000 g 15 minutes obtain platelet-poor plasma (platelet count < 10 x 10^9/L)\nAliquot plasma labeled plastic tubes\nFreeze plasma -20°C -70°C needed test later date\nThaw samples room temperature testing\n\ncoagulation tests, plasma tested within 4 hours collection frozen testing later. Specifics vary lab lab.Centrifuge sample 1500-2000 g 15 minutes obtain platelet-poor plasma (platelet count < 10 x 10^9/L)Aliquot plasma labeled plastic tubesFreeze plasma -20°C -70°C needed test later date\nThaw samples room temperature testing\nThaw samples room temperature testing","code":""},{"path":"laboratory.html","id":"analytical-phase","chapter":"Laboratory","heading":"Analytical Phase","text":"phase encompasses actual testing sample quality control proceduresInstrumentation:\nUse Properly Calibrated Instruments: Ensure coagulation analyzers properly calibrated maintained according manufacturer’s instructions\nUse Correct Reagents: Verify reagents appropriate test performed expired\nUse Properly Calibrated Instruments: Ensure coagulation analyzers properly calibrated maintained according manufacturer’s instructionsUse Correct Reagents: Verify reagents appropriate test performed expiredTest Performance:\nFollow Standard Operating Procedures: Adhere standardized operating procedures (SOPs) performing coagulation tests\nUse Appropriate Controls: Run control materials regular intervals (e.g., daily, batch samples) assess accuracy precision tests\nMonitor Results: Review control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)\nTake Corrective Action: control results outside acceptable range, take corrective action testing patient samples\nFollow Standard Operating Procedures: Adhere standardized operating procedures (SOPs) performing coagulation testsUse Appropriate Controls: Run control materials regular intervals (e.g., daily, batch samples) assess accuracy precision testsMonitor Results: Review control results evaluate using statistical methods (e.g., Levey-Jennings charts, Westgard rules)Take Corrective Action: control results outside acceptable range, take corrective action testing patient samplesSample Handling:\nEnsure samples properly identified stored\nThaw frozen samples completely testing mix gently\nCheck hemolysis, lipemia, interfering substances\nnecessary, perform corrective actions minimize interference (e.g., saline replacement lipemia)\nEnsure samples properly identified storedThaw frozen samples completely testing mix gentlyCheck hemolysis, lipemia, interfering substancesIf necessary, perform corrective actions minimize interference (e.g., saline replacement lipemia)Common Test Specific Procedures\n* Prothrombin Time (PT):\n* Measures function extrinsic common pathways\n* Add thromboplastin reagent plasma measure time clot formation\n* Report results seconds International Normalized Ratio (INR) standardize PT results\n* INR = (Patient PT / Mean Normal PT)ISI (ISI = International Sensitivity Index)\n* INR used monitor warfarin therapy\n* Activated Partial Thromboplastin Time (aPTT):\n* Measures function intrinsic common pathways\n* Add contact activator (e.g., silica, kaolin), phospholipid, calcium chloride plasma measure time clot formation\n* Used monitor heparin therapy\n* Fibrinogen Assay:\n* Measures concentration fibrinogen plasma\n* Clauss method: functional assay measures rate clot formation addition thrombin\n* D-Dimer Assay:\n* Measures level D-dimer plasma\n* Uses latex agglutination immunoturbidimetric methods\n* Elevated conditions increased fibrinolysis (e.g., DVT, PE, DIC)Monitoring Troubleshooting:\nMonitor Instrument Performance: Regularly monitor instrument’s performance detect malfunctions errors\nTroubleshoot Problems: Follow established procedures troubleshooting instrument errors unexpected results\nConsult Supervisor Pathologist: Seek guidance supervisor pathologist cause problem determined\nMonitor Instrument Performance: Regularly monitor instrument’s performance detect malfunctions errorsTroubleshoot Problems: Follow established procedures troubleshooting instrument errors unexpected resultsConsult Supervisor Pathologist: Seek guidance supervisor pathologist cause problem determined","code":""},{"path":"laboratory.html","id":"post-analytical-phase","chapter":"Laboratory","heading":"Post-Analytical Phase","text":"phase encompasses steps occur tests performed, including result review, interpretation, reportingResult Review:\nReview test results quality control data\nCheck flags, alarms, abnormal results\nVerify results consistent patient’s clinical information previous laboratory results\nReview test results quality control dataCheck flags, alarms, abnormal resultsVerify results consistent patient’s clinical information previous laboratory resultsResult Interpretation:\nInterpret results context patient’s clinical history, medication list, laboratory findings\nConsider potential causes abnormal results\nRecognize patterns results suggestive specific coagulation disorders\nInterpret results context patient’s clinical history, medication list, laboratory findingsConsider potential causes abnormal resultsRecognize patterns results suggestive specific coagulation disordersCritical Value Notification:\nImmediately notify physician authorized personnel critical values (e.g., markedly prolonged PT aPTT, low fibrinogen level)\nFollow laboratory’s policy critical value reporting\nImmediately notify physician authorized personnel critical values (e.g., markedly prolonged PT aPTT, low fibrinogen level)Follow laboratory’s policy critical value reportingReporting:\nReport test results clear, concise, accurate manner\nInclude reference range parameter\nNote interfering substances corrective actions taken\nAdd interpretive comments report guide clinician’s interpretation results\nReport test results clear, concise, accurate mannerInclude reference range parameterNote interfering substances corrective actions takenAdd interpretive comments report guide clinician’s interpretation resultsDocumentation:\nMaintain accurate complete records test results, quality control data, corrective actions taken\nFollow regulatory accreditation requirements documentation\nMaintain accurate complete records test results, quality control data, corrective actions takenFollow regulatory accreditation requirements documentation","code":""},{"path":"laboratory.html","id":"key-terms-84","chapter":"Laboratory","heading":"Key Terms","text":"PT (Prothrombin Time): Test extrinsic common pathwaysaPTT (Activated Partial Thromboplastin Time): Test intrinsic common pathwaysINR (International Normalized Ratio): standardized ratio PT used monitor warfarin therapyFibrinogen: protein converted fibrin, main component blood clotD-dimer: fibrin degradation product elevated thrombotic conditionsPre-Analytical Phase: steps occur sample analyzedAnalytical Phase: actual performance testsPost-Analytical Phase: steps occur tests performedQuality Control: Procedures used monitor accuracy precision laboratory testingCritical Value: test result represents life-threatening condition requires immediate notification","code":""},{"path":"ptinr.html","id":"ptinr","chapter":"PT/INR","heading":"PT/INR","text":"","code":""},{"path":"ptinr.html","id":"overview-of-the-ptinr-test","chapter":"PT/INR","heading":"Overview of the PT/INR Test","text":"Prothrombin Time (PT):\nDefinition: coagulation test measures time (seconds) takes plasma clot addition thromboplastin calcium\nPurpose:\nEvaluate extrinsic common pathways coagulation\nMonitor oral anticoagulant therapy warfarin (Coumadin)\nAssess liver function\nEvaluate coagulation factor deficiencies\n\nPrinciple:\nThromboplastin (Tissue Factor): reagent contains tissue factor, phospholipids, calcium\nAddition Thromboplastin: Activates extrinsic pathway coagulation, leading thrombin formation fibrin clot formation\nClot Detection: time clot formation measured, either manually using automated coagulation analyzer\n\nDefinition: coagulation test measures time (seconds) takes plasma clot addition thromboplastin calciumPurpose:\nEvaluate extrinsic common pathways coagulation\nMonitor oral anticoagulant therapy warfarin (Coumadin)\nAssess liver function\nEvaluate coagulation factor deficiencies\nEvaluate extrinsic common pathways coagulationMonitor oral anticoagulant therapy warfarin (Coumadin)Assess liver functionEvaluate coagulation factor deficienciesPrinciple:\nThromboplastin (Tissue Factor): reagent contains tissue factor, phospholipids, calcium\nAddition Thromboplastin: Activates extrinsic pathway coagulation, leading thrombin formation fibrin clot formation\nClot Detection: time clot formation measured, either manually using automated coagulation analyzer\nThromboplastin (Tissue Factor): reagent contains tissue factor, phospholipids, calciumAddition Thromboplastin: Activates extrinsic pathway coagulation, leading thrombin formation fibrin clot formationClot Detection: time clot formation measured, either manually using automated coagulation analyzerInternational Normalized Ratio (INR):\nDefinition: standardized ratio calculated patient’s PT result used monitor warfarin therapy\nPurpose:\nreduce inter-laboratory variability PT results due differences thromboplastin reagents\nprovide consistent reliable measure degree anticoagulation\n\nCalculation:\nINR = (Patient PT / Mean Normal PT)^ISI\nPatient PT: patient’s prothrombin time seconds\nMean Normal PT (MNPT): average PT value group healthy individuals tested laboratory using thromboplastin reagent\nInternational Sensitivity Index (ISI): value assigned thromboplastin reagent manufacturer, reflecting sensitivity vitamin K-dependent coagulation factors\n\nDefinition: standardized ratio calculated patient’s PT result used monitor warfarin therapyPurpose:\nreduce inter-laboratory variability PT results due differences thromboplastin reagents\nprovide consistent reliable measure degree anticoagulation\nreduce inter-laboratory variability PT results due differences thromboplastin reagentsTo provide consistent reliable measure degree anticoagulationCalculation:\nINR = (Patient PT / Mean Normal PT)^ISI\nPatient PT: patient’s prothrombin time seconds\nMean Normal PT (MNPT): average PT value group healthy individuals tested laboratory using thromboplastin reagent\nInternational Sensitivity Index (ISI): value assigned thromboplastin reagent manufacturer, reflecting sensitivity vitamin K-dependent coagulation factors\nINR = (Patient PT / Mean Normal PT)^ISIPatient PT: patient’s prothrombin time secondsMean Normal PT (MNPT): average PT value group healthy individuals tested laboratory using thromboplastin reagentInternational Sensitivity Index (ISI): value assigned thromboplastin reagent manufacturer, reflecting sensitivity vitamin K-dependent coagulation factors","code":""},{"path":"ptinr.html","id":"components-of-the-ptinr-test","chapter":"PT/INR","heading":"Components of the PT/INR Test","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate results:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged PT/INR results\nOverfilling tube can lead falsely shortened PT/INR results\n\nSpecimen Collection:Collection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate results:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged PT/INR results\nOverfilling tube can lead falsely shortened PT/INR results\n9:1 ratio blood anticoagulantUnderfilling tube can lead falsely prolonged PT/INR resultsOverfilling tube can lead falsely shortened PT/INR resultsReagents:\nThromboplastin: Contains tissue factor, phospholipids, calcium ions, initiate extrinsic pathway coagulation\nCalcium Chloride: Provides calcium ions, essential activity coagulation factors\nStandard: Used create clot based known sample.\nReagents:Thromboplastin: Contains tissue factor, phospholipids, calcium ions, initiate extrinsic pathway coagulationCalcium Chloride: Provides calcium ions, essential activity coagulation factorsStandard: Used create clot based known sample.Instrumentation:\nAutomated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\n\nInstrumentation:Automated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\nOptical Method: Measures changes light transmission clot formsMechanical Method: Detects movement probe wire clot forms","code":""},{"path":"ptinr.html","id":"procedure-for-performing-the-ptinr-test","chapter":"PT/INR","heading":"Procedure for Performing the PT/INR Test","text":"Sample Preparation:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LAutomated Method:\nFollow instrument manufacturer’s instructions\nAdd thromboplastin reagent plasma\nAdd calcium chloride initiate coagulation\nMeasure time clot formation (PT seconds)\nFollow instrument manufacturer’s instructionsAdd thromboplastin reagent plasmaAdd calcium chloride initiate coagulationMeasure time clot formation (PT seconds)INR Calculation:\ninstrument automatically calculates INR using formula:\nINR = (Patient PT / Mean Normal PT)^ISI\ninstrument automatically calculates INR using formula:\nINR = (Patient PT / Mean Normal PT)^ISIQuality Control:\nRun control materials regular intervals assess accuracy precision test\nReview control results take corrective action necessary\nRun control materials regular intervals assess accuracy precision testReview control results take corrective action necessary","code":""},{"path":"ptinr.html","id":"interpreting-results-2","chapter":"PT/INR","heading":"Interpreting Results","text":"Prothrombin Time (PT):\nReference Range: Varies depending thromboplastin reagent instrument used (e.g. 11-13 seconds)\nProlonged PT: Indicates deficiency dysfunction one factors extrinsic common pathways (Factors II, V, VII, X, fibrinogen)\nLiver Disease: Impaired synthesis coagulation factors\nVitamin K Deficiency: Impaired carboxylation vitamin K-dependent factors\nWarfarin Therapy: Inhibition vitamin K-dependent factors\nDisseminated Intravascular Coagulation (DIC): Consumption coagulation factors\nFactor VII Deficiency: Specific deficiency Factor VII\n\nProthrombin Time (PT):Reference Range: Varies depending thromboplastin reagent instrument used (e.g. 11-13 seconds)Prolonged PT: Indicates deficiency dysfunction one factors extrinsic common pathways (Factors II, V, VII, X, fibrinogen)\nLiver Disease: Impaired synthesis coagulation factors\nVitamin K Deficiency: Impaired carboxylation vitamin K-dependent factors\nWarfarin Therapy: Inhibition vitamin K-dependent factors\nDisseminated Intravascular Coagulation (DIC): Consumption coagulation factors\nFactor VII Deficiency: Specific deficiency Factor VII\nLiver Disease: Impaired synthesis coagulation factorsVitamin K Deficiency: Impaired carboxylation vitamin K-dependent factorsWarfarin Therapy: Inhibition vitamin K-dependent factorsDisseminated Intravascular Coagulation (DIC): Consumption coagulation factorsFactor VII Deficiency: Specific deficiency Factor VIIInternational Normalized Ratio (INR):\nTarget INR Range Warfarin Therapy:\nTypically 2.0-3.0 indications (e.g., atrial fibrillation, venous thromboembolism)\nHigher INR ranges (e.g., 2.5-3.5) may used patients mechanical heart valves\n\nINR < Target Range: Indicates subtherapeutic anticoagulation increased risk thrombosis\nINR > Target Range: Indicates supratherapeutic anticoagulation increased risk bleeding\nInternational Normalized Ratio (INR):Target INR Range Warfarin Therapy:\nTypically 2.0-3.0 indications (e.g., atrial fibrillation, venous thromboembolism)\nHigher INR ranges (e.g., 2.5-3.5) may used patients mechanical heart valves\nTypically 2.0-3.0 indications (e.g., atrial fibrillation, venous thromboembolism)Higher INR ranges (e.g., 2.5-3.5) may used patients mechanical heart valvesINR < Target Range: Indicates subtherapeutic anticoagulation increased risk thrombosisINR > Target Range: Indicates supratherapeutic anticoagulation increased risk bleeding","code":""},{"path":"ptinr.html","id":"factors-affecting-ptinr-results","chapter":"PT/INR","heading":"Factors Affecting PT/INR Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nImproper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nLipemia Icterus: Can interfere optical clot detection\nHigh Factor V Level: Can artificially shorten PT\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsLipemia Icterus: Can interfere optical clot detectionHigh Factor V Level: Can artificially shorten PTPatient-Related Variables:\nMedications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test results\nDiet: Vitamin K intake can affect warfarin therapy\nLiver Disease: Impairs synthesis coagulation factors\nGenetic Factors: Rare genetic variations can affect coagulation factor levels\nMedications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test resultsDiet: Vitamin K intake can affect warfarin therapyLiver Disease: Impairs synthesis coagulation factorsGenetic Factors: Rare genetic variations can affect coagulation factor levels","code":""},{"path":"ptinr.html","id":"troubleshooting-erroneous-results","chapter":"PT/INR","heading":"Troubleshooting Erroneous Results","text":"PT/INR result inconsistent patient’s clinical presentation previous results:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances (e.g., lipemia)\nReview patient’s medication list medical history\nPerform mixing study rule factor inhibitors\nCheck sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substances (e.g., lipemia)Review patient’s medication list medical historyPerform mixing study rule factor inhibitors","code":""},{"path":"ptinr.html","id":"key-terms-85","chapter":"PT/INR","heading":"Key Terms","text":"Prothrombin Time (PT): Test extrinsic common pathwaysThromboplastin: Reagent used initiate PT testInternational Normalized Ratio (INR): standardized ratio PT used monitor warfarin therapyWarfarin (Coumadin): oral anticoagulant inhibits vitamin K-dependent coagulation factorsExtrinsic Pathway: pathway coagulation cascade initiated tissue factorCommon Pathway: final pathway coagulation cascade, leading fibrin formationCoagulation Factors: Proteins involved coagulation cascadeControl Materials: Samples known values used assess accuracy precision instrumentReagents: Substances used carry chemical reaction","code":""},{"path":"aptt.html","id":"aptt","chapter":"APTT","heading":"APTT","text":"","code":""},{"path":"aptt.html","id":"overview-of-activated-partial-thromboplastin-time-aptt","chapter":"APTT","heading":"Overview of Activated Partial Thromboplastin Time (aPTT)","text":"Definition: coagulation test measures time (seconds) takes plasma clot activation contact factors (intrinsic pathway) addition calcium phospholipidPurpose:\nEvaluate intrinsic common pathways coagulation\nMonitor heparin therapy\nDetect coagulation factor deficiencies\nInvestigate unexplained bleeding thrombotic events\nScreen lupus anticoagulants\nEvaluate intrinsic common pathways coagulationMonitor heparin therapyDetect coagulation factor deficienciesInvestigate unexplained bleeding thrombotic eventsScreen lupus anticoagulantsPrinciple:\nActivation Contact Factors: contact activator (e.g., kaolin, silica, celite) added plasma activate Factor XII, initiating intrinsic pathway\nAddition Phospholipids: Phospholipids provide surface assembly coagulation complexes\nAddition Calcium: Calcium ions added initiate coagulation cascade\nClot Detection: time clot formation measured, either manually using automated coagulation analyzer\nActivation Contact Factors: contact activator (e.g., kaolin, silica, celite) added plasma activate Factor XII, initiating intrinsic pathwayAddition Phospholipids: Phospholipids provide surface assembly coagulation complexesAddition Calcium: Calcium ions added initiate coagulation cascadeClot Detection: time clot formation measured, either manually using automated coagulation analyzer","code":""},{"path":"aptt.html","id":"components-of-the-aptt-test","chapter":"APTT","heading":"Components of the aPTT Test","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\n\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\n9:1 ratio blood anticoagulantUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulantOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulantReagents:\nContact Activator: substance activates Factor XII (e.g., kaolin, silica, celite)\nPartial Thromboplastin: phospholipid reagent provides surface assembly coagulation complexes\nCalcium Chloride: Provides calcium ions, essential activity coagulation factors\nContact Activator: substance activates Factor XII (e.g., kaolin, silica, celite)Partial Thromboplastin: phospholipid reagent provides surface assembly coagulation complexesCalcium Chloride: Provides calcium ions, essential activity coagulation factorsInstrumentation:\nAutomated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\n\nAutomated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\nOptical Method: Measures changes light transmission clot formsMechanical Method: Detects movement probe wire clot forms","code":""},{"path":"aptt.html","id":"procedure-for-performing-the-aptt-test","chapter":"APTT","heading":"Procedure for Performing the aPTT Test","text":"Sample Preparation:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LAutomated Method:\nFollow instrument manufacturer’s instructions\nAdd contact activator phospholipid reagent plasma\nIncubate mixture 37°C specific period (e.g., 3-5 minutes)\nAdd calcium chloride initiate coagulation\nMeasure time clot formation (aPTT seconds)\nFollow instrument manufacturer’s instructionsAdd contact activator phospholipid reagent plasmaIncubate mixture 37°C specific period (e.g., 3-5 minutes)Add calcium chloride initiate coagulationMeasure time clot formation (aPTT seconds)Quality Control:\nRun control materials regular intervals assess accuracy precision test\nReview control results take corrective action necessary\nRun control materials regular intervals assess accuracy precision testReview control results take corrective action necessary","code":""},{"path":"aptt.html","id":"interpreting-results-3","chapter":"APTT","heading":"Interpreting Results","text":"Activated Partial Thromboplastin Time (aPTT):\nReference Range: Varies depending reagent instrument used (e.g., 25-35 seconds)\nProlonged aPTT: Indicates deficiency dysfunction one factors intrinsic common pathways (Factors XII, XI, IX, VIII, X, V, prothrombin, fibrinogen)\nHeparin Therapy: aPTT used monitor unfractionated heparin therapy\ntarget aPTT range typically 1.5-2.5 times control value\n\nCoagulation Factor Deficiencies:\nHemophilia (Factor VIII deficiency)\nHemophilia B (Factor IX deficiency)\nFactor XI deficiency\n\nLupus Anticoagulant (LA): May prolong aPTT\nVitamin K Deficiency: May prolong aPTT severe\nDisseminated Intravascular Coagulation (DIC): Consumption coagulation factors\n\nReference Range: Varies depending reagent instrument used (e.g., 25-35 seconds)Prolonged aPTT: Indicates deficiency dysfunction one factors intrinsic common pathways (Factors XII, XI, IX, VIII, X, V, prothrombin, fibrinogen)\nHeparin Therapy: aPTT used monitor unfractionated heparin therapy\ntarget aPTT range typically 1.5-2.5 times control value\n\nCoagulation Factor Deficiencies:\nHemophilia (Factor VIII deficiency)\nHemophilia B (Factor IX deficiency)\nFactor XI deficiency\n\nLupus Anticoagulant (LA): May prolong aPTT\nVitamin K Deficiency: May prolong aPTT severe\nDisseminated Intravascular Coagulation (DIC): Consumption coagulation factors\nHeparin Therapy: aPTT used monitor unfractionated heparin therapy\ntarget aPTT range typically 1.5-2.5 times control value\ntarget aPTT range typically 1.5-2.5 times control valueCoagulation Factor Deficiencies:\nHemophilia (Factor VIII deficiency)\nHemophilia B (Factor IX deficiency)\nFactor XI deficiency\nHemophilia (Factor VIII deficiency)Hemophilia B (Factor IX deficiency)Factor XI deficiencyLupus Anticoagulant (LA): May prolong aPTTVitamin K Deficiency: May prolong aPTT severeDisseminated Intravascular Coagulation (DIC): Consumption coagulation factors","code":""},{"path":"aptt.html","id":"factors-affecting-aptt-results","chapter":"APTT","heading":"Factors Affecting aPTT Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nImproper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nLipemia Icterus: Can interfere optical clot detection\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsLipemia Icterus: Can interfere optical clot detectionPatient-Related Variables:\nMedications: Heparin, direct oral anticoagulants, medications can affect coagulation test results\nLiver Disease: Impairs synthesis coagulation factors\nGenetic Factors: Rare genetic variations can affect coagulation factor levels\nMedications: Heparin, direct oral anticoagulants, medications can affect coagulation test resultsLiver Disease: Impairs synthesis coagulation factorsGenetic Factors: Rare genetic variations can affect coagulation factor levels","code":""},{"path":"aptt.html","id":"troubleshooting-erroneous-results-1","chapter":"APTT","heading":"Troubleshooting Erroneous Results","text":"aPTT result inconsistent patient’s clinical presentation previous results:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances (e.g., lipemia)\nReview patient’s medication list medical history\nPerform mixing study rule factor inhibitors\nCheck sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substances (e.g., lipemia)Review patient’s medication list medical historyPerform mixing study rule factor inhibitors","code":""},{"path":"aptt.html","id":"mixing-studies","chapter":"APTT","heading":"Mixing Studies","text":"Used differentiate factor deficiencies factor inhibitorsProcedure:\nMix equal parts patient’s plasma normal plasma\nMeasure aPTT mixture immediately incubation 37°C 1-2 hours\nInterpretation:\nCorrection: aPTT corrects within normal range mixing, suggests factor deficiency\nCorrection: aPTT correct (remains prolonged) mixing, suggests presence factor inhibitor\n\nMix equal parts patient’s plasma normal plasmaMeasure aPTT mixture immediately incubation 37°C 1-2 hoursInterpretation:\nCorrection: aPTT corrects within normal range mixing, suggests factor deficiency\nCorrection: aPTT correct (remains prolonged) mixing, suggests presence factor inhibitor\nCorrection: aPTT corrects within normal range mixing, suggests factor deficiencyNo Correction: aPTT correct (remains prolonged) mixing, suggests presence factor inhibitor","code":""},{"path":"aptt.html","id":"reflex-testing","chapter":"APTT","heading":"Reflex Testing","text":"aPTT prolonged mixing study suggests factor deficiency, next step perform individual factor assays identify specific factor deficientIf aPTT prolonged mixing study suggests factor inhibitor, testing needed characterize inhibitor:\nFactor VIII Inhibitor Assay: detect quantify Factor VIII inhibitors\nLupus Anticoagulant Testing:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\n\nFactor VIII Inhibitor Assay: detect quantify Factor VIII inhibitorsLupus Anticoagulant Testing:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\nDilute Russell’s Viper Venom Time (dRVVT)Silica Clotting Time (SCT)Hexagonal Phase Phospholipid Neutralization Assay","code":""},{"path":"aptt.html","id":"key-terms-86","chapter":"APTT","heading":"Key Terms","text":"aPTT (Activated Partial Thromboplastin Time): Test intrinsic common pathwaysContact Activator: Reagent used initiate intrinsic pathwayPhospholipid: substance needed assembly coagulation complexesFactor Assay: laboratory test measure activity specific coagulation factorMixing Study: test differentiate factor deficiencies factor inhibitorsLupus Anticoagulant (LA): antibody interferes phospholipid-dependent coagulation assays","code":""},{"path":"fibrinogen.html","id":"fibrinogen","chapter":"Fibrinogen","heading":"Fibrinogen","text":"","code":""},{"path":"fibrinogen.html","id":"overview-of-fibrinogen-assay","chapter":"Fibrinogen","heading":"Overview of Fibrinogen Assay","text":"Definition: quantitative assay measures concentration fibrinogen (Factor ) plasma. Fibrinogen key protein coagulation cascade, essential forming fibrin clotClinical Significance:\nDiagnosis Bleeding Disorders: Low fibrinogen levels can contribute bleeding tendencies\nEvaluation Liver Function: Fibrinogen synthesized liver, levels can decreased liver disease\nAssessment Disseminated Intravascular Coagulation (DIC): Fibrinogen levels often decreased DIC due consumption\nDiagnosis Inherited Fibrinogen Disorders: Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia\nAssessment Thrombotic Risk: Fibrinogen acute-phase reactant, elevated levels may associated increased risk thrombosis\nDiagnosis Bleeding Disorders: Low fibrinogen levels can contribute bleeding tendenciesEvaluation Liver Function: Fibrinogen synthesized liver, levels can decreased liver diseaseAssessment Disseminated Intravascular Coagulation (DIC): Fibrinogen levels often decreased DIC due consumptionDiagnosis Inherited Fibrinogen Disorders: Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemiaAssessment Thrombotic Risk: Fibrinogen acute-phase reactant, elevated levels may associated increased risk thrombosisMethods:\nClauss Method (Functional Assay)\nImmunologic Methods\nClauss Method (Functional Assay)Immunologic Methods","code":""},{"path":"fibrinogen.html","id":"clauss-method-functional-assay","chapter":"Fibrinogen","heading":"Clauss Method (Functional Assay)","text":"Principle: Clauss method functional assay measures rate clot formation addition high concentration thrombin diluted plasma. clotting time inversely proportional fibrinogen concentrationProcedure:\nPlasma Dilution: patient’s plasma diluted buffer specific concentration\nThrombin Addition: high concentration thrombin added diluted plasma\nClot Detection: time clot formation measured, either manually using automated coagulation analyzer\nCalculation: fibrinogen concentration determined comparing clotting time calibration curve generated using fibrinogen standards known concentrations\nPlasma Dilution: patient’s plasma diluted buffer specific concentrationThrombin Addition: high concentration thrombin added diluted plasmaClot Detection: time clot formation measured, either manually using automated coagulation analyzerCalculation: fibrinogen concentration determined comparing clotting time calibration curve generated using fibrinogen standards known concentrationsAdvantages:\nMeasures functional activity fibrinogen, important assessing patient’s ability form stable clot\nRelatively simple widely available\nMeasures functional activity fibrinogen, important assessing patient’s ability form stable clotRelatively simple widely availableLimitations:\nCan affected inhibitors thrombin (e.g., heparin, direct thrombin inhibitors)\nMay inaccurate patients dysfibrinogenemia (abnormal fibrinogen molecule)\nCan affected inhibitors thrombin (e.g., heparin, direct thrombin inhibitors)May inaccurate patients dysfibrinogenemia (abnormal fibrinogen molecule)","code":""},{"path":"fibrinogen.html","id":"immunologic-methods","chapter":"Fibrinogen","heading":"Immunologic Methods","text":"Principle: methods measure amount fibrinogen protein, regardless functionMethods:\nNephelometry: Measures turbidity caused formation antigen-antibody complexes\nTurbidimetry: Measures decrease light transmission solution antigen-antibody complexes form\nNephelometry: Measures turbidity caused formation antigen-antibody complexesTurbidimetry: Measures decrease light transmission solution antigen-antibody complexes formProcedure:\nAdd specific antibody targets fibrinogen sample\nAntigen-Antibody Complexes forms turbidity\nMeasures amount turbidity determine much fibrinogen sample\nAdd specific antibody targets fibrinogen sampleAntigen-Antibody Complexes forms turbidityMeasures amount turbidity determine much fibrinogen sampleAdvantages:\naffected inhibitors thrombin\nMay accurate patients dysfibrinogenemia\naffected inhibitors thrombinMay accurate patients dysfibrinogenemiaLimitations:\nassess functional activity fibrinogen\nCan affected interfering substances (e.g., lipemia, high protein levels)\nassess functional activity fibrinogenCan affected interfering substances (e.g., lipemia, high protein levels)","code":""},{"path":"fibrinogen.html","id":"specimen-collection-and-handling","chapter":"Fibrinogen","heading":"Specimen Collection and Handling","text":"Collection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\n9:1 ratio blood anticoagulantUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulantOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulantProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nTest performed within 4 hours collection plasma frozen maintain optimal value fibrongien\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LTest performed within 4 hours collection plasma frozen maintain optimal value fibrongien","code":""},{"path":"fibrinogen.html","id":"factors-affecting-fibrinogen-results","chapter":"Fibrinogen","heading":"Factors Affecting Fibrinogen Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Fibrinogen can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nImproper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Fibrinogen can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nLipemia Icterus: Can interfere optical clot detection turbidimetric measurements\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsLipemia Icterus: Can interfere optical clot detection turbidimetric measurementsPatient-Related Variables:\nMedications: Fibrinolytic agents (e.g., tPA, streptokinase) can decrease fibrinogen levels\nLiver Disease: Impairs synthesis fibrinogen\nDisseminated Intravascular Coagulation (DIC): Consumption fibrinogen\nMedications: Fibrinolytic agents (e.g., tPA, streptokinase) can decrease fibrinogen levelsLiver Disease: Impairs synthesis fibrinogenDisseminated Intravascular Coagulation (DIC): Consumption fibrinogen","code":""},{"path":"fibrinogen.html","id":"interpreting-results-4","chapter":"Fibrinogen","heading":"Interpreting Results","text":"Reference Range: Varies depending method laboratory; typical range 200-400 mg/dLElevated Fibrinogen:\nAcute Phase Reaction: Fibrinogen acute-phase reactant, levels can increase inflammation, infection, trauma, surgery\nPregnancy: Fibrinogen levels increase pregnancy\nOral Contraceptive Use\nIncreased Risk Thrombosis\nAcute Phase Reaction: Fibrinogen acute-phase reactant, levels can increase inflammation, infection, trauma, surgeryPregnancy: Fibrinogen levels increase pregnancyOral Contraceptive UseIncreased Risk ThrombosisDecreased Fibrinogen:\nDisseminated Intravascular Coagulation (DIC): Consumption fibrinogen\nLiver Disease: Impaired fibrinogen synthesis\nInherited Fibrinogen Disorders:\nAfibrinogenemia: Complete absence fibrinogen (rare)\nHypofibrinogenemia: Reduced levels fibrinogen\nDysfibrinogenemia: Presence dysfunctional fibrinogen molecule clot properly\nAmylodosis\n\nDisseminated Intravascular Coagulation (DIC): Consumption fibrinogenLiver Disease: Impaired fibrinogen synthesisInherited Fibrinogen Disorders:\nAfibrinogenemia: Complete absence fibrinogen (rare)\nHypofibrinogenemia: Reduced levels fibrinogen\nDysfibrinogenemia: Presence dysfunctional fibrinogen molecule clot properly\nAmylodosis\nAfibrinogenemia: Complete absence fibrinogen (rare)Hypofibrinogenemia: Reduced levels fibrinogenDysfibrinogenemia: Presence dysfunctional fibrinogen molecule clot properlyAmylodosis","code":""},{"path":"fibrinogen.html","id":"troubleshooting-erroneous-results-2","chapter":"Fibrinogen","heading":"Troubleshooting Erroneous Results","text":"fibrinogen result inconsistent patient’s clinical presentation previous results:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances (e.g., lipemia)\nReview patient’s medication list medical history\nCheck sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substances (e.g., lipemia)Review patient’s medication list medical history","code":""},{"path":"fibrinogen.html","id":"key-terms-87","chapter":"Fibrinogen","heading":"Key Terms","text":"Fibrinogen: protein (Factor ) converted fibrin, main component blood clotClauss Method: functional assay measure fibrinogen concentrationDysfibrinogenemia: Presence dysfunctional fibrinogen moleculeAfibrinogenemia: Complete absence fibrinogenHypofibrinogenemia: Reduced levels fibrinogenDisseminated Intravascular Coagulation (DIC): consumptive coagulopathy widespread clotting bleedingCryoprecipitate: blood product rich fibrinogen","code":""},{"path":"d-dimer.html","id":"d-dimer","chapter":"D-dimer","heading":"D-dimer","text":"","code":""},{"path":"d-dimer.html","id":"overview-of-d-dimer-assays","chapter":"D-dimer","heading":"Overview of D-dimer Assays","text":"Definition: D-dimer assays quantitative tests used measure level D-dimer plasma. D-dimer specific fibrin degradation product (FDP) results breakdown cross-linked fibrinClinical Significance:\nExclusion Venous Thromboembolism (VTE): D-dimer assays primarily used rule venous thromboembolism (deep vein thrombosis [DVT] pulmonary embolism [PE]) patients low intermediate pretest probability\nDiagnosis Disseminated Intravascular Coagulation (DIC): D-dimer markedly elevated DIC\nMonitoring Thrombolytic Therapy: Can used monitor effectiveness thrombolytic therapy\nAssessment Conditions: Elevated D-dimer levels can also seen conditions, including pregnancy, infection, inflammation, malignancy, recent surgery\nExclusion Venous Thromboembolism (VTE): D-dimer assays primarily used rule venous thromboembolism (deep vein thrombosis [DVT] pulmonary embolism [PE]) patients low intermediate pretest probabilityDiagnosis Disseminated Intravascular Coagulation (DIC): D-dimer markedly elevated DICMonitoring Thrombolytic Therapy: Can used monitor effectiveness thrombolytic therapyAssessment Conditions: Elevated D-dimer levels can also seen conditions, including pregnancy, infection, inflammation, malignancy, recent surgeryLimitations:\nPoor Specificity: Elevated D-dimer levels specific VTE can seen variety conditions\nAge-Related Increase: D-dimer levels tend increase age\nUseful Monitoring Anticoagulation: D-dimer used monitor anticoagulant therapy\nPoor Specificity: Elevated D-dimer levels specific VTE can seen variety conditionsAge-Related Increase: D-dimer levels tend increase ageNot Useful Monitoring Anticoagulation: D-dimer used monitor anticoagulant therapy","code":""},{"path":"d-dimer.html","id":"principle-of-d-dimer-assays","chapter":"D-dimer","heading":"Principle of D-dimer Assays","text":"D-dimer assays based immunochemical methods use monoclonal antibodies specific D-dimerLatex Agglutination Assay:\nLatex particles coated monoclonal antibodies D-dimer\nreagent mixed sample containing D-dimer, antibodies bind D-dimer, causing latex particles agglutinate (clump together)\nagglutination measured turbidimetrically nephelometrically, result compared calibration curve\nLatex particles coated monoclonal antibodies D-dimerWhen reagent mixed sample containing D-dimer, antibodies bind D-dimer, causing latex particles agglutinate (clump together)agglutination measured turbidimetrically nephelometrically, result compared calibration curveEnzyme-Linked Immunosorbent Assay (ELISA):\nMicroplate wells coated monoclonal antibodies D-dimer\nsample added wells, D-dimer present binds antibodies\nsecondary antibody conjugated enzyme added, binds D-dimer-antibody complex\nsubstrate enzyme added, resulting color change measured spectrophotometrically\nMicroplate wells coated monoclonal antibodies D-dimerThe sample added wells, D-dimer present binds antibodiesA secondary antibody conjugated enzyme added, binds D-dimer-antibody complexA substrate enzyme added, resulting color change measured spectrophotometricallyImmunoturbidimetric Assay:\nAntibodies D-dimer added sample\nantibodies bind D-dimer, immune complexes form\nturbidity solution measured, proportional D-dimer concentration\nAntibodies D-dimer added sampleAs antibodies bind D-dimer, immune complexes formThe turbidity solution measured, proportional D-dimer concentrationChemiluminescent Immunoassay:\nSimilar ELISA, uses chemiluminescent substrate instead enzyme-linked substrate\nemitted light measured, proportional D-dimer concentration\nSimilar ELISA, uses chemiluminescent substrate instead enzyme-linked substrateThe emitted light measured, proportional D-dimer concentration","code":""},{"path":"d-dimer.html","id":"procedure-for-performing-d-dimer-assay","chapter":"D-dimer","heading":"Procedure for Performing D-dimer Assay","text":"Sample Collection Preparation:\nCollect blood sodium citrate (light blue top) tube\nProcess sample within specified timeframe obtain platelet-poor plasma (PPP)\nFollow manufacturer’s instructions sample storage handling\nCollect blood sodium citrate (light blue top) tubeProcess sample within specified timeframe obtain platelet-poor plasma (PPP)Follow manufacturer’s instructions sample storage handlingAssay Performance:\nFollow manufacturer’s instructions specific assay used\nEnsure reagents properly prepared stored\nLoad samples reagents onto automated analyzer\nStart assay allow instrument perform analysis\nFollow manufacturer’s instructions specific assay usedEnsure reagents properly prepared storedLoad samples reagents onto automated analyzerStart assay allow instrument perform analysisQuality Control:\nRun control materials regular intervals (e.g., daily, batch samples) assess accuracy precision assay\nEvaluate control results take corrective action necessary\nRun control materials regular intervals (e.g., daily, batch samples) assess accuracy precision assayEvaluate control results take corrective action necessaryResult Calculation:\nautomated analyzer calculates D-dimer concentration based calibration curve\nEnsure results within assay’s linear range\nautomated analyzer calculates D-dimer concentration based calibration curveEnsure results within assay’s linear range","code":""},{"path":"d-dimer.html","id":"reporting-results-16","chapter":"D-dimer","heading":"Reporting Results","text":"Report D-dimer concentration appropriate units (e.g., ng/mL, μg/L)Include reference range assayNote abnormal results flagsDocument quality control procedures corrective actions taken","code":""},{"path":"d-dimer.html","id":"interpreting-results-5","chapter":"D-dimer","heading":"Interpreting Results","text":"Negative D-dimer Result:\nD-dimer level established cut-value assay\npatients low intermediate pretest probability VTE, negative D-dimer result used rule DVT PE\nD-dimer level established cut-value assayIn patients low intermediate pretest probability VTE, negative D-dimer result used rule DVT PEElevated D-dimer Result:\nD-dimer level cut-value\nIndicates presence fibrin degradation products plasma, suggesting coagulation fibrinolysis activated\nCauses Elevated D-dimer:\nVenous Thromboembolism (VTE): DVT PE\nDisseminated Intravascular Coagulation (DIC)\nSurgery\nTrauma\nPregnancy\nMalignancy\nInfection\nInflammation\nAdvanced Age\n\nNote: elevated D-dimer result specific VTE, testing (e.g., imaging studies) required confirm diagnosis\nD-dimer level cut-valueIndicates presence fibrin degradation products plasma, suggesting coagulation fibrinolysis activatedCauses Elevated D-dimer:\nVenous Thromboembolism (VTE): DVT PE\nDisseminated Intravascular Coagulation (DIC)\nSurgery\nTrauma\nPregnancy\nMalignancy\nInfection\nInflammation\nAdvanced Age\nVenous Thromboembolism (VTE): DVT PEDisseminated Intravascular Coagulation (DIC)SurgeryTraumaPregnancyMalignancyInfectionInflammationAdvanced AgeNote: elevated D-dimer result specific VTE, testing (e.g., imaging studies) required confirm diagnosis","code":""},{"path":"d-dimer.html","id":"factors-affecting-d-dimer-results","chapter":"D-dimer","heading":"Factors Affecting D-dimer Results","text":"Pre-Analytical Variables:\nImproper Sample Collection:\nClotted sample: D-dimer accurately measured\nUnderfilled collection tube: Can affect blood--anticoagulant ratio\n\nDelayed Processing:\nProlonged storage room temperature can lead falsely elevated D-dimer levels\nSamples processed tested soon possible stored according manufacturer’s instructions\n\nLipemia Icterus:\nCan interfere optical measurements\n\nPre-Analytical Variables:Improper Sample Collection:\nClotted sample: D-dimer accurately measured\nUnderfilled collection tube: Can affect blood--anticoagulant ratio\nClotted sample: D-dimer accurately measuredUnderfilled collection tube: Can affect blood--anticoagulant ratioDelayed Processing:\nProlonged storage room temperature can lead falsely elevated D-dimer levels\nSamples processed tested soon possible stored according manufacturer’s instructions\nProlonged storage room temperature can lead falsely elevated D-dimer levelsSamples processed tested soon possible stored according manufacturer’s instructionsLipemia Icterus:\nCan interfere optical measurements\nCan interfere optical measurementsAnalytical Variables:\nAssay Type: Different D-dimer assays different sensitivities specificities\nCut-Values: Cut-values positivity can vary laboratories\nInstrument Malfunction: Ensure proper calibration maintenance analyzer\nAnalytical Variables:Assay Type: Different D-dimer assays different sensitivities specificitiesCut-Values: Cut-values positivity can vary laboratoriesInstrument Malfunction: Ensure proper calibration maintenance analyzerPatient-Related Variables:\nAge: D-dimer levels tend increase age\nAge-Adjusted Cut-Offs: laboratories use age-adjusted D-dimer cut-values improve specificity older adults\nAge-Adjusted Cut-= 0.50 μg/mL + (Age x 0.01 μg/mL)\n\n\nPregnancy: D-dimer levels normally elevated pregnancy\nMedical Conditions:\nInflammation\nInfection\nMalignancy\nLiver Disease\nKidney Disease\n\nPatient-Related Variables:Age: D-dimer levels tend increase age\nAge-Adjusted Cut-Offs: laboratories use age-adjusted D-dimer cut-values improve specificity older adults\nAge-Adjusted Cut-= 0.50 μg/mL + (Age x 0.01 μg/mL)\n\nAge-Adjusted Cut-Offs: laboratories use age-adjusted D-dimer cut-values improve specificity older adults\nAge-Adjusted Cut-= 0.50 μg/mL + (Age x 0.01 μg/mL)\nAge-Adjusted Cut-= 0.50 μg/mL + (Age x 0.01 μg/mL)Pregnancy: D-dimer levels normally elevated pregnancyMedical Conditions:\nInflammation\nInfection\nMalignancy\nLiver Disease\nKidney Disease\nInflammationInfectionMalignancyLiver DiseaseKidney Disease","code":""},{"path":"d-dimer.html","id":"troubleshooting-erroneous-results-3","chapter":"D-dimer","heading":"Troubleshooting Erroneous Results","text":"D-dimer result inconsistent patient’s clinical presentation:\nCheck sample clots, hemolysis, lipemia\nRepeat test fresh sample\nEnsure test performed within acceptable timeframe\nConsider possibility interfering substances\nReview patient’s medical history medication list\nConsult pathologist coagulation expert\nD-dimer result inconsistent patient’s clinical presentation:Check sample clots, hemolysis, lipemiaRepeat test fresh sampleEnsure test performed within acceptable timeframeConsider possibility interfering substancesReview patient’s medical history medication listConsult pathologist coagulation expert","code":""},{"path":"d-dimer.html","id":"key-terms-88","chapter":"D-dimer","heading":"Key Terms","text":"D-dimer: specific fibrin degradation product elevated thrombotic conditionsFibrinolysis: enzymatic breakdown fibrin clotsVenous Thromboembolism (VTE): condition includes deep vein thrombosis (DVT) pulmonary embolism (PE)Deep Vein Thrombosis (DVT): blood clot deep vein, usually legPulmonary Embolism (PE): blood clot travels lungsDisseminated Intravascular Coagulation (DIC): complex disorder widespread clotting bleedingSensitivity: ability test correctly identify individuals condition (true positive rate)Specificity: ability test correctly identify individuals condition (true negative rate)","code":""},{"path":"thrombin-time.html","id":"thrombin-time","chapter":"Thrombin Time","heading":"Thrombin Time","text":"","code":""},{"path":"thrombin-time.html","id":"overview-of-thrombin-time-tt","chapter":"Thrombin Time","heading":"Overview of Thrombin Time (TT)","text":"Definition: thrombin time (TT), also known thrombin clotting time (TCT), coagulation test measures time (seconds) takes clot form plasma addition thrombinPurpose:\nAssess final common pathway coagulation, specifically conversion fibrinogen fibrin\nDetect quantitative qualitative abnormalities fibrinogen\nDetect presence thrombin inhibitors (e.g., heparin, direct thrombin inhibitors, fibrin degradation products)\nAssess final common pathway coagulation, specifically conversion fibrinogen fibrinDetect quantitative qualitative abnormalities fibrinogenDetect presence thrombin inhibitors (e.g., heparin, direct thrombin inhibitors, fibrin degradation products)Principle:\nThrombin added plasma, bypassing intrinsic extrinsic pathways coagulation\nrate clot formation depends concentration function fibrinogen, well presence thrombin inhibitors\nThrombin added plasma, bypassing intrinsic extrinsic pathways coagulationThe rate clot formation depends concentration function fibrinogen, well presence thrombin inhibitors","code":""},{"path":"thrombin-time.html","id":"components-of-the-thrombin-time-test","chapter":"Thrombin Time","heading":"Components of the Thrombin Time Test","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\n\nSpecimen Collection:Collection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\nUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulant\nOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulant\n9:1 ratio blood anticoagulantUnderfilling tube can lead falsely prolonged clotting times due excess anticoagulantOverfilling tube can lead falsely shortened clotting times due insufficient anticoagulantReagents:\nThrombin Reagent: solution purified thrombin\nconcentration thrombin carefully controlled ensure consistent results\n\nCalcium Chloride: Provides calcium ions, essential thrombin-fibrinogen reaction\nBuffer: Tris buffer suitable buffer maintain stable pH\nReagents:Thrombin Reagent: solution purified thrombin\nconcentration thrombin carefully controlled ensure consistent results\nconcentration thrombin carefully controlled ensure consistent resultsCalcium Chloride: Provides calcium ions, essential thrombin-fibrinogen reactionBuffer: Tris buffer suitable buffer maintain stable pHInstrumentation:\nAutomated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\n\nInstrumentation:Automated Coagulation Analyzer: Detects clot formation using optical mechanical methods:\nOptical Method: Measures changes light transmission clot forms\nMechanical Method: Detects movement probe wire clot forms\nOptical Method: Measures changes light transmission clot formsMechanical Method: Detects movement probe wire clot forms","code":""},{"path":"thrombin-time.html","id":"procedure-for-performing-the-thrombin-time-test","chapter":"Thrombin Time","heading":"Procedure for Performing the Thrombin Time Test","text":"Sample Preparation:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LAutomated Method:\nFollow instrument manufacturer’s instructions\nIncubate plasma 37°C\nAdd thrombin reagent plasma\nMeasure time clot formation (TT seconds)\nFollow instrument manufacturer’s instructionsIncubate plasma 37°CAdd thrombin reagent plasmaMeasure time clot formation (TT seconds)Quality Control:\nRun control materials regular intervals assess accuracy precision test\nReview control results take corrective action necessary\nRun control materials regular intervals assess accuracy precision testReview control results take corrective action necessary","code":""},{"path":"thrombin-time.html","id":"interpreting-results-6","chapter":"Thrombin Time","heading":"Interpreting Results","text":"Thrombin Time (TT):\nReference Range: Varies depending reagent instrument used (e.g., 9-13 seconds)\nProlonged Thrombin Time: Indicates deficiency dysfunction fibrinogen presence thrombin inhibitors\nHypofibrinogenemia: Decreased levels fibrinogen\nDysfibrinogenemia: Abnormal fibrinogen molecule clot properly\nHeparin: Inhibits thrombin activity\nDirect Thrombin Inhibitors (DTIs): Dabigatran, argatroban, bivalirudin\nFibrin Degradation Products (FDPs): Can interfere fibrin polymerization\nAmyloidosis: Causes fibrin form large, poorly formed clots\n\nReference Range: Varies depending reagent instrument used (e.g., 9-13 seconds)Prolonged Thrombin Time: Indicates deficiency dysfunction fibrinogen presence thrombin inhibitors\nHypofibrinogenemia: Decreased levels fibrinogen\nDysfibrinogenemia: Abnormal fibrinogen molecule clot properly\nHeparin: Inhibits thrombin activity\nDirect Thrombin Inhibitors (DTIs): Dabigatran, argatroban, bivalirudin\nFibrin Degradation Products (FDPs): Can interfere fibrin polymerization\nAmyloidosis: Causes fibrin form large, poorly formed clots\nHypofibrinogenemia: Decreased levels fibrinogenDysfibrinogenemia: Abnormal fibrinogen molecule clot properlyHeparin: Inhibits thrombin activityDirect Thrombin Inhibitors (DTIs): Dabigatran, argatroban, bivalirudinFibrin Degradation Products (FDPs): Can interfere fibrin polymerizationAmyloidosis: Causes fibrin form large, poorly formed clots","code":""},{"path":"thrombin-time.html","id":"factors-affecting-thrombin-time-results","chapter":"Thrombin Time","heading":"Factors Affecting Thrombin Time Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Fibrinogen can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Fibrinogen can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: High levels paraproteins (e.g., multiple myeloma) can interfere clot detection\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: High levels paraproteins (e.g., multiple myeloma) can interfere clot detectionPatient-Related Variables:\nMedications: Heparin, direct thrombin inhibitors, anticoagulants\nLiver Disease: Impairs synthesis fibrinogen\nDisseminated Intravascular Coagulation (DIC): Consumption fibrinogen\nInherited Fibrinogen Disorders: Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia\nPatient-Related Variables:Medications: Heparin, direct thrombin inhibitors, anticoagulantsLiver Disease: Impairs synthesis fibrinogenDisseminated Intravascular Coagulation (DIC): Consumption fibrinogenInherited Fibrinogen Disorders: Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia","code":""},{"path":"thrombin-time.html","id":"troubleshooting-erroneous-results-4","chapter":"Thrombin Time","heading":"Troubleshooting Erroneous Results","text":"thrombin time result inconsistent patient’s clinical presentation previous results:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nConsider performing additional tests investigate fibrinogen abnormalities (see )\nthrombin time result inconsistent patient’s clinical presentation previous results:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyConsider performing additional tests investigate fibrinogen abnormalities (see )","code":""},{"path":"thrombin-time.html","id":"reflex-testing-1","chapter":"Thrombin Time","heading":"Reflex Testing","text":"thrombin time prolonged, testing may performed determine cause prolongation:\nReptilase Time: Measures time takes clot form addition reptilase (enzyme cleaves fibrinogen)\nNormal Reptilase Time: Suggests presence heparin direct thrombin inhibitor\nProlonged Reptilase Time: Suggests deficiency dysfunction fibrinogen\n\nFibrinogen Assay: Measures concentration fibrinogen plasma\nLow Fibrinogen: Suggests hypofibrinogenemia afibrinogenemia\nNormal Fibrinogen: Suggests dysfibrinogenemia presence thrombin inhibitor\n\nThrombin Inhibitor Assay: detect quantify thrombin inhibitors\nthrombin time prolonged, testing may performed determine cause prolongation:Reptilase Time: Measures time takes clot form addition reptilase (enzyme cleaves fibrinogen)\nNormal Reptilase Time: Suggests presence heparin direct thrombin inhibitor\nProlonged Reptilase Time: Suggests deficiency dysfunction fibrinogen\nNormal Reptilase Time: Suggests presence heparin direct thrombin inhibitorProlonged Reptilase Time: Suggests deficiency dysfunction fibrinogenFibrinogen Assay: Measures concentration fibrinogen plasma\nLow Fibrinogen: Suggests hypofibrinogenemia afibrinogenemia\nNormal Fibrinogen: Suggests dysfibrinogenemia presence thrombin inhibitor\nLow Fibrinogen: Suggests hypofibrinogenemia afibrinogenemiaNormal Fibrinogen: Suggests dysfibrinogenemia presence thrombin inhibitorThrombin Inhibitor Assay: detect quantify thrombin inhibitors","code":""},{"path":"thrombin-time.html","id":"key-terms-89","chapter":"Thrombin Time","heading":"Key Terms","text":"Thrombin Time (TT): test measures time takes clot form addition thrombinThrombin: key enzyme coagulation cascade converts fibrinogen fibrinFibrinogen: protein (Factor ) converted fibrin, main component blood clotReptilase Time: test measures time takes clot form addition reptilaseHypofibrinogenemia: Reduced levels fibrinogenDysfibrinogenemia: Presence dysfunctional fibrinogen moleculeThrombin Inhibitor: substance inhibits activity thrombinPre-analytical Variable: variable can affect results test occurs analysisAnalytical Variable: variable can affect results test occurs analysis","code":""},{"path":"mixing-studies-1.html","id":"mixing-studies-1","chapter":"Mixing Studies","heading":"Mixing Studies","text":"","code":""},{"path":"mixing-studies-1.html","id":"overview-of-mixing-studies","chapter":"Mixing Studies","heading":"Overview of Mixing Studies","text":"Definition: Mixing studies, also known inhibitor studies correction studies, coagulation tests used distinguish factor deficiencies factor inhibitors cause prolonged Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT)Principle:\npatient’s plasma (prolonged PT aPTT) mixed normal plasma 1:1 ratio\nclotting time mixture measured immediately incubation specified period time (typically 1-2 hours 37°C)\nprolonged clotting time corrects within normal range upon mixing, suggests factor deficiency\nprolonged clotting time correct partially corrects mixing, suggests presence factor inhibitor\npatient’s plasma (prolonged PT aPTT) mixed normal plasma 1:1 ratioThe clotting time mixture measured immediately incubation specified period time (typically 1-2 hours 37°C)prolonged clotting time corrects within normal range upon mixing, suggests factor deficiencyIf prolonged clotting time correct partially corrects mixing, suggests presence factor inhibitorClinical Significance:\nDifferentiation Coagulation Disorders: Distinguishes factor deficiencies (require replacement therapy) factor inhibitors (require immunosuppression bypassing agents)\nEvaluation Unexplained Bleeding Thrombosis: Helps identify underlying coagulation abnormalities\nManagement Patients Anticoagulant Therapy: Can useful evaluating unexpected results patients warfarin heparin therapy\nDifferentiation Coagulation Disorders: Distinguishes factor deficiencies (require replacement therapy) factor inhibitors (require immunosuppression bypassing agents)Evaluation Unexplained Bleeding Thrombosis: Helps identify underlying coagulation abnormalitiesManagement Patients Anticoagulant Therapy: Can useful evaluating unexpected results patients warfarin heparin therapyLimitations:\nLabor-intensive time-consuming\ninterpretation results can subjective, especially cases weak inhibitors\ninhibitors easily detected mixing studies\nLabor-intensive time-consumingThe interpretation results can subjective, especially cases weak inhibitorsNot inhibitors easily detected mixing studies","code":""},{"path":"mixing-studies-1.html","id":"components-of-a-mixing-study","chapter":"Mixing Studies","heading":"Components of a Mixing Study","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n\nProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\n\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n9:1 ratio blood anticoagulantProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LReagents:\nNormal Pooled Plasma (NPP): Pooled plasma multiple healthy donors, used source normal coagulation factors\nnormal levels coagulation factors\n\naPTT Reagent: Contains contact activator (e.g., silica, kaolin) phospholipid\nPT Reagent: Thromboplastin reagent containing tissue factor calcium\nCalcium Chloride: Provides calcium ions, essential activity coagulation factors\nNormal Pooled Plasma (NPP): Pooled plasma multiple healthy donors, used source normal coagulation factors\nnormal levels coagulation factors\nnormal levels coagulation factorsaPTT Reagent: Contains contact activator (e.g., silica, kaolin) phospholipidPT Reagent: Thromboplastin reagent containing tissue factor calciumCalcium Chloride: Provides calcium ions, essential activity coagulation factors","code":""},{"path":"mixing-studies-1.html","id":"procedure-for-performing-a-mixing-study","chapter":"Mixing Studies","heading":"Procedure for Performing a Mixing Study","text":"Prepare Plasma Samples:\nPatient Plasma: plasma sample patient prolonged PT aPTT\nNormal Pooled Plasma (NPP): pooled plasma healthy donors\nPatient Plasma: plasma sample patient prolonged PT aPTTNormal Pooled Plasma (NPP): pooled plasma healthy donorsMix Plasma Samples:\nPrepare 1:1 mixture patient plasma normal pooled plasma\nUse accurate pipetting techniques ensure proper mixing ratios\nPrepare 1:1 mixture patient plasma normal pooled plasmaUse accurate pipetting techniques ensure proper mixing ratiosPerform Immediate aPTT (PT) Mixture:\nRun aPTT (PT) patient’s plasma, normal pooled plasma, 1:1 mixture immediately preparing mixture\nmeasures initial clotting time mixture\nRun aPTT (PT) patient’s plasma, normal pooled plasma, 1:1 mixture immediately preparing mixtureThis measures initial clotting time mixtureIncubate Mixture:\nIncubate 1:1 mixture 37°C 1-2 hours (exact incubation time depends laboratory’s protocol)\nIncubation allows time inhibitors exert effect\nIncubate 1:1 mixture 37°C 1-2 hours (exact incubation time depends laboratory’s protocol)Incubation allows time inhibitors exert effectPerform Delayed aPTT (PT) Mixture:\nincubation, run aPTT (PT) 1:1 mixture\nmeasures clotting time mixture incubation\nincubation, run aPTT (PT) 1:1 mixtureThis measures clotting time mixture incubationCalculate Percentage Correction:\nCompare clotting time mixture clotting time normal pooled plasma:\nPercentage Correction = [(Mixture Clotting Time - Normal Plasma Clotting Time) / Patient Clotting Time] x 100\nCompare clotting time mixture clotting time normal pooled plasma:Percentage Correction = [(Mixture Clotting Time - Normal Plasma Clotting Time) / Patient Clotting Time] x 100","code":""},{"path":"mixing-studies-1.html","id":"interpreting-results-7","chapter":"Mixing Studies","heading":"Interpreting Results","text":"Correction:\naPTT (PT) mixture corrects within normal reference range within defined percentage normal plasma control:\nSuggests factor deficiency\naddition normal plasma provides missing factor, allowing mixture clot normally\n\naPTT (PT) mixture corrects within normal reference range within defined percentage normal plasma control:\nSuggests factor deficiency\naddition normal plasma provides missing factor, allowing mixture clot normally\nSuggests factor deficiencyThe addition normal plasma provides missing factor, allowing mixture clot normallyNo Correction (Inhibition):\naPTT (PT) mixture remains prolonged (correct within normal range)\nSuggests presence inhibitor interfering coagulation process\ninhibitor neutralized addition normal plasma\naPTT (PT) mixture remains prolonged (correct within normal range)Suggests presence inhibitor interfering coagulation processThe inhibitor neutralized addition normal plasmaTime Dependent Inhibition:\ninitial correction, values slowly decline time. implies inhibitor taking time inactivate target, means testing must performed\ninitial correction, values slowly decline time. implies inhibitor taking time inactivate target, means testing must performed","code":""},{"path":"mixing-studies-1.html","id":"types-of-inhibitors","chapter":"Mixing Studies","heading":"Types of Inhibitors","text":"Factor-Specific Inhibitors:\nAntibodies specifically target neutralize activity particular coagulation factor (e.g., Factor VIII inhibitor)\nMay cause severe bleeding\nTypically demonstrate time-dependent inhibition (clotting time becomes prolonged longer incubation times)\nFactor-Specific Inhibitors:Antibodies specifically target neutralize activity particular coagulation factor (e.g., Factor VIII inhibitor)May cause severe bleedingTypically demonstrate time-dependent inhibition (clotting time becomes prolonged longer incubation times)Lupus Anticoagulants (LA):\nAutoantibodies bind phospholipids phospholipid-binding proteins\nInterfere phospholipid-dependent coagulation reactions vitro, leading prolonged clotting times\nExhibit phospholipid dependence: prolonged clotting times pronounced assays lower phospholipid concentrations\nAssociated increased risk thrombosis vivo\nLupus Anticoagulants (LA):Autoantibodies bind phospholipids phospholipid-binding proteinsInterfere phospholipid-dependent coagulation reactions vitro, leading prolonged clotting timesExhibit phospholipid dependence: prolonged clotting times pronounced assays lower phospholipid concentrationsAssociated increased risk thrombosis vivo","code":""},{"path":"mixing-studies-1.html","id":"pattern-of-correction-results","chapter":"Mixing Studies","heading":"Pattern of Correction Results","text":"Full Correction: Factor DeficiencyPartial Correction: Weak Inhibitor PresentNo Correction: Strong Inhibitor Present","code":""},{"path":"mixing-studies-1.html","id":"factors-affecting-mixing-study-results","chapter":"Mixing Studies","heading":"Factors Affecting Mixing Study Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nImproper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents, follow manufacturer’s instructions\nInadequate Incubation Time: Insufficient incubation time may allow inhibitors fully exert effect\nTemperature Variations: Maintain consistent temperature incubation\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents, follow manufacturer’s instructionsInadequate Incubation Time: Insufficient incubation time may allow inhibitors fully exert effectTemperature Variations: Maintain consistent temperature incubationPatient-Related Variables:\nMedications: Anticoagulants (e.g., heparin, direct oral anticoagulants)\nLiver Disease: May affect levels coagulation factors inhibitors\nAcute Phase Reactants: Can affect results\nMedications: Anticoagulants (e.g., heparin, direct oral anticoagulants)Liver Disease: May affect levels coagulation factors inhibitorsAcute Phase Reactants: Can affect results","code":""},{"path":"mixing-studies-1.html","id":"troubleshooting-erroneous-results-5","chapter":"Mixing Studies","heading":"Troubleshooting Erroneous Results","text":"mixing study results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nEnsure incubation time temperature correct\nInvestigate potential interfering substances medications\nmixing study results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsEnsure incubation time temperature correctInvestigate potential interfering substances medications","code":""},{"path":"mixing-studies-1.html","id":"reflex-testing-2","chapter":"Mixing Studies","heading":"Reflex Testing","text":"mixing study suggests factor deficiency:\nPerform individual factor assays identify specific factor deficient\nmixing study suggests factor deficiency:Perform individual factor assays identify specific factor deficientIf mixing study suggests presence factor inhibitor:\nPerform inhibitor assays identify quantify inhibitor\nFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): detect quantify Factor VIII inhibitors\nLupus Anticoagulant Testing:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\n\n\nConsider additional testing factor inhibitors (e.g., Factor V inhibitor) clinically indicated\nmixing study suggests presence factor inhibitor:Perform inhibitor assays identify quantify inhibitor\nFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): detect quantify Factor VIII inhibitors\nLupus Anticoagulant Testing:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\n\nFactor VIII Inhibitor Assay (Bethesda Assay Nijmegen-Bethesda Assay): detect quantify Factor VIII inhibitorsLupus Anticoagulant Testing:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\nDilute Russell’s Viper Venom Time (dRVVT)Silica Clotting Time (SCT)Hexagonal Phase Phospholipid Neutralization AssayConsider additional testing factor inhibitors (e.g., Factor V inhibitor) clinically indicated","code":""},{"path":"mixing-studies-1.html","id":"key-terms-90","chapter":"Mixing Studies","heading":"Key Terms","text":"Mixing Study: coagulation test differentiate factor deficiencies factor inhibitorsInhibitor: antibody interferes function coagulation factorCorrection: aPTT PT mixture returns within normal range, suggesting factor deficiencyNo Correction: aPTT PT mixture remains prolonged, suggesting presence inhibitorFactor Assay: laboratory test measure activity specific coagulation factorLupus Anticoagulant (LA): antibody binds phospholipids proteins associated cell membrane","code":""},{"path":"factor-assays.html","id":"factor-assays","chapter":"Factor Assays","heading":"Factor Assays","text":"","code":""},{"path":"factor-assays.html","id":"overview-of-factor-assays","chapter":"Factor Assays","heading":"Overview of Factor Assays","text":"Definition: Factor assays quantitative laboratory tests used measure activity level individual coagulation factors plasma. activity level reflects concentration functional capacity factorClinical Significance:\nDiagnosis Hereditary Factor Deficiencies: Confirms diagnosis hemophilia (Factor VIII deficiency), hemophilia B (Factor IX deficiency), inherited factor deficiencies\nDiagnosis Acquired Factor Deficiencies: Helps identify factor deficiencies caused liver disease, vitamin K deficiency, DIC\nMonitoring Treatment: Used monitor effectiveness factor replacement therapy treatments\nEvaluation Unexplained Bleeding: Helps identify subtle factor deficiencies may contribute bleeding tendency\nDiagnosis Hereditary Factor Deficiencies: Confirms diagnosis hemophilia (Factor VIII deficiency), hemophilia B (Factor IX deficiency), inherited factor deficienciesDiagnosis Acquired Factor Deficiencies: Helps identify factor deficiencies caused liver disease, vitamin K deficiency, DICMonitoring Treatment: Used monitor effectiveness factor replacement therapy treatmentsEvaluation Unexplained Bleeding: Helps identify subtle factor deficiencies may contribute bleeding tendencyPrinciple: Factor assays typically performed using coagulation analyzer based principle :\nMixing patient’s plasma factor-deficient plasma\nMeasuring clotting time addition reagent activates coagulation cascade\nextent patient’s plasma corrects clotting time factor-deficient plasma proportional activity factor measured\nMixing patient’s plasma factor-deficient plasmaMeasuring clotting time addition reagent activates coagulation cascadeThe extent patient’s plasma corrects clotting time factor-deficient plasma proportional activity factor measured","code":""},{"path":"factor-assays.html","id":"types-of-factor-assays","chapter":"Factor Assays","heading":"Types of Factor Assays","text":"One-Stage Clotting Assay:\ncommon type factor assay\nProcedure:\nPrepare Dilution Series: patient’s plasma diluted various concentrations\nMix Factor-Deficient Plasma: diluted patient plasma mixed commercially available plasma known deficient specific factor measured\nInitiate Coagulation: reagent (e.g., aPTT reagent PT reagent) added activate coagulation cascade\nMeasure Clotting Time: time clot formation measured\nCompare Standard Curve: clotting times compared standard curve generated using plasma known factor concentrations\nCalculate Factor Activity: factor activity level patient’s plasma determined based standard curve\n\nAdvantages:\nRelatively simple perform\nWidely available\n\nLimitations:\nCan affected inhibitors\nLess accurate low factor levels\n\nOne-Stage Clotting Assay:common type factor assayProcedure:\nPrepare Dilution Series: patient’s plasma diluted various concentrations\nMix Factor-Deficient Plasma: diluted patient plasma mixed commercially available plasma known deficient specific factor measured\nInitiate Coagulation: reagent (e.g., aPTT reagent PT reagent) added activate coagulation cascade\nMeasure Clotting Time: time clot formation measured\nCompare Standard Curve: clotting times compared standard curve generated using plasma known factor concentrations\nCalculate Factor Activity: factor activity level patient’s plasma determined based standard curve\nPrepare Dilution Series: patient’s plasma diluted various concentrationsMix Factor-Deficient Plasma: diluted patient plasma mixed commercially available plasma known deficient specific factor measuredInitiate Coagulation: reagent (e.g., aPTT reagent PT reagent) added activate coagulation cascadeMeasure Clotting Time: time clot formation measuredCompare Standard Curve: clotting times compared standard curve generated using plasma known factor concentrationsCalculate Factor Activity: factor activity level patient’s plasma determined based standard curveAdvantages:\nRelatively simple perform\nWidely available\nRelatively simple performWidely availableLimitations:\nCan affected inhibitors\nLess accurate low factor levels\nCan affected inhibitorsLess accurate low factor levelsChromogenic Assay:\nBased principle measuring activity chromogenic substrate cleaved coagulation factor\nProcedure:\nMix patient’s plasma reagent containing specific coagulation factor chromogenic substrate\ncoagulation factor cleaves substrate, releasing colored product\namount colored product measured spectrophotometrically\nfactor activity level determined based amount colored product produced\n\nAdvantages:\nsensitive clotting assays\nLess affected inhibitors\nCan automated\n\nChromogenic Assay:Based principle measuring activity chromogenic substrate cleaved coagulation factorProcedure:\nMix patient’s plasma reagent containing specific coagulation factor chromogenic substrate\ncoagulation factor cleaves substrate, releasing colored product\namount colored product measured spectrophotometrically\nfactor activity level determined based amount colored product produced\nMix patient’s plasma reagent containing specific coagulation factor chromogenic substrateThe coagulation factor cleaves substrate, releasing colored productThe amount colored product measured spectrophotometricallyThe factor activity level determined based amount colored product producedAdvantages:\nsensitive clotting assays\nLess affected inhibitors\nCan automated\nsensitive clotting assaysLess affected inhibitorsCan automated","code":""},{"path":"factor-assays.html","id":"components-of-a-factor-assay","chapter":"Factor Assays","heading":"Components of a Factor Assay","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n\nProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nTest performed within 4 hours collection plasma frozen testing performed later\n\nSpecimen Collection:Collection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n9:1 ratio blood anticoagulantProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nTest performed within 4 hours collection plasma frozen testing performed later\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LTest performed within 4 hours collection plasma frozen testing performed laterReagents:\nFactor-Deficient Plasma: Plasma specifically deficient factor measured\nPT aPTT Reagent: Depending specific assay, either PT aPTT reagent may used initiate coagulation\nCalcium Chloride: Provides calcium ions, essential activity coagulation factors\nThrombin Substrate: Solution used measure thrombin end point quantitative analysis fibrin formation.\nBuffers Diluents: Use dilute perform tests.\nReagents:Factor-Deficient Plasma: Plasma specifically deficient factor measuredPT aPTT Reagent: Depending specific assay, either PT aPTT reagent may used initiate coagulationCalcium Chloride: Provides calcium ions, essential activity coagulation factorsThrombin Substrate: Solution used measure thrombin end point quantitative analysis fibrin formation.Buffers Diluents: Use dilute perform tests.Instrumentation:\nAutomated Coagulation Analyzer: Detects clot formation using optical mechanical methods\nSpectrophotometer Chromatic Analyzer: Machines read color changes test\nInstrumentation:Automated Coagulation Analyzer: Detects clot formation using optical mechanical methodsSpectrophotometer Chromatic Analyzer: Machines read color changes test","code":""},{"path":"factor-assays.html","id":"procedure-for-performing-a-factor-assay","chapter":"Factor Assays","heading":"Procedure for Performing a Factor Assay","text":"Prepare Reagents: Follow manufacturer’s instructionsPrepare Plasma Dilutions: Prepare dilution series patient’s plasma normal control plasmaMix Patient Plasma Factor-Deficient Plasma: Mix diluted patient plasma factor-deficient plasmaInitiate Coagulation: Add appropriate reagent initiate coagulationMeasure Clotting Time: Measure time clot formationCreate Standard Curve: Create standard curve plotting clotting times normal control plasma dilutions known factor concentrationsDetermine Factor Activity: Use standard curve determine factor activity level patient’s plasmaReport Factor Activity Level: Report factor activity percentage normal (e.g., 50% normal)","code":""},{"path":"factor-assays.html","id":"interpreting-results-8","chapter":"Factor Assays","heading":"Interpreting Results","text":"Reference Range: Varies depending factor measured laboratory; typically 50-150%Decreased Factor Activity:\nFactor Activity < 50%: Suggests significant factor deficiency may associated bleeding symptoms\nSevere Deficiency (Factor Activity < 1%): Often associated severe bleeding (e.g., hemophilia)\nFactor Activity < 50%: Suggests significant factor deficiency may associated bleeding symptomsSevere Deficiency (Factor Activity < 1%): Often associated severe bleeding (e.g., hemophilia)Increased Factor Activity:\nMay seen acute phase reactions patients taking certain medications\nGenerally clinically significant\nMay seen acute phase reactions patients taking certain medicationsGenerally clinically significantReported abnormal aPTT PT used confirm results","code":""},{"path":"factor-assays.html","id":"factors-affecting-factor-assay-results","chapter":"Factor Assays","heading":"Factors Affecting Factor Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detection\nInhibitors: Presence factor-specific inhibitors can affect results (see )\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detectionInhibitors: Presence factor-specific inhibitors can affect results (see )Patient-Related Variables:\n* Medications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test resultsPatient-Related Variables:\n* Medications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test results","code":""},{"path":"factor-assays.html","id":"troubleshooting-erroneous-results-6","chapter":"Factor Assays","heading":"Troubleshooting Erroneous Results","text":"factor assay result inconsistent patient’s clinical presentation laboratory findings:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nPerform inhibitor studies rule factor inhibitors\nfactor assay result inconsistent patient’s clinical presentation laboratory findings:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyPerform inhibitor studies rule factor inhibitors","code":""},{"path":"factor-assays.html","id":"reflex-testing-3","chapter":"Factor Assays","heading":"Reflex Testing","text":"factor assay results abnormal, additional testing may performed :\nConfirm diagnosis\nCharacterize nature factor deficiency (e.g., quantitative vs. qualitative)\nEvaluate presence factor inhibitors\nConfirm diagnosisCharacterize nature factor deficiency (e.g., quantitative vs. qualitative)Evaluate presence factor inhibitors","code":""},{"path":"factor-assays.html","id":"key-terms-91","chapter":"Factor Assays","heading":"Key Terms","text":"Factor Assay: laboratory test measure activity specific coagulation factorFactor-Deficient Plasma: Plasma specifically deficient factor measuredStandard Curve: graph used determine concentration analyte based absorbance measurementChromogenic Assay: type assay measures activity enzyme measuring production colored productInhibitor: antibody substance interferes function coagulation factorInternational Units (IU): standard unit measurement enzyme activity","code":""},{"path":"inhibitor-assays.html","id":"inhibitor-assays","chapter":"Inhibitor Assays","heading":"Inhibitor Assays","text":"","code":""},{"path":"inhibitor-assays.html","id":"overview-of-inhibitor-assays","chapter":"Inhibitor Assays","heading":"Overview of Inhibitor Assays","text":"Definition: Inhibitor assays laboratory tests used detect quantify presence inhibitors plasma. Inhibitors substances, typically antibodies, interfere normal function coagulation factors, leading prolonged clotting times potential risk bleeding thrombosisClinical Significance:\nDiagnosis Acquired Hemophilia: Factor VIII inhibitors common cause acquired hemophilia, rare serious bleeding disorder\nEvaluation Prolonged Clotting Times: Used investigate unexplained prolonged PT aPTT results correct upon mixing normal plasma\nAssessment Thrombotic Risk: inhibitors, lupus anticoagulants, associated increased risk thrombosis\nMonitoring Immunosuppressive Therapy: Used monitor effectiveness immunosuppressive therapy patients acquired factor inhibitors\nDiagnosis Acquired Hemophilia: Factor VIII inhibitors common cause acquired hemophilia, rare serious bleeding disorderEvaluation Prolonged Clotting Times: Used investigate unexplained prolonged PT aPTT results correct upon mixing normal plasmaAssessment Thrombotic Risk: inhibitors, lupus anticoagulants, associated increased risk thrombosisMonitoring Immunosuppressive Therapy: Used monitor effectiveness immunosuppressive therapy patients acquired factor inhibitorsTypes Inhibitors:\nFactor-Specific Inhibitors: Antibodies specifically target neutralize activity particular coagulation factor (e.g., Factor VIII inhibitor, Factor V inhibitor)\nLupus Anticoagulants (LA): Autoantibodies bind phospholipids phospholipid-binding proteins, interfering phospholipid-dependent coagulation reactions\nFactor-Specific Inhibitors: Antibodies specifically target neutralize activity particular coagulation factor (e.g., Factor VIII inhibitor, Factor V inhibitor)Lupus Anticoagulants (LA): Autoantibodies bind phospholipids phospholipid-binding proteins, interfering phospholipid-dependent coagulation reactions","code":""},{"path":"inhibitor-assays.html","id":"factor-viii-inhibitor-assay-bethesda-assay","chapter":"Inhibitor Assays","heading":"Factor VIII Inhibitor Assay (Bethesda Assay)","text":"Principle:\nBethesda assay semi-quantitative assay measures ability patient plasma inhibit activity Factor VIII normal plasma\npatient’s plasma incubated normal plasma containing known amount FVIII\nresidual FVIII activity measured incubation, inhibitor titer calculated\nBethesda assay semi-quantitative assay measures ability patient plasma inhibit activity Factor VIII normal plasmaThe patient’s plasma incubated normal plasma containing known amount FVIIIThe residual FVIII activity measured incubation, inhibitor titer calculatedProcedure:\nPrepare Serial Dilutions Patient Plasma: patient’s plasma diluted buffer (e.g., imidazole buffer) create series dilutions\nPrepare Normal Plasma: Normal pooled plasma (NPP) used source Factor VIII\nNPP known FVIII activity level (typically 1.0 IU/mL)\n\nMix Patient Plasma Normal Plasma: Mix equal volumes diluted patient plasma normal pooled plasma\nPrepare control mixture normal plasma buffer (patient plasma)\n\nIncubate Mixtures: Incubate mixtures 37°C 2 hours\nallows time inhibitor patient plasma react FVIII normal plasma\n\nMeasure Residual FVIII Activity: incubation, measure FVIII activity level mixture using factor assay\nFVIII activity typically measured using chromogenic clotting-based assay\n\nCalculate Bethesda Units (BU):\nCalculate percentage FVIII neutralized patient plasma dilution\nOne Bethesda Unit (BU) defined amount inhibitor neutralizes 50% FVIII normal plasma\nBethesda titer determined plotting percentage FVIII neutralized dilution patient plasma\n\nPrepare Serial Dilutions Patient Plasma: patient’s plasma diluted buffer (e.g., imidazole buffer) create series dilutionsPrepare Normal Plasma: Normal pooled plasma (NPP) used source Factor VIII\nNPP known FVIII activity level (typically 1.0 IU/mL)\nNPP known FVIII activity level (typically 1.0 IU/mL)Mix Patient Plasma Normal Plasma: Mix equal volumes diluted patient plasma normal pooled plasma\nPrepare control mixture normal plasma buffer (patient plasma)\nPrepare control mixture normal plasma buffer (patient plasma)Incubate Mixtures: Incubate mixtures 37°C 2 hours\nallows time inhibitor patient plasma react FVIII normal plasma\nallows time inhibitor patient plasma react FVIII normal plasmaMeasure Residual FVIII Activity: incubation, measure FVIII activity level mixture using factor assay\nFVIII activity typically measured using chromogenic clotting-based assay\nFVIII activity typically measured using chromogenic clotting-based assayCalculate Bethesda Units (BU):\nCalculate percentage FVIII neutralized patient plasma dilution\nOne Bethesda Unit (BU) defined amount inhibitor neutralizes 50% FVIII normal plasma\nBethesda titer determined plotting percentage FVIII neutralized dilution patient plasma\nCalculate percentage FVIII neutralized patient plasma dilutionOne Bethesda Unit (BU) defined amount inhibitor neutralizes 50% FVIII normal plasmaThe Bethesda titer determined plotting percentage FVIII neutralized dilution patient plasmaReporting:\nReport FVIII inhibitor titer Bethesda Units (BU/mL)\nReport presence absence FVIII inhibitor\nInterpretation:\nInhibitor Present: Bethesda titer ≥ 0.6 BU/mL\nInhibitor Absent: Bethesda titer < 0.6 BU/mL\n\nReport FVIII inhibitor titer Bethesda Units (BU/mL)Report presence absence FVIII inhibitorInterpretation:\nInhibitor Present: Bethesda titer ≥ 0.6 BU/mL\nInhibitor Absent: Bethesda titer < 0.6 BU/mL\nInhibitor Present: Bethesda titer ≥ 0.6 BU/mLInhibitor Absent: Bethesda titer < 0.6 BU/mL","code":""},{"path":"inhibitor-assays.html","id":"lupus-anticoagulant-la-testing","chapter":"Inhibitor Assays","heading":"Lupus Anticoagulant (LA) Testing","text":"Lupus anticoagulants heterogenous group autoantibodies bind phospholipids phospholipid-binding proteins. presence antibodies can associated increased risk thrombosis (arterial venous) recurrent pregnancy lossPrinciple: Testing LA involves series phospholipid-dependent coagulation assays:\nProlonged Clotting Times: LA prolongs phospholipid-dependent clotting tests (e.g., aPTT, dRVVT)\nMixing Studies: prolonged clotting times correct upon mixing normal plasma (due presence inhibitor)\nPhospholipid Dependence: prolonged clotting times pronounced assays lower phospholipid concentrations\nPhospholipid Neutralization: prolonged clotting times corrected addition excess phospholipid\nProlonged Clotting Times: LA prolongs phospholipid-dependent clotting tests (e.g., aPTT, dRVVT)Mixing Studies: prolonged clotting times correct upon mixing normal plasma (due presence inhibitor)Phospholipid Dependence: prolonged clotting times pronounced assays lower phospholipid concentrationsPhospholipid Neutralization: prolonged clotting times corrected addition excess phospholipidRecommended Testing Sequence:\nScreening Test:\naPTT-LA (aPTT low phospholipid concentration): modified aPTT reagent low phospholipid concentration used enhance sensitivity LA\nDilute Russell’s Viper Venom Time (dRVVT): test sensitive presence LA\n\nMixing Study:\nscreening test prolonged, perform mixing study determine prolongation due factor deficiency inhibitor\nMix equal volumes patient’s plasma normal pooled plasma measure clotting time immediately incubation 37°C 1-2 hours\nclotting time correct, suggests presence inhibitor\n\nConfirmatory Testing:\nPhospholipid Neutralization Procedure:\ntest confirms presence phospholipid-dependent inhibitor\nprolonged clotting time corrected addition excess phospholipid\nHexagonal Phase Phospholipid Neutralization Assay (Staclot LA):\nsensitive specific test LA\nUses hexagonal phase phospholipids neutralize inhibitor\n\n\ndRVVT Mixing Study Correction:\ndRVVT repeated without addition excess phospholipid\nratio dRVVT phospholipid dRVVT without phospholipid calculated\nratio > 1.2 indicates presence LA\n\n\nScreening Test:\naPTT-LA (aPTT low phospholipid concentration): modified aPTT reagent low phospholipid concentration used enhance sensitivity LA\nDilute Russell’s Viper Venom Time (dRVVT): test sensitive presence LA\naPTT-LA (aPTT low phospholipid concentration): modified aPTT reagent low phospholipid concentration used enhance sensitivity LADilute Russell’s Viper Venom Time (dRVVT): test sensitive presence LAMixing Study:\nscreening test prolonged, perform mixing study determine prolongation due factor deficiency inhibitor\nMix equal volumes patient’s plasma normal pooled plasma measure clotting time immediately incubation 37°C 1-2 hours\nclotting time correct, suggests presence inhibitor\nscreening test prolonged, perform mixing study determine prolongation due factor deficiency inhibitorMix equal volumes patient’s plasma normal pooled plasma measure clotting time immediately incubation 37°C 1-2 hoursIf clotting time correct, suggests presence inhibitorConfirmatory Testing:\nPhospholipid Neutralization Procedure:\ntest confirms presence phospholipid-dependent inhibitor\nprolonged clotting time corrected addition excess phospholipid\nHexagonal Phase Phospholipid Neutralization Assay (Staclot LA):\nsensitive specific test LA\nUses hexagonal phase phospholipids neutralize inhibitor\n\n\ndRVVT Mixing Study Correction:\ndRVVT repeated without addition excess phospholipid\nratio dRVVT phospholipid dRVVT without phospholipid calculated\nratio > 1.2 indicates presence LA\n\nPhospholipid Neutralization Procedure:\ntest confirms presence phospholipid-dependent inhibitor\nprolonged clotting time corrected addition excess phospholipid\nHexagonal Phase Phospholipid Neutralization Assay (Staclot LA):\nsensitive specific test LA\nUses hexagonal phase phospholipids neutralize inhibitor\n\ntest confirms presence phospholipid-dependent inhibitorThe prolonged clotting time corrected addition excess phospholipidHexagonal Phase Phospholipid Neutralization Assay (Staclot LA):\nsensitive specific test LA\nUses hexagonal phase phospholipids neutralize inhibitor\nsensitive specific test LAUses hexagonal phase phospholipids neutralize inhibitordRVVT Mixing Study Correction:\ndRVVT repeated without addition excess phospholipid\nratio dRVVT phospholipid dRVVT without phospholipid calculated\nratio > 1.2 indicates presence LA\ndRVVT repeated without addition excess phospholipidThe ratio dRVVT phospholipid dRVVT without phospholipid calculatedA ratio > 1.2 indicates presence LAReporting:\nReport results test performed (screening test, mixing study, confirmatory test)\nIndicate whether patient positive negative lupus anticoagulant\nNote limitations testing (e.g., presence heparin direct oral anticoagulants)\nReport results test performed (screening test, mixing study, confirmatory test)Indicate whether patient positive negative lupus anticoagulantNote limitations testing (e.g., presence heparin direct oral anticoagulants)","code":""},{"path":"inhibitor-assays.html","id":"general-procedure-considerations","chapter":"Inhibitor Assays","heading":"General Procedure Considerations","text":"Sample Quality: Samples must free clots hemolysis must collected stored properlySample Quality: Samples must free clots hemolysis must collected stored properlyInstrumentation Reagents: Follow manufacturer’s instructions instrument calibration, reagent preparation, test performanceInstrumentation Reagents: Follow manufacturer’s instructions instrument calibration, reagent preparation, test performanceControls: Run control materials (normal abnormal) ensure test performing correctlyControls: Run control materials (normal abnormal) ensure test performing correctly","code":""},{"path":"inhibitor-assays.html","id":"factors-affecting-inhibitor-assay-results","chapter":"Inhibitor Assays","heading":"Factors Affecting Inhibitor Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors inhibitors can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors inhibitors can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detection\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detectionPatient-Related Variables:\nMedications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test results\nPatient-Related Variables:Medications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test results","code":""},{"path":"inhibitor-assays.html","id":"troubleshooting-erroneous-results-7","chapter":"Inhibitor Assays","heading":"Troubleshooting Erroneous Results","text":"inhibitor assay results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nPerform additional testing confirm presence absence inhibitor\ninhibitor assay results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyPerform additional testing confirm presence absence inhibitor","code":""},{"path":"inhibitor-assays.html","id":"key-terms-92","chapter":"Inhibitor Assays","heading":"Key Terms","text":"Inhibitor: antibody interferes function coagulation factorFactor VIII Inhibitor: antibody specifically targets neutralizes Factor VIIILupus Anticoagulant (LA): antibody binds phospholipids phospholipid-binding proteins prolongs clotting times vitroMixing Study: test used differentiate factor deficiencies factor inhibitorsBethesda Assay: method quantifying Factor VIII inhibitorsPhospholipid Dependence: characteristic lupus anticoagulants, prolonged clotting time pronounced assays lower phospholipid concentrationsCorrection: aPTT PT mixture returns within normal range, suggesting factor deficiencyNo Correction: aPTT PT mixture remains prolonged, suggesting presence inhibitor","code":""},{"path":"von-willebrand-assays.html","id":"von-willebrand-assays","chapter":"von Willebrand Assays","heading":"von Willebrand Assays","text":"","code":""},{"path":"von-willebrand-assays.html","id":"overview-of-von-willebrand-assays","chapter":"von Willebrand Assays","heading":"Overview of von Willebrand Assays","text":"Definition: panel laboratory tests used assess quantity function von Willebrand factor (vWF), protein essential normal blood clottingPurpose:\nDiagnosis von Willebrand Disease (vWD): Confirms diagnosis helps classify type vWD\nDifferentiation vWD Bleeding Disorders: Helps distinguish vWD hemophilia platelet function disorders\nEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleeding\nMonitoring Treatment: Used monitor response treatment vWD (e.g., desmopressin, vWF concentrates)\nDiagnosis von Willebrand Disease (vWD): Confirms diagnosis helps classify type vWDDifferentiation vWD Bleeding Disorders: Helps distinguish vWD hemophilia platelet function disordersEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleedingMonitoring Treatment: Used monitor response treatment vWD (e.g., desmopressin, vWF concentrates)Key Assays:\nvWF Antigen (vWF:Ag)\nvWF Activity (vWF:RCo)\nFactor VIII Activity (FVIII:C)\nvWF Multimeric Analysis\nPlatelet Function Analyzer (PFA-100) - though specific vWF, can assist diagnosis\nvWF Antigen (vWF:Ag)vWF Activity (vWF:RCo)Factor VIII Activity (FVIII:C)vWF Multimeric AnalysisPlatelet Function Analyzer (PFA-100) - though specific vWF, can assist diagnosis","code":""},{"path":"von-willebrand-assays.html","id":"components-of-von-willebrand-assays","chapter":"von Willebrand Assays","heading":"Components of von Willebrand Assays","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n\nProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nTest performed within 4 hours collection plasma frozen testing performed later. Specifics vary lab lab\n\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentrationBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n9:1 ratio blood anticoagulantProcessing:\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)\nPPP platelet count < 10 x 10^9/L\nTest performed within 4 hours collection plasma frozen testing performed later. Specifics vary lab lab\nCentrifuge sodium citrate tube obtain platelet-poor plasma (PPP)PPP platelet count < 10 x 10^9/LTest performed within 4 hours collection plasma frozen testing performed later. Specifics vary lab labReagents:\nvWF:Ag Reagent: Contains antibodies specific vWF\nvWF:RCo Reagent: Contains ristocetin, substance induces vWF-dependent platelet agglutination\nFactor VIII Reagent: Contains purified factor VIII\nvWF:Ag Reagent: Contains antibodies specific vWFvWF:RCo Reagent: Contains ristocetin, substance induces vWF-dependent platelet agglutinationFactor VIII Reagent: Contains purified factor VIII","code":""},{"path":"von-willebrand-assays.html","id":"individual-assays","chapter":"von Willebrand Assays","heading":"Individual Assays","text":"von Willebrand Factor Antigen (vWF:Ag):\nPrinciple: Measures amount vWF protein plasma, regardless function\nMethods:\nImmunoturbidimetry: Measures turbidity caused formation antigen-antibody complexes\nNephelometry: Measures light scattered antigen-antibody complexes\nELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect vWF\n\nProcedure:\nAdd anti-vWF antibodies\nRead test used whether measuring antibody test light determine concentration reference range\n\nReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-200%)\n\nInterpretation:\nDecreased vWF:Ag: Suggests quantitative deficiency vWF (seen type 1 type 3 vWD)\nNormal vWF:Ag: rule vWD; may seen qualitative vWF defects (type 2 vWD)\n\nvon Willebrand Factor Antigen (vWF:Ag):Principle: Measures amount vWF protein plasma, regardless functionMethods:\nImmunoturbidimetry: Measures turbidity caused formation antigen-antibody complexes\nNephelometry: Measures light scattered antigen-antibody complexes\nELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect vWF\nImmunoturbidimetry: Measures turbidity caused formation antigen-antibody complexesNephelometry: Measures light scattered antigen-antibody complexesELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect vWFProcedure:\nAdd anti-vWF antibodies\nRead test used whether measuring antibody test light determine concentration reference range\nAdd anti-vWF antibodiesRead test used whether measuring antibody test light determine concentration reference rangeReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-200%)\nReported percentage normal IU/dLReference Range: Varies depending laboratory assay used (e.g., 50-200%)Interpretation:\nDecreased vWF:Ag: Suggests quantitative deficiency vWF (seen type 1 type 3 vWD)\nNormal vWF:Ag: rule vWD; may seen qualitative vWF defects (type 2 vWD)\nDecreased vWF:Ag: Suggests quantitative deficiency vWF (seen type 1 type 3 vWD)Normal vWF:Ag: rule vWD; may seen qualitative vWF defects (type 2 vWD)von Willebrand Factor Activity (vWF:RCo):\nPrinciple: Measures ability vWF bind platelets presence ristocetin, cofactor promotes vWF-dependent platelet agglutination\nMethod:\nRistocetin-Induced Platelet Agglutination (RIPA):\nMeasures rate platelet agglutination addition ristocetin vWF-containing plasma\ndegree agglutination proportional vWF activity\n\nAutomated vWF Activity Assays:\nUse modified latex particles coated GPIbα (vWF receptor platelets)\nMeasure binding vWF latex particles presence ristocetin\nAutomated latex agglutination test can also called vWF:Glycoprotein 1b Binding Assay (vWF:GPIbM)\n\n\nProcedure:\nTest ran analyzer\nagglutination read\n\nReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-200%)\n\nInterpretation:\nDecreased vWF:RCo: Suggests functional defect vWF (seen types vWD)\nIncreased vWF:RCo: Seen type 2B vWD (vWF increased affinity platelets)\n\nvon Willebrand Factor Activity (vWF:RCo):Principle: Measures ability vWF bind platelets presence ristocetin, cofactor promotes vWF-dependent platelet agglutinationMethod:\nRistocetin-Induced Platelet Agglutination (RIPA):\nMeasures rate platelet agglutination addition ristocetin vWF-containing plasma\ndegree agglutination proportional vWF activity\n\nAutomated vWF Activity Assays:\nUse modified latex particles coated GPIbα (vWF receptor platelets)\nMeasure binding vWF latex particles presence ristocetin\nAutomated latex agglutination test can also called vWF:Glycoprotein 1b Binding Assay (vWF:GPIbM)\n\nRistocetin-Induced Platelet Agglutination (RIPA):\nMeasures rate platelet agglutination addition ristocetin vWF-containing plasma\ndegree agglutination proportional vWF activity\nMeasures rate platelet agglutination addition ristocetin vWF-containing plasmaThe degree agglutination proportional vWF activityAutomated vWF Activity Assays:\nUse modified latex particles coated GPIbα (vWF receptor platelets)\nMeasure binding vWF latex particles presence ristocetin\nAutomated latex agglutination test can also called vWF:Glycoprotein 1b Binding Assay (vWF:GPIbM)\nUse modified latex particles coated GPIbα (vWF receptor platelets)Measure binding vWF latex particles presence ristocetinAutomated latex agglutination test can also called vWF:Glycoprotein 1b Binding Assay (vWF:GPIbM)Procedure:\nTest ran analyzer\nagglutination read\nTest ran analyzerThe agglutination readReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-200%)\nReported percentage normal IU/dLReference Range: Varies depending laboratory assay used (e.g., 50-200%)Interpretation:\nDecreased vWF:RCo: Suggests functional defect vWF (seen types vWD)\nIncreased vWF:RCo: Seen type 2B vWD (vWF increased affinity platelets)\nDecreased vWF:RCo: Suggests functional defect vWF (seen types vWD)Increased vWF:RCo: Seen type 2B vWD (vWF increased affinity platelets)Factor VIII Activity (FVIII:C):\nPrinciple: Measures activity factor VIII, coagulation protein bound stabilized vWF\nMethods:\nChromogenic Assay: Measures amount activated Factor X (Factor Xa) produced presence Factor VIII coagulation factors\nClotting Assay: Measures ability plasma correct aPTT Factor VIII-deficient plasma\n\nProcedure:\nFollow Factor Assay procedure\n\nReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-150%)\n\nInterpretation:\nDecreased FVIII:C: Suggests vWD type 2N (decreased binding vWF FVIII) hemophilia (Factor VIII deficiency)\n\nFactor VIII Activity (FVIII:C):Principle: Measures activity factor VIII, coagulation protein bound stabilized vWFMethods:\nChromogenic Assay: Measures amount activated Factor X (Factor Xa) produced presence Factor VIII coagulation factors\nClotting Assay: Measures ability plasma correct aPTT Factor VIII-deficient plasma\nChromogenic Assay: Measures amount activated Factor X (Factor Xa) produced presence Factor VIII coagulation factorsClotting Assay: Measures ability plasma correct aPTT Factor VIII-deficient plasmaProcedure:\nFollow Factor Assay procedure\nFollow Factor Assay procedureReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 50-150%)\nReported percentage normal IU/dLReference Range: Varies depending laboratory assay used (e.g., 50-150%)Interpretation:\nDecreased FVIII:C: Suggests vWD type 2N (decreased binding vWF FVIII) hemophilia (Factor VIII deficiency)\nDecreased FVIII:C: Suggests vWD type 2N (decreased binding vWF FVIII) hemophilia (Factor VIII deficiency)vWF Multimeric Analysis:\nPrinciple: Evaluates distribution vWF multimers, polymers vWF subunits\nMethod:\nGel Electrophoresis: vWF multimers separated electrophoresis agarose gel\nImmunoblotting: separated multimers transferred membrane detected antibody specific vWF\nVisualization: multimers visualized using staining detection method\n\nInterpretation:\nNormal Multimer Pattern: full range vWF multimers present\nAbnormal Multimer Pattern: Decreased high-molecular-weight multimers (HMW multimers) seen type 2A vWD\n\nClinical Significance: Helps differentiate type 2A vWD subtypes vWD\nvWF Multimeric Analysis:Principle: Evaluates distribution vWF multimers, polymers vWF subunitsMethod:\nGel Electrophoresis: vWF multimers separated electrophoresis agarose gel\nImmunoblotting: separated multimers transferred membrane detected antibody specific vWF\nVisualization: multimers visualized using staining detection method\nGel Electrophoresis: vWF multimers separated electrophoresis agarose gelImmunoblotting: separated multimers transferred membrane detected antibody specific vWFVisualization: multimers visualized using staining detection methodInterpretation:\nNormal Multimer Pattern: full range vWF multimers present\nAbnormal Multimer Pattern: Decreased high-molecular-weight multimers (HMW multimers) seen type 2A vWD\nNormal Multimer Pattern: full range vWF multimers presentAbnormal Multimer Pattern: Decreased high-molecular-weight multimers (HMW multimers) seen type 2A vWDClinical Significance: Helps differentiate type 2A vWD subtypes vWD","code":""},{"path":"von-willebrand-assays.html","id":"pfa-100-platelet-function-analyzer","chapter":"von Willebrand Assays","heading":"PFA-100 (Platelet Function Analyzer)","text":"Principle: Measures platelet function high shear stress aspirating blood small aperture coated collagen epinephrine collagen ADPProcedure:\ncitrated whole blood sample aspirated small aperture coated collagen either epinephrine ADP\ntime takes aperture become occluded platelet plug measured (closure time)\ncitrated whole blood sample aspirated small aperture coated collagen either epinephrine ADPThe time takes aperture become occluded platelet plug measured (closure time)Results:\nClosure Time (CT):\nEpinephrine Closure Time (Epi-CT): Measures platelet function response collagen epinephrine\nADP Closure Time (ADP-CT): Measures platelet function response collagen ADP\n\nClosure Time (CT):\nEpinephrine Closure Time (Epi-CT): Measures platelet function response collagen epinephrine\nADP Closure Time (ADP-CT): Measures platelet function response collagen ADP\nEpinephrine Closure Time (Epi-CT): Measures platelet function response collagen epinephrineADP Closure Time (ADP-CT): Measures platelet function response collagen ADPInterpretation:\nProlonged Closure Time: Suggests platelet dysfunction\nProlonged Epi-CT ADP-CT: May seen vWD, aspirin use, platelet function disorders\n\nNormal Closure Time: rule vWD platelet function disorders\nProlonged Closure Time: Suggests platelet dysfunction\nProlonged Epi-CT ADP-CT: May seen vWD, aspirin use, platelet function disorders\nProlonged Epi-CT ADP-CT: May seen vWD, aspirin use, platelet function disordersNormal Closure Time: rule vWD platelet function disordersLimitations:\nAffected Hematocrit: Must performed samples hematocrit within specified range\nAffected Platelet count: Must performed samples platelet count within specified range\nSpecific vWD: Prolonged closure time can seen platelet function disorders\nAffected Hematocrit: Must performed samples hematocrit within specified rangeAffected Platelet count: Must performed samples platelet count within specified rangeNot Specific vWD: Prolonged closure time can seen platelet function disorders","code":""},{"path":"von-willebrand-assays.html","id":"interpreting-von-willebrand-assay-results","chapter":"von Willebrand Assays","heading":"Interpreting von Willebrand Assay Results","text":"following table summarizes typical patterns results seen different types vWD:","code":""},{"path":"von-willebrand-assays.html","id":"factors-affecting-von-willebrand-assay-results","chapter":"von Willebrand Assays","heading":"Factors Affecting von Willebrand Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: vWF FVIII can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: vWF FVIII can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: Lipemia icterus can interfere optical clot detection\nAssay Sensitivity: Different assays different sensitivities detecting vWF abnormalities\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: Lipemia icterus can interfere optical clot detectionAssay Sensitivity: Different assays different sensitivities detecting vWF abnormalitiesPatient-Related Variables:\nBlood Type: vWF levels typically lower individuals blood type O\nAge: vWF levels increase age\nPregnancy: vWF levels increase pregnancy\nEstrogen Therapy: Increases vWF levels\nAcute Phase Reactants: vWF acute phase reactant, levels can increase inflammation infection\nPatient-Related Variables:Blood Type: vWF levels typically lower individuals blood type OAge: vWF levels increase agePregnancy: vWF levels increase pregnancyEstrogen Therapy: Increases vWF levelsAcute Phase Reactants: vWF acute phase reactant, levels can increase inflammation infection","code":""},{"path":"von-willebrand-assays.html","id":"troubleshooting-erroneous-results-8","chapter":"von Willebrand Assays","heading":"Troubleshooting Erroneous Results","text":"vWF assay results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nConsider repeating vWF assays period stability (account normal fluctuations vWF levels)\nEvaluate potential interfering substances medications\nConsult pathologist coagulation expert\nvWF assay results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsConsider repeating vWF assays period stability (account normal fluctuations vWF levels)Evaluate potential interfering substances medicationsConsult pathologist coagulation expert","code":""},{"path":"von-willebrand-assays.html","id":"reflex-testing-4","chapter":"von Willebrand Assays","heading":"Reflex Testing","text":"initial vWF assays abnormal, testing may performed :\nCharacterize type vWD (e.g., multimer analysis, FVIII binding assay)\nRule causes bleeding (e.g., platelet function disorders)\nPerform genetic testing identify specific vWF gene mutations\ninitial vWF assays abnormal, testing may performed :Characterize type vWD (e.g., multimer analysis, FVIII binding assay)Rule causes bleeding (e.g., platelet function disorders)Perform genetic testing identify specific vWF gene mutations","code":""},{"path":"von-willebrand-assays.html","id":"key-terms-93","chapter":"von Willebrand Assays","heading":"Key Terms","text":"von Willebrand Factor (vWF): protein mediates platelet adhesion carries factor VIIIvWF Antigen (vWF:Ag): Measures amount vWF proteinvWF Activity (vWF:RCo): Measures ability vWF bind plateletsFactor VIII (FVIII:C): coagulation protein carried vWFRistocetin: antibiotic induces vWF-dependent platelet agglutinationMultimer Analysis: Evaluates distribution vWF multimersPlatelet Function Analyzer (PFA): test measures platelet function high shear stressDesmopressin (DDAVP): synthetic analog vasopressin stimulates release vWF factor VIIIType 1 vWD: Partial quantitative deficiency vWFType 2 vWD: Qualitative defects vWF functionType 3 vWD: Severe quantitative deficiency vWF","code":""},{"path":"platelet-function.html","id":"platelet-function","chapter":"Platelet Function","heading":"Platelet Function","text":"","code":""},{"path":"platelet-function.html","id":"overview-of-platelet-function-testing","chapter":"Platelet Function","heading":"Overview of Platelet Function Testing","text":"Definition: Platelet function tests group laboratory assays used evaluate ability platelets perform role primary hemostasis (forming initial platelet plug)Purpose:\nDiagnosis Platelet Disorders: Helps identify inherited acquired disorders platelet function\nEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleeding (e.g., nosebleeds, easy bruising, prolonged bleeding minor cuts)\nAssessment Antiplatelet Therapy: Used monitor effects antiplatelet medications (e.g., aspirin, clopidogrel)\nPreoperative Assessment: Helps assess risk bleeding surgery\nDiagnosis Platelet Disorders: Helps identify inherited acquired disorders platelet functionEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleeding (e.g., nosebleeds, easy bruising, prolonged bleeding minor cuts)Assessment Antiplatelet Therapy: Used monitor effects antiplatelet medications (e.g., aspirin, clopidogrel)Preoperative Assessment: Helps assess risk bleeding surgeryTypes Platelet Function Tests:\nScreening Tests:\nPlatelet Function Analyzer (PFA)\n\nConfirmatory Tests:\nPlatelet Aggregation Studies\nFlow Cytometry Assays\nPlatelet Secretion Assays\nGenetic Testing\n\nScreening Tests:\nPlatelet Function Analyzer (PFA)\nPlatelet Function Analyzer (PFA)Confirmatory Tests:\nPlatelet Aggregation Studies\nFlow Cytometry Assays\nPlatelet Secretion Assays\nGenetic Testing\nPlatelet Aggregation StudiesFlow Cytometry AssaysPlatelet Secretion AssaysGenetic Testing","code":""},{"path":"platelet-function.html","id":"platelet-function-analyzer-pfa","chapter":"Platelet Function","heading":"Platelet Function Analyzer (PFA)","text":"Principle:\nPFA-100 PFA-200 systems vitro assays simulate high-shear conditions found small blood vessels\nWhole blood aspirated small aperture (hole) cartridge coated platelet agonist (collagen/epinephrine collagen/ADP)\nblood passes aperture, platelets adhere collagen activated agonist\nplatelets aggregate eventually occlude aperture, stopping flow blood\ntime takes aperture become occluded measured reported Closure Time (CT)\nPrinciple:PFA-100 PFA-200 systems vitro assays simulate high-shear conditions found small blood vesselsWhole blood aspirated small aperture (hole) cartridge coated platelet agonist (collagen/epinephrine collagen/ADP)blood passes aperture, platelets adhere collagen activated agonistThe platelets aggregate eventually occlude aperture, stopping flow bloodThe time takes aperture become occluded measured reported Closure Time (CT)Key Components PFA System:\nInstrumentation:\nPFA-100 PFA-200 analyzer\n\nCartridges:\nCollagen/Epinephrine (CEPI) Cartridge: Coated collagen epinephrine; primarily detects aspirin-related platelet dysfunction\nCollagen/ADP (CADP) Cartridge: Coated collagen ADP; detects broader range platelet function defects\n\nQuality Control Materials:\nNormal controls verify instrument performance\n\nKey Components PFA System:Instrumentation:\nPFA-100 PFA-200 analyzer\nPFA-100 PFA-200 analyzerCartridges:\nCollagen/Epinephrine (CEPI) Cartridge: Coated collagen epinephrine; primarily detects aspirin-related platelet dysfunction\nCollagen/ADP (CADP) Cartridge: Coated collagen ADP; detects broader range platelet function defects\nCollagen/Epinephrine (CEPI) Cartridge: Coated collagen epinephrine; primarily detects aspirin-related platelet dysfunctionCollagen/ADP (CADP) Cartridge: Coated collagen ADP; detects broader range platelet function defectsQuality Control Materials:\nNormal controls verify instrument performance\nNormal controls verify instrument performanceProcedure:\nSample Collection:\nCollect whole blood sodium citrate (light blue top) tube\nEnsure tube filled correct volume maintain proper blood--anticoagulant ratio\n\nSample Preparation:\nMix blood sample gently thoroughly\nTest sample within specified timeframe (usually within 2-4 hours collection)\nEnsure hematocrit platelet count within acceptable range instrument\n\nCartridge Insertion:\nInsert appropriate PFA cartridge (CEPI CADP) analyzer\n\nSample Aspiration:\nAspirate small amount whole blood sample analyzer\n\nTest Initiation:\nStart test allow instrument perform analysis\nanalyzer measure time takes aperture become occluded (Closure Time)\n\nQuality Control:\nRun control materials regular intervals verify instrument performance\nDocument QC results\n\nResults:\ninstrument reports Closure Time (CT) seconds CEPI CADP cartridges\n\nProcedure:Sample Collection:\nCollect whole blood sodium citrate (light blue top) tube\nEnsure tube filled correct volume maintain proper blood--anticoagulant ratio\nCollect whole blood sodium citrate (light blue top) tubeEnsure tube filled correct volume maintain proper blood--anticoagulant ratioSample Preparation:\nMix blood sample gently thoroughly\nTest sample within specified timeframe (usually within 2-4 hours collection)\nEnsure hematocrit platelet count within acceptable range instrument\nMix blood sample gently thoroughlyTest sample within specified timeframe (usually within 2-4 hours collection)Ensure hematocrit platelet count within acceptable range instrumentCartridge Insertion:\nInsert appropriate PFA cartridge (CEPI CADP) analyzer\nInsert appropriate PFA cartridge (CEPI CADP) analyzerSample Aspiration:\nAspirate small amount whole blood sample analyzer\nAspirate small amount whole blood sample analyzerTest Initiation:\nStart test allow instrument perform analysis\nanalyzer measure time takes aperture become occluded (Closure Time)\nStart test allow instrument perform analysisThe analyzer measure time takes aperture become occluded (Closure Time)Quality Control:\nRun control materials regular intervals verify instrument performance\nDocument QC results\nRun control materials regular intervals verify instrument performanceDocument QC resultsResults:\ninstrument reports Closure Time (CT) seconds CEPI CADP cartridges\ninstrument reports Closure Time (CT) seconds CEPI CADP cartridgesReporting Interpretation:\nClosure Time (CT):\nEpinephrine Closure Time (Epi-CT):\nReference Range: Varies depending laboratory PFA instrument (e.g., 84-169 seconds)\nProlonged Epi-CT: Suggests aspirin-related platelet dysfunction severe platelet defect\nADP Closure Time (ADP-CT):\nReference Range: Varies depending laboratory PFA instrument (e.g., 71-118 seconds)\nProlonged ADP-CT: Suggests platelet function defect related aspirin (e.g., P2Y12 inhibitors, von Willebrand disease, Glanzmann thrombasthenia)\n\nReporting Interpretation:Closure Time (CT):\nEpinephrine Closure Time (Epi-CT):\nReference Range: Varies depending laboratory PFA instrument (e.g., 84-169 seconds)\nProlonged Epi-CT: Suggests aspirin-related platelet dysfunction severe platelet defect\nADP Closure Time (ADP-CT):\nReference Range: Varies depending laboratory PFA instrument (e.g., 71-118 seconds)\nProlonged ADP-CT: Suggests platelet function defect related aspirin (e.g., P2Y12 inhibitors, von Willebrand disease, Glanzmann thrombasthenia)\nEpinephrine Closure Time (Epi-CT):Reference Range: Varies depending laboratory PFA instrument (e.g., 84-169 seconds)Prolonged Epi-CT: Suggests aspirin-related platelet dysfunction severe platelet defectADP Closure Time (ADP-CT):Reference Range: Varies depending laboratory PFA instrument (e.g., 71-118 seconds)Prolonged ADP-CT: Suggests platelet function defect related aspirin (e.g., P2Y12 inhibitors, von Willebrand disease, Glanzmann thrombasthenia)","code":""},{"path":"platelet-function.html","id":"interpreting-pfa-results","chapter":"Platelet Function","heading":"Interpreting PFA Results:","text":"normal results?\nCEPI test - ~84-169 Seconds\nCADP test - ~71-118 Seconds\nranges can vary depending institution, please note institution’s specific ranges!\n\nCEPI test - ~84-169 SecondsFor CADP test - ~71-118 Seconds\nranges can vary depending institution, please note institution’s specific ranges!\nranges can vary depending institution, please note institution’s specific ranges!higher normal range?\nindicate patient taking platelet inhibitors asprin\nVon Willebrand Disease\nmay Glanzmann Thrombasthenia\nindicate patient taking platelet inhibitors asprinThey Von Willebrand DiseaseThey may Glanzmann Thrombasthenia","code":""},{"path":"platelet-function.html","id":"factors-affecting-pfa-results","chapter":"Platelet Function","heading":"Factors Affecting PFA Results","text":"Pre-Analytical Variables:\nSample Collection: Traumatic venipuncture use small-gauge needle can activate platelets affect results\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube can alter test results\nDelayed Testing: Platelet function can change time, test performed within specified timeframe (usually 2-4 hours collection)\nStorage Temperature: Improper storage temperatures can affect platelet function\nPre-Analytical Variables:Sample Collection: Traumatic venipuncture use small-gauge needle can activate platelets affect resultsIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube can alter test resultsDelayed Testing: Platelet function can change time, test performed within specified timeframe (usually 2-4 hours collection)Storage Temperature: Improper storage temperatures can affect platelet functionAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance PFA instrument\nReagent Problems: Use fresh, properly stored cartridges\nHematocrit: Hematocrit values outside specified range can affect closure time\nLow Hematocrit: Can prolong closure time\nHigh Hematocrit: Can shorten closure time\n\nPlatelet Count: Platelet counts outside specified range can affect closure time\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance PFA instrumentReagent Problems: Use fresh, properly stored cartridgesHematocrit: Hematocrit values outside specified range can affect closure time\nLow Hematocrit: Can prolong closure time\nHigh Hematocrit: Can shorten closure time\nLow Hematocrit: Can prolong closure timeHigh Hematocrit: Can shorten closure timePlatelet Count: Platelet counts outside specified range can affect closure timePatient-Related Variables:\nMedications:\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 production, leading prolonged Epi-CT\nP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor platelets, leading prolonged ADP-CT Epi-CT\n\nUnderlying Medical Conditions:\nvon Willebrand Disease (vWD): Deficiency dysfunction vWF can impair platelet adhesion prolong closure times\nThrombocytopenia: Low platelet count can affect closure times\n\nPatient-Related Variables:Medications:\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 production, leading prolonged Epi-CT\nP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor platelets, leading prolonged ADP-CT Epi-CT\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 production, leading prolonged Epi-CTP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor platelets, leading prolonged ADP-CT Epi-CTUnderlying Medical Conditions:\nvon Willebrand Disease (vWD): Deficiency dysfunction vWF can impair platelet adhesion prolong closure times\nThrombocytopenia: Low platelet count can affect closure times\nvon Willebrand Disease (vWD): Deficiency dysfunction vWF can impair platelet adhesion prolong closure timesThrombocytopenia: Low platelet count can affect closure times","code":""},{"path":"platelet-function.html","id":"troubleshooting-erroneous-results-9","chapter":"Platelet Function","heading":"Troubleshooting Erroneous Results","text":"PFA results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nVerify hematocrit platelet count within acceptable range instrument\nRepeat test fresh sample\nReview patient’s medication list medical history\nConsider performing platelet aggregation studies specialized tests\nPFA results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisVerify hematocrit platelet count within acceptable range instrumentRepeat test fresh sampleReview patient’s medication list medical historyConsider performing platelet aggregation studies specialized tests","code":""},{"path":"platelet-function.html","id":"reflex-testing-5","chapter":"Platelet Function","heading":"Reflex Testing","text":"PFA results abnormal, additional testing may performed :\nInvestigate potential underlying causes platelet dysfunction\nPlatelet Aggregation Studies: assess platelet aggregation response various agonists (ADP, collagen, epinephrine, thrombin, arachidonic acid, ristocetin)\nFlow Cytometry: measure platelet surface markers assess platelet activation\nBleeding Time: Seldom performed now days\n\nPFA results abnormal, additional testing may performed :Investigate potential underlying causes platelet dysfunction\nPlatelet Aggregation Studies: assess platelet aggregation response various agonists (ADP, collagen, epinephrine, thrombin, arachidonic acid, ristocetin)\nFlow Cytometry: measure platelet surface markers assess platelet activation\nBleeding Time: Seldom performed now days\nPlatelet Aggregation Studies: assess platelet aggregation response various agonists (ADP, collagen, epinephrine, thrombin, arachidonic acid, ristocetin)Flow Cytometry: measure platelet surface markers assess platelet activationBleeding Time: Seldom performed now days","code":""},{"path":"platelet-function.html","id":"key-terms-94","chapter":"Platelet Function","heading":"Key Terms","text":"Platelet Function Analyzer (PFA): vitro assay measures platelet function high shear stressClosure Time (CT): time takes aperture PFA cartridge become occluded platelet plugEpinephrine Closure Time (Epi-CT): Closure time using cartridge coated collagen epinephrineADP Closure Time (ADP-CT): Closure time using cartridge coated collagen ADPPlatelet Aggregation: clumping together plateletsvon Willebrand Disease (vWD): inherited bleeding disorder caused deficiency dysfunction von Willebrand factorAspirin: medication inhibits platelet function inhibiting cyclooxygenase (COX)P2Y12 Inhibitors: Medications block ADP receptor platelets, inhibiting platelet activation aggregation","code":""},{"path":"platelet-aggregation.html","id":"platelet-aggregation","chapter":"Platelet Aggregation","heading":"Platelet Aggregation","text":"","code":""},{"path":"platelet-aggregation.html","id":"overview-of-platelet-aggregation-studies","chapter":"Platelet Aggregation","heading":"Overview of Platelet Aggregation Studies","text":"Definition: Platelet aggregation studies vitro tests measure ability platelets aggregate (clump together) response various agonistsPurpose:\nDiagnosis Platelet Function Disorders: Helps identify inherited acquired disorders platelet function\nEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleeding\nAssessment Antiplatelet Therapy: Used monitor effects antiplatelet medications (e.g., aspirin, clopidogrel)\nResearch: Used study platelet physiology pharmacology\nDiagnosis Platelet Function Disorders: Helps identify inherited acquired disorders platelet functionEvaluation Unexplained Bleeding: Used investigate patients personal family history mucocutaneous bleedingAssessment Antiplatelet Therapy: Used monitor effects antiplatelet medications (e.g., aspirin, clopidogrel)Research: Used study platelet physiology pharmacologyKey Principle: Measures change light transmission platelet-rich plasma (PRP) sample platelets aggregateAgonists Used: Different agonists stimulate platelet aggregation via different pathways, allowing assessment specific platelet functions:\nAdenosine Diphosphate (ADP)\nCollagen\nEpinephrine\nArachidonic Acid (AA)\nRistocetin\nThrombin Receptor-Activating Peptide (TRAP)\nAdenosine Diphosphate (ADP)CollagenEpinephrineArachidonic Acid (AA)RistocetinThrombin Receptor-Activating Peptide (TRAP)","code":""},{"path":"platelet-aggregation.html","id":"components-of-platelet-aggregation-studies","chapter":"Platelet Aggregation","heading":"Components of Platelet Aggregation Studies","text":"Specimen Collection:\nCollection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration. important use correct sodium citrate concentration fill collection tube way fill line.\nBlood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n\nCollection Technique: Atraumatic venipuncture avoid platelet activation\nTransport Storage: Transport sample laboratory promptly (within 30 minutes).\nMaintain sample room temperature (18-24°C)\nrefrigerate freeze sample\n\nPatient Preparation:\nMedication Restrictions: Patients avoid taking aspirin antiplatelet medications least 7-10 days testing\n\nSpecimen Collection:Collection Tube: Sodium citrate (light blue top) tube 3.2% 3.8% sodium citrate concentration. important use correct sodium citrate concentration fill collection tube way fill line.Blood--Anticoagulant Ratio: correct ratio critical accurate coagulation testing:\n9:1 ratio blood anticoagulant\n9:1 ratio blood anticoagulantCollection Technique: Atraumatic venipuncture avoid platelet activationTransport Storage: Transport sample laboratory promptly (within 30 minutes).\nMaintain sample room temperature (18-24°C)\nrefrigerate freeze sample\nMaintain sample room temperature (18-24°C)refrigerate freeze samplePatient Preparation:\nMedication Restrictions: Patients avoid taking aspirin antiplatelet medications least 7-10 days testing\nMedication Restrictions: Patients avoid taking aspirin antiplatelet medications least 7-10 days testingReagents:\nPlatelet Aggregating Agents (Agonists): ADP, collagen, epinephrine, arachidonic acid, ristocetin, thrombin receptor-activating peptide (TRAP)\nPlatelet-Poor Plasma (PPP): Used blank calibrate aggregometer reference 100% light transmission\nSaline Buffer: Used dilute reagents samples\nQuality Control Materials: Commercially available control materials pooled normal plasma may used monitor performance assay\nReagents:Platelet Aggregating Agents (Agonists): ADP, collagen, epinephrine, arachidonic acid, ristocetin, thrombin receptor-activating peptide (TRAP)Platelet-Poor Plasma (PPP): Used blank calibrate aggregometer reference 100% light transmissionSaline Buffer: Used dilute reagents samplesQuality Control Materials: Commercially available control materials pooled normal plasma may used monitor performance assayInstrumentation:\nPlatelet Aggregometer: specialized instrument measures platelet aggregation monitoring changes light transmission stirred suspension platelet-rich plasma\nComponents Aggregometer:\nLight Source: Provides beam light passes sample\nCuvette Holder: Holds sample cuvette\nStirring Mechanism: Continuously stirs sample maintain homogenous suspension platelets\nDetector: Measures amount light transmitted sample\nRecording Device: Records change light transmission time, generating aggregation curve\n\nInstrumentation:Platelet Aggregometer: specialized instrument measures platelet aggregation monitoring changes light transmission stirred suspension platelet-rich plasmaComponents Aggregometer:\nLight Source: Provides beam light passes sample\nCuvette Holder: Holds sample cuvette\nStirring Mechanism: Continuously stirs sample maintain homogenous suspension platelets\nDetector: Measures amount light transmitted sample\nRecording Device: Records change light transmission time, generating aggregation curve\nLight Source: Provides beam light passes sampleCuvette Holder: Holds sample cuvetteStirring Mechanism: Continuously stirs sample maintain homogenous suspension plateletsDetector: Measures amount light transmitted sampleRecording Device: Records change light transmission time, generating aggregation curve","code":""},{"path":"platelet-aggregation.html","id":"procedure-for-performing-platelet-aggregation-studies","chapter":"Platelet Aggregation","heading":"Procedure for Performing Platelet Aggregation Studies","text":"Prepare Platelet-Rich Plasma (PRP):\nCentrifuge sodium citrate whole blood sample low speed (e.g., 150-200 g) 10-20 minutes obtain PRP\nCarefully remove PRP layer without disturbing RBC layer\nCentrifuge sodium citrate whole blood sample low speed (e.g., 150-200 g) 10-20 minutes obtain PRPCarefully remove PRP layer without disturbing RBC layerAdjust Platelet Count:\nAdjust platelet count PRP standardized level (typically 200-300 x 10^9/L) adding autologous platelet-poor plasma (PPP)\nAccurate platelet count adjustment critical obtaining reliable reproducible results\nAdjust platelet count PRP standardized level (typically 200-300 x 10^9/L) adding autologous platelet-poor plasma (PPP)Accurate platelet count adjustment critical obtaining reliable reproducible resultsPrepare Reagents:\nDilute platelet aggregating agents (agonists) appropriate concentrations according manufacturer’s instructions\nWarm reagents room temperature\nDilute platelet aggregating agents (agonists) appropriate concentrations according manufacturer’s instructionsWarm reagents room temperatureRun Assay:\nPipette specific volume PRP cuvette\nPlace cuvette aggregometer\nAllow sample equilibrate 37°C specific period (e.g., 2-5 minutes)\nAdd agonist PRP\nStart stirring mechanism recording device\nMonitor change light transmission time\nPipette specific volume PRP cuvettePlace cuvette aggregometerAllow sample equilibrate 37°C specific period (e.g., 2-5 minutes)Add agonist PRPStart stirring mechanism recording deviceMonitor change light transmission time","code":""},{"path":"platelet-aggregation.html","id":"interpreting-results-9","chapter":"Platelet Aggregation","heading":"Interpreting Results","text":"Aggregation Curve:\naggregometer records change light transmission time, generating aggregation curve\ncurve typically consists two phases:\nPrimary Aggregation: Initial wave aggregation, caused agonist-induced shape change adhesion single platelets\nSecondary Aggregation: Sustained aggregation, caused release mediators platelet granules (e.g., ADP, thromboxane A2) activation additional platelets\n\nAggregation Curve:aggregometer records change light transmission time, generating aggregation curveThe curve typically consists two phases:\nPrimary Aggregation: Initial wave aggregation, caused agonist-induced shape change adhesion single platelets\nSecondary Aggregation: Sustained aggregation, caused release mediators platelet granules (e.g., ADP, thromboxane A2) activation additional platelets\nPrimary Aggregation: Initial wave aggregation, caused agonist-induced shape change adhesion single plateletsSecondary Aggregation: Sustained aggregation, caused release mediators platelet granules (e.g., ADP, thromboxane A2) activation additional plateletsParameters Evaluated:\nMaximum Aggregation: highest percentage light transmission achieved aggregation response\nSlope Curve: rate aggregation\nLag Phase: time addition agonist start aggregation\nShape Curve: presence absence secondary wave aggregation\nParameters Evaluated:Maximum Aggregation: highest percentage light transmission achieved aggregation responseSlope Curve: rate aggregationLag Phase: time addition agonist start aggregationShape Curve: presence absence secondary wave aggregationNormal Aggregation Response:\nNormal aggregation agonists (ADP, collagen, epinephrine, arachidonic acid, ristocetin)\nNormal Aggregation Response:Normal aggregation agonists (ADP, collagen, epinephrine, arachidonic acid, ristocetin)Abnormal Aggregation Responses:\nAbsent Reduced Aggregation: Indicates platelet function defect\nMay specific certain agonists may affect agonists\n\nNormal Aggregation Agonists, Abnormal Others: Suggests specific defect particular platelet activation pathway\nAbnormal Aggregation Responses:Absent Reduced Aggregation: Indicates platelet function defect\nMay specific certain agonists may affect agonists\nMay specific certain agonists may affect agonistsNormal Aggregation Agonists, Abnormal Others: Suggests specific defect particular platelet activation pathway","code":""},{"path":"platelet-aggregation.html","id":"specific-patterns-of-platelet-aggregation","chapter":"Platelet Aggregation","heading":"Specific Patterns of Platelet Aggregation","text":"Glanzmann Thrombasthenia (GT):\nAbsent severely reduced aggregation ADP, collagen, epinephrine, thrombin\nNormal aggregation ristocetin (vWF binding GPIb/IX/V intact)\nAbsent severely reduced aggregation ADP, collagen, epinephrine, thrombinNormal aggregation ristocetin (vWF binding GPIb/IX/V intact)Bernard-Soulier Syndrome (BSS):\nNormal aggregation ADP, collagen, epinephrine\nAbsent aggregation ristocetin (even added normal plasma)\nNormal aggregation ADP, collagen, epinephrineAbsent aggregation ristocetin (even added normal plasma)von Willebrand Disease (vWD):\nDecreased aggregation ristocetin\nagonists may show normal mildly reduced aggregation\nDecreased aggregation ristocetinOther agonists may show normal mildly reduced aggregationAspirin Effect:\nNormal aggregation ADP epinephrine\nAbsent reduced aggregation collagen arachidonic acid\nNormal aggregation ADP epinephrineAbsent reduced aggregation collagen arachidonic acidP2Y12 Inhibitors (e.g., Clopidogrel, Prasugrel):\nReduced aggregation ADP\nNormal aggregation agonists\nReduced aggregation ADPNormal aggregation agonists","code":""},{"path":"platelet-aggregation.html","id":"factors-affecting-platelet-aggregation-results","chapter":"Platelet Aggregation","heading":"Factors Affecting Platelet Aggregation Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Traumatic venipuncture can activate platelets affect results\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube can alter test results\nDelayed Testing: Platelet function can change time, test performed within specified timeframe (usually within 2-4 hours collection)\nStorage Temperature: Improper storage temperatures can affect platelet function\nPre-Analytical Variables:Improper Collection Technique: Traumatic venipuncture can activate platelets affect resultsIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube can alter test resultsDelayed Testing: Platelet function can change time, test performed within specified timeframe (usually within 2-4 hours collection)Storage Temperature: Improper storage temperatures can affect platelet functionAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance aggregometer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nAir Bubbles: Air bubbles sample can interfere light transmission\nInadequate Stirring: Proper stirring essential maintaining homogenous suspension platelets\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance aggregometerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsAir Bubbles: Air bubbles sample can interfere light transmissionInadequate Stirring: Proper stirring essential maintaining homogenous suspension plateletsPatient-Related Variables:\nMedications:\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 production\nP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor platelets\nGPIIb/IIIa Inhibitors: Abciximab, eptifibatide, tirofiban block GPIIb/IIIa receptor\n\nUnderlying Medical Conditions:\nMyeloproliferative Neoplasms (MPNs): Platelets may abnormal function\nUremia (Chronic Kidney Disease): Uremic toxins can impair platelet function\nLiver Disease: Can affect platelet function\nCertain Infections\n\nPatient-Related Variables:Medications:\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 production\nP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor platelets\nGPIIb/IIIa Inhibitors: Abciximab, eptifibatide, tirofiban block GPIIb/IIIa receptor\nAspirin NSAIDs: Inhibit cyclooxygenase (COX) impair thromboxane A2 productionP2Y12 Inhibitors: Clopidogrel, prasugrel, ticagrelor block ADP receptor plateletsGPIIb/IIIa Inhibitors: Abciximab, eptifibatide, tirofiban block GPIIb/IIIa receptorUnderlying Medical Conditions:\nMyeloproliferative Neoplasms (MPNs): Platelets may abnormal function\nUremia (Chronic Kidney Disease): Uremic toxins can impair platelet function\nLiver Disease: Can affect platelet function\nCertain Infections\nMyeloproliferative Neoplasms (MPNs): Platelets may abnormal functionUremia (Chronic Kidney Disease): Uremic toxins can impair platelet functionLiver Disease: Can affect platelet functionCertain Infections","code":""},{"path":"platelet-aggregation.html","id":"troubleshooting-erroneous-results-10","chapter":"Platelet Aggregation","heading":"Troubleshooting Erroneous Results","text":"platelet aggregation results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots air bubbles\nVerify hematocrit platelet count within acceptable range instrument\nRepeat test fresh sample\nReview patient’s medication list medical history\nEnsure reagents controls within expiration dates stored properly\nConsider pre-analytical analytical factors may affected results\nplatelet aggregation results unexpected inconsistent patient’s clinical presentation:Check sample clots air bubblesVerify hematocrit platelet count within acceptable range instrumentRepeat test fresh sampleReview patient’s medication list medical historyEnsure reagents controls within expiration dates stored properlyConsider pre-analytical analytical factors may affected results","code":""},{"path":"platelet-aggregation.html","id":"reflex-testing-6","chapter":"Platelet Aggregation","heading":"Reflex Testing","text":"platelet aggregation studies abnormal, additional testing may performed :\nIdentify specific platelet function defects\nFlow Cytometry: measure platelet surface markers (e.g., GPIIb/IIIa, GPIb/IX/V)\nPlatelet Secretion Assays: measure release substances platelet granules (e.g., ADP, serotonin)\nElectron Microscopy: examine platelet ultrastructure\nplatelet aggregation studies abnormal, additional testing may performed :Identify specific platelet function defectsFlow Cytometry: measure platelet surface markers (e.g., GPIIb/IIIa, GPIb/IX/V)Platelet Secretion Assays: measure release substances platelet granules (e.g., ADP, serotonin)Electron Microscopy: examine platelet ultrastructure","code":""},{"path":"platelet-aggregation.html","id":"key-terms-95","chapter":"Platelet Aggregation","heading":"Key Terms","text":"Platelet Aggregation: clumping together plateletsAgonist: substance stimulates platelet activation aggregationGPIIb/IIIa: platelet glycoprotein complex binds fibrinogenRistocetin: antibiotic induces vWF-dependent platelet agglutinationPlatelet Aggregometer: instrument measures platelet aggregationLight Transmission: measure amount light passes sampleMucocutaneous Bleeding: Bleeding skin mucous membranes","code":""},{"path":"thromboelastography.html","id":"thromboelastography","chapter":"Thromboelastography","heading":"Thromboelastography","text":"","code":""},{"path":"thromboelastography.html","id":"overview-of-thromboelastography-teg","chapter":"Thromboelastography","heading":"Overview of Thromboelastography (TEG)","text":"Definition: Thromboelastography (TEG) rotational thromboelastometry (ROTEM) viscoelastic hemostatic assays provide comprehensive assessment hemostasis, including:\nCoagulation: formation fibrin clot\nPlatelet Function: contribution platelets clot strength\nFibrinolysis: breakdown clot\nCoagulation: formation fibrin clotPlatelet Function: contribution platelets clot strengthFibrinolysis: breakdown clotPrinciple:\nWhole Blood Analysis: TEG analyzes entire coagulation process whole blood, providing comprehensive assessment hemostasis traditional plasma-based coagulation tests (PT aPTT)\nViscoelastic Measurements: Measures viscoelastic properties developing clot time, including:\nClot Strength\nClotting Time\nFibrinolysis\n\nDynamic Assessment: Provides dynamic assessment clot formation breakdown, reflecting interactions coagulation factors, platelets, fibrinolytic proteins\nWhole Blood Analysis: TEG analyzes entire coagulation process whole blood, providing comprehensive assessment hemostasis traditional plasma-based coagulation tests (PT aPTT)Viscoelastic Measurements: Measures viscoelastic properties developing clot time, including:\nClot Strength\nClotting Time\nFibrinolysis\nClot StrengthClotting TimeFibrinolysisDynamic Assessment: Provides dynamic assessment clot formation breakdown, reflecting interactions coagulation factors, platelets, fibrinolytic proteinsClinical Significance:\nAssessment Bleeding Risk: Helps identify patients risk bleeding surgery invasive procedures\nGoal-Directed Hemostatic Therapy: Guides use blood products hemostatic agents bleeding patients\nMonitoring Anticoagulation: Can used monitor effects anticoagulants\nDiagnosis Coagulation Disorders: Can help identify inherited acquired coagulation disorders\nAssessment Trauma-Induced Coagulopathy: Useful assessing coagulopathy trauma patients\nAssessment Bleeding Risk: Helps identify patients risk bleeding surgery invasive proceduresGoal-Directed Hemostatic Therapy: Guides use blood products hemostatic agents bleeding patientsMonitoring Anticoagulation: Can used monitor effects anticoagulantsDiagnosis Coagulation Disorders: Can help identify inherited acquired coagulation disordersAssessment Trauma-Induced Coagulopathy: Useful assessing coagulopathy trauma patientsInstruments:\nThromboelastograph (TEG): Older technology, measures movement pin suspended cup whole blood\nRotational Thromboelastometry (ROTEM): Newer technology, measures rotation pin suspended cup whole blood\nThromboelastograph (TEG): Older technology, measures movement pin suspended cup whole bloodRotational Thromboelastometry (ROTEM): Newer technology, measures rotation pin suspended cup whole blood","code":""},{"path":"thromboelastography.html","id":"components-of-the-tegrotem-system","chapter":"Thromboelastography","heading":"Components of the TEG/ROTEM System","text":"Instrumentation:\nTEG ROTEM Analyzer: instrument performs viscoelastic measurements\nCups Pins: Disposable cups pins used hold blood sample measure clot formation\nPipettes: Accurate pipettes measuring reagents samples\nTemperature Control: System maintain sample constant temperature (typically 37°C)\nInstrumentation:TEG ROTEM Analyzer: instrument performs viscoelastic measurementsCups Pins: Disposable cups pins used hold blood sample measure clot formationPipettes: Accurate pipettes measuring reagents samplesTemperature Control: System maintain sample constant temperature (typically 37°C)Reagents:\nActivators: Reagents activate coagulation cascade\nKaolin: contact activator initiates intrinsic pathway\nTissue Factor (TF): Activates extrinsic pathway\nEllagic Acid: Activates contact pathway\n\nInhibitors (Optional): Used assess specific components coagulation system\nCytochalasin D: Inhibits platelet function\nAprotinin: Inhibits fibrinolysis\n\nQuality Control Materials: Commercially available control materials used monitor performance instrument\nReagents:Activators: Reagents activate coagulation cascade\nKaolin: contact activator initiates intrinsic pathway\nTissue Factor (TF): Activates extrinsic pathway\nEllagic Acid: Activates contact pathway\nKaolin: contact activator initiates intrinsic pathwayTissue Factor (TF): Activates extrinsic pathwayEllagic Acid: Activates contact pathwayInhibitors (Optional): Used assess specific components coagulation system\nCytochalasin D: Inhibits platelet function\nAprotinin: Inhibits fibrinolysis\nCytochalasin D: Inhibits platelet functionAprotinin: Inhibits fibrinolysisQuality Control Materials: Commercially available control materials used monitor performance instrumentSample Preparation:\nWhole Blood Collection:\nCollect whole blood specialized tube recommended manufacturer (typically citrate tube specific formulation)\nEnsure tube filled correct volume maintain proper blood--anticoagulant ratio\nGentle Mixing: Gently invert collection tube 5-10 times mix blood anticoagulant\n\nTimely Analysis:\nTest sample within timeframe recommended manufacturer (typically within 1-4 hours collection)\nStore sample room temperature (22-25°C) testing\n\nSample Preparation:Whole Blood Collection:\nCollect whole blood specialized tube recommended manufacturer (typically citrate tube specific formulation)\nEnsure tube filled correct volume maintain proper blood--anticoagulant ratio\nGentle Mixing: Gently invert collection tube 5-10 times mix blood anticoagulant\nCollect whole blood specialized tube recommended manufacturer (typically citrate tube specific formulation)Ensure tube filled correct volume maintain proper blood--anticoagulant ratioGentle Mixing: Gently invert collection tube 5-10 times mix blood anticoagulantTimely Analysis:\nTest sample within timeframe recommended manufacturer (typically within 1-4 hours collection)\nStore sample room temperature (22-25°C) testing\nTest sample within timeframe recommended manufacturer (typically within 1-4 hours collection)Store sample room temperature (22-25°C) testing","code":""},{"path":"thromboelastography.html","id":"procedure-for-performing-tegrotem","chapter":"Thromboelastography","heading":"Procedure for Performing TEG/ROTEM","text":"Sample Preparation:\nFollow instrument manufacturer’s instructions sample preparation\nEnsure blood sample well-mixed free clots\nFollow instrument manufacturer’s instructions sample preparationEnsure blood sample well-mixed free clotsReagent Preparation:\nPrepare reagents according manufacturer’s instructions\nEnsure reagents properly stored expired\nPrepare reagents according manufacturer’s instructionsEnsure reagents properly stored expiredInstrument Setup:\nTurn instrument allow warm \nLoad appropriate cups pins instrument\nEnter patient information test order instrument software\nTurn instrument allow warm upLoad appropriate cups pins instrumentEnter patient information test order instrument softwareRunning Assay:\nPipette specific volume whole blood sample cup\nAdd appropriate activator (e.g., kaolin tissue factor) sample\nStart test allow instrument perform analysis\ninstrument continuously monitor viscoelastic properties developing clot generate TEG ROTEM tracing\nPipette specific volume whole blood sample cupAdd appropriate activator (e.g., kaolin tissue factor) sampleStart test allow instrument perform analysisThe instrument continuously monitor viscoelastic properties developing clot generate TEG ROTEM tracing","code":""},{"path":"thromboelastography.html","id":"interpreting-tegrotem-results","chapter":"Thromboelastography","heading":"Interpreting TEG/ROTEM Results","text":"Key Parameters:\nR (Reaction Time):\ntime start test first evidence clot formation (initial fibrin formation)\nRepresents activity coagulation factors\nProlonged R: Indicates deficiency inhibition coagulation factors\n\nK (Clot Formation Time):\ntime end R clot reaches certain level strength\nRepresents rate fibrin clot formation\nProlonged K: Suggests deficiency dysfunction fibrinogen\n\nα (Alpha Angle):\nangle R K parameters\nReflects speed clot formation\nDecreased Alpha Angle: Suggests deficiency dysfunction fibrinogen platelets\n\nMA (Maximum Amplitude):\nmaximum strength clot, reflecting interaction platelets fibrin\nRepresents contribution platelets clot strength\nLow MA: Suggests thrombocytopenia platelet dysfunction\n\nCI (Clotting Index):\nglobal measure hemostasis\n\nLY30 (Lysis 30 Minutes):\npercentage decrease clot amplitude 30 minutes MA\nReflects degree fibrinolysis\nIncreased LY30: Suggests hyperfibrinolysis\n\nKey Parameters:R (Reaction Time):\ntime start test first evidence clot formation (initial fibrin formation)\nRepresents activity coagulation factors\nProlonged R: Indicates deficiency inhibition coagulation factors\ntime start test first evidence clot formation (initial fibrin formation)Represents activity coagulation factorsProlonged R: Indicates deficiency inhibition coagulation factorsK (Clot Formation Time):\ntime end R clot reaches certain level strength\nRepresents rate fibrin clot formation\nProlonged K: Suggests deficiency dysfunction fibrinogen\ntime end R clot reaches certain level strengthRepresents rate fibrin clot formationProlonged K: Suggests deficiency dysfunction fibrinogenα (Alpha Angle):\nangle R K parameters\nReflects speed clot formation\nDecreased Alpha Angle: Suggests deficiency dysfunction fibrinogen platelets\nangle R K parametersReflects speed clot formationDecreased Alpha Angle: Suggests deficiency dysfunction fibrinogen plateletsMA (Maximum Amplitude):\nmaximum strength clot, reflecting interaction platelets fibrin\nRepresents contribution platelets clot strength\nLow MA: Suggests thrombocytopenia platelet dysfunction\nmaximum strength clot, reflecting interaction platelets fibrinRepresents contribution platelets clot strengthLow MA: Suggests thrombocytopenia platelet dysfunctionCI (Clotting Index):\nglobal measure hemostasis\nglobal measure hemostasisLY30 (Lysis 30 Minutes):\npercentage decrease clot amplitude 30 minutes MA\nReflects degree fibrinolysis\nIncreased LY30: Suggests hyperfibrinolysis\npercentage decrease clot amplitude 30 minutes MAReflects degree fibrinolysisIncreased LY30: Suggests hyperfibrinolysisInterpretation Based Specific Clinical Scenarios:\nBleeding Patient:\nProlonged R: Factor deficiency (e.g., hemophilia)\nProlonged K Decreased α: Fibrinogen deficiency dysfunction\nLow MA: Thrombocytopenia platelet dysfunction\nIncreased LY30: Hyperfibrinolysis (e.g., DIC)\n\nThrombotic Patient:\nShortened R K: Hypercoagulability\nIncreased MA: Increased platelet reactivity\nDecreased LY30: Impaired fibrinolysis\n\nMonitoring Anticoagulation:\nHeparin: Prolonged R K, normal MA LY30\nDirect Thrombin Inhibitors: Prolonged R K, normal MA LY30\nFibrinolytic Agents: Increased LY30\n\nInterpretation Based Specific Clinical Scenarios:Bleeding Patient:\nProlonged R: Factor deficiency (e.g., hemophilia)\nProlonged K Decreased α: Fibrinogen deficiency dysfunction\nLow MA: Thrombocytopenia platelet dysfunction\nIncreased LY30: Hyperfibrinolysis (e.g., DIC)\nProlonged R: Factor deficiency (e.g., hemophilia)Prolonged K Decreased α: Fibrinogen deficiency dysfunctionLow MA: Thrombocytopenia platelet dysfunctionIncreased LY30: Hyperfibrinolysis (e.g., DIC)Thrombotic Patient:\nShortened R K: Hypercoagulability\nIncreased MA: Increased platelet reactivity\nDecreased LY30: Impaired fibrinolysis\nShortened R K: HypercoagulabilityIncreased MA: Increased platelet reactivityDecreased LY30: Impaired fibrinolysisMonitoring Anticoagulation:\nHeparin: Prolonged R K, normal MA LY30\nDirect Thrombin Inhibitors: Prolonged R K, normal MA LY30\nFibrinolytic Agents: Increased LY30\nHeparin: Prolonged R K, normal MA LY30Direct Thrombin Inhibitors: Prolonged R K, normal MA LY30Fibrinolytic Agents: Increased LY30","code":""},{"path":"thromboelastography.html","id":"factors-affecting-tegrotem-results","chapter":"Thromboelastography","heading":"Factors Affecting TEG/ROTEM Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nClotted Sample: Invalidates results\nDelayed Testing: Coagulation factors platelets can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisClotted Sample: Invalidates resultsDelayed Testing: Coagulation factors platelets can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nAir Bubbles: Avoid introducing air bubbles sample reagents\nTemperature: Maintain constant temperature (37°C) assay\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsAir Bubbles: Avoid introducing air bubbles sample reagentsTemperature: Maintain constant temperature (37°C) assayPatient-Related Variables:\nMedications: Anticoagulants, antiplatelet agents, medications can affect TEG/ROTEM results\nUnderlying Medical Conditions: Liver disease, kidney disease, conditions can affect coagulation fibrinolysis\nHypothermia: Can prolong clotting times\nHemodilution: Can affect results trauma patients\nPatient-Related Variables:Medications: Anticoagulants, antiplatelet agents, medications can affect TEG/ROTEM resultsUnderlying Medical Conditions: Liver disease, kidney disease, conditions can affect coagulation fibrinolysisHypothermia: Can prolong clotting timesHemodilution: Can affect results trauma patients","code":""},{"path":"thromboelastography.html","id":"troubleshooting-erroneous-results-11","chapter":"Thromboelastography","heading":"Troubleshooting Erroneous Results","text":"TEG/ROTEM results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nVerify instrument reagent quality control results\nEnsure sample reagents handled stored properly\nReview patient’s medication list medical history\nConsult pathologist coagulation expert\nTEG/ROTEM results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleVerify instrument reagent quality control resultsEnsure sample reagents handled stored properlyReview patient’s medication list medical historyConsult pathologist coagulation expert","code":""},{"path":"thromboelastography.html","id":"reflex-testing-7","chapter":"Thromboelastography","heading":"Reflex Testing","text":"TEG/ROTEM results abnormal, additional testing may performed :\nIdentify specific factor deficiencies: Factor assays\nDetect platelet function defects: Platelet aggregation studies, flow cytometry\nQuantify fibrinolysis: D-dimer assay, plasminogen activator inhibitor-1 (PAI-1) assay\nAssess heparin direct thrombin inhibitor (DTI) levels\nTEG/ROTEM results abnormal, additional testing may performed :Identify specific factor deficiencies: Factor assaysDetect platelet function defects: Platelet aggregation studies, flow cytometryQuantify fibrinolysis: D-dimer assay, plasminogen activator inhibitor-1 (PAI-1) assayAssess heparin direct thrombin inhibitor (DTI) levels","code":""},{"path":"thromboelastography.html","id":"key-terms-96","chapter":"Thromboelastography","heading":"Key Terms","text":"Thromboelastography (TEG): viscoelastic hemostatic assay measures clot formation, strength, breakdownRotational Thromboelastometry (ROTEM): similar viscoelastic hemostatic assay uses different type instrumentR (Reaction Time): Time initial clot formationK (Clot Formation Time): Time reach certain clot strengthα (Alpha Angle): Rate clot formationMA (Maximum Amplitude): Maximum clot strengthCI (Clotting Index): global measure hemostasisLY30 (Lysis 30 Minutes): Percentage decrease clot amplitude 30 minutes MAHypercoagulability: increased tendency clotHypofibrinolysis: Decreased breakdown fibrin clotsHyperfibrinolysis: Excessive breakdown fibrin clotsPoint Care Testing (POCT): Performance laboratory tests near site patient care","code":""},{"path":"hypercoagulability.html","id":"hypercoagulability","chapter":"Hypercoagulability","heading":"Hypercoagulability","text":"","code":""},{"path":"hypercoagulability.html","id":"overview-of-hypercoagulability-assessment","chapter":"Hypercoagulability","heading":"Overview of Hypercoagulability Assessment","text":"Definition: Laboratory testing performed identify inherited acquired factors increase risk thrombosis (blood clots)Purpose:\nEvaluate patients :\nUnexplained venous thromboembolism (VTE): Deep vein thrombosis (DVT) pulmonary embolism (PE)\nArterial thrombosis young individuals unusual sites\nRecurrent thrombosis\nFamily history thrombosis\nRecurrent pregnancy loss\n\nGuide management decisions regarding anticoagulation therapy\nEvaluate patients :\nUnexplained venous thromboembolism (VTE): Deep vein thrombosis (DVT) pulmonary embolism (PE)\nArterial thrombosis young individuals unusual sites\nRecurrent thrombosis\nFamily history thrombosis\nRecurrent pregnancy loss\nUnexplained venous thromboembolism (VTE): Deep vein thrombosis (DVT) pulmonary embolism (PE)Arterial thrombosis young individuals unusual sitesRecurrent thrombosisFamily history thrombosisRecurrent pregnancy lossGuide management decisions regarding anticoagulation therapyKey Considerations:\nTesting indicated patients thrombosis\ndecision perform thrombophilia testing based clinical judgment consideration patient’s risk factors\nTesting generally performed acute thrombotic event resolved patient anticoagulant therapy (anticoagulation discontinued several weeks), anticoagulants can interfere results\nTesting indicated patients thrombosisThe decision perform thrombophilia testing based clinical judgment consideration patient’s risk factorsTesting generally performed acute thrombotic event resolved patient anticoagulant therapy (anticoagulation discontinued several weeks), anticoagulants can interfere results","code":""},{"path":"hypercoagulability.html","id":"assays-for-assessing-hypercoagulability","chapter":"Hypercoagulability","heading":"Assays for Assessing Hypercoagulability","text":"tests evaluate function levels various components coagulation systemLupus Anticoagulant (LA) Testing:\nPrinciple: series phospholipid-dependent coagulation assays detect presence lupus anticoagulants (LA), autoantibodies interfere phospholipid-dependent coagulation reactions vitro\nLupus Anticoagulant (LA) Testing:Principle: series phospholipid-dependent coagulation assays detect presence lupus anticoagulants (LA), autoantibodies interfere phospholipid-dependent coagulation reactions vitroProtein C Activity Assay:\nPrinciple: Measures activity protein C, vitamin K-dependent anticoagulant protein\nProtein C activated thrombin-thrombomodulin complex endothelial cells\nActivated protein C (APC), along cofactor protein S, inactivates Factors Va VIIIa, inhibiting thrombin generation\n\nProtein C Activity Assay:Principle: Measures activity protein C, vitamin K-dependent anticoagulant protein\nProtein C activated thrombin-thrombomodulin complex endothelial cells\nActivated protein C (APC), along cofactor protein S, inactivates Factors Va VIIIa, inhibiting thrombin generation\nProtein C activated thrombin-thrombomodulin complex endothelial cellsActivated protein C (APC), along cofactor protein S, inactivates Factors Va VIIIa, inhibiting thrombin generationProtein S Activity Antigen Assays:\nPrinciple: Measures activity amount protein S, cofactor activated protein C\nProtein S exists two forms plasma:\nFree Protein S: active form acts cofactor APC\nBound Protein S: Bound C4b-binding protein\n\n\nProtein S Activity Antigen Assays:Principle: Measures activity amount protein S, cofactor activated protein C\nProtein S exists two forms plasma:\nFree Protein S: active form acts cofactor APC\nBound Protein S: Bound C4b-binding protein\n\nProtein S exists two forms plasma:\nFree Protein S: active form acts cofactor APC\nBound Protein S: Bound C4b-binding protein\nFree Protein S: active form acts cofactor APCBound Protein S: Bound C4b-binding proteinAntithrombin Activity Antigen Assays:\nPrinciple: Measures activity amount antithrombin (), natural anticoagulant inhibits thrombin coagulation factors\nAntithrombin Activity Antigen Assays:Principle: Measures activity amount antithrombin (), natural anticoagulant inhibits thrombin coagulation factors","code":""},{"path":"hypercoagulability.html","id":"molecular-testing-for-inherited-thrombophilias","chapter":"Hypercoagulability","heading":"Molecular Testing for Inherited Thrombophilias","text":"Factor V Leiden Mutation Analysis:\nPrinciple: Detects presence Factor V Leiden mutation (R506Q) F5 gene\nFactor V Leiden Mutation Analysis:Principle: Detects presence Factor V Leiden mutation (R506Q) F5 geneProthrombin G20210A Mutation Analysis:\nPrinciple: Detects presence prothrombin G20210A mutation F2 gene\nProthrombin G20210A Mutation Analysis:Principle: Detects presence prothrombin G20210A mutation F2 gene","code":""},{"path":"hypercoagulability.html","id":"considerations-for-testing-and-interpretation","chapter":"Hypercoagulability","heading":"Considerations for Testing and Interpretation","text":"Clinical Context: Interpret test results context patient’s clinical history, medication use, laboratory findingsTesting Timing: Perform thrombophilia testing patient acutely thrombotic anticoagulant therapy (anticoagulation discontinued several weeks)Sequential Testing: Follow logical testing algorithm evaluate thrombophiliaRepeat Testing: Repeat positive results antiphospholipid antibodies (LA, aCL, anti-β2GPI) least 12 weeks apart confirm persistenceHeterozygous vs. Homozygous: test can help distinguish heterozygous homozygous mutations, required.Reference Ranges: Use appropriate reference ranges patient’s age sexQuality Control: Follow established laboratory procedures quality control guidelines","code":""},{"path":"hypercoagulability.html","id":"algorithm-for-thrombophilia-testing","chapter":"Hypercoagulability","heading":"Algorithm for Thrombophilia Testing","text":"(general guideline. Always follow laboratory’s specific protocol)Clinical Suspicion ThrombophiliaInitial Testing:\nPT aPTT (screen coagulation abnormalities)\nPlatelet Count\nPT aPTT (screen coagulation abnormalities)Platelet CountIf aPTT Prolonged, Consider Lupus Anticoagulant TestingIf Thrombophilia Testing Warranted (Patient Acutely Thrombotic Anticoagulated):\nFactor V Leiden Mutation Analysis\nProthrombin G20210A Mutation Analysis\nProtein C Activity Antigen Assays\nFree Protein S Antigen Total Protein S Antigen Assays\nAntithrombin Activity Antigen Assays\nAntiphospholipid Antibody Testing (LA, aCL, anti-β2GPI)\nFactor V Leiden Mutation AnalysisProthrombin G20210A Mutation AnalysisProtein C Activity Antigen AssaysFree Protein S Antigen Total Protein S Antigen AssaysAntithrombin Activity Antigen AssaysAntiphospholipid Antibody Testing (LA, aCL, anti-β2GPI)Interpret Results:\nInterpret results context patient’s clinical presentation laboratory findings\nRefer hematologist thrombosis specialist evaluation management\nInterpret results context patient’s clinical presentation laboratory findingsRefer hematologist thrombosis specialist evaluation management","code":""},{"path":"hypercoagulability.html","id":"key-terms-97","chapter":"Hypercoagulability","heading":"Key Terms","text":"Hypercoagulable State (Thrombophilia): condition increased risk thrombosisFactor V Leiden: common genetic mutation causes resistance activated protein CProthrombin G20210A Mutation: genetic mutation leads increased prothrombin levelsProtein C: vitamin K-dependent anticoagulant proteinProtein S: cofactor activated protein CAntithrombin: serine protease inhibitor inhibits thrombin coagulation factorsAntiphospholipid Syndrome (APS): autoimmune disorder characterized thrombosis, pregnancy morbidity, antiphospholipid antibodiesLupus Anticoagulant (LA): antibody interferes phospholipid-dependent coagulation assaysThrombosis: Formation blood clot inside blood vessel","code":""},{"path":"assays.html","id":"assays","chapter":"Assays","heading":"Assays","text":"","code":""},{"path":"assays.html","id":"overview-of-assays-for-hypercoagulability-assessment","chapter":"Assays","heading":"Overview of Assays for Hypercoagulability Assessment","text":"Purpose: identify deficiencies abnormalities natural anticoagulant factors contribute increased risk thrombosis (hypercoagulable state, thrombophilia)Consider Testing:\nUnprovoked venous thromboembolism (VTE)\nVTE young age (<50 years)\nRecurrent VTE\nVTE unusual sites (e.g., mesenteric, cerebral)\nFamily history thrombophilia\nRecurrent pregnancy loss\nArterial thrombosis young individuals\nUnprovoked venous thromboembolism (VTE)VTE young age (<50 years)Recurrent VTEVTE unusual sites (e.g., mesenteric, cerebral)Family history thrombophiliaRecurrent pregnancy lossArterial thrombosis young individualsImportant Note: Testing best performed patient acutely thrombotic anticoagulant therapy, factors can affect results.","code":""},{"path":"assays.html","id":"key-assays","chapter":"Assays","heading":"Key Assays","text":"’s detailed breakdown key assays used assess hypercoagulable states, focusing testing principles result interpretation:Lupus Anticoagulant (LA) Testing\nDetects: Lupus anticoagulants (LAs) type antiphospholipid antibody bind phospholipids phospholipid-binding proteins. Despite name, increase risk thrombosis vivo\nSignificance: LAs associated :\nAntiphospholipid Syndrome (APS): systemic autoimmune disorder characterized thrombosis, pregnancy morbidity, presence antiphospholipid antibodies\nIncreased risk venous arterial thrombosis\nRecurrent pregnancy loss\n\nTesting Strategy: series tests required LA detection antibodies interfere phospholipid-dependent coagulation reactions vitro, leading prolonged clotting times. tests must demonstrate:\nProlongation phospholipid-dependent clotting tests (screening tests)\nFailure correct mixing studies (indicating inhibitor)\nCorrection addition excess phospholipid (demonstrating phospholipid dependence\n\nCommon Tests Used:\nActivated Partial Thromboplastin Time (aPTT-LA): modified aPTT reagent low phospholipid concentration used enhance sensitivity LA\nPrinciple: Phospholipid neutralizes, part, inhibitor, less phospholipid added, prolonged clotting time.\n\nDilute Russell’s Viper Venom Time (dRVVT): sensitive test LA\nPrinciple: RVV directly activates Factor X, bypassing Factors VIII, IX, XI, requires phospholipids.\ndRVVT Confirm: Perform test high concentration phospholipids.\n\nHexagonal Phase Phospholipid Neutralization Assay (Staclot LA): specific test\nPrinciple: Phospholipids hexagonal phase used neutralize inhibitor\n\n\nInterpretation:\nProlonged screening test (aPTT-LA dRVVT)\nFailure correct mixing normal plasma\nCorrection addition excess phospholipid\nRequires persistent positivity (present two occasions, least 12 weeks apart)\nNote: false positives possible, testing repeated confirmation\n\nLupus Anticoagulant (LA) TestingWhat Detects: Lupus anticoagulants (LAs) type antiphospholipid antibody bind phospholipids phospholipid-binding proteins. Despite name, increase risk thrombosis vivoWhat Detects: Lupus anticoagulants (LAs) type antiphospholipid antibody bind phospholipids phospholipid-binding proteins. Despite name, increase risk thrombosis vivoSignificance: LAs associated :\nAntiphospholipid Syndrome (APS): systemic autoimmune disorder characterized thrombosis, pregnancy morbidity, presence antiphospholipid antibodies\nIncreased risk venous arterial thrombosis\nRecurrent pregnancy loss\nSignificance: LAs associated :Antiphospholipid Syndrome (APS): systemic autoimmune disorder characterized thrombosis, pregnancy morbidity, presence antiphospholipid antibodiesIncreased risk venous arterial thrombosisRecurrent pregnancy lossTesting Strategy: series tests required LA detection antibodies interfere phospholipid-dependent coagulation reactions vitro, leading prolonged clotting times. tests must demonstrate:\nProlongation phospholipid-dependent clotting tests (screening tests)\nFailure correct mixing studies (indicating inhibitor)\nCorrection addition excess phospholipid (demonstrating phospholipid dependence\nTesting Strategy: series tests required LA detection antibodies interfere phospholipid-dependent coagulation reactions vitro, leading prolonged clotting times. tests must demonstrate:Prolongation phospholipid-dependent clotting tests (screening tests)Failure correct mixing studies (indicating inhibitor)Correction addition excess phospholipid (demonstrating phospholipid dependenceCommon Tests Used:\nActivated Partial Thromboplastin Time (aPTT-LA): modified aPTT reagent low phospholipid concentration used enhance sensitivity LA\nPrinciple: Phospholipid neutralizes, part, inhibitor, less phospholipid added, prolonged clotting time.\n\nDilute Russell’s Viper Venom Time (dRVVT): sensitive test LA\nPrinciple: RVV directly activates Factor X, bypassing Factors VIII, IX, XI, requires phospholipids.\ndRVVT Confirm: Perform test high concentration phospholipids.\n\nHexagonal Phase Phospholipid Neutralization Assay (Staclot LA): specific test\nPrinciple: Phospholipids hexagonal phase used neutralize inhibitor\n\nCommon Tests Used:Activated Partial Thromboplastin Time (aPTT-LA): modified aPTT reagent low phospholipid concentration used enhance sensitivity LA\nPrinciple: Phospholipid neutralizes, part, inhibitor, less phospholipid added, prolonged clotting time.\nPrinciple: Phospholipid neutralizes, part, inhibitor, less phospholipid added, prolonged clotting time.Dilute Russell’s Viper Venom Time (dRVVT): sensitive test LA\nPrinciple: RVV directly activates Factor X, bypassing Factors VIII, IX, XI, requires phospholipids.\ndRVVT Confirm: Perform test high concentration phospholipids.\nPrinciple: RVV directly activates Factor X, bypassing Factors VIII, IX, XI, requires phospholipids.dRVVT Confirm: Perform test high concentration phospholipids.Hexagonal Phase Phospholipid Neutralization Assay (Staclot LA): specific test\nPrinciple: Phospholipids hexagonal phase used neutralize inhibitor\nPrinciple: Phospholipids hexagonal phase used neutralize inhibitorInterpretation:\nProlonged screening test (aPTT-LA dRVVT)\nFailure correct mixing normal plasma\nCorrection addition excess phospholipid\nRequires persistent positivity (present two occasions, least 12 weeks apart)\nNote: false positives possible, testing repeated confirmation\nInterpretation:Prolonged screening test (aPTT-LA dRVVT)Failure correct mixing normal plasmaCorrection addition excess phospholipidRequires persistent positivity (present two occasions, least 12 weeks apart)Note: false positives possible, testing repeated confirmationProtein C Activity/Antigen Assay\nDetects: Deficiency Protein C, vitamin K-dependent serine protease inactivates Factors Va VIIIa, thus inhibiting coagulation\nSignificance: Protein C deficiency increases risk venous thrombosis\nTesting:\nProtein C Activity Assay:\nPrinciple: Measures functional activity protein C\nMethod: chromogenic clotting assay used measure ability protein C inactivate Factor Va\n\nProtein C Antigen Assay:\nMeasures amount protein C protein present\nCan used differentiate type (quantitative deficiency) type II (qualitative deficiency) protein C deficiency\n\n\nInterpretation:\nDecreased Protein C Activity: Suggests protein C deficiency\nDecreased Protein C Antigen: Suggests type protein C deficiency (quantitative)\nNormal Protein C Antigen, Decreased Activity: Suggests type II protein C deficiency (qualitative)\nNote: activity antigen levels assessed accurate diagnosis.\n\nProtein C Activity/Antigen AssayWhat Detects: Deficiency Protein C, vitamin K-dependent serine protease inactivates Factors Va VIIIa, thus inhibiting coagulationSignificance: Protein C deficiency increases risk venous thrombosisTesting:\nProtein C Activity Assay:\nPrinciple: Measures functional activity protein C\nMethod: chromogenic clotting assay used measure ability protein C inactivate Factor Va\n\nProtein C Antigen Assay:\nMeasures amount protein C protein present\nCan used differentiate type (quantitative deficiency) type II (qualitative deficiency) protein C deficiency\n\nProtein C Activity Assay:\nPrinciple: Measures functional activity protein C\nMethod: chromogenic clotting assay used measure ability protein C inactivate Factor Va\nPrinciple: Measures functional activity protein CMethod: chromogenic clotting assay used measure ability protein C inactivate Factor VaProtein C Antigen Assay:\nMeasures amount protein C protein present\nCan used differentiate type (quantitative deficiency) type II (qualitative deficiency) protein C deficiency\nMeasures amount protein C protein presentCan used differentiate type (quantitative deficiency) type II (qualitative deficiency) protein C deficiencyInterpretation:\nDecreased Protein C Activity: Suggests protein C deficiency\nDecreased Protein C Antigen: Suggests type protein C deficiency (quantitative)\nNormal Protein C Antigen, Decreased Activity: Suggests type II protein C deficiency (qualitative)\nNote: activity antigen levels assessed accurate diagnosis.\nDecreased Protein C Activity: Suggests protein C deficiencyDecreased Protein C Antigen: Suggests type protein C deficiency (quantitative)Normal Protein C Antigen, Decreased Activity: Suggests type II protein C deficiency (qualitative)Note: activity antigen levels assessed accurate diagnosis.Protein S Activity/Antigen Assay\nDetects: Deficiency Protein S, vitamin K-dependent cofactor activated Protein C\nSignificance: Protein S deficiency increases risk venous thrombosis\nTesting:\nProtein S Activity Assay:\nMeasures functional activity protein S cofactor APC\nn aPTT-based assay used measure ability APC prolong clotting time presence protein S\n\nTotal Protein S Antigen Assay:\nMeasures total amount protein S protein present\nImmunoturbidimetric ELISA-based methods used\n\nFree Protein S Antigen Assay:\nMeasures amount protein S bound C4b-binding protein (active form protein S)\nImportant measure protein S can bound C4b-binding protein, rendering nonfunctional\n\n\nInterpretation:\nDecreased Protein S Activity: Suggests protein S deficiency\nDecreased Free Protein S Antigen: Suggests protein S deficiency\nInterpretation Protein S Results Complex Due Different Types Deficiencies:\nType : Low total free protein S antigen levels, low protein S activity\nType II: Normal total free protein S antigen levels, low protein S activity\nType III: Normal total protein S antigen level, low free protein S antigen level, low protein S activity\n\n\nProtein S Activity/Antigen AssayWhat Detects: Deficiency Protein S, vitamin K-dependent cofactor activated Protein CSignificance: Protein S deficiency increases risk venous thrombosisTesting:\nProtein S Activity Assay:\nMeasures functional activity protein S cofactor APC\nn aPTT-based assay used measure ability APC prolong clotting time presence protein S\n\nTotal Protein S Antigen Assay:\nMeasures total amount protein S protein present\nImmunoturbidimetric ELISA-based methods used\n\nFree Protein S Antigen Assay:\nMeasures amount protein S bound C4b-binding protein (active form protein S)\nImportant measure protein S can bound C4b-binding protein, rendering nonfunctional\n\nProtein S Activity Assay:\nMeasures functional activity protein S cofactor APC\nn aPTT-based assay used measure ability APC prolong clotting time presence protein S\nMeasures functional activity protein S cofactor APCn aPTT-based assay used measure ability APC prolong clotting time presence protein STotal Protein S Antigen Assay:\nMeasures total amount protein S protein present\nImmunoturbidimetric ELISA-based methods used\nMeasures total amount protein S protein presentImmunoturbidimetric ELISA-based methods usedFree Protein S Antigen Assay:\nMeasures amount protein S bound C4b-binding protein (active form protein S)\nImportant measure protein S can bound C4b-binding protein, rendering nonfunctional\nMeasures amount protein S bound C4b-binding protein (active form protein S)Important measure protein S can bound C4b-binding protein, rendering nonfunctionalInterpretation:\nDecreased Protein S Activity: Suggests protein S deficiency\nDecreased Free Protein S Antigen: Suggests protein S deficiency\nInterpretation Protein S Results Complex Due Different Types Deficiencies:\nType : Low total free protein S antigen levels, low protein S activity\nType II: Normal total free protein S antigen levels, low protein S activity\nType III: Normal total protein S antigen level, low free protein S antigen level, low protein S activity\n\nDecreased Protein S Activity: Suggests protein S deficiencyDecreased Free Protein S Antigen: Suggests protein S deficiencyInterpretation Protein S Results Complex Due Different Types Deficiencies:\nType : Low total free protein S antigen levels, low protein S activity\nType II: Normal total free protein S antigen levels, low protein S activity\nType III: Normal total protein S antigen level, low free protein S antigen level, low protein S activity\nType : Low total free protein S antigen levels, low protein S activityType II: Normal total free protein S antigen levels, low protein S activityType III: Normal total protein S antigen level, low free protein S antigen level, low protein S activity","code":""},{"path":"assays.html","id":"factors-affecting-assay-results","chapter":"Assays","heading":"Factors Affecting Assay Results","text":"Pre-Analytical Variables\nProper Specimen Collection: Follow guidelines collection tube type, blood--anticoagulant ratio, order draw\nPrompt Processing Testing: Analyze samples within recommended timeframe minimize pre-analytical changes\nAvoid Contamination: use samples clots hemolysis\nProper Specimen Collection: Follow guidelines collection tube type, blood--anticoagulant ratio, order drawPrompt Processing Testing: Analyze samples within recommended timeframe minimize pre-analytical changesAvoid Contamination: use samples clots hemolysisAnalytical Variables\nReagent Quality: Use fresh, properly stored reagents\nInstrument Calibration: Ensure proper calibration maintenance coagulation analyzer\nInterfering Substances: aware potential interferences lipemia, icterus, drugs\nReagent Quality: Use fresh, properly stored reagentsInstrument Calibration: Ensure proper calibration maintenance coagulation analyzerInterfering Substances: aware potential interferences lipemia, icterus, drugsPatient-Related Variables\nAnticoagulant Therapy: Warfarin, heparin, direct oral anticoagulants (DOACs) can significantly affect results\nAcute Thrombotic Events: May consume coagulation factors, affecting results\nPregnancy: Protein S levels decrease pregnancy\nLiver Disease: Impairs synthesis coagulation factors\nVitamin K Status: Affects levels vitamin K-dependent coagulation factors (Factors II, VII, IX, X, well Proteins C S)\nAnticoagulant Therapy: Warfarin, heparin, direct oral anticoagulants (DOACs) can significantly affect resultsAcute Thrombotic Events: May consume coagulation factors, affecting resultsPregnancy: Protein S levels decrease pregnancyLiver Disease: Impairs synthesis coagulation factorsVitamin K Status: Affects levels vitamin K-dependent coagulation factors (Factors II, VII, IX, X, well Proteins C S)","code":""},{"path":"assays.html","id":"troubleshooting-erroneous-results-12","chapter":"Assays","heading":"Troubleshooting Erroneous Results","text":"test results inconsistent patient’s clinical presentation laboratory findings, consider following:\nVerify patient’s medication list history anticoagulant use\nCheck sample clots hemolysis\nRepeat test fresh sample\nReview quality control data assay\nInvestigate potential interfering substances\ntest results inconsistent patient’s clinical presentation laboratory findings, consider following:Verify patient’s medication list history anticoagulant useCheck sample clots hemolysisRepeat test fresh sampleReview quality control data assayInvestigate potential interfering substances","code":""},{"path":"assays.html","id":"reflex-testing-8","chapter":"Assays","heading":"Reflex Testing","text":"initial thrombophilia testing reveals abnormality, testing may performed :\nConfirm diagnosis\nCharacterize type severity deficiency abnormality\nEvaluate presence multiple thrombophilic risk factors\nConfirm diagnosisCharacterize type severity deficiency abnormalityEvaluate presence multiple thrombophilic risk factors","code":""},{"path":"assays.html","id":"key-terms-98","chapter":"Assays","heading":"Key Terms","text":"Thrombophilia (Hypercoagulable State): increased tendency develop blood clotsLupus Anticoagulant (LA): antibody interferes phospholipid-dependent coagulation reactionsProtein C S: Vitamin K-dependent anticoagulant proteinsVTE (Venous Thromboembolism): condition includes deep vein thrombosis (DVT) pulmonary embolism (PE)","code":""},{"path":"antiphospholipids.html","id":"antiphospholipids","chapter":"Antiphospholipids","heading":"Antiphospholipids","text":"","code":""},{"path":"antiphospholipids.html","id":"overview-of-antiphospholipid-antibody-apl-assays","chapter":"Antiphospholipids","heading":"Overview of Antiphospholipid Antibody (aPL) Assays","text":"Definition: group laboratory tests used detect measure levels antiphospholipid antibodies (aPL) serum plasma. aPLs autoantibodies directed phospholipids phospholipid-binding proteins, presence associated increased risk thrombosis pregnancy morbidityClinical Significance:\nDiagnosis Antiphospholipid Syndrome (APS): presence aPLs, along specific clinical criteria (thrombosis pregnancy morbidity), used diagnose APS\nRisk Stratification: aPL titers profiles can help assess risk thrombosis pregnancy complications individuals APS\nEvaluation Unexplained Thrombosis Pregnancy Loss: aPL testing recommended patients unexplained venous arterial thrombosis, recurrent pregnancy loss, clinical features suggestive APS\nDiagnosis Antiphospholipid Syndrome (APS): presence aPLs, along specific clinical criteria (thrombosis pregnancy morbidity), used diagnose APSRisk Stratification: aPL titers profiles can help assess risk thrombosis pregnancy complications individuals APSEvaluation Unexplained Thrombosis Pregnancy Loss: aPL testing recommended patients unexplained venous arterial thrombosis, recurrent pregnancy loss, clinical features suggestive APSKey Assays: main aPL assays include:\nLupus Anticoagulant (LA) Testing\nAnticardiolipin (aCL) Antibody Assay\nAnti-β2 Glycoprotein (anti-β2GPI) Antibody Assay\nLupus Anticoagulant (LA) TestingAnticardiolipin (aCL) Antibody AssayAnti-β2 Glycoprotein (anti-β2GPI) Antibody Assay","code":""},{"path":"antiphospholipids.html","id":"key-concepts-target-antigens-and-antibody-isotypes","chapter":"Antiphospholipids","heading":"Key Concepts: Target Antigens and Antibody Isotypes","text":"aPLs can target various phospholipid-binding proteins, clinically relevant :Cardiolipin (aCL): negatively charged phospholipid found cell membranesβ2-Glycoprotein (β2GPI): plasma protein binds negatively charged phospholipidsAntibody Isotypes: IgG, IgM, IgA isotypes aCL anti-β2GPI antibodies measured, IgG isotypes generally strongest association thrombosis pregnancy morbidity","code":""},{"path":"antiphospholipids.html","id":"lupus-anticoagulant-la-testing-1","chapter":"Antiphospholipids","heading":"Lupus Anticoagulant (LA) Testing","text":"Principle:\nLA prolongs phospholipid-dependent clotting tests vitro interfering assembly coagulation complexes phospholipid surfaces\nLA true anticoagulant vivo; associated increased risk thrombosis\nPrinciple:LA prolongs phospholipid-dependent clotting tests vitro interfering assembly coagulation complexes phospholipid surfacesLA true anticoagulant vivo; associated increased risk thrombosisTesting Algorithm:\nLA testing involves series tests demonstrate:\nProlongation phospholipid-dependent clotting tests (screening tests)\nFailure correct mixing studies (presence inhibitor)\nCorrection addition excess phospholipid (phospholipid dependence)\n\nTest Selection Interpretation\nScreening Test: Sensitive presence LA\nMixing Study: process addition test subjects correct issues outside. doesn’t correct, inhibitor present\nConfirmatory Test: confirm phospholipid present performing hexagonal phase\n\nTesting Algorithm:LA testing involves series tests demonstrate:\nProlongation phospholipid-dependent clotting tests (screening tests)\nFailure correct mixing studies (presence inhibitor)\nCorrection addition excess phospholipid (phospholipid dependence)\nProlongation phospholipid-dependent clotting tests (screening tests)Failure correct mixing studies (presence inhibitor)Correction addition excess phospholipid (phospholipid dependence)Test Selection Interpretation\nScreening Test: Sensitive presence LA\nMixing Study: process addition test subjects correct issues outside. doesn’t correct, inhibitor present\nConfirmatory Test: confirm phospholipid present performing hexagonal phase\nScreening Test: Sensitive presence LAMixing Study: process addition test subjects correct issues outside. doesn’t correct, inhibitor presentConfirmatory Test: confirm phospholipid present performing hexagonal phaseConfirmatory Tests:\nDilute Russell’s Viper Venom Time (dRVVT)\nSilica Clotting Time (SCT)\nHexagonal Phase Phospholipid Neutralization Assay\nConfirmatory Tests:Dilute Russell’s Viper Venom Time (dRVVT)Silica Clotting Time (SCT)Hexagonal Phase Phospholipid Neutralization AssayInterpretation:\nProlonged Screening Test: Suggests presence inhibitor\nFailure Correct Mixing: Confirms presence inhibitor\nPhospholipid Dependence: Correction excess phospholipid confirms inhibitor lupus anticoagulant\nRequires Persistent Positivity: meet laboratory criteria APS, LA must present two occasions, least 12 weeks apart\nInterpretation:Prolonged Screening Test: Suggests presence inhibitorFailure Correct Mixing: Confirms presence inhibitorPhospholipid Dependence: Correction excess phospholipid confirms inhibitor lupus anticoagulantRequires Persistent Positivity: meet laboratory criteria APS, LA must present two occasions, least 12 weeks apart","code":""},{"path":"antiphospholipids.html","id":"anticardiolipin-acl-antibody-assay","chapter":"Antiphospholipids","heading":"Anticardiolipin (aCL) Antibody Assay","text":"Principle:\nELISA-based assay measures levels IgG /IgM antibodies bind cardiolipin, negatively charged phospholipid\nPrinciple:ELISA-based assay measures levels IgG /IgM antibodies bind cardiolipin, negatively charged phospholipidProcedure:\nMicroplate Wells Coated Cardiolipin\nPatient Sample added determine happens lipid testing.\nenzyme-labeled secondary antibody (e.g., anti-human IgG anti-human IgM) added determine anti-cardiolipin antibodies.\nsubstrate used detect anti-cardiolipin, light passes help determine.\nProcedure:Microplate Wells Coated CardiolipinPatient Sample added determine happens lipid testing.enzyme-labeled secondary antibody (e.g., anti-human IgG anti-human IgM) added determine anti-cardiolipin antibodies.substrate used detect anti-cardiolipin, light passes help determine.Reporting:\nResults reported GPL units (IgG aCL) MPL units (IgM aCL)\nReported negative, low positive, medium positive, high positive based established cut-values:\nNegative: <20 GPL MPL units\nLow Positive: 20-39 GPL MPL units\nMedium Positive: 40-79 GPL MPL units\nHigh Positive: ≥80 GPL MPL units\n\nReporting:Results reported GPL units (IgG aCL) MPL units (IgM aCL)Reported negative, low positive, medium positive, high positive based established cut-values:\nNegative: <20 GPL MPL units\nLow Positive: 20-39 GPL MPL units\nMedium Positive: 40-79 GPL MPL units\nHigh Positive: ≥80 GPL MPL units\nNegative: <20 GPL MPL unitsLow Positive: 20-39 GPL MPL unitsMedium Positive: 40-79 GPL MPL unitsHigh Positive: ≥80 GPL MPL unitsInterpretation:\nElevated aCL Levels: Suggests presence aCL antibodies\nRequires Persistent Positivity: meet laboratory criteria APS, aCL antibodies must present two occasions, least 12 weeks apart\nClinical Significance:\nHigh titers IgG aCL antibodies strongly associated thrombosis pregnancy morbidity\n\nInterpretation:Elevated aCL Levels: Suggests presence aCL antibodiesRequires Persistent Positivity: meet laboratory criteria APS, aCL antibodies must present two occasions, least 12 weeks apartClinical Significance:\nHigh titers IgG aCL antibodies strongly associated thrombosis pregnancy morbidity\nHigh titers IgG aCL antibodies strongly associated thrombosis pregnancy morbidity","code":""},{"path":"antiphospholipids.html","id":"anti-β2-glycoprotein-i-anti-β2gpi-antibody-assay","chapter":"Antiphospholipids","heading":"Anti-β2 Glycoprotein I (anti-β2GPI) Antibody Assay","text":"Principle:\nELISA-based assay measures levels IgG /IgM antibodies bind β2-glycoprotein , plasma protein binds negatively charged phospholipids\nPrinciple:ELISA-based assay measures levels IgG /IgM antibodies bind β2-glycoprotein , plasma protein binds negatively charged phospholipidsProcedure:\nMicroplate wells coated Beta-2-Glycoprotein mixed plasma.\nenzyme-labeled secondary antibody (e.g., anti-human IgG anti-human IgM) added well determine.\npositive, result enzyme causing increased signal.\nProcedure:Microplate wells coated Beta-2-Glycoprotein mixed plasma.enzyme-labeled secondary antibody (e.g., anti-human IgG anti-human IgM) added well determine.positive, result enzyme causing increased signal.Reporting:\nResults reported units/mL arbitrary units (AU/mL)\nReported negative, low positive, medium positive, high positive based established cut-values:\nNegative: <20 units/mL\nLow Positive: 20-39 units/mL\nMedium Positive: 40-79 units/mL\nHigh Positive: ≥80 units/mL\n\nReporting:Results reported units/mL arbitrary units (AU/mL)Reported negative, low positive, medium positive, high positive based established cut-values:\nNegative: <20 units/mL\nLow Positive: 20-39 units/mL\nMedium Positive: 40-79 units/mL\nHigh Positive: ≥80 units/mL\nNegative: <20 units/mLLow Positive: 20-39 units/mLMedium Positive: 40-79 units/mLHigh Positive: ≥80 units/mLInterpretation:\nElevated anti-β2GPI Levels: Suggests presence anti-β2GPI antibodies\nRequires Persistent Positivity: meet laboratory criteria APS, anti-β2GPI antibodies must present two occasions, least 12 weeks apart\nClinical Significance:\nHigh titers IgG anti-β2GPI antibodies strongly associated thrombosis pregnancy morbidity\n\nInterpretation:Elevated anti-β2GPI Levels: Suggests presence anti-β2GPI antibodiesRequires Persistent Positivity: meet laboratory criteria APS, anti-β2GPI antibodies must present two occasions, least 12 weeks apartClinical Significance:\nHigh titers IgG anti-β2GPI antibodies strongly associated thrombosis pregnancy morbidity\nHigh titers IgG anti-β2GPI antibodies strongly associated thrombosis pregnancy morbidity","code":""},{"path":"antiphospholipids.html","id":"general-factors-affecting-apl-assay-results","chapter":"Antiphospholipids","heading":"General Factors Affecting aPL Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: May activate coagulation factors affect results\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: aPLs can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: May activate coagulation factors affect resultsIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: aPLs can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nReagent Quality: Use fresh, properly stored reagents, follow manufacturer’s instructions\nInstrument Calibration: Ensure proper calibration maintenance instruments\nInterfering Substances: High levels lipids, bilirubin, paraproteins can interfere ELISA-based assays\nAnalytical Variables:Reagent Quality: Use fresh, properly stored reagents, follow manufacturer’s instructionsInstrument Calibration: Ensure proper calibration maintenance instrumentsInterfering Substances: High levels lipids, bilirubin, paraproteins can interfere ELISA-based assaysPatient-Related Variables:\nMedications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test results\nAcute Thrombotic Events: May consume coagulation factors aPLs, leading falsely negative results\nInfections: Transiently elevated aPL levels can seen infections\nAutoimmune Disorders: presence autoimmune antibodies (e.g., antinuclear antibodies) can affect aPL results\nPatient-Related Variables:Medications: Warfarin, heparin, direct oral anticoagulants, medications can affect coagulation test resultsAcute Thrombotic Events: May consume coagulation factors aPLs, leading falsely negative resultsInfections: Transiently elevated aPL levels can seen infectionsAutoimmune Disorders: presence autoimmune antibodies (e.g., antinuclear antibodies) can affect aPL results","code":""},{"path":"antiphospholipids.html","id":"troubleshooting-erroneous-results-13","chapter":"Antiphospholipids","heading":"Troubleshooting Erroneous Results","text":"aPL assay results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nEnsure aPLs positive two occasions, least 12 weeks apart\naPL assay results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyEnsure aPLs positive two occasions, least 12 weeks apart","code":""},{"path":"antiphospholipids.html","id":"key-terms-99","chapter":"Antiphospholipids","heading":"Key Terms","text":"Antiphospholipid Antibodies (aPL): Autoantibodies directed phospholipids phospholipid-binding proteinsLupus Anticoagulant (LA): antibody interferes phospholipid-dependent coagulation assays vitro associated thrombosis vivoAnticardiolipin (aCL) Antibodies: Antibodies bind cardiolipin, negatively charged phospholipidAnti-β2 Glycoprotein (anti-β2GPI) Antibodies: Antibodies bind β2-glycoprotein , plasma protein binds phospholipidsAntiphospholipid Syndrome (APS): autoimmune disorder characterized thrombosis, pregnancy morbidity, presence antiphospholipid antibodiesELISA: Enzyme-Linked Immunosorbent Assay, common type immunoassayThrombosis: Formation blood clot inside blood vessel","code":""},{"path":"protein-c.html","id":"protein-c","chapter":"Protein C","heading":"Protein C","text":"","code":""},{"path":"protein-c.html","id":"overview-of-protein-c-assays","chapter":"Protein C","heading":"Overview of Protein C Assays","text":"Definition: Laboratory tests used measure activity /concentration Protein C, vitamin K-dependent anticoagulant protein, plasmaClinical Significance:\nDiagnosis Inherited Protein C Deficiency: Helps identify individuals genetic predisposition thrombosis\nEvaluation Thrombotic Events: Used investigate patients unexplained venous thromboembolism (VTE) arterial thrombosis\nAssessment Warfarin-Induced Skin Necrosis: Helps identify patients risk developing rare serious complication starting warfarin therapy\nDifferentiation Thrombophilia Risk Factors: Used determine protein C deficiency contributing increased risk thrombosis\nDiagnosis Inherited Protein C Deficiency: Helps identify individuals genetic predisposition thrombosisEvaluation Thrombotic Events: Used investigate patients unexplained venous thromboembolism (VTE) arterial thrombosisAssessment Warfarin-Induced Skin Necrosis: Helps identify patients risk developing rare serious complication starting warfarin therapyDifferentiation Thrombophilia Risk Factors: Used determine protein C deficiency contributing increased risk thrombosisTypes Assays:\nProtein C Activity Assay (Functional Assay)\nProtein C Antigen Assay (Immunological Assay)\nProtein C Activity Assay (Functional Assay)Protein C Antigen Assay (Immunological Assay)","code":""},{"path":"protein-c.html","id":"protein-c-background-and-function","chapter":"Protein C","heading":"Protein C: Background and Function","text":"Protein C:\nvitamin K-dependent serine protease synthesized liver\nCirculates blood inactive form\nvitamin K-dependent serine protease synthesized liverCirculates blood inactive formActivation Protein C:\nThrombin binds thrombomodulin, endothelial cell receptor\nthrombin-thrombomodulin complex activates protein C Activated Protein C (APC)\nThrombin binds thrombomodulin, endothelial cell receptorThe thrombin-thrombomodulin complex activates protein C Activated Protein C (APC)Anticoagulant Function APC:\nActivated Protein C (APC), along cofactor Protein S, inactivates Factors Va VIIIa, inhibiting thrombin generation\nAPC also promotes fibrinolysis inhibiting plasminogen activator inhibitor-1 (PAI-1)\nActivated Protein C (APC), along cofactor Protein S, inactivates Factors Va VIIIa, inhibiting thrombin generationAPC also promotes fibrinolysis inhibiting plasminogen activator inhibitor-1 (PAI-1)","code":""},{"path":"protein-c.html","id":"types-of-protein-c-deficiency","chapter":"Protein C","heading":"Types of Protein C Deficiency","text":"Type (Quantitative Deficiency):\nReduced production Protein C, resulting decreased levels Protein C activity antigen\nCaused mutations affect protein synthesis secretion\nReduced production Protein C, resulting decreased levels Protein C activity antigenCaused mutations affect protein synthesis secretionType II (Qualitative Deficiency):\nNormal levels Protein C protein, Protein C molecule dysfunctional\nNormal Protein C antigen level decreased Protein C activity\nCaused mutations affect catalytic activity cofactor binding Protein C\nNormal levels Protein C protein, Protein C molecule dysfunctionalNormal Protein C antigen level decreased Protein C activityCaused mutations affect catalytic activity cofactor binding Protein C","code":""},{"path":"protein-c.html","id":"protein-c-activity-assay","chapter":"Protein C","heading":"Protein C Activity Assay","text":"Principle:\nMeasures functional activity protein C plasma\nBased ability activated protein C (APC) prolong clotting time modified aPTT assay\nPatient plasma mixed reagent containing thrombin thrombomodulin generate APC\nability generated APC prolong clotting time measured\nMeasures functional activity protein C plasmaBased ability activated protein C (APC) prolong clotting time modified aPTT assayPatient plasma mixed reagent containing thrombin thrombomodulin generate APCThe ability generated APC prolong clotting time measuredMethods:\nClotting-Based Assay:\nAPC Resistance Assay: Measures ability APC prolong aPTT presence Factor V Leiden. actually test Factor V Leiden, Protein C. ’s included Protein C Factor V interact, test detects Factor V Leiden.\nProtein C Clotting Assay: Measures ability generated protein C prolong clotting time modified aPTT assay.\nnow rarely used generally replaced chromogenic assays\n\nChromogenic Assay:\nsynthetic chromogenic substrate cleaved APC\namount colored product released measured spectrophotometrically\nintensity color proportional APC activity\n\nClotting-Based Assay:\nAPC Resistance Assay: Measures ability APC prolong aPTT presence Factor V Leiden. actually test Factor V Leiden, Protein C. ’s included Protein C Factor V interact, test detects Factor V Leiden.\nProtein C Clotting Assay: Measures ability generated protein C prolong clotting time modified aPTT assay.\nnow rarely used generally replaced chromogenic assays\nAPC Resistance Assay: Measures ability APC prolong aPTT presence Factor V Leiden. actually test Factor V Leiden, Protein C. ’s included Protein C Factor V interact, test detects Factor V Leiden.Protein C Clotting Assay: Measures ability generated protein C prolong clotting time modified aPTT assay.now rarely used generally replaced chromogenic assaysChromogenic Assay:\nsynthetic chromogenic substrate cleaved APC\namount colored product released measured spectrophotometrically\nintensity color proportional APC activity\nsynthetic chromogenic substrate cleaved APCThe amount colored product released measured spectrophotometricallyThe intensity color proportional APC activityProcedure:\nFollow manufacturer’s instructions specific assay used\nTypically involves:\nPreparing patient plasma sample\nAdding reagents activate protein C\nMeasuring chromogenic activity determine Protein C’s function\n\nFollow manufacturer’s instructions specific assay usedTypically involves:\nPreparing patient plasma sample\nAdding reagents activate protein C\nMeasuring chromogenic activity determine Protein C’s function\nPreparing patient plasma sampleAdding reagents activate protein CMeasuring chromogenic activity determine Protein C’s functionReporting:\nReported percentage normal IU/dL\nReference Range: Varies depending laboratory assay used (e.g., 70-130%)\nReported percentage normal IU/dLReference Range: Varies depending laboratory assay used (e.g., 70-130%)Interpretation:\nDecreased Protein C Activity:\nSuggests Protein C deficiency\nLevels reference range indicate normal amount Protein C\n\nDecreased Protein C Activity:\nSuggests Protein C deficiency\nLevels reference range indicate normal amount Protein C\nSuggests Protein C deficiencyLevels reference range indicate normal amount Protein C","code":""},{"path":"protein-c.html","id":"protein-c-antigen-assay","chapter":"Protein C","heading":"Protein C Antigen Assay","text":"Principle:\nMeasures amount Protein C protein plasma, regardless function\nBased immunochemical methods use antibodies specific Protein C\nMeasures amount Protein C protein plasma, regardless functionBased immunochemical methods use antibodies specific Protein CMethods:\nEnzyme-Linked Immunosorbent Assay (ELISA):\nMicroplate wells coated antibodies protein C\nsample added wells, protein C present binds antibodies\nsecondary antibody conjugated enzyme added, binds protein C-antibody complex\nsubstrate enzyme added, resulting color change measured spectrophotometrically\n\nImmunoturbidimetric Assay:\nAntibodies protein C added sample\nantibodies bind protein C, immune complexes form\nturbidity solution measured, proportional protein C concentration\n\nEnzyme-Linked Immunosorbent Assay (ELISA):\nMicroplate wells coated antibodies protein C\nsample added wells, protein C present binds antibodies\nsecondary antibody conjugated enzyme added, binds protein C-antibody complex\nsubstrate enzyme added, resulting color change measured spectrophotometrically\nMicroplate wells coated antibodies protein CThe sample added wells, protein C present binds antibodiesA secondary antibody conjugated enzyme added, binds protein C-antibody complexA substrate enzyme added, resulting color change measured spectrophotometricallyImmunoturbidimetric Assay:\nAntibodies protein C added sample\nantibodies bind protein C, immune complexes form\nturbidity solution measured, proportional protein C concentration\nAntibodies protein C added sampleAs antibodies bind protein C, immune complexes formThe turbidity solution measured, proportional protein C concentrationProcedure:\nFollow manufacturer’s instructions specific assay used\nTypically involves:\nPreparing patient plasma sample\nIncubating sample antibody reagent\nMeasuring absorbance turbidity determine Protein C levels\n\nFollow manufacturer’s instructions specific assay usedTypically involves:\nPreparing patient plasma sample\nIncubating sample antibody reagent\nMeasuring absorbance turbidity determine Protein C levels\nPreparing patient plasma sampleIncubating sample antibody reagentMeasuring absorbance turbidity determine Protein C levelsReporting:\nReported concentration (e.g., mg/dL IU/mL)\nReference Range: Varies depending laboratory assay used (e.g., 70-130%)\nReported concentration (e.g., mg/dL IU/mL)Reference Range: Varies depending laboratory assay used (e.g., 70-130%)Interpretation:\nDecreased Protein C Antigen: Suggests protein C deficiency\nHelps distinguish type (quantitative) type II (qualitative) protein C deficiency\nType : Decreased antigen activity\nType II: Normal antigen, decreased activity\n\n\nDecreased Protein C Antigen: Suggests protein C deficiency\nHelps distinguish type (quantitative) type II (qualitative) protein C deficiency\nType : Decreased antigen activity\nType II: Normal antigen, decreased activity\n\nHelps distinguish type (quantitative) type II (qualitative) protein C deficiency\nType : Decreased antigen activity\nType II: Normal antigen, decreased activity\nType : Decreased antigen activityType II: Normal antigen, decreased activity","code":""},{"path":"protein-c.html","id":"interpreting-protein-c-results","chapter":"Protein C","heading":"Interpreting Protein C Results","text":"Decreased Protein C Activity Antigen: Suggests quantitative deficiency (Type )Decreased Protein C Activity Normal Protein C Antigen: Suggests qualitative deficiency (Type II)Important Considerations:\nVitamin K Antagonists (e.g., Warfarin): Warfarin inhibits production vitamin K-dependent coagulation factors, including protein C, leading decreased activity antigen levels\nPatients warfarin least 2 weeks testing protein C deficiency\n\nAcute Thrombosis: Protein C levels may decreased acute thrombotic event due consumption\nTesting performed acute event resolved\n\nLiver Disease: Liver disease impairs synthesis protein C, leading decreased activity antigen levels\nPregnancy Oral Contraceptives: Can affect protein C levels\nVitamin K Antagonists (e.g., Warfarin): Warfarin inhibits production vitamin K-dependent coagulation factors, including protein C, leading decreased activity antigen levels\nPatients warfarin least 2 weeks testing protein C deficiency\nPatients warfarin least 2 weeks testing protein C deficiencyAcute Thrombosis: Protein C levels may decreased acute thrombotic event due consumption\nTesting performed acute event resolved\nTesting performed acute event resolvedLiver Disease: Liver disease impairs synthesis protein C, leading decreased activity antigen levelsPregnancy Oral Contraceptives: Can affect protein C levels","code":""},{"path":"protein-c.html","id":"factors-affecting-protein-c-assay-results","chapter":"Protein C","heading":"Factors Affecting Protein C Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Protein C can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Protein C can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: Heparin can interfere protein C assays\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: Heparin can interfere protein C assaysPatient-Related Variables:\nWarfarin Therapy: Warfarin inhibits production vitamin K-dependent coagulation factors, including Protein C\nAcute Thrombosis: Protein C levels may decreased due consumption thrombotic event\nLiver Disease: Impairs synthesis Protein C\nPregnancy Oral Contraceptives: Can affect Protein C levels\nL-asparaginase therapy\nPatient-Related Variables:Warfarin Therapy: Warfarin inhibits production vitamin K-dependent coagulation factors, including Protein CAcute Thrombosis: Protein C levels may decreased due consumption thrombotic eventLiver Disease: Impairs synthesis Protein CPregnancy Oral Contraceptives: Can affect Protein C levelsL-asparaginase therapy","code":""},{"path":"protein-c.html","id":"troubleshooting-erroneous-results-14","chapter":"Protein C","heading":"Troubleshooting Erroneous Results","text":"protein C results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nWait weeks without anticoagulation therapy (appropriate) repeat testing\nprotein C results unexpected inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyWait weeks without anticoagulation therapy (appropriate) repeat testing","code":""},{"path":"protein-c.html","id":"key-terms-100","chapter":"Protein C","heading":"Key Terms","text":"Protein C: vitamin K-dependent anticoagulant protein inactivates Factors Va VIIIaActivated Protein C (APC): active form protein CProtein S: cofactor activated protein CThrombomodulin: endothelial cell receptor binds thrombin activates protein CThrombophilia (Hypercoagulable State): increased tendency develop blood clotsVitamin K-Dependent Factors: Coagulation factors require vitamin K synthesis (Factors II, VII, IX, X, Proteins C S)","code":""},{"path":"protein-s.html","id":"protein-s","chapter":"Protein S","heading":"Protein S","text":"","code":""},{"path":"protein-s.html","id":"overview-of-protein-s-in-hemostasis","chapter":"Protein S","heading":"Overview of Protein S in Hemostasis","text":"Definition: Protein S vitamin K-dependent glycoprotein synthesized liver functions cofactor activated protein C (APC) inactivation Factors Va VIIIa, key components coagulation cascadeSignificance: Protein S, along Protein C, acts natural anticoagulant, helping regulate thrombin generation prevent excessive clot formation. Protein S deficiency well-established risk factor venous thromboembolism (VTE)Two Forms Protein S:\nFree Protein S: active form functions cofactor APC\nBound Protein S: Bound C4b-binding protein (C4BP), acute-phase reactant. bound form inactive function cofactor APC\nFree Protein S: active form functions cofactor APCBound Protein S: Bound C4b-binding protein (C4BP), acute-phase reactant. bound form inactive function cofactor APC","code":""},{"path":"protein-s.html","id":"assays-for-protein-s","chapter":"Protein S","heading":"Assays for Protein S","text":"Protein S Activity Assay:\nPrinciple: Measures functional activity protein S, .e., ability act cofactor APC inactivation Factor Va\nMethods:\nActivated Partial Thromboplastin Time (aPTT)-Based Assay:\nmodified aPTT assay used, aPTT performed presence absence APC\ndegree APC prolongs aPTT proportional amount functional Protein S present\n\nChromogenic Assay:\nchromogenic substrate used measure activity APC presence Protein S\n\n\nInterpretation:\nDecreased Protein S Activity: Suggests Protein S deficiency\n\nProtein S Activity Assay:Principle: Measures functional activity protein S, .e., ability act cofactor APC inactivation Factor VaMethods:\nActivated Partial Thromboplastin Time (aPTT)-Based Assay:\nmodified aPTT assay used, aPTT performed presence absence APC\ndegree APC prolongs aPTT proportional amount functional Protein S present\n\nChromogenic Assay:\nchromogenic substrate used measure activity APC presence Protein S\n\nActivated Partial Thromboplastin Time (aPTT)-Based Assay:\nmodified aPTT assay used, aPTT performed presence absence APC\ndegree APC prolongs aPTT proportional amount functional Protein S present\nmodified aPTT assay used, aPTT performed presence absence APCThe degree APC prolongs aPTT proportional amount functional Protein S presentChromogenic Assay:\nchromogenic substrate used measure activity APC presence Protein S\nchromogenic substrate used measure activity APC presence Protein SInterpretation:\nDecreased Protein S Activity: Suggests Protein S deficiency\nDecreased Protein S Activity: Suggests Protein S deficiencyTotal Protein S Antigen Assay:\nPrinciple: Measures total amount Protein S protein present, regardless whether free bound form\nMethods:\nImmunoturbidimetry: Antibodies specific protein S added sample, turbidity solution measured\nNephelometry: Measures light scattered immune complexes\nELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect protein S\n\nInterpretation:\nDecreased Total Protein S Antigen: Suggests quantitative deficiency Protein S\n\nTotal Protein S Antigen Assay:Principle: Measures total amount Protein S protein present, regardless whether free bound formMethods:\nImmunoturbidimetry: Antibodies specific protein S added sample, turbidity solution measured\nNephelometry: Measures light scattered immune complexes\nELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect protein S\nImmunoturbidimetry: Antibodies specific protein S added sample, turbidity solution measuredNephelometry: Measures light scattered immune complexesELISA (Enzyme-Linked Immunosorbent Assay): Uses enzyme-labeled antibodies detect protein SInterpretation:\nDecreased Total Protein S Antigen: Suggests quantitative deficiency Protein S\nDecreased Total Protein S Antigen: Suggests quantitative deficiency Protein SFree Protein S Antigen Assay:\nPrinciple: Measures amount Protein S bound C4b-binding protein (C4BP). free Protein S anticoagulant activity\nMethods:\nImmunometric Assay Precipitation: Free Protein S captured antibody, total protein S measured dissociation\n\nInterpretation:\nDecreased Free Protein S Antigen: Suggests deficiency active, free form Protein S\n\nFree Protein S Antigen Assay:Principle: Measures amount Protein S bound C4b-binding protein (C4BP). free Protein S anticoagulant activityMethods:\nImmunometric Assay Precipitation: Free Protein S captured antibody, total protein S measured dissociation\nImmunometric Assay Precipitation: Free Protein S captured antibody, total protein S measured dissociationInterpretation:\nDecreased Free Protein S Antigen: Suggests deficiency active, free form Protein S\nDecreased Free Protein S Antigen: Suggests deficiency active, free form Protein S","code":""},{"path":"protein-s.html","id":"interpreting-protein-s-assay-results","chapter":"Protein S","heading":"Interpreting Protein S Assay Results","text":"interpretation Protein S assay results can complex due different types Protein S deficiency influence C4b-binding protein (C4BP) levelsTypes Protein S Deficiency (based laboratory findings):\nType : (Quantitative Deficiency)\nDecreased Total Protein S Antigen\nDecreased Free Protein S Antigen\nDecreased Protein S Activity\n\nType II: (Qualitative Deficiency)\nNormal Total Protein S Antigen\nNormal Free Protein S Antigen\nDecreased Protein S Activity\n\nType III: (Low Free Protein S)\nNormal Total Protein S Antigen\nDecreased Free Protein S Antigen\nDecreased Protein S Activity\n\nTypes Protein S Deficiency (based laboratory findings):Type : (Quantitative Deficiency)\nDecreased Total Protein S Antigen\nDecreased Free Protein S Antigen\nDecreased Protein S Activity\nDecreased Total Protein S AntigenDecreased Free Protein S AntigenDecreased Protein S ActivityType II: (Qualitative Deficiency)\nNormal Total Protein S Antigen\nNormal Free Protein S Antigen\nDecreased Protein S Activity\nNormal Total Protein S AntigenNormal Free Protein S AntigenDecreased Protein S ActivityType III: (Low Free Protein S)\nNormal Total Protein S Antigen\nDecreased Free Protein S Antigen\nDecreased Protein S Activity\nNormal Total Protein S AntigenDecreased Free Protein S AntigenDecreased Protein S ActivityImportant Considerations:\nPregnancy: Pregnancy associated decreased Protein S levels, making interpretation difficult\nOral Contraceptives Hormone Replacement Therapy: Can decrease Protein S levels\nAcute Thrombosis: Acute thrombotic events can consume Protein S\nInflammation: C4b-binding protein (C4BP) acute-phase reactant. Increased C4BP can bind Protein S, leading decreased free Protein S levels\nImportant Considerations:Pregnancy: Pregnancy associated decreased Protein S levels, making interpretation difficultOral Contraceptives Hormone Replacement Therapy: Can decrease Protein S levelsAcute Thrombosis: Acute thrombotic events can consume Protein SInflammation: C4b-binding protein (C4BP) acute-phase reactant. Increased C4BP can bind Protein S, leading decreased free Protein S levelsRecommendations:\n* Confirm results repeating testing patient acutely ill pregnant, taking oral birth control.\n* Check C4b-binding protein level confirm increased level lowering free protein SRecommendations:\n* Confirm results repeating testing patient acutely ill pregnant, taking oral birth control.\n* Check C4b-binding protein level confirm increased level lowering free protein S","code":""},{"path":"protein-s.html","id":"factors-affecting-protein-s-assay-results","chapter":"Protein S","heading":"Factors Affecting Protein S Assay Results","text":"Pre-Analytical Variables:\nImproper Specimen Collection: Traumatic venipuncture, underfilled collection tube, clots sample\nDelayed Testing: Protein S activity antigen levels can decrease prolonged storage\nImproper Storage: Samples stored properly maintain protein S activity\nPre-Analytical Variables:Improper Specimen Collection: Traumatic venipuncture, underfilled collection tube, clots sampleDelayed Testing: Protein S activity antigen levels can decrease prolonged storageImproper Storage: Samples stored properly maintain protein S activityAnalytical Variables:\nReagent Quality: Use fresh, properly stored reagents\nInstrument Calibration: Ensure proper calibration instrument\nInterfering Substances: Heparin, lupus anticoagulants, substances can interfere assays\nAnalytical Variables:Reagent Quality: Use fresh, properly stored reagentsInstrument Calibration: Ensure proper calibration instrumentInterfering Substances: Heparin, lupus anticoagulants, substances can interfere assaysPatient-Related Variables:\nAnticoagulant Therapy: Warfarin can affect Protein S levels\nPregnancy: Protein S levels decrease pregnancy\nLiver Disease: Impairs synthesis Protein S\nNephrotic Syndrome: Protein S loss urine\nPatient-Related Variables:Anticoagulant Therapy: Warfarin can affect Protein S levelsPregnancy: Protein S levels decrease pregnancyLiver Disease: Impairs synthesis Protein SNephrotic Syndrome: Protein S loss urine","code":""},{"path":"protein-s.html","id":"troubleshooting-erroneous-results-15","chapter":"Protein S","heading":"Troubleshooting Erroneous Results","text":"Protein S results unexpected inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nVerify quality control data\nRepeat test fresh sample, ensuring proper collection handling\nConsider possibility interfering substances medications\nReview patient’s medical history medication list\nRepeat test period stability (e.g., pregnancy discontinuing warfarin)\nCheck sample clots hemolysisVerify quality control dataRepeat test fresh sample, ensuring proper collection handlingConsider possibility interfering substances medicationsReview patient’s medical history medication listRepeat test period stability (e.g., pregnancy discontinuing warfarin)","code":""},{"path":"protein-s.html","id":"reflex-testing-9","chapter":"Protein S","heading":"Reflex Testing","text":"initial Protein S activity antigen level low, testing may performed :\nRule Acquired Causes Protein S Deficiency:\nCheck liver function tests\nEvaluate nephrotic syndrome (urine protein)\nRule DIC\n\nAssess C4b-Binding Protein (C4BP) Level: Elevated C4BP can lead decreased free protein S\nPerform Genetic Testing: identify specific PROS1 gene mutations (rarely done)\nRule Acquired Causes Protein S Deficiency:\nCheck liver function tests\nEvaluate nephrotic syndrome (urine protein)\nRule DIC\nCheck liver function testsEvaluate nephrotic syndrome (urine protein)Rule DICAssess C4b-Binding Protein (C4BP) Level: Elevated C4BP can lead decreased free protein SPerform Genetic Testing: identify specific PROS1 gene mutations (rarely done)","code":""},{"path":"protein-s.html","id":"key-terms-101","chapter":"Protein S","heading":"Key Terms","text":"Protein S: vitamin K-dependent anticoagulant protein acts cofactor activated protein CThrombophilia (Hypercoagulable State): increased tendency develop blood clotsVitamin K-Dependent Factors: Coagulation factors (II, VII, IX, X) anticoagulant proteins (C S) require vitamin K synthesisFree Protein S: active form protein S bound C4b-binding proteinTotal Protein S: total amount protein S, including free bound formsC4b-Binding Protein (C4BP): acute-phase reactant binds protein S, reducing amount free protein SVTE (Venous Thromboembolism): condition includes deep vein thrombosis (DVT) pulmonary embolism (PE)","code":""},{"path":"molecular.html","id":"molecular","chapter":"Molecular","heading":"Molecular","text":"","code":""},{"path":"molecular.html","id":"overview-of-molecular-testing-in-hypercoagulability-assessment","chapter":"Molecular","heading":"Overview of Molecular Testing in Hypercoagulability Assessment","text":"Purpose: Molecular testing performed identify genetic mutations associated increased risk thrombosis (hypercoagulable state)Consider Molecular Testing:\nUnexplained recurrent venous thromboembolism (VTE)\nVTE young age (<50 years)\nFamily history thrombophilia\nThrombosis unusual sites (e.g., mesenteric, cerebral)\nRecurrent pregnancy loss\nUnexplained recurrent venous thromboembolism (VTE)VTE young age (<50 years)Family history thrombophiliaThrombosis unusual sites (e.g., mesenteric, cerebral)Recurrent pregnancy lossImportant Considerations:\nMolecular testing generally performed acute thrombotic event resolved patient anticoagulant therapy\ndecision perform molecular testing based clinical judgment consideration patient’s risk factors likelihood finding clinically significant mutation\npositive result molecular testing guarantee patient develop thrombosis, can provide useful information risk stratification management decisions\nMolecular testing generally performed acute thrombotic event resolved patient anticoagulant therapyThe decision perform molecular testing based clinical judgment consideration patient’s risk factors likelihood finding clinically significant mutationA positive result molecular testing guarantee patient develop thrombosis, can provide useful information risk stratification management decisions","code":""},{"path":"molecular.html","id":"key-molecular-tests","chapter":"Molecular","heading":"Key Molecular Tests","text":"’s detailed breakdown common molecular tests used assess inherited thrombophilias:Factor V Leiden Mutation Analysis (F5 Gene):\nBackground: Factor V Leiden common inherited thrombophilia\nFactor V Leiden Mutation Analysis (F5 Gene):Background: Factor V Leiden common inherited thrombophiliaProthrombin G20210A Mutation Analysis (F2 Gene):\nBackground: second common inherited thrombophilia\nProthrombin G20210A Mutation Analysis (F2 Gene):Background: second common inherited thrombophilia","code":""},{"path":"molecular.html","id":"general-molecular-testing-procedures","chapter":"Molecular","heading":"General Molecular Testing Procedures","text":"Regardless specific mutation tested, general procedure molecular testing involves:DNA Extraction: Extract DNA blood samplePCR Amplification: Use PCR amplify region gene contains mutationMutation Detection: Use various techniques detect presence mutation:Allele-Specific PCR (-PCR): Uses primers specific mutated sequenceRestriction Fragment Length Polymorphism (RFLP) Analysis: Uses restriction enzymes cut DNA specific sites, creating fragments different lengths depending presence absence mutationReal-Time PCR: Uses fluorescent probes detect amplified DNA product quantify amount mutated sequenceNext Generation Sequencing: negative Factor V Leiden Prothrombin, good option. can test many mutations associated thrombophilia","code":""},{"path":"molecular.html","id":"key-terms-102","chapter":"Molecular","heading":"Key Terms","text":"Thrombophilia (Hypercoagulable State): condition increased risk thrombosisFactor V Leiden: common genetic mutation causes resistance activated protein CProthrombin G20210A Mutation: genetic mutation leads increased prothrombin levelsMutation: change DNA sequence gene","code":""},{"path":"fv-leiden.html","id":"fv-leiden","chapter":"FV Leiden","heading":"FV Leiden","text":"","code":""},{"path":"fv-leiden.html","id":"overview-of-factor-v-leiden","chapter":"FV Leiden","heading":"Overview of Factor V Leiden","text":"Definition: Factor V Leiden specific genetic mutation F5 gene (encoding Factor V) results resistance inactivation Activated Protein C (APC)Significance: common inherited thrombophilia, associated increased risk venous thromboembolism (VTE), deep vein thrombosis (DVT) pulmonary embolism (PE)Key Points:\nMolecular Test: Diagnosis made detecting presence Factor V Leiden mutation using DNA-based molecular assays\nCure: mutation isn’t always symptomatic, ’s essential know mutation present, higher level care required\nIncreased Risk: prone clotting\nMolecular Test: Diagnosis made detecting presence Factor V Leiden mutation using DNA-based molecular assaysNo Cure: mutation isn’t always symptomatic, ’s essential know mutation present, higher level care requiredIncreased Risk: prone clotting","code":""},{"path":"fv-leiden.html","id":"the-f5-gene-and-factor-v-leiden-mutation","chapter":"FV Leiden","heading":"The F5 Gene and Factor V Leiden Mutation","text":"F5 Gene:\nLocation: Chromosome 1 (1q24.2)\nEncodes: Factor V, key coagulation factor acts cofactor Factor Xa prothrombinase complex, converts prothrombin thrombin\nLocation: Chromosome 1 (1q24.2)Encodes: Factor V, key coagulation factor acts cofactor Factor Xa prothrombinase complex, converts prothrombin thrombinThe Factor V Leiden Mutation:\nDescription: point mutation F5 gene (G1691A)\nAmino Acid Substitution: Results glutamine (Q) arginine (R) substitution amino acid position 506 (R506Q)\nEffect APC Cleavage Site: substitution alters one cleavage sites Factor V normally recognized activated protein C (APC)\nDescription: point mutation F5 gene (G1691A)Amino Acid Substitution: Results glutamine (Q) arginine (R) substitution amino acid position 506 (R506Q)Effect APC Cleavage Site: substitution alters one cleavage sites Factor V normally recognized activated protein C (APC)Mechanism Resistance APC:\nNormal Inactivation Factor V: APC, along cofactor protein S, normally inactivates Factor Va cleaving specific sites\nFactor V Leiden Resistance: R506Q mutation makes Factor V resistant inactivation APC, leading prolonged activity Factor Va increased thrombin generation\nNormal Inactivation Factor V: APC, along cofactor protein S, normally inactivates Factor Va cleaving specific sitesFactor V Leiden Resistance: R506Q mutation makes Factor V resistant inactivation APC, leading prolonged activity Factor Va increased thrombin generation","code":""},{"path":"fv-leiden.html","id":"testing-principles","chapter":"FV Leiden","heading":"Testing Principles","text":"Molecular Testing Required: Factor V Leiden mutation detected using DNA-based molecular assays. can done simple blood draw mutation present birthThese tests analyze patient’s DNA determine mutation present, ","code":""},{"path":"fv-leiden.html","id":"molecular-testing-procedures","chapter":"FV Leiden","heading":"Molecular Testing Procedures","text":"general procedure detecting Factor V Leiden mutation involves following steps:DNA Extraction:\nExtract DNA blood sample (typically EDTA whole blood) using commercially available DNA extraction kit\nEnsure DNA high quality free inhibitors\nExtract DNA blood sample (typically EDTA whole blood) using commercially available DNA extraction kitEnsure DNA high quality free inhibitorsPCR Amplification:\nUse polymerase chain reaction (PCR) amplify specific region F5 gene contains R506Q mutation\nUse primers flank region interest specific F5 gene\nUse polymerase chain reaction (PCR) amplify specific region F5 gene contains R506Q mutationUse primers flank region interest specific F5 geneMutation Detection: Use various techniques detect presence Factor V Leiden mutation:\nAllele-Specific PCR (-PCR):\nUses primers specific either normal sequence mutated sequence\npresence PCR product indicates presence specific allele\n\nRestriction Fragment Length Polymorphism (RFLP) Analysis:\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequence\nPCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresis\npresence different fragment sizes indicates presence Factor V Leiden mutation\n\nReal-Time PCR (qPCR):\nUses fluorescent probes detect amplified DNA product real time\nCan used quantify amount normal mutated alleles\n\nNext-Generation Sequencing (NGS):\nCan used sequence entire F5 gene identify known novel mutations\ncommonly used genetic abnormalities suspected\n\nAllele-Specific PCR (-PCR):\nUses primers specific either normal sequence mutated sequence\npresence PCR product indicates presence specific allele\nUses primers specific either normal sequence mutated sequenceThe presence PCR product indicates presence specific alleleRestriction Fragment Length Polymorphism (RFLP) Analysis:\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequence\nPCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresis\npresence different fragment sizes indicates presence Factor V Leiden mutation\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequenceThe PCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresisThe presence different fragment sizes indicates presence Factor V Leiden mutationReal-Time PCR (qPCR):\nUses fluorescent probes detect amplified DNA product real time\nCan used quantify amount normal mutated alleles\nUses fluorescent probes detect amplified DNA product real timeCan used quantify amount normal mutated allelesNext-Generation Sequencing (NGS):\nCan used sequence entire F5 gene identify known novel mutations\ncommonly used genetic abnormalities suspected\nCan used sequence entire F5 gene identify known novel mutationsMore commonly used genetic abnormalities suspected","code":""},{"path":"fv-leiden.html","id":"interpretation-of-results-2","chapter":"FV Leiden","heading":"Interpretation of Results","text":"Normal (Homozygous Wild-Type): patient two copies normal F5 gene carry Factor V Leiden mutationHeterozygous: patient one copy normal F5 gene one copy Factor V Leiden mutated gene\nIncreased risk venous thrombosis\nIncreased risk venous thrombosisHomozygous: patient two copies Factor V Leiden mutated gene\nHigher risk venous thrombosis compared heterozygotes\nHigher risk venous thrombosis compared heterozygotesImportant Note: interpretation results always made context patient’s clinical history, family history, laboratory findings","code":""},{"path":"fv-leiden.html","id":"key-considerations-1","chapter":"FV Leiden","heading":"Key Considerations:","text":"Results qualitative, determine treatment","code":""},{"path":"fv-leiden.html","id":"factors-affecting-test-results","chapter":"FV Leiden","heading":"Factors Affecting Test Results","text":"Pre-Analytical Variables:\nSample Collection:\nCollect blood EDTA (purple-top) tube\nAvoid clots hemolysis\n\nSample Storage:\nStore samples properly prevent DNA degradation\n\nSample Collection:\nCollect blood EDTA (purple-top) tube\nAvoid clots hemolysis\nCollect blood EDTA (purple-top) tubeAvoid clots hemolysisSample Storage:\nStore samples properly prevent DNA degradation\nStore samples properly prevent DNA degradationAnalytical Variables:\nReagent Quality:\nUse high-quality reagents ensure expired\n\nProper Controls:\nInclude positive negative controls PCR run monitor performance assay\n\nContamination:\nTake precautions prevent contamination PCR reagents samples\n\nReagent Quality:\nUse high-quality reagents ensure expired\nUse high-quality reagents ensure expiredProper Controls:\nInclude positive negative controls PCR run monitor performance assay\nInclude positive negative controls PCR run monitor performance assayContamination:\nTake precautions prevent contamination PCR reagents samples\nTake precautions prevent contamination PCR reagents samplesPatient-Related Variables:\nRecent Blood Transfusion:\nMay affect results transfused blood contains different F5 genotype patient’s cells\nWait several weeks transfusion performing test\n\nHematopoietic Stem Cell Transplantation (HSCT):\nF5 genotype may reflect donor’s genotype rather patient’s original genotype\n\nRecent Blood Transfusion:\nMay affect results transfused blood contains different F5 genotype patient’s cells\nWait several weeks transfusion performing test\nMay affect results transfused blood contains different F5 genotype patient’s cellsWait several weeks transfusion performing testHematopoietic Stem Cell Transplantation (HSCT):\nF5 genotype may reflect donor’s genotype rather patient’s original genotype\nF5 genotype may reflect donor’s genotype rather patient’s original genotype","code":""},{"path":"fv-leiden.html","id":"troubleshooting-erroneous-results-16","chapter":"FV Leiden","heading":"Troubleshooting Erroneous Results","text":"molecular test results unexpected inconsistent patient’s clinical presentation:\nVerify sample identity chain custody\nRepeat test fresh sample\nCheck quality control data assay\nInvestigate potential interfering substances technical errors\nConsider possibility rare novel F5 mutation\nmolecular test results unexpected inconsistent patient’s clinical presentation:Verify sample identity chain custodyRepeat test fresh sampleCheck quality control data assayInvestigate potential interfering substances technical errorsConsider possibility rare novel F5 mutation","code":""},{"path":"fv-leiden.html","id":"key-terms-103","chapter":"FV Leiden","heading":"Key Terms","text":"F5 Gene: gene encodes Factor VFactor V Leiden: specific mutation F5 gene (R506Q) causes resistance activated protein CHypercoagulability (Thrombophilia): increased tendency develop blood clotsVenous Thromboembolism (VTE): condition includes deep vein thrombosis (DVT) pulmonary embolism (PE)Allele-Specific PCR (-PCR): PCR technique uses primers specific either normal mutated sequenceRestriction Fragment Length Polymorphism (RFLP): technique uses restriction enzymes cut DNA specific sitesReal-Time PCR (qPCR): PCR technique allows quantification amplified DNA product","code":""},{"path":"pt-20210.html","id":"pt-20210","chapter":"PT 20210","heading":"PT 20210","text":"","code":""},{"path":"pt-20210.html","id":"overview-of-prothrombin-g20210a-mutation-testing","chapter":"PT 20210","heading":"Overview of Prothrombin G20210A Mutation Testing","text":"Definition: Molecular testing prothrombin G20210A mutation involves detecting specific genetic variation prothrombin (F2) geneClinical Significance:\nAssesses Prothrombin Mutation Body\nEvaluation Thrombotic Risk\nAssesses Prothrombin Mutation BodyEvaluation Thrombotic RiskKey Points:\nMolecular Test: common way detect analyze\nCure: everyone gets issues disorder, just implies easy patients mutation develop\nMolecular Test: common way detect analyzeNo Cure: everyone gets issues disorder, just implies easy patients mutation develop","code":""},{"path":"pt-20210.html","id":"the-f2-gene-and-prothrombin-g20210a-mutation","chapter":"PT 20210","heading":"The F2 Gene and Prothrombin G20210A Mutation","text":"F2 Gene:\nLocation: Chromosome 11 (11p11.2)\nEncodes: Prothrombin (Factor II), vitamin K-dependent coagulation factor converted thrombin prothrombinase complex\nLocation: Chromosome 11 (11p11.2)Encodes: Prothrombin (Factor II), vitamin K-dependent coagulation factor converted thrombin prothrombinase complexThe Prothrombin G20210A Mutation:\nDescription: point mutation 3’-untranslated region (3’UTR) F2 gene\nNucleotide Change: guanine (G) adenine () substitution position 20210 (G20210A)\nEffect Prothrombin Levels: mutation leads increased prothrombin mRNA stability, resulting elevated plasma prothrombin levels\nDescription: point mutation 3’-untranslated region (3’UTR) F2 geneNucleotide Change: guanine (G) adenine () substitution position 20210 (G20210A)Effect Prothrombin Levels: mutation leads increased prothrombin mRNA stability, resulting elevated plasma prothrombin levels","code":""},{"path":"pt-20210.html","id":"molecular-testing-procedures-1","chapter":"PT 20210","heading":"Molecular Testing Procedures","text":"general procedure detecting prothrombin G20210A mutation involves following steps:DNA Extraction:\nExtract DNA blood sample (typically EDTA whole blood) using commercially available DNA extraction kit\nEnsure DNA high quality free inhibitors\nExtract DNA blood sample (typically EDTA whole blood) using commercially available DNA extraction kitEnsure DNA high quality free inhibitorsPCR Amplification:\nUse polymerase chain reaction (PCR) amplify specific region F2 gene contains G20210A mutation\nUse primers flank region interest specific F2 gene\nUse polymerase chain reaction (PCR) amplify specific region F2 gene contains G20210A mutationUse primers flank region interest specific F2 geneMutation Detection:\nAllele-Specific PCR (-PCR):\nUses primers specific either normal sequence mutated sequence\npresence PCR product indicates presence specific allele\n\nRestriction Fragment Length Polymorphism (RFLP) Analysis:\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequence\nPCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresis\npresence different fragment sizes indicates presence prothrombin G20210A mutation\n\nReal-Time PCR (qPCR):\nUses fluorescent probes detect amplified DNA product real time\nCan used quantify amount normal mutated alleles\n\nNext-Generation Sequencing (NGS):\nCan used sequence entire F2 gene identify known novel mutations\nLess commonly used routine prothrombin G20210A testing, may useful cases atypical presentations\n\nAllele-Specific PCR (-PCR):\nUses primers specific either normal sequence mutated sequence\npresence PCR product indicates presence specific allele\nUses primers specific either normal sequence mutated sequenceThe presence PCR product indicates presence specific alleleRestriction Fragment Length Polymorphism (RFLP) Analysis:\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequence\nPCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresis\npresence different fragment sizes indicates presence prothrombin G20210A mutation\nUses restriction enzyme recognizes cuts normal DNA sequence cut mutated sequenceThe PCR product digested restriction enzyme, resulting fragments analyzed gel electrophoresisThe presence different fragment sizes indicates presence prothrombin G20210A mutationReal-Time PCR (qPCR):\nUses fluorescent probes detect amplified DNA product real time\nCan used quantify amount normal mutated alleles\nUses fluorescent probes detect amplified DNA product real timeCan used quantify amount normal mutated allelesNext-Generation Sequencing (NGS):\nCan used sequence entire F2 gene identify known novel mutations\nLess commonly used routine prothrombin G20210A testing, may useful cases atypical presentations\nCan used sequence entire F2 gene identify known novel mutationsLess commonly used routine prothrombin G20210A testing, may useful cases atypical presentations","code":""},{"path":"pt-20210.html","id":"interpreting-results-10","chapter":"PT 20210","heading":"Interpreting Results","text":"Normal (Homozygous Wild-Type): patient two copies normal F2 gene carry prothrombin G20210A mutationHeterozygous: patient one copy normal F2 gene one copy prothrombin G20210A mutated gene\nIncreased risk venous thrombosis\nIncreased risk venous thrombosisHomozygous: patient two copies prothrombin G20210A mutated gene\nHigher risk venous thrombosis compared heterozygotes\nHigher risk venous thrombosis compared heterozygotesImportant Notes:\ninterpretation results always made context patient’s clinical history, family history, laboratory findings\nPatients prothrombin G20210A mutation risk high prothrombin levels\nIncreased risk venous thromboembolism\nPregnancy loss\nArterial thrombotic events (less common)\ninterpretation results always made context patient’s clinical history, family history, laboratory findingsPatients prothrombin G20210A mutation risk high prothrombin levelsIncreased risk venous thromboembolismPregnancy lossArterial thrombotic events (less common)","code":""},{"path":"pt-20210.html","id":"factors-affecting-test-results-1","chapter":"PT 20210","heading":"Factors Affecting Test Results","text":"Pre-Analytical Variables:\nSample Collection:\nCollect blood EDTA (purple-top) tube\nAvoid clots hemolysis\n\nSample Storage:\nStore samples properly prevent DNA degradation\n\nPre-Analytical Variables:Sample Collection:\nCollect blood EDTA (purple-top) tube\nAvoid clots hemolysis\nCollect blood EDTA (purple-top) tubeAvoid clots hemolysisSample Storage:\nStore samples properly prevent DNA degradation\nStore samples properly prevent DNA degradationAnalytical Variables:\nReagent Quality:\nUse high-quality reagents ensure expired\n\nProper Controls:\nInclude positive negative controls PCR run monitor performance assay\n\nAnalytical Variables:Reagent Quality:\nUse high-quality reagents ensure expired\nUse high-quality reagents ensure expiredProper Controls:\nInclude positive negative controls PCR run monitor performance assay\nInclude positive negative controls PCR run monitor performance assayPatient-Related Variables:\nRecent Blood Transfusion:\nMay affect results transfused blood contains different F2 genotype patient’s cells\nWait several weeks transfusion performing test\n\nPatient-Related Variables:Recent Blood Transfusion:\nMay affect results transfused blood contains different F2 genotype patient’s cells\nWait several weeks transfusion performing test\nMay affect results transfused blood contains different F2 genotype patient’s cellsWait several weeks transfusion performing test","code":""},{"path":"pt-20210.html","id":"troubleshooting-erroneous-results-17","chapter":"PT 20210","heading":"Troubleshooting Erroneous Results","text":"molecular test results unexpected inconsistent patient’s clinical presentation:\nVerify sample identity chain custody\nRepeat test fresh sample\nCheck quality control data assay\nInvestigate potential interfering substances technical errors\nConsider possibility rare novel F2 mutation\nmolecular test results unexpected inconsistent patient’s clinical presentation:Verify sample identity chain custodyRepeat test fresh sampleCheck quality control data assayInvestigate potential interfering substances technical errorsConsider possibility rare novel F2 mutation","code":""},{"path":"pt-20210.html","id":"reflex-testing-10","chapter":"PT 20210","heading":"Reflex Testing","text":"generally isn’t reflex test, F2/Prothrombin mutation generally either present . However, finding mutation, might:\n* Run protein levels evaluate much Prothrombin patient making\n* tests may used thrombophilias","code":""},{"path":"pt-20210.html","id":"key-terms-104","chapter":"PT 20210","heading":"Key Terms","text":"F2 Gene: gene encodes prothrombin (Factor II)Prothrombin G20210A Mutation: genetic mutation 3’-untranslated region F2 geneThrombophilia (Hypercoagulable State): increased tendency develop blood clotsVenous Thromboembolism (VTE): condition includes deep vein thrombosis (DVT) pulmonary embolism (PE)Allele-Specific PCR (-PCR): PCR technique uses primers specific either normal mutated sequenceRestriction Fragment Length Polymorphism (RFLP): technique uses restriction enzymes cut DNA specific sitesReal-Time PCR (qPCR): PCR technique allows quantification amplified DNA product","code":""},{"path":"anti-xa.html","id":"anti-xa","chapter":"Anti-Xa","heading":"Anti-Xa","text":"","code":""},{"path":"anti-xa.html","id":"overview-of-anti-xa-assays","chapter":"Anti-Xa","heading":"Overview of Anti-Xa Assays","text":"Definition: Anti-Xa assays laboratory tests used measure activity anticoagulant drugs inhibit Factor Xa (FXa), key enzyme coagulation cascadePurpose:\nMonitoring Low-Molecular-Weight Heparin (LMWH) Therapy: Used monitor LMWH therapy, especially patients :\nRenal insufficiency\nObesity\nPregnancy\nChildren\nconditions standard dosing may reliable\n\nMonitoring Unfractionated Heparin (UFH) Therapy: May used alternative aPTT certain situations\nMonitoring Direct Oral Anticoagulants (DOACs): Used measure plasma concentration direct oral anticoagulants (DOACs) inhibit Factor Xa (e.g., rivaroxaban, apixaban, edoxaban) specific situations\nAssessing Heparin Contamination: Used detect heparin contamination blood samples indwelling catheters\nMonitoring Low-Molecular-Weight Heparin (LMWH) Therapy: Used monitor LMWH therapy, especially patients :\nRenal insufficiency\nObesity\nPregnancy\nChildren\nconditions standard dosing may reliable\nRenal insufficiencyObesityPregnancyChildrenOther conditions standard dosing may reliableMonitoring Unfractionated Heparin (UFH) Therapy: May used alternative aPTT certain situationsMonitoring Direct Oral Anticoagulants (DOACs): Used measure plasma concentration direct oral anticoagulants (DOACs) inhibit Factor Xa (e.g., rivaroxaban, apixaban, edoxaban) specific situationsAssessing Heparin Contamination: Used detect heparin contamination blood samples indwelling cathetersPrinciple: Anti-Xa assays measure ability anticoagulant drug inhibit Factor Xa activity plasma sample","code":""},{"path":"anti-xa.html","id":"key-concepts-anticoagulant-mechanisms-of-action","chapter":"Anti-Xa","heading":"Key Concepts: Anticoagulant Mechanisms of Action","text":"Heparin (UFH LMWH):\nMechanism: Enhances activity antithrombin, natural anticoagulant\nAntithrombin inhibits several coagulation factors, including Factors IIa (thrombin), IXa, Xa\nLMWHs greater effect Factor Xa inhibition compared UFH\nMechanism: Enhances activity antithrombin, natural anticoagulantAntithrombin inhibits several coagulation factors, including Factors IIa (thrombin), IXa, XaLMWHs greater effect Factor Xa inhibition compared UFHFondaparinux:\nsynthetic pentasaccharide selectively inhibits Factor Xa via antithrombin\nsynthetic pentasaccharide selectively inhibits Factor Xa via antithrombinDirect Oral Anticoagulants (DOACs):\nDirect Thrombin Inhibitors (DTIs): Inhibit thrombin (Factor IIa) directly (e.g., dabigatran)\nFactor Xa Inhibitors: Inhibit Factor Xa directly (e.g., rivaroxaban, apixaban, edoxaban)\nDirect Thrombin Inhibitors (DTIs): Inhibit thrombin (Factor IIa) directly (e.g., dabigatran)Factor Xa Inhibitors: Inhibit Factor Xa directly (e.g., rivaroxaban, apixaban, edoxaban)","code":""},{"path":"anti-xa.html","id":"components-of-the-anti-xa-assay-system","chapter":"Anti-Xa","heading":"Components of the Anti-Xa Assay System","text":"Instrumentation:\nAutomated Coagulation Analyzer: Capable performing chromogenic clot-based assays\nSpectrophotometer: Used measure absorbance colored product chromogenic assays\nAutomated Coagulation Analyzer: Capable performing chromogenic clot-based assaysSpectrophotometer: Used measure absorbance colored product chromogenic assaysReagents:\nAntithrombin: Purified antithrombin reagent\nFactor Xa: Purified Factor Xa reagent\nChromogenic Substrate: synthetic peptide substrate cleaved Factor Xa, releasing colored product\nBuffer: Tris buffer suitable buffer maintain stable pH\nCalibrators: Standards known concentrations anticoagulant drug\nControl Materials: perform instrument calibration\nAntithrombin: Purified antithrombin reagentFactor Xa: Purified Factor Xa reagentChromogenic Substrate: synthetic peptide substrate cleaved Factor Xa, releasing colored productBuffer: Tris buffer suitable buffer maintain stable pHCalibrators: Standards known concentrations anticoagulant drugControl Materials: perform instrument calibrationSample Preparation:\nPlasma: isolate plasma, sample must centrifuged\nSpecific anticoagulant required collection; test specifications dictate collection can use heparin citrate\nPlasma: isolate plasma, sample must centrifugedSpecific anticoagulant required collection; test specifications dictate collection can use heparin citrate","code":""},{"path":"anti-xa.html","id":"procedure-for-performing-an-anti-xa-assay","chapter":"Anti-Xa","heading":"Procedure for Performing an Anti-Xa Assay","text":"Chromogenic Method (Common):\nPatient Plasma Preparation: Dilute patient’s plasma specific buffer\nAdd Antithrombin Factor Xa: Mix diluted plasma antithrombin known amount Factor Xa\nanticoagulant drug patient’s plasma inhibit Factor Xa, amount inhibition measured\n\nIncubate: Incubate mixture specific period allow reaction proceed\nAdd Chromogenic Substrate: Add chromogenic substrate specific Factor Xa\nUninhibited Factor Xa cleave substrate, releasing colored product\n\nMeasure Absorbance: Measure absorbance solution specific wavelength\nCalculation: Calculate anti-Xa activity based calibration curve prepared using standards known concentrations anticoagulant drug\nChromogenic Method (Common):Patient Plasma Preparation: Dilute patient’s plasma specific bufferAdd Antithrombin Factor Xa: Mix diluted plasma antithrombin known amount Factor Xa\nanticoagulant drug patient’s plasma inhibit Factor Xa, amount inhibition measured\nanticoagulant drug patient’s plasma inhibit Factor Xa, amount inhibition measuredIncubate: Incubate mixture specific period allow reaction proceedAdd Chromogenic Substrate: Add chromogenic substrate specific Factor Xa\nUninhibited Factor Xa cleave substrate, releasing colored product\nUninhibited Factor Xa cleave substrate, releasing colored productMeasure Absorbance: Measure absorbance solution specific wavelengthCalculation: Calculate anti-Xa activity based calibration curve prepared using standards known concentrations anticoagulant drugClotting Method (Less Common):\nMeasures prothrombin time. less accurate sensitive thus becoming obsolete\nClotting Method (Less Common):Measures prothrombin time. less accurate sensitive thus becoming obsolete","code":""},{"path":"anti-xa.html","id":"interpreting-results-11","chapter":"Anti-Xa","heading":"Interpreting Results","text":"Anti-Xa Activity Level:\nReported units activity (e.g., IU/mL μg/mL)\nReference Range: Varies depending anticoagulant drug clinical indication\nRefer laboratory’s established therapeutic range drug\n\nReported units activity (e.g., IU/mL μg/mL)Reference Range: Varies depending anticoagulant drug clinical indication\nRefer laboratory’s established therapeutic range drug\nRefer laboratory’s established therapeutic range drugTherapeutic Range:\nLMWH: Typical therapeutic ranges LMWH depend dosing schedule (-daily twice-daily) clinical indication (e.g., treatment VTE, prophylaxis)\nUFH: target range may established\nDOACs: labs offer DOAC specific testing\nLMWH: Typical therapeutic ranges LMWH depend dosing schedule (-daily twice-daily) clinical indication (e.g., treatment VTE, prophylaxis)UFH: target range may establishedDOACs: labs offer DOAC specific testing","code":""},{"path":"anti-xa.html","id":"factors-affecting-anti-xa-assay-results","chapter":"Anti-Xa","heading":"Factors Affecting Anti-Xa Assay Results","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tube\nClotted Sample: Invalidates results\nDelayed Testing: Anticoagulant drugs can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nImproper Collection Technique: Tissue thromboplastin contamination hemolysisIncorrect Blood--Anticoagulant Ratio: Underfilling overfilling collection tubeClotted Sample: Invalidates resultsDelayed Testing: Anticoagulant drugs can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructions\nInterfering Substances: Heparin-induced thrombocytopenia (HIT) antibodies can interfere assay\nSpecific test: Reagents, lots numbers, expirations\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents follow manufacturer’s instructionsInterfering Substances: Heparin-induced thrombocytopenia (HIT) antibodies can interfere assaySpecific test: Reagents, lots numbers, expirationsPatient-Related Variables:\nMedications: medications affect coagulation can influence anti-Xa results\nLiver Disease: Impairs synthesis antithrombin coagulation factors\nKidney Disease: Can affect drug clearance anticoagulant levels\nMedications: medications affect coagulation can influence anti-Xa resultsLiver Disease: Impairs synthesis antithrombin coagulation factorsKidney Disease: Can affect drug clearance anticoagulant levels","code":""},{"path":"anti-xa.html","id":"troubleshooting-erroneous-results-18","chapter":"Anti-Xa","heading":"Troubleshooting Erroneous Results","text":"anti-Xa result inconsistent patient’s clinical presentation previous results:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nConsider possibility heparin contamination\nanti-Xa result inconsistent patient’s clinical presentation previous results:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyConsider possibility heparin contamination","code":""},{"path":"anti-xa.html","id":"reflex-testing-11","chapter":"Anti-Xa","heading":"Reflex Testing","text":"anti-Xa result outside therapeutic range, consider:\nRepeat test confirm result\nAssess patient adherence medication regimen\nEvaluate drug interactions\nConsider adjusting anticoagulant dose\nheparin contamination suspected, perform heparin neutralization assay\nRepeat test confirm resultAssess patient adherence medication regimenEvaluate drug interactionsConsider adjusting anticoagulant doseIf heparin contamination suspected, perform heparin neutralization assay","code":""},{"path":"anti-xa.html","id":"key-terms-105","chapter":"Anti-Xa","heading":"Key Terms","text":"Anti-Xa Assay: laboratory test measure activity anticoagulant drugs inhibit Factor XaFactor Xa: key enzyme coagulation cascadeLow-Molecular-Weight Heparin (LMWH): type anticoagulant drug (e.g., enoxaparin, dalteparin)Unfractionated Heparin (UFH): anticoagulant drug monitored using aPTT anti-Xa assayDirect Oral Anticoagulants (DOACs): class anticoagulant drugs includes direct thrombin inhibitors (e.g., dabigatran) Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban)Antithrombin: natural anticoagulant inhibits thrombin coagulation factorsHeparin-Induced Thrombocytopenia (HIT): prothrombotic disorder caused antibodies heparin-platelet factor 4 complexesChromogenic Assay: type assay measures activity enzyme measuring production colored product","code":""},{"path":"thrombin-inhibitors.html","id":"thrombin-inhibitors","chapter":"Thrombin Inhibitors","heading":"Thrombin Inhibitors","text":"","code":""},{"path":"thrombin-inhibitors.html","id":"overview-of-direct-thrombin-inhibitors-dtis","chapter":"Thrombin Inhibitors","heading":"Overview of Direct Thrombin Inhibitors (DTIs)","text":"Definition: Direct thrombin inhibitors (DTIs) class anticoagulant medications directly bind inhibit activity thrombin (Factor IIa), key enzyme coagulation cascadeDefinition: Direct thrombin inhibitors (DTIs) class anticoagulant medications directly bind inhibit activity thrombin (Factor IIa), key enzyme coagulation cascadeMechanism Action: DTIs bind thrombin prevent :\nCleaving fibrinogen form fibrin\nActivating coagulation factors (e.g., Factors V, VIII, XI, XIII)\nActivating platelets\nMechanism Action: DTIs bind thrombin prevent :Cleaving fibrinogen form fibrinActivating coagulation factors (e.g., Factors V, VIII, XI, XIII)Activating plateletsAdvantages Warfarin:\nPredictable anticoagulant response: DTIs predictable anticoagulant effect warfarin, reducing need routine monitoring many patients\nRapid onset action: DTIs rapid onset action, allowing immediate anticoagulation\nFewer drug food interactions: DTIs fewer interactions medications foods compared warfarin\nAdvantages Warfarin:Predictable anticoagulant response: DTIs predictable anticoagulant effect warfarin, reducing need routine monitoring many patientsRapid onset action: DTIs rapid onset action, allowing immediate anticoagulationFewer drug food interactions: DTIs fewer interactions medications foods compared warfarinTypes DTIs:\nUnivalent (Small Molecule) DTIs:\nBind active site thrombin\nExamples:\nDabigatran (oral)\nArgatroban (IV)\n\nBivalent DTIs:\nBind active site exosite 1 thrombin\nHirudin: naturally derived leeches, often used anymore\nBivalirudin (IV)\n\n\nTypes DTIs:Univalent (Small Molecule) DTIs:\nBind active site thrombin\nExamples:\nDabigatran (oral)\nArgatroban (IV)\n\nBivalent DTIs:\nBind active site exosite 1 thrombin\nHirudin: naturally derived leeches, often used anymore\nBivalirudin (IV)\n\nBind active site thrombinExamples:\nDabigatran (oral)\nArgatroban (IV)\nDabigatran (oral)Argatroban (IV)Bivalent DTIs:\nBind active site exosite 1 thrombin\nHirudin: naturally derived leeches, often used anymore\nBivalirudin (IV)\nBind active site exosite 1 thrombinHirudin: naturally derived leeches, often used anymoreBivalirudin (IV)","code":""},{"path":"thrombin-inhibitors.html","id":"laboratory-monitoring-of-dtis","chapter":"Thrombin Inhibitors","heading":"Laboratory Monitoring of DTIs","text":"DTIs offer several advantages warfarin, laboratory monitoring may necessary certain situations:Situations Requiring Monitoring:\nPatients renal insufficiency\nPatients extremes body weight\nPatients high risk bleeding thrombosis\nPatients undergoing urgent surgery invasive procedures\nSuspected overdose\nPatients liver disease (argatroban)\nPatients renal insufficiencyPatients extremes body weightPatients high risk bleeding thrombosisPatients undergoing urgent surgery invasive proceduresSuspected overdosePatients liver disease (argatroban)Tests Used Monitoring DTIs:\nDiluted Thrombin Time (dTT)\nEcarin Clotting Time (ECT)\nAnti-IIa Assay (Chromogenic Assay)\naPTT (Activated Partial Thromboplastin Time): Less sensitive specific, may used argatroban monitoring\nDiluted Thrombin Time (dTT)Ecarin Clotting Time (ECT)Anti-IIa Assay (Chromogenic Assay)aPTT (Activated Partial Thromboplastin Time): Less sensitive specific, may used argatroban monitoring","code":""},{"path":"thrombin-inhibitors.html","id":"dabigatran-pradaxa","chapter":"Thrombin Inhibitors","heading":"Dabigatran (Pradaxa)","text":"Mechanism Action: direct thrombin inhibitor binds reversibly free clot-bound thrombin, preventing cleaving fibrinogen fibrinMechanism Action: direct thrombin inhibitor binds reversibly free clot-bound thrombin, preventing cleaving fibrinogen fibrinLaboratory Monitoring:\nDiluted Thrombin Time (dTT): preferred test assessing dabigatran levels\nPrinciple: Measures prolongation thrombin time diluted plasma sample\nProcedure:\nDilute patient’s plasma specific buffer\nAdd known concentration thrombin diluted plasma\nMeasure clotting time\n\nInterpretation: clotting time directly proportional dabigatran concentration\n\nEcarin Clotting Time (ECT):\nAnother test measuring dabigatran levels\nsensitive dTT less widely available\n\nAnti-IIa Assay (Chromogenic Assay):\nchromogenic assay measures inhibition thrombin activity dabigatran\nspecific dTT, less commonly used routine monitoring\n\naPTT (Activated Partial Thromboplastin Time):\nProlonged dabigatran, sensitive specific dTT ECT\nrecommended routine monitoring\n\nLaboratory Monitoring:Diluted Thrombin Time (dTT): preferred test assessing dabigatran levels\nPrinciple: Measures prolongation thrombin time diluted plasma sample\nProcedure:\nDilute patient’s plasma specific buffer\nAdd known concentration thrombin diluted plasma\nMeasure clotting time\n\nInterpretation: clotting time directly proportional dabigatran concentration\nPrinciple: Measures prolongation thrombin time diluted plasma sampleProcedure:\nDilute patient’s plasma specific buffer\nAdd known concentration thrombin diluted plasma\nMeasure clotting time\nDilute patient’s plasma specific bufferAdd known concentration thrombin diluted plasmaMeasure clotting timeInterpretation: clotting time directly proportional dabigatran concentrationEcarin Clotting Time (ECT):\nAnother test measuring dabigatran levels\nsensitive dTT less widely available\nAnother test measuring dabigatran levelsMore sensitive dTT less widely availableAnti-IIa Assay (Chromogenic Assay):\nchromogenic assay measures inhibition thrombin activity dabigatran\nspecific dTT, less commonly used routine monitoring\nchromogenic assay measures inhibition thrombin activity dabigatranMore specific dTT, less commonly used routine monitoringaPTT (Activated Partial Thromboplastin Time):\nProlonged dabigatran, sensitive specific dTT ECT\nrecommended routine monitoring\nProlonged dabigatran, sensitive specific dTT ECTNot recommended routine monitoringInterpretation Results:\nTherapeutic Range: Varies depending clinical indication specific assay used\nRefer laboratory’s established therapeutic range\n\nElevated dTT, ECT, Anti-IIa Activity: Indicates increased dabigatran levels\nMay increase risk bleeding\n\nDecreased dTT, ECT, Anti-IIa Activity: Indicates decreased dabigatran levels\nMay increase risk thrombosis\n\nInterpretation Results:Therapeutic Range: Varies depending clinical indication specific assay used\nRefer laboratory’s established therapeutic range\nRefer laboratory’s established therapeutic rangeElevated dTT, ECT, Anti-IIa Activity: Indicates increased dabigatran levels\nMay increase risk bleeding\nMay increase risk bleedingDecreased dTT, ECT, Anti-IIa Activity: Indicates decreased dabigatran levels\nMay increase risk thrombosis\nMay increase risk thrombosisIdarucizumab (Praxbind):\nspecific reversal agent dabigatran\nmonoclonal antibody binds dabigatran neutralizes anticoagulant activity\nUsed emergency situations reverse effects dabigatran (e.g., life-threatening bleeding, urgent surgery)\nIdarucizumab (Praxbind):specific reversal agent dabigatranA monoclonal antibody binds dabigatran neutralizes anticoagulant activityUsed emergency situations reverse effects dabigatran (e.g., life-threatening bleeding, urgent surgery)","code":""},{"path":"thrombin-inhibitors.html","id":"argatroban","chapter":"Thrombin Inhibitors","heading":"Argatroban","text":"Mechanism Action: direct thrombin inhibitor binds reversibly active site thrombinMechanism Action: direct thrombin inhibitor binds reversibly active site thrombinLaboratory Monitoring:\naPTT: commonly used test monitoring argatroban therapy\ntarget aPTT range typically 1.5-3 times baseline aPTT\n\nEcarin Clotting Time (ECT):\nCan used alternative aPTT\nsensitive argatroban aPTT\n\nAnti-IIa Assay (Chromogenic Assay):\nMeasures inhibition thrombin activity argatroban\nCan used confirm argatroban levels specific situations\n\nLaboratory Monitoring:aPTT: commonly used test monitoring argatroban therapy\ntarget aPTT range typically 1.5-3 times baseline aPTT\ntarget aPTT range typically 1.5-3 times baseline aPTTEcarin Clotting Time (ECT):\nCan used alternative aPTT\nsensitive argatroban aPTT\nCan used alternative aPTTMore sensitive argatroban aPTTAnti-IIa Assay (Chromogenic Assay):\nMeasures inhibition thrombin activity argatroban\nCan used confirm argatroban levels specific situations\nMeasures inhibition thrombin activity argatrobanCan used confirm argatroban levels specific situationsInterpretation Results:\naPTT ECT within Therapeutic Range: Indicates adequate anticoagulation\nProlonged aPTT ECT: Indicates excessive anticoagulation increased risk bleeding\nShortened aPTT ECT: Indicates subtherapeutic anticoagulation increased risk thrombosis\nInterpretation Results:aPTT ECT within Therapeutic Range: Indicates adequate anticoagulationProlonged aPTT ECT: Indicates excessive anticoagulation increased risk bleedingShortened aPTT ECT: Indicates subtherapeutic anticoagulation increased risk thrombosisNo Specific Reversal Agent: specific antidote reverse effects argatroban\nManagement bleeding:\nDiscontinue argatroban\nAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])\nConsider hemodialysis (argatroban dialyzable)\n\nSpecific Reversal Agent: specific antidote reverse effects argatrobanManagement bleeding:\nDiscontinue argatroban\nAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])\nConsider hemodialysis (argatroban dialyzable)\nDiscontinue argatrobanAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])Consider hemodialysis (argatroban dialyzable)","code":""},{"path":"thrombin-inhibitors.html","id":"bivalirudin","chapter":"Thrombin Inhibitors","heading":"Bivalirudin","text":"Mechanism Action: direct thrombin inhibitor binds active site exosite 1 thrombinMechanism Action: direct thrombin inhibitor binds active site exosite 1 thrombinLaboratory Monitoring:\naPTT: Can used monitor bivalirudin therapy, relationship aPTT bivalirudin concentration variable\nEcarin Clotting Time (ECT):\nsensitive bivalirudin aPTT\nMay preferred monitoring bivalirudin therapy\n\nAnti-IIa Assay (Chromogenic Assay):\nMeasures inhibition thrombin activity bivalirudin\nCan provide direct measurement bivalirudin concentration\n\nLaboratory Monitoring:aPTT: Can used monitor bivalirudin therapy, relationship aPTT bivalirudin concentration variableEcarin Clotting Time (ECT):\nsensitive bivalirudin aPTT\nMay preferred monitoring bivalirudin therapy\nsensitive bivalirudin aPTTMay preferred monitoring bivalirudin therapyAnti-IIa Assay (Chromogenic Assay):\nMeasures inhibition thrombin activity bivalirudin\nCan provide direct measurement bivalirudin concentration\nMeasures inhibition thrombin activity bivalirudinCan provide direct measurement bivalirudin concentrationInterpretation Results:\naPTT ECT within Therapeutic Range: Indicates adequate anticoagulation\nProlonged aPTT ECT: Indicates excessive anticoagulation increased risk bleeding\nShortened aPTT ECT: Indicates subtherapeutic anticoagulation increased risk thrombosis\nInterpretation Results:aPTT ECT within Therapeutic Range: Indicates adequate anticoagulationProlonged aPTT ECT: Indicates excessive anticoagulation increased risk bleedingShortened aPTT ECT: Indicates subtherapeutic anticoagulation increased risk thrombosisNo Specific Reversal Agent: specific antidote reverse effects bivalirudin\nManagement bleeding:\nDiscontinue bivalirudin\nAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])\nBivalirudin short half-life, effects wear relatively quickly\n\nSpecific Reversal Agent: specific antidote reverse effects bivalirudinManagement bleeding:\nDiscontinue bivalirudin\nAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])\nBivalirudin short half-life, effects wear relatively quickly\nDiscontinue bivalirudinAdminister procoagulant factors (e.g., prothrombin complex concentrate [PCC])Bivalirudin short half-life, effects wear relatively quickly","code":""},{"path":"thrombin-inhibitors.html","id":"general-considerations-for-dti-assays","chapter":"Thrombin Inhibitors","heading":"General Considerations for DTI Assays","text":"Pre-Analytical Variables:\nImproper Collection Technique: Tissue thromboplastin contamination hemolysis\nCorrect Blood--Anticoagulant Ratio: Ensure collection tube filled correct volume\nClotted Sample: Invalidates results\nDelayed Testing: Anticoagulant drugs can degrade time\nImproper Storage: Incorrect storage temperatures can affect results\nPre-Analytical Variables:Improper Collection Technique: Tissue thromboplastin contamination hemolysisCorrect Blood--Anticoagulant Ratio: Ensure collection tube filled correct volumeClotted Sample: Invalidates resultsDelayed Testing: Anticoagulant drugs can degrade timeImproper Storage: Incorrect storage temperatures can affect resultsAnalytical Variables:\nInstrument Malfunction: Ensure proper calibration maintenance coagulation analyzer\nReagent Problems: Use fresh, properly stored reagents, follow manufacturer’s instructions\nInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detection\nAnalytical Variables:Instrument Malfunction: Ensure proper calibration maintenance coagulation analyzerReagent Problems: Use fresh, properly stored reagents, follow manufacturer’s instructionsInterfering Substances: High levels bilirubin, lipids, paraproteins can interfere optical clot detectionPatient-Related Variables:\nMedications: medications affect coagulation can influence DTI assay results\nLiver Disease: Can affect clearance DTIs\nKidney Disease: Can affect clearance DTIs\nPatient-Related Variables:Medications: medications affect coagulation can influence DTI assay resultsLiver Disease: Can affect clearance DTIsKidney Disease: Can affect clearance DTIs","code":""},{"path":"thrombin-inhibitors.html","id":"troubleshooting-erroneous-results-19","chapter":"Thrombin Inhibitors","heading":"Troubleshooting Erroneous Results","text":"DTI assay result inconsistent patient’s clinical presentation:\nCheck sample clots hemolysis\nRepeat test fresh sample\nEnsure correct blood--anticoagulant ratio used\nVerify instrument reagent quality control results\nInvestigate potential interfering substances\nReview patient’s medication list medical history\nConsult pathologist coagulation expert\nDTI assay result inconsistent patient’s clinical presentation:Check sample clots hemolysisRepeat test fresh sampleEnsure correct blood--anticoagulant ratio usedVerify instrument reagent quality control resultsInvestigate potential interfering substancesReview patient’s medication list medical historyConsult pathologist coagulation expert","code":""},{"path":"thrombin-inhibitors.html","id":"key-terms-106","chapter":"Thrombin Inhibitors","heading":"Key Terms","text":"Direct Thrombin Inhibitor (DTI): anticoagulant drug directly inhibits thrombin (Factor IIa)Thrombin Time (TT): test measures time takes clot form addition thrombinaPTT (Activated Partial Thromboplastin Time): test intrinsic common pathways coagulationAnti-IIa Assay: chromogenic assay measures inhibition thrombin activityDabigatran: direct thrombin inhibitor administered orallyArgatroban: direct thrombin inhibitor administered intravenouslyBivalirudin: direct thrombin inhibitor administered intravenouslyIdarucizumab: specific reversal agent dabigatranEcarin Clotting Time (ECT): coagulation test sensitive direct thrombin inhibitors","code":""},{"path":"heparin-neutralization.html","id":"heparin-neutralization","chapter":"Heparin Neutralization","heading":"Heparin Neutralization","text":"","code":""},{"path":"heparin-neutralization.html","id":"overview-of-heparin-neutralization-assays","chapter":"Heparin Neutralization","heading":"Overview of Heparin Neutralization Assays","text":"Definition: Heparin neutralization assays group laboratory tests used determine heparin interfering coagulation assays assess presence heparin-induced antibodiesDefinition: Heparin neutralization assays group laboratory tests used determine heparin interfering coagulation assays assess presence heparin-induced antibodiesPurpose:\nDistinguishing heparin contamination true coagulation factor deficiencies patients prolonged clotting times (PT /aPTT)\nInvestigating unexpected unexplained bleeding\nEvaluating heparin responsiveness\nDetecting heparin-dependent antibodies (e.g., heparin-induced thrombocytopenia - HIT)\nPurpose:Distinguishing heparin contamination true coagulation factor deficiencies patients prolonged clotting times (PT /aPTT)Investigating unexpected unexplained bleedingEvaluating heparin responsivenessDetecting heparin-dependent antibodies (e.g., heparin-induced thrombocytopenia - HIT)Two Main Categories:\nHeparin Neutralization Correct Clotting Assays: Used determine heparin causing prolonged clotting times\nHeparin Antibody Assays: Used detect identify antibodies heparin-platelet factor 4 (PF4) complexes, Heparin Induced Thrombocytopenia (HIT)\nTwo Main Categories:Heparin Neutralization Correct Clotting Assays: Used determine heparin causing prolonged clotting timesHeparin Antibody Assays: Used detect identify antibodies heparin-platelet factor 4 (PF4) complexes, Heparin Induced Thrombocytopenia (HIT)","code":""},{"path":"heparin-neutralization.html","id":"heparin-neutralization-to-correct-clotting-assays","chapter":"Heparin Neutralization","heading":"Heparin Neutralization to Correct Clotting Assays","text":"Principle: assays involve adding heparin-neutralizing agent patient’s plasma inactivate heparin present, repeating prolonged clotting test (PT /aPTT)Principle: assays involve adding heparin-neutralizing agent patient’s plasma inactivate heparin present, repeating prolonged clotting test (PT /aPTT)Rationale: prolonged clotting time corrects heparin neutralization, suggests prolongation due heparin interference, rather true factor deficiency inhibitorRationale: prolonged clotting time corrects heparin neutralization, suggests prolongation due heparin interference, rather true factor deficiency inhibitorMethods:\nPolybrene Neutralization:\nPolybrene positively charged compound binds neutralizes heparin (negatively charged)\nPolybrene added patient’s plasma performing clotting assay (PT aPTT)\n\nProtamine Sulfate Neutralization:\nProtamine sulfate positively charged protein binds neutralizes heparin\nProtamine sulfate added patient’s plasma performing clotting assay (PT aPTT)\n\nHeparinase Digestion:\nHeparinase enzyme degrades heparin\npatient’s plasma incubated heparinase remove heparin, clotting assay performed\n\nMethods:Polybrene Neutralization:\nPolybrene positively charged compound binds neutralizes heparin (negatively charged)\nPolybrene added patient’s plasma performing clotting assay (PT aPTT)\nPolybrene positively charged compound binds neutralizes heparin (negatively charged)Polybrene added patient’s plasma performing clotting assay (PT aPTT)Protamine Sulfate Neutralization:\nProtamine sulfate positively charged protein binds neutralizes heparin\nProtamine sulfate added patient’s plasma performing clotting assay (PT aPTT)\nProtamine sulfate positively charged protein binds neutralizes heparinProtamine sulfate added patient’s plasma performing clotting assay (PT aPTT)Heparinase Digestion:\nHeparinase enzyme degrades heparin\npatient’s plasma incubated heparinase remove heparin, clotting assay performed\nHeparinase enzyme degrades heparinThe patient’s plasma incubated heparinase remove heparin, clotting assay performedProcedure:\nPrepare Patient’s Plasma: Collect prepare platelet-poor plasma (PPP) patient’s blood sample\nPerform Baseline Clotting Assay (PT aPTT): Measure PT aPTT untreated patient plasma\nPrepare Neutralized Plasma:\nAdd Polybrene, Protamine Sulfate, Heparinase: Add heparin-neutralizing agent portion patient’s plasma, following manufacturer’s instructions\nIncubate: Incubate neutralized plasma recommended time (usually minutes)\n\nPerform Clotting Assay Neutralized Plasma: Measure PT aPTT neutralized plasma\nCompare Results: Compare clotting time untreated plasma clotting time neutralized plasma\nProcedure:Prepare Patient’s Plasma: Collect prepare platelet-poor plasma (PPP) patient’s blood samplePerform Baseline Clotting Assay (PT aPTT): Measure PT aPTT untreated patient plasmaPrepare Neutralized Plasma:\nAdd Polybrene, Protamine Sulfate, Heparinase: Add heparin-neutralizing agent portion patient’s plasma, following manufacturer’s instructions\nIncubate: Incubate neutralized plasma recommended time (usually minutes)\nAdd Polybrene, Protamine Sulfate, Heparinase: Add heparin-neutralizing agent portion patient’s plasma, following manufacturer’s instructionsIncubate: Incubate neutralized plasma recommended time (usually minutes)Perform Clotting Assay Neutralized Plasma: Measure PT aPTT neutralized plasmaCompare Results: Compare clotting time untreated plasma clotting time neutralized plasmaInterpretation:\nCorrection Clotting Time: clotting time corrects (returns normal reference range) heparin neutralization, suggests heparin cause prolonged clotting time\nCorrection Clotting Time: clotting time remains prolonged heparin neutralization, suggests factor deficiency inhibitor present, heparin sole cause prolonged clotting time\nInterpretation:Correction Clotting Time: clotting time corrects (returns normal reference range) heparin neutralization, suggests heparin cause prolonged clotting timeNo Correction Clotting Time: clotting time remains prolonged heparin neutralization, suggests factor deficiency inhibitor present, heparin sole cause prolonged clotting time","code":""},{"path":"heparin-neutralization.html","id":"heparin-antibody-assays-for-heparin-induced-thrombocytopenia---hit","chapter":"Heparin Neutralization","heading":"Heparin Antibody Assays (for Heparin-Induced Thrombocytopenia - HIT)","text":"Overview: assays used detect antibodies heparin-platelet factor 4 (PF4) complexes, characteristic heparin-induced thrombocytopenia (HIT)Overview: assays used detect antibodies heparin-platelet factor 4 (PF4) complexes, characteristic heparin-induced thrombocytopenia (HIT)HIT: Quick Review:\nHIT prothrombotic disorder caused formation antibodies bind complexes heparin platelet factor 4 (PF4)\nAntibody binding activates platelets, leading thrombocytopenia (low platelet count) increased risk thrombosis\nHIT: Quick Review:HIT prothrombotic disorder caused formation antibodies bind complexes heparin platelet factor 4 (PF4)Antibody binding activates platelets, leading thrombocytopenia (low platelet count) increased risk thrombosisHIT Diagnostic Algorithm\n4Ts Score: Estimate clinical likelihood HIT (Thrombocytopenia, Timing, Thrombosis, causes Thrombocytopenia)\nscore indicates high intermediate likelihood HIT, perform following tests\nHIT Diagnostic Algorithm4Ts Score: Estimate clinical likelihood HIT (Thrombocytopenia, Timing, Thrombosis, causes Thrombocytopenia)score indicates high intermediate likelihood HIT, perform following testsAssay Types\nEnzyme-Linked Immunosorbent Assay (ELISA):\nPrinciple: Detects antibodies heparin-PF4 complexes\nProcedure:\nMicroplate wells coated heparin-PF4 complexes\npatient’s serum plasma added wells, antibodies present bind heparin-PF4 complexes\nenzyme-labeled secondary antibody (e.g., anti-human IgG) added, binds bound antibodies\nsubstrate enzyme added, resulting color change measured spectrophotometrically\n\nInterpretation:\nOptical Density (OD) values measured, higher OD correlating antibodies present\nCan differentiate IgG, IgM, IgA antibodies\npositive result indicates presence heparin-PF4 antibodies, confirm platelet activation\n\n\nFunctional Assays:\nSerotonin Release Assay (SRA) Heparin-Induced Platelet Aggregation (HIPA)\nPrinciple: Measures platelet activation presence heparin patient serum/plasma\nProcedure:\nPatient serum incubated normal donor platelets heparin\nPlatelet activation measured :\nSerotonin Release Assay (SRA): Measuring release serotonin platelets\nHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregation\n\n\nInterpretation:\nPositive: Indicates presence platelet-activating antibodies, confirming HIT\n\n\nAdvantages Functional Assays:\nHigher specificity ELISA\nDetect platelet-activating antibodies, clinically relevant\n\n\nAssay TypesEnzyme-Linked Immunosorbent Assay (ELISA):\nPrinciple: Detects antibodies heparin-PF4 complexes\nProcedure:\nMicroplate wells coated heparin-PF4 complexes\npatient’s serum plasma added wells, antibodies present bind heparin-PF4 complexes\nenzyme-labeled secondary antibody (e.g., anti-human IgG) added, binds bound antibodies\nsubstrate enzyme added, resulting color change measured spectrophotometrically\n\nInterpretation:\nOptical Density (OD) values measured, higher OD correlating antibodies present\nCan differentiate IgG, IgM, IgA antibodies\npositive result indicates presence heparin-PF4 antibodies, confirm platelet activation\n\nPrinciple: Detects antibodies heparin-PF4 complexesProcedure:\nMicroplate wells coated heparin-PF4 complexes\npatient’s serum plasma added wells, antibodies present bind heparin-PF4 complexes\nenzyme-labeled secondary antibody (e.g., anti-human IgG) added, binds bound antibodies\nsubstrate enzyme added, resulting color change measured spectrophotometrically\nMicroplate wells coated heparin-PF4 complexesThe patient’s serum plasma added wells, antibodies present bind heparin-PF4 complexesAn enzyme-labeled secondary antibody (e.g., anti-human IgG) added, binds bound antibodiesA substrate enzyme added, resulting color change measured spectrophotometricallyInterpretation:\nOptical Density (OD) values measured, higher OD correlating antibodies present\nCan differentiate IgG, IgM, IgA antibodies\npositive result indicates presence heparin-PF4 antibodies, confirm platelet activation\nOptical Density (OD) values measured, higher OD correlating antibodies presentCan differentiate IgG, IgM, IgA antibodiesA positive result indicates presence heparin-PF4 antibodies, confirm platelet activationFunctional Assays:\nSerotonin Release Assay (SRA) Heparin-Induced Platelet Aggregation (HIPA)\nPrinciple: Measures platelet activation presence heparin patient serum/plasma\nProcedure:\nPatient serum incubated normal donor platelets heparin\nPlatelet activation measured :\nSerotonin Release Assay (SRA): Measuring release serotonin platelets\nHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregation\n\n\nInterpretation:\nPositive: Indicates presence platelet-activating antibodies, confirming HIT\n\n\nAdvantages Functional Assays:\nHigher specificity ELISA\nDetect platelet-activating antibodies, clinically relevant\n\nSerotonin Release Assay (SRA) Heparin-Induced Platelet Aggregation (HIPA)\nPrinciple: Measures platelet activation presence heparin patient serum/plasma\nProcedure:\nPatient serum incubated normal donor platelets heparin\nPlatelet activation measured :\nSerotonin Release Assay (SRA): Measuring release serotonin platelets\nHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregation\n\n\nInterpretation:\nPositive: Indicates presence platelet-activating antibodies, confirming HIT\n\nPrinciple: Measures platelet activation presence heparin patient serum/plasmaProcedure:\nPatient serum incubated normal donor platelets heparin\nPlatelet activation measured :\nSerotonin Release Assay (SRA): Measuring release serotonin platelets\nHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregation\n\nPatient serum incubated normal donor platelets heparinPlatelet activation measured :\nSerotonin Release Assay (SRA): Measuring release serotonin platelets\nHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregation\nSerotonin Release Assay (SRA): Measuring release serotonin plateletsHeparin-Induced Platelet Aggregation (HIPA): Measuring platelet aggregationInterpretation:\nPositive: Indicates presence platelet-activating antibodies, confirming HIT\nPositive: Indicates presence platelet-activating antibodies, confirming HITAdvantages Functional Assays:\nHigher specificity ELISA\nDetect platelet-activating antibodies, clinically relevant\nHigher specificity ELISADetect platelet-activating antibodies, clinically relevant","code":""},{"path":"heparin-neutralization.html","id":"factors-affecting-results","chapter":"Heparin Neutralization","heading":"Factors Affecting Results","text":"Pre-analytical:\nInappropriate sample type\nClotted samples\nImproper handling storage sample\nInappropriate sample typeClotted samplesImproper handling storage sampleAnalytical:\nKit reagent performance\nSpectrophotometer functionality\nReader alignment accuracy\nKit reagent performanceSpectrophotometer functionalityReader alignment accuracyPatient-related:\nRecent heparin exposure\nConcurrent medication factors\nRecent heparin exposureConcurrent medication factors","code":""},{"path":"heparin-neutralization.html","id":"troubleshooting-1","chapter":"Heparin Neutralization","heading":"Troubleshooting","text":"results unexpected, repeat test ensure steps performed correctly","code":""},{"path":"heparin-neutralization.html","id":"reflex-testing-12","chapter":"Heparin Neutralization","heading":"Reflex Testing","text":"Positive HIT Antibody ELISA: test can high false-positive results must confirmed SRA HIPA assay","code":""},{"path":"heparin-neutralization.html","id":"key-terms-107","chapter":"Heparin Neutralization","heading":"Key Terms","text":"Heparin Neutralization: Inactivation heparin’s anticoagulant activityPolybrene Protamine Sulfate: Positively charged compounds neutralize heparinHeparinase: enzyme degrades heparinHeparin-Induced Thrombocytopenia (HIT): prothrombotic disorder caused antibodies heparin-PF4 complexesFunctional Assay: Testing samples ability perform certain task, used confirm presence functional antibodyELISA: Enzyme-Linked Immunosorbent Assay, uses binding properties antibodies confirm presence quantity.PF4: Platelet Factor 4","code":""}]
